IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz

Scientific Report 2025

1 We are all IdiPAZ

Your contribution adds to the impact of research

2 Research career

Boost your scientific career at IdiPAZ

3 Repositories

Share knowledge, expand its reach

4 Innovation

Turn ideas into solutions with real-world impact

5 Nursing

Caring also means reseaching and innovating

6 Primary care

Research starts close to people

7 Research placements

Broaden your horizons, share expertise and build partnerships

8 Share your science


Make your research reach further

9 Impact on Society

We turn research into value for society

10 Training

Lean, evolve and keep growing with IdiPAZ



Published by:
Instituto de Investigación Sanitaria del Hospital Universitario la Paz - IdiPAZ

Crafted by:
Raúl Román Cañizares
Paloma Gómez Campelo
Isabel Polo Campos

IdiPAZ Scientific Report 2025 has been approved by the Internal Scientific Committee of IdiPAZ during its meeting on September 21, 2026.

Scientific Report 2025

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Hospital Universitario La Paz is facing the future with a conviction that has guided its work for more than six decades: excellence in healthcare cannot be understood without research, innovation and the generation of knowledge. This close relationship between healthcare and research is one of our greatest strengths, enabling us to move towards increasingly precise and personalised medicine, capable of providing new answers for our patients.

Throughout 2025, the Health Research Institute of Hospital Universitario La Paz, IdiPAZ, has continued to consolidate its position as one of the leading biomedical research centres in Spain. The quality of its scientific output, its participation in competitive research projects and clinical trials, its growing collaboration with national and international institutions, and its ability to translate research findings into clinical practice all reflect the dedication and commitment of its professionals.

But beyond the figures, the true value of our research activity lies in its impact on people's health. Every line of research finds its ultimate purpose when the knowledge generated can be translated into better diagnostic tools, new treatments, more personalised care or new opportunities for our patients.

This translational vocation is one of IdiPAZ's defining characteristics. The close interaction between researchers and healthcare professionals makes it possible for questions arising at the patient's bedside to be taken into the laboratory, and for scientific advances to subsequently return to clinical practice. This is a relationship that we are committed to strengthening further and which is essential to addressing the major challenges facing medicine today.

This is taking place alongside the transformation of Hospital Universitario La Paz itself. The development of the future Ciudad de la Salud represents an extraordinary opportunity to move towards a model in which healthcare, research, innovation and education are even more closely interconnected. The new spaces and infrastructure dedicated to research will enable us to strengthen multidisciplinary collaboration, incorporate cutting-edge technologies and foster an ecosystem capable of attracting talent and generating knowledge with national and international impact.

None of this would be possible without our people. Researchers, healthcare professionals, technical and management staff, universities, institutions and partner organisations form a scientific community whose expertise and commitment make the continued growth of IdiPAZ possible.

Our challenge in the years ahead is to continue moving in this direction: to conduct more research, collaborate more effectively and, above all, ensure that the knowledge we generate is translated into better health. Because research is not an activity separate from healthcare; it is an essential part of how we understand our hospital and of our commitment to our patients and to society.



Dr. Rafael Pérez-Santamarina Feijóo
Managing Director of HULP
Chairman of the Board of FIBHULP

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

We are pleased to present the IdiPAZ Research Report for 2025, an opportunity to once again recognize the work of a community that seeks to make research a fundamental pillar of excellence in patient care. This year's results reflect a solid, competitive institute with an enormous capacity for scientific output, but they also invite us to look beyond the numbers and ask ourselves what our ambitions should be for the coming years and which areas we need to improve or strengthen.

In 2025, IdiPAZ researchers contributed to 1,665 scientific publications, serving as first, last, or corresponding author in 642 of them. More than half of the articles published in JCR journals were ranked in the first quartile, and more than one in five in the first decile. These are figures of which we should be proud, because they speak to quality, leadership, and the ability to compete at the most demanding levels of biomedical research.

But there is another statistic that I consider particularly relevant: nearly 90% of our publications were collaborative. The science that truly transforms medicine is becoming less individual and more collective. We need to integrate disciplines, connect basic and clinical research, share knowledge across departments and groups, and strengthen our national and international partnerships. The fact that nearly one-third of our publications involve collaboration among researchers at IdiPAZ itself is a positive sign, but it also serves as an incentive to continue breaking down internal barriers and fostering truly interdisciplinary projects.

This scientific output is essential for driving the generation and attraction of resources. The Hospital Universitario La Paz Foundation for Biomedical Research closed out 2025 with revenues of nearly 29 million euros. Clinical research and collaborations exceeded 10 million euros, and 107 agreements were formalized with public and private institutions during the year. Behind these figures lie clinical trials, competitive projects, strategic alliances, talent programs, scientific-technical platforms, and professionals who make it possible for ideas to become projects and projects to yield results.

These are good results, but we cannot allow ourselves to become complacent. We must look to other centers that surpass us in the quality and quantity of their scientific output; they must serve as our guiding beacons. It is true that we currently face several barriers that limit this growth: the need for space is a serious problem that prevents us from attracting talented new researchers; the growing burden of patient care; the imperative to transition toward an essential generational turnover; and the persistent lack of resources at all levels—material, but above all, human.

We are also aware that our country's funding for research is very limited, especially following the reduction in European funds earmarked for COVID recovery. Therefore, in such a competitive environment, we must seek solutions and new avenues for securing funding. Europe is one of the areas where we must continue to focus our efforts, as evidenced by our tireless work in securing European projects. But we also need to turn our attention to calls for private projects or seek sponsorship, as other centers do.

Innovation is a fundamental pillar for transforming knowledge and talent into value, and our institution has all the necessary means to do so: patients, professionals, and resources. Innovation can occur at all levels and among all professionals, as we can develop it in processes, technologies, research outcomes, artificial intelligence, biomodels and biomaterials, and the secondary use of data…

Clinical trials deserve special mention—an area of research we must promote for several reasons. First, because it offers the best opportunity for patients to receive the most innovative treatments as quickly as possible. But no less important is the fact that clinical trials represent the best way to maintain excellence in patient care while also offering the opportunity to significantly increase economic returns. Economic returns, not only in terms of savings on drug costs but also in terms of increased research revenue. In an increasingly restrictive environment, clinical trials are a unique opportunity we cannot afford to miss when it comes to securing resources.

For all these reasons, I believe we have reached a point where we must take it a step further. Our success cannot be measured solely by the number of publications, their impact factor, the projects we've secured, or the resources we've raised. All of these are essential, but they do not constitute the ultimate goal of a health research institute. Our true measure of success must be the impact we are able to make on health.

Impact means that research leads to a better understanding of a disease, earlier diagnosis,

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

prevention, the development of a new treatment, or more effective use of existing treatments. It means that a clinical trial offers new opportunities to our patients, that an innovation is implemented in clinical practice, or that the knowledge generated by our research groups helps transform the way we care for people. Ultimately, it means ensuring that research translates into a tangible improvement in patients' lives and adds value to our hospital and to society.

That, in my view, must be IdiPAZ's greatest challenge for the coming years: not to compromise on growth in scientific excellence, but to pair that excellence with a greater capacity for transformation and for securing resources. We must strengthen our leadership in high-impact research, foster collaboration among groups and departments, expand our international presence, attract and develop talent, reinforce clinical and translational research, and ensure that innovation and knowledge reach patients more quickly and efficiently.

Nothing outlined in this Annual Report would be possible without the people who make up IdiPAZ. I would like to extend special thanks to our researchers, the professionals in clinical services and primary care units, the research groups, the scientific-technical platforms and support units, and the management teams for their efforts. The results for 2025 are the product of their talent, their commitment, and, in many cases, an effort that goes far beyond what the indicators reflect.

This Annual Report demonstrates how far we have come. But above all, it highlights how far we can go. We have an extraordinary scientific foundation, a leading hospital, excellent professionals, and a research community capable of tackling some of medicine's greatest challenges. Our ambition must be to live up to that potential. Only then can we move closer to our ultimate mission: to work toward research that transforms medical care—and, ultimately, people's lives.



Dr. Javier de Castro
Scientific Director of IdiPAZ



Mission

To carry out research activities in the prioritized lines, enhancing collaboration with other centers and research groups, thus conceiving itself as a multidisciplinary biomedical research space oriented towards clinical translation and technological transfer.

Vision

To establish itself as a benchmark in translational biomedical research of excellence both nationally and with international reach

Values

- Multidisciplinary Institute focused on excellence
- Willingness to belong to the organization
- International vocation
- Leader in innovation and transfer
- Focus on sustainability
- It focuses on cooperation and establishing alliances

IdiPAZ Instituto de Investigación Hospital Universitario La Paz



Scientific Report 2025

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

2 Executive summary

2.1 Global Analysis
2.1.1. Scientific Analysis
2.1.2 Scientific Production
2.1.3. Annual Accounts

2.2 Research Structure

2.3 Training Report and Teaching
2.3.1. Doctoral Theses
2.3.2 Master Theses
2.3.3 Final Degree Theses
2.3.4 Training Plan

2.4 IdiPAZ quality committe

2.5 Platforms
2.5.1. ISCIII Strategic Platforms
2.5.2. IdiPAZ Platforms

2.6. Mentor and prementor program
2.6.1. Mentor Program
2.6.2. Prementor Program

2.7 CIBERs and RETICs

2.8 Communication and public engagement
2.8.1. Selected media appearances
2.8.2. Scientific Newsletter: IdiPAZ+ii News
2.8.3. Our new website
2.8.4. Formative Pills about Sustainable Development Goals and Responsible Research and Innovation

2.9. IdiPAZ Research Impact and Societal Engagement

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.1 Global Analysis

2.1.1 Scientific analysis

In 2025, IdiPAZ's scientific output comprised more than 1,600 publications. Of these, nearly 39% (642) were authored by researchers affiliated with the institute, acting as first, last or corresponding authors. IdiPAZ researchers produced over 1,370 original research articles and review papers, more than 55% of which were published in journals positioned in the first quartile of their subject category, and over 21% in journals ranked within the top decile.

2025	Total	%Q1	%D1
Publications	1,665	55.50	21.68
Owned Publications	642	43.77	13.08
Un-owned Publications	1,023	69.74	27.25
Originals	1,370	55.26	21.02
Owned Originals	503	42.74	16.70
Un-owned Originals	867	62.51	26.18
JCR Indexed Articles and Reviews	1,473	57.64	21.79
Owned JCR Indexed Articles and Reviews	525	46.48	12.38
Un-owned JCR Indexed Articles and Reviews	948	63.82	27.00

IdiPAZ researchers demonstrated a strong presence in national and international scientific networks, with more than 88% of all publications (88.47%) produced in collaboration. Of these collaborative works, 47.66% involved national partners, while 52.34% were developed through international collaborations.

Collaboration within IdiPAZ itself was also noteworthy. Publications co-signed by different research groups of the institute represent 14.41% of the total output. Considering only original articles and reviews, intra-institute collaborations accounted for 31.71% of the publications.

2025	Total	% National Collaboration	% International Collaboration
Collaborative Publications	1,473	47,66	52,34
Owned Collaborative Publications	451	64,89	35,11
Un-owned Collaborative Publications	1,022	40,08	59,92
Collaborative Originals	1,228	48,78	51,22
Owned Collaborative Originals	361	65,93	34,07
Un-owned Collaborative Originals	867	41,64	58,36
Collaborative JCR Indexed Articles and Reviews	1,343	47,13	52,87
Owned Collaborative JCR Indexed Articles and Reviews	396	64,90	35,10
Un-owned Collaborative JCR Indexed Articles and Reviews	947	39,70	60,30

2025	Total	% Intra-Institute Documents
Intra-Institute Publications	528	31,71
Owned Intra-Institute Publications	285	53,98
Un-owned Intra-Institute Publications	243	46,02
Intra-Institute Originals	448	32,70
Owned Intra-Institute Original	235	52,46
Un-owned Intra-Institute Original	213	47,54
Intra-Institute JCR Indexed Articles and Reviews	471	31,98
Owned Intra-Institute JCR Indexed Articles and Reviews	242	51,38
Un-owned Intra-Institute JCR Indexed Articles and Reviews	229	48,62

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction


2 Executive summary

3 Research areas and groups


4 Associated clinicians

IdiPAZ maintained the positive trajectory of its scientific activity observed in recent years. The impact of the institute's research is reflected in the fact that 55.5% of its publications were published in leading journals within their respective subject categories.


Distribution of Publicactions by Quartile 2021-2025




Distribution of originals by quartile 2021-2025



Papers with international collaboration between 2021-2025



Owned originals between 2021-2025



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.1.2 Scientific Production

The following list show the journals that are ranked in the top decile of their subject category in which IdiPAZ researchers have published paper in 2025.

Journal	ISSN	Impact Factor
ACS Sensors	2379-3694	10.9
Ageing Research Reviews	1568-1637	15.5
Aging and Disease	2152-5250	9.6
Allergy	0105-4538	11.3
American Journal of Hematology	0361-8609	9.4
American Journal of Human Genetics	0002-9297	7.7
American Journal of Psychiatry	0002-953X	15.9
American Journal of Respiratory and Critical Care Medicine	1073-449X	21.7
American Journal of Transplantation	1600-6135	8.1
Anaesthesia Critical Care & Pain Medicine	2352-5568	5.4
Annals of Internal Medicine	0003-4819	17.2
Annals of Neurology	0364-5134	7.5
Annals of Oncology	0923-7534	80.4
Annals of Surgery	0003-4932	7.4
Annals of the Rheumatic Diseases	0003-4967	24
Antioxidants	2076-3921	8.2
Archives of Toxicology	0340-5761	10.9
Archivos de Bronconeumologia	0300-2896	8.7
Arthritis & Rheumatology	2326-5191	9.9
Asian Journal of Surgery	1015-9584	5.2
Atherosclerosis	0021-9150	7.1
Basic Research in Cardiology	0300-8428	9.2
Biosensors & Bioelectronics	0956-5663	11.8
BJS Open	2474-9842	4.9
BJS-British Journal of Surgery	0007-1323	8.7
Blood	0006-4971	23.9
BMC Medicine	1741-7015	8.7
BMC Nursing	1472-6955	5.2
BMJ Health & Care Informatics	2632-1009	6.2
BMJ Mental Health	2755-9734	6.6
Bone & Joint Journal	2049-4394	4.8
Brain Behavior and Immunity	0889-1591	7.5
British Journal of Dermatology	0007-0963	8.2
Cancer Discovery	2159-8274	29.5
Cancer Research	0008-5472	22.6
Cardiovascular Diabetology	1475-2840	15.6

Journal	ISSN	Impact Factor
Cell Reports Medicine	2666-3791	14
Chest	0012-3692	9.8
Circulation-Arrhythmia and Electrophysiology	1941-3149	9.3
Clinical Cancer Research	1078-0432	10.9
Clinical Chemistry	0009-9147	8.3
Clinical Infectious Diseases	1058-4838	8.3
Clinical Journal of the American Society of Nephrology	1555-9041	7
Clinical Microbiology and Infection	1198-743X	8.7
Clinical Nutrition	0261-5614	7.9
Clinical Reviews in Allergy & Immunology	1080-0549	11.5
Cognitive Computation	1866-9956	7.4
Communications Biology	2399-3642	5.8
Computers in Biology and Medicine	1879-0534	6.3
Critical Care	1364-8535	11.4
Current Research in Food Science	2665-9271	7.7
Ebiomedicine	2352-3964	11.2
Eclinicalmedicine	2589-5370	12.8
Emerging Infectious Diseases	1080-6040	7.9
Endoscopy	0013-726X	11.8
Eurointervention	1774-024X	9.2
Europace	1099-5129	10.2
European Heart Journal	0195-668X	45.3
European Journal of Anaesthesiology	0265-0215	7.8
European Journal of Cardiovascular Nursing	1474-5151	5.4
European Journal of Heart Failure	1388-9842	10,3
European Journal of Internal Medicine	0953-6205	8.1
European Journal of Preventive Cardiology	2047-4873	10
European Journal of Vascular and Endovascular Surgery	1078-5884	8.5
European Neuropsychopharmacology	0924-977X	8.1
European Psychiatry	0924-9338	7.9
European Urology Oncology	2588-9311	8.5
Eurosurveillance	1025-496X	8.3
Experimental Hematology & Oncology	2162-3619	17.5
Food Chemistry	0308-8146	10.4
Food Research International	0963-9969	8.8
Free Radical Biology and Medicine	0891-5849	8

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Journal	ISSN	Impact Factor
Frontiers in Veterinary Science	2297-1769	3.1
Genome Medicine	1756-994X	10.8
Gynecologic Oncology	0090-8258	4.5
Hearing Research	0378-5955	3
Hemasphere	2572-9241	11.3
Hepatology	0270-9139	18
Human Resources for Health	1478-4491	5.4
IEEE Internet of Things Journal	2327-4662	8.7
Immunity	1074-7613	30.6
Immunity & Ageing	1742-4933	8.3
Industrial Crops and Products	0926-6690	6.4
Innovation in Aging	2399-5300	6.2
Intensive Care Medicine	0342-4642	22
International Journal of Gynecological Cancer	1048-891X	5.4
JACC: Cardiooncology	2666-0873	15.5
JACC-Cardiovascular Interventions	1936-8798	12.7
JACC-Heart Failure	2213-1779	11.9
JACC-Journal of the American College of Cardiology	0735-1097	22.3
JAMA Cardiology	2380-6583	15.2
JAMA Network Open	2574-3805	11.7
JHEP Reports	2589-5559	8.7
JMIR Medical Education	2369-3762	13.9
Journal of Allergy and Clinical Immunology	0091-6749	11.7
Journal of Allergy and Clinical Immunology-In Practice	2213-2198	7.2
Journal of Biomedical Science	1021-7770	14.5
Journal of Cachexia Sarcopenia and Muscle	2190-5991	9.9
Journal of Clinical Oncology	0732-183X	44.7
Journal of Crohns & Colitis	1873-9946	10.3
Journal of Extracellular Vesicles	2001-3078	21.7
Journal of Headache and Pain	1129-2369	8.7
Journal of Hematology & Oncology	1756-8722	47.8
Journal of Hepatology	0168-8278	40.1
Journal of Infection	0163-4453	10
Journal of Internal Medicine	0954-6820	7.6
Journal of Medical Internet Research	1439-4456	8.2
Journal of Neuroinflammation	1742-2094	11.5
Journal of Pathology	0022-3417	5.4
Journal of Pediatrics	0022-3476	3.6


Journal	ISSN	Impact Factor
Journal of Robotic Surgery	1863-2483	4.2
Journal of Sport and Health Science	2213-2961	13.1
Journal of Stroke	2287-6391	11
Journal of the American College of Cardiology	0735-1097	22.3
Journal of Travel Medicine	1195-1982	10.6
Journals of Gerontology Series A-Biological Sciences and Medical Sciences	1079-5006	4.6
Lancet	0140-6736	109
Lancet Child & Adolescent Health	2352-4642	13.4
Lancet Diabetes & Endocrinology	2213-8587	36.3
Lancet Gastroenterology & Hepatology	2468-1253	39.1
Lancet HIV	2352-3018	14.6
Lancet Oncology	1470-2045	33.7
Lancet Regional Health-Europe	2666-7762	15.7
Lancet Respiratory Medicine	2213-2600	34.7
Med	2666-6359	13.3
Medical Mycology	1369-3786	3.5
Medical Sciences	2076-3271	5.9
Mmwr-Morbidity and Mortality Weekly Report	0149-2195	16.2
Modern Pathology	0893-3952	6.6
Molecular Cancer	1476-4598	42.2
Molecular Psychiatry	1359-4184	10.4
Nature	0028-0836	56.1
Nature Cancer	2662-1347	28
Nature Communications	2041-1723	18.1
Nature Genetics	1061-4036	25.5
Nature Medicine	1078-8956	52.5
Nature Mental Health	2731-6076	9.3
Nature Reviews Gastroenterology & Hepatology	1759-5045	57.5
Nature Reviews Nephrology	1759-5061	46.7
Neonatology	1661-7800	3.8
Nephrology Dialysis Transplantation	0931-0509	8.3
Neurology-Neuroimmunology & Neuroinflammation	2332-7812	8
Neuroscience and Biobehavioral Reviews	0149-7634	8.5
New England Journal of Medicine	0028-4793	84.5
New Microbes and New Infections	2052-2975	6
Nucleic Acids Research	0305-1048	15
Obstetrics and Gynecology	0029-7844	5.1
Particle and Fibre Toxicology	1743-8977	10.6

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians


Journal	ISSN	Impact Factor
Pediatric Critical Care Medicine	1529-7535	4.9
Plos Pathogens	1553-7366	4.9
Radiology	0033-8419	17.6
Redox Biology	2213-2317	16.2
Research in Developmental Disabilities	0891-4222	2.9
Reviews in Endocrine & Metabolic Disorders	1389-9155	8.7
Rhinology	0300-0729	5.7
Small	1613-6810	11.8
Spine Journal	1529-9430	5.1
Stroke	0039-2499	11.1
Supportive Care in Cancer	0941-4355	3.4
Thorax	0040-6376	9.1
Transplantation	0041-1337	4.9
Travel Medicine and Infectious Disease	1477-8939	5.6
Trends in Immunology	1471-4906	13.1
Ultrasound in Obstetrics & Gynecology	0960-7692	5.3
World Journal of Emergency Surgery	1749-7922	7.7

2.1.3 Annual Accounts

Economic Income Overhead 2025



Economic Income 2025



	2024	2025
INCOME	**27,986,542.72**	**29,057,414.76**
Grants	9,788,148.18	10,473,476.58
Corporate collaboration agreements and sponsorships	436,517.52	5,636,488.99
Grants and other private research projects	1,924,237.66	813,294.19
Scientific research (clinical trials, collaborations...)	13,445,827.97	10,498,261.74
Financial Income	1,845,791.29	1,633,863.17
Positive exchange rate differences	78,115.74	2,030.09
Extraordinary income	467,904.36	0.00
COST	**27,858,901.26**	**28,964,585.00**
Monetary aid and other	202,748.84	152,078.58
Operating consumption	1,885,424.86	1,879,813.18
Leases and royalties	10,429.71	3,974.91
Repair and maintenance	1,497.70	0.00
Professional Services	3,160,789.46	3,526,626.59
Other expenses	4,061,707.82	5,245,285.65
Other taxes	14,804.81	13,135.28
Wages and salaries	9,510,462.31	11,289,681.25
Social charges	2,921,056.13	3,449,009.37
Compensations	81,353.37	87,843.91
Amortization of fixed assets	1,557,517.80	1,022,036.87
Provisions (Provision - Excess)	4,086,347.54	1,436,446.18
Financial expenses	117,097.73	398,286.39
Negative exchange differences	2,190.93	79,188.43
Refund of grants, donations and legacies	245,472.25	154,760.25
R&D expenses	0.00	226,418.16
SURPLUS FOR THE FINALCIAL YEAR	**127,641.46**	**92,829.76**

In 2025, FIBHULP received a nominative transfer from the *Consejeria de Sanidad de la Comunidad de Madrid,* under program 312D "Biomedical Research Foundations", to support the following items:

- Researchers and support staff funded through the I3, I3SNS, Miguel Servet I, Miguel Servet II, Río Hortega, Sara Borrell, Juan de la Cierva, Marie Skłodowska-Curie, and Juan Rodés programs.
- Intensification programs for healthcare professionals.
- Activities for the promotion and dissemination of research and scientific culture.
- Accreditations of research activity.
- Support for Technical Units and Platforms for Research and Management of R+D+i

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

In addition, IdiPAZ formalized 107 agreements with public and private entities, distributed as follows:

- Service contracts: 18
- Sponsorship contracts: 72
- Training contracts: 17

The main entities with which these agreements were established include:

Organization	Nº Agreements
Abbvie Spain S. L. U.	6
Alcon Healthcare S. A.	1
Alexion Pharma Spain S. L	2
Allinky Biopharma S. L.	1
Aristo Pharma Iberia S. L.	1
Astellas Pharma S. A.	2
Astrazeneca Farmaceutica Spain S. A.	5
Ayuntamiento de Colmenar Viejo	1
Baxter S.L.	1
Bayer Hispania S. L.	2
Beyondspring Pharmaceuticals Inc	1
Biocryst España S. L.	1
Boehringer Ingelheim España S. A.	3
Boston Scientific Ibérica S. A.	1
Bristol Myers Squibb S. A. U.	1
Canal Estrategia Editorial S. L.	1
Cardiva 2 S. L.	1
Chiesi España S. A.	1
Clover Soluciones Globales de Marketing S. L.	1
Colegio de Enfermería de la Comunidad de Madrid	1
CSL Behring S. A.	1
Ediciones Mayo S. A.	2
Editorial Médica Awwe S. A.	1
Esteve Pharmaceuticals S. A.	3
F.Hoffmann-La Roche Ltd	1
Fundación ECO	3
Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda	1
Glaxosmithkline S. A.	5
GMV Soluciones Globales Internet S. A. U.	1
Grifols Shared Services North America Inc	1
Grunenthal Pharma S. A.	2
Janssen Cilag Farmacéutica S. A.	1
Johnson & Johnson de Chile S. A.	1
Laboratorio Menarini S. A.	1
Laboratorios Gebro Pharma S. A.	1
Laboratorios Leo Pharma S. A.	1
Laboratorios Servier S. L.	1
Lilly S. A.	1
Lofarma Ibérica S. L. U.	1
Lundbeck España S. A.	1
MBA Incorporado S. L. U.	1
Med-El Elektromedizinische Geräte Gesellschaft M.B.H.	1
Mediwound Germany GMBH	1
Merck Sharp and Dohme de España S. A.	1
Neuraxpharm S. L.	1
Norrdia BV	1
Novartis Farmaceutica S. A.	4
Novo Nordisk A/S	1
Novo Nordisk Pharma S. A.	3
Olympus Iberia S. A. U.	1
Organon Salud S. L.	1
Otsuka Pharmaceutical S. A.	1
Permanyer Mexico S. A.	1
Permanyer Portugal Marketing Publicidade e Ediçoes Ltda.	1
Pfizer S. L. U.	1
Prim S. A.	1
Recordati España S. L.	1
Roche Farma S. A.	3
Sandoz Farmacéutica S. A.	2
Sanofi Aventis S. A.	4
Smart Scoliosis Developments S. L.	1
Springer Healthcare Ibérica S. L. U.	1
Stryker Iberia S. L.	1
Swedish Orphan Biovitrum S. L.	1
Takeda Farmaceutica España S. A.	3
Thermo Fisher Diagnostics S.L. U.	1
UCB Pharma S. A.	1
Venter Pharma S. L.	1
Vifor Pharma España S. L.	2

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.2. Research Structure

SCIENTIFIC DIRECTOR

Javier de Castro Carpeño

SCIENTIFIC DEPUTY DIRECTOR

Alberto Borobia Pérez

TECHNICAL DEPUTY DIRECTOR

Paloma Gómez Campelo



GOVERNING COUNCIL

Chairperson

Laura Gutiérrez Barreno. *Deputy Minister of Health of the Community of Madrid*

Vice President

Amaya Mendikoetxea Pelayo. *Rector of the UAM*

Members

Rafael Pérez-Santamarina Feijóo. *Chairperson of the Board of Trustees*
Francisco García Río. *FIBHULP Trustee*
Rodolfo Álvarez-Sala Walther. *FIBHULP Trustee*
Almudena Castro Conde. *FIBHULP Trustee*
Alicia Portas Martínez. *FIBHULP Trustee*
Antonio Pérez Martínez. *FIBHULP Trustee*
Inmaculada Ibáñez de Cáceres. *FIBHULP Trustee*
Alicia Hernández Gutiérrez. *FIBHULP Trustee*
Víctor Jiménez Yuste. *FIBHULP Trustee*
Exuperio Díez Tejedor. *HULP Representative*
Susana Noval Martín. *HULP Representative*
Paloma Gómez Campelo. *HULP Representative*
Pilar López García. *UAM Representative*
José Manuel González Sancho. *UAM Representative*
María Ángeles Martín Cabrejas. *UAM Representative*
Zita Quintela González. *HUG Manager*
Javier de Castro Carpeño. *Scientific Director. FIBHULP Trustee*
David Sanz Rosa. *EU Representative*

Secretary

Ana Coloma Zapatero. *Director of FIBHULP*

DELEGATE COMMISION

Chairperson

Rafael Pérez-Santamarina Feijóo. *President of FIBHULP; permanent delegation to Rodolfo Álvarez-Sala Walther*

Board members

Javier de Castro Carpeño. *Scientific Director of IdiPAZ*
Alberto Borobia Pérez. *Scientific Deputy Director of IdiPAZ*
Paloma Gómez Campelo. *Technical Deputy Director of IdiPAZ*
Pilar López García. *Dean of the UAM*
Eduardo López Collazo. *Stabilized research representative.*
Francisco García Río. *HULP Representative*
Exuperio Díez Tejedo. *HULP Representative*
Francisco Arnalich Fernández. *Representative of the UAM*
Zita Quintela González. *HUG Manager*
Nuria García Montes. *HUG Representative*
David Sanz Rosa. *EU Representative*

Secretary

Ana Coloma Zapatero. *Director of FIBHULP*

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

FIBHULP

Director
Ana Coloma Zapatero

Foundation's board
Rafael Pérez-Santamarina Feijóo. *Chairperson of the Board of Trustees*
Francisco García Río. *Vice-Chair Trustee*
Rodolfo Álvarez-Sala Walther. *Member*
Almudena Castro Conde. *Member*
Alicia Portas Martínez. *Member*
Antonio Pérez Martínez. *Member*
Javier de Castro Carpeño. *Member*
Inmaculada Ibáñez de Cáceres. *Member*
Alicia Hernández Gutierrez. *Member*
Victor Jimenez Yuste. *Member*
Ana Coloma Zapatero. *Secretary*

Delegated Commission of the FIBHULP
Francisco García Río. *President*
Rodolfo Álvarez-Sala Walther. *Member*
Javier de Castro Carpeño. *Member*
Victor Jimenez Yuste. *Member*
Ana Coloma Zapatero. *Secretary*

Human Resources
Responsible: María Quintanar Jaime

Private Projects Management
Responsible: F. G. G.

Clinical Trials Management
Responsible: Sara Moral Álamo

Public Projects Management
Responsible: Silvia Arce Santamaría

European Projects Management
Responsible: José Luis Narro Villanueva

Contracting and Legal
Responsible: Sara Fernández Morata

Accounting
Responsible: Laura López Revuelta

Safety, Health and Wellbeing
Responsible: Aitana López Redondo

TECHNICAL SECRETARY
Mercedes Ruiz Balibrea

HEALTH AND SAFETY COMMITTEE

Compostion
Gema Vallés Pérez. *FIBHULP Representative / President*
Sara Fernández Morata. *FIBHULP Representative*
Estela Sánchez Simón. *FIBHULP Representative*
Laura Saldaña Quero. *Prevention Delegate / Secretary*
Berta Rodés Soldevilla. *Prevention Delegate*
FGG. *Prevention Delegate*
Aitana López Redondo.
Head of the In-House Prevention Service
Sergio Palomero Lorente.
In-House Prevention Service Technician
Sonsoles Bedia Olmeda.
In-House Prevention Service Technician

Guest
External Prevention Service Technician

WORKS COMMITTEE

Chairperson
Ángel Campos Barros

Members
Nuria Vilaboa Díaz
Berta Rodés Soldevila
Rosa Rodríguez Pérez
Laura Saldaña Quero
Rocío López Vacas
Pilar Sánchez-Corral Gómez
F.G.G.
Sara García Bercenilla
Vega Mauleón Martínez
Laura Vitón Vara
Laura González Rodríguez
Marina Arranz Álvarez

Secretary
Juan Ángel Fresno Vara

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

EXTERNAL SCIENTIFIC COMMITTEE



Juan Tamargo Menéndez. *Professor. Institute of Pharmacology and Toxicology, Spanish National Research Council (CSIC) - Complutense University of Madrid. Madrid.*



Joaquín Arribas López. *Director of Research at Parc de Salut Mar (PSMAR) and director of the Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), as well as ICREA research professor at the Vall d'Hebron Institut d'Oncologia (VHIO) Barcelona. Chairperson of the Technical Committee on Cancer Screening Health Research Fund (FIS). Institute of Health Carlos III.*



Jacinta Cecilia Bustamante. *Université Paris Cité, Laboratorio de Genética Humana de Enfermedades Infecciosas (INSERM U1163), Instituto Imagine. Centro para el Estudio de Inmunodeficiencias Primarias, Necker Enfants-Malades Hospital, Paris*



Isabel Fabregat Romero. *Research Group Coordinator. Centre d´Oncologia Molecular. L´Hospitalet, Barcelona IDIBELL- Bellvitge Biomedical Research Institute. Barcelona.*



Juan Pedro Bolaños Hernández. *Departament of Biochemistry and Molecular Biology. University of Salmanca. Institute of Functional Biology and Genomics. Salamanca.*



Pablo Pelegrin Vivancos. *Scientific Assistant Director. Principal Investigator in Group: Digestive Surgery, Endocrine and Abdominal Organ Transplantation. Virgen de la Arrixaca Biosanitary Research Institute. Murcia.*



Jean-Claude. *Tardif Cardiologist, Montreal Heart Institute, Canada Director, Research Chair, Canada Research Chair in Translational and Personalized Medicine Professor of Medicine Montreal Heart Institute, University of Montreal, Canada Director, Montreal Heart Institute Research Centre, Montreal Heart Institute, Canada*



Sonia Villapol Assistant Professor of Neurosurgery. *Department of Neurosurgery, Institute of Academic Medicine, Houston Methodist Research Institute, Houston, TX.*

INTERNAL SCIENTIFIC COMMITTEE

Chairperson

Javier de Castro Carpeño. *Scientific Director*

Secretary

Nora Butta Coll. *HULP representative*

Members

Alberto Borobia Pérez. *Scientific Deputy Director of IdiPAZ*
Paloma Gómez Campelo. *Technical Deputy Director of IdiPAZ and Coordinator of the Training Committee*
Javier de Castro Carpeño. *Coordinator of the Innovation Platform*
José Jonay Ojeda Feo. *Coordinator of the Quality Committee*

Member by Hospital Universitario La Paz

Exuperio Díez Tejedor. *Coordinator of the Neuroscience Area*
María Fernández Velasco. *Coordinator of the Cardiovascular Area*
Eduardo López-Collazo. *Coordinator of the Infectious Diseases and Immunity Area and Director of the Biobank Platform*
Francisco García Río. *Coordinator of the Large Systems Pathology Area*
Javier de Castro Carpeño. *Coordinator of the Cancer and Human Molecular Genetics Area*
Nuria Vilaboa Díaz. *Coordinator of the Surgery, Transplants and Health Technologies Area*
Cristina Calvo Rey. *Coordinator of the Maternal, Child and Adolescent Area*
Rocío Menéndez Colino. *Coordinator of the Multidisciplinary Research Area on Aging*
Alberto Borobia Pérez. *Director of the Central Unit for Clinical Research and Clinical Trials*
Nora Butta Coll. *Researcher in the Cardiovascular Area*
José Ramón Arribas López. *Researcher in the Area of Infectious Diseases and Immunity*

Pre-doctoral representatives

Tamara Domingo Pérez. *Director of group Health Care Research*

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Members by Universidad Autónoma de Madrid

Francisco Arnalich Fernández
Gemma Domínguez Muñoz
Concepción Peiró Vallejo
Belén Pérez González
María Carmen Sellán Soto

Members by Hospital Universitario de Getafe

Rocío Vázquez Vázquez
Joaquín Alonso Martín
Leocadio Rodríguez Mañas

Members by Universidad Europea de Madrid

David Sanz Rosa

Representative of patients or patient associations (permanent guest)

David Trigos Herráez. *European Patients' Academy on Therapeutic Innovation (EUPATI)*

ANIMAL WELFARE ORGAN

Carmen Fernández Criado. *Director of the Veterinary Clinic at the Faculty of Medicine of the Universidad Autónoma de Madrid (UAM). She specializes in Animal Health and Welfare as an external advisor.*
Fernando Carceller Benito. *Assistant Professor of Neurosurgery at HULP, as a physician and researcher in the "Neurology and Cerebrovascular Diseases" Group at IdiPAZ.*
Nuria Vilaboa Díaz. *IdiPAZ researcher. Internal Advisor*
Carlota Largo Aramburu. *Head of the Animal Facility of the Experimental Surgery Service at HULP, as the Center's Animal Health and Welfare Specialist.*

RESEARCH ETHICS COMMITTEE WITH MEDICAL PRODUCTS

Chairperson

Almudena Castro Conde. *Head of Section of Cardiology Department*

Vice-Chair

Rosa Villanueva Peña.
Assistant Physician-Psychiatry Department

Members

Ainara Albadalejo Santamaría. *Nurse, Cardiac Rehabilitation Coordinator - IdiPAZ*
Nora Viviana Butta Coll. *Head of the Coagulopathies and Hemostasis Disorders Research Laboratory. Representative of the Research Commission.*
Fernando Cabañas González. *Head of the Pediatrics and Neonatology Department at Salud Quirón Hospital in Madrid. Researcher at IdiPAZ*
Antonio J. *Carcas Sansuán. Head of Clinical Pharmacology Service. HULP*
Mariana Díaz Almiron. *Data analyst. Biostatistics Platform. IdiPAZ*
Jorge Díaz-Garzón Marco. *Assistant Pharmacist. Clinical Analysis Service. HULP*
María Dolores Diestro Tejeda. *Assistant Physician, Gynecology and Obstetrics Department, HULP*
Rosa Feltes Ochoa. *Assistant Physician, Dermatology Service, HULP*
Angelo Gámez Pozo. *Researcher at INGEMM - IdiPAZ*
Irene García García. *Clinical Pharmacology Specialist. HULP*
María Justa García-Matres Cortés. *Associate Physician in the Urology Department. Representative of the Healthcare Ethics Committee. HULP*
Mercedes Gasior Kabat. *Associate Physician in the Hematology Department. HULP*
David Hernández Herrero. *Head of the Physical Medicine and Rehabilitation Service. HULP*
Natalia Hormaeche Abecassis. *Law graduate. Head of Legal Services. Data protection expert*
Carlos Lahoz Rallo. *Attending Physician, Internal Medicine Department, HULP*
Celia Martín Cubillo. *Clinical Engineer, IT Department. HULP*
Montserrat Aránzazu Rodríguez Aguirregabiria. *Deputy Physician of the Intensive Medicine Service. HULP*
Nuria Rodríguez Salas. *Associate Physician in the Oncology Department. HULP*
Jorge Rodríguez Pardo. *Associate Physician, Neurology Department, HULP*
Miriam Romero Portales. *Assistant Physician, Digestive System Service, HULP*
Elena Villamañán Bueno. *Assistant Pharmacist in the Pharmacy Department. HULP*
Yale Tung Chen. *Attending Physician, Internal Medicine Service, HULP*

Members from outside the institution

Juan Manuel Martín Baranda. *Patient representative*
Evaristo Moliné Jorques. *Patient representative*
Eva Prieto Utiel. *Assistant Clinical Pharmacist of Primary Care-Pharmacy Department*

Technical Secretary

Emma Fernández de Uzquiano. *Head of CEIm Technical Secretary. Pharmacist*
Elena García Mendez. *Pharmacist*
Laura Díez Ricote. *Biologist*
Susana Martín López. *Pharmacologist*
Sol de Gracia García. *Administrative Assistant*
María Isabel Arribas Álvarez. *Administrative*

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

QUALITY COMMITTEE & INTEGRATED MANAGEMENT SYSTEM

Coordinator

José Jonay Ojeda Feo. *Executive Committee President. HULP Representative*

Integrated management system Responsible

Gema Vallés Pérez. *Executive Committee Member. FIBHULP Representative*

Secretary

Isabel Polo Campos. *Executive Committee Member. FIBHULP Representative*

Members:

Paloma Gómez Campelo. *Executive Committee Member. FIBHULP Representative*
Ana Coloma Zapatero. *Executive Committee Member. FIBHULP Representative*
Aitana López Redondo. *Executive Committee Member. FIBHULP Representative*
Estela Sánchez Simón. *Executive Committee Member. FIBHULP Representative*
Cristina Lázaro- Carrasco Escarpizo-Lorenzana. *FIBHULP Representative*
Blanca Fuentes Gimeno. *HULP Representative*
María Luisa Díaz Martínez. *UAM Representative*

TRAINING COMMITTEE

Chairperson

Paloma Gómez Campelo. *HULP Representative*

Secretary

Mercedes Ruiz Balibrea. *HULP Representative*

Members

María Teresa García Morales. *Biostatistics Platform*
Ana Martínez Virto. *HULP Representative*
Ana García Redondo. *R3 Researcher, UAM Representative*
María Gutiérrez Fernández. *R4 Researcher, Neurosciences Area, IdiPAZ*
María Fernández Velasco. *R4 Researcher, Cardiovascular Area, IdiPAZ*
Pilar Sánchez-Corral Gómez. *R4 Researcher, Infectious Diseases and Immunity Area, IdiPAZ, Representative of the Works Council*
Beatriz Castelo. *HULP Representative*
Ana Sastre Perona. *R4 Researcher, Surgery, Transplants and Health Technologies Area, IdiPAZ, FIBHULP Representative*
Ane Miren Andrés Moreno. *Representative HULP Maternal, Child and Adolescent Area*
FGG. *Management Representative Works Council*
Aitana López Redondo. *FIBHULP Occupational Health and Safety Service*
Ana Martín de la Flor. *Management Representative FIBHULP*

EQUALITY, DIVERSITY AND CONFLICT RESOLUTION COMMISSION (ID&RC)

Members

María Quintanar Jaime. *FIBHULP Representative*
Paloma Gómez Campelo. *FIBHULP Representative*
Aitana López Redondo. *FIBHULP Representative*
Nuria Vilaboa Díaz. *Employee's FIBHULP Representative*
Juan Ángel Fresno Vara. *Employee's FIBHULP Representative*

CITIZEN PARTICIPATION COMMITTEE

Chairperson

Paloma Gómez Campelo. *Technical Deputy Director of IdiPAZ - CSR, SDGs and Agenda 2030 Coordinator of IdiPAZ/FBIHULP*

Vice-Chair

Manuel Arellano Armisen. *Second Vice-President of the Platform of Patients' Organizations, Vice-President of the ALCER National Federation and member of the Board of the European Patients' Forum*

Secretary

Aitana López Redondo. *Responsible for SDGs and Agenda 2030 at IdiPAZ/FIBHULP*

Members

Ana Coloma Zapatero. *Director of FIBHULP*
María Quintanar Jaime. *Human Resources Department of FIBHULP - Head of CSR of IdiPAZ/FIBHULP*
Isabel Polo Campos. *Communication Department of FIBHULP*
Sergio Palomero Lorente. *Occupational Risk Prevention Service of FIBHULP*
Eva M. *Ortiz Vivanco. Nursing Representative HULP*
Shona Brown. *Representative of the British Embassy*
With the participation of REDS-SDSN. *Spanish Network for Sustainable Development*

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH AREAS

Neuroscience and Brain Health Area

Coordinator: Exuperio Díez Tejedor; María Gutiérrez Fernández

Psychiatry and Mental Health
Director: Celso Arango López
Neurology and Cerebrovascular Diseases
Directors: Exuperio Díez Tejedor
María Gutiérrez Fernández
Neuroprotective Strategies in Neurodegenerative Diseases
Director: Ana Isabel Rojo Sanchís
Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies
Director: Francisco Zafra Gómez
Mechanisms and Biomarkers in Neurodegenerative Diseases
Director: Isabel Lastres Becker
Multiple Sclerosis Research
Director: Yolanda Aladró Benito



Cardiovascular Area

Coordinators: José Raúl Moreno Gómez; María Fernández Velasco

Translational Clinical and Invasive Cardiology Research – ICCIT-IdiPaz
Directors: José Raúl Moreno Gómez
María Fernández Velasco
Coagulopathies and Alterations of Haemostasis
Director: Víctor Jiménez Yuste
Vascular Physiology and Pharmacology
Director: Ana María Briones Alonso
Vascular Pharmacology and Metabolism (FARMAVSM)
Directors: Concepción Peiró Vallejo
Carlos F. Sánchez Ferrer
Paediatric Cardiology Research
Director: Federico Gutiérrez-Larraya Aguado



Infectious Diseases and Immunity Area

Coordinator: Eduardo López-Collazo

AIDS and Infectious Diseases
Director: José Ramón Arribas López
Molecular Microbiology
Director: Jesús Mingorance Cruz
Immuno-Rheumatology
Director: María Eugenia Miranda Carús
Innate Immune Response
Directors: Eduardo López-Collazo
Carlos del Fresno Sánchez
Alterations of the Complement System in Human Pathology
Directors: Margarita López Trascasa
Pilar Sánchez-Corral Gómez
Lymphocyte Pathophysiology in Immunodeficiencies
Director: Eduardo López Granados
Drug Hypersensibility and Innate Immune Response
Director: Teresa Bellón Heredia
Immunomediate Gastrointestinal Diseases and other Digestive Pathologies
Director: María Dolores Martín Arranz
MicroRNA Regulation of Immune Tolerance, Autoimmunity and Cancer
Director: Alicia González Martín
Systemic Immune-Mediated Diseases
Director: Juan José Ríos Blanco

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



Large System Pathology Area

Coordinator: Francisco García Río

Internal Medicine and Systemic Diseases
Director: María Angustias Quesada Simón
Organic Dysfunction and Failure in the Aggression
Director: José Manuel Añón Elizalde
Respiratory Diseases
Directors: Francisco García Río
Carolina Cubillos Zapata
Regulation of Gene Expression and by Hypoxia
Director: Luis del Peso Ovalle
Nephrology
Director: María Gemma Fernández Juárez
Diagnosis and Treatment of Allergic Diseases
Director: Santiago Quirce Gancedo
Management of the Bleeding Patient
Director: Manuel Quintana Díaz
Health Care Nurses Research
Directors: Esther Rey Cuevas
Tamara Domingo Pérez
Emergency and Critical Pathology
Director: César Carballo Cardona
Hospital Pharmacy
Director: Alicia Herrero Ambrosio
Translational Hepatology
Director: Francisco Javier García-Samaniego Rey
NEURO-CURE
Director: Javier Marco Martínez
iPanC: Imaging, Innovation and Clinical Pancreatology*
Director: Eva Marín Serrano
**Group recently created, December 2026*



Cancer and Human Molecular Genetics Area

Coordinator: Javier de Castro Carpeño

INGEMM- Institute of Medical and Molecular Genetics
Director: Pablo Lapunzina Badía
Translational Oncology
Director: Jaime Feliú Battle
Experimental Therapies and Biomarkers in Cancer
Directors: Olga Vera Puente
Javier de Castro Carpeño
Otorhinolaryngology and Head and Neck Surgery Research
Director: Luis Lassaletta Atienza
Molecular Pathology of Cancer And Therapeutic Targets
Director: David Hardisson Hernáez
Mechanisms of Tumour Progression
Director: José Manuel González Sancho
Research and Diagnosis of Inherited Metabolic Diseases
Director: María Belén Pérez González
Dyslipemias of Genetic Origin and Metabolic Diseases
Director: Sonia Rodríguez Novoa
Human Genetic Variability
Director: Ana Fernández Santander



Surgery, Transplant and Health Technologies Area

Coordinator: Nuria Vilaboa Díaz

Osteoarticular Surgery Translational Research**
Directors: Nuria Vilaboa Díaz
Enrique Gómez Barrena
Cellular Engineering
Director: María Paz de Miguel González
Clinical Pharmacology
Director: Antonio J. Carcas Sansuán
Translational Research in Maxillofacial Surgery and Head and Neck Cancer
Directors: José Luis Cebrián Carretero
Ana Sastre Perona
Research in Patient Safety and Quality
Director: Elena Ramírez García
Translational Research and Innovation in General and Digestive Surgery
Director: Constantino Fondevila Campo
Anesthesia-Resuscitation Maternity
Director: Isabel Valbuena Gómez
AI Health
Director: Juan José Beunza Nuin
Advanced Medical Informatics Laboratory (LIMA)
Director: Paloma Oliver Sáez

*** This group was formed in 2025 through the merger of the Osteoarticular Surgery Research – GICOA group and the Bone Pathophysiology and Biomaterials group.*

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Maternal Infant Child and Youth Research

Coordinators: Cristina Calvo Rey;
Antonio Pérez Martínez

Neonatology
Director: Adelina Pellicer Martínez
Molecular Hepatology
Director: Esteban Frauca Remacha
Maternal-Fetal Medicine
Director: José Luis Bartha Rasero
Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response
Director: Cristina Calvo Rey
Pediatric Systemic Infections; HIV, tuberculosis, Imported and Emergent Diseases
Director: Talía Sainz Costa
Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy
Director: Antonio Pérez Martínez
Congenital Malformations, Transplantation and Oncological Surgery
Director: Francisco Hernández Oliveros
Research in Endometriosis
Director: Alicia Hernández Gutiérrez
Research on Comprehensive Care for Transplanted Children and Adolescents
Directors: María Jesús Pascau González-Garzón
Luz Yadira Bravo Gallego
Food Oxidative Stress and Cardiovascular Health
Director: Silvia M. Arribas Rodríguez

Multidisciplinar Research In Healthy Aging

Coordinator: Rocio Menéndez Colino

Aging and Fragility In The Elderly
Director: Rocío Menéndez Colino
Frailty and Healthy Aging
Director: Leocadio Rodríguez Mañas
Frailty, Multimorbidity Patterns and Mortality in the Elderly Population Residing in the Community
Director: Miguel Ángel Salinero Fort



PUBLIC RESEARCH CONTRACTS

Ramón y Cajal Stabilisation Contracts (I3) - CM
Karen Elise Heath. *INGEMM - Institute of Medical and Molecular Genetics Group*
Jesús Mingorance Cruz. *Molecular Microbiology Group*
Rebeca Pérez de Diego. *Innate Immune Response Group*

Miguel Servet Stabilisation Contracts (I2) - ISCIII/ CM
Teresa Bellón Heredia. *Drug Hypersensibility and Innate Immune Response Group*
Juan Ángel Fresno Vara. *Translational Oncology Group*
Ángel Campos Barros. *INGEMM - Institute of Medical and Molecular Genetics Group*
María Paz de Miguel González. *Cellular Engineering Group*
Eduardo López-Collazo. *Innate Immune Response Group*
Berta Rodés Soldevila. *AIDS and Infectious Diseases Group*
Pilar Sánchez-Corral Gómez. *Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group*
María Rosa Torres Jiménez. *Metabolic-Vascular Unit Group*
David Vicent López. *Molecular Hepatology Group*
Nuria Vilaboa Díaz. *Bone Pathophysiology and Biomaterials Group*
Nora Viviana Butta Coll. *Coagulopathies and Alterations of Haemostasis Group*
María Inmaculada Ibáñez de Cáceres. *Experimental Therapies and Biomarkers in Cancer Group*
Rosa María Rodríguez Pérez. *Diagnosis and Treatment of Allergic Diseases Group*
Laura Saldaña Quero. *Bone Pathophysiology and Biomaterials Group*
María Fernández Velasco (CPII16/00047). *Innate Immune Response Group*
Carolina Cubillos Zapata (MS18/00208). *Respiratory Diseases Group*
María Dolores Gutiérrez Fernández. *Neurology and Cerebrovascular Diseases Group*
Ana Sastre Perona. *Translational Research in Maxillofacial Surgery and Head and Neck Cancer Group*
Carlos del Fresno Sánchez. *Innate Immune Response Group*

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Miguel Servet Contracts Type I - ISCIII
Elias Dahdouh (CP23/00036). *Molecular Microbiology Group*
Olga Vera Puente (CP24/00005). *Experimental Therapies and Biomarkers in Cancer Group*
Adriana Mañas Núñez (CP24/00030). *Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy Group*

Intensification Contracts – ISCIII
Talía Sainz Costa (INT24/00011). *Systemic Infections in Pediatrics: HIV, Tuberculosis, Imported Diseases, and Emerging Diseases Group*
María Alonso de Leciñana (INT24/00034). *Neurology and Cerebrovascular Diseases Group*
Enmanuela Spagnolo (INT24/00022). *Research in Endometriosis Group*
Francisco Javier Diaz de Terán (INT25/00068). *Neurology and Cerebrovascular Diseases Group*
Javier de Castro Carpeño (INT25/00091). *Experimental Therapies and Biomarkers in Cancer Group*

Río Hortega Contracts - ISCIII
Berta Sufrate Vergara (CM24/00016). *Associated Clinican*
Carlos Hervás Testal (CM24/00153). *Associated Clinican*
Alejandro de Gea Grela (CM24/00182). *AIDS and Infectious Diseases Group*
María del Mar Arcos Rueda (CM24/00234). *AIDS and Infectious Diseases Group*
Alfredo Maldonado Barrueco (CM24/00250). *Associated Clinican*
Alejandro Diez Vidal (CM25/00014). *AIDS and Infectious Diseases Group*
Sonia Milkova Ivanova (CM25/00017). *Associated Clinican*
Celia Permuy Romero (CM25/00070). *Associated Clinican*
Carlos R. *Gonzalez Pérez (CM25/00105). Associated Clinican*
Eduardo Mariño Trillo (CM25/00155). *Neurology and Cerebrovascular Diseases Group*
Juan Bautista Raffo Nogueira (CM25/00198). *Associated Clinican*
Carlos Delgado Miguel (CM25/00240). *Congenital Malformations and Transplantation Group*

Juan Rodés Contracts - ISCIII
Sara Ruiz Martínez (JR22/00019). *Maternal-Fetal Medicine Group*
Carlos Daniel Grasa Lozano (JR22/00044). *Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response Group*
Irene García García (JR22/00036). *Clinical Pharmacology Group*
Victor Galán Gómez (JR24/00003). *Associated Clinican*
Elisa Alonso López (JR24//00004). *Neurology and Cerebrovascular Diseases Group*
Paula Rodríguez Molino (JR24/00015). *Pediatric Systemic Infections; HIV, tuberculosis, Imported and Emergent Diseases Group*
Borja Rivero Santana (JR25/00012). *Associated Clinican*
Gonzalo Solis Garcia (JR25/00017). *Neonatology Group*

Sara Borrell Contracts - ISCIII
Clara Correa Paz (CD23/00005). *Neurology and Cerebrovascular Diseases Group*
Alba Tamargo García (CD24/00190). *Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response Group*
Roberto del Amparo Temporao (CD24/00191). *Pediatric Systemic Infections; HIV, tuberculosis, Imported and Emergent Diseases Group*
Alicia Villacampa Calvo (CD24/00217). *Vascular Physiology and Pharmacology Group*
Laura Hurtado Navarro (CD25/00102). *Innate Immune Response Group*

Predoctoral Fellowship - ISCIII
Andrea Guzmán de Antonio (FI22/00182). *Clinical Pharmacology Group*
María Paz López Molina (FI22/00009). *Neurology and Cerebrovascular Diseases Group*
Javier Pozo Novoa (FI22/00187). *Neurology and Cerebrovascular Diseases Group*
Lucía Gutiérrez Garcia (FI23/00061). *AIDS and Infectious Diseases Group*
Paula Pérez Moreno (FI23/00151). *Respiratory Diseases Group*
Ángela Calzado González (FI24/00043). *Neurology and Cerebrovascular Diseases Group*
Ana Belén Griso Acevedo (FI24/00184). *Translational Research in Maxillofacial Surgery and Head and Neck Cancer Group*
Octavia Santiesteban (FI25/00200). *Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy Group*
Sara Ruiz Buceta (FI25/00260). *Experimental Therapies and Biomarkers in Cancer Group*
Patricia Vizuete Cano (FI25/00034). *Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response Group*
Isabel Garcia Perez (FI25/00026). *Molecular Microbiology Group*

Predoctoral Contract – MINECO
Merdeces León López (PREP2023-001933). *Associated Clinician*

Technical Support Stabilisation Contracts - CM
Francisco Gayá Moreno. *AIDS and Infectious Diseases Group*
María Teresa Vallejo Cremades. *Congenital Malformation Surgery Group*
Eva Jaraba Redondo. *Associated Clinician*

Youth Guarantee Contracts - CM

Graduate
Daniel Brihuega Frontera (PEJ-2024-AI/SAL-GL-33116). *Associated Clinician*
Adriana Cuevas Domínguez (PEJ-2024-AI/SAL-GL-31793). *Associated Clinician*
Pamela Karime Heredia G Cantón (PEJ-2024-AI/SAL-GL-32542). *Associated Clinician*
Ruth Martín Martín (PEJ-2024-AI/SAL-GL-31793). *Associated Clinician*

Technical Support
Sara Rodríguez Díez (PEJ-2024-TL/SAL-GL-33182). *AIDS and Infectious Diseases Group*
Marina de Pablo Rodríguez (PEJ-2024-TL/SAL-GL-33168). *Associated Clinician*
Beatriz Horcajo Morera (PEJ-2024-TL/SAL-GL-31713). *Associated Clinician*
Alicia Román San Martín (PEJ-2024-TL/SAL-GL-32466). *Neurology and Cerebrovascular Diseases Group*

IdiPAZ Instituto de Investigación Hospital Universitario La Paz


1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

DATA: HUMAN RESOURCES

PROGRAMME	ORGANISATION	TOTAL
Ramón y Cajal Stabilisation Contracts (I3)	CM	3
Miguel Servet Stabilisation Contracts (I2)	ISCIII/ CM	19
Technical Support Stabilisation Contracts	CM	3
TOTAL ESTABLISHED		**25**
Miguel Servet Contracts CP Type 1	ISCIII	3
Intensification Contracts	ISCIII	5
Río Hortega Contracts	ISCIII	12
Juan Rodés Contracts	ISCIII	8
Sara Borrell Contract	ISCIII	5
Predoctoral Fellowship	ISCIII	11
Predoctoral Contract	MINECO	1
Youth Guarantee Contracts	CM	8
TOTAL PROGRAMMES		**53**
TOTAL ESTABLISHED + PROGRAMMES		**78**
UCICEC	CAIBER	4
FIS Projects	ISCIII	62
European Projects	EU	31
Research Network	ISCIII	14
Research Network	CM	4
SAF/MAT	MINECO	3
Biobank	ISCIII	2
Commercial clinical trials	ISCIII	7
Commercial clinical trials	EECC Promoters	60
Private projects	Pharmaceutical Industry	71
In-house Projects	FIBHULP	4
ITEMAS Network	ISCIII	3
TOTAL EMPLOYEES DEPENDET ON P.I.		**265**
TOTAL STAFF DEPENDENT ON P.I.		**343**
Technical Unit Staff	FIBHULP	39
TOTAL TECHNICAL UNIT		**39**
TOTALw		**382**

Researcher profile

The following graphs show the classification of IdiPAZ researchers according to the EURAXES regulations proposed by the European Union. In addition, in the following image we can see the evolution of this classification that has occurred in the last year.



1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.3. Training Report and Teaching

Some of the goals of IdiPAZ are to generate knowledge, to train specialists in the biomedical, to promote research and to transfer the knowledge not only to clinical practice but to the society too.

2.3.1. Doctoral Theses

17th November 2025: 7th PhDay IdiPAZ

This year, a new feature was introduced whereby three oral presentation were selected from among PhD candidates in the third and fourth years of thesis doctoral studies. The selected presenters were:

- Mari Paz López Molina
- Ana Belén Griso Acevedo
- David Albandea Rodríguez

Selecting the best poster presentation proved particularly challenging due to the outstanding quality of both the presentations and the research projects. The following awards were made:

- Best poster presentation (Years 1 – 2 of the PhD): **María Octavia de Santisteban y Javier García Rodríguez**
- Best poster presentation (Years 3 – 4 of the PhD): **Jenifer Araque García y Lucia Gutierrez García**

In 2025, 44 Doctoral Theses have been read and/or supervised by IdiPAZ researchers, and 3 of them was thesis with International Doctorate mention ★.



7ª Jornada PhDay

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Doctoral Student	Title	Directors	Defense Date	University
Alfaro García E	Mecanismos de la actividad física en el sistema inmune de los pacientes de enfermedad pulmonar obstructiva crónica (EPOC)	Cubillos Zapata C, García-Río F	**12/3/25**	**UAM**
Álvarez Troncoso J	Prevalencia y factores de riesgo de cardiopatía e hipertensión pulmonar en pacientes con lupus eritematoso sistémico	Ríos Blanco JJ	**10/3/25**	**UAM**
Busca Arenzana C	Evaluación de factores de riesgo y validación de marcadores no invasivos de esteatosis y fibrosis hepática en personas monoinfectadas por el Virus de la Inmunodeficiencia Humana en tratamiento antiretroviral estable	González García JJ, Montes Ramírez ML	**16/12/25**	**UAM**
Cabezudo Ballesteros S	Evaluación de un dispositivo de CPAP de Alto Flujo como estrategia de "Weaning" de ventilación mecánica prolongada en pediatría	Reinoso Barber F, Sanabria Carretero P	**7/3/25**	**UAM**
Carnicero Senabre D	Defining the role of transcription factor NRF2 in the maintenance of synaptic homeostasis	Rojo Sanchís AI	**4/7/25**	**UAM**
Casado Fernández L	Perfil proteómico de las vesículas extracelulares como biomarcadores de daño y reparación en la hemorragia cerebral	Alonso de Leciñana Cases M, Gutiérrez Fernández M	**14/10/25**	**UAM**
Casitas Mateos R	Evaluación de la repercusión funcional y morfológica a medio y largo plazo del síndrome de distrés respiratorio agudo grave secundario a Covid-19	Álvarez-Sala Walther R, García Río F	**24/2/25**	**UAM**
Cordero García-Galán E	Desinfección de implantes ortopédicos metálicos mediante calor generado por inducción electromagnética	Gomez Barrena E	**30/6/25**	**UAM**
de Ceano-Vivas La Calle M	Evaluación del desarrollo psicomotor en niños con infección del sistema nervioso central por enterovirus y parechovirus	Calvo Rey C, Garcia Garcia ML	**1/7/25**	**UAM**
del Pozo Herce P	Evaluación de conductas de riesgo asociadas a la práctica de Chemsex	Juárez-Vela R, Baca Garcia E	**12/5/25**	**UAM**
Díaz Suárez I	La imagen de las enfermeras y de la enfermería en la prensa española.	Hildegart Gonzalez L, Choperena A	**12/12/25**	**UPN**
Díez Sánchez B	Artroplastia de cabeza radial en fracturas con inestabilidad compleja aguda del codo. Estudio comparativo entre un diseño anatómico y un espaciador	Barco Laakso R, Antuña Antuña S	**17/2/25**	**UCM**
Escudero Ruiz FJ	Testado de eribulina y su combinación con otros fármacos en líneas celulares de sarcomas	Redondo Sánchez A	**17/6/25**	**UAM**
Fabré Estremera B ★	Role of Cardiac Biomarkers in Clinical Practice and Epidemiological Research	Buño Soto A	**20/11/2025**	**UAM**
Fernández Gómez P	Nanotecnología en el tratamiento y evaluación farmacológica en enfermedades neurodegenerativas.	Palomo Ruiz MV	**3/10/25**	**UCM**
Fernández-Fournier Fernández M	Valor de la presencia en vesículas extracelulares de anticuerpos frente al EBNA-1 y el VCA del virus de Epstein-Barr como biomarcadores en pacientes con esclerosis múltiple	Otero Ortega L, Díez Tejedor E	**6/3/25**	**UAM**
Fuentes Redondo T	Estudio anatomo-clínico de las malformaciones de la vena de galeno. Métodos diagnósticos y opciones terapéuticas	Navia Álvarez P	**19/10/25**	**UCM**

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Doctoral Student	Title	Directors	Defense Date	University
García Guede A	Estudio de MAFG como biomarcador en Cáncer de Pulmón No Microcítico: Causa y consecuencia en la regulación de factores implicados en cáncer	Vera Puente O	24/7/25	UAM
García Sánchez P	Tenencia de mascotas en niños inmunodeprimidos. evaluación de riesgos para la adquisición de zoonosis	Méndez Echevarría AM	3/2/25	UAM
Gómez Bris R ★	Sistema inmunitario y modulación celular específica de Lamina A/C como reguladores y biomarcadores en el desarrollo de tumores y la enfermedad inflamatoria intestinal	Gonzalez Granado JM, Arribas Rodriguez SM	22/4/25	UAM
González Bertolín I	Analítica sanguínea en la infección urinaria febril pediátrica	Calvo Rey C, López López R	31/1/25	UAM
González Moro A	Avances en estrategias terapéuticas para alteraciones vasculares asociadas al envejecimiento acelerado: diferencias entre sexos en el modelo SAMP8 y optimización de la encapsulación de senoterapéuticos en vesículas extracelulares de células madre	de la Cuesta Marina F	18/9/25	UAM
González Muñoz B	Rentabilidad de la ecografía clínica multi-órgano como complemento al proceso diagnóstico en una consulta de Medicina Interna	Tung Chen Y,Quesada Simón MA	8/7/25	UAM
Hernández Santillán GA	Prevalencia y factores asociados a síntomas depresivos en madres y padres en los seis primeros meses postparto y alteración del vínculo materno-infantil	Bravo Ortiz MF, Alcamí Pertejo M	18/7/25	UAM
Jiménez Villegas J	NRF2 at the intersection of redox imbalance and stress granule dynamics in amyotrophic lateral sclerosis	Rojo Sanchís AI	27/10/25	UAM
Lerma Juárez MA	Control espaciotemporal de la expresión transgénica mediante vectores adenovirales	Vilaboa Díaz N	23/1/25	UAM
Mestre Durán C	Las células natural killer en la leucemia pediátrica: mecanismos de inmunovigilancia y su papel en la eficacia del tratamiento en un haplo-hsct	Pérez Martínez A, Ferreras Puente C	30/7/25	UAM
Molina Baena MB	β-hydroxy-β-methylbutyrate in Frailty, Sarcopenia, and Sarcopenic Obesity	Rodríguez Mañas L	26/11/2026	UAM
Moraga Alapont P	Barreras y potenciales herramientas para facilitar el reclutamiento de sujetos en ensayos clínicos de fases tempranas	Borobia Pérez AM	19/9/25	UAM
Morales Rodríguez de Lope M	Estandarización de vesículas de origen vegetal: potencial de las nanovesículas como agentes terapéuticos y caracterización de marcadores de identidad en vesículas extracelulares	de la Cuesta Marina F	4/12/25	UAM
Palao Ocharan PE	Calidad de vida en angioedema hereditario por déficit de c1 inhibidor. estudio psicométrico del cuestionario genérico de calidad de vida relacionada con la salud (CVRS) SF-36 versión 2.0 (SF-36V2). Análisis de CVRS y estudio exploratorio de los determinantes de la CVRS mediante el cuestionario SF-36V2	Caballero Molina MT	5/5/25	UAM
Pastor Morete D	Identificación de las bases moleculares de la carcinomatosis peritoneal mediante técnicas ómicas. Papel del delta p73	Prieto Nieto MI	5/5/25	UAM
Ramírez Martín R	Impacto de la valoración geriátrica integral y la presencia de fragilidad en la decisión clínica y la evolución de pacientes mayores intervenidos de cáncer colorrecta	González Montalvo JI, Menéndez Colino R	4/3/25	UAM

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Doctoral Student	Title	Directors	Defense Date	University
Riera López N	Impacto de la pandemia COVID-19 en la atención del código ictus por el Servicio de Urgencias Médicas de Madrid (SUMMA 112). Aprendizaje para situaciones epidémicas similares.	Fuentes Gimeno B, Díez Tejedor E	**4/2/25**	**UAM**
Rigual Bobillo RJ	Continuación del tratamiento anticoagulante en la fase aguda del infarto cerebral con fuente cardioembólica mayor: Estudios RECOALA y COALA	Fuentes Gimeno B, Díez Tejedor E	**2/12/25**	**UAM**
Rivero Santana B	Inflamación y Remodelado Ventricular Adverso tras el Infarto Agudo de Miocardio: Papel del Inflamasoma NLRP3	Jurado Román A, Fernández Velasco M	**21/2/25**	**UAM**
Rol García MJ	Inlfuencia del dolor, ansiedad y depresión periparto en la atención obstétrica y lactancia materna	Bartha Rasero JL, Cuerva González MJ	**25/4/25**	**UAM**
Ruz Caracuel I	Identificación de factores pronósticos de recaída en carcinomas de endometrio de bajo grado en estadios iniciales mediante técnicas ómicas	Hardisson Hernáez D, Peláez García A	**18/6/25**	**UAM**
Shamoon L	SARS-CoV-2 S protein impact on endothelial cell senescence, cytoprotection exhaustion and vascular damage: a protective role of klotho and angiotensin-(1-7)	Peiró Vallejo C, Sánchez Ferrer CF	**28/2/25**	**UAM**
Silva Fernández CS ★	Factores psicosociales relacionados con la vulnerabilidad materna en la atención sanitaria del embarazo, parto y posparto	Garrosa Hernández E, Ramiro Cortijo D	**8/10/25**	**UAM**
Silva Llanes I	Nuevas estrategias terapéuticas para el tratamiento de la demencia frontotemporal	Lastres Becker I	**26/9/25**	**UAM**
Torres Iglesias G	Vesículas extracelulares sanguíneas como biomarcador diagnóstico y de respuesta al tratamiento en esclerosis múltiple	Puertas Muñoz I, Otero Ortega L	**3/6/25**	**UAM**
Torres Luna R	Eficacia de la hipnosis como técnica no farmacológica para el control del dolor en pacientes intervenido de cirugía ortopédica mayor	Sellán Soto MC	**28/4/25**	**UAM**
Valle Simón P	Evaluación de la factibilidad y beneficio de la implementación de un Comité de Medicina Personalizada en un Servicio de Hemato-Oncología Pediátrica en un hospital público de tercer nivel.	Borobia Pérez AM, Pérez Martínez A	**14/2/25**	**UAM**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.3.2. Master Theses

In 2025, 50 Master Theses have been read and/or supervised by IdiPAZ researchers

Student	Title	Director	University
Aldea Mas C	Abordaje urgente y emergente al paciente intoxicado por ácido γ-hidroxibutírico (GHB)	Ramiro Cortijo D	**UB+UAM**
Arroyo García C	Formación y concienciación para docentes sobre el trastorno por déficit de atención e hiperactividad	Mateo Martínez G	**UAM**
Ascunce Abad M	Estatus distónico en pediatría: revisión sistemática	Climent Alcalá FJ	**UNIR**
Ayala Jiménez E	Terapias personalizadas de células NK adoptivas en sarcomas pediátricos	Bareke H	**UCM**
Blázquez Valero A	Impacto de la pérdida de STAG2 en la interacción entre células de sarcoma de Ewing y células NK	Bareke H	**Universidad San Pablo CEU**
Bravo Queipo de Llano B	Profilaxis post-exposición frente al VIH en niños y adolescentes	Sainz Costa T	**URJC**
Bruno M	Implementation of improvement strategies in a personalized medicine committee in pediatric oncology	Borobia Pérez AM	**UAM**
Coccolo Góngora A	Dificultades en el uso de medicación en pacientes pediátricos con patología crónica y complejidad. Revisión y propuesta de guía clínica.	Climent Alcalá FJ	**UNIR**
Curiel L	Design and Implementation of an Artificial Intelligence System for the Automatic Estimation of the Comprehensive Complication Index (CCI) in Hospital Discharge Reports	Fondevila Campo C	**UPM**
de Gea Grla A	Tendencias, indicaciones y seguimiento en los contactos sexuales de riesgo que requieren profilaxis post-exposición frente al VIH en jóvenes	Sainz Costa T	**URJC**
del Valle de León N	Análisis retrospectivo en el proyecto multicéntrico CarbaPED-1. Bacteriemias por bacilos Gram-negativos con resistencia adquirida a carbapenémicos en pediatría. Características clínicas, microbiológicas y factores predictores de mortalidad	Grasa Lozano C, Escosa L	**UCM**
Díaz Huertas S	Antidiabetic drugs as regulators of the NLRP3 inflammasome and protectors of the vascular system	Peiró Vallejo C, Sánchez Ferrer CF	**UAM**
Díaz López C	Impacto del síndrome de abstinencia iatrogénico infantil en las experiencias de las madres	Vázquez Sellán A	**UAM**
Escamilla S	SIDLE, una aproximación a caracterizar la microbiota de muestras parafinadas (FFPE)	Gámez Pozo A	**Universidad Francisco de Vitoria**
Etxebarria Cortes R	Entender las vivencias de las enfermeras en la limitación del esfuerzo terapéutico en la uci quirúrgica de la FJD	Sellán Soto MC	**UAM**
Fernández Cañizares M	Exposure to Sustained and Intermittent Hypoxia mimicking Chronic Obstructive Respiratory Disorders: effects on Brown Adipose Tissue	del Peso Ovalle L	**UAM**
Fernández Escudero D	Use of 3D printing to support clinical information for patients with incidental cerebral aneurysms and its impacto n perceived quality of life.	Borjas Gómez JT, Sánchez González P, Fuentes Gimeno B	**UPM**
García A	Desarrollo de nanosensores para enfermedades neurodegenerativas	Palomo Ruiz MV	**UCM**
García Saavedra S	El rol de la enfermería en la recuperación de pacientes con trastorno por consumo de alcohol	Mateo Martínez G	**UAM**
González Reina S	Del cuerpo alegórico al rostro clínico. Una hermenéutica de los cuidados enfermeros en salud mental desde el Bosco hasta Géricault	Mateo Martínez G	**UAM**
Guadrón Meléndez A	Exploring potential metabolomic biomarkers in pediatric renal transplant patients treated with tacrolimus	Carcas Sansuán AJ	**UAM**
Gutiérrez Cañas N	Análisis del impacto de un programa de mindfulness en la omisión de cuidados de enfermería en Unidades de Cuidados Intensivos: estudio de intervención aleatorizado por conglomerados	Ramiro Cortijo D	**UB+UAM**
Heredia G Cantón PM	Desarrollo e implementación de un Beacon Fhir para la interoperabilidad y el acceso seguro a la información genética procedente de estudios de secuenciación masiva.	Rodriguez Antolin C	**UAM**
Hernández García S	Mejorar el afrontamiento y la salud mental de los estudiantes de enfermería	Mateo Martínez G	**UAM**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Student	Title	Director	University
Hernández Matellano S	Programa de educación para la salud a padres/madres/tutores de adolescentes con anorexia nerviosa tras su primer ingreso en unidad de hospitalización breve	Mateo Martínez G	**UAM**
Huachin Gonzales SM	Percepción de los padres cuyos hijos con enfermedades raras participan en ensayos clínicos	Mateo Martínez G	**UAM**
Jiménez Baena E	Seguimiento clínico de pacientes con cardiopatía isquémica sometidos a nueva angioplastia	Dalmau González-Gallarza R	**UCAM**
López de Coca Hernández A	Características clínicas, enfoques terapéuticos y factores pronósticos de la candidemia de origen urinario: estudio de cohorte retrospectivo.	Díaz Pollán B,	**UAH**
Lumbreras García C	Evaluación del papel de MAFG y sus genes diana en la progresión del melanoma cutáneo	Vera Puente O	**UAM**
Marcos Blasco A, Fierro Castillo C	Satisfacción familiar con un Programa de Acogida de pacientes pediátricos en espera de trasplante de órgano sólido.	Pascau González-Garzón MJ, Martínez Campos P	**UAM**
Mariscal de Blas I	Optimizando la práctica segura en el transporte intrahospitalario del paciente crítico. Revisión sistemática exploratoria	Díaz Martínez ML	**UAM**
Martínez Castillo L	Experiencia de los padres y madres en el proceso de trasplante cardiaco ABO incompatible	Sellán Soto MC	**UAM**
Martínez Dorado E	Método madre canguro y su influencia en el desarrollo cerebral de los neonatos prematuros extremos	Vázquez Sellán A	**UAM**
Martínez Gómez M	Estrategias más eficaces en la prevención del delirium en el paciente adulto en cuidados intensivos. Una revisión de alcance	Díaz Martínez ML	**UAM**
Mayor Díaz A	Estudio prospectivo sobre la adherencia a la terapia compresiva con medias de compresión en pacientes con insuficiencia venosa crónica en nuestro centro	Fernández-Heredero A	**UE**
McConnachie E	Un estudio exploratorio de las necesidades y expectativas de las partes interesadas con respecto a la participación de los legos en la investigación biomédica	Borobia Pérez AM	**UAM**
Mihaila G	Análisis del efecto de la hipertensión arterial sobre el proceso neurodegenerativo en un modelo murino de la enfermedad de Parkinson	Lastres Becker I	**UAM**
Mora Rodríguez M	Pharmacogenetics in statin therapy: Interim descriptive analysis from the PREVESTATGx trial	Borobia Pérez AM	**UAM**
Morán Benito Y	Factores determinantes de la calidad de vida del paciente del paciente con ELA en el contexto de cuidado humanizado: de la evidencia a la experiencia	Mateo Martínez G	**UCAV**
Peñafiel González L	Evaluación longitudinal de biomarcadores de envejecimiento biológico en personas con infección por VIH	Rodés Soldevila B, Esteban Cantos A	**UAM**
Pérez Calero B	Estudios preclínicos de colágeno impreso en 3D en condiciones GMP en el tratamiento del melting corneal	de Miguel González MP	**Universidad CEU San Pablo**
Rodrigo Castro A	Estudio transversal de especificidades no HLA y autoanticuerpos en pacientes pediátricos trasplantados	Sánchez Zapardiel E, Nozal Aranda P	**UCM**
Ruiz Buceta S	Caracterización de los cambios no genéticos en el desarrollo y progresión del melanoma.	Vera Puente O	**UCM**
Sánchez L	Combination strategies to enhance the efficacy of Natural Killer cell therapy in neuroblastoma	Mañas Núñez A	**UAM**
Sánchez Lara C	Optimización de la detección de CNVS en paneles y exomas mediante secuenciación masiva: implementación y validación clínica	Rodriguez Antolin C	**UAM**
Segovia Herreras D	Evaluación de los pacientes de Cardiología bajo tratamiento con iPSCK9 en la isla de Lanzarote	Dalmau González-Gallarza R	**UCAM**
Smith Gallego C	Terapia combinada en sarcomas pediátricos: células NK de memoria y regorafenib como estrategia inmunoterapéutica	Bareke H	Universidad San Pablo CEU
Suárez Fonseca J	Analysis of the pyroptosis process in Amyotrophic Lateral Sclerosis: comparative study between a murine model and patient samples	Lastres Becker I	UAM
Tapia Narváez JC	The role of microRNAs in the regulation of immune tolerance and autoimmunity	González Martín A	UAM
Vivar García I	Mechanisms of vascular smooth muscle protection by anakinra and the anti-diabetic drug canagliflozin	Peiró Vallejo C, Villacampa Calvo A	UAM

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.3.3. Final Degree Theses

In 2025, 58 Final Degree Theses have been read and/or supervised by IdiPAZ researchers

Student	Title	Director	University
Acuña Butta P	Estudio clínico y de laboratorio en el tratamiento de la hemofilia con terapias no sustitutivas	Álvarez Román MT, Jiménez Yuste V	**UAM**
Alonso Medela I	Factores relacionados con la toma de decisiones en la elección de tratamiento en pacientes añosos con enfermedad renal crónica avanzada (ERCA)	del Peso Gilsanz G	**UAM**
Arés Ballesteros S	Trastornos neurológicos inmunomediados asociados a la vacunación frente a COVID-19	Frank García A, Lacruz Ballester L	**UAM**
Arroyo Muñoz A	Development of a genetic diagnosis methodology for a Hereditary Angioedema variant due to Carboxypeptidase N deficiency and patient screening	López Lera A	**UAM**
Burrel Bernal M	Personalización de videos con inteligencia artificial generativa como apoyo a a la rehabilitación del lenguaje en personas con afasia.	Larraga García B, Fuentes Giemeno B	**UPM**
Bustillo Gómez S	Experiencia y percepción de la enfermera en los cuidados de fin de vida pediátricos	Díaz Martínez ML	**UAM**
Bustillo Gómez S	Experiencia y percepción de la enfermera en los cuidados de fin de vida pediátricos	Díaz Martínez ML	**UAM**
Cadenas Garcia C	Ejercicio físico en cuidadores principales de pacientes con demencia. Revisiones sistemática.	Piqueras Rodríguez P	**UAX**
Calderón Sacristán R	Caracterización funcional de miRNAs y sus genes diana en inmunidad antitumoral	González Martín A	**UAM**
Castro Sánchez-Clemente S	Análisis de mutaciones en KMT2D en pacientes con cáncer de vejiga y su repercusión en inmunoterapia.	Novillo Villajos A	**UCM**
Cobo Martínez L	Papel de la enfermera en la depresion posparto durante el puerperio tardia	Araque García J	**UAM**
Cózar López R	Identificación de globulinas en bellota de Quercus ilex como fuente de alergias.	Rodríguez Pérez MR	**Universidad de Córdoba**
del Pozo López C	Fomento de la alimentación y el deporte en la infancia para la reducción de problemas cardiometabólicos en niños/as prematuros durante su etapa adulta	Arribas Rodríguez SM	**UAM**
Domínguez Ruiz S	Optimización de la bioimpresión 3D de colágeno tipo I bajo el cumplimiento de Buenas Prácticas de Fabricación para la regeneración de la córnea	de Miguel González MP	**URJC**
Esteban de Nicolás N	Diseño e implementación de un sistema de generación de videos para la rehabilitación de pacientes con afasia mediante el uso de inteligencia artificial generativa	Gutiérrez Martín A, Fuentes Gimeno B	**UPM**
Fernández Fernández M	Estudio de la inducción de MAFG por radiación ultravioleta como evento iniciador en la transformación melanocítica	Vera Puente O	**Universidad Francisco de Vitoria**
Galeano Pablo A	Torquetenovirus como predictor de respuesta inmune a vacuna en pacientes pediátricos inmunodeprimidos: Optimización de muestras y técnicas.	Sainz Costa T, Sánchez Aparicio MT	**UAH**
García Hernández D	Efecto de distintas suplementaciones nutricionales con hidrolizados proteicos sobre la sarcopenia asociada al envejecimiento	Blanco Rivero J	**UAM**
Giménez-Muñoz C	Development of a system for automatic clinical coding from hospital discharge reports	Tung Chen Y,	**UAM**
Giraldo Jaldo C	Aprovechamiento del suero lácteo en la industria alimentaria y farmacéutica: Impacto Medioambiental y Económico	Aguilera Gutiérrez Y	**UAM**
Giribaldi F	Implication of ΔNp73 oncogene and its effector targets in the response to neoadjuvant therapy in patients with locally advanced colorectal cancer	Domínguez Muñoz G	**UAM**
Gómez Castro P	Cuidados de enfermería para la prevención de la hemorragia intraventricular en neonatos prematuros	Vázquez Sellán A	**UAM**
Gómez de la Morena R	Electroquimioterapia.Experiencia en el tratmaiento de tumores cutáneos primarioa y secundarios en el Hospital La Paz	Prieto Nieto MI	**UAM**
Heredia García M	Impacto emocional materno tras el ingreso urgente de su hijo en la unidad de hospitalización neonatal para el tratamiento de la ictericia	Vázquez Sellán A	**UAM**
Latorre Soler J	Abordaje fármaco-nutricional de la obesidad y diabetes tipo ii y empleo de semaglutida	de la Cuesta Marina F	**UAM**
Lominchar J	Infecciones de transmision sexual tras agresiones sexuales en adolescentes	Sainz Costa T	**UAM**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Student	Title	Director	University
Lopez Jarrín M	Screening de patologia importada en candidatos a inmunosupresión en pediatría	Sainz Costa T	**UAM**
López Jorrín M	Cribado de infecciones importadas en el paciente pediátrico que va a recibir inmunosupresión	del Rosal Rabes T, Sainz Costa T	**UAM**
Madroñal B	Preclinical research no CAR T-Cell therapy for pediatric leukemias	Minguillón J	**Universidad San Pablo CEU**
Marcos Fuentes D	Inmunogenicidad de la vacuna nonvalente frente al VPH en niños y adolescentes inmunocomprometidos	Sainz Costa T	**UAH**
Martínez González M	Intervenciones enfermeras en los cuidadores principales de pacientes con Alzheimer	Piqueras Rodríguez P	**UAX**
Matesanz A	Estrategias de mejora de la terapia CAR T NKG2D en tumores cerebrales pediátricos	Clares L	**UAH**
Menchén Jareño A	Eficacia del método madre canguro en la recuperación de los prematuros extremos	Vázquez Sellán A	**UAM**
Miranda Amar T	Papel de la enfermera en el abordaje de la desnutricion del paciente ingresado	Calso Gonzalez M	**UAM**
Moreno Gómez M	Impacto psicosocial de la donación de leche en familas víctimas de duelo perinatal	Araque García J	**UAM**
Navarro Alfaro E	Diseño e implementación de una plataforma automatizada para la evaluación cinemática del déficit motor de las manos en pacientes con enfermedades neurológicas	Ruiz Vitte A, de Leciñana Cases MA	**UPM**
Navarro Hernández P	Revisión sobre el impacto de los cuidados de enfermería en los cuidados paliativos	Piqueras Rodríguez P	**UAX**
Ochoa Grille I	Cáncer de endometrio: clasificación molecular y estratificación de riesgo	Hardisson Hernáez D	**UAM**
Ortega Carro M	Resultados de la profilaxis en la Enfermedad de von Willebrand	Álvarez Román MT, Jiménez Yuste V	**UAM**
Ortiz del Amo M	Investigando la función inmunomoduladora de podoplanina en la inflamación cutánea	Matin Villar E	**UFV**
Pineda Morales DN	Nutricosmética Sostenible: Aprovechamiento de Subproductos del Café y Cacao para la Salud y la Estética	Aguilera Gutiérrez Y	**UAM**
Ponceliz K	Instauración de un protocolo de estimulación de asa eferente previo a cierre de ileostomía en el Hospital Universitario La Paz	Rubio Pérez I	**UAM**
Ramos López M	Identificación de biomarcadores farmacogenéticos predictivos de toxicidad a tratamiento en cáncer de colon.	Rosas Alonso R	**Universidad Francisco de Vitoria**
Rey Hernández M	Impacto de la endometriosis sobre la supervivencia en mujeres con cancer de ovario asociado	Spagnolo E	**Universidad San Pablo CEU**
Ríos Ciriero A	Abordaje enfermero en neonatos con hidrocefalia: principales intervenciones y manejo de sistemas de derivación	Vázquez Sellán A	**UAM**
Salinas Lujan A	Identificación y frecuencia de reconocimiento IgE mediado de los alérgenos del polen de Quercus ilex en pacientes sensibilizados	Rodríguez Pérez MR	**UAH**
San Martín A	Identification of response biomarkers to neoadjuvant treatment in patients with locally advanced rectal cancer	Domínguez Muñoz G	**UAM**
Sánchez del Álamo B	Inflamasoma nlrp3 en pérdida auditiva: exploración de su potencial terapéutico en modelos in vitro.	Murillo Cuesta S	**UAM**
Sánchez Peña C	Papel de la ruta HIF/BHLHE40 en la homeostasis metabólica y adaptación a hipoxia	del Peso Ovalle L	**UAM**
Segira Galeote C	Cuidar al que cuida, ejercicio físico como actividad enfermera para los cuidadores principales de pacientes con demencia	Piqueras Rodríguez P	**UAX**
Serrada Acebes B	Fenotipo clínico y respuesta a agonistas de receptores de trombopoyetina en pacientes ancianos con trombocitopenia inmune	Álvarez Román MT, Jiménez Yuste V	**UAM**
Simón Zuquin PS	Del gen al tratamiento: explorando el rol de las mutaciones en PBRM1 y su impacto en la inmunoterapia del carcinoma renal.	Novillo Villajos A	**UCM**
Suanzes C	Estrategias para mejorar la infiltración de la terapia con células NK en modelos de organoides de neuroblastoma	Mañas Núñez A	**Universidad San Pablo CEU**
Suarez Vega M	Impacto de la nutrición en la evaluación clínica y en el perfil analitico de las pacientes con endometriosis	Hernández Gutiérrez A, Spagnolo E	**UAM**
Teresa León Alonso L	Evaluación de PMI y Omaveloxolona como moduladores de NRF2 en un modelo celular de α-SINUCLEÍNA para la enfermedad de Parkinson.	Lastres Becker I	**UAM**
Trejo Bragulat A	Efecto de una infusión de pulpa de café sobre la inflamación producida por el ejercicio físico en población sana no entrenada	Ramiro Cortijo D, Arribas Rodríguez SM	**UAM**
Tuca M	Interpretación de las alteraciones en el electrocardiograma del paciente adulto con infarto agudo de miocardio: una revisión narrativa.	Blanco Rivero J	**UAM**
Vega Domínguez J	Optimización de un sistema de rehabilitación audiovisual para pacientes con afasia usando inteligencia artificial generativa.	Larraga García B, Fuentes Gimeno B	**UPM**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.3.4. Training Plan

The Training Committee established a Training Plan, which specifies the training strategy for the institute´s human resources and covers the research training needs of their members. Annually it´s developed the training offer with several proposals to make up the plan. Also, it's developed a residents training program have been started for residents doctors of the University Hospital La PAZ.

The own training offer is mainly based on a series of transversal courses in research methodology and courses related of the different lines of research.

The plan included several activities such as conferences, scientific seminars and other activities linked to these areas.

In addition, The Training Committee established a Residents training program for residents of the University Hospital La Paz.

Members:

President:
Paloma Gómez Campelo.

Secretary:
Mercedes Ruiz Balibrea

HULP representative:
Ana Martínez Virto
Beatriz Castelo. *Cancer and Human Molecuar Area*
Ane Miren Andrés Moreno. *Maternal-Child and Adolescent Area*

FIBHULP representative:
Aitana López Redondo
Ana María Martín de la Flor
María Teresa García Morales
María Gutiérrez Fernández. *Neuroscience Area*
María Fernández Velasco. *Cardiovascular Area*
Ana Sastre Perona. *Surgery. Transplants and Health Area*

UAM representative:
Ana García Redondo

Employee's representative:
Pilar Sánchez-Corral Gómez. *Infectious Diseases and Immunity Area*
F.G.G



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.3.4.1. Training Program

Habilidades de liderazgo y coordinación de equipos de trabajo
Coordinator: Mercedes Ruiz Balibrea

Gestión del estrés: Mindfulness
Coordinator: Aitana López / Ana María Martín

Igualdad de género y diversidad en el ámbito de I+D+i
Coordinator: Aitana López / Ana María Martín

Diseño y gestión de bases de datos: REDCap - Protección de datos y procesos de anonimización
Coordinator: Mª Teresa García Morales

Cómo pasar de SPSS a R: análisis de datos
Coordinator: Mª Teresa García Morales

Bioinformática en las técnicas ómicas
Coordinators: Ana Sastre / María Gutiérrez

Inteligencia artificial y Big data
Coordinators: Ana García/ Paloma Gómez Campelo



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.3.4.2 Scientific Seminars

IdiPAZ Scientific Seminars program welcomes renowned researchers and clinical investigators to our Institute to share, discuss and debate latest insights, discovery and next directions in oncology with our students, postdocs and senior faculty from our research groups.

Scientific Moderator:

- Ana Sastre Perona

Research Area	Date	Speaker	Researcher Centre	Seminar title
 CANCER AND HUMAN MOLECULAR GENETICS AREA	2/21/25	Olga Vera	IdiPAZ	**MAFG is a novel oncogene in melanoma with therapeutic potential**
 NEUROSCIENCES AREA	2/28/25	María Jesús Bullido Gómez de las Heras	CBM	**Papel del Virus del Herpes Simple en la Patogénesis de la Enfermedad de Alzheimer.**
 CARDIOVASCULAR AREA	3/21/25	Almudena Val Blasco	IdiPAZ	**Nucleotidebinding oligomerization domain type I a new player in heart failure**
 INFECTIOUS DISEASES AND IMMUNITY AREA	3/28/25	Paulino Gómez-Puertas	CBM	**Simulación dinámica de macromoléculas. Su aplicación en el diseño de fármacos antibacterianos y antivirales y en el estudio de enfermedades raras**
 INFECTIOUS DISEASES AND IMMUNITY AREA	4/11/25	Fernando Corrales	CNB	**Proteómica: un conjunto de herramientas para comprender la biología y las enfermedades del hígado**
 MATERNAL INFANT CHILD AND YOUTH RESEARCH AREA	4/25/25	Adriana Mañas	IdiPAZ	**iroNKiller – Joining the forces of ferroptosis and natural killer cells to treat neuroblastoma**
 INFECTIOUS DISEASES AND IMMUNITY AREA	5/30/25	Arantxa Cruz	UCM	**Metabolic Control of ILC3 Function by HIF1α and Its Implications in colitis associated colorectal Cancer.**

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Research Area	Date	Speaker	Researcher Centre	Seminar title
 CANCER AND HUMAN MOLECULAR GENETICS AREA	6/13/25	Javier Redondo	CIB	**Cambios nucleares como reguladores de la migración e invasión de células de leucemia aguda**
 INFECTIOUS DISEASES AND IMMUNITY AREA	6/27/25	Laura Fernández Parrondo	ThermoFisher	**Diseño de paneles de citometría de flujo: consejos, soporte y herramientas**
 SURGERY, TRANSPLANTS AND HEALTH TECHNOLOGIES	11/7/25	Danial Roshandel	UWA Medical School	**OfftheShelf Stem Cells: A New Dawn for Corneal Blindness?**
 MATERNAL INFANT CHILD AND YOUTH RESEARCH AREA	12/12/25	Jordi Minguillón	IdiPAZ	**Clinical and translational research on CAR Tcell therapy for pediatric cancer**

2.3.4.3. Scientific Clinical Sessions-Hospital Universitario La Paz

Date	Service	Title	Speakers
08/01/2025	Microbiology	Papel de la secuenciación masiva en el conocimiento de la dinámica de las enfermedades transmisibles en el hospital	**Speakers:** Jesús Mingorance (IdiPAZ), Fernando Lázaro (Microbiology), Ivan Bloise (Microbiology) **Moderator**: Jesús Mingorance (IdiPAZ)
15/01/2025	Rheumatology Clinical Analyses Nephrology	Enfermedad metabólica ósea y Fgf23: una visión interdisciplinar	**Speakers:** Pilar Aguado (Rheumatology), Carolina Tornero (Rheumatology), Sara García Carazo (Rheumatology), María Luisa González Casaus (Clinical Analyses), Carlos Jiménez (Nephrology) **Moderator**: Eugenio de Miguel (Rheumatology)
22/01/2025	General Surgery Obstetrics and Gynecology Thoracic Surgery Nursing Urology	Implementación del programa de cirugía robótica Da Vinci en el HULP	**Speakers**: Amelia Hessheimer (General Surgery), Jaime Siegrist (Obstetrics and Gynecology), Asier Leivar (Urology), Alfredo Aguilera (Urology), Laura Rey Olivas (Nursing) **Moderators**: Constantino Fondevila (General Surgery), José Luis Gil (Thoracic Surgery), Alicia Hernández (Obstetrics and Gynecology), Luis Martínez Piñeiro (Urology)
29/01/2025	Cardiology Pathology	Varón de 51 años que ingresa en asistolia, con hermano fallecido por muerte súbita	**Speakers**: Juan Caro Codón (Cardiology), Víctor Macarrón Aguilera (Pathology) **Moderators**: Raúl Moreno (Cardiology), Alberto Berjón (Pathology)
05/02/2025	Nursing	Proyecto Nursing Research Challenge: avances en investigación enfermera para optimizar el cuidado	**Speakers**: Tamara Domingo (Nursing), Jesús Castro (Nursing), María Torres (Nursing), Esther Sánchez (Nursing) **Moderator**: Esther Rey Cuevas (Nursing)

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Date	Service	Title	Speakers
06/02/2025	Clinical Pharmacology Preventive Medicine Management Patient Safety	Incidentes y eventos adversos en el hospital: ESINEA 2023	**Speakers**: Elena Ramírez (Clinical Pharmacology), Fiorela Dueñas (Clinical Pharmacology), Yuri Villán (Preventive Medicine) **Moderators**: Javier Cobas (Management), Angélica Rivera (Patient Safety)
12/02/2025	Pulmonology Thoracic Surgery Anesthesia and Resuscitation	Actualización en broncoscopia	**Speakers**: Sergio Alcolea (Pulmonology), María Hidalgo (Pulmonology), Sandra Pardo (Thoracic Surgery), Julia Álvarez del Vayo (Anesthesia and Resuscitation) **Moderators**: Rodolfo Álvarez-Sala (Pulmonology), José Luis Gil (Thoracic Surgery), María Carmen Hernández Gancedo (Anesthesia and Resuscitation)
19/02/2025	Radiophysics and Radiation Protection Occupational Safety and Health Radiation Oncology Nuclear Medicine	Radiación y embarazadas: actualización en protección radiológica para pacientes y trabajadores	**Speakers**: Moisés Sáez (Radiophysics and Radiation Protection), Juan González de Abreu (Occupational Safety and Health), Domenico Monachello (Nuclear Medicine), Raúl Sánchez (Radiophysics and Radiation Protection), Ana Castaño (Radiation Oncology), Pablo Galiano (Radiophysics and Radiation Protection), David García Riñón (Radiophysics and Radiation Protection) **Moderator**: Moisés Sáez (Radiophysics and Radiation Protection)
26/02/2025	Intensive Care Medicine Pathology	Varón de 47 años, con reinfección por SARS-COV-2 y neumonía multilobar	**Speakers**: Pablo Millán Estañ (Intensive Care Medicine), Guillermo Escuer Albero (Pathology) **Moderators**: José Manuel Añón (Intensive Care Medicine), Alberto Berjón (Pathology)
05/03/2025	Emergency Geriatrics	Urgencia del paciente mayor institucionalizado (UPAMI)	**Guest Speakers:** Rosa Capilla (Puerta de Hierro Majadahonda), Rocío Menéndez (Geriatrics), María Auxiliadora González (Emergency), Begoña Reche (Emergency) **Moderator**: Alberto Iglesias Sigüenza (Emergency)
12/03/2025	Pediatric Intensive Care Pediatric Rheumatology Pediatric Hematology-Oncology Pediatrics	Dermatomiositis con afectación pulmonar rápidamente progresiva, soporte con ECMO, y primer CAR-T pediátrico en patología autoinmune	**Speakers**: Cristina Verdú (Pediatric Intensive Care), Rosa Alcobendas (Pediatric Rheumatology), Isabel Martínez (Pediatric Hematology-Oncology) **Moderators**: Berta González (Pediatric Hematology-Oncology), Francisco Climent (Pediatrics)
19/03/2025	Neurology Internal Medicine Pathology	Varón de 70 años, con encefalitis y antecedentes de linfoma NH estadio IV	**Speakers**: Laura Lacruz (Neurology), Beatriz Díaz Pollán (Internal Medicine), María Peredes Petrino (Pathology) **Moderators**: Ana Frank (Neurology), Alberto Berjón (Pathology)
26/03/2025	Patient Safety Anesthesia and Resuscitation Management Legal Counsel Quality	Cirugía segura: pequeñas acciones, grandes resultados	**Speakers**: Angélica Rivera (Patient Safety), Francisco Cruz (Pilot, SEPLA), María Carmen Hernández Gancedo (Anesthesia and Resuscitation), Natalia Hormaeche (Legal Counsel) **Moderators**: Javier Cobas (Management), Bárbara Martínez de Miguel (Quality)
02/04/2025	Pediatric Surgery Vascular Surgery Cardiology Internal Medicine Intensive Care Medicine	Tromboembolia pulmonar grave intraoperatoria	**Speakers**: Juan Carlos López Gutierrez (Pediatric Surgery), Elena Marín (Vascular Surgery), Emilio Arbas (Cardiology), Daniel Tébar (Cardiology), Alicia Lorenzo (Internal Medicine) **Moderators**: Raúl Moreno (Cardiology), José Manuel Añón (Intensive Care Medicine)
03/04/2025	Preventive Medicine Deputy Medical Director	Infecciones asociadas a la asistencia sanitaria en el HULP 2024	**Speakers**: Luisa Serpa (Preventive Medicine), Almudena Quintas (Preventive Medicine), Lucía Hernández (Preventive Medicine) **Moderators**: Marta Moro (Deputy Medical Director), Verónica Pérez (Preventive Medicine)
09/04/2025	Obstetrics and Gynecology Neonatology Pediatrics	Manejo multidisciplinar de la infección congénita por CMV	**Speakers**: María de la Calle (Obstetrics and Gynecology), Eugenia Antolín (Obstetrics and Gynecology), Marta Ybarra (Neonatology), Fernando Baquero (Pediatrics) **Moderators**: José Luis Bartha (Obstetrics and Gynecology), María de la Calle (Obstetrics and Gynecology)

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Date	Service	Title	Speakers
23/04/2025	Pathology Pediatric Hematology-Oncology	Varón de 21 años, trasplante de progenitores de medula hematopoyética, infiltrados pulmonares y fracaso multiorgánico	**Speakers**: Luisa Sisinni (Pediatric Hematology-Oncology), Eva Sánchez (Pathology) **Moderators**: David Bueno (Pediatric Hematology-Oncology), Carmen González García (Pathology)
30/04/2025	Allergology Pulmonology Internal Medicine Rheumatology	Manejo multidisciplinar de la GEPA (granulomatosis eosinofílica con poliangeitis)	**Speakers**: Javier Domínguez Ortega (Allergology), Daniel Laorden (Pulmonology), Ana Noblejas (Internal Medicine), Gema Bonilla (Rheumatology) **Moderators**: Santiago Quirce (Allergology), Eugenio de Miguel (Rheumatology)
07/05/2025	Gynecology and Obstetrics Rehabilitation Plastic Surgery Physical Therapy	Manejo interdisciplinar del linfedema	**Speakers**: Elisa Moreno (Gynecology and Obstetrics), Florencio Jiménez (Rehabilitation), Luis Landín (Plastic Surgery), María González Fernandez (Physical Therapy) **Moderator**: Francisco Leyva (Plastic Surgery)
14/05/2025	Cardiology Pathology	Varón de 34 años con miocardiopatía hipertrófica obstructiva e insuficiencia respiratoria	**Speakers**: Eduardo Armada (Cardiology), Vivian Díaz Castro (Pathology) **Moderators**: Raúl Moreno (Cardiology), Carmen González García (Pathology)
21/05/2025	Immunology INGEMM Pediatric Hepatology Pediatric Surgery Management Medical Director	Internacionalización a través de las redes europeas de referencia	**Speakers**: Yadira Bravo (Immunology), Karen Heath (IGENMM), Esteban Frauca (Pediatric Hepatology), Leopoldo Martínez (Pediatric Surgery) **Moderator**: Javier Cobas (Management), Susana Noval (Medical Director)
28/05/2025	Psychiatry	Hospital de día en salud mental: atención intensiva, recuperación activa	**Speakers**: Ainoa Muñoz Sanjose (Psychiatry), Rubén Navarro (Psychiatry), Diana Hernando (Psychiatry), María Escamilla (Psychiatry) **Moderator**: Carmen Bayón (Psychiatry)
04/06/2025	Experimental Surgery Pediatric Surgery Plastic Surgery	Formación e investigación. Cirugía experimental, un modelo al lado de los humanos	Speakers: Carlota Largo Aramburu (Experimental Surgery), Javier Serradilla (Pediatric Surgery), Jorge Bonastre Juliá (Plastic Surgery) **Moderator**: Carlota Largo (Experimental Surgery)
05/06/2025	Computer Science Digital Strategy Management Subdivision Management	PROMS y PREMS en la práctica clínica de nuestro hospital	**Speakers:** Celia Martin (Computer Science), Rosario Torres (Digital Strategy Management Subdivision), Fernando Martin (Digital Strategy Management Subdivision) **Moderator**: Fernando Martín (Management)
11/06/2025	Medical Oncology Pathology	Varón con 62 años con prótesis esofágica por carcinoma de esófago y parada cardiorrespiratoria	**Speakers**: Ana Custodio Carretero (Medical Oncology), Gabriel López Arze (Pathology) **Moderators**: Jaime Feliu (Medical Oncology), Carmen González García (Pathology)
18/06/2025	Internal Medicine Social Work Emergency	Respuesta a retos actuales sobre el VIH en el entorno del HULP	**Speakers**: Juan González (Internal Medicine), Diana Pérez-Solero (Social Work), Guillermina Bejarano (Emergency), María Luisa Montes (Internal Medicine), María Jesús Roldan (Internal Medicine), Ignacio Bernardino (Internal Medicine) **Moderator**: José Ramón Arribas (Internal Medicine)
25/06/2025	Pediatric Emergency Care Pediatrics	Prevención del virus respiratorio sincitial ¿dónde estamos?	**Speakers**: Cristina Calvo (Pediatrics), María de Ceano-Vivas (Pediatric Emergency Care) **Moderator**: Fernando Baquero (Pediatrics)
24/09/2025	Medical Director	Orígenes tempranos de las enfermedades crónicas del adulto	**Guest Speaker**: Alvar Agustí (Hospital Clinic de Barcelona) **Moderator**: Francisco García Río (Medical Director)
01/10/2025	Cardiology Rheumatology Pathology	Mujer de 69 años con antecedentes de poliartritis, insuficiencia cardiaca y miocardiopatia	**Speakers**: Lucia Fernández Gasso (Cardiology), Gema Bonilla (Rheumatology), Sara Quiñones (Pathology) **Moderators**: Raul Moreno (Cardiology), Eugenio de Miguel (Rheumatology), Alberto Berjón (Pathology)

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Date	Service	Title	Speakers
08/10/2025	Outpatient Clinic, Maternity Hospital Outpatient Clinic, General Hospital Nursing Department Orthopedics Medical Oncology Nursing Department Management	La enfermera gestora de casos: liderazgo clínico y eje estratégico en la coordinación asistencial de los equipos multidisciplinares en oncología	**Speakers**: Judith Hernández Alonso (Outpatient Clinic, Maternity Hospital), Sonia Garrido Mallach (Outpatient Clinic, Maternity Hospital), Laura Nogales Alfaro (Outpatient Clinic, Maternity Hospital), Concepción López Lietor (Outpatient Clinic, General Hospital), Eduardo Ortiz (Orthopedics) **Moderators**: Andrés Redondo (Medical Oncology), Esther Rey (Nursing Department), Javier Cobas (Management)
15/10/2025	Medical Oncology Digestive System (Includes the presentation of the Mutual Médica Award for Best Resident)	Equilibrio delicado: manejo y gestión de las complicaciones gastrointestinales y hepáticas en inmunoterapia	**Speakers:** Oliver Higuera (Medical Oncology), Marta Abadía (Digestive System), María Sánchez Azofra (Digestive System), **Moderator**: María Dolores Martín Arranz (Digestive System)
22/10/2025	Pediatric Neurology Pediatrics Rehabilitation Orthopedics	Como ha cambiado el tratamiento de la atrofia espinal tipo 1 en los últimos años	**Speakers**: Miguel Angel Fernández (Pediatric Neurology), Mar García Romero (Pediatric Neurology), Paula Fresno (Pediatrics), Sandra Espinosa (Rehabilitation), José Manuel Sánchez Márquez (Orthopedics) **Moderators:** Samuel Antuña (Orthopedics), Nicómedes Fernández-Baillo (Orthopedics)
29/10/2025	Nephrology Intensive Care Medicine Pathology	Varón de 77 años con pluripatología, insuficiencia renal en tratamiento con diálisis, neumonía y fracaso multiorgánico	**Speakers**: Rafael Sánchez (Nephrology), Eva Perales (Intensive Care Medicine), María Augusta Abad (Pathology) **Moderators**: Gema Fernández Juárez (Nephrology), José Añón (Intensive Care Medicine), María Carmen González (Pathology)
05/11/2025	Endocrinology Cardiology Nuclear Medicine	Varón de 43 años con paraganglioma cardiaco funcionante	**Speakers:** Patricia Martín-Rojas (Endocrinology), Regina Dalmau (Cardiology), Sonia Rodado (Nuclear Medicine) **Moderators:** Raul Moreno (Cardiology), Cristina Álvarez Escolá (Endocrinology)
12/11/2025	Gynecology and Obstetrics Maternity Pediatric Emergency Care	Asistencia sanitaria urgente a víctimas de violencia sexual (códigos VISEM y VISNNA)	**Speakers**: Mar Muñoz (Gynecology and Obstetrics), Rosa Alba (Maternity), Marta Bueno (Pediatric Emergency Care) **Moderators**: Alicia Hernández (Gynecology and Obstetrics), María de Ceano-Vivas (Pediatric Emergency Care)
19/11/2025	Pulmonology Pathology	Varón de 64 años con destete difícil que presentó fallo renal, encefalitis, hemoptisis y hematuria	**Speakers**: Ana Santiago (Pulmonology), Pilar Cuesta (Pathology) **Moderators**: Rodolfo Álvarez-Sala (Pulmonology), María Carmen González (Pathology)
20/11/2025	UAM Graduate School Medical Director	Como doctorarse en la UAM	**Speakers:** Lourdes Ruiz Desviat (UAM Graduate School) **Moderators**: David Fernández De Sevilla (Associate Dean for Research FUAM), Francisco García Río (Medical Director)
26/11/2025	Clinical Pharmacology Medical Oncology Medical Director IdiPAZ	Investigación: El ADN del Hospital La Paz	**Speakers**: Alberto Borobia (Clinical Pharmacology-IdiPAZ), Darío Sanchez Cabrero (Medical Oncology), Carlos del Fresno (IdiPAZ) **Moderators**: Javier de Castro (Medical Oncology-IdiPAZ), Francisco García Río (Medical Director)
03/12/2025	Clinical Services Geriatrics Pharmacy Geriatrics	Manejo interdisciplinar del paciente mayor institucionalizado	**Speakers**: Elena Pérez Pascual (North Clinical Services), Montserrat Barcons (Geriatrics), Cristina Bilbao (Pharmacy), Maria Cristina Ardines (Geriatrics) **Moderator:** Rocío Menéndez (Geriatrics)
10/12/2025	Hospital Pharmacy Pediatric Neurology Neurology	Farmacia hospitalaria en enfermedades raras: un puente entre especialidades	**Speakers:** Tamara Pérez (Hospital Pharmacy), Mar Gloria Romero (Pediatric Neurology), Marta Moreno (Hospital Pharmacy), Francisco Javier Rodríguez de Rivera (Neurology), Francisco Moreno (Hospital Pharmacy), Ester Zamarrón (Neurology) **Moderators**: Alicia Herrero (Hospital Pharmacy)
17/12/2025	Medical Director	La neuropercepción de la belleza, un recorrido por el arte en la ciudad de Venecia	**Guest Speaker**: Carmen Fernández Jakob (Asociación Española de Médicos Escritores y Artistas) **Moderator:** Francisco García Río (Medical Director)

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.4. IdiPAZ Quality Committee

The search for quality and excellence in research management has been one of the main goals of IdiPAZ since its origin in 2009. This is shown in the fact that external quality audits of its Integrated Management System that jointly respond to the most relevant standards like ISO 9001, UNE 166002 and IQNet SR-10 were satisfactorily completed in April and October. After this last cycle, the System covers a total of 7 management units, 7 supporting platforms and 3 collegiate bodies of IdiPAZ, highlighting on this occasion as a novelty the incorporation of the management unit responsible for the implementation of CSR and SDG in the organization and the prevention of occupational risks unit. Likewise, a significant effort has been made finishing the integration into the System of the Social Responsibility Management System and the Certification of the Sustainability Strategy aligned with the UN.

Although the first certification of the Quality Management System was given in 2013 and its development has been a strategic objective all these years, its growth and consolidation has been especially notable in the last years, currently being included in the scope for 4 different standards including in the scope the following units, platforms and bodies:

- Quality Commission: body.
- Project application support: unit.
- Innovation Support Unit: platform.
- UICEC: platform.
- Biostatistics: platform
- SANGER sequencing: platform.
- Management of scientific production and communication: platform.
- Training Commission: body.
- Cell Culture Unit: platform.
- Molecular Imaging and Immunohistochemistry Unit: platform.
- Project management: unit.
- Accounting: unit.
- Legal and Contracting: unit.
- HR: unit.
- Collegiate Governing Bodies: body.
- Social responsibility and SDG management: unit.
- Prevention of occupational risks: unit.

Quality certificates to all units, platforms and bodies involved were delivered during the presentation of the Scientific Report of IdiPAZ 2024, which took place November 19th 2025.

Finally, specific training webinars were developed by the Committee in order to strengthen the competence of IdiPAZ members in quality management, thus ensuring the sharing of best practices among them. These webinars are accessible at IdiPAZ website: *Integrated Management System IdiPAZ*



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.4.1 Protocol/Clinical pathway

Protocol/Clinical Pathway	Status
Analgesia epidural para el parto	Review
Atención a menores que migran sólos a su llegada a nuestro país	Review
Atención al final de la vida del paciente crítico	Review
Bacteriemia asociada a catéter en pediatría	Review
Conciliación de medicamentos de alta del área de urgencias del paciente mayor institucionalizado a su centro sociosanitario	Review
Consulta anestésica	Review
Cribado de infecciones pacientes inmunodeprimidos	Review
Cribado SHL	Review
Cuidados de enfermería en el mantenimiento del potencial donante adulto	Review
Cuidados intensivos orientados a la donación	Review
Detección de potenciales donantes	Review
Diagnóstico de muerte encefálica y mantenimiento del potencial donantes	Review
Donación cardiaca en asistolia controlada en paciente pediátrico	Review
Donación de tejidos procedentes de donante cadáver	Review
Donación en asistolia controlada pediátrica con perfusión normotérmica infantil	Review
Donación tras prestación de ayuda a morir	Review
ETEV y Trauma	Review
Extracción osteotendinosa	Review
Guía rápida de tromboprofilaxis	Review
Administración ambulatoria de verde de indocianina en cirugía de HBP	Review
Identificación pacientes alérgicos	Review
Manejo antitrombótico en procedimientos de ablación con catéter de sustaratos arrítmicos	Review
Manejo de pancreatitis aguda	Review
Manejo perinatas en menores de 26 semanas	Review
Normotermia perioperatoria adultos	Review
Prevención de la neumonía con la asistenica sanitarias	Review
Procedimiento de actuación antes urgencuas y emergencias en consultas externas del hospital	Review
Protocolo de enfermnería de banco de huesos	Review
Protocolo rabia	Review
Sedación profunda y analgesia	Review
Seguimiento para pacientes con acondroplasia	Review
Síndrome postrombótico	Review
Soporte al cribado microbiológico del posible donante de órganos	Review
Tratamiento de la infección del tracto urinario en pediatría	Review
Utilización de plasma rico en plaquetas en el tratamiento de tendinopatías condropatías	Review

Protocol/Clinical Pathway	Status
Valoración inicial en trasplantes de donante vivo en receptores no residentes	Review
Recomendaciones para la administración de fármacos vía parental en el área de pediatría	Review
Abñación alta el mismo día arritmias	Review
Recomendaciones para la admiistración de fáramcos vía parenteral en el área de pediatría	Review
Manejo trombectomía venosa en MMII	Review
Prevención de UPP en pacientes adultos	Review
Proyectos zero pacientes adultos	Review
Vigilancia infección nosocomial	Review
Protocolo de ingreso en la Unidad de Quemados	Review
Preoperatorio en la Unidad de Quemados	Review
Sedoanalgesia	Review
Tratamiento quemado crítico agudo	Review
Rehabilitación unidad de Quemados	Review
Nutrición enteral en la Unidad de Quemados	Review
Seguimiento y rehabilitación al alta de la unidad de Quemados	Review
Quemados infantil	Review
Tratamiento del dolor agudo en la Unidad de quemados	Review
Preoperatorio en la Unidad de Quemados	Review
Curas unidad de Quemados	Review
Cicatrices unidad de Quemados	Review
Control de la infección al alta de la Unidad de Quemados	Review
Protocolo de Salud Mental de la Unidad de quemados	Review
Anticoagulación en urgencias	Review
SAFO	Review
RM sin sedación	Review
Infecciones por clostridium difficile en pediatría	Review
Inmunización de niños receptores de trasplantes de progenitores hematopoyéticos	Review
Vacunación y profilaxis anti-infeccioasas en pacientes tratados con anticuepros monoclonales y otros agente biológicos	Review
Ventriculitis Zero	Review
Comision de Tejidos y Tumores	Review
Comités de Tumores	Review
Infusisóin de lidocaína intravenosa	Review
Diabetes y embarazo	Review
Gestante VIH Positivo: Prevención de la transmisión perinatal	Review

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.5. Platforms

2.5.1. ISCIII Strategic Platforms

2.5.1.1 Innovation Support Unit (UAI)

itemas isciii

Plataforma de dinamización e innovación de las capacidades industriales del Sistema Nacional de Salud

2.5.1.1.1. Innovation and Transfer Activities

The institute has two main units (the Innovation Support Unit and the Knowledge Transfer Office) that are key to carrying out the transfer of knowledge and the exploitation and market transfer of technologies developed within IdiPAZ.

The Innovation Support Unit, UAI, of FIBHULP was created in June 2010 within the framework of the ITEMAS Network –currently called ITEMAS Platform- of the Carlos III Institute of Health. Since its creation, the Innovation Support Unit has contributed to promoting and protecting innovative/ground breaking research conducted by IdiPAZ. The Innovation Unit also intends to harness our institute's considerable innovative potential generated, as a step prior to its subsequent transfer to society.

Therefore, one of the main commitments of the Innovation Unit is that researchers and health personnel perceive it as a resource at their service, to provide support and advice in all that relates to the identification, management, protection, transfer, marketing and dissemination of their research results.

The OTC was registered in the Registry of Knowledge Transfer Offices on May 7, 2024, under number 76.

The IdiPAZ OTC is the main body for knowledge transfer that carries out the identification, development and promotion of innovative ideas among research and healthcare staff in the HULP IdiPAZ environment, as well as their subsequent valorisation for transfer to society. In addition, these two units, the UAI and the OTC, have the support of the other IdiPAZ support platforms.

The OTC, together with the UAI, aims to ensure that all the knowledge and applied research developed for years at IdiPAZ is reflected and returned to society and provides a direct benefit in improving patient care.

ACTIVITIES

The main aim of the UAI is to identify the potential transferable research results generated within our institute and to accompany and support the researcher throughout the whole innovation process: from the birth of the idea to its placement on the market.

Since the UAI has been in operation, several projects sponsored by the institute itself have been managed and different collaboration agreements have been signed with important private institutions and organisations to promote innovation.

Our main objectives are:

- Promoting a culture of innovation and entrepreneurship within the institute by fostering the generation of innovative ideas and solutions that meet the needs of patients and society, in general, and supporting their development through various initiatives.
- Actively searching and identifying knowledge and research results emerged within the institute and transferable to the market.
- Fostering and managing the protection and transfer of knowledge and research results to society and promoting the current technology portfolio of the institute while getting an economic return which allows its reinvestment in research and development.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups


4 Associated clinicians

- Promoting the participation of industry in the innovation process acting as a stakeholder actively involved in it.
- Formalising business alliances, including technology companies as well as industrial and financial partners, to develop collaborative projects and to transfer the results to the market.
- Generating resources that achieve the greatest impact on society, enabling a better quality health care and at the same time contributing to the sustainability of the National Health System.
- Boosting a fruitful collaboration among all entities that make up the ITEMAS Platform.
- Scientific and legal advice on the initiative's protection potential and scope. Advice and support for researchers on intellectual and industrial property issues, through meetings with them in which the various procedures and steps to follow for the protection of their idea and the application for a potential patent are explained.
- Search for trends in technology. In this sense, the search for new technology trends emerges as an eminently necessary activity for the generation of an anticipation and preparation factor that improves the approach by the OTC (to exercise an effective knowledge transfer).
- The search for funding. The search for funding is a fundamental element for organizations like IdiPAZ, as funding is another of the most pressing constraints on their natural activity, as research requires a large amount of resources, both financial and material.
- Exploitation of results. For an innovation to be considered successful, it must produce a return for the institution, either through the commercialization of the results or through internal process improvements. To introduce an innovation to the market, the institution must plan the actions to be carried out, considering aspects such as:
  - » Identification of the intellectual and industrial property environment in the target markets.
  - » Development of the marketing and sales plan.
  - » Ensure the availability of necessary funds and resources.
  - » Establish production, supply chain, customer service, and training of the agents involved as appropriate.

The technology transfer plan aims to strengthen the links between the public and private sectors in research, development and innovation I+D+i to increase the socioeconomic impact of public investment in research and boost the innovative capacity of research institutes.

In the last years the UAI has definitely consolidated its presence and visibility in the whole environment Hospital-Institute. Among the greatest achievements of the Innovation Support Unit are the following:


UAI PORTFOLIO BREAKDOWN BY PROJECT DEVELOPMENT 2025




IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

UAI PORTFOLIO BREAKDOWN BY PROJECT TYPE 2025



PRIORITY OF IDIPAZ'S PATENT FAMILIESIN FORCE DURING 2025



1. The UAI has become one of IdiPAZ's most in-demand and requested platforms as it is responsible for promoting, supporting and managing all innovation projects.

At December 31 2025 the UAI had 315 innovation projects or ideas in active state, 29 of which were in the capture phase, 81 in the evaluation phase, 67 in development, 92 in transfer and 46 in the market. According to these data, it follows that 15% of the projects have been successfully exploited and positioned in the market, a very positive percentage (although far lower than the aspired figure) given the precariousness of the times we go through and the resources (both human and financial) with which the UAI counts. The analysis of IdiPAZ's technology portfolio according to the type of project show how Health ICT, Bio and Medical Device, and Materials and Devices types stand out above the others, with practically the same number of projects for all three types.


2. The UAI has built a wide and diverse technology portfolio. Each year the number of innovation projects managed by the UAI increases with respect to the previous year, also increasing the number of Hospital services, research groups and professionals in general who join IdiPAZ's innovation community.

During 2025 the UAI filed 2 priority patents (Spanish patent kind) and 1 PCT. UAI´s portfolio of patent families in active state during the period 2025 reached the figure of 24 patent families (10 of them with Spanish priority, 12 of them of European priority and 2 of them having US priority).


In the period of 2025 2 new computer softwares have been protected by the UAI.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

TOTAL OF IP LEGAL FIGURES IN FORCE DURING 2025



TECHNOLOGIES LICENSED OR IN COMERCIAL EXPLORATION 2025



Special mention should also be made to the UAI trademark portfolio. During the period 2025, 6 European trademark applications were filed and 9 European trademark were granted. The total number of trademark families active and in force during 2025 was 42.

As well, in this year the UAI has made the applications to a new legal figure, the industrial design. Into this category, 1 Spanish was counted.

The totally of Intellectual Property figures in force during 2025 is the following 24 patent families, 43 SW, 42 trademark families, 9 IP Works and 5 know-how, and 2 industrial model.

It is important to note that these trademarks, besides allowing IdiPAZ to distinguish its products or services from competitors' products or services, are associated with the know-how of the institution, know-how that has been transferred along with the distinctive sign in the case of the license agreements signed by the institution in respect of trademarks.

3. The UAI has prepared a catalogue of technology offers -based on specification sheets-, which includes the complete portfolio of exploitable IdiPAZ results. This catalogue aims to promote the transfer of IdiPAZ's technology portfolio to the industrial sector, generate collaborative projects for technological development and foster the exploitation of research results. Those validated specification sheets are published on IdiPAZ's website. The catalogue is updated as the Institute's technology portfolio grows.

4. The UAI has been, is, and will continue to be the principal architect for the transfer and exploitation of IdiPAZ's technology portfolio. Until 2025, the UAI succeeded in signing 21 license agreements -19 of which related to intellectual property works and 2 know-how- and the portfolio of licensed or commercially exploited inventions reached the figure of 24 technologies, 14 patents, 1 utility model, 4 SW, 2 trademarks, 2 IP Works and 1 know-how.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

5. It should be noted that a new spin-off company, in which FIBHULP holds a stake, will be established in 2026. The company, named Polyfil Diagnostics S.L., is developing a liquid blood biopsy for the differential diagnosis of patients with colon polyps or tumors. It has received awards and grants, such as the one previously mentioned from the Pfizer Foundation – ITEMAS for the best health innovation project emerging from the Units and Associated Units of the ITEMAS-ISCIII Platform. It has also received funding from private investors (Genesis Boost Transfer) and has participated in numerous entrepreneurship programs, such as Aptenisa (a startup ideation and acceleration program), Startup Health VIII, and Genesis CEO Academy 2025, among others.

6. Through the promotion of a culture of innovation, the UAI has managed to create a large community of innovative professionals. Over the last year, its promotional activity has consisted in the celebration of several working days, workshops, seminars, etc. Among all the promotional activities organised, the following stand out:

- Jornadas formativas de Calidad 2025. 19/02/2025, 25/06/2025, 23/04/2025.
- Conoce a la Unidad de Apoyo a la Innovación. 13/10/2025.
- II Encuentro de asociaciones de pacientes en IdiPAZ. 24/10/2025.
- Igualdad de género y diversidad en el ámbito de I+D+i. 1/12/2025.
- II Jornada del HUB de Plataformas Estratégicas ISCIII-IDIPAZ. 26/10/2025.

At the strategic level, IdiPAZ is part of the Community of Madrid's Health Innovation Network (RISCM) and the EDIH Madrid Region 2.0 Digital Innovation Hub. Integration into this HUB, whose mission is the digitization of the public sector, enables the institute to implement disruptive technologies—with a special emphasis on Artificial Intelligence solutions in validation and testing phases—which will significantly improve its competitiveness, efficiency, and capacity for innovation. Within this ecosystem, IdiPAZ has already submitted two projects to carry out their respective proof-of-concept tests.

7. The UAI has succeeded in creating a wide-ranging network of contacts. By virtue of its membership in the ITEMAS Platform, the Unit has continued to strengthen ties and creating synergies with the members of this Platform in order to achieve its established objectives.

Apart from the above results, it is important to highlight the increasing amount of innovation projects managed by the UAI that has been awarded with prestigious awards and aids. The following are some of the projects that won grants or awards during 2025:

A. FarmaTOX: The project involves the development of an innovative mobile app, designed with a highly user-friendly interface for smartphones and aimed at optimizing the daily clinical practice of healthcare professionals. This tool incorporates advanced Artificial Intelligence (AI) techniques that facilitate quick access to and intuitive visualization of adverse drug reactions. In this way, the app pursues a dual objective: on the one hand, to foster a much deeper and more up-to-date understanding of side effects, and on the other, to actively promote the safe prescription and use of medications, minimizing risks and improving patient safety.

The Pharmacy Department, in collaboration with the Pulmonology Department, has developed 'FarmaTOX', an innovative application for consulting and obtaining information on adverse drug reactions. Designed for healthcare professionals, this tool aims to promote the safe use of medications and enhance knowledge of their effects.

In this context, the UAM-Roche Chair in Pharmacotherapy for Patients with Chronic Diseases, in collaboration with hospital pharmacists and pulmonologists, as well as the Department of Communication and Control Systems at the National University of Distance Education (UNED), has developed this tool. Created with the technological collaboration of In2AI, it is based on artificial intelligence and uses advanced language models to provide information on adverse drug reactions and strengthen clinical safety.

B. ProFlex Spine: A Dynamic Solution for Scoliosis

ProFlex Spine is a minimally invasive treatment for adolescent idiopathic scoliosis that offers a clear alternative to conventional surgery and external bracing. Functioning as an "active internal brace," it eliminates the physical limitations of traditional braces and the permanent rigidity of standard spinal fusion.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

At the core of the ProFlex Spine system is the superelastic SMROD implant, crafted from advanced shape-memory alloys (SMA). Designed specifically for growing adolescents, this dynamic approach:

- Corrects spinal curvature instantly during surgery.
- Facilitates progressive, ongoing correction post-operation.
- Preserves the spine's natural mobility and flexibility.
- Seamlessly adapts to the adolescent's physical growth.

The Procedure and Recovery The surgery is minimally invasive, utilizing small incisions to significantly reduce tissue damage. To ensure maximum precision and patient safety, the procedure incorporates state-of-the-art technologies, including intraoperative CT navigation and robotic assistance.

- Surgical Time: Approximately 1 hour and 30 minutes.
- Hospital Stay: Patients are typically discharged within 1 to 2 days.
- Recovery: Most adolescents can return to school in about two weeks.

C. **Novocornea:** Corneal melting is a life-threatening condition with an immediate risk of eye perforation that can result from severe eye infections, autoimmune diseases such as rheumatoid arthritis, advanced corneal ulcers, chemical burns, or complications following eye surgery, in which the corneal tissue rapidly breaks down and loses its protective function.

This 3D-printed human collagen implant is designed to immediately stabilize the cornea, acting as a biological scaffold that reinforces the damaged tissue and buys time for the eye to recover—something that until now was very difficult to achieve. The implant has been designed to provide stable structural support in corneas with severe loss of thickness and a high risk of perforation. Thanks to its biocompatibility and its ability to integrate into damaged corneal tissue without inducing inflammation, this development represents an innovative alternative for patients in whom conventional treatments have failed.

With this breakthrough, Madrid's hospitals are reinforcing their leadership in biomedical innovation. The project is led by Dr. María P. De Miguel, director of the Cell Engineering Group at the Health Research Institute of La Paz University Hospital (IdiPAZ).

The approval of this clinical trial by the Spanish Agency for Medicines and Health Products (AEMPS) marks a major milestone for regenerative ophthalmology.

The public hospitals La Paz and Ramón y Cajal of the Community of Madrid, through their research institutes (IdiPAZ and IRYCIS, respectively), are leading Spain's first human clinical trial of a 3D-printed corneal implant for the treatment of corneal melting, a severe complication that compromises the integrity of the eyeball and vision. Until now, treatment options have been limited and, in many cases, dependent on the urgent availability of donor tissue. One of the most significant advantages of this technology is its potential to reduce reliance on donor tissue, which is not always available, particularly in urgent or complex cases.

The Cellular Engineering Group at IdiPAZ is developing a biomimetic corneal substitute aimed at providing a regenerative alternative to conventional corneal transplantation. The concept is to create an artificial cornea using 3D printing and collagen, the same material that makes up the natural cornea. Stem cells are incorporated into the collagen scaffold, promoting tissue integration and reducing the risk of rejection so that the implant can function as a natural cornea. In this way, the need for a donor can be avoided. The project is currently in an advanced preclinical stage, integrating optical characterization, biomechanical analysis, and cellular biocompatibility assessment. We have recently received approval to conduct a clinical trial using this technology without stem cells as an initial approach to evaluate its safety. Until now, treatment options have been limited and dependent on the urgent availability of donor tissue. Through this technology, however, dependence on donor tissue can potentially be eliminated altogether.

Patients suffering from corneal melting are in an extremely critical clinical situation, facing an immediate risk of eye perforation. This condi-

IdiPAZ Instituto de Investigación Hospital Universitario La Paz


1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

tion may arise as a consequence of severe ocular infections, autoimmune diseases such as rheumatoid arthritis, advanced corneal ulcers, chemical burns, or complications following ocular surgery, all of which can lead to rapid degradation of corneal tissue and loss of its protective function. Vision loss has a profound social and emotional impact, with high rates of unemployment and an increased prevalence of depression among individuals with visual impairment. This implant is designed to provide immediate stabilization of the cornea, acting as a biological scaffold that reinforces damaged tissue and provides time for the eye to recover. Thanks to its biocompatibility and its ability to integrate into damaged corneal tissue without inducing inflammation, this development represents an innovative alternative for patients in whom conventional treatments have failed.



8. The Madrid Science Park (PCM), in collaboration with EIT Health Spain, has announced the winning projects of the 3rd Health to Market Awards, an initiative that recognizes the most innovative startups in healthcare and biomedicine. Among the awarded initiatives is PolyFIL, a project developed at the La Paz University Hospital Research Institute (IdiPAZ) and Smart Scoliosis Development. In this edition, the jury particularly valued the healthcare impact of the proposals, their disruptive nature, commercial viability, and internationalization potential.

PolyFIL has been recognized for the development of a laboratory kit capable of detecting polyps and colorectal cancer from a simple blood sample using a liquid biopsy technique. This technology represents a faster, more accessible, and cost-effective alternative to current diagnostic methods, addressing a health issue of major relevance among people over the age of 50 worldwide. The project originated at IdiPAZ and has benefited from the continuous support of the Innovation Unit, which has promoted its technological maturation and market-oriented development.

Smart Scoliosis consists of an implantable medical device for the treatment of spinal deformities, particularly scoliosis, although it may also be applicable to other conditions such as pathological lordosis or kyphosis. The device is based on a vertebral correction system that incorporates a correction rod made of a superelastic shape-memory metal alloy, which can be connected to a set of pedicle screws implanted in the vertebrae.

9. MITIGA, an innovative initiative designed to improve home-based care for people living with Alzheimer's disease, has launched its pilot phase in Tres Cantos. This municipality is the first in Spain to participate in the project.

Developed through a collaboration between our hospital and the company Dekipling, the program aims to improve the quality of life of patients and their caregivers by enhancing medication management,

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



CONTACT

Coordinator
Javier de Castro Carpeño

Responsible
Estela Sánchez Simón

Members
Marta Navas Romero
Patricia Goyanes Rodrigo

preventing avoidable hospital admissions, and reducing falls. The initiative focuses on the systematic observation and monitoring of patients, enabling immediate action whenever changes in their health status are detected.

The pilot study will begin with the participation of 12 to 15 families receiving support from the Tres Cantos Social Services Department, each with a family member diagnosed with early- or mid-stage cognitive impairment. Participants will be carefully selected, and caregivers and support staff will receive appropriate training to implement the program.

Ana Frank, Head of Neurology at La Paz Hospital, explains that MITIGA "does not replace the physician, but it transforms information collected at home into a key clinical resource for making better decisions."

ORGANISATION

Since its implementation, the Innovation Support Unit has been integrated into the organisational structure of FIBHULP, as one of the Support Platforms for IdiPAZ research.

The UAI is directed by Dr. Javier de Castro Carpeño, M.D. and Ph.D. in Medicine and he's a member of the Medical Oncology Department of the La Paz University Hospital, Autonomous University of Madrid and of the Translational Oncology Unit of IdiPAZ.

The UAI also consists of a team of three experts in fostering innovation and protecting research results and technology transfer:

Responsible: Estela Sánchez Simón, Law Graduate;
Innovation manager: Marta Navas Romero, Biomedical Engineer.
Innovation manager: Patricia Goyanes Rodrigo, Telecommunication Engineer.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.5.1.1.2. Patents and trademarks

NEUROSCIENCES AREA

Psychiatry and Mental Health

Rodríguez Vega B, author; FIBHULP, assignee. Trademark name: En calma; ESM 3.695.071; 2017 December 12.

En Calma

Rodríguez Vega B, Mediavilla Torres R, Bravo Ortiz MF, Muñoz San José A, Bayón Pérez C, Lahera Forteza G, Palao Tarrero A. authors; FIBHULP, assignee. Trademark name: SocialMind; ESM 3.748.550; 2018 December 17.

SocialMind

Neurology and Cerebrovascular Diseases Group

Valdivieso Amate F, Bullido Gómez-Heras MJ, Martínez García A, inventors; UAM, assignee. Method of identifying compounds that induce or inhibit endoplasmic reticulum stress or oxidative stress. P200702997, PCT/ES2008/000705, EP2221379, US20100304384; 2007 November 13.

Vergés Milano J, García García A, Ruhí Roura R, Montell Bonaventura E, García López M, Aláez Versón CR, Escaich Ferrer J, Egea Máiquez J, Lorrio González S, Negredo Madrigal P, inventors; BIOIBÉRICA S.A., UAM, assignees. Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases. P200902399, PCT/EP2010/070613, US20120309707, CA20102785237; 2010 December 22.

Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C, Sastre Merlín I, inventors; UAM, CSIC, assignees. Method of identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases caused by human herpes viruses. P200400965, PCT/ES2005/000209, EP1769677, US20070218004, AT447321, AU2005235319, CA2562787, JP2007533315; 2004 April 21.

Valdivieso Ámate F, Montoliú JL, Pozueta Larios J, inventors; UAM, CSIC, assignees. Alzheimer's disease animal model, method for obtaining same and uses thereof. P200503002, PCT/ES2006/000673, EP1956091, EP20060841725, US20090222932, CA2638983, JP2009517066; 2005 December 02.

Ballesteros García P, López Larrubia P, Domínguez Mateo L, Marco Contelles JL, Cerdán García-Estellers S, inventors; Universidad Nacional de Educación a Distancia, CSIC, assignees. Set of magnetic resonance imaging and spectroscopy cell acidity extrinsic indicators comprise polyol derivatives based on alditols. P200300936; 2003 April 23.

Gil Martínez A, author; FIBHULP, assignee. Trademark name: Specular Face; ESM 4.022.981; 2019 June 10.

SPECULAR FACE

Egea Máiquez FJ, Farré Alins V, Palomino Antolín A, Narros Fernández P, Martins Rosa J, Parada Pérez E, Hernández García BJ, Roda Frade JM, Yus Teruel S, Lagares Gómez-Abascal A, Sánchez Carabias C, Gandía Juan L, inventors; Fundación Hospital La Princesa, FIBHULP, Fundación Hospital 12 de Octubre, UAM, assignees. Method for determining the progression of acute brain damage and pharmaceutical composition for its treatment. P202031194, PCT/ES2021/070856; 2020 November 30.

Gil Martínez A, Gil Castillo J, inventors; FIBHULP, Centro Superior de Estudio Universitarios La Salle, Javier Gil Castillo, assignees. Dispositivo de medición y/o entrenamiento de la fuerza o presión de los músculos de la cavidad oral y su uso para rehabilitación. MU 1201U MU202230128. 2022 July, 26.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Alonso de Leciñana M, Díez Tejedor E, Fuentes Gimeno B, Rodríguez-Pardo de Donlebun J, Lopez Martín D, Gutierrez Martín A and Fernandez Martín F, authors; FIBHULP and Universidad Politécnica de Madrid, assignee. Trademark name: Neuro Data Tracker; ESM 018860324; 2023 April 11



Martín Montes A, Blanco de Miguel D, Rodríguez-Pardo de Donlebun J, Medina López A, Alonso de Leciñana Cases M, Frank García A, inventors; FIBHULP, assignee. Cognipaz. Nº019095718; 2024 October 24.



Alonso de Leciñana M, Díez Tejedor E, Fuentes Gimeno B, Rodríguez-Pardo de Donlebun J, Lopez Martín D, Gutierrez Martín A and Fernandez Martín F, authors; FIBHULP and Universidad Politécnica de Madrid, assignee. Trademark name: Neuro Data Tracker; ESM 018860324; 2023 April 11

Neuroprotective Strategies in Neurodegenerative Diseases Group

Cuadrado Pastor A, Innamorato NG, inventors: CSIC, UAM. Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.

León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.

León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October15.

Cuadrado Pastor A, Fernández-Ginés R, León Martínez R, Encinar JA, Rodríguez Franco MI, García López MG, Rojo Sanchís AI, inventors. UAM, CSIC, UMH y Fundación de Investigación Biomédica del Hospital Universitario de la Princesa, assigness. Treatment of NRF2-Related diseases. PCT/2022/382025.1.

Molecular Mechanisms and Biomarkers in Neurodegenerative Diseases

López-Rodríguez ML, Viso A, Ortega S, Lastres-Becker I, González S, Fernández-Ruiz JJ, Ramos JA, inventors; Universidad Complutense de Madrid, assignees; Nuevos derivads de ácido araquidónico con afinidad por el transportador de anandamide. P200001920. 2020 nov 5

Martínez A, Gil C, Madruga E, Garcia-Rubia A, Lastres-Becker I, inventors; CSIC, assignees; Compuestos inhibidores de SGK1 y su uso para el tratamiento de enfermedades neurodegenerativas y/o cardiovasculares. ESP202430463. 2024 jun 5

CARDIOVASCULAR AREA

Research on Invasive Clinical Cardiology- ICCI-PAZ Group

Riera del Moral LF, inventor; FIBHULP, assignee. Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.

Filgueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees. Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.

Castro Conde A, author; FIBHULP, assignee. Trademark name: RECAR Programa de Rehabilitación Cardiaca; CM 18457042; 2021 April 20.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Pérez Gómez AL, González Lafuente L, Pelegrín Vivancos P, Cuevas González S, Egea Maíquez J, Fernández Velasco M, Alquézar Burillo C, Bartolomé Robledo F, Ruiz Hurtado G; Hospital Universitario 12 de Octubre, Universidad de Murcia, FFIS-IMIB, FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario La Princesa. Método de detección y cuantificación de motas extracelulares de ASC en muestras biológicas mediante citometría espectral. P202531231; 2025 Diciembre 22.

Coagulopathies and Alterations of Hemostasis

Nora Butta JY. Trademark name: WELCOME von willebrand active e-learnig course. CM M4190835; 2022 November 8.

Arias-Salgado, MT Álvarez Román, V Jiménez Yuste, N Butta Coll, García Rivera Francisco Julián, García Rivera Mª Carmen, Carballo García Mª Ángeles, inventors. FIBHULP, García Rivera Mª Carmen, Carballo García Mª Ángeles, asignees. Dispositivo de recogida de muestras biológicas. ES2958529. 2022 July 22.

Vascular Physiology and Pharmacology Group

Pérez Girón JV, Ruiz-Castellanos MJ, de Luis Jiménez O, Pérez Boto V, Sanz González R, Hernández Vélez MC, Mas Gutiérrez JA, Alonso Gordo MJ, Salaíces Sánchez M, Ros Pérez M, Coloma Jerez A, Asenjo Barahona A, Sanz Montaña JL, Puente Prieto J, Jensen J, inventors; NANOATE, S.L., assignee. Method for producing biosensors. P201031224, PCT/ES2011/070536; 2010 August 05.

Miguel Castro M, López-Alonso Fandiño R, Recio Sánchez MI, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis. P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, DE602004012289, DK1661913, JP2007523045; 2003 July 31.

Miguel Castro M, López-Alonso Fandiño R, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Production of and antihypertensive properties of peptides derived from egg white proteins. P200501246 PCT/ES2006/070067; 2005 May 23.

Recio Sánchez MI; Quirós del Bosque A, Hernández Ledesma B, Gómez Ruiz JA, Miguel Castro M, Amigo Garrido L, López Expósito I, Ramos González MM, Aleixandre de Artiñano A, (Contreras Gómez M), inventors; CSIC, assignee. Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same. P200501373, PCT/ES2006/070079, EP1905779, EP2495250, US8354502, AU2006256720, BRPI0611729, CA2611416, CN101305017, CN103254278, JP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08.

Garcés Rimón M, Miguel Castro M, López-Alonso Fandiño R, López-Miranda González V, Uranga Ocio J, inventors; CSIC, Universidad Rey Juan Carlos, assignees; Use of multifunctional bioactive products derived from the enzymatic hydrolysis of egg white proteins for treating metabolic syndrome. P201331767, PCT/ES2014/070880; 2013 December 04.

Miguel Castro M, Garcés Rimón M, López-Alonso Fandiño R, Sandoval Huertas M, inventors; CSIC, Mario Sandoval Huertas, assignees. Healthy food compositions having gel or foam textures and comprising hydrolyzed egg products. P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, JP2015130856, MX2014015135; 2013 December 20.

González-Muñiz R, Pérez de Vega MJ, Miguel M, Balsera-Paredes B, Moreno S, inventors; CSIC, assignee. Triazolyl polyphenols with antioxidant activity and uses thereof; P201531450; 2015 November 08.

González-Muñiz R, Miguel Castro M, Pérez de Vega MJ, Balsera-Paredes B, S Moreno, inventors; CSIC, assignee. Compounds with antioxidant activity and uses thereof. P201630362; 2016 March 29.

León Martínez R, Abril Comesaña S, Duarte Flórez P, Crisman Vigil E, Michalska P, Salaices Sánchez M, Menéndez Ramos JC, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees. Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas. P201930908. 2019 October 14.

León Martínez R, Abril Comesaña S, Michalska P, Buendia Abaitua I, Salaices Sánchez M, Menéndez

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Ramos JC, García López M; inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees. Compuestos derivados de 2-iodo-7-(((2-(5-metoxi-1H-indol-3-il)etil)amino)metil)-1-alquil/aril-6,7,7a,8-tetrahidro-3H-pirrolo[2,1-j]quinolina-3,9(5H)-diona como agentes antioxidantes, inductores de NRF2 y moduladores nicotínicos para el tratamiento de enfermedades neurodegenerativas. P201930190. 2019 March 01.

Miguel Castro M, Garcés Rimón M, authors; Miguel Castro M, Garcés Rimón M, assignee. Trademark name: leggie. ESM4044711; 2019 November 22.

leggie

Miguel M, Bruna E, Redondo BI, Gómez J, Gómez Sánchez J. inventors: : Cárnicas Joselito S.L: assigne. Extracto procedente de la grasa de cerdo, método de obtención, composición alimenticia que lo comprende y usos del mismo. P2021130236. 2021 March 17

Miguel M, Bruna E, Redondo BI, Gómez J, Gómez Sánchez J, Sabater-Muñoz B. inventors: Cárnicas Joselito S.L. assignee. Composición farmacéutica que comprende un extracto procedente de la grasa de jamón de cerdo como principio activo y su uso en medicina para la prevención cardiovascular e inflamación intestinal. P202131111. 2021 november 30

Alonso Gordo MJ, Hernanz Martín R, Martínez Casales M, González Carnicero Z, León Martínez R, Michalska Djzma P. inventors; Universidad Rey Juan Carlos, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, assinees; (E)-3-(4-hidroxi-3-metoxifenil)-acrilato de 3-(2-acetamidoetil)-1H-indol-5-ilo para uso en la prevenciaón y/o tratamiento de la hipertensión arterial y las alteraciones cardiovasculares asociadas. P202230523. P202230523. 2022 june 15

Martínez Gil A, Gil Ayuso-Gontán C, Madruga Mayordomo E, García-Rubia A, Lastres Becker I, Oliver Pérez E, Briones Alonso AM, inventores; Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid, assignes. SGK1-Inhibitor Compounds and use thereof for the treatment of diseases. PCT/ES2025/070297. WO 2025/253033 A1. 2024 june 07

INFECTIOUS DISEASES AND IMMUNITY AREA

AIDS and Infectious Diseases Group

Romero Gómez M, Solá Lamoglia R, González García JJ, inventors; Servicio Andaluz de Salud, Universidad de Sevilla, Fundació Institut Mar D'Investigacions Mèdiques, FIBHULP, assignees. Kit for decision making in patients with Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21.

Molecular Microbiology Group

Vicente Muñoz M, Mingorance Cruz J, Rueda González MS,inventors; CSIC, assignee. Method for determining state of growth and viability of bacterial FTsZ population, whether natural or cultivated, is based on determining existence of FTsZ rings in actively growing individual cells. P200200370; 2002 February 15.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES S.A., assignee. Composition, method and kit for detecting bacteria by means of sequencing. PCT/ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; 2009 October 22.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; 2B BLACKBIO S.L., assignee. Composition, method and kit for detecting fungi and yeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02.

Immuno-Rheumatology Group

Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia Rodríguez C, authors; FIBHULP, assignee. Trademark name: BioDrug Analysis BIDA. CM 13.808.531, 2015 March 10.

BioDrug Analysis BIDA

Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P,Varela Egocheaga I, Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Valdecilla, Servi-

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

cio Cántabro de Salud, Universidad de Cantabria, FUNDACIÓ HOSPITAL UNIVERSITARI VALL D´HEBRON - INSTITUT DE RECERCA (VHIR), assignees. Method for predicting the clinical response to anti-inflammatory agent therapies. P201600636, PCT/ES2017/000089; 2016 July 26.

Plasencia C. Trademark name: MAM Modelo Asistencial Mixto; CM 18637540; 2022 January 13.

Innate Immune Response Group

Llamas Matías MA, López-Collazo E, inventors; FIBHULP, Llamas Matías MA, Empireo S.L., assignees. Method for determine the risk of developing an infectious disease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27.

Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees. Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application; 2018 March 13.

del Fresno Sánchez C, Cantero Cid R, López-Collazo EM, inventors; FIBHULP, assignee. In vitro method and uses thereof for the differential diagnosis of CRC (colorectal cancer) and/or colorectal adenomas. EP24382100, PCT/EP2025/052243; 2024 February 1.

Del Fresno Sánchez C, Cantero Cid R, López Collazo E, inventors; FIBHULP, assignee. PolyFIL. N°019200741. 2025 November 25.

Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group

López Trascasa M, authors; FIBHULP, assignee. Trademark name: COMPLEMENTest; CM 009.658.791; 2011, January 14.

Lymphocyte Pathophysiology in Immunodeficiencies Group

Van Dongen JJM, Orfao de Matos Correia E Vale JA, Van Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vlkova M, López Granados E, Blanco Álvarez E, Kienzler AK, inventors; Erasmus University Medical Center Rotterdam, assignee. Reagents, methods, and kits for diagnosing primary immunodeficiencies. PCT/NL2015/050762, US62/072,498; 2014 Oct 30.

Lopez Granados E, del Pino L, authors; FIBHULP, CIBERer, assigne. Brand name: IMMUNE SIGNAL ®. EU 01906321; 2024, August 02

Drug Hypersensibility and Innate Immune Response Group

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2] pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

MicroRNA Regulation of Immune Tolerance, Autoimmunity And Cancer
Voss J, Huang D, Gonzalez-Martin A, Andrabi R, Burton D, inventors; The Srcipps Research Institute, assignees. B Cell receptor modification in B cells. PCT/US/45255. 2018 August 3

Gonzalez-Martin A, Gonzalez-Molina MdP, inventors; MicroRNAs for use in the stimulation of T-cell anti- tumor response. PCT/EP2024/064900. 2024 September 20

Systemic Immune-Mediated Diseases
Ríos Blanco JJ. A phase 1 open-label trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of subcutaneous vis171 in participants with autoimmune disease(s). Type/Phase: I Sponsored by: Visterra Inc. Signature date: 18/06/2025

LARGE SYSTEM PATHOLOGIES AREA

Organic Dysfunction and Failure in the Agression Group
Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Trademark name: SINOIRES; CM 13.080.056; 2014 July 14.

Respiratory Diseases Group
Díaz García E, Laxman Nanwani K, Quintana Díaz M, García Río F, Cubillos-Zapata C, inventors; FIHULP, CIBER, assignees. Biomarcadores para el pronóstico de pacientes que han sufrido una hemorragia subaracnoidea aneurismática (SAH). P202130180; 2021 March 3

Villamañán E, Contreras J, Romero D, Carpio C, Álvarez-Sala R, Herrero A, Quirce S, inventors; FIBHULP, assignee. Expertasma. N°018981670; 2024 June 14.

Nephrology Group
Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2] pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J, inventors; Fresenius Medical Care Deutschland GMBH, assignee. Pharmaceutical compositions containing steviosides. EP14191301.2, PCT/EP2015/074955, CN107073022, US10213452; 2014 October 31.

López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R, Passlickdeetjen J. Buechel J, Steppan S, inventors; Fresenius Medical Care AG & Co. KGaA, assignee. Method and kit for diagnosing epithelial to mesenchymal transition of the peritoneum (EMT-Chip). DE102015115158.8, PCT/EP2016/071149, CN108449998B, EP3347715B1, ES2833553T3, JP6869963B2, US2018246098A1; 2015 September 09.

Diagnosis and Treatment of Allergic Diseases Group
Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.

Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee. Trademark name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees. Food allergen extracts and methods of producing and using the same. EP16382413.9 (EP3290438); 2016 September 06.

del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, inventors; FIISFJD, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees.*In vitro* method for identifying severity levels in bronchial asthma patients. P201730739, PCT/ES2018/070390, EP3633050; 2017 May 29.

Villamañán E, Contreras J, Romero D, Carpio C, Álvarez-Sala R, Herrero A, Quirce S, inventors; FIBHULP, assignee. Expertasma. N°018981670; 2024 June 14.

Patient Blood Management

Díaz García E, Laxman Nanwani K, Quintana Díaz M, García Río F, Cubillos-Zapata C, inventors; FIHULP, CIBER, assignees. Biomarcadores para el pronóstico de pacientes que han sufrido una hemorragia subaracnoidea aneurismática (SAH). P202130180; 2021 March 3

Hospital Pharmacy

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Trademark name: SINOIRES; CM 13.080.056; 2014 July 14.

Villamañán E, Contreras J, Romero D, Carpio C, Álvarez-Sala R, Herrero A, Quirce S, inventors; FIBHULP, assignee. Expertasma. N°018981670; 2024 June 14.

Villamañán E, Ros S, Carpio C, Gómez L, Prados Mª C, Rodríguez J L, Álvarez-Sala R, Herrero A, Sobrino C, González L, Caumel L, inventors; FIBHULP, assignee. FarmaTOX. N°019153050; 2025 July 13.

Villamañán E, Carpio C, Gómez L, Álvarez-Sala R, Herrero A, inventors; FIBHULP, assignee. ExpertEPID. N°019153209; 2025 July 13.

Muñoz M, Villamañán E, Álvarez A, Quirce S, González D, Sánchez S, Antolín D, Carpio C, Prados Mª C, Álvarez-Sala R, Herrero A, Domínguez J, inventors; FIBHULP, assignee. CHECKLIST Atención Farmacéutica en ASMA GRAVE. N°019168760; 2025 August 02.

Translational Hepatology

Castán P, Gil-García AI, Madejón A, Sainz-Martínez E, Montoya JJ, OUAHID YOUNESS, inventors; MIRNAX BIOSENS S.L., assignee. Bivalent reverse primers Aplication number (EPO): 20382336.4-1118. 2020 April 24.

Madejón A; inventor; Agile Life Sciences LTD, assignee. Kit and methods Aplication number: GB202010372.A. 2020 July 6.

Associated Clinician

De la Oliva Senovilla P, inventor; FIBHULP, Instituto de Salud Carlos III, assignees. Shut-off valve

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

for the interruption technique used in the analysis of respiratory mechanics. PCT/ES2005/000271, EP1897578; 2005 May 16.

Carballo Cardona C; author; FIBHULP, assignee. Trademark name: Diagether. CM15869911, 2016 September 29.

CANCER AND HUMAN MOLECULAR GENETICS AREA

INGEMM- Institute of Medical and Molecular Genetics Group

Friedman S, Li D, Narla G, Martignetti J, Heath K, inventors; Mount Sinai School of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein. PCT/US2001/025046, EP1332362, CA2419064, AU8479001, US2005181374, US2011059899; 2000 August 09.

INGEMM, author; FIBHULP, assignee. Trademark name: INGEMM INSTITUTO DE GENÉTICA MÉDICA Y MOLECULAR DEL HOSPITAL UNIVERSITARIO LA PAZ; ESM 2.884.849, USM 77.891.143, CM 8.746.869; 2009 July 16, 2009 December 11, 2009 December 10.

INGEMM, author; FIBHULP, assignee. Trademark name: KaryoArray; USM 79.078.751, CM8.512.907; 2010 January 07, 2009 August 27.



INGEMM, author; FIBHULP, assignee. Trademark name: OverGrowthArray; ESM 2.958.709-3, USM 85.334.932, CM10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.

INGEMM, author; FIBHULP, assignee. Trademark name: MetabolArray; ESM 2.958.711-5, USM 85.334.903, CM10.009.348; 2010 December 02, 2011 June 01, 2011 May 31.

Palomares M, Lapunzina P, Nevado J, Vallespin E, Vallcorba I, Melero J, authors; FIBHULP, Hospital Infanta Cristina (Badajoz) Fundesalud, assignees. Trademark name: OncoHematoArray; ESM 2.958.703-4, USM 85.334.842, CM10.009.181; 2010 December 02, 2011 June 01, 2011 May 31.

Lapunzina P, Nevado J, Solera J, Vallespin E, Martínez P, Martínez-González V, authors; FIBHULP, assignee. Trademark name: ONCOSeq; USM 85.457.843, CM9.969.064; 2011 October 27, 2011 May 16.

INGEMM, author; FIBHULP, assignee. Trademark name: OncoArray; ESM 2.962.910, USM 85.363.107, CM10.091.882; 2011 January 05, 2011 July 05, 2011 July 01.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Moreno JC, Moya CM, Vallespin E, Lapunzina P, Nevado J, authors; FIBHULP, assignee. Trademark name: ThyroArray; USM 85.686.688, CM10.904.951; 2012 July 25, 2012 May 23.

Lapunzina Badía P, Borobia Pérez AM, Carcas Sanjuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Trademark name: PharmArray; USM 86.004.412, CM11.608.403; 2013 July 08, 2013 February 27.

Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray., CM15489511; 2016 May 31, 2016 September 07.

Palomares Bralo M, Vallespín García E, del Pozo Mate A, Santos Simarro F, authors; FIBHULP, assignee. Trademark name: RD-Seq Sequencing Rare Diseases; CM 17.911.029; 2018 May 31.

Translational Oncology Group

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez Navarro I, inventors; FIBHULP, assignee. Method for tumor subclassification. P200803509, PCT/ES2009/070533; 2008 December 11.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez de Molina AI, Reglero Rada G, Vargas Alonso T, Molina Arranz S, González-Vallinas Garrachón M, inventors; FIBHULP, Fundación Imdea Alimentacion, assignees. Methods and kits for the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 December 10.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López Vacas R, Berges Soria J, inventors; FIBHULP, assignee. Method for tumor subclassification. P201430887, 2014 June 09.

Miranda Utrera N, Castellano D, Villacampa Aubá F, Fresno Vara JA, Gámez Pozo A, inventors; FIBH12O, FIBHULP, assignees. Prognostic method for determining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for the same. P201531360, PCT/EP2016/072723, EP3353322B1, US20180346990, CN108174608, DE3353322, FR3353322, GB3353322; 2015 September 23.

Feliú Battle, J, Fernández Martos C, Fresno Vara JA, Ghanem Cañete I, Gámez Pozo A, Trilla Fuertes L, inventors; Biomedica Molecular Medicine SL (BMM), Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD), assignees. In vitro method for the prognosis of anal squamous cell carcinoma. EP19382982.7; 2019 November 11.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Fernández Martos C, Trilla Fuertes L, Fresno Vara JA, Gámez Pozo A, Ghanem Cañete I, Feliú Battle J, inventors; Biomedica Molecular Medicine SL, Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD), assigne. In vitro method for the prognosis of anal squamous cell carcinoma. EP19382982.7; 2019; 2019 November 11.

Experimental Therapies and Biomarkers in Cancer Group

Perona Abellón R, Sánchez Pérez I, Machado Pinilla R, Sastre Garzón L, Murguía Ibáñez JR, inventors; CSIC, UAM, Universidad Politécnica de Valencia, assignees. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining the same, therapeutic compositions and applications thereof. P200502511, PCT/ES2006/070152, EP1947175, US20090202503, US2015337022, AT469212, CA2625981, DK1947175, JP2009511036, JP5560398, PT1947175; 2005 October 14.

Perona Abellón R, Sastre Garzón L, Machado Pinilla R, Sánchez Pérez I, inventors; CSIC, UAM, assignees. Use of inductor agents GSE24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence. P200703106, PCT/ES2008/070212, EP2216043, US2011300115, JP2011504483, CA2706467; 2007 November 23.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cáncer. P201130863, PCT/ES2012/070379; 2011 May 26.

Martínez Máñez R, Murguía Ibáñez JR, Perona Abellón R, Agostini A, Mondragón Martínez L, Moreno Torres M, Manguán García C, Marcos Martínez MD, Soto Camino J, Sancenón Galarza F, inventors; Universidad Politécnica de Valencia, CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), assignees. Release of substances into senescent cells. P201231370, PCT/ES2013/070581, EP2893923, JP2015529216, US2015306037; 2012 September 04.

Ibáñez de Cáceres I, Belda Iniesta C, Pernía Arias O, Perona Abellón R, Cortés Sempere M; inventors. FIBHULP, CSIC, UAM, Fundación Hospital de Madrid, assignees. Method for predicting the response to a treatment consisting of radiotherapy combined with cisplatin-based chemotherapy. P201330783, PCT/ES2014/070433, EP3006572, US20160122828, IT1660.13, ES1660.13, FR1660.13, DE1660.13, GB1660.13; 2013 May 29.

Perona Abellón R, Sastre Garzón L, Pintado Berninches L, Carrillo García J, Molina Pachón A, Irradiccio Silva L, Manguán García C, inventors; CSIC, UAM, Advanced Medical Projects, Centro de Investigación Biomédica en Red (CIBER), assignees. Peptides derived from GSE 24.2 for treating diseases caused by oxidative stress and damage to DNA. P201331573, AU2014338820, CA2931429, EP3061815 PCT/ES2014/070803; 2013 October 25.

Ibáñez de Cáceres I, Pernía Arias O, de Castro Carpeño J, Vera Puente O, Jiménez Hernández J, Perona Abellón R, Rojo Todo F, inventors; FIBHULP, CSIC, UAM, Instituto de Investigación Sanitaria FJD, assignees. Determination of methylation and miRNA levels in response to a platinum-based antitumor compound. P201530997, PCT/ES2016/070516; 2015 July 09.

Ibáñez de Cáceres I, de Castro Carpeño J, Vera Puente O, Pernía Arias O, Rodríguez Antolín C, González Muñoz VM, Martín Palma ME, Salgado Figueroa AM, inventors; FIBHULP, FIBIOHRC, assignees. MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells. EP17382610.8 (EP3681515), PCT/EP2018/068156, US16/647,368; 2017 September 15.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Rodríguez Jiménez C, Rosas Alonso R, Cruz Castellanos P, Burdiel Herencia M, Pernía Arias O, Diestro Tejada MD, Esteban Rodríguez MI, inventors; FIBHULP, assignee. miR-151A-3p as an universal endogenous control for exosome cargo normalization. EP19382252.5 (EP3719144), PCT/EP2020/059774 PCT Direct, EP20719957.1 (EP3947733), US17/601,657; 2019 April 05.

Ibáñez de Cáceres I, de Castro Carpeño J, Rosas Alonso R, Pernía Arias O, Martínez Marín V, Esteban Rodríguez MI, inventors; FIBHULP, assignee. Method for determining the percentage of methylation of the promoter of the gene O6-methylguanine-DNA methyltransferase (MGMT) in circulating exosomes. EP19382299.6 (EP3725899), PCT/EP2020/060753 PCT Direct, EP20723998.9 (EP3956475), US17/604,172; 2019 April 16.

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Vera Puente O, Rosas Alonso R, Pernía Arias O, Losantos García I, inventors; FIBHULP, assignee. Method for determining the response to treatment of a patient affected by non-small cell lung carcinoma (NSCLC). EP19382614.6 (EP3999664), PCT/EP2020/069659; 2019 July 19.

Oto-Neurosurgery Research Group

Polak M, Roca-Ribas Serdá F, Gavilán Bouzas J, Lassaletta Atienza L, Miró Castillo N, Rodrigo Dacosta J, inventors;

MED-EL Elektromedizinische Geraete GmbH, assignee. Hearing treatment in patients with questionable cochlear nerve functionality. US2011275953, PCT/US2011/035312; 2010 May 05.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Martínez Vega R, Cediel Algovia R, inventors; CSIC, UCM, assignees. Anechoic acoustic chamber for evaluating the auditory function in laboratory animals. P201031720; 2010 November 23.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediel Algovia R, inventors; CSIC, UCM, assignees. Method for designing a reverberating acoustic chamber for hearing test with animals. Procedimiento para diseñar una cámara acústica reverberante para ensayos auditivos con animales. P200802895, PCT/ES2009/070433; 2008 October 14.

Marco Contelles JL, Varela Nieto I, Murillo Cuesta S, Rodríguez de la Rosa L, Alcázar Gonzalez A, inventors; CSIC, CIBERER, FIBIOHRC, assignees. Quinolylnitrone derivatives for use in the prevention and/or treatment of hearing loss. EP22382706.4; 2023 July 22

Cancer Molecular Pathology and Therapeutics Targets Group

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Laparoscopic surgical instrument. P201230950, PCT/ES2013/000139; 2012 June 18.

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Surgical device. P201330532, PCT/ES2014/070277; 2013 April 15.

Mechanisms of Tumour Progression Group

Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee. Materials and methods for the derepression of the E-cadherin promoter. US20060003956; 2004 March 03.

Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García A, inventors; UAM, CSIC, assignees. Method for the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.

Research and Diagnosis of Inherited Metabolic Diseases Group

Pérez González B, Ruiz Desviat L, Jorge Finnigan A, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, Barnejee R, inventors; UAM, Universidad de Bergen, Universidad de Michigan, assignees; Compounds useful for the treatment of methylmalonic aciduria. P201330171; 2013 February 11.

Pérez González B, Gámez Abascal MA, Yuste Checa P, Arduim Brasil S, Ugarte Pérez M, Martínez Ruiz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

A, Underhaug J, inventors; UAM, University of Bergen, assignees; Compounds for treating congenital disorders of glycosylation. EP16382373.5, PCT/EP2017/069147; 2016 July 29.

Ruiz-Desviat L, Martínez-Pizarro A, Picó S, Lucas JJ, Andresen BS, inventors; UAM, CSIC,University of Southern Denmark, assignes; Splice shifting oligonucleotides for use in the treatment of diseases characterized by altered inclusion of microexons. PCT/EP2022/077882, EP4163373A1 2023 April 12

Dyslipidemias of Genetic Origin and Metabolic Diseases

Rodríguez Novoa SM, del Monte Vergara A, Rosas Alonso R, Queiruga Parada J, Yuste González F, authors; FIBHULP, assignee. Trademark name: Pharma Genfinder; CM18332183; 2020 November 05.

PHARMA GENFINDER

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Rodríguez Jiménez C, Rosas Alonso R, Cruz Castellanos P, Burdiel Herencia M, Pernía Arias O, Diestro Tejada MD, Esteban Rodríguez MI, inventors; FIBHULP, assignee. miR-151A-3p as an universal endogenous control for exosome cargo normalization. EP19382252.5 (EP3719144), PCT/EP2020/059774 PCT Direct, EP20719957.1 (EP3947733), US17/601,657; 2019 April 05.

Associated Clinician

Glaría Enríquez A, Mañas Rueda A, Velázquez Soto R, inventors; FIBHULP, assignee. Isolation and immobilization device for test animals. P201031519, PCT/ES2011/070709; 2010 October 14.

SURGERY, TRANSPLANT AND HEALTH TECHNOLOGIES AREA

Bone Pathophysiology and Biomaterials Group

González Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich Rodríguez M, Olalde Graells B, Atorrasagasti Goyalde G, Argarate Madariaga N, Pacha Olivenza MA, Fernández Calderón MC, Saldaña Quero L, González Martín ML, Pérez Giraldo C, Gallardo Moreno AM, inventors; CSIC, Fundación Tecnalia Research & Innovation, FIBHULP, Universidad de Extremadura, Centro de Investigación Biomédica en Red (CIBER). Moldable, biodegradable, biocompatible and bioresorbable implant material, method for its preparation and uses thereof. P201530683; 2015 May 18.

Martín Saavedra FM, Vilaboa Díaz NE, Cebrián Hernando V, Arruebo Gordo M, Santamaría Ramiro J, Gómez Navascués L, inventors; FIBHULP, CIBER-BBN, Universidad de Zaragoza, assignees. Fibrin hydrogel with plasmonic nanoparticles; P201330894, PCT/ES2014/070484; 2013 June 14.

Vilaboa Díaz NE, Calzado Martín A, Crespo García L, Saldaña Quero L, Moreo Calvo P, Alastrué Vera V, inventors; FIBHULP, CIBER-BBN, assignees. Chamber device for dynamic cell culture on biomaterials; P201330040, PCT/ES2013/070819; 2013 January 16.

Vilaboa Díaz NE, González Carrasco JL, Saldaña Quero L, Frutos Torres E. inventors; FIBHULP, CSIC, CIBER-BBN, assignees. Method to obtain a metallic-coated biomaterial; P201030949, PCT/ES2011/070400; 2010 June 21.

Vilaboa Díaz NE, Gónzalez Carrasco JL, Multigner Domínguez M, Lieblich Rodríguez M, Muñoz Hernández M, Frutos Torres E, Saldaña Quero L, inventors; FIBHULP, CSIC, CIBER-BBN, Universidad Alfonso X El Sabio, assignees. Magnesium/polymer composite biomaterial for biomedical applications; P201030950, PCT/ES2011/070440; 2010 June 21.

Voellmy R, Vilaboa Díaz NE, inventors; HSF Pharmaceuticals S.A., assignee. Inhibitors of heat shock factor I and uses thereof. US 16501272, 2023 March 7.

Cellular Engineering Group

de Miguel González MP, Arnalich Montiel F, Royuela MM, inventors; FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Universidad de Alcalá, assignees. Corneal endothelium injector; P201131222, PCT/ES2012/070543; 2011 July 18.

De Miguel González MP., Arnalich-Montiel F, Cadenas Martín M, Moratilla Riofrío A.inventors; FIBHULP, FIBHRYC, assignees. Constructos artificiales para su uso en oftalmología, su procedimiento de obtención y utilización del mismo. Patente Europea EP22382119.0 2022 February 14 . PCT/EP2023/053668 2023 February 14.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Clinical Pharmacology Group

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Trademark name: IBJ IberoAmerican Journals; ESM 3.063.048; 2013 February 12.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Trademark name: IberoAmerican Journals Plus; ESM 3.063.052; 2013 February 12.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Trademark name: IberoAmerican Journals Clinical Pharmacology; ESM 3.063.053; 2013 February 12.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Trademark name: IberoAmerican Journals Medicine; ESM 3.063.049; 2013 February 12.

Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Trademark name: PharmArray; USM 86.004.412, CM11.608.403; 2013 July 08, 2013 February 27.

Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP, assignee. Trademark name: CRDataX; CM13.681.614; 2015 May 28.

Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Trademark name: ClinPharmarray. USM87054978, CM15489511; 2016 May 31, 2016 September 07.

Borobia A M, Diago E I, Dueñas F C, García I, Rosas R, Arias P, inventors; FIBHULP, assignee. PREDICT dose. N°019178452; 2025 September 04.

Borobia A M, Diago E I, Dueñas F C, García I, Rosas R, Arias P, inventors; FIBHULP, assignee. Psico PREDICT. N°019178454; 2025 September 04.

Osteoarticular Surgery Research- GICOA Group

Arenas Vara MA, Conde del Campo A, De Damborenea González JJ, Matykina E, Esteban Moreno J, Gómez Barrena E, Pérez-Jorge Peremarch C, Pérez Tanoira R, inventors; CSIC, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, assignees. Titanium materials anodised with fluorine. P201030720, PCT/ES2011/070342; 2010 May 14.

Gómez Barrena E, Cordero García-Galán E, Rico Nieto A, Pozo JJ, Esteban Moreno J, Sarnago H, Lucía

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Gil O, Acero Acero J, Burdío JM. Portable desinfection system based on induction heating; September 2022.

Translational research in maxillofacial surgery and head and neck cancer

Cuéllar Navarro C, Cebrián JL, Magaña Menéndez J, inventors; Hospital General Universitario Gregorio Marañón and Hospital Universitario La Paz, assignees. Dispositivo de determinación de avance mandibular para un usuario con apnea. P202430809; 2024 October 8.

Patients Safety and Quality Research

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES. CM 13.080.056; 2014 July 14.

Translational Research and Innovation in General and Digestive Surgery

Álvarez Gallego M, Castejón Sisamón C, García Prada JC, Meneses Alonso J, inventors; FIBHULP, UC3M, assignees. Rectoscope. P201630551, PCT/ES2017/070249, EP17788865.8, US20190200853; 2016 April 29.

Álvarez Gallego M, inventor; FIBHULP, assignee. Device for the extraction of surgical specimens by insufflation and suction. P201031490, PCT/ES2011/002357; 2010 October 07.

Salinas Gómez J, García Sanz M; inventors; FIBHULP and DISTRIBUCIONES CLINICAS S.A. (DICLISA), assignees. Two-way probe for flushing and/or draining. U202100070; 2021 February 19.

Associated Clinician

Castell Gómez JT, inventor; FIBHULP, assignee. System of "partial" or "total" openings and buttonholes for patient pyjama or nightgown. P200401758; 2004 July 16.

García Fernández J, inventor; FIBHULP, assignee. Anaesthesia machine simulator. P200702128, PCT/ES2008/070109, US20090044803; 2007 July 30.

de Miguel del Campo E, Posadas Mañanes SJ, Reglero Rada GJ, Largo Aramburu C, García Grande A, Merino Martín JJ, Caz Bonillo V, Fornari Reale T, Rodríguez García-Risco M, Señorans Rodríguez FJ, inventors; FIBHULP, UAM, assignees. Composition for the protection of tissues from the digestive tract and the nervous system of radiotherapy patients; P200931189; 2009 December 17.

Goldman Tarlovky L, inventor; FIBHULP, assignee. System and method to obtain data on a patient's breathing cycle. P201030927, PCT/ES2011/070242; 2010 June 16.

de Miguel del Campo E, Reglero Rada GJ, Largo Aramburu C, Fornari Reale T, Rodríguez García-Risco M, Jaime de Pablo L, Santoyo Díez S, Señorans Rodríguez FJ, García Grande A, Merino Martín J, Caz Bonillo JV, Posadas Mañanes SJ, inventors; FIBHULP, UAM, assignees. Composition for the reduction of symptoms associated with menopause; P201031225, PCT/ES2011/070586; 2010 August 05.

Castell Gómez JT, inventor; FIBHULP, assignee. Surgical device for interrupted suture. P201031491, PCT/ES2011/002352, EP2626014, US13/878035; 2010 October 07.

de Miguel del Campo E, Largo Aramburu C, Tabernero Urbieta M, Reglero Rada GJ, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez García-Risco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees. Functional heart-healthy beverage containing wine and extracts of hops; P201131014, PCT/ES2012/070443; 2011 June 16.

Reglero Rada GJ, de Miguel del Campo E, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A, Largo Aramburu C, Tabernero Urbieta M, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez García-Risco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees. Method to obtain extract of hop and the extract obtained. P201230584, PCT/ES2012/070443; 2011 June 16.

Brian Gahan P, Stroun M, García del Olmo D, García Arranz M, Vega Clemente ML, inventors; Peter Brian Gahan, Maurice Stroun, FIBHULP, assignees. Meth-

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

od for blocking tumour growth. EP2808027; 2013 May 29.

Castell Gómez JT, Carrascal Morillo T, inventors; FIBHULP, UNED, assignees. Synthetic surgical mesh. P201331453, PCT/ES2014/000161; 2013 October 03.

Froilán Torres C, de María Pallarés P, Díaz Lantada A, Ortego García P, inventors; FIBHULP, UPM, assignees. Endoscopic accessory.P201730569; 2017 March 31.

Azabal Agudo A, Ruiz-Valdepeñas Martín de Almagro S; Julián García Rivera F, de la Quintana Jiménez P, inventors; UP DEVICES AND TECHNOLOGIES, S.L., FIBHULP, assignees. Dispositivo de corte automático de discos de ostomía. P201830718, PCT/ES2019/070492. 2018 July 16.

Ramírez de Molina A, Tabernero Urbieta M, Reglero Rada G, Torres Olivares CF, Largo Aramburu C, Santamaría Ramiro M, Polo Paredes G, Ruiz Pérez D, de Miguel del Campo E, Álvarez Gómez de Segura I, inventors; Fundación IMDEA Alimentación, UAM, FIBHULP, IGENFARMA, assignees. Composición para la reducción del declive metabólico asociado al envejecimiento y/o el tratamiento de trastornos relacionados al metabolismo lípidico. P201830740; 2018 July 20.

Martín Mateos P, Acedo Gallardo P, Jorcano Noval JL, Díaz Ojeda L, Bonastre Juliá J, Martínez Méndez JR, Largo Aramburu C, inventors; UC3M and FIBHULP, assignees. Device for monitoring the perfusion status of skin flaps. P202130486; 2021 May 31.

Muñoz Caro JM; Azabal Agudo A, Ruiz-Valdepeñas Martín de Almagro S, inventors; FIBHULP and Up Devices and Technologies S.L. assignees. Light diffusing device for photodynamic therapy treatment of anogenital region. U202131773; 2021 September 03.

Gómez Candela C, López Plaza B, Bermejo López L, authors; FIBHULP, assignee. Trademark name: NUTRinvest Grupo de investigación en Nutrición y Alimentos Funcionales; ESM3.649.812-2; 2017 February 02.

De la Quintana Jiménez P, authors; FIBHULP, assignee. Trademark name: #OdeOstomía; CM 016922734; 2017 September 21.

De la Quintana Jiménez P, authors; FIBHULP, assignee. Trademark name: CM 016922858; 2017 September 21.

De la Quintana Jiménez P, authors; FIBHULP, assignee. Trademark name: Ostomía; CM 017131822; 2017 August 22.

Asensio L, inventor; FIBHULP, assignee. Invención. M4250256; 2024 January 26.

MATERNAL INFANT CHILD AND YOUTH RESEARCH

Neonatology Group

Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo C, assignee. Positioning device for neonates (Utility model). U201330102; 2013 January 31.

Pediatric systemic infections; HIV, tuberculosis, imported and emergent diseases

Mellado MJ, Piñeiro R, authors; Asociación Española de Pediatria (AEPED), assignee. Trademark name: PEDIAMÉCUM; ESM 3079824; 2013 June13.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Translational research in pediatric oncology, hematopoietic transplantation and cell therapy
Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees.Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application, IB2019/052042; 2018 March 13.

Pérez Martínez A, Ferreras Puente C,B, inventors; UAM, FIBHULP, Universidad Miguel Hernández de Elche (UMH), Fundación de la Comunitat Valenciana para la gestión del Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), assignees. Memory T cells as adoptive cell therapy for viral infections. EP20382850.4 (EP3974029), PCT/EP2021/076516; 2020 September 25.


Mayán Santos M, Acea Nebril B, Varela Eirín M, Rodríguez-Candela Mateos M, Díaz Carballa CC, Fonseca Capdevila E, Barrio LC, Escudero López A, inventors; Fundación Profesor Novoa Santos- Instituto de Investigación Biomédica de A Coruña (INIBIC), assignees. Composición para el tratamiento de los efectos secundarios de la radioterapia y/o quimioterapia. PCT/ES2020/070269: 2020 April 27

Research in Endometriosis
Hernández A, López A, Spagnolo E, authors; FIBHULP, assignees; Brand name: EndoPaz: 018876162. 2023 May 17, 2023 September 27



Congenital Malformations and Transplantation
Hernández Oliveros F, Nana Gómez Mayoral N, Raya González L, Guijarro Fernández E, authors; FIBHULP, HePA, U-TAD, Guijarro Fernández E, assignees. Trademark name: VTR Virtual Transplant Reality; CM18.000.131;2018 December 14.

Associated Clinician
Martínez A, inventor; FIBHULP, assignee. Pedidosis. N°019079682; 2024 September 16.



OTHER TRADEMARKS OF IdiPAZ
FIBHULP, author; FIBHULP, assignee. Trademark name: IdiPAZ Instituto de Investigación Hospital Universitario La Paz; USM 85.078.878, CM8.871.873; 2010 July 06, 2010 February 10.

FIBHULP, author; FIBHULP, assignee. Trademark name: CEASEC Centro Avanzado de Simulación y Entrenamiento Clínico; ESM 3.567.901-8; 2015 June 22.

CEASEC
Centro Avanzado de Simulación y Entrenamiento Clínico

FIBHULP, author; FIBHULP, assignee. Trademark name: InnoPAZ Plataforma de Innovación Hospital Universitario La Paz; ESM 3.572.575-3; 2015 July 27.

InnoPAZ
Plataforma de Innovación Hospital Universitario La Paz

FIBHULP, author; FIBHULP, assignee. Trademark name: CEASEC Centro Avanzado de Simulación y Entrenamiento Clínico; ESM 3.567.901-8; 2015 June 22.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.5.1.2. Biobank

The Hospital La Paz Institute for Health Research Biobank (IdiPAZ Biobank) is a platform of support service to the Institute's research, product of the integration of different pre-existing nodes with a long and fruitful research trajectory within the University Hospital La Paz. The IdiPAZ Biobank works to obtain, store, manage and distribute large collections of human biological samples of diseases of interest for researchers.

In 2020, the Biobank increased its capacity with the incorporation of new scientific-technical services, and as result the platform has been renamed as Biobanks and Biomodels platform.

This service is created with the collaboration of the University Hospital La Paz, the Foundation for Biomedical Research of the University Hospital La Paz (FIBHULP) and the Carlos III Health Institute, being integrated into the Network of Hospital Biobanks (RetBioH). The Biobank of the University Hospital La Paz - Institute of Health Research of the University Hospital La Paz –IdiPAZ is registered in the National Biobank Network of the Carlos III Health Institute with the code B.0000684.

The *Platform for Biobanks and Biomodels of IdiPAZ* (PT23/00028) belongs to the *ISCIII Biobanks and Biomodels platform* (*https://www.isciiibiobanksbiomodels.es/*) to support research in Biomedicine and Health Sciences from Strategic Health Action 2017-2023 of the Carlos III Health Institute.

The ISCIII Biobanks and Biomodels Platform has joined the European Biobanking Infrastructure (BBMRI-ERIC) as an observing member, acting as the national node in BBMRI-ERIC, one of the most relevant research platforms in the European Union.

Since 2018, the Biobank of IdiPAZ was certified according to the ISO 9001:2015 quality management system standard within the scope of IQNet Certificate IdiPAZ Number ES-0512/2018.

Objectives

The main objective of the IdiPAZ Biobank is to promote biomedical research, which will increase and improve the quality of scientific production in Spain. This is a specialized work in the management of human biological samples and their associated data for biomedical research in accordance with the legislation in force in Spain, Law 14/2007 on Biomedical Research and the RD of Biobanks 1716/2011. This guarantees the confidentiality of the samples and associated data.

The IdiPAZ Biobank provides researchers with an agile channel to access samples; their products and data associated with quality assurances and ethical-legal adaptation.

The obtaining, and if necessary, the revocation, of the patient's informed consent is controlled. Special attention is given to guarantee the protection of privacy and the confidential treatment of personal data contained in the IdiPAZ Biobank, clinical data and research results.

Thanks to this, the development of a continuous dynamic of analysis and evaluation of the needs of the users of the Biobank is favored. In addition, the activity of the IdiPAZ Biobank is made known and valued to society and, especially, in the field of patient and affected associations.

The IdiPAZ Biobank will provide benefits at different levels, starting with donors, patients, society in general and the clinicians and researchers involved. It also aims to facilitate communication and cooperation of different groups with common interests both nationally and internationally.

All of this will result in a higher quality of research and an increase in scientific production, without forgetting the strict compliance with the regulations on Data Protection and the Rights to Privacy and Confidentiality of all patients (Organic Law 3/2018 and Regulation General Data Protection 2016/679).

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Composition

Scientific Director
Eduardo López Collazo (PhD)

Coordinators
Marina Arranz Álvarez (MSc)
Laura Córdoba García (PhD)


Senior Experts in Pathology and Cytology
Sandra Nieto Torrero

HUB Organoids Manager
Laura Córdoba García (PhD)

CONTACT
biobanco.hulp@salud.madrid.org
Phone: Biobank Laboratory (+34) 91 207 11 91

Scientific Committee
David Hardisson Hernáez (MD, PhD)
Enrique Espinosa Arranz (MD, PhD)
Olga Vera Puente (PhD)
Alicia Hernández Gutiérrez (MD, PhD)
Eduardo López Granados (MD, PhD)

Biobank and biomodels (BB)



1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Equipment

- Seven -80ºC deep freezers equipped with remote alarm temperature control and a CO2 backup system. Seven of these are equipped with an open door control software.
- One tank of liquid nitrogen at its gas phase with an alarm temperature control and a lack of CO2 detector.
- W-2D tube system with a data matrix codification for liquids, with a scanner to read col boxes and reader for the identification and the traceability of the tubes.
- Combined refrigerator of 4° C y – 20° C.
- Cryostat to cut frozen samples.
- Microtome y bath/coating to cut paraffin samples
- Laser Microdissector.
- Biological safety cabins IIA.
- Centrifuge with capacity to process samples in tubes and Eppendorfs.
- Automatic platform to manipulate and trace liquids.
- One mini coolers to freeze inclined biological samples below 1ºC.
- Two containers to freeze and transport Isopentane
- One container for the transport of isopentame samples.
- Vortex Mixer /agitator.
- Spectrophotometer (Nanodrop®) – Located in AP service.
- Fungibility: basically kits and the necessary products to process and preserve tissues, blood, and cells.
- Printer/photocopier/scanner.
- 4 computers and a management computer system
- Label printing system and a bar code reader connected to the management software.
- Portfolio of services.

Portfolio of services

HUB Biobank

Technical and scientific assessment:

- Collection and management of new collection
- Work Methodology/ Methods.
- Quality control of DNA/ARN sample treatment
- Expert training to use Biobank management system.
- Training and advice on the use of Biobank management software.
- Information to the investigator on the custody, deposit, availability and transfer of samples associated with the biobank.
- Training of trainees (FCTs) of training cycles.

Sample/collection management:

- Coordinating a collection of samples in multiple study/research centers.
- Storage of pre-existing collections under LIB 14/2007.
- Storage of preexisting samples in accordance with Spain's Biobank laws LIB 14/2007 and 1716/2011 Royal Decree.
- Management and control of Informed Consent (CI) and/or clinic's regarding samples.
- Aliquot of blood/serum/plasma/other liquids
- Sample reception and codification.

Histology techniques:

- Making paraffin block
- Making frozen tissue blocks
- Paraffin/frozen cuts
- Hematoxylin and eosin stain (H&E)
- Other kinds of stains
- Laser microdissection

Cell techniques:

- Purifying and freezing of mononuclear cells of peripheral blood (PMBCs)

Molecular Techniques:

- DNA and RNA quantification via spectrophotometer (NANODROP)

Researchers who wish to deposit their collections in IdiPAZ' Biobank will have to sign an agreement of sample deposit (in which the terms and conditions under which the Biobank will deposit the samples) and in agreement with the existing legislation on the subject. Also, researchers who wish to use our samples will have to sign a Transfer Agreement (Material Transfer Agreement) in which the terms and conditions under which the Biobank will grant the samples.

HUB Organoids

IdiPAZ´s Biobank is working on the establishment of a living biobank of organoid 3D models directly generated from patient biopsies. Patient derived organoids (PDOs) are novel in vitro 3D cell models

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

that preserve the molecular, structural and functional characteristics of their tissues of origin, representing a clinically-relevant alternative to traditional 2D cell lines and an effective tool to study the biology of human tissues in health and disease. Currently we have a comprehensive collection of over 70 highly characterized human intestinal organoids, including rectum and colon, derived from both healthy and colorectal cancer biopsy tissue. This organoid patient-derived collection includes a detailed description of associated patient clinical and pathological data of great value for translational research purposes, as well as histological and molecular characterization of both the tissue of origin and the resulting organoid cultures.

Areas of application

- Studies of tissue morphogenesis and organ development
- Modelling of infectious, genetic and inflammatory diseases
- Oncology and immuno-oncology
- Identification of diagnostic and prognostic biomarkers
- Drug screening for toxicity and efficacy
- Personalized and precision medicine

Portfolio of services

- Culture of human healthy intestine organoids derived from donor biopsies
- Culture of human tumoral intestine organoids derived from donor biopsies
- Paraffin/OCT embeding and sectioning
- Hematoxilin and eosin characterization
- Characterization by immunofluorescence and confocal microscopy of organoid sections and 3D organoids
- Cryopreservation and biobanking

Biobank's scientific indicators

I. N° of samples

During the analysed period (January 2024 – June 2025), the Biobank managed a total of 199,066 samples from various active nodes. This volume reflects strong sample collection and management activity, with a particular focus on strategic areas such as oncology, maternal and child health, infectious diseases, and autoimmunity.

Nodo	Lugar de procedencia	Previo-2023-Disponible	2023-Disponible	2024-Disponible	2025-Disponible	Total
Biobanco IdiPAZ	Banco de líquidos	2.107			2	2.109
Biobanco IdiPAZ	Banco de tumores	23.678	41	1.000	447	25.166
Biobanco IdiPAZ	Cardiología	1.050	9	287	121	1.467
Biobanco IdiPAZ	Dietética y nutrición	171				171
Biobanco IdiPAZ	Digestivo-Inflamatoria	5.049				5.049
Biobanco IdiPAZ	Hematología	170				170
Biobanco IdiPAZ	Inmunología	221				221
Biobanco IdiPAZ	Inmunología II	358				358
Biobanco IdiPAZ	Inmunología celular I	2.897				2.897

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Nodo	Lugar de procedencia	Previo-2023-Disponible	2023-Disponible	2024-Disponible	2025-Disponible	Total
Biobanco IdiPAZ	Inve-Complemento	5.000	37	1.002	79	6.118
Biobanco IdiPAZ	Inve-Hepatología Molecular	2.388				2.388
Biobanco IdiPAZ	Inve-Ingeniería Celular	122				122
Biobanco IdiPAZ	Inve-Patología Oncológica	34.030	58	1.483	600	36.171
Biobanco IdiPAZ	Inve-Reumatología	50		12		62
Biobanco IdiPAZ	Medicina interna	496			45	541
Biobanco IdiPAZ	Microbiología	11.822		732	1.024	13.578
Biobanco IdiPAZ	Neonatología	1.143		84	15	1.242
Biobanco IdiPAZ	Neurología	2.183				2.183
Biobanco IdiPAZ	Nodo COVID	2.302		2.800		5.102
Biobanco IdiPAZ	Nodo central	3.270				3.270
Biobanco IdiPAZ	Obstetricia	31.160	2	17	4	31.183
Biobanco IdiPAZ	Organoides	444		25		469
Biobanco IdiPAZ	Psiquiatría	907				907
Biobanco IdiPAZ	SEIMC-GESIDA	10.945				10.945
Biobanco IdiPAZ	Tumor Inmunología	2				2
Biobanco IdiPAZ	Unidad de VIH	6.929				6.929
Biobanco IdiPAZ	Urología-Nefrología	19.032	253	4.866	3.195	27.346
INGEMM	INGEMM	358		12		370
Inve-hipersensibilidad	Inve-hipersensibilidad	7.807		50	29	7.886
Neonatología	Neonatología				2.951	2.951
Neurología	Neurología				416	416
Terapia Celular	Terapia Celular	958		282	24	1.264
Unidad de trasplantes digestivos	Digestivo-Inflamatoria				13	13
		177.049	**400**	**12.652**	**8.965**	**199.066**


IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

II. Number of Strategic Collections Created

At the Biobank, we consider strategic collections to be those that, in addition to complying with regulatory and quality requirements, are aligned with institutional, healthcare, or scientific priorities, and provide added value in the field of translational biomedical research. The criteria that define a strategic collection include:

- Public health relevance, such as highly prevalent, emerging, or closely monitored diseases (e.g., COVID-19, HIV, cancer).
- Integration into national or international research networks, consortia, or platforms, or involvement in competitively funded projects.
- Usefulness in personalized or precision medicine, through inclusion of detailed clinical data, biomarkers, or genetic/immunological profiles.
- Application of innovative technologies, such as organoids, cell therapies, advanced molecular biology, or tissue engineering.

As such, the strategic collections created during this period include:

- COVID Node
- HIV Unit / SEIMC-GESIDA
- Tumor Bank
- INGEMM
- Organoids
- UCICEC Node
- Inve-Molecular Hepatology
- Cell Therapy
- Inve-Cellular Engineering
- Psychiatry
- Neurology

These collections not only address current health needs, but also offer essential infrastructure for the advancement of high-impact biomedical research.

III. % of Collections with Standardized or Detailed Clinical Data

In accordance with Royal Decree 1716/2011 of November 18, which regulates the basic requirements for the authorization and operation of biobanks for biomedical research purposes—as well as the processing and transfer of human biological samples—all collections managed by a biobank must be associated with relevant clinical data, sufficiently standardized and coded to ensure their traceability and scientific utility in research.

In compliance with this regulation, and following the guidelines of Decree 9/2016 of the Community of Madrid, which governs the operation of biobanks at the regional level, it is guaranteed that 100% of the collections held by the Biobank include standardized or detailed clinical data, integrated into secure information systems and accessible for use in accordance with authorized scientific purposes

IV. Compliance with ISO 9001:2015 and ISO 20387:2018

The Biobank was included in the Integrated Management System (SIG) of IdiPAZ/FIBHULP from January 20, 2020, until May 5, 2025, following the last external audit for ISO 9001:2015 conducted at the Institute. During this period, and in accordance with the Biobank's operational processes included in the system, the AENOR certificate ER-0512/2028 covered the following scope: "Reception, preparation, preservation, and distribution of human biological samples for biomedical research purposes under Biobank governance."

On May 20, 2025, the Quality Commission of IdiPAZ resumed meetings with Biobank representatives to initiate its reintegration into the SIG in preparation for the upcoming certification cycle scheduled for June 2026.

In parallel, the Biobank is actively preparing to meet the requirements of ISO 20387:2018, the specific accreditation standard for biobanks. Unlike ISO 9001:2015, this standard sets stricter requirements and must be accredited exclusively by ENAC, the national accreditation body. It is not a voluntary certification but a high-standard regulation aimed at ensuring technical competence and procedural quality. Although the Biobank's adaptation to ISO 20387:2018 is already well advanced, the formal application for accreditation has not yet been submitted. The defined strategy consists of first consolidating ISO 9001:2015 certification in the upcoming 2026 cycle and, once achieved, progressing toward ISO 20387:2018 accreditation as the next step.

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

V. Publications with the mention of IdiPAZ Biobank authorship attribution

TIPO DE PUBLICACIÓN	AUTORES	TÍTULO	REVISTA	PMID
Artículo original	Guillén-Yunta M, García-Aldea A, Valcárcel-Hernández V, Sanz-Bógalo A, Muñoz-Moreno E, Gisele Matheus M, Grijota-Martínez C, Montero-Pedrazuela A, Guadaño-Ferraz A, Bárez-López S	Defective thyroid hormone transport to the brain leads to astroglial alterations	Neurobiol Dis	39097035
Pre-print	de Lourdes Moreno M, González-Rovira M, Martínez-Pancorbo C, Martín-Cameán M, Nájar-Moyano A.M, Romero M, de la Hoz E, López-Beltrán C, Mellado E, Bartha J.L, Brodin P, Rodríguez-Herrera A, Sainz-Bueno J.L, Sousa C.	Fetal-maternal interactions with gluten immunogenic peptides during pregnancy: a new determinant on the coeliac exposome	medRxiv	39020299
Artículo original	Feliu J, Gámez-Pozo A, Martínez-Pérez D, Pérez-Wert P, Matamala-Luengo S, Viñal D, Kunz L, López- Vacas R, Dittmann A, Rodríguez-Salas N, Custodio A, Fresno Vara J.A, and Trilla-Fuertes L.	Functional proteomics of colon cancer Consensus Molecular Subtypes	British Journal of Cancer	38486123
Artículo original	Guerrero L, Vindel-Alfageme J, Hierro L, Stark L, Vicent D, S. Sorzano C.O and J. Corrales F.	Discrimination of Etiologically Different Cholestasis by Modeling Proteomics Datasets	Int. J. Mol. Sci.	38612495
Artículo original	Bustamante-Madrid P, Barbáchano A, Albandea-Rodríguez D, Rodríguez-Cobos J, Rodríguez-Salas N, Prieto I, Burgos A, Martínez de Villarreal J, X. Real F, González-Sancho J.M, Larriba M.J, Lafarga M, Muñoz A and Fernández-Barral A.	Vitamin D opposes multilineage cell differentiation induced by Notch inhibition and BMP4 pathway activation in human colon organoids	Cell Death and Disease	38684650
Artículo original	Pastor-Morate D, Amigo-Morán L, Garranzo-Asensio M, Rejas-González R, Carnicero P, Rodríguez N, Pérez-Robledo J.P, Barderas R, Prieto-Nieto I and Domínguez G	ΔNp73 and its effector targets promote colorectal peritoneal carcinosis and predict survival	The Journal of Pathology	38629257
Artículo original	Pinto A, Trilla-Fuertes L, Pedregosa-Barbas J, García-Fernández E, L Wisultschew-Puigdellivol A, Zambrana F, Martinez I, Gajate P, Dittmann A, Lopez Vacas R, Kunz L, Rubio G, Nieto-Torrero S, Lalanda-Delgado P, Pertejo A, Saiz A, González-Peramato M.P, Fresno-Vara J.A, and Gámez-Pozo A.	Response to neoadjuvant chemotherapy according to molecular subtypes in muscle-invasive bladder carcinoma	Journal of Clinical Oncology	270325339
Artículo original	Lorenzo-Sanz L, Lopez-Cerda M, da Silva-Diz V, H. Artés M, Llop S, M. Penin R, Oriol Bermejo J, Gonzalez-Suarez E, Esteller M, Viñals F, Espinosa E, Oliva M, M. Piulats J, Martin-Liberal J & Muñoz P.	Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma	Nature Communications	38914547
Artículo original	Perez Wert J.P., Hernández-Fernández S., Gámez A., Arranz-Alvarez M., Ghanem I.,. López-Vacas R, Diaz-Almirón M., Mendez C., Fresno-Vara J-A., Feliu J., Custodio A., Trilla L.	Layer analysis based on RNA-seq data of TCGA reveals gastric cancer's molecular complexity	Annals of Oncology	39518924
Artículo original	de Lourdes Moreno M, González-Rovira M, Martínez-Pancorbo C, Martín-Cameán M, Nájar-Moyano A.M, Romero M, de la Hoz E, López-Beltrán C, Mellado E, Bartha J.L, Brodin P, Rodríguez-Herrera A, Sainz-Bueno J.L, Sousa C.	Foetal gluten immunogenic peptides during pregnancy: a new determinant on the coeliac exposome	BMC Med	39020299

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

TIPO DE PUBLICACIÓN	AUTORES	TÍTULO	REVISTA	PMID
Artículo original	Pinto A, Trilla-Fuertes L, Pedregosa-Barbas J, García-Fernández E, L Wisultschew-Puigdellivol A, Zambrana F, Martinez I, Gajate P, Dittmann A, Lopez Vacas R, Kunz L, Rubio G, Nieto-Torrero S, Lalanda-Delgado P, Pertejo A, González-Peramato M.P, Fresno-Vara J.A, and Gámez-Pozo A.	Prediction of response and identification of mechanisms of resistance to neoadjuvant chemotherapy according to molecular subtypes in muscle-invasive bladder carcinoma	Annals of Oncology	---
Artículo original	Perez Wert J.P., Hernández-Fernández S., Gámez A., Arranz-Alvarez M., Ghanem I.,. López-Vacas R, Diaz-Almirón M., Mendez C., Fresno-Vara J-A., Feliu J., Trilla L. and Custodio A.	Layer Analysis Based on RNA-Seq Reveals Molecular Complexity of Gastric Cancer	Int. J. Mol. Sci.	39518924
Artículo original	Mendiola M, Heredia-Soto V, Ruz-Caracuel I, Baillo A, Ramon-Patino J.L, Berjon A, Escudero F.J, Pelaez-Garcia A, Hernandez A, Feliu J, Hardisson D, Redondo A.	Performance of the Idylla microsatellite instability test in endometrial cancer	Molecular and Cellular Probes	39069012
Artículo original	Mato S, Carità L , Colmenero A, Andrés M, Balagué O, Andión M, Astigarraga I, Celis V, Mendoza C, Guerra-García P, Valero L, Galera A, Tallón M, Pol M, Castrejón-de-Anta N, Frauenfeld L, Garcia N, Campo E, Salaverria I, Verdú-Amorós J.	Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents	Br J Haematol	40011029
Artículo original	Arriero-País E.M, Bajo-Rubio MA,Arrojo-García R, Sandoval P, González-Mateo T, Albar-Vizcaíno P, del Peso-Gilsanz G, Ossorio-González M, Majano P, López-Cabrera M , RICORS 2040-Renal	Biomarker and clinical data–based predictor tool (MAUXI) for ultrafiltration failure and cardiovascular outcome in peritoneal dialysis patients:a retrospective and longitudinal study	BMJ Health Care Inform	40021191
Artículo original	Chocarro-Calvo A, Jociles-Ortega M,García-Martinez J.M, Louphrasitthiphol P, Carvalho-Marques S, Vivas-García Y, Ramírez-Sánchez A, Chuhan J, Fiuza M.C, Druan M, Sánchez-Danés A, R. Goding C and García-Jiménez C.	Fatty acid uptake activates an AXL–CAV1–β-catenin axis to drive melanoma progression	Genes & Development	40015991
Artículo original	Pinto-Marín A, Trilla-Fuertes L, Miranda Poma J, S. Vasudev N, García-Fernández E, López-Vacas R, Miranda N, Wilson M, López-Camacho E, Pertejo A, Dittmann A, Kunz L, Brown J, Pedroche-Just Y, Zapater-Moros A, de Velasco G, Castellano D, González-Peramato P, Espinosa E, E. Banks R, Fresno Vara J.A and Gámez-Pozo A	A prognostic microRNA-based signature for localized clear cell renal cell carcinoma: the Bio-miR study	British Journal of Cancer	40335662
Artículo original	Lozano-Rodríguez R, Hierro L, Quiles MJ, Pascual-Iglesias A, Terrón-Arcos V, Muñoz-Bartolo G, Frauca E, Cueto FJ, Calvo C, Córdoba-García L, Fernández-Felipe J, Hurtado-Navarro L, Del Prado-Montero J, Sáenz de Santa María-Diez G, Arvelo-Rosario D, Jara P, Del Fresno C, López-Collazo E.	Comprehensive immune profiling and predictive modelling of paediatric acute hepatitis of unknown aetiology from a Spanish cohort	Frontiers in Immunology	37774733

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.5.1.3. UCICEC-Central Unit for Clinical Research and Clinical Trials

The Central Unit for Clinical Research and Clinical Trials of La Paz University Hospital (UICEC-HULP) is one of IdiPAZ's research support platforms. It was created with funding from the Ministries of Health and of Science and Innovation to establish research support structures, and it is part of the Spanish Clinical Research Network (SCReN), whose General Coordination it has held since 2021. Over the past five years the Unit has led or participated in more than 130 academic clinical trials.



Objectives

The fundamental objective of the UICEC La Paz is to establish a clinical research support infrastructure at La Paz University Hospital capable of promoting the health and well-being of citizens. To this end it has the human and material resources, and the operational and functional procedures, needed to:

- Advance clinical research and its projection into healthcare development and innovation.
- Contribute to the resolution of healthcare problems.
- Promote participation in national and international clinical research, especially within the European Framework Programmes for R&D&I.
- Promote the transfer of clinical research results into clinical practice.

Its broad portfolio offers support to researchers in the design, implementation (submission to Ethics Committees and regulatory agencies), management, monitoring, analysis and report writing of clinical trials and research projects. The Unit also performs clinical trial coordination, feasibility assessment, administrative tasks, audit and inspection preparation, and data and adverse-reaction management. Nursing tasks (sample collection, processing and shipping) are carried out in accordance with Good Clinical Practice (GCP). The UICEC also runs a Phase I–II Clinical Trials Unit for early-phase trials in healthy volunteers and patients.

Activity

Over the past five years the UICEC has led or participated in more than 130 academic clinical trials, and contributing to several hundred comercial clinical research studies across Phases I to IV. Its activity is especially strong in highly specialized areas, including paediatric haemato-oncology, early-phase advanced therapies (cell and gene therapy) and first-in-human Phase I trials in both healthy volunteers and patients; the Phase I Unit is one of the few in Spain validated by EFPIA for first-in-human studies and has been ITCC-accredited since 2016. The Unit holds ISO 9001:2015 certification (since 2017) and has successfully passed, on average, seven private-sponsor audits per year, as well as inspections by the AEMPS and the FDA, all satisfactory. It has acted as national coordinator of major European clinical trials within the VACCELERATE, EU-RESPONSE and IMI-CARE projects, while its director coordinates the IHI-READI consortium (80 organizations across 18 EU countries) and leads work packages in ERA4TB, LIVERATION and ECRIN2030.

Facilities and equipment

The UICEC operates across three locations: a main site on the semi-basement floor of the Outpatient Clinic Building at La Paz University Hospital, satellite offices in the IdiPAZ research institute building, and a satellite office in the Pediatrics Hospital. Its facilities include a monitoring room with four workstations for external staff, a medical consultation room, a meeting room, a centralized laboratory and sample-collection point, work offices and a multipurpose room. The Phase I Unit has eight inpatient beds and four patient chairs and is fully equipped for early-phase trials, with a crash cart and defibrillator, electrocardiographs, blood-pressure monitors, continuous monitoring systems (ECG, blood pressure and SatO2), telemetry devices and infusion pumps. The Unit also has telemedicine systems integrated with the hospital information systems (acquired under the UICM24 grant), including ten kits with a thermometer, pulse oximeter, blood-pressure monitor, digital stethoscope, tablet and smartwatch, as well as computers for all staff, dedicated WiFi and two advanced videoconferencing systems. The clinical area is fully integrated into the hospital's care circuit, with access to its Critical Care, Radiology, Laboratory, Cardiology, Genetics and Pathology services.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Composition

Management and cross-functional staff

Dr. Alberto M. Borobia Pérez
Director of the UICEC; Head of the Clinical Pharmacology Department; General Coordinator of the SCReN Platform.
Dr. Irene García García
Deputy Director and Scientific Coordinator; Deputy Coordinator of the SCReN Platform.
Blanca Duque Bascuñana
Quality Assurance Manager
Cristina Miragall Roig
Administrative Secretary
Pilar Ayllón García
Laboratory Technician

Scientific staff – support to investigator-driven clinical research (Investigators)

Dr. Alicia Marín Candón
First-in-human trials coordinator (also pharmacovigilance support)
Dr. Elena Diago Sempere
Head of Pharmacovigilance
Dr. Javier Guijarro Eguinoa
Advanced therapies scientific support coordinator
Dr. Arturo Gómez López de las Huertas
Phase I trials and population pharmacokinetics coordinator
Dr. Mikel Urroz Elizalde
Clinical Pharmacologist

Academic trial management and monitoring

Dr. Rocío Mª Prieto Pérez
Head of the monitoring team

Trial managers
Suriñe Valdespina Macaya, Noa Baz Baz

Monitors
Celia Cano Sanz, Jimena de Andrés Codina, Lucía García de la Fuente

Data management and statistics

Data managers
Mª Teresa García Morales, Diego Alvaredo Rodrigo

Statistics and pharmacometrics
María Jiménez González, Vega Rey Mauleón

International projects management

Paloma Moraga Alapont
International activities coordinator

International monitors/managers
Belén Ortiz del Castillo, Cristina Marian Revilla, Ignacia Ceballos

SCReN Platform Coordination support

Five managers funded under the Platform Coordination grant (PTC23)
Víctor Alelú, Victoria Hernández, María José Rubira, Gema de Prado, Amparo Sánchez

Support to industry-sponsored trials

Nursing supervisor
Tamara Domingo

Nursing coordinators
Vega Mauleón Martínez (nursing team coordinator), Raquel de Madariaga Castell, Laura Vitón Vara, Ana Ortega Pita, Cristina López Crespo, María Almena Rueda

Specific-area trial coordinators
Carlos M. Oñoro López (infectious and immune-mediated diseases), Andrés Gómez Dávila (paediatric haemato-oncology), María García Llorente (paediatric haemato-oncology)

Data entry
Silvia Llorente Gómez, Beatriz Llorente Robledo, Sira Alonso Collado

Clinical Trial Assistants
Laura Lozano Infante, Marta Alonso López

Waste management
Eduardo Royón Gómez

Portfolio of services

- Study design and protocol development
- Submission to Ethics Committees and regulatory agencies
- Feasibility assessment
- Scientific advice
- Statistical analysis plans and sample-size calculation
- Statistical analysis and pharmacometrics
- Development of electronic data collection notebooks (eCRD)
- Data management and data entry
- Pharmacovigilance planning and conduct
- Project management and study start-up
- Development of monitoring plans and monitoring of clinical trials
- Clinical trial coordination and patient recruitment support
- Medical and nursing procedures
- Management of biological sample shipment
- Preparation of final and expert reports
- Publication of results
- Academic CRO activities (ARO and SCReN)

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.5.2. IdiPAZ Platforms

2.5.2.1 Biostatistic and Bioinformatics Platform

The Biostatistics and Bioinformatics Platform is a pioneer in the field of research support in hospitals and performs work that is recognised by the vast majority of professionals who, for several decades, have requested statistical advice for their research work or for other studies with immediate application to healthcare practice.

The Biostatistics and Bioinformatics Platform aims to provide high-quality support for research, providing statistical consulting services for research projects or other studies with immediate application in clinical practice.

It is structured into three areas:

- Observational studies
- Clinical trials
- Data management and development of case report forms (eCRFs)

Portfolio of services Biostatistics

- Methodological consulting for the design of research projects and clinical trials, including protocol development and statistical analysis plan (SAP) preparation.
- Sample size determination and power calculations for clinical trials and research studies.
- Statistical analysis of research and clinical trial data, preparation of interim and final study reports, and futility analyses.
- Data management for research projects and clinical trials, including eCRF design in Macro and REDCap, preparation of data management plans, and data validation procedures.
- Development of dedicated software tools for the extraction and preprocessing of data from healthcare and research information systems.
- Support in the interpretation of scientific literature and assessment of its applicability to clinical practice.
- Evaluation and validation of diagnostic tests.
- Development of clinical scales, scoring systems, and predictive indices.

Composition

Director
Alberto M. Borobia. MD, PhD

Head of Statistics
María Jiménez González

Clinical Biostatisticians
Vega Rey Mauleón
María Martínez Balaguer
Itsaso Losantos García
Odelaisy León Triana

Clinical epidemiologist
Jesús Díez Sebastián. MD, PhD.

Head of Data Management
María Teresa García Morales

Data Managers
Francisco Gayá Moreno
Elisa Medrano Buendía
Diego Alvaredo Rodrigo

Bioinformatic Coordinator
Carlos Rodríguez Antolín

Bioinformatics
Antonio Giráldez Trujillo
Claudia Sánchez Lara
Beatriz Ruz Caracuel
Lucía de Dios Blázquez
Pamela Karime Heredia G. Canton

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Portfolio of services Bioinformatics

1. Experimental Design and Methodological Support

- Guidance in omics experimental design (protocol optimization, methodological planning, and validation strategies).
- Support for the interpretation of results and the preparation of scientific publications.
- Retrieval of omics datasets from publicly available external repositories.
- Support for accessing omics datasets hosted in private external repositories.
- Submission of omics datasets to external repositories (e.g., GEO, SRA, or ENA).
- Training courses and educational workshops.
- Short-term data storage.
- Long-term data storage.

2. Data Analysis

- DNA-seq (targeted panels, exomes, and whole genomes; germline, somatic, mitochondrial, mosaicism analyses, etc.).
- RNA-seq (poly(A)-selected, total RNA, small RNA, and long non-coding RNA).
- Methyl-seq.
- ATAC-seq.
- ChIP-seq.
- Microarrays (DNA methylation, gene expression, and genotyping arrays).
- CRISPR-Cas9 screening.
- Pharmacogenomics.
- Long-read sequencing.
- Single-cell omics.
- Spatial genomics.
- Multi-omics data integration.
- Development of classification and predictive models through the application of artificial intelligence algorithms to omics datasets.
- Discovery of genomic and epigenomic signatures.
- Quality control of omics datasets.



Biostatiscs Activity in 2025

In 2025, ISO 9001:2015 certification was achieved for the activities carried out by the Biostatistics and Bioinformatics Platform.
In 2025, there were 263 requests (almost 71.45% more than in 2023).

Services requested	Number of requests
Methodological design consulting	51
Sample size calculation	45
Data analysis	189
eCRD design	63*

**Note: an increase of more than 50% compared to last year.*

The response time to the request registered by the investigador through the Platform is 48-72 hours.

Within the IDIPAZ MENTOR program, the Biostatistics and Bioinformatic Platform provides support to investigators reviewing proposals, calculating sample sizes, and providing methodological advice. In 2025, more than 100 applications were received for the MENTOR program.

The Biostatistics and Bioinformatics Platform is fully integrated with ISCIII platforms such as SCReN (Spanish Clinical Research Network), providing support in methodological, data management and statistics tasks for national and international clinical studies.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians


2.5.2.2. Experimental surgery

Research and teaching at IdiPAZ involving the use of laboratory animals are managed through the experimental surgery platform of IdiPAZ, supervised by Dr. Carlota Largo Aramburu. This department develops biomedical research projects, specialized training courses in various areas, as well as procedures to implement new diagnostic techniques or therapies involving the use of experimental animals.

All experimental procedures are conducted in accordance with Spanish and European regulations regarding the protection of animals used for research and teaching purposes (RD 53/2013; EU 63/2010). Special emphasis is placed on the application of the 3Rs principle in biomedical research: Replacement, Reduction, and Refinement.

All procedures are evaluated by the Center's Ethics Committee and authorized by the competent authority (CAM)

The Experimental Surgery Section includes a microsurgery room, an operating room, an animal facility, and service areas (changing rooms, office, and staff room). The microsurgery room is used for performing microsurgical procedures on small species, mainly rodents. It is equipped with surgical microscopes, inhalation anesthesia systems, and cardiovascular monitoring. It also has mobile tables and fixed benches that allow for flexible arrangements, making it versatile for both microsurgery courses and laparoscopic simulation. The operating room is fully equipped with complete surgical stations: surgical tables, anesthesia stations, and cardiovascular monitoring systems. It also has laparoscopic, ultrasound, and X-ray equipment. This room is used for all procedures involving large animals (rabbits, pigs, or sheep), as well as training courses in various specialties such as laparoscopic surgery, anesthesia, trauma care, and the development of surgical techniques.









IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Animal facility

The animal facility is located on the second basement level of the IdiPAZ building within the hospital complex and is structured into two zones based on the level of barrier protection employed: a conventional multi-species area and an SPF-barrier zone designed primarily for working with immunocompromised models.

The conventional multi-species area has a total of seven rooms for housing animals, both in breeding and experimental phases, plus one room for handling animals and experimental procedures. The wash room is equipped with a cage washer, an autoclave, and a pressure-washing system. To ensure proper operation, it is connected to the other departments of the Experimental Surgery unit, which include a double operating room, a multipurpose microsurgery room, and various additional rooms (changing rooms, offices, and storage areas).

The species typically used include rodents (rats, mice, and gerbils), rabbits, pigs, and occasionally sheep, and goats. There is also a housing unit for fish (zebrafish). To avoid contamination and ensure an efficient workflow, the rooms for housing large animals are physically separated from those for rodents and the rest of the facilities (washing area, storerooms, or handling room). Additionally, all rooms are equipped with an external video camera system to monitor the interior and avoid unauthorized personnel entry.

All animals have a species-appropriate enrichment system (balls, wooden blocks, or nesting material) that allows them to engage in natural behaviors. Additionally, socialization and habituation protocols have been developed to minimize stress associated with handling and experimental procedures.







The cages provide the minimum dimensions required for housing pigs and/or small ruminants. The structure of each cage includes stainless steel anchored to the wall, with sliding separators that allow the expansion of space by joining two cages. The rooms have the necessary slope to encourage the elimination of solid residue through a drain located at the rear of the cage, equipped with protection systems to prevent the entry of rodents or insects.

The rabbit housing room includes modular mobile racks of 3, 6, or 9 cages, in which the rabbits are housed in individual stainless steel cages with plastic grids, complemented by an internal box structure that allows the animals to hide or climb to a higher position.

The rodent area is separated from the rest of the facility by a system of doors without locks, where staff can dress appropriately before entering (boots, gown, gloves, cap, and mask). This area contains tree rooms for housing rats and mice. There is also a storeroom for food and shavings, as well as a room for handling and performing procedures.

The SPF area for immunodeficient mice with capacity for 4 ventilated racks, a housing area for them, and an SPF laboratory. This room is located in an isolated area within the biocontainment facility, with restricted access and airlock systems to prevent the entry of pathogens. The door has controlled access and features a HEPA filtration and ventilation system for both incoming and outgoing air, ensuring the air circulates without introducing pathogens.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Composition Staff

The Experimental Surgery Section has specialized staff dedicated to animal care and the execution of various activities. This means that, in addition to specific healthcare training, all staff members must be certified by the competent authority (CAM) to work with laboratory animals, in accordance with Royal Decree 53/2013 (February 1)—which establishes basic regulations for the protection of animals used in experimentation and other scientific purposes, including teaching—and Training Order ECC/566/2015, which outlines the mandatory training requirements and continuing education needed to maintain this certification.

The team consists of: a veterinarian specializing in animal health and welfare; nursing staff, including a nursing supervisor and two nursing care technicians; a laboratory technician; an administrative technician responsible for activity coordination and management; and three animal care attendants.

Section Head and Veterinarian:
Carlota Largo Aramburu

Manager:
Verónica Priego Álvarez

Technicians and assistants:
María del Mar Varona García
Fernando Gil Villaverde
Rubén Ruiz Garzón
Paloma Guijarro Bachiller
Mª del Carmen Rius Copoví
Lourdes Hernanz del Álamo
Elena Martín de Castro



Portfolio of service

- Animals for experimentation (own breeding)
- Housing and maintenance of animals
- Leasing of spaces for conducting courses (microsurgery laboratories and operating room)
- Performance of surgical procedures on large animals (leasing space and anaesthesia, does not include surgery)

Animal experimentation projects approved by the competent authority in 2025.

- "Effect of peripheral nerve injury on the development of post-traumatic joint stiffness in an experimental rat model." Dr. Samuel Antuña.
- "Fighting Pancreatic Cancer: A New Therapy Combining Intraperitoneal Hyperthermia and Local Chemotherapy" Dra. Nuria Vilaboa.
- "Diagnosis and Treatment of Cerebrovascular Diseases Using Advanced Imaging and Multimodal Therapy Technologies" Dra. María Gutierrez.
- "Normothermic regional perfusion with ECMO: pulsatile vs. linear flow in an animal model" Dra. Belén Estébanez.
- "Strategic activation of regulatory T cells to treat inflammation and promote tissue regeneration". Dr. Luiz Stark.

Currently, there are more than 15 investigations with living experimental models.

Training activity

The experimental surgery platform has hosted more than 25 training activities in addition to the fine-tuning of new surgical techniques or medical device and the training of multidisciplinary teams and residents.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



2.5.2.3. Internationalisation

The Internationalisation Platform of IdiPAZ is the office in charge of mobilising, promoting and managing the international projection of the research groups. Our continuous objective is to promote the different research groups that make up the institute at an international level, identifying possible synergies between groups and centres, new partners and sources of funding, as well as the formation of strategic alliances. To this end, we try to maintain open dialogues, not only with our researchers but also with the policy centres involved in the designing and planning the future of research in the European Union.

Throughout 2025, the Platform has relied on the efforts of its structural staff:
José Luis NARRO VILLANUEVA, MBA
Santi RELLO VARONA, PhD
Marta CASALES SANTA, BSc

Besides, the Platform wish to thank to all the management personnel hired under the international funded projects granted to the institute, for their collaboration and efforts towards the successful execution of all the actions.

During 2025, the Internationalisation officers have navigated the increasing effort required to apply with success to Horizon Europe (HE), while managing the 31 internationally funded projects active during the year. We have attended 71 events, workshops and information days concerning the deployment of new rules, tips for proposal preparation, brokerage events and the deployment of new standards of international research and innovation. In addition, we have organised and performed three training courses, workshops or research stages.

In 2025, we explored our involvement in 58 initiatives, which translated into 52 proposals (almost a three-fold increase from 2024) for competitive international research public funding (HE, EU4HEALTH and Partnerships) of which, nine new projects have been already granted.

Among the granted projects, we highlight COMPASS as an example of the capacity of the Platform to identify a call (HORIZON-JU-IHI-2025-09-single-stage), exploring and contacting building-up consortia and presenting the idea to IdiPAZ's researchers. As a result, the cardiotoxicology group, led by Dr. Teresa LÓPEZ FERNÁNDEZ will contribute to the development of new technologies for the benefit of those patients.

Year 2025 represented also the end of the first Horizon project coordinated by the institute, RISEinFAMILY, with a final event organised in Belgrade (Serbia). And the beginning of the READI project, also coordinated by the institute, with a big kick-off event held in January.

Besides, the Platform's staff participates directly in the IdiPAZ involvement in the Experts' Group assessing the Spanish National Representative for EU Health Research, *Red de Entidades Gestoras de Investigación Clínica* (REGIC) and the Coalition on Advancement of Research Assessment (CoARA).

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Throughout 2025 we have managed the following financed and active international projects:

Project		Programme	Logo
ASSIST	AI-powered triage of acute myocardial infarction and chronic heart disease	EIT-HEALTH	ASSIST
CARE	Corona Accelerated R&D in Europe	H2020-IMI	CARE
CLARITY	Causative Link between respirAtory syncytial viRus and chronic lung diseases: Identifying Targets for therapY	HE	CLARITY
CORDIAL	Clinical validation of a continuous flow peritoneal dialysis system, with dialysate regeneration	H2020	CORDIAL
EHRA-PATHS	Addressing multimorbidity in elderly atrial fibrillation patients through interdisciplinary, tailored, patient-centred care pathways	H2020	EHRA-PATHS
ERA4HEALTH	Fostering a European Research Area for Health Research	HE	ERA4Health Partnership
ERA4TB	European Tuberculosis Regimen Accelerator	H2020-IMI	ERA4TB
ERICA	European Rare Disease Research Coordination and Support Action	H2020	ERICA
ERN BOND	European Reference Network on Rare BONe Diseases 2023-2027	EU4HEALTH	ERN BOND
EUnetCCC	The European Comprehensive Cancer Centre Network	EU4HEALTH	EUnetCCC

Project		Programme	Logo
EU-RESPONSE	European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases	H2020	EU RESPONSE
EUROHEARTPATH	EuroHeartPath: Leading Innovation in Cardiovascular Pathways for Improved Patient Outcomes	HE-IHI	EuroHeartPath
GRACE	bridGing gaps in caRdiAC health managEment	HE-IHI	Grace
iroNKiller	Joining the forces of Natural Killer Cells and Ferroptosis to treat Refractory Neuroblastoma	HE-MSCA	IRONKILLER
ISIDORe	Integrated Services for Infectious Diseases Outbreak Research	HE	ISIDORe
JARDIN	Joint Action on ERN Integration	EU4HEALTH	JARDIN
LIVERATION	Unravelling the impact of Radiofrequency in liver surgery: the key to decrease local recurrence?	HE-MISSION CANCER	Liveration

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Project		Programme	Logo
MIMECOR	Biomimetic Cornea fabrication by 3D printing and adult Mesenchymal Stem Cell directed differentiation	HE-MSCA	
MPX-RESPONSE	A clinical research network to improve the management of Monkeypox virus disease.	HE	
ORTHO-ALLO-UNION	ORTHOpaedic treatment with ALLOgenic combined ATMP in long bone fracture delayed UNION and nonunion	HE	
PROACT EU-RESPONSE	A European proactive adaptative Clinical Trials network	HE	
PROTECT CHILD	A PRivacy-prOTecting Environment for Child Transplants health-related and genomic data integration in the European Reference Network.	HORIZON EUROPE	
READI (Coordinated by IDIPAZ)	Research in Europe and Diversity Inclusion	HE-IHI	
RELECOV 2.0	Consolidation of WGS and RT-PCR activities for SARS-CoV-2 in Spain towards sustainable use and integration of enhanced infrastructure and processes in the RELECOV network	EU4HEALTH	
RESPIN-VAR	REstoring balance: Specialized Proresolvin mediators for resolution of INflammation and VAscular Repair in humans at high cardiovascular risk	PARTNERSHIP-ERA 4HEALTH	

Project		Programme	Logo
RISEinFAMILY (Coordinated by IdiPAZ)	Alliance for Family Integrated Care (FICare) Implementation in Neonatal Intensive Care Units	H2020-MSCA	
SHIELD	Strategic Health Initiatives for Effective Disease Prevention	HE	
SPIDeRR	Stratification of Patients using advanced Integrative modeling of Data Routinely acquired for diagnosing Rheumatic complaints	HE	
TransplantChild 2023-2027 (Coordinated by IDIPAZ)	ERN TransplantChild 2023-27	EU4HEALTH	
UNDINE	The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalized medicine.	HE	
VACCELERATE	European Corona Vaccine Trial Accelerator Platform	H2020	
VERDI	SARS-coV2 variants Evaluation in pRegnancy and paeDIatrics cohorts	HE	

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.5.2.4. Documentalist

The documentalist platform is responsible for the analysis, maintenance and dissemination of the scientific production generated by the Institute. This production is collected both in the bibliometric reports that are published on the IdiPAZ website as well as in the Institute's Research Report which is published annually and in which all the research activity of our research groups is collected. Also key is the support of the unit to the scientific management when carrying out internal evaluations of researchers or research groups.

The platform provides support to all IdiPAZ researchers when performing bibliographic searches, managing ORCID, CVN or different researcher profiles, advising on scientific evaluation, advising on quality criteria for scientific publications and any training related to this service.

This platform has also played a key role in publicizing and promoting open access policies, as well as participating in the initiatives carried out by public institutions for the creation of institutional repositories.

The platform also manages the Institute's research groups, including their creation as well as the addition and removal of staff members from the groups. Since the launch of the new IdiPAZ website, these tasks can be carried out through the site using the forms created for this purpose.

In the context of Open Science policies, institutional repositories play an essential role in facilitating open access, preservation, and dissemination of scientific output, as well as compliance with the requirements established by funding agencies and research institutions. Our platform provides training support for researchers. Below are some examples of institutional repositories that are managed and maintained through our platform, tailored to the specific needs of each institution and the requirements of the Open Science ecosystem:

The Institutional Repository of the Department of Health of the Community of Madrid (RIMASalud) is an open digital platform designed to collect, preserve, and make available to anyone interested the scientific output generated by professionals at all centers and services of the Department of Health as a result of their clinical, research, and teaching activities, thereby ensuring its preservation and open access and promoting its visibility and dissemination.

REPISALUD is the institutional repository of the Carlos III Health Institute (ISCIII) and its affiliated foundations—the National Center for Cardiovascular Research (CNIC) and the National Cancer Research Center (CNIO)—created to bring together the scientific output of these leading centers in their respective fields into a single, open-access digital archive. Its main objectives are, on the one hand, to increase the visibility and dissemination of new knowledge generated at these research centers and, on the other hand, to serve as an essential tool to help researchers comply with the requirements of both national and international funding agencies, allowing them to deposit all documents subject to such requirements in open access.

Since 2018, the Documentalist Platform of IdiPAZ was certified according to the ISO 9001:2015 quality management system standard ES-0512/2018.

Objetives

The main objectives of the platform are:

- To show society the relevance of scientific research conducted at IdiPAZ.
- Facilitate transparency and maximize the impact of the scientific production of the institute.
- Collaborate in the transmission of knowledge generated in the IdiPAZ environment.

Composition

Head:
Raúl Román Cañizares

Portfolio of services

- Elaboration of Research Report: Design of forms to collect information, bibliographic searches and calculation of bibliometric indicators.
- Collaboration with researchers: Collaboration with research personnel in the search and location of documents useful for their research.
- Elaboration of bibliometric reports: Creation of control tools to keep a record of the Institute's publications.
- Evaluation of researchers: Calculation of bibliometric indicators for decision making in calls where there is a quota of researchers.
- Bibliometric evaluation of research groups: Calculation of bibliometric indicators to determine the scientific production of both established IdiPAZ groups and new groups for their subsequent inclusion in the Institute.
- Advice on bibliographic search tools: Help in the knowledge of the different valid tools for conducting bibliographic searches in specialized databases.
- Advice on the use of bibliometric techniques: Assistance in the knowledge and application of bibliometric indicators to scientific production.
- Guidance on the use and understanding of institutional repositories

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.5.2.5. Flow Cytometry Laboratory

The Flow Cytometry Core is an integrated facility into the Hospital La Paz Institute for Health Research (IdiPAZ), that provides all its members and external groups access to affordable and high-quality flow cytometry services, along with decisively scientific expertise using this technology in research.

We highlight a wide variety of flow cytometry applications: phenotypic analysis of cellular subpopulations using extracellular and intracellular staining, preliminary studies for subsequent clinical application, complex multicolor flow cytometry analysis, etc. This technology is an indispensable biomedicine tool, promoting symbiosis between clinical and basic researchers, as well as cooperation with external institutions.

The services provided include:

- Theoretical seminars and hands-on workshops training.
- Scientific and technical support.
- Experimental design, data analysis and interpretation assistance.
- Development of novel multicolor flow cytometry techniques assistance.

Equipment

Currently, the unit has three analyzers:

- Two Becton Dickinson FACSCalibur™ cytometer analysers:

A system that supports a wide variety of research and clinical applications and is complemented by a broad suite of intuitive software solutions to streamline analysis for a wide range of applications including enumeration of lymphocyte subsets, stem cells, residual white blood cells, and reticulocytes.

Each analyser has two lasers: Blue argon laser (3 detectors), and Red solid state Diode (1 detector), with which FACSCalibur™ can analyse four colors simultaneously.

- One Becton Dickinson FACSCelesta™ cytometer analyser:

It is designed to make multicolored flow cytometry more accessible and allow researchers to benefit from new equipment and reagent technological innovations. These optical and reagent technology parallel advances allow multi-laser equipment to complement with new bright fluorochromes, providing a deeper and more powerful insight into cell analysis.

This analyser has three lasers: Blue solid state Diode (4 detectors), Violet solid state Diode (6 detectors), and Ultra Violet solid state Diode (2 detectors), with which FACSCelesta™ can analyse twelve colors simultaneously.

These support a wide range of flow cytometry applications, and the possibility of developing new ones responding to facility needs and/or upon users demand. In addition, during the current year, the Flow Cytometry Core endured quality levels required according to ISO 9001:2015 standard.

Composition


Head
Kilian Gutiérrez Viñas

Secretary
Susana García Pérez


1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

INDICATORS


Groups Activity (%)



Cytometers Activity



Cytometers Activity Distribution



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.5.2.6. Cell Cuture Unit

The Cell Culture Unit has been established as a core support division that is integrated into and supported by the Hospital La Paz Institute for Health Research (IdiPAZ) and La Paz University Hospital (HULP). This unit facilitates the establishment and management of in vitro model systems and the application of experimental techniques for various research purposes. These include the elucidation of molecular and cellular mechanisms involved in several biological processes, the prediction of cellular and tissue responses to specific microenvironments and the identification and development of potential therapeutic drugs, compounds, or cellular targets. Therefore, this platform provides a fundamental basis for the development of research initiatives in the fields of Health Sciences and Biomedical and Pharmacological Research.

Objetives

The Cell Culture Unit accomplishes its mission by providing users with assistance and support at the scientific, technical and instrumental levels through access to knowledge, equipment, materials, and human resources. According to IdiPAZ strategic plan and other institutional guidelines, this division contributes to the translation of biomedical research by fostering synergies and cooperation among traslational- oriented research groups belonging to IdiPAZ as well as with external institutions. It also provides a dynamic and shared operational environment that serves as a foundation for the exchange and dissemination of the scientific knowledge, innovation and creativity as well as fostering collaborations and alliances among researchers from various fields and disciplines. Moreover, the association and proximity to other IdiPAZ core facilities such as the Molecular Imaging and Immunohistochemistry Unit, the Flow Cytometry Unit, and the BSL2-Virology Unit, enable users to develop complementary techniques, explore and refine research hypotheses, and extend or improve their objectives.

Composition

Coordinator:
Gema Vallés Pérez (PhD)
Technician:
Eva Jaraba Redondo
Secretary:
Susana García Pérez

Equipment and facilities

The Cell Culture Unit consists of an experimentation laboratory, a cryopreservation room and a warehouse. All facilities are located in the IdiPAZ building.

The experimentation laboratory was fitted in 2024 with the following equipment:

Cabinets:
4 Telstar Bio-II-A biological safety cabinets
2Telstar Bio-II Advanced 3 biological safety cabinets
2 Nuaire NU-437-400E biological safety cabinets
1 Heraeus HS-12 biological safety cabinet
1 Faster BH-EN 2004 biological safety cabinet
1 Gelaire BSB 4A biological safety cabinet
1 Esco Class II BSC biological safety cabinet
1 Labogene Mars Pro 1200 biological safety cabinet
1 Faster BIO 48 vertical laminar flow cabinet
1 Telstar Bio II Advance Plus biological safety cabinet

Incubators:
3 Thermo Forma 311 incubators
2 HERAcell incubators
1 Biotech Galaxy S incubator
3 Nuaire Autoflow incubators
1 Sanyo O2/CO2 incubator
1 POL-EKO incubator
1 Binder CB-S 260 incubator

This equipment is complemented with a centralized and alarmed gas system, which guarantees a constant and controlled supply of CO2 and N2.

Microscopes:
1 Nikon DIAPHOT TMD inverted light microscope connected to a Nikon D80 digital camera.
1 Leica DMIL inverted light microscope connected to a Canon Powershot S70 digital camera.
1 Optika inverted light microscope
1 Motic AE2000 inverted light microscope connected to an automatic counter Celeromics

Centrifuges:
2 Eppendorf 5810R refrigerated centrifuges
2 Eppendorf 5804 centrifuges
1 Hettich Universal 32R refrigerated centrifuge
1 Kubota 2010 centrifuge
1Eppendorf 5415D centrifuge
1 Heraeus Megafuge 1.0 R centrifuge

Freezing and refrigerating systems:
5 Liebherr refrigerators (4 ° C and -20 ° C

Other equipment:
2 Presoclave 75 P-Selecta autoclave
1 Heidolph Reax 2000 vortex
1 Raypa BAE-4 thermostatic waterbath
1 Memmert WNB thermostatic waterbath
2 P-Selecta Precisterm thermostatic waterbaths
1 Grant JB Aqua 12 Plus thermostatic waterbath

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Vacuum pumps, pipettes, counters, automatic pipettors, freezing containers, cell counting cameras, etc ....

The cryopreservation room is equipped with:
2 Statebourne Biorack 3000 liquid nitrogen tank
1 Thermo Locator 6 Plus liquid nitrogen tank
1 10 K Taylor Wharton liquid nitrogen tank
1 MVE Cryosystem 4000 liquid nitrogen tank
1 Cryo Diffusion B2016 liquid nitrogen tank
1 Cryo diffusion B2048 liquid nitrogen tank
1 Cryo Diffusion B2011 liquid nitrogen tank
1 SEO GT40 liquid nitrogen tank
1 Cryo Plus 7405 liquid nitrogen tank
1 Worthington LS SERIES liquid nitrogen tank
1 VWR 1478-0274 liquid nitrogen tank
1 Arpege 110 liquid nitrogen tank
1 Arpege 70 liquid nitrogen tank
1 Arpege 140 liquid nitrogen tank

The infrastructure for cryopreservation is completed with a liquid nitrogen transfer device and an alarmed Oxygen O2 detector coupled to a mechanical ventilation system.

Portfolio of services

In general, this Division offers support for experimental approaches across an extensive range of areas including cell experimentation, consumables and reagents, equipment and laboratory, technical assistance, training and research.

The main aspects of this support include:

- Scientific and technical advice, personalized support and consultation: guidance on experimental setup and design, study planning, optimization of techniques and protocols, acquisition of reagents and materials, cell supply, troubleshooting, and analysis and interpretation of results.
- Basic training and hands-on experiments (encouraging the self-service) in accordance with biosafety, waste disposal and good laboratory practice guidelines.
- Access to facilities, including instrumentation, equipment, materials and reagents.
- Preparation and supply of specific materials, reagents and sterile solutions.
- Management and general supervision, including good laboratory practices and work habits, occupational health and safety, cleaning and waste disposal, and operation and maintenance of equipment.
- Performance of experimental procedures, incuding establishment, maintenance, and propagation of cell lines and primary cultures, cryopreservation and resuscitation, and assessment of cell viability and proliferation.
- Control and maintenance of cryopreserved stock cells.
- Elaboration and management of protocols and guidelines, standard operating procedures, reports and other required documentation.
- Detection, identification and treatment of contaminations in cell cultures.

The Cell Culture Unit was certified in accordance with the ISO 9001:2015 quality management system standard within the scope of the IQNet Certificate issued to the INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL UNIVERSITARIO LA PAZ (Certificate No. ES-0512/2018).


The personnel associated with the Unit express their gratitude to the users and collaborating users and staff who have contributed directly or indirectly to this achievement.

Cell Culture Unit's scientific indicators

135 Projects

41 Funding Institutions


PROJECTS: Distribution according to IdiPAZ research areas




IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

USERS: Distribution according to academic profile and IdiPAZ research





National and International Collaborations: CIBER, Cooperative Health Research Networks and Consortiums

ciber-bbn isciii
ciberes isciii
ERA4Health Partnership
Cell Culture Unit
IdiPAZ Instituto de Investigación Hospital Universitario La Paz
AENOR GESTIÓN DE LA CALIDAD ISO 9001
cibercv isciii
ciberer isciii
Co-funded by the European Union
Instituto de Salud Carlos III

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.5.2.7. Molecular Imaging and Immunohistochemistry Unit

The Molecular Imaging and Immunohistochemistry Unit (UII) is one of the shared research facilities provided by IdiPAZ to support basic, clinical, and translational research. The mission of the UII is to offer a centralized service equipped with state-of-the-art histology, immunohistochemistry, and imaging technologies, together with scientific and technical support for researchers. Its activities are aligned with the objectives established in the IdiPAZ Strategic Plan, focusing on management improvement, continuous training, and the promotion of innovation. The Unit pursues these objectives through technical excellence and innovation, enhancing laboratory facilities and processes while promoting the application of bioimaging techniques in clinical research and the basic health sciences. This integrated infrastructure ensures high reproducibility, traceability, and adaptability to diverse experimental designs in health sciences research.

Located within the IdiPAZ building at La Paz University Hospital, the UII comprises two sections: the Immunohistochemistry Laboratory and the Microscopy Laboratory. The Immunohistochemistry Laboratory, situated on the first floor of the IdiPAZ building, provides protocols and equipment for cytospin preparation, tissue fixation (paraffin embedding and frozen samples), tissue sectioning using microtomes and cryostats, and both conventional and advanced immunostaining procedures.




IMAGE UNIT
Microscopy and Immunohistochemistry labs.
IdiPAZ.

The Microscopy Laboratory, located on floor −1, houses a range of conventional, fluorescence, and confocal microscopes, as well as a Nanosight instrument equipped with nanoparticle tracking analysis technology. These systems enable the acquisition of high-quality images from fixed and live samples for the study of cell proliferation, apoptosis, morphology, viability, and nanoparticle characterization. In addition, the laboratory provides access to image analysis software, including NIS-Elements AR, NanoSight NTA 3.1, LAS AF, Image-Pro Plus, and ImageJ.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Composition

Head
María Teresa Vallejo Cremades (PhD)

Technician
Onys Camps Ortega

Resources, equipment and management of the laboratory

The services of the UII are available to all researchers through different access models: collaborative projects, Do-It-Yourself (DIY) access, and fee-for-service support. For fee-for-service requests, users should contact the Head of the Facility, as services are provided subject to staff availability. DIY users may access the facilities only after completing the appropriate training provided by facility staff. Training sessions can be arranged throughout the year according to user needs. In addition, the facility offers fee-for-service access to external institutions and private companies. Access to the labs requires an individual magnetic identification card, restricted for authorized users.

Facility staff provide all new users with guidance on laboratory safety regulations and good laboratory practices. Users are not permitted to operate any equipment until their training has been completed and approved by facility personnel. The use of all instruments must be scheduled in advance, and booking through the reservation system is mandatory for all facility equipment.

Equipment of Molecular Image and Immunohistochemistry Unit

- Immunohistochemistry Laboratory:
  - Tissue processor providing efficient, reliable and timely processing of paraffin wax (Leica TP1020)
  - Embedding unit for high quality paraffin blocking (Leica Arcadia HC)
  - Selecta Wax dispenser, paraffin wax dispenser with adjustable temperature from ambient to 100 °C
  - 2 microtomes for specimen sectioning Leica RM2255
  - Leica EG 1150C Cold plate
  - 2 thermostatic Leica HI 1210 baths
  - 1 thermostatic Selecta bath
  - 2 Cryostat for frozen sectioning (Leica CM 3050S and Leica CM1950)
  - 2 ChemFast 6 and 9 fume hoods
  - PTLink DAKO
  - senSION pH3 pH meter
  - Liebher combi (-20°C and 4°C)
  - Liebher economy freezer (-20°C)
  - Shandon Cytospin 2
  - Memmert BE 500 and UN30, Termaks and Selecta ovens.
  - Selecta Agimatic-E magnetic stirrer with heating
  - Olympus CH microscope, for practical laboratory applications
  - Gilson pipette sets
  - Selecta Agimatic-E magnetic stirrer with heating
  - Staining area with manual options for Do-It-Yourself staining and cover slipping.
  - Olympus BX41 (Bright feld) upright microscope with an attached Digital camera
  - Zeiss Axio Lab.Al microscope five objectives from 5x to100x. ERC5S Axocan camera.
  - Nanosight LM10 viewing unit measures nanoparticles, exosomes, vesicles's size based on the scattering of light, includes
    - a microscope, a LM10 viewing unit with an objective x20
    - a Marlin camera connected to an image analysis software.
    - Laser camera
    - injector

The laboratory is equipped with shared facilities from Translational Oncology and Anatomopathology Breast and Gynecological Cancer groups that use them for diagnostic and clinical research purpose (ESCO fume hood and Crison Microtome). Permission to use must be asked to the head of these laboratories.

- The Microscopy laboratory equipment includes:
  - Stellaris 8 Leica confocal. Leica DMI8 inverted microscope;
    - Ilumination source, White and diode 405 Lasers
    - equipped with incubation chamber Oko Lab
      - Oko Lab incubation system
      - Oko-Lab Gas Controller Bold line

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

  - » Microscope culture plates adapter
- Microscope culture plates adapter
- NIKON microscope ECIPSE IT to conventional and fluorescence microscopy, in vivo imaging and High Content (equipped with incubation chamber)
  - » Camera IMAGING SOURCE
  - » Lauda Ecoline Star incubator edition 003
  - » Hotplate (OKO LAB)
  - » Oko-Lab DualGas Mixer (Okolab)
  - » Microscope culture plates adapter
- Leica DMI6000B inverted microscope. Filter cubes: A4(UV), L5 (green), N3 (red) and Y5 (far red)
- Zeiss Axioplan 2 upright microscope with five objectives from 5x to 100x, phase contrast and fuorescent capabilities
- Digital microscopy (photography with a Leica DFC 350 FXR2 digital camera attached)
- Image ProPlus 5.0 image analysis software
- Leica LASX and LAS AF image analysis software
- NIS elements image analysis software
- Analysis work station with Huygens deconvolution software, Image J, LASAF Lite programme and related image analysis software.

The laboratory is equipped with shared facility from Neuroscience group, Leica TCS SPE inverted confocal. Leica DMI4000B inverted microscope; Ilumination source, Lasers diode 405, Lasers diode 488, Lasers diode 532 and Lasers diode 635; Dishes, Standard microscope slides.

Service Portfolio

- Collection and processing for fixing and decalcification of samples.
- Sample processing in paraffin by hand or automatic.
  - Complete paraffin embedding processing.
  - Serial cut in microtome and tissue assembly.
- Antibodies' validation.
- Buffer preparation and distribution of consumables.
- Sample processing frozen.
  - Preparation of freeze blocks.
  - Serial sections of blocks freeze and cuts collected on slides or floating.
- Staining.
  - Hematoxylin - eosin.
  - Masson trichrome.
  - PAS.
- Cytochemical and immunohistochemical techniques.
  - Decalcification of samples required.
  - Dewaxing cuts, performing staining.
  - Immunohistochemical staining automated system Autostainer.
  - Protocols for Immunofluorescence in frozen and paraffin tissue.
  - Dehydration and slide assembly.
- Image acquisition. Viewing and digital format acquisition.
  - Light microscopy.
  - Light microscopy with phase contrast.
  - Epifluorescence.
  - Confocal microscopy.
  - Advanced Microscopy in living cell.
  - Nanoparticles measures, exosomes, vesicles's size based on the scattering of light
- Fluorescence colocalization by confocal microscopy.
- 3D reconstruction.
- Morphometry in biological samples.
- Large images acquisitions (scanning the entire slide) for bright field and fluorescence.
- Collaboration for sample processing protocols for microscopy (fastening, staining, marking, etc.) and advice for planning projects that could require the use of microscopy.

Research highlights

In 2025, the Unit successfully maintained its AENOR quality certification for its processes, in accordance with the UNE-EN ISO 9001:2015 standard. In 2025, the Unit actively participated in public engagement and science communication initiatives aimed at increasing public awareness of biomedical research and advanced imaging technologies.

As part of the 2025 European Researchers' Night, held at CaixaForum Madrid under the theme "Research Night: Bringing Researchers into the Light", the Unit organized the workshop "Light and Colour to Trace the Molecular Footprints of Diseases in Our Cells" (19:00–20:00), introducing participants to the application of imaging technologies in biomedical research.

The Unit also participated in the XXV Madrid Science Week (November 2025) with the activity "Light and Colour to Trace the Molecular Footprints of Diseases in Our Cells: Guided Visit and Workshop at the Molecular Imaging and Immunohistochemistry Unit", held on 4 November 2025. This activity

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

provided visitors with first-hand experience of the methodologies and technologies used in the Unit and highlighted the role of advanced imaging techniques in the study of human diseases.

Throughout 2025, the Molecular Imaging and Immunohistochemistry Unit actively collaborated with research groups across various IdiPAZ areas, including:

- Neurosciences
- Infectious Disease and Immunity
- Cancer and Human Molecular Genetics
- Cardiovascular
- Organ System Pathologies
- Surgery, Transplant, and Health Technologies

These collaborations resulted in significant scientific output, including international publications and presentations at prestigious congresses, such as:

> Chavarría-Cubel I, Molina YL, Babiy B, Lerma M, Martínez-Botas J, de la Peña G, Vallejo MT, Villanueva-Blanco T, Gómez-Coronado D, Alcazar A, Lasunción MA, Pastor Ó, Busto R. The synthetic TRPML1 agonist ML-SA1 mitigates intracellular lipid accumulation induced by antipsychotics in vitro by stimulating release of extracellular microvesicles. Biochim Biophys Acta Mol Cell Biol Lipids. 2025 May;1870(4):159611.

A particularly noteworthy collaboration was established with the IdiPAZ research group *Congenital Malformations and Transplantation*. The Imaging Unit provided technical support and expertise in image acquisition and analysis, contributing to the development of several research projects. As a result of this collaboration, two scientific communications were presented at national and international conferences:

> Javier Serradilla1, 2 , Paula Burgos2, 3, María Velayos1, 2, Leandro Vecchio2, 4, Alba Sánchez1, 2, Juan Cruz Abate2, 4, Alejandro Madurga1, María López1, María San Basilio1, Carla Ramirez1, Raquel Ibáñez5, Paloma Talayero6, Onys Camps7, María Teresa Vallejo7, Olaia Rodríguez8, Alida Alcolea2, 9, Esther Ramos Boluda2, 9, Carlota Largo2, 4, Pablo Stringa2, 10, Ane Miren Andrés1, 2, Francisco Hernánde Oliveros1, 2 .Comparative study between static cold storage, normothermic Perfusion and hypothermic oxygenated perfusion in experimental Intestinal transplantation. XIX Congress of the International Intestinal Rehabilitation and Transplantation Association (CIIRTA) 2025

> Javier Serradilla1, 2 , Paula Burgos2, 3, Alba Sánchez, Leandro Vecchio, 2, Juan Cruz Abate2, 4, Alejandro Madurga1, María López1, María San Basilio1, Carla Ramirez1, Raquel Ibáñez5, Paloma Talayero6, Onys Camps7, Mayte Vallejo7, Olaia Rodríguez8, Alida Alcolea2, 9, Esther Ramos Boluda2, 9, Carlota Largo2, 4, Ane Miren Andrés1, 2, Francisco Hernández Oliveros1, 2 Estudio Comparativo entre preservación fría estática, perfusión normotérmica e hipotérmica oxigenada en trasplante intestinal experimental. VI Congreso Ibérico de Cirugía Pediátrica. Badajoz, 8-10 mayo 2025


Furthermore, the Unit is a member of the Spanish Network of Microscopy Cores (REMOA). This membership enhances our collaboration with other imaging core facilities and ensures we remain at the forefront of recent advances in bioimaging techniques.

The time of use of the equipment in 2025 has increased the ratio of usage by 2%, compared to previous years.

In 2025, the primary users of the platform were from FIBHULP, including both basic and clinical research groups (FIBHULP I+D and HULP). Meanwhile, the usage time by external research groups (UCM, CSIC, etc.) remained practically unchanged.

As observed in previous years, during 2025, the most of inner users are interested in both Microscopy and Immunohistochemistry labs.

EQUIPMENT USAGE RATIO



IdiPAZ Instituto de Investigación Hospital Universitario La Paz


1 Introduction


2 Executive summary

3 Research areas and groups

4 Associated clinicians

TIME OF USE. EQUIPMENT METRICS (HOURS)





2.5.2.8. Radioisotope Functional Unit

The radioisotope laboratory of IdiPAZ is a second category radioactive facility authorized by the Nuclear Safety Council for the use of non-encapsulated radioactive sources. The radioisotopes authorized at the facility are: ^{3}H, ^{33}P, ^{32}P, ^{125}I, ^{14}C, ^{51}Cr.

The laboratory has equipment and working space for the performance of molecular biology and biochemical procedures and experiments with cell cultures. Currently the most common procedures are cell proliferation tests with tritiated thymidine.

The use of the facility both by staff of the institution and by external users requires prior authorization by those responsible for the facility that approves both the technical suitability of the users to work with radioactivity, and the procedures to be employed. The HULP Radiation Protection Service is responsible for control of the facility and of the radioactive wastes generated.

Composition

Head:
Nuria Vilaboa Díaz
David Vicent López

Secretary:
Susana García Pérez

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.5.2.9. BSL2 Virology Laboratory

The BSL-2 Virology laboratory is an IdiPAZ platform created in September 2019 to support the Institute's research. Numerous research groups have benefited from the platform to conduct their research safely, as working with samples infected with specific pathogens requires facilities with an adequate level of biosafety. The BSL-2 Virology laboratory is certified according to the ISO 9001 quality management standard within the scope of IQNet

Objectives

The BSL-2 Virology laboratory has been adapted to work with human samples infected with HIV, HBV, and HCV, as well as risk group 1 and 2 GMOs. It also allows researchers to develop certain experimental processes with other viral pathogens that require biosafety level 2. The laboratory provides researchers with the necessary equipment to perform their own experimental procedures and analyses, as well as offering training and assistance

Composition

Coordinator
Berta Rodés Soldevila

Secretary
Susana García Pérez









1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



New facility

Since July 2023, the IdiPAZ building has had a new BSL-2 Virology laboratory. The new 44.5 m2 facility represents an increase of more than 50% of the previously available space.

The new laboratory consists of an anteroom equipped with a SAS (Safety Airlock System), an autoclave, and a hands-free sink, followed by a changing room located before the entrance to the experimental laboratory. The laboratory's airflow is controlled by a negative pressure system and passes through HEPA filters.

Permitted laboratory processes

- Processing of different types of blood cells from people living with HIV (PLWH)
- Preparation of samples from PLWH for cytometry. Studies of cellular polyfunctionality in the immune response against HIV.
- Handling and experimental processes of cell cultures.
- Measurement of the impact of antiretroviral drugs on mitochondrial function in PBMCs.
- Construction of viral protein expression vectors in eukaryotic expression vectors.
- Constructs of gene expression with viral vectors (lentiviruses and retroviruses)
- ELISA techniques of infectious samples.
- In May 2020 the laboratory was authorized for use of blood samples from patients with covid-19 and certain related processes.

Resources

The experimental laboratory is equipped with the following equipment:

- Type II Biological Safety Cabinets (BSC):
  - 2 BSC Telstar BIO-II-A/P
  - 1 BSC Neuroaire CSB120
- CO2 incubators:
  - 2 HERAEUS BB-6220 incubators
- Centrifuges:
  - 1 HERAEUS Biofuge primor refrigerated centrifuge
  - 1 Hettich Universal 320 non-refrigerated centrifuge
  - 1 Hettich Universal 320 R
  - 1 Hettich Mikro 220 R
- Microscope:
  - 1 NIKON Eclipse TS100 Inverted Optical Microscope
  - 1 OPTIKA Microscopio XDS3
- Refrigeration systems:
  - 1 Liebherr upright freezer (-20°C)
  - 1 Liebherr profi line fridge (4°C)
- Other equipment:
  - 1 P-Selecta Precisterm thermostatic bath
  - 1 Inteliwasher 3D-IW8 BIOSAN
  - 1 Automatic cell counter LUNA II

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.5.2.10 3D Managment Laboratory

In recent years, there have been significant changes and advances in the field of 3D medicine, with the inclusion of technologies such as CAD/CAM (Computer Assisted Design/Computer Assisted Manufacturing), 3D printing, and navigation, which have paved the way in various medical and surgical fields, aiming to improve quality and offer more predictable and safe results.

In this regard, HULP-IDIPAZ believes it necessary to develop a 3D laboratory where the various services can access 3D imaging software, navigation software, and 3D printers, among others. It is important that this laboratory be organized and, above all, that the teams involved be trained in order to carry out the various activities efficiently and safely.

The Laboratory: Objectives and Services

The 3D Management Laboratory has a multidisciplinary focus, serving all the hospital's specialties, as an environment that can encompass the entire process, from design to manufacturing on our premises. This represents not only a radical change in the workflow of the departments involved, but also makes the departments self-sufficient for the design and generation of 3D models, whether for clinical, research, or educational purposes. The use of in-house technology for the development of surgical elements and tools, such as cutting guides or virtual planning, can be economically beneficial for the hospital. Furthermore, we must keep in mind that in-house production reduces lead times and encourages staff training and involvement in the design and creation of models, allowing the knowledge to remain within the institution.

Furthermore, the Fab-Lab has established a partnership with Rayo Seco Systems to launch a virtual platform, b-onic , used for traceability in the 3D development process of customized medical devices and for storing well-classified, high-quality normal and pathological models. These models will have multiple uses: printing, visualization, patient communication, research, patent creation, etc. They are a fundamental tool in the design of surgical plans and as a means of communication with the scientific community in the fields of research and training.

Composition

Manager/Director:
José Luis Cebrián Carretero

Technical/Compliance:
Javier Cobas Gamallo

Substitute coach:
Sergio Rico Elvira

Quality:
Barbara Martinez de Miguel

Surveillance:
José Luis Cebrián Carretero

Manufacturing Technician:
Rubén Rubio Bolívar

Engineering:
José Tadeo Borjas
Celia del Peso Ley

Data management:
Celia Martín Cubillo

Shopping:
Javier Campaño

Medical image:
Montserrat Bret Zurita

Investigation
Ramón Cantero Cid

Sterilization
Ana Martínez Pérez

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

To achieve this, it is necessary to have the appropriate personnel for its management, operation and maintenance, as well as having quality accreditation in the ISO 13485 standard and obtaining a license as a manufacturer of personalized medical devices (custom-made medical devices) up to group 2A .

Regarding the physical location, the laboratory is located on the 7th floor of the General Hospital , with two adjoining rooms, one serving as an office dedicated to office tasks, computer design and project management where applicants are received and cases are studied and worked on, and the other exclusively for manufacturing using 3D printing.

Dotation:

The 3D laboratory has the following resources:

- Certified design and planning software (Mimics by Materialize)
- 3D printers: Quality standards require the use of bio-printers, which work with materials that can come into contact with the body.
  - FDM. Plastic printing using filament
  - SLA. Plastic printing of resins, some of which are biocompatible.
- We currently have 3 filament printers (Ultimaker 2 and 5, Bamboo) and three resin printers (Formlabs 2 and 2 plus, Formlabs 3

2.5.2.11. PAIN Platform

The Support Platform for Early-Stage Researchers (Plataforma de Apoyo al Investigador Novel) from IdiPAZ is a platform that aims to promote the design and development of research projects in health areas. Focused in our early-stage professional researchers, training and research development will be encouraged to achieve our clinicians a better performance in competitive calls.

Composition

Head:
Paloma Gómez Campelo

Technical Manager:
Daniel Quijada Alcón

Portfolio of services

- Methodological and epidemiological support to the study design of the professionals in early-stage research.
- Technical and methodological support in developing a research protocol for a study.
- Analysis of the grounds for refusal of rejected project proposals.
- Methodological support to write grant proposals to access all available funding programs.
- Technical support in writing other scientific documents.
- Management of the Mentor and Prementor Programmes.

Mentor program

In 2025, IdiPAZ, with the support of La Paz University Hospital, has implemented the **5th Mentor Program** with the purpose of supporting our clinical early-stage researchers in the achievement of competitive projects, mainly from the main national call for health research projects: "Acción Estratégica en Salud (AES)", granted by *Instituto de Salud Carlos III*.

The Mentor Program plans a scientific and technical support in the preparation and tracking of research proposals. Furthermore, it takes into account the experience and scientific knowledge from our senior researchers to help our early-stage researchers from the beginning of their research career.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

The objectives of the program are:

- Increasing the number of clinical research in IdiPAZ.
- Avoiding a generational leap of clinical researchers.
- Strengthening the research profile of our clinical staff.
- Positioning IdiPAZ as a model of clinical research, at the same level as it is in clinical trials.
- Performing an internal cultural change in clinical research.

Mentor Program includes different action plans have been implemented:

- To update the standardized curriculum for researchers.
- Enable synergies to create research groups.
- Support from the different platforms of IdiPAZ.
- Services of medical writing.
- Stand out the impact and the strategic priorities of the projects for the National Health System.

In the **5th Mentor Program** 115 participants were included:

RESEARCHER	# PROPOSAL SUBMITTED
Ainoa Muñoz San José	PI26/01101
Alberto Alonso Babarro	PI26/00014
Alfonso Alba Bernal	PI26/00689
Almudena Val Blasco	
Álvaro Sada Malumbres	
Ana Cruz Pardos	PI26/00626
Ana Fernández Santander	PI26/00731
Ana Isabel Borobia Pérez	PI26/02065
Ana Lourdes Luis Huertas	PI26/00399
Ana Martínez Feito	PI26/00142
Ana Méndez Echevarría	PI26/00007
Ane Miren Andrés Moreno	PI26/01579
Ángela Palao Tarrero	PI26/00465
Angelo Gámez Pozo	PI26/00640
Atilano José Carcavilla Urqui	PI26/01608
Áurea Díez Tascón	
Beatriz Barquiel Alcalá	PI26/00617
Beatriz Díaz Pollán	PI26/00759
Blanca Tapia Salinas	PI26/00168
Borja Rivero Santana	PI26/01863
Carlos Antonio Álvarez Ortega	PI26/00774
Carlos Delgado Miguel	
Carlos Zozaya Nieto	PI26/01854

RESEARCHER	# PROPOSAL SUBMITTED
Carmen Busca Arenzana	PI26/00218
Carmen Martín Hervás	PI26/01012
Carmen Rodríguez Jiménez	PI26/00750
Carmen Sobrino Jiménez	
Covadonga Martínez Díaz-Caneja	PI26/01101
Cristina García Quero	PI26/00749
Cristina Julia Suárez Ferrer	PI26/00746
Daniel Laorden Escudero	
David Ramiro Cortijo	PI26/00734
Diego Carracedo Sanchidrián	
Eduardo Fernández Jiménez	PI26/00007
Elena Gómez García	
Elena I. Diago Sempere	PI26/00913
Elena Ramírez García	PI26/00142
Emanuela Spagnolo	PI26/01281
Emilio Cendejas Bueno	PI26/01617
Ester Carreño Salas	PI26/00028
Eva Marín Serrano	PI26/00512
Fe Amalia García Santiago	PI26/01024
Francisca García-Moreno Nisa	PI26/01805
Gabriel Torres Iglesias	PI26/00732
Gerardo Ruiz Ares	PI26/00162
Gina Asunta Hernández Santillán	PI26/02069

RESEARCHER	# PROPOSAL SUBMITTED
Gonzalo Solís García	PI26/01767
Guillermo García Pérez de Sevilla	PI26/01191
Halin Bareke	PI26/00690
Hortensia de la Corte Rodríguez	
Ignacio García Cabeza	PI26/00738
Irene Ruiz Martín	
Isabel González Bertolín	PI26/00481
Isabel Valbuena Gómez	PI26/00920
Ismael Ghanem Cañete	PI26/01630
Jara Llenas García	PI26/00591
Javier de Andrés Ares	PI26/00283
Javier García-Samaniego Rey	PI26/01396
Javier Gómez Pavón	
Jesús Fernández Felipe	
Jorge Álvarez Troncoso	PI26/00882
Jorge Díaz Garzón Marco	PI26/00707
Jorge Rodríguez Pardo de Donlebún	PI26/00609
José Luis Encinas Hernández	PI26/00421
Juan Andrés Jiménez Estrada	PI26/01024
Juan José Menéndez Suso	PI26/00116
Juan José Ríos Blanco	PI26/01014
Julio González Luis	PI26/00950
Laura Córdoba García	

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCHER	# PROPOSAL SUBMITTED
Laura Gutiérrez Sainz	PI26/00058
Laura Hurtado Navarro	PI26/00840
Lucía Deiros Bronte	PI26/00734
Lucía Fernández Gassó	
Luis Alberto Glaría Enríquez	PI26/01006
Luis Rodrigo Merino Rueda	PI26/00626
Luna Cordeiro Minute	
Luz Martín Carbonero	PI26/01500
Mª Angustias Quesada Simón	PI26/00408
Manuel Quintana Díaz	PI26/00428
Marcos Javier Cuerva González	PI26/00642
María Concepción Prados Sánchez	PI26/01510
María del Pilar Martínez Fernández	PI26/00561
María Isabel Prieto Nieto	PI26/00845
María José Rol García	PI26/00446
María Martínez Redondo	
María Recarte Rico	
Marta Díaz Menéndez	PI26/00702
Marta Gambra Arzoz	PI26/00668
Marta Gil Fernández	
Marta Ossorio González	PI26/00775
Mercedes Gasior Kabat	PI26/00881
Mercedes López Martínez	PI26/00749
Milagros Merino Andreu	
Mireya Covadonga Fernández-Fournier Fernández	PI26/01021
Natalia Arruti Vázquez	
Onica M. Armijo Suárez	
Óscar Peñuelas Rodríguez	PI26/01863
Paloma Moraga Alapont	
Raquel Casitas Mateos	PI26/00688
Raquel de Paz Arias	
Raquel Herrero Hernández	PI26/01151
Raúl Galera Martínez	PI26/00688
Ricardo Jaime Rigual Bobillo	PI26/00997
Roberto Lozano Rodríguez	
Rocío Menéndez Colino	PI26/00914
Rocío Rosas Alonso	PI26/00121
Rosa Mª Morera López	PI26/00900
Rubén Mera Pérez	PI26/00119
Sandra Ofelia Rosillo Rodríguez	
Sara Ruiz Martínez	PI26/01291
Sonia López García	PI26/01023
Sonia Rodríguez Novoa	PI26/01391
Susana Noval Martín	PI26/01548
Víctor Galán Gómez	PI26/00167
Virginia Amesty Morello	PI26/00113

Below is the family collage of the participants in the 5th Mentor Program:




IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

The number of researchers who have participated in the program can be seen since the launch of the Mentor Program at IdiPAZ in the following chart:

NUMBER OF MENTOREES PER YEAR



The program is supported by a network of senior mentors from different fields and professional expertise. The mentors provide mentees constructive feedback, putting at their disposal all their experience, dedication and motivation, supporting the process of preparing their research project proposals.

In the 5th **Mentor Program** 32 senior mentor have collaborated:

MENTOR	# MENTORED PROPOSAL
ADELINA PELLICER MARTÍNEZ, PhD	PI26/01767
ALBERTO M. BOROBIA PÉREZ, PhD	PI26/00142 PI26/00283 PI26/00617 PI26/00774 PI26/00913 PI26/00920 PI26/01863 PI26/02065
ANTONIO PÉREZ MARTÍNEZ, PhD	PI26/00167 PI26/00689 PI26/00690 PI26/01014
BLANCA FUENTES GIMENO, PhD	PI26/00162 PI26/00738
CARLOS DEL FRESNO SÁNCHEZ, PhD	PI26/00399 PI26/00421
CELSO ARANGO LÓPEZ, PhD	PI26/00007 PI26/00119 PI26/01101 PI26/02069
CONSTANTINO FONDEVILA CAMPO, PhD	PI26/00113 PI26/00900 PI26/01805
CRISTINA CALVO REY, PhD	PI26/00116
EDUARDO LÓPEZ COLLAZO, PhD	PI26/00840 PI26/01006 PI26/01012
EXUPERIO DÍEZ TEJEDOR, PhD	PI26/00014 PI26/00609 PI26/00997 PI26/01021 PI26/01191
FCO. JAVIER DE CASTRO CARPEÑO, PhD	PI26/00058 PI26/00121
FERNANDO MARTÍN SÁNCHEZ, PhD	PI26/00668 PI26/00707
FRANCISCO GARCÍA RÍO, PhD	PI26/00688
ISABEL LASTRES BECKER, PhD	PI26/00732
JAIME FELIÚ BATLLE, PhD	PI26/01630
JOSÉ LUIS BARTHA RASERO, PhD	PI26/00642 PI26/01291
JOSÉ LUIS CEBRIÁN CARRETERO, PhD	PI26/00168
JOSÉ Mª MOSTAZA PRIETO, PhD	PI26/00750 PI26/01391
JOSÉ RAMÓN ARRIBAS LÓPEZ, PhD	PI26/00408 PI26/00591 PI26/00702 PI26/00759 PI26/00882
JUAN ÁNGEL FRESNO VARA, PhD	PI26/00640
JUAN J. GONZÁLEZ GARCÍA, PhD	PI26/00218 PI26/01500
KAREN HEATH, PhD	PI26/00561 PI26/01024
Mª EUGENIA MIRANDA CARÚS, PhD	PI26/00028
MARÍA FERNÁNDEZ VELASCO, PhD	PI26/01863
MARÍA GUTIÉRREZ FERNÁNDEZ, PhD	PI26/01579
MIGUEL SÁENZ DE PIPAÓN MARCOS, PhD	PI26/00734 PI26/01854
NORA VIVIANA BUTTA COLL, PhD	PI26/00881
NURIA VILABOA DÍAZ, PhD	PI26/00626
OLGA VERA PUENTE, PhD	PI26/00512 PI26/00731 PI26/01281
REBECA PÉREZ DE DIEGO, PhD	PI26/00746
RODOLFO ÁLVAREZ-SALA WALTHER, PhD	PI26/00749 PI26/01510
TALÍA SÁINZ COSTA, PhD	PI26/00481
SUPPORT PLATFORM FOR EARLY-STAGE RESEARCHERS	PI26/00428 PI26/00446 PI26/00465 PI26/00775 PI26/00914 PI26/00950 PI26/01023 PI26/01151 PI26/01396 PI26/01548 PI26/01608 PI26/01617

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians


In order to ensure that the research project proposals submitted by our early-stage researchers have a high degree of excellence, the Mentor Program has a training plan structured in webinars for each section of the application report.

In 2025, the following webinars were held as part of the Mentor Program training plan:

TOPIC	DATE	SPEAKER
EXPERIENCES OF PARTICIPATION IN THE MENTOR PROGRAM	13/11/2025	DANIEL QUIJADA ALCÓN
ELISA ALONSO LÓPEZ, PhD		
FIS PROJECT PREPARATION KEYS. PROJECT EVALUATION.	27/11/2025	DANIEL QUIJADA ALCÓN
CARLOS DEL FRESNO SÁNCHEZ, PhD		
OBJECTIVES AND METHODOLOGY: STRUCTURE, BIASES AND CONTINGENCY PLAN	04/12/2025	DANIEL QUIJADA ALCÓN
CVA & ORCID IDENTIFIER (in-person seminar)	11/12/2025	RAÚL ROMÁN CAÑIZARES
GENDER PERSPECTIVE AND DIMENSION IN RESEARCH	18/12/2025	DANIEL QUIJADA ALCÓN
STATISTICAL ANALYSIS	08/01/2026	MARÍA JIMÉNEZ GONZÁLEZ
METHODOLOGICAL PLANNING FOR OBSERVATIONAL STUDIES	13/01/2026	IRENE GARCÍA GARCÍA, PhD
PI PROFILE, DORA CRITERIA & BIBLIOMETRIC INDICATORS (in-person seminar)	15/01/2026	RAÚL ROMÁN CAÑIZARES
METHODOLOGICAL PLANNING FOR CLINICAL TRIALS	22/01/2026	ALBERTO M. BOROBIA PÉREZ, PhD
STRATEGIC INTEREST OF THE PROJECT AND CITIZEN ENGAGEMENT PLAN	29/01/2026	DANIEL QUIJADA ALCÓN
STORYTELLING FOR PROJECT WRITING	05/02/2026	RAQUEL AGUIRRE ZANDUETA
HOW TO PREPARE A GOOD BUDGET	12/02/2026	SILVIA ARCE SANTAMARÍA
JÉSSICA GARCÍA MOSCATEL		
DATA MANAGEMENT PLAN. DATA PROTECTION	19/02/2026	DANIEL QUIJADA ALCÓN
WEB APPLICATION TUTORIAL (in-person seminar)	04/03/2026	MERCEDES RUIZ BALIBREA

In its fifth year, carried out as part of the Mentor Programme have helped to ensure that a large number of proposals have been submitted to Acción Estratégica en Salud (AES) call for health research projects by IdiPAZ researchers:

RESEARCH PROPOSALS APPLIED TO AES CALL



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Prementor program

IdiPAZ, with the support of La Paz University Hospital, has implemented the 1st Prementor Program with the purpose of supporting our predoctoral researchers in the achievement of their Doctorate.

The objectives of the program are:

- Increasing the number of researchers with a PhD in IdiPAZ.
- Promote high quality training of researchers.
- Performing an internal cultural change in translational research in biomedicine.

The Prementor Program planned a formative and technical support during the second and third tutorial courses of our predoctoral researchers' doctoral studies. The following webinars have been held as part of the Prementor Program training plan:

DATE	TOPIC	SPEAKER
20/09/2024	1_ HOW TO ESTABLISH A RESEARCH QUESTION/HYPOTHESIS	DANIEL QUIJADA ALCÓN
18/10/2024	2_ ETHICS AND SCIENTIFIC FRAUD	NORA BUTTA COLL
15/11/2024	3_ PREPARING AND CLEANING DATABASES	MARÍA TERESA GARÍA MORALES
20/12/2024	4_ FIGURES, VISUALIZATION AND DATA ANALYSIS	MARÍA JIMÉNEZ GONZÁLEZ
17/01/2025	5_ IDIPAZ SUPPORT PLATFORMS FOR EXPERIMENTAL WORK	GEMA VALLÉS PÉREZ
21/02/2025	6_ ORAL COMMUNICATIONS AND POSTER DESIGN	EMANUELA SPAGNOLO
25/04/2025	7_ PROTECTION OF RESULTS	ESTELA SÁNCHEZ SIMÓN
23/05/2025	8_ TOOLS FOR THE EMOTIONAL MANAGEMENT DURING THE DEVELOPMENT OF THE THESIS	ÁNGELA PALAO TARRERO
13/06/2025	9_ TIPS FOR PUBLICATION AND SCIENTIFIC DISSEMINATION	ANA Mª SASTRE PERONA
20/06/2025	10_ THESIS DEFENSE	REBECA PÉREZ DE DIEGO

In the 1st Prementor Program 69 participants were included:

DOCTORAL STUDENT	UNIVERSITY
AARON ABDELKADER GUILLÉN	UNIVERSIDAD AUTÓNOMA DE MADRID
ALEJANDRO DE GEA GRELA	UNIVERSIDAD AUTÓNOMA DE MADRID
ALICIA MARÍN CANDÓN	UNIVERSIDAD AUTÓNOMA DE MADRID
ANDREA BUENO SEN	UNIVERSIDAD AUTÓNOMA DE MADRID
ANDREA GUZMÁN DE ANTONIO	UNIVERSIDAD AUTÓNOMA DE MADRID
ANDREA LOPEZ SUAREZ	UNIVERSIDAD COMPLUTENSE DE MADRID
ARIADNA WITTE CASTRO	UNIVERSIDAD COMPLUTENSE DE MADRID
BEATRIZ NIETO CARVALHAL	UNIVERSIDAD AUTÓNOMA DE MADRID
BLANCA FABRE ESTREMERA	UNIVERSIDAD AUTÓNOMA DE MADRID
CARLOS DELGADO MIGUEL	UNIVERSIDAD AUTÓNOMA DE MADRID
CARLOS RODRÍGUEZ ANTOLÍN	UNIVERSIDAD AUTÓNOMA DE MADRID
COLOMA GRAU VAN LAAK	UNIVERSIDAD AUTÓNOMA DE MADRID
CRISTINA DE MANUEL GÓMEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
CRISTINA MARCELO CALVO	UNIVERSIDAD AUTÓNOMA DE MADRID
DARÍO SÁNCHEZ CABRERO	UNIVERSIDAD AUTÓNOMA DE MADRID
DIEGO MORANTE MARTÍNEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
EDUARDO CAZALLA IBÁÑEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
ELENA MARTÍNEZ ROBLES	UNIVERSIDAD AUTÓNOMA DE MADRID
ENRIQUE ALFARO GARCIA	UNIVERSIDAD AUTÓNOMA DE MADRID
FRANCISCO DE BORJA NAVA HURTADO DE SARACHO	UNIVERSIDAD AUTÓNOMA DE MADRID
GABRIEL TORRES IGLESIAS	UNIVERSIDAD AUTÓNOMA DE MADRID
GEMA YAGÜE DE ANTONIO	UNIVERSIDAD DE LEÓN
GONZALO SÁENZ DE SANTA MARÍA DIEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
GUILLERMO MANUEL SIBÓN SANCHO	UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA
GUILLERMO MARTÍN ÁVILA	UNIVERSIDAD EUROPEA DE MADRID
IGNACIO SILVA LLANES	UNIVERSIDAD AUTÓNOMA DE MADRID
IRENE BARRIENTOS RUIZ	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL DIAZ SUAREZ	UNIVERSIDAD DE NAVARRA

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

DOCTORAL STUDENT	UNIVERSITY
ISABEL GONZÁLEZ BERTOLÍN	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL MELLADO SOLA	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL MELLADO SOLA	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL MORENO PARRO	UNIVERSIDAD AUTÓNOMA DE MADRID
JAVIER POZO NOVOA	UNIVERSIDAD AUTÓNOMA DE MADRID
JAVIER SERRADILLA RODRIGUEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
JESÚS PEÑA LÓPEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
JOSÉ MARÍA RODRÍGUEZ PIÑAS	UNIVERSIDAD EUROPEA DE MADRID
JULIA DEL PRADO MONTERO	UNIVERSIDAD AUTÓNOMA DE MADRID
LAURA BRAVO ROBLES	UNIVERSIDAD AUTÓNOMA DE MADRID
LAURA CLARES VILLA	UNIVERSIDAD AUTÓNOMA DE MADRID
LAURA GARCIA ESPINOSA	UNIVERSIDAD AUTÓNOMA DE MADRID
LUCIA GUTIÉRREZ GARCÍA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARI PAZ LÓPEZ MOLINA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA DE CEANO-VIVAS LA CALLE	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA DEL ROSARIO GARCÍA SÁNCHEZ	UNIVERSIDAD COMPLUTENSE DE MADRID
MARIA JESUS ESPINOSA PASCUAL	UNIVERSIDAD COMPLUTENSE DE MADRID
MARIA JOSE ROL GARCIA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA PÉREZ PASCUAL	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA SÁNCHEZ MARTÍN	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA SANZ DE PEDRO	UNIVERSIDAD AUTÓNOMA DE MADRID

DOCTORAL STUDENT	UNIVERSITY
MARIA VARELA CERDEIRA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARTA LUISA MUNER HERNANDO	UNIVERSIDAD AUTÓNOMA DE MADRID
MIKEL FERNÁNDEZ ARTAZCOZ	UNIVERSIDAD AUTÓNOMA DE MADRID
MÓNICA BEOBIDE CONDE	UNIVERSIDAD REY JUAN CARLOS
NEILA RODRÍGUEZ ROCA	UNIVERSIDAD AUTÓNOMA DE MADRID
NURIA LOURDES PÉREZ CHULIÁ	UNIVERSIDAD AUTÓNOMA DE MADRID
PALOMA MARTÍNEZ CAMPOS	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA ARAGÓN RAMOS	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA CANTOLLA PABLO	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA PATRICIA BURGOS MORALES	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA PÉREZ MORENO	UNIVERSIDAD AUTÓNOMA DE MADRID
PELAYO FERNÁNDEZ CIDÓN	PENDIENTE
RAQUEL CASITAS MATEO	UNIVERSIDAD AUTÓNOMA DE MADRID
REBECA GALLEGO RUIZ	UNIVERSIDAD AUTÓNOMA DE MADRID
RICARDO JAIME RIGUAL BOBILLO	UNIVERSIDAD AUTÓNOMA DE MADRID
SONIA ALCOLEA	UNIVERSIDAD AUTÓNOMA DE MADRID
SONIA MILKOVA IVANOVA	UNIVERSIDAD AUTÓNOMA DE MADRID
TAMARA DOMINGO PÉREZ	UNIVERSIDAD DE NAVARRA
TERESA MATO PATINO	UNIVERSIDAD AUTÓNOMA DE MADRID
VICTORIA ARNALICH MONTIEL	UNIVERSIDAD AUTÓNOMA DE MADRID

Others activities carried in 2025

Throughout 2025, the PAIN platform has participated in the Science and Innovation Week. In this dissemination activity, a conference entitled: 'Solving the mystery: the scientific method in biomedical research' was planned and attended by a to secondary-school-students group from IES Arturo Soria.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.5.2.12. Sequencing Platform

Biomedical research is the main core of IdiPAZ institute and automatic sequencing facility is proud to participate in this working arear of the hospital. Our facility is a support for translational research in the hospital in terms of genomic analysis and supporting diagnosis units. The facility has helped to incorporate research results in the routine of the hospital.

Automatic sequencing facility has the necessary equipment and infrastructure to perform tasks such as conventional sequencing (Sanger method), marker DNA genotyping and other molecular biology techniques based on capillary electrophoresis. The equipment can use up to five simultaneous colours on the same sample when it migrates to the genetic analyzers. Therefore, we are able to detect more than 30 polymorphic markers per sample. The expertise of the staff allows us to offer design, protocol development, and data analysis support and task training in genomic techniques.

On the other hand, the Genomic Analysis core offers assistance services in Next Generation Sequencing to the institute's research lines, providing support in the analysis of WES and WGS data.

During the last year, collaborations with different research groups has resulted in the co-authorship of six articles in international journals.

The Genomic Analysis core has managed to develop two lines of research in the area of immunology and the Conventional Sequencing core has joined in another line of research in the area of paediatric thanks to the granting of two research projects.

Both Sanger Sequencing and Genomic analysis cores are committed to quality work by maintaining ISO 9001:2015 certification. In addition, lab participates in international external quality controls annual evaluations (EMQN) and quality control evaluations with other laboratories.

Composition

Coordinator:
María del Rocío Mena de la Cruz

Conventional sequencing
Head:
María del Rocío Mena de la Cruz

Technical Staff
Rubén de Sancho Martín
Carolina Pilar Blanco Agudo

Genomic Analysis
Head:
Rebeca Pérez de Diego

Technical Staff
Ana María Van Den Rym Mayoral

Equipment

- Eppendrof 5415D Centrifuge.
- Veriti Termocycler(Applied Biosystems).
- Genetic Analyzer SeqStudio (Thermo Fisher Scientific).

Software:

- Sequencing Analysis v5.7
- Sequence Scanner v1.0
- GeneMapper v4.1

Portofolio Service

Conventional sequencing

- Nucleic Acid quantitation (Tecan, Nanodrop).
- PCR purification for Sanger sequencing (Exosap).
- Sanger Sequencing.
- Migration Sanger samples.
- Fragments Analysis:
  - STRs analysis
  - QF-PCR.
  - MLPAs (multiplex ligation-dependent probe amplification).
  - Microsatellite instability (MSI).
  - AZF.
  - SnapShot.
  - TP-PCR.
  - ARMS.
  - AFLPs

Genomic Analysis

- Genetic analysis from annotated variants of PID Sequencing Panel.
- Genetic analysis from annotated whole exome sequencing (WES) variants.
- Genetic analysis from annotated whole genome sequencing (WGS) variants.
- Genetic analysis from raw data in FASQ format from PID Sequencing Panel.
- Genetic analysis from raw data in whole exome sequencing (WES) FASQ format.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2025 Facility Activity:


Conventional sequencing

Research Area	Total 2024 samples	Total 2025 samples
Infectious diseases and immunity	2717	1634
Cardiovascular	4705	1185
Organ system pathologies	2767	1849
Cancer and human molecular genetics	7258	12561
External synergy	365	0
Total	**17812**	**17229**

Genomic Analysis

Research Area	Genetic analysis from annotated variants of PID Sequencing Panel	Genetic analysis from annotated whole exome sequencing (WES) variants	Genetic analysis from annotated whole genome sequencing (WGS) variants	Total samples
External researches	1	20	0	21

DISTRIBUTION CONVENTIONAL SEQUENCING CORE SERVICE



Projects:

1. UNDINE_The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalised medicine." programa marco europeo Horizonte Europa con acuerdo de subvención 101057100
2. Identificación de nuevos errores innatos de la inmunidad hacia el diagnóstico de precisión y prevención de enfermedades inmunológicas. FIS PI22/00790
3. Paving the way for personalized medicine in neonatal and pediatric intensive care units. PI22/01743

Publications:

1. *IEIVariantFilter: a bioinformatics tool to speed up genetic diagnosis of inborn errors of immunity patients.*
   Pereda J, Espinosa R, García-Solís B, Guerra-Galán T, Van-Den-Rym A, Kars ME, Mena R, Galán V, de Andrés-Martín A, Rodríguez-Gallego C, López-Lera A, Corvillo F, Pérez-Martínez A, López-Collazo E, Sánchez-Ramón S, Martínez-Barricarte R, Quintana-Murci L, Lorenzo-Salazar JM, Itan Y, Flores C, **Pérez-de-Diego R.** NAR Genom Bioinform. 2025 May 28;7(2):lqaf069. doi: 10.1093/nargab/lqaf069. eCollection 2025 Jun. PMID: 40438610 Free PMC article.

2. *Phosphoinositide-3-kinase δ as an immune check-pathway in cancer Immunology. Therapeutic prospects.*
   Palacios-Ortega M, Corbí ÁL, García-Solís B, **Pérez de Diego R**, Sierra M, Fernández-Arque-

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

ro M, Ocaña A, Pérez-Segura P, Sánchez-Ramón S. Expert Rev Clin Immunol. 2025 Jul;21(7):943-960. doi: 10.1080/1744666X.2025.2522265. Epub 2025 Jul 14. PMID: 40539430 Free article. Review.

3. *Do Obesity and Adipose Tissue Cytokines Influence the Response to Janus Kinase Inhibitors in Rheumatoid Arthritis?*
Novella-Navarro M, Van Den Rym A, López-Pedrera C, Martínez-Feito A, Nieto-Carvalhal B, Reche K, López-Medina C, Escudero-Contreras A, Nozal P, Miranda-Carús ME, Monjo I, De Miguel E, Balsa A, **Pérez-De Diego R**, Plasencia-Rodríguez C. Nutrients. 2025 Feb 27;17(5):820. doi: 10.3390/nu17050820. PMID: 40077690 Free PMC article.


4. *Serum adipsin levels in rheumatic diseases: defining its role in disease activity and progression in rheumatoid arthritis and axial spondyloarthritis.*
Novella-Navarro M, González-Sánchez L, Hernández-Breijo B, **Pérez De Diego R**, Sánchez-Corral P, López-Trascasa M, Miranda-Carús ME, Villalba A, Balsa A, De Miguel E, Plasencia-Rodríguez C, Corvillo F. Front Immunol. 2025 Aug 6;16:1636158. doi: 10.3389/fimmu.2025.1636158. eCollection 2025. PMID: 40842998 Free PMC article.

5. *Identification of a De Novo Heterozygous Frameshift Variant in FMR1 in a Female With Fragile X Syndrome.*
Parra A, Jimenez-Estrada JA, Vásquez-Amell V, Cazalla M, Rodríguez-Canó M, Gallego-Zazo N, Miranda L, Mora-Gómez M, Vallespín E, Mena R, Fernández L, Silván C, Arias P, Dominguez-Jiménez M, Guillén-Navarro E, Nevado J, Tenorio-Castano J, Ruiz-Pérez VL, Lapunzina P.Clin Genet. 2025 Aug;108(2):224-226. doi: 10.1111/cge.14761. Epub 2025 May 8.PMID:40344221


6. *Improving the performance of polymerase chain reaction for microsatellite instability testing in endometrial cancer.*
Mendiola M, Heredia-Soto V, Baillo A, Ruz-Caracuel I, Mena R, Berjón A, Escudero FJ, Pedregosa J, Hernandez A, Feliu J, Hardisson D, Redondo A.Sci Rep. 2025 Dec 22;15(1):44262. doi: 10.1038/s41598-025-27895-w.PMID: 41429820 Free PMC article.

Conventional sequencing:

A



B




1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Genomic Analysis core:



1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.5.2.13 SIMUPAZ

Composition

Members
Dr Javier Cobas Gamallo
Ms Ana Coloma Zapatero
Dr Manuel Quintana Díaz
Ms María A. Peinado Quesada
Ms Laura Gómez Lage
Mr Javier Rubio Bolívar
Mr Sergio Rico Elvira
Mr Eduardo Godfrey Quintana
Mr Carlos González Díaz
Ms Lucia Curiel Garrido
Ms Elena Martín de Castro
Ms Alicia Portas Martínez
Dr Ramón Cantero Cid
Dr Ana M.ª Sánchez Torres
Ms Estela Sánchez Simón
Dr Esther Rey Cuevas
Dr Marta Cortés León

Chair of the Governing Council
Dr Manuel Quintana Díaz

Secretariat of the Governing Council
Ms Ana Coloma Zapatero
Ms Estela Sánchez Simón

Localization

Calle de Pedro Rico, 6, 28029 Madrid.
1st floor, IdiPAZ building.

Introduction

The SimuPAZ Clinical Simulation Platform is the scientific and technical infrastructure of La Paz University Hospital and the IdiPAZ Institute for Health Research, dedicated to developing training, research, innovation and knowledge transfer activities based on clinical simulation. It aims to drive improvements in healthcare through a safe, innovative and evidence-based learning environment that fosters the development of healthcare professionals' skills, the generation of knowledge and the transfer of solutions that have an impact on clinical practice.

Clinical simulation is currently one of the most advanced tools for skills development and the generation of applied knowledge. As well as facilitating learning in a safe and controlled environment, it enables the analysis of healthcare teams' behaviour, the assessment of human factors, the validation of new technologies, the optimisation of clinical processes and the evaluation of the implementation of procedures before their introduction into clinical practice, thereby reducing risks and fostering safer and more efficient healthcare innovation.

From a multidisciplinary perspective, SimuPAZ integrates clinical care, teaching, research and innovation within a single working ecosystem, fostering collaboration across disciplines and promoting the generation of knowledge that directly impacts clinical practice, professional training and healthcare innovation.

Development and impact

SimuPAZ's track record reflects the consolidation of a clinical simulation model with a growing impact on professional training, applied research and the improvement of healthcare practice.

In recent years, the sustained growth of its activities, the expansion of its focus areas and the strengthening of its capabilities have helped to consolidate its position as a leading centre for clinical simulation.

Beyond the quantitative aspect, SimuPAZ's development reflects the consolidation of a project that has progressively increased its capacity to generate value, drive professional development and contribute to the improvement of healthcare organisations.

Development of activities

The evolution of the key indicators highlights SimuPAZ's growth in recent years and shows the progressive consolidation of its activities. The increase in the number of activities carried out, professionals trained, projects launched, and partnerships established reflects sustained growth, consistent with the centre's development since its inception.

The following figures set out the key activity indicators and summarise SimuPAZ's development across its various areas of operation.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Impact of training (2025)

3,384 Professionals trained

208 Training activities

1,801 Training hours

Evolution 2024–2025



Professionals trained by category



Medicine	1,503	(44.4%)
Nursing	555	(16.4%)
Medicine + Nursing	874	(25.8%)
Multidisciplinary team	217	(6.4%)
Other professionals	235	(6.9%)

Internal training vs. external training

INTERNAL TRAINING	EXTERNAL TRAINING
88 Training activities	120 Training activities
577.5 Training hours	1,223.5 Training hours
1,466 Professionals trained	1,918 Professionals trained


1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Evolution of activity (2018–2025)



Impact of the activity

The impact of SimuPAZ goes beyond activity indicators and is reflected in its contribution to the development of better-trained professionals, more coordinated teams and healthcare organisations committed to continuous improvement.

The centre's work has fostered the adoption of new methodologies, strengthened the culture of clinical simulation and led to the development of initiatives with direct applications in clinical practice, thereby helping to improve the quality, safety and efficiency of healthcare.

Similarly, collaboration with healthcare institutions, universities, technology centres, scientific societies and public authorities has helped to progressively expand SimuPAZ's reach and consolidate its role as a leading centre for clinical simulation, recognised for its ability to integrate training, research and innovation within a single environment.

Strategic areas of activity

SimuPAZ's activities are structured around four strategic areas: training, research, innovation and knowledge transfer. These areas form an integrated operational model aimed at making an impact on clinical practice, patient safety and the development of the healthcare system.

Simulation-based training

Training at SimuPAZ is based on *Simulation-Based Education* (SBE) methodologies and includes pro-

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

grammes for students, healthcare professionals and clinical teams, designed to deliver experiential learning that advances professional development, clinical excellence, patient safety and the continuous improvement of healthcare organisations.

The training provision is delivered both through SimuPAZ's own initiatives and in collaboration with universities, scientific societies, healthcare institutions, public authorities and other organisations, promoting the exchange of knowledge and experiences, as well as the development of programmes tailored to the needs of the healthcare system.

A description of the main training programmes developed by SimuPAZ is set out in *Annex I: Catalogue of Training Programmes*.

Training areas

Programs tailored to the needs of healthcare professionals and oriented to excellence in patient care

TRAINING AREA	SCOPE OF ACTION
Instructor Training	Faculty development in clinical simulation. Programs designed to build teaching, technical, and facilitation skills in simulated environments.
Continuing Education	Updating of professional competencies. Courses and programs aimed at continuous professional development across different clinical areas.
Team Training	Development of non-technical skills. Programs focused on teamwork, communication, leadership, and crisis management in complex clinical environments.
Life Support and Critical Patient Care	Training in emergency care, critical care, and trauma. Basic and advanced life support, emergencies, and critical patient management programs.
Procedures and Clinical Skills	Technical and procedural training. Acquisition and improvement of clinical skills through high- and low-fidelity simulation.
University and Specialized Training	Training at undergraduate, postgraduate, and residency levels. Integration of simulation into academic curricula and institutional programs.

Strategic training areas

Training activities are organised around different strategic areas tailored to the needs of various professional profiles. This flexible model allows for the design and implementation of programmes of varying complexity and scope, combining different resources and simulation methods according to the training and competency objectives of each activity.

Among the main areas of specialisation is the training of clinical simulation instructors, a well-established field that supports the development of new teaching teams and the implementation of simulation methodologies across various clinical and academic settings. Alongside this, training in life support, critical care and acute trauma constitutes one of the long-standing pillars of SimuPAZ's teaching activity. These areas provide progressive training tailored to different levels of experience, enabling participants to manage situations of high clinical complexity.

The evolution of the healthcare system has also driven the development of new strategic areas focused on emerging fields such as leadership and healthcare management, advanced therapies, patient safety and the humanisation of care. These initiatives broaden the scope of clinical simulation and consolidate a cross-cutting, multidisciplinary training programme aligned with the current challenges facing the healthcare system.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Research

As a platform integrated into the Institute for Healthcare Research at La Paz University Hospital (IdiPAZ), SimuPAZ drives research projects aimed at generating scientific evidence on the impact of clinical simulation on professional training, clinical practice, patient safety and the improvement of healthcare processes.

The main lines of research focus on simulation-based education, innovation in teaching methodologies, adaptive leadership, human factors, biomedical engineering and the development of new tools and methodologies applied to clinical training.

These areas take the form of applied research projects aimed at assessing the impact of clinical simulation on patient safety, team performance, decision-making, competency assessment and the improvement of care processes, with direct application within the healthcare system.

The main research and innovation projects carried out by SimuPAZ are presented in *Annex II: Research and Innovation Projects*.

Innovation

Innovation at SimuPAZ is based on an open innovation model focused on the design, evaluation and validation of new teaching methodologies, healthcare technologies and innovative solutions that address the current and future challenges facing the healthcare system.

In addition to developing new tools, SimuPAZ provides a specialised environment for the evaluation and validation of technologies, devices, procedures and organisational models before their introduction into the clinical setting, contributing to a safer, more efficient and evidence-based implementation.

Its main areas of work include biomedical engineering, simulator development, 3D printing and the incorporation of immersive technologies into clinical simulation.

One of SimuPAZ's distinguishing features is its collaborative innovation model, based on close cooperation between the hospital, the university and the business sector. It is within this context that **SIMUPAZ LAB** operates: SimuPAZ's collaborative innovation initiative, designed as a meeting place for healthcare professionals, researchers, universities and companies to design, develop and validate prototypes, devices and innovative solutions.

Research projects

Physiological and performance metrics during cardiopulmonary resuscitation (CPR)	Evaluation of physiological and performance metrics during CPR to analyze cognitive load and optimize the training of healthcare professionals in emergency situations.
Augmented reality application for age-related macular degeneration	Development of an immersive application to simulate different stages of the disease and improve training, awareness, and functional evaluation of patients and healthcare professionals.
Optimization of management processes at SimuPAZ	Design of a digital platform to optimize educational activity management through process digitization, resource management, and data analysis to support decision-making.
Design and development of 3D models for coronary intervention training	Development of anatomical models using 3D printing for training in complex cardiovascular procedures and management of complications, enhancing safe and realistic clinical practice.
Development of an ultrasound simulator for the detection of venous thromboembolism	Design of a low-cost simulator for training in clinical ultrasound applied to the diagnosis of deep vein thrombosis, improving professional skills and patient safety.
Research on adaptive leadership in medical-surgical teams	Study of leadership, teamwork, and organizational adaptability to improve the performance of medical-surgical teams and enhance patient safety in dynamic clinical environments.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Key areas of innovation

ARTIFICIAL INTELLIGENCE	Development and application of artificial intelligence–based tools to support training, assessment, and the improvement of healthcare processes.
IMMERSIVE TECHNOLOGIES	Application of virtual, augmented, and mixed reality technologies to design innovative, interactive, and highly realistic learning experiences.
3D PRINTING AND BIOMEDICAL ENGINEERING	Design and manufacturing of simulators, anatomical models, and devices for clinical training and applied research.
DEVELOPMENT AND VALIDATION OF SIMULATORS	Creation and evaluation of new simulators and training models tailored to the educational and clinical needs of healthcare professionals.
HEALTHCARE TECHNOLOGY ASSESSMENT	Validation of devices, procedures, and technological solutions in simulated environments prior to their implementation in clinical practice.
DIGITAL TRANSFORMATION	Development of digital tools that optimize the management of educational, research, and organizational activities at SimuPAZ.

Knowledge transfer and academic collaboration

Knowledge transfer is the unifying element of SimuPAZ's activities, enabling the results of training, research and innovation to be translated into clinical practice. This transfer takes the form of training programmes, research projects, innovation initiatives, specialist consultancy activities and collaboration with healthcare institutions, universities, scientific societies and other academic and professional bodies, thereby promoting the practical application of the knowledge generated and its integration into clinical care, teaching and healthcare management.

Furthermore, SimuPAZ actively participates in national and international clinical simulation networks, promoting the exchange of best practice and contributing to the advancement of Simulation-Based Education and healthcare innovation.

Institutional collaboration

SimuPAZ carries out its activities in close coordination with La Paz University Hospital and the IdiPAZ Institute for Health Research, whilst also maintaining an ongoing relationship with public authorities, healthcare institutions and organisations involved in the development of training and innovation in the health sector.

In this context, SimuPAZ is actively involved in establishing the future **Network of Advanced Clinical Simulation Centres in the Community of Madrid**, promoted by the Sub-Directorate-General for Healthcare Training and Accreditation. This initiative aims to establish a stable framework for collaboration with the main simulation centres of the Madrid Health Service in order to share knowledge, coordinate training programmes, promote joint projects and foster the consistent development of clinical simulation as a tool for improving training and healthcare provision.

Infrastructure and capabilities

SimuPAZ has a flexible and highly specialised infrastructure, designed to meet the training, research and innovation needs of healthcare professionals and research groups. Its facilities replicate different healthcare settings and provide space for teaching activities, applied research projects, technology validation and team training.

The infrastructure comprises spaces specifically designed for clinical simulation, procedural training, experimentation and the analysis of professional

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

performance, incorporating technologies capable of recreating complex clinical scenarios with a high degree of realism.

The SimuPAZ facility is organised into different functional areas that support the centre's teaching, research and innovation activities, notably:

- Simulated clinical care areas: inpatient wards, intensive care unit (ICU), operating theatre, A&E, consultation rooms and other clinical care settings.
- Skills and procedures training areas: spaces specifically designed for training in techniques, clinical procedures and professional skills.
- Teaching and analysis areas: spaces dedicated to delivering theoretical content, viewing procedures and megacodes live or via recordings, as well as conducting briefing, debriefing and activity analysis sessions.

The facilities are complemented by audiovisual recording and broadcasting systems that facilitate observation, performance analysis and the conduct of structured *debriefing*.

From a technological perspective, SimuPAZ integrates simulators of varying levels of fidelity, anatomical models, standardised patients and other training tools that enable each activity to be tailored to its educational, research or innovation objectives. Furthermore, the platform is progressively incorporating emerging technologies, such as 3D printing, virtual and augmented reality, artificial intelligence and other digital solutions applied to clinical simulation.

High-fidelity simulator at SimuPAZ



The flexible configuration of the spaces and technological resources makes it possible to replicate everything from specific clinical procedures to complex multidisciplinary scenarios, facilitating skills training, analysis of human factors, evaluation of care processes and the validation of technologies before their incorporation into clinical practice.

The combination of infrastructure, technological resources and specialised spaces provides SimuPAZ with the necessary capacity to carry out highly complex activities in different healthcare contexts, adapting flexibly to the healthcare system's needs for training, research and innovation.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

ANNEX

Annex I. Catalogue of training programmes

The training provision comprises established programmes and new strategic initiatives designed to address emerging challenges within the healthcare system. This structure allows each activity to be tailored to the participants' skills profile and promotes progressive, interdisciplinary learning that is aligned with the real-world needs of clinical practice.

Clinical Simulation Instructor Training

- Instructor training is one of SimuPAZ's most established teaching programmes and one of the key distinguishing features of its educational model. It aims to equip healthcare professionals to design, develop, facilitate and evaluate Simulation-Based Education activities, thereby fostering the creation of new teaching teams and the implementation of this methodology across different healthcare settings, universities and specialist training programmes.
- The programme is delivered in a blended learning format, combining an online tutoring phase with an intensive face-to-face phase focused on practical training. During this process, participants acquire skills related to instructional design, scenario planning, conducting *briefings* and *debriefings*, assessing learning, and facilitating simulation experiences aimed at skills development.

Training in Life Support

- Training in Life Support is one of the long-standing pillars of SimuPAZ's teaching activities and aims to prepare healthcare professionals to respond effectively to situations of cardiopulmonary arrest and other time-critical emergencies. Based on the recommendations of *the European Resuscitation Council* (ERC), this programme integrates theoretical content, practical training and simulation scenarios tailored to the participants' profiles.
- The training programme comprises Basic Life Support, Immediate Life Support and Advanced Life Support courses, aimed at professionals with different levels of clinical responsibility. These courses provide training in skills relating to cardiopulmonary resuscitation, airway management, defibrillation, the treatment of arrhythmias and coordinated teamwork in emergencies.

Training in Acute Traumatic Conditions

- Under the **TRAUMADRID** brand, SimuPAZ runs a specific training programme focused on the comprehensive management of patients with acute trauma. This programme addresses the need to train healthcare professionals in managing highly complex clinical situations through simulation scenarios that faithfully replicate the pressure typical of such situations.
- The programme is structured around different training levels (SIMU, SAVA and SEPA), with the complexity of scenarios adapted to participants' experience level.
- The methodology combines practical workshops, high-fidelity clinical simulation and structured debriefing processes, promoting clinical reasoning, decision-making and interdisciplinary work.

Critical Care Training

- Critical care training is one of SimuPAZ's main areas of educational collaboration with Specialised Healthcare Training programmes. It aims to develop the skills required for the management of critically ill patients through progressive scenarios tailored to the residents' level of experience.
- The programme includes distinct pathways for first-year residents and for those at advanced stages of their training, allowing for a progressive progression from the acquisition of basic skills to training in situations of high clinical and organisational complexity.

Training in Advanced Therapies

- The development of advanced therapies has led to the creation of the **SimuPAZ Inmuno-Training** programme, which is designed to train multidisciplinary teams involved in the care of patients receiving CAR-T therapies and other cellular immunotherapy strategies.
- The programme combines theoretical content with high-fidelity clinical simulation scenarios that enable participants to practise recognising and managing the main complications associated with these treatments.
- The training also promotes coordination between the various professionals involved in the care process, fostering a multidisciplinary approach and shared decision-making in highly complex clinical contexts.

Leadership and Healthcare Management

- Intending to strengthen the managerial skills of healthcare professionals, SimuPAZ has

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

developed LEADSIM (Leading in Healthcare), a programme focused on training in adaptive leadership through simulation applied to organisational scenarios.

- The training is aimed at service managers, middle managers, senior managers and professionals with coordination roles, geared towards developing skills related to communication, change management, strategic decision-making, team coordination and conflict resolution.
- The use of simulated scenarios facilitates the analysis of complex situations in a safe environment, encouraging reflection on the exercise of leadership and its impact on the functioning of healthcare organisations.

Training in Obstetric Emergencies

- As part of the new strategic initiatives promoted by SimuPAZ, the **SimuOBS** programme has been developed to prepare obstetricians, gynaecologists, junior doctors and midwives to manage critical obstetric situations.
- The programme combines theoretical content, practical workshops and high-fidelity simulation scenarios in which participants practise skills related to the management of obstetric haemorrhage, shoulder dystocia, cardiopulmonary resuscitation in pregnant women, pre-eclampsia and other highly complex obstetric complications.
- This approach promotes coordination amongst healthcare teams and helps to improve patient safety and the quality of obstetric care.

Humanisation of Care

- The person-centred care model is one of the strategic pillars of SimuPAZ's recent development. Within this framework, the **Comprehensive and Humanised Care for Critical Patients** programme has been developed, aimed at integrating clinical competencies with the communication, interpersonal and organisational skills necessary to provide high-quality care.
- Through simulation scenarios, *role-play* exercises and structured reflection processes, participants practise aspects relating to communication, interprofessional collaboration, family involvement, emotional management and addressing post-ICU syndrome.
- This programme reflects SimuPAZ's commitment to a care model based on safety, human dignity and the humanisation of care.

Social Impact Programmes

- As an expression of its commitment to society, SimuPAZ develops initiatives aimed at extending training beyond the strictly professional sphere. Among these, the **Paediatric Basic Life Support programme for Parents and Carers** stands out; it aims to provide the general public with the knowledge and skills needed to respond to paediatric emergencies.
- The training takes the form of face-to-face workshops with a strongly practical focus, in which participants learn to recognise an emergency, perform paediatric cardiopulmonary resuscitation and respond to airway obstruction caused by a foreign body.
- These initiatives help to foster a culture of prevention, improve the public's ability to respond to emergencies, and reinforce SimuPAZ's social commitment to public education and safety.

Annex II.
Research and Innovation Projects.

The projects led by SimuPAZ are carried out in collaboration with universities, research groups, hospitals, technology centres and companies, using a multidisciplinary model that brings together healthcare professionals, researchers and engineers to address clinical, educational and organisational challenges.

Physiological and performance metrics during a cardiopulmonary resuscitation simulation with real-time feedback to estimate cognitive load.

- Researchers: *Blanca L.G., Verónica R.B., Xabier O., Javier R.B., Manuel Q.D. and Álvaro G.*
- **Objective:** to analyse the relationship between multitasking, working memory and performance during cardiopulmonary resuscitation, assessing the impact of cognitive load on the quality of chest compressions by recording various physiological and performance parameters.
- **Methods:** Eighteen first-year junior doctors took part in the study, performing cardiopulmonary resuscitation manoeuvres using a simulator with real-time feedback whilst carrying out secondary tasks. During the simulations, physiological variables such as heart rate, respiratory rate, skin conductance response, body temperature and eye movements were recorded, along with indicators relating to the quality of chest compressions.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

- **Results:** The results showed that multitasking reduces the quality of chest compressions, although physiological variations depend on the type of secondary task performed. These findings contribute to a better understanding of the influence of cognitive load on clinical performance and enable the design of more effective training strategies for first responders.

Application of augmented reality for macular degeneration.

- Researcher: *David Méndez Encinas* (UTAD)
- **Objective**: to develop an augmented reality application capable of simulating the different stages of age-related macular degeneration (AMD), to facilitate training, raise awareness and study the functional impact of this condition on vision.
- **Development**: this project involved the development of an augmented reality application capable of reproducing the different stages of age-related macular degeneration. This condition causes the onset of a central scotoma, which, in its advanced stages, can lead to a significant loss of visual acuity and affects approximately 20 per cent of the European population aged between 65 and 75. The tool enables the collection of information on the user's visual patterns and performance whilst carrying out everyday activities, facilitating the analysis of the condition's functional impact and offering an immersive experience that enhances understanding of its effects.
- **Results**: The results demonstrated that an increase in the size of the central scotoma significantly impedes the performance of simple tasks, such as recognising colours and shapes, increasing the time required to complete them. Furthermore, the application has helped to raise awareness amongst healthcare professionals, patients and their families regarding the limitations caused by AMD, highlighting the potential of immersive technologies as a tool for training, research and awareness-raising in the field of ophthalmology.

Optimisation of process management in SimuPAZ. Alfonso Jurado (UPM)

- Researcher: *Alfonso Jurado* (Polytechnic University of Madrid, UPM).
- **Objective**: to design and implement a digital tool aimed at optimising the management of SimuPAZ's training processes, improving the organisation of teaching activities, resource management and the availability of information for decision-making.
- **Development**: as part of this project, a digital platform was developed capable of collecting, storing and analysing the information generated during the planning and delivery of the centre's training activities. The system incorporates a centralised repository with web access, multi-user management, real-time synchronisation and intuitive interfaces that facilitate the administration of teaching activities. It also integrates specific forms for course applications, the management of material and human resources, and the monitoring of enrolments, enabling a more efficient and structured management of internal processes.
- **Results:** validation of the platform demonstrated a significant improvement over traditional management procedures, optimising logistical organisation and facilitating data-driven decision-making. Future development plans include integration with business intelligence tools such as Power BI, the automatic generation of reports ( ) the incorporation of predictive maintenance models, and the development of modules for managing satisfaction surveys and other quality indicators.

Design and development of 3D models for training in coronary intervention.

- Researcher: *Jaime Llinás* (Autonomous University of Madrid).
- **Objective**: to design and develop anatomical models using 3D printing to improve training in coronary intervention and other invasive procedures, promoting the integration of theoretical knowledge with practical training in a safe and realistic environment.
- **Development**: This project arose from a collaboration between the Cardiology Department at La Paz University Hospital, the 3D Laboratory and SimuPAZ. As a result of this collaboration, specific simulators were developed for training in the placement of coronary *stents* and the performance of pericardiocentesis, enabling clinical procedures to be reproduced with a high degree of realism and facilitating the gradual acquisition of technical skills before their application in patients.
- **Results**: The simulators developed demonstrated significant potential as a teaching tool for training in invasive procedures. During one of the training sessions, 27 cardiologists

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

particularly highlighted the usefulness, realism and value of the pericardiocentesis simulator for learning and refining the technique, reinforcing the value of 3D printing as a resource for clinical simulation.

- **Scope of application:** 3D printing, biomedical engineering, procedural simulation, interventional cardiology and educational innovation.

Development of a simulator for the detection of venous thromboembolism.

- **Researcher**: *Inés López Ramos* (URJC)
- **Objective**: to develop a simulator for the diagnosis of deep vein thrombosis using ultrasound.
- **Development**: Venous thromboembolism is a serious and potentially life-threatening condition, the diagnosis of which using compression ultrasound requires specific training. With the aim of facilitating this training, a simulator was developed using 3D printing and a simulated blood flow system, designed to realistically reproduce the ultrasound examination for deep vein thrombosis.
- **Results**: The simulator enables realistic and cost-effective training in the ultrasound diagnosis of deep vein thrombosis, improving professionals' skills and helping to reduce the need for invasive procedures and the impact of diagnostic errors.



Research into adaptive leadership in medical-surgical teams.

- **Researchers:** *Ramón Rico* (Carlos III University of Madrid), *Manuel Quintana* (Autonomous University of Madrid – La Paz University Hospital), *María Peinado* (Autonomous University of Madrid – La Paz University Hospital) and *Laura Gómez* (La Paz University Hospital – IdiPAZ).
- **Objective:** to analyse the impact of adaptive leadership in medical-surgical teams and to develop a training programme that strengthens this competence, promoting team effectiveness and the well-being of its members in complex healthcare settings.
- **Methodology:** This project, carried out at IdiPAZ and funded by the Ministry of Science and Innovation, examines adaptive leadership as the ability of leaders and team members to dynamically adjust their leadership style to the demands of each situation. The study assesses the impact of this competence on teams that alternate between routine situations and novel scenarios, to design a specific training programme for medical and surgical teams. To this end, three study groups are being compared: a group receiving training aimed at both leaders and team members, a second group receiving training exclusively for leaders, and a control group. In collaboration with the Official College of Nursing of Madrid (CODEM).
- **Results:** the project's findings will help to expand scientific knowledge on adaptive leadership in the healthcare sector and will serve as a basis for the development of a specific training programme for healthcare professionals.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.5.2.13 Spectral Cytometry Sorter Platform


This platform incorporates state-of-the-art spectral cytometry technology applied to cell sorting, enabling not only the detailed simultaneous identification of multiple cell populations but also their isolation with high levels of purity, viability, and reproducibility. This capability is essential for projects in immunology, oncology, infectious diseases, hematology, advanced organoids, precision medicine, and single-cell studies.

The use of this technology overcomes the limitations of conventional sorting systems, facilitating the analysis and separation of rare cell populations, complex immunological subpopulations, and cells of special biological interest, even when they occur at very low frequencies within the sample.

Its key capabilities include:

- high-precision cell isolation via cell sorting
- identification and separation of rare cell populations
- single-cell sorting for functional studies,
- methodological guidance on experimental design and analysis of results

The platform offers comprehensive scientific and technical support, from experimental planning to the isolation of purified cell populations ready for subsequent functional, molecular, or translational analysis. This support significantly improves the methodological quality of projects and enhances their competitiveness in national and international funding calls.



Furthermore, the Platform actively participates in the Institute's strategic projects and in the development of new methodological approaches in advanced biomedical research, establishing itself as an essential resource for studies involving high technological complexity.

The Spectral Cytometry Sorter is not merely an instrumental tool; it is a key technology for answering biological questions that, until a few years ago, were technically inaccessible, bringing precision research closer to clinical practice and the development of new diagnostic and therapeutic strategies.

Composition
Coordinator:
Eduardo López Collazo

Technical Manager:
Gonzalo Sánez de Santamaría

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.6. Mentor and prementor program



2.6.1. Mentor Program

In 2025, IdiPAZ, with the support of La Paz University Hospital, has implemented the 5th **Mentor Program** with the purpose of supporting our clinical early-stage researchers in the achievement of competitive projects, mainly from the main national call for health research projects: "Acción Estratégica en Salud (AES)", granted by *Instituto de Salud Carlos III*.

The Mentor Program plans a scientific and technical support in the preparation and tracking of research proposals. Furthermore, it takes into account the experience and scientific knowledge from our senior researchers to help our early-stage researchers from the beginning of their research career.

The objectives of the program are:

- Increasing the number of clinical research in IdiPAZ.
- Avoiding a generational leap of clinical researchers.
- Strengthening the research profile of our clinical staff.
- Positioning IdiPAZ as a model of clinical research, at the same level as it is in clinical trials.
- Performing an internal cultural change in clinical research.

Mentor Program includes different action plans have been implemented:

- To update the standardized curriculum for researchers.
- Enable synergies to create research groups.
- Support from the different platforms of IdiPAZ.
- Services of medical writing.
- Stand out the impact and the strategic priorities of the projects for the National Health System.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

In the 5th Mentor Program 115 participants were included:

RESEARCHER	# PROPOSAL SUBMITTED
Ainoa Muñoz San José	PI26/01101
Alberto Alonso Babarro	PI26/00014
Alfonso Alba Bernal	PI26/00689
Almudena Val Blasco	
Álvaro Sada Malumbres	
Ana Cruz Pardos	PI26/00626
Ana Fernández Santander	PI26/00731
Ana Isabel Borobia Pérez	PI26/02065
Ana Lourdes Luis Huertas	PI26/00399
Ana Martínez Feito	PI26/00142
Ana Méndez Echevarría	PI26/00007
Ane Miren Andrés Moreno	PI26/01579
Ángela Palao Tarrero	PI26/00465
Angelo Gámez Pozo	PI26/00640
Atilano José Carcavilla Urqui	PI26/01608
Áurea Díez Tascón	
Beatriz Barquiel Alcalá	PI26/00617
Beatriz Díaz Pollán	PI26/00759
Blanca Tapia Salinas	PI26/00168
Borja Rivero Santana	PI26/01863
Carlos Antonio Álvarez Ortega	PI26/00774
Carlos Delgado Miguel	
Carlos Zozaya Nieto	PI26/01854
Carmen Busca Arenzana	PI26/00218
Carmen Martín Hervás	PI26/01012
Carmen Rodríguez Jiménez	PI26/00750
Carmen Sobrino Jiménez	
Covadonga Martínez Díaz-Caneja	PI26/01101
Cristina García Quero	PI26/00749
Cristina Julia Suárez Ferrer	PI26/00746

RESEARCHER	# PROPOSAL SUBMITTED
Daniel Laorden Escudero	
David Ramiro Cortijo	PI26/00734
Diego Carracedo Sanchidrián	
Eduardo Fernández Jiménez	PI26/00007
Elena Gómez García	
Elena I. Diago Sempere	PI26/00913
Elena Ramírez García	PI26/00142
Emanuela Spagnolo	PI26/01281
Emilio Cendejas Bueno	PI26/01617
Ester Carreño Salas	PI26/00028
Eva Marín Serrano	PI26/00512
Fe Amalia García Santiago	PI26/01024
Francisca García-Moreno Nisa	PI26/01805
Gabriel Torres Iglesias	PI26/00732
Gerardo Ruiz Ares	PI26/00162
Gina Asunta Hernández Santillán	PI26/02069
Gonzalo Solís García	PI26/01767
Guillermo García Pérez de Sevilla	PI26/01191
Halin Bareke	PI26/00690
Hortensia de la Corte Rodríguez	
Ignacio García Cabeza	PI26/00738
Irene Ruiz Martín	
Isabel González Bertolín	PI26/00481
Isabel Valbuena Gómez	PI26/00920
Ismael Ghanem Cañete	PI26/01630
Jara Llenas García	PI26/00591
Javier de Andrés Ares	PI26/00283
Javier García-Samaniego Rey	PI26/01396
Javier Gómez Pavón	
Jesús Fernández Felipe	

RESEARCHER	# PROPOSAL SUBMITTED
Jorge Álvarez Troncoso	PI26/00882
Jorge Díaz Garzón Marco	PI26/00707
Jorge Rodríguez Pardo de Donlebún	PI26/00609
José Luis Encinas Hernández	PI26/00421
Juan Andrés Jiménez Estrada	PI26/01024
Juan José Menéndez Suso	PI26/00116
Juan José Ríos Blanco	PI26/01014
Julio González Luis	PI26/00950
Laura Córdoba García	
Laura Gutiérrez Sainz	PI26/00058
Laura Hurtado Navarro	PI26/00840
Lucía Deiros Bronte	PI26/00734
Lucía Fernández Gassó	
Luis Alberto Glaría Enríquez	PI26/01006
Luis Rodrigo Merino Rueda	PI26/00626
Luna Cordeiro Minute	
Luz Martín Carbonero	PI26/01500
Mª Angustias Quesada Simón	PI26/00408
Manuel Quintana Díaz	PI26/00428
Marcos Javier Cuerva González	PI26/00642
María Concepción Prados Sánchez	PI26/01510
María del Pilar Martínez Fernández	PI26/00561
María Isabel Prieto Nieto	PI26/00845
María José Rol García	PI26/00446
María Martínez Redondo	
María Recarte Rico	
Marta Díaz Menéndez	PI26/00702
Marta Gambra Arzoz	PI26/00668
Marta Gil Fernández	
Marta Ossorio González	PI26/00775

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCHER	# PROPOSAL SUBMITTED
Mercedes Gasior Kabat	PI26/00881
Mercedes López Martínez	PI26/00749
Milagros Merino Andreu	
Mireya Covadonga Fernández-Fournier Fernández	PI26/01021
Natalia Arruti Vázquez	
Onica M. Armijo Suárez	
Óscar Peñuelas Rodríguez	PI26/01863
Paloma Moraga Alapont	
Raquel Casitas Mateos	PI26/00688
Raquel de Paz Arias	
Raquel Herrero Hernández	PI26/01151
Raúl Galera Martínez	PI26/00688
Ricardo Jaime Rigual Bobillo	PI26/00997
Roberto Lozano Rodríguez	
Rocío Menéndez Colino	PI26/00914
Rocío Rosas Alonso	PI26/00121
Rosa Mª Morera López	PI26/00900
Rubén Mera Pérez	PI26/00119
Sandra Ofelia Rosillo Rodríguez	
Sara Ruiz Martínez	PI26/01291
Sonia López García	PI26/01023
Sonia Rodríguez Novoa	PI26/01391
Susana Noval Martín	PI26/01548
Víctor Galán Gómez	PI26/00167
Virginia Amesty Morello	PI26/00113


Below is the family collage of the participants in the 5th Mentor Program:



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

The number of researchers who have participated in the program can be seen since the launch of the Mentor Program at IdiPAZ in the following chart:



The program is supported by a network of senior mentors from different fields and professional expertise. The mentors provide mentees constructive feedback, putting at their disposal all their experience, dedication and motivation, supporting the process of preparing their research project proposals.

In the 5th Mentor Program 32 senior mentor have collaborated:

MENTOR	# MENTORED PROPOSAL
ADELINA PELLICER MARTÍNEZ, PhD	PI26/01767
ALBERTO M. BOROBIA PÉREZ, PhD	PI26/00142 PI26/00283 PI26/00617 PI26/00774 PI26/00913 PI26/00920 PI26/01863 PI26/02065
ANTONIO PÉREZ MARTÍNEZ, PhD	PI26/00167 PI26/00689 PI26/00690 PI26/01014
BLANCA FUENTES GIMENO, PhD	PI26/00162 PI26/00738
CARLOS DEL FRESNO SÁNCHEZ, PhD	PI26/00399 PI26/00421
CELSO ARANGO LÓPEZ, PhD	PI26/00007 PI26/00119 PI26/01101 PI26/02069
CONSTANTINO FONDEVILA CAMPO, PhD	PI26/00113 PI26/00900 PI26/01805
CRISTINA CALVO REY, PhD	PI26/00116
EDUARDO LÓPEZ COLLAZO, PhD	PI26/00840 PI26/01006 PI26/01012
EXUPERIO DÍEZ TEJEDOR, PhD	PI26/00014 PI26/00609 PI26/00997 PI26/01021 PI26/01191
FCO. JAVIER DE CASTRO CARPEÑO, PhD	PI26/00058 PI26/00121
FERNANDO MARTÍN SÁNCHEZ, PhD	PI26/00668 PI26/00707
FRANCISCO GARCÍA RÍO, PhD	PI26/00688
ISABEL LASTRES BECKER, PhD	PI26/00732
JAIME FELIÚ BATLLE, PhD	PI26/01630
JOSÉ LUIS BARTHA RASERO, PhD	PI26/00642 PI26/01291
JOSÉ LUIS CEBRIÁN CARRETERO, PhD	PI26/00168
JOSÉ Mª MOSTAZA PRIETO, PhD	PI26/00750 PI26/01391
JOSÉ RAMÓN ARRIBAS LÓPEZ, PhD	PI26/00408 PI26/00591 PI26/00702 PI26/00759 PI26/00882
JUAN ÁNGEL FRESNO VARA, PhD	PI26/00640
JUAN J. GONZÁLEZ GARCÍA, PhD	PI26/00218 PI26/01500
KAREN HEATH, PhD	PI26/00561 PI26/01024
Mª EUGENIA MIRANDA CARÚS, PhD	PI26/00028
MARÍA FERNÁNDEZ VELASCO, PhD	PI26/01863
MARÍA GUTIÉRREZ FERNÁNDEZ, PhD	PI26/01579
MIGUEL SÁENZ DE PIPAÓN MARCOS, PhD	PI26/00734 PI26/01854
NORA VIVIANA BUTTA COLL, PhD	PI26/00881
NURIA VILABOA DÍAZ, PhD	PI26/00626
OLGA VERA PUENTE, PhD	PI26/00512 PI26/00731 PI26/01281
REBECA PÉREZ DE DIEGO, PhD	PI26/00746
RODOLFO ÁLVAREZ-SALA WALTHER, PhD	PI26/00749 PI26/01510
TALÍA SÁINZ COSTA, PhD	PI26/00481
SUPPORT PLATFORM FOR EARLY-STAGE RESEARCHERS	PI26/00428 PI26/00446 PI26/00465 PI26/00775 PI26/00914 PI26/00950 PI26/01023 PI26/01151 PI26/01396 PI26/01548 PI26/01608 PI26/01617


1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

In order to ensure that the research project proposals submitted by our early-stage researchers have a high degree of excellence, the Mentor Program has a training plan structured in webinars for each section of the application report.
In 2025, the following webinars were held as part of the Mentor Program training plan:

TOPIC	DATE	SPEAKER
EXPERIENCES OF PARTICIPATION IN THE MENTOR PROGRAM	13/11/2025	DANIEL QUIJADA ALCÓN
ELISA ALONSO LÓPEZ, PhD		
FIS PROJECT PREPARATION KEYS. PROJECT EVALUATION.	27/11/2025	DANIEL QUIJADA ALCÓN
CARLOS DEL FRESNO SÁNCHEZ, PhD		
OBJECTIVES AND METHODOLOGY: STRUCTURE, BIASES AND CONTINGENCY PLAN	04/12/2025	DANIEL QUIJADA ALCÓN
CVA & ORCID IDENTIFIER (in-person seminar)	11/12/2025	RAÚL ROMÁN CAÑIZARES
GENDER PERSPECTIVE AND DIMENSION IN RESEARCH	18/12/2025	DANIEL QUIJADA ALCÓN
STATISTICAL ANALYSIS	08/01/2026	MARÍA JIMÉNEZ GONZÁLEZ
METHODOLOGICAL PLANNING FOR OBSERVATIONAL STUDIES	13/01/2026	IRENE GARCÍA GARCÍA, PhD
PI PROFILE, DORA CRITERIA & BIBLIOMETRIC INDICATORS (in-person seminar)	15/01/2026	RAÚL ROMÁN CAÑIZARES
METHODOLOGICAL PLANNING FOR CLINICAL TRIALS	22/01/2026	ALBERTO M. BOROBIA PÉREZ, PhD
STRATEGIC INTEREST OF THE PROJECT AND CITIZEN ENGAGEMENT PLAN	29/01/2026	DANIEL QUIJADA ALCÓN
STORYTELLING FOR PROJECT WRITING	05/02/2026	RAQUEL AGUIRRE ZANDUETA
HOW TO PREPARE A GOOD BUDGET	12/02/2026	SILVIA ARCE SANTAMARÍA JÉSSICA GARCÍA MOSCATEL
DATA MANAGEMENT PLAN. DATA PROTECTION	19/02/2026	DANIEL QUIJADA ALCÓN
WEB APPLICATION TUTORIAL (in-person seminar)	04/03/2026	MERCEDES RUIZ BALIBREA


In its fifth year, carried out as part of the Mentor Programme have helped to ensure that a large number of proposals have been submitted to *Acción Estratégica en Salud (AES)* call for health research projects by IdiPAZ researchers:

RESEARCH PROPOSALS APPLIED TO AES CALLS



1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.6.2. Prementor Program



IdiPAZ, with the support of La Paz University Hospital, has implemented the 1st **Prementor Program** with the purpose of supporting our predoctoral researchers in the achievement of their Doctorate.

The objectives of the program are:

- Increasing the number of researchers with a PhD in IdiPAZ.
- Promote high quality training of researchers.
- Performing an internal cultural change in translational research in biomedicine.

The Prementor Program planned a formative and technical support during the second and third tutorial courses of our predoctoral researchers' doctoral studies. The following webinars have been held as part of the Prementor Program training plan:

DATE	TOPIC	SPEAKER
20/09/2024	HOW TO ESTABLISH A RESEARCH QUESTION/HYPOTHESIS	DANIEL QUIJADA ALCÓN
18/10/2024	ETHICS AND SCIENTIFIC FRAUD	NORA BUTTA COLL
15/11/2024	PREPARING AND CLEANING DATABASES	MARÍA TERESA GARÍA MORALES
20/12/2024	FIGURES, VISUALIZATION AND DATA ANALYSIS	MARÍA JIMÉNEZ GONZÁLEZ
17/01/2025	IDIPAZ SUPPORT PLATFORMS FOR EXPERIMENTAL WORK	GEMA VALLÉS PÉREZ
21/02/2025	ORAL COMMUNICATIONS AND POSTER DESIGN	EMANUELA SPAGNOLO
25/04/2025	PROTECTION OF RESULTS	ESTELA SÁNCHEZ SIMÓN
23/05/2025	TOOLS FOR THE EMOTIONAL MANAGEMENT DURING THE DEVELOPMENT OF THE THESIS	ÁNGELA PALAO TARRERO
13/06/2025	TIPS FOR PUBLICATION AND SCIENTIFIC DISSEMINATION	ANA Mª SASTRE PERONA
20/06/2025	THESIS DEFENSE	REBECA PÉREZ DE DIEGO

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

In the 1st Prementor Program 69 participants were included:

DOCTORAL STUDENT	UNIVERSITY
AARON ABDELKADER GUILLÉN	UNIVERSIDAD AUTÓNOMA DE MADRID
ALEJANDRO DE GEA GRELA	UNIVERSIDAD AUTÓNOMA DE MADRID
ALICIA MARÍN CANDÓN	UNIVERSIDAD AUTÓNOMA DE MADRID
ANDREA BUENO SEN	UNIVERSIDAD AUTÓNOMA DE MADRID
ANDREA GUZMÁN DE ANTONIO	UNIVERSIDAD AUTÓNOMA DE MADRID
ANDREA LOPEZ SUAREZ	UNIVERSIDAD COMPLUTENSE DE MADRID
ARIADNA WITTE CASTRO	UNIVERSIDAD COMPLUTENSE DE MADRID
BEATRIZ NIETO CARVALHAL	UNIVERSIDAD AUTÓNOMA DE MADRID
BLANCA FABRE ESTREMERA	UNIVERSIDAD AUTÓNOMA DE MADRID
CARLOS DELGADO MIGUEL	UNIVERSIDAD AUTÓNOMA DE MADRID
CARLOS RODRÍGUEZ ANTOLÍN	UNIVERSIDAD AUTÓNOMA DE MADRID
COLOMA GRAU VAN LAAK	UNIVERSIDAD AUTÓNOMA DE MADRID
CRISTINA DE MANUEL GÓMEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
CRISTINA MARCELO CALVO	UNIVERSIDAD AUTÓNOMA DE MADRID
DARÍO SÁNCHEZ CABRERO	UNIVERSIDAD AUTÓNOMA DE MADRID
DIEGO MORANTE MARTÍNEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
EDUARDO CAZALLA IBÁÑEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
ELENA MARTÍNEZ ROBLES	UNIVERSIDAD AUTÓNOMA DE MADRID
ENRIQUE ALFARO GARCIA	UNIVERSIDAD AUTÓNOMA DE MADRID
FRANCISCO DE BORJA NAVA HURTADO DE SARACHO	UNIVERSIDAD AUTÓNOMA DE MADRID
GABRIEL TORRES IGLESIAS	UNIVERSIDAD AUTÓNOMA DE MADRID
GEMA YAGÜE DE ANTONIO	UNIVERSIDAD DE LEÓN
GONZALO SÁENZ DE SANTA MARÍA DIEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
GUILLERMO MANUEL SIBÓN SANCHO	UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA
GUILLERMO MARTÍN ÁVILA	UNIVERSIDAD EUROPEA DE MADRID
IGNACIO SILVA LLANES	UNIVERSIDAD AUTÓNOMA DE MADRID
IRENE BARRIENTOS RUIZ	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL DIAZ SUAREZ	UNIVERSIDAD DE NAVARRA
ISABEL GONZÁLEZ BERTOLÍN	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL MELLADO SOLA	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL MELLADO SOLA	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL MORENO PARRO	UNIVERSIDAD AUTÓNOMA DE MADRID
JAVIER POZO NOVOA	UNIVERSIDAD AUTÓNOMA DE MADRID
JAVIER SERRADILLA RODRIGUEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
JESÚS PEÑA LÓPEZ	UNIVERSIDAD AUTÓNOMA DE MADRID

DOCTORAL STUDENT	UNIVERSITY
JOSÉ MARÍA RODRÍGUEZ PIÑAS	UNIVERSIDAD EUROPEA DE MADRID
JULIA DEL PRADO MONTERO	UNIVERSIDAD AUTÓNOMA DE MADRID
LAURA BRAVO ROBLES	UNIVERSIDAD AUTÓNOMA DE MADRID
LAURA CLARES VILLA	UNIVERSIDAD AUTÓNOMA DE MADRID
LAURA GARCIA ESPINOSA	UNIVERSIDAD AUTÓNOMA DE MADRID
LUCIA GUTIÉRREZ GARCÍA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARI PAZ LÓPEZ MOLINA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA DE CEANO-VIVAS LA CALLE	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA DEL ROSARIO GARCÍA SÁNCHEZ	UNIVERSIDAD COMPLUTENSE DE MADRID
MARIA JESUS ESPINOSA PASCUAL	UNIVERSIDAD COMPLUTENSE DE MADRID
MARIA JOSE ROL GARCIA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA PÉREZ PASCUAL	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA SÁNCHEZ MARTÍN	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA SANZ DE PEDRO	UNIVERSIDAD AUTÓNOMA DE MADRID
MARIA VARELA CERDEIRA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARTA LUISA MUNER HERNANDO	UNIVERSIDAD AUTÓNOMA DE MADRID
MIKEL FERNÁNDEZ ARTAZCOZ	UNIVERSIDAD AUTÓNOMA DE MADRID
MÓNICA BEOBIDE CONDE	UNIVERSIDAD REY JUAN CARLOS
NEILA RODRÍGUEZ ROCA	UNIVERSIDAD AUTÓNOMA DE MADRID
NURIA LOURDES PÉREZ CHULIÁ	UNIVERSIDAD AUTÓNOMA DE MADRID
PALOMA MARTÍNEZ CAMPOS	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA ARAGÓN RAMOS	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA CANTOLLA PABLO	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA PATRICIA BURGOS MORALES	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA PÉREZ MORENO	UNIVERSIDAD AUTÓNOMA DE MADRID
PELAYO FERNÁNDEZ CIDÓN	PENDIENTE
RAQUEL CASITAS MATEO	UNIVERSIDAD AUTÓNOMA DE MADRID
REBECA GALLEGO RUIZ	UNIVERSIDAD AUTÓNOMA DE MADRID
RICARDO JAIME RIGUAL BOBILLO	UNIVERSIDAD AUTÓNOMA DE MADRID
SONIA ALCOLEA	UNIVERSIDAD AUTÓNOMA DE MADRID
SONIA MILKOVA IVANOVA	UNIVERSIDAD AUTÓNOMA DE MADRID
TAMARA DOMINGO PÉREZ	UNIVERSIDAD DE NAVARRA
TERESA MATO PATINO	UNIVERSIDAD AUTÓNOMA DE MADRID
VICTORIA ARNALICH MONTIEL	UNIVERSIDAD AUTÓNOMA DE MADRID

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.7. CIBERs and RETICs

In 2025, IdiPAZ engaged actively in various thematic networks and research consortiums officially acknowledged by the Carlos III Health Institute.

PROJECT	ACRONYM	IMAGE	CIBER	FUNDING ORGANISATIONS	PRINCIPAL RESEARCHER	IdiPAZ GROUP	INSTITUTION
CB06/05/0007	CIBERNED	ciber NED	Centro de Investigación en Red de Enfermedades neurodegenerativas	Carlos III Health Institute	Bullido Gómez-Heras MJ.	Neurology and Cerebrovascular Diseases	FIBHULP
CB06/05/0010	CIBERNED	ciber NED	Centro de Investigación Biomédica en Enfermedades Neurodegenerativas	Carlos III Health Institute	Cuadrado Pastor, A.	Neuroprotective Strategies in Neurodegenerative Diseases	UAM
CB07/08/0033	CIBERDEM	ciber DEM	Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas	Carlos III Health Institute	Martínez Valverde, A.M.	Neuroprotective Strategies in Neurodegenerative Diseases	CSIC
CB16/11/00286	CIBERCV	ciber CV	Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares	Carlos III Health Institute	Briones Alonso, AM.	Vascular Physiology and Pharmacology	UAM
CB21/13/00039	CIBERInfect	ciber INFEC	Centro de Investigación Biomédica en Red de Enfermedades Infecciosas	Carlos III Health Institute	Arribas López, JR.	AIDS and Infectious Diseases	FIBHULP
CB19/07/00042	CIBERer	ciber ER	Centro de Investigación Biomédica en Red de Enfermedades Raras	Carlos III Health Institute	López Granados E.	Lymphocytic Pathophysiology in Immunodeficiencies	FIBHULP
CB15/00037	CIBERes	ciber ES	CIBER de Enfermedades Respiratorias	Carlos III Health Institute	García Río, F.	Respiratory diseases	FIBHULP
CB06/07/1033	CIBERer	ciber ER	Centro de Investigación en Red de Enfermedades Raras	Carlos III Health Institute	Caballero Molina, M.T.	Diagnosis and treatment of allergic diseases	FIBHULP
CB06/07/1005	CIBERer	ciber ER	CIBER Enfermedades Raras	Carlos III Health Institute	Lapunzina Badía P.	INGEMM - Institute of Medical and Molecular Genetics	FIBHULP
CB16/12/00398	CIBERonc	ciber ONC	Networked Biomedical Research Center for Cancer	Carlos III Health Institute	Feliú Batlle J.	Translational Oncology	FIBHULP
CB06/07/1021	CIBERer	ciber ER	Centro de Investigación en Red de Enfermedades Raras	Carlos III Health Institute	Varela Nieto, I.	Otorhinolaryngology and Head and Neck Surgery Research	CSIC
CB06/07/1029	CIBERer	ciber ONC	Centro de Investigación en Red de Enfermedades Raras	Carlos III Health Institute	Ruiz Pérez, V.L.	INGEMM - Institute of Medical and Molecular Genetics	CSIC
CB16/12/00273	CIBERonc	ciber ER	Networked Biomedical Research Center for Cancer	Carlos III Health Institute	Muñoz Terol A.	Mechanisms of Tumor Progression	CSIC
CB06/07/0004	CIBERer	ciber ER	Centro de Investigación en Red de Enfermedades Raras	Carlos III Health Institute	Pérez González MB.	Research and Diagnosis of Hereditary Metabolic Diseases	UAM
CB06/01/0008	CIBER-BBN	ciber ONC	Networked Biomedical Research Center for Bio-engineering, Biomaterials and Nanomedicine	Carlos III Health Institute	Vilaboa Díaz, N. E.	Bone Pathophysiology and Biomaterials	FIBHULP
CB06/04/0011	CIBERehd	ciber EHD	CIBER de Enfermedades Hepáticas y Digestivas	Carlos III Health Institute	Fondevila Campo, C.	Translational research and innovation in general and digestive surgery	FIBHULP
CB21/13/00025	CIBERINFEC	ciber INFEC	Centro de Investigación Biomédica en Res en Enfermedades Infecciosas	Carlos III Health Institute	Calvo Rey, C.	Respiratory, systemic and neurological infectious pathology in childhood, and host immune response	FIBHULP

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

PROJECT	ACRONYM	IMAGE	CIBER	FUNDING ORGANISATIONS	PRINCIPAL RESEARCHER	IdiPAZ GROUP	INSTITUTION
CB16/10/00464	CIBERFES	ciber FES	Centro de Investigación Biomédica en Red en Fragilidad y Envejecimiento Saludable	Carlos III Health Institute	Rodríguez Mañas, L.	Frailty and Healthy Aging	FIBHUG
CB16/11/00286	CIBERCV	ciber CV	Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares	Carlos III Health Institute	Bosca Gomar, L.	Innate Immune Response	CSIC
CB/07/09/0023	CIBERSAM	ciber SAM	Centro de Investigación Biomédica en Red de Salud Mental	Carlos III Health Institute	Arango López, C.	Psychiatry and Mental Health	SERMAS

Networks and Platforms

IdiPAZ is integrated into various Platforms and Networks for Cooperative Research in Health, which are collaborative frameworks aimed at executing interdisciplinary research initiatives.

PROJECT	ACRONYM	IMAGE	RETICS	FUNDING ORGANISATIONS	PRINCIPAL RESEARCHER	IdiPAZ GROUP	INSTITUTION	END DATE
RD21/0006/0012	RICORS	RICORS-ICTUS Instituto de Salud Carlos III	Enfermedades vasculares cerebrales	Carlos III Health Institute	Fuentes Gimeno, B.	Neurology and Cerebrovascular Diseases	FIBHULP	31/12/2025
RD21/0002/ CRG11	RICORS	Red de Enfermedades Inflamatorias RICORS (RD21/0002)	Inflamación	Carlos III Health Institute	Otero Ortega, L.	Neurology and Cerebrovascular Diseases	FIBHULP	31/12/2025
CA20121	BenBedPhar	BenBedPhar	Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases	EU European COST Action	Cuadrado Pastor A, Rojo Sanchís AI.	Neuroprotective Strategies in Neurodegenerative Diseases	Victor Babes Research (Romania)	18/10/2025
	ECLip	European Consortium of Lipodystrophies	The European Consortium of Lipodystrophies	European Union	López Trascasa, M.	Alterations of the Complement System in Human Pathology	FIBHULP	31/12/2025
RD21/0005/0030		RICORS2040	Inflamación e inmunopatología de órganos y sistemas	Carlos III Health Institute	Fernández Juárez, G.M.	Nephrology	FIBHULP	31/12/2025

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

PROJECT	ACRONYM	IMAGE	RETICS	FUNDING ORGANISATIONS	PRINCIPAL RESEARCHER	IdiPAZ GROUP	INSTITUTION	END DATE
	SCReN		Unidad de Investigación clínica y ensayos clínicos del Hospital Universitario la Paz	Carlos III Health Institute	Borobia Pérez, A.	Clinical Pharmacology	FIBHULP	31/12/2026
	ECRIN		European Clinical Research Infraestructures Network	Carlos III Health Institute	Borobia Pérez, A.	Clinical Pharmacology	FIBHULP	31/12/2026
	SCReN		Plataforma ISCIII de soporte para la Investigación Clínica	Carlos III Health Institute	Borobia Pérez, A.	Clinical Pharmacology	FIBHULP	31/12/2026
	SAMID		Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin	Carlos III Health Institute	Cabañas González, F.	Neonatology	FIBHULP	31/12/2025
	RARE-LIVER		ERN on Hepatological diseases	European Union	Frauca Remacha, E	Molecular Hepatology	FIBHULP	31/12/2027
	TransplantChild		ERN on Transplantation in children	European Union	Hernández Oliveros, F.	Congenital Malformations, Transplantation and Oncological Surgery	FIBHULP	31/12/2027
	RELECOV		Red de Laboratorios Españoles de secuenciación Genómica de SARS-CoV-2	European Union	Casas Flecha, I.	Respiratory, systemic and neurological infectious pathology in childhood, and host immune response	ISCIII	31/12/2025
RD21/0017/0025	RICORS		Terapias avanzadas	Carlos III Health Institute	Pérez Martínez A.	Translational research in childhood cancer, hematopoietic transplantation, and cell therapy	FIBHULP	01/01/2025

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

PROJECT	ACRONYM	IMAGE	RETICS	FUNDING ORGANISATIONS	PRINCIPAL RESEARCHER	IdiPAZ GROUP	INSTITUTION	END DATE
RD24/0014/0001	RICORS		Terapias avanzadas	Carlos III Health Institute	Pérez Martínez A.	Translational research in childhood cancer, hematopoietic transplantation, and cell therapy	FIBHULP	31/12/2027
	RICAPPS		Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud	Carlos III Health Institute	Salinero-Fort, M.A.	Frailty, multimorbidity patterns and mortality in the community-dwelling elderly population	FIIBAP	31/12/2025
	RICAPPS		Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud	Carlos III Health Institute	Castell Alcalá, V.	Frailty, multimorbidity patterns and mortality in the community-dwelling elderly population	FIIBAP	31/12/2025
PT23/00028	BIOBANCO		Plataforma ISCIII de Biomodelos y Biobancos	Carlos III Health Institute	López Collazo, E.	Innate Immune Response	FIBHULP	31/12/2026
PT23/00035	INNOVA		Plataforma ISCIII de Dinamización e Innovación de las capacidades industriales del SNS	Carlos III Health Institute	De Castro Carpeño, J.	Experimental Therapies and Biomarkers in Cancer	FIBHULP	31/12/2026
PT23/00064	UICEC		Plataforma ISCIII de soporte para la Investigación Clínica	Carlos III Health Institute	Borobia Pérez, A.	Clinical Pharmacology	FIBHULP	31/12/2026
	EUnetCCC		The European Comprehensive Cancer Centre Network	European Union	De Castro Carpeño, J.	Experimental Therapies and Biomarkers in Cancer	FIBHULP	31/12/2028
	JARDIN		Joint Action on ERN Integration	European Union	Noval Martín, S.	Congenital Malformations, Transplantation and Oncological Surgery	FIBHULP	31/12/2026
	ERA4HEALTH		Fostering a European Research Area for Health Research	European Union	Borobia Pérez, A.	Clinical Pharmacology	FIBHULP	31/12/2029

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

PROJECT	ACRONYM	IMAGE	RETICS	FUNDING ORGANISATIONS	PRINCIPAL RESEARCHER	IdiPAZ GROUP	INSTITUTION	END DATE
	CoARA		Coalition for Advancing Research Assessment	European Union	Coloma, A. Rello Varona, S.	FIBHULP	FIBHULP	
	ERN BOND		ERN on Rare Bone diseases	European Union	Heath, K.	INGEMM - Institute of Medical and Molecular Genetics	FIBHULP	31/12/2027
	ERN EYE		ERN on Rare Eye Diseases	European Union	Noval Martín, S. Moreno, M.N.	Congenital Malformations, Transplantation and Oncological Surgery	FIBHULP	31/12/2027
	ITHACA		ERN on rare malformation syndromes and rare itellectual and neurodevelopmental disorders	European Union	Santos, F. Lapunzina Badía, P.	INGEMM - Institute of Medical and Molecular Genetics	FIBHULP	31/12/2027
	ERNICA		ERN on rare inherited and cogenital anomalies	European Union	Martínez L. Ramos Boluda, E.	Associated Clinicians	FIBHULP	31/12/2027
	RITA		ERN on rare immunological disorders and PID	European Union	López Granados, E. Remesal, A.	Lymphocytic Pathophysiology in Immunodeficiencies	FIBHULP	31/12/2027
	PaedCan		ERN on Paediatric Oncology	European Union	Pérez Martínez, A. Ortiz-Cruz, E.	Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy	FIBHULP	31/12/2027
	eUROGEN		ERN on urogenital diseases	European Union	López Pereira, P.	Associated Clinicians	FIBHULP	31/12/2027
	RND		ERN on neurological diseases	European Union	Rodríguez de Rivera Garrido, F.J. Rizea, C.	Neurology and Cerebrovascular Diseases	FIBHULP	31/12/2027
	EATRIS		European Infrastructure for Translational Medicine	European Union	López Collazo, E.	Innate Immune Response	FIBHULP	31/12/2026
	TEDDY Network		European Network of Excellence for Paediatric Clinical Research	European Union	Calvo Rey, C. Piñeiro, R.	Infectious respiratory, systemic and neurological pathology in childhood, and host immune response	FIBHULP	

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.8. Communication and public engagement

The main goals of Scientific Communications are to publish the research conducted by the talented scientists at IdiPAZ and to strengthen our connections with other institutions and the public.

We have seen a boost in media coverage for our research and activities, with a noticeable rise in press appearances and social media engagement. This surge is largely due to the active participation of many of IdiPAZ's researchers.

Thanks to the collaborative efforts of our center's scientists, IdiPAZ has taken part in events like the European Researchers' Night, Science and Innovation Week, and the International Day of Women and Girls in Science. We have also organized guided tours for high school students, offering both virtual and in-person visits, along with talks and workshops tailored for kids and schools.


We want to extend our gratitude to the communication office at **La Paz University Hospital** for their support.

2.8.1. Selected media appearances

In 2025, we have published many press releases highlighting IdiPAZ's scientific achievements. Below is a summary of the year's most significant headlines.



13/01/2025 – La Comunidad de Madrid celebra el 15º aniversario del Instituto IdiPAZ al frente de la investigación biomédica en España



16/01/2025 – La Comunidad de Madrid lidera un proyecto europeo para mejorar la inclusión de poblaciones infrarrepresentadas en los ensayos clínicos



31/01/2025 – La Comunidad de Madrid, anfitriona de la I Reunión Nacional Multidisciplinar sobre la Esclerosis Lateral Amiotrófica | Comunidad de Madrid



21/03/2025 – El Hospital público La Paz refuerza su compromiso con la calidad gracias a la mejora continua de los procesos




05/05/2025 – La sanidad pública madrileña, pionera mundial al tratar con éxito una enfermedad rara autoinmune con terapia CAR-T



16/06/2025 – Investigadores del Hospital público La Paz vinculan las apneas del sueño con peor pronóstico en cáncer de pulmón y melanoma



03/07/2025 – La sanidad pública madrileña atiende a 95 niños con enfermedades autoinflamatorias en un servicio médico único en España



07/08/2025 – El Hospital Universitario La Paz integra ingeniería clínica en el quirófano para cirugía torácica pediátrica con navegación virtual

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



01/09/2025 – Profesionales del Hospital público La Paz impulsan la formación en simulación y emergencias obstétricas en Paraguay



15/09/2025 – La Comunidad de Madrid presenta su Estrategia Biofarmacéutica para impulsar la innovación, el empleo y la inversión en el sector



10/10/2025 – Los avances en hemofilia y coagulopatías adquiridas mejoran el control del sangrado antes, durante y después de una cirugía



05/11/2025 – El Hospital público La Paz lidera un proyecto piloto europeo para mejorar la atención cardiovascular en pacientes oncológicos



26/11/2025 – El Instituto de Investigación del Hospital público La Paz mantiene su liderazgo en investigación biomédica



29/12/2025 – Nacimientos simulados y muertes controladas: así es un centro de entrenamiento para salvar vidas

2.8.2. Scientific Newsletter: IdiPAZ+ii News

In the year 2024, the scientific culture unit has published two newsletters, each concentrating on different subjects pertinent to researchers.











IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

2.8.4. Formative Pills about Sustainable Development Goals and Responsible Research and Innovation

We are dedicated to promoting good practices related to the Sustainable Development Goals (SDGs) through our bite-sized training sessions. As a new initiative introduced in 2025, IdiPAZ has incorporated the assignment of the SDGs to all news items disseminated through our institutional newsletter. This initiative enables each communication to be linked to one or more SDGs, highlighting the contribution of the Institute's research and innovation activities to the achievement of the 2030 Agenda while facilitating the monitoring of their impact. During the year, a total of 174 news items were assigned SDGs, reinforcing the integration of sustainability into IdiPAZ's scientific communication strategy and demonstrating the Institute's commitment to generating and disseminating knowledge aligned with the social, environmental and health challenges addressed by the Sustainable Development Goals.

22 de diciembre – IdiPAZ os desea unas felices fiestas
19 de diciembre – Encuesta de formaciones formativas
19 de diciembre – Difusión oferta educativa SEPE
19 de diciembre – Seguridad Vial - Baliza V16
19 de diciembre – Pre-anuncio de convocatorias BrainHealth 2026
19 de diciembre – IdiPAZ News: Resumen 2025
18 de diciembre – Recordatorio - 5º Seminario Mentor 2026
17 de diciembre – Jornada PhDay 2025
17 de diciembre – Recomendaciones sobre el uso de mascarilla ante el inicio de la temporada de virus respiratorios
16 de diciembre – Boletín nº28 IdiPAZ News - II Encuentro de asociaciones de pacientes en IdiPAZ
16 de diciembre – 5º Seminario Mentor AES 2026: Perspectiva de Género
15 de diciembre – La revista BMJ incluye en su edición especial de Navidad un artículo de Alejandro Díez-Vidal y José Ramón Arribas
15 de diciembre – Nueva página de Dona en IdiPAZ
15 de diciembre – Agradecimiento a los investigadores - Semana de la Ciencia 2025
12 de diciembre – Nueva convocatoria Caixa
11 de diciembre – Seminario Científico - Mañana 12 de diciembre a las 10
09 de diciembre – Seminario Científico 12 de diciembre a las 10
09 de diciembre – 4º Seminario Mentor AES 2026: CVA (presencial)
05 de diciembre – Preanuncio de Convocatoria BE READY
04 de diciembre – Recordatorio - 3º Seminario Mentor 2026

04 de diciembre – Programa de trabajo 2026 de Global Health EDCTP3
04 de diciembre – IV Jornada Formativa 2025 - Comisión de Calidad del IdiPAZ
04 de diciembre – PolyFIL, proyecto de IdiPAZ premiado en los III Health to Market
02 de diciembre – Semana de la Lucha contra el SIDA
02 de diciembre – 3º Seminario Mentor AES 2026: Objetivos y diseño metodológico
28 de noviembre – II Congreso Science L: La ciencia como puente – Wetenschap als brug
27 de noviembre – Recordatorio 9:00 2º Seminario Mentor 2026
27 de noviembre – IdiPAZ Informa Repositorio
26 de noviembre – Nueva convocatoria La Caixa
26 de noviembre – Seminario Científico 12 de diciembre a las 10
25 de noviembre – 2º Seminario Mentor AES 2026: Evaluación
25 de noviembre – Sesión formativa Transplantchild – Fernando Martín ASD
25 de noviembre – V Premios Ennova Health
25 de noviembre – Difusión ERN TransplantChild: Live Case Discussion Noviembre
25 de noviembre – Sesión General: Investigación, el ADN del Hospital La Paz
24 de noviembre – Sesión General: Investigación, el ADN del Hospital La Paz
24 de noviembre – II Encuentro de asociaciones de pacientes en IdiPAZ
24 de noviembre – Difusión ERN TransplantChild: Live Case Discussion Noviembre
21 de noviembre – 6ª Jornada de Geriatría Transversal
21 de noviembre – CAMBIO DE UBICACIÓN – II Encuentro de asociaciones de pacientes en IdiPAZ
20 de noviembre – APP Gestión de Salas
20 de noviembre – Nueva Convocatoria La Caixa

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

20 de noviembre – Javier de Castro, nuevo presidente de la Sociedad Española de Oncología Médica (SEOM)
19 de noviembre – URGENTE Becas Luis Álvarez
19 de noviembre – II Encuentro de asociaciones de pacientes en IdiPAZ
19 de noviembre – Presentación de la Memoria Científica 2024
19 de noviembre – URGENTE Becas Luis Álvarez
18 de noviembre – Presentación de la Memoria Científica 2024
17 de noviembre – Presentación de la Memoria Científica 2024
14 de noviembre – Día Mundial de la Diabetes
14 de noviembre – Séptimo PhDay 2025
13 de noviembre – Recordatorio Seminario Mentor 2026 9:00
12 de noviembre – Programa Seminarios Mentor AES 2026
11 de noviembre – Becas Dr. Luis Álvarez 2025 (corrección de errores)
07 de noviembre – Evento Innovaciones en PCR y Proteómica
07 de noviembre – Séptimo PhDay 2025
06 de noviembre – Séptimo PhDay 2025
06 de noviembre – Seminario Científico mañana día 7 de noviembre a las 10
06 de noviembre – Sesión de Información en la Modalidad 7 de las Becas Luis Álvarez
06 de noviembre – Presentación de la Memoria Científica 2024 día 19 de noviembre
05 de noviembre – Publicación Convocatoria Intramural – Becas Dr. Luis Álvarez 2025
04 de noviembre – V Jornada Investigación Sanitaria de la Comunidad de Madrid
04 de noviembre – II Encuentro de asociaciones de pacientes en IdiPAZ
31 de octubre – Convocatorias Ramón y Cajal y Juan de la Cierva 2025
30 de octubre – Sociedad Española de Cardiología (SEC)
30 de octubre – Pre-anuncio de la Convocatoria 2026 de ERDERA
30 de octubre – Pre-anuncio de la convocatoria THCS 2026
30 de octubre – Semana de la Ciencia 2025
29 de octubre – Seminario Científico día 7 de noviembre a las 10
28 de octubre – Pre-anuncio de la convocatoria EP PerMed CARMEN2026
28 de octubre – V Jornada Investigación Sanitaria de la Comunidad de Madrid
24 de octubre – Symposium - Neuroinmunología y Esclerosis Múltiple
22 de octubre – Pre-anuncio de la convocatoria Prevent-OO
21 de octubre – Difusión ERN TransplantChild: Live Case Discussion (30/10/2025)
21 de octubre – REGIC Píldora formativa 46 – Facturación electrónica
17 de octubre – Nuevos grupos IdiPAZ – Ensayo clínico en la UCICEC
17 de octubre – Próximos cursos de nuestro Plan de Formación 2025
17 de octubre – Renovación de nuestro compromiso con la Carta de la Diversidad
15 de octubre – Día Mundial del Lavado de Manos
15 de octubre – Séptimo PhDay 2025
14 de octubre – Comienza la campaña de vacunación 2025-2026 para trabajadores sanitarios de gripe estacional y COVID-19
14 de octubre – REGIC Píldora formativa 46 – Facturación electrónica y Reportes fiscales
14 de octubre – Pre-anuncio de la convocatoria Trials4Health 2026
10 de octubre – Día Mundial de la Salud Mental
09 de octubre – Presentación de la Memoria Científica IdiPAZ 2024
06 de octubre – 6º TransplantChild workshop (23/10/25)
06 de octubre – Difusión ERN TransplantChild: Webinar 14/10/2025
03 de octubre – IV Jornadas de la Red de Terapias Avanzadas
03 de octubre – Séptimo PhDay 2025
02 de octubre – Ensayo Oftalmología / Día Desperdicio Alimentario
01 de octubre – Evento Participación Ciudadana en el marco del Proyecto Europeo READI
IdiPAZ Sostenible 01 de octubre – Día Desperdicio Alimentario / Mantenimiento Agua Caliente
30 de septiembre – Próximos cursos de nuestro Plan de Formación 2025
30 de septiembre – REGIC Píldora formativa 45 – Premio Congreso Neurorradiología
29 de septiembre – Próximos cursos de nuestro Plan de Formación 2025
24 de septiembre – Curso de "Farmacovigilancia en Ensayos Clínicos"
24 de septiembre – Noche de los investigadores 2025
22 de septiembre – Día Mundial sin coche
22 de septiembre – Cambios importantes para los usuarios de VPN del hospital
16 de septiembre – Difusión ERN TransplantChild: Workshop día 23 de octubre
16 de septiembre – REGIC Píldora formativa 44 IA generativa en la gestión biomédica
15 de septiembre – Cambios importantes para los usuarios de VPN del hospital
12 de septiembre – Curso básico de Calidad ISO 9001:2015
11 de septiembre – Difusión ERN TransplantChild: Webinar 16/09/2025 y LCD
11 de septiembre – Próximos cursos de nuestro Plan de Formación 2025
10 de septiembre – Difusión ERN TransplantChild: webinar Dr. George Mazariegos 15/09/2025
09 de septiembre – Curso de "Farmacovigilancia en la Práctica clínica (1ª edición)"
09 de septiembre – Charla por el Día Mundial para la Prevención del Suicidio

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

09 de septiembre – REGIC Píldora formativa 44 IA generativa en la gestión biomédica
08 de septiembre – Difusión ERN TransplantChild: webinars acreditados (09/09/25) y (11/09/25)
04 de septiembre – Curso de "Farmacogenética en la Práctica clínica (1ª edición)"
02 de septiembre – REGIC Píldora formativa 44 IA generativa en la gestión biomédica
29 de agosto – ¿Qué hacer ante un ciberincidente?
26 de agosto – REGIC Próximas píldoras formativas
18 de agosto – ÁEstamos nominados! ¿Nos ayudas con tu voto?
29 de julio – Detectada una campaña de phishing
28 de julio – Plan Implementación 2FA
03 de julio – Memoria de sostenibilidad 2024
02 de julio – Nueva aplicación para la reserva de salones de actos
01 de julio – Información de hidratación de IdiPAZ
27 de junio – Día del Orgullo
27 de junio – Este verano, navega de forma segura
23 de junio – Recordatorio III Jornada formativa de la Comisión de Calidad
23 de junio – Los 100 españoles LGTBIQ+ más influyentes de España en 2025
19 de junio – III Jornada formativa de la Comisión de Calidad del IdiPAZ
16 de junio – Último recordatorio Semana de la Ciencia
16 de junio – III Jornada formativa de la Comisión de calidad del IdiPAZ
13 de junio – Día Mundial del Cáncer de Piel
10 de junio – REGIC Píldora formativa 43
05 de junio – Día Mundial de la Movilidad Sostenible
03 de junio – REGIC Píldoras formativas 42 y 43
03 de junio – Semana de la Ciencia enviado
02 de junio – El hospital celebra el Día Nacional del Donante de Órganos y Tejidos
29 de mayo – Difusión ERN TransplantChild: Webinars Acreditados
27 de mayo – Curso Redacción científica en inglés – Plan de Formación 2025
27 de mayo – Noche de la investigación 2025
27 de mayo – REGIC Píldoras formativas 41 y 42
26 de mayo – Curso de Actualización BPC para Investigadores
23 de mayo – Semana de la Ciencia
20 de mayo – Ciudad de la Salud – Internacionalización – Día sin Tabaco
20 de mayo – TransplantChild Webinars
20 de mayo – REGIC Píldora formativa 42
19 de mayo – Recordatorio Ponencia ONLINE de la Unidad de Innovación
13 de mayo – TransplantChild Webinars
13 de mayo – Recordatorio REGIC Píldora formativa 41
12 de mayo – Cada gota cuenta – Dia Internacional de la Enfermería – Uso Correo
12 de mayo – Cursos FECYT gratuitos
09 de mayo – TransplantChild Webinars
08 de mayo – Plan de Formación 2025
08 de mayo – Plan de Formación 2025
08 de mayo – Ponencia ONLINE de la Unidad de Innovación
06 de mayo – Recordatorio REGIC Píldora formativa 41
05 de mayo – Día Mundial de la Higiene de Manos
29 de abril – REGIC Píldora formativa 41
28 de abril – Día Mundial de la Seguridad y Salud en el Trabajo
22 de abril – II Jornada de la Comisión de Calidad del IdiPAZ del año 2025
21 de abril – Curso Neurogenética – La Sinergia del Trabajo Multidisciplinar
21 de abril – XX Maratón de donación de sangre
16 de abril – Próximas sesiones formativas de la red Transplanchild en el hospital
14 de abril – Curso Neurogenética – La Sinergia del Trabajo Multidisciplinar
14 de abril – Plan de Formación 2025 actualizado
11 de abril – II Jornada de la Comisión de Calidad del IdiPAZ del año 2025
11 de abril – Plan de Formación 2025
09 de abril – Curso Marcado CE
08 de abril – Curso Formación Bioinformática
08 de abril – REGIC Resumen Píldora 40
IdiPAZ Sostenible 07 de abril – Día Mundial de la Salud
02 de abril – Convocatoria Premios al Proyecto más innovador 2025
01 de abril – REGIC 41 y 42 Píldoras formativas
IdiPAZ Sostenible 12 de febrero – Día internacional de la Mujer y la Niña en la Ciencia
IdiPAZ Sostenible 10 de febrero – Jornada de puertas abiertas para mujeres con endometriosis
IdiPAZ Sostenible 31 de enero – Día Mundial de las Enfermedades Tropicales Desatendidas
IdiPAZ Sostenible 29 de enero – Sesión Building a greener Health ecosystem
IdiPAZ Sostenible 27 de enero – Cambio de ubicación de la parada de la lanzadera

1 Introduction


2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.9. Responsible Research and Innovation in IdiPAZ

As a Health Research Institute accredited by the Carlos III Health Institute (ISCIII), **IdiPAZ** is recognised as a leading centre for translational biomedical research, firmly committed to excellence, sustainability and multidisciplinary collaboration. In line with its mission and core values, **Responsible Research and Innovation (RRI)** is a fundamental pillar underpinning the Institute's activities.



The primary aim of RRI is to bridge the gap between the scientific community and society by ensuring that all stakeholders involved in research and innovation work towards shared goals. Although the principles underpinning RRI have been recognised for decades, they gained renewed prominence through the **Science with and for Society (SwafS)** programme promoted by the European Commission under **Horizon 2020**.

RRI promotes a more open, inclusive, transparent and collaborative approach to research, strengthening the relationship between science and society. Its key dimensions include:

- **Public engagement**: actively involving citizens and stakeholders in research and innovation processes.
- **Science education**: encouraging scientific careers and nurturing future research talent to ensure the long-term sustainability of science and technology.
- **Open Science**: promoting open research practices and unrestricted access to scientific knowledge and research outputs.
- **Ethics and research integrity**: implementing codes of conduct and whistleblowing mechanisms to ensure accountability, integrity and transparency.
- **Gender equality**: integrating the gender dimension into research and innovation activities.
- **Governance**: fostering robust governance frameworks that encourage shared responsibility among stakeholders and institutions.

IdiPAZ promotes these principles through a range of initiatives, including:

- **Specialised training**: annual accredited courses, such as "Responsible Research and Innovation in Biomedicine", delivered by leading experts and open to all research staff.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

- **Scientific meetings**: lectures and dedicated RRI sessions within internal scientific events, reinforcing awareness and promoting continuous learning.
- **Communication and public engagement**: dissemination of research activities through platforms such as "IdiPAZ Informa", alongside the Institute's Open Science policy, ensuring that both the scientific community and the wider public remain informed about its research and activities.

Ethics and Research Integrity

At IdiPAZ, we are committed to conducting research responsibly by implementing codes of conduct that uphold scientific integrity, respect for fundamental rights, and transparency throughout every stage of the research process.

We provide confidential and accessible reporting channels to facilitate the identification and monitoring of potential research misconduct and other breaches of good practice, thereby ensuring an ethical, safe and accountable research environment committed to continuous improvement (*FIBHULP/IdiPAZ Suggestions, Complaints and Whistleblowing Channels*).

HR EXCELLENCE IN RESEARCH

Human Resources Strategy for Researchers (HRS4R) is based on the principles of the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers, encompassing a gap analysis, the Open, Transparent and Merit-bases Recruitment (OTM-R) policy, and the implementation of a continuous Action Plan. In 2020, the European Commission awarded IdiPAZ the 'HR Excellence in Research Award' in recognition of its commitment to aligning its human resources policies with these principles.

Following the successful completion of the interim assessment and the update of its Action Plan, IdiPAZ has now entered the third stage of the HRS4R process, the Renewal Phase. During this new implementation cycle, our efforts are focused on consolidating the progress achieved, further embedding the principles of the Charter and Code across the institution, and implementing the revised Action Plan. At the same time, we are preparing for the forthcoming renewal evaluation, reaffirming our long-term commitment to fostering an attractive, supportive and excellence-driven research environment for researches at all career stages.

Today, we continue to be dedicated to realizing the primary benefits provided by this strategy:

- Encouraging a supportive working atmosphere for research personnel.
- Promoting a transformation in the workplace culture.
- Becoming a member of the European network of research institutions.
- Enhancing human resources policies.
- Assisting in increasing the international visibility of the institute
- Own Ethics Committee: *Research Ethics Committee for Medical Products* and *Animal Welfare Organization*.
- International Organization for Standardization (ISO) 9001 Certification for Committees and Platforms of IdiPAZ.

Open Access

Open Science represents a fundamental transformation in the way scientific knowledge is generated, funded, communicated and evaluated. It reflects a significant shift in the research paradigm, influencing how research is conducted, how results are disseminated, and how research performance is assessed. The knowledge generated through research should be openly available and reusable in accordance with the FAIR Principles (Findable, Accessible, Interoperable and Reusable).

At IdiPAZ, we promote and encourage our researchers to upload their papers and research data to institutional Open-Access Repositories.

Good Practice Recommendations Guidelines:

- Open Access: Review and update of our own Open Access Guideline of IdiPAZ (07/03/2025).
- Repisalud of Carlos III Health Institute
- Institutional Repository of the Regional Health System of the Community of Madrid
- Biblos-e Archivo of the Universidad Autónoma de Madrid

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Repositories allow researchers to collect, preserve, and make scientific production available to any interested person. This production is generated by professionals as a result of their assistance, research, and teaching activities, thus guaranteeing its conservation, open access, and promoting its visibility and dissemination.

Creation and promotion of the Scientific Seminars web archive, including online video recordings to connect with the scientific community and society.

IdiPAZ is a member of the European Open Science Cloud (EOSC) Association (*https://eosc.eu*) to:

- Accelerate the creation of open knowledge,
- Increase the re-use of research databases by the larger community,
- Inspire ways to share medical data that ensure respect for the privacy of personal information,
- Promote education in Open Science practices,
- Spur innovation and foster new jobs aimed at sustaining openness and the curation of research.

Implementation of Act 19/2013, of December 9, on transparency, access to public information, and good governance. FIBHULP has been registered in the Transparency Register of the Madrid AR since March 4, 2021, with registration number 202100170.

FIBHULP is currently listed in the European Union Transparency Register as of May 10, 2021, under registration number 86699642652-90.

The Institute informs all its members of IdiPAZ's commitments to current European policies regarding Open Science and RRI through its *website*.

Science Education

In recent years, IdiPAZ has strengthened its commitment to RRI through a range of initiatives, with the *Ciencia por la Calle* programme standing out as one of its flagship outreach activities.

Launched in 2022, *Ciencia por la Calle* is an IdiPAZ initiative designed to bring scientific knowledge closer to society and take biomedical research beyond the laboratory. Its main features include:

- **Educational activities and workshops**: engaging secondary school, vocational education and training (VET), and university students in hands-on scientific experiences.
- **Engagement with vulnerable communities**: extending activities to care homes for older people, centres supporting children and young people at risk of social exclusion, and community organisations.
- **A people-centred approach**: promoting a more accessible and inclusive vision of science by making research relevant to all stakeholders, in line with the principles of RRI and the United Nations Sustainable Development Goals (SDGs).
- **Scientific dissemination activities**: At IdiPAZ, we have a Communication Plan focused on planning the Institute's communication actions, both internal and external. In this way, the Citizen Participation Commission of IdiPAZ carries out activities and workshops with educational centers, associations, and the public, bringing science closer to society in a more humane way.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

- Activities for International Day of Women and Girls in Science
- Activities for International Women's Day
- Activities for Science and Innovation Week
- Activities for European Researchers' Night
- 'Ciencia por la calle' program
- Scientific Culture and Innovation Unit of IdiPAZ

ACTIVITY



✔ ***Ciencias y científicas en la investigación clínica, un trabajo en equipo*** 12-feb
Organizado por distintos grupos de IdiPAZ y personal de gestión

✔ ***IdiPAZ: investigación al servicio de la salud y la medicina*** 26-sep
Unidad de Cultivos Celulares y Grupo de Investigación Traslacional de Cirugía Maxilofacial y Cáncer de Cabeza y Cuello

decimosexta noche europea de los investigadores madrid

✔ ***Secretos a la luz: ADN, tinta invisible y ciencia que brilla*** 26-sep
Grupo Infecciones Sistémicas en Pediatría: VIH, Tuberculosis, Patología importada y Enfermedades emergentes

✔ ***Purple Corner: Noche de los investigadores*** 26-sep
Grupo Malformaciones Congénitas y Trasplante y Grupo Infecciones Sistémicas en Pediatría: VIH, Tuberculosis, Patología importada y Enfermedades emergentes

✔ ***Mural Colaborativo: "Dibujando a personal investigador" Noche de los investigadores*** 26-sep
Grupo Infecciones Sistémicas en Pediatría: VIH, Tuberculosis, Patología importada y Enfermedades emergentes

✔ ***Taller: "Misión Visión: Exploradores del Ojo"*** 26-sep
Grupo Ingeniería Celular

✔ ***Taller: "Células del corazón y la sangre: motor y gasolina"*** 26-sep
Grupo Investigación en Cardiología Clínica y Traslacional - ICCIT-PAZ

✔ ***Taller: "Luz y color para descubrir las huellas moleculares de las enfermedades en nuestras células"*** 26-sep
Unidad de Imagen Molecular e Inmunohistoquímica

✔ ***Cuentacuentos: "Capitán Interferón y el Enigma del Virus Latente"*** 26-sep
Grupo Malformaciones Congénitas y Trasplante

✔ ***Cuentacuentos: "El lenguaje secreto de las ranas: Comunicación química y cambio climático en Madagascar"*** 26-sep
Grupo Infecciones Sistémicas en Pediatría: VIH, Tuberculosis, Patología importada y Enfermedades emergentes

✔ ***Conmoción cerebral relacionada con el deporte: identificación de marcadores evolutivos"*** 26-sep
Grupo Neurología y Enfermedades Cerebrovasculares

✔ ***Investigación en Cardiología Traslacional*** 03-nov y 12-nov
Grupo Cardiología Clínica y Traslacional

✔ ***Reproduciendo la alergia en un tubo de ensayo*** 04-nov
Grupo Hipersensibilidad a medicamentos y Respuesta Inmune Innata y Grupo Diagnóstico y tratamiento de las enfermedades alérgicas

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

✔ ***Diálogo esencial: la profesión de enfermería en la Siglo XXI*** 04-nov
Grupo Cuidados de la Salud

✔ ***IdiPAZ: investigación al servicio de la salud y la medicina*** 04-nov y 11-nov
Unidad de Cultivos Celulares, Grupo de Investigación Traslacional de Cirugía Maxilofacial y Cáncer de Cabeza y Cuello y Grupo de Respuesta Inmune Innata

✔ ***Luz y color para seguir las huellas moleculares de las enfermedades en nuestras células*** 04-nov y 11-nov
Unidad de Imagen Molecular e Inmunohistoquímica

✔ ***Rat and furious: combatiendo el ictus desde el laboratorio*** 05-nov y 06-nov
Laboratorio de ciencias neurológicas y cerebrovascular

✔ ***Resolviendo misterios: el método científico en la investigación biomédica*** 06-nov
Plataforma PAIN

✔ ***Acercar los ensayos clínicos, a través del prisma de diferentes profesionales sanitarios*** 07-nov y 14-nov
Grupo Coagulopatías Congénitas y Trastornos de la Hemostasia

✔ ***Cómo diagnosticar una alergia a medicamentos*** 07-nov
Grupo Hipersensibilidad a medicamentos y Respuesta Inmune Innata y Grupo Diagnóstico y tratamiento de las enfermedades alérgicas

✔ ***Aproximación a la investigación en biología molecular en cáncer*** 07-nov
Terapias Experimentales y Biomarcadoes en Cáncer

✔ ***¿Cómo nos defendemos? Viaje en la carrera de un investigador para estudiar el sistema inmune*** 11-nov
Grupo Respuesta Inmune Innata

✔ ***¡Saca el ADN! Ciencia divertida para pequeños investigadores*** 11-nov
Grupo Infecciones Sistémicas en Pediatría: VIH, Tuberculosis, Patología importada y Enfermedades emergentes

✔ ***Aproximación a la Enseñanza de la Medicina mediante la Simulación Clínica*** 11-nov
Plataforma de Simulación Clínica

✔ ***Visita del CEIP Julián Marías para descubrir qué es un centro de investigación…*** 12-nov
Grupo Neurología y Enfermedades Cerebrovasculares

✔ ***Infecciones en el hospital: una oportunidad de mejora. Proyecto Vent-PCR-ZERO*** 13-nov
Unidad de infecciosas - Medicina interna

✔ ***La córnea*** 13-nov
Grupo Ingeniería celular

✔ ***Maria Salomea Sklodowska: una científica pionera*** 13-nov
Grupo Ingeniería celular

✔ ***Usos terapéuticos de las células madre*** 13-nov
Grupo Ingeniería celular

✔ ***Buscando defectos en genes y en proteínas: tanto monta, monta tanto*** 14-nov
Grupo Alteraciones del Sistema del Complemento en Patología Humana

19th November 2025: Presentation of the 2024 Scientific Report

As part of its commitment to Responsible Research and Innovation (RRI), IdiPAZ annually presents its Scientific Annual Report, a key institutional document showcasing the Institute's research activity, scientific achievements and progress over the previous year.

The launch event provides an opportunity for researchers, healthcare professionals and institutional representatives to reflect on the impact of the Institute's work, while fostering a culture of transparency, knowledge sharing and scientific excellence. The event also recognises outstanding research achievements

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

through the presentation of IdiPAZ Awards and Diplomas, highlighting excellence in scientific performance and encouraging the development of early-career researchers.



Highest-Impact Publication Award: **Teresa López Fernández**

- Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. 2024; 46(3): 273-84. Article. IF: 35,6; D1

Public engagement

Citizen engagement at IdiPAZ is essential to ensuring that scientific and technological advances are aligned with the needs and expectations of society, as well as with those of other key non-scientific stakeholders.

Committed to high-quality biomedical research, IdiPAZ recognises the importance of actively involving citizens in its research activities. This involvement helps to strengthen transparency, build public trust in science, and ensure that studies and projects are conducted in an ethical and equitable manner.

Through a range of initiatives, such as round tables, surveys and working groups, citizens can share their concerns, provide their perspectives and contribute to identifying research priorities. This ensures that the projects developed respond to wider social and ethical needs.

This interaction not only promotes transparency and public confidence in scientific progress, but also helps to foster a collaborative environment that benefits both science and society as a whole, encouraging a more inclusive and responsible approach to research.

To put this commitment into practice, IdiPAZ implements a range of actions aimed at promoting citizen engagement and strengthening the connection between research and society:









IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

- Providing patients and the public with up-to-date information on ongoing clinical trials and research studies.
- Encouraging societal participation through sponsorship opportunities and the *Pazito: Dona* patronage strategy.
- Publishing the IdiPAZ+ii News bulletin, which highlights the Institute's research and innovation activities and raises public awareness of biomedical research undertaken at La Paz University Hospital.

Citizen and Public Engagement Indicators: To monitor and strengthen the impact of its public engagement activities, IdiPAZ has established a set of indicators to assess the reach, scope and development of its engagement with society. These indicators provide a quantitative overview of the Institute's efforts to promote scientific literacy, foster dialogue and collaboration with patients and other societal stakeholders, increase the visibility of its research, and encourage the involvement of non-scientific stakeholders in the research process. The 2025 indicators presented below provide a snapshot of these activities and support the ongoing evaluation and improvement of IdiPAZ's contribution to a more open, inclusive and socially responsive research and innovation ecosystem.

Indicator	Description	2025
Science communication training activities	Number of training activities on science communication aimed at civil society	2
Public engagement activities	Activities, workshops and events involving patient associations and the wider public	33
Research and societal impact initiatives	Actions aimed at increasing the visibility of the Health Research Institute, strengthening the strategic objectives of the engagement plan, and supporting the translation of research and its impact on society and the National Health System (SNS)	7
Research projects involving non-scientific stakeholders	Percentage of research projects involving key non-scientific stakeholders in research design	76,70%
Committees involving non-scientific stakeholders	Number of institutional committees involving key non-scientific stakeholders, including patients, patients associations and other societal stakeholders	8

Media Engagement and Science Communication: A key component of this public engagement strategy is the Institute's commitment to science communication through the media.

IdiPAZ researchers actively engage with the media to communicate research findings, promote evidence-based health information and foster public understanding of science. Through interviews, opinion articles, and other media appearances, researchers contribute to informed public debate and strengthen the relationship between science and society.

During 2025, IdiPAZ researchers and institutional representatives generated 348 media appearances across more than 50 national and regional media outlets, specialised health publications, radio programmes, institutional platforms and scientific organisations. This broad media presence reflects the Institute's commitment to communicating research beyond the scientific community, promoting evidence-based health information and increasing public awareness of biomedical research.



1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Through interviews, expert commentary, news features and institutional communications, IdiPAZ has strengthened public engagement with science, enhanced the visibility and societal impact of its research and contributed to informed public debate on major health and biomedical research issues.

The following selection of media in which IdiPAZ featured during 2025 illustrates the breadth and diversity of its media presence across national, regional and specialised platforms.

Governance

IdiPAZ promotes a participatory, transparent and accountable governance model in which researchers, healthcare professionals, patients, citizens and other stakeholders contribute to research and innovation aligned with society's needs and values.

Within the framework of Responsible Research and Innovation (RRI), governance is based on open, inclusive and reflective processes that encourage the active involvement of all relevant stakeholders, ensure transparency in decision-making and support the continuous assessment of the ethical, social and environmental impacts of research activities.

This approach is underpinned by mechanisms for dialogue and accountability that facilitate two-way communication with society, fostering a culture of responsibility, continuous improvement and responsiveness to emerging scientific and societal challenges.

In this context, the IdiPAZ Citizen Participation Committee plays a key role in implementing the principles of RRI and Open Science, in line with the recommendations of the European Commission. The Committee also promotes the social and scientific responsibility of the Institute's research community, supporting excellent research that delivers meaningful benefits for society. Its membership includes representatives from patients' organisations, environmental organisations, La Paz University Hospital, and FIBHULP/IdiPAZ.

As part of this commitment, IdiPAZ has integrated the United Nations Sustainable Development Goals (SDGs) and the 2030 Agenda into its institutional strategy. This work was recognised through the award of the AENOR Sustainable Strategy Certification in June 2022, which was successfully renewed in 2025, reaffirming the Institute's long-term commitment to sustainability and continuous improvement.

IdiPAZ is a member of the Coalition for Advancing Research Assessment (CoARA), supporting the transition towards responsible research assessment practices. Through this commitment, the Institute promotes a broader and more holistic approach to research evaluation, aligned with the principles of *DORA* and the Human Resources Strategy for Researchers (*HRS4R*).

Patient Participation in Governance: Through the European Reference Network for Paediatric Transplantation (*ERN TransplantChild*), coordinated by our institution, the TransplantChild Patients Committee ensure that patients and families actively contribute to governance and decision-making processes.

Research Ethics Committee with Medical Products: This committee independently reviews research involving medicinal products and ensures compliance with the highest ethical and regulatory standards.

Ethics and Reporting Channels: To promote transparency, integrity and accountability, IdiPAZ has established several institutional policies and reporting mechanisms, including:

- Code of Conduct
- Code of Ethics and Good Scientific Practice
- Anti-Harassment Protocol
- Anti-Fraud, Anti-Corruption and Conflict of Interest Policy
- Recruitment Complaints and Suggestions Channel

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Gender Equality

IdiPAZ is committed to promoting socially responsible research that actively integrates gender equality throughout the research and innovation process. This commitment includes ensuring equal opportunities and non-discrimination, fostering the equitable participation of women and men in scientific careers, and encouraging the consideration of sex and gender dimensions where relevant to research design and outcomes. Through these actions, IdiPAZ contributes to a more inclusive, diverse and socially responsive research environment.

The IdiPAZ Equality and Diversity Commission plays a central role in advancing this commitment by promoting policies and initiatives that foster equality, diversity and inclusion across the Institute. Among its key achievements is the development and implementation of the *Protocol for the Prevention and Response to Discriminatory Harassment, Workplace Bullying, Sexual Harassment and Harassment based on gender*, which aims to prevent and address inappropriate behaviour in the workplace while promoting a safe, respectful and inclusive working environment.

IdiPAZ also supports the International Day of Women and Girls in Science through awareness-raising and engagement activities, reinforcing the visibility of women researchers and encouraging future generations to pursue careers in science.

This commitment is supported by a range of institutional policies, action plans and procedures, including:

- II *Equality and Diversity Plan*, registered with REGCON (***Registro y Depósito de Convenios Colectivos, acuerdos colectivos de trabajo y Planes de Igualdad***) with code 28109182112021
- *Protocol for the Prevention and Response to Discriminatory Harassment, Workplace Bullying, Sexual Harassment and Harassment based on gender*
- *Protocol for the Prevention and Management of Internal Conflict, Violence and Harassment in Biomedical Research Foundations*
- *Human Resources Strategy for Researchers (HRS4R), including implementation of the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers, gap analysis, the Open, Transparent and Merit-based Recruitment (OTM-R) policy, and the associated action plan*
- *LGTBIQ+ Action Plan*
- *Employment Inclusion Policy for People with Disabilities*

Social Responsibility

The Institute has received accreditation from AENOR in Corporate Social Responsibility and Sustainable Strategy, marking a significant achievement as the first Health Research Institute in the Community of Madrid to earn this certification. This recognition highlights our dedication to responsibility across economic, environmental, and social domains, as well as in ethical management and transparency-core values that the institution upholds.

IQNet SR10:2015 Certification of the Social Responsibility Management System of IdiPAZ. This certification covers the multidisciplinary biomedical research activities and research management of IdiPAZ. The initial certification date was 19/03/2021, and it remains valid from 21/01/2025 to the present.

Certification of the Sustainability Strategy of IdiPAZ and its contribution to the SDGs. This involves the development of a sustainability management model aligned with the United Nations' proposals. The first certification date was 14/07/2022, and it is valid from 21/01/2025 to the present.

As a Health Research Institute, IdiPAZ holds a unique position within society, driving biomedical research and innovation while disseminating knowledge to the community and patients. IdiPAZ is committed to the Sustainable Development Goals (SDGs) set forth by the UN, and its integration into the 2030 Agenda represents a strategic and cross-cutting commitment that requires aligning its research and management activities with these goals.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

In addition, we have continued our commitment to the *Sustainable Development Goals and the 2030 Agenda, as well as our corporate social responsibility policy*, which includes the activities and guidelines that are carried out to fulfil this commitment.

Goals to Transform Our World (SDGs)

In line with the Social Responsibility Strategy, IdiPAZ began working in 2021 on the Sustainable Development Goals proposed by the 2030 Agenda for Sustainable Development, which was adopted by all Member States of the United Nations. This agenda is a shared plan for peace and prosperity for people and the planet, now and in the future, and includes 17 Sustainable Development Goals (SDGs). After months of work, IdiPAZ achieved its first AENOR certification in sustainable strategy in June 2022, and it remains valid to the present.

A materiality study was conducted through a process of sending questionnaires to the institute's stakeholders, identifying and mapping all the institute's lines of research and projects. As a result of the analysis, IdiPAZ prioritized four Sustainable Development Goals, which were included in its Strategic Plan for research and innovation as follows:

Strategic SDG:

- 3. Good Health
- 4. Quality education
- 8. Decent work and Economic Growth
- 9. Innovation and Infrastructure

Relevant SDG:

- 5. Gender Equality
- 10. Reduced inequalities
- 17. Partnerships for the goals

Other SDG:

- 7. Affordable and clean energy
- 12. Responsible consumption and production
- 13. Climate action

The priority SDGs have been aligned with the objectives and strategic priorities of the Research and Innovation Strategic Plan 2026-2030. In addition, the first Sustainability Report was published and has since been updated annually to document the Institute's progress in implementing the SDGs, as well as the actions undertaken and those planned to further advance their integration across the organisation.

Through the implementation of its strategic priorities, IdiPAZ aims to contribute to the achievement of the SDGs and their associated targets. The Institute's short and long-term objectives are outlined below:

IdiPAZ Sostenible


AENOR

Declaración de Verificación

Estrategia de Sostenibilidad y su contribución a los Objetivos de Desarrollo Sostenible (ODS)

Declaración de Verificación de AENOR para

INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL UNIVERSITARIO LA PAZ

relativa al período

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



3.3 By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases.
3.4 By 2030, reduce by one-third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.
3.5 Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol.
3.A Strengthen the implementation of the World Health Organisation Framework Convention on Tobacco Control in all countries, as appropriate.
3.B Support the research and development of vaccines and medicines for the communicable and no communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all.
3.C Substantially increase health financing and the recruitment, development, training and retention of the health workforce in developing countries, especially in least developed countries and small island developing States.
3.D Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks.



4.3 By 2030, ensure equal access for all women and men to affordable and quality technical, vocational and tertiary education, including university
4.4 By 2030, substantially increase the number of youth and adults who have relevant skills, including technical and vocational skills, for employment, decent jobs and entrepreneurship
4.7 By 2030, ensure that all learners acquire the knowledge and skills needed to promote sustainable development, including, among others, through education for sustainable development and sustainable lifestyles, human rights, gender equality, promotion of a culture of peace and non-violence, global citizenship and appreciation of cultural diversity and of culture's contribution to sustainable development
4.B By 2020, substantially expand globally the number of scholarships available to developing countries, in particular least developed countries, small island developing States and African countries, for enrolment in higher education, including vocational training and information and communications technology, technical, engineering and scientific programmes, in developed countries and other developing countries



5.1 End all forms of discrimination against all women and girls everywhere
5.2 Eliminate all forms of violence against all women and girls in the public and private spheres, including trafficking, sexual, and other types of exploitation
5.4 Recognize and value unpaid care and domestic work through the provision of public services, infrastructure and social protection policies and the promotion of shared responsibility within the household and the family as nationally appropriate
5.5 Ensure women's full and effective participation and equal opportunities for leadership at all levels of decision making in political, economic and public life
5.B Enhance the use of enabling technology, in particular information and communications technology, to promote the empowerment of women
5.C Adopt and strengthen sound policies and enforceable legislation for the promotion of gender equality and the empowerment of all women and girls at all levels


IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



8.3 Promote development-oriented policies that support productive activities, decent job creation, entrepreneurship, creativity and innovation, and encourage the formalisation and growth of micro-, small- and medium-sized enterprises, including through access to financial services.

8.4 Improve progressively, through 2030, global resource efficiency in consumption and production and endeavour to decouple economic growth from environmental degradation, in accordance with the 10-year framework of programmes on sustainable consumption and production, with developed countries taking the lead

8.5 By 2030, achieve full and productive employment and decent work for all women and men, including for young people and persons with disabilities, and equal pay for work of equal value

8.8 Protect labour rights and promote safe and secure working environments for all workers, including migrant workers, in particular women migrants, and those in precarious employment



9.1 Develop quality, reliable, sustainable and resilient infrastructure, including regional and trans-border infrastructure, to support economic development and human well-being, with a focus on affordable and equitable access for all

9.2 Promote inclusive and sustainable industrialization and, by 2030, significantly increase the contribution of industry to employment and gross domestic product, in accordance with national circumstances, and double that contribution in the least developed countries.

9.4 By 2030, upgrade infrastructure and retrofit industries to make them sustainable, with increased resource-use efficiency and greater adoption of clean and environmentally sound technologies and industrial processes, with all countries taking action in accordance with their respective capabilities

9.5 Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending

9.A Facilitate sustainable and resilient infrastructure development in developing countries through enhanced financial, technological and technical support to African countries, least developed countries, landlocked developing countries and small island developing States 18

9.B Support domestic technology development, research and innovation in developing countries, including by ensuring a conducive policy environment for, inter alia, industrial diversification and value addition to commodities

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



10.2 By 2030, empower and promote the social, economic and political inclusion of all, irrespective of age, sex, disability, race, ethnicity, origin, religion or economic or other status

10.3 Ensure equal opportunity and reduce inequalities of outcome, including by eliminating discriminatory laws, policies and practices and promoting appropriate legislation, policies and action in this regard

10.4 Adopt policies, especially fiscal, wage and social protection policies, and progressively achieve greater equality



12.4 By 2020, achieve the environmentally sound management of chemicals and all wastes throughout their life cycle, in accordance with agreed international frameworks, and significantly reduce their release to air, water and soil in order to minimise their adverse impacts on human health and the environment

12.5 By 2030, substantially reduce waste generation through prevention, reduction, recycling and reuse



13.3 Improve education, awareness-raising and human and institutional capacity on climate change mitigation, adaptation, impact reduction and early warning



16.6 Develop effective, accountable and transparent institutions at all levels

16.A Strengthen relevant national institutions, including through international cooperation, for building capacity at all levels, in particular in developing countries, to prevent violence and combat terrorism and crime

16.B Promote and enforce non-discriminatory laws and policies for sustainable development



17.17 Encourage and promote effective public, public-private and civil society partnerships, building on the experience and resourcing strategies of partnerships.

17.19 By 2030, build on existing initiatives to develop measurements of progress on sustainable development that complement gross domestic product, and support statistical capacity-building in developing countries

In our sustainability report, you can find information on our sustainability management and the implementation of the Sustainable Development Goals in our institute, as well as all the action plans that will be carried out in the coming years.

In relation to our commitment to the SDGs, throughout 2025, we have developed a series of campaigns that favor their achievement and support the environmental and social improvement of our surroundings.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

Scientific Report 2025

IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz

3 Research areas and groups



3.1. Neuroscience and Brain Heath Area

Documents: 200 | Originals: 176 | D1: 47 | Q1: 118

3.2.Cardiovascular Area

Documents: 202 | Originals: 157 | D1: 62 | Q1: 115

3.3. Infectious Diseases and Immunity Area

Documents: 305 | Originals: 254 | D1: 69 | Q1: 184

3.4. Large System Pathology Area

Documents: 273 | Originals: 212 | D1: 53 | Q1: 156

3.5. Cancer and Human Molecular Genetics Area

Documents: 215 | Originals: 183 | D1: 47 | Q1: 108

3.6. Surgery, Transplant and Health Technologies Area

Documents: 191 | Originals: 151 | D1: 21 | Q1: 82

3.7. Maternal Infant Child and Youth Research

Documents: 257 | Originals: 214 | D1: 57 | Q1: 156

3.8. Multidisciplinar Research In Healthy Aging

Documents: 70 | Originals: 62 | D1: 12 | Q1: 31

3.1. Neuroscience and Brain Heath Area

Documents: 200 | Originals: 176 | D1: 47 | Q1: 118

Area coordinators: Exuperio Díez Tejedor/María Gutiérrez Fernández



RESEARCH GROUPS

3.1.1 Psychiatry and Mental Health
Celso Arango López

3.1.2 Neurology and Cerebrovascular Diseases
Exuperio Díez Tejedor/María Gutiérrez Fernández

3.1.3 Neuroprotective Strategies in Neurodegenerative Diseases
Ana Isabel Rojo Sanchís

3.1.4 Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies
Francisco Zafra Gómez

3.1.5 Molecular Mechanisms and Biomarkers of Neurodegenerative Diseases
Isabel Lastres Becker

3.1.6 Multiple Sclerosis Research
Yolanda Aladró Benito

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Strategic Objectives	Development forecast for the coming years:	Actions
Neuroscience Area is composed of 5 research groups and has as general objectives the promotion of teaching, research and dissemination of knowledge in the field of neurosciences and neurological diseases, particularly in relation to clinical neurosciences.	Cohesion between different disciplines (biomedical research, engineering).	Performing annual workshops and seminars science
	Encourage and promote research among the healthcare staff who sometimes perceive research as something negative.	Training in research methodology in specialized health personnel and in training
	Innovation and technology transfer	Innovation promotion program that involves health organizations, research institutions and companies

HIGH IMPACT PUBLICATIONS

Cuadrado A, Cazalla E, Bach A, Bathish B, Naidu SD, Denicola GM, Dinkova-Kostova AT, Fernández-Ginés R, Grochot-Przeczek A, Hayes JD, Kensler TW, León R, Liby KT, López MG, Manda G, Shivakumar AK, Hakomaki H, Moerland JA, Motohashi H, Rojo AI, Sykiotis GP, Taguchi K, Valverde AM, Yamamoto M, Levonen AL. Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases. Redox Biol. 2025; 81: 103569. Article. IF: 16,2; D1

Rojo AI, Buttari B, Cadenas S, Carlos AR, Cuadrado A, Falcao AS, López MG, Georgiev MI, Grochot-Przeczek A, Gumeni S, Jimenez-Villegas J, Horbanczuk JO, Konu O, Lastres-Becker I, Levonen AL, Maksimova V, Michaeloudes C, Mihaylova L, Mickael ME, Milisav I, Miova B, Rada P, Santos M, Seabra MC, Strac DS, Tenreiro S, Trougakos IP, Dinkova-Kostova AT. Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases. Redox Biol. 2025; 79: 103464. Article. IF: 16,2; D1

Carnicero-Senabre D, Barata MA, Jimenez-Villegas J, Almeida CG, Cuadrado A, **Rojo AI.** NRF2 deficiency is associated with synaptic alterations and ether-linked phospholipid imbalance in the hippocampus. Redox Biol. 2025; 86: 103853. Article. IF: 16,2; D1

López-Cuadrado T, Mortier P, Alonso J, **Martínez-Alés G.** Trends of non-lethal intentional self-harm and suicide in Spain 2018-2023: a nationwide registry-based study. Lancet Reg Health Eur. 2025; 58: 101467. Article. IF: 15,7; D1.SI

García-Yagüe AJ, Cañizares-Moscato L, Encinar JA, Cazalla E, Fernández-Ginés R, Escoll M, Rojo AI, **Cuadrado A.** A novel β-TrCP1/NRF2 interaction inhibitor for effective anti-inflammatory therapy. J Biomed Sci. 2025; 32(1): 65. Article. IF: 14,5; D1

Scientific Events by Neurosciences Area

- **28/02/2025 -** Seminario presencial y online: Papel del Virus del herpes simple en la patogénesis de la enfermedad de Alzheimer.
- **24/06/2025 -** Innovaciones en el síndrome de piernas inquietas
- **28/10/2025 -** XIV Symposium neuroinmunología y esclerosis múltiple
- **01/12/2025 -** Curso ecografía preclínica
- **15/12/2025 –** Neurosonología. Curso teórico y taller práctico

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.1.1 Psychiatry and Mental Health Group

Publications: 52 | Q1:39

COMPOSITION

Celso Arango López.
Jefe del Departamento Psiquiatría del Niño y del Adolescente. Hospital Universitario La Pazadrid

- **María Fe Bravo Ortíz.** *Profesora Honoraria. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Pablo Aguirre Morán.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Teresa Alonso Poza.** *Investigadora Predoctoral. FIBHULP*
- **Jorge Andreo Jover.** *Investigador Predoctoral. FIBHULP*
- **Carmen Bayón Pérez.** *Jefa de sección Hospital de Día Adultos. Hospital Universitario La Paz; Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Laura Caraballo Romero.** *Enfermera Especialista en Salud Mental. Hospital Universitario La Paz*
- **Diego Carracedo Sanchidrián.** *Facultativo Especialista en Psicología Clínica. Hospital Universitario La Paz*
- **Susana Cebolla Lorenzo.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Javier Curto Ramos.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **María Jesús de la Iglesia Mansilla.** *Enfermera Especialista en Salud Mental. Hospital Universitario La Paz*
- **Eduardo Fernández Jiménez.** *Facultativo Especialista de Área en Psicología Clínica. Hospital Universitario La Paz*
- **Omar Ariel Gaona Casas.** *Investigador Predoctoral. FIBHULP*
- **Ignacio García Cabeza.** *Jefe de Servicio de Psiquiatría. Hospital Dr. Rodríguez Lafora*
- **Blanca García Vázquez.** *Facultativa Especialista de Área en Psicología Clínica. Hospital Universitario La Paz*
- **Jessica Garrido Boltón.** *Facultativa Especialista de Área en Psicología Clínica. Hospital Universitario La Paz*
- **Nieves González Suárez.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Paula Herrero Ortega.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Eduardo Jiménez Sola .** *Facultativo Especialista de Área en Psiquiatría . Hospital Universitario La Paz*
- **Jesús Martí Esquitino.** *Facultativo Especialista de Área en Psicología Clínica. Hospital Universitario La Paz*
- **Gonzalo Martínez-Ales García.** *Psiquiatra e Investigador. Icahn School of Medicine at Mount Sinai*
- **Convadonga Martínez Díaz-Caneja.** *Facultativo Especialista de Área en Psiquiatría. FIBHULP*
- **María del Carmen Moreno Ruiz.** *Jefa de Sección de Psiquiatría del Niño y del Adolescente. Hospital Universitario La Paz*
- **Ainoa Muñoz San José.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Patricia Nieva Tejado.** *Enfermera Especialista en Salud Mental. Hospital Universitario La Paz*
- **Luis Nocete Navarro.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz. Consejería de Sanidad CM*
- **Alberto Oliva Lozano.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Óscar Pajares González-Gallego.** *Enfermero Especialista en Salud Mental CSM Fuencarral. Hospital Universitario La Paz*
- **Ángela Palao Tarrero.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Irene Pérez de Ciriza Galarza.** *Enfermera Especialista en Salud Mental. Hospital Universitario La Paz*
- **Pau Pérez Sales.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Rosa Villanueva Peña.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

STRATEGIC OBJETIVES

- The group focuses its objectives on evaluating the effectiveness of psychotherapeutic techniques as part of the treatment for mental disorders and other medical conditions.
- Their main areas of research are: research into severe mental illness (first-episode psychosis and bipolar disorder), suicide prevention, and other medical conditions such as cancer and chronic pain, as well as the psychological and social impact of the Covid-19 pandemic, and transplants in children. They participate in clinical trials on new treatments and specific therapies to improve the prognosis for these disorders.
- It also focuses on researching the interaction of genetic and environmental factors in the etiology and evolution of mental disorders, especially psychosis.
- We are especially focused on evaluating the efficacy and effectiveness of third-generation psychotherapies, including mindfulness, and other low-intensity psychological interventions.
- In addition, the group is involved in the evaluation of new treatments or new indications in mental illnesses through participation in clinical trials."

RESEARCH LINES

- Psychotherapeutic interventions in mental disorders
- Suicide prevention
- Psychological and social impact of the COVID-19 pandemic
- Online health interventions
- Mindfulness-based interventions
- Environment/gene interaction in the first episode of psychosis
- Impact on the mental health of children and adolescents undergoing transplantation

RESEARCH ACTIVITY

Doctoral Theses

- **Carracedo Sanchidrián D.** *Terapia Cognitiva Basada en Mindfulness frente a Intervención Psicoeducativa en Pacientes con Trastorno Bipolar con Síntomas Subsindrómicos Depresivos: Estudio Controlado Aleatorizado [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(14/10/2024). Director: Dios Perrino C, Lahera Forteza G*
- **Hernández Santillán GA.** *Prevalencia y factores asociados a síntomas depresivos en madres y padres en los seis primeros meses postparto y alteración del vínculo materno-infantil. UAM (18/07/2025). Directoras: María Fe Bravo Ortiz, Margarita Alcamí Pertejo*

Publications

- **Addington J, Liu L, Chu M, Jungert K, Penzel N, Pasternak O, Farina E, Carrion RE, Corcoran CM, Mittal VA, Strauss GP, Yung AR, Alameda L, Arango C, Borders O, Bouix S, Breitborde NJK, Broome MR, Cadenhead KS, Castillo-Passi R, Chen EYH, Choi J, Coleman MJ, Conus P, Díaz-Caneja CM, Ellman LM, Poli PF, Gaspar PA, Gerber C, Glenthoj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Kapur T, Kelly S, Kerr MJ, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Lewandowski KE, Mamah D, Marcy PJ, Mathalon DH, Mourgues C, Nordentoft M, Nunez AR, Pearlson GD, Pérez J, Perkins DO, Powers AR, Rogers J, Sabb FW, Schiffman J, Seitz-Holland J, Shah JL, Silverstein SM, Smesny S, Stone WS, Thompson JL, Upthegrove R, Verma S, Wang JJ, Wolf DH, Zhang TH, Addamo L, Buccilli K, Dwyer D, Todd S, Cho YT, Fontenau C, Tamayo Z, Bearden CE, Kane JM, McGorry PD, Kahn RS, Shenton ME, Woods SW, Nelson B, Calkins ME.** *Baseline clinical characterization of participants in the accelerating medicines partnership schizophrenia program. Schizophr Bull Open. 2025; 6(1): sgaf012. Article. IF: 2.4; Q3*
- **Addington J, Shalev A, Liu L, Jahraus C, Chu MNC, Farina E, Poli PF, Marcy PJ, Nunez AR, Calkins ME, Alameda L, Arango C, Borders O, Bouix S, Breitborde NJK, Broome MR, Cadenhead KS, Carrion RE, Castillo-Passi R, Chen EYH, Choi J, Coleman MJ, Conus P, Corcoran CM, Díaz-Caneja CM, Ellman LM, Gaspar PA, Gerber C, Glenthoj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Kapur T, Kelly S, Kerr MJ, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Lewandowski KE, Mamah D, Mathalon DH, Mittal VA, Mourgues C, Nordentoft M, Pasternak O, Pearlson GD, Penzel N, Pérez J, Perkins DO, Powers AR, Rogers J, Sabb FW, Schiffman J, Seitz-Holland J, Shah JL, Silverstein SM, Smesny S, Stone WS, Strauss GP, Thompson JL, Upthegrove R, Verma S, Wang JJ, Wolf DH, Yung AR, Zhang TH, Addamo L, Buccilli K, Todd S, Dwyer D, Bearden CE, Kane JM, Mcgorry PD, Kahn RS, Shenton ME, Woods SW, Nelson B.** *Sample ascertainment and recruitment sources in the accelerating medicines partnership schizophrenia program. Schizophr Bull Open. 2025; 6(1): sgaf013. Article. IF: 2.4; Q3*
- **Andrés-Camazón P, Díaz-Caneja CM, Ballem R, Chen JY, Calhoun VD, Iraji A.** *Neurobiology-based cognitive biotypes using multi-scale intrinsic connectivity networks in psychotic disorders. Schizophrenia (Heidelb). 2025; 11(1): 45. Article. IF: 4.5; Q1*
- **Arango C, Baeza I, García-Rizo C, Crespo-Facorro B, Lahera G, Vieta E, Becker F, Dwyer G, Bourke S, Gibson AEJ, Gabarda-Inat I, Álvarez-Barón E.** *Exploring the impact of schizophrenia and its pharmacological treatment on health-related quality of life and treatment preferences. Patient Prefer Adher. 2025; 19: 2647-61. Article. IF: 2.6; Q2*
- **Arango C, Fiorillo A, Dom G, López-Morinigo JD.** *Responsiveness of European countries to the population mental health needs: A cross-national comparison study. Eur Psychiat. 2025; 68(1): e102. Article. IF: 7.9; D1*
- **Arango C, Vieta E.** *Cibersam: A change in the paradigm of mental health research in Spain. Span J Psychiatry Ment Health. 2025; 18(1): 3-5. Editorial Material. IF: 2.6; Q2*
- **Arregui-Gallego B, Orts-Cortés MI, Moreno-Casbas MT, Abad-Corpa E, Camacho-Bejarano R, Cidoncha-Moreno MA, Feria-Raposo I, Iruzubieta-Barragán J, Carmona M, Cristóbal-Domínguez E, Bernués-Caudillo L, Casado-Ramírez E, Recas-Martin A, Sánchez-López D, Company-Sancho MC, Rascón NL, Esteban-Sepúlveda S, Vidal-Thomàs MC, Alonso I, Muñoz-Jiménez D, Segura-Heras JV, Moncho J, Rich-Ruiz M.** *Factors modulating the impact of the COVID-19 pandemic on posttraumatic stress symptomatology of the Spanish healthcare workers: A cohort study. Plos One. 2025; 20(6): e0323777. Article. IF: 2.8; Q2*
- **Asgari-Targhi A, Yao BE, Brown L, García S, Nagendra A, Chin K, Billah T, Penzel N, John O, Prunier N, Veale S, Kotler E, Jacobs GR, Zhan M, Coleman MJ, Bouix S, Pasternak O, Cecci G, Baker JT, Mathalon DH, Kelly SM, Corcoran CM, Reichenberg A, Rossum IWV, Kubicki M, Spark J, Dwyer D, Arango C, Fusar-Poli P, Calkins M, Shah JL, Mittal V, Thompson A,**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

McGorry PD, Kahn RS, Kane JM, Bearden CE, Woods SW, Nelson B, Shenton ME, Staglin B, Larrauri CA, Lewandowski KE, Kapur T. *Bridging Science and Hope: integrating and communicating lived experience in accelerating medicines partnership® schizophrenia program. Schizophrenia (Heidelb). 2025; 11(1): 57. Editorial Material. IF: 4.5; Q1*

- **Aymerich C, Pedruzo B, de Pablo GS, Labad J, McCutcheon R, Pillinger T, González-Torres MA, Sanchez-Gistau V, Oliver D, Alonso-Alconada D, Navalón P, Sugranyes G, Vieta E, Arango C, McGuire P, Fusar-Poli P, Catalan A.** *Do biological alterations precede the onset of psychosis? A systematic review and meta-analysis of immune, cardiometabolic, prolactin and HPA axis alterations in clinical high-risk for psychosis. Brain Behav Immun. 2025; 128: 219-33. Article. IF: 7.5; D1*
- **Basic D, Czepiel D, Hoek HW, Martínez AM, Mccormack C, Susser ES, Mascayano F, Moro MF, Carta MG, Martínez-Alés G, Fernández-Jiménez E, Barathie JA, Karam EG, Nishi D, Asaoka H, Ayinde O, Gureje O, Afolabi O, Olaopa O, Ramírez J, Basagoitia A, Soto MTS, Durand-Arias S, Seblová J, Seblova D, Tenorio A, Ballester D, Burrone MS, Alvarado R, Santaella-Tenorio J, Ouali U, Isahakyan A, Lindert J, Sapag JC, Ramírez DE, Alnasser L, Rivera-Segarra E, Balalian A, Mediavilla R, van der Ven E.** *Trusting in times of the COVID-19 crisis: Workplace and government trust and depressive symptoms among healthcare workers. Glob Ment Health (Camb). 2025; 12: e130. Article. IF: 3.4; Q2*
- **Bernardo M, Marsá MD, González-Pinto A, Carrasco MM, Sola VP, Sáiz PA, Vieta E, Torrens M, Arango C, Crespo-Facorro B.** *Efficacy of lurasidone in first-episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel. Neurol Ther. 2025; 14(1): 85-98. Review. IF: 4.7; Q1*
- **Bioque M, Llorca-Bofi V, MacDowell KS, Amoretti S, Mezquida G, Cuesta MJ, Díaz-Caneja CM, Ibáñez A, Segarra R, González-Pinto A, Roldán A, Sáiz PA, Mané A, Lobo A, Martínez-Pinteño A, Cano-Escalera G, Berrocoso E, Bernardo M.** *Impact of relapse in BDNF receptors expression in patients with a first episode of schizophrenia. Schizophrenia Bull. 2025; 51(5): 1339-50. Article. IF: 5.7; Q1*
- **Cortese S, Moreno C.** *Advancing the evidence base for child and adolescent psychopharmacology. Bmj Ment Health. 2025; 28(1): e301634. Editorial Material. IF: 6.6; D1*
- **de la Serna E, Moreno D, Sugranyes G, Camprodon-Boadas P, Ilzarbe D, Bigorra A, Mora-Maltas B, Baeza I, Flamarique I, Parrilla S, Díaz-Caneja CM, Moreno C, Borras R, Torrent C, García-Rizo C, Castro-Fornieles J.** *Effects of parental characteristics on the risk of psychopathology in offspring: a 4-year follow-up study. Eur Child Adoles Psy. 2025; 34(10): 3035-45. Article. IF: 4.4; Q1*
- **de Pablo GS, Pérez-Rodríguez V, Olivares JD, Camacho-Rubio J, Sharma A, Catalán A, Breedvelt J, Aymerich C, Pop M, Moreno C, Kelleher I, Anderson J, Fusar-Poli P, Correll CU, Young AH.** *Development and predictors of bipolar disorder in children and adolescents with depressive disorders: a systematic review, meta-analysis, and meta-regression. Eur Psychiat. 2025; 68(1): e16. Review. IF: 7.9; D1*
- **Demjaha A, Stahl D, Arango C, Glenthoj B, Rodríguez-Jiménez R, Díaz-Caneja CM, Baandrup L, Ebdrup B, García-Portlla MP, Díaz-Marsa M, Winter-van Rossum I, Kahn R, Dazzan P, McGuire P.** *Confirmatory factor analysis of competing PANSS negative symptom models: data from OPTiMiSE first-episode schizophrenia study. Bjpsych Open . 2025; 12(1): e12. Article. IF: 4.0; Q1*
- **Dickson SL, Tracey I, Cirulli F, Kas MJH, Konradsson-Geuken Å, Rostasy K, Kestens E, Arango C, Mohr P, Balazs J, Simon J, Weemaes K, Boselli S, Hall J, Asakawa T, Quoidbach V.** *Prioritizing brain health in youth: bringing neuroscience to society and informing policy, lessons learnt from the european brain council expert meeting held at the Federation of European Neuroscience Societies Forum 2024. Eur J Neurosci. 2025; 61(2): e16680. Editorial Material. IF: 2.5; Q3*
- **Domínguez-Alonso S, Tubio-Fungueiriño M, González-Peñas J, Fernández-Prieto M, Parellada M, Arango C, Carracedo A, Rodríguez-Fontenla C.** *Alternative splicing analysis in a Spanish ASD (Autism Spectrum Disorders) cohort: in silico prediction and characterization. Sci Rep-Uk. 2025; 15(1): 10730. Article. IF: 4.9; Q1*
- **Ecker C, Pretzsch CM, Leyhausen J, Berg LM, Gurr C, Seelemeyer H, McAlonan G, Puts NA, Loth E, Dell'Aqua F, Mason L, Charman T, Oakley B, Bourgeron T, Beckmann C, Buitelaar JK, Arango C, Banaschewski T, Chiocchetti AG, Freitag CM, Hattingen E, Krueger-Burg D, Schmeisser MJ, Repple J, Reif A, Murphy DG.** *Transcriptomic decoding of surface-based imaging phenotypes and its application to pharmacotranscriptomics. Nat Commun. 2025; 16(1): 6727. Article. IF: 18.1; D1*
- **Ferraro L, Di Forti M, La Barbera D, La Cascia C, Morgan C, Tripoli G, Jongsma H, Seminerio F, Sartorio C, Sideli L, Tarricone I, Carloni AL, Szoke A, Pignon B, Bernardo M, de Haan L, Arango C, Velthorst E, Gayer-Anderson C, Kirkbride J, Rutten BPF, Lasalvia A, Tosato S, Del Ben CM, Menezes PR, Bobes J, Arrojo M, Tortelli A, Jones P, Selten JP, van Os J, Murray R, Quattrone D, Vassos E.** *Cognitive presentation at psychosis onset through premorbid deterioration and exposure to environmental risk factors. Psychol Med. 2025; 55: e12. Article. IF: 5.2; Q1*
- **Galvañ J, Suárez-Campayo J, Ayora M, Gil S, Rossum IWV, Berger G, Leucht S, Kahn RS, Arango C, Díaz-Caneja CM.** *Extrapyramidal symptoms as early clinical predictors in first-episode schizophrenia and schizophreniform disorder: findings from the OPTiMiSE trial. Eur Neuropsychopharm. 2025; 98: 35-45. Article. IF: 8.1; D1*
- **García-Vázquez B, Muñoz-Sanjosé A, Fernández-López A, Pérez-de-Ciriza I, Nocete-Navarro L, Almaraz-Garzón E, Martín-Palacios MT, Novella B, Bravo-Ortiz MF, Ayuso-Mateos JL, Bayón C, Mediavilla R.** *A stress-reduction eHealth intervention for healthcare workers in primary care settings: an implementation study. Front Public Health. 2025; 13: 1600059. Article. IF: 4.1; Q1*
- **Gárriz-Luis A, Rodríguez-Toscano E, Burdeus-Olavarrieta M, Arango C, Parellada M, Díaz-Caneja CM.** *Clinical and neuropsychological characterization of Jacobsen syndrome (del11q). J Neurodev Disord. 2025; 18(1): 4. Article. IF: 3.6; Q2*
- **González-Ortega I, Díaz-Marsa M, López-Peña P, Fernández-Sevillano J, Andreo-Jover J, Bobes J, Bravo-Ortiz MF, Cebria AI, Crespo-Facorro B, de la Torre-luque A, Elices M, Fernández-Rodrigues V, Garrido-Torres N, Grande I, Palao-Tarrero A, Pemau A, Roberto N, Ruiz-Veguilla M, Seijo-Zazo E, Alberich S, González-Pinto A, Pérez V.** *Clinical predictors and psychosocial risk factors of suicide attempt severity. Span J Psychiatry Ment Health. 2025; 18(3): 182-90. Article. IF: 2.6; Q2*
- **Gorwood P, Yildirim M, Madera-McDonough J, Fagiolini A, Arango C, Correll CU, Arcà E, Barlassina A, Selveindran S, Sahota N, Kane JM.** *Assessment of functional recovery in patients with schizophrenia, with a focus on early-phase disease: results from a Delphi consensus and narrative review. Bmc Psychiatry. 2025; 25(1): 398. Article. IF: 4.6; Q1*
- **Howes OD, Bukala BR, Chen EYH, Correll CU, Hasan A, Honer WG, Kane JM, Leucht S, Siafis S, Agid O, Akena D, Arango C, Atwoli L, Barnes TRE, Birnbaum ML, Bitter I, Breier A, Buchanan RW, Citrome L, Cotter DR, Crossley N, Davidson M, De Bartolomeis A, Delisi LE, Dollfus S, Dursun SM, Ebdrup BH, Elkis H, Emsley R, Falkai P, Fernández-Egea E, Fleischhacker W, Freudenreich O, Gadelha A, Gaebel W, Graff-Guerrero A, Gridley A, Hallak JEC, Homan P, Kahn RS, Kaiser S, Kapi M, Kennedy JL, Kim E, Kinon BJ, Kwon JS, Lawrie SM, Lee J, Leweke FM, Li T, Libiger J, Marder SR, Melle I, Meltzer H, Mucci A, Naber D, Nakajima S, Nielsen J, O'Brien O, Ojagbemi A, Omlor W, Pantelis C, Peuskens J, Raedler TJ, Ran MS, Marques TR, Remington G, Rossell S, Rubio JM, Sachs G, Scott J, Si TM, Siskind D, Siu CO, Sommer IE, Suzuki T, Takeuchi H, Tandon R, Taylor D, Teferra S, Thomas N, Tiihonen J, Uchida H, Ucok A, Umbricht D, Venkatasubramanian**

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

G, Wagner E, Walters JTR, Wang CY, Weiser M, Wright C, Yu X, McCutcheon RA. *Relapse in schizophrenia: a systematic review of criteria for clinical studies and international consensus guidelines to improve them. Am J Psychiat. 2025; 182(11): 969-83. Review. IF: 15.9; D1*

- **Janssen J, Gallego AG, Díaz-Caneja CM, Lois NG, Janssen N, González-Peñas J, Gordaliza PM, Buimer E, van Haren N, Arango C, Kahn R, Pol HEH, Schnack HG.** *Heterogeneity of morphometric similarity networks in health and schizophrenia. Schizophrenia (Heidelb). 2025; 11(1): 70. Article. IF: 4.5; Q1*
- **Kuzman MR, Nordentoft M, Raballo A, Mohr P, Fiorillo A, Dom G, Mihajlovic G, Jendricko T, Chumakov E, Barjaktarov S, Carpiniello B, Patarák M, Martin L, Dudek D, Samochowiec J, Taube M, Courtet P, Babic D, Racetovic G, Catthoor K, Arango C, Maruta N, Basar K, Vahip S, Szekeres G, Lien LR, Popova A, Zhelev R, Jääskeläinen E, Delic M, Chkonia E, Chichai J, Telles-Correia D, Cosman DCM, Beezhold J, Falkai P.** *Schizophrenia treatment preferences of psychiatrists versus guidelines: A European perspective. Eur Psychiat. 2025; 68(1): e107. Review. IF: 7.9; D1*
- **Lefaucheur JP, Colzi C, Hollander E, Pampaloni I, Van Ameringen M, Baeken C, Fusar-Poli P, Arango C, Fontenelle LF, Batail JM, Brunoni AR, Nicolini H, Haffen E, Soriano-Mas C, Rodríguez CI, Dell'Osso BM, Vieta E, Sauvaget A, Szekely D, Mayer-Linderberg A, Denys D, Stein DJ, Drapier D, Voon V, Pallanti S.** *Comparison between accelerated and standard or sham rTMS in the treatment of depression: A systematic review. Neurosci Biobehav R. 2025; 173: 106140. Article. IF: 8.5; Q1*
- **Leppanen J, Kieseppä V, Eskelinen S, Säynäjäkangas V, Rutten B, Gülöksüz S, Halt AH, Riipinen P, Díaz-Caneja CM, Kelleher I.** *Clinical predictors of readmission to psychiatric inpatient care: A 20-year follow up study of former adolescent inpatients. Psychiat Res. 2025; 351: 116606. Article. IF: 5.1; Q1*
- **Llorca-Bofí V, Garriga M, Mezquida G, García-Rizo C, Vieta E, Díaz-Caneja CM, Bernardo M, Madero S, Pina-Camacho L, Cuesta MJ, Bergé D, Baeza I, Bioque M, Amoretti S.** *Comparing PANSS-6 and PANSS-30 for clinical and functional outcomes in first-episode psychosis: A 2-year follow-up in a Spanish cohort. Eur Neuropsychopharm. 2025; 95: 9-13. Article. IF: 8.1; D1*
- **López-Cuadrado T, Mortier P, Alonso J, Martínez-Alés G.** *Trends of non-lethal intentional self-harm and suicide in Spain 2018-2023: a nationwide registry-based study. Lancet Reg Health Eur. 2025; 58: 101467. Article. IF: 15.7; D1*
- **López-Morinigo JD, Fiorillo A, Dom G, Arango C.** *Mental health status of the European population and its determinants: A cross-national comparison study. Eur Psychiat. 2025; 68(1): e103. Article. IF: 7.9; D1*
- **Mathalon DH, Nicholas S, Roach BJ, Billah T, Lavoie S, Whitford T, Hamilton HK, Addamo L, Anohkin A, Bekinschtein T, Belger A, Buccilli K, Cahill J, Carrion RE, Damiani S, Dzafic I, Ebdrup BH, Izyurov I, Jarcho J, Jenni R, Jo A, Kerins S, Lee CRC, Martin EA, Mayol-Troncoso R, Niznikiewicz MA, Parvaz M, Pogarell O, Prieto-Montalvo J, Rabin R, Roalf DR, Rogers J, Salisbury DF, Shaik R, Shankman S, Stevens MC, Suen YN, Swann NC, Tang XC, Thompson JL, Tso I, Wenzel J, Zhou JH, Addington J, Alameda L, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Calkins ME, Castillo-Passi RI, Chen EYH, Choi J, Conus P, Corcoran CM, Cornblatt BA, Díaz-Caneja CM, Ellman LM, Fusar-Poli P, Gaspar PA, Gerber C, Glenthoj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Mamah D, Mittal VA, Nordentoft M, Pearlson GD, Pérez J, Perkins DO, Powers AR, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Stone WS, Strauss GP, Upthegrove R, Verma SK, Wang JJ, Wolf DH, Zhang TH, Bouix S, Pasternak O, Cho KIK, Coleman MJ, Dwyer D, Nunez A, Tamayo Z, Wood SJ, Kahn RS, Kane JM, Mcgorry PD, Bearden CE, Nelson B, Woods SW, Shenton ME, Light GA.** *The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures. Schizophrenia (Heidelb). 2025; 11(1): 85. Article. IF: 4.5; Q1*
- **Medel V, Alliende LM, Bethlehem R, Seidlitz J, Ringlein G, Arango C, Arnatkeviciute A, Asmal L, Bellgrove M, Benegal V, Bernardo M, Billeke P, Bosch-Bayard J, Bressan R, Busatto G, Castro M, Chaim-Avancini T, Costanzi M, Czepielewski L, Dazzan P, de la Fuente-sandoval C, Díaz-Caneja CM, Di Forti M, Díaz-Zuluaga AM, Du Plessis S, Duran F, Fittipaldi S, Fornito A, Freimer N, Gadelha A, Gama C, Garani R, García-Rizo C, Campo CG, González-Valderrama A, Guinjoan S, Holla B, Ibañez A, Ivanovic D, Jackowski A, Leon-Ortiz P, Lochner C, López-Jaramillo C, Luckhoff H, Massuda R, Mcguire P, Miyata J, Mizrahi R, Murray R, Ozerdem A, Pan PD, Parellada M, Phahladira L, Ramirez-Mahaluf JP, Reckziegel R, Marques TR, Reyes-Madrigal F, Roos A, Rosa P, Salum G, Scheffler F, Schumann G, Serpa M, Stein DJ, Tepper A, Tiego J, Ueno T, Undurraga J, Undurraga EA, Valdes-Sosa P, Valli I, Villarreal M, Winton-Brown TT, Yalin N, Zamorano F, Zanetti M, Winkler AM, Evans-Lacko S, Crossley NA.** *Human development, inequality, and their associations with brain structure across 29 countries. Eur Psychiat. 2025; 68(1): e100. Article. IF: 7.9; D1*
- **Moreno C, Abregú-Crespo R, Mayoral M.** *Childhood trauma: the elephant in the room in child and adolescent psychiatry. Eur Child Adoles Psy. 2025; 34(9): 2627-9. Editorial Material. IF: 4.4; Q1*
- **Olazagoitia-Garmendia A, Rojas-Márquez H, Trobisch T, Moreno-Castro C, Etxebarria AR, Mentxaka J, Tripathi A, Yang BB, Ruiz IM, Anguita J, Meana JJ, Ding YL, Dutta R, Schirmer L, Igoillo-Esteve M, Santin I, Castellanos-Rubio A.** *An inflammation-associated lncRNA induces neuronal damage via mitochondrial dysfunction. Mol Ther Nucleic Acids. 2025; 36(2): 102533. Article. IF: 6.5; Q1*
- **Palagini L, Arango C, Bassetti CLA, Bastien C, Geoffroy PA, Elder G, Ellis J, Hedner J, Khullar A, Nobili L, Partinen M, Saletu M, Vieta E, Morin CM, Riemann D, Strambi LF, Fiorillo A.** *The need to prioritize insomnia disorder in public health agendas: a wakeup call position paper from European and Canadian experts in sleep and mental health. Sleep Med. 2025; 135: 106763. Article. IF: 4.1; Q1*
- **Pemau A, de la Torre-luque A, Marín-Martín C, Díaz-Marsa M, Andreo-Jover J, Ayad-Ahmed W, Ortiz MFB, Bobes-Bascarán MT, Canal-Rivero M, García IC, Cebrià AI, Crespo-Facorro B, Boti MA, Elices M, González-Pinto A, Grande I, Jiménez-Treviño L, Palao DJ, Palao-Tarrero A, Pérez-Guerra C, Roberto N, Veguilla MR, Sáiz PA, SURVIVE Consortium, Pérez V.** *Symptomatic networks in suicide attempt and reattempt: Relevance of psychiatric comorbidity. Eur Psychiat. 2025; 68(1): e4. Article. IF: 7.9; D1*
- **Penzel N, Polosecki P, Addington J, Arango C, Asgari-Targhi A, Billah T, Bouix S, Calkins ME, Campbell DE, Cannon TD, Castro E, Cho KIK, Coleman MJ, Corcoran CM, Dwyer D, Frangou S, Fusar-Poli P, Glynn RJ, Haidar A, Harms MP, Jacobs GR, Kambeitz J, Kapur T, Kelly SM, Koutsouleris N, Abhinandan KR, Kucukemiroglu S, Kwon JS, Lewandowski KE, Li QS, Mantua V, Mathalon DH, Mittal VA, Nicholas S, Pandina GJ, Perkins DO, Potter A, Reichenberg A, Reinen J, Sand MS, Seitz-Holland J, Shah JL, Srinivasan V, Srivastava A, Stone WS, Torous J, Vangel MG, Wang JJ, Wolff P, Yao BE, Anticevic A, Wolf DH, Zhu H, Bearden CE, McGorry PD, Nelson B, Kane JM, Woods SW, Kahn RS, Shenton ME, Cecchi G, Pasternak O.** *Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program. Schizophrenia (Heidelb). 2025; 11(1): 53. Article. IF: 4.5; Q1*
- **Petri-Romao P, Martínez-Alés G, Martinez-Morata I, Moreno-Küstner B, Fernández-Jiménez E, Hecker I, Melchior M, Mittendorfer-Rutz E, Sijbrandij M, Walter H, Witteveen AB, Ayuso-Mateos JL, Bravo-Ortiz**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

MF, Kalisch R, Puhlmann LMC, Mediavilla R. *Resilience changes and occupational resilience factors among healthcare workers during and after the COVID-19 pandemic: A 2-year prospective cohort study. Sci Rep-Uk. 2025; 15(1): 29263. Article. IF: 4.9; Q1*

- **Petri-Romao P, Mediavilla R, Restrepo-Henao A, Puhlmann LMC, Zerban M, Ahrens KF, Barbui C, Basten U, Bayon C, Chmitorz A, Felez-Nobrega M, Kollmann B, Lieb K, McDaid D, McGreevy KR, Melchior M, Muñoz-Sanjosé A, Neumann RJ, Park AL, Plichta MM, Purgato M, Reif A, Schenk C, Schick A, Sebastian A, Sijbrandij M, Smith P, Tüscher O, Wessa M, Witteveen AB, Yuen KSL, Haro JM, Ayuso-Mateos JL, Kalisch R.** *Positive appraisal style predicts long-term stress resilience and mediates the effect of a pro-resilience intervention. Nat Commun. 2025; 16(1): 10269. Article. IF: 18.1; D1*
- **Pujadas ER, Díaz-Caneja CM, Stevanovic D, Quintero MF, Martin-Isla C, Hernández-González J, Atehortúa A, Lazrak N, Pries L, Delespaul P, Camacho M, Gülöksüz S, Rutten BPF, Lekadir K.** *Longitudinal prediction of mental health outcomes in vulnerable youth using machine learning. Cogn Comput. 2025; 17(5): -152. Article. IF: 7.4; D1*
- **Rodríguez-Rodríguez GJ, Martínez-Alés G, López-Cuadrado T.** *Suicide Among Older People in Spain: The role of sex and urbanicity. Int J Geriatr Psych. 2025; 40(3): e70071. Article. IF: 3.3; Q2*
- **Saracaydin G, van Rooij D, Kleine-Deters R, Messchendorp M, Naaijen J, Penzol MJ, Rosa M, Aggensteiner PM, Baumeister S, Holz N, Banaschewski T, Saam M, Schulze UME, Sethi A, Craig M, Castro-Fornieles J, Arango C, Walitza S, Werhahn J, Brandeis D, Franke B, Ruisch IH, Buitelaar JK, Dietrich A, Hoekstra PJ.** *Disentangling the neural underpinnings of response inhibition in disruptive behavior and co-occurring ADHD. Eur Child Adoles Psy. 2025; 34(7): 2253-67. Article. IF: 4.4; Q1*
- **Schalk L, Sethi A, Saam MC, Flamarique I, Naaijen J, Dietrich A, Hoekstra PJ, Banaschewski T, Aggensteiner PM, Holz N, Baumeister S, Borràs R, Rosa-Justicia M, Santosh P, Sagar-Ouriaghli I, Arango C, Penzol MJ, Brandeis D, Walitza S, Werhahn JE, Franke B, Glennon JC, Zwiers MP, Schulze UME, Castro-Fornieles J, Buitelaar JK, Craig MC.** *White matter microstructure of the cingulum bundle and the uncinate fasciculus in primary and secondary callous-unemotional traits. Eur Child Adoles Psy. 2025; 34(12): 4035-51. Article. IF: 4.4; Q1*
- **Segura AG, Verdolini N, Valli I, García-Rizo C, Díaz-Caneja CM, Vieta E, Mezquida G, Lobo A, González-Pinto A, Andreu-Bernabeu A, Roldan A, Martinez-Aran A, Baeza I, Mane A, Labad J, Müller DJ, Guasch-Capella N, Bernardo M, Mas S, Bioque GM, González J, Andrés P, Cavone V, Corripio I, Duque A, Mar-Barrutia L, Marin J, De-la-Camara C, Vaquero-Puyuelo D, Rivero O, Fabra MJE, Trabsa A, Legido T, Forte MF, Serra-Navarro M, de la Serna H, Castro-Fornielles J, Contreras F, García-Portilla MP, González-Blanco L, Echevarría RS, Rabadán AZ, Rodríguez-Jimenez R, Martínez-Gras I, Usall J, Barajas A, Sarro S, Pomarol-Clotet E, Ibañez A, Cuesta MJ.** *Polygenic risk score of glycemic homeostasis, Type 2 Diabetes Mellitus and glycemic components in first episode psychosis. Schizophr Res. 2025; 285: 265-75. Article. IF: 3.7; Q2*
- **Sideli L, Aas M, Alameda L, Trotta G, La Barbera D, La Cascia C, Ferraro L, Velthorst E, Tripoli G, Schimmenti A, Fontana A, Quattrone D, Gayer-Anderson C, Rodríguez V, Spinazzola E, Stilo S, Seminerio F, Sartorio C, Marrazzo G, Lasalvia A, Tosato S, Tarricone I, D'Andrea G, Arango C, Arrojo M, Bernardo M, Bobes J, Sanjuán J, Santos JL, Menezes PR, Del-Ben CM, Jongsma HE, Jones PB, Kirkbride JB, Llorca P, Tortelli A, Pignon B, de Haan L, Selten J, Van Os J, Rutten BP, Di Forti M, Murray RM, Morgan C, Fisher HL.** *Interplay between childhood maltreatment, subclinical post-traumatic stress symptoms, and IQ: Findings from the EU-GEI Multicentre Case-Control Study. Early Interv Psychia. 2025; 19(8): e70079. Article. IF: 2.3; Q3*
- **Stringaris A, Burman C, Delpech R, Uher R, Bhudia D, Miliou D, Rokas IM, Kyriakopoulos M, Foulkes L, Moreno C, Cortese S, Lewis G, Krebs G.** *Comparing apples and oranges in youth depression treatments? A quantitative critique of the evidence base and guidelines. BMJ Ment Health. 2025; 28(1): e301162. Article. IF: 6.6; D1*
- **Szmulewicz AG, Martinez-Alés G, Logan R, Joober R, Ferrara M, Kelly C, Fredrikson D, Thorpe LE, Conderino S, Díaz-Caneja CM, Srihari V, Yatham LN, Sarpal DK, Shinn AK, Arango C, Shah JL, Öngür D, Hernán MA.** *Comparative effectiveness of long-acting injectable versus oral antipsychotic medication after a first episode of psychosis. Nat Ment Health. 2025; 3(4): 1EJ8M. Article. IF: 9.3; D1*
- **van de Burgt NA, Kulsvehagen L, Mané-Damas M, Lutz L, Lecourt AC, Monserrat C, Vinke AM, Küçükali CI, Zong SH, Hoffmann C, González-Vioque E, Arango C, Leibold NK, Losen M, Molenaar PC, Tüzün E, van Beveren NJM, Mané A, Rouhl RPW, van Amelsvoort TAMJ, Pröbstel AK, Martinez-Martinez P.** *Autoantibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with psychotic symptoms. Front Neurol. 2025; 16: 1593042. Article. IF: 3.3; Q2*
- **Vieta E, Ahmed N, Arango C, Cleare AJ, Demyttenaere K, Dold M, Ito T, Kambarov Y, Krüger S, Llorca PM, Mcintyre RS, Sani G, von Holt C, Rive B.** *Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study. Eur Neuropsychopharm. 2025; 93: 29-39. Article. IF: 8.1; D1*

Research projects

- **Arango C.** Ambiente y genes en esquizofrenia-grupos de investigación de la comunidad de Madrid (AGES-CM 3-CM) (B2022/BMD-7216). Biomedicina-Comunidad de Madrid. 2023-2026. Managment centre: HGUGM
- **Arango C.** Estudio de coste-efectividad del programa de coordinación y enlace en salud mental infanto-juvenil para centros escolares (2024-DON004 FAK). Fundación Alicia Koplowitz. 2023-2026. Managment centre: HGUGM
- **Arango C.** Interacciones genes-ambiente en las trayectorias de salud mental de los jóvenes (PI22/01824). ISCIII. 2023-2025. Managment centre: HGUGM
- **Arango C.** The impact of social isolation on aging health in schizophrenia (loneliness-NIH) (NIH-2022/Aging). US National Institutes of Health (NIH). 2022-2027. Managment centre: HGUGM
- **Bravo Ortiz MF.** Ambiente y genes en esquizofrenia. (S2022/BMD-7216 AGES 3-CM). CM. 2023-2026. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Apoyo a investigadores que han participado como mentores. (Dr. Luis Alvarez 2023). Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2024-2025. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Contrato garantía juvenil ayudante de investigación. (PEJ-2021-AI/SAL-22352). CM. 2023-2024. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Estudio De Coste Efectividad De Un Programa De Hospitalización Domiciliaria De Salud Mental En Infancia Y Adolescencia En Dos Áreas De Influencia De Dos Hospitales De Madrid (Hospital Universitario La Paz Y Hospital Universitario Príncipe De Asturias). Fundación Nemesio Diez. 2024-Ongoing. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Estudio longitudinal de una cohorte representativa: superando la heterogeneidad clínica y biológica en primeros episodios psicóticos. (PI20/01113). ISCIII. 2021-2025. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Impacto de la pandemia de COVID-19 en la salud mental de trabajadores en dispositivos sanitarios. Estudio internacional multicéntrico: the COVID-19 Heroes Study. (PI-4099-BRAVO ORTIZ). Sociedad Española de Psiquiatría. 2020-Ongoing. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Improving the Preparedness of Health Systems to Reduce Mental Health and Psychosocial Concerns resulting from the COVID-19 Pandemic. (RESPOND). UE. 2020-2024. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Programa de enlace de salud mental y educación (CELSO ARANGO-MMA 2024). Fundación Mutua Madrileña. 2024-Ongoing. Managment centre: FIBHULP
- **Fernández Jiménez E.** Identificación de necesidades pre- y post-quirúrgica y evolución

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



neuropsicológica y biopsicosocial en población infantojuvenil sometida a cirugía de trasplante de órgano sólido y pectus excavatum. proyecto psycmajorsurgeries. (PI-5223/2022014). Fundación Alicia Koplowitz. 2022-Ongoing. Managment centre: FIBHULP

- **Fernández Jiménez E.** Marcadores neurocognitivos y perfil psicológico en población infantil, adolescente y en adultos jóvenes receptores de terapia con células CAR-T y trasplante hematopoyético: Estudio observacional comparativo. (Dr. Luis Alvarez 2023). FIBHULP. 2023-2024. Managment centre: FIBHULP
- **Fernández Jiménez E.** Marcadores neurocognitivos y perfil psicológico en población infantil, adolescente y en adultos jóvenes receptores de terapia con células car-t y trasplante hematopoyético: estudio observacional comparativo. (PI-5562/2023.063). Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2022-Ongoing. Managment centre: FIBHULP
- **Fernández Jiménez E.** PsyCARTkids: impacto bio-psicológico del entrenamiento cognitivo y mindfulness en menores tras terapia car-t, trasplante hematopoyético o quimioterapia: estudio de métodos mixtos y ensayo controlado-aleatorizado (PI23/00179). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Martínez Díaz-Caneja C.** Bridging Gaps in Mental Health Support: A Comprehensive European Strategy YOUTHreach (101156514-2). HORIZON-HLTH-2024-DISEASE-03-two-stage. 2025-2030. Managment centre: FIBHULP
- **Martínez Díaz-Caneja C.** Estudio piloto de implementación de una herramienta de cribado para la prevención, diagnóstico y tratamiento de pacientes con un trastorno psiquiátrico del neurodesarrollo: utilización del síndrome deleción 22q11.2 (PMP22/00088). Medicina Personalizada y de Precisión. Carlos III, Ministerio de Ciencia, Innovación y Universidades. 2023-2025. Managment centre: HGUGM
- **Martínez Díaz-Caneja C.** Hacia una intervención estratificada en psiquiatría: Predicción de trayectorias de riesgo y resiliencia para la salud mental en una muestra transdiagnóstica de jóvenes (proyecto PREMY) (PI23/00625). ISCIII. 2024-2026. Managment centre: HGUGM
- **Martínez Díaz-Caneja C.** Youth-GEMs:Gene Environment interactions in Mental health trajectories of Youth (HORIZON-HLTH-2021-STAYHLTH-01) Comisión Europea. 2022-2027. Managment centre: HGUGM
- **Moreno C.** Bootstrap: Boosting Societal Adaptation and Mental Health in a Rapidly Digitalizing, Post-Pandemic Europe (HE BOOTSTRAP 101080238-1). HORIZON-HLTH-2021-STAYHLTH-01-02. 2023-2028. Managment centre: HGUGM
- **Moreno C.** Mecanismos etiofisiopatológicos implicados en la desregulación emocional en depresión y riesgo de suicidio en adolescentes (FFA24/02). Fundación Familia Alonso. 2024-2026. Managment centre: HGUGM
- **Moreno C.** Psych-STRATA: Stratified Treatment Algorithm in Psychiatry: A program on stratified pharmacogenomics in severe mental illness (HORIZON-HLTH-2021-STAYHLTH-01-02). Comisión Europea. 2022-2027. Managment centre: HGUGM
- **Muñoz San José A.** Hacia una intervención estratificada en psiquiatría: predicción de trayectorias de riesgo y resiliencia para la salud mental en una muestra transdiagnóstica de jóvenes (PI23/00380). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Nocete Navarro L.** Fostering and Strengthening Approaches to Reducing Coercion in European Mental Health Services (CA19133). 2024-Ongoing. Managment centre: FIBHULP
- **Palao Tarrera A.** Intensificación de la actividad investigadora de investigadores participantes del programa mentor. FIBHULP. 2023-2024. Managment centre: FIBHULP
- **Palao Tarrera A.** SMARTomicS: prevención de la conducta suicida mediante intervenciones terapéuticas guiadas por fenotipo digital y farmacogenética (PMP24/00026). Medicina Personalizada y de Precisión. Carlos III, Ministerio de Ciencia, Innovación y Universidades. 2025-2026. Managment centre: FIBHULP
- **Palao Tarrera A.** SURVIVE 2: un estudio de cohorte extendida para investigar la conducta suicida en España y la eficacia de estrategias de prevención secundaria (PI23/01469). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Rodríguez Vega B.** Prevención e intervención en suicidio (SURVIVE): estudio de cohorte y ensayos clínicos controlados anidados de programas de prevención secundaria para intentos de suicidio. (PI19/00941). ISCIII. 2020-2024. Managment centre: FIBHULP
- **Rodríguez Vega B.** Traducción y validación de los instrumentos reflective functioning questionnaire e inventary of personality onganization. Fundación Vasca de Innovacion e Investigación Sanitarias. 2018-Ongoing. Managment centre: FIBHULP
- **Villanueva Peña R.** A Randomnized, Double-blind, Multicenter, Parallel-group, Placebo-controlled. Study to evaluated the efficacy, safety, and tolerability of aticaprant 10 mg as adjunctive therapy in adult participants with major depressive disorder (MDD) with moderated-to-severe anhedonia and inadequate response to current antidepressant therapy protocol 67953964MDD3001 VENTURA-1;PAHASE 3. Janssen Pharmaceutica. 2023-2024. Managment centre: FIBHULP

Clinical Trials

- **Villanueva Peña R.** A two-part multicenter, double-blind, randomized placebo-controlled study to evaluate efficacy and safety and the maintenance of effect of 20-mg seltorexant as adjunctive therapy to antidepressants in adult and elderly patients with major depressive disorder with insomnia symptoms.
  Type/Phase: III
  Sponsored by: Icon Clinical Research Limited.
  Signature date: 13/05/2025
- **"Villanueva Peña R.** A cohort, non-interventional, prospective, real-world study of functional remission in trd patients treated with esketamine nasal spray estudio de cohortes, no intervencionista, prospectivo, de practica real para evaluar la remisión funcional en pacientes con trd tratados con esketamina intranasal.
  Type/Phase: EOm prospectivo
  Sponsored by: Janssen-Cilag España, S.A.
  Signature date: 05/03/2025"

Patents and Trademarks

Rodríguez Vega B, authors; FIBHULP, assignee. Brand name: En calma; ESM 3.695.071; 2017 December 12.

Rodríguez Vega B, Mediavilla Torres R, Bravo Ortiz MF, Muñoz San José A, Bayón Pérez C, Lahera Forteza G, Palao Tarrero A. authors; FIBHULP, assignee. Brand name: SocialMind; ESM 3.748.550; 2018 December 17.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.1.2 Neurology and Cerebrovascular Diseases

Publications: 72 | Q1:39

COMPOSITION

Exuperio Díez Tejedor.
Investigador Emérito. FIBHULP; Catedrático Neurología. Departamento de Medicina. Universidad Autónoma de Madrid

María Gutiérrez Fernández.
Investigadora Titular Senior. FIBHULP. Coordinadora Laboratorio Ciencias Neurológicas y Cerebrovascular .



- **María José Aguilar-Amat Prior.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **María Alonso de Leciñana Cases .** *Jefe de Sección. Servicio de Neurología. Hospital Universitario La Paz/Profesora asociada. Universidad Autónoma de Madrid7*
- **Elisa Alonso López.** *Contrato Juan Rodés. Hospital Universitario La Paz*
- **Cristina Aramendia Zabaleta.** *Enfermera. FIBHULP*
- **Francisco Javier Arpa Gutiérrez.** *Profesor Honorario. Universidad Autónoma de Madrid*
- **María Jesús Bullido Gómez-Heras.** *Profesora Titular. Departamento de Biología Molecular. Facultad de Ciencias. CBM "Severo Ochoa"*
- **Ángela Calzado González.** *Investigadora Predoctoral. FIBHULP*
- **Fernando Carceller Benito.** *Facultativo Especialista de Área en Neurocirugía. Hospital Universitario La Paz*
- **Laura Casado Fernández.** *Investigadora Río Hortega. FIBHULP*
- **Jorge Eduardo Collazos Castro.** *Jefe de Laboratorio de Reparación Neural y Biomateriales. Hospital Nacional de Parapléjicos de Toledo*
- **Clara Correa Paz.** *Investigadora Sara Borrell. FIBHULP*
- **Francisco Javier Díaz de Terán Velasco.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Nerea Díaz Gamero.** *Ayudante de investigación. FIBHULP*
- **Josué Fernández Carnero.** *Profesor e Investigador Postdoctoral. Centro Superior de Estudios Universitarios La Salle*
- **Andrés Francisco Fernández Prieto.** *Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz*
- **Mireya Fernández-Fournier Fernández.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Ana Frank García.** *Jefe de Sección en Servicio de Neurología. Hospital Universitario La Paz/ Profesora Titular de Neurología. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Remedios Frutos Martínez.** *Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz*
- **Blanca Fuentes Gimeno.** *Jefe de Sección. Servicio de Neurología. Hospital Universitario La Paz/ Profesora Asociada. Universidad Autónoma de Madrid*
- **Rebeca Gallego Ruiz.** *Investigadora Predoctoral. FIBHULP*
- **María Luisa Gandía González.** *Facultativa Especialista de Área en Neurocirugía. Hospital Universitario La Paz*
- **Iván García Suárez.** *Facultativo Especialista de Área en Urgencias. Hospital Universitario San Agustín*
- **Alfonso Gil Martínez.** *Fisioterapeuta. Hospital Universitario La Paz*
- **Laura González Martín.** *Médico Adjunto en Neurología. Hospital Universitario La Paz*
- **Juan Granja López.** *Facultativo Especialista de Área de Neurología. Hospital Universitario La Paz*
- **Ana Cristina Guadaño Ferraz.** *Científico Titular. Departamento de Fisiopatología Endocrina y del Sistema Nervioso. IIB "Sols-Morreale"*
- **María Hernández Barral.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **David Hernández Herrero.** *Jefe de Servicio de Rehabilitación y Medicina Física. Hospital Universitario La Paz*
- **Laura Lacruz Ballester.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **María Pilar López Larrubia.** *Científica Titular. CSIC. IIB "Sols-Morreale"*
- **María Paz López Molina.** *Investigador Predoctoral. FIBHULP*
- **Eduardo Mariño Trillo.** *Facultativo Especialista de Área de Neurología. Hospital Universitario La Paz*
- **Begoña Marín Aguilera.** *Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz*
- **Juan Andrés Martín Gonzalo.** *Profesor Titular. Escuela Universitaria de Fisioterapia de la ONCE*
- **Ángel Martín Montes.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Marta María Martínez Martínez.** *Facultativo Especialista de Área en Neurología Profesora Asociada. Hospital Infanta Sofía Universidad Europea de Madrid*
- **Javier Pedro Mascias Cadavid.** *Facultativo Especialista de Área de Neurología. Hospital Universitario La Paz*
- **Marta Naranjo Castresana.** *Facultativo Médico Especialista de Área en Neurofisiología Clínica. Hospital Universitario La Paz*
- **Pedro Navía Álvarez.** *Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz*
- **Pilar Negredo Madrigal.** *Profesor Interino. Departamento de Anatomía, Histología y Neurociencia. Universidad Autónoma de Madrid*
- **Jesús Oliván Palacios.** *Facultativo Especialista de Área en Neurofisiología Clínica. Hospital Universitario La Paz*

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

- **Laura Otero Ortega.** *Investigadora Postdoctoral. Hospital Universitario La Paz*
- **María del Valle Palomo Ruiz.** *Coordinador del Laboratorio de Biosensores en Neurociencia. Fundación IMDEA Nanociencia*
- **Joaquín Pardo Montero.** *Profesor Titular. Centro Superior de Estudios Universitarios La Salle*
- **José Francisco Paz Solís.** *Facultativo Especialista de Área en Neurocirugía. Hospital Universitario La Paz*
- **Irene Peirotén Pascual.** *Enfermera. FIBHULP*
- **Javier Pozo Novoa.** *Investigador Predoctoral. FIBHULP*
- **Inmaculada Puertas Muñoz.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Estrella Rausell Tamayo.** *Catedrática. Departamento de Anatomía, Histología y Neurociencias. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Ricardo Jaime Rigual Bobillo.** *Facultativo Especialista de Area de Neurología. Hospital Universitario La Paz*
- **Ivón Yamileth Rivera Derás.** *Facultativo Especialista de Área en Geriatría. Hospital Universitario La Paz*
- **Irene Rodríguez Andonaegui.** *Profesor Ayudante. Escuela Universitaria de Fisioterapia de la ONCE*
- **Jorge Rodríguez de Pardo de Donlebún.** *Facultativa Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Francisco Javier Rodríguez de Rivera Garrido.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Ana Rodríguez Sanz.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Alicia Román San Martín.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Aranzazu Royo Orejas.** *Jefe de Sección de Radiología. Hospital Universitario La Paz*
- **Gerardo Ruiz Ares.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*



- **María Teresa Salas Campos.** *Técnico Superior Psicología. Servicio de Neurología. Hospital Universitario La Paz*
- **Susana Santiago Pérez.** *Facultativo Especialista de Área en Neurofisiología. Hospital Universitario La Paz*
- **Soledad Serrano López.** *Facultativa Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Pablo Alonso Singer.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Gabriel Torres Iglesias.** *Contrato Río Hortega. FIBHULP*
- **Gema Torrijos Barbero.** *Especialista en Neuropsicología. Unidad de Memoria y Demencias. Hospital de Cantoblanco-Hospital Universitario La Paz*
- **Arturo Ugalde Canitrot.** *Facultativo Especialista de Área en Neurofisiología Clínica. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

CEREBROVASCULAR

- Development of translational research studies (both animal and clinical) in cerebrovascular diseases, with the objectives of increasing knowledge of the pathogenesis of cerebral infarction and cerebral hemorrhage. Analysis of the influence of hyperglycemia on stroke progression. Identification of prognostic biomarkers and therapeutic targets primarily aimed at brain protection and repair (cell therapy, trophic factors, extracellular vesicles). Analysis of the contribution of comorbidities to the mechanisms that occur after stroke in animal models.
- Cell therapy clinical trials in acute stroke (AMASCIS clinical trial).
- Analyzing the recovery of post-stroke aphasia through a dubbing tool and the development of a communication app (VerbalizApp).
- To evaluate the use of virtual reality in the recovery of post-stroke motor and cognitive sequelae, as well as the computational analysis of movement.
- To evaluate the effectiveness of maintaining oral or parenteral anticoagulation in the acute phase of cardioembolic ischemic stroke.
- To evaluate the effectiveness of maintaining oral or parenteral anticoagulation in the acute phase of cardioembolic ischemic stroke.
- Discovering factors that anticipate the development of atrial fibrillation through abnormalities in the electrocardiogram and echocardiogram in cryptogenic stroke.
- Impact of the COVID-19 pandemic on stroke care and outcomes
- Analysis of patient-reported outcome measures (PROM) and patient-reported experience measures (PREM) in stroke.
- Analyze the differences between general anesthesia and high-flow nasal cannula sedation in the endovascular treatment of ischemic stroke.

HEADACHES AND NEUROPATHIC PAIN

- Analysis of the expression of the central painful awareness phenomenon in different primary and secondary headaches.
- Central sensitization and pain perception in patients with cluster headache.
- Refractory migraine database.
- Short-term prophylaxis of cluster headache: A comparative study.
- Study of chronic craniofacial neuropathic pain.
- CGRP pathway drugs in patients with refractory migraine (including autoimmune diseases and the elderly) and medication overuse headache.
- Multicenter collaboration in post-COVID headache research
- Characteristics and results of refractory chronic cluster headache treated with greater occipital nerve stimulation.
- Registry of chronic cluster headaches.
- Treatment of chronic cluster headaches with transcranial magnetic stimulation. Clinical study.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

STRATEGIC OBJETIVES

Alzheimer's disease

- Study of the involvement of the lysosomal pathway in a model of neurodegeneration and cholesterol dysregulation in Alzheimer's disease.
- Study of genetic polymorphism related to PSP in the context of a multicenter genome-wide association study (GWAS)
- Neurodegenerative and Vascular Dementia. Role of Extracellular Vesicles of the Neurovascular Unit as a Biomarker

Parkinson's disease

- Tremor as a negative predictive factor in the development of dementia associated with Parkinson's disease.
- Evaluation of the benefits and risks of continuous intraduodenal levodopa infusion in idiopathic Parkinson's disease.
- Hereditary ataxias
- Evaluation of the therapeutic response to Frenkel training exercises enhanced with the Wii game console in patients with cerebellar ataxia.
- Participation in the Registry of the European Consortium EFACTS (European Friedreich's Ataxia Consortium for Translational Studies) aimed at improving the knowledge of the epigenetic mechanisms related to the silencing of frataxin expression and the pathogenesis of the disease, identification of biomarkers and genes that modify the clinical expression of the disease, development of new therapies as well as cellular and animal models for the study of Friedreich's Ataxia.

NEUROIMMUNOLOGY / NEUROINFLAMMATION

Multiple Sclerosis

- Analysis of extracellular vesicles as biomarkers in patients with multiple sclerosis.
- Analysis of molecular biomarkers and neuroimaging of brain damage and repair in multiple sclerosis.
- Search for diagnostic biomarkers, disease monitoring and treatment response in multiple sclerosis
- Development of parametric tests in multiple sclerosis using photometric strategies.

Autoimmune encephalitis and other autoimmune neurological diseases

- Neurological syndromes associated with anti-GAD antibodies
- Paraneoplastic syndromes and other antibody-associated neurological diseases.

Autonomic Nervous System

- Evaluation of the autonomic nervous system in movement disorders.
- Evaluation of the autonomic nervous system in focal autonomic neuropathies and Fabry disease.
- COMPASS-31 Study (collaboration with the Mayo Clinic): Registry of patients and controls with central and peripheral dysautonomia.

NEUROMUSCULAR DISEASES

- Develop a hand thermography tool for the diagnosis of small fiber neuropathy.
- Analysis of the different profiles of cognitive impairment in patients with ALS. Adaptation and validation of ALS-specific cognitive scales for Spanish patients.
- Study of cognitive potentials for the identification of possible specific EEG endophenotypes in ALS patients.
- Participation in the MinE Project: An international program that analyzes the genome of 15,000 patients and controls using the same genotyping platform.
- Participation in the National Pompe Disease Registry.

DREAM

- Development and evaluation of intervention protocols in the treatment of childhood insomnia.
- Analysis of the sleep microstructure in newborns with Prader-Willi syndrome.
- Study on the effectiveness of treating childhood insomnia with oral iron supplements versus placebo.

EPILEPSY

- Analysis of the factors that influence the recurrence of seizures, tolerance and adherence to drugs, during the first monotherapy in patients with epilepsy.
- Analysis of neuropsychological disorders in primary generalized epilepsy.
- Impact of perampanel in patients with epileptic encephalopathies. A multicenter study.
- Management of refractory status epilepticus. Analysis of the different anesthetic agents commonly used in an intensive care unit.

DIGITAL TECHNOLOGIES APPLIED TO NEUROLOGICAL DISEASES

- Objective assessment of motor deficits or other functional deficits (stroke, movement disorders, multiple sclerosis)
- Environmental enrichment to promote early stroke recovery
- Virtual reality in promoting cognitive and motor recovery
- New applications of ultrasound for the diagnosis and research of neurological diseases
- Artificial intelligence applied to diagnosis and clinical management

NEUROSTIMULATION

- Neurostimulation in brain and spinal cord injuries

PLASTICITY AND REPAIR AFTER BRAIN DAMAGE. TRANSLATIONAL RESEARCH

- Therapies with trophic factors, stem cells and extracellular vesicles.
- Biomarkers of damage and repair in neurological diseases
- Ultrasound monitoring and visualization of the brain and peripheral organs in animal models."

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH LINES

- Cerebrovascular Diseases
- Headaches and Neuropathic Pain
- Neurodegenerative diseases: cognitive disorders, movement disorders, and spinocerebellar ataxias.
- Neuroimmunology. Multiple Sclerosis
- Neuromuscular diseases. Motor neuron diseases. Amyotrophic lateral sclerosis.
- Digital technologies applied to neurological diseases
- Neurostimulation in brain and spinal cord injuries.
- Plasticity and repair after brain damage. Translational research.

RESEARCH ACTIVITY

Doctoral Theses

- **Torres Iglesias G.** Vesículas extracelulares sanguíneas como biomarcador diagnóstico y de respuesta al tratamiento en esclerosis múltiple[dissertation]. Madrid: UAM: 2025(03/06/2025). Director: Puertas Muñoz I, Otero Ortega L.
- **Fernández-Fournier Fernández M.** Valor de la presencia en vesículas extracelulares de anticuerpos frente al EBNA-1 y el VCA del virus de Epstein-Barr como biomarcadores en pacientes con esclerosis múltiple[dissertation]. Madrid: UAM: 2025(06/03/2025). Director: Otero Ortega L, Díez Tejedor E.
- **Casado Fernández L.** Perfil proteómico de las vesículas extracelulares como biomarcadores de daño y reparación en la hemorragia cerebral[dissertation]. Madrid: UAM: 2025(14/10/2025). Director: Alonso de Leciñana Cases M, Gutiérrez Fernández M.
- **Rigual Bobillo RJ.** Continuación del tratamiento anticoagulante en la fase aguda del infarto cerebral con fuente cardioembólica mayor: Estudios RECOALA y COALA[dissertation]. Madrid: UAM: 2025(02/12/2025). Director: Fuentes Gimeno B, Díez Tejedor E.
- **Fuentes Redondo T.** Estudio anatomo-clínico de las malformaciones de la vena de galeno. Métodos diagnósticos y opciones terapéuticas[dissertation]. Madrid: UCM: 2025(19/10/2025). Director: Navia Álvarez P.
- **Riera López N.** Impacto de la pandemia COVID-19 en la atención del código ictus por el Servicio de Urgencias Médicas de Madrid (SUMMA 112). Aprendizaje para situaciones epidémicas similares.[dissertation]. Madrid: UAM: 2025(04/02/2025). Director: Fuentes Gimeno B, Díez Tejedor E.
- **Fernández Gómez P.** Nanotecnología en el tratamiento y evaluación farmacológica en enfermedades neurodegenerativas. [dissertation]. Madrid: UCM: 2025(03/10/2025). Director: Palomo Ruiz MV.

Master Theses

- **Fernández Escudero D.** Use of 3D printing to support clinical information for patients with incidental cerebral aneurysms and its impacto n perceived quality of life. [dissertation]. Madrid: UPM: 2025(25/09/2025). Director: Borjas Gómez JT, Sánchez González P, Fuentes Gimeno B.
- **García A.** Desarrollo de nanosensores para enfermedades neurodegnerativas[dissertation]. Madrid: UCM: 2025(02/07/2025). Director: Palomo Ruiz MV.

Final Degree Theses

- **Esteban de Nicolás N.** Diseño e implementación de un sistema de generación de videos para la rehabilitación de pacientes con afasia mediante el uso de inteligencia artificial generativa[dissertation]. Madrid: UPM: 2025(31/01/2025). Director: Gutiérrez Martín A, Fuentes Gimeno B.
- **Vega Domínguez J.** Optimización de un sistema de rehabilitación audiovisual para pacientes con afasia usando inteligencia artificial generativa. [dissertation]. Madrid: UPM: 2025(02/07/2025). Director: Larraga García B, Fuentes Gimeno B.
- **Burrel Bernal M.** Personalización de videos con inteligencia artificial generativa como apoyo a a la rehabilitación del lenguaje en personas con afasia. [dissertation]. Madrid: UPM: 2025(14/07/2025). Director: Larraga García B, Fuentes Gimeno B.
- **Arés Ballesteros S.** Trastornos neurológicos inmunomediados asociados a la vacunación frente a COVID-19[dissertation]. Madrid: UAM: 2025(25/06/2025). Director: Frank García A, Lacruz Ballester L.
- **Navarro Alfaro E.** Diseño e implementación de una plataforma automatizada para la evaluación cinemática del déficit motor de las manos en pacientes con enfermedades neurológicas[dissertation]. Madrid: UPM: 2025(45834). Director: Ruiz Vitte A, de Leciñana Cases MA.

Publications

- **Aguilera-Simón A, Guasch-Jiménez M, Moniche F, Puig N, Pardo-Galiana B, Benítez S, Freijo MD, Marín R, Luna A, Gallego-Fabrega C, Fernández-Pérez I, Ezcurra-Díaz G, Jiménez-Conde J, Lambea-Gil A, Gómez-Vicente B, Martínez-Domeño A, Arenillas JF, Prats-Sánchez L, Rodríguez-Pardo J, Ramos-Pachón A, de Celis-Ruiz E, Martínez-González JP, Trillo S, Ortega-Quintanilla J, Martí-Fàbregas J, Camps-Renom P.** Vascular endothelial growth factor-a and collateral circulation in patients with acute ischemic stroke due to intracranial large vessel occlusion. Transl Stroke Res. 2025; 17(1): 3. Article. IF: 4.2; Q1
- **Akdeniz Bayram Cevdet, Bahrami Shahram, Hagen Espen, Fuhrer Julian, Fominykh Vera, Shadrin Alexey, Filiz Tahir Tekin, Athanasiu Lavinia, Grenier-Boley Benjamin, Bellenguez Celine, de Rojas Itziar, Kucukali Fahri, Schneider Anja, Kleineidam Luca, Rujescu Dan, Scherbaum Norbert, Deckert Jurgen, Riedel-Heller Steffi, Hausner Lucrezia, Molina-Porcel Laura, Grimmer Timo, Heilmann-Heimbach Stefanie, Moebus Susanne, Scarmeas Nikolaos, García-Alberca Jose Maria, Franco-Macias Emilio, Mir Pablo, Real Luis M, Rodríguez-Rodríguez Eloy, Royo Jose Luis, Saez Maria Eugenia, Carracedo Angel, de Munain Adolfo López, Amer-Ferrer Guillermo, Calero Miguel, Medina Miguel, García-Ribas Guillermo, Mendioroz Maite, Dols-Icardo Oriol, Moreno Fermin, Pérez-Tur Jordi, Bullido Maria J, Alvarez Victoria, Soininen Hilkka, Heikkinen Sami, de Mendonca Alexandre, Mehrabian Shima, Traykov Latchezar, Hort Jakub, Vyhnalek Martin, Sandau Nicolai, Thomassen Jesper Qvist, Luo Jiao, Pijnenburg Yolande A L, Tesi Niccolo, van Swieten John, Giedraitis Vilmantas, Williams Julie, Nicolas Gael, Debette Stephanie, Amouyel Philippe, Grunblatt Edna, Popp Julius, Bosso Paola, Galimberti Daniela, Rossi Giacomina, Arosio Beatrice, Mecocci Patrizia, Squassina Alessio, Tremolizzo Lucio, Borroni Barbara, Nacmias Benedetta, Seripa Davide, Rainero Innocenzo, Daniele Antonio, Piras Fabrizio, Masullo Carlo, Kehoe Patrick Gavin, Frikke-Schmidt Ruth, Ghidoni Roberta, Ruiz Agustin, Fernández Victoria, Sanchez-Juan Pascual, Sleegers Kristel, Ingelsson Martin, Hiltunen Mikko, Sims Rebecca, Ramirez Alfredo, Broce Iris J, Haavik Jan, Selbak Geir, Knapskog Anne-Brita, Saltvedt Ingvild, Bergh Sverre, Aakhus Eivind, Kirsebom Bjorn-Eivind, Watne Leiv Otto, Rongve Arvid, Arsland Dag, Djurovic Srdjan, Stordal Eystein, Toft Mathias, Scheffler Katja, Fladby Tormod, Lambert Jean-Charles, Dale Anders, Frei Oleksandr, Andreassen Ole.** Polygenic hazard score for predicting age-associated risk of alzheimer's disease in european populations: development and validation. Medrxiv. 2025 (Prerint) Not Indexed
- **Alexander JJ, DiSano KS, Patrucco L, Fernández-Fournier M.** Editorial: Women in multiple sclerosis and neuroimmunology:

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

from bench to bedside. Front Neurol. 2025; 16: 1677618. Editorial Material. IF: 3.3; Q2

- **Alonso-Alonso ML, Sampedro-Viana A, Fernández-Bueno I, Pérez-Mato M, Correa-Paz C, Pérez-Gayol L, Romaus-Sanjurjo D, Ouro A, Blanco-Santero J, Oblitas CM, Castillo J, Hervella P, Iglesias-Rey R.** Blood-brain barrier leakage in renovascular hypertensive rats: A quantitative MRI analysis. Neuroimage. 2025; 315: 121283. Article. IF: 5.3; Q1
- **Alwakaa O, Kasem RA, Ramírez-Velandía F, Wadhwa A, Han KMY, Levitt MR, Alaraj A, Jabbour P, Kim JT, Howard B, Alawieh A, Wolfe SQ, Starke RM, Psychogios MN, Shaban A, Goyal N, Dye J, Ezzeldin M, Yoshimura S, Sconzo D, Filo J, Pettersson S, Fiorella D, Tanweer O, Romano DG, Navia P, Cuellar H, Fragata I, Polifka A, Mascitelli J, Osbun J, Siddiqui F, Moss M, Limaye K, Mokin M, Matouk C, Park MS, Brinjikji W, Daglioglu E, Williamson R, Altschul DJ, Maier I, Crosa R, Gory B, Grandhi R, Paul A, Kan PT, Casagrande W, Chowdhry S, Stiefel MF, Rai A, Spiotta AM, Taussky P, Ogilvy CS, Granstein JH.** How do patient outcomes in mechanical thrombectomy for large-core stroke vary based on neuroimaging modalities used for patient selection? a multicenter multinational study. Transl Stroke Res. 2025; 16(6): 2158-72. Article. IF: 4.2; Q1
- **Amaya-Pascasioa L, Donlebun JRPD, Arjona-Padillo A, Fernández-Domínguez J, Martínez-Martínez M, Muñoz-Arrondo R, García-Sánchez JM, Blanca JPPD, Carneado-Ruiz J, Martínez-Sánchez P.** Point-of-care ultrasound for transient ischemic attack assessment in transient ischemic attack clinics: Consensus document of the Spanish Society of Neurosonology. Neurología. 2025; 40(5): 473-82. Article. IF: 2.8; Q2
- **Anandan S, Maciak K, Breinbauer R, Otero-Ortega L, Feliciello G, Guzvic NS, Torkildsen O, Myhr KM.** In-Depth characterization of L1CAM+ extracellular vesicles as potential biomarkers for anti-CD20 therapy response in relapsing-remitting multiple sclerosis. Int J Mol Sci. 2025; 26(15): 7213. Article. IF: 5.6; Q1
- **Ares G, Alonso M, Rigual R, Testal C, Iglesias G, Fernández L, Ruiz E, Pardo J, Muñoz J, Martín L, de Leciñana M, Fuentes B.** Digital tool as speech and language therapy for patients with post-stroke aphasia. Digit Health. 2025; 11: 20552076251314600. Article. IF: 3.9; Q1
- **Ávila-Gómez P, Vieites-Prado A, Correa-Paz C, del Pozo-Filíu L, Palomar-Alonso N, Campos F, López-Arias E.** Therapeutic modulation of protein RBM3 for ischemic stroke treatment. Front Pharmacol. 2025; 16: 1555115. Review. IF: 5.4; Q1
- **Bottini M, Zanier O, Da Mutten R, Gandía-González ML, Edström E, Elmi-Terander A, Regli L, Serra C, Staartjes VE.** Generation of synthetic CT-like imaging of the spine from biplanar radiographs: comparison of different deep learning architectures. Neurosurg Focus. 2025; 59(1): E13. Article. IF: 3.3; Q1
- **Bracher-Smith M, Melograna F, Ulm B, Bellenguez C, Grenier-Boley B, Duroux D, Nevado AJ, Holmans P, Tijms BM, Hulsman M, de Rojas I, Campos-Martin R, van der Lee S, Castillo A, Kuçukali F, Peters O, Schneider A, Dichgans M, Rujescu D, Scherbaum N, Deckert J, Riedel-Heller S, Hausner L, Molina-Porcel L, Düzel E, Grimmer T, Wiltfang J, Heilmann-Heimbach S, Moebus S, Tegos T, Scarmeas N, Dols-Icardo O, Moreno F, Pérez-Tur J, Bullido MJ, Pastor P, Sánchez-Valle R, Alvarez V, Boada M, García-González P, Puerta R, Rodríguez-Rodríguez E, Soininen H, de Mendonça A, Mehrabian S, Traykov L, Hort J, Vyhnalek M, Sandau N, Thomassen JQ, Pijnenburg YAL, Holstege H, van Swieten J, Ramakers I, Verhey F, Scheltens P, Graff C, Papenberg G, Giedraitis V, Williams J, Amouyel P, Boland A, Deleuze JF, Nicolas G, Dufouil C, Pasquier F, Hanon O, Debette S, Grünblatt E, Popp J, Solfrizzi V, Parnetti L, Squassina A, Tremolizzo L, Borroni B, Wagner M, Nacmias B, Spallazzi M, Seripa D, Rainero I, Jessen F, Kehoe P, Magda T, Sánchez-Juan P, Sleegers K, Ingelsson M, Hiltunen M, Sims R, van der Flier W, Andreassen OA, Ruiz A, Ramirez A, Frikke-Schmidt R, Amin N, Roshchupkin G, Lambert JC, Van Steen K, van Duijn C, Escott-Price V, Jansen I, Andrade V, Fernández V, Dalmasso MC, Kleineidam L, Ahmad S, Aarsland D, Cano A, Abdelnour C, Alarcón-Martín E, Alcolea D, Alegret M, Alvarez I, Armstrong NJ, Anthoula T, Appollonio I, Arcaro M, Archetti S, Pastor AA, Athanasiu L, Bailly H, Banaj N, Baquero M, Pastor AB, Berr C, Besse C, Bessi V, Binetti G, Fostinelli S, Bellini S, Bizarro A, Blesa R, Boada M, Boschi S, Bossù P, Bråthen G, Bresner C, Brodaty H, Brookes KJ, Buiza-Rueda D, Bûrger K, Burholt V, Calero M, Chene G, Carracedo A, Cecchetti R, Cervera-Carles L, Charbonnier C, Chillotti C, Ciccone S, Claassen JAHR, Clarimon J, Clark C, Conti E, Corma-Gómez A, Giuffrè GM, Custodero C, Daian D, Dardiotis E, Dartigues JF, de Deyn PP, del Ser T, Denning N, Diehl-Schmid J, Díez-Fairen M, Rossi PD, Djurovic S, Duron E, Engelborghs S, Blázquez J, Ewers M, Fabrizio T, Nielsen SF, Farotti L, Fenoglio C, Fernández-Fuertes M, Ferreira CB, Ferri E, Fin B, Fischer P, Fladby T, Fliessbach K, Fortea J, Foroud T, Fostinelli S, Fox NC, Franco-Macías E, Frank-García A, Froelich L, García-Alberca JM, García-González P, García-Madrona S, García-Ribas G, Giegling I, Giorgio G, Goldhardt O, González-Pérez A, Grande G, Green E, Grünblatt E, Guetta-Baranes T, Haapasalo A, Hadjigeorgiou G, Hampel H, Hardy J, Hartmann AM, Leonenko G, Harwood J, Helisalmi S, Heneka MT, Hernández I, Herrmann MJ, Hoffmann P, Holmes C, Vilas RH, Hulsman M, Biessels GJ, Johansson C, Kilander L, Ståhlbom AK, Kivipelto M, Koivisto A, Kornhuber J, Kosmidis MH, Lage C, Laukka EJ, Lauria A, Lehtisalo J, Lerch O, Lleó A, de Munain AL, Love S, Löwemark M, Luckcuck L, Macias J, MacLeod CA, Maier W, Mangialasche F, Marco S, Marquié M, Marshall R, Montes AM, Rodríguez CM, Mead S, Medina M, Meggy A, Mendoza S, Menéndez-González M, Mol M, Montrreal L, Morgan K, Nöthen MM, Ngandu T, Nordestgaard BG, Olaso R, Orellana A, Orsini M, Capdevila M, Padovani A, Paolo C, Martinez-Lucas M, Pericard P, Pineda JA, Pisanu C, Polak T, Posthuma D, Priller J, Puerta R, Quenez O, Quintela I, Rábano A, Reinders MJT, Riederer P, Olivé C, Rongve A, Allende IR, Rosende-Roca M, Royo JL, Rubino E, Sáez ME, Sakka P, Saltvedt I, García-Gutierrez F, Sánchez-Arjona MB, Sanchez-García F, Sánchez-Valle R, Sando SB, Scamosci M, Scarpini E, Scherer M, Schmid M, Schott JM, Selbæk G, Shadrin AA, Skrobot O, Solomon A, Sorbi S, Sotolongo-Grau O, Spottke A, Stordal E, Miguel A, Tárraga L, Tesí N, Thalamuthu A, Thomas T, Traykov L, Tybjærg-Hansen A, Uitterlinden A, Ullgren A, Ulstein I, Valero S, Van Broeckhoven C, Van Dongen J, van Rooij J, Vandenberghe R, Vidal JS, Vita MG, Vogelgsang J, Wagner M, Wallon D, Weinhold L, Windle G, Woods B, Yannakoulia M, Zulaica M, Ghanbari M, Sachdev P, Mather K, Ikram MA, Melograna F, Heikkinen S, Arosio B, Masullo C, Real LM, Piñol-Ripoll G, Galimberti D, Piras F, García-Alberca JM, Mecocci P, Rossi G, Mir P, Ghidoni R, Daniele A.** Machine learning in Alzheimer's disease genetics. Nat Commun. 2025; 16(1): 6726. Article. IF: 18.1; D1
- **Broocks G, Bendszus M, Simonsen CZ, Thomalla G, Gizewski ER, Aamodt AH, Krajina A, Pierot L, Zelenák K, Fuentes B, Hill MD, Kemmling A, Gellissen S, Fiehler J, Meyer L, Kniep H.** Net water uptake at ct predicts the treatment effect of thrombectomy for low ASPECTS stroke. Radiology. 2025; 317(2): e250708. Article. IF: 17.6; D1
- **Cabezas-Camarero S, Pérez-Alfayate R, García-Barberán V, Gandía-González ML, García-Feijóo P, López-Cade I, Lorca V, Casado-Fariñas I, Cerón MA, Paz-Cabezas M, Sotelo MJ, Conde MG, Delgado HR, Medina YS, Díaz-Millán I, Pérez-Segura P.** ctDNA detection in cerebrospinal fluid and plasma and mutational concordance with the primary tumor in a multicenter prospective study of patients with glioma. Ann Oncol. 2025; 36(6): 660-72. Article. IF: 80.4; D1
- **Cadavid JM, Bravo AM, Barkhaus P, Barnes B, Benatar M, Breevoort S, Brown A, Carter GT, Crayle J, Foucher J, Heiman-Patterson T, Hobson E, Jackson C, Jhooty S, Mallon E, Mcdermott C, Pattee G, Pierce K, Pioro E, Ratner D, Rivner M, Tito E, Wicks P, Bedlack**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

R. ALSUntangled #80: ISRIB (Integrated stress response InhiBitor). Amyotroph Lat Scl Fr. 2025; 26(7-8): 821-4. Article. IF: 2.4; Q3

- **Cadavid JM, Radakovic R, Radakovic C, Benito YM, Esteban SM, Rodríguez-Santos F, Campos TS.** Spanish adaptation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS). Amyotroph Lat Scl Fr. 2025; 26(3-4): 375-8. Article. IF: 2.4; Q3
- **Caro C, Arias-Ramos N, Urbano-Gámez JD, González-Alday R, López-Larrubia P, García-Martín ML.** A multiparametric perspective on C6 and F98 cell lines in orthotopic rat models for glioblastoma research. Sci Rep-Uk. 2025; 15(1): 22547. Article. IF: 4.9; Q1
- **Ciobanu-Caraus O, Grob A, Rohr J, Stumpo V, Ricciardi L, Maldaner N, Eversdijk HAJ, Vieli M, Raco A, Miscusi M, Perna A, Proietti L, Lofrese G, Dughiero M, Cultrera F, D'Andrea M, An SB, Ha Y, Amelot A, Cadelo JB, Vinuela-Prieto JM, Gandía-González ML, Girod PP, Lener S, Koegl N, Abramovic A, Laux CJ, Farshad M, O'Riordan D, Loibl M, Galbusera F, Mannion AF, Scerrati A, De Bonis P, Molliqaj G, Tessitore E, Schroeder ML, Stienen MN, Brandi G, Regli L, Serra C, Staartjes VE.** Sex differences in patient-rated outcomes after lumbar spinal fusion for degenerative disease a multicenter cohort study. Spine. 2025; 50(13): 924-31. Article. IF: 3.7; Q1
- **Cruchaga Carlos, Timsina Jigyasha, Jiang Chenyang, McCartney Daniel, Tao Feifei, Dalmasso Maria Carolina, Najar Jenna, Anastasi Federica, Ohlei Olena, Puerta Raquel, Bradley Joseph, Western Daniel, Ali Muhammad, Wang Ciyang, Yang Chengran, Wu Ying, Liu Menghan, Budde John, Williams Julie, Mahoney Rebecca, Castillo Atahualpa, Hohman Timothy, Dumitrescu Logan, Wang Ting-Chen, Tesi Niccolo, Kern Silke, Waern Margda, Skoog Ingmer, van Harten Argonde, van der Flier Wiesje, Sanchez-Juan Pascual, Rodríguez-Rodríguez Eloy, Kleineidam Luca, Peters Oliver, Schneider Anja, Kucukali Fahri, Bellenguez Celine, Grenier-Boley Benjamin, Heikkinen Sami, de Rojas Itziar, Rujescu Dan, Scherbaum Norbert, Hausner Lucrezia, Duzel Emrah, Grimmer Timo, Wiltfang Jens, Vandenberghe Rik, Engelborghs Sebastiaan, Heilmann-Heimbach Stefanie, Schmid Matthias, Tegos Thomas, Scarmeas Nikolaos, Dols-Icardo Oriol, Moreno Fermin, Pérez-Tur Jordi, Bullido Maria J, Sanchez-Valle Raquel, Alvarez Victoria, García-González Pablo, Mir Pablo, Real Luis, Pinol-Ripoll Gerard, García-Alberca Jose Maria, Seelaar Harro, Ramakers Inez, Papma Janne, Hulsman Marc, Laske Christoph, Teipel Stefan, Priller Josef, Perneczky Robert, Buerger Katharina, Nothen Markus, Lewczuk Piotr, Kornhuber Johannes, Maier Wolfgang, Hampel Harald, Giegling Ina, Goldhardt Oliver, Diehl-Schmid Janine, Andrade Victor, Heneka Michael, Froelich Lutz, Vogelgsang Jonathan, Graff Caroline, Thonberg Hakan, Ullgren Abbe, Papenberg Goran, Boland Anne, Deleuze Jean-Francois, Wagner Michael, Jessen Frank, Holstege Henne, van Duijn Cornelia, Lebouvier Thibaud, Hanon Olivier, Leinonen Ville, Soininen Hilkka, Herukka Sanna-Kaisa, Giedraitis Vilmantas, Lowenmark Malin, Kilander Lena, Genius Patricia, Rodríguez Blanca, Luckett Emma, Navarro Arcadi, Cano Amanda, Marquie Marta, Blennow Kaj, Zetterberg Henrik, Lleo Alberto, Boada Merce, Laza Agustin Ruiz, Lee Virginia, Deerlin Vivianna Van, Deming Yuetiva, Johnson Sterling, Engelman Corinne, Pastor Pau, Alvarez Ignacio, Peskind Elaine, Heslegrave Amanda, Saykin Andrew, Nho Kwangsik, Schindler Suzanne, Morris John, Holtzman David, McDade Eric, Renton Alan, Goate Alison, Ibanez Laura, Riemenschneider Matthias, Albert Marilyn, Laws Simon, Porter Tenielle, O'Brien Eleanor, Shaw Leslie, Tijms Betty, Ingelsson Martin, Visser Pieter Jelle, Hiltunen Mikko, Sleegers Kristel, Ritchie Craig, Sims Rebecca, Lambert Jean-Charles, Vilor-Tejedor Natalia, Fernández Maria, Li Qingqin, Nagle Michael, Marioni Riccardo, Ramirez Alfredo, Bertram Lars, van der Lee Sven.** GWAS meta-analysis of CSF Alzheimer's disease biomarkers 18,948 individuals reveal novel loci and genes regulating lipid metabolism, brain volume and autophagy. Res Sq. 2025 (Prerint)
- **Cunningham C, Hubbard Z, Kasem RA, Elawady SS, Sowlat MM, Matsukawa H, Maier I, Jabbour P, Kim JT, Wolfe SQ, Rai AT, Starke RM, Psychogios MN, Samaniego EA, Goyal N, Yoshimura S, Cuellar H, Howard BM, Alawieh A, Alaraj A, Ezzeldin M, Romano DG, Tanweer O, Mascitelli JR, Fragata I, Polifka AJ, Siddiqui F, Osbun JW, Grandhi R, Crosa RJ, Matouk C, Park MS, Levitt MR, Brinjikji W, Moss M, Daglioglu E, Williamson R, Navia P, Kan P, De Leacy RA, Chowdhry SA, Altschul D, Al Kasab S, Spiotta AM.** Mechanical thrombectomy in elderly stroke patients with low ASPECTS: insights from STAR. J Neurointerv Surg. 2025; 17(E2): e206-15. Article. IF: 4.4; Q1
- **Fernández BM, Solís JFP, Romero MDG, García MAF, de Aragón MR, Benito FC, Pascual SI.** Difficulty of administration of nusinersen in complex-column spinal muscular atrophy: New alternative technique by means of cervical intrathecal access through an Ommaya reservoir. Eur J Paediatr Neuro. 2025; 54: 107-12. Article. IF: 2.9; Q1
- **Fierro-Marrero J, Reina-Varona A, Pardo-Montero J, Paris-Alemany A, La Touche R.** Development and content validity of the evaluation of multidimensional functioning and risks in aging scale. PEERJ. 2025; 13: e20108. Article. IF: 2.9; Q2
- **Fuentes OP, Ballester LL, Troncoso JA, Abánades CIS, Mozo AN, Marhuenda AR, Blanco JJR, Sancerni BG, Rodríguez IE, Mora ET, Robles EM.** Inflammatory cerebral pseudotumour as a rare manifestation of neuro-Behçet's disease: A case report and literature review. J Neuroimmunol. 2025; 405: 578652. Review. IF: 3.1; Q3
- **García-González P, Lara HR, Compta Y, Fernández M, van der Lee SJ, de Rojas I, Saiz L, Painous C, Camara A, Muñoz E, Martí MJ, Valldeoriola F, Puerta R, Illán-Gala I, Pagonabarraga J, Dols-Icardo O, Kulisevsky J, Fortea J, Lleó A, Olivé C, de Boer SCM, Hulsman M, Pijnenburg YAL, Belloso RD, Muñoz-Delgado L, Rueda DB, Gómez-Garre P, Aldecoa I, Aragonés G, Vara JH, Mendioroz M, Pérez-Tur J, Visser PJ, den Braber A, Papma JM, Montes AM, Rodríguez-Rodríguez E, Blázquez-Folch J, Miguel A, García-Gutiérrez F, Cano A, Valero S, Marquié M, Capdevila-Bayo M, Rosende-Roca M, Quintela I, Carracedo A, Tàrraga L, Real LM, Royo JL, Erro ME, Guerrero C, Torres DC, Blázquez-Estrada M, San Millán B, Teijeira S, Rolan DV, Hernández I, Sánchez-Soblechero A, de la Casa-Fages B, López SS, Baviera-Muñoz R, Lavín A, Taipa R, Amer G, Martinez-Saez E, Fernández-Matarrubia M, Lage-Martínez C, Alvarez V, Molina-Porcel L, Holstege H, Mir P, Belbin O, Boada M, Fernández V, Bullido MJ, Rábano A, Sánchez-Juan P, Ruiz A.** A Spanish-Portuguese GWAS of progressive supranuclear palsy reveals a novel risk locus in NFASC. Eur J Hum Genet. 2025; 33(7): 960-5. Article. IF: 4.6; Q1
- **Gómez-González E, Núñez NO, Caro C, García-Martín ML, Moreno JMM, Hamdi A, López-Larrubia P, Becerro AI, Ocaña M.** Sodium lanthanide tungstate-based nanoparticles as bimodal probes for T1-T2 magnetic resonance imaging and X-ray computed tomography. Dalton T. 2025; 54(44): 16562-72. Article. IF: 3.3; Q2
- **Gottschalk S, Koenig HH, Subtil F, Bonekamp S, Denis A, Aamodt AH, Fuentes B, Gizewski ER, Hill MD, Krajina A, Pierot L, Simonsen CZ, Zelenak K, Bendszus M, Thomalla G, Dams J.** Cost-effectiveness of endovascular thrombectomy for acute ischemic stroke with established large infarct in Germany: a decision tree and Markov model. J Neurointerv Surg. 2025; 17(7): 683-90. Article. IF: 4.4; Q1
- **Guasch-Jiménez M, Camps-Renom P, Toscano-Prat C, Guisado-Alonso D, Martinez-Domeño A, Prats-Sánchez L, Ramos-Pachon A, Fernández-Cadenas I, Martínez-González JP, Fernández-Pérez I, Avellaneda-Gómez C, de Celis-Ruiz E, Rodríguez-Pardo J, Freijo MD, Luna A, Moniche F, Pardo-Galiana B, Ortega-Quintanilla J, Arenillas JF, Cortijo E, Martí-Fàbregas J.** Influence of dehydration on collateral circulation and clinical outcome after endovascular therapy in patients with acute ischemic stroke. Neurología. 2025; 40(9): 822-9. Article. IF: 2.8; Q2
- **Guasch-Jiménez M, Dhar R, Kumar A, Cifarelli J, Ezcurra-Díaz G, Lambea-Gil A,**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Ramos-Pachón A, Martínez-Domeño A, Prats-Sánchez L, Guisado-Alonso D, Fernández-Cadenas I, Aguilera-Simón A, Marín R, Martínez-González J, Ortega-Quintanilla J, Fernández-PérezI, Avellaneda-Gómez C, Rodríguez-Pardo J, de Celis E, Moniche F, Freijo M, Cortijo E, Trillo S, Camps-Renom P, Martí-Fábregas J. Early automated cerebral edema assessment following endovascular therapy: impact on stroke outcome. J Neurointerv Surg. 2025; 17(4): 354-9. Article. IF: 4.4; Q1

- **Guillén-Yunta M, Guadaño-Ferraz A, Valcárcel-Hernández V.** Magnetic resonance imaging techniques for investigating the mct8-deficient brain in murine disease models. Methods Mol Biol. 2025; 2876: 175-86. Article. Not Indexed
- **Hermann DM, Bacigaluppi M, Bassetti CL, Bassotti G, Boltze J, Chan A, Dalkara T, Denes A, Diez-Tejedor E, Dodel R, Doeppner TR, Dzyubenko E, ElAli A, Fulop T, Gerhard A, Giebel B, Gronewold J, Gunzer M, Heinbockel T, Huang K, Iriti M, Karnath HO, Trenite KN, Kilic E, Lanza G, Liesz A, Magnus TU, Mandrioli J, Mohamud-Yusuf A, Müller T, Pan S, Peruzzotti-Jametti L, Pluchino S, Pluta R, Popa-Wagner A, Rezayof A, Seghier ML, Shu X, Singh V, Sipilä J, Slevin M, Tang Y, Tsivgoulis G, Varrassi G, Wang C, Yilmaz B, Zaki MS, Zhang J.** Most prominent challenges in translational neuroscience and strategic solutions to bridge the gaps: Perspectives from an editorial board interrogation. Explor Neurosci. 2025; 4: 1006106. Article. Not Indexed
- **Iglesias GT, Chavarría-Miranda A, López-Molina M, del Fresno C, Mata-Martínez P, Nozal P, Chico-García JL, Fernández-Fournier M, Ballester LL, Sanchez D, Montero-Calle A, Barderas R, Bravo S, Puertas I, York E, Díez-Tejedor E, Gutiérrez-Fernández M, Otero-Ortega L.** Extracellular vesicles as novel biomarkers for tumor association in intermediate-risk paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2025; 12(6): e200483. Article. IF: 8.0; Q1
- **Iglesias GT, Martínez-Feito A, Otero-Ortega L, López-Molina M, Puertas I, González-Torbay A, Rita CG, Fernández-Fournier M, Velasco SS, Chamorro B, Díez-Tejedor E, López-Granados E.** Immunological monitoring during anti-cd20 therapies to predict infection risk and treatment response in multiple sclerosis patients. Diseases. 2025; 13(12): 387. Article. IF: 3.7; Q2
- **Jesper Qvist Thomassen Leonard Hampton Brittany Ulms Benjamin Grenier-Boley Sami Heikkinen Pablo García Atahualapa Castillo-Morales Masataka Kikuchi Jungsoo Gim0 Han Cao Fahri Küçükali Najaf Amin Dabin Yoon0 Itziar de Rojas Pilar Alvarez Jerez Victoria Alvarez0 Beatrice Arosio Celine Bellenguez Sverre Bergh Kimberly Billingsley Cornelis Blauwendraat Merce Boada Barbara Borroni Paola Bossù María J Bullido 0 Antonio Daniele Ángel Carracedo Alexandre de Mendonça Mark Cookson Jürgen Deckert Martin Dichgans Srdjan Djurovic 0 Oriol Dols-Icardo Carole Dufouil Emrah Düzel Valentina Escott-Price Tormod Fladby Laura Fratiglioni0 Amy K Y Fu Daniela Galimberti Jose Maria García-Alberca Vilmantas Giedraitis Guillermo García-Ribas Caroline Graff0 Timo Grimmer Edna Grünblatt 0 Olivier Hanon Lucrezia Hausner Stefanie Heilmann-Hemibach Jakub Hort Frank Jessen Kendall Jensen Caroline Jonson Yoontae Kim 0 Nicole Kuznetsov Ville Leinonen 0 Anssi Lipponen Jiao Luo Mary Makarious Henna Martiskainen Carlo Masullo Patrizia Mecocci Shima Mehrabian Pablo Mir Akinori Miyashita Susanne Moebus Kin Y Mok 0 Laura Molina Porcel Fermin Moreno Benedetta Nacmias Lucilla Parnetti Pau Pastor Jordi Pérez-Tur0 Oliver Peters Yolande A L Pijnenburg Gerard Piñol-Ripoll Julius Popp Innocenzo Rainero 00 Luis M Real 0 0 Steffi Riedel-Heller 0 Eloy Rodríguez-Rodríguez0 Arvid Rongve 0 Giacomina Rossi 0 Jose Luis Royo 0 Dan Rujescu 0 0 Ingvild Saltvedt 0 María Eugenia Sáez 0 Raquel Sánchez-Valle Florentino Sanchez-García Nicolai Sandau Nikolaos Scarmeas Katja Scheffler 0 Norbert Scherbaum Anja Schneider Geir Selbæk 0 Davide Seripa Vincenzo Solfrizzi Marco Spallazzi Alessio Squassina Eystein Stordal Niccoló Tesi Lucio Tremolizzo0 Kumar P Tripathi Wiesje M van der Flier Julie Williams Jens Wiltfang Dag Aarsland 0 Andrew B Singleton Philippe Amouyel Stéphanie Debette Gael Nicolas Sven van der Lee Henne Holstege Maria Victoria Fernández Patrick Gavin Kehoe Kristel Sleegers Martin Ingelsson Roberta Ghidoni Ole A Andreassen Peter A Holmans Pascual Sánchez-Juan Rebecca Sims Nancy Y Ip Kun Ho Lee0 Takeshi Ikeuchi Alfredo Ramirez Agustin Ruiz Mikko Hiltunen Jean-Charles Lambert Cornelia van Duijn Mike Nalls Ruth Frikke-Schmidt.** APOE stratified genome-wide association studies provide novel insights into the genetic etiology of Alzheimers's disease. Medrxiv (Prerint) Not Indexed
- **Kniep HC, Gellissen S, Thomalla G, Bendszus M, Winkelmeier L, Broocks G, Bechstein M, Subtil F, Bonekamp S, Aamodt AH, Fuentes B, Gizewski ER, Hill MD, Krajina A, Pierot L, Simonsen CZ, Zelenák K, Blauenfeldt RA, Cheng B, Denis A, Deutschmann H, Dorn F, Flottmann F, Gerber JC, Goyal M, Haring J, Herweh C, Hopf-Jensen S, Hua VT, Jensen M, Kastrup A, Keil CF, Klepanec A, Kurca E, Mikkelsen R, Möhlenbruch M, Müller-Hülsbeck S, Münnich N, Pagano P, Papanagiotou P, Petzold GC, Pham M, Puetz V, Raupach J, Reimann G, Ringleb PA, Schell M, Schlemm E, Schönenberger S, Tennoe B, Ulfert C, Valis K, Vítková E, Vollherbst DF, Wick W, Fiehler J, Meyer L.** Thrombectomy with low ASPECTS: The roles of infarct volume and postacute neurological status. Stroke. 2025; 56(5): 1116-27. Article. IF: 11.1; D1
- **La Touche R, Reina-Varona A, Grande-Alonso M, León-Hernández JV, Pardo-Montero J, Requejo-Salinas N, Ferrer-Peña R, Paris-Alemany A.** Student satisfaction in social media-based learning environments: development, validation, and psychometric evaluation of the cuSAERS (questionnaire of satisfaction with educational activities performed on social media). JMIR Med Educ. 2025; 11: e73805. Article. IF: 13.9; D1
- **Laso-García F, Alonso-López E, Piniella D, Díez-Tejedor E, Frutos MCGD, Casado-Fernández L, Otero-Ortega L, López-Molina MP, Gallego-Ruiz R, Pozo-Novoa J, Calzado-González A, Díaz-Gamero N, Martín ARS, Bravo S, Barderas R, Docando F, Fuentes B, Juárez-Martín B, De Leciñana MA, Gutiérrez-Fernández M.** Infection-driven proteomic signatures in immune cell-derived extracellular vesicles reflect hemorrhagic stroke outcome. J Neuroinflamm. 2025; 23(1): 22. Article. IF: 11.5; D1
- **Laso-García F, Díaz-Gamero N, Gallego-Ruiz R, Casado-Fernández L, Díez-Tejedor E, Calzado-González A, Pozo-Novoa J, Otero-Ortega L, de Leciñana MA, Gutiérrez-Fernández M.** Extracellular vesicles from poor-outcome intracerebral hemorrhage patients reveal limited reparative potential in a preclinical model. Int J Mol Sci. 2025; 26(21): 10648. Article. IF: 5.6; Q1
- **Le Borgne J, Gomez L, Heikkinen S, Amin N, Ahmad S, Choi SH, Bis J, Grenier-Boley B, Rodríguez OG, Kleineidam L, Young J, Tripathi KP, Wang L, Varma A, Campos-Martin R, van der Lee S, Damotte V, de Rojas I, Palmal S, Lipton R, Reiman E, McKee A, De Jager P, Bush W, Small S, Levey A, Saykin A, Foroud T, Albert M, Hyman B, Petersen R, Younkin S, Sano M, Wisniewski T, Vassar R, Schneider J, Henderson V, Roberson E, DeCarli C, LaFerla F, Brewer J, Swerdlow R, Van Eldik L, Hamilton-Nelson K, Paulson H, Naj A, López O, Chui H, Crane P, Grabowski T, Kukull W, Asthana S, Craft S, Strittmatter S, Cruchaga C, Leverenz J, Goate A, Kamboh MI, St George-Hyslop P, Valladares O, Kuzma A, Cantwell L, Riemenschneider M, Morris J, Slifer S, Dalmasso C, Castillo A, Küçükali F, Peters O, Schneider A, Dichgans M, Rujescu D, Scherbaum N, Deckert J, Riedel-Heller S, Hausner L, Molina-Porcel L, Düzel E, Grimmer T, Wiltfang J, Heilmann-Heimbach S, Moebus S, Tegos T, Scarmeas N, Dols-Icardo O, Moreno F, Pérez-Tur J, Bullido MJ, Pastor P, Sánchez-Valle R, Alvarez V, Boada M, García-González P, Puerta R, Mir P, Real LM, Piñol-Ripoll G, García-Alberca JM, Royo JL, Rodríguez-**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Rodríguez E, Soininen H, de Mendonça A, Mehrabian S, Traykov L, Hort J, Vyhnalek M, Thomassen JQ, Pijnenburg YAL, Holstege H, van Swieten J, Ramakers I, Verhey F, Scheltens P, Graff C, Papenberg G, Giedraitis V, Boland A, Deleuze JF, Nicolas G, Dufouil C, Pasquier F, Hanon O, Debette S, Grünblatt E, Popp J, Ghidoni R, Galimberti D, Arosio B, Mecocci P, Solfrizzi V, Parnetti L, Squassina A, Tremolizzo L, Borroni B, Nacmias B, Spallazzi M, Seripa D, Rainero I, Daniele A, Bossù P, Masullo C, Rossi G, Jessen F, Fernández V, Kehoe PG, Frikke-Schmidt R, Tsolaki M, Sánchez-Juan P, Sleegers K, Ingelsson M, Haines J, Farrer L, Mayeux R, Wang LS, Sims R, DeStefano A, Schellenberg GD, Seshadri S, Amouyel P, Williams J, van der Flier W, Ramirez A, Pericak-Vance M, Andreassen OA, Van Duijn C, Hiltunen M, Ruiz A, Dupuis J, Martin E, Lambert JC, Kunkle B, Bellenguez C. X-chromosome-wide association study for Alzheimer's disease. Mol Psychiatr. 2025; 30(6): 2335-46. Article. IF: 10.4; D1

- **Li XY, Wicks P, Brown A, Shivaprasad A, Greene M, Crayle J, Barnes B, Jhooty S, Ratner D, Olby N, Glass JD, Jackson C, Cole N, Armon C, Cadavid JM, Pattee G, Mcdermott CJ, Chang VC, Maragakis N, Bertorini T, Bowser R, Bedlack R.** ALSUntangled #76: Wahls protocol. Amyotroph Lat Scl Fr. 2025; 26(1-2): 181-5. Article. IF: 2.4; Q3
- **Loebel F, Sánchez CV, Álvarez LB, Misch M, Moritz I, Loma MT, Utrilla C, Rodríguez-Domínguez V, Guerrero AI, Vajkoczy P, Gandía-González ML.** Profiles of survival prediction in glioblastoma. Brain Spine. 2025; 5: 104324. Article. IF: 2.7; Q3
- **López-Molina M, Iglesias GT, de Santa María-Díez GS, Valentín-Quiroga J, Laso-García F, Gallego R, Pozo-Novoa J, Chamorro B, López-Collazo E, Puertas I, Díez-Tejedor E, Gutiérrez-Fernández M, Otero-Ortega L.** Immune checkpoint-based biomarkers for therapeutic response in patients with multiple sclerosis. Front Immunol. 2025; 16: 1694021. Article. IF: 7.0; Q1
- **Marcos A, del Cerro MCR, Fernández RM, Pásaro E, Arias-Ramos N, López-Larrubia P, González-Peramato P, Guillamon A, De Miguel MP.** The GnRH agonist triptorelin causes reversible, focal, and partial testicular atrophy in rats, maintaining sperm production. Int J Mol Sci. 2025; 26(14): 6566. Article. IF: 5.6; Q1
- **Mariño E, Rodríguez-Pardo J, Vidal L, Zmork G, Garcíal-Leal A, Díaz-Pollán B, Lacruz L.** Paradoxical reactions of central nervous system tuberculosis: report of three immunocompetent cases. Case Rep Infect Dis. 2025; 2025(1): 5416948. Article. IF: 0.8; Q4
- **Marto JP, Riegler C, Gebert P, Reiff T, Sykora M, Wiacek M, Pakizer D, Araújo A, ter Schiphorst A, Sousa JA, Reich A, Pina BF, Mayer-Suess L, Hobeanu C, Zedde M, Ramos JN, Tsivgoulis G, Castro P, Poli S, Alves JN, Dusart A, Fuentes B, Meza HT, Demeestere J, Wegener S, Kellert L, Calleja P, Panea C, Vollmuth C, Pereira L, Leker RR, Uphaus T, Zini A, Gensicke H, Duloquin G, Ebrahimi T, Salerno A, Tiu C, Nguyen TN, García-Madrona S, Bilik M, Yaghi S, Sienkiewicz-Jarosz H, Karlinski M, Krebs S, Hurtíková E, Ferreira N, Sargento-Freitas J, Pinho J, Caamaño IR, Gizewski ER, Seners P, Pascarella R, Psychogios K, Exposito AG, Gomes S, Bellante F, Rodríguez-Pardo J, Lacambra MB, Lemmens R, Inauen C, Wischmann J, Ostos F, Tiu V, Haeusler KG, Rodrigues M, Metanis I, Hahn M, Viola MM, Truessel S, Bejot Y, Nitsch L, Strambo D, Terecoasa EO, Abdalkader M, de Felipe A, Khan F, Arquizan C, Ribeiro M, Roubec M, Tomaszewska-Lampart I, Ferrari J, Ringleb P, Nolte CH.** Endovascular treatment for isolated cervical internal carotid artery occlusion: ETIICA study. Eur Stroke J. 2025; 10(3): 694-704. Article. IF: 5.2; Q1
- **Marto JP, Strambo D, Ntaios G, Nguyen TN, Wrona P, Escalard S, Marcheselli S, Mansour OY, Fuentes B, Dorobek M, Nowakowska-Kotas M, Terecoasa EO, Coutinho JM, Carvalho-Dias M, Calleja P, Sargento-Freitas J, Paiva-Nunes A, Srámek M, Khandelwal P, Meira T, Abdalkader M, Jabbour P, Kovár M, Ayo-Martin O, Michel P, Marto JP, Strambo D, Ntaios G, Nguyen TN, Wrona P, Escalard S, Marcheselli S, Mansour OY, Fuentes B, Dorobek M, Nowakowska-Kotas M, Terecoasa EO, Coutinho JM, Carvalho-Dias M, Calleja P, Sargento-Freitas J, Paiva-Nunes A, Srámek M, Khandelwal P, Meira T, Abdalkader M, Jabbour P, Kovár M, Ayo-Martin O, Michel P, Herzig R, Czlonkowksa A, Demeestere J, Nogueira RG, Salerno A, Wegener S, Baumgartner P, Cereda CW, Bianco G, Beyeler M, Arnold M, Carrera E, Machi P, Altersberger V, Bonati L, Gensicke H, Bolognese M, Peters N, Wetzel S, Magriço M, Ramos JN, Machado R, Maia C, Machado E, Ferreira P, Pinho-e-Melo T, Paula A, Correia MA, Castro P, Azevedo E, Albuquerque L, Nuno-Alves J, Ferreira-Pinto J, Pereira L, Rodrigues M, Araújo A, Rodrigues M, Rocha M, Pereira-Fonseca A, Ribeiro L, Varela R, Malheiro S, Cappellari M, Zivelonghi C, Sajeva G, Zini A, Gentile M, Forlivesi S, Migliaccio L, Sessa M, La Gioia S, Pezzini A, Sangalli D, Zedde M, Pascarella R, Ferrarese C, Beretta S, Diamanti S, Schwarz G, Frisullo G, Seners P, Sabben C, Piotin M, Maier B, Charbonnier G, Vuillier F, Legris L, Cuisenier P, Vodret FR, Marnat G, Liegey JS, Sibon I, Flottmann F, Broocks G, Gloyer NO, Bohmann FO, Schaefer JH, Nolte CH, Audebert H, Siebert E, Sykora M, Lang W, Ferrari J, Mayer-Suess L, Knoflach M, Gizewski ER, Stolp J, Stolze LJ, Nederkoorn PJ, Van-Den-Wijngaard I, de Meris J, Lemmen R, De Raedt S, Vandervorst F, Rutgers MP, Guilmot A, Dusart A, Bellante F, Ostos F, González-Ortega G, Martín-Jiménez P, García-Madrona S, Cruz-Culebras A, Vera R, Matute MC, Alonso-De-Leciñana M, Rigual R, Díez-Tejedor E, Pérez-Sánchez S, Montaner J, Díaz-Otero F, Pérez-De-La-Ossa N, Flores-Pina B, Muñoz-Narbona L, Chamorro A, Rodríguez-Vázquez A, Renú A, Hernandez-Fernández F, Segura T, Tejada-Meza H, Sagarra-Mur D, Serrano-Ponz M, Hlaing T, See I, Simister R, Werring DJ, Kristoffersen ES, Nordanstig A, Jood K, Rentzos A, Simune L, Krajícková D, Krajina A, Mikulík R, Cviková M, Vinklárek J, Skoloudík D, Roubec M, Hurtikova E, Hruby R, Ostry S, Skoda O, Skoda O, Kocí L, Eichlová Z, Jíra M, Pansky M, Mencl P, Palouskova H, Tomek A, Jansky P, Olserová A, Havlícek R, Maly P, Trakal L, Fiksa J, Slovák M, Karlinsk M, Nowak M, Sienkiewicz-Jarosz H, Bochynska A, Homa T, Sawczynska K, Slowik A, Wlodarczyk E, Wiacek M, Tomaszewska-Lampart I, Sieczkowski B, Bartosik-Psujek H, Bilik M, Bandzarewicz A, Zielinska-Turek J, Obara K, Urbanowski P, Budrewicz S, Guzinski M, Switonska M, Rutkowska I, Sobieszak-Skura P, Labuz-Roszak B, Debiec A, Staszewski J, Stepien A, Zwiernik J, Wasilewski G, Tiu C, Radu RA, Negrila A, Dorobat B, Panea C, Tiu V, Petrescu S, Özcan-Özdemir A, Mahmoud M, El-Samahy H, Abdelkhalek H, Al-Hashel J, Ismail II, Salmeen A, Ghoreishi A, Sabetay S, Gross H, Klein P, El Naamani K, Tjoumakaris S, Abbas R, Mohamed GA, Chebl A, Min JY, Hovingh M, Tsai JP, Khan MA, Nalleballe K, Onteddu S, Masoud HE, Michael M, Kaur N, Maali L, Abraham M, Bach I, Ong M, Babici D, Khawaja AM, Hakemi M, Rajamani K, Cano-Nigenda V, Arauz A, Amaya P, Llanos N, Arango A, Vences MA, Barrientos JD, Caetano R, Targa R, Scollo S, Yalung P, Nagendra S, Gaikwad A, Seo KD.** Recanalization outcomes and procedural complications in patients with acute ischemic stroke and COVID-19 receiving endovascular treatment. J Stroke. 2025; 27(1): 128-32 Letter. IF: 11.0; D1
- **Matsukawa H, Chen HW, Elawady SS, Cunningham C, Uchida K, Sowlat MM, Maier I, Jabbour P, Kim JT, Wolfe SQ, Rai A, Starke RM, Psychogios MN, Samaniego EA, Arthur A, Yoshimura S, Cuellar H, Grossberg JA, Alawieh A, Romano DG, Tanweer O, Mascitelli J, Fragata I, Polifka A, Osbun J, Crosa R, Matouk C, Park MS, Levitt MR, Brinjikji W, Moss M, Williamson R Jr, Navia P, Kan PT, De Leacy R, Chowdhry S, Ezzeldin M, Spiotta AM.** Predicting futile recanalization after endovascular thrombectomy for patients with stroke with large cores: The SNAP score. Neurosurgery. 2025; 96(5): 1080-8. Article. IF: 3.8; Q1
- **Matsukawa H, Uchida K, Elawady SS, Cunningham C, Sowlat MM, Maier I, Jabbour P, Kim JT, Wolfe SQ, Rai A, Starke RM, Psychogios MN, Samaniego EA, Arthur AS,**

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Yoshimura S, Cuellar-Saenz H, Grossberg JA, Alawieh A, Romano DG, Tanweer O, Mascitelli J, Fragata I, Polifka A, Osbun J, Crosa R, Matouk C, Park MS, Levitt MR, Brinjikji W, Moss M, Williamson R Jr, Navia P, Kan P, De Leacy R, Chowdhry S, Ezzeldin M, Spiotta AM. The influence of prestroke disability on outcome in patients with a low Alberta Stroke Program Early CT Score who underwent endovascular thrombectomy. J Neurosurg. 2025; 143(1): 266-73. Article. IF: 3.8; Q1

- **Meyer L, Broocks G, Alexandrou M, Luettich A, Larrea JA, Schwindt W, Krähling H, Naziri W, Behme D, Thormann M, Styczen H, Deuschl C, Kabbasch C, Zaeske C, Weyland C, Petzsche MRH, Maegerlein C, Zimmermann H, Ernst M, Jamous A, Gamazo MM, Pérez-García C, Navia P, Prieto AF, Yeo L, Tan B, Gopinathan A, Siebert E, Miszczuk M, Schob S, Sporns P, Parra JZ, Parrilla G, Arnberg F, Andersson T, Zelenák K, Papanagiotou P, Psychogios M, Möhlenbruch M, Kemmling A, Dorn F, Elsharkawy M, Fiehler J, Stracke CP.** Endovascular versus Best medical treatment for Acute Carotid Occlusion BelOw Circle of Willis (ACOBOW): The ACOBOW Study. Radiology. 2025; 314(1): e240293. Article. IF: 17.6; D1
- **Montero-Pedrazuela A, Grijota-Martinez C, Guadaño-Ferraz A, Barez-López S.** A sensitive radioimmunoassay for T3 and T4 determinations in plasma and tissues. Methods Mol Biol. 2025; 2876: 37-59. Article. Not Indexed
- **Naser PV, Tsitsopoulos P, Zacharias F, Castaño-Leon AM, Buki A, Depreitere B, Van Essen T, Korhonen TK, Mee H, Hossain I, Posti J, Lippa L, Papadopoulos MC, Terpolilli N, Marklund N, Petr O, Toth P, Luoto T, Krieg SM, Unterberg AW, Younsi A, European Cranioplasty Survey Grp (Gandía-González ML).** The current state of cranioplasty in Europe - Results from a European cranioplasty survey. Brain Spine. 2025; 5: 104214. Article. IF: 2.7; Q3
- **Navia P, Barrios AJ, Utrilla C, Fuentes B, Fernández-Prieto A, Álvarez-Muelas A, Frutos R, Marín B, Royo A, García-Raya P, Fernández-Zubillaga A, de Celis E, Puig J, Comas-Cufi M, Arráez-Aybar LA, Garzón G.** Middle cerebral artery M2 occlusions: impact of segment dominance and benefit of direct aspiration for the first-pass effect. J Neuroimaging. 2025; 35(1): e70001. Article. IF: 2.5; Q2
- **Navia P, Fernández-Prieto A, Álvarez-Muelas A, Calleja A, Ortega J, Domínguez C, Sagredo A, Rodríguez-Benítez A, García-Villanego J, Martínez-Calvo A, Cubillo-Prieto D, de la Rosa C, Mosqueira A, Bermejo-Garcés R, Chaviano J, Bermúdez-Coronel I, Pérez-García C, Rodríguez-Paz CM, Hidalgo-Barranco C, Maynar J, Caniego JL, Molina-Nuevo JD, Maestro V, Sanchís-García JM, Balboa O, Martínez-Galdamez M, Garmendia E, Comas-Cufí M, Puig J, Zamarro J.** Contact aspiration alone or combined with stent retriever thrombectomy for middle cerebral artery large vessel occlusion. J Neuroimaging. 2025; 35(4): e70065. Article. IF: 2.5; Q2
- **Nicolas A, Sherva R, Grenier-Boley B, Kim Y, Kikuchi M, Timsina J, de Rojas I, Dalmasso MC, Zhou XP, Le Guen Y, Arboleda-Bustos CE, Bicalho MAC, Guerchet M, van der Lee S, Goss M, Castillo A, Bellenguez C, Küçükali F, Satizabal CL, Fongang B, Yang Q, Peters O, Schneider A, Dichgans M, Rujescu D, Scherbaum N, Deckert J, Riedel-Heller S, Hausner L, Molina-Porcel L, Duezel E, Grimmer T, Wiltfang J, Heilmann-Heimbach S, Moebus S, Tegos T, Scarmeas N, Dols-Icardo O, Moreno F, Pérez-Tur J, Bullido MJ, Pastor P, Sánchez-Valle R, Alvarez V, Cao H, Ip NY, Fu AKY, Ip FCF, Olivar N, Muchnik C, Cuesta C, Campanelli L, Solis P, Politis DG, Kochen S, Brusco LI, Boada M, García-González P, Puerta R, Mir P, Real LM, Pinol-Ripoll G, García-Alberca JM, Royo JL, Rodríguez-Rodríguez E, Soininen H, Heikkinen S, de Mendonça A, Mehrabian S, Traykov L, Hort J, Vyhnalek M, Rasmussen KL, Thomassen JQ, Pijnenburg YAL, Holstege H, van Swieten JC, Seelaar H, Claassen JAHR, Jansen WJ, Ramakers I, Verhey F, van der Lugt A, Scheltens P, Ortega-Rojas J, Mera AGC, Mahecha MF, Pardo R, Arboleda G, Bahrami S, Fominykh V, Selbaek G, Graff C, Papenberg G, Giedraitis V, Boland A, Deleuze JF, de Marco LA, de Moraes EN, Viana BD, Cintra MTG, Juarez-Cedillo T, Griswold AJ, Forund T, Haines J, Farrer L, Destefano A, Wijsman E, Mayeux R, Pericak-Vance M, Kunkle B, Goate A, Schellenberg GD, Vardarajan B, Wang LS, Leung YY, Dalgard CL, Nicolas G, Wallon D, Dufouil C, Pasquier F, Hanon O, Debette S, Gruenblatt E, Popp J, Angel B, Gloger S, Chacon MV, Aranguiz R, Orellana P, Slachevsky A, González-Billault C, Albala C, Fuentes P, Sachdev P, Mather KA, Hauger RL, Merritt V, Panizzon M, Zhang R, Gaziano JM, Ghidoni R, Galimberti D, Arosio B, Mecocci P, Solfrizzi V, Parnetti L, Squassina A, Tremolizzo L, Borroni B, Nacmias B, Caffarra P, Seripa D, Rainero I, Daniele A, Piras F, Leonard HL, Yokoyama JS, Nalls MA, Miyashita A, Hara N, Ozaki K, Niida S, Williams J, Masullo C, Amouyel P, Preux PM, Mbelesso P, Bandzouzi B, Saykin A, Jessen F, Kehoe PG, Van Duijn C, Ben Salem N, Frikke-Schmidt R, Cherni L, Greicius MD, Tsolaki M, Sánchez-Juan P, Silva MAR, Porter T, Laws SM, Sleegers K, Ingelsson M, Dartigues JF, Seshadri S, Rossi G, Morelli L, Hiltunen M, Sims R, van der Flier W, Andreassen OA, Arboleda H, Cruchaga C, Escott-Price V, Ruiz A, Lee KH, Ikeuchi T, Ramirez A, Gim J, Logue M, Lambert JC.** Transferability of European-derived Alzheimer's disease polygenic risk scores across multiancestry populations. Nat Genet. 2025; 57(7): 1598-610. Article. IF: 25.5; D1
- **Parvin R, El-Hajj VG, Staartjes VE, Ricciardi L, Gandía-González M, Feijoo PG, Núñez MTF.** How I do it: simple ad-hoc pulsatile pump model for realistic microsurgical training under pulsatile flow. Acta Neurochir. 2025; 167(1): 220. Article. IF: 1.9; Q2
- **Pastor-Yvorra S, Dahl-Cruz F, Ramírez-Torres M, Ubago IDMD, de Donlebun JRP, Rigual-Bobillo R, de Celis-Ruiz E, Leciñana-Cases MAD, Frutos-Martínez R, Marín-Aguilera B, Fernández-Prieto A, Fuentes-Gimeno B, Díez-Tejedor E, Ruiz-Ares G.** Transcranial duplex ultrasound as an outcome predictor tool in spontaneous intracerebral hemorrhage. World Neurosurg. 2025; 198: 124010. Article. IF: 2.0; Q2
- **Pérez-Liva M, de Leciñana MA, Gutiérrez-Fernández M, Dias JCS, Cruza J, Rodríguez-Pardo J, García-Suárez I, Laso-García F, Herraiz JL, Segura LE.** Dual photoacoustic/ultrasound technologies for preclinical research: current status and future trends. Phys Med Biol. 2025; 70(7): 07TR01. Review. IF: 3.1; Q2
- **Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, Ma CS, Goodman SG, Oldgren J, Hammett C, Lopes RD, Akao M, De Caterina R, Kirchhof P, Gorog DA, Hemels M, Rienstra M, Jones WS, Harrington J, Lip GYH, Ellis SJ, Rockhold FW, Neumann C, Alexander JH, Viethen T, Hung J, Coppolecchia R, Mundl H, Caso V; (Fuentes B).** Asundexian versus Apixaban in patients with atrial fibrillation. New Engl J Med. 2025; 392(1): 23-32. Article. IF: 84.5; D1
- **Portocarrero-Sánchez L, Rizea C, Díez-Tejedor E, León-Ruiz M, Díaz-de-Terán J.** Evaluating repetitive transcranial magnetic stimulation for refractory chronic cluster headache prevention: insights from a randomized crossover pilot trial. Brain Sci. 2025; 15(6): 554. Article. IF: 3.4; Q2
- **Prego-Domínguez J, Laso-García F, Palomar-Alonso N, Pérez-Mato M, López-Arias E, Dopico-López A, Hervella P, Gutiérrez-Fernández M, de Leciñana M, Polo E, Pelaz B, del Pino P, Campos F, Correa-Paz C.** Nanoparticles for thrombolytic therapy in ischemic stroke: a systematic review and meta-analysis of preclinical studies. Pharmaceutics. 2025; 17(2): 208. Review. IF: 6.9; Q1
- **Puerta R, de Rojas I, García-González P, Olivé C, Sotolongo-Grau O, García-Sánchez A, García-Gutiérrez F, Montrreal L, Tartari JP, Sanabria A, Pytel V, Lage C, Quintela I, Aguilera N, Rodríguez-Rodríguez E, Alarcón-Martín E, Orellana A, Pastor P, Pérez-Tur J, Piñol-Ripoll G, de Munain AL, García-Alberca JM, Royo JL, Bullido MJ, Álvarez V, Real LM, Anchuelo AC, Gómez-Garre D, Larrad MTM, Franco-Macías E, Mir P, Medina M, Sánchez-Valle R, Dols-Icardo O, Sáez ME, Carracedo A, Tárraga L, Alegret M, Valero S, Marquié M, Boada M, Juan PS, Cavazos JE, Cabrera-Socorro A, Cano A, Ruiz A, Alzheimers Dis**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Neuroimaging Initiative. Linking genomic and proteomic signatures to brain amyloid burden: insights from GR@ACE/DEGESCO. Funct Integr Genomic. 2025; 25(1): 73. Article. IF: 4.0; Q2

- **Rodrigo-Gisbert M, Ribo M, Möhlenbruch M, Nayak S, Cognard C, Fiehler J, Defreyne L, González E, Vega P, Tsang A, Orion D, Piasecki P, Ribeiro M, Fernández-Prieto A, Gentric JC, Vila O, Elsheikh S, Barbier C, Machi P, Stockx L, Costalat V, Lylyk P, González A, Lagios K, Naggara O, Spelle L, Larrea JA, Eker OF, Lobotesis K, Rautio R, Mordasini P.** Contemporary results of mechanical thrombectomy and impact of first-line technique on outcome: The INSPIRE-S Global Registry. Am J Neuroradiol. 2025; 46(11): 2285-91. Article. IF: 3.5; Q2
- **Rodríguez-Pardo J, Carneado-Ruiz J, Martínez-Martínez M, Moltó-Jordá JM, Irimia P, Serena-Leal J, Ayo-Martín O, Martínez-Sánchez P, Pagola J, Fernández-Domínguez J.** Status of Neurosonology in Spain. A study from the Spanish Society of Neurosonology (SONES). Neurologia. 2025; 40(6): 548-57. Article. IF: 2.8; Q2
- **Ruiz-Vitte A, Gutiérrez-Fernández M, Laso-García F, Piniella D, Gómez-de Frutos MC, Díez-Tejedor E, Gutiérrez A, Alonso de Leciñana M.** Ledged beam walking test automatic tracker: artificial intelligence-based functional evaluation in a stroke model. Comput Biol Med. 2025; 186: 109689. Article. IF: 6.3; D1
- **Sagris D, Korompoki E, Strambo D, Mavraganis G, Michel P, Eskandari A, Vemmos K, Lastras C, Rodríguez-Pardo J, Fuentes B, Díez-Tejedor E, Tiili P, Lehto M, Putaala J, Cuadrado-Godia E, Farington-Terrero E, Arauz A, Kamel H, Rosales JS, Pérez MSR, Schneider MG, Barboza M, Tsiskaridze A, Ntaios G.** Prevalence and factors associated with carotid stenosis in acute ischemic stroke patients with atrial fibrillation. Neuroepidemiology. 2025; 59(2): 140-9. Article. IF: 2.9; Q2
- **Sánchez CV, Rodríguez MIE, García AP, Taravilla-Loma M, Rodríguez-Domínguez V, Rodríguez-Antolín C, Rosas-Alonso R, Losantos-García I, Guerrero AI, Gandía-González ML.** Clinical impact of a next-generation sequencing approach for glioblastoma patients. Cancers (Basel). 2025; 17(5): 744. Article. IF: 4.8; Q2
- **Sánchez-Kuhn A, Fernández-Martín P, Rodríguez-Herrera R, García-Pinteño J, León JJ, Soto-Ontoso M, Amaya-Pascasio L, de Leciñana MA, Martínez-Sánchez P, Flores P.** Lower reward sensitivity in frontostriatal stroke: Influence of depression and resting-state functional connectivity. Cogn Affect Behav Ne. 2025; 25(6): 1779-94. Article. IF: 3.6; Q1
- **Schär RT, Wilson JR, Ivanov M, Barbagallo G, Petrova Y, Reizinho C, González MLG, Tessitore E, Maciejczak A, Gabrovsky N, Depreitre B, Shiban E, Demetriades AK, Ringel F.** Treatment practices for geriatric type II odontoid fractures-A survey by the European Association of Neurosurgical Societies Spine Section. Brain Spine. 2025; 5: 104295. Article. IF: 2.7; Q3
- **Taravilla-Loma M, Giner García J, Rodríguez-Domínguez V, García-Feijoo P, Gandía-González ML, Isla Guerrero A.** Robot-assisted lumbar fixation in single lateral position: OLIF L4-5, ALIF L5-S1, and L4-S1 percutaneous pedicle screws. Neurosurg Focus Video. 2025; 13(1): V4. Article. Not Indexed
- **Tirado-García P, Ferreiro A, González-Alday R, Arias-Ramos N, Lizarbe B, López-Larrubia P.** Aquaporin-4 inhibition alters cerebral glucose dynamics predominantly in obese animals: an MRI study. Sci Rep-Uk. 2025; 15(1): 15649. Article. IF: 4.9; Q1
- **Torres-Iglesias G, López-Molina M, Ayala-Suárez R, Egido B, Laso-García F, Chamorro B, Puertas I, Fernández-Fournier M, Montero-Calle A, Barderas R, Alonso-López E, Díez-Tejedor E, Gutiérrez-Fernández M, Ortega LO.** Extracellular vesicle-derived microRNAs as a biomarker for therapeutic response in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2025; 12(4): e200420. Article. IF: 8.0; Q1
- **Vázquez P, Escalona-Garrido C, Pescador N, Hitos AB, González-Moreno D, de Benito-Bueno A, Sierra-Filardi E, Boya P, Montero-Pedrazuela A, Guadaño-Ferraz A, Valverde AM.** Sirtuin 1 overexpression in mice preserves insulin and thermogenic responses in subcutaneous inguinal white adipose tissue under proinflammatory conditions. J Physiol Biochem. 2025; 81(4): 1019-35. Article. IF: 5.1; Q1
- **Winkelmeier L, Kniep H, Thomalla G, Bendszus M, Subtil F, Bonekamp S, Aamodt AH, Fuentes B, Gizewski ER, Hill MD, Krajina A, Pierot L, Simonsen CZ, Zelenák K, Blauenfeldt RA, Cheng BS, Denis A, Deutschmann H, Dorn F, Gellissen S, Gerber JC, Goyal M, Haring J, Herweh C, Hopf-Jensen S, Hua VT, Jensen M, Kastrup A, Keil CF, Klepanec A, Kurca E, Mikkelsen R, Möhlenbruch M, Müller-Hülsbeck S, Münnich N, Pagano P, Papanagiotou P, Petzold GC, Pham M, Puetz V, Raupach J, Reimann G, Ringleb PA, Schell M, Schlemm E, Schönenberger S, Tennoe B, Ulfert C, Valis K, Vitková E, Vollherbst DF, Wick W, Fiehler J, Flottmann F, Tension Investigators.** Arterial collaterals and endovascular treatment effect in acute ischemic stroke with large infarct: a secondary analysis of the TENSION Trial. Radiology. 2025; 314(2): e242401. Article. IF: 17.6; D1
- **Zorowitz RD, Barrenechea LS, Butet S, Groppa S, Herrero DH, Prasad R, Sandars S, Meloni S, Page S, Maisonobe P, Picelli A.** How many stroke survivors develop problematic spasticity requiring pharmacological therapy? An international (Europe and USA) observational study protocol. BMJ Open. 2025; 15(1): e087404. Article. IF: 2.5; Q2

Research projects

- **Alonso de Leciñana Cases M, Gutiérrez Fernández MD.** Desarrollo de un tratamiento basado en administración de proteínas encapsuladas para mejorar la recuperación funcional tras una hemorragia cerebral. Una aproximación traslacional (PI23/00436). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Alonso López E.** Estudio de las isoformas de TAU en las Vesículas Extracelulares de la Unidad Neuronal-Glial-Vascular como Biomarcadores plasmáticos en la Enfermedad de Alzheimer y en su diagnóstico diferencial con otras Taupatías y con la Demencia Vascular. FIBHULP. 2025-2026. Managment centre: FIBHULP
- **Díaz de Terán Velasco FJ, Gil Martínez A.** Búsqueda de predictores al estimulador del nervio occipital en pacientes con cefalea en racimos crónica refractaria (PI24/01254). ISCIII. 2025-27. Managment centre: FIBHULP
- **Díez Tejedor E, Otero Ortega L.** Moléculas moduladores del sistema inmune como biomarcadores de respuesta al tratamiento en esclerosis múltiple: estudio traslacional (PI21/00918). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Fuentes Gimeno B.** Ensayo clínico piloto dulcinea (dubbing language-therapy cinemabased in aphasia post-stroke). A feasibility cross-over pilot-trial (FUENTES GIMENO 5405 CAIXA). Fundacion Bancaria Caixa D'estalvis i Pensions de Barcelona La Caixa. 2019-2025. Managment centre: FIBHULP
- **Fuentes Gimeno B.** Glucemia y daño cerebral por isquemia reperfusión en pacientes con infarto cerebral agudo tratados con trombectomía mecánica. Estudio GLIAS-TM (PI21/00962). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Gil Martínez A.** Efectividad de un programa de ejercicios en pacientes con enfermedad de COVID-19 ingresados en planta del Hospital Universitario La Paz (Gil Martinez-COVID PI-4109). Colegio Oficial de Fisioterapeutas de la Comunidad de Madrid. 2020-2025. Managment centre: FIBHULP
- **Guadaño Ferraz A.** Regulation of thyroid hormone availability during neurodevelopment in health and disease (PID2023-152523OB-I00). MICINN. 2024-2027. Managment centre: IIBM
- **Gutiérrez Fernández MD.** Descifrando el papel de las vesículas extracelulares como modulares de la respuesta inmunológica para promover la recuperación tras hemorragia intracerebral: estudio translacional (PI20/00243). ISCIII. 2021-2025. Managment centre: FIBHULP
- **Hernández Herrero D.** Primer portofolio de dispositivos de uso doméstico destinado a la rehabilitación de pacientes afectados por trastornos de la marcha (PMPTA22/00212). ISCIII. 2023-2025. Managment centre: FIBHULP

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

- **Palomo Ruiz MV.** A TDP-43 sensor for the diagnosis of neurodegenerative diseases (LCF/TR/CI25/56020021). Fundación la Caixa. 2025-2027. Managment centre: IMDEA Nanociencia
- **Palomo Ruiz MV.** ELA Sight. HealthStart Madrid. 2025-2026. Managment centre: IMDEA Nanociencia
- **Rodríguez de Rivera Garrido FJ.** Validación de una plataforma tecnológica basada en la reprogramación del sistema inmunológico en humanos; Leading Asset en Miastenia Gravis (CPP2023-010523). MICINN. 2024-2027. Managment centre: FIBHULP
- **Rodríguez Pardo de Donlebun J.** Diagnóstico y tratamiento de enfermedades cerebrovasculares mediante tecnologías de imagen y terapia multimodal avanzadas (TEC-2024/TEC-43). CM. 2025-2028. Managment centre: FIBHULP

Cibers and Retics

- **Bullido Gómez-Heras MJ.** Centro de Investigación en Red de Enfermedades neurodegenerativas (CIBERNED) (CB06/05/0007). ISCIII. (31/12/2024). FIBHULP
- **Fuentes Gimeno B.** Enfermedades vasculares cerebrales (RICORS/RD24/0009/0009). ISCIII. (31/12/2025). FIBHULP
- **Otero Ortega L.** Inflamación (RICORS/RD21/0002/CRG11). ISCIII. (31/12/2025). FIBHULP

Clinical Trials

- **Díaz De Terán Velasco Fj.** An interventional efficacy and safety, phase 3, double-blind, parallel-group study to investigate intermittent prevention of menstrual migraine with rimegepant compared with placebo in women participants 18 to 45 years of age.
  Type/Phase: III
  Sponsored by: Pfizer Inc.
  Signature date: 04/09/2025
- **Díaz De Terán Velasco Fj.** Ensayo clínico de fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico y con un período de extensión para evaluar la eficacia y la seguridad de inyecciones de xeomin® para la prevención de la migraña crónica.
  Type/Phase: III
  Sponsored by: Merz Therapeutics Gmbh.
  Signature date: 30/07/2025
- **Díaz De Terán Velasco Fj.** Ensayo clínico de fase III, aleatorizado, doble ciego, controlado con placebo, multicéntrico y con un período de extensión para evaluar la eficacia y la seguridad de inyecciones de xeomin® para la prevención de la migraña episódica.
  Type/Phase: III
  Sponsored by: Merz Therapeutics Gmbh.
  Signature date: 24/09/2025
- **Díaz De Terán Velasco Fj.** Ensayo en fase IV, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y tolerabilidad de rimegepant para el tratamiento agudo de migraña en adultos no aptos para el uso de triptanos.
  Type/Phase: IV
  Sponsored by: Biohaven Pharmaceuticals.
  Signature date: 25/03/2025
- **Díaz De Terán Velasco Fj.** Estudio de fase II, aleatorizado, multicéntrico, de tratamiento con grupos paralelos y con enmascaramiento doble para investigar la seguridad y eficacia de medi0618 subcutáneo en la reducción de los días de cefalea migrañosa en comparación con placebo en participantes adultos con migraña episódica.
  Type/Phase: II
  Sponsored by: Astrazeneca Ab.
  Signature date: 17/10/2025
- **Díaz De Terán Velasco Fj.** Estudio de fase II/III, multicéntrico, de preinclusión de 8 semanas de duración, seguido de un estudio prospectivo, de grupos paralelos, doble ciego, aleatorizado, controlado con placebo y de retirada de 12 semanas de duración, con una extensión abierta de 52 semanas, para evaluar la eficacia y la seguridad de 1,5 mg a 3,5 mg diarios de basimglurant en pacientes con dolor asociado a neuralgia del trigémino con respuesta subóptima a su tratamiento actual contra el dolor.
  Type/Phase: II
  Sponsored by: Noema Pharma Ag.
  Signature date: 27/02/2025
- **Díaz De Terán Velasco Fj.** Estudio fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo con una extensión abierta para evaluar la eficacia, la seguridad y la tolerabilidad de atogepant para el tratamiento preventivo de la migraña menstrual.
  Type/Phase: III
  Sponsored by: Abbvie Deutschland GMBH & Co. Kg.
  Signature date: 27/06/2025
- **Díaz De Terán Velasco Fj.** Real-world prospective study on the use of anti-cgrp drugs in migraine.
  Type/Phase: EOm prospectivo
  Sponsored by: Fundacio Hospital Vall D'Hebron.
  Signature date: 15/04/2025
- **Díez Tejedor E.** A randomized, double-blind, placebo-controlled phase 3 trial of descartes-08 in patients with generalized myasthenia gravis (mg).
  Type/Phase: III
  Sponsored by: Cartesian Therapeutics Inc.
  Signature date: 06/08/2025
- **Díez Tejedor E.** A randomized, double-blind, placebo-controlled phase 3 trial of descartes-08 in patients with generalized myasthenia gravis (mg).
  Type/Phase: III
  Sponsored by: Cartesian Therapeutics Inc.
  Signature date: 29/10/2025
- **Díez Tejedor E.** Estudio de fase III multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la seguridad y la eficacia de sovateltida en pacientes con accidente cerebrovascular isquémico agudo.
  Type/Phase: III
  Sponsored by: Pharmazz, Inc.
  Signature date: 17/03/2025
- **Frank García A.** A multicenter, randomized, double-blind, placebo-controlled, flexible-dose study to assess the efficacy, safety, and tolerability of iti-1284 in patients with psychosis associated with alzheimer's disease.
  Type/Phase: IIb
  Sponsored by: Intra-Cellular Therapies, Inc.
  Signature date: 15/07/2025
- **Fuentes Gimeno B.** Optimización de la reperfusión para mejorar el desenlace y la función neurológica (orion: optimizing reperfusion to improve outcomes and neurologic function): estudio en fase II/III, multicéntrico, doble ciego, controlado con placebo, aleatorizado y de grupos paralelos para evaluar la eficacia y la seguridad de jx10 en el ictus isquémico agudo con manifestaciones tardías.
  Type/Phase: II
  Sponsored by: Corxel Pharmaceuticals Hong Kong Limited.
  Signature date: 10/07/2025
- **Fuentes Gimeno B.** Salacunar (laci-2-polyphenols): ensayo clínico multicéntrico aleatorizado y comparado con práctica clínica habitual para evaluar la eficacia de un extracto de salicornia rico en polifenoles en la progresión del deterioro cognitivo en una cohorte de pacientes con infartos lacunares.
  Type/Phase:
  Sponsored by: Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla.
  Signature date: 06/10/2025
- **Fuentes Gimeno B.** Statins use in intracerebral hemorrhage patients.
  Type/Phase: III
  Sponsored by: Institut De Recerca De L'Hospital De Santa Creu I Sant Pau.
  Signature date: 29/01/2025
- **García Feijoo P.** Ensayo clínico de fase 1b/2a en lesión aguda de la médula espinal: ensayo de prueba de concepto, de ocultación simple, aleatorizado para la determinación de la seguridad, tolerabilidad y eficacia de tz-161.
  Type/Phase: IIa
  Sponsored by: Technophage S.A.
  Signature date: 31/03/2025
- **Hernández Barral M.** Estudio de fase II, aleatorizado, doble ciego, comparativo con placebo y con grupos paralelos del vhb937 de la esclerosis lateral amiotrófica (ela) de 40 semanas de duración seguidas de una prolongación en abierto (astrals).
  Type/Phase: II
  Sponsored by: Novartis Pharma Services Ag.
  Signature date: 27/01/2025
- **Hernández Herrero D.** Estudio prospectivo y multinacional para estimar la incidencia de espasticidad posterior a un accidente cerebrovascular y proporcionar un modelo de

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



mejores prácticas para supervisar su aparición. epitome study.
Type/Phase: No EPA
Sponsored by: Ipsen Pharma S.P.S.
Signature date: 13/11/2025

- **Martín Montes A.** Desarrollo y validación de biomarcadores digitales para el diagnóstico precoz del deterioro cognitivo leve.
Type/Phase: PRODUCTO SANITARIO
Sponsored by: Martín Montes, Ángel.
Signature date: 26/06/2025
- **Merino Andreu M.** Epidemiology of narcolepsy type 1 and type 2 in spain. hypnos study.
Type/Phase: EOm no prospectivo
Sponsored by: Takeda Farmaceutica España, S.A. (Antes - Nycomed Pharma S.A.).
Signature date: 11/12/2025
- **Navía Álvarez P.** Prospective, single-arm, multicentre study to evaluate the efficacy and safety of the instroke 4f thromboaspiration catheter in patients with acute ischaemic stroke due to primary distal medium vessel occlusions (dmvo).
Type/Phase: OTROS
Sponsored by: Ivascular.
Signature date: 26/11/2025

Patents and Trademarks

- **Valdivieso Amate F, Bullido Gómez-Heras MJ, Martínez García A, inventors; UAM, assignee.** Method of identifying compounds that induce or inhibit endoplasmic reticulum stress or oxidative stress. P200702997, PCT/ES2008/000705, EP2221379, US20100304384; 2007 November 13.
- **Vergés Milano J, García García A, Ruhí Roura R, Montell Bonaventura E, García López M, Aláez Versón CR, Escaich Ferrer J, Egea Máiquez J, Lorrio González S, Negredo Madrigal P, inventors; BIOIBÉRICA S.**A., UAM, assignees. Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases. P200902399, PCT/EP2010/070613, US20120309707, CA20102785237; 2010 December 22.
- **Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C, Sastre Merlín I, inventors; UAM, CSIC, assignees.** Method of identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases caused by human herpes viruses. P200400965, PCT/ES2005/000209, EP1769677, US20070218004, ATE447321, AU2005235319, CA2562787, JP2007533315; 2004 April 21.
- **Valdivieso Ámate F, Montoliú JL, Pozueta Larios J, inventors; UAM, CSIC, assignees.** Alzheimer's disease animal model, method for obtaining same and uses thereof. P200503002, PCT/ES2006/000673, EP1956091, EP20060841725, US20090222932, CA2638983, JP2009517066; 2005 December 02.
- **Ballesteros García P, López Larrubia P, Domínguez Mateo L, Marco Contelles JL, Cerdán García-Esteller S, inventors; Universidad Nacional de Educación a Distancia, CSIC, assignees.** Set of magnetic resonance imaging and spectroscopy cell acidity extrinsic indicators comprise polyol derivatives based on alditols. P200300936; 2003 April 23.
- **Gil-Martínez A, inventors; FIBHULP, assignees.** Specular Face. 4022981/5. 2019 December 10
- **Egea Máiquez FJ, Farré Alins V, Palomino Antolín A, Narros Fernández P, Martins Rosa J, Parada Pérez E, Hernández García BJ, Roda Frade JM, Yus Teruel S, Lagares Gómez-Abascal A, Sánchez Carabias C, Gandía Juan L, inventors; Fundación Hospital La Princesa, FIBHULP, Fundación Hospital 12 de Octubre, UAM, assignees.** Method for determining the progression of acute brain damage and pharmaceutical composition for its treatment. P202031194, PCT/ES2021/070856; 2020 November 30.
- **Gil Martínez A, Gil Castillo J, inventors; FIBHULP, Centro Superior de Estudio Universitarios La Salle, Javier Gil Castillo, assignees.** Dispositivo de medición y/o entrenamiento de la fuerza o presión de los músculos de la cavidad oral y su uso para rehabilitación. MU 1201U MU202230128. 2022 July, 26.
- **Alonso de Leciñana M, Díez Tejedor E, Fuentes Gimeno B, Rodríguez-Pardo de Donlebun J, Lopez Martín D, Gutierrez Martín A and Fernandez Martín F, authors; FIBHULP and Universidad Politécnica de Madrid, assignee.** Trademark name: Neuro Data Tracker; ESM 018860324; 2023 April 11
- **Martín Montes A, Blanco de Miguel D, Rodríguez-Pardo de Donlebun J, Medina López A, Alonso de Leciñana Cases M, Frank García A, inventors; FIBHULP, assignee.** Cognipaz. Nº019095718; 2024 October 24.
- **Ruiz Ares G, Fuentes Gimeno B, Martín Alonso M, Juárez Martín B, Alonso de Leciñana M, Belinchón Jiménez IH, Payo Tante A, inventors; FIBHULP, assignes.** Vaso disfagia. U202530874, ES1320336. 2025 may 15

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.1.3 Neuroprotective Strategies in Neurodegenerative Diseases



Publications: 12 | Q1:11

COMPOSITION

Ana Isabel Rojo Sanchís.
Profesora Titular. Universidad Autónoma de Madrid

- **Daniel Carnicero Senabre.** *Investigador Predoctoral. Universidad Autónoma de Madrid*
- **Eduardo Cazalla Ibáñez.** *Investigador Predoctoral. Universidad Autónoma de Madrid*
- **Antonio Cuadrado Pastor.** *Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid*
- **María Isabel Escoll Guerrero.** *Investigadora Postdoctoral. CIBERNED*
- **Raquel Fernández Ginés.** *Investigadora Postdoctoral. Universidad Autónoma de Madrid*
- **Ángel Juan García Yagüe.** *Investigador Postdoctoral. CIBERNED*
- **Ángela Martínez Valverde.** *Científica Titular. CSIC. IIB "Sols-Morreale"/UAM-CISC*
- **Patricia Rada Llano.** *Investigadora Postdoctoral. CIBERNED*

STRATEGIC OBJETIVES

- Oxidative stress is a key element in the etiopathogenesis of neurodegenerative diseases and their comorbidities. Our laboratory studies the antioxidant protection mechanisms activated by extracellular signals and how this response could be pharmacologically regulated to provide a therapeutic benefit in these diseases.
- To achieve these two objectives, we are studying signaling pathways that regulate antioxidant metabolism and provide a general protective response. A key finding of this group was the observation that the PI3K/AKT/GSK-3 survival pathway regulates the transcription factor NRF2, a guardian of cellular redox homeostasis, which provides protection against oxidative, inflammatory, and proteotoxic stress. Over the past year, we have been working on validating this transcription factor as a novel therapeutic target to modify the progression of Parkinson's and Alzheimer's diseases, as well as comorbid retinopathy and type II diabetes.

RESEARCH LINES

- Role of oxidative stress in neuronal death and neuroinflammation in neurodegenerative diseases
- Validation of NRF2 as a new therapeutic target in neurodegenerative diseases.
- Use of the NRF2 transcriptional signature as a biomarker of prognosis, progression, and therapeutic efficacy
- Identification of NRF2 activating compounds by inhibiting their interaction with β-TrCP.
- Relevance of the NRF2 transcriptional signature in altered molecular processes in ALS models
- Molecular basis of the role of Nrf2 in type 2 diabetes and its complications (diabetic retinopathy and nephropathy)

RESEARCH ACTIVITY

Doctoral Theses

- **Carnicero Senabre D.** Defining the role of transcription factor NRF2 in the maintenance of synaptic homeostasis[dissertation]. Madrid: UAM: 2025(04/07/2025). Director: Rojo Sanchís AI.
- **Jiménez Villegas J.** NRF2 at the intersection of redox imbalance and stress granule dynamics in amyotrophic lateral sclerosis[dissertation]. Madrid: UAM: 2025(27/10/2025). Director: Rojo Sanchís AI.

Publications

- **Buttari B, Tramutola A, Rojo AI, Chondrogianni N, Saha S, Berry A, Giona L, Miranda JP, Profumo E, Davinelli S, Daiber A, Cuadrado A, Di Domenico F.** Proteostasis decline and redox imbalance in age-related diseases: the therapeutic potential of NRF2. Biomolecules. 2025; 15(1): 113. Review. IF: 5.6; Q1
- **Carnicero-Senabre D, Barata MA, Jimenez-Villegas J, Almeida CG, Cuadrado A, Rojo AI.** NRF2 deficiency is associated with synaptic

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

alterations and ether-linked phospholipid imbalance in the hippocampus. Redox Biol. 2025; 86: 103853. Article. IF: 16.2; D1

- **Cuadrado A, Cazalla E, Bach A, Bathish B, Naidu SD, Denicola GM, Dinkova-Kostova AT, Fernández-Ginés R, Grochot-Przeczek A, Hayes JD, Kensler TW, León R, Liby KT, López MG, Manda G, Shivakumar AK, Hakomaki H, Moerland JA, Motohashi H, Rojo AI, Sykiotis GP, Taguchi K, Valverde AM, Yamamoto M, Levonen AL.** Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases. Redox Biol. 2025; 81: 103569. Article. IF: 16.2; D1
- **Duarte P, Sánchez-Porro FJ, Crisman E, Cores A, Jiménez I, Cuadrado A, Menéndez JC, León R.** Network-based drug optimization toward the treatment of Parkinson's disease: NRF2, MAO-B, oxidative stress, and chronic Neuroinflammation. J Med Chem. 2025; 68(3): 3495-517. Article. IF: 7.3; Q1
- **Fernández-González I, Freire-Agulleiro O, Ferreira V, Silveira-Loureiro M, Rial-Pensado E, Garrido-Gil P, Martínez G, Rada P, Labandeira-García JL, Mittag J, González-García I, Diéguez C, Nogueiras R, Valverde AM, Davis RJ, Sabio G, Barca-Mayo O, López M.** JNK1 in SF1 neurons regulates the central action of thyroid hormones on hepatic lipid metabolism. Mol Metab. 2025; 98: 102170. Article. IF: 6.3; Q1
- **García-Yague AJ, Cañizares-Moscato L, Encinar JA, Cazalla E, Fernández-Ginés R, Escoll M, Rojo AI, Cuadrado A.** A novel β-TrCP1/NRF2 interaction inhibitor for effective anti-inflammatory therapy. J Biomed Sci. 2025; 32(1): 65. Article. IF: 14.5; D1
- **García-Yagüe AJ, Cueto-Díaz EJ, Escoll M, Okunishi I, Hayes JD, Rodríguez-Franco MI, Rojo AI, Cuadrado A.** Dual targeting of Keap1 and Gsk-3 by hexaraphane in the regulation of transcription factor Nrf2. Free Radical Bio Med. 2025; 239: 579-93. Article. IF: 8.0; D1
- **Jakubowska M, Costa VM, Krzeptowski W, Dominkus PP, Santos M, Demirdögen BC, Genç S, Trougakos IP, Kanninen KM, Winklhofer-Roob BM, Copple IM, Cuadrado A, Dolzan V, Morgenstern C.** Altered NRF2 signalling in systemic redox imbalance: Insights from non-communicable diseases. Redox Biol. 2025; 87: 103891. Article. IF: 16.2; D1
- **Kozlov A, Blázquez-Llorca L, Benavides-Piccione R, Kastanauskaite A, Rojo AI, Muñoz A, Cuadrado A, Defelipe J, Grillner S.** Mouse and human striatal projection neurons compared - somatodendritic arbor, spines and in silico analyses. Plos Comput Biol. 2025; 21(10): e1013569. Article. IF: 3.7; Q1
- **Marañón P, Isaza SC, Rey E, Rada P, García-García Y, Dear JW, García-Monzón C, Valverde AM, Egea J, González-Rodríguez A.** BMP6 participates in the molecular mechanisms involved in APAP hepatotoxicity. Arch Toxicol. 2025; 99(3): 1187-202. Article. IF: 10.9; D1
- **Moreso F, Miñano JAP, Fructuoso AS, Jacas C, Alegret M, Ferrer M, Colmenero J, Belmonte AA, Jiménez VL, Pascual S, Blanca AM, Galiano APV, Cachero A, Rivero A, Crespo M, Cuadrado A, Marcos AC, Diéguez MLG, Álvarez CA, Kareaga NM, Martinez JMA, Pagano G, Santana EN, Torres IB, Flores IP, Alonso-Titos J, Rodríguez-Soler M, Alarcón LM, Álvarez TMG, Castelló IB, González-Vilatarsana E, Miras F, Bravo MAG.** Development and validation of the Neuro-Score: a specific scale to detect and monitor cognitive impairment in kidney or liver transplant recipients. Am J Transplant. 2025; 25(5): 1059-69. Article. IF: 8.1; D1
- **Romero-ElKhayat L, Dakterzada F, Huerto R, Carnes-Vendrell A, Mínguez O, Sabaté MP, Targa A, Barbé F, Milanesi E, Dobre M, Manda G, Cuadrado A, Piñol-Ripoll G.** Inflammatory and redox blood gene expression fingerprint of severe obstructive sleep apnoea in patients with mild Alzheimer's disease. J Inflamm Res. 2025; 18: 1609-21. Article. IF: 4.6; Q2

Research projects


- **Cuadrado Pastor A, Seabra M.** NRF2 as a novel therapeutic target in age-related macular degeneratio (HR22-00569). Fundación La Caixa. 2022-2026. Managment centre: UAM
- **Cuadrado Pastor A.** Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (1004040104). Europeo. Programa COST. 2021-2025. Managment centre: Victor Babes National Institute of Pathology
- **Cuadrado Pastor A.** Optimización y validación in vivo de fármacos innovadores para el tratamiento de taupatías (1004020195). CAM. 2023-2026. Managment centre: UAM
- **Cuadrado Pastos A, Rojo Sanchís AI.** Papel del factor de transcripción NRF2 en protección sináptica en las Taupatías. (1004020200). MICIN. 2023-2026. Managment centre: UAM

Cibers and Retics

- **Cuadrado Pastor A.** Centro de Investigación Biomédica en Enfermedades Neurodegenerativas (CIBERned). ISCIII. (31/12/2025). UAM
- **Martínez Valverde A.** Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem). ISCIII. (31/12/2025). CSIC
- **Cuadrado Pastor A, Rojo Sanchís AI.** Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (BenBedPhar). EU European COST Action. (18/10/2025). Victor Babes Research Institute (Romania)

Patents and Trademarks

- **Cuadrado Pastor A, Innamorato NG, inventors: CSIC, UAM.** Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.
- **León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.**A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.
- **León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS NEUROSCIENCE S.**A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October15.
- **Cuadrado Pastor A, Fernández-Ginés R, León Martínez R, Encinar JA, Rodríguez Franco MI, García López MG, Rojo Sanchís AI, inventors.** UAM, CSIC, UMH y Fundación de Investigación Biomédica del Hospital Universitario de la Princesa, assigness. Treatment of NRF2-Related diseases. PCT/2022/382025.1.



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.1.4 Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies

Publications: 2 | Q1:2

COMPOSITION

Francisco Zafra Gómez.
Catedrático. Facultad de Ciencias. Universidad Autónoma de Madrid

- **María del Carmen Aragón Rueda.** *Profesora Titular. Facultad de Ciencias. Universidad Autónoma de Madrid*
- **Beatriz Fuensanta López Corcuera.** *Profesora Titular. Facultad de Ciencias. Universidad Autónoma de Madrid*
- **Enrique Núñez Balbuena.** *Investigador Postdoctoral. Universidad Autónoma de Madrid*
- **Eva María Porlan Alonso.** *Profesora Contratada Doctora. Universidad Autónoma de Madrid*

STRATEGIC OBJETIVES

- Role of glutamate and glycine transporters in physiological and pathological aspects of glutamatergic and glycinergic neurotransmission.
- Involvement of glutamate transporters in excitotoxicity, ischemia, and traumatic brain injury
- Glycinergic neurotransmission pathologies such as hyperekplexia and pain
- Role of adult neurogenesis in neurorepair.
- Role of GABAergic neurotransmission in epilepsy

RESEARCH LINES

- Physiological and pathological aspects of glutamate flows in the brain as a potential target to prevent excitotoxicity, associated with brain dysfunctions such as ischemia or head trauma, with special interest in intracellular trafficking and characterization of interactomes of transporters and receptors of glutamatergic synapses.
- Glycinergic neurotransmission. Identification and characterization of novel mutations in GlyT2 (SLC6A5 gene) associated with human hyperekplexia. Effects of the mutations on the structure, function, proteostasis, and glycinergic neurotransmission of the transporter. Role of different genes related to GlyT2 trafficking, interactome, and post-translational modifications in presynaptic hyperekplexia. Rescue interventions.
- Study of the plastic adaptations affecting glycine transporters in physiological and pathological nociception. Regulation of GlyTs by receptors that modulate nociceptive signaling (P2XR, P2YR, mAch, nAch, α2 adrenergic, 5-HT). Signaling pathways.
- Neuron-glia dialogue via microRNAs and exosomes
- Physiological and pathological aspects of neuronal repair by adult neurogenesis: Identification of new regulatory mechanisms of adult neurogenesis by kinases.Identification of new regulatory mechanisms of adult neurogenesis by microRNAs and other non-coding RNAs."
- GABAergic neurotransmission. Identification and characterization of new mutations in the SLC6A1 gene (GABA transporter, GAT-1) associated with epilepsy. Effects of the mutations on the structure and function of the transporter in GABAergic neurotransmission. Pharmacological treatments with chaperones. (GABA transporter GAT-1) associated to epilepsy. Effects of the mutations on transporter structure, function in GABAergic neurotransmission. Pharmacological treatments with pharmacochaperones.



RESEARCH ACTIVITY

Publications

- **Sarmiento-Jiménez J, Felipe R, Núñez E, Ferrando-Muñoz A, Benito-Muñoz C, Gago F, Vázquez J, Camafeita E, Clement E, Wilson B, López-Corcuera B.** A New GlyT2 variant associated with hyperekplexia. Int J Mol Sci. 2025; 26(14): 6753. Article. IF: 5.6; Q1
- **Sebastián-Serrano A, Simón-García A, Santos-Galindo M, Sánchez-Carralero MP, H-Alcántara A, Clemente C, Pose-Utrilla J, Campanero MR, Porlan E, Lucas JJ, Iglesias T.** Down-regulation of neuroprotective protein kinase D in Huntingtons disease. Cell Death Dis. 2025; 16(1): 418. Article. IF: 12.2; Q1

Research projects

- **Patologias del transportador neuronal de glicina GlyT2: hiperplexia y dolor.** PID2023-150608OB-I00 (López Corcuera B, Zafra Gómez F. Patologias del transportador neuronal de glicina GlyT2: hiperplexia y dolor (PID2023-150608OB-I00). AEI. 2024-2027. Managment centre: UAM). López Corcuera B, Zafra Gómez F. AEI-2024. Managment centre: 2027
- **Dianas farmacológicas en las decisiones del destino de las celulas madre:implicaciones para la regeneración.** PID2023-146945NB-I00 (Porlan Alonso E . Dianas farmacológicas en las decisiones del destino de las celulas madre:implicaciones para la regeneración (PID2023-146945NB-I00). AEI. 2024-2027. Managment centre: UAM). Porlan Alonso E . AEI-2024. Managment centre: 2027

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.1.5 Molecular Mechanisms and Biomarkers of Neurodegenerative Diseases



Publications: 3 | Q1: 2

COMPOSITION

Isabel Lastres Becker.
Profesora Titular. Universidad Autónoma de Madrid

- **Marina Arribas Blázquez.** *Investigadora Postdoctoral. Universidad Autónoma de Madrid*
- **Pablo Beceiredo Macho.** *Investigador Predoctoral. Universidad Autónoma de Madrid*
- **Daniel Flores Téllez.** *Investigador Predoctoral. Universidad Autónoma de Madrid*
- **Ignacio Silva Llanes.** *Investigador Predoctoral. Universidad Autónoma de Madrid*
- **Virginia Solar Fernández.** *Investigadora Postdoctoral. Universidad Autónoma de Madrid*
- **Javier Suárez Fonseca.** *Investigador Predoctoral. Universidad Autónoma de Madrid*

STRATEGIC OBJETIVES

- As our society's population grows older, we face mounting challenges in healthcare and social support systems. The rise in age-related conditions brings increased physical limitations and illnesses, creating significant strain not only on medical resources but also on those affected and their loved ones. Among the most concerning aspects of aging are neurodegenerative conditions, particularly frontotemporal dementia (FTD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). A critical societal priority is developing effective treatments for these conditions, which requires advances in biomarker identification, pharmaceutical development, and technological innovation. Our laboratory focuses on understanding neurodegeneration at the molecular level. We employ a comprehensive research strategy that bridges fundamental science with clinical applications, utilizing various experimental approaches including cell cultures, mouse models, and analysis of tissue samples from individuals who had FTD, PD and ALS

RESEARCH LINES

- **Targeting pyroptosis in TAU-induced neurodegeneration: mechanisms and modulation.** Frontotemporal dementia (FTD) is an early-onset progressive neurodegenerative disease primarily characterized by neuronal degeneration in the frontal and temporal lobes, followed by hippocampal atrophy. FTD is the second most common cause of dementia in adult patients and the most frequent in patients under 65 years of age. From a molecular perspective, FTD is mainly characterized by aggregates of TAU or TDP-43 proteins. There is also a dysregulation of redox homeostasis and low-grade chronic neuroinflammation. Recent research has revealed a strong connection between neuroinflammation and TAU protein-related neurodegeneration. A key discovery shows that the NLRP3 inflammasome, when activated, can significantly impact TAU pathology and subsequent neuronal death. This process involves pyroptosis - a specific form of cell death that occurs when the NLRP3 inflammasome assembles, leading to GASDERMIN D (GSDMD) cleavage and the subsequent release of inflammatory molecules IL-1β and IL-18. To better understand this relationship, our laboratory investigated pyroptosis's role in TAU-driven neurodegeneration using two distinct experimental approaches.
- **CB2 Cannabinoid Receptor Modulation as a New Therapeutic Strategy to Protect Against TAU-dependent FTD Neurodegeneration.** TAU protein is the main component of intracellular filamentous deposits that define a series of neurodegenerative diseases called tauopathies. Generally, tauopathies are characterized by alterations in synaptic plasticity, cell death, proteinopathy, and neuroinflammation. Despite enormous efforts to find a cure for these diseases, an effective treatment does not yet exist. In our laboratory, we approach this challenge with two different approaches. We have demonstrated both in vitro and in vivo that neurons with TAU accumulation induce the expression of the CB2 cannabinoid receptor, which enhances neurodegeneration. Therefore, in our first approach, we focus on studying the pharmacological modulation of the CB2 receptor and its effects on TAU-induced neurodegeneration. Currently, there are no specific biomarkers for tauopathies that would allow for prognosis/diagnosis of these diseases.
- **Differential Function of Mitochondria in Neuron and Astrocyte α-synuclein-dependent Parkinson's Disease.** Parkinson's Disease (PD) is the most prevalent neurodegenerative disease with motor alterations characterized by the degeneration of dopaminergic (DA) neurons in the substantia nigra and the accumulation of protein aggregates in so-called Lewy bodies, where the most abundant protein is alpha-synuclein (α-SYN). In addition to the neurodegenerative process and protein accumulation, PD is characterized by low-grade chronic inflammation and oxidative stress, which are associated with mitochondrial alterations. PD has been predominantly approached from a neuron-centric point of view, without considering other cell types, such as astrocytes, which are part of the tripartite synapse. However, we cannot rule out that mitochondrial dynamics and function may also be altered in astrocytes and differently from DAergic neurons, contributing to the onset and propagation of the disease. Therefore, in this research project, we aim to address the hypothesis that mitochondrial dynamics and function may be different between neurons and astrocytes in α-SYN-associated PD.
- **Fighting against Parkinson's Disease with SGK1 inhibitors.** Parkinson's disease (PD) is the second most common neurodegenerative disorder characterized by the degeneration of dopaminergic neurons of the substantia nigra and the accumulation of protein aggregates, called Lewy bodies, where the most abundant is alpha-synuclein (a-SYN). In addition to the neurodegeneration and the accumulation of proteins, PD is characterized by chronic low-grade inflammation and mitochondrial alterations that lead to oxidative stress. Currently, PD patients are only treated with dopamine replacement therapy (levodopa), with serious side effects and which also does not stop the degenerative condition. or this reason, in this innovative research project we want to address this challenge by developing new SGK1 kinase inhibitors to alleviate the 3 main hallmarks: neuroinflammation, autophagy/mitophay and oxidative stress. Preliminary results of our research groups support this hypothesis. For this, we will carry

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

out a multidisciplinary approach from in vitro assays, evaluate new small molecules capable of selectively inhibit SGK1 and finally, we will evaluate the efficacy of these molecules in preclinical trials in a murine model of PD. The results obtained from this project have an immediate projection as a possible clinical tool for the treatment of patients with PD

- **Exploring the Pathophysiological Links Between Parkinson's Disease, Hypertension, and Acute Lung Inflammation**. This research line examines the interplay between PD, hypertension, and acute lung inflammation (ALI), aiming to elucidate shared pathophysiological mechanisms and their impact on disease progression and patient outcomes. The project focuses on how systemic processes, particularly inflammation, vascular dysfunction, and altered autonomic regulation, may contribute simultaneously to neurodegeneration, cardiovascular dysregulation, and pulmonary injury. By integrating molecular profiling with functional assessments across brain, cardiovascular, and lung systems, the study seeks to clarify whether acute inflammatory events in the lung and chronic blood pressure alterations can exacerbate PD-related pathology or symptom severity. Ultimately, this work aims to identify convergent biological pathways and potential therapeutic strategies capable of addressing neurological, cardiovascular, and respiratory complications in a unified framework.

RESEARCH ACTIVITY

Doctoral Theses

- **Silva Llanes I.** Nuevas estrategias terapéuticas para el tratamiento de la demencia frontotemporal. [dissertation]. Madrid: UAM: 2025(28/09/2025). Director: Lastres Becker I.

Master Theses

- **Suárez Fonseca J.** Analysis of the pyroptosis process in Amyotrophic Lateral Sclerosis: comparative study between a murine model and patient samples[dissertation]. Madrid: UAM: 2025(01/06/202). Director: Lastres Becker I.
- **Mihaila G.** Análisis del efecto de la hipertensión arterial sobre el proceso neurodegenerativo en un modelo murino de la enfermedad de Parkinson[dissertation]. Madrid: UAM: (01/06/2025). Director: Lastres Becker I.

Final Degree Theses

- **León Alonso LT.** Evaluación de PMI y Omaveloxolona como moduladores de NRF2 en un modelo celular de α-SINUCLEÍNA para la enfermedad de Parkinson. [dissertation]. Madrid: UAM: 2025(01/05/2025). Director: Lastres Becker I.

Publications

- **Rojo AI, Buttari B, Cadenas S, Carlos AR, Cuadrado A, Falcao AS, López MG, Georgiev MI, Grochot-Przeczek A, Gumeni S, Jimenez-Villegas J, Horbanczuk JO, Konu O, Lastres-Becker I, Levonen AL, Maksimova V, Michaeloudes C, Mihaylova L, Mickael ME, Milisav I, Miova B, Rada P, Santos M, Seabra MC, Strac DS, Tenreiro S, Trougakos IP, Dinkova-Kostova AT.** Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases. Redox Biol. 2025; 79: 103464. Article. IF: 16.2; D1
- **Silva-Llanes I, Madruga E, Martínez A, Lastres-Becker I.** RIPK1 expression and inhibition in tauopathies: implications for neuroinflammation and neuroprotection. Front Neurosci. 2025; 18: 1530809. Article. IF: 4.0; Q2
- **Silva-Llanes I, Rodríguez-López S, González-Naranjo P, del Sastre E, López MG, Páez JA, Campillo N, Lastres-Becker I.** Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model. Brain Behav Immun. 2025; 127: 251-68. Article. IF: 7.5; D1

Research projects

- **Lastres-Becker I.** A-Synuclein-dependent neuron-astrocyte differential function of mitochondria in Parkinson's disease (PID2022-137065OB-I00). MICIN. 2023-2026. Managment centre: UAM
- **Lastres-Becker I.** Receptor cannabinoide CB2: Validación como Biomarcador en Demencias TAU-dependientes. FIBHULP. 2024-2026. Managment centre: FIBHULP
- **Lastres-Becker I.** Targeting SGK1: Bridging Therapies for Parkinson and Cardiovascular Diseases (SGK1-4PDCar) (NED24PI02/2024). CIBER. 2024-2026. Managment centre: CIBERNED

Patents and Trademarks

- **López-Rodríguez ML, Viso A, Ortega S, Lastres-Becker I, González S, Fernández-Ruiz JJ, Ramos JA, inventors; Universidad Complutense de Madrid, assignees; Nuevos derivads de ácido araquidónico con afinidad por el transportador de anandamide.** P200001920. 2020 nov 5
- **Martínez Gil A, Gil Ayuso-Gontán C, Madruga Mayordomo E, Garcia-Rubia A, Oliver Pérez E, Briones Alonso AM, Lastres-Becker, inventors; CSIC-UAM.** assignees; Compuestos inhibidores de SGK1 y su uso para el tratamiento de enfermedades neurodegenerativas y/o cardiovasculares. PCT/ES2025/070297. España 2024 jun 7



1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.1.6 Multiple Sclerosis Research

Publications: 7 | Q1: 4

COMPOSITION

Yolanda Aladró Benito.
Médico Adjunto Neurología. Hospital Universitario de Getafe/Profesor Asociado. Universidad Europea de Madrid

- **Judith Díaz Díaz.** *Facultativo Especialista de Área en Neurología. Hospital Universitario de Getafe*
- **Laura Lillo Triguero.** *Facultativo Especialista de Área en Neurología. Hospital Universitario de Getafe*
- **Guillermo Martín Ávila.** *Facultativo Especialista de Área en Neurología. Hospital Universitario de Getafe*
- **Alejandro Méndez Burgos.** *Facultativo Especialista Adjunto Neurología. Hospital Universitario de Getafe*
- **Belén Pilo de la Fuente.** *Facultativo Especialista de Área en Neurología. Hospital Universitario de Getafe*

STRATEGIC OBJETIVES

- To evaluate the progression of multiple sclerosis by analyzing gait with inertial sensors to find more objective, sensitive, and reliable measures for detecting and monitoring the clinical progression of progressive MS. To validate selected measures provided by inertial sensors for gait monitoring in a prospective cohort of patients with MS in the early stages (primary and secondary)

RESEARCH LINES

- Gait study with biosensors in patients with multiple sclerosis.
- Covid-19 in multiple sclerosis
- Late-onset multiple sclerosis
- Use of motion sensors in essential tremor

RESEARCH ACTIVITY

Publications

- **Domiínguez-Mozo M, López-Mecández D, Villar L, Costa-Frossard L, Villarrubia N, Aladró Y, Pilo B, Montalbán X, Comabella M, Casanova-Peño I, González-Suárez I, Martínez-Ginés M, García-Domínguez J, García-Calvo E, Machuca-Marcos A, Luque-García J, García-Martinez M, Arroyo R, Alvarez-Lafuente R.** Short-chain fatty acids in multiple sclerosis: Associated with disability, number of T2 lesions, and inflammatory profile. Ann Clin Transl Neurol. 2025; 12(3): 478-90. Article. IF: 3.9; Q2
- **García-Castillo MC, Sierra-Mencía A, Caronna E, Toledo-Alfocea D, Jaimes A, Urtiaga S, Casas-Limón J, Muñoz-Vendrell A, Santos-Lasaosa S, Martín VG, Avila GM, Polanco M, Villar-Martínez MD, Trevino-Peinado C, Rubio-Flores L, Sánchez-Soblechero A, Sánchez LP, Luque-Buzo E, Lozano-Ros A, Gago-Veiga AB, Díaz-De-Terán J, García AR, Rodríguez JC, García AG, Salaices MG, Campoy S, Minguez-Olaondo A, Maniataki S, González-Quintanilla V, Porta-Etessam J, Cuadrado ML, Peral ALG, Pozo-Rosich P, Rodríguez-Vico J, Huerta-Villanueva M, Pascual J, Goadsby PJ, González-Martínez A.** Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine: towards integrated management strategies. J Neurol. 2025; 272(6): 443. Article. IF: 5.4; Q1
- **Lillo-Triguero L, del Castillo-Rueda A, Bellón JM, Peraita-Adrados R.** Prospective study of restless legs syndrome in a blood donors' sample. Rev Clin Esp. 2025; 225(1): 9-15. Article. IF: 1.7; Q2
- **Martín-García R, Triguero LL, García-Malo C.** Augmentation in restless legs syndrome: a comprehensive observational study of a Spanish cohort. Sleep Med. 2025; 136: 106855. Article. IF: 4.1; Q1
- **Monreal E, Fernández-Velasco JI, de la Maza SS, Espiño M, Villarrubia N, Roldán-Santiago E, Aladró Y, Cuello JP, Ayuso-Peralta L, Rodero-Romero A, Chico-García JL, Rodríguez-Jorge F, Quiroga-Varela A, Rodríguez-Martín E, de la Fuente BP, Martín-Avila G, Martínez-Ginés ML, García-Domínguez JM, Rubio L, Llufriu S, Comabella M, Montalbán X, Álvarez-Bravo G, Veiga-González JL, Masjuan J, Costa-Frossard L, Villar LM.** Combining CSF and serum biomarkers to differentiate mechanisms



of disability worsening in multiple sclerosis. Int J Mol Sci. 2025; 26(14): 6898. Article. IF: 5.6; Q1
- **Ordieres-Meré J, Grijalvo M, Martín-Avila G, Aladró Y.** Remote gait monitoring system to facilitate assessment of people with multiple sclerosis. IEEE Internet Things J. 2025; 12(24): 54348-67. Article. IF: 8.7; D1
- **Pastor AG, Ramírez IL, Tena AB, Seoane D, Calleja P, Ostos F, De Celis-Ruiz E, Escalonilla CG, Simal P, López-Jurado ALF, Gil DP, Lechuga RV, Moreno-López C, Fernández-Ferro JC, Moraleda MTM, Escobar JR, Torres AG, Vinagre IN, Escamilla EE, Carpio RT, Ávila GM, Mohedano AMI, Montero MV, Núñez AG.** Technical effectiveness and safety of emergent stenting in patients with acute ischemic stroke and carotid near-occlusion. Neuroradiology. 2025; 67(12): 3377-85. Article. IF: 2.8; Q2

Clinical Trials


- **Aladró Benito Y.** efectividad y tolerabilidad del tratamiento con 2,7 mg delta-9 -tetrahidrocannabinol / 2,5 mg cannabidiol (sativexò) en pacientes con espasticidad secundaria a esclerosis múltiple y síndrome de piernas inquietas en práctica clínica habitual. Type/ Phase: EOm prospectivo Sponsored by: Aladró Benito, Yolanda. Signature date: 20/05/2025

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

3.2. Cardiovascular Area

Documents: 202 | Originals: 157 | D1: 62 | Q1: 115

Area coordinators: José Raúl Moreno Gómez/ María Fernández Velasco



RESEARCH GROUPS

3.2.1 Research on Invasive Clinical and Translational Cardiology - ICCIT-PAZ
José Raúl Moreno Gómez/María Fernández Velasco

3.2.2 Coagulopathies and Alterations of Haemostasis
Víctor Jiménez Yuste

3.2.3 Vascular Physiology and Pharmacology
Ana María Briones Alonso

3.2.4 Vascular Pharmacology and Metabolism (FARMAVSM)
Carlos F. Sánchez Ferrer/Concepción Peiró Vallejo

3.2.5 Research in Pediatric Cardiology
Federico Gutiérrez-Larraya Aguado

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Strategic Objectives	Development forecast for the coming years:	Actions
Cardiovascular Area is composed of 5 groups that carry out basic, experimental and clinical research in the fields of cardiology and cardiovascular risk factors. The area has an important activity in the performance of international clinical trials of wide impact and applicability. The scientific production of the cardiovascular area is supported by a high impact factor. The groups also have extensive experience in training researchers.	To merge the groups by research lines in order to avoid the duplicities that make the group lose strength and competitiveness and to bet on being more competitive and to take better advantage of the resources.	Foster and support translational research lines.
	The area should be focused on consolidated and multidisciplinary research lines rather than structured by pathologies. The collaboration with research groups from other organizations should be the norm.	Establish relationships/ collaboration/alliances with other IdiPAZ research groups and with groups from other institutions and maintain those already started.
	Resources should be focused on priorities established by the researchers themselves, or directly by IdiPAZ after analyzing the scientific production of each group.	Analyze the scientific production of each group
	Clinical research through the resources it provides (clinical trials) should guide basic research projects in order to offer the ideal field for translational medicine. This type of research also provides a stronger link between international research groups.	Encourage participation in clinical trials of researchers.

HIGH IMPACT PUBLICATIONS

López-Fernández T, van der Meer P, Lyon AR. An update on the European Society of Cardiology Council of Cardio-Oncology. Eur Heart J. 2025; 46(16): 1466-8. Article. IF: 45,3; D1

Rivero-Santana B, Saldaña-García J, Caro-Codón J, Zamora P, Moliner P, Monzonis AM, Zatarain E, Alvarez-Ortega C, Gómez-Prieto P, Pernas S, Rodríguez I, Soto AB, Cadenas R, Ozores PP, Ramírez SP, Salvador MM, Valbuena S, Gasso LF, Juárez V, Severo A, Terol B, Alvarez TD, Rodríguez O, Brion M, González-Costello J, Albendea MC, González-Juanatey JR, Moreno R, López-Sendón J, **López-Fernández T**. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. 2025; 46(3): 273-84. Article. IF: 45,3; D1

Ameri P, Lyon AR, **Fernández TL**. ESC cardio-oncology conference hits the ground running. Eur Heart J. 2025; 46(42): 4354-5. Article. IF: 45,3; D1

Parés-Guillén E, Yuste L, Rojo F, **Moreno R**. The ISPpu9 insertion sequence of Pseudomonas putida KT2440 generates various circular intermediates enabling modular transposition. Nucleic Acids Res. 2025; 53(14): gkaf668. Article. IF: 15; D1

Jurado-Román A, Gómez-Menchero A, Rivero-Santana B, Amat-Santos IJ, Jiménez-Valero S, Caballero-Borrego J, Ojeda S, Miñana G, Gonzálvez-García A, Tébar-Márquez D, Camacho-Freire S, Ocaranza-Sánchez R, Domínguez A, Galeote G, **Moreno R**. Rotational Atherectomy, Lithotripsy, or Laser for Calcified Coronary Stenosis The ROLLER COASTR-EPIC22 Trial. JACC-Cardiovasc Inte. 2025; 18(5): 606-18. Article. IF: 12,7; D1

Scientific Events by Cardiovascular Area

- **21/03/2025** -Seminario Presencial y Online: Nucleotide-binding oligomerization domain type I a new player in heart failure
- **18/09/2025** - Jornada Insuficiencia Cardiaca para Atención Primaria

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.2.1 Research on Invasive Clinical and Translational Cardiology - ICCIT-PAZ

Publications: 125 | Q1:82

COMPOSITION

José Raúl Moreno Gómez.
Jefe de Servicio de Cardiología. Hospital Universitario La Paz
María Fernández Velasco.
Investigadora Senior (Contrato Miguel Servet-Tipo I). Jefa de Laboratorio. FIBHULP

- **Joaquín Jesús Alonso Martín.** *Jefe de Servicio de Cardiología. Hospital Universitario Getafe*
- **Isabel Antorrena Miranda.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Eduardo Armada Romero.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Paula Awamleh García.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario Getafe*
- **Andrea Bueno Sen.** *Investigadora Predoctoral. FIBHULP*
- **Paula Cantolla Pablo.** *Investigadora Predoctoral. FIBHULP*
- **Juan Caro Codón.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Almudena Castro Conde.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Regina Dalmau González-Gallarza.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Francisco Javier Domínguez Melcón.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Carlos Escobar Cervantes.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **María Jesús Espinosa Pascual.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario Getafe*
- **Jaime Fernández de Bobadilla Osorio.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Lucía Fernández Gasso.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Alfonso Fraile Sanz.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario Getafe*
- **Javier Fuertes Beneítez.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Guillermo Galeote García.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Marta Gil Fernández.** *Investigadora Predoctoral. IIB Sols-Morreale*
- **Elvira Ana González García.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Teresa González Gallego.** *Investigadora Senior (Contrato Ramón y Cajal). IIB Sols-Morreale*
- **Gabriela Guzmán Martínez.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Ángel Manuel Iniesta Manjavacas.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Bárbara Izquierdo Coronel.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario de Getafe*
- **Santiago Jiménez Valero.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Alfonso Jurado Román.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Teresa López Fernández.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Esteban López de Sá y Areses.** *Jefe de Sección de Cuidados Intensivos Cardiológicos. Hospital Universitario La Paz*
- **José Luis López-Sendón Hentschel.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*



- **José Luis Merino Llorens.** *Facultativo Especialista de Área en Cardiología. Director Unidad Investigación en Arritmias/Electrofisiología Robótica. Hospital Universitario La Paz*
- **Pablo Merás Colunga.** *Médico Adjunto Cardiología. Hospital Universitario La Paz*
- **María del Mar Moreno Yangüela.** *Jefe de Sección de Imagen Cardiaca. Hospital Universitario La Paz*
- **Martín Negreira Caamaño.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario de Getafe*
- **Rene Olsen Rodríguez.** *Médico Interno Residente. Hospital Universitario de Getafe*
- **Rafael Peinado Peinado.** *Jefe de Sección de Arritmias y Electrofisiología. Hospital Universitario La Paz*
- **Jesús Ángel Perea Egido.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario de Getafe*
- **Esther Pérez David.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Inés Ponz de Antonio.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Patricia Prieto Chinchilla.** *Profesora Contratada Doctora. Universidad Complutense de Madrid*
- **Elsa Prieto Moriche.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Elena Refoyo Salicio.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Juan Ramón Rey Blas.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Luis Riera del Moral.** *Facultativo Especialista de Área en Angiología y Cirugía Vascular. Hospital Universitario La Paz/Profesor Asociado Departamento de Cirugía. Universidad Autónoma de Madrid*
- **Adriana Rodríguez Chaverri.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Inmaculada Roldán Rabadán.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Sandra Rosillo Rodríguez.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **José Ruiz Cantador.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Silvia Cayetana Valbuena López.** *Médico Interno Residente en Cardiología. Hospital Universitario La Paz*

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

STRATEGIC OBJETIVES

- The group is made up of the different care units of the Cardiology Service of the La Paz Hospital: Clinic/Coronary Unit, Interventional Cardiology, Cardiac Imaging, Electrophysiology, Rehabilitation and Congenital Heart Disease in Adults.
- The main lines of research focus on providing clinical answers, with direct participation in international multicenter clinical trials and registries. In turn, the translational aspect is strengthened through an institutional relationship with the CNIC (Spanish National Cardiovascular Research Center)
- Dr. José Raúl Moreno Gómez, MD, PhD. Head of the Cardiology Department, HULP. Director of the ICCIT-IdiPAZ Group. Coordinator of the Cardiovascular Research Area, IdiPAZ
- The clinical arm of the ICCIT-IdiPAZ group comprises a team of cardiologists who conduct significant clinical research across various areas of cardiovascular disease. This includes research on the pathophysiology and treatment of acute coronary syndromes, new non-invasive cardiac imaging techniques, the treatment of cardiac arrhythmias, congenital heart disease, hereditary heart disease, cardiotoxicity from antineoplastic drugs, new treatments for heart failure, and new drugs for cardiovascular prevention. This research group is part of international cardiovascular research networks, which translates, among other things, into participation in numerous international clinical trials and publication in high-impact journals.
- Dr. María Fernández Velasco, PhD. Head of the Cardiac Pathophysiology Laboratory at IdiPAZ. Co-Director of the ICCIT-IdiPAZ Group. Coordinator of the Cardiovascular Research Area at IdiPAZ.
- The translational section of the group is led by Dr. María Fernández Velasco. Her multidisciplinary translational group comprises young basic and clinical researchers who study how key factors of the innate immune system are involved in the development of some of the most prevalent cardiac pathologies worldwide and in Spain, such as acute myocardial infarction and heart failure , as well as in less prevalent but significant pathologies such as heart transplants in patients with congenital heart disease . They are also developing a line of research in the field of immunity related to the cardiotoxic effects of antitumor treatments such as anthracyclines and immunotherapy. The development of these lines of research is made possible through close collaboration between the group and clinical researchers in the cardiology departments of various public hospitals and, fundamentally, through the group's integration into the cardiology department of La Paz University Hospital. Furthermore, the group has international collaborations that also contribute to the development, scope, and impact of its work. View publications: https://pubmed.ncbi.nlm.nih.gov/?term=Fernandez-Velasco%2C+M&sort=date

RESEARCH LINES

- Myocardial ischemia. Acute and chronic. Diagnosis, prognosis, and treatment. Post-cardiac arrest hypothermia. Line Manager: José Raúl Moreno Gómez
- Cardiovascular prevention strategies.
- Cardiac arrhythmias. Catheter navigation systems. Diagnosis and treatment.
- Heart failure. Diagnosis and treatment. Cardiotoxicity and antineoplastic agents
- Cardiac imaging diagnosis
- Valvular pathologies. Diagnosis and treatment
- Congenital heart disease in adults
- Translational research in cardiology. Search for new biomarkers and molecular mechanisms involved in the most prevalent cardiac pathologies. Research line leader: María Fernández Velasco

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

RESEARCH ACTIVITY

Doctoral Theses

- **Rivero Santana B.** Inflamación y Remodelado Ventricular Adverso tras el Infarto Agudo de Miocardio: Papel del Inflamasoma NLRP3[dissertation]. Madrid: UAM: 2025(21/02/2025). Director: Jurado Román A, Fernández Velasco M.

Master Theses

- **Segovia Herreras D.** Evaluación de los pacientes de Cardiología bajo tratamiento con iPSCK9 en la isla de Lanzarote[dissertation]. Murcia: UCAM: 2025(20/02/2025). Director: Dalmau González-Gallarza R.
- **Jiménez Baena E.** Seguimiento clínico de pacientes con cardiopatía isquémica sometidos a nueva angioplastia[dissertation]. Murcia: UCAM: 2025(20/02/2025). Director: Dalmau González-Gallarza R.

Publications

- **Alfonso F, Shaburishvili T, Farah B, Gogorishvili I, Monsegu J, Baranauskas A, Bressollette E, Shaburishvili G, Cuesta J, Rivero F, Moreno R, Sabate M.** First-in-man study of a novel everolimus-coated balloon for the treatment of coronary in-stent restenosis. Coronary Artery Dis. 2025; 36(2): 91-8. Article. IF: 2.2; Q3
- **Althoff TF, Anderson RH, Goetz C, Petersen SE, Díaz PM, Nijveldt R, Maurovich-Horvat P, Bax J, Hussain S, Schmidt C, Spicer DE, Sánchez-Quintana D, Corsi C, Dössel O, Climent AM, Rodríguez B, Schotten U, Loewe A, Guillem MS, Cabrera JA, Merino JL, Wijnmaalen AP, Bertrand PB, de Groot N, Derval N, Didenko M, Donal E, Dweck MR, Ho SY.** Regionalization of the atria for 3D electroanatomical mapping, cardiac imaging, and computational modelling: a clinical consensus statement of the European Heart Rhythm Association and the European Association of Cardiovascular Imaging of the ESC. Europace. 2025; 27(7): euaf134. Article. IF: 10.2; D1
- **Ameri P, Lyon AR, Fernández TL.** ESC cardio-oncology conference hits the ground running. Eur Heart J. 2025; 46(42): 4354-5. News Item. IF: 45.3; D1
- **Andrès E, Escobar C, Doi K.** Machine Learning and Artificial Intelligence in Clinical Medicine-Trends, Impact, and Future Directions. J Clin Med. 2025; 14(22): 8137. Editorial Material. IF: 3.3; Q1
- **Arenillas C, Celada L, Ruiz-Cantador J, Calsina B, Datta D, García-Galea E, Fasani R, Moreno-Cárdenas AB, Alba-Linares JJ, Miranda-Barrio B, Martínez-Montes AM, Alvarez-Escola C, Lecumberri B, García AG, Flores SK, Esquivel E, Ding YL, Peitzsch M, Robles-Guirado JA, Zapata RMR, Pozo-Kreilinger JJ, Iglesias C, Dwight T, Muir CA, Oleaga A, Rodríguez-Monte MEGL, Del Cerro MJ, Martínez-Bendayán I, Álvarez-González E, Cubiella T, Lourenço DM Jr, Pereira MAA, Burnichon N, Buffet A, Broberg C, Dickson PV, Fraga MF, Pendás JLL, Soriano JR, Fuentes FB, Toledo SPA, Clifton-Bligh R, Dienstmann R, Villanueva J, Capdevila J, Gimenez-Roqueplo AP, Favier J, Nuciforo P, Young WF Jr, Bechmann N, Opotowsky AR, Vaidya A, Bancos I, Weghorn D, Robledo M, Casteràs A, Dos-Subirà L, Adameyko I, Chiara MD, Dahia PLM, Toledo RA.** Convergent genetic adaptation in human tumors developed under systemic hypoxia and in populations living at high altitudes. Cancer Discov. 2025; 15(5): 1037-62. Article. IF: 29.5; D1
- **Aznar MC, Bergler-Klein J, Boriani G, Cutter DJ, Hurkmans C, Levis M, López-Fernández T, Lyon AR, Maraldo MV.** Perfect is the enemy of good: Reply to Struikmans et al. Radiother Oncol. 2025; 202: 110585. Letter. IF: 5.8; Q1
- **Basile M, Gómez-Menchero A, Rivero-Santana B, Amat-Santos IJ, Jiménez-Valero S, Caballero-Borrego J, Ojeda S, Miñana G, Gonzálvez-García A, Tébar-Márquez D, Roa-Garrido MJ, Camacho-Freire S, Ocaranza-Sánchez R, Domínguez A, Galeote G, Moreno R, Jurado-Román A.** Rotational atherectomy, lithotripsy, or laser for calcified coronary stenosis: one-year outcomes from the Roller Coaster-EPIC22 Trial. Catheter Cardio Inte. 2025; 106(1): 702-10. Article. IF: 1.9; Q3
- **Basile M, Jiménez-Valero S, De la Osa G, Rivero-Santana B, Zubiaur-Zamacola J, Tebar-Márquez D, Gonzálvez-García A, Galeote G Jurado-Roman**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

A, Moreno R. Thrombectomy and stenting for svc thrombosis in a post-heart transplant patient with congenital heart disease. JACC Case Rep . 2025; 30(40): 105856. Article. Not Indexed

- **Beiert T, Knappe V, Zietzer A, Schmidt V, Purerfellner H, Sommer P, Sohns C, Veltmann C, Steven D, Chun KRJ, Maury P, Gandjbakhch E, Laredo M, Willems S, Borlich M, Füting A, Spittler R, Richter S, Schade A, Kuniss M, Wunderlich C, Shin DI, Meininghaus DG, Bonsels M, Reek D, Wiegand U, Bauer A, Metzner A, Eckardt L, Krahnefeld O, Sticherling C, Kühne M, Nguyen DQ, Roten L, Linz D, van der Voort P, Mulder BA, Vijgen J, Almorad A, Guenancia C, Fauchier L, Boveda S, De Greef Y, Da Costa A, Jais P, Milhem A, Jesel L, García R, Poty H, Khoueiry Z, Seitz J, Laborderie J, Mechulan A, Brigadeau F, Zhao A, Saludas Y, Piot O, Ahluwalia N, Martin CA, Chen J, Antolic B, Leventopoulos G, Özcan EE, Yorgun H, Cay S, Yalin K, Botros MS, Jedrzejczyk-Patej E, Inaba O, Okumura K, Ejima K, Khakpour H, Catanzaro JN, Reddy V, Natale A, Blessberger H, Yang B, Vogler J, Kuck KH, Merino JL, Keelani A, Heeger CH, Popescu SS, Tilz RR.** Influence of proton pump inhibitors on the incidence and clinical course of oesophageal fistula following catheter ablation for atrial fibrillation: a subanalysis of the POTTER-AF study. Europace. 2025; 27(10): euaf212. Article. IF: 10.2; D1
- **Bernardino JI, Dalmáu R, Rodríguez-Torres D, Saiz-Medrano G, Fernández-Velilla M, Pinilla I, Rodríguez-Centeno J, Esteban-Cantos A, Jiménez-González M, Mata T, Ramos C, Rodés B, Estébanez M.** DNA N6-methyladenine and ABCA1 methylation associations with subclinical coronary atherosclerosis in people with HIV. Clin Epigenetics. 2025; 17(1): 158. Article. IF: 5.7; Q1
- **Biscaglia S, Erriquez A, Guiducci V, Escaned J, Moreno R, Lanzilotti V, Santarelli A, Cerrato E, Sacchetta G, Menozzi A, Amat-Santos I, Gil JLD, Ruozzi M, Barbierato M, Fileti L, Picchi A, Pavasini R, Cimaglia P, Colaiori I, Casella G, Menozzi M, Cavazza C, Caretta G, Scarsini R, D'Amico G, Vadalà G, Pilato G, Moscarella E, Tebaldi M, Campo G.** Physiology-guided complete revascularization in older patients with myocardial infarctionthree-year outcomes of a randomized clinical trial. JAMA Cardiol. 2025; 10(11): 1130-7. Article. IF: 15.2; D1
- **Bordignon S, Mills MT, Futyma P, Sultan A, Metzner A, Migliore F, Perrotta L, Anic A, Merino JL, Pürerfellner H, Chun JKR.** European Heart Rhythm Association survey on the perceived severity of complications in atrial fibrillation ablation: development of a standardized scoring model. Europace. 2025; 27(11): euaf254. Review. IF: 10.2; D1
- **Boriani G, Brachmann J, Lewalter T, Wright DJ, Badertscher P, Gale CP, Merino JL, Pürerfellner H, Lip GYH.** Access and reimbursement of ambulatory cardiac monitoring across Europe. Eur Heart J Digit Health. 2025; 6(6): 1282-92. Review. IF: 5.3; Q1
- **Boriani G, Imberti JF, Asteggiano R, Ameri P, Mei DA, Farkowski M, Chun J, Merino JL, López-Fernández T, Lyon AR.** Mobile/wearable digital devices for care of active cancer patients: a survey from the ESC Council of Cardio-Oncology. Eur Heart J Digit Health. 2025; 6(2): 162-9. Article. IF: 5.3; Q1
- **Camilli M, Occhipinti G, Potere N, Laudani C, Freixa X, Lombardo A, Burzotta F, Di Nisio M, Carrier M, López-Fernández T, Maurea N, Rocca B.** Management of cancer-associated venous thromboembolism: Perspectives on optimizing current therapeutics with a focus on factor XI inhibition. J Thromb Thrombolys. 2025; 58(8): 1095-108. Review. IF: 2.1; Q3
- **Cantone A, Verardi FM, Vadalà G, Guiducci V, Casella G, Cavazza C, Cerrato E, Sacchetta G, Moreno R, Serenelli M, Santos IA, Gill JLD, Scarsini R, Picchi A, Cocco M, Colaiori I, Barbierato M, Arioti M, Marchini F, Pavasini R, Caglioni S, Lanzilotti V, Menozzi M, Erriquez A, Campo G, Biscaglia S.** Renal function-stratified comparison of complete vs culprit-only revascularization in older patients with myocardial infarction and multivessel disease. JACC-Cardiovasc Inte. 2025; 18(23): 2849-59. Article. IF: 12.7; D1
- **Caro-Codón J, Castrejón S, Cadenas R, Casanova C, Vélez A, Basurte M, Lacuey G, Climent V, Salvador O, Severo-Sánchez A, Fernández L, Pérez-David E, Peinado R, Valbuena-López S, Guzmán G, Jiménez-Mas A, Moreno R, Merino JL.** Extended ECG monitoring in patients with hypertrophic cardiomyopathy: The Tempo-HCM Study. J Clin Med. 2025; 14(20): 7432. Article. IF: 3.3; Q1
- **Castrejón-Castrejón S, Cossiani MM, Sola NB, Roldán JDR, Criado JLI, Osca J, Roca-Luque I, Moya A, Quesada A, Olivares VMH, Castellano NP, Fernández-Gómez JM, Macías-Ruiz R, Villanueva BB, Bada NG, Torres CF, Verdejo BS, Somonte PS, Cervantes CE, Moreno R, Merino JL.** High-power short-duration radiofrequency application for faster and safer pulmonary vein isolation The POWER-FAST III Trial. JACC Clin Electrophysiol. 2025; 11(2): 350-61. Article. IF: 7.2; Q1
- **Criado JLI, Ortiz M, García-Fernández J, Martínez-Alday JD, Font ER, Moreno J, López MA, Almor JM, Gil ML, Medina DG, Granell RR, Peinado RP, Gelizo VB, Muñoz JJS, Medina O, Díaz-Parreño SA, Criado AI, González JM, Merodio JMO, Almendral J.** Can ICD electrograms help ventricular tachycardia ablation? results from the multicenter randomized AIDEG-VTA Trial. J Am Coll Cardiol. 2025; 85(11): 1124-37. Article. IF: 22.3; D1
- **Cuadros M, Abadía M, Castillo P, Martín-Arranz MD, Gonzalo N, Romero M, García-Sánchez A, García-Samaniego J, Olveira A, Ruiz-Cantador J, González-Fernández O, Ponz I, Merás P, Merino C, Rodríguez-Chaverri A, Balbacid E, Froilán C.** Role of transient elastography in the diagnosis and prognosis of Fontan-associated liver disease. World J Gastroentero. 2025; 31(11): 103178. Article. IF: 7.7; Q1
- **Dauccia C, Agostinetto E, Arecco L, Lobo-Martins S, Gitto M, Lyon AR, López-Fernández T, Dent S, Casalino G, Agarwala V, de Azambuja E.** Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care. ESMO Open. 2025; 10(6): 105128. Review. IF: 10.6; Q1
- **de la Torre-Hernández JM, Alfonso F, Moreno R, Ojeda S, de Prado AP, Romaguera R.** REC: Interventional cardiology is now indexed in PubMed Central, the ultimate indexing. REC-Interv Cardiol. 2025; 7(4): 195-201. Editorial Material. IF: 1.5; Q3
- **del Prado-Montero J, Guevara-Martínez J, Cantero-Cid R, Mata-Martínez P, Cueto EJ, Lozano-Rodríguez R, Terrón-Arcos V, Abad-Moret R, Díaz-Serrano E, de Diego RP, Fernández-Velasco M, del Fresno C, Hurtado-Navarro L, López-Collazo E.** Age-stratified circulating immune signatures reveal non-invasive biomarkers for colorectal cancer detection. Immun Ageing. 2025; 22(1): 40. Article. IF: 8.3; D1
- **d'Entremont MA, Cheema Z, Pitt B, Kedev S, Cornel JH, Stankovic G, Moreno R, Storey R, Bossard M, Chauhan A, Montalescot G, Beygui F, Zannad F, Jolly S.** Mineralocorticoid receptor antagonists in myocardial infarction patients a systematic review and meta-analysis of randomized trials. JACC Heart Fail. 2025; 13(9): 102531. Article. IF: 11.9; D1
- **Desteghe L, Lee G, Antoniou S, Merino JL, Neubeck L, Ross C, Svennberg E, Hendriks JM.** A multidisciplinary team approach in the 2024 ESC guidelines for the management of patients with Atrial Fibrillation-what is the role of nurses and allied professionals? A Clinical Consensus Statement of the Association of Cardiovascular Nursing and Allied Professions (ACNAP) and the European Heart Rhythm Association (EHRA) of the ESC. Eur J Cardiovasc Nur. 2025; 24(6): 828-40. Review. IF: 5.4; D1
- **Doehner W, Boriani G, Potpara T, Blomstrom-Lundqvist C, Passman R, Sposato LA, Dobrev D, Freedman B, Van Gelder IC, Glotzer T, Healey JS, Karapanayiotides T, Lip GYH, Merino JL, Ntaios G, Schnabel RB, Svendsen JH, Svennberg E, Wachter R, Haeusler KG, Camm AJ.** Atrial fibrillation burden in clinical practice, research, and technology development: a clinical consensus statement of the European Society of Cardiology Council on Stroke and the European Heart Rhythm Association. Europace. 2025; 27(3): euaf019. Article. IF: 10.2; D1
- **Escobar C, Aldeguer X, Vivas D, Fernández SM, Caballero EG, Martín AG, Barrios V, Freixa-Pamias R.** The gut microbiota and its role in the development of cardiovascular disease. Expert Rev Cardiovasc Ther. 2025; 23(1-2): 23-34. Review. IF: 2.5; Q2
- **Escobar C, Camafort M, Fortuny E, Grymonprez M, Pérez-Cabeza AI, de Backer TL.** Practical

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

comprehensive approach to current atrial fibrillation challenges: insights from an expert panel. J Clin Med. 2025; 14(15): 5199. Article. IF: 3.3; Q1

- **Escobar C, Caravaca-Pérez P, Rodríguez JMF, Gómez-Otero I, Lozano-Bahamonde A, Pérez-Cabeza AI, Pérez-Silvestre J, Rafols C, Esteban-Fernández A.** Effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction: a narrative review of real-world evidence studies. Front Cardiovasc Med. 2025; 12: 1644646. Review. IF: 3.0; Q2
- **Escobar C, Facila L, Vidal-Pérez R, Lapeña AP, Vivas D, Martín AG, Fernández SM, Caballero EG, Barrios V, Freixa-Pamias R.** Artificial intelligence: a promising tool for the clinical cardiologist. Expert Rev Cardiovasc Ther. 2025; 23(5): 209-23. Review. IF: 2.5; Q2
- **Escobar C, Palacios B, Villarreal M, Gutiérrez M, Capel M, Hernández I, García M, Lledó L, Arenillas JF.** Clinical and economic impact of a first major bleeding event in non-anticoagulated patients in spain: a 3-year retrospective observational cohort study. J Clin Med. 2025; 14(4): 1377. Article. IF: 3.3; Q1
- **Escobar C, Pascual-Figal D, Guiu-Segura JM, Capel M, Mallol EP, Caudron C.** Cost-utility analysis of dapagliflozin for the treatment of symptomatic chronic heart failure in Spain. BMC Health Serv Res. 2025; 25(1): 974. Article. IF: 3.3; Q2
- **Escobar C, Saldaña J, Merino JL, Peinado R.** Vericiguat in patients with heart failure and implantable cardioverter-defibrillator. Drugs Context. 2025; 14: 2024105. Article. IF: 2.2; Q1
- **Escobar-Cervantes C, Saldaña-García J, Torremocha-López A, Contreras-Lorenzo C, Lara-García A, Canales-Muñoz L, Martínez-González R, Vila-García J, Banach M.** Integrating new technologies in lipidology: a comprehensive review. J Clin Med. 2025; 14(14): 4984. Review. IF: 3.3; Q1
- **Esteban-Fernández A, Recio-Mayoral A, López-Vilella R, de Lara G, Barrantes-Castillo M, Gómez-Otero I, Nuñez-Villota J, Robles-Gamboa C, López-Aguilera J, Iniesta-Manjavacas A, Fluvió P, Pastor-Pérez F, Belarte-Tornero L, Alonso-Salinas G, Díez-Villanueva P, ERISEC Registry Researchers.** Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial. Front Cardiovasc Med . 2025; 11: 1504427. Article. IF: 3.0; Q2
- **Farkowski MM, Scherr D, Boriani G, Kazakiewicz D, Haim M, Huculeci R, Malaczynska-Rajpold K, Petersen SE, Timmis A, Traykov V, Vardas PE, Pürerfellner H, Merino JL.** Arrhythmia care in ESC member countries: the 2025 ESC-EHRA atlas on heart rhythm disorders. Europace. 2025; 27(7): euaf124. Article. IF: 10.2; D1
- **Fengsrud E, Blomström-Lundqvist C, Camm AJ, Goette A, Kowey PR, Merino JL, Piccini JP, Saksena S, Reiffel JA, Boriani G.** Antiarrhythmic drug use in atrial fibrillation among different European countries - as determined by a physician survey. Int J Cardiol Heart Vasc. 2025; 59: 101709. Article. IF: 2.9; Q2
- **Fernández MG, Sen AB, Pablo PC, Blasco AV, Hurtado GR, Delgado C, Cubillos C, Boscá L, Velasco MF.** Atrial myopathy and heart failure: immunomolecular mechanisms and clinical implications. Int J Mol Sci. 2025; 26(17): 8210. Review. IF: 5.6; Q1
- **Fernández-Olmo R, Cordero A, Oterino A, Blanco-Echevarría A, Vivas D, Escobar C, Ortega E, Torres-Fonseca M, Sánchez-Peinador C, Quiroga B, Pascual V, Martínez-Losas P, Escribano D, Freijo MD, Hernández RMS, Viana A, Freixa-Pamias R, Castro A, Doblas JJG.** Planning of lipid-lowering treatment in atherosclerotic vascular disease. Consensus SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N. Clin Investig Arterioscler. 2025; 37(4): 500799. Article. IF: 1.9; Q3
- **Gabani R, Brugaletta S, Bujak K, Pèrez-Vizcayno MJ, Jiménez-Quevedo P, Arévalos V, Muñoz-García E, Trillo-Nouche R, del Valle R, Hernández JMD, Salido L, Gutiérrez E, Pan MN, Sánchez-Gila J, del Blanco BG, Moreno R, Mata RB, Oteo JF, Amat-Santos I, Regueiro A, Ten F, Nogales JM, Fernández-Nofrerías E, Andraka L, Ferrer MC, Pinar E, Romaguera R, Ramón CC, Alfonso F, García-Blas S, Piñero A, Ignasi J, Mèndez RD, Bordes P, Meseguer J, Nombela-Franco L, Sabaté M.** Impact of gender on in-hospital and long-term outcomes after transcatheter aortic valve implantation: an analysis of the Spanish TAVI registry. Rev Esp Cardiol (Engl Ed). 2025; 78(4): 338-46. Article. IF: 4.2; Q2
- **Gale CP, Hindricks G, Nadarajah R, Tijssen J, Boveda S, Nielsen JC, Merino JL, Lenarczyk R, Taborsky M, Dagres N.** Implantable cardioverter defibrillators in heart failure with reduced ejection fraction after myocardial infarction: the need for contemporary evidence. Eur Heart J Qual Care Clin Outcomes. 2025; 11(6): 816-24. Review. IF: 5.6; Q1
- **Galeote G, Zubiaur J, Jurado-Román A, Fernández-Portales J, Romani S, Salinas P, García-Tejada J, Subinas A, Rodríguez M, Palazuelos-Molinero J, Flores X, López M, Planas A, Arroyo E, Bastos G, Vera-Vera S, Jiménez-Valero S, Santana BR, Tebar D, Gonzálvez A, Moreno R.** Coronary rotational atherectomy elective versus bailout in patients with severely calcified lesions and chronic renal failure (CRATER) trial. Catheter Cardio Inte. 2025; 106(3): 1702-12. Article. IF: 1.9; Q3
- **García IA, Pérez PV, Plaza BL, Matabuena M, Moreno RMG, Milla SP, De Lucas EZ, Sánchez MCP, De Villar NGP.** Continuous glucose monitoring as an alternative for cystic fibrosis related diabetes screening and diagnosis. Diabetes Res Clin Pr. 2025; 229: 112952. Article. IF: 4.6; Q2
- **Gassó LF, David EP, Moreno R.** Transgastric views: an adjunct in left atrial appendage evaluation. Rev Esp Cardiol (Engl Ed). 2025; 78(3): 284-5. Editorial Material. IF: 4.2; Q2
- **Ghigo A, Ameri P, Asnani A, Bertero E, de Boer RA, Farmakis D, González A, Heymans S, Ibáñez B, López-Fernández T, Lyon AR, Pollesello P, Rakisheva A, Stellos K, Streckfuss-Bömeke K, Tocchetti CG, Thum T, van der Meer P, Van Rooij E, Ponikowski P, Metra M, Rosano G, Van Linthout S.** Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart. Eur J Heart Fail. 2025; 27(6): 1028-46. Article. IF: 10.3; D1
- **Gonzálvez-García A, Abelleira-Pardeiro C, Jiménez-Valero S, Balbacid-Domingo E, Gutiérrez-Larraya F, Moreno R.** Self-made fenestrated device for closure of atrial septal defect. Cardiovasc Interv Ther. 2025; 40(3): 725-6. Article. IF: 5.5; Q1
- **Gonzálvez-García A, Jiménez-Valero S, Balbacid-Domingo E, Abelleira-Pardeiro C, Gutiérrez-Larraya F, Moreno R.** Combined percutaneous pulmonary valve-in-valve and closure of paravalvular leak. Cardiovasc Interv Ther. 2025; 40(2): 449-50. Editorial Material. IF: 5.5; Q1
- **Gunawardene MA, Pürerfellner H, Merino JL, Linz D, Sultan A, Scherr D, Deharo JC, Wohlmuth P, Feldhege J, Costa FM, Ribeiro S, Charitakis E, Verstrael A, Anselmino M, Szeplaki G, Simovic S, Jadczyk T, Adelino R, Katsoularis I, Liebregts M, Tilz RR, Chun KRJ.** PULSE survey: Population Survey on Knowledge, Gaps and Perception of Heart Rhythm disorders-an initiative of the Scientific Initiatives Committee of the European Heart Rhythm Association. Europace. 2025; 27(4): euaf032. Review. IF: 10.2; D1
- **Hausvater A, Anthopolos R, Seltzer A, Spruill TM, Spertus JA, Peteiro J, López-Sendón JL, Celutkiene J, Demchenko EA, Kedev S, Beleslin BD, Sidhu MS, Grodzinsky A, Fleg JL, Maron DJ, Hochman JS, Reynolds HR.** Sex differences in psychosocial factors and angina in patients with chronic coronary disease. J Am Heart Assoc. 2025; 14(5): e037909. Article. IF: 6.0; Q1
- **Helms Thomas M, Boriani G, Brunner-La Rocca HP, Klein C, Koehler F, Krzesinski P, Maaser Y, Neumann A, Merino JL, Schultz C, Wright DJ, Zippel-Schultz B, Hindricks G.** The present and future of cardiological telemonitoring in Europe: astatement from seven European countries. Herzschrittmacherther Elektrophysiol. 2025; 36(2): 138-48. Review. Not Indexed
- **Herrmann J, López-Fernández T, Lyon AR.** The year in cardiovascular medicine 2024: the top 10 papers in cardio-oncology. Eur Heart J. 2025; 46(13): 1186-8. Editorial Material. IF: 45.3; D1
- **Jaén RI, Sánchez-García S, Fernández-Velasco M, Cuadrado I, de las Heras B, Boscá L, Prieto P.** New biomarkers in the diagnosis and prognosis of dilated cardiomyopathy: pro-resolving lipids and miRNAs. Cells. 2025; 14(23): 1916. Article. IF: 6.0; Q2
- **Jolly SS, d'Entremont MA, Lee SF, Mian R, Tyrwhitt J, Kedev S, Montalescot G, Cornel**

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

JH, Stankovic G, Moreno R, Storey RF, Henry TD, Mehta SR, Bossard M, Kala P, Layland J, Zafirovska B, Devereaux PJ, Eikelboom J, Cairns JA, Shah B, Sheth T, Sharma SK, Tarhuni W, Conen D, Tawadros S, Lavi S, Yusuf S. Colchicine in acute myocardial infarction. New Engl J Med. 2025; 392(7): 633-42. Article. IF: 84.5; D1

- **Jolly SS, d'Entremont MA, Pitt B, Lee SF, Mian R, Tyrwhitt J, Kedev S, Montalescot G, Cornel JH, Stankovic G, Moreno R, Storey RF, Henry TD, Mehta SR, Bossard M, Kala P, Bhindi R, Zafirovska B, Devereaux PJ, Eikelboom J, Cairns JA, Natarajan MK, Schwalm JD, Sharma SK, Tarhuni W, Conen D, Tawadros S, Lavi S, Asani V, Topic D, Cantor WJ, Bertrand OF, Pourdjabbar A, Yusuf S.** Routine spironolactone in acute myocardial infarction. New Engl J Med. 2025; 392(7): 643-52. Article. IF: 84.5; D1
- **Jurado-Román A, Gómez-Menchero A, Rivero-Santana B, Amat-Santos IJ, Jiménez-Valero S, Caballero-Borrego J, Ojeda S, Miñana G, Gonzálvez-García A, Tébar-Márquez D, Camacho-Freire S, Ocaranza-Sánchez R, Domínguez A, Galeote G, Moreno R.** Rotational atherectomy, lithotripsy, or laser for calcified coronary stenosis the Roller Coaster-EPIC22 Trial. JACC-Cardiovasc Inte. 2025; 18(5): 606-18. Article. IF: 12.7; D1
- **Jurado-Román A, Gonzálvez-García A, Jiménez-Valero S, Galeote G, Moreno R.** REPLY: Intrastent techniques in the Roller-Ccoastr-EPIC22 trial a missing piece of the puzzle? JACC-Cardiovasc Inte. 2025; 18(14): 1830. Letter. IF: 12.7; D1
- **Jurado-Román A, Tébar-Márquez D, Basile M, Rivero-Santana B, Zubiaur J, Moreno R.** REPLY: Optimizing debulking strategies for heavily calcified coronary lesions. JACCC-Cardiovasc Inte. 2025; 18(16): 2074-5. Letter. IF: 12.7; D1
- **Keramida K, López-Fernández T, Anker MS, Petrie MC, Ameri P, Anderson LJ, Bergler-Klein J, Deswal A, Farmakis D, Ibañez B, Lam CSP, Lang NN, Lyon AR, Mirabel M, Moura B, Paulus WJ, Rakisheva A, Savarese G, Senni M, Tocchetti CG, Metra M, Filippatos G.** Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail. 2025; 27(11): 2152-67. Article. IF: 10.3; D1
- **Kotecha D, Bunting KV, Mehta S, Sommer P, Sterlinski M, Rajappan K, Mont L, Guasch E, Boveda S, Boriani G, Sun YZ, van Deutekom C, Gale CP, De Potter TJR, van Gelder IC, Allali Y.** Education of healthcare professionals to improve guideline adherence in atrial fibrillation: the STEEER-AF cluster-randomized clinical trial. Nat Med. 2025; 31(8): 2647-54. Article. IF: 52.5; D1
- **Kowalewski M, Dabrowski EJ, Kurasz A, Swieczkowski M, Raffa GM, Kawczynski M, Aerts L, Kuzma L, Wanha W, Batko J, Litwinowicz R, Urbanowicz T, Stec S, Lorusso R, Hanke T, Maesen B, Meani P, Ronco D, Pilato M, Musumeci F, McCarthy P, Cox JL, Pannone L, Merino JL, Pürerfellner H, Badhwar V, La Meir M, de Asmundis C, Lip GYH, Suwalski P.** Surgical ablation of atrial fibrillation with concomitant cardiac surgery: a state-of-the-art review. Eur J Cardio-Thorac. 2025; 67(7): ezaf187. Review. IF: 3.3; Q1
- **Lara-García A, Jurado-Román A, Márquez DT, García AG, Valero SJ, Moreno R.** Percutaneous mechanical thrombectomy in subacute pulmonary embolism. Rev Esp Cardiol (Engl Ed). 2025; 78(9): 825-8. Letter. IF: 4.2; Q2
- **López-Fernández T, Ameri P.** Glucagon-like peptide 1 agonists in cardio-oncology: is it time for a specific focus? Eur J Prev Cardiol. 2025: zwaf064. Editorial Material. IF: 10.0; D1
- **López-Fernández T, van der Meer P, Lyon AR.** An update on the European Society of Cardiology Council of Cardio-Oncology. Eur Heart J. 2025; 46(16): 1466-8. Article. IF: 45.3; D1
- **Maron DJ, Newman JD, Anthopolos R, Lu Y, Stevens S, Boden WE, Mavromatis K, Linefsky J, Nair RG, Bockeria O, Gosselin G, Perna GP, Demchenko E, Foo D, Shapiro MD, Champagne MA, Ballantyne C, McCullough P, López-Sendon JL, Rockhold F, Harrell F, Rosenberg Y, Stone GW, Bangalore S, Reynolds HR, Spertus JA, Hochman JS.** Guideline-directed medical therapy and outcomes in the ISCHEMIA Trial. J Am Coll Cardiol. 2025; 85(12): 1317-31. Article. IF: 22.3; D1
- **Márquez DT, Jiménez-Valero S, Jurado-Román A, Galeote G, Meras-Colunga P, Aroca A, Leyra F, Higuera I, Cantador JR, Moreno R.** Life-saving combination of extracorporeal membrane oxygenation, percutaneous aspiration, and valvuloplasty in a pulmonary prosthetic valve endocarditis. Can J Cardiol. 2025; 41(4): 761-3. Editorial Material. IF: 5.7; Q1
- **Mcgrath BP, Pinilla-Echeverri N, Wood DA, Bainey KR, Sheth T, Schampaert E, Tanguay JF, Dzavík V, Storey RF, Mehran R, Bossard M, Moreno R, Campo G, Rao SV, Cantor WJ, Lavi S, Johnston PV, Guiducci V, Kim HH, Mani T, Nguyen H, Cairns JA, Mehta SR.** Left Anterior Descending Nonculprit Lesions and Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction. JACC-Cardiovasc Inte. 2025; 18(3): 297-307. Article. IF: 12.7; D1
- **Meras P, Cobarro L, Merino C, Ruiz-Cantador J, Jiménez S, Balbacid E, Abelleira C, Moreno R.** Prevalence and prognostic value of malnutrition in adults with Fontan circulation: retrospective cohort study. Cardiol Young. 2025; 35(4): 836-41. Article. IF: 0.8; Q4
- **Merino JL, Rossa MV.** Contemporary use of antiarrhythmic drugs: practical messages for clinical cardiologists from the EHRA compendium. Rev Fed Arg Cardiol. 2025; 54(4): 203-11. Review. IF: 0.4; Q4
- **Merino JL, Rossa MV.** Contemporary use of antiarrhythmic drugs: practical messages for clinical cardiologists from the EHRA compendium. Rev Fed Arg Cardiol. 2025; 54(4): 224-232. Article. IF: 0.4; Q4
- **Merino JL, Tamargo J, Blomström-Lundqvist C, Boriani G, Crijns HJGM, Dobrev D, Goette A, Hohnloser SH, Naccarelli G, Reiffel JA, Tfelt-Hansen J, Martínez-Cossiani M, Camm AJ.** Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology. Europace. 2025; 27(8): euaf076. Article. IF: 10.2; D1
- **Merino JL.** Aiming for the STARs: radiotherapy for ventricular tachycardia-bright future or cosmic gamble? Europace. 2025; 27(1): euae306. Editorial Material. IF: 10.2; D1
- **Miserachs M, Martinez-Bueno C, Castro A, Pallarés-Carratalá V, Pijuan-Domenech A, Gordon B, Farràs A, Del Barco E, Higueras T, Carreras E, Goya M.** Adverse pregnancy outcomes and cardiovascular disease: a Spanish Cohort. Healthcare (Basel). 2025; 13(7): 728. Article. IF: 3.4; Q1
- **Moreno FJA, García JE, Simarro FL, Gutiérrez LA, Peña CM, Vilches AM, Belinchón MR, Hidalgo PP, Cervantes CE.** Optimization of adherence to fixed-dose combination therapy in the treatment of cardiovascular risk factors in primary care. SEMERGEN. 2025; 51(1): 102337. Article. IF: 1.0; Q4
- **Moreno R, Dzavík V, Cairns J, Balasubramanian K, Martínez R, Cantor WJ, Kedev S, Stankovic G, Bertrand O, Pinilla N, Sibbald M, Akl E, Jolly SS.** Stent thrombosis in the setting of ST-segment elevation acute myocardial infarction in the contemporary practice: results from the TOTAL randomized trial. Coronary Artery Dis. 2025; 36(2): 126-38. Article. IF: 2.2; Q3
- **Moreno R, Souza J, Smolnik R, Nombela-Franco L, Van Mieghem NM, Hengstenberg C, Valgimigli M, Jin JM, Ohlmann P, Dangas G, Unverdorben M, Möllmann H.** Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trial. Clin Res Cardiol. 2025; 114(3): 313-22. Article. IF: 3.4; Q2
- **Moreno R.** In asymptomatic severe AS, early surgery vs. conservative therapy reduced a composite of death, MI, stroke, or HF hospitalization at 63 mo. Ann Intern Med. 2025; 178(1): JC6. Editorial Material. IF: 17.2; D1
- **Morrone D, Stefanini G, De Carlo M, Giannini C, Toth G, Prunea D, Zivelonghi C, Benedetti A, De Bruyne B, Wilgenhof A, Kanovsky J, Kala P, Holmvang L, Hasbak M, Hildick-Smith D, Cockburn J, Amabile N, Veugeois A, Hovasse T, Neylon A, Honton B, Farah B, Gori T, Knorr M, Wolf A, Schmit T, Hausleiter J, Stark KK, Abdel-Waha M, Feistritzer HJ, Woitek F, Linke A, Leick J, Afzal S, Alexopoulos D, Varlamos C, Tsioufis K, Dimitriadis K, Testa L, Squillace M, Conrotto F, D'Ascenzo F, Campo G, Cocco M, Di Mario C, Caniato F, Ribichini FL, Prati D, Tarantini G, Cardaioli F, Burzotta F, Paraggio L, Bedogni F, Arzuffi L, Chieffo A, Ghizzoni G, Davidavicius G, Budrys P, Van Mieghem N, Daemen J, Brinkmann R, Bante H, Lesiak M, Iwanczyk S, Pregowski J, Skowronski J,**

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Madeira S, Raposo L, Estevez-Loureiro R, Sisinni A, Escaned J, Jeronimo A, Moreno R, Jiménez-Valero S, Vriesendorp P, Pustjens T, Van Geuns R, Damman P, Van de Hoef T, Van der Harst P, Mamas MA, Duckett S, Mikhail G, Lucarelli C, Berry C, De Caterina R. Myocardial infarction with nonobstructive coronary arteries - the European PERspective (SNIPER) survey. J Cardiovasc Med. 2025; 26(12): 731-40. Article. IF: 2.6; Q2

- **Muñoz LC, Sánchez-Somonte P, Castrejón-Castrejón S, Martinez-Cossiani M, Al Razzo O, Merino JL.** When leads are not an option: Optimizing subcutaneous implantable cardioverter-defibrillator and leadless pacemaker interaction. Heartrhythm Case Rep. 2025; 11(11): 1236-9. Article. Not Indexed
- **Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, Lincoff AM, McGuire DK, Miller D, Nauck MA, Nishiyama H, Nissen SE, Sattar N, Weerakkody G, Wiese RJ, Zinman B, Zoungas S, Basile J, Davies MJ, Giorgino F, Kellerer M, Ji LN, Varkonyi T, Menon V, Broder JC, Herschtal A, D'Alessio D, (Castro Conde A).** Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. New Engl J Med. 2025; 393(24): 2409-20. Article. IF: 84.5; D1
- **Nuche J, Ponz I, Sánchez VS, Bóbeda J, Gaitán A, López-Linares K, García-Cosío MD, Cebada FS, González JS, Ynsaurriaga FA, Ruíz-Cabello J, Ibáñez B, Delgado JF.** Four-Dimensional magnetic resonance pulmonary flow imaging for assessing pulmonary vasculopathy in patients with postcapillary pulmonary hypertension. J Clin Med. 2025; 14(3): -929. Article. IF: 3.3; Q1
- **Önder R, Desteghe L, Vijgen J, Collins R, Dabrowski R, Farkowski MM, Figueiredo MJD, Hereijgers MJM, Hofer D, Lau CP, Lee G, Linz D, Lobeek M, López T, McAuliffe C, Merino JL, Potpara T, Sanders P, Shamloo AS, Sterlinski M, Svennberg E, van Deutekom C, Van Gelder I, Rienstra M, Heidbuchel H.** Development of three-step holistic care pathways to detect and manage comorbidities in patients with atrial fibrillation: the Horizon 2020 EHRA-PATHS consortium. Eur Heart J Open. 2025; 5(5): oeaf120. Article. IF: 4.3; Q2
- **Ortiz MR, Arbelo E, Rabadan IR, Marín F, Cabeza AP, Rivas RM, Peinado RP, Alberca AV, Criado AI, Muñoz AV, Asensi JO, Lechuga AD, Somoza EJE, Sánchez MA.** The European Society of Cardiology quality indicators in atrial fibrillation in centers of excellence in Spain: the SEC-EXCELENTE FA registry. Rev Esp Cardiol (Engl Ed). 2025; 78(5): 389-400. Article. IF: 4.2; Q2
- **Pallarés-Carratalá V, Ruiz-García A, Fragoso AS, Escobar-Cervantes C, Cervera-Pérez MI, Alonso-Moreno FJ, Arranz-Martínez E, Barquilla-García A, Rey-Aldana D, Polo-García J, Cinza-Sanjurjo S.** Improvement of cardiometabolic control with dapagliflozin in patients with type 2 diabetes in primary care: The AGORA-AP Study. Med Lith. 2025; 61(12): 2087. Article. IF: 2.9; Q1
- **Parés-Guillén E, Yuste L, Rojo F, Moreno R.** The ISPpu9 insertion sequence of Pseudomonas putida KT2440 generates various circular intermediates enabling modular transposition. Nucleic Acids Res. 2025; 53(14): gkaf668. Article. IF: 15.0; D1
- **Pérez-Blanco A, González-Vilchez F, González-Costello J, Royo-Villanova M, Miñambres E, Cuenca JJ, Cánovas SJ, Garrido IP, Moreno-González G, Sbraga F, García-Quintana A, Peña VJ, Portela FA, Almenar-Bonet L, Martinez-León J, Tur A, Ruiz-Arranz A, Caravaca-Pérez P, Sandoval E, Gómez-Bueno M, Pérez-Redondo M, Villar S, Cobo M, Nistal JF, Adsuar-Gómez A, Peinado AA, Blázquez-Bermejo Z, Coll E, Crespo-Leiro MG, Cuerpo G, de la Calle B, Estébanez B, Fernández-García ME, Mosteiro F, Ponz I, Sánchez-Rivas J, Sánchez-Vicario F, Sobrino JM, Domínguez-Gil B.** DCDD heart transplantation with thoraco-abdominal normothermic regional perfusion and static cold storage: The experience in Spain. Am J Transplant. 2025; 25(7): 1526-39. Article. IF: 8.1; D1
- **Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, Ma CS, Goodman SG, Oldgren J, Hammett C, Lopes RD, Akao M, De Caterina R, Kirchhof P, Gorog DA, Hemels M, Rienstra M, Jones WS, Harrington J, Lip GYH, Ellis SJ, Rockhold FW, Neumann C, Alexander JH, Viethen T, Hung J, Coppolecchia R, Mundl H, Caso V, (Merino Llorens JL).** Asundexian versus Apixaban in Patients with Atrial Fibrillation. New Engl J Med. 2025; 392(1): 23-32. Article. IF: 84.5; D1
- **Praz F, Borger MA, Lanz J, Marin-Cuartas M, Abreu A, Adamo M, Marsan NA, Barili F, Bonaros N, Cosyns B, De Paulis R, Gamra H, Jahangiri M, Jeppsson A, Klautz RJM, Mores B, Pérez-David E, Pöss J, Prendergast BD, Rocca B, Rossello X, Suzuki M, Thiele H, Tribouilloy CM, Wojakowski W.** 2025 ESC/EACTS Guidelines for the management of valvular heart disease Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2025; 46(44): 4635-6. Review. IF: 45.3; D1
- **Praz F, Borger MA, Lanz J, Marin-Cuartas M, Abreu A, Adamo M, Marsan NA, Barili F, Bonaros N, Cosyns B, De Paulis R, Gamra H, Jahangiri M, Jeppsson A, Klautz RJM, Mores B, Pérez-David E, Pöss J, Prendergast BD, Rocca B, Rossello X, Suzuki M, Thiele H, Tribouilloy CM, Wojakowski W.** 2025 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardio-Thorac. 2025; 67(8): ezaf276. Article. IF: 3.3; Q1
- **Rao VU, Deswal A, Lenihan D, Dent S, López-Fernández T, Lyon AR, Barac A, Palaskas N, Chen MH, Villarraga HR, Sadler D, Campbell CM, Skurka K, Wagner MJ, Totzeck M, Ruddy KJ, Heidenreich P, Thomas R, Addison D, Ganatra S, Cheng RC, Reeves D, Ghosh AK, Herrmann J.** Quality-of-care measures for cardio-oncology an IC-OS and ACC cardio-oncology leadership council perspective. Jacc Cardiooncol. 2025; 7(3): 191-202. Article. IF: 15.5; D1
- **Redondo EA, Rodríguez SOR, Rodrigo CU, Codón JC, Roman AJ, Moreno R.** Percutaneous decannulation of peripheral veno-arterial extracorporeal membrane oxygenation using the Manta closure device. REC-Interv Cardiol. 2025; 7(3): 187-9. Letter. IF: 1.5; Q3
- **Rienstra M, Woite-Silva AC, Kuijper A, Eijsbouts S, Kraaier K, Janota T, Van Ofwegen C, Tuininga Y, Badings E, Merino JL, Ruskin JN, Camm AJ, Kowey PR, Dufton C, Maupas J, Parsell D, Belardinelli L.** Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial. Europace. 2025; 27(4): euaf064. Article. IF: 10.2; D1
- **Rivero-Santana B, Balbacid-Domingo E, Abelleira-Pardeiro C, de Lera CL, del Val VA, Jiménez-Valero S, Fernández-Velasco M, Moreno R, Gutiérrez-Larraya F.** Microcirculatory dysfunction and its role in diagnosing acute rejection in pediatric heart transplantation: a pilot study. Diagnostics (Basel). 2025; 15(5): 545. Article. IF: 3.8; Q1
- **Rivero-Santana B, Saldaña-García J, Caro-Codón J, Zamora P, Moliner P, Monzonis AM, Zatarain E, Alvarez-Ortega C, Gómez-Prieto P, Pernas S, Rodríguez I, Soto AB, Cadenas R, Ozores PP, Ramírez SP, Salvador MM, Valbuena S, Gasso LF, Juárez V, Severo A, Terol B, Alvarez TD, Rodríguez O, Brion M, González-Costello J, Albendea MC, González-Juanatey JR, Moreno R, López-Sendón J, López-Fernández T.** Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. 2025; 46(3): 273-84. Article. IF: 45.3; D1
- **Rivero-Santana B, Saldaña-García J, Jurado-Román A, Cantolla-Pablo P, Gil-Fernández M, López-Sendón J, Tardif JC, Moreno R, Fernández-Velasco M.** Early anti-inflammatory therapy in acute myocardial infarction: A network meta-analysis of timing-dependent effects in 23 randomized trials and 28,220 patients. Atherosclerosis. 2025; 408: 120443. Article. IF: 7.1; D1
- **Ruiz-García A, Arranz-Martínez E, Serrano-Cumplido A, Cinza-Sanjurjo S, Escobar-Cervantes C, Polo-García J, Pallarés-Carratalá V.** From Metabolic Syndrome to Cardio-Kidney-Metabolic Syndrome in the SIMETAP Study: Prevalence rates of metabolic syndrome and its independent associations with cardio-renal-metabolic disorders other than its defining criteria. Biomedicines. 2025; 13(3): 590. Article. IF: 4.5; Q2
- **Ruiz-García A, Pallarés-Carratalá V, Serrano-Cumplido A, Pascual-Fuster V, Arranz-Martínez E, Escobar-Cervantes C.** From the cardiovascular-kidney-metabolic disorders to the atherosclerotic cardiovascular diseases: their prevalence rates and

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

independent associations in the SIMETAP Study. J Clin Med. 2025; 14(11): 3940. Article. IF: 3.3; Q1

- **Saksena S, Slee A, Merino JL, Goette A, Boriani G, Kowey PR, Piccini JP, Reiffel JA, Blomström-Lundqvist C, Camm AJ.** An international physician survey of current ablation practices in atrial fibrillation: An AIM-AF substudy. Heart Rhythm. 2025; 22(9): 2174-82. Article. IF: 7.0; Q1
- **Sales JC, Cervantes CE, Gómez-Barrado JJ, Cayuelas JMA, del Egido AG, Martin JJC, Rodrigo AIH, Corbi-Pascual M, Cancelo AV, Vidal-Pérez R, Fernández-Friera L, Olmeda ES, Aguilera-Saborido A, Romero AF, Hidalgo AS, Pérez-Sádaba F, Freixa-Pamias R.** Impact of therapeutic inertia in lipid-lowering therapy in patients at very high cardiovascular risk. Clin Investig Arterioscler. 2025; 37(6): 500773. Article. IF: 1.9; Q3
- **Salinas GLA, León AM, Cano DA, Esteban-Fernández A, Flórez JMV, Díaz SD, Górriz-Magaña J, Delgado GD, González-Manzanares R, Caravaca-Pérez P, Pastor-Pérez FJ, Valdivieso-Moré S, Quiles J, Ponz I, Escolar V, Lincango EOB, Báez-Ferrer N, Gallego G, Almenar L, de la Varga LG, Codina P, Mayoral AR, Fort A, Lozano MJP, González-Calle D, Gómez-Otero I, Mosteiro CS, Cobo M, Piqueras-Flores J, Bonanad C, Huerta A, Vallverdú MF, Díez-Villanueva P.** Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry. Esc Heart Fail. 2025; 12(4): 3163-72. Article. IF: 3.8; Q2
- **Salinas P, Álvarez ABC, Pérez PJ, Vázquez-Álvarez ME, Jurado-Román A, Juárez M, Corbí-Pascual M, Martín MV, Jiménez-Mazuecos J, Rodríguez SOR, Quevedo VR, Lázaro M, Viana-Tejedor A, Moreiras JM, Martín-Asenjoi R.** Catheter-directed interventions in acute pulmonary embolism. Position statement of SEC-Interventional Cardiology Association/SEC-Ischemic Heart Disease and Acute Cardiovascular Care Association/SEC-Working Group on Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed). 2025; 78(3): 239-51. Article. IF: 4.2; Q2
- **Sambola A, Campuzano R, Castro A, Goya M, Coronado P, Fernández-Olmo R, María-Tablado MA, Ortiz-Cortés C, Ortolà X, Pallarés-Carratala V, Pijuan-Domenech A, Plata RM, Sánchez-Hernández RM, Siurana JM, Timoteo C, Viejo-Hernández B.** Primary and secondary cardiovascular prevention through life cycles in women. Consensus document of the SEC-GT CVD in Women, ACP-SEC, SEGO, AEEM, SEEN, semFYC, SEMERGEN, AEP, and AEM. Rev Esp Cardiol (Engl Ed). 2025; 78(7): 639-51. Article. IF: 4.2; Q2
- **Samuel M, Berry C, Dubé MP, Koenig W, López-Sendón J, Maggioni AP, Pinto FJ, Roubille F, Tardif JC.** Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis. Eur Heart J. 2025; 46(26): 2552-63. Article. IF: 45.3; D1
- **Sánchez-Recalde A, Domínguez-Rodríguez LM, Rosseel L, Nombela-Franco L, Pfister R, Amat-Santos I, Butter C, Di Mauro M, Cruz-González I, Freixa X, Swaans M, Wilde C, Cacela D, Sarnago F, del Trigo M, Estévez-Loureiro R, López-Mínguez JR, De Torres F, Montenegro M, Pérez-Fernández R, Guzmán G, Pajín F, Mylotte D, Pan MN, Kristoff C, Carrillo-Suárez X, Torre JMD, Quevedo VR, Salido L, Parraga R, Altlhoff J, Fernández-Cordón C, Guarracini S, López-Tejero S, Altisent OAJ, Lautenschläger L, Ramos R, Puri R, Zamorano JL.** Bicaval TricValve implantation in patients with severe tricuspid regurgitation 1-year outcomes from the TricBicaval Registry. JACC-Cardiovasc Inte. 2025; 18(15): 1913-24. Article. IF: 12.7; D1
- **Santamaria R, Escobar C, Aranda U, Palacios B, Capel M, Hernández I, Cebrián A, Alcázar R, Gorostidi M.** Cardiovascular and renal outcomes according to KDIGO stages of chronic kidney disease in the Spanish population: Insights from real-world evidence. Nefrología. 2025; 45(8): 501340. Article. IF: 2.1; Q3
- **Santamaría R, Escobar C, Aranda U, Palacios B, Capel M, Hernández I, Cebrián A, Alcazar R, Gorostidi M.** Magnitude of chronic kidney disease in Spain. Nefrología (Engl Ed). 2025; 45(5): 415-7-. Letter. Not Indexed
- **Sarti A, Erríquez A, Dal Passo B, Casella G, Guiducci V, Moreno R, Escaned J, Marchini F, Cocco M, Verardi FM, Clò S, Caglioni S, Farina J, Barbato E, Vadalà G, Cavazza C, Capecchi A, Gallo F, Campo G, Biscaglia S.** Complete revascularization in older patients with myocardial infarction with or without complex nonculprit lesions. Circ-Cardiovasc Inte. 2025; 18(11): e015902. Article. IF: 7.2; Q1
- **Skouri H, Girerd N, Monzo L, Petrie MC, Boehm M, Adamo M, Mullens W, Savarese G, Yilmaz MB, Amir O, Bayes-Genis A, Bozkurt B, Butler J, Chioncel O, Mebazaa A, Merino JL, Moura B, Ponikowski P, Seferovic P, Rosano GMC, Metra M.** Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2025; 27(4): 707-22. Article. IF: 10.3; D1
- **Slater J, Maron DJ, Jones PG, Bangalore S, Reynolds HR, Fu ZX, Stone GW, Kirby R, Hochman JS, Spertus JA, ISCHEMIA Res Grp (López-Sendon JL, Castro Conde A, Refoyo Salicio E, Guzman G, Galeote G, Valbuena S) .** Evaluating the appropriate use criteria for coronary revascularization in stable ischemic heart disease using randomized data from the ISCHEMIA Trial. Circ-Cardiovasc Qual. 2025; 18(3): e010849. Article. IF: 6.9; Q1
- **Svennberg E, Merino JL, Andrade J, Anselmino M, Arbelo E, Boersma E, Boriani G, Breithardt G, Chung MN, Chyou J, Cohen A, Nielsen JC, Dichtl W, Diederichsen SZ, Dobrev D, Doehner W, Dworatzek E, Fabritz L, Filgueiras-Rama D, Gimpelewicz C, Hack G, Hatem S, Healey J, Heidbuchel H, Hijazi Z, Holst AG, Hove-Madsen L, Jalife J, van Leerdam R, Linz D, Lip GYH, Lubitz S, de Melis M, Meyer R, Orczykowski M, Parwani AS, Porta-Sánchez A, de Potter T, Ravens U, Rienstra M, Rillig A, Rivard L, Scherr D, Schnabel RB, Schotten U, Simovic S, Sinner M, Sohns C, Sommer P, Steinbeck G, Steven D, Sultan A, Thomalla G, Toennis T, Tzeis S, Voigt N, Wadhwa M, Wakili R, Witt H, Goette A, Kirchhof P.** Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference. Europace. 2025; 27(12): euaf318. Article. IF: 10.2; D1
- **Tamburrini G, García CD, López-Fernández T.** Advances in cardioprotection strategies: focusing on breast cancer and beyond through novel biomarkers and pharmacological approaches. Eur Cardiol. 2025; 20: 23. Review. IF: 4.6; Q1
- **Tébar D, Jurado-Román A, Jiménez-Valero S, Galeote G, Gonzálvez A, Rivero B, García A, Elizalde JMA, Lorenzo A, Capitán CF, Torres R, Soto C, Alcolea S, Rosillo S, Codón JC, Arbas E, Tejera F, Plaza I, Boscá L, Moreno R.** Percutaneous pulmonary thrombectomy with aspiration catheters in patients with high-risk pulmonary embolism and absolute contraindication to systemic thrombolysis. Cardiovasc Revasc Med. 2025; 70: 56-61. Article. IF: 2.3; Q3
- **Tébar-Márquez D, Díez-Vidal A, Tung-Chen Y.** Antithrombotic therapy after percutaneous left atrial appendage closure: should it be the same for everyone? Rev Esp Cardiol (Engl Ed). 2025; 78(8): 679-81. Editorial Material. IF: 4.2; Q2
- **Tilz RR, Popescu SS, Pürerfellner H, Kuck KH, Xiang K, Uzunoglu EC, Heeger CH, Vogler J, Tandri H, Assis F, Shantha G, Merino JL, Catanzaro JN.** Impact of ablation energy on mortality after oesophageal fistula and injury complicating atrial fibrillation ablation procedures: results from a worldwide FDA database, the POTTER-AF 2 study. Eur Heart J Open. 2025; 5(6): oeaf146. Article. IF: 4.3; Q2
- **Tilz RR, Pürefellner H, Kuck KH, Merino JL, Schmidt V, Vogler J, Xiang K, Uzunoglu EC, Heeger CH, Tandri H, Assis F, Steven D, Veltmann C, Catanzaro JN, Popescu SS.** Underreporting of complications following AF ablation: Comparison of the manufacturer and user facility device experience FDA database and a voluntary invitation-based registry: The POTTER-AF 3 study. Heart Rhythm. 2025; 22(6): 1472-9. Article. IF: 7.0; Q1
- **Tiong D, Pinilla-Echeverri N, Wood DA, Mehran R, Storey RF, Feldman L, Moreno R, Rao S, Cantor WJ, Welsh R, Bainey KR, Cohen EA, Tsang MB, Sibbald M, Natarajan MK, Wijesena D, Mani T, Nguyen H, Cairns JA, Mehta SR.** Impact of complete revascularisation in relation to left ventricular function in patients with ST-segment elevation myocardial infarction and multivessel disease: a post hoc analysis of the COMPLETE randomised trial. Eurointervention. 2025; 21(20): e1198-208. Article. IF: 9.2; D1

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

- **Torremocha A, Tébar D, Jurado A.** The role of non-invasive tests in pulmonary embolism. Interv Cardiol. 2025; 20: e26. Article. IF: 2.0; Q3
- **Traykov V, Puererfellner H, Burri H, Foldesi CL, Scherr D, Duncker D, Arbelo E, Botto GL, Boriani G, Heidbuchel H, Malaczynska-Rajpold K, Farkowski MM, Dagres N, Szymanski P, Huculeci R, Casado-Arroyo R, Boveda S, Merino JL.** EHRA perspective on the digital data revolution in arrhythmia management: insights from the association's annual summit. Europace. 2025; 27(8): euaf149. Article. IF: 10.2; D1
- **van der Waerden RGA, Volleberg RHJA, Luttikholt TJ, Cancian P, van der Zande JL, Stone GW, Holm NR, Kedhi E, Escaned J, Pellegrini D, Guagliumi G, Mehta SR, Pinilla-Echeverri N, Moreno R, Räber L, Roleder T, van Ginneken B, Sánchez C, Isgum I, van Royen N, Thannhauser J.** Artificial intelligence for the analysis of intracoronary optical coherence tomography images: a systematic review. Eur Heart J Digit Health. 2025; 6(2): 270-84. Review. IF: 5.3; Q1
- **Vázquez-Sánchez S, Blasco A, Fernández-Corredoira P, Cantolla P, Mercado-García E, Rodríguez-Sánchez E, González-Lafuente L, Poveda J, González-Moreno D, Matutano A, Peribañez S, García-Consuegra I, Volpe M, Fernández-Velasco M, Ruilope LM, Ruiz-Hurtado G.** Recombinant Klotho administration after myocardial infarction reduces ischaemic injury and arrhythmias by blocking intracellular calcium mishandling and CaMKII activation. J Pathol. 2025; 265(3): 342-56. Article. IF: 5.4; Q1
- **Vila-García J, Hernández GD, Manjavacas AMI, López SCV, García GG, Moriche EP, Moreno R.** A Torn leaflet an unusual complication of a degenerated transcatheter aortic valve prosthesis. JACC-Cardiovasc Inte. 2025; 18(8): 1062-4. Editorial Material. IF: 12.7; D1
- **Viñas-Mendieta AE, Gallardo-Grajeda A, López-Fernández T.** Cardio-oncology: chances and challenges. Basic Res Cardiol. 2025; 120(1): 3-9. Review. IF: 9.2; D1
- **White HD, O'Brien SM, Boden WE, Fremes SE, Bangalore S, Reynolds HR, Stone GW, Ali ZA, Parakh N, López-Sendón JL, Wang YX, Chen YQ, Mark DB, Chaitman BR, Spertus JA, Maron DJ, Hochman JS, ISCHEMIA Res Grp.** Use of coronary artery bypass graft surgery and percutaneous coronary intervention and associated outcomes in the ISCHEMIA trial. Am Heart J. 2025; 289: 78-94. Article. IF: 3.4; Q2
- **Wilkinson C, Bhatty A, Batra G, Aktaa S, Smith AB, Dwight J, Rucinski M, Chappell S, Alfredsson J, Erlinge D, Ferreira J, Guomundsdóttir IJ, Hrafnkelsdóttir TJ, Ingimarsdottir IJ, Irs A, Jánosi A, Jarai Z, Oliveira-Santos M, Popescu BA, Vasko P, Vinereanu D, Yap J, Bugiardini R, Cenko E, Nadarajah R, Sydes MR, James S, Maggioni AP, Wallentin L, Casadei B, Gale CP, Global Cardiovasc Outcomes Consortium, ACNAP, ACVC, EACVI, EAPC, EAPCI, EHRA, ESC Comm Young CV Professionals, ESC Registry Comm, HFA, ESC Patient Forum These Working Grp ()Merino Llorens JL).** Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). Eur Heart J. 2025; 46(2): 190-214. Article. IF: 45.3; D1
- **Zamorano JL, Vörös G, Calvi V, Osca J, Quesada A, Vernooy K, Martínez JG, Maass AH, Nof E, Tolosana JM, Pardo M, Barr C, Fernández I, Merino JL, Ellery S, Ricoy-Martínez E, Belotti G, Seidlmayer L, García S, Tönnis T, Campbell NG, Foley P, Brockmeier J, Nürnberg M, Ruiz-Granell R, Prinzen FW, Lorente-Ros A, Moreno A, Pinart M, Ver Heyen M, Van Erven L.** Sex-specific response to cardiac resynchronization therapy: the BIO|WOMEN trial. Int J Cardiol. 2025; 438: 133526. Article. IF: 3.3; Q2
- **Zeppenfeld K, Rademaker R, Al-Ahmad A, Carbucicchio C, De Chillou C, Cvek J, Ebert M, Ho G, Kautzner J, Lambiase P, Merino JL, Lloyd M, Misra S, Pruvot E, Sapp J, Schiappacasse L, Sramko M, Stevenson WG, Zei PC, Wichterle D, Chrispin J, Siklody CH, Neuwirth R, Pelargonio G, Reichlin T, Robinson C, Tondo C.** Patient selection, ventricular tachycardia substrate delineation, and data transfer for stereotactic arrhythmia radioablation: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology and the Heart Rhythm Society. Europace. 2025; 27(4): euae214. Article. IF: 10.2; D1

Research projects

- **Alonso Martín JJ.** Inflamación y disfunción endotelial en el infarto agudo de miocardio con arterias coronarias con y sin lesiones significativas (PI24/02079). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Fernández Velasco M.** Determinación de nuevos mediadores del sistema inmune innato como biomarcadores de daño cardiaco en el infarto agudo de miocardio. Sociedad Española de Cardiología (SEC). 2019-Ongoing. Managment centre: FIBHULP
- **Fernández Velasco M.** New inflammatory targets for atrial myopathy associated with heart failure (PI20/01482). ISCIII. 2021-2025. Managment centre: FIBHULP
- **Fernández Velasco M.** Nuevos mecanismos nanomoleculares implicados en la fisiopatología de la insuficiencia cardíaca (CNS2023-145161). MICINN. 2024-2026. Managment centre: FIBHULP
- **Fernández Velasco M.** Papel de los receptores nod1 en la cardiotoxicidad inducida por inmunoterapia en pacientes oncológicos (PI23/01014). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Jurado Román A.** ASSIST_AI scalable solution for st myocardial infarction (2023391). EIT-HEALTH. 2023-2025. Managment centre: FIBHULP
- **López Fernández T.** Creación de la base de datos etiquetada más grande del mundo para potenciar el análisis de ECG impulsado por ia para el diagnóstico temprano y predictivo de enfermedades cardiovasculares (CPP2024-011665). MICINN. 2025-2028. Managment centre: FIBHULP
- **López Fernández T.** The Legacy of Anthracycline Imprints in Bone Marrow: Uncovering Long-Term Cardiovascular Risks in Cancer Survivors" (TERESA LOPEZ-CNIC CAIXA CNIO). FUNDACION CENTRO NACIONAL INVESTIGACIONES CARDIOVASCULARES. 2025-2028. Managment centre: FIBHULP
- **López-Sendón Hentschel JL.** Dinamización de ciencia disruptiva en predictores de enfermedades tumorales, infecciosas y hereditarias como base de la medicina personalizada (FORT23/00006_GRUPO II). ISCIII. 2024-2027. Managment centre: FIBHULP
- **Merino Llorens JL.** Ablación mediante aislamiento de venas pulmonares solo o combinado con ablación lineal para eliminar recurrencias de fa persistente: un ensayo clínico multicéntrico aleatorizado (SUPAFER) (PI22/00278). ISCIII. 2023-2027. Managment centre: FIBHULP
- **Merino Llorens JL.** Addressing multimorbidity in elderly atrial fibrillation patients through interdisciplinary, tailored, patient-centred care pathways (EHRA-PATHS_JOSE LUIS MERINO). UE. 2021-2026. Managment centre: FIBHULP
- **Merino Llorens JL.** Aplicaciones de radiofrecuencia de alta potencia para ablación de venas pulmonares más rápida y segura (5064 POWERFAST III). FIBHULP. 2019-Ongoing. Managment centre: FIBHULP
- **Merino Llorens JL.** European Research Institute on Simulation (HORIZON-WIDERA-2024-ERA-02-01). EU. 2025-2028. Managment centre: HULP
- **Merino Llorens JL.** Impacto del aislamiento de venas pulmonares combinado con líneas de ablación en pacientes con insuficiencia tricuspídea severa y fibrilación auricular persistente sin indicación convencional de ablación (TRIABLA-AF) (SECARIT-INVMUL 25/04). Sociedad Española de Cardiología (SEC). 2025-2026. Managment centre: HULP
- **Merino Llorens JL.** Implementation of personalised risk prediction and prevention of sudden cardiac death after myocardial infarction (PROFID EHRA) (GA 847999). EU. 2023-2026. Managment centre: FIBHULP
- **Moreno Gómez JR.** BridGing gaps in caRdiAC health managEment (GRACE_MORENO). UE. 2025-2029. Managment centre: FIBHULP
- **Moreno Gómez JR.** Leading Innovation in Cardiovascular Pathways for Improved Patient Outcomes (EUROHEARTPATH_MORENO). UE. 2025-2030. Managment centre: FIBHULP
- **Pérez David E.** Caracterización de la fibrosis miocárdica en transposición de grandes vasos y ventrículo derecho sistémico mediante técnicas de imagen y biomarcadores moleculares y asociacíon con eventos adversos (PI22/00707). ISCIII. 2023-2027. Managment centre: FIBHULP
- **Pérez David E.** Medical augmented reality and digital twins (TEC-2024/COM-44). CM. 2025-2028.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Managment centre: FIBHULP

- **Pérez David E.** Rigorous atrial analysis in advanced interatrial block (ARABIA) (PI21/01501_ CONVENIO). FUNDACION BIOMEDICA HOSPITAL GREGORIO MARAÑON. 2025-2025. Managment centre: FIBHULP

Clinical Trials

- **Antorrena Miranda MI.** Estudio de fase iii, aleatorizado, doble ciego, controlado con placebo y motivado por los acontecimientos para demostrar la eficacia y seguridad de milvexian, un inhibidor oral del factor xia, después de padecer un síndrome coronario agudo reciente.
  Type/Phase: III
  Sponsored by: Janssen Research & Development, Llc.
  Signature date: 01/10/2025
- **Antorrena Miranda MI.** Phase 2, multicentre, randomised, double-blind, placebo-controlled safety and efficacy study of cdr132l on reverse cardiac remodelling in participants with heart failure with preserved ejection fraction and left ventricular hypertrophy.
  Type/Phase: II
  Sponsored by: Novo Nordisk A/S.
  Signature date: 10/12/2025
- **Antorrena Miranda MI.** Phase 2, multicentre, randomised, double-blind, placebo-controlled safety and efficacy study of cdr132l on reverse cardiac remodelling in participants with heart failure with preserved ejection fraction and left ventricular hypertrophy.
  Type/Phase: II
  Sponsored by: Novo Nordisk A/S.
  Signature date: 29/05/2025
- **Antorrena Miranda MI.** Phase 2, multicentre, randomised, double-blind, placebo-controlled safety and efficacy study of cdr132l on reverse cardiac remodelling in participants with heart failure with reduced/mildly reduced ejection fraction and left ventricular hypertrophy.
  Type/Phase: II
  Sponsored by: Novo Nordisk A/S.
  Signature date: 06/05/2025
- **Antorrena Miranda MI.** Phase 2, multicentre, randomised, double-blind, placebo-controlled safety and efficacy study of cdr132l on reverse cardiac remodelling in participants with heart failure with reduced/mildly reduced ejection fraction and left ventricular hypertrophy.
  Type/Phase: II
  Sponsored by: Novo Nordisk A/S.
  Signature date: 10/12/2025
- **Castro Conde A.** Comparación del efecto de tirzepatida frente al de dulaglutida sobre los acontecimientos cardiovasculares mayores en pacientes con diabetes de tipo 2 (surpass-cvot).
  Type/Phase: I
  Sponsored by: Lilly, S.A.
  Signature date: 14/04/2025
- **Guzmán Martínez G.** Registro multicéntrico español sobre la insuficiencia aórtica moderada y severa.
  Type/Phase: No EPA
  Sponsored by: Guzmán Martínez, Gabriela.
  Signature date: 30/10/2025
- **Galeote García G.** safety and effectiveness of short-term single antiplatelet therapy after left atrial appendage closure with the lambre device in patients with nonvalvular atrial fibrillation: a multinational real-world registry. (s-sapt secure-lambre registry).
  Type/Phase: EOm prospectivo
  Sponsored by: Fundación Epic.
  Signature date: 13/03/2025
- **Iniesta Manjavacas AM.** EASI-HF Reduced – Ensayo de superioridad de fase III, doble ciego, aleatorizado y con grupos paralelos para evaluar la eficacia y la seguridad del uso combinado del vicadrostat (bi 690517) y la empagliflozina por vía oral en comparación con un placebo y la empagliflozina en participantes con insuficiencia cardíaca crónica sintomática (ic: grado ii-iv de la clasificación de la nyha) y una fracción de eyección ventricular izquierda (fevi) <40 %.
  Type/Phase: III
  Sponsored by: Boehringer Ingelheim International Gmbh. S
  ignature date: 15/09/2025
- **Iniesta Manjavacas AM.** Estrategia de descongestión guiada por reds en pacientes hospitalizados por insuficiencia cardíaca: el estudio Reds-Safe HF II.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Fundacion Hospital Ramon Y Cajal.
  Signature date: 03/07/2025
- **Iniesta Manjavacas AM.** Estudio clínico controlado y abierto para evaluar el biomarcador hsa-rna-chr8:96 en el diagnóstico de miocarditis aguda.
  Type/Phase: OTROS
  Sponsored by: Fundación Para La Formación E Investigación Sanitarias De La Región De Murcia.
  Signature date: 18/02/2025
- **Iniesta Manjavacas AM.** Retrospective observational study to describe real-world treatment patterns and clinical profile of patients with chronic heart failure and reduced ejection fraction treated with vericiguat in routine clinical practice in spain: veripract study.
  Type/Phase: EPA-OD
  Sponsored by: Bayer Hispania S. L. U.
  Signature date: 16/01/2025
- **Iniesta Manjavacas AM.** Triton-CM: estudio global de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de nucresirán en pacientes con amiloidosis por transtiretina con miocardiopatía (amiloidosis attr con miocardiopatía).
  Type/Phase: III
  Sponsored by: Alnylam Pharmaceuticals Inc.
  Signature date: 03/10/2025
- **Jurado Román A.** Reduced stent strategy versus conventional percutaneous coronary revascularization in patients presenting with st-segment elevation myocardial infarction.
  Type/Phase: OTROS
  Sponsored by: Jurado Román, Alfonso.
  Signature date: 22/07/2025
- **Merino Llorens JL.** Anexo 1 6631 marcapasos para la bradicardia con modulación del intervalo av para el tratamiento de la tensión arterial.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Orchestra Biomed, Inc.
  Signature date: 25/03/2025
- **Merino Llorens JL.** Easthigh - Afnet 11 ensayo: ablación temprana de fibrilación auricular para la prevención de accidentes cerebrovasculares en pacientes con alta carga de comorbilidades.
  Type/Phase: OTROS
  Sponsored by: Kompetenznetz Vorhofflimmern E.V.
  Signature date: 18/06/2025
- **Merino Llorens JL.** Marcapasos para la bradicardia con modulación del intervalo av para el tratamiento de la tensión arterial.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Orchestra Biomed, Inc.
  Signature date: 10/09/2025
- **Moreno Gómez JR.** A multicenter, double-blind, randomized, placebo-controlled study of orticumab in participants with prior myocardial infarction who have elevated coronary inflammation based on fat attenuation index (fai) score assessed by coronary computed tomography angiography (ccta).
  Type/Phase: IIb
  Sponsored by: Abcentra Llc.
  Signature date: 20/05/2025
- **Moreno Gómez JR.** A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of an oral branched-chain ketoacid dehydrogenase inhibitor, PF-07328948, in adults with heart failure (branch-hf).
  Type/Phase: II
  Sponsored by: Pfizer Inc.
  Signature date: 09/07/2025
- **Moreno Gómez JR.** A phase 2A, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of JTT-861 administered for 12 weeks in subjects with heart failure with reduced ejection fraction (power-hf).
  Type/Phase: IIa
  Sponsored by: Akros Pharma Inc.
  Signature date: 10/07/2025
- **Moreno Gómez JR.** Anexo randomised, double-blind, placebo-controlled study to investigate a single administration of BI765845 on top of standard of care in patients with acute myocardial infarction.
  Type/Phase: II
  Sponsored by: Boehringer Ingelheim International Gmbh.
  Signature date: 21/01/2025
- **Moreno Gómez JR.** Clinical impact of underexpansion criteria of the acurate neo2 valve.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Fundacion Para La Investigacion Biomedica De Cordoba Fibico.
  Signature date: 30/09/2025
- **Moreno Gómez JR.** Efectos de ziltivekimab versus placebo en los resultados cardiovasculares

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



en pacientes con infarto agudo de miocardio y evidencia angiográfica de enfermedad arterial coronaria.
Type/Phase: IIIa
Sponsored by: Novo Nordisk Pharma, S.A.
Signature date: 15/07/2025

- **Moreno Gómez JR.** Ensayo de fase 2, adaptativo, doble ciego, controlado con placebo, aleatorizado y multicéntrico para evaluar la eficacia, seguridad y tolerabilidad de la infusión intracoronaria de ab-1002 en sujetos adultos con insuficiencia cardíaca de clase funcional iii de la nyha (new york heart association) y miocardiopatía no isquémica (genephit).
  Type/Phase: II
  Sponsored by: Asklepios Biopharmaceutical (Askbio).
  Signature date: 16/07/2025
- **Moreno Gómez JR.** Ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo en el que se evalúa el efecto de la disminución de la lipoproteína (a) con pelacarsén (tqj230) en la progresión de la estenosis valvular aórtica calcificada.
  Type/Phase: II
  Sponsored by: Novartis Pharma Services Ag.
  Signature date: 26/09/2025
- **Moreno Gómez JR.** Ensayo multicéntrico, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de omecamtiv mecarbilo en pacientes con insuficiencia cardíaca sintomática con fracción de eyección gravemente reducida.
  Type/Phase: III
  Sponsored by: Cytokinetics Inc.
  Signature date: 21/04/2025
- **Moreno Gómez JR.** Estudio de fase 2, doble ciego, aleatorizado, controlado con placebo, de 4 grupos para estudiar los síntomas, la funcionalidad, la calidad de vida relacionada con la salud y la seguridad de la administración subcutánea repetida de ponsegromab comparado con placebo en participantes adultos con insuficiencia cardíaca.
  Type/Phase: II
  Sponsored by: Pfizer Inc.
  Signature date: 13/03/2025
- **Moreno Gómez JR.** Estudio de fase 3 controlado con placebo, aleatorizado, doble ciego que evalúa la eficacia y la seguridad de maridebart cafraglutida en la mortalidad y morbilidad en participantes con insuficiencia cardíaca con fracción de eyección conservada o levemente reducida y obesidad (maritime-hf).
  Type/Phase: III
  Sponsored by: Amgen Inc.
  Signature date: 16/06/2025
- **Moreno Gómez JR.** Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de mk-0616 para reducir las complicaciones cardiovasculares graves en participantes con riesgo cardiovascular elevado.
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 13/08/2025
- **Moreno Gómez JR.** Monotherapy with a p2y12 inhibitor followed by a direct-acting oral anticoagulant in patients with atrial fibrillation undergoing supraflexcruz coronary stent implantation (matrix-2).
  Type/Phase: III
  Sponsored by: Insel Gruppe Ag.
  Signature date: 07/05/2025
- **Moreno Gómez JR.** Prospective, multicenter, randomized controlled trial to investigate the value of coronary ct angiography in the understanding an management of coronary calciun. the optimal trial.
  Type/Phase: EOm prospectivo
  Sponsored by: Fundación Epic.
  Signature date: 27/11/2025
- **Moreno Gómez JR.** Registro prospectivo español mylead: alteraciones tardías y tempranas de la conducción inducidas por myval mylead spanish prospective registry: myval induced late and early conduction disturbances.
  Type/Phase: OTROS
  Sponsored by: Instituto De Estudios Ciencias Salud Castilla Instituto De Estudios Ciencias.
  Signature date: 01/07/2025
- **Peinado Peinado R.** Reducción de descargas mediante ráfagas múltiples de estimulación antitaquicardia para taquicardias ventriculares rápidas en portadores de desfibrilador automático implantable.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Fundacion Idibell.
  Signature date: 07/02/2025
- **Rey Blas JR.** Eficacia y seguridad combinadas de una estrategia de tratamiento intensiva con finerenona y un inhibidor de sglt2 en pacientes hospitalizados con insuficiencia cardíaca (confirmation-hf).
  Type/Phase: III
  Sponsored by: CPC Clinical Research.
  Signature date: 14/05/2025
- **Rey Blas JR.** Estudio pragmático, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia clínica de la finerenona en pacientes con insuficiencia cardíaca y fracción de eyección reducida que son intolerantes o no son aptos para el tratamiento con antagonistas esteroideos del receptor de mineralocorticoides (finality-hf).
  Type/Phase: III
  Sponsored by: CPC Clinical Research.
  Signature date: 13/06/2025
- **Rodriguez Chaverri A.** Estudio de correlación del grado de congestión en insuficiencia cardiaca con el dispositivo sensocor.
  Type/Phase: OTROS
  Sponsored by: Ffdis.
  Signature date: 12/05/2025
- **Rosillo Rodríguez S.** Arise RCT - a randomized controlled study of the neurescue device as an adjunct to advanced cardiac life support (acls).
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Neurescue Aps.
  Signature date: 03/09/2025
- **Sanz Andrés A.** retirada del tratamiento neurohormonal en pacientes con miocardiopatía no isquémica, sin realce tardío de gadolinio y con test genético negativo, que hayan sido super-respondedores a la terapia de resincronización cardiaca.
  Type/Phase:
  Sponsored by: Fundacion Idibell.
  Signature date: 12/12/2025


Patents and trademarks

- **Riera del Moral LF, inventor; FIBHULP, assignee.** Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.
- **Filgueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees.** Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.
- **Castro Conde A, author; FIBHULP, assignee.** Trade-mark name: RECAR Programa de Rehabilitación Cardiaca; CM 18457042; 2021 April 20.
- **Pérez Gómez AL, González Lafuente L, Pelegrín Vivancos P, Cuevas González S, Egea Maíquez J, Fernández Velasco M, Alquézar Burillo C, Bartolomé Robledo F, Ruiz Hurtado G; Hospital Universitario 12 de Octubre, Universidad de Murcia, FFIS-IMIB, FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario La Princesa.** Método de detección y cuantificación de motas extracelulares de ASC en muestras biológicas mediante citometría espectral. P202531231; 2025 Diciembre 22.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.2.2 Coagulopathies and Alterations of Haemostasis Group



Publications: 18 | Q1: 7

COMPOSITION

Víctor Manuel Jiménez Yuste.
Jefe de Servicio de Hematología. Hospital Universitario La Paz/Profesor Asociado. Universidad Autónoma de Madrid

- **María Teresa Álvarez Román.** *Jefa de Sección de Coagulopatías. Hospital Universitario La Paz/Profesor Asociado. Universidad Autónoma de Madrid*
- **Nora Viviana Butta Coll.** *Investigadora Senior (Contrato Miguel Servet - Tipo 2). Jefa de Laboratorio. Hospital Universitario La Paz*
- **Hortensia de la Corte Rodríguez.** *Facultativo Especialista de Área en Hematología y Hemoterapia. Hospital Universitario La Paz*
- **Raquel Fernández Morata.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **Sara García Barcenilla.** *Coordinadora de Estudios. Hospital Universitario La Paz*
- **Mercedes Gassior Kabat.** *Facultativo Especialista de Área en Hematología y Hemoterapia. Hospital Universitario La Paz*
- **Mónica Martín Salces.** *Facultativo Especialista de Área en Hematología y Hemoterapia. Hospital Universitario La Paz*
- **Elena Monzón Manzano.** *Investigadora Postdoctoral. FIBHULP*
- **Isabel Rivas Pollmar.** *Médico Adjunto en Hematología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- The research group's activities address various relevant issues in the field of hematology, focusing on characterizing the genetic and molecular basis of coagulation and hemostatic function. Our group investigates physiological processes such as coagulation, hemostasis, innate immunity, inflammation, cell adhesion and migration, and cell signaling, with particular emphasis on their relevance to pathological processes. Furthermore, we conduct epidemiological studies to facilitate patient data analysis and therapeutic intervention.

RESEARCH LINES

- Hemophilia A and B: Individualizing treatment according to patient characteristics
- New hemostatic treatments for bleeding disorders
- Hemostasis in patients with thrombocytopenia

RESEARCH ACTIVITY

Final Degree Theses

- **Ortega Carro M.** Resultados de la profilaxis en la Enfermedad de von Willebrand[dissertation]. Madrid: UAM: 2025(25/06/2025). Director: Álvarez Román MT, Jiménez Yuste V.
- **Acuña Butta P.** Estudio clínico y de laboratorio en el tratamiento de la hemofilia con terapias no sustitutivas[dissertation]. Madrid: UAM: 2025(24/06/2025). Director: Álvarez Román MT, Jiménez Yuste.
- **Serrada Acebes B.** Fenotipo clínico y respuesta a agonistas de receptores de trombopoyetina en pacientes ancianos con trombocitopenia inmune[dissertation]. Madrid: UAM: 2025(17/06/2025). Director: Álvarez Román MT, Jiménez Yuste V

Publications

- **Buckner TW, Kessler C, Castaman G, Hermans C, Jiménez-Yuste V, Mahlangu J, Miesbach W, Oldenburg J, Recht M, Valentino LA, Wheeler AP, Pipe SW.** Pain reduction following eptacog beta treatment of bleeding episodes in adolescents and adults with haemophilia A or B complicated by inhibitors. Haemophilia. 2025; 31(4): 713-21. Article. IF: 3.0; Q2
- **Butta N, van der Wal DE.** Desialylation by neuraminidases in platelets, kiss of death or bittersweet? Curr Opin Hematol. 2025; 32(1): 43-51. Article. IF: 2.9; Q2
- **Castaman G, Croteau SE, Quon D, Lee LCY, Polito L, Jiménez-Yuste V.** A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors. Res Pract Thromb Haemost. 2025; 9(1): 102693. Review. IF: 3.5; Q2
- **Castaman G, Jiménez-Yuste V, Mahlangu J.** Concizumab, a Non-Replacement therapy for persons with hemophilia with inhibitors. J Clin Med. 2025; 14(9): 2961. Review. IF: 3.3; Q1

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

- **de Bustamante JMM, Rivas-Pollmar MI, Acedo N, Butta N, Jiménez-Yuste V, Álvarez-Román MT.** Real-world experience with eptacog beta for on-label and off-label indications: the Spanish Experience. Pharmaceuticals (Basel). 2025; 18(11): 1640. Article. IF: 5.7; Q1
- **Hermans C, Astermark J, Trakymien SS, Jiménez-Yuste V.** Haemophilia B: an illustrative review of current challenges and opportunities. Res Pract Thromb Haemost. 2025; 9(8): e103229. Review. IF: 3.5; Q2
- **Klamroth R, von Drygalski A, Hermans C, Park YS, Chan AKC, Kupesiz A, Álvarez-Román MT, Malec L, Santagostino E, Neill G, Bystrická L, Dumont J, Abad-Franch L, Fetita LS, Khoo L.** Perioperative management with efanesoctocog alfa in patients with haemophilia a in the phase 3 XTEND-1 and XTEND-kids studies. Haemophilia. 2025; 31(3): 391-400. Article. IF: 3.0; Q2
- **Mancuso ME, Chowdary P, Valentino LA, Jiménez-Yuste V, Klamroth R, Hermans C.** Deconstructing the ISTH Hemophilia Guidelines for the clinician: comment from Mancuso et al. J Thromb Haemost. 2025; 23(5): 1735-6. Letter. IF: 5.2; Q1
- **Marín-Quílez A, Sánchez-Fuentes A, Zamora-Cánovas A, Gómez-González PL, Díaz-Ajenjo L, Benito R, Rodríguez-Alén A, Sevivas T, Murciano T, Murillo L, Butta NV, Revilla N, Campos R, Escribano P, Esteve J, Fernández-Mosteirin N, Ferrer-Marín F, Hernández L, Huerta-Aragonés J, León A, López-Duarte M, López E, Martín-Salces M, Nomdedeu M, Oña R, Peláez-Pleguezuelos I, Ramos F, Sebastián E, Serrano C, Sierra-Aisa C, Vidal-Laso R, González-Porras JR, Lozano ML, Bastida JM, Rivera J.** Insights into the clinical, platelet and genetic landscape of inherited thrombocytopenia with malignancy risk. Brit J Haematol. 2025; 207(4): 1565-77. Article. IF: 3.6; Q2
- **Matino D, Palladino A, Taylor CT, Hwang E, Raje S, Nayak S, Mcdonald R, Acharya SS, Mahlangu J, Jiménez-Yuste V, Choraria N, Yang RC, Li CK, Al-Khabori M, Wali Y, Adrian JM, Park YS, Zülfikar OB, Teeter J.** Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. Blood. 2025; 146(14): 1654-63. Article. IF: 23.9; D1
- **Mendoza A, Rivas I, Hidalgo OB, Cid AR, Olivieri M, Ranta S, Labarque V, Andersson NG, de Kovel M, Álvarez-Román MT.** Impact of family history of haemophilia on diagnosis, management and outcomes in severe haemophilia. Haemophilia. 2025; 31(4): 679-86. Article. IF: 3.0; Q2
- **Miesbach W, Boban A, Chowdary P, Coppens M, Jiménez-Yuste V, Klamroth R, Mulders G, Crato M, Peyvandi F.** Qualification criteria of gene therapy for haemophilia-opinion of the EAHAD gene therapy working group. Haemophilia. 2025; 31(5): 966-72. Article. IF: 3.0; Q2
- **Molina LD, Manzano EM, Gianelli C, Gallego LY, Fernández JB, Acuña P, Serrano YS, Yebra KR, García-Morato MB, Zapardiel ES, Arias-Salgado EG, Pena RR, Butta N, Granados EL.** Effects of two different variants in the MAGT1 gene on B cell subsets, platelet function, and cell glycome composition. Front Immunol. 2025; 16: 1547808. Article. IF: 7.0; Q1
- **Pascual-Izquierdo C, Llacer-Ferrandis MJ, de-la-Iglesia A, Monsalvo-Saornil S, Menor-Gómez M, Gil-Fernández JJ, Chica-Gullón E, Álvarez-Román MT, Perez-Segura G, Zafra D, Ortuzar-Pasalodos A, González-Gascón-y-Marín IT, Moreno G, Arquero-Portero T, Moreno-Carbonell M, Revilla N.** Avatrombopag in adults with immune thrombocytopenia: A multicentre real-life observational study in Madrid, Spain (AVAMAD study). Brit J Haematol. 2025; 206(2): 652-6. Article. IF: 3.6; Q2
- **Quintana-Castanedo L, Maseda R, Pérez-Conde I, Butta N, Monzón-Manzano E, Acuña-Butta P, Crespo MG, Buño-Soto A, Jiménez E, Valencia J, Arriba MC, Zuluaga P, de Lucas R, del Rio M, Vicente A, Escámez MJ, Sacedón R.** Interplay between iron metabolism, inflammation, and EPO-ERFEhepcidin axis in RDEB-associated chronic anemia. Blood Adv. 2025; 9(9): 2321-35. Article. IF: 7.7; Q1
- **Rodríguez-Merchán EC, de la Corte-Rodríguez H, Antuña S, Gomez-Cardero P, Álvarez-Román MT, Jiménez-Yuste V.** Shoulder arthroplasty in hemophilia. Arch Bone Jt Surg. 2025; 13(3): 164-9. Article. IF: 1.6; Q3
- **Sánchez-Sánchez C, Suarez-Trujillo F, Ramírez C, Soleto I, Mercado J, Orejudo M, Martínez PJ, Collado CR, Orts M, Franco MJR, Planas A, Acedo N, Butta N, Chaparro M, Gisbert JP, Baldán-Martín M.** Effect of Tofacitinib on hemostasis in patients with ulcerative colitis: a comparative ex vivo study. Pharmaceuticals (Basel). 2025; 18(4): 557. Article. IF: 5.7; Q1
- **Srivastava A, Kanny A, Langer F, Kubicek-Hofmann C, Román MTA, Vázquez RN, Boban A, Dejanova-Ilijevska V, Miljic P, Garcia J, Halimeh S, Drillaud N, Valentin JB, Mancuso ME, Castaman G, Santoro RC, Lehtinen AE, Abraham A, Hashimoto M, Knaub S.** NuPOWER (Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis): protocol for an open-label, single-arm, multicentre study. BMJ Open. 2025; 15(10): e102657. Article. IF: 2.5; Q2


Research projects

- **Álvarez Román MT.** Fenotipo clínico y respuesta a agonistas de receptores de trombopoyetina en pacientes ancianos con trombocitopenia inmune (PI22/01489). ISCIII. 2023-2027. Managment centre: FIBHULP
- **Jiménez Yuste VM, García Arias-Salgado E.** Desarrollo de nuevas estrategias para mejorar el manejo terapéutico de los pacientes con hemofilia a en presencia de inhibidor (PI22/01461). ISCIII. 2023-2027. Managment centre: FIBHULP
- **Jiménez Yuste VM.** HEAD-US Mobile APP: Desing and implementation. Pfizer. 2017-Ongoing. Managment centre: FIBHULP

Clinical Trials

- **Jiménez Yuste VM.** Open-label, long-term safety and efficacy study of mim8 in participants with haemophilia a with or without inhibito.
  Type/Phase: IIIb
  Sponsored by: Novo Nordisk A/S.
  Signature date: 14/11/2025
- **Álvarez Román MT.** Estudio en fase III, abierto, paralelo y de dos grupos para investigar la eficacia y la seguridad de la profilaxis con fitusirán en participantes del género masculino de 1 a menos de 12 años con hemofilia a o b con o sin anticuerpos inhibidores de los factores viii o ix.
  Type/Phase: III
  Sponsored by: Sanofi Aventis S.A.
  Signature date: 03/11/2025
- **Jiménez Yuste VM.** Estudio abierto de extensión para evaluar la seguridad a largo plazo, la tolerabilidad y la eficacia de marstacimab en profilaxis en pacientes con hemofilia a grave (actividad del factor de coagulación <1 %) con o sin inhibidores o en pacientes con hemofi.
  Type/Phase: III
  Sponsored by: Pfizer, S.L.U.
  Signature date: 31/03/2025
- **Jiménez Yuste VM.** Eficacia y seguridad de la administración de concizumab en profilaxis en pacientes con hemofilia a o b con inhibidores.
  Type/Phase: III
  Sponsored by: Novo Nordisk Pharma, S.A.
  Signature date: 06/06/2025
- **Jiménez Yuste VM.** Estudio abierto para investigar la eficacia, la seguridad y la farmacocinética de la profilaxis con concizumab en niños menores de 12 años con hemofilia a o b con o sin inhibidores.
  Type/Phase: IIIa
  Sponsored by: Novo Nordisk A/S.
  Signature date: 05/06/2025
- **Jiménez Yuste VM.** Estudio en fase I/II para evaluar la seguridad, tolerabilidad, farmacocinética,

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



farmacodinámica y eficacia de nxt007 en personas con hemofilia a grave o moderada.
Type/Phase: I
Sponsored by: F.Hoffmann-La Roche Ltd.
Signature date: 26/05/2025

- **Jiménez Yuste VM.** Open-label, long-term safety and efficacy study of mim8 in participants with haemophilia a with or without inhibito.
Type/Phase: IIIb
Sponsored by: Novo Nordisk A/S.
Signature date: 26/05/2025
- **Álvarez Román MT.** Estudio de fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos con una extensión abierta para evaluar la eficacia y la seguridad de rilzabrutinib por vía oral (prn1008) en adultos y adolescentes con trombocitopenia inmunitaria (tpi) persistente o crónica.
Type/Phase: III
Sponsored by: Principia Biopharma Inc.
Signature date: 04/04/2025
- **Jiménez Yuste VM.** Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending peroral doses of inno8 in people with haemophilia a.
Type/Phase: I
Sponsored by: Novo Nordisk A/S.
Signature date: 04/07/2025
- **Álvarez Román MT.** Estudio global, abierto y de diseño adaptativo para investigar la eficacia y la seguridad de serpinpc en pacientes con hemofilia a grave o con hemofilia b de moderadamente grave a grave.
Type/Phase: IIb
Sponsored by: Apcintex Ltd.
Signature date: 26/02/2025
- **Álvarez Román MT.** Registro RESTI: registro español de la trombocitopenia inmune primaria y otras trombocitopenias inmunes.
Type/Phase: EOm prospectivo
Sponsored by: Fundación Española Hematología Y Hemoterapia (Fehh).
Signature date: 30/04/2025
- **Álvarez Román MT.** Estudio abierto, multinacional de profilaxis con fitusiran en pacientes pediátricos varones de 1 a menos de 12 años de edad con hemofilia a o b.
Type/Phase: II
Sponsored by: Sanofi Aventis S.A.
Signature date: 07/01/2025
- **Gasior Kabat M.** Estudio de evidencia de vida real sobre mielofibrosis mediante la aplicación de técnicas de inteligencia artificial. remyel-ai.
Type/Phase: EPA-OD
Sponsored by: Glaxosmithkline Research And Development Limited.
Signature date: 18/02/2025
- **Jiménez Yuste VM.** Phase 3, open-label, singledose, multicenter study investigating efficacy, safety, and tolerability of csl222 (etranacogene dezaparvovec) administered to adolescent male subjects (≥ 12 to < 18 years of age) with severe or moderately severe hemophilia b.
Type/Phase: III
Sponsored by: C. S. L. Behring.
Signature date: 16/12/2025
- **Álvarez Román MT.** Registro español de sindrome de von willebrand adquirido.
Type/Phase: EOm prospectivo
Sponsored by: Octapharma, S.A.
Signature date: 19/05/2025
- **Jiménez Yuste VM.** Estudio no intervencional multicéntrico para evaluar las hemorragias y la calidad devida relacionada con la salud en pacientes con enfermedad de von willebrand de tipo 3 contratamiento profiláctico de referencia.
Type/Phase: EOm prospectivo
Sponsored by: Roche Farma, S.A.
Signature date: 26/02/2025
- **Jiménez Yuste VM.** Estudio de fase III, multicéntrico y abierto para evaluar la eficacia, la seguridad, la farmacocinética y la farmacodinámica de la profilaxis con emicizumab en pacientes con enfermedad de von willebrand de tipo 3.
Type/Phase: III
Sponsored by: F. Hoffmann-La Roche Ltd.
Signature date: 18/03/2025
- **Jiménez Yuste VM.** Estudio abierto en dos partes de regv131-lnp1265, un tratamiento de inserción de genes del factor ix de la coagulación basado en crispr/cas9 en participantes con hemofilia b.
Type/Phase: II
Sponsored by: Regeneron Pharmaceuticals, Inc.
Signature date: 13/06/2025
- **Garcia Romero MM.** An open-label extension study of erydex in patients with ataxia telangiectasia following participation in study iedat-04-2022 (neat).
Type/Phase: OTROS
Sponsored by: Quince Therapeutics S.P.A.
Signature date: 30/01/2025
- **Jiménez Yuste VM.** Estudio observacional de seguimiento a largo plazo posautorización para caracterizar la eficacia y la seguridad de hemgenix® (etranacogén dezaparvovec) en pacientes con hemofilia b.
Type/Phase: EPA-SP
Sponsored by: C. S. L. Behring.
Signature date: 22/04/2025

Patents and trademarks

- **García Rivera MC, Jiménez Yuste VM, García Rivera FJ, Butta Coll NV, Carballo Carrillo MA, Álvarez Román MT, García Arias-Salgado E.**, inventors; FIBHULP, assignes; Dispositivo para conservación de muestras biológicas. P202230651, ES2958529. 2024 feb 09

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.2.3 Vascular Physiology and Pharmacology Group

Publications: 10 | Q1:6

COMPOSITION

Ana María Briones Alonso.
Profesora Titular. Dpto. Farmacología, Facultad de Medicina. Universidad Autónoma de Madrid

- **María Jesús Alonso Gordo.** *Catedrática. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos*
- **Constanza Ballesteros Martínez.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **María Teresa Barrús Ortiz.** *Profesora Contratada Doctora. Departamento de Ciencias de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos*
- **Javier Blanco Rivero.** *Profesor Titular. Departamento de Fisiología. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Naoual Boukich El Houari.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Ana Belén García Redondo.** *Profesora Permanente Laboral. Universidad Autónoma de Madrid*
- **Raquel González Blázquez.** *Profesora Titular. Universidad San Pablo CEU*
- **Zoe González Carnicero.** *Investigadora Postdoctoral. Universidad Rey Juan Carlos*
- **Raquel Hernanz Martín.** *Profesora TItular. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos*
- **Ángela Martín Cortes.** *Profesora Contratada Doctor. Departamento de Ciencias de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos*
- **Marta Martínez Casales.** *Profesora Visitante. Universidad Rey Juan Carlos*
- **Abraham Merino López.** *Ayudante de Investigación. Universidad Autónoma de Madrid*
- **Marta Miguel Castro.** *Científico Titular. Instituto de Investigación en Ciencias de la Alimentación. Consejo Superior de Investigaciones Científicas*
- **Roberto Palacios Ramírez.** *Investigador Postdoctoral. Universidad Rey Juan Carlos*
- **Mercedes Salaices Sánchez.** *Catedrática. Departamento de Farmacología. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Lucía Serrano Díaz del Campo.** *Investigadora predoctoral. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- Our group is a well-established research group with more than 30 years of experience in the study of the mechanisms involved in the functional, structural and mechanical alterations of the vasculature in various cardiovascular pathologies such as ageing, diabetes and, in particular, hypertension.
- The group is located at the Faculty of Medicine (UAM) as well as URJC, CIAL and U San Pablo (CEU) and maintains research collaborations with investigators at various universities in Spain and in other countries. Our main objective is to gain further insight into the physiological and molecular mechanisms involved in alterations of resistance and conductance arteries in cardiovascular pathologies. To conduct our research, we generally use various experimental approaches including in vivo animal models, ex vivo experiments and in vitro cellbased studies combined with physiological, pharmacological and molecular biology techniques. In addition, we have begun to translate this knowledge into human studies. In terms of the mediators involved, we have a particular interest in proinflammatory prostanoids, reactive oxygen species (and their interaction among each other or with other mediators such as nitric oxide) and proresolvin lipid mediators. This research is important given the essential role these mediators play in the control of vascular smooth muscle tone and vascular structure.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH LINES

- The role of menopause in the development of hypertension and cardiovascular disorders associated with the use of anti-cancer drugs
- The effect of GLP-1 analogues on hypertension-associated cardiovascular alterations in menopause
- Inflammation and vascular function and remodelling. Changes with hypertension and other cardiovascular pathologies.
- Adipose tissue and vascular alterations in cardiovascular pathologies.
- Neural control of vascular tone.
- Cardiovascular effects of heavy metals.
- Antioxidant and antihypertensive properties of food bioactive compounds.
- Resolution of inflammation as a therapeutic approach for cardiovascular diseases
- Effect of gut microbiota modulation in different physiopathological sitiuations

RESEARCH ACTIVITY

Final Degree Theses


- **García Hernández D.** Efecto de distintas suplementaciones nutricionales con hidrolizados proteicos sobre la sarcopenia asociada al envejecimiento[dissertation]. Madrid: Universidad Autónoma de Madrid: (25/05/2025). Director: Blanco Rivero J.
- **Tuca M.** Interpretación de las alteraciones en el electrocardiograma del paciente adulto con infarto agudo de miocardio: una revisión narrativa[dissertation]. Madrid: Universidad Autónoma de Madrid: (25/05/2025). Director: Blanco Rivero J.

Publications

- **Soudant J, González-Blázquez R, Merino A, Ballesteros-Martinez C, Rodrigues-DÍez R, Moreno-Carriles R, Nistal JF, Guerra S, Redondo JM, Salaices M, Briones AM, García-Redondo AB.** Interferon stimulated gene 15 (ISG15) modulates phenotype of vascular smooth muscle cells and pathological vascular remodeling. Clin Investig Arterioscler. 2025; 37(5): 500769. Article. IF: 1.9; Q3
- **Gabarre P, Palacios R, Perez K, Seksik P, Bonnard B, Loens C, Lefranc C, de Barros JPP, Anjou L, Tamzali Y, Zahr N, Jaisser F, Tourret J.** Immunosuppressive drugs and diet interact to modify the gut microbiota and cardiovascular risk factors, and to trigger diabetes. Plos One. 2025; 20(3): e0320438. Article. IF: 2.8; Q2
- **Briones AM, Hernanz R, García-Redondo AB, Rodríguez C, Blanco-Colio LM, Val-Blasco A, Alonso MJ, Salaices M.** Role of inflammatory and proresolving mediators in endothelial dysfunction. Basic Clin Pharmacol. 2025; 136(5): e70026. Review. IF: 3.6; Q2
- **Méndez-Albiñana P, Cros-Brunsó L, Rodrigues-Díez R, Rodríguez-Rodríguez P, Santamaría L, Muñoz-Labrador A, Requena T, Casani L, Caballero FF, Prieto-Nieto MI, Villamiel M, Blanco-Rivero J.** Synbiotic administration improves systemic and vascular alterations in rats with experimental microsurgical extrahepatic cholestasis: role of perivascular mesenteric innervation. Bioact Carbohydr Diet Fibre. 2025; 34: 100505. Article. IF: 3.3; Q2
- **van der Taelen L, Briones AM, Unger T, Staals J, van Oostenbrugge RJ, Foulquier S.** Circulating immune cells in cerebral small vessel disease: a systematic review. Biogerontology. 2025; 26(3): 101. Review. IF: 5.3; Q1
- **Almendra-Pegueros R, Rodríguez C, Camacho M, Sánchez-Infantes D, Sánchez-Quesada JL, Cáncer S, Pérez-Marlasca E, Medina-Gómez G, Martinez-González J, García-Redondo AB, Galán M.** Identification of endoplasmic reticulum stress- associated lncRNAs influencing inflammation and VSMC function in abdominal aortic aneurysm. Clin Sci. 2025; 139(6): 357-72. Article. IF: 7.3; Q1
- **Méndez-Albiñana P, Rodrigues-Díez R, Rodríguez-Rodríguez P, Moreno R, Muñoz-Valverde D, Casani L, Villamiel M, Blanco-Rivero J.** Structure and properties of citrus pectin as influencing factors of biomarkers of metabolic syndrome in rats fed with a high-fat diet. Curr Res Food Sci. 2025; 10: 101014. Article. IF: 7.7; D1
- **Palacios-Ramírez R, Francés DE, Motiño García-Miguel O.** Autophagy in age-related liver disease. Geroscience. 2025; 1: 202509. Article. IF: 6.0; Q1
- **Rahman J, Bibby JA, Singh P, Merle NS, West EE, Bohrer A, Mayer-Barber K, Liu CY, Brinster LR, Afzali B, Briones AM, Alehashemi S, Bhuyan F, Ge JH, Chen XJ, Zhou YB, Clarke MCH, Liu B, Goldbach-Mansky R, Serezani CH, Kemper C.** A CD4+T cell-intrinsic complement C5aR2-prostacyclin-IL-1R2 axis orchestrates Th1 cell contraction. Immunity. 2025; 58(6): 1438-55. Article. IF: 30.6; D1
- **Ganse FG, Ernst LM, Rodríguez C, Ruiz-Meana M, Inserte J, Martínez-González J, Briones AM, García-Redondo AB, Consegal M, Miro-Casas E, Yáñez-Bisbe L, Pomposo A, Prades-Martínez M, Ferreira-González I, Puntes V, Benito B, Rodríguez-Sinovas A.** Insights into the causal role of diesel exhaust particles in ventricular arrhythmogenesis: protective effects of antioxidant cerium oxide nanoparticles. Part Fibre Toxicol. 2025; 22(1): 36. Article. IF: 10.6; D1

Research projects

- **Briones Alonso AM.** Células endoteliales como diana de mediadores resolutivos y genes estimulados por interferon (PID2024-159672OB-I00). AEI. 2025-2029. Managment centre: UAM
- **Briones Alonso AM.** Deciphering the role of novel inflammatory mediators derived from interferon and the inefficient resolution of inflammation in the cardiovascular damage associated to hypertension (Hyper-resolution). (PID2020-116498RB-I00). AEI. 2021-2025. Managment centre: UAM
- **Briones Alonso AM.** Restaurando el balance: mediadores proresolutivos especializados para la resolución de la inflamación y la reparación vascular en humanos con alto riesgo cardiovascular (AC23_2/00044). ISCIII. 2024-2026. Managment centre: FIBULP
- **Briones Alonso AM.** Targeting SGK1: Bridging Therapied for Parkinson and Cardiovascular Diseases (SGK1- 4PDCar). CiberCV. 2024-2027. Managment centre: CiberCV
- **Hernanz Martin R, Alonso Gordo MJ.** GLP-1 y ECA2 como nuevas dianas para el tratamiento de la hipertensión en la menopausia. (2025/00009/006). URJC. 2025-2025. Managment centre: URJC



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Ciber y Retics

- **Briones Alonso AM.** Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV)(CB16/11/00286). IISCIII. (31/12/2025). UAM

Patents and Trademarks

- **Pérez Girón JV, Ruiz-Castellanos MJ, de Luis Jiménez O, Pérez Boto V, Sanz González R, Hernández Vélez MC, Mas Gutiérrez JA, Alonso Gordo MJ, Salaíces Sánchez M, Ros Pérez M, Coloma Jerez A, Asenjo Barahona A, Sanz Montaña JL, Puente Prieto J, Jensen J, inventors; NANOATE, S.**L., assignee. Method for producing biosensors. P201031224, PCT/ES2011/070536; 2010 August 05.
- **Miguel Castro M, López-Alonso Fandiño R, Recio Sánchez MI, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee.** Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis. P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, DE602004012289, DK1661913, JP2007523045; 2003 July 31.
- **Miguel Castro M, López-Alonso Fandiño R, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee.** Production of and antihypertensive properties of peptides derived from egg white proteins. P200501246 PCT/ES2006/070067; 2005 May 23.
- **Recio Sánchez MI; Quirós del Bosque A, Hernández Ledesma B, Gómez Ruiz JA, Miguel Castro M, Amigo Garrido L, López Expósito I, Ramos González MM, Aleixandre de Artiñano A, (Contreras Gómez M), inventors; CSIC, assignee.** Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same. P200501373, PCT/ES2006/070079, EP1905779, EP2495250, US8354502, AU2006256720, BRPI0611729, CA2611416, CN101305017, CN103254278, JP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08.
- **Garcés Rimón M, Miguel Castro M, López-Alonso Fandiño R, López-Miranda González V, Uranga Ocio J, inventors; CSIC, Universidad Rey Juan Carlos, assignees; Use of multifunctional bioactive products derived from the enzymatic hydrolysis of egg white proteins for treating metabolic syndrome.** P201331767, PCT/ES2014/070880; 2013 December 04.



- **Miguel Castro M, Garcés Rimón M, López-Alonso Fandiño R, Sandoval Huertas M, inventors; CSIC, Mario Sandoval Huertas, assignees.** Healthy food compositions having gel or foam textures and comprising hydrolyzed egg products. P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, JP2015130856, MX2014015135; 2013 December 20.
- **González-Muñiz R, Pérez de Vega MJ, Miguel M, Balsera-Paredes B, Moreno S, inventors; CSIC, assignee.** Triazolyl polyphenols with antioxidant activity and uses thereof; P201531450; 2015 November 08 .
- **González-Muñiz R, Miguel Castro M, Pérez de Vega MJ, Balsera-Paredes B, S Moreno, inventors; CSIC, assignee.** Compounds with antioxidant activity and uses thereof. P201630362; 2016 March 29.
- **León Martínez R, Abril Comesaña S, Duarte Flórez P, Crisman Vigil E, Michalska P, Salaices Sánchez M, Menéndez Ramos JC, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees.** Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas. P201930908. 2019 October 14 .
- **León Martínez R, Abril Comesaña S, Michalska P, Buendia Abaitua I, Salaices Sánchez M, Menéndez Ramos JC, García López M; inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees.** Compuestos derivados de 2-iodo-7-(((2-(5-metoxi-1H-indol-3-il)etil)amino)metil)-1-alquil/aril-6,7,7a,8-tetrahidro-3H-pirrolo[2,1-j]quinolina-3,9(5H)-diona como agentes antioxidantes, inductores de NRF2 y moduladores nicotínicos para el tratamiento de enfermedades neurodegenerativas. P201930190. 2019 March 01 .
- **Miguel Castro M, Garcés Rimón M, authors; Miguel Castro M, Garcés Rimón M, assignees.** Brand name: leggie. ESM4044711; 2019 November 22. Concesión 8 Junio 2020

leggie

- **Miguel M, Bruna E, Redondo BI, Gómez J, Gómez Sánchez J.** inventors: : Cárnicas Joselito S.L: assigne. Extracto procedente de la grasa de cerdo, método de obtención, composición alimenticia que lo comprende y usos del mismo. P2021130236. 2021 March 17
- **Miguel M, Bruna E, Redondo BI, Gómez J, Gómez Sánchez J, Sabater-Muñoz B.** inventors: Cárnicas Joselito S.L. assignee. Composición farmacéutica que comprende un extracto procedente de la grasa de jamón de cerdo como principio activo y su uso en medicina para la prevención cardiovascular e inflamación intestinal. P202131111. 2021 november 30
- **Alonso Gordo MJ, Hernanz Martín R, Martínez Casales M, González Carnicero Z, León Martínez R, Michalska Djzma P.** inventors; Universidad Rey Juan Carlos, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, assinees; (E)-3-(4-hidroxi-3-metoxifenil)-acrilato de 3-(2-acetamidoetil)-1H-indol-5-ilo para uso en la prevenciaón y/o tratamiento de la hipertensión arterial y las alteraciones cardiovasculares asociadas. P202230523
- **Martinez A, Gil C, Madruga E, Garcia-Rubia A, Lastres-Becker I, Oliver E, Briones AM.** SGK1-Inhibitor Compounds and use thereof for the treatment of diseases. Priority date: 7/06/2024. WO 2025/253033 A1. Owner: CSIC/UAM.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.2.4 Vascular Pharmacology and Metabolism (FARMAVSM) Group



Publications: 10 | Q1: 7

COMPOSITION

Carlos Félix Sánchez Ferrer.
Catedrático de Farmacología. Universidad Autónoma de Madrid
Concepción Peiró Vallejo.
Catedrática de Farmacología. Universidad Autónoma de Madrid

- **Diego Berlanas Vicente.** *Ayudante de Investigación. Universidad Autónoma de Madrid*
- **Ana Cuadrado Gómez.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Fernando de la Cuesta Marina.** *Investigador Postdoctoral. Universidad Autónoma de Madrid*
- **Jorge Francisco Gómez Cerezo.** *Jefe de Servicio de Medicina Interna. Hospital Universitario Infanta Sofía*
- **Fátima Ainara González Moro.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Ángel Moreno Luque.** *Ayudante de Investigación. Universidad Autónoma de Madrid*
- **Carmen María Parra Moreno.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Alan Andrés Rivera Tenorio.** *Investigador Predoctoral . Universidad Autónoma de Madrid*
- **Ibone Rubio Sánchez-Pajares.** *Ayudante de Investigación. Universidad Autónoma de Madrid*
- **Alicia Villacampa Calvo.** *Investigadora postdoctoral. Universidad Autónoma de Madrid*

STRATEGIC OBJETIVES

- Our research addresses challenge 1 of the Spanish Strategy for Science, Technology and Innovation: "Health, demographic change and well-being." The main objective is to improve our understanding of vascular aging, both in healthy and pathological conditions, such as obesity and type 2 diabetes mellitus. Vascular aging is associated with complex structural and functional changes in blood vessels. This process is crucial for the health status of older adults and represents the main risk factor in the development of cardiovascular diseases.
- Obesity and type 2 diabetes mellitus are highly prevalent and closely related diseases, to the point that the term "diabesity" has been coined. Diabesity constitutes one of the greatest health and socioeconomic challenges in Western countries, especially due to its cardiovascular complications. Epidemiological studies indicate that patients with diabesity have a reduced life expectancy, closely linked to the development of diseases such as hypertension and atherosclerosis. Diabesity is also considered an age-related disease and a progeroid entity, sharing similar cellular and molecular mechanisms with age-induced vascular dysfunction. Understanding the pathways involved in vascular damage and premature aging associated with diabesity could help delay vascular complications.
- Furthermore, preserving vascular function during aging should not only reduce deaths and disabilities secondary to cardiovascular events, but should also mitigate other negative aspects of aging that lead to loss of function and/or disability, such as motor impairment and cognitive frailty. In fact, it is now clear that robustness in old age cannot be achieved without preserving vascular function.

RESEARCH LINES

- 1. Mechanisms of human vascular aging
- 2. Mechanisms of vascular damage in diabetes mellitus
- 3. Obesity, adipokines, insulin resistance, and vascular dysfunction
- 4. Role of the angiotensin-(1-7)/Mas receptor axis in vascular function and inflammation.
- 5. Development of new therapies based on extracellular vesicles for cardiovascular diseases

RESEARCH ACTIVITY

Doctoral Theses

- **Shamoon L.** SARS-CoV-2 S protein impact on endothelial cell senescence, cytoprotection exhaustion and vascular damage: a protective role of klotho and angiotensin-(1-7)[dissertation]. Madrid: UAM: 2025(28/02/2025). Director: Peiró Vallejo C, Sánchez Ferrer CF
- **González Moro FA.** Avances en estrategias terapéuticas para alteraciones vasculares asociadas al envejecimiento acelerado: diferencias entre sexos en el modelo samp8 y optimización de la encapsulación de senoterapéuticos en vesículas extracelulares de células madre[dissertation]. Madrid: UAM: 2025(18/09/2025). Director: de la Cuesta Marina F.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



- **Morales Rodríguez de Lope M.** Estandarización de vesículas de origen vegetal: potencial de las nanovesículas como agentes terapéuticos y caracterización de marcadores de identidad en vesículas extracelulares[dissertation]. Madrid: UAM: 2025(04/12/2025). Director: de la Cuesta Marina F

Master Theses

- **Díaz Huertas S.** Antidiabetic drugs as regulators of the NLRP3 inflammasome and protectors of the vascular system[dissertation]. Madrid: UAM: 2025(04/09/2025). Director: Peiró Vallejo C, Sánchez Ferrer CF. PID2023-147378OB-I00
- **Vivar García I.** Mechanisms of vascular smooth muscle protection by anakinra and the anti-diabetic drug canagliflozin[dissertation]. Madrid: UAM: 2025(15/09/2025). Director: Peiró Vallejo C, Villacampa Calvo A.

Final Degree Theses

- **Latorre Soler J.** Abordaje fármaco-nutricional de la obesidad y diabetes tipo II y empleo de semaglutida[dissertation]. Madrid: UAM: 2025(25/05/2028). Director: de la Cuesta Marina F.

Publications

- **Campuzano R, Mostaza JM, Barrios V, Egocheaga-Cabello I, Gómez-Cerezo JF, Pallarés-Carratalá V, Martínez-López I, Castellanos M, Hernández-Subirá I, Morant-Talamante N, Parrondo J, Arigita-Lastra L, Gámez JM.** Assessing LDL-C levels and lipid-modifying therapies in a real-world cohort of patients with atherosclerotic cardiovascular disease: The REALITY Study. J Clin Med. 2025; 14(7): 2340. Article. IF: 3.3; Q1
- **de Lope MMR, Sánchez-Pajares IR, Herranz E, López-Vázquez CM, González-Moro A, Rivera-Tenorio A, González-Sanz C, Sacristán S, Chicano-Gálvez E, de la Cuesta F.** Acompendium of bona fide reference markers for genuine plant extracellular vesicles and their degree of phylogenetic conservation. J Extracell Vesicles. 2025; 14(9): e70147. Article. IF: 21.7; D1
- **Gómez-Cerezo JF, Fernández-Martín J, Barba-Romero MA, Sánchez-Martínez R, Hermida-Ameijeiras A, Camprodon-Gómez M, Ortolano S, López-Rodríguez MA.** Current status of the immunogenicity of enzyme replacement therapy in fabry disease. Orphanet J Rare Dis. 2025; 20(1): 253. Review. IF: 3.6; Q2
- **González-Moro A, Herranz E, de Lope MMR, Sánchez-Pajares IR, Sánchez-Ramírez J, Rivera-Tenorio A, Shamoon L, Sánchez-Ferrer CF, Peiró C, de la Cuesta F.** Sex-specific molecular hallmarks point to increased atherogenesis susceptibility in male senescence-accelerated mice. Life Sci. 2025; 369: 123529. Article. IF: 6.4; Q1
- **Kardassis D, Stancu CS, Toma L, Gafencu AV, Georgescu A, Alexandru-Moise N, Molica F, Kwak BR, Burlacu A, Hall IF, Butoi E, Magni P, Wu JX, Novella S, Gamon LF, Davies MJ, Caporali A, de la Cuesta F, Mitic T, Vindis C.** Unravelling molecular mechanisms in atherosclerosis using cellular models and omics technologies. Vasc Pharmacol. 2025; 158: 107452. Article. IF: 3.7; Q2
- **Magalhaes GS, Villacampa A, Rodrigues-Machado MG, Campagnole-Santos MJ, Santos RAS, Sánchez-Ferrer CF, Peiró C.** Oral Angiotensin-(1-7) formulation after established elastase-induced emphysema suppresses inflammation and restores lung architecture. Front Pharmacol. 2025; 16: 1540475. Article. IF: 5.4; Q1
- **Magni P, Mitic T, Devaux Y, Pierre P, Sopic M, de la Cuesta F, Vitorino R.** Deciphering immune dynamics in atherosclerosis: Inflammatory mediators as biomarkers and therapeutic target. Eur J Clin Invest. 2025; 55(6): e70043. Review. IF: 4.1; Q1
- **Mitic T, Georgescu A, Alexandru-Moise N, Davies MJ, Vindis C, Novella S, Gerdts E, Kararigas G, Wettinger SB, Formosa MM, Kwak BR, Molica F, Amigo N, Caporali A, de la Cuesta F, Hall IF, Chroni A, Martelli F, Schmid JA, Magni P, Kardassis D.** Current status and challenges of multi-omics research using animal models of atherosclerosis. J Mol Cell Cardiol Plus. 2025; 13: 100476. Article. IF: 2.2; Q3
- **Tejedor-Santamaría L, Márquez-Expósito L, Villacampa A, Marchant V, Battaglia-Vieni A, Rayego-Mateos S, Rodrigues-Diez RR, Santos FM, Valentijn FA, Knoppert SN, Broekhuizen R, Ruiz-Torres MP, Goldschmeding R, Ortiz A, Peiró C, Nguyen TQ, Ramos AM, Ruiz-Ortega M.** CCN2 Activates cellular senescence leading to kidney fibrosis in folic acid-induced experimental nephropathy. Int J Mol Sci. 2025; 26(9): 4401. Article. IF: 5.6; Q1
- **Villacampa A, Shamoon L, Valencia I, Morales C, Figueiras S, de la Cuesta F, Sánchez-Niño D, Díaz-Araya G, Sánchez-Pérez I, Lorenzo O, Sánchez-Ferrer CF, Peiró C.** SARS-CoV-2 S Protein reduces cytoprotective defenses and promotes human endothelial cell senescence. Aging Dis. 2025; 16(3): 1626-38. Article. IF: 9.6; D1

Research projects

- **de la Cuesta Marina F.** Developing novel nanotherapies for atherosclerosis by delivering senolytics to the plaque using mesenchymal stem cell-derived extracellular vesicles (2019-T1/IND-13794 y 2023-5A/IND-28938). CM. 2020-2025. Managment centre: UAM
- **de la Cuesta Marina F.** Nueva terapia senolítica para enfermedad vascular asociada al envejecimiento mediante bioingeniería de vesículas extracelulares de células madre para administración dirigida (PID2021-126274OB-I00). AEI. 2022-2025. Managment centre: UAM
- **de la Cuesta Marina F.** Terapias senoliticas avanzadas basadas en nanoparticulas biologicas para tratar el envejecimiento vascular (CNS2022-135368). AEI. 2023-2025. Managment centre: UAM
- **de la Cuesta Marina F.** Escalado y fabricación GMP de vesículas extracelulares de células madre mesenquimales para terapias avanzadas (IND2023/BMD-27323). CM. 2024-2027. Managment centre: UAM
- **Peiro Vallejo C, Sánchez Ferrer CF.** NLRP3 inflamasome at the crossroad of vascular inflammageing: a novel target for senomorphic drugs (PID2023-147378OB-I00). Plan Nacional de I+D+i. 2024-2027. Managment centre: UAM

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.2.5 Research in Pediatric Cardiology



Publications: 10 | Q1:3

COMPOSITION

Federico Gutiérrez-Larraya Aguado.
Jefe de Servicio de Cardiología Pediátrica. Hospital Universitario La Paz. Profesor Titular. Universidad Francisco de Vitoria.

- **César Abelleiro Pardeiro.** *Facultativo Especialista de Área en Cardiología Pediátrica. Hospital Universitario La Paz*
- **Viviana Arreo del Val.** *Facultativo Especialista de Área en Cardiología Pediátrica. Hospital Universitario La Paz*
- **Antonio Javier Cartón Sánchez.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Lucía Deiros Bronte.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Marta Gambra Arzoz.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Luis García-Guereta Silva.** *Jefe de Sección de Cardiología Pediátrica. Hospital Universitario La Paz*
- **Irene Herruzo Priego.** *Investigadora senior, Profesora adjunta y Coordinadora de embriología. Universidad Francisco de Vitoria*
- **Carlos Labrandero de Lera.** *Facultativo Especialista de Área en Cardiología Pediátrica. Hospital Universitario La Paz*
- **Álvaro Lafuente Romero.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **José Luis López Guillén.** *Médico Adjunto en Cardiología Pediátrica. FIBHULP*
- **Celia Martín Cubillo.** *Ingeniera Clínico. Hospital Universitario La Paz*
- **Diana Salas Mera.** *Médico Adjunto Cardiología Pediátrica. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Establishment of Heart Disease Registries: Creation of comprehensive databases that comply with all legal regulations regarding security, confidentiality and data protection.
- Advances in Diagnostic Imaging: Innovation and improvement of imaging techniques for accurate characterization of pediatric heart disease.
- Minimally Invasive Diagnostic and Therapeutic Techniques: Development and application of procedures that minimize the impact and improve patient recovery.
- Research on Vascular Risk and Environmental Factors: Studies dedicated to understanding how environmental factors and lifestyle influence pediatric heart disease and its prevention.
- Role of Exercise in Pediatric Cardiology: Research on the importance of physical exercise in the detection and treatment of cardiac disorders in children.
- Telemedicine and Cardiac Monitoring: Implementation of telemedicine solutions and use of IoT devices for efficient, real-time cardiac monitoring.
- Omics Research for Pediatric Cardiology: Search for biomarkers and therapeutic targets through genomic, proteomic and metabolomic studies.
- Scientific Dissemination and Industrial Collaboration: Publication of research in high-impact journals and collaboration with the pharmaceutical sector for the development of new therapies.
- Creation of Specialized Care Units: Formation of multidisciplinary teams based on the latest research to offer the best care.
- Continuing Education and Public Awareness: Development of educational programs for professionals and families, and collaboration with media to increase the visibility of pediatric heart disease.

RESEARCH LINES

- Application of Artificial Intelligence and New Technologies: Exploration and adoption of technological advances to improve the diagnosis, treatment and monitoring of pediatric heart disease.
- Innovation in Medical Devices and Pharmacology: Development and evaluation of advanced medical devices and new pharmacological compounds adapted to the specific needs of the pediatric population.
- Vascular Risk Management in Pediatrics: Study and management of vascular risk from the earliest stages of life, focusing on the prevention and early detection of cardiovascular diseases.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH ACTIVITY



Publications

- **David SO, Lucia DB, Lucia D, Marta FR, Juvenal RL, Diana SM, Carlos LD, Carlos LGJ, Federico GL.** Case Report: Two-month-old infant with PHACE syndrome: facial hemangioma and severe complex coarctation of the aorta. Front Cardiovasc Med . 2025; 12: 1539168. Article. IF: 3.0; Q2
- **González-García A, Abelleira-Pardeiro C, Jiménez-Valero S, Balbacid-Domingo E, Gutiérrez-Larraya F, Moreno R.** Self-made fenestrated device for closure of atrial septal defect. Cardiovasc Interv Ther. 2025; 40(3): 725-6. Article. IF: 5.5; Q1
- **González-García A, Jiménez-Valero S, Balbacid-Domingo E, Abelleira-Pardeiro C, Gutiérrez-Larraya F, Moreno R.** Combined percutaneous pulmonary valve-in-valve and closure of paravalvular leak. Cardiovasc Interv Ther. 2025; 40(2): 449-50. Editorial Material. IF: 5.5; Q1
- **Meras P, Cobarro L, Merino C, Ruiz-Cantador J, Jiménez S, Balbacid E, Abelleira C, Moreno R.** Prevalence and prognostic value of malnutrition in adults with Fontan circulation: retrospective cohort study. Cardiol Young. 2025; 35(4): 836-41. Article. IF: 0.8; Q4
- **Permuy C, Sánchez-Holgado M, López-Ortego P, Bret M, Labrandero C, Sampedro M, Rey J, Mazarío E, Pellicer A.** Myocardial calcifications in a neonate with surgically corrected truncus arteriosus: Case report. J Neonatal Perinatal Med. 2025; 18(5): 496-500. Article. IF: 1; Q3
- **Ramchandani B, Polo L, Torres B, Rey J, Gonzalez A, Labrandero C, Del Peso C, Aroca A.** Paediatric HeartMate 3 implant due to anthracycline-induced cardiomyopathy. Multimed Man Cardiothorac Surg. 2025: 2025. Article. Not Indexed
- **Rivero-Santana B, Balbacid-Domingo E, Abelleira-Pardeiro C, de Lera CL, del Val VA, Jimenez-Valero S, Fernández-Velasco M, Moreno R, Gutiérrez-Larraya F.** Microcirculatorydysfunction and its role in diagnosing acute rejection in pediatric heart transplantation: a pilot study. Diagnostics (Basel). 2025; 15(5): 545. Article. IF: 3.8; Q1
- **Romero PSG, Lafuente-Romero A, Domingo EB, Pardeiro CA.** Pulmonary flow modulation with diabolo stent technique over the subpulmonary outflow tract. Catheter Cardio Inte. 2025; 105(1): 184-6. Article. IF: 1.9; Q3
- **Socuellamos PG, Ruiz-Robles JM, Cruz FM, Macías A, Vera-Zambrano A, Moreno-Manuel AI, Prior C, Carton AJ, Valenzuela C, Jalife J.** MOG1L18F-mediated increase in late sodium current produces Long QT Syndrome. Medrxiv. 2025. (Preprint). Not Indexed
- **Tejerizo FB, Sánchez FC, Bastante T, Álvarez ABC, Álvarez-Fuente M, Domingo EB, Blasco PB, Mata RB, Carrasco JI, Bellón JMC, López JME, Fernández MF, Gómez-Jaume A, Albert BI, Valero SJ, Lalaguna LA, Pineda SO, Guerrero AP, Rodríguez AR, Gila JS, Sanz-Ruiz R, Vázquez-Álvarez ME, Argüelles JIZ.** Spanish cardiac catheterization in congenital heart diseases registry. Fourth official report from the ACI-SEC and the GTH SECPCC (2023). REC-Interv Cardiol. 2025; 7(4):238-24. Article. IF: 1.5; Q3

Clinical Trial

- **Gutiérrez-Larraya Aguado F.** Anexo 1 pi-6234 abbott structural heart device registry (abbott sh registry).
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Abbott Medical España S. A.
  Signature date: 24/01/2025
- **Labrandero De Lera C.** Estudio clínico de fase 2/3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética del vericiguat en pacientes pediátricos con insuficiencia cardíaca debido a disfunción sistólica sistémica del ventrículo izquierdo (valor).
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 16/06/2025
- **Salas Mera D.** Ensayo de extensión abierto y de un solo brazo para evaluar la seguridad de finerenona, añadida al tratamiento estándar, en pacientes pediátricos con insuficiencia cardíaca, desde el nacimiento hasta los 18 años de edad, con disfunción sistólica del ventrículo izquierdo (dsvi).
  Type/Phase: III
  Sponsored by: Bayer AG.
  Signature date: 28/11/2025
- **Salas Mera D.** ensayo de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, seguridad, farmacocinética y farmacodinámica de finerenona, añadida al tratamiento estándar, en pacientes pediátricos, de 6 meses a < 18 años de edad, con disfunción sistólica del ventrículo izquierdo (dsvi).
  Type/Phase: III
  Sponsored by: Bayer AG.
  Signature date: 18/11/2025

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

3.3. Infectious Diseases and Immunity Area

Documents: 305 | Originals: 254 | D1: 69 | Q1: 184

Area coordinator: Eduardo López-Collazo

RESEARCH GROUPS

3.3.1 AIDS and Infectious Diseases
José Ramón Arribas López

3.3.2 Molecular Microbiology
Jesús Mingorance Cruz

3.3.3 Immuno-Rheumatology
María Eugenia Miranda Carús

3.3.4 Innate Immune Response
Eduardo López-Collazo/Carlos del Fresno Sánchez

3.3.5 Alterations of the Complement System in Human Pathology
Margarita López Trascasa/Pilar Sánchez-Corral Gómez


3.3.6 Lymphocyte Pathophysiology in Immunodeficiencies
Eduardo López Granados

3.3.7 Drug Hypersensitivity and Innate Immune Response
Teresa Bellón Heredia

3.3.8 Immunomediate Gastrointestinal Diseases and Other Digestive Pathologies
María Dolores Martín Arranz

3.3.9 MicroRNA Regulation of Immune Tolerance, Autoimmunity and Cancer
Alicia González Martín

3.3.10 Systemic Immune-Mediated Diseases
Juan José Ríos Blanco



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Strategic Objectives	Development forecast for the coming years:	Actions
Infectious Diseases and Immunity Area is composed of 11 groups focused on the study of diseases related to the immune system such as HIV, autoimmune diseases, cancer, etc., as well as the molecular mechanisms that explain the phenomena associated with these pathologies.	To identify priority research topics in our area and if necessary expand some of them.	Promote the priority research line identified
	To generate and develop scientific research projects that allow the production of knowledge in the biomedical area.	Obtain national and international scientific research projects in biomedical area
	To generate a significant number of research products/results, such as publications in nationally and internationally indexed journals, journals that contribute to the social appropriation of knowledge.	Improve the annual number of publications in the first quartile and decile, and total impact factor of the area
	To socialize the research resultsby presenting papers at national and international events	Increase the presence of area researchers in national and international events
	To establish agreements and strategic alliances with other communities of knowledge that allow academic discussion and project development.	Search for synergies with other groups with similar and complement research lines.
	To promote the training of young researchers and undergraduate and graduate students.	Training in research methodology undergraduate, predoctoral and postdoctoral personal.
	To develop a good system of applied research so that everything studied in the laboratory has repercussions on both our patients and our entities.	Promote the synergies of translational researchers and clinical researchers, and their incorporation into groups

HIGH IMPACT PUBLICATIONS

Navarro-Compán V, Sepriano A, Capelusnik D, Baraliakos X. Axial spondyloarthritis. Lancet. 2025; 405(10473): 159-72. Article. IF: 109; D1

Berenguer J, Aldámiz-Echevarría T, Hontañón V, Fanciulli C, Quereda C, Busca C, Domínguez L, Hernández C, Vergas J, Gaspar G, García-Fraile LJ, Díez C, De Miguel M, Bellón JM, Bañares R, **González-García J**. Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis. Hepatology. 2025; 81(1): 238-53. Article. IF: 18; D1

Mata-Martinez P, Celada L, Cueto FJ, Maria GSD, Fernández J, Terron-Arcos V, Valdes N, Moreira VG, del Toro MIE, Lopez-Collazo E, Chiara MD, **del Fresno C**. A blood-based liquid biopsy analyzing soluble immune checkpoints and cytokines identifies distinct neuroendocrine tumors. J Exp Clin Canc Res. 2025; 44(1): 82. Article. IF: 14,3; Q1

De Miguel R, Sebastian MD, Arévalo JLB, Pinto-Martinez A, Montejano R, Liarte AG, Navarro-Soler R, Cañas-Ruano E, Inciarte A, Martin-Carbonero L, Imaz A, Gutiérrez CH, Ocampo A, Divasson PG, Delgado R, Pulido F, **Arribas JR.** Dolutegravir/Lamivudine for maintenance of virological suppression in persons with historical suspected or confirmed resistance to lamivudine: week 48 results of a single-arm, open-label, multicenter, phase IIa clinical trial. Clin Infect Dis. 2025; 81(3): 491-8. Article. IF: 8,3; D1

del Prado-Montero J, Guevara-Martínez J, Cantero-Cid R, Mata-Martínez P, Cueto FJ, Lozano-Rodríguez R, Terrón-Arcos V, Abad-Moret R, Díaz-Serrano E, de Diego RP, Fernández-Velasco M, del Fresno C, Hurtado-Navarro L, **López-Collazo E.** Age-stratified circulating immune signatures reveal non-invasive biomarkers for colorectal cancer detection. Immun Ageing. 2025; 22(1): 40. Article. IF: 8,3; D1.

Scientific Events by Infectious Diseases and Immunity Area

- **28/03/2025** - Seminario Presencial y Online: Simulación dinámica de macromoléculas. Su aplicación en el diseño de fármacos antibacterianos y antivirales y en el estudio de enfermedades raras
- **01/04/2025** - Curso Una Salud Global: la realidad integrada que compartimos
- **13/06/2025** - Seminario presencial y Online: Papel del Virus del Herpes Simple en la Patogénesis de la Enfermedad de Alzheimer.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.3.1 AIDS and Infectious Diseases Group



Publications: 71 | Q1: 41

COMPOSITION

José Ramón Arribas López.
Jefe de Sección del Servicio de Medicina Interna (Unidad de Infecciosas). Hospital Universitario La Paz. Profesor Titular. Universidad Autónoma de Madrid

- **María del Mar Arcos Rueda.** *Facultativo Especialista de Área de medicina Interna. Hospital Universitario La Paz*
- **Marta Arsuaga Vicente.** *Médico Adjunto en Medicina Interna. Hospital Universitario La Paz*
- **José Ignacio Bernardino de la Serna.** *Facultativo Especialista de Área en Medicina Interna. Unidad VIH. Hospital Universitario La Paz*
- **Carmen Busca Arenzana.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Julen Cadiñanos Loidi.** *Contrato Río Hortega. Hospital Universitario La Paz*
- **Irene Casado Juárez.** *Técnico de Grado Superior. FIBHULP*
- **Fernando de la Calle Prieto.** *Médico adjunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Universitario La Paz/Profesor Colaborador. Universidad Autónoma de Madrid*
- **Alejandro de Gea Grela.** *Facultativo Especialista de Área en Medicina Interna. HULP*
- **Rosa de Miguel Buckley.** *Facultativo Especialista Adjunto en Medicina Interna. Hospital Universitarios La Paz*
- **Marta Díaz Menéndez.** *Médico adjunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Universitario La Paz*
- **Beatriz Díaz Pollán.** *Facultativo Especialista de Área en Medicina Interna. Unidad de Enfermedades Infecciosas y Microbiología Clínica. Hospital Universitario La Paz*
- **Alejandro Díez Vidal.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Sara Díez.** *Técnico de Grado Superior. FIBHULP*
- **Andrés Esteban Cantos.** *Investigador Postdoctoral (R2A). Hospital Universitario La Paz*
- **Marta Gálvez Charro.** *Enfermera. Unidad de VIH. Hospital Universitario La Paz*
- **Nicolás García-Arenzana Les.** *Facultativo Especialista de Área en Medicina Preventiva. Hospital Universitario La Paz*
- **Francisco Gayá Moreno.** *Investigador Predoctoral (Contrato de Estabilización de Técnicos de Apoyo). Hospital Universitario La Paz*
- **Juan Julián González García.** *Facultativo Especialista de Área en Medicina Interna. Unidad de VIH. Hospital Universitario La Paz*
- **Juan Carlos González Rodríguez.** *Técnico de Grado Superior. FIBHULP*
- **Lucía Gutierrez García.** *Investigadora Predoctoral. FIBHULP*
- **Pedro Herranz Pinto.** *Facultativo Especialista de Área en Dermatología. Jefe de Sección. Hospital Universitario La Paz*
- **Víctor Hontañón Antoñana.** *Investigador predoctoral. Hospital Universitario La Paz*
- **María Jiménez González.** *Bioestadística. FIBHULP*
- **María del Mar Lago Núñez.** *Facultativo Especialista de Área en Medicina Interna. Unidad de Medicina Tropical. Hospital Universitario La Paz*
- **Jara Llenas García.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Cristina Marcelo Calvo.** *Contrato Rio Hortega. Hospital Universitario La Paz*
- **Luz Martín Carbonero.** *Facultativo Especialista de Área. Hospital Universitario La Paz*
- **Patricia Martínez Martín.** *Médico Adjunto en Medicina Interna. Hospital Universitario La Paz*
- **Mario Mayoral Muñoz.** *Enfermero. Hospital Universitario La Paz*
- **Juan José Miguel Castro.** *Enfermero. Hospital Universitario La Paz*
- **Rocío Montejano Sánchez.** *Investigadora Postdoctoral. Hospital Universitario La Paz*
- **María Luisa Montes Ramírez.** *Facultativo Especialista de Área de Medicina Interna. Unidad de VIH. Hospital Universitario La Paz*
- **Marta Mora Rillo.** *Facultativo Especialista de Área de Medicina Interna. Unidad de Enfermedades Infecciosas y Microbiología Clínica. Hospital Universitario La Paz*
- **Francisco Moreno Ramos.** *Farmacéutico. Hospital Universitario La Paz*
- **Carlos Manuel Oñoro López.** *Médico Interno Residente. FIBHULP*
- **Juan Carlos Ramos Ramos.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Luis Ramos Ruperez.** *Investigación Rio Hortega. Hospital Universitario La Paz*
- **Berta Rodés Soldevila.** *Investigadora Titular. Responsable laboratorio BSL2-Virología. Hospital Universitario La Paz*
- **Javier Rodríguez Centeno.** *Investigador postdoctoral. Hospital Universitario La Paz*
- **Elena Sendagorta Cudós.** *Facultativo Especialista de Área de Dermatología. Hospital Universitario La Paz*
- **Lucía Serrano Morago.** *Investigadora predoctoral. Hospital Universitario La Paz*
- **Eulalia Valencia Ortega.** *Facultativo Especialista de Área en Medicina Interna. Hospital Univeristario La Paz*

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

STRATEGIC OBJETIVES

- Although great progress has been made, HIV infection remains an incurable disease. Even under the best circumstances, HIV-infected patients receiving current antiretroviral therapy have a survival disadvantage compared to the general uninfected population, with an estimated life expectancy 15 years shorter than that of the general population.
- HIV infection has a high prevalence in Spain. Among Western European countries, Spain has the second highest prevalence. A significant local characteristic of the HIV-infected population in Spain is the high prevalence of hepatitis C coinfection.
- This line of research encompasses four main areas of investigation in HIV infection: antiretroviral treatment, HIV-HCV coinfection, metabolic complications, and HIV resistance to antiretroviral drugs. In addition, we plan to initiate another research project on infections other than HIV.
- The group has started a new line of research on aging and HIV infection.
- Tropical diseases are on the rise as a consequence of global travel. However, these diseases remain relatively rare, and therefore, their treatment is often suboptimal when administered by non-specialists. Furthermore, the number of travelers with special needs (pregnant women, those with comorbidities, and immunocompromised individuals) traveling abroad increases each year, adding complexity to the need for timely and effective diagnosis and treatment. The Tropical and Travel Medicine Unit provides pre- and post-travel assistance for imported infectious diseases. The Unit's objective is to provide efficient and effective specialized care for confirmed or suspected tropical diseases, along with specific travel-related preventive advice and recommendations for internationally recommended travel vaccinations.

RESEARCH LINES

- Antiretroviral therapy and resistance.
- Metabolic complications of antiretroviral therapy.
- Liver Disease
- Neurocognitive impairment
- Pediatric HIV infection and TMI.
- Epigenetic and cellular factors related to HIV progression
- Optimization of antibiotic therapy (non-HIV ID)
- Tropical Diseases
- Emerging and re-emerging viruses
- Molecular and cellular biomarkers of aging

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

RESEARCH ACTIVITY

Doctoral Theses

- **Busca Arenzana C.** Evaluación de factores de riesgo y validación de marcadores no invasivos de esteatosis y fibrosis hepática en personas monoinfectadas por el Virus de la Inmunodeficiencia Humana en tratamiento antiretroviral estable[dissertation]. Madrid: UAM: 2025(16/12/2025). Director: González García JJ, Montes Ramírez ML.

Master Theses

- **Peñafiel González L.** Evaluación longitudinal de biomarcadores de envejecimiento biológico en personas con infección por VIH[dissertation]. Madrid: UAM: 2025(16/09/2025). Director: Rodés Soldevila B, Esteban Cantos A.
- **López de Coca Hernández A.** Características clínicas, enfoques terapéuticos y factores pronósticos de la candidemia de origen urinario: estudio de cohorte retrospectivo.[dissertation]. Alcalá de Henares: UAH: 2025(21/05/2026). Director: Díaz Pollán B, .

Publications

- **Abbaraa A, González-Sanz M, Alkharrat A, Khalife M, Elferruh Y, Almhawish N, Abbara S, Marroush S, Shortall C, Ahmed SH, Alhazmi A, Alvarez-Martinez MJ, Asaduzzaman M, Al Balushi A, Barboza AP, Brekke H, Di Carlo P, Cascio A, Chiodini P, Colpani A, Díaz-Menéndez M, Elkheir N, Farkas FB, Garga P, Grüner B, Guimaraes AR, Holmberg V, Ioannou P, Jordao S, Kim JA, Lakatos B, Leblebicioglua H, Llenas-García J, Losada-Galván I, Martinez GE, Monka EJM, Nedu E, Nwofe JO, O'Regan R, Paggia R, Pinho JH, Pontali E, Priyadarshi M, Rath B, Rathish B, Rezzonico LF, Rizk N, Ronnberg C, Morante-Ruiz M, Salvati A, Scarso S, Sempere-Alcocer MA, Sepulcri C, Strachinaru DIC, Tamarozzi F, Tavares R, Ursini T, Verweij JJ, Wejse CM, Rodriguez-Morales AJ.** Leishmaniasis in Syria - A call for action of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Study Groups for Infections in Travellers and Migrants (ESGITM) and for Clinical Parasitology (ESGCP). Travel Med Infect Di. 2025; 66: 102849. Article. IF: 5.6; D1
- **Amatya B, Pandey P, McGuinness SL, Grobusch MP, Muhi S, Leder K, Díaz-Menéndez M, Stroffolini G, Gobbi F, Oliveira-Souto I, Waggoner JJ, Theunissen C, de Miguel R, Kazmi K, Dawadi S, Pradhan R, Goorhuis A, Connor BA, Hamer DH, Leung D.** GeoSentinel analysis of travelers' diarrhea antimicrobial resistance patterns. JAMA Netw Open. 2025; 8(12): e2551089. Article. IF: 11.7; D1
- **Amstutz A, Schandelmaier S, Ewald H, Speich B, Schwenke JM, Schönenberger CM, Schobinger S, Agoritsas T, Tomashek KM, Nayak S, Makowski M, Morales-Ortega A, Bernal-Bello D, Pomponio G, Ferrarini A, Ghazaeian M, Hall F, Bond S, García-Morales MT, Jiménez-González M, Arribas JR, Guimaraes PO, Tavares CAM, Berwanger O, Yazdanpanah Y, Simensen VC, Lacombe K, Hites M, Ader F, Tacconelli E, Mentré F, Belhadi D, Massonnaud CR, Laouénan C, Diallo A, Baldé A, Assoumou L, Costagliola D, Ponzi E, Rueegg CS, Olsen IC, Troseid M, Briel M.** Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials. Lancet Respir Med . 2025; 13(6): 530-44. Article. IF: 34.7; D1
- **Arca-Lafuente S, Lara-Aguilar V, Llamas-Adán M, Grande-García S, de la Casa AD, Martín-Carbonero L, Ryan P, de los Santos I, Matarranz M, Jiménez-Sousa MA, Fernández-Rodríguez A, Briz V.** IFNL4-rs12979860 CC genotype predisposes to accelerated terminal exhaustion and senescence in HIV/HCV-chronic infection. J Transl Med. 2025; 23(1): 1432. Article. IF: 9.7; Q1

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

- **Armario-Hita JC, Pereyra-Rodriguez JJ, de Frutos FJD, Herranz P, Silvestre-Salvador JF, Serna MR, Serra E, Tribó MJ, Carrascosa JM, Flórez A, Ratón JA, Ruiz-Villaverde R.** Clinical characteristics, diagnostic approaches, therapeutic management, and associated comorbidities of prurigo nodularis (chronic nodular prurigo): an observational study in clinical practice in Spain. Int J Dermatol. 2025; 64(9): 1623-31. Article. IF: 4.2; Q1
- **Augustín M, Bewley A, Brüggen MC, de Bruin-Weller MS, Ezzedine K, Ferrucci SM, Gkalpakiotis S, Herranz P, Johansson EK, Kampe T, Lapeere H, Legat FJ, Rehbinder EM, Szepietowski JC, Torres T, Vestergaard C, Werfel T, Domenech A, Massana E, Koscielny V, Narayanan S, Kasujee I, Gutermuth J.** European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol. BMJ Open. 2025; 15(7): e102155. Article. IF: 2.5; Q2
- **Bailón L, Alarcón-Soto Y, Arribas JR, Curran A, Llano A, Cedeño S, Paredes R, Vendrame E, SenGupta D, Wallin JJ, Geleziunas R, Malice MP, McGowan I, Brander C, Moltó J, Mothe B.** Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1. Commun Med (Lond). 2025; 6(1): 11. Article. IF: 7.4; Q1
- **Bailón L, Moltó J, Curran A, Cadiñanos J, de Quirós JCLB, de los Santos I, Ambrosioni J, Imaz A, Benet S, Suanzes P, Navarro J, González-García J, Busca C, Pérez-Latorre L, Berenguer J, García-Fraile LJ, Mejia-Abril G, Miró JM, Scévola S, Moreno S, Domingo P, Tian Y, Frankot M, Lim D, Cai YH, Vendrame E, Guo S, Wallin JJ, Geleziunas R, Sengupta D, Alarcón-Soto Y, Leal I, Aranguen A, Garcia-Garcia M, McGowan I, Brander C, Arribas JR, Mothe B.** Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial. Nat Commun. 2025; 16(1): 2146. Article. IF: 18.1; D1
- **Barac A, Gupta N, Jokelainen P, Tsiodras S, Mora-Rillo M, Gkrania-Klotsas E, Paño-Pardo JR, Bulescu C, Pellejero-Sagastizabal G, Goorhuis A, Mendoza MPG, van der Ende J, Lescure FX, Grobusch MP, Drexler JF.** Yellow fever in South America in 2025: a concerning increase, but a true resurgence? Clin Microbiol Infec. 2025; 31(12): 1941-44. Editorial Material. IF: 8.7; DI
- **Behrens GMN, Assoumou L, De Wit S, MacDonald R, de Castro N, Rokx C, Middleditch H, Johnson M, Casado JL, Arribas JR, Blanco JR, Fletcher C, Eteve-Pitsaer C, Baldé A, Pozniak A, Martinez E.** Morbidity and risk factors of COVID-19 in people with HIV-1 in Europe: A combined observational cohort and nested case-control study. Hiv Med. 2025; 26(11): 1657-72. Article. IF: 3.2; Q2
- **Berenguer J, Aldámiz-Echevarría T, Hontañón V, Fanciulli C, Quereda C, Busca C, Domínguez L, Hernández C, Vergas J, Gaspar G, García-Fraile LJ, Díez C, de Miguel M, Bellón JM, Bañares R, González-García J.** Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis. Hepatology. 2025; 81(1): 238-53. Article. IF: 18.0; D1
- **Berenguer J, Bellón JM, Bañares R, González-García J.** Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis. Hepatology. 2025; 81(1): E6-7. Letter. IF: 18.0; D1
- **Bernal E, Martínez-Rodríguez R, Gómez JM, Tomás C, García-Villalba E, Valero S, Muñoz A, Alcaraz A, Díez C, García-Fraile LJ, Gómez-García T, Navarro-Marcotegui M, Alemán-Valls MR, Olalla J, Masiá M, Gutiérrez F.** Low-level viremia linked to virological failure but not clinical events. Aids. 2025; 39(11): 1545-57. Article. IF: 2.9; Q2
- **Bernardino JI, Dalmau R, Rodríguez-Torres D, Saiz-Medrano G, Fernández-Velilla M, Pinilla I, Rodriguez-Centeno J, Esteban-Cantos A, Jiménez-González M, Mata T, Ramos C, Rodés B, Estébanez M.** DNA N6-methyladenine and ABCA1 methylation associations with subclinical coronary atherosclerosis in people with HIV. Clin Epigenetics. 2025; 17(1): 158. Article. IF: 5.7; Q1
- **Buzón-Martín L, Montes ML, Pedrero R, Galindo MJ, Santacreu-Guerrero M, Alemán MR, Torralba M, de Santiago AD, Fanjul F, Rodríguez A, Cabello A, Crusells MJ, Navarro MD, Aguilera M, Hidalgo-Tenorio C, Morano-Amado LE, Vinuesa D, De Andres C, Bernal-Morell E, Martínez-Alvarez RM, Cabello-Clotet N, Tiraboschi J, Montero MD, Vivancos-Gallego MJ, Díez C, Calderón R, De Zárraga MA, Gisbert L, Romero-Palacios A, Cabo R, Soler JF, Sepúlveda MA, Sánchez-Guirao AJ, Escrich C, de las Revillas FA, Ferreira E, Valentín B, Lérida A, Llenas-García J, Gómez A, Losa JE, Alonso B, Sanz J, Masiá M, Pernas H, Corte JJ, Garcinuño MA, Gainzarain JC, Estébanez M, García-Navarro MD, Barragán P, Ramos N, Clavero M, Millán M, Del Alamo M, Egido M, de la Calle B, Ferrero OL, Troya J.** A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study). J Antimicrob Chemoth. 2025; 80(12): 3438-51. Article. IF: 4.1; Q1
- **Cabello-Ubeda A, de Quirós JCLB, Mena A, Torralba M, Carbonero LM, Gutierrez A, Vergas J, Pinto A, Tejerina F, Palmier E, Sanz J, Górgolas M, Pulido F.** Dolutegravir (DTG) plus Lamivudine (3 TC) in antiretroviral-naive adults with hiv with and without genotypic resistance testing results: 96-week effectiveness and tolerability of REDOLA study. JAIDS-J Acq Imm Def. 2025; 100(2): e4-7. Letter. IF: 2.3; Q3
- **Cairoli V, Valle-Millares D, Ryan P, Domínguez L, Martín-Carbonero L, de los Santos I, de Matteo E, Ameigeiras B, De Sousa M, Briz V, Preciado M, Fernández-Rodriguez A, Valva P.** Extracellular vesicles derived microRNAs as non-invasive markers of liver fibrosis in chronically infected HCV patients: a pilot study. Non-Coding Rna Res. 2025; 12: 132-40. Article. IF: 5.6; Q1
- **Cano-Smith J, Delgado-Hierro A, Ramos-Ruperto L, Busca C, Mican R, Montes ML, Martín-Carbonero L, Arcos MdM, de Miguel R, Montejano R, Valencia E, de Miguel M, Pérez-Sadaba FJ, Pérez-Rambla C, Arribas J, González-García J, Bernardino JI.** Preparing for the next physician's visit: usability and validity of a mobile health app for people living with HIV. Aids Behav. 2025; 29(10): 3045-53. Article. IF: 2.5; Q2
- **Chafino S, Tarancón-Díez L, Hurtado-Gallego J, Flores-Piñas M, Alcolea S, Olveira A, Navarro ML, Fernández-Arroyo S, Viladés C, Montes ML, Vidal F, Peraire J, Rull A, Sainz T.** Metabolomics for searching non-invasive biomarkers of metabolic dysfunction-associated steatotic liver disease in youth with vertical HIV. Commun Med (Lond). 2025; 5(1): 433. Article. IF: 7.4; Q1
- **Corominas J, Garriga C, Prenafeta A, Moros A, Cañete M, Barreiro A, González-González L, Madrenas L, Güell I, Clotet B, Izquierdo-Useros N, Raïch-Regué D, Gallemí M, Blanco J, Pradenas E, Trinité B, Prado JG, Pérez-Caballero R, Bernad L, Plana M, Esteban I, Aurrecoechea E, Abu Taleb R, Mcskimming P, Soriano A, Nava J, Anagua JO, Ramos R, Lluch RM, Comes AC, Romero SO, Martínez-Gómez X, Camacho-Arteaga L, Molto J, Benet S, Bailón L, Arribas JR, Borobia AM, Parada JQ, Navarro-Pérez J, Giner MJF, Lucas RO, Jiménez MDV, Fernández MJL, Alvarez-Mon M, Troncoso D, Arana-Arri E, Meijide S, Imaz-Ayo N, García PM, de la Villa S, Fernández SR, Prat T, TorroellaÉ, Ferrer L.** Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial. Vaccine. 2025; 47: 126685. Article. IF: 3.4; Q2
- **de Gea-Grela A, Micán R, de Miguel R, Serrano L, Marcelo C, Montes ML, Ramos-Ruperto L, Busca C, Arcos-Rueda MD, Montejano R, Arribas JR, González-García J, Bernardino JI, Martín-Carbonero L.** Three-year effectiveness of Bictegravir/Emtricitabine/Tenofovir alafenamide as a switch strategy in the real world. Open Forum Infect Dis. 2025; 12(3): ofaf087. Article. IF: 3.8; Q2
- **de la Casa AD, Grande-García S, Arca-Lafuente S, Llamas-Adán M, Lara-Aguilar V, Carbonero**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

LM, Lagarde M, Ryan P, de los Santos I, Fernández-Rodríguez A, Briz V. Impact of HCV elimination on metabolism markers in people living with HIV. Sci Rep-Uk. 2025; 15(1): 18937. Article. IF: 4.9; Q1

- **de Miguel R, Sebastián MD, Arévalo JLB, Pinto-Martinez A, Montejano R, Liarte AG, Navarro-Soler R, Cañas-Ruano E, Inciarte A, Martín-Carbonero L, Imaz A, Gutiérrez CH, Ocampo A, Divasson PG, Delgado R, Pulido F, Arribas JR.** Dolutegravir/Lamivudine for maintenance of virological suppression in persons with historical suspected or confirmed resistance to lamivudine: week 48 results of a single-arm, open-label, multicenter, phase IIa clinical trial. Clin Infect Dis. 2025; 81(3): 491-8. Article. IF: 8.3; D1
- **del Mar ARM, Luis RR, Carmen B, Alejandro DG, Fernando FH, Ana DH, Inmaculada QM, Alfredo MB, Rafael M, Luz MC, Ignacio BJ.** Retrospective analysis of sexually transmitted infections among people living with HIV and pre-exposure prophylaxis users in Spain. BMC Infect Dis. 2025; 26(1): 167. Article. IF: 3.2; Q2
- **Díaz-Menéndez M, Arsuaga M.** It's time to properly classify dengue. Med Clin-Barcelona. 2025; 164(6): 317-8. Editorial Material. IF: 2.8; Q1
- **Díaz-Menéndez M, Buckley RD, de la Calle-prieto F, Arsuaga M.** Efficacy of benznidazole treatment in advanced chronic digestive Chagas disease. Enferm Infec Micr Cl. 2025; 43(4): 236-7. Letter. IF: 2.2; Q3
- **Díaz-Menéndez M, de la Calle-Prieto F, de Miguel-Buckley R, Barreiro P, Lago M, Vicente MA.** Beyond the guidelines: real-world challenges in rabies post-exposure prophylaxis. J Travel Med. 2025; 32(8): taaf084. Editorial Material. IF: 10.6; D1
- **Díez-Vidal A, Arribas JR.** How recent is recent? Retrospective analysis of suspiciously timeless citations. Brit Med J. 2025; 391: e086941. Article. Not Indexed
- **Díez-Vidal A, Fernández-Hinojal F, Marcelo-Calvo C, Hernández-García B, Cendejas-Bueno E, Grandioso-Vas D, Pérez-Chulia N, Civantos-Martín B, Martinez-Martín P, Novo-González C, García-Arenzana N, Giner-García J, Paredes-Garza F, Vallejo-Oliva MI, Arribas JR, Díaz-Pollán B.** Ventriculitis: a retrospective cohort study of clinical features, outcomes and device management practices. Open Forum Infect Dis. 2025; 12(8): ofaf424. Article. IF: 3.8; Q2
- **Díez-Vidal A, Gil-Garrote S, Díaz-Pollán B, Rodríguez-Sevilla G, Martínez-Martín P, Marcelo-Calvo C, Díaz-Menéndez M.** Amebic liver abscess presenting in a nonendemic region after a 12-year latency in a patient with well controlled HIV infection. AIDS. 2025; 39(2): 211-3. Letter. IF: 2.9; Q2
- **Gkrania-Klotsas E, Jokelainen P, Wyllie AL, Gupta N, Paño-Pardo JR, Barac A, Mora-Rillo M, Grobusch MP, Holmes CB, Koopmans M, Lescure FX.** Is a human highly pathogenic avian influenza A H5N1 pandemic inevitable? Clin Microbiol Infec. 2025; 31(9): 1424-6. Editorial Material. IF: 8.7; DI
- **Grobusch MP, Díaz-Menéndez M, de Gomensoro EB, Mächler C, Milovanovic B.** The burden of dengue fever in travellers: a systematic literature review. New Microbes New Infect. 2025; 67: 101631. Review. IF: 6.0; D1
- **Grobusch MP, Jokelainen P, Wyllie AL, Gupta N, Paño-Ramo JR, Barac A, Bulescu C, Pellejero-Sagástiza G, Goorhuis A, Lescure FX, Gkrania-Klotsas E, Mora-Rillo M.** Marburg virus disease outbreak in Rwanda, 2024. Clin Microbiol Infec. 2025; 31(2): 161-3. Editorial Material. IF: 8.7; D1
- **Guevara-Hernández P, Llenas-García J, Díaz-Menéndez M, Serre-Delcor N, Crespillo-Andújar C, Salvador F, Ruiz-Giardin JM, Goikoetxea-Agirre J, Torrús-Tendero D, de la Calle-prieto F, Oliveira-Souto I, Bosch-Nicolau P, Wikman P, Pérez-Molina JA.** Imported fever in returning travellers and migrants in Spain, 2009-2021. Analysis by the plus REDIVI network. Travel Med Infect Di. 2025; 65: 102833. Article. IF: 5.6; D1
- **Gupta N, Grobusch MP, Jokelainen P, Wyllie AL, Barac A, Mora-Rillo M, Gkrania-Klotsas E, Pellejero-Sagastizabal G, Paño-Pardo JR, Duizer E, Lescure FX.** Poliomyelitis in Gaza. Clin Microbiol Infec. 2025; 31(2): 154-6. Editorial Material. IF: 8.7; D1
- **Gutiérrez-García L, Esteban-Cantos A, Rodríguez-Centeno J, Marcelo-Calvo C, Arribas JR, Rodés B.** Duplex digital PCR assay on microfluidic chamber arrays for total HIV DNA reservoir quantification in persons with HIV. Sci Rep-Uk. 2025; 15(1): 31658. Article. IF: 4.9; Q1
- **Izquierdo R, Rava M, Gutiérrez F, García-Fraile LJ, Riera M, Imaz A, Sotomayor C, Reus S, Rubio R, Iribarren JA, Jarrín I.** Increased mortality and morbidity risk in people with early HIV care interruption in Spain. AIDS. 2025; 39(9): 1224-34. Article. IF: 2.9; Q2
- **Izquierdo R, Suárez-García I, Gómez-García T, Marco-Sánchez C, Puente-Ferreiro J, Moreno C, Díaz A, Cabello-Clotet N, Vinuesa D, Blanco JL, Melús E, Gómez-Ayerbe C, Olalla J, Riera M, Bernardino JI, de Quirós JCDB, Moreno S, Jarrín I.** Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain. HIV Med. 2025; 26(2): 308-18. Article. IF: 3.2; Q2
- **Izquierdo R, Suárez-García I, Marco-Sánchez C, Pérez-Latorre L, Riera M, Cano J, Viladés C, Reus S, Olalla J, González-Ruano P, Orviz E, Díaz A, Moreno S, Jarrín I, CoRIS cohort.** Health-related quality of life in people with HIV from the multicentre CoRIS cohort in Spain: Associated factors and short-term changes over time. Hiv Med. 2025; 26(4): 606-20. Article. IF: 3.2; Q2
- **Izquierdo R, Vallejo A, Suárez-García I, Martín-Hondarza A, Gutiérrez F, Perez-Molina JA, García DV, Macías J, Rivero A, Olalla J, Montero-Alonso M, Asensi V, Moreno S, Jarrín I, Rava M.** Markers of Inflammation and Immune Dysfunction and Non-AIDS Cancer Risk in Adults With HIV. JAIDS-J Acq Imm Def. 2025; 99(3): 274-82. Article. IF: 2.3; Q3
- **Jokelainen P, Wyllie AL, Gupta N, Barac A, Gkrania-Klotsas E, Bulescu C, Paño-Pardo JR, Mora-Rillo M, Grobusch MP, Lescure FX.** Complex mpox situation, 2024. Clin Microbiol Infec. 2025; 31(2): 152-3. Editorial Material. IF: 8.7; D1
- **Lindner AK, Popescu C, Perez-Molina JA, Díaz-Menéndez M, Rothe C, Asgeirsson H, Schwob JM, Grobusch MP, Neumayr A, Weitzel T, Schlagenhauf P.** Shortage of praziquantel in Europe: a clarion call for urgent action. New Microbes New Infect. 2025; 66: 101613. Editorial Material. IF: 6.0; D1
- **López JRA, Seco MPR, Fanjul F, Pollán BD, Pérez PGR, Beltrán AF, Buckley RD, Horcajada LP, Pérez CD, Carvalho PJBS, Jaume MR.** Remdesivir associated with reduced mortality in hospitalized COVID-19 patients: treatment effectiveness using real-world data and natural language processing. BMC Infect Dis. 2025; 25(1): 513. Article. IF: 3.2; Q2
- **López MJ, Vázquez MD, Álvarez-Mon M, Arribas JR, Arana-Arri E, Muñoz P, Navarro-Pérez J, Ramos R, Molto J, Otero-Romero S, Aurrecoechea E, Pomarol R, Bernad L, Esteban I, Pérez-Caballero R, Plana M, Prado JG, Soriano A.** Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study. Hum Vacc Immunother. 2025; 21(1): 2474775. Article. IF: 4.2; Q2
- **Maldonado-Barrueco A, de la Calle-prieto F, Díaz-Menéndez M, Arsuaga M, García-Rodríguez J, Ruiz-Carrascoso G.** Impact of the SARS-CoV-2 pandemic on the prevalence and incidence of enteric protozoa in a spanish tertiary-care hospital and a referral center for tropical diseases, 2019-2023. Med Sci (Basel). 2025; 13(1): 23. Article. IF: 5.9; D1
- **Mariño E, Rodríguez-Pardo J, Vidal L, Zmork G, Garcial-Leal A, Díaz-Pollán B, Lacruz L.** Paradoxical reactions of central nervous system tuberculosis: report of three immunocompetent cases. Case Rep Infect Dis. 2025; 1: 5416948. Article. IF: 0.8; Q4
- **Martorell C, Ramgopal M, Hagins D, Osiyemi O, Arribas JR, Berhe M, Yazdanpanah Y, Orkin C, Santiago L, Rosero C, Unger N, Liu H, Rogers R, Hindman JT, Wurapa A.** Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies. HIV Med. 2025; 26(6): 858-69. Article. IF: 3.2; Q2

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

- **Montes ML, Busca C, Martín-Torres J, Bernardino JI, de las Revillas FA, Martín-Carbonero L, Villegas JS, Micán R, Dalmau D, Arcos MM, Sánchez MDL, de Gea A, Ugarte SI, Arribas JR, González-García J.** Triglyceride-glucose index and FIB-4 score in relation to cardiovascular disease risk among people with HIV: a retrospective cohort study. Front Med (Lausanne). 2025; 12: 1638071. Article. IF: 3.6; Q1
- **Morales-Múnera CE, Montoya F, de Loredo N, Sendagorta E.** AEDV expert document on the management of ulcerative venereal infections. Actas Dermosifiliogr. 2025; 116(2): T159-68. Article. IF: 2.9; Q2
- **Nathan M, Chatzistamatiou K, Gallio N, Cappello C, Loughlin P, Bock S, Blanco JL, Sendagorta E, Etienney I, Albuquerque A, Vieira-Baptista P, Schmidt PT, Gultekin M, Surmont M, Ahmad S, Bowring J, Lyons D, Cuming T, Preti M, Cruickshank ME.** Current practices in HPV-related anogenital neoplasia care in Europe - a survey analysis. BMC Cancer. 2025; 25(1): 1223. Article. IF: 4.1; Q2
- **Norman FF, Arce OA, Díaz-Menéndez M, Belhassen-García M, González-Sanz M.** Changes in the epidemiology of Crimean-Congo hemorrhagic fever: Impact of travel and a One Health approach in the European region. Travel Med Infect Di. 2025; 64: 102806. Article. IF: 5.6; D1
- **Ochoa RAF, Cudós ES, Gallego MA, Pérez-Ramos L, Pinto PH.** Retrospective study of risk markers for developing high-grade anal intraepithelial neoplasm in men who have sex with men living with HIV. Actas Dermosifiliogr. 2025; 116(1): T39-46. Article. IF: 2.9; Q2
- **Pellejero-Sagastizábal G, Bulescu C, Gupta N, Jokelainen P, Gkrania-Klotsas E, Barac A, Goorhuis A, Jacob ST, Agnandji ST, Ntoumi F, Mora-Rillo M, Paño-Pardo JR, Lescure FX, Grobusch MP.** Delayed correct diagnoses in emerging disease outbreaks: historical patterns and lessons for contemporary responses. Clin Microbiol Infec. 2025; 31(8): 1298-306. Review. IF: 8.7; D1
- **Pérez-Valero I, Mata DC, Espejo AC, Gallo M, de Morales AGGR, Fanciulli C, Martín-Carbonero L, Isbert SC, Gutiérrez CH, Asensi V, Juarez AR, Rivero A.** Real-world effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in comparison with other regimens in people with human immunodeficiency virus starting therapy with aids-defining conditions: results from the CoRIS Cohort-The ACTUAS II Study. Clin Infect Dis. 2025; 81(4): e93-101. Article. IF: 8.3; D1
- **Pozniak A, Orkin C, Yazdanpanah Y, Baumgarten A, Mounzer K, D'Antoni ML, Huang HL, Liu H, Andreatta K, Vanderveen LA, Callebaut C, Hindman JT, Arribas JR.** Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) after a viremic event: a pooled analysis of studies in people with HIV. Infect Dis Ther. 2025; 14(6): 1201-17. Article. IF: 5.6; Q1
- **Rodríguez-Morales AJ, Alhazmi AH, Katime A, Hameed AA, Morales A, Lepetic AC, Risquez A, Forero-Delgadillo AJ, Holguin A, Faccini-Martínez AA, Guerrero A, Ribeiro A, Al Balushi A, Ozkan AT, Rathish B, Díaz B, Porras-Pedroza BE, Hunsajarupan B, Lakatos B, Álvarez-Moreno C, Torres-Martínez CN, Ronnberg C, Perret C, Wejse CM, Adhikari A, Popescu CP, Abbara A, Biscayart C, Bonilla-Aldana DK, Fasan D, Calderón D, de Luna D, Forero-Peña DA, Costescu-Strachinaru DI, Pedro DM, Monk EJM, Iliaki E, Pontali E, Ngbede EO, Farkas FB, González-Sanz M, Escarrá F, Mariotti F, Norman FF, Di Gennaro F, Membrillo FJ, Arrieta G, Guido G, Fuster AV, Grández-Castillo GA, Leblebicioglu H, de Jong HK, Vargas H, Kim J, Cardona-Ospina JA, Torres JR, Llenas-García J, Wagenhäuser I, Oteo JA, Braun JFG, Sepulveda-Arias JC, Hernández JP, Saenz JR, Nwofe JO, Kowalska J, Jackson KE, Aykac K, Rezzonico LF, Reyes LF, Frallonardo L, Krone M, Malagon MF, Sempere-Alcocer MA, Luque MT, Carlos M, Onorbe MDF, Moreno MS, Lauriola M, Masana M, Fernández M, Martínez-Gutiérrez M, Díaz-Menéndez M, Martínez MJ, Cabada MM, Morante-Ruiz M, Álvarez-Martínez MJ, Sandoval-Paiz N, Chávez N, Joean O, Arce O, Koch O, Epaulard O, Cirit OS, Recen ÖT, Quispe P, Passerini PLG, Velikov P, Hueda-Zavaleta M, Ioannou P, Luga P, Rath RS, Echavarría R, O'Regan R, Paggi R, Angerami RN, Abbara S, Mattar S, Scarso S, Gaggioli S, Verbanaz S, Fauzi SMM, Jordao S, Lloveras S, Ursini T, Chaves T, Weitzel T, Orduna T, Manciulli T, Rampling T, Acero V, Lezcano V, Moncada-Navas WK, Villamil-Gomez W, Özsürekçi Y, Roque Y, Noreen N, Yonga P, Ferrara P, Harboe ZB.** Yellow fever in South America - A plea for action and call for prevention also in travelers from SLAMVI, ESGITM, EVASG, ALEIMC, GEPI-SEIMC, SEMEVI, and CMTZMV-ACIN. Travel Med Infect Di. 2025; 67: 102871. Article. IF: 5.6; D1
- **Rolle CP, Arribas JR, Ortiz R, Underwood M, Parry CM, Grove R, Dimondi VP, Jones B, Kisare M.** Efficacy and safety outcomes in adults initiating Dolutegravir/Lamivudine with high viral load in the GEMINI-1/-2 and STAT trials. Open Forum Infect Dis. 2025; 12(3): ofaf135. Article. IF: 3.8; Q2
- **Romero EE, Toldos-Torres M, López-Diego D, Luna M, Failde M, González-Tobio B, Zamora F, Falces-Romero I, Montes ML, García-Mendiola T.** Dendrimer-based DNA biosensor for HIV virus detection. Biosens Bioelectron. 2025; 290: 118014. Article. IF: 11.8; D1
- **Ryan P, Berenguer J, Ramos-Ruperto L, Vera M, Martín-Carbonero L, Pérez-Latorre L, de los Santos I, Pinto A, Vivancos MJ, Orviz E, Álvarez B, Sanz J, Ruiz-Seco P, Torres R, Brazal B, de Miguel M, Lopez-Centeno B, Jarrín I, Resino S, Bellón JM, González-García J.** Epidemiology and risk factors for HCV infection among MSM with or at risk of HIV in Madrid (2022-2024). Open Forum Infect Dis. 2025; 12(12): ofaf678. Article. IF: 3.8; Q2
- **Schoepf IC, Haerry D, Esteban-Cantos A, Arribas JR, Tarr PE.** Perspective: clinical relevance of epigenetic aging and HIV. Epigenomics-Uk. 2025; 17(8): 523-7. Article. IF: 3.1; Q2
- **Sepúlveda-Crespo D, Sánchez-Merino V, Amigot-Sánchez R, Rubio-Pérez A, Díez C, Hontañón V, Berenguer J, González-García J, García F, Martínez I, Yuste E, Resino S.** Persistent low anti-hiv neutralizing antibody titers in HIV/HCV coinfection despite HCV cure: a 5-year longitudinal analysis. Vaccines (Basel). 2025; 13(5): 539. Article. IF: 3.5; Q2
- **Silvestre JF, Ruiz-Villaverde R, Pérez-García B, Pinto PH, Domínguez-Cruz JJ, Gentile M, Belloso RMI.** Real-world clinical, psychosocial and financial burden of atopic dermatitis: results from the spanish cohort of the measure-ad trial. Actas Dermosifiliogr. 2025; 116(1): T5-14. Article. IF: 2.9; Q2
- **Suárez-García I, Alejos B, Moreno C, Torres JM, Masiá M, García-Fraile LJ, Riera M, Dalmau D, Rodríguez-Rosado R, Muga R, Moreno S, Jarrín I.** Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks. J Antimicrob Chemoth. 2025; 80(3): 682-91. Article. IF: 4.1; Q1
- **Suárez-García I, Moreno C, Alejos B, Izquierdo R, de la Cámara SP, Pardo OB, Arenzana CB, Pérez-Elías MJ, López TP, Imaz A, Curran A, Hernando V, Jarrín I.** Pregnancy in women with HIV: Incidence and outcomes over 19 years in a multi-center cohort in Spain. AIDS Patient Care St. 2025; 39(10): 385-96. Article. IF: 4.4; Q1
- **Tarazona ED, Moraga E, Vaquer R, Sánchez-Palomino S, de Lazzari E, Luna L, Vicens-Artés S, Fraile LJG, Peraire J, García-Gasalla M, Balsalobre L, Martinez SG, Cortes LFL, Jarrin I, Serrano-Villar S, Alcami J, Moreno S.** Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size. Sci Rep-Uk. 2025; 15(1): 25306. Article. IF: 4.9; Q1
- **Torres T, Yeung JS, Prajapati VH, Ribero S, Balato A, Marzano AV, Cruz MJ, Lopes MJP, Lazaridou E, Carrascosa JM, Alvarenga JM, Farinha P, Duarte B, Munera-Campos M, Sood S, Rankin BD, Ortoncelli M, Caccavale S, Ferrucci SM, Rosa GP, Daponte AI, Silvi G, Peris K, Gori N, Prignano F, Kolios A, Herranz**

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

P, Gregoriou S, Rompoti N, Gkalpakiotis S, Chiricozzi A. Real-world effectiveness and safety of dupilumab, tralokinumab, and upadacitinib in patients with atopic dermatitis: a 52-week international, multicenter retrospective cohort study. Dermatol Ther (Heidelb). 2025; 15(8): 2295-305. Article. IF: 4.6; Q1

- **Troya J, Montes ML, Losa JE, Buzón-Martín L.** Long-acting CAB plus RPV: It's not about weight, It's about the weight of the evidence. Clin Infect Dis. 2025; 81(2): e33-4. Letter. IF: 8.3; D1
- **Valencia ME, Pirogova T, Romera D, Montero M, Tasías M, Sanz J, Arranz A, Vergas J, Tellez MJ, Fanjul F, Campins A, Cervero M, Jarrín I, de Miguel M, Carbonero LM, Yllescas M, González J.** Prospective study for the early detection of lung carcinoma in patients with HIV infection (GESIDA study 8815). Enferm Infec Micr Cl. 2025; 43(3): 125-32. Article. IF: 2.2; Q3
- **Vicente MA, Ruiz-Carrascoso G, de la Calle-Prieto F, Gallego JS, de Miguel-Buckley R, Nuñez ML, Martinez DM, Menéndez MD.** Outbreak of Schistosomiasis mansoni in a Spanish dance and percussion ensemble acquired in the Republic of Guinea. Enferm Infec Micr Cl. 2025; 43(9): 571-6. Article. IF: 2.2; Q3
- **Virseda-Berdices A, Brochado-Kith O, Berenguer J, González-García J, Pérez-Latorre L, Busca C, Díez C, Micán R, Fernández-Rodríguez A, Jiménez-Sousa MA, Resino S.** PBMCs gene expression predicts liver fibrosis regression after successful HCV therapy in HIV/HCV-coinfected patients. Front Pharmacol. 2025; 15: 1436198. Article. IF: 5.4; Q1
- **Virseda-Berdices A, Requena B, Berenguer J, Gónzalez-Garcia J, González-Riano C, Diez C, Hontañón V, Muñoz-Garcia P, Fernández-Rodriguez A, Barbas C, Resino S, Martin-Escolano R, Jimenez-Sousa MA.** Long-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis. J Infect Public Health. 2025; 18(12): -102981. Article. IF: 4.8; Q1

Research projects

- **Arribas López JR.** A European practive adaptative Clinical Trials network. (EU-PROACT_ARRIBAS). UE. 2025-2029. Managment centre: FIBHULP
- **Arribas López JR.** Biomarcadores epigenéticos de envejecimiento como predictores de eventos SIDA no-SIDA y enf. propias del envejecimiento (PI22/00285). ISCIII. 2023-2026. Managment centre: FIBHULP
- **Arribas López JR.** Dinamización de ciencia disruptiva en predictores de enfermedades tumorales, infecciosas y hereditarias como base de la medicina personalizada (FORT23/00006_GRUPO IV). ISCIII. 2024-2027. Managment centre: FIBHULP
- **Arribas López JR.** European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases (EU-RESPONSE_ARRIBAS). UE. 2020-2026. Managment centre: FIBHULP
- **Arribas López JR.** Meltformina vs placebo para la reversión de la aceleración de la edad biológica en personas de 50 años o mayores que viven con el VIH y con replicación viral suprimida (ICI20/00043). ISCIII. 2021-2026. Managment centre: FIBHULP
- **Arribas López JR.** MPX-RESPONSE_A clinical research network to improve the management of Monkeypox virus disease. (2022565). UE. 2022-2026. Managment centre: FIBHULP
- **Arribas López JR.** Un ensayo clínico aleatorizado, doble ciego, de fase II, controlado con placebo, de un solo centro para evaluar la metformina en comparación con el placebo para la reversión del envejecimiento biológico acelerado en personas que viven con el VIH de 50 años o más y con replicación virológica suprimida (5971 METFORAGING). Ongoing. 2021-Ongoing. Managment centre: FIBHULP
- **Bernardino de la Serna JI.** Biological age and cardiovascular ischemic events or diabtes in HIV-infected patients (DR.BERNARDINO SUBV GILEAD). Gilead Sciences S.L. 2017-Ongoing. Managment centre: FIBHULP
- **Bernardino de la Serna JI.** Ensayo clínico aleatorizado, controlado con placebo de colchicina para reducir la inflamación arterial coronaria en personas con VIH - COLCOVIH (ICI24/00059). ISCIII. 2025-2028. Managment centre: FIBHULP
- **Bernardino de la Serna JI.** Un ensayo clínico fase IV adaptativo, multicéntrico, controlado, aleatorizado y simple ciego para evaluar la eficacia, seguridad y coste eficacia de una estrategia de genotipado anticipado en una población en riesgo de enfermedad cardiovascular y susceptible de recibir de estatinas de alta o moderada (2023912). FIBHULP. 2024-Ongoing. Managment centre: FIBHULP
- **de Miguel Buckley R.** Proof of concept, pilot, open, single center randomized study of a group intervention vs. robotic companion pets to reduce loneliness in elderly persons living with HIV (GLD23/00017). Gilead Sciences S.L. 2024-Ongoing. Managment centre: FIBHULP
- **Díaz Pollán B.** Identification and validation of clinical phenotypes in Staphylococcus aureus bacteremia and their association with development of complicated bacteremia and mortality (FEN-AUREUS study) (PI21/01801). ISCIII. 2022-2024. Managment centre: Fundacion Publica Andaluza para la Gestion de la Investigacion en Salud de Sevilla
- **Díaz Pollán B.** Diseño de pautas optimizadas de tratamiento antimicrobiano de infecciones respiratorias por Pseudomonas aeruginosa. Estudio clínico observacional, microbiológico y farmacodinámico mediante el modelo in vitro hollow fiber (PI22/00011). ISCIII. 2023-2025. Managment centre: Institut Hospital Del Mar D´Investigacions Médiques (IMIM)
- **González García JJ.** Infecciones agudas/recientes y reinfecciones por VHC en hombres que tienen sexo con hombres con y sin VIH (PI20/00507). UE. 2021-2025. Managment centre: FIBHULP
- **Montejano Sánchez R.** Aceleración de la edad epigenética en personas que viven con VIH: impacto de factores biológicos y de comportamiento (PI21/01349). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Montejano Sánchez R.** Caracterización clínica y biológica de la viremia no suprimible en personas con VIH en tratamiento antirretroviral (PI24/00928). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Rodés Soldevila B.** Efecto de la metformina sobre el reservorio viral en personas con VIH:caracterización virológica, genética y epigenética (PI24/00927). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Rodés Soldevila B.** Perfiles de metilación del ADN y transcripción génica como marcadores del agotamiento de las células t en individuos VIH+ no tratados y crónicos avirémicos (PI21/00177). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Rodríguez Centeno J.** Marcadores de respuesta post-vacunal en población inmunocomprometida (MARVIC): oportunidades para el desarrollo de nuevas inmunoterapias para la prevención de la COVID-19 (2024128). Fundacio de la Lluita Contra el SIDA. 2023-Ongoing. Managment centre: FIBHULP
- **Sendagorta Cudos E.** ClearPap: dispositivo de terapia fotodinámica para el tratamiento de lesiones anales asociadas a VPH (2022627). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Serrano Villar S.** Microbiome-Based Interventions in Inflammaging: Discovery and Preclinical Testing of Antiinflammatory Agents (MIMIC) (IN24_01). CIBER. 2025-2026. Managment centre: CIBER

Ciber and Retics

- **Arribas López JR.** Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERInfect) (CB21/13/00039). ISCIII. (31/12/2025). FIBHULP

Clinical trials

- **Arribas Lopez JR.** Brand-specific covid-19 vaccine effectiveness against severe covid-19 disease in europe.
  Type/Phase: EPA-SP
  Sponsored by: P95 B.V.
  Signature date: 12/08/2025
- **Arribas Lopez JR.** Brand-specific respiratory syncytial virus vaccine effectiveness in europe.
  Type/Phase: EPA-SP

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Sponsored by: P95 Bv.
Signature date: 12/08/2025

- **Arribas Lopez JR.** Surveillance study of respiratory pathogens in adults hospitalised for sari across europe.
  Type/Phase: OTROS
  Sponsored by: P95 Bv.
  Signature date: 12/08/2025
- **Bernardino De La Serna JI.** Estudio de fase 2/3, aleatorizado, comparativo con tratamiento activo, abierto (fase 2) y doble ciego (fase 3), para evaluar la actividad antirretroviral, la seguridad y la tolerabilidad de islatravir (isl) y ulonivirina (ulo) una vez a la semana, en comparación con bictegravir/emtricitabina/tenofovir alafenamida (bic/ftc/taf) una vez al día, en participantes adultos con infección por el vih-1 sin tratamiento previo.
  Type/Phase: II
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 15/10/2025
- **Bernardino De La Serna JI.** Evaluación de la eficacia y la seguridad del cambio de un inhibidor de la proteasa potenciado a fostemsavir en personas que viven con vih (plwh) con opciones terapéuticas limitadas.
  Type/Phase: IV
  Sponsored by: Neat Id Foundation.
  Signature date: 05/03/2025
- **Bernardino De La Serna JI.** Supporting healthcare professionals to find undiagnosed hiv in european hospitals. an implementation project.
  Type/Phase: OTROS
  Sponsored by: Erasmus University Medical Center.
  Signature date: 15/07/2025
- **Díaz Pollán B.** Anexo estudio fase 1/2, observador ciego, aleatorizado, controlado con placebo y multicéntrico para evaluar la seguridad e inmunogenicidad de una vacuna frente las infecciones del tracto urinario (itu) en adultos de 18 a 64 años, así como su eficacia clínica cuando se administra a mujeres de 18 a 64 años.
  Type/Phase: I
  Sponsored by: Glaxosmithkline, S.A.
  Signature date: 23/05/2025
- **Díaz Pollán B.** Ensayo de fase IIB, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de azd5148 en la prevención de la recurrencia por la infección de clostridioides difficile en pacientes de 18 años de edad en adelante.
  Type/Phase: IIb
  Sponsored by: Astrazeneca Ab.
  Signature date: 16/12/2025
- **Díaz Pollán B.** Estudio en fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia, la seguridad y la inmunogenicidad de la vacunación con expec9v en la prevención de la enfermedad por escherichia coli patógena extraintestinal invasiva en adultos de 60 años de edad en adelante con antecedentes de infección urinaria en los últimos 2 años.
  Type/Phase: III
  Sponsored by: Janssen Research & Development, Llc.
  Signature date: 14/08/2025
- **Díaz Pollán B.** Estudio fase 1/2, observador ciego, aleatorizado, controlado con placebo y multicéntrico para evaluar la seguridad e inmunogenicidad de una vacuna frente las infecciones del tracto urinario (itu) en adultos de 18 a 64 años, así como su eficacia clínica cuando se administra a mujeres de 18 a 64 años.
  Type/Phase: I
  Sponsored by: Glaxosmithkline, S.A.
  Signature date: 04/03/2025
- **Díaz Pollán B.** Estudio fase 1/2, observador ciego, aleatorizado, controlado con placebo y multicéntrico para evaluar la seguridad e inmunogenicidad de una vacuna frente las infecciones del tracto urinario (itu) en adultos de 18 a 64 años, así como su eficacia clínica cuando se administra a mujeres de 18 a 64 años.
  Type/Phase: I
  Sponsored by: Glaxosmithkline, S.A.
  Signature date: 30/09/2025
- **Díaz Pollán B.** Ventriculitis zero: diagnóstico de meningitis y ventriculitis relacionadas con la asistencia sanitaria mediante una pcr específica y estrategias adaptativas para el manejo de catéteres intracraneales.
  Type/Phase: OTROS



Sponsored by: Díaz Pollán, Beatriz.
Signature date: 11/03/2025

- **Gonzalez García JJ.** Estudio de fase 2b, aleatorizado, abierto y controlado con tratamiento activo que evalúa la seguridad y la eficacia de vh4524184 oral coadministrado con emtricitabina y tenofovir alafenamida, en personas con vih-1 virémicas que no han recibido tratamiento previo (estudio innovate).
  Type/Phase: IIb
  Sponsored by: Viiv Healthcare Uk Limited.
  Signature date: 13/11/2025
- **Gonzalez García JJ.** Estudio exploratorio de fase 1b, multicéntrico, aleatorizado y abierto para investigar el impacto de la administración de vh3810109 intravenoso con o sin fostemsavir oral en combinación con terapia antirretroviral basada en inhibidores de la integrasa sobre el reservorio viral en adultos que viven con vih-1 (entrance).
  Type/Phase: I
  Sponsored by: Laboratorios Viiv Healthcare, S.L.
  Signature date: 26/08/2025
- **Herranz Pinto P.** A phase 2, multi-center study consisting of a randomized, placebo-controlled period, followed by an open-label extension period to assess the efficacy, safety, and tolerability of tibulizumab in adults with hidradenitis suppurativa.
  Type/Phase: II
  Sponsored by: Zura Bio Inc.
  Signature date: 10/07/2025
- **Herranz Pinto P.** A phase 3, 2-part, open-label and double-blind, randomised study to evaluate the effectiveness and safety of lebrikizumab treatment in adults and adolescents with moderate-to-severe atopic dermatitis.
  Type/Phase: IIIb
  Sponsored by: Almirall S. A.
  Signature date: 08/05/2025
- **Herranz Pinto P.** Ensayo en fase II, aleatorizado, con enmascaramiento doble, comparativo con placebo, multicéntrico y de búsqueda de dosis para evaluar la eficacia y la seguridad de zasocitinib en participantes con vitiligo no segmentario.
  Type/Phase: II
  Sponsored by: Takeda Development Center Americas, Inc.
  Signature date: 19/11/2025
- **Herranz Pinto P.** Estudio abierto, multinacional y multicéntrico para evaluar la seguridad,

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

tolerabilidad y eficacia a largo plazo de amlitelimab por vía subcutánea en adultos con dermatitis atópica de moderada a grave.
Type/Phase: II
Sponsored by: Sanofi-Aventis Recherche & Developpement.
Signature date: 12/05/2025

- **Herranz Pinto P.** Estudio de extensión de fase III, multinacional, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos de 48 semanas para evaluar la respuesta al tratamiento y la seguridad de dos pautas posológicas de amlitelimab administradas en monoterapia mediante inyección subcutánea en participantes de 12 años de edad y mayores con dermatitis atópica de moderada a severa.
Type/Phase: III
Sponsored by: Sa Sanofi-Aventis Recherche Et Developp.
Signature date: 16/06/2025
- **Herranz Pinto P.** Estudio de extensión de pacientes con psoriasis en placas de moderada a grave para evaluar la seguridad, la eficacia y la durabilidad de la respuesta a largo plazo de esk-001 (onward3).
Type/Phase: III
Sponsored by: Alumis Inc.
Signature date: 05/06/2025
- **Herranz Pinto P.** Estudio de fase 2 aleatorizado, doble-ciego, controlado con placebo, de rango de dosis de sar442970 seguido de un periodo de mantenimiento en participantes con hidradenitis supurativa moderada a severa.
Type/Phase: IIb
Sponsored by: Sanofi Aventis S.A.
Signature date: 04/11/2025
- **Herranz Pinto P.** Estudio de fase 3, multicéntrico, aleatorizado, doble ciego, con doble simulación y controlado con placebo en el que se evalúan la eficacia, la seguridad y la tolerabilidad de 2 dosis de remibrutinib a lo largo de un periodo de tratamiento de 68 semanas en pacientes adultos con hidradenitis supurativa de moderada a grave.
Type/Phase: III
Sponsored by: Novartis Pharma Services Ag.
Signature date: 23/04/2025
- **Herranz Pinto P.** Estudio de fase ii multicéntrico, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de ro7790121 en pacientes con dermatitis atópica moderada a grave.
Type/Phase: II
Sponsored by: F.Hoffmann-La Roche Ltd.
Signature date: 28/05/2025
- **Herranz Pinto P.** Estudio de fase iii, doble ciego, aleatorizado y controlado con vehículo sobre la eficacia y la seguridad del ruxolitinib crema en niños y adolescentes (de ≥6 a <18 años) con dermatitis atópica moderada.
Type/Phase: IIIb
Sponsored by: Incyte Corporation.
Signature date: 18/11/2025
- **Herranz Pinto P.** Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo y comparador activo para evaluar la eficacia y la seguridad de esk-001 en pacientes con psoriasis en placas de moderada a grave (onward2).
Type/Phase: III
Sponsored by: Alumis Inc.
Signature date: 25/02/2025
- **Herranz Pinto P.** Estudio en fase III de retirada aleatorizada, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de pf-04965842 en pacientes de 12 o más años de edad con dermatitis atópica moderada o grave con la opción de un tratamiento de rescate para aquellos pacientes que presenten un empeoramiento de la enfermedad.
Type/Phase: III
Sponsored by: Pfizer Inc.
Signature date: 14/02/2025
- **Herranz Pinto P.** Estudio en fase III, aleatorizado, con enmascaramiento doble, comparativo con placebo, sobre la eficacia y la seguridad de povorcitinib en participantes con prurigo nodular.
Type/Phase: III
Sponsored by: Incyte Corporation.
Signature date: 01/10/2025
- **Herranz Pinto P.** Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, con 3 ramas de tratamiento, multinacional y multicéntrico para evaluar la eficacia y la seguridad de amlitelimab en monoterapia mediante inyección subcutánea en participantes de 12 años de edad y mayores con dermatitis atópica de moderada a severa.
Type/Phase: III
Sponsored by: Sa Sanofi-Aventis Recherche Et Developp.
Signature date: 20/03/2025
- **Herranz Pinto P.** Estudio observacional, ambispectivo y exploratorio sobre las características de los pacientes que influyen en las decisiones de los médicos respecto a la terapia y la dosificación de tildrakizumab y la satisfacción del paciente con el tratamiento en la psoriasis en placa de moderada a grave an observational, ambispective, explorative study on patient characteristics influencing physicians decisions regarding tildrakizumab therapy and dosing and patient treatment satisfaction in moderate-tosevere plaque psoriasis.
Type/Phase: EOm prospectivo
Sponsored by: Almirall S. A.
Signature date: 14/11/2025
- **Herranz Pinto P.** Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa.
Type/Phase: III
Sponsored by: Moonlake Immunotherapeutics Ag.
Signature date: 27/10/2025
- **Llenas García J.** Ensayo clínico fase III aleatorizado, doble-ciego, multicéntrico que evalúa la eficacia y seguridad de dexametasona comparado con placebo en pacientes con gripe grave.
Type/Phase: III
Sponsored by: Instituto De Investigacion Sanitaria Y Biomedica De Alicante (Isabial).
Signature date: 26/11/2025
- **Marcelo Calvo C.** A phase 4 study using a test-negative design to evaluate the effectiveness of a 20-valent pneumococcal conjugate vaccine against vaccine-type radiologically-confirmed community-acquired pneumonia in adults ≥ 65 years of age.
Type/Phase: IV
Sponsored by: Pfizer Inc.
Signature date: 19/06/2025
- **Martín Carbonero L.** Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad del tratamiento con bepirovirsen en participantes portadores crónicos del virus de la inmunodeficiencia humana y del virus de la hepatitis b, que reciben tratamiento antirretroviral.
Type/Phase: IIb
Sponsored by: Glaxosmithkline Research And Development Limited ,.
Signature date: 16/12/2025
- **Ramos Ramos JC.** An interventional efficacy and safety, phase 3, randomized, double-blind, 3-arm study to investigate ibuzatrelvir in adults with symptomatic covid-19 who are severely immunocompromised.
Type/Phase: III
Sponsored by: Pfizer Inc.
Signature date: 03/06/2025

Patents and trademarks

- **Romero Gómez M, Solá Lamoglia R, González García JJ, inventors; Servicio Andaluz de Salud, Universidad de Sevilla, Fundació Institut Mar D'Investigacións Mèdiques, FIBHULP, assignees.** Kit for decision making in patients with Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.3.2 Molecular Microbiology Group

Publications: 68 | Q1: 34

COMPOSITION

Jesús Mingorance Cruz.
Investigador Titular. Hospital Universitario La Paz

- **Iván Bloise Sánchez.** *Facultativo Especialista en Microbiología y Parasitología Clínica. Hospital Universitario La Paz*
- **Emilio Cendejas Bueno.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Fernando José Corrales Izquierdo.** *Investigador científico. CSIC*
- **Elias Dahdouh.** *Investigador Postdoctoral Miguel Servet. Hospital Universitario La Paz*
- **Iker Falces Romero.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Silvia García Bujalance.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **María Jesús García García.** *Profesora Emérita del Departamento de Medicina Preventiva y Salud Pública y Microbiología. Facultad de Medicina de la UAM. Universidad Autónoma de Madrid*
- **Isabel García Pérez.** *Investigadora predoctoral. FIBHULP*
- **Julio García Rodríguez.** *Jefe de Servicio de Microbiología. Hospital Universitario La Paz/ Profesor Asociado de la Facultad de Medicina. Universidad Autónoma de Madrid*
- **Paulino Gómez Puertas.** *Científico Titular CSIC. CBM Severo Ochoa. Profesor Honorario. Universidad Autónoma de Madrid*
- **Rocío González Soltero.** *Catedrática de Genética Molecular. Universidad Europea*
- **David Grandioso Vas.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Almudena Gutiérrez Arroyo.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Fernando Lázaro Perona.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **María Fátima López Fabal.** *Facultativo Especialista en Microbiología. Hospital Universitario La Paz*
- **María Belén Loeches Yagüe.** *Médico Adjunto. Unidad de Enfernedades Infecciosas. Hospital Universitario La Paz*
- **María del Carmen Menéndez Gómez.** *Profesora contratada Doctora del Departamento de Medicina Preventiva y Salud Pública y Microbiología. Facultad de Medicina de la UAM. Universidad Autónoma de Madrid*
- **Alberto Paradela Elizalde.** *Investigador Científico. CSIC*
- **Verónica Pérez Blanco.** *Facultativo Especialista de Área en Medicina Preventiva. Hospital Universitario La Paz*
- **Rafael Carlos Prados Rosales.** *Investigador Postdoctoral. Universidad Autónoma de Madrid*
- **María Inmaculada Quiles Melero.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Alicia Rico Nieto.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Graciela Rodríguez Sevilla.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Mario David Ruiz Bastián.** *Facultativo Especialista en Microbiología y Parasitología Clínica. Hospital Universitario La Paz*
- **Guillermo Ruiz Carrascoso.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Carlos Toro Rueda.** *Facultativo Especialista de Área en Microbiología. Hospital Carlos III-Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- The Molecular Microbiology research group originated in the Microbiology Service of Hospital La Paz, and a significant portion of its members are staff physicians from the Service with clinical activity. This shapes the group's strategic approach, which is why the various research lines focus on different aspects of clinical microbiology and infectious pathology.
- A core line, Clinical Microbiology, stems directly from the Service's clinical activity. However, our work in this area goes beyond, delving into the methodological and epidemiological challenges that arise in daily routine.
- In this context, another line focuses on developing molecular methods for the typing and characterization of pathogenic microorganisms. These methods have applications in microbiological diagnosis, epidemiological analysis, and the detection and characterization of antibiotic-resistant bacteria. We have extensive experience in techniques such as PCR, Sanger sequencing, massive sequencing (NGS), bioinformatics analysis, and proteomics.
- Since the emergence of the first carbapenemases between 2008 and 2010, an important line has concentrated on studying the epidemiology, hospital ecology, and evolution of carbapenemase-producing Enterobacteriaceae, especially Klebsiella pneumoniae.
- Related to this line and the difficulties in developing new antibiotics, we utilize molecular dynamics methods to search for novel carbapenemase inhibitors.
- Additionally, several group members, who belong to the UAM Faculty of Medicine, have a long research history in the Molecular Biology and Pathogenesis of Mycobacterium tuberculosis and other mycobacteria.
- Finally, we are exploring the gut microbiome and its alterations in relation to various pathologies and clinical conditions.

RESEARCH LINES

- Molecular epidemiology and evolution of pathogens
- Molecular methods for diagnostics of infectious diseases
- Genomics of hospital microbial pathogens
- Design of new metallo-beta-lactamase inhibitors using computational molecular dynamics simulations of protein-ligand interactions.
- Molecular Biology and Pathogenesis of *Mycobacterium tuberculosis*

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH ACTIVITY

Master Theses

- **Muruzábal Gil M.** Estudio piloto de la microbiota intestinal[dissertation]. Madrid: UAM: 2025(30/06/2025). Director: Mingorance Cruz J.
- **Fay C.** Determinación de cambios en el microbioma intestinal en pacientes pediátricos nutricional alto al nacimiento[dissertation]. Madrid: UE: 2025(26/06/2025). Director: Dahdouh E.

Final Degree Theses

- **Sevillano M.** Utilidad diagnóstica de la cuantificación relativa de Streptococcus pneumoniae en muestras clínicas de origen respiratorio[dissertation]. Madrid: UAM: 2025(20/09/2025). Director: Mingorance Cruz J.
- **López Yagual C.** Determinación de Cargas Intestinales de Torque Tino Virus en pacientes inmunodeprimidos [dissertation]. Madrid: UE: 2025(26/06/2025). Director: Dahdouh E.

Publications

- **Aguilera-Alonso D, Sánchez-Cañete J, McArdle LV, del Rosal T, Santaeufemia FJS, Soto B, Saavedra-Lozano J, Tato LP, Álvarez FJM, Navarro SB, Cercenado E, Marín M, Rivas G, Bueno EC, Abad MJG, Arana DM, Yuste J, Baquero-Artigao F, Calvo C.** Impact of the COVID-19 pandemic on pediatric bacterial community-acquired pneumonia: a multicenter retrospective study in madrid, Spain. Pediatr Infect Dis J. 2025; 44(2): 151-3. Article. IF: 2.3; Q2
- **Arnedo M, Ros-Pardo D, Puisac B, Lucia-Campos C, Gil-Salvador M, Latorre-Pellicer A, Marcos-Alcalde I, Pie J, Gómez-Puertas P.** Ligand-enzyme interaction modeling of missense variants implicated in mitochondrial hmg-coa synthase deficiency. Int J Mol Sci. 2025; 26(17): 8266. Article. IF: 5.6; Q1
- **Bober SL, Li QJ, Ros-Pardo D, Faultless T, Marcos-Alcalde I, Gómez-Puertas P, Gollob MH.** HCN4 mutation causing familial inappropriate sinus tachycardia leads to a conformational change mimicking camp binding and induces constitutive channel activity. Circ-Arrhythmia Elec. 2025; 18(11): e013899. Article. IF: 9.3; D1
- **Bravo-Queipo-de-Llano B, Jiménez B, Garcia-Lorenzo M, Melendo S, Carrasco-Colom J, Olteanu-Olteanu FC, Lacuey BR, Calle-Miguel L, Harillo L, Falces-Romero I, Ruiz-Carrascoso G, Marcos DP, de Gopegui ER, Larrosa N, Viñado B, Permuy C, Sampedro M, Ruiz-Azcarate J, del Rosal T, Sainz T, Calvo C, Méndez-Echevarría A.** Community-acquired methicillin-resistant staphylococcus aureus infection in children: key features and comparison to colonization. Pediatr Infect Dis J. 2025; 44(10): 931-6. Article. IF: 2.3; Q2
- **Cabrera Romero V, Ramírez-Martín R, Palacios Revilla CD, Quiles Melero MI, Rico Nieto A.** Septic arthritis related to Lactobacillus sakei: A case report. Rev Esp Geriatr Gerontol. 2025; 60(2): 101562. Article. Not Indexed
- **Calderón-Parra J, Escrihuela F, Cuervo G, López-Azor JC, Muñoz P, Machado M, Marín M, Rodríguez-Esteban MA, Rodríguez-García R, Gutiérrez F, Meda JMM, Goenaga MA, Goikoetxea-Agirre J, de Alarcón A, Vidal-Bonnet L, Ramos-Martinez A.** First year after surgery is the optimal period to define early prosthetic valve endocarditis: a cohort study. Open Heart. 2025; 12(1): e003378. Article. IF: 3.1; Q2
- **Cifuentes C, Horndler L, Grosso P, Oeste CL, Hortal AM, Castillo J, Fernández-Pisonero I, Paradela A, Bustelo X, Alarcón B.** The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior. J Hematol Oncol. 2025; 18(1): 41. Article. IF: 47.8; D1
- **Cobo-Vázquez E, Aguilera-Alonso D, Grandioso-Vas D, Gamell A, Rello-Saltor V, Oltra-Benavent M, Cervantes E, Sanz-Santaeufemia F, Carrasco-Colom J, Manzanares-Casteleiro A, Martin-Pedraz L, de Arellano ER, Falcón-Neira L, Martínez-Campos L, Colino-Gil E, Jiménez-Montero B, Calavia O, Hernández-Ventura A, del Castillo-Navio E, Matias-Del Pozo V, Calle-Miguel L, Soto B, Fernández B, Camil-Olteanu F, Pareja-León M, López-Segura N, Ara-Montojo F, Ruiz-Sáez B, Calvo-Monge C, Sánchez-Códez M, Reinoso T, Badillo K, Vázquez C, Villalón P, Oteo-Iglesias J, Mellado-Sola I, Cercenado E, Blázquez-Gamero D, Menasalvas A, González-Abad MJ, Guarch B, Ibáñez-Alcalde M, Carazo B, Lung M, Calvo C, Saavedra-Lozano J.** Sharp increase in the incidence and severity of invasive Streptococcus pyogenes infections in children after the COVID-19 pandemic (2019-2023): A nationwide multicenter study. Int J Infect Dis. 2025; 159: 107982. Article. IF: 4.6; Q1
- **Cuervo G, Hernández-Meneses M, de Alarcón A, Luque-Márquez R, Alonso-Socas MM, López-Lirola A, González-Ramallo V, Goikoetxea-Agirre AJ, Nicolás D, Goenaga MA, Merino E, Escrihuela-Vidal F, Martín-Dávila P, Loeches B, Boix-Palop L, Gasch O, Camprecios M, Hernández-Torres A, García-Alvarez L, Pajarón M, Ribas MA, Blanes-Hernández R, López-Montesinos I, López-Cortés LE, Vidal B, Fernández-Pittol M, Navarro D, Moreno A, Sala C, Ambrosioni J, Miró JM.** Oral vs. Outpatientparenteral antimicrobial treatment for infective endocarditis: study protocol for the spanish OraPAT-IE GAMES trial. Infect Dis Ther. 2025; 14(3): 643-55. Article. IF: 5.6; Q1
- **Cukoski S, Brehm TT, Büttner S, Van Praet J, Dolff S, Eberwein L, Falces-Romero I, Cornely OA, Wanken M, Müller RU, Burst V, Koehler FC.** Design and set-up of the leptospirosis registry LeptoScope for epidemiology, outbreaks and clinical studies on human leptospirosis. Front Public Health. 2025; 13: 1687249. Article. IF: 4.1; Q1
- **Dahdouh E, García-Pérez I, Reyes-Zuñagua DS, Mingorance J, Vicente M.** Revisiting classical Escherichia coli cell division mutants by whole-genome sequencing. Microb Genom. 2025; 11(11): 1558. Article. IF: 4.5; Q1
- **de Schrijver S, Vanhulle E, Ingenbleek A, Alexakis L, Johannesen CK, Broberg EK, Harvala H, Fischer TK, Benschop KSM.** Epidemiological and clinical insights into enterovirus circulation in europe, 2018-2023: a multicenter retrospective surveillance study. J Infect Dis. 2025; 232(1): e104-e115. Article. IF: 4.1; Q1
- **del Mar ARM, Luis RR, Carmen B, Alejandro DG, Fernando FH, Ana DH, Inmaculada QM, Alfredo MB, Rafael M, Luz MC, Ignacio BJ.** Retrospective analysis of sexually transmitted infections among people living with HIV and pre-exposure prophylaxis users in Spain. BMC Infect Dis. 2025; 26(1): 167. Article. IF: 3.2; Q2
- **Díaz-Navarro M, Cercenado E, Visedo A, Marín M, Machado M, Irigoyen-von-Sierakowski A, Loeches B, Cacho-Calvo J, García-Rodríguez J, Di Domenico EG, Muñoz P, Guembe M.** Assessment of the anti-biofilm effect of cefiderocol against 28 clinical strains of multidrug-resistant gram-negative bacilli. Antibiotics (Basel). 2025; 14(8): 738. Article. IF: 5.5; Q1
- **Díez-Vidal A, Gil-Garrote S, Díaz-Pollán B, Rodríguez-Sevilla G, Martínez-Martín P, Marcelo-Calvo C, Díaz-Menéndez M.** Amebic liver abscess presenting in a nonendemic region after a 12-year latency in a patient with well controlled HIV infection. Aids. 2025; 39(2): 211-3. Letter. IF: 2.9; Q2
- **Escudero-Sánchez R, Morata L, Buzón L, de la Villa S, Rico A, Orantos MJN, Carrion LG, Pitarch MT, del Pozo JL, Barbero JM, Gómez-Junyent J, Pais MJG, Luque PB, Marcos FJM, Cobo J.** Dalbavancin as suppressive therapy for implant-associated osteoarticular infections. Antibiotics (Basel). 2025; 14(11): 1171. Article. IF: 5.5; Q1
- **Fernández-Veiga L, Fuertes M, Geijo MV, Elguezabal N, Serrano-Mestre JL, Vázquez-Iniesta L, Prados-Rosales R, Michelet L, Boschiroli ML, de Val BP, Jones GJ, Juste RA, Garrido JM, Sevilla IA.** Protection and diagnostic interference induced by heat-

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

inactivated, phage-inactivated and live vaccine prototypes against animal tuberculosis. Front Vet Sci. 2025; 12: 1620497. Article. IF: 3.1; D1


- **Frías-García R, García PM, Vílchez MM, Caballero GC, Rodríguez-García R, Rodríguez-Esteban MA, Fariñas-Álvarez MC, Meda JMM, Villanueva AG, Ojeda-Burgos G, Goikoetxea-Agirre AJ, Palacios MB, Martínez-Sellés M.** Body mass index and prognosis of infective endocarditis. Infect Dis (Lond). 2025; 57(8): 793-800. Article. IF: 2.5; Q3
- **García-Boyano M, Alcalá FJC, Alonso AR, de Villalta MGF, Alonso OZ, Retolaza IR, Melero IQ, Calvo C, Escosa-García L.** Tracheobronchitis in noncritically ill children with tracheostomy: can quantitative tracheal cultures assist in the management? Pediatr Pulm. 2025; 60(1): e27489. Article. IF: 2.4; Q2
- **Garcia-Boyano M, Alcalá FJC, Alonso AR, de Villalta MGF, Alonso OZ, Retolaza IR, Melero IQ, Calvo C, García LE.** Antibiotic choice and outcomes for respiratory infections in children with tracheostomies. Hosp Pediatr. 2025; 15(1): 17-27. Article. IF: 2.2; Q2
- **García-Cobos S, Alberca NS, Bravo-Queipo-de-Llano B, Casquero-García V, de Arellano ER, Calvo C, Ruíz-Carrascoso G, Falces-Romero I, Escartín NL, Viñado-Perez B, Martínez-López MA, Pérez SM, de Gopegui ER, Vázquez SP, Carrasco-Colom J, García BA, Pérez-Vázquez M, Méndez-Echevarría A, Iglesias JO.** Genomic analysis of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) causing infections in children-a Spanish multicenter study. Front Microbiol. 2025; 16: 1534840. Article. IF: 5.8; Q1
- **García-Pérez I, Lázaro-Perona F, Reyes-Zuñagua DS, Sotelo J, Rodríguez-Tejedor M, Cañada-García JE, Bloise I, Portugués-Rodríguez SM, Mingorance J, Oteo-Iglesias J, Dahdouh E.** NanoMLST: A high-throughput bacterial multi-locus sequence typing workflow using oxford nanopore next-generation sequencing for ESKAPE plus e pathogens. Microbiologyopen. 2025; 14(6): e70204. Article. IF: 3.6; Q2
- **Garcia-Rodriguez J, Janvier F, Kill C.** Key insights into respiratory virus testing: sensitivity and clinical implications. Microorganisms. 2025; 13(1): 63. Review. IF: 4.7; Q2
- **Gverdtsiteli S, Hammer TB, Hermann X, Andersen NB, Ros-Pardo D, Marcos-Alcalde I, Gómez-Puertas P, Brook AH, Silahtaroglu A, Tümer Z.** ROGDI-related disorder resulting from disruption of complex interactive neuro-dental developmental networks: a review and description of the first missense variant. Genes (Basel). 2025; 16(10): 1207. Review. IF: 3.1; Q2
- **Hidalgo-Tenorio C, Sadyrbaeva-Dolgova S, Aparicio-Minguijón E, Alarcon A, Plata A, Marcos FJM, Álvarez-Álvarez B, Loeches B, Varisco B, Estévez A, Herrero C, Escrihuela-Vidal F, Boix-Palop L, Ruch Y, Valour F, Issa N, Thill P, Nguyen S, Poloni S, Millot R, Peiffer-Smadja N, Boyer-Chammard T, Diallo K, Larcher R, Miró JM, Luque-Paz D.** Real-world evidence of dalbavancin effectiveness as consolidation therapy in infective endocarditis due to Enterococcus spp. J Microbiol Immunol. 2025; 58(4): 429-36. Article. IF: 3.8; Q2
- **Hildonen M, Ciolfi A, Ferilli M, Cappelletti C, Al Alam C, Amor DJ, Barakat TS, Benoit V, Birk OS, Callewaert B, Cazurro-Gutiérrez A, De Wachter M, Doco-Fenzy M, Gómez-Puertas P, Hammer TB, Jamra RA, Kaiyrzhanov R, Kameyama S, Keren B, Kresge C, Krey I, Lederer D, Marcos-Alcalde I, Maroofian R, Matsumoto N, Mizuguchi T, Moey LH, Morgan A, Munell F, Platzer K, Pletcher BA, Ros-Pardo D, Rumping L, Szakszon K, Van Schil K, Verdura E, Vogt J, Wassmer E, Zamani M, Tümer Z, Tartaglia M.** Biallelic loss-of-function variants in ZNF142 are associated with a robust DNA methylation signature affecting a limited number of genomic loci. Eur J Hum Genet. 2025; 33(7): 896-903. Article. IF: 4.6; Q1
- **Hirvonen A, Johannesen CK, Simmonds P, Fischer TK, Harvala H, Benschop KSM.** Sustained circulation of enterovirus D68 in Europe in 2023 and the continued evolution of enterovirus D68 B3-lineages associated with distinct amino acid substitutions in VP1 protein. J Clin Virol. 2025; 178: 105785. Article. IF: 3.7; Q2
- **Izquierdo R, Suárez-García I, Gómez-García T, Marco-Sánchez C, Puente-Ferreiro J, Moreno C, Diaz A, Cabello-Clotet N, Vinuesa D, Blanco JL, Melús E, Gómez-Ayerbe C, Olalla J, Riera M, Bernardino JI, de Quirós JCDB, Moreno S, Jarrín I.** Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain. HIV Med. 2025; 26(2): 308-18. Article. IF: 3.2; Q2
- **Izquierdo R, Suárez-García I, Marco-Sánchez C, Pérez-Latorre L, Riera M, Cano J, Viladés C, Reus S, Olalla J, González-Ruano P, Orviz E, Díaz A, Moreno S, Jarrín I, CoRIS cohort.** Health-related quality of life in people with HIV from the multicentre CoRIS cohort in Spain: Associated factors and short-term changes over time. HIV Med. 2025; 26(4): 606-20. Article. IF: 3.2; Q2
- **Juanes-Velasco P, Pérez-Arévalo JC, Arias-Hidalgo C, Nuño-Soriano A, Corrales F, Landeira-Viñuela A, Bernardo D, Cuesta-Sancho S, Rojo-Rello S, Lécrevisse Q, Góngora R, Sánchez-Santos JM, de las Rivas J, Hernández AP, Fuentes M.** Assessment of humoral response at SARS-Cov-2 infection by multipronged functional proteomics approaches. J Proteome Res. 2025; 24(2): 515-25. Article. IF: 3.8; Q2
- **Lazaro-Perona F, Navarro-Carrera P, Bloise I, Prieto-Casado P, García-Perez I, Paradela A, Corrales F, Cacho-Calvo J, Mingorance J.** Multiple mechanisms drive linezolid resistance in clinical Enterococcus faecium isolates by increasing poxtA gene expression. J Glob Antimicrob Resist. 2025; 42: 113-9. Article. IF: 3.7; Q2
- **Maldonado-Barrueco A, Almazán-Garate E, Armijo-Suárez O, Iniesta-Pérez S, Sanz-González C, Álvarez-López C, Cacho-Calvo J, Quiles-Melero I.** Detection of bacterial vaginosis-associated bacteria and outcomes during clinical gynaecological conditions using qPCR: A retrospective cohort study. Diagn Micr Infec Dis. 2025; 113(4): 117065. Article. IF: 1.8; Q3
- **Maldonado-Barrueco A, Almazán-Garate E, Armijo-Suárez O, Iniesta-Pérez S, Sanz-González C, Falces-Romero I, Álvarez-López C, Cacho-Calvo J, Quiles-Melero I.** Utility of sexually transmitted infection screening in diagnosing clinical gynaecological conditions using endometrial specimens. Diagn Micr Infec Dis. 2025; 112(4): 116830. Article. IF: 1.8; Q3
- **Maldonado-Barrueco A, de la Calle-prieto F, Díaz-Menéndez M, Arsuaga M, García-Rodríguez J, Ruiz-Carrascoso G.** Impact of the SARS-CoV-2 pandemic on the prevalence and incidence of enteric protozoa in a spanish tertiary-care hospital and a referral center for tropical diseases, 2019-2023. Med Sci (Basel). 2025; 13(1): 23. Article. IF: 5.9; D1
- **Maldonado-Barrueco A, Pinilla I, Feijoo PG, Almazán-Garate E, Regojo RM, Bernal-Martínez L, Alcázar-Fuoli L, Quiles-Melero I, García-Rodríguez J, Díaz-Pollán B, Barreiro P.** Disseminated paracoccidioidomycosis in a migrant from Paraguay. J Travel Med. 2025; 32(8): taaf121. Article. IF: 10.6; D1
- **Maldonado-Barrueco A, Quiles-Melero I, Garcia-Rodriguez J.** Current diagnostic approach to fungal infection in the critically ill patient. Rev Esp Quim. 2025; 38: 32-7. Review. IF: 2.8; Q3
- **Maldonado-Barrueco A, Rubio-Mora E, Bloise I, Cacho-Calvo J, Hernández-Rivas L, Dahdouh E, García-Rodríguez J, Rodríguez-Aguirregabiria M, Ramos-Ramos JC, Pérez-Blanco V, Mingorance J, Lázaro-Perona F.** Genomic analysis of carbapenem resistant Acinetobacter baumannii outbreak in a burn intensive care unit of a tertiary-care hospital in Madrid, Spain. Antimicrob Resist Infect Control. 2025; 14(1): 124. Article. IF: 5.2; Q1
- **Maldonado-Barrueco A, Ruiz-Carrascoso G, de Miguel-Buckley R, Ayuela-García S, García-Rodríguez J, Mora-Rillo M.** Photo Quiz: Incidental cyst lesions during COVID-19 pneumonia admission. J Clin Microbiol. 2025; 63(2): e0049424. Editorial Material. IF: 5.9; Q1
- **Maldonado-Barrueco A, Sanz-González C, Avellón A, Montero-Vega D, Vidales-Míguez C, Carisimo-Benavente L, Falces-Romero I.** Comparison of AmpliSens® HCV genotypeFRT-g-1-6 PCR kit with Abbott® Real

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Time HCV genotype II assay for hepatitis C virus genotyping. Rev Esp Quim. 2025; 38(1): 59-61. Letter. IF: 2.8; Q3

- **Maldonado-Barrueco A, Sanz-González C, Rubio-Mora E, Quiles-Melero I, García-Rodríguez J.** Evaluation and clinical impact of the combination of Wako® (1,3)-β-d-glucan in serum and RT-PCR in oral wash for Pneumocystis jirovecii infection diagnosis: A retrospective cohort study. Med Mycol. 2025; 63(10): myaf085. Article. IF: 3.5; D1
- **Martínez-Martín P, Rodríguez SR, Clement IM, Díez-Vidal A, Quiles-Melero I, Ramchandani B, Rico A, Loeches B.** Post-surgical mediastinitis caused by Aspergillus calidoustus in a heart transplant recipient: A case report and review of the literature. Diagn Micr Infec Dis. 2025; 112(2): 116796. Article. IF: 1.8; Q3
- **Martínez-Planas A, Baquero-Artigao F, Méndez-Echevarría A, Del Rosal T, Rodríguez-Molino P, Toro-Rueda C, Bustillo-Alonso M, Lafuente M, Canet A, Manzanares A, Tagarro A, Sanz-Santaeufemia FJ, Guillén-Martín S, Cilleruelo MJ, Falcón-Neyra L, Santiago B, Rincón E, Lillo M, Soriano-Arandes A, Sedda L, Fortuny C, Monsonís M, González-Martín J, Tebruegge M, Noguera-Julian A.** A 28-year multicenter cohort study of nontuberculous mycobacterial lymphadenitis in children, Spain. Emerg Infect Dis. 2025; 31(3): 536-46. Article. IF: 7.9; D1
- **Maserumule C, Passemar C, Oh OSH, Hegyi K, Brown K, Weimann A, Dinan A, Dávila S, Klapholz C, Bryant J, Verma D, Gadwa J, Krishnananthasivam S, Vongtongsalee K, Kendall E, Trelles A, Hibberd ML, Sanz J, Bertol J, Vázquez-Iniesta L, Andi K, Kumar SS, Ordway D, Prados-Rosales R, MacAry PA, Floto RA.** Phagosomal RNA sensing through TLR8 controls susceptibility to tuberculosis. Cell Rep. 2025; 44(5): -115657. Article. IF: 7.7; Q1
- **Medina D, Ávila R, Rodríguez-Sevilla G, Gumucio V, Bonilla M, Abelenda-Alonso G, Niubó J, Saumoy M, Tiraboschi J, Fuset MP, Imaz A.** Severe ARDS due to disseminated toxoplasmosis in a person with HIV successfully treated with ECMO: a case report. Front Med (Lausanne). 2025; 11: 1446762. Article. IF: 3.6; Q1
- **Palom-Grau C, Cuervo G, Muñoz P, Arriaza MM, Martínez-Sellés M, González-Ramallo V, de Alarcón A, Poyato-Borrego M, Rodríguez-García R, Rodríguez-Esteban MA, Fariñas MC, González-Rico C, Goenaga MA, Ojeda-Burgos G, Goikoetxea-Agirre AJ, Calderón-Parra J, López-Azor JC, García-Vázquez E, Loeches B, Quintana E, de la Mària CG, Llopis J, Miró JM.** A contemporary picture of coagulase-negative staphylococcal endocarditis a nationwide GAMES cohort study. J Am Coll Cardiol. 2025; 85(4): 305-18. Article. IF: 22.3; D1
- **Pena-Burgos EM, Regojo-Zapata RM, Caballero-Ferrero A, Martínez-Payo C, Vinuela-Benéitez MD, Montero D, de la Calle M.** The spectrum of placental findings of first-trimester cytomegalovirus infection related to the presence of symptoms in the newborns and stillbirths. Modern Pathol. 2025; 38(9): 100808. Article. IF: 6.6; D1
- **Peñalver M, Cestero JJ, Paradela A, Cava F, García-del Portillo F.** Salmonella encodes murein lipoproteins differing in the anchoring to peptidoglycan and intermolecular association. Cell Surf. 2025; 14: 100161. Article. IF: 9.3; D1
- **Pérez-Illana M, Schachner A, Hernando-Pérez M, Condezo GN, Paradela A, Martínez M, Marabini R, Hess M, San Martín C.** Aviadenovirus structure: A highly thermostable capsid in the absence of stabilizing proteins. Plos Pathog. 2025; 21(10): e1013553. Article. IF: 4.9; D1
- **Pérez-Valero I, Mata DC, Espejo AC, Gallo M, de Morales AGGR, Fanciulli C, Martín-Carbonero L, Isbert SC, Gutiérrez CH, Asensi V, Juarez AR, Rivero A.** Real-world effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in comparison with other regimens in people with human immunodeficiency virus starting therapy with aids-defining conditions: results from the CoRIS Cohort-The ACTUAS II Study. Clin Infect Dis. 2025; 81(4): e93-101. Article. IF: 8.3; D1
- **Rando E, Delgado-Valverde M, Aguirre JG, Carrión LG, Vidal MJB, Andrés JLB, Rodríguez MTP, Lamas LM, de las Revillas FA, Armiñanzas C, de Alegría-Puig CR, Aguilar PJ, Martínez-Rubio MD, Sáez-Béjar C, de las Cuevas C, Martín-Aspas A, Galán F, Yuste JR, Leiva-León J, Bou G, González PC, Boix-Palop L, Xercavins-Valls M, Goenaga-Sánchez MA, Anza DV, Castón JJ, Rufián MR, Merino E, Rodríguez JC, Loeches B, Rosso-Fernández C, Bravo-Ferrer JM, Retamar-Gentil P, Rodríguez-Baño J, Cortés LEL.** Effectiveness of oral step-down therapy and early oral switch for bloodstream infections caused by Enterobacterales: A post hoc emulation trial of the SIMPLIFY trial. Int J Infect Dis. 2025; 156: 107917. Article. IF: 4.6; Q1
- **Relinque JJ, Campos EM, León-Calero M, Rodríguez-Rodríguez L, Nieto-Díaz M, Novillo-Algaba I, Artola K, Fernández RG, Mingorance J, García I, Rodríguez-Hernández J.** Fabrication of 3D printed swabs in University Hospital's: Point of care manufacturing, study of mechanical properties and biological compatibility. Polymer. 2025; 323: 128162. Article. IF: 5.1; Q1
- **Rodríguez-Ayala M, Cacho-Calvo J, Cendejas-Bueno E.** Use of a rapid detection test for extended-spectrum beta-lactamase from direct blood culture: an antimicrobial stewardship tool in a tertiary hospital in Spain. Rev Esp Quim. 2025; 38(2): 84-96. Article. IF: 2.8; Q3
- **Rodríguez-Ayala M, Vizcarra P, Díaz-Pollán B, Lázaro-Perona F, Cendejas-Bueno E.** Invasive Streptococcus pseudopneumoniae infection in an adult patient with acute community-acquired meningitis: a case report. Eur J Clin Microbiol. 2025; 44(1): 187-92. Article. IF: 3.2; Q2
- **Romero EE, Toldos-Torres M, Lopez-Diego D, Luna M, Failde M, González-Tobio B, Zamora F, Falces-Romero I, Montes ML, García-Mendiola T.** Dendrimer-based DNA biosensor for HIV virus detection. Biosens Bioelectron. 2025; 290: 118014. Article. IF: 11.8; D1
- **Rubio-Mora E, Amoroto-Bengoetxea M, Nieto AR, Díez-Vidal A, Mingorance J, Quiles-Melero I.** Complete genome sequence of a Neisseria meningitidis isolate from an ankle joint with septic arthritis. Microbiol Resour Announc. 2025; 14(6): e0011125. Article. IF: 0.6; Q4
- **Rubio-Mora E, Bloise-Sánchez I, Quiles-Melero I, Cacho-Calvo J, Cendejas-Bueno E.** Neonatal sepsis: Epidemiology and comparison between preterm and term newborns. Enferm Infec Micr Cl. 2025; 43(4): 197-204. Article. IF: 2.2; Q3
- **Rubio-Mora E, Lázaro-Perona F, Bloise-Sánchez I, Cacho-Calvo J, Almazán-Garate E, Ruiz-Carrascoso G.** Emergence of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole carrying IMP-8 metallo-betalactamase in Spain. Int J Antimicrob Ag. 2025; 66(6): -107597. Letter. IF: 5.0; Q1
- **Ruedas-López A, Tato M, Lerma L, Esteban J, Muñoz-Egea MC, Toro C, Domingo D, Prados-Rosales R, López-Roa P.** Infection model of THP-1 cells, growth dynamics, and antimicrobial susceptibility of clinical Mycobacterium abscessus isolates from cystic fibrosis patients: Results from a multicentre study. Plos One. 2025; 20(3): -e0319710. Article. IF: 2.8; Q2
- **Salgueiro-Toledo VC, Bertol J, Gutiérrez C, Serrano-Mestre JL, Ferrer-Luzón N, Vázquez-Iniesta L, Palacios A, Pasquina-Lemonche L, Espaillat A, Lerma L, Weinrick B, Lavin JL, Elortza F, Azkargorta M, Prieto A, Buendía-Nacarino P, Luque-García JL, Neyrolles O, Cava F, Hobbs JK, Sanz J, Prados-Rosales R.** Maintenance of cell wall remodeling and vesicle production are connected in Mycobacterium tuberculosis. Elife. 2025; 13: RP94982. Article. Not Indexed
- **Salmantón-García J, Falci DR, Cornely OA, Pasqualotto AC, (García Rodríguez J).** Elevating fungal care: bridging Brazil's healthcare practices to global standards. Microbiol Spectr. 2025; 13(4): e0211224. Article. IF: 4.1; Q2
- **Salmanton-García J, Marchesi F, Navrátil M, Piukovics K, del Principe MI, Criscuolo M, Bilgin YM, Fracchiolla NS, Vena A, Romano A, Falces-Romero I, Sgherza N, Heras-**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



Fernando I, Biernat MM, Petzer V, Zák P, Weinbergerová B, Samarkos M, Erben N, van Praet J, López-García A, Labrador J, Lahmer T, Drgona L, Merelli M, Cuccaro A, Martín-Pérez S, Dávila-Valls J, Farina F, Cattaneo C, Pinczés LI, Magyari F, Espigado I, Buquicchio C, Vinh DC, Stoma I, Cernan M, Prezioso L, Papa MV, Plantefeve G, Khedr RA, Batinic J, Magliano G, Erdem S, Khostelidi S, Colovic N, Nappi D, García-Ramírez P, Góra J, Callejas-Charavia M, Tlusty J, Bakker M, Wojtyniak E, Antic D, Magdziak A, Dargenio M, Idrizovic L, Pantic N, Stojanoski Z, Eisa N, Otasevic V, Marchetti M, Mackenzie E, Garcia-Vidal C, Aujayeb A, Almasari A, Miranda-Castillo C, Gavriilaki E, Coppola N, Busca A, Adzic-Vukicevic T, Schönlein M, Hersby DS, Gräfe SK, Glenthoj A, Aiello TF, Cvetanoski M, Mitrovic M, Cerchione C, Prin R, Varricchio G, Arellano E, Córdoba R, Mayer J, Vísek B, Wolf D, Anastasopoulou AN, Delia M, Musto P, Leotta D, Bavastro M, Limongelli A, Sciumé M, van den Ven L, Fianchi L, Brunetti SC, Drozd-Sokolowska J, Dabrowska-Iwanicka A, Cornely OA, Pagano L. Respiratory viruses in patients with hematological malignancy in boreal autumn/winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report. Am J Hematol. 2025; 100(3): 358-74. Article. IF: 9.4; D1

- **Sangorrin-Lapieza L, Ruedas-López A, Esteban J, Toro C, Barrado L, Ruiz-Serrano MJ, Anel J, Domingoi D, Reyes A, López-Roa P.** Human mycobacterium bovis infection: a multicentre retrospective study conducted by the madrid study group for mycobacteria (GEMIMAD). Enferm Infec Micr Cl. 2025; 43(5): 267-271. Article. IF: 2.2; Q3
- **Sedik S, Egger M, Wolfgruber S, Salmantón-García J, Bassetti M, Mikulska M, Özenci V, Arikan-Akdagli S, Akova M, Gangneux JP, Bandera A, Alastruey-Izquierdo A, Barac A, Rautemaa-Richardson R, de Jonge NA, Loughlin L, Blennow O, Lanternier F, Meijer EFJ, Khanna N, García-Vidal C, Dávila-Valls J, Klimko N, Khostelidi SN, White PL, Akalin H, Rogers B, Ruiz M, Garcia-Rodríguez J, Akyol D, Longval T, Danion F, Prattes J, Krause R, Biswas SK, Arendrup MC, Koehler P, Cornely OA, Hoenigl M.** Risk factors for persistent candidemia and prognostic implications: Results from the ECMM Candida III study. J Infection. 2025; 91(5): 106629. Article. IF: 10.0; D1
- **Suárez-García I, Alejos B, Moreno C, Torres JM, Masiá M, García-Fraile LJ, Riera M, Dalmau D, Rodríguez-Rosado R, Muga R, Moreno S, Jarrín I.** Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks. J Antimicrob Chemoth. 2025; 80(3): 682-91. Article. IF: 4.1; Q1
- **Tarazona ED, Moraga E, Vaquer R, Sánchez-Palomino S, de Lazzari E, Luna L, Vicens-Artés S, Fraile LJG, Peraire J, García-Gasalla M, Balsalobre L, Martinez SG, Cortes LFL, Jarrin I, Serrano-Villar S, Alcami J, Moreno S.** Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size. Sci Rep-Uk. 2025; 15(1): 25306. Article. IF: 4.9; Q1
- **Velasco M, Flores-Chávez MD, Llenas-García J, Rodríguez MG, Vázquez EG, Lopez-Medrano F, Len O, Esquerra JE, Pérez AM, Díaz-Menéndez M, García ZM, Ayala AP, Guardado AR, Puig AA, Alguacil M, Alvarez-Martínez MJ, Vicente MA, Garcia MB, Buitrago MJ, Calabuig E, de la Calle F, Dopico E, Fernández-Ruiz M, Gudiol C, Herrero-Martínez JM, Serrano ABL, Martin O, Martin-Dávila P, de Miguel R, Fernández MM, Beltrá MN, Norman FF, Gutiérrez JJP, Pérez-Jacoiste A, Rodríguez-Sevilla G, Zúñiga DR, Salvador F, Montalvá AS, Seral C, González AV, Jorgensen PEW, Igual ES.** Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC: GEPI, GeSIDA, GESITRA-IC, GEIRAS) on screening for imported infectious diseases in immunocompromised patients. Enferm Infec Micr Cl. 2025; 43(9): 611-5. Article. IF: 2.2; Q3
- **Vicente MA, Ruiz-Carrascoso G, de la Calle-prieto F, Gallego JS, De Miguel-Buckley R, Nuñez ML, Martinez DM, Menéndez MD.** Outbreak of Schistosomiasis mansoni in a Spanish dance and percussion ensemble acquired in the Republic of Guinea. Enferm Infec Micr Cl. 2025; 43(9): 571-6. Article. IF: 2.2; Q3
- **Vizcarra P, Vas DG, Melero MIQ, Calvo JC, Bueno EC.** Cerebrospinal fluid multiplex PCR cycle thresholds may predict ICU admission in community-acquired meningoencephalitis. Diagn Micr Infec Dis. 2025; 111(3): 116704. Article. IF: 1.8; Q3

Research projects

- **García Rodríguez J.** Harmonization process of European Reference Laboratories for in vitro diagnosis. (EURL-IVD-1_GARCÍA). UE. 2024-2025. Managment centre: FIBHULP
- **Mingorance Cruz J.** Identificación de los factores que modifican la carga intestinal de EPCS y desarrollo de modelos predictivos del riesgo de infección mediante algoritmos de inteligencia artificial (PI22/01523). ISCIII. 2023-2026. Managment centre: FIBHULP
- **Dahdouh E.** Seguimiento de los cambios en la microbiota intestinal en pacientes pediátricos inmunocomprometidos a lo largo del tiempo en relación con las intervenciones y variables clínicas (IMI-PIP) (PI24/00310). ISCIII. 2025-2027. Managment centre: FIBHULP

Clinical trials

- **Loeches Yagüe MB.** Observational, retrospective, multicentric study to evaluate the efficacy and safety of meropenemvaborbactam compared to the best available therapy in the treatment of infections produced by klebsiella pneumoniae carbapenemase (kpc) - producing enterobacteria (carbamen study).
  Type/Phase: EOm no prospectivo
  Sponsored by: Laboratorio Menarini Sa.
  Signature date: 17/07/2025
- **Loeches Yagüe MB.** Cefiderocol for mbl-producing carbapenem-resistant enterobacterales in spain – a retrospective chart review study (circe study) / cefiderocol para enterobacterias resistentes a carbapanémicos productoras de mbl en españa - un estudio retrospectivo de revisión de historias clínicas (estudio circe).
  Type/Phase: EOm no prospectivo
  Sponsored by: Shionogi S.L.
  Signature date: 05/06/2025

Patents and trademarks

- **Vicente Muñoz M, Mingorance Cruz J, Rueda González MS, inventors; CSIC, assignee.** Method for determining state of growth and viability of bacterial FTsZ population, whether natural or cultivated, is based on determining existence of FTsZ rings in actively growing individual cells. P200200370; 2002 February 15.
- **Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; Biotools Biotechnological & Medical Laboratories S.**A., assignee. Composition, method and kit for detecting bacteria by means of sequencing. PCT/ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; 2009 October 22.
- **Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; 2B Blackbio S.**L., assignee. Composition, method and kit for detecting fungi and yeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02.

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.3.3 Immuno-Rheumatology Group

Publications: 55 | Q1: 38

COMPOSITION

María Eugenia Miranda Carús.
Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

- **Pilar Aguado Acín.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Alejandro Balsa Criado.** *Jefe de Sección de Reumatología. Hospital Universitario La Paz/ Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid*
- **María Gema Bonilla Hernán.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Ana Castilla Plaza.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Eugenio de Miguel Mendieta.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Francisco de Borja Hernández de Breijo.** *Investigador Postdoctoral . Hospital Universitario La Paz*
- **Paula Fortea Gordo.** *Investigadora Predoctoral. Hospital Universitario La Paz*
- **Sara García Carazo.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Emilio Martín Mola.** *Jefe de Servicio de Reumatología. Hospital Universitario La Paz/ Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Ana Martínez Feito.** *Investigadora Predoctoral. Hospital Universitario La Paz*
- **Irene Monjo Henry.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*



- **María Victoria Navarro Compán.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Laura Nuño Nuño.** *Médico Adjunto Interino en Reumatología. Hospital Universitario La Paz*
- **María Dora Pascual-Salcedo Pascual.** *Químico Adjunto en Inmunología. Hospital Universitario La Paz*
- **Chamaida Plasencia Rodríguez.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Diana Peiteado López.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Alejandro Villalba Yllán.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Our objective is to investigate the pathogenesis and evolution of rheumatic diseases, specifically focusing on imaging, genetics, metabolic pathways and immunopathogenesis.

RESEARCH LINES

- Immunopathogenesis, genetic, evolution, prognosis and biomarkers of inflammatory and autoimmune arthritis
- Imaging of inflammatory and autoimmune arthritis
- Immunopathogenesis and genetics of osteoporosis
- Immunogenicity of biological therapies with monoclonal antibodies
- Immunopathogenesis, evolution, prognosis and biomarkers of ocular inflammatory pathology
- Classification and Clinical outcomes of patients with inflammatory and autoimmune arthritis

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH ACTIVITY

Publications

- **Altabás-González I, Rua-Figueroa I, Roberts K, Mamani IL, Mouriño C, Martinez-Barrio J, Izquierdo MG, Calvo-Alén J, Erausquin C, Serrano-Benavente B, Uriarte E, Tomero E, Freire-González M, Blanco R, Salgado E, Gomez-Sabater S, Fernández-Nebro A, Sangüesa C, Narváez J, Vázquez NM, Menor-Almagro R, de Salazar JCRG, Aurrecoechea E, Ibarguengoitia-Barrena O, Montilla C, Bonilla G, Segarra VT, Juan-Mas A, García-Villanueva MJ, Morales CM, Horcada L, Lozano-Rivas N, Iñiguez C, Arevalo M, Paredes B, Exposito L, Toyos FJ, Flores-Fernández E, Medina JN, Gil JJF, Bohorquez C, Pego-Reigosa JM.** Validation of proposals for definitions of moderate and severe disease activity in SLE: impact on flares, quality of life, damage accrual, hospitalisations and mortality. Lupus Sci Med. 2025; 12(2): e001766. Article. IF: 4.2; Q1
- **Atienza-Mateo B, Serrano-Combarro A, Martos JL, Vegas-Revenga N, López MM, Castañeda S, Melero-González RB, Vázquez NM, Carrasco-Cubero C, Morrondo CD, Corredor DC, Rodríguez TRV, Valle AG, Bonilla G, López MR, Abascal IB, Herrera SMR, Sarmiento-Monroy JC, Brazal PA, Ferrer D, Ferraz-Amaro I, Blanco R.** Real-world evidence of the antifibrotic nintedanib in rheumatoid arthritis-interstitial lung disease. National multicenter study of 74 patients. Semin Arthritis Rheu. 2025; 72: 152710. Article. IF: 3.8; Q2
- **Balsa A, Andreu JL, Hermosa-Hernán JC, Pico JN, León-Navarro J, Venegas JJP, Romero-Yuste S, Sanmarti R, Gómez-Portillo AIT, Valenzuela-Gámez JC, Cohen J.** Integrating different perspectives to define a concept of comprehensive remission in rheumatoid arthritis: The SUMAR project. Reumatol Clin. 2025; 21(1): 101800. Article. IF: 1.5; Q3
- **Balsa A, Seoane-Mato D, Domínguez-Alvaro M, Alperi M, Ruiz-Esquide V, Bachiller-Corral J, Díaz-González F.** Study of the impact of the inclusion of global pain and functional capacity assessment in the definition of remission and its maintenance for rheumatoid arthritis. AIMS and methodology. Reumatol Clin. 2025; 21(5): 501895. Article. IF: 1.5; Q3
- **Bauer CJ, Chrysidis S, Dejaco C, Koster MJ, Kohler MJ, Monti S, Schmidt WA, Mukhtyar CB, Karakostas P, Milchert M, Ponte C, Duftner C, de Miguel E, Hocevar A, Iagnocco A, Terslev L, Dohn UM, Nielsen BD, Juche A, Seitz L, Keller KK, Karalilova R, Daikeler T, Mackie SL, Torralba K, van der Geest KSM, Boumans D, Bosch P, Tomelleri A, Aschwanden M, Kermani TA, Diamantopoulos A, Fredberg U, Inanc N, Petzinna SM, Albarqouni S, Behning C, Scha VS.** Exploring the limit of image resolution for human expert classification of vascular ultrasound images in giant cell arteritis and healthy subjects: the GCA-US-AI project. Ann Rheum Dis. 2025; 84(9): 1528-37. Article. IF: 24.0; D1
- **Belletti M, Izquierdo-Escámez R, Tornero C, Olivas-Vergara O, Peiteado D, Carreño E.** Safe use of corticosteroids in non-infectious uveitis. J Inflamm Res. 2025; 18: 14441-55. Review. IF: 4.6; Q2
- **Benavent D, Iniesta-Chamorro J, Novella-Navarro M, Pérez-Martínez M, Martínez-Sánchez N, Kaffati M, Juárez-García M, Molinari-Pérez M, González-Torbay A, Gutiérrez M, López-Juanes N, Navarro-Compán V, Monjo-Henry I, Rodríguez-Rosales G, Bachiller J, Calvo-Aranda E, Michelena X, Berbel-Arcobé L, Balsa A, Gómez EJ, Plasencia-Rodríguez C.** Digital health intervention for patient monitoring in immune-mediated inflammatory diseases: cocreation and feasibility study of the IMIDoc platform. Jmir Hum Factors. 2025; 12: e58095. Article. IF: 3.9; Q1
- **Benavent D, Navarro-Compán V, Capelusnik D, Ramiro S.** Does symptom duration impact on treatment response in axial spondyloarthritis? A meta-analysis of randomized controlled trials. Rheumatology. 2025; 64(11): 5872-82. Article. IF: 4.7; Q1
- **Benavent D, Tapia M, Bernabeu D, Muley , Juárez M, Balsa A, Plasencia CH, Navarro-Compan.** Can we identify axial spondyloarthritis among young adults referred to non-rheumatology specialists? Results from the SHERPAS study. Semin Arthritis Rheu. 2025; 74: 152780. Article. IF: 3.8; Q2
- **Blanco R, Aldasoro V, Maiz O, Melero R, Romero-Yuste S, de Miguel E, Ferraz-Amaro I, Lopez-Gutierrez F, Castaneda S, Loricera J, Tocilizumab in giant cell arteritis spanish collaborative group.** tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases. Rheumatology. 2025; 64(5): 2928-36. Article. IF: 4.7; Q1
- **Blockmans D, Penn SK, Setty AR, Schmidt WA, Rubbert-Roth A, Hauge EM, Keen HI, Ishii T, Khalidi N, Dejaco C, Cid MC, Hellmich B, Liu M, Zhao WH, Lagunes I, Romero AB, Wung PK, Merkel PA, (Blasa Criado A).** A phase 3 trial of upadacitinib for giant-cell arteritis. New Engl J Med. 2025; 392(20): 2013-24. Article. IF: 84.5; D1
- **Cobo-Ibáñez T, Castellví I, Pros A, Domínguez-Álvaro M, Nuño-Nuño L, Martínez-Barrio J, Jovaní V, Romero-Bueno F, Ruiz-Lucea E, Tomero E, Trallero-Araguás E, Narváez J, Camins-Fàbregas J, Ruiz-Román A, Loarce-Martos J, Holgado-Pérez S, Flores-Rodríguez VM, Sivera F, Merino-Argumanez C, Juan-Mas A, Altabás-González I, Martín-López M, Belzunegui-Otano JM, Carrasco-Cubero C, Freire-González M, Rua-Figueroa I, Lozano-Rivas N, Suarez-Cuba JD, Martínez O, Ortega-Castro R, Alcocer P, Gómez-Gómez A, Sánchez-Pernaute O, Tandaipan JL, Carrión-Barberà I, Plasencia-Rodríguez C, Ibarguengoitia-Barrena O, Vidal-Montal P, Ortiz-Santamaria V, Garrido-Puñal N, Riveros A, Delgado-Frías E, López-Gómez JM, Barbadillo C, Pego-Reigosa JM, Joven-Ibáñez BE, Valero-Jaimes JA, Naveda E, Turrión-Nieves AI, Seoane-Mato D, Prado-Galbarro FJ, Puche-Larrubia MA.** Disease activity in patients with idiopathic inflammatory myopathy according to time since diagnosis and positivity to antisynthetase autoantibodies: data from the Myo-Spain registry. Arthritis Res Ther. 2025; 27(1): 5. Article. IF: 5.4; Q1
- **Deodhar A, Navarro-Compán V, Poddubnyy D, Gensler LS, Ramiro S, Tomita T, Marzo-Ortega H, Fleurinck C, Vaux T, Massow U, de Peyrecave N, van der Heijde D, Baraliakos X.** Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension. RMD Open. 2025; 11(1): e005081. Article. IF: 5.3; Q1
- **Edwards CJ, Kroenke G, Avouac J, Li ZG, Conti F, Balsa A, Mo DJ, Haladyj E, Fischer P, Tanaka M, Takita Y, Hagimori K, Takeuchi T.** Baricitinib dose reduction in patients with rheumatoid arthritis achieving sustained disease control: final results from the RA-BEYOND study. J Rheumatol. 2025; 52(4): 316-22. Article. IF: 3.7; Q2
- **Fernández-Fernández E, Brugarolas E, Monjo-Henry I, Novella-Navarro M, Balsa A, De Miguel E.** The influence of the cardiac cycle on the halo sign and its impact on the ultrasound diagnosis of giant cell arteritis. Rheumatology. 2025; 64(3): 1459-63. Article. IF: 4.7; Q1
- **García-Escudero P, López-Gómez M, López BM, Dorta AG, Frade-Sosa B, Lizarzaburu MS, Rúa-Figueroa I, Fiallo DV, de Miera FJTS, Melero-González RB, Santos DD, Miranda JA, Belando CG, Boselli G, Boteanu AL, Villalobos L, Selaya CC, Santos CS, Álvarez ED, Font J, Alonso ER, Araguás ET, Merayo EE, Rodríguez-Laguna M, Monjo I, Gómez IV, Vela-Casasempere P, Merino C, Martínez MI, Beriain JAH, Ruiz-Román A, Calvo-Alén J.** VEXAS syndrome through a rheumatologist's lens: insights from a Spanish national cohort. Rheumatology. 2025; 64(6): 3747-55. Article. IF: 4.7; Q1
- **García-Salinas R, Mejia-Maggi N, Almada F, Magri S, Navarro-Compán V.** Prevalence and clinical features of early axial spondyloarthritis according to ASAS definition: a cross-sectional analysis from the reuma-check cohort. Rheumatol Int. 2025; 45(5): 122. Article. IF: 3.5; Q2
- **Garrido-Cumbrera M, Marzo-Ortega H, Correa-Fernández J, Christen L, Navarro-Compán V.** Impact of working from home on the psychological well-being of 365 european patients with rheumatic diseases during COVID-19 pandemic. Results of the REUMAVID

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Study. Musculoskeletal Care. 2025; 23(2): e70094. Article. IF: 1.5; Q3

- **Gómez CMB, Plasencia-Rodríguez C, Novella-Navarro M, Martínez-Feito A, Balsa A, Calvo-Aranda E, Hernández-Breijo B.** Exosomal protein biomarkers in arthritis: deciphering the inflammatory profiles of RA and OA. Biomedicines. 2025; 13(6): 1283. Article. IF: 4.5; Q2
- **González-Gay MA, Ferraz-Amaro I, Castañeda S, Tasende JAP, Uriarte-Ecenarro M, Plaza Z, Sánchez-Alonso F, Gómez CG, González-Juanatey C, Llorca J, CARMA Project Collaborative Grp.** The metabolic score for insulin resistance predicts the risk of cardiovascular disease in patients with psoriatic arthritis: results from the 10-year prospective CARMA cohort. Rmd Open. 2025; 11(1): e005352. Article. IF: 5.3; Q1
- **Ibarguengoitia-Barrena O, Riancho-Zarrabeitia L, Plaza Z, Rúa-Figueroa I, Roberts K, Martinez-Taboada V, Menor-Almagro R, Serrano-Benavente B, Rubio-Munoz P, Galindo-Izquierdo M, Fernández-Nebro A, Ruiz-Lucea ME, Calvo-Alen J, Tomero-Muriel EG, Uriarte-Isacelaya E, Pecondon-Espano A, Freire M, Garcia-Fernández J, Exposito L, Ibánez-Barcelo M, Aurrecoechea E, Montilla C, Salazar JRGD, García-Villanueva MJ, Cano-Alameda R, de Miera FJTS, Novoa-Medina FJ, Moriano-Morales C, Bonilla G, Narváez FJ, Andréu JL, Arévalo-Salaet M, Horcada L, Cobo T, Lozano-Rivas N, Bohórquez C, Iñíguez-Ubiaga CL, Salgado-Pérez E, Torrente-Segarra V, Monte TCS, Oller JE, Pego-Reigosa JM.** Serological clusters in systemic lupus erythematosus and its clinical and prognostic implications: A longitudinal cohort study. Semin Arthritis Rheu. 2025; 74: 152819. Article. IF: 3.8; Q2
- **Kaczmarczyk B, de la Calle-Fabregat C, Conde A, Duarte AC, Mena-Vazquez N, Fernández-Nebro A, Triguero-Martinez A, Castañeda S, Sobrin RDS, Mera-Varela A, Lopez-Pedrera C, Escudero-Contreras A, Vela-Casasempere P, Molina M, Narváez J, Retuerto-Guerrero M, Pablos JL, Sarmiento-Monroy JC, Sanmartí R, Gomez-Carrera L, Bonilla G, Remuzgo-Martinez S, González-Gay MA, Leiro-Fernández V, Pérez-Gómez N, Vadillo-Font C, Abasolo L, Casafont-Sole I, Mateo-Soria L, Castillo-González AC, Marras C, Perez-Pampin E, Ballestar E, González A.** DNA methylome biomarkers of rheumatoid arthritis-associated interstitial lung disease reflecting lung fibrosis pathways, an exploratory case-control study. Sci Rep-Uk. 2025; 15(1): 15123. Article. IF: 4.9; Q1
- **Llorca J, Castaneda S, Ferraz-Amaro I, Plaza Z, Sánchez-Alonso F, García-Gómez C, González-Juanatey C, González-Gay MA, (Bonilla G).** Performance of four cardiovascular risk scales in chronic inflammatory rheumatic disease patients: 10-year follow-up data. Rheumatology. 2025; 64(7): 4227-35. Article. IF: 4.7; Q1
- **Llorca J, Ferraz-Amaro I, Castañeda S, Raya E, Rodríguez-Rodríguez L, Rodríguez-Montero S, Sánchez-Nievas G, López-Meseguer A, Plaza Z, Sánchez-Alonsoj F, García-Gómez C, González-Juanateyl C, González-Gay MA, (Bonilla G).** Evaluating the reliability of cardiovascular risk scales in patients with chronic inflammatory rheumatic diseases. Semin Arthritis Rheu. 2025; 72: 152694. Article. IF: 3.8; Q2
- **Martínez-Feito A, Novella-Navarro M, Hernández-Breijo B, Nozal P, Peiteado D, Villalba A, Nuño L, Monjo I, Pascual-Salcedo D, Balsa A, Plasencia-Rodríguez C.** Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases. Rheumatology. 2025; 64(1): 344-51. Article. IF: 4.7; Q1
- **Martín-Gutiérrez A, Loricera J, Aldasoro V, Maiz O, de Miguel E, Galíndez-Agirregoikoa E, Ferraz-Amaro I, Castañeda S, Blanco R.** Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice. Semin Arthritis Rheu. 2025; 71: 152640. Article. IF: 3.8; Q2
- **Martín-Gutiérrez A, Loricera J, Prieto-Peña D, Aldasoro V, Maiz O, de Miguel E, Galíndez-Agirregoikoa E, Ferraz-Amaro I, Castaneda S, Blanco R.** Tocilizumab monotherapy versus combined in aortitis associated with giant cell arteritis: Factors associated with imaging remission in a multicenter open-label study of 196 patients. Semin Arthritis Rheu. 2025; 75: 152869. Article. IF: 3.8; Q2
- **Marzo-Ortega H, Navarro-Compán V, Dubreuil M, Mease PJ, Magrey M, Rudwaleit M, D'Agostino MA, Gaffney K, Kay J, de la Loge C, Massow U, Taieb V, Vaux T, Deodhar A.** Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies. RMD Open. 2025; 11(4): e006013. Article. IF: 5.3; Q1
- **Molina-Collada J, Domínguez-Álvaro M, Melero-González RB, de Miguel E, Silva-Díaz M, Jaimes JAV, González I, Martín JS, Narváez J, Calvet J, Casafont-Solé I, Ivorra JAR, Arrabal SL, Rocha MV, Iñiguez CL, Reyes MSB, Fernández CC, Villar MA, Mas AJ, Blanco R, ARTESER Project Collaborative Grp.** Mortality in patients with giant cell arteritis in Spain: results from the ARTESER registry. Arthritis Res Ther. 2025; 27(1): 4. Article. IF: 5.4; Q1
- **Molina-Collada J, Monjo-Henry I, Fernández-Fernández E, Alvaro-Gracia JM, de Miguel E.** The OMERACT giant cell arteritis ultrasonography score: a potential predictive outcome for assessing the risk of relapse during follow-up. Rheumatology. 2025; 64(3): 1448-52. Article. IF: 4.7; Q1
- **Monjo-Henry I, Nieto-Carvalhal B, Uyaguari M, García-Carazo S, Balsa A, de Miguel E, Miranda-Carús ME.** Circulating PD-1hi CXCR5- and CXCR5+CD4 T cells are elevated in patients with newly diagnosed giant cell arteritis, and predict relapse. Rheumatology. 2025; 64(6): 3996-4004. Article. IF: 4.7; Q1
- **Monjo-Henry I, Uyaguari M, Nuño L, Nieto-Carvalhal B, Fernández-Fernández E, Peiteado D, Villalba A, García-Carazo S, Balsa A, Miranda-Carús ME.** Circulating Tfh cells are differentially modified by abatacept or TNF blockers and predict treatment response in rheumatoid arthritis. Rheumatology. 2025; 64(2): 517-25. Article. IF: 4.7; Q1
- **Muñoz HMA, Molina-Collada J, Castrejón I, Monjo-Henry I, Fernández-Fernández E, Álvaro-Gracia JM, de Miguel E.** Different giant cell arteritis phenotypes may present distinct types of ischaemic complications. Clin Exp Rheumatol. 2025; 43(4): 668-73. Article. IF: 3.2; Q2
- **Narváez J, Domínguez-Álvaro M, Hernández-Rodríguez I, de Miguel E, Silva-Díaz M, Belzunegui JM, Moriano C, Sánchez-Martín J, Lluch J, Calvo I, Aldasoro V, Abasolo L, Loricera J, Garrido N, Castañeda S, Vasques-Rocha M, Iñiguez CL, Hernández-Hernández V, Campos-Fernández C, Alcalde-Villar M, Juan-Mas A, Blanco R.** Epidemiology of major and minor relapses in giant cell arteritis according to EULAR definitions: insights from the ARTESER registry. Rheumatology. 2025; 64(9): 4985-94. Article. IF: 4.7; Q1
- **Navarro-Compán V, Reveille JD, Rahman P, Maldonado-Cocco JA, Magrey M, Bolce R, Panni T, Kronbergs A, Rudwaleit M.** Ixekizumab improves signs, symptoms, and quality of life in patients with axial spondyloarthritis irrespective of symptom duration. Adv Ther. 2025; 42(9): 4706-16. Article. IF: 4.7; Q1
- **Navarro-Compán V, Rudwaleit M, Dubreuil M, Magrey M, Marzo-Ortega H, Mease PJ, Walsh JA, Dougados M, de la Loge C, Fleurinck C, Massow U, Vaux T, Taieb V, Deodhar A.** Improved pain, morning stiffness, and fatigue with bimekizumab in axial spondyloarthritis: results from the phase III BE MOBILE Studies. J Rheumatol. 2025; 52(1): 23-32. Article. IF: 3.7; Q2
- **Navarro-Compán V, Sepriano A, Capelusnik D, Baraliakos X.** Axial spondyloarthritis. Lancet. 2025; 405(10473): 159-72. Article. IF: 109.0; D1
- **Navarro-Compán V, van den Bosch F, Sampaio-Barros PD, Östör AJK, Parikh B, Kato K, Gao TM, Stigler J, Ramiro S.** Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease. RMD Open. 2025; 11(1): e005110. Article. IF: 5.3; Q1
- **Novella-Navarro M, González-Sánchez L, Hernández-Breijo B, de Diego RP, Sánchez-Corral P, López-Trascasa M, Miranda-Carús ME, Villalba A, Balsa A, De Miguel E, Plasencia-Rodríguez C, Corvillo F.** Serum adipsin levels in rheumatic diseases: defining its role in disease

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

activity and progression in rheumatoid arthritis and axial spondyloarthritis. Front Immunol. 2025; 16: 1636158. Article. IF: 7.0; Q1

- **Novella-Navarro M, van den Rym A, López-Pedrera C, Martínez-Feito A, Nieto-Carvalhal B, Reche K, López-Medina C, Escudero-Contreras A, Nozal P, Miranda-Carús ME, Monjo I, De Miguel E, Balsa A, Pérez-de Diego RPD, Plasencia-Rodríguez C.** Do obesity and adipose tissue cytokines influence the response to janus kinase inhibitors in rheumatoid arthritis? Nutrients. 2025; 17(5): 820. Article. IF: 5.8; Q1
- **Poddubnyy D, Baraliakos X, Navarro-Compa V, van der Heijde D.** Response to the correspondence by Wendling et al on 'ASAS consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis'. Ann Rheum Dis. 2025; 84(6): e25-7. Letter. IF: 24.0; D1
- **Poddubnyy D, Garrido-Cumbrera M, Sommerfleck F, Navarro-Compán V, Bundy C, Makri S, Correa-Fernández J, Akerkar S, Davies J, Karam E.** Diagnostic delay in patients from the international map of axial spondyloarthritis: geographic, sociodemographic and disease-related factors. Rheumatology. 2025; 64(4): 1873-9. Article. IF: 4.7; Q1
- **Poddubnyy D, Navarro-Compán V, Torgutalp M, Arends S, Aydin SZ, Battista S, van den Bosch F, Bundy C, Cauli A, Davies J, Dougados M, Duruöz T, El-Zorkany B, Fong W, van Gaalen F, Garcia-Salinas R, Cumbrera MG, Géher P, Gensler L, Grazio S, Huang F, Kishimoto M, Landewé R, Leung YY, Machado P, Marzo-Ortega H, Meghnathi B, Molto A, Nikiphorou E, Ramiro S, Rudwaleit M, Saad C, Sepriano A, Wei J, Baraliakos X, van der Heijde D.** The assessment of spondyloarthritis international society (asas) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis. Ann Rheum Dis. 2025; 84(4): 538-46. Article. IF: 24.0; D1
- **Poddubnyy D, Parikh B, Elewaut D, Navarro-Compán V, Siebert S, Paley M, Coombs D, Lagunes I, Biljan A, Nakasato P, Wung P, Lubrano E.** Development of extramusculoskeletal manifestations in upadacitinib-treated patients with psoriatic arthritis or axial spondyloarthritis. Arthritis Rheumatol. 2025; 77(5): 536-46. Article. IF: 9.9; D1
- **Rodríguez-Merlos P, Cabrera-Alarcón JL, Ruiz-Esquide V, Chacur CA, Sanmartí R, de Miguel-Mendieta E, Álvaro-Gracia JM, Balsa A, Plasencia-Rodríguez C, Novella-Navarro M.** Early-onset difficult-to-treat rheumatoid arthritis: proposal of data-driven predictors and temporal threshold. Arthritis Res Ther. 2025; 27(1): 153. Article. IF: 5.4; Q1
- **Rua-Figueroa I, Pérez-Veiga N, Rodríguez-Almaraz E, Galindo-Izquierdo M, Erausquin C, Fernández-Nebro A, Itzazelaia EU, Serrano-Benavente B, Alén JC, Manrique-Arija S, Senabre JM, Bernal JA, Narváez J, Tomero E, Aurrecoechea E, Ibáñez-Barceló M, Segarra VT, Sangüesa C, Freire-González M, García-Villanueva MJ, Taboada VM, Arevalo M, Morales CM, Iñiguez C, Perez A, Salgado E, Carrión-Barberà I, Andreu JL, Cobo T, Horcada L, Bonilla G, Lozano-Rivas N, Exposito L, Montilla C, Toyos FJ, Ibarguengoitia-Barrena O, Pascual EV, Medina JN, Menor-Almagro R, Ivorra JAR, Jiménez AM, Nolla JM, Pego-Reigosa JM.** Comorbidity clusters and their relationship with severity and outcomes of index diseases, in a large multicentre systemic lupus erythematosus cohort. Lupus Sci Med. 2025; 12(2): e001633. Article. IF: 4.2; Q1
- **Rudwaleit M, Navarro-Compán V, Russ H, Panni T, Filippi E, Nassab MH, Liu-Leage S, Goëb V, Ciccia F, Dudler J.** BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis of ixekizumab in radiographic axial spondyloarthritis. Rheumatol Adv Pract. 2025; 9(2): rkaf012. Article. IF: 2.8; Q2
- **Salmoral A, Peris P, Medina CL, Flórez H, Barceló M, Pastor MP, Ros I, Grados D, Aguado P, García S, López L, Gifre L, Cerdá D, Aguilar FJ, Panero B, Costa E, Casado E, Hernández B, Ferrer AM, Graña J, Gómez I, Guañabens N, Spanish Soc Rheumatology.** Bisphosphonate drug holidays in osteoporosis according to fracture risk profile. Osteoporosis Int. 2025; 36(2): 245-54. Article. IF: 5.4; Q1
- **Sawada H, Kishimoto M, Tada K, Deshpande GA, Kobayashi D, Okada M, Benavent D, Plasencia-Rodriguez C, Navarro-Compán V, López-Medina C, Molto A, Dougados M, Tamura N.** Disease phenotype and management of axial psoriatic arthritis in Japan compared with other regions, particularly other Asian countries: results of the ASAS-PerSpA study. Bmc Rheumatol. 2025; 9(1): 130. Article. IF: 3.1; Q2
- **Schremmer T, Dejaco C, Recker F, Aschwanden M, Boumans D, Bruyn GA, Chrysidis S, Daikeler T, Nielsen B, de Miguel E, Diamantopoulos AP, Dohn UM, Duftner C, Germano G, Haagsma C, Hartung W, Hocevar A, Iagnocco A, Juche A, Karakostas P, Karalilova R, Keller KK, Sarker B, Smith K, Tischler V, Macchioni P, Milchert M, Monti S, Mukhtyar C, Naredo E, Schmidt WA, Seitz L, Terslev L, Wakefield RJ, Schäfer VS.** OMERACT GCA phantom project: validation of a 3D-printed ultrasound training phantom for diagnosis of giant cell arteritis. Rmd Open. 2025; 11(1): e005316. Article. IF: 5.3; Q1
- **Serrano-Combarro A, Atienza-Mateo B, Martín-Gutiérrez A, Loarce-Martos J, Dubuc CAE, Mena MP, Melero-González RB, Lopez MM, Vazquez NM, Carrasco-Cubero C, Garcia CP, Valle AG, Bonilla G, Madrigal JMB, Astigarraga-Urquia U, Revenga NV, Albadalejo LP, Castro RO, Palma-Sánchez D, Ortiz AMF, Viejo PL, Lasanta ML, Bufort MG, Sole IC, Lamua-Riazuelo JR, Abascal IB, Ruiz-Esquide V, Perez ECC, Robles BJF, Martinez-Vidal MP, Morales JM, Urruticoechea-Arana A, Rosas J, Fernández-Lozano D, Corredor DC, Ferraz-Amaro I, Castaneda S, Blanco R.** Baricitinib in rheumatoid arthritis-interstitial lung disease: a literature review and national multicentre study of 72 patients. Rheumatology. 2025; 64(10): 5471-80. Article. IF: 4.7; Q1
- **Tornero C, Martos-Moreno GA, Guañabens N, Flórez H, Ribera A, Aguado P.** Clinical characterization and impact of hypophosphatasia in Spain: An observational analysis of the Spanish cohort included in the Global HPP Registry. Med Clin-Barcelona. 2025; 165(5): 107120. Article. IF: 2.8; Q1
- **van der Heijde D, Navarro-Compán V, Landewé R, Sieper J, van Gaalen F, Gensler LS, Machado PM, Marzo-Ortega H, Poddubnyy D, Protopopov M, Ramiro S, Sepriano A, Baraliakos X.** 1995-2025: thirty years of ASAS and its contribution to the understanding of spondyloarthritis. Ann Rheum Dis. 2025; 84(3): 382-7. Article. IF: 24.0; D1
- **Van Gaalen FA, Navarro-Compán V, Baraliakos X, van den Bosch F, Gensler LS, Hmamouchi I, Landewé R, Machado PM, Marzo-Ortega H, Rodriguez VR, Poddubnyy D, Ramiro S, van der Heijde D.** ASAS recommendations on reporting axial spondyloarthritis clinical trials. Ann Rheum Dis. 2025; 84(11): 1770-8. Article. IF: 24.0; D1
- **Villalba A, Nuno L, Benito-Miguel M, Nieto-Carvalhal B, Monjo I, Novella-Navarro M, Peiteado D, García-Carazo S, Balsa A, Miranda-Carús ME.** Transiently increased circulating CD39+FoxP3+ Treg cells predicts the clinical response to methotrexate in early rheumatoid arthritis. Rheumatology. 2025; 64(4): 2282-9. Article. IF: 4.7; Q1

Research projects

- **Aguado Acín P.** Caracterización e historia natural de la hipofosfatasia en pacientes adultos con confirmacion genetica frente a pacientes con fosfatasa alcalina baja y test genético negativo. Hipofosfatasia del adulto. Alexion Pharmaceutical Inc. 2017-Ongoing. Managment centre: FIBHULP
- **de Miguel Mendieta E.** Analisis de imagenes ecograficas para el diagnostico de arteritis de celulas gigantes mediante tecnicas de deep learning. Roche Farma S.A. 2021-Ongoing. Managment centre: FIBHULP
- **Miranda Carús ME.** Células t helper foliculares t foliculares reguladoras y t helper periféricas en artritis reumatoide preclínica, temprana y establecida: herramientas para la medicina personalizada (PI20/00141). ISCIII. 2021-2025. Managment centre: FIBHULP
- **Miranda Carús ME.** Efecto del metotrexato en la frecuencia y función de las células T helper foliculares; implicaciones patogénicas y pronósticas. Laboratorios Gebro Pharma S. A. 2020-Ongoing. Managment centre: FIBHULP
- **Miranda Carús ME.** Frecuencia y función de las células T helper foliculares circulantes y plasmablastos en pacientes con artritis reumatoide, y su relación con los niveles de autoanticuerpos: odificaciones asociadas con el bloqueo de la coestimulación por Abatacept. Bristol

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Myers Squibb S. A. U. 2016-Ongoing. Managment centre: FIBHULP

- **Miranda Carús ME.** Stratification of Patients using advanced Integrative modeling of Data Routinely acquired for diagnosing Rheumatic complaints (SPIDeRR_EUGENIA MIRANDA). UE. 2023-2028. Managment centre: FIBHULP
- **Navarro Compán MV.** Resonancia magnética de sacroilíacas y desarrollo de un cuestionario para identificar espondiloartritis axial precoz en pacientes con dolor lumbar crónico remitidos a otros especialistas distintos al reumatólogo. Novartis Farmaceutica S.A. 2021-Ongoing. Managment centre: FIBHULP
- **Peiteado Lopez MD.** ERfficacy, safety and costeffectiveness of methotrexate, adalimumab, or their combination in non infectious non anterior uveitis: a multicenter, randomized, parallel 3 arm, active-controlled, phase 3 open label with blinded outcome assessment study (5681 CO-THEIA). Fundacion para la Investigacion Biomedica del Hospital Clinico San Carlos. 2021-2025. Managment centre: FIBHULP
- **Plasencia Rodríguez, C.** Hacia la telemonitorización en enf. Inflamatorias inmunomediadas: implementación de un modelo asistencial mixto en una unidad de terapias complejas (PI22/00777). ISCIII. 2023-2027. Managment centre: FIBHULP

Clinical trials

- **Aguado Acín P.** A multicenter, open-label, phase 1/2, dose-escalation and subsequent safety extension study of subcutaneous kk8123 in adult patients with x-linked hypophosphatemia.
  Type/Phase: II
  Sponsored by: Kyowa Kirin Farmaceutica Sl.
  Signature date: 11/12/2025
- **Aguado Acín P.** A multicenter, open-label, phase 1/2, dose-escalation and subsequent safety extension study of subcutaneous kk8123 in adult patients with x-linked hypophosphatemia.
  Type/Phase: II
  Sponsored by: Kyowa Kirin Farmaceutica Sl.
  Signature date: 14/03/2025
- **Bohorquez Heras C.** Systemic lupus erythematosus longitudinal cohort generation and multi-omics characterization" (smiles project) generación de una cohorte longitudinal y caracterización multiómica del lupus eritematoso sistémico (proyecto smiles).
  Type/Phase: OTROS
  Sponsored by: Fundacio Hospital Vall D'Hebron.
  Signature date: 05/03/2025
- **Bonilla Hernán MG.** Anexo 1 6503 a phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dazodalibep in participants with sjögren's syndrome with moderate-to-severe systemic disease activity.
  Type/Phase: III
  Sponsored by: Horizon Therapeutics Ireland Dac.
  Signature date: 21/01/2025
- **Bonilla Hernán MG.** Eficacia y seguridad de sar441344 para el tratamiento del lupus eritematoso sistémico: estudio aleatorizado, doble ciego,controlado con placebo, fase 2, prueba de concepto.
  Type/Phase: II
  Sponsored by: Sanofi Aventis S.A.
  Signature date: 28/01/2025
- **Bonilla Hernán MG.** Observational retrospective study to describe characteristics and clinical outcomes of patients withsystemic lupus erythematosus initiating saphnelo (anifrolumab) in a real-world setting. Estudio azahar.
  Type/Phase: EOm no prospectivo
  Sponsored by: Astrazeneca Farmaceutica Spain S.A.
  Signature date: 04/02/2025
- **De Miguel Mendieta E.** A phase 3, parallel-group, randomized, double-blind, 4-arm, placebo-controlled, multicenter study with risankizumab as active reference arm to investigate the efficacy and safety of subcutaneous sonelokimab in male and female participants aged 18 years and over with active psoriatic arthritis and previous inadequate response or intolerance to tumor necrosis factor-α inhibitors.
  Type/Phase: III
  Sponsored by: Moonlake Immunotherapeutics Ag.
  Signature date: 20/02/2025
- **De Miguel Mendieta E.** Estudio de fase 3 para evaluar la eficacia y la seguridad del zasocitinib (tak-279) en sujetos con artritis psoriásica activa estratificados por uso previo de biofármacos.
  Type/Phase: III
  Sponsored by: Takeda Development Center Americas.
  Signature date: 18/11/2025
- **De Miguel Mendieta E.** Estudio de fase 3 para evaluar la eficacia y la seguridad del zasocitinib (tak-279) en sujetos con artritis psoriásica activa estratificados por uso previo de biofármacos.
  Type/Phase: III
  Sponsored by: Takeda Development Center Americas.
  Signature date: 29/01/2025
- **De Miguel Mendieta E.** Estudio de fase 3b/4, aleatorizado, comparativo con un tratamiento activo, con grupos paralelos, en el que se evalúa baricitinib en pacientes con artritis reumatoide.
  Type/Phase: III
  Sponsored by: Lilly, S.A.
  Signature date: 24/01/2025
- **De Miguel Mendieta E.** Estudio en fase III, aleatorizado, con doble enmascaramiento, de tres grupos paralelos, comparativo con placebo y multicéntrico para evaluar la eficacia y la seguridad de sonelokimab subcutáneo en participantes de ambos sexos de 18 años en adelante con artritis psoriásica activa que no han recibido antes tratamiento con farme biológicos.
  Type/Phase: III
  Sponsored by: Moonlake Immunotherapeutics Ag.
  Signature date: 13/03/2025
- **De Miguel Mendieta E.** Peris: prospective multi-country, real-world, multi-arm study of treatment persistence with risankizumab in psoriatic arthritis. Peris: estudio prospectivo en vida real sobre la persistencia del tratamiento con risankizumab para la artritis psoriásica en varios países.
  Type/Phase: EOm prospectivo
  Sponsored by: Abbvie Spain S. L. U.
  Signature date: 14/02/2025
- **De Miguel Mendieta E.** Programa en fase III aleatorizado, comparativo con placebo, doble ciego y con grupos paralelos para evaluar la eficacia y la seguridad de filgotinib en participantes adultos con espondiloartritis axial activa.
  Type/Phase: III
  Sponsored by: Alfasigma S.P.A Galapagos NV.
  Signature date: 06/10/2025
- **De Miguel Mendieta E.** Programa en fase III aleatorizado, comparativo con placebo, doble ciego y con grupos paralelos para evaluar la eficacia y la seguridad de filgotinib en participantes adultos con espondiloartritis axial activa.
  Type/Phase: III
  Sponsored by: Alfasigma S.P.A Galapagos NV.
  Signature date: 09/12/2025
- **De Miguel Mendieta E.** Randomised, multicentre, double-blind clinical trial to evaluate the efficacy and safety of montelukast vs. placebo in patients with erosive/inflammatory osteoarthritis of the hands. mother study.
  Type/Phase: III
  Sponsored by: Farmalider Sa.
  Signature date: 14/11/2025
- **Navarro Compán MV.** Estudio axioma: axial spondyloarthritis international outcome assessment.
  Type/Phase: No EPA
  Sponsored by: Maatschap Reumatologie Heelen/ Sittard.
  Signature date: 03/11/2025

Patents and trademarks

- **Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia Rodríguez C, authors; FIBHULP, assignee.** Brand name: BioDrug Analysis BIDA. CM 13.808.531, 2015 March 10.
- **Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P, Varela Egocheaga I, Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, Fundació Hospital Universitari Vall D´Hebron - Institut de Recerca (VHIR), assignees.** Method for predicting the clinical response to anti-inflammatory agent therapies. P201600636, PCT/ES2017/000089; 2016 July 26.
- **Plasencia C.** Trademark name: MAM Modelo Asistencial Mixto; CM 18637540; 2022 January 13.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.3.4 Innate Immune Response Group



Publications: 24 | Q1: 17

COMPOSITION

Eduardo López-Collazo.
Investigador Senior. Contrato Miguel Servet - Tipo II. Jefe de Laboratorio. FIBHULP
Carlos del Fresno Sánchez.
Investigador Titutlar. Contrato Miguel Servet - Tipo I. FIBHULP

- **Susana Alemany de la Peña.** *Investigadora Senior. Jefe de Laboratorio. IIB Sols Morreale*
- **Daniel Arvelo del Rosario.** *Investigador Predoctoral. FIBHULP*
- **Gülce Bicakcioglu.** *Técnico Grado Superior. FIBHULP*
- **Gloria Cristina Bonel Pérez.** *Ayudante de investigación. FIBHULP*
- **Lisardo Boscá Gomar.** *Investigador Senior. Jefe de Laboratorio. IIB Sols Morreale*
- **Laura Bravo Robles.** *Investigadora Predoctoral. FIBHULP*
- **Antonio Castrillo Viguera.** *Investigador Senior. Jefe de Laboratorio. IIB Sols Morreale*
- **Luna Ridan Cordeiro Minute.** *Investigadora Sara Borrel. FIBHULP*
- **Laura Córdoba García.** *Resposable HUB - Organoides. FIBHULP*
- **Francisco Javier Cueto Rodríguez.** *Investigador Senior. FIBHULP*
- **Julia del Prado Montero.** *Investigadora Predoctoral. FIBHULP*
- **Jesús Fernández Felipe.** *Investigador Postdoctoral. FIBHULP*
- **Olivia Fernández Molina.** *Ayudante de Investigación. FIBHULP*
- **Jaime Fernández Pascual.** *Técnico Antomía Patológica. FIBHULP*
- **Laura Gómez Lage.** *Enfermera. Hospital Universitario La Paz*
- **Santiago Gómez Ruiz.** *Profesor Titular. Universidad Rey Juan Carlos*
- **María Susana Guerra García.** *Investigadora Postdoctoral. Universidad Autónoma de Madrid*
- **Kilián Jesús Gutiérrez Viñas.** *Responsable de laboratorio de Citometría de Flujo. FIBHULP*
- **Laura Hurtado Navarro.** *Investigadora Postdoctoral. FIBHULP*
- **Roberto Lozano Rodríguez.** *Investigador Predoctoral. FIBHULP*
- **Cristina de Manuel Gómez.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Charbel Antonio Maroun Eid .** *Facultativo Especialista de Área en Urgencias. Hospital del Norte*
- **Pablo Mata Martínez.** *Investigador Predoctoral. FIBHULP*
- **Elena Muñoz del Val.** *Facultativo especialista de área en Medicina Familiar y Comunitaria. Hospital Universitario La Paz*
- **Alejandro Pascual Iglesias.** *Bioinformático. FIBHULP*
- **Rebeca Pérez de Diego.** *Investigadora Senior (Contrato Ramón y Cajal). FIBHULP*
- **Sanjiv Prashar.** *Profesor Titular. Universidad Rey Juan Carlos*
- **Marta Roche Molina.** *Investigadora Postdoctoral. FIBHULP*
- **Gonzalo Saénz de Santamaría Díez.** *Investigador Predoctoral. FIBHULP*
- **Verónica Terrón Arcos.** *Técnico de Laboratorio. FIBHULP*
- **Jaime Valentín Quiroga.** *Investigador Predoctoral . FIBHULP*

STRATEGIC OBJETIVES

- This group focuses on the study of immune response reprogramming in the context of inflammatory diseases (e.g., sepsis, cystic fibrosis, lung and colon cancer) by describing the various molecular mechanisms underlying monocyte/macrophage reprogramming.

RESEARCH LINES

- Molecular and cellular mechanisms of sepsis.
- Markers of evolution: a molecular/cellular basis of persistent Covid-19.
- Evolution and prognostic markers in infectious diseases (sepsis and COVID-19) and tumors (lung, breast, colorectal).
- Molecular and cellular mechanisms of metastasis (lung, breast and colorectal).
- Immunomodulation in various clinical contexts (infectious diseases, tumors, cystic fibrosis, etc.).
- Immunophenotyping and immune response to vaccines (HIV, tumors, etc.).

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH ACTIVITY

Publications

- **Benito JM, Jiménez-Carretero D, Valentín-Quiroga J, Mahillo I, Ligos JM, Restrepo C, Cabello A, López-Collazo E, Sánchez-Cabo F, Górgolas M, Rallón N.** Long-term elite controllers of hiv-1 infection exhibit a deep perturbation of monocyte homeostasis. Int J Mol Sci. 2025; 26(9): 3926. Article. IF: 5.6; Q1
- **Carvalho G, Guerra S, Martínez-Jiménez MI, Blanco L.** Mouse primpol outperforms its human counterpart as a robust dna primase. Int J Mol Sci. 2025; 26(14): 6947. Article. IF: 5.6; Q1
- **Córdoba L, Cueto FJ, Cantero-Cid R, Abad-Moret R, Díaz E, Álvarez-Benayas J, Fernández-Felipe J, Jiménez-Rodríguez J, Arvelo-Rosario D, Mata-Martínez P, Arranz-Alvarez M, Pedroche-Just Y, Nieto-Torrero S, Valentín-Quiroga J, Terrón-Arcos V, Fernández-Pascual J, Gómez-Campelo P, Cubo-Mateo N, Fernández-Medina O, Hurtado-Navarro L, de Santa María GS, del Prado-Montero J, Santos AL, Lozano-Rodríguez R, Del Fresno C, López-Collazo E.** Colorectal air-liquid interface organoids preserve tumour-immune architecture and reveal local treg expansion after pd-1 blockade. Cancers (Basel). 2025; 18(1): 132. Article. IF: 4.8; Q2
- **del Prado-Montero J, Guevara-Martínez J, Cantero-Cid R, Mata-Martínez P, Cueto FJ, Lozano-Rodríguez R, Terrón-Arcos V, Abad-Moret R, Díaz-Serrano E, de Diego RP, Fernández-Velasco M, del Fresno C, Hurtado-Navarro L, López-Collazo E.** Age-stratified circulating immune signatures reveal non-invasive biomarkers for colorectal cancer detection. Immun Ageing. 2025; 22(1): 40. Article. IF: 8.3; D1
- **Fernandes S, Pedicone C, Dungan OM, Pacherille A, Meyer ST, Dormann S, del Fresno C, Sancho D, Toms B, Walker B, Bernard D, Chisholm JD, Kerr WG.** SHIPi improves hematologic recovery after chemotherapy. Mol Med. 2025; 31(1): 314. Article. IF: 8.3; Q1
- **Gil Fernández M, Bueno Sen A, Cantolla Pablo P, Val Blasco A, Ruiz Hurtado G, Delgado C, Cubillos C, Boscá L, Fernández Velasco M.** Atrial myopathy and heart failure: immunomolecular mechanisms and clinical implications. Int J Mol Sci. 2025; 26(17): 8210. Review. IF: 5.6; Q1
- **Garcia-Arriaza J, Falqui M, Perez P, Coloma R, Perdiguero B, Alvarez E, Marcos-Villar L, Astorgano D, Campana-Gomez I, Sorzano COS, Esteban M, Gomez CE, Guerra S.** ISG15 as a potent immune adjuvant in mva-based vaccines against zika virus and SARS-CoV-2. Vaccines (Basel). 2025; 13(7): 696. Article. IF: 3.5; Q2
- **Glaría E, Martínez PR, Font-Díaz J, de la Rosa JV, Castrillo A, Crawshaw DJ, Taboada JMV, Saura J, Matalonga J, Chini EN, Caelles C, Valledor AF.** Liver X receptors and inflammatory-induced C/EBPβ selectively cooperate to control CD38 transcription. J Innate Immun. 2025; 17(1): 56-77. Article. IF: 4.6; Q2
- **Iglesias GT, Chavarría-Miranda A, López-Molina M, del Fresno C, Mata-Martínez P, Nozal P, Chico-Garcia JL, Fernández-Fournier M, Ballester LL, Sánchez D, Montero-Calle A, Barderas R, Bravo S, Puertas I, York E, Díez-Tejedor E, Gutiérrez-Fernández M, Otero-Ortega L.** Extracellular vesicles as novel biomarkers for tumor association in intermediate-risk paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2025; 12(6): e200483. Article. IF: 8.0; Q1
- **Jaén RI, Sánchez-García S, Fernández-Velasco M, Cuadrado I, de las Heras B, Boscá L, Prieto P.** New biomarkers in the diagnosis and prognosis of dilated cardiomyopathy: pro-resolving lipids andmiRNAs. Cells. 2025; 14(23): 1916. Article. IF: 6.0; Q2
- **López-Collazo E, Hurtado-Navarro L.** Cell fusion as a driver of metastasis: re-evaluating an old hypothesis in the age of cancer heterogeneity. Front Immunol. 2025; 16: 1524781. Review. IF: 7.0; Q1
- **López-Molina M, Iglesias GT, de Santa María-Diez GS, Valentín-Quiroga J, Laso-García F, Gallego R, Pozo-Novoa J, Chamorro B, López-Collazo E, Puertas I, Díez-Tejedor E, Gutiérrez-Fernández M, Otero-Ortega L.** Immune checkpoint-based biomarkers for therapeutic response in patients with multiple sclerosis. Front Immunol. 2025; 16: 1694021. Article. IF: 7.0; Q1
- **Lozano-Rodríguez R, Hierro L, Quiles MJ, Pascual-Iglesias A, Terrón-Arcos V, Muñoz-Bartolo G, Frauca E, Cueto FJ, Calvo C, Córdoba-García L, Fernández-Felipe J, Hurtado-Navarro L, del Prado-Montero J, María-Diez GSD, Arvelo-Rosario D, Jara P, del Fresno C, López-Collazo E.** Comprehensive immune profiling and predictive modelling of paediatric acute hepatitis of unknown aetiology from a Spanish cohort. Front Immunol. 2025; 16: 1599982. Article. IF: 7.0; Q1
- **Martínez-Fleta P, Pertusa C, Fernández-Delgado I, Izquierdo-Serrano R, Ramírez-Huesca M, Fernández-Gallego N, Calzada-Fraile D, Moya-Ruiz E, Castillo-González R, Guerra S, Martín-Gayo E, Sánchez-Madrid F.** ISG15 modulates inflammatory profiles and ability to activate CD8+T cells in bone marrow-derived dendritic cells. Cell Mol Life Sci. 2025; 82(1): 362. Article. IF: 6.5; Q1
- **Mata-Martinez P, Celada L, Cueto FJ, Maria GSD, Fernández J, Terrón-Arcos V, Valdes N, Moreira VG, del Toro MIE, Lopez-Collazo E, Chiara MD, del Fresno C.** A blood-based liquid biopsy analyzing soluble immune checkpoints and cytokines identifies distinct neuroendocrine tumors. J Exp Clin Canc Res. 2025; 44(1): 82. Article. IF: 14.3; Q1
- **Minute L, Montalbán-Hernández K, Bravo-Robles L, Conejero L, Iborra S, del Fresno C.** Trained immunity-based mucosal immunotherapies for the prevention of respiratory infections. Trends Immunol. 2025; 46(4): 270-83. Review. IF: 13.1; D1
- **Notario L, Guerrero-Espinosa E, Nistal M, Lauzurica P, Aranda A, Alemany S.** Thyroid hormone deficiency worsens outcomes in vaccinia virus infection. J Virol. 2025; 99(12): e0129425. Article. IF: 4.1; Q1
- **O'Connell KS, Koromina M, van der Veen T, Boltz T, David FS, Yang JMK, Lin KH, Wang X, Coleman JRI, Mitchell BL, McGrouther CC, Rangan AV, Lind PA, Koch E, Harder A, Parker N, Bendl J, Adorjan K, Agerbo E, Albani D, Alemany S, Alliey-Rodriguez N, Als TD, Andlauer TFM, Antoniou A, Ask H, Bass N, Bauer M, Beins EC, Bigdeli TB, Pedersen CB, Boks MP, Borte S, Bosch R, Brum M, Brumpton BM, Brunkhorst-Kanaan N, Budde M, Bybjerg-Grauholm J, Byerley W, Cabana-Domínguez J, Cairns MJ, Carpiniello B, Casas M, Cervantes P, Chatzinakos C, Chen HC, Clarence T, Clarke TK, Claus I, Coombes B, Corfield EC, Cruceanu C, Cuellar-Barboza A, Czerski PM, Dafnas K, Dale AM, Dalkner N, Degenhardt F, DePaulo JR, Djurovic S, Drange OK, Escott-Price V, Fanous AH, Fellendorf FT, Ferrier IN, Forty L, Frank J, Frei O, Freimer NB, Fullard JF, Garnham J, Gizer IR, Gordon SD, Gordon-Smith K, Greenwood TA, Grove J, Guzman-Parra J, Ha TH, Hahn T, Haraldsson M, Hautzinger M, Havdahl A, Heilbronner U, Hellgren D, Herms S, Hickie IB, Hoffmann P, Holmans PA, Huang MC, Ikeda M, Jamain S, Johnson JS, Jonsson L, Kalman JL, Kamatani Y, Kennedy JL, Kim E, Kim J, Kittel-Schneider S, Knowles JA, Kogevinas M, Kranz TM, Krebs K, Kushner SA, Lavebratt C, Lawrence J, Leber M, Lee HJ, Liao C, Lucae S, Lundberg M, MacIntyre DJ, Maier W, Maihofer AX, Malaspina D, Manchia M, Maratou E, Martinsson L, Mattheisen M, McGregor NW, McInnis MG, McKay JD, Medeiros H, Meyer-Lindenberg A, Millischer V, Morris DW, Moutsatsou P, Mühleisen TW, O'Donovan C, Olsen CM, Panagiotaropoulou G, Papiol S, Pardiñas AF, Park HY, Perry A, Pfennig A, Pisanu C, Potash JB, Quested D, Rapaport MH, Regeer EJ, Rice JP, Rivera M, Schulte EC, Senner F, Shadrin A, Shilling PD, Sigurdsson E, Sindermann L, Sirignano L, Siskind D, Slaney C, Sloofman LG, Smeland OB, Smith DJ, Sobell JL, Artigas MS, Stein DJ, Stein F, Su MH, Sung H, Swiatkowska B, Terao C, Tesfaye M, Tesli M, Thorgeirsson TE, Thorp JG, Toma C, Tondo L, Tooney PA, Tsai SJ, Tsermpini EE, Vawter MP, Vedder H, Vreeker A, Walters JTR, Winsvold BS, Witt SH, Won HH, Ye R, Young AH, Zandi PP, Zillich L, Adolfsson R, Alda M, Alfredsson L, Backlund L, Baune BT, Bellivier F, Bengesser S, Berrettini WH, Biernacka JM, Boehnke M, Borglum AD, Breen G, Carr VJ, Catts S, Cichon S, Corvin A, Craddock N, Dannlowski U, Dikeos D, Etain B, Ferentinos P, Frye M, Fullerton JM, Gawlik M, Gershon ES, Goes FS, Green MJ, Grigoroiu-Serbanescu M, Hauser J, Henskens FA, Hjerling-Leffler J, Hougaard DM, Hveem K,**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Iwata N, Jones I, Jones LA, Kahn RS, Kelsoe JR, Kircher T, Kirov G, Kuo PH, Landén M, Leboyer M, Li QS, Lissowska J, Lochner C, Loughland C, Luykx JJ, Martin NG, Mathews CA, Mayoral F, McElroy SL, McIntosh AM, McMahon FJ, Medland SE, Melle I, Milani L, Mitchell PB, Morken G, Mors O, Mortensen PB, Müller-Myhsok B, Myers RM, Myung W, Neale BM, Nievergelt CM, Nordentoft M, Nöthen MM, Nurnberger JI, O'Donovan MC, Oedegaard KJ, Olsson T, Owen MJ, Paciga SA, Pantelis C, Pato CN, Pato MT, Patrinos GP, Pawlak JM, Ramos-Quiroga JA, Reif A, Reininghaus EZ, Ribasés M, Rietschel M, Ripke S, Rouleau GA, Roussos P, Saito T, Schall U, Schalling M, Schofield PR, Schulze TG, Scott LJ, Scott RJ, Serretti A, Smoller JW, Squassina A, Stahl EA, Stefansson H, Stefansson K, Stordal E, Streit F, Sullivan PF, Turecki G, Vaaler AE, Vieta E, Vincent JB, Waldman ID, Weickert CS, Weickert TW, Werge T, Whiteman DC, Zwart JA, Edenberg HJ, McQuillin A, Forstner AJ, Mullins N, Di Florio A, Ophoff RA, Kim JW, Lee YK, Kang JH, Cheon MJ, Kim DJ, Aslan M, Harvey PD, Andreassen OA, Huang GD. Genomics yields biological and phenotypic insights into bipolar disorder. Nature. 2025; 639(8056): 968-75. Article. IF: 56.1; D1

- **Pereda J, Espinosa R, García-Solís B, Guerra-Galán T, Van-Den-Rym A, Kars ME, Mena R, Galán V, de Andrés-Martín A, Rodríguez-Gallego C, López-Lera A, Corvillo F, Pérez-Martínez A, López-Collazo E, Sánchez-Ramón S, Martínez-Barricarte R, Quintana-Murci L, Lorenzo-Salazar JM, Itan Y, Flores C, Pérez-de-Diego R.** IEIVariantFilter: a bioinformatics tool to speed up genetic diagnosis of inborn errors of immunity patients. Nar Genom Bioinform. 2025; 7(2): lqaf069. Article. IF: 3.0; Q2
- **Robles-Vera I, Jarit-Cabanillas A, Brandi P, Martínez-López M, Martínez-Cano S, Rodrigo-Tapias M, Femenía-Muiña M, Redondo-Urzainqui A, Nuñez V, González-Correa C, Moleón J, Duarte J, Conejero L, Mata-Martínez P, Díez-Rivero CM, Bergón-Gutiérrez M, Fernández-López I, Gómez MJ, Quintas A, Dopazo A, Sánchez-Cabo F, Pariente E, del Fresno C, Subiza JL, Iborra S, Sancho D.** Microbiota translocation following intestinal barrier disruption promotes Mincle-mediated training of myeloid progenitors in the bone marrow. Immunity. 2025; 58(2): 381-96. Article. IF: 30.6; D1
- **Sánchez-García S, Jaén RI, Lozano-Rodríguez R, Avendaño-Ortiz J, Pascual-Iglesias A, Hurtado-Navarro L, López-Collazo E, Boscá L, Prieto P.** Lipoxin A4 levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkers. Front Immunol. 2025; 15: 1509188. Article. IF: 7.0; Q1
- **Soudant J, González-Blázquez R, Merino A, Ballesteros-Martínez C, Rodrigues-Díez R, Moreno-Carriles R, Nistal JF, Guerra S, Redondo JM, Salaices M, Briones AM, Garcia-Redondo AB.** Interferon stimulated gene 15 (ISG15) modulates phenotype of vascular smooth muscle cells and pathological vascular remodeling. Clin Investig Arterioscler. 2025; 37(5): 500769. Article. IF: 1.9; Q3
- **Tébar D, Jurado-Román A, Jiménez-Valero S, Galeote G, Gonzálvez A, Rivero B, García A, Elizalde JMA, Lorenzo A, Capitán CF, Torres R, Soto C, Alcolea S, Rosillo S, Codón JC, Arbas E, Tejera F, Plaza I, Boscá L, Moreno R.** Percutaneous pulmonary thrombectomy with aspiration catheters in patients with high-risk pulmonary embolism and absolute contraindication to systemic thrombolysis. Cardiovasc Revasc Med. 2025; 70: 56-61. Article. IF: 2.3; Q3
- **Valentín-Quiroga J, Zarauza-Santoveña A, López-Collazo E, Ferreira LMR.** Chimeric anti-HLA antibody receptor engineered human regulatory T cells suppress alloantigen-specific B cells from pre-sensitized transplant recipients. Front Immunol. 2025; 16: 1601385. Article. IF: 7.0; Q1

Research projects

- **del Fresno Sánchez C.** Ampliación de la biopsia líquida inmune polifuncional (polyfil) al seguimiento de adenomas de colon, diagnóstico de cáncer de recto (PI24/01106). ISCIII. 2025-2027. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Biopsia poli-funcional inmunitaria líquida (polifil): una nueva plataforma para predecir y mejorar respuestas a inmunoterapia del cáncer usando moduladores inmunes innatos (PI21/01178). ISCIII. 2025-2026. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Desarrollo avanzado y validación clínica de sistemas de diagnóstico y pronóstico del cáncer basados en ca10 (ca10advance) (CPP2024-011282). ISCIII. 2025-2028. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Heat-killed bacteria as mucosal immunotherapies against lung cancer and pulmonary metastasis. Bacterias muertas por calor como inmunoterapias mucosas contra el cáncer y las metástasis pulmonares. (LABAE259414DELF). ISCIII. 2025-2029. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Identificación de los mecanismos efectores de una vacuna antineoplásica basada en CA10 y su potencial aplicación clínica (IND2022/BMD-23669). CM. 2022-2025. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Luis Alvarez Carlos 2024. FIBHULP. 2025-2025. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Prueba en concepto para nuevas inmunoterapias contra el cáncer dirigidas a la memoria inmunitaria innata (AECC 2022-CARLOS DEL FRESNO). Fundación Asociación Española Contra el Cáncer. 2022-2025. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Training induced by heat-killed Mycobacterium tuberculosis and underlying epigenetic mechanisms as therapeutic innovation for colon cancer.Fundación Asociación Española Contra el Cáncer. 2025-2028. Managment centre: FIBHULP
- **López Collazo E.** Abordaje multiómico y estructural al estudio de los mecanismos de respuesta del hepatocito al daño inflamatorio (S2022/BMD-7232-TomoXliver2-C). CM. 2023-2026. Managment centre: FIBHULP
- **López Collazo E.** Contribucion de las celulas gibridas tumorales a la metastasis del cancer de pulmon: estudio exhastivo en modelos animales y pacientes con metastasis avanzada. FIBHULP. 2018-Ongoing. Managment centre: FIBHULP
- **López Collazo E.** Desvelando el papel de la familia siglec en la evolución de la sepsis: hacia un manejo personalizado del paciente (PI24/00910). ISCIII. 2025-2027. Managment centre: FIBHULP
- **López Collazo E.** Dinamización de ciencia disruptiva en predictores de enfermedades tumorales, infecciosas y hereditarias como base de la medicina personalizada (FORT23/00006_GRUPO II). ISCIII. 2024-2027. Managment centre: FIBHULP
- **López Collazo E.** Plataforma de caracterización celular de alta dimensionalidad (CellDA) (IFCS21/00009). ISCIII. 2022-2026. Managment centre: FIBHULP
- **López Collazo E.** Sepsis: un estudio longitudina exhaustivo de la resupuesta inmune para la estratificación de los pacientes y una medicina personalizada (PI21/00869). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Pérez de Diego R.** Identificación de nuevos errores innatos de la inmunidad hacia el diagnóstico de precisión y prevención de enfermedades inmunológicas (PI22/00790). ISCIII. 2023-2027. Managment centre: FIBHULP
- **Pérez de Diego R.** The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalized medicine (UNDINE_REBECA PEREZ). UE. 2022-2026. Managment centre: FIBHULP

Ciber and Retics

- **López Collazo E.** Plataforma de Biomodelos y Biobanco de IdiPAZ. ISCIII. (31/12/2026). FIBHULP

Patents and trademarks

- **Llamas Matías MA, López-Collazo E, inventors; FIBHULP, Llamas Matías MA, Empireo S.**L., assignees. Method for determine the risk of developing an infectious disease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27.
- **Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees.** Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application; 2018 March 13.
- **del Fresno C, Cantero Cid R, Lopez Collazo, López Collazo E, inventors; FIBHULP, assignes.** Poly Functional Immune Liquid Biopsy (PolyFIL Biopsy) for the differential diagnosis of colon adenoma and carcinoma differential diagnosis of colon adenoma and carcinoma. PCT/EP2025/052243, 29 January 2025
- **"del Fresno C, Cantero Cid R, Lopez Collazo, inventors; FIBHULP, assignes.** Trademark name: PolyFIL Diagnostics; 019200741; 2025 September 25.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.3.5 Alterations of the Complement System in Human Pathology



Publications: 9 | Q1: 6

COMPOSITION

Margarita López Trascasa.
Investigadora "Ad honorem". IdiPAZ. Profesora de la Facultad de Medicina. Universidad Autónoma de Madrid

Pilar Sánchez Corral Gómez.
Investigadora Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. Hospital Universitario La Paz

- **Fernando Corvillo Rodríguez.** *Investigador postdoctoral. Hospital Universitario La Paz*
- **Laura Espinosa Román.** *Jefa de Servicio Nefrología Pediátrica. Hospital Universitario La Paz*
- **María del Rosario García Sánchez.** *Investigadora predoctoral. FIBHULP*
- **Laura González Sánchez.** *Investigadora postdoctoral. Hospital Universitario La Paz*
- **Alberto López Lera.** *Investigador Postdoctoral. Contratado CIBERER. Hospital Universitario La Paz*
- **Marta Melgosa Hijosa.** *Facultativo Especialista de Área en Nefrología Infantil. Jefa de Servicio Nefrología Pediátrica. Hospital Universitario La Paz*
- **Pilar Nozal Aranda.** *Facultativo Especialista de Área en Inmunología. Investigadora Postdoctoral. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- This is a national reference group for the study of primary or acquired defects in the complement system.
- The main aim is to gain an understanding of the molecular mechanisms underlying in complement deficiency or dysregulation in several human diseases, the majority of which are classified as rare diseases.
- In this context, the group implements and applies various methodological strategies (immunological, biochemical, proteomic and genetic) to detect clinically relevant deficiencies or functional defects in complement components. By following a clearly translational approach, the group also develops new diagnostic tests which are implemented in the clinical practice, especially for treatment adjustment and patient follow-up.
- The research lines could be classified as: screening and characterization of genetic or acquired complement defects that cause renal pathology (I), functional and molecular diagnosis of deficiencies affecting individual components of the complement system (II), diagnosis and molecular studies in Hereditary Angioedema and screening for disease modifying genes (III), study of pathogenic mechanisms in acquired lipodystrophies (IV).

RESEARCH LINES

- Screening and characterization of genetic and acquired Complement defects in renal disease.
- Biochemical and molecular diagnosis of isolated Complement deficiencies.
- Biochemical and molecular diagnosis of Hereditary and Acquired forms of bradykinin-mediated Angioedema.
- Pathogenic mechanisms of adquired lipodistrhphies: Barraquer-Simons syndrome, and Lawrence syndrome.
- Complement defects in Age Related Macular Degeneration

RESEARCH ACTIVITY

Master Theses

- **Rodrigo Castro A.** Estudio transversal de especificidades no HLA y autoanticuerpos en pacientes pediátricos trasplantados[dissertation]. Madrid: UCM: 2025(26/06/2025). Director: Sánchez Zapardiel E, Nozal Aranda P.


Final Degree Theses

- **Arroyo Muñoz A.** Development of a genetic diagnosis methodology for a Hereditary Angioedema variant due to Carboxypeptidase N deficiency and patient screening [dissertation]. Madrid: UAM: 2025(23/06/2025). Director: López Lera A.

Publications

- **Bellos E, van Leeuwen K, Duret A, Hodeib S, Mashbat M, Kohlfuerst DS, Boeddha NP, Schlapbach LJ, Wright VJ, Fink CG, van der Flier M, van Deuren M, Sprong T, López-Trascasa M, Lopez-Lera A, Martinon-Torres F, Salas A, Santillo D, Zenz W, Driessen**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



GJ, Anderson ST, Secka F, Paulus S, de Groot R, Emonts M, Carrol ED, Herberg J, Levin M, Sancho-Shimizu V, Kuijpers T. Genetic determinants of the complement and coagulation pathways in invasive meningococcal disease. J Allergy Clin Immun. 2025; 156(6): 1743-51. Article. IF: 11.7; D1

- **Caravaca-Fontán F, Toledo-Rojas R, Huerta A, Pérez-Canga JL, Martínez-Miguel P, Miquel R, Da Silva I, Verdalles U, Albornoz M, López CMD, Mon C, Fernández-Juárez G, Praga M.** Comparative analysis of proteinuria and longitudinal outcomes in immune complex membranoproliferative glomerulonephritis and c3 glomerulopathy. Kidney Int Rep. 2025; 10(4): 1223-36. Article. IF: 6.2; Q1
- **Ferrara AL, Palestra F, Piscitelli F, Petraroli A, Suffritti C, Firinu D, López-Lera A, Caballero T, Bork K, Spadaro G, Marone G, Di Marzo V, Bova M, Loffredo S.** Altered levels of phospholipases C, diacylglycerols, endocannabinoids, and N-acylethanolamines in patients with hereditary angioedema due to FXII mutation. Allergy. 2025; 80(1): 287-96. Article. IF: 11.3; Q1
- **Iglesias GT, Chavarría-Miranda A, López-Molina M, del Fresno C, Mata-Martínez P, Nozal P, Chico-García JL, Fernández-Fournier M, Ballester LL, Sánchez D, Montero-Calle A, Barderas R, Bravo S, Puertas I, York E, Díez-Tejedor E, Gutiérrez-Fernández M, Otero-Ortega L.** Extracellular vesicles as novel biomarkers for tumor association in intermediate-risk paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2025; 12(6): e200483. Article. IF: 8.0; Q1
- **López-Lera A, Corvillo F, González-Sánchez L, Melgosa M, Sánchez-Corral P.** Relevance of the complement and contact coagulation system interactions on renal pathology. Nefrologia. 2025; 45(8): 501347. Review. IF: 2.1; Q3
- **Novella-Navarro M, González-Sánchez L, Hernández-Breijo B, de Diego RP, Sánchez-Corral P, López-Trascasa M, Miranda-Carús ME, Villalba A, Balsa A, De Miguel E, Plasencia-Rodríguez C, Corvillo F.** Serum adipsin levels in rheumatic diseases: defining its role in disease activity and progression in rheumatoid arthritis and axial spondyloarthritis. Front Immunol. 2025; 16: 1636158. Article. IF: 7.0; Q1
- **Pereda J, Espinosa R, García-Solís B, Guerra-Galán T, Van-Den-Rym A, Kars ME, Mena R, Galán V, de Andrés-Martín A, Rodríguez-Gallego C, López-Lera A, Corvillo F, Pérez-Martínez A, López-Collazo E, Sánchez-Ramón S, Martínez-Barricarte R, Quintana-Murci L, Lorenzo-Salazar JM, Itan Y, Flores C, Pérez-de-Diego R.** IEIVariantFilter: a bioinformatics tool to speed up genetic diagnosis of inborn errors of immunity patients. Nar Genom Bioinform. 2025; 7(2): lqaf069. Article. IF: 3.0; Q2
- **Triaille C, Corvillo F, Mertens A, Hoffman I, Roskams T, López-Trascasa M, De Somer L, Casteels K.** Perilipin-1 autoantibodies are a robust marker of acquired lipodystrophy and may precede clinical detection. Pediat Allerg Imm-Uk. 2025; 36(1): e70026. Letter. IF: 4.5; Q2
- **Zuraw BL, Bork K, Bouillet L, Christiansen SC, Farkas H, Germenis AE, Grumach AS, Kaplan A, López-Lera A, Magerl M, Riedl MA, Adatia A, Banerji A, Betschel S, Boccon-Gibod I, Bova M, Boysen HB, Caballero T, Cancian M, Castaldo AJ, Cohn DM, Corcoran D, Drouet C, Fukunaga A, Hide M, Katelaris CH, Li PH, Longhurst H, Peter J, Psarros F, Reshef A, Ritchie B, Selva CN, Zanichelli A, Maurer M.** Hereditary angioedema with normal c1 inhibitor: an updated international consensus paper on diagnosis, pathophysiology, and treatment. Clin Rev Allerg Immu. 2025; 68(1): 24. Review. IF: 11.5; D1

Research projects

- **Corvillo Rodríguez F.** Mecanismos patogénicos de las Lipodistrofias. Factores genéticos y adquiridos del sistema del Complemento (PI25/00388). ISCIII. 2026-2028. Managment centre: FIBHULP
- **López-Lera A.** Identificación y caracterización funcional de variantes genéticas asociadas a fenotipos clínicos específicos en angioedema hereditario por déficit de C1 inhibidor (GENOMAEH_01). Takeda Farmacéutica España. 2024-2026. Managment centre: Fundació Hospital Universitari Vall d'Hebrón
- **Nozal Aranda, P.** Detección y caracterización de autoanticuerpos frente a perilipina 1 en pacientes con lipodistrofia generalizada adquirida (síndrome de Lawrence) (). Asociación Internacional de Familiares y Afectados de Lipodistrofias. 2024-Ongoing. Managment centre: FIBHULP
- **Sánchez-Corral Gómez P.** Caracterización de patrones de expresión del FH y proteínas FHRS del complemento mediante western-blot e inteligencia artificial. correlación genotipo-fenotipo en patología renal y ocular (PI22/00211). ISCIII. 2023-2027. Managment centre: FIBHULP
- **Sánchez-Corral Gómez P.** El sistema del complemento en salud y enfermedad (Complemento III-CM) (P2022/BMD-7278). Comunidadd de Madrid. 2023-2026. Managment centre: CSIC/FIBHULP

Ciber and Retics

- **López Trascasa M.** The European Consortium of Lipodystrophies (Eclip). EU. (31/12/2025). FIBHULP
- **Sánchez-Corral Gómez P.** Red Nacional de Complemento (RED2022-134750-T). MICINN. (31/12/2025). FIBHULP

Patents and trademarks

- **López Trascasa M, authors; FIBHULP, assignee.** Brand name: COMPLEMENTest; CM 009.658.791; 2011, January 14.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.3.6 Lymphocyte Pathophysiology in Immunodeficiencies

Publications: 18 | Q1: 5

COMPOSITION

Eduardo López Granados.
Coordinador de Inmunología. Hospital Universitario La Paz

- **María Bravo García-Morato.** *Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz*
- **Carmen Cámara Hijón.** *Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz*
- **Álvaro Clemente Bernal.** *Técnico de Grado Superior. FIBHULP*
- **Ricardo Cuesta Martín de la Cámara.** *Biólogo Interno Residente en la especialidad de Inmunología. Hospital Universitario La Paz*
- **Andrea González Torbay.** *Médico Interno Residente en Inmunología. Hospital Universitario La Paz*
- **Carla Cecilia Gianelli.** *Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz*
- **Diego Plaza López de Sabando.** *Facultativo Especialista de Área en Hemato-Oncología Pediátrica. Hospital Universitario La Paz*
- **Keren Reche Yebra.** *Técnico de Laboratorio. FIBHULP*
- **Ángel Julián Robles Marhuenda.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Rebeca Rodríguez Pena.** *Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz*
- **María Carmen Salcedo Moreno.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **Elena Sánchez Zapardiel.** *Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz*
- **Ana Sastre Urguelles.** *Facultativo Especialista de Área en Hemato-Oncología Pediátrica. Hospital Universitario La Paz*
- **Juan Manuel Torres Canizales.** *Médico Inmunólogo. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Our group is working to unravel the molecular basis of primary immunodeficiencies (PIDs), a broad group of rare diseases (more than 400 types described to date) that affect virtually every type of immune system cell and increase patients' risk of infections, autoimmunity, and cancer. We take a multidisciplinary approach, incorporating clinical, anatomical, genetic, epigenetic, and functional perspectives. By correlating clinical and experimental data, we aim to gain a better understanding of these rare diseases and lay the groundwork for repurposed or new, more effective treatments.
- Leveraging the knowledge and resources developed to dissect the immune system in primary immunodeficiency disorders (PIDs), we are developing new immune monitoring schemes for transplant patients to better estimate immunosuppression and tolerance, and to detect serious complications such as infections and rejection early. Finally, we are exploring new approaches for monitoring and fine-tuning immunotherapies.
- Leveraging the knowledge and resources developed to analyze the immune system in primary immunodeficiency patients (PIDs), we are developing new protocols for immunological monitoring in transplant recipients to better estimate immunosuppression and tolerance, as well as to detect serious complications such as infections and rejection early.

RESEARCH LINES

- To define the anatomical, cellular, molecular and (epi)genetic bases of immune dysfunction in patients diagnosed with primary immunodeficiency in our clinic.
- The maturation and functional specialization of human B lymphocytes, and their pathophysiology in primary and secondary antibody immunodeficiencies.
- Analysis of immunological reconstitution after hematopoietic stem cell transplantation, and discovery and clinical validation of immunological biomarkers of immunosuppression and tolerance in solid organ transplantation.
- The development and clinical application of patient-adapted and widely used immunotherapy monitoring schemes.

RESEARCH ACTIVITY

Final Degree Theses

- **Rodrigo Castro A.** Estudio transversal de especificidades no HLA y autoanticuerpos en pacientes pediátricos trasplantados[dissertation]. Madrid: UCM: 2025(26/06/2025). Director: Sánchez Zapardiel E, Nozal Aranda P.

Publications

- **Berenguel LM, Gianelli C, Pérez EM, del Rosal T, Echevarría AM, Marhuenda AR, Rodríguez MF, Molina MTC, García LM, Garrido BS, Díaz SH, Martínez LA, Aranda PN, Hijón CC, Granados EL, Pena RR, García-Morato MB.** Molecular assessment of splicing variants in a cohort of patients with inborn errors of immunity: methodological approach and interpretation remarks. Front Immunol. 2025; 15: 1499415. Article. IF: 7.0; Q1
- **Cabrera-Alarcón JL, Cruz R, Rosa-Moreno M, Latorre-Pellicer A, de Almeida SD, Riancho JA, Rojas-Martínez A, Flores C, Lapunzina P, Sánchez-Cabo F, Carracedo A, Enriquez JA, (López-Granados E) .** Shaping current European mitochondrial haplogroup frequency in response to infection: the case ofSARS-CoV-2severity. Commun Biol. 2025; 8(1): 33. Article. IF: 5.8; D1
- **Carrasco-Molina S, Robles-Marhuenda A, Ríos-Blanco JJ, Tung-Chen Y.** Counter-reply: comment to the special article [Utility of point-of-care ultrasound (POCUS) in hospitalized patients with acute confusional syndrome of unclear etiology]. Rev Clin Esp. 2025; 225(7): 502337. Letter. IF: 1.7; Q2
- **Carrasco-Molina S, Robles-Marhuenda A, Ríos-Blanco JJ, Tung-Chen Y.** Utility of point-of-care ultrasound (POCUS) in hospitalized patients with acute confusional syndrome of unclear etiology. Rev Clin Esp. 2025; 225(4): 231-9. Article. IF: 1.7; Q2
- **Chanson N, Galvagni A, Ramos-Casals M, Ruiz JI, Suijkerbuijk KPM, Gente K, Kerschen P, Karam JD, Belkhir R, Outh R, Closs-Prophette F, Morillo JSG, Robles-Marhuenda A, Michot JM, Voisin AL, Messayke S, Laparra A, Robert C, Suarez-Almazor M, Mariette X, Lambotte O, ICIR.** Immune checkpoint inhibitors-associated vasculitis: a heterogeneous condition with possible severe disease course. Rheumatology. 2025; 64(6): 3685-90. Article. IF: 4.7; Q1
- **de la Cámara RCM, Miguel-Berenguel L, Cámara C, Losantos-García I, Frauca-Remacha E, Hierro-Llanillo L, Muñoz-Bartolo G, Lledín-Barbacho MD, Martínez-Feito A, López-Granados E, Sánchez-Zapardiel E.** Immune monitoring and

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

risk of infection in pediatric liver transplantation: a prospective study. Front Immunol. 2025; 16: 1605716. Article. IF: 7.0; Q1

- **Del Rosal T, Morillas-Mingorance A, García-Morato MB, Rodríguez-Pena R, Bravo-Gallego LY, Méndez-Echevarria A.** Infectious and inflammatory events in 2 siblings with IRF9 deficiency under immunoglobulin replacement therapy. J Allergy Clin Immun. 2025; 156(5): 1433-5. Letter. IF: 11.7; D1
- **Fuentes OP, Ballester LL, Troncoso JA, Abánades CIS, Mozo AN, Marhuenda AR, Blanco JJR, Sancerni BG, Rodríguez IE, Mora ET, Robles EM.** Inflammatory cerebral pseudotumour as a rare manifestation of neuro-Behçet's disease: A case report and literature review. J Neuroimmunol. 2025; 405: 578652. Review. IF: 3.1; Q3
- **Fuentes OP, Cepeda JG, Cabrera CV, de Bustamante JMM, Marhuenda AR, Troncoso JA, Robles EM, Mozo JAN, Blanco JJR, Fernández EG, Abánades CIS.** Renal involvement in primary Sjogren's syndrome: Beyond tubulointerstitial nephritis. Nefrologia. 2025; 45(7): 501341. Letter. IF: 2.1; Q3
- **González-Martínez B, Galán-Gómez V, Navarro-Zapata A, Mirones-Aguilar I, Cobo M, Pernas-Sánchez A, Vallejo S, Sánchez-Zapardiel E, León-Triana O, Echecopar C, Martínez-Romera I, Guerra-García P, San Román-Pacheco S, Escudero A, Izquierdo E, Izquierdo M, Naharro S, Martín-Ayuso A, Bareke H, París-Muñoz A, Hu PR, Schneider D, Orentas RJ, Minguillón J, Pérez-Martínez A.** Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL. Ebiomedicine. 2025; 118: 105872. Article. IF: 11.2; D1
- **González-Torbay A, Reche-Yebra K, Clemente-Bernal A, Serrano YS, Bravo-Gallego LY, López AF, Rodríguez-Pena R, García-Morato MB, López-Granados E, del Pino-Molina L.** Functional insights of an uncommon hypomorphic variant in IL2RG as a monogenic cause of CVID-like disease with antibody deficiency and T CD4 lymphopenia. Front Immunol. 2025; 16: 1544863. Article. IF: 7.0; Q1
- **Iglesias GT, Martínez-Feito A, Otero-Ortega L, Lopez-Molina M, Puertas I, González-Torbay A, Rita CG, Fernández-Fournier M, Velasco SS, Chamorro B, Díez-Tejedor E, Lopez-Granados E.** Immunological monitoring during anti-cd20 therapies to predict infection risk and treatment response in multiple sclerosis patients. Diseases. 2025; 13(12): 387. Article. IF: 3.7; Q2
- **Molina LD, Manzano EM, Gianelli C, Gallego LY, Fernández JB, Acuña P, Serrano YS, Yebra KR, García-Morato MB, Zapardiel ES, Arias-Salgado EG, Pena RR, Butta N, Granados EL.** Effects of two different variants in the MAGT1 gene on B cell subsets, platelet function, and cell glycome composition. Front Immunol. 2025; 16: 1547808. Article. IF: 7.0; Q1
- **Moral PM, García-Bustos V, Balastegui-Martin H, Mercader SM, Bracke C, Mateu L, Solanich X, Antolí A, Carrillo-Linares JL, Robles-Marhuenda A, Puchades F, Ballesta AP, López-Osle N, Torralba-Cabeza MA, Masdeu AMB, Niño JG, Gaya NT, Castellanos GP, Sánchez-Martínez R, Barragán-Casas JM, González-García A, de la Peña JLP, López-Wolf D, Rufete AM, Mora AC, Cabañero-Navalon MD.** Real-world patterns of immunoglobulin replacement therapy for infection prevention in common variable immunodeficiency: a multicenter nationwide study. Front Immunol. 2025; 16: 1640290. Article. IF: 7.0; Q1
- **Neth O, Alsina L, Riviere JG, López-Granados E, Seoane-Reula ME, Granado LG, Sánchez-Ramón S, Rodríguez-Gallego C.** Spanish Consensus on the Diagnosis and Management of Patients With Activated PI3K Delta Syndrome (APDS). J Invest Allerg Clin. 2025; 35(2): 87-102. Review. IF: 6.6; Q1
- **Papa-Gobbi R, Stringa P, Gentilini MV, Ivanoff I, Machuca M, Arreola NM, Serradilla J, Estefanía-Fernández K, Talayero P, Velayos M, Sánchez-Zapardiel E, Gondolesi G, Andrés-Moreno A, Rumbo M, Hernández-Oliveros F.** Low regulatory T-cells frequency is associated with graft rejection after small bowel transplantation: Clinical and experimental evidence. Plos One. 2025; 20(1): e0307534. Article. IF: 2.8; Q2
- **París-Munoz A, Alcobendas-Rueda RM, Verdú-Sánchez C, Udaondo C, Galán-Gomez V, González-Martinez B, Menéndez JJ, Martínez-Romera I, Minguillón J, Pertínez L, de Manuel-Gómez C, de la Cruz-benito A, Sanz-Rupérez A, Remesal A, Cámara C, Sánchez-Zapardiel E, del Pino-Molina L, Gómez-Zamora A, Serrano-Olmedo MG, Espanol-Rego M, Valbuena MRD, Climent F, Dorao P, Ríos-Blanco JJ, Andrade JD, Ruiz-Zurita G, Fernández-García MA, Pérez-Martinez A.** CD19 CAR-T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease. Med. 2025; 6(8): 100676. Article. IF: 13.3; D1
- **Pérez-Andrés M, van der Burg M, Kalina T, Bonroy C, Silva SL, López-Granados E, Arriba-Méndez S, Serrano C, Torres RC, Paiva A, González-Granado LI, Sousa AE, Hofmans M, van Dongen JJM, Orfao A.** T, B, and NK cells versus the primary immunodeficiency orientation tube for diagnostic screening of IEIs. J Allergy Clin Immun. 2025; 156(6): 1772-5. Letter. IF: 11.7; D1

Research projects

- **López Granados E.** Alteraciones madurativas y funcionales de los linfocitos b en la inmunodeficiencia común variable y su potencial réplica en algunas enfermedades autoinmunes (PI24/01303). ISCIII. 2025-2027. Managment centre: FIBHULP
- **López Granados E.** Desarrollo de ensayos de validación funcional como complemento del diagnóstico molecular de errores congénitos de la respuesta inmunológica (2022.335). Fundacion Mutua Madrileña. 2023-2026. Managment centre: FIBHULP
- **López Granados E.** Europan Rare dIsease research Coordination and support Action (ERICA - 964908). UE. 2021-2025. Managment centre: FIBHULP

Ciber and Retics

- **López Granados E.** Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER). ISCIII. (31/12/2025). FIBHULP

Clinical trials

- **López Granados E.** Estudio observacional prospectivo multicéntrico de un solo brazo para evaluar los patrones de uso de fármacos en la vida real, la tolerabilidad y los resultados percibidos por pacientes en edad pediátrica y adultos con inmunodeficiencia tratados con xembify®. Estudio flex-up.
  Type/Phase: EOm prospectivo
  Sponsored by: Grifols S.A.
  Signature date: 16/12/2025
- **Plaza Lopez De Sabando D.** Estudio en fase II, aleatorizado y abierto para evaluar abemaciclib en combinación con temozolomida comparado con la temozolomida en monoterapia en niños y adultos jóvenes con glioma de alto grado recién diagnosticado después de la radioterapia.
  Type/Phase: II
  Sponsored by: Eli Lilly Co Uk Ltd.
  Signature date: 21/07/2025
- **Robles Marhuenda AJ.** Estudio de fase II abierto para evaluar la eficacia clínica, la seguridad y la tolerabilidad de mas825 en participantes pediátricos y adultos con enfermedad de still.
  Type/Phase: II
  Sponsored by: Novartis Pharma Services Ag.
  Signature date: 18/12/2025
- **Robles Marhuenda AJ.** Estudio de fase II, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del obexelimab en pacientes con lupus eritematoso sistémico.
  Type/Phase: II
  Sponsored by: Zenas Biopharma (Usa), Llc.
  Signature date: 17/06/2025
- **Robles Marhuenda AJ.** Single-arm open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of bi 3000202 in adult patients with selected type 1 interferonopathies.
  Type/Phase: I
  Sponsored by: Boehringer Ingelheim España S.A.
  Signature date: 22/01/2025

Patents and trademarks

- **Van Dongen JJM, Orfao de Matos Correia E Vale JA, Van Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vlkova M, López Granados E, Blanco Álvarez E, Kienzler AK, inventors; Erasmus University Medical Center Rotterdam, assignee.** Reagents, methods, and kits for diagnosing primary immunodeficiencies. PCT/NL2015/050762, US62/072,498; 2014 Oct 30.
- **López Granados E, del Pino L, authors; FIBHULP, CIBERer, assigne.** Brand name: IMMUNE SIGNAL ®. EU 01906321; 2024, August 02

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.3.7 Drug Hypersensitivity and Innate Immune Response

Publications: 2 | Q1: 1

COMPOSITION

Teresa Bellón Heredia.
Investigadora Senior (Contrato Miguel Servet -I2). Jefe de laboratorio. Hospital Universitario La Paz

- **María del Rosario Cabañas Moreno.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Sofía Caiqin Linares Reyes.** *Investigadora Predoctoral. FIBHULP*
- **Guillermo Servera Negre.** *Facultativo Especialista en Dermatología Médico-Quirúrgica y Venereología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Cutaneous drug hypersensitivity reactions are unpredictable and encompass a wide range of diseases with varying degrees of severity. The spectrum ranges from mild reactions to life-threatening multisystemic illnesses. The most important severe cutaneous drug hypersensitivity reactions include acute generalized exanthematous pustulosis (AGEP), drug-induced hypersensitivity syndrome with eosinophilia (DRESS), also known as drug-induced hypersensitivity syndrome or simply hypersensitivity syndrome (DiHS/HSS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). The most severe diseases are SJS and TEN, now considered severe variants of the same clinical entity, characterized by keratinocyte necrosis and subsequent epidermal detachment with the formation of subepidermal blisters. From an immunopathogenic standpoint, these reactions fall under the category of type IV hypersensitivity reactions, mediated by T lymphocytes. However, T cell activation can give rise to different types of immune responses, and this functional heterogeneity has led to a subclassification of type IV hypersensitivity reactions into four subtypes (IVa-IVd) based on the predominant cytokine production pattern in each case and the involvement of other effector cell subpopulations that contribute to inflammation and tissue damage. Currently, an active role of cytotoxic lymphocytes is postulated in several of these clinical entities.
- Our project aims to better understand the immune mechanisms involved in the etiopathogenesis of these diseases. The study is being carried out within the framework of the PIELenRed consortium (Interdisciplinary Platform for the Study of Severe Skin Lesions), comprised of researchers from various hospitals in the Community of Madrid.
- Reactivation of latent herpesviruses has been described during the course of some of the aforementioned clinical entities. To improve our understanding of immune system behavior during viral replication, we have established a collaboration with the renal transplant unit of the Nephrology Department at La Paz University Hospital. Samples from renal transplant recipients are evaluated immediately before transplantation, and patients are subsequently monitored to identify those with active cytomegalovirus (CMV/HHV-5) replication.

PIELenRed



- General objectives for the next 5 years
- The group's objectives are:
  1. Creation and maintenance of a Biobank of biological samples from patients with severe cutaneous hypersensitivity reactions to medicines (DRESS, AGEP and SJS/TEN) associated with the PIELenRed epidemiological registry, and integrated into the international RegiSCAR registry.
  2. Research into the development of new "in vitro" tests for the study and diagnosis of drug causality.
  3. To explore the involvement of the innate immune response (particularly cytotoxic cell activity) during the development of severe cutaneous hypersensitivity reactions to drugs.
  4. Search for susceptibility biomarkers.
  5. Search for biomarkers of disease and early response to treatments.
  6. To explore the potential of microRNAs as disease biomarkers in SJS/TEN as well as their relationship with the etiopathogenesis of the reaction.
  7. Analyze the evolution of the cytotoxic response in patients with CMV replication.
  8. To compare the innate immune response in patients with CMV replication after kidney transplantation and in patients with severe cutaneous hypersensitivity reactions to medications.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH LINES

- Maintenance of a Biobank of biological samples from patients with severe cutaneous hypersensitivity reactions to medications.
- Development and evaluation of "in vitro" tests for determining causality
- Identification of susceptibility markers.
- Involvement of NK receptors in the etiopathogenesis of Stevens-Johnson syndrome/toxic epidermal necrolysis (SSJ/TEN).
- Differential study of the cytokine pattern involved in the different severe cutaneous drug hypersensitivity reactions (PEAG, DRESS, SSJ/TEN).
- Study of miRNAs as potential biomarkers of disease and response to treatments.

RESEARCH ACTIVITY

Publications


- **Moreno JA, Cabañas R, Bellón T, Fernández EG, Raso IV, Aldana S, Maldonado M, León-Machado L, Shabaka A, Becerra BR, Cabrera CV, Juárez GF.** Lymphocyte transformation test: A promising tool for identifying the causative agent in drug-induced acute interstitial nephritis. Kidney Int Rep. 2025; 10(5): 1562-5. Editorial Material. IF: 6.2; Q1
- **Rodríguez-Pérez R, Pulido E, Bellón T, Rodríguez-Álvarez M, Gómez-Traseira C, López-Matas MA, Domínguez-Ortega J, Carnés J, Pedrosa M.** FcεRI-bound OVM-sIgE detection: A promising predictor of boiled egg white OFC outcomes. Pediat Allerg Imm-Uk. 2025; 36(7): e70149. Letter. IF: 4.5; Q2

Research projects

- **Bellón Heredia T.** Creación de un centro de referencia para el estudio de los mecanismos implicados en las reacciones de hipersensibilidad a las membranas de hemodiálisis basadas en polysulfona (PI-3009). FIBHULP. 2017-ongoing. Managment centre: FIBHULP
- **Bellón Heredia T.** ELISpot como método diagnóstico para identificación del fármaco causal en pacientes con reacciones graves de hipersensibilidad cutánea a medicamentos: comparación con TTL (Beca Luis Álvarez). FIBHULP. 2020-2026. Managment centre: FIBHULP
- **Bellón Heredia T.** Estudio de la inmunomodulación celular inducida en las desensibilizaciones a quimioterápicos tras reacciones alérgicas inmediatas mediadas por IGE y tardías mediadas por linfocitos T específicos (PI24/01046). ISCIII. 2025-2027. Managment centre: FIBHULP

Patents and trademarks

- **Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees.** Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.
- **Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees.** Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.3.8 Immunomediate Gastrointestinal Diseases and Other Digestive Pathologies

Publications: 23 | Q1: 14

COMPOSITION

María Dolores Martín Arranz.
Jefa de Sección de Aparato Digestivo (Jefa de Servicio en funciones). Hospital Universitario La Paz. Profesora Asociada. Unidad Autónoma de Madrid


- **Clara Amiama Roig.** *Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz*
- **Laura García Ramírez.** *Investigadora Predoctoral. FIBHULP*
- **Eduardo Martin Arranz.** *Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz*
- **Jesús Noci Belda.** *Enfermero. Hospital Universitario La Paz*
- **Joaquín Poza Cordón.** *Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz*
- **José Luis Rueda García.** *Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz*
- **María Sánchez Azofra.** *Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz*
- **Cristina Julia Suárez Ferrer.** *Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz*
- **Tamara Verges Martínez-Meco.** *Investigadora Predoctoral. FIBHULP*

STRATEGIC OBJETIVES

- Our work focuses on diseases of the Digestive System with special dedication to Inflammatory Bowel Disease (IBD) and other immune-mediated diseases.
- The group is formed by gastroenterologists, biologists, pharmacists and nurses; all of them are part of a multidisciplinary working group.
- In addition to promoting our own research projects in our area, we participate in numerous clinical trials of molecules in development.
- Our objectives are to optimize existing treatments, promote measures to improve the quality of life and translational research in search of precision medicine, incorporating new technologies to the management of our patients.

RESEARCH LINES

- Correlation of drug levels with therapeutic response
- Intestinal ultrasound
- Dysplasia detection techniques in IBD
- Hypercoagulability studies in IBD
- Immunological basis of inflammatory bowel disease: changes in cellular and inflammatory mediator expression with different therapies.



RESEARCH ACTIVITY

Publications

- **Alcolea NG, Arranz MDM, Vera BM, Gallego MA, Sebastián JD, Miguelañez IP.** Multidisciplinary management of perianal fistula in Crohn's disease: Protocol implementation and its clinical and quality of life outcomes. Cir Espan. 2025; 103(11): 800230. Article. IF: 1.5; Q3
- **Argüelles-Arias F, Cordón JP, Arranz MDM, Téllez L, Iglesias J, Iborra M, Gómez J, Orive A, Rodríguez RG.** SEPD-AEED Position Statement - Integration of digestive ultrasound in gastroenterology services as a clinical, educational and organizational necessity. Rev Esp Enferm Dig. 2025; 117(10): 554-6. Editorial Material. IF: 4.8; Q1
- **Casanova MJ, de Célix CR, Riestra S, Lucendo AJ, Benítez JM, Navarro-Llavat M, Barrio J, Morales-Alvarado VJ, Rivero M, Busquets D, Leo-Carnerero E, Nantes-Castillejo O, Navarro P, Van Domselaar M, Gutiérrez-Casbas A, Alonso-Abreu I, Acosta MBD, Fernández-Salazar L, Iborra M, Martín-Arranz MD, Garcia-Morales**

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

N, Guardiola J, Bouhmidi-Assakali A, Esteve M, Muñoz-Villafranca C, Rodríguez-Lago I, Ceballos D, Guerra I, Mañosa M, Marín-Jiménez I, Vera-Mendoza I, Garre A, Chaparro M, Gisbert JP. Long-term outcomes following withdrawal of anti-tumour necrosis factor treatment in inflammatory bowel disease patients in remission: the exit long-term study of GETECCU. Aliment Pharm Ther. 2025; 62(1): 59-71. Article. IF: 6.8; Q1

- **Costa CA, Ferrer CS, Ramírez LG, Martín-Arranz E, Cordón JP, García JLR, Azofra MS, Diaz IG, Roig CA, Martín-Arranz MD.** Evaluation of the transition from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease. Gastroent Hepat-Barc. 2025; 48(3): 502201. Article. IF: 2.0; Q3
- **Costa CA, Vázquez JF, Martín-Arranz MD.** Diffuse large B-cell lymphoma and gastrointestinal Kaposi's sarcoma: a rare cause of upper gastrointestinal bleeding. Rev Esp Enferm Dig. 2025; 117(6): 338-9. Editorial Material. IF: 4.8; Q1
- **Cuadros M, Abadía M, Castillo P, Martín-Arranz MD, Gonzalo N, Romero M, García-Sánchez A, García-Samaniego J, Olveira A, Ruiz-Cantador J, González-Fernández O, Ponz I, Merás P, Merino C, Rodríguez-Chaverri A, Balbacid E, Froilán C.** Role of transient elastography in the diagnosis and prognosis of Fontan-associated liver disease. World J Gastroentero. 2025; 31(11): 103178. Article. IF: 7.7; Q1
- **Domenech E, Fortuny J, Martínez D, Tormos A, Huang ZP, Hill DD, Weinstein C, Esslinger S, Krumme AA, Otero-Lobato M, Mines D, Gisbert JP.** Colectomy and neoplasia outcomes of patients with ulcerative colitis receiving golimumab: a post-authorisation safety study using the spanish ENEIDA registry. Pharmacoepidem Dr S. 2025; 34(8): e70176. Article. IF: 2.6; Q2
- **Fuentes-Valenzuela E, Bastón-Rey I, García-Alonso FJ, Elosua A, San Martín LZ, Carnerero EL, de la Filia IG, Pérez AP, Chumillas RMS, Oliver AP, Villafranca CM, Moreno V, Ferrer CS, Molina G, Ferreiro-Iglesias R, Villaamil PV, Mateos DG, Segarra-Ortega JX, Marín AG, Doallo A, Alonso-Galán H, Brunet-Mas E, García NJ, Romero-Salazar FL, Velayos B, Carballo-Folgoso L, Santamaría CP, Román LM, Ortiz AN, Barrio J, Barreiro-de Acosta MD, Gutiérrez-Casbas A.** Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study of GETECCU. J Crohns Colitis. 2025; 19(5): jjaf058. Article. IF: 10.3; D1
- **García JLR, Benitez JM, Rey IB, Sard MC, Ferrer CS.** Thromboembolic phenomena in inflammatory bowel disease and risk with JAK inhibitor treatments. Gastroent Hepat-Barc. 2025; 48(1): 502257. Editorial Material. IF: 2.0; Q3
- **García JLR, Löwenberg M.** Towards tailored surveillance strategies in inflammatory bowel disease: still a long way to go. J Crohns Colitis. 2025; 19(12): jjaf217. Editorial Material. IF: 10.3; D1
- **García JLR, Suárez-Ferrer C, Roig CA, Ramírez LG, Rojas CG, Martín-Arranz E, Cordón JP, Azofra MS, Noci J, Garcia CC, Martín-Arranz MD.** Association of early therapeutic drug monitoring of adalimumab with biologic remission and drug survival in Crohn's Disease. Ther Adv Gastroenterol. 2025; 18: 17562848251324200. Article. IF: 3.8; Q2
- **García MJ, Brenes Y, Vicuña M, Bermejo F, Sierra-Ausín M, Vicente R, Arroyo MT, Montiel PM, Villoria A, Ferrer JA, Hernandez V, Piñero A, Carrillo-Palau M, Martín-Arranz MD, Miranda-Bautista J, Pajares R, Hernández LA, Bejarano A, Guardiola J, Iyo E, Muñoz-Villafranca C, Talavera A, Alonso-Galan H, Acosta MBD, Bosca-Watts M, Rey TV, Echarri A, Rodriguez-Grau MD, Gutiérrez A, Huguet JM, López-Martín MC, Mesonero F, Pérez-Martínez I, Plaza R, de la Piscina PR, Gisbert JP, Chaparro M.** Persistence, Effectiveness, andsafety of upadacitinib in crohn's disease and ulcerative colitis in real life: results from a spanish nationwide study (Ureal Study). Am J Gastroenterol. 2025; 120(7): 1593-604. Article. IF: 8.5; Q1
- **Giordano A, Pérez-Martínez I, Gisbert JP, Ricart E, Martín-Arranz MD, Mesonero F, Parga MLD, Rivero M, Iglesias E, Fernández-Prada S, Calafat M, Villarino MTA, Turrión MAD, Hernández-Camba A, Lidón RV, Carpio D, Brunet E, Moranta FR, García LA, Cuquerella JT, Bermejo F, Madero L, Esteve M, González-Muñoza C, Martínez-Montiel P, Huguet JM, Calle JLP, Rodríguez-Lago I, Ausín MS, Poyatos RHL, García-Bosch O, Marín GS, Taxonera C, Ponferrada-Diaz A, Barreiro-de Acosta M, Bujanda L, Serra RB, Ramos L, Vera I, Abizanda ES, Piqueras M, Gómez CS, García-Sepulcre MF, Arregui MV, Murillo NR, Llaó J, Lucendo AJ, Marín-Jiménez I, Camps-Aler B, Villafranca CM, Ceballos D, Ver Y, Fernández-Salazar LI, Alcaín G, Valldosera G, Andrés PR, Martínez-Flores C, Coronel AF, Ginard D, García L, Gomez IB, Argueelles-Arias F, Miyashiro EI, de la Piscina PR, Villalba LH, Notari PA, Martínez-Pérez TD, Fernández H, Gilabert P, Rosas CM, Nos P, Gil JL, López VMN, Muñoz F, Palomares MTDL, Lucio AS, Merino O, de Prado IN, Leal C, de Carpi JM, Sánchez LB, Arce NM, Frago S, Mateu BB, Domènech E, Planella EG, ENEIDA Project GETECCU.** Ileal predominance in Crohn's disease is associated with increased intestinal surgery and biological therapy use, with lower treatment persistence. Am J Gastroenterol. 2025; 120(1): 194-203. Article. IF: 8.5; Q1
- **Guijarro LG, de Castro-Martínez P, Chaparro M, Acero-Sanz J, de Leon D, Guerra I, Iborra M, Cabriada JL, Bujanda L, Alba C, García-Sánchez V, Marín-Jiménez I, Acosta MBD, Vera I, Martín-Arranz MD, Mesonero F, Sempere L, Gomollon F, Hinojosa J, Hernández-Breijo B, Alvarez-Mon M, Gisbert JP, Ortega MA.** Comparative efficacy and immunogenicity of infliximab and adalimumab in crohn's disease: a prospective cohort study. Med Lith. 2025; 61(12): 2165. Article. IF: 2.9; Q1
- **Llao J, Mañosa M, Martín-Arranz E, Zabana Y, Navarro-Llavat M, Téller M, García-Planella E, Busquets D, Monfort D, Pineda JR, Gutiérrez A, Villoria A, Menchén L, Bastida G, García-**



1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Alonso EJ, Rivero M, Chaparro M, de Francisco R, Merino O, Rodríguez-Lago I, Acosta MBD, Rodríguez-Fortúnez P, Rodríguez-Jiménez C, Calafat M, Domènech E. Addition of pulse corticosteroids to oral prednisone in moderately active ulcerative colitis: a randomized, multicentre, open-label study by GETECCU. J Crohns Colitis. 2025; 19(11): jjaf182. Article. IF: 10.3; D1

- **Mañosa M, Calafat M, Francia E, Riba F, Mesonero F, Suárez C, García-López S, Losfablos F, Calvet X, Domènech E, Casbas AG, Ordás I, Menchén L, Rodríguez-Moranta F, Zabana Y.** GETECCU position paper on fragility, advanced age and inflammatory bowel disease. Gastroent Hepat-Barc. 2025; 48(10): 502529. Article. IF: 2.0; Q3
- **Marín-Serrano E, de Villar NGP, Manuel MPJ, Fernández-Martos R, Cano AB, Martín-Arranz MD.** Pancreatic fat infiltration: a key marker in the metabolic continuum. Pancreas. 2025; 54(9): e757-64. Article. IF: 2.2; Q3
- **Marín-Serrano E, Fuentes AK, Fernández-Martos R, Prieto JM, Llorente AV, Cano AB, Hernández PLM, Martín-Arranz MD.** Treatment of severe hypertriglyceridemia through therapeutic plasma exchange in patients with acute pancreatitis or at risk of developing it. Gastroent Hepat-Barc. 2025; 48(1): 502229. Article. IF: 2.0; Q3
- **Mesonero F, Alicia LG, José MB, Cristina RD, Ignacio MJ, Cristina SF, Albert MC, Esteban FV, Alejando M, Andrés C, Cristina R, Agnès FC, Jerusalén GPC, Begoña AH, José GM, Xavier SOJ, Carmen RGM, Francisco LRS, Ignacio O, Daniel MR, María GV, Angel PD, Iria BR, María BJ, Cristina R, Alejandro LGE, Genaro DGP, Leyanira T, Alejandro HC, Lorena B, Gisela P, Eduard B, Martín I, Miquel MC, Yamile Z, Ana G.** Therapeutic management and risk of colectomy in patients with acute severe ulcerative colitis and previous exposure to anti-tumor necrosis factor drugs: a comparative study of GETECCU. J Crohns Colitis. 2025; 19(12): jjaf183. Article. IF: 10.3; D1
- **Mesonero F, Zabana Y, Fernández-Clotet A, Solá A, Caballol B, Leo-Carnerero E, García MJ, Bertoletti F, Bastida G, Suris G, Casis B, Ferreiro-Iglesias R, Calafat M, Jiménez I, Miranda-Bautista J, Lamuela LJ, Fajardo I, Torrealba L, Nájera R, Sáiz-Chumillas RM, González-Partida I, Vicuña M, García-Morales N, Gutiérrez A, López-García A, Benítez JM, de Célix CR, Tejido C, Brunet E, Hernández-Camba A, Suárez C, Rodríguez-Lago I, Piqueras M, Castaño A, Ramos L, Sobrino A, Rodríguez-Grau MC, Elosua A, Montoro M, Baltar R, Huguet JM, Hermida B, Caballero-Mateos A, Sánchez-Guillén L, Bouhmidi A, Pajares R, Baston-Rey I, López-Sanromán A, Albillos A, Barreiro-de Acosta M.** Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU. Digest Liver Dis. 2025; 57(2): 66-573. Article. IF: 4.9; Q1
- **Peris MA, Francisco JD, Mateu PN, Piudo AE, Moya MC, Gros B, Martín-Arranz MD, Boquet EM, Agustín SI, Martínez AV, Correcher M, Barreiro-de Acosta M, Ciria MM, Rodriguez-Moranta F, Zabana Y, Casbas AG.** Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of telemedicine in inflammatory bowel disease. Gastroent Hepat-Barc. 2025; 48(6): 502320. Article. IF: 2.0; Q3
- **Ripolles T, Poza J, Martínez-Pérez MJ, Suárez Ferrer C, Blanc E, Paredes JM.** Evaluation of Crohn's disease activity: validation of a segmental simple ultrasound score in a multicenter study. Inflamm Bowel Dis. 2025; 31(8): 2081-7. Article. IF: 5.5; Q1
- **Tejedor-Tejada J, Martínez-Domínguez SJ, Hernández L, Cano-Català A, Parra P, Moreira L, Nyssen OP, Gisbert JP.** Management of helicobacter pylori infection in spain beyond the data collected in the european registry on h. pylori management (Hp-EuReg): Results of a nationwide survey. Helicobacter. 2025; 30(2): e70028. Article. IF: 4.6; Q1

Research projects

- **Martín Arranz MD.** Dinámica de las células dendríticas y células t en enfermedad inflamatoria intestinal. Medicina personalizada con terapias biológicas basadas en la vía de señalización de la interleucina 12-23 (PI24/01435). ISCIII. 2025-2027. Managment centre: FIBHULP

Clinical trials

- **Martín Arranz E.** Validación de biomarcadores multiómicos predictores de respuesta terapéutica en pacientes con enfermedad inflamatoria intestinal: un paso hacia la medicina personalizada.
  Type/Phase: EOm prospectivo
  Sponsored by: Fundacion Para La Investigacion Biomedica Hospital Universitario La Paz.
  Signature date: 20/03/2025
- **Martín Arranz MD.** A double-blind, placebo-controlled phase iia study to evaluate the efficacy and safety of azd7798 in patients with moderate to severe crohn's disease (amalthea).
  Type/Phase: IIa
  Sponsored by: Astrazeneca Ab.
  Signature date: 04/02/2025
- **Martín Arranz MD.** A phase 2, multicenter, randomized, double-blind, placebo controlled, dose-ranging study to evaluate the efficacy and safety of brivekimig in adults with moderate to severe crohn's disease.
  Type/Phase: II
  Sponsored by: Sa Sanofi-Aventis Recherche Et Developp.
  Signature date: 08/09/2025
- **Martín Arranz MD.** A phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of sar441566 in adults with moderate to severe crohn's disease.
  Type/Phase: II
  Sponsored by: Sa Sanofi-Aventis Recherche Et Developp.
  Signature date: 06/08/2025
- **Martín Arranz MD.** A phase 2b multi-national, multi-center, randomized, double-blind, placebo-controlled, dose-ranging study followed by a long term extension to evaluate the efficacy and safety of sar442970 in adult participants with moderate to severe ulcerative colitis.
  Type/Phase: IIb
  Sponsored by: Sa Sanofi-Aventis Recherche Et Developp.
  Signature date: 11/09/2025
- **Martín Arranz MD.** Estudio aleatorizado multicéntrico para evaluar la seguridad y la eficacia del lutikizumab como tratamiento de inducción y mantenimiento en sujetos con colitis ulcerosa activa de moderada a grave.
  Type/Phase: IIa
  Sponsored by: Abbvie Deutschland GMBH & Co. Kg.
  Signature date: 17/06/2025
- **Martín Arranz MD.** Estudio de fase 2, adaptativo y de búsqueda de la dosis de eltrekibart administrado en monoterapia o en combinación con mirikizumab para el tratamiento de pacientes adultos con colitis ulcerosa activa de moderada a grave.
  Type/Phase: II
  Sponsored by: Eli Lilly Co Uk Ltd.
  Signature date: 26/02/2025
- **Martín Arranz MD.** Estudio de fase 2b, aleatorizado, en doble ciego, controlado con principio activo y con placebo, de grupos paralelos y multicéntrico, para evaluar la eficacia y la seguridad de la combinación de guselkumab y golimumab como tratamiento de inducción y de mantenimiento en participantes con colitis ulcerosa activa de grado moderado o severo.
  Type/Phase: IIb
  Sponsored by: Janssen Research & Development, Llc.
  Signature date: 18/12/2025
- **Martín Arranz MD.** Estudio de fase 3b, aleatorizado, multicéntrico y comparativo entre mirikizumab y placebo o mirikizumab y tirzepatida en participantes adultos con colitis ulcerosa activa de moderada a grave y obesidad o sobrepeso.
  Type/Phase: IIIb
  Sponsored by: Lilly, S.A.
  Signature date: 22/08/2025
- **Martín Arranz MD.** Estudio de fase 3b, aleatorizado, multicéntrico y comparativo entre mirikizumab y placebo o mirikizumab y tirzepatida en participantes adultos con enfermedad de crohn activa de moderada a grave y obesidad o sobrepeso.
  Type/Phase: IIIb

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians




Sponsored by: Lilly, S.A.
Signature date: 10/09/2025

- **Martín Arranz MD.** Estudio de fase iii aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de abx464 administrado una vez al día como tratamiento de inducción en sujetos con colitis ulcerosa activa moderada o grave – abtec.
  Type/Phase: III
  Sponsored by: Abivax.
  Signature date: 27/03/2025
- **Martín Arranz MD.** Estudio de fase iii, multicéntrico, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad del tratamiento continuo de inducción y mantenimiento con ro7790121 en pacientes con colitis ulcerosa activa de moderada a grave.
  Type/Phase: III
  Sponsored by: F.Hoffmann-La Roche Ltd.
  Signature date: 07/07/2025
- **Martín Arranz MD.** Estudio de prolongación de fase 3, multicéntrico, sin enmascaramiento, para evaluar la eficacia y la seguridad a largo plazo de mirikizumab en pacientes con colitis ulcerosa activa de moderada a grave.
  Type/Phase: III
  Sponsored by: Lilly, S.A.
  Signature date: 03/12/2025
- **Martín Arranz MD.** Estudio en fase iiib, aleatorizado, con enmascaramiento doble para evaluar la eficacia y la seguridad a corto y a largo plazo del tratamiento dirigido doble con vedolizumab intravenoso y upadacitinib oral en comparación con vedolizumab intravenoso y placebo oral para la inducción, seguido de monoterapia con vedolizumab intravenoso para el tratamiento de mantenimiento de adultos con enfermedad de crohn activa de moderada a grave.
  Type/Phase: IIIb
  Sponsored by: Takeda Development Center Americas.
  Signature date: 15/12/2025
- **Martín Arranz MD.** Estudio multicéntrico aleatorizado, doble ciego y controlado con placebo, con tratamiento de mantenimiento durante 52 semanas y una extensión abierta para evaluar la eficacia y la seguridad de risankizumab en sujetos con enfermedad de crohn.
  Type/Phase: III
  Sponsored by: Abbvie Deutschland GMBH.
  Signature date: 04/02/2025
- **Martín Arranz MD.** Programa de fase 3, aleatorizado, con doble enmascaramiento y comparativo con placebo para evaluar la eficacia y la seguridad de tulisokibart en participantes con enfermedad de crohn activa moderada o grave.
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 04/07/2025
- **Martín Arranz MD.** Programa de fase 3, aleatorizado, con doble enmascaramiento y comparativo con placebo para evaluar la eficacia y la seguridad de tulisokibart en participantes con enfermedad de crohn activa moderada o grave.
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 08/08/2025
- **Martín Arranz MD.** Programa de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de mk-7240 en participantes con colitis ulcerosa activa moderada o grave.
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 23/01/2025
- **Martín Arranz MD.** Programa de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de mk-7240 en participantes con colitis ulcerosa activa moderada o grave.
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 30/05/2025
- **Martín Arranz MD.** Study on the management of patients with ulcerative colitis with biological drugs or small molecules.
  Type/Phase: EPA-SP
  Sponsored by: Mistranscripciones Msdv Services B.V.
  Signature date: 09/10/2025

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.3.9 MicroRNA Regulation of Immune Tolerance, Autoimmunity and Cancer

Publications: 1 | Q1: 1



COMPOSITION

Alicia González Martín.
Investigadora Ramón y Cajal. Universidad Autónoma de Madrid

- **Rocío Bartolomé Cabrero.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **María del Pilar González Molina.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Laura Gámez Reche.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Laura Mañas Cordero.** *Técnico de Investigación. Universidad Autónoma de Madrid*
- **Eleftheria Papaioannou.** *Investigadora Juan de la Cierva. Universidad Autónoma de Madrid*
- **Ana María Prieto Muñoz.** *Técnico de Investigación. Universidad Autónoma de Madrid*
- **Javier Sanz Gallardo.** *Investigador Predoctoral. Universidad Autónoma de Madrid*

STRATEGIC OBJETIVES

- Our laboratory is interested in understanding the cellular and molecular mechanisms of immune tolerance, autoimmunity, and cancer. Specifically, we focus on studying how microRNAs (miRNAs) and their target genes regulate immune tolerance, autoimmune diseases, and antitumor immunity. In addition, we are actively developing innovative genomic engineering strategies for therapeutic purposes.
- MicroRNAs have recently emerged as important factors in the post-transcriptional control of protein concentrations in metazoan organisms. In recent years, we have studied the functions of miRNAs in the mammalian immune system. We identified the first miRNA that regulates B cell tolerance and established its causal role in the development of lethal autoimmunity (González-Martin et al., Nature Immunology, 2016 Apr; 17: 433–40). We also discovered critical roles for other microRNAs in different mechanisms of immune tolerance and autoimmune diseases (González-Martin and Lai et al., Nature Communications, 2016 Aug 2; 7:12207; Ichiyama et al., Immunity, 2016 Jun 21; 44:1284–98; and Liu et al., Journal of Experimental Medicine, Aug 22; 213:1901–19). Furthermore, we developed the first B-cell receptor reprogramming strategy using the latest genome editing technologies (Elife, 2019 Jan 17; 8). Previous work on tumor immunology established an important role for the chemokine receptor CCR5 in T-cell antitumor responses (Gonzalez-Martin et al, Cancer Research, 2011 Aug 15; 71:5455-66). Overall, our studies have established that microRNAs are critical regulators of immune tolerance and autoimmunity, and have revealed novel mechanisms that control antitumor immunity.
- Current research in the laboratory continues to identify and study the functions of microRNAs (miRNAs) and their target genes in immune tolerance, autoimmunity, and tumor immunology by combining genetic, genomic, biochemical, and functional screening approaches to understand the molecular functions and mechanisms of miRNA control at the molecular, cellular, and system levels. The identified mechanisms could provide valuable biomarkers or therapeutic targets for the treatment of autoimmune diseases and for cancer immunotherapy.

RESEARCH LINES

- Identification of miRNAs and target genes that regulate B lymphocyte tolerance and study of their potential role in the development and progression of autoimmune diseases, with the aim of identifying new therapeutic targets for the treatment of these diseases.
- Identification of new therapeutic targets to improve the effectiveness of cancer immunotherapy.
- B-cell genome engineering for the development of cell-based vaccines.

RESEARCH ACTIVITY

Master Theses

- **Tapia Narváez JC.** The role of microRNAs in the regulation of immune tolerance and autoimmunity[dissertation]. Madrid: UAM: 2025(26/06/2025). Director: González Martín A.

Final Degree Theses

- **Calderón Sacristán R.** Caracterización funcional de miRNAs y sus genes diana en inmunidad antitumoral[dissertation]. Madrid: UAM: 2025(26/06/2025). Director: González Martín A.

Publications

- **Mastrangelo A, Robles-Vera I, Mañanes D, Galán M, Femenía-Muiña M, Redondo-Urzainqui A, Barrero-Rodríguez R, Papaioannou E, Amores-Iniesta J, Devesa A, Lobo-González M, Carreras A, Beck KR, Ivarsson S, Gummesson A, Georgiopoulos G, Rodrigo-Tapias M, Martínez-Cano S, Fernández-López I, Nuñez V, Ferrarini A, Inohara N, Stamatelopoulos K, Benguría A, Cibrian D, Sánchez-Madrid F, Alonso-Herranz V, Dopazo A, Barbas C, Vázquez J, López JA, González-Martín A, Nuñez G, Stellos K, Bergström G, Bäckhed F, Fuster V, Ibañez B, Sancho D.** Imidazole propionate is a driver and therapeutic target in atherosclerosis. Nature. 2025; 645(8079): 254-61. Article. IF: 56.1; D1

Research projects

- **González Martín A.** Systematic analysis of tumor-specific B cell immunity (CNS2022-136069). Agencia Estatal de Investigación. 2023-2025. Managment centre: UAM
- **González Martín A.** Harnessing microRNAs for improved lung cancer immunotherapies. Fundación Ramón Areces. 2023-2026. Managment centre: UAM
- **González Martín A.** MicroRNA regulatory networks in B cell tolerance and autoimmunity (PID2021-128244OB-I00). Agencia Estatal de Investigación. 2022-2026. Managment centre: UAM
- **González Martín A.** Harnessing microRNAs for improved lung cancer immunotherapies. Fundación FERO. 2023-2026. Managment centre: UAM
- **González Martín A.** B cell engineering in murine and human primary B cells (OPP11839562019). Bill and Melinda Gates Foundation. 2019-2025. Managment centre: UAM

Patents and trademarks

- **Gonzalez-Martin A, González-Molina MdP, inventors; UAM, assignee.** MicroRNAs for use in the stimulation of T-cell anti- tumor response. PCT/EP2024/064900; EP24728247. 2024 May 30
- **Voss J, Huang D, Gonzalez-Martin A, Andrabi R, Burton D, inventors; The Srcipps Research Institute, assignees.** B Cell receptor modification in B cells. WO2019028417A1-PCT/US/45255. 2018 August 3.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians


3.3.10 Systemic Immune-Mediated Diseases

Publications: 7 | Q1: 2

COMPOSITION

Juan José Ríos Blanco.
Coordinador Unidad EAS / FEA Medicina Interna. Hospital Universitario La Paz / IdiPAZ

- **Sergio Carrasco Molina.** *FEA Medicina Interna. Hospital Universitario La Paz / FIBHULP*
- **Belén del Pilar Gutiérrez Sancerni.** *FEA Medicina Interna. Hospital Universitario La Paz*
- **Ana María Noblejas Mozo.** *FEA Medicina Interna. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

1. Establishment and consolidation of the group
- To create an efficient organizational structure for clinical research in systemic immune-mediated diseases
- Develop standardized protocols for clinical data collection
- Implement a unified database of patients with immune-mediated diseases

2. Development of clinical research excellence
- Design and conduct clinical trials in systemic immune-mediated diseases
- Establish collaborations with other national and international research groups
- Create prospective patient registries for observational studies

3. Implementation of translational research
- Establish a specific biobank for samples from patients with immune-mediated diseases
- Develop projects that connect clinical findings with basic research
- Identify biomarkers with potential clinical application

4. Development of innovative cell therapies
- Establish a cell therapy unit for immune-mediated diseases
- Develop personalized cell therapy protocols
- Implement clinical trials with advanced cell therapies

5. Training and education
- To train new researchers in the field of immune-mediated diseases
- Establish specific doctoral and master's programs
- Organize specialized seminars and workshops

RESEARCH LINES

1. Clinical and epidemiological characterization of systemic immune-mediated diseases
- Studies of natural history and prognostic factors
- Registration and monitoring of rare clinical manifestations
- Analysis of comorbidities and their therapeutic implications

2. Therapeutic optimization in immune-mediated diseases
- Studies of the effectiveness and safety of conventional and biological therapies
- Development of customized treatment algorithms
- Monitoring of adverse events and complications

3. Cell therapy in immune-mediated diseases
- Development of mesenchymal stem cell protocols
- CAR-T cell research for autoimmune diseases
- Studies of immune modulation using cell therapy

4. Biomarkers and personalized medicine
- Identification of prognostic and predictive biomarkers
- Development of specific activity and damage scores
- Implementation of precision medicine in clinical practice

5. Pathogenic mechanisms and new therapeutic targets
- Study of altered immunological pathways
- Identification of new therapeutic targets
- Clinical validation of basic findings

6. Research on patient-reported outcomes (PROs)
- Development and validation of specific questionnaires
- Quality of life and satisfaction studies
- Implementation of PROs in routine clinical practice

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

RESEARCH ACTIVITY

Doctoral Theses

- **Álvarez Troncoso J.** Prevalencia y factores de riesgo de cardiopatía e hipertensión pulmonar en pacientes con lupus eritematoso sistémico[dissertation]. Madrid: UAM: 2025(10/03/2025). Director: Ríos Blanco JJ.

Publications

- **Carrasco-Molina S, Robles-Marhuenda A, Ríos-Blanco JJ, Tung-Chen Y.** Counter-reply: comment to the special article [Utility of point-of-care ultrasound (POCUS) in hospitalized patients with acute confusional syndrome of unclear etiology. Rev Clin Esp. 2025; 225(7)]: 502337. Letter. IF: 1.7; Q2
- **Carrasco-Molina S, Robles-Marhuenda A, Ríos-Blanco JJ, Tung-Chen Y.** Utility of point-of-care ultrasound (POCUS) in hospitalized patients with acute confusional syndrome of unclear etiology. Rev Clin Esp. 2025; 225(4): 231-9. Article. IF: 1.7; Q2
- **Fuentes OP, Ballester LL, Troncoso JA, Abánades CIS, Mozo AN, Marhuenda AR, Blanco JJR, Sancerni BG, Rodríguez IE, Mora ET, Robles EM.** Inflammatory cerebral pseudotumour as a rare manifestation of neuro-Behçet's disease: A case report and literature review. J Neuroimmunol. 2025; 405: 578652. Review. IF: 3.1; Q3
- **Fuentes OP, Cepeda JG, Cabrera CV, de Bustamante JMM, Marhuenda AR, Troncoso JA, Robles EM, Mozo JAN, Blanco JJR, Fernández EG, Abánades CIS.** Renal involvement in primary Sjogren's syndrome: Beyond tubulointerstitial nephritis. Nefrologia. 2025; 45(7): 501341. Letter. IF: 2.1; Q3
- **Morales E, Rua-Figueroa I, Callejas Rubio JL, Ávila Bernabeu A, Blanco Alonso R, Cid Xutgla MC, Fernández Juárez G, Mena-Vázquez N, Ríos Blanco JJ, Manrique Escola J, Narváez García FJ, Sopena B, Quintana Porras LF, Romero-Yuste S, Solans Laque R.** Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis. Nefrologia (Engl Ed). 2025; 45(1): 15-58. Review. Not Indexed
- **Morejón L, Quirce S, Domínguez-Ortega J, Romero D, Nobleja A, Ríos-Blanco J, De Las Vecillas L.** Mepolizumab as an effective alternative to immunosuppressive and teratogenic therapies for the early treatment of EGPA: A case report. J Invest Allerg Clin. 2025; 35(5): 389-91. Editorial Material. IF: 6.6; Q1
- **París-Muñoz A, Alcobendas-Rueda RM, Verdú-Sánchez C, Udaondo C, Galán-Gómez V, González-Martínez B, Menéndez JJ, Martínez-Romera I, Minguillón J, Pertínez L, de Manuel-Gómez C, de la Cruz-benito A, Sanz-Rupérez A, Remesal A, Cámara C, Sánchez-Zapardiel E, del Pino-Molina L, Gómez-Zamora A, Serrano-Olmedo MG, Espanol-Rego M, Valbuena MRD, Climent F, Dorao P, Ríos-Blanco JJ, Andrade JD, Ruiz-Zurita G, Fernández-García MA, Pérez-Martínez A.** CD19 CAR-T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease. Med. 2025; 6(8): 100676. Article. IF: 13.3; D1

Clinical trials

- **Ríos Blanco JJ.** A phase 1 open-label trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of subcutaneous vis171 in participants with autoimmune disease(s).
  Type/Phase: I
  Sponsored by: Visterra Inc.
  Signature date: 18/06/2025

3.4. Large System Pathologies Area

Documents: 273 | Originals: 212 | D1: 53 | Q1: 156

Area coordinator: Francisco García Río

RESEARCH GROUPS

3.4.1 Internal Medicine and Systemic Diseases
María Angustias Quesadas Simón

3.4.2 Organic Dysfunction and Failure in the Aggression
José Manuel Añón Elizalde

3.4.3 Respiratory Diseases
Francisco García Río/Carolina Cubillos Zapata

3.4.4 Regulation of Gene Expression and by Hypoxia
Luis del Peso Ovalle

3.4.5 Nephrology
María Gemma Fernández Juárez

3.4.6 Diagnosis and Treatment of Allergic Diseases
Santiago Quirce Gancedo

3.4.7 Patient Blood Management
Manuel Quintana Díaz

3.4.8 Health Care Nurses Research
Esther Rey Cuevas/Tamara Domingo Pérez

3.4.9 Emergency and Critical Pathology
César Carballo Cardona

3.4.10 Hospital Pharmacy
Alicia Herrero Ambrosio

3.4.11 Translational Hepatology
Francisco Javier García-Samaniego Rey

3.4.12 Neuro-Cure
Javier Marco Martínez

3.4.13 iPanC: Imaging, Innovation and Clinical Practice in the Pancreas
Eva Marín Serrano



1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Strategic Objectives	Development forecast for the coming years:	Actions
Large System Pathologies Area includes 16 research groups that focus their interest on the study of pathogenic mechanisms and therapeutic options in some of the most prevalent diseases in our environment: respiratory, allergological, renal, digestive, gynaecological, and ophthalmological and paediatric, both in stable phase and at different levels of severity. In addition, we maintain interest in their involvement in the different phases of development, analyzing both the neonatal phase and old age.	Redefinition of the area with a more transversal character. Although this proposal requires a greater elaboration and consensus of all the groups in the area, the reformulation of the area is proposed as a new one focused, for example, on inflammation and hypoxia.	Conduct seminars and coordination meetings among groups of different areas
	Incorporation of related groups from other areas (immunorheumatology, hepatology, among others) and consolidation of some emerging groups.	Promote work and synergies with other research groups of the institute with a deeper trajectory
	To ensure that 50% of the publications are in the first quartile of each thematic area.	Improve the annual number of publications in the first quartile
	To promote intramural collaborations between groups.	Promote work and synergies with other research groups of the institute with a deeper trajectory.

HIGH IMPACT PUBLICATIONS

Villamizar PR, Thille AW, Doblas MM, Frat JP, Sanz PL, Alonso E, País V, Morales G, Colinas L, Propín A, Olivares AF, Balaguer MM, Rodrigo DA, **Hernández G.** Best clinical model predicting extubation failure: a diagnostic accuracy post hoc analysis. Intens Care Med. 2025; 51(1): 106-14. Article. IF: 22; D1

Díaz-García E, Alfaro E, Pérez-Moreno P, Lopez-Fernández C, García-Sánchez A, Martínez-Garcia MA, Mañas E, Cano-Pumarega I, Casitas R, Campos-Rodríguez F, Sánchez-de-la-Torre M, Nagore E, Martorell-Calatayud A, Blasco LH, Pastor E, Abad-Capa J, Montserrat JM, Cabriada-Nuño V, Corral-Peñafiel J, Arias E, Mediano O, Somoza-González M, Dalmau-Arias J, Almendros I, Troncoso-Acevedo F, Gotera-Rivera C, Pérez-Warnisher T, Peces-Barba G, Seijo LM, Gozal D, García-Rio F, **Cubillos-Zapata C**. Immune checkpoint biomarkers Galectin-9 and TIM-3 predict melanoma and lung cancer mortality in obstructive sleep apnoea. Arch Bronconeumol. 2025; 61(12): 735-48. Article. IF: 8,7; D1

Padilla JM, Alfaro E, Casitas R, Galera R, Martínez-Cerón E, Díaz-García E, Torres MV, López-Fernández C, Pérez-Moreno P, Soler-Cataluña JJ, Cubillos-Zapata C, **García-Río F.** Original characterization of inactive copd patients: barriers to physical activity and perceived impact of inactivity. Arch Bronconeumol. 2025; 61(9): 555-63. Article. IF: 8,7; D1

Caravaca-Fontán F, Alonso-Riano M, Shabaka A, Villacorta J, de Lorenzo A, Quintana LF, Rodríguez E, Gadola L, Cobo MA, Oliet A, Sierra-Carpio M, Cobelo C, Iglesias E, Cordón A, Praga M, **Fernández-Juárez G,** Spanish Grp Study Glomerular Dis GLOSEN. A predicting tool for kidney function recovery after drug-induced acute interstitial nephritis. Nephrol Dial Transpl. 2025; 40(9): 1707-16. Article. IF: 8,3; D1

Cuadros M, Abadía M, Castillo P, Martín-Arranz MD, Gonzalo N, Romero M, García-Sánchez A, García-Samaniego J, Olveira A, Ruiz-Cantador J, González-Fernández O, Ponz I, Merás P, Merino C, Rodríguez-Chaverri A, Balbacid E, Froilán C. Role of transient elastography in the diagnosis and prognosis of Fontan-associated liver disease. World J Gastroentero. 2025; 31(11): 103178. Article. IF: 7,7; Q1

Scientific Events by Large System Pathologies

- **19/03/2025** -Curso Avanzado de Simulación en Ecografía
- **20/03/2025** -Jornada: LEAN como motor de la transformación sanitaria
- **11/04/2025** - Seminario Presencial y Online: Proteómica: un conjunto de herramientas para comprender la biología y las enfermedades del hígado
- **05/06/2025** - I Curso de soporte vital inmediato
- **19/09/2025** - EPALS Septiembre - Curso europeo soporte vital avanzado pediátrico y neonatal
- **29/10/2025** - III Curso actualización en alergología
- **30/10/2025** - RETINA La Paz - Cirugía 3D en directo y actualización en retina médica y quirúrgica
- **05/11/2025** - Curso soporte vital avanzado

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.4.1 Internal Medicine and Systemic Diseases



Publications: 24 | Q1: 7

COMPOSITION

María Angustias Quesada Simón.
Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz/Profesora asociada ciencias de la Salud. Facultad Medicina UAM. Universidad Autónoma de Madrid

- **Francisco Arnalich Fernández.** *Investigador "Ad honorem". IdiPAZ/. Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Belén Gutiérrez Sancerni.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **María del Carmen Fernández Capitán.** *Jefa de Servicio de Medicina Interna. Hospital Universitario La Paz/Profesora asociada ciencias de la Salud. Facultad Medicina UAM. Universidad Autónoma de Madrid*
- **Clara Hernández Blanco.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Alicia Lorenzo Hernández.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Raquel Marín Baselga.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Carmen Montiel López.** *Catedrática. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Alberto Moreno Fernández.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Giorgina Gabriela Salgueiro Origlia.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Teresa Sancho Bueso.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Yale Tung Chen .** *Facultativo Especialista de Área de Medicina Interna. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- The Group's current lines of research are numerous and constantly changing and evolving. Some of the most relevant are listed below, in relation to the research lines.

RESEARCH LINES

SARS-CoV-2 INFECTION: DIFFERENTIATED MANIFESTATIONS AND UPDATED TREATMENT

- Main Objective To study the clinical and microbiological evolution of COVID-19 in the different waves of the pandemic and compare the clinical characteristics between patients requiring hospitalization due to severity with those who can be treated on an outpatient basis. - To accurately characterize the current behavior of COVID-19 and provide guidance on the most appropriate measures to take once social distancing measures can be relaxed without endangering the most vulnerable population.

THROMBOEMBOLIC DISEASE. PREVENTION, DIAGNOSIS AND TREATMENT

- Main objectives: Improve the diagnosis, treatment, prognosis and monitoring of patients with VTE. Improve VTE prevention (Thromboprophylaxis). Transmit our knowledge to Hospital and Primary Care professionals. Spread knowledge of VTE to patients themselves and to society in general.

Thromboembolic Disease: Prevention, Diagnosis, and Treatment. Main objectives:

- To improve the diagnosis, treatment, prognosis, and follow-up of patients with venous thromboembolism (VTE). To improve VTE prevention (thromboprophylaxis). To share our knowledge with hospital and primary care professionals. To disseminate knowledge about VTE to patients and the general public.

HEART FAILURE. MECHANISMS, DIAGNOSIS AND TREATMENT UPDATE:

- The mechanisms of coronary microvascular dysfunction (CMD) leading to pre-existing heart failure with preserved ejection fraction (HFpEF) aim to help individuals with suspected cardiac ischemia but without obstructive coronary artery disease better understand the associated risks of cardiac damage and early mortality, as well as potential targets for treatment and prevention of HFpEF.

VASCULAR RISK AND INFLAMMATION: PREVENTION, DIAGNOSIS, AND TREATMENT:

- Atherosclerosis involves hardening of the arteries and an accumulation of fat and cholesterol that impedes proper blood flow. Despite these characteristics, during the first years of the disease, atherosclerosis may not show symptoms in the patient. Therefore, it is vitally important to identify new risk factors capable of predicting the progression of the disease in people who do not yet exhibit clinical sequelae.

CLINICAL ULTRASOUND IN INTERNAL MEDICINE:

- Clinical ultrasound as another complementary tool for the internist (helping them resolve the specific problem for which the patient is consulting, what is called a second-level ultrasound, more comprehensive and usually performed by radiologists). Main objectives: To improve the medical history and physical examination from this global and comprehensive approach. To promote the specific use of clinical ultrasound in the consultation (point of care) to document the clinical diagnosis, making it more decisive and more effective.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

DIGITAL MEDICINE

- Digital Health Research consists of investigating, developing, and innovating in the use of Information and Communication Technologies (ICTs) in healthcare, with the aim of improving people's health and well-being. To carry out this activity, the Unit is currently organized into four areas: Interoperability and Information Systems, Platforms and Devices, Validation, and Clinical Evaluation.
- Lines of study framed within basic research projects:
- Study of the pathophysiological role of nicotinic7 and dup-a7 receptors expressed in human macrophages, neurons, and lung carcinoma cells.
- Identification of the signaling pathways that connect alpha7 nicotinic receptors and negative regulators of TLR-mediated inflammation in human macrophages.

RESEARCH ACTIVITY

Doctoral Theses

- **González Muñoz B.** Rentabilidad de la ecografía clínica multi-órgano como complemento al proceso diagnóstico en una consulta de Medicina Interna[dissertation]. Madrid: UAM: 2025(08/07/2025). Director: Tung Chen Y,Quesada Simón MA.

Final Degree Theses

- **Giménez-Muñoz C.** Development of a system for automatic clinical coding from hospital discharge reports[dissertation]. Madrid: UAM: 2025(09/06/2025). Director: Tung Chen Y.

Publications

- **Abbasi S, Wahd AS, Ghosh S, Ezzelarab M, Panicker M, Chen YT, Jaremko JL, Hareendranathan A.** Improved A-line and b-line detection in lung ultrasound using deep learning with boundary-aware dice loss. Bioengineering-Basel. 2025; 12(3): 311. Article. IF: 4.4; Q2
- **Barca-Hernando M, Otalora-Valderrama S, López-Núñez JJ, Portillo-Sánchez J, Pagan-Escribano J, López-Miguel P, Mahe I, Mena-Muñoz E, Jou-Segovia I, Imbalzano E, Blas PAD, Lorenzo-Hernández A, Díaz-Pedroche C, Aibar-Gallizo J, de la Red-bellvis G, del Molino-Sanz F, Amado-Fernández C, Fernández-Reyes JL, Villalobos-Sánchez A, López-Sáez JB, Díaz-Brasero AM, Marcos-Jubilar M, Meireles J, Marchena-Yglesias PJ, Díaz-Peromingo JA, Marín-Romero S, Elias-Hernández T, Andrade-Ruiz HA, Mehdipour G, Bikdeli B, Jara-Palomares L.** Occult cancer in patients with unprovoked venous thromboembolism: Rationale, design, and methods of the VaLRIETEs study and the SOME-RIETE trial. Am Heart J. 2025; 284: 81-93. Article. IF: 3.4; Q2
- **Cabrera-Alarcón JL, Cruz R, Rosa-Moreno M, Latorre-Pellicer A, de Almeida SD, Riancho JA, Rojas-Martínez A, Flores C, Lapunzina P, Sánchez-Cabo F, Carracedo A, Enríquez JA.** Shaping current European mitochondrial haplogroup frequency in response to infection: the case ofSARS-CoV-2severity. Commun Biol. 2025; 8(1): 33. Article. IF: 5.8; D1
- **Carrasco-Molina S, Robles-Marhuenda A, Ríos-Blanco JJ, Tung-Chen Y.** Counter-reply: comment to the special article Utility of point-of-care ultrasound (POCUS) in hospitalized patients with acute confusional syndrome of unclear etiology. Rev Clin Esp. 2025; 225(7): 502337. Letter. IF: 1.7; Q2
- **Carrasco-Molina S, Robles-Marhuenda A, Ríos-Blanco JJ, Tung-Chen Y.** Utility of point-of-care ultrasound (POCUS) in hospitalized patients with acute confusional syndrome of unclear etiology. Rev Clin Esp. 2025; 225(4): 231-9. Article. IF: 1.7; Q2
- **Díez-Canedo PE, Fernández AM, Tung-Chen Y.** The effectiveness of optic nerve sheath diameter in predicting large vessel occlusion in ischemic stroke patients. Med Ultrason. 2025; 27(3):365-6. Letter. IF: 1.8; Q2
- **Díez-Canedo PE, Marín-Baselga R, Tung-Chen Y.** Prospective ultrasonographic evaluation of femoral and vastus intermedius muscles as predictors of ICU-acquired weakness in critically ill patients. J Ultrasound. 2025; 28(4): 1105-6. Letter. IF: 1.6; Q3
- **Díez-Canedo PE, Tung-Chen Y.** Predicting benign and malignant subpleural pulmonary lesions with nomogram model using clinical and b-mode ultrasound parameters. Ultrasound Med Biol. 2025; 51(10): 1859-60. Letter. IF: 2.8; Q2
- **Dubois-Silva A, Bikdeli B, Jiménez D, Barbagelata-López C, Fernández- Capitán C, Skride A, Pham KQ, Porras JA, Pacheco-Gómez N, Monreal M.** Clinical presentation and prognosis of acute symptomatic pulmonary embolism in patients with concomitant upper-extremity versus lower-extremity deep vein thrombosis. Thorax. 2025; 80(6): 369-77. Article. IF: 9.1; D1
- **Ferrer-Reyes G, Tung-Chen Y.** Diagnóstico precoz de trombosis venosa profunda en pacientes internados. Sangre. 2025; 44(X): 1-2. Article. Not Indexed
- **Gómez-Rojas MA, Tung-Chen Y.** Comment on vicente-rabaneda et al. a proposal for a new lung ultrasound score in rheumatoid arthritis: the reliability of lung ultrasound for rheumatoid arthritis-associated interstitial lung disease diagnosis. J. Clin. Med. 2025; 14: 3701. J Clin Med. 2025; 14(22): 8118. Letter. IF: 3.3; Q1
- **Jossein T, Mazzolai L, Hernández AL, Valderrama SO, Zdraveska M, Guerrero AR, Ruiz AL, Di Micco P, Monreal M, Hugli O.** Failure rate of the pulmonary embolism rule-out criteria rule for adults 35 years or younger: Findings from the RIETE Registry. Acad Emerg Med. 2025; 32(4): 414-25. Article. IF: 3.2; Q1
- **Luordo, D; Arrese, MT; Calvo, CT; Shani, KDS; Cruz, LMR; Sánchez, FJG; Gómez-Abascal, AL; García, RR; Jiménez, JD; Carreras, MP; Lobato, RD; Martínez, JJG; Tung-Chen, Y; Garrido, MVV.** Application of artificial intelligence as an aid for the correction of the objective structured clinical examination (OSCE). Appl Sci-Basel. 2025; 15(3): 1153. Article. IF: 2.9; Q2
- **Mateo EM, Alonso RG, Sánchez CS, Tung-Chen Y, Rodilla E, Romero LB, García-Donaire JA, Bonilla-Hernández MV, Muñoz-Rivas N, Castilla-Guerra L.** Positioning for the use of multivessel clinical ultrasound in vascular risk evaluation: VASUS plus protocol. 2024 recommendations of the vascular risk group, clinical ultrasound of the Spanish Society of Internal Medicine and Spanish Society of Hypertension and Vascular Risk. Rev Clin Esp. 2025; 225(4): 223-30. Article. IF: 1.7; Q2
- **Mateo EM, Alonso RG, Sánchez CS, Tung-Chen Y, Rodilla E, Romero LB, García-Donaire JA, Bonilla-Hernández MV, Muñoz-Rivas N, Castilla-Guerra L.** Positioning for the use of multivessel clinical ultrasound in vascular risk evaluation: VASUS+ protocol. 2024 recommendations of the Vascular Risk Group, clinical ultrasound of the Spanish Society of Internal Medicine and Spanish Society of Hypertension and Vascular Risk. Hipertens Riesgo Vasc. 2025; 42(2): 108-15. Article. IF: 1.2; Q4
- **Morán-Martínez J, Tung-Chen Y.** Limitations and potential of lung ultrasound in elderly patients with COVID-19. Galicia Clin. 2025; 85(3): 5-6. Editorial Material. IF: 0.1; Q4
- **Muñoz M, Han X, Camacho J, Perrone T, Smargiassi A, Inchingolo R, Tung-Chen Y, Demi L.** Evaluating deep learning approaches for AI-assisted lung ultrasound diagnosis: an international multi-center and multi-scanner study. Ultrasound J. 2025; 17(1): 45. Article. IF: 3.6; Q1
- **Nopp S, Spielvogel C, Bikdeli B, Alberich-**

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



Conesa A, Hernández-Blasco L, Peris ML, Otero R, Jimenez D, Monreal M, Ay C, de Blas PA, Aibar J, Alberich-Conesa A, Alda-Lozano A, Alfonso J, Alonso-Carrillo J, Alvarez-Vega P, Amado C, Angelina-Garcia M, Arcelus JI, Ballaz A, Barba R, Barbagelata C, Barrón M, Barrón-Andres B, Bascuñana J, Blanco-Molina A, Bustos-Carpio J, Casado I, Chasco L, Claver G, De Juana-Izquierdo C, Del Toro J, Demelo-Rodriguez P, Diaz-Brasero AM, Diaz-Pedroche MC, Diaz-Peromingo JA, Dubois-Silva A, Escribano JC, Fernández-Capitán C, Fernández-Jimenez B, Fernández-Reyes JL, Fidalgo MA, Francisco I, Gabara C, Galeano-Valle F, Garcia-Bragado F, Garcia-González C, Garcia-Ortega A, Gavin-Sebastián O, de Gómez MAG, Gil-Diaz A, Gómez-Cepeda C, Gómez-Cuervo C, González-Martínez J, González-Munera A, Gorostidi J, Grau E, Guirado L, Gutierrez-Guisado J, Hernández-Blasco L, Jara-Palomares L, Jimenez D, Jou I, Joya MD, Láinez-Justo S, Lecumberri R, Lobo JL, López-Jimenez L, López-Miguel P, López-Núñez JJ, López-Ruiz A, López-Sáez JB, Lorenzo A, Madridano O, Maestre A, Marchena PJ, Marcos M, Pozo MMD, Martin-Martos F, Maza JM, Mercado MI, Molino A, Monreal M, Monzón L, Navas MS, Nieto JA, Núñez-Fernández MJ, Ordieres L, Ortiz O, Otálora S, Otero R, Pacheco-Gómez N, Pagán J, Parra-Caballero P, Pedrajas JM, Perez-Amorós J, Perez-Cabezas A, Perez-Ductor C, Perez-Pinar M, Peris ML, Pesce ML, Porras JA, Puchades R, Puche G, Rivas A, Rivera-Civico F, Rodriguez-Cobo A, Romero-Bruguera M, Salgueiro G, Sánchez-Juez A, Sancho T, Sendin V, Sigüenza P, Soler S, Sota-Yoldi LA, Suárez-Fernández S, Tirado R, Torrents-Vilar A, Torres MI, Trujillo-Santos J, Uresandi F, Valle R, Varona JF, Vázquez E, Villalobos A, Villarejo C, Villares P, Ay C, Nopp S, Pabinger I, Vanassche T, Verhamme P, Verstraete A, Rocha AT, Yoo HHB, Montenegro AC, Morales SN, Roa J, Hirmerova J, Maly R, Acassat S, Bertoletti L, Brehon M, Bura-Riviere A, Catella J, Chopard R, Couturaud F, Espitia O, Le Mao R, Leclercq B, Mahe I, Moustafa F, Plaisance L, Poenou G, Quere I, Sarlon-Bartoli G, Suchon P, Versini E, Schellong S, Rashidi F, Sadeghipour P, Tahmasbi F, Brenner B, Kennet G, Tzoran I, Barillari G, Basaglia M, Bilora F, Bissacco D, Brandolin B, Casana R, Ciammaichella MM, Colaizzo D, Di Micco P, Giorgi-Pierfranceschi M, Grandone E, Lambertenghi-Deliliers D, Marcon C, Poz A, Prandoni P, Simioni P, Siniscalchi C, Taflaj B, Tufano A, Visonà A, Zalunardo B, Skride A, Tazi-Mezalek Z, Fonseca S, Marques R, Meireles J, Pinto S, Bosevski M, Zdraveska M, Barco S, Bounameaux H, Keller S, Mazzolai L, Porceddu E, Aujayeb A, Angiolillo DJ, Bikdeli B, Caprini JA, Khalil A, Ortega-Paz L, Tafur J, Weinberg I, Bui HM. A machine learning approach to identify patients at risk for long-term consequences after pulmonary embolism. Sci Rep-Uk. 2025; 15(1): 32744. Article. IF: 4.9; Q1

- **Oblitas CM, Demelo-Rodríguez P, Barrera-López L, Galeano-Valle F, Rubio-Rivas M, del Pino JL, Galvañ VG, Paredes-Ruíz D, Martínez RFM, Aseguinolaza MG, Gómez-Huelgas R, Fernández FA, Peña JDT, González JIM, Méndez-Bailón M, Monge DM, Castro SJF, Valverde CP, Rodilla-Sala E, García MG, Rivas-Carmenado M, Gallo CM, Ribis MAP, Casas-Rojo JM, Núñez-Cortés JM.** Impact of SARS-CoV-2 infection therapies on the risk of venous thromboembolism and cardiovascular events from the SEMI-COVID-19 Registry. Sci Rep-Uk. 2025; 15(1): 7722. Article. IF: 4.9; Q1
- **Pagan Escribano, J; Castilla Guerra, L; Guitiérrez-Sánchez, E; Gómez-Escobar, A; García Alonso, R; Arias-Barquet, L; Madridano Cobo, O; Martín Asenjo, M; Rubio Velázquez, E; Lorenzo Hernández, A; Puche Palao, G.** Position paper on retinal vein occlusion. SEMI-SERV. Rev Clin Esp. 2025; 225(6): 502307. Review. Not Indexed
- **Tébar D, Jurado-Román A, Jiménez-Valero S, Galeote G, Gonzálvez A, Rivero B, García A, Elizalde JMA, Lorenzo A, Capitán CF, Torres R, Soto C, Alcolea S, Rosillo S, Codón JC, Arbas E, Tejera F, Plaza I, Boscá L, Moreno R.** Percutaneous pulmonary thrombectomy with aspiration catheters in patients with high-risk pulmonary embolism and absolute contraindication to systemic thrombolysis. Cardiovasc Revasc Med. 2025; 70: 56-61. Article. IF: 2.3; Q3
- **Tébar-Márquez D, Díez-Vidal A, Tung-Chen Y.** Antithrombotic therapy after percutaneous left atrial appendage closure: should it be the same for everyone?. Rev Esp Cardiol (Engl Ed). 2025; 78(8): 679-81. Editorial Material. IF: 4.2; Q2
- **Tung-Chen Y, Muñoz FJT, Belando SA, Franco BB, Romero LB, Bernabeu-Wittel M, Tascón GC, Delgado-Cuesta J, Moya CE, Serna JSE, Sánchez GGD, Gil DG, Rubio SG, Jiménez DL, Baselga RM, Macho JT, Porcel JM.** Percutaneous core needle biopsy guided by ultrasound: a narrative review. J Ultrasound. 2025; 28(3): 575-85. Review. IF: 1.6; Q3
- **Tung-Chen Y, Robles MB, Gracia JR, Sánchez GGD, Iborra PL, Rubio SG, Bailón MM, Hernández EM, Marteles MS, Arrese MT, Macho JT, Silvestre JP.** Position statement on the use of point-of-care ultrasound in heart failure: Recommendations from the Heart Failure and Atrial Fibrillation, and Clinical Ultrasound Working Groups of the Spanish Society of Internal Medicine (SEMI). Rev Clin Esp. 2025; 225(3): 148-56. Article. IF: 1.7; Q2

Research projects

- **Montiel Lopez C, Soria Chacartegui P, Zubiaur Precioso P.** Utilidad de la farmacogenéticapara mejorar la prescripción de estatinas en atencion primaria y especializada: percepciones y formación de medicos prescriptores. (PI22/01655). ISCIII. 2023-2025. Managment centre: UAM

Clinical trials

- **Lorenzo Hernández A.** Evaluación de la efectividad y seguridad del tratamiento a largo plazo con heparinas de bajo peso molecular en pacientes con trombosis asociada al cáncer: un estudio en vida real usando inteligencia artificial (bemicat).
  Type/Phase: EOm no prospectivo
  Sponsored by: Laboratorios Farmaceúticos Rovi, S.A.
  Signature date: 10/04/2025

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.4.2 Organic Dysfunction and Failure in the Aggression

Publications: 19 | Q1: 13

COMPOSITION

José Manuel Añón Elizalde.
Jefe de Servicio en Medicina Intensiva. Hospital Universitario La Paz

- **Alexander Agrifoglio Rotaeche.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **María Soledad Arellano Serrano.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **María José Asensio Martín.** *Jefa de Sección en Medicina Intensiva. Hospital Universitario La Paz*
- **Lucía Cachafeiro Fuciños.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Belén Civantos Martín.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Claudia Díaz Alvariño.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **María Belén Estebánez Montiel.** *Facultativo Especialista de Área en Medicina Intensiva. Coordinador de Trasplante. Hospital Universitario La Paz*
- **Juan Carlos Figueira Iglesias.** *Jefe de Sección en Medicina Intensiva. Hospital Universitario La Paz*
- **Eva Mercedes Flores Cabeza.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Andoni García Muñoz.** *Médico Adjunto en Unidad de Cuidados Intensivos. Hospital Universitario La Paz*
- **Raquel Herrero Hernández.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz/Profesora Asociada. Universidad Autónoma de Madrid*
- **Mónica Hernández Bernal.** *Médico Adjunto en Unidad de Cuidados Intensivos. Hospital Universitario La Paz*
- **Gonzalo Hernández Martínez.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario Virgen de la Salud*
- **Alba López Fernández.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Jesús Javier Manzanares Gómez.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Pablo Millán Estañ.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Kapil Laxman Nanwani Nanwani.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Óscar Peñuelas Rodríguez.** *Jefe de sección en Medicina Intensiva. Hospital Universitario de Getafe*
- **Eva Perales Ferrera.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Montserrat Aránzazu Rodríguez Aguirregabiria.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Jorge Rodríguez Peláez.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Santos Manuel Sánchez Sánchez.** *Jefe de Sección de Medicina Intensiva. Hospital Universitario La Paz*
- **Santiago Yus Teruel.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- The research group Dysfunction and Organ Failure in Aggression has the general objective of managing the care of patients admitted in a life-threatening situation who present - both at admission and during evolution - a high incidence of dysfunction and multiple organ failure (D-FMO), a situation that is associated with an increase in morbidity and mortality.
- This D-FMO situation is related to the severity and concomitant pathology of the patient, as well as the therapeutic efforts that must be precise and directed towards the precise objectives.
- Furthermore, support measures focused on situations (sepsis, trauma, etc.) as well as on organs and systems: hemodynamic, nutromatbolic, respiratory, renal, and coagulation, among others, and seeking the least added aggression will result in both a more efficient use of resources and better clinical outcomes.
- Finally, the detection of D-FMO, using not only standard, primary or clinical markers (intermediate or final, such as length of stay and survival) if there are no secondary or biomarkers (basic biochemical, advanced biochemical, molecular…) that are clearly early and often specific to an organ or system, will result in greater efficiency and better outcomes.

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians


RESEARCH LINES

- Biomarkers
- Resuscitation admissions
- Therapeutic support
- Mechanical ventilation
- Artificial airway
- Post intensive care syndrome
- Sedation

RESEARCH ACTIVITY

Publications

- **Añón JM, Escuela MP, García-Muñoz A, Villar J.** Volatile agents: when generalization doesn't help. Crit Care. 2025; 29(1): 305. Letter. IF: 11.4; D1
- **Añón JM, Escuela MP, Oliva-Navarro J, Pérez-Lucendo A, Suarez-Sipmann F.** Exploring volatile anesthetics in critical care: Facts and uncertainties. Med Intensiva. 2025; 49(8): 502174. Editorial Material. IF: 2.5; Q3
- **Barbeta E, Barreiros C, Forin E, Guzzardella A, Motos A, Fernández-Barat L, Gabarrús A, Ceccato A, Ferrer R, Riera J, Peñuelas O, Lorente JA, de Gonzalo-Calvo D, Gonzalez J, Amaya-Villar R, Añón JM, Balan A, Barberà C, Barberán J, Blandino A, Boado MV, Bustamante-Munguira E, Caballero J, Cantón-Bulnes ML, Carbajales C, Carbonell N, Catalán-González M, Franco N, Galbán C, Gumucio-Sanguino VD, de la Torre MD, Díaz E, Estella A, Gallego E, Gómez JM, Huerta A, García RNJ, Loza-Vázquez A, Marin-Corral J, Delgado MCM, Martínez A, Martínez I, Lopez J, Albaiceta GM, Nieto MT, Novo MA, Peñasco Y, Pérez-García F, Ricart P, Rodríguez A, Sagredo V, Sánchez-Miralles A, Sancho S, Roche-Campo F, Socias L, Solé-Violan J, Tamayo L, Trenado J, Ubeda A, Valdivia LJ, Vidal P, Barbé F, Vallverdú J, Torres A.** Mechanical power is not associated with mortality in COVID-19 mechanically ventilated patients. Ann Intensive Care. 2025; 15(1): 27. Article. IF: 6.9; Q1
- **Cruz-Garcinuño M, Juárez-Vela R, Chover-Sierra E, Navas-Echazarreta N, Czapla M, Ballestar-Tarín ML, Martínez-Pascual RM, Nanwani-Nanwani K, Serrano-Lazaro A, del Val-Rey I, Quintana-Díaz M, Martinez-Sabater A.** Sex differences and gender-oriented characteristics in intensive care unit admissions for patients with traumatic brain injury in Spain. Front Med (Lausanne). 2025; 12: 1622422. Article. IF: 3.6; Q1
- **Díez-Vidal A, Fernández-Hinojal F, Marcelo-Calvo C, Hernández-García B, Cendejas-Bueno E, Grandioso-Vas D, Pérez-Chulia N, Civantos-Martín B, Martinez-Martín P, Novo-González C, García-Arenzana N, Giner-García J, Paredes-Garza F, Vallejo-Oliva MI, Arribas JR, Díaz-Pollán B.** Ventriculitis: A retrospective cohort study of clinical features, outcomes and device management practices. Open Forum Infect Dis. 2025; 12(8): ofaf424. Article. IF: 3.8; Q2
- **Fernández-Barat L, Motos A, Canseco-Ribas J, Gabarrús A, López-Aladid R, Alvaro-Meca A, Ceccato A, García N, Ferrer M, Battaglini D, Álvarez-Napagao S, Garcia-Gasulla D, Ferrer R, de Gonzalo-Calvo D, Lorente JA, Menéndez R, Peñuelas O, Riera J, Rodríguez A, Villar RA, Añón JM, Mariño AB, Barberà C, Barberán J, Ortiz AB, Boado MV, Bofill N, Bustamante-Munguira E, Caballero J, Canton-Bulnes ML, Pérez CC, Carbonell N, Catalán-González M, de la Torre MD, Díaz E, Estella A, Figueras A, de Frutos R, Franco N, Galbán C, Gallego E, Garmendia JLG, González J, Gómez JM, Gumucio-Sanguino VD, Huerta A, García RNJ, Loza-Vázquez A, Marin-Corral J, Delgado MCM, de la Gándara AM, Varela IM, Albaiceta GM, Nieto M, Peñasco Y, Pérez-Bastida L, Pérez-García F, Pozo-Laderas JC, Ricart P, Sagredo V, Sánchez-Miralles A, Chinesta SS,**



Socias L, Solé-Violan J, Suarez-Sipmann F, Lomas LT, Trenado J, Ubeda A, Valdivia LJ, Vidal P, Bermejo-Martin J, Barbé F, Torres A. Outcomes and predictors of mortality in patients with severe COVID 19 and COPD admitted to ICU: A multicenter study. Anaesth Crit Care Pain Med. 2025; 44(5): 101558. Review. IF: 5.4; D1
- **Frat JP, Grieco DL, De Jong A, Gibbs K, Carteaux G, Roca O, Lemiale V, Piquilloud L, Rittayamai N, Pisani L, Hernandez G, Thille AW.** Noninvasive respiratory supports in ICU. Intens Care Med. 2025; 51(8): 1476-89. Review. IF: 22.0; D1
- **Galli F, Forin E, Motos A, Saldarriaga FJM, Gabarrus A, Canseco J, Fernández-Barat L, Barbeta E, Calabretta D, Ceccato A, Bermejo-Martín JF, Ferrer R, Riera J, Peñuelas O, Lorente JA, de Gonzalo-Calvo D, Menéndez R, González J, Palomeque A, Soler-Comas A, Amaya-Villar R, Añón JM, Marino AB, Barbera C, Barberán J, Ortiz AB, Bustamante-Munguira E, Caballero J, Canton-Bulnes ML, Pérez CC, Carbonell N, Catalán-González M, De Frutos R, Franco N, Galbán C, Lago AL, Gumucio-Sanguino VD, de la Torre MD, Diaz E, Estella A, Curto EG, García-Garmendia**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

JL, Gómez JM, Huerta A, García RNJ, Loza-Vázquez A, Marín-Corral J, Delgado MCM, de la Gandara AM, Varela IM, Messa JL, Albaiceta GM, Nieto MT, Novo MA, Penasco Y, Pérez-García F, Pozo-Laderas JC, Ricart P, Sagredo V, Sánchez-Miralles A, Chinesta SS, Roche-Campo F, Socias L, Sole-Violan J, Suarez-Sipmann F, Lomas LT, Trenado J, Ubeda A, Valdivia LJ, Vidal P, Boado MV, Rodriguez A, Ferrer M, Barbe F, Torres A.** Immunosuppressed patients with COVID-19 pneumonia in ICU: clinical characteristics and factors influencing outcomes. Pneumonia (Nathan). 2025; 17(1): 30. Article. IF: 3.8; Q2

- **Giménez-Esparza C, Relucio MA, Nanwani-Nanwani KL, Añón JM.** Impact of patient safety on outcomes. From prevention to the treatment of post-intensive care syndrome. Med Intensiva. 2025; 49(4): 224-36. Article. IF: 2.5; Q3
- **Hernández G, Dianti J, Paredes I, Moran F, Marquez M, Calle A, Colinas L, Alonso G, Carneiro P, Morales G, Suarez-Sipmann F, Canabal A, Goligher E, Roca O.** Humidified noninvasive ventilation versus high-flow therapy to prevent reintubation in patients with obesity a randomized clinical trial. Am J Resp Crit Care. 2025; 211(2): 222-9. Article. IF: 21.7; D1
- **Hernández G, Hill NS.** How to prevent postextubation respiratory failure. Curr Opin Crit Care. 2025; 31(1): 93-100. Review. IF: 3.8; Q2
- **Maldonado-Barrueco A, Rubio-Mora E, Bloise I, Cacho-Calvo J, Hernández-Rivas L, Dahdouh E, García-Rodríguez J, Rodríguez-Aguirregabiria M, Ramos-Ramos JC, Pérez-Blanco V, Mingorance J, Lázaro-Perona F.** Genomic analysis of carbapenem resistant Acinetobacter baumannii outbreak in a burn intensive care unit of a tertiary-care hospital in Madrid, Spain. Antimicrob Resist Infect Control. 2025; 14(1): 124. Article. IF: 5.2; Q1
- **Pérez-Blanco A, González-Vilchez F, González-Costello J, Royo-Villanova M, Miñambres E, Cuenca JJ, Cánovas SJ, Garrido IP, Moreno-González G, Sbraga F, García-Quintana A, Peña VJ, Portela FA, Almenar-Bonet L, Martinez-León J, Tur A, Ruiz-Arranz A, Caravaca-Pérez P, Sandoval E, Gómez-Bueno M, Pérez-Redondo M, Villar S, Cobo M, Nistal JF, Adsuar-Gómez A, Peinado AA, Blázquez-Bermejo Z, Coll E, Crespo-Leiro MG, Cuerpo G, de la Calle B, Estébanez B, Fernández-García ME, Mosteiro F, Ponz I, Sánchez-Rivas J, Sánchez-Vicario F, Sobrino JM, Domínguez-Gil B.** DCDD heart transplantation with thoraco-abdominal normothermic regional perfusion and static cold storage: The experience in Spain. Am J Transplant. 2025; 25(7): 1526-39. Article. IF: 8.1; D1
- **Rodríguez-Aguirregabiria M.** Therapeutic management of health care-associated pneumonia. Rev Esp Quim. 2025; 38: 43-50. Review. IF: 2.8; Q3
- **Thille AW, Hernandez G.** How should spontaneous breathing trials be performed in the light of recent literature? Ann Intensive Care. 2025; 15(1): 102. Editorial Material. IF: 6.9; Q1
- **Villamizar PR, Thille AW, Doblas MM, Frat JP, Sanz PL, Alonso E, País V, Morales G, Colinas L, Propín A, Olivares AF, Balaguer MM, Rodrigo DA, Hernández G.** Best clinical model predicting extubation failure: a diagnostic accuracy post hoc analysis. Intens Care Med. 2025; 51(1): 106-14. Article. IF: 22.0; D1
- **Villar J, González-Martín JM, Fernández C, Añón JM, Ferrando C, Mora-Ordoñez JM, Martínez D, Mosteiro F, Ambrós A, Fernández L, Murcia I, Vidal A, Pestaña D, Romera MA, Montiel R, Domínguez-Berrot AM, Soler JA, Gómez-Bentolila E, Steyerberg EW, Szakmany T.** Early prediction of icu mortality in patients with acute hypoxemic respiratory failure using machine learning: The MEMORIAL Study. J Clin Med. 2025; 14(5): 1711. Article. IF: 3.3; Q1
- **Villar J, González-Martín JM, Fernández C, Soler JA, Rey-Ábalo M, Mora-Ordóñez JM, Ortiz-Díaz-Miguel R, Fernández L, Murcia I, Robaglia D, Añon JM, Ferrando C, Parrilla D, Dominguez-Berrot AM, Cobeta P, Martínez D, Amaro-Harpigny A, Andaluz-Ojeda D, Fernández MM, Gómez-Bentolila E, Steyerberg EW, Camporota L, Szakmany T.** Predicting outcome and duration of mechanical ventilation in acute hypoxemic respiratory failure: The PREMIER Study. J Clin Med. 2025; 14(22): 7903. Article. IF: 3.3; Q1
- **Wendel-Garcia PD, Ceccato A, Motos A, Franch-Llasat D, Pérez-Moreno MO, Doménech-Spanedda MF, Chamarro-Martí E, Ferrer R, Fernández-Barat L, Riera J, Álvarez-Napagao S, Peñuelas O, Lorente JA, Almansa R, Gabarrús A, de Gonzalo-Calvo D, González J, Añón JM, Barberà C, Barberán J, Blandino-Ortiz A, Bustamante-Munguira E, Caballero J, Carbajales-Pérez C, Carbonell N, Catalán-González M, Barral-Segade P, Mañez R, de la Torre MC, Díaz E, Estella A, Gallego E, García-Garmendia JL, Garnacho-Montero J, Amaya-Villar R, Gómez JM, Huerta A, Jorge-García RN, Loza-Vázquez A, Marín-Corral J, Martin-Delgado MC, Gándara AMD, Martínez-Varela IY, López-Messa J, Muñiz-Albaiceta G, Novo MA, Peñasco Y, Pozo-Laderas JC, Ricart P, Sánchez-Miralles A, Sancho S, Socias L, Solé-Violan J, Suárez-Sipmann F, Tamayo L, Trenado J, Barbé F, Torres A, Roche-Campo F, CIBERESUCICOVID Investigators.** Empirical antibiotic therapy improves outcomes in mechanically ventilated patients with COVID-19: An emulated targeted trial within a prospective, multicentre cohort study. J Infection. 2025; 90(2): 106411. Article. IF: 10.0; D1

Research projects

- **Estebánez Montiel MB.** Perfusion regional normotermica en la donacion en asistolia con flujo pulsatil versus lineal en modelo animal (DRA ESTEBAÑEZ AYUDA SMT 2024). Sociedad Madrileña de Trasplantes. 2025-Ongoing. Managment centre: FIBHULP
- **Añón Elizalde JM.** Sedación inhalada en el enfermo crítico: ensayo multicéntrico y aleatorizado (PI24/00266). ISCIII. 2025-2027. Managment centre: FIBHULP

Clinical trials

- **Añón Elizalde JM.** Sedación inhalada en el enfermo crítico: ensayo clínico multicéntrico y aleatorizado.
  Type/Phase: IV
  Sponsored by: Fundacion Para La Investigacion Biomedica Hospital Universitario La Paz.
  Signature date: 11/04/2025
- **Cachafeiro Fuciños L.** Ensayo en fase III aleatorizado, comparado con placebo, doble ciego y multicéntrico, para evaluar la eficacia y la seguridad de la trimodulina (bt588) en sujetos adultos hospitalizados con neumonía grave adquirida en la comunidad (ngac).
  Type/Phase: III
  Sponsored by: Biotest Ag.
  Signature date: 30/04/2025
- **Rodríguez Aguirregabiría MA.** Diseño de un modelo predictivo de mortalidad en pacientes críticos colonizados por bacterias gram negativas multirresistentes.
  Type/Phase: EOm prospectivo
  Sponsored by: Fundacion Seimc-Gesida.
  Signature date: 08/07/2025

Patents and trademarks

- **Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee.** Trademark name: SINOIRES; CM 13.080.056; 2014 July 14.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.4.3 Respiratory Diseases

Publications:21 | Q1: 17

COMPOSITION

Francisco José García Río.
Jefe de Sección de Neumología. Hospital Universitario La Paz/Catedrático de Universidad Facultad de Medicina. Universidad Autónoma de Madrid

Carolina Cubillos Zapata.
Investigadora Postdoctoral. Contrato Miguel Servet tipo I. Hospital Universitario La Paz

- **Sergio Alcolea Batres.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Rodolfo Álvarez-Sala Walther.** *Jefe de Servicio de Neumología. Hospital Universitario La Paz/ Catedrático. Facultad de Medicina. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Victoria Arnalich Montiel.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Carlos Javier Carpio Segura.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Raquel Casitas Mateo.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Raúl Galera Martínez.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Luis Gómez Carrera.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **María Antonia Gómez Mendieta.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **María Hidalgo Sánchez.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Cristina López Fernández.** *Técnico de Laboratorio. FIBHULP*
- **Pablo Mariscal Aguilar.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Elisabet Martínez Cerón.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Paula Pérez Moreno.** *Investigadora Predoctoral. Hospital Universitario La Paz*
- **Concepción Prados Sánchez.** *Jefe de Sección de Neumología. Hospital Universitario La Paz*
- **David Romero Ribate.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Ana Santiago Recuerda.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Ana Santiago Recuerda.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Ester Zamarrón de Lucas.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- Our group studies the molecular mechanisms of cardiovascular morbidity associated with sleep breathing disorders, in particular, the sleep apnoeahypopnea syndrome(SAHS).
- We also provide evidence for making clinical decisions on patients with these disorders. We conduct studies to evaluate the mechanisms involved in the development of arterial hypertension, arrhythmias, heart failure, ischaemic heart disease, pulmonary hypertension, pulmonary embolism, and carbohydrate metabolism disorders.
- In terms of the pathogenesis of airflow limitations, several of our projects have focused on small airway function, bronchial hyperresponsiveness and exercise adaptation in a number of obstructive diseases, particularly COPD, asthma and cystic fibrosis. We also evaluate the objective measurement of daily physical activity in these patients and contribute to the best definition of its determinants and its clinical and prognostic usefulness. We collaborate with other research groups to study the contribution of the innate immune system to the evolution of these diseases and the relationship between the response to hypoxia and the clinical expression of COPD and SAHS.
- Finally, in the field of the systematisation of lung function testing, we create reference values for various population groups and define the methodological aspects of the measurement of exhaled breath condensate and nitric oxide.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH LINES

- Morbidity of sleep-disordered breathing
- Pathogenesis of airflow limitation
- Systematization of lung function testing

RESEARCH ACTIVITY

Doctoral Theses

- **Casitas Mateos R.** Evaluación de la repercusión funcional y morfológica a medio y largo plazo del síndrome de distrés respiratorio agudo grave secundario a Covid-19[dissertation]. Madrid: UAM: 2025(24/02/2025). Director: Álvarez-Sala Walther R, García Río F.
- **Alfaro García E.** Mecanismos de la actividad física en el sistema inmune de los pacientes de enfermedad pulmonar obstructiva crónica (EPOC)[dissertation]. Madrid: UAM: 2025(12/03/2025). Director: Cubillos Zapata C, García-Río F .

Publications

- **Alfaro E, Díaz-García E, García-Tovar S, Galera R, Casitas R, Martínez-Cerón E, Torres-Vargas M, Padilla JM, Fernández CL, Pérez-Moreno P, García-Río F, Zapata CC.** Physical activity attenuates PD-1/PD-L1 expression and enhances CD4+ T-cell function in COPD patients. Sci Rep-Uk. 2025; 16(1): 1674. Article. IF: 4.9; Q1
- **Baloira LE, de Lucas EZ, Segura CC, Baratas ML, Velilla MF, Sánchez MIT, Fernández IP, Aguilar PM, Walther RAS, Sánchez CP.** Association between lung parenchymal attenuation in computed tomography and airflow limitation in adults with cystic fibrosis. Diagnostics (Basel). 2025; 15(1): 107. Article. IF: 3.8; Q1
- **Dalmases M, Sánchez-de-la-Torre M, Martinez D, Minguez O, Vaca R, Pascual L, Aguilá M, Gracia-Lavedan E, Benítez ID, Pinilla L, Cortijo A, Gort-Paniello C, Claret RB, Martinez-Garcia MA, Mediano O, Peralta SR, Fortuna-Gutierrez AM, Marquez PP, Drager LF, Cabrini M, Masa JF, Penafiel JC, Vázquez S, Abad J, García-Río F, Casitas R, Lee CH, Barbé F, Torres G.** The effect of obstructive sleep apnea on subclinical target organ damage in patients with resistant hypertension. Arch Bronconeumol. 2025; 61(3): 147-55. Article. IF: 8.7; D1
- **Díaz-García E, Alfaro E, Pérez-Moreno P, Lopez-Fernández C, García-Sánchez A, Martínez-Garcia MA, Mañas E, Cano-Pumarega I, Casitas R, Campos-Rodríguez F, Sánchez-de-la-Torre M, Nagore E, Martorell-Calatayud A, Blasco LH, Pastor E, Abad-Capa J, Montserrat JM, Cabriada-Nuño V, Corral-Peñafiel J, Arias E, Mediano O, Somoza-González M, Dalmau-Arias J, Almendros I, Troncoso-Acevedo F, Gotera-Rivera C, Pérez-Warnisher T, Peces-Barba G, Seijo LM, Gozal D, García-Rio F, Cubillos-Zapata C.** Immune checkpoint biomarkers galectin-9 and tim-3 predict melanoma and lung cancer mortality in obstructive sleep apnoea. Arch Bronconeumol. 2025; 61(12): 735-48. Article. IF: 8.7; D1
- **Díaz-García E, Alfaro E, Pérez-Moreno P, López-Fernández C, García-Sánchez A, Martínez-García MA, Mañas E, Cano-Pumarega I, Casitas R, Campos-Rodríguez F, Sánchez-de-la-Torre M, Nagore E, Martorell-Calatayud A, Blasco LH, Pastor E, Abad-Capa J, Montserrat JM, Cabriada-Nuño V, Corral-Peñafiel J, Arias E, Mediano O, Somoza-González M, Dalmau-Arias J, Almendros I, Troncoso-Acevedo F, Gotera-Rivera C, Pérez-Warnisher T, Peces-Barba G, Seijo LM, Gozal D, García-Rio F, Cubillos-Zapata C.** From bench to bedside: Exploring the role of sCD25 in melanoma and lung cancer among sleep apnea patients. Pulmonology. 2025; 31(1): 2590870. Article. IF: 5.3; Q1
- **Fernández MG, Sen AB, Pablo PC, Blasco AV, Hurtado GR, Delgado C, Cubillos C, Boscá L, Velasco MF.** Atrial myopathy and heart failure: immunomolecular mechanisms and clinical implications. Int J Mol Sci. 2025; 26(17): 8210. Review. IF: 5.6; Q1
- **García-Rio F.** The evolving role of pulmonary function interpretation: clinical implications of the new ers/ats standards in asthma care. J Invest Allerg Clin. 2025; 35(2): 76-86. Article. IF: 6.6; Q1
- **Laorden D, Domínguez-Ortega J, Romero D, Villamañán E, Mariscal-Aguilar P, Granda P, Quirce S, alvarez-Sala R, ASMAGRAVE HULP Grp.** Efficacy assessment of biological treatments in severe asthma. J Clin Med. 2025; 14(2): 321. Review. IF: 3.3; Q1
- **Longas M, Aponte CS, Laorden D, Romero D, Quirce S, Álvarez-Sala R.** Long term effectiveness of mepolizumab in the treatment of chronic eosinophilic pneumonia. Open Respir Arch. 2025; 7(3): 100462. Article. Not Indexed
- **López-Beneyto J, Ponte E, Martínez-Sanjuán V, Fernandez-Velilla M, Mata-Escolano F, Torres-Sánchez M, Garcia-Rio F, Nalla S, Ercan I, Sanchis-Gimeno JA.** Lung volumetry of osteogenesis imperfecta type 3 subjects is not correlated with thoracic scoliosis and anthropometric data. Orphanet J Rare Dis. 2025; 20(1): 265. Article. IF: 3.6; Q2
- **López-Monzoni S, Benito GH, Romero-Peralta S, Silgado-Martínez L, Viejo-Ayuso ME, Álvarez-Balado L, Matarranz ER, Izquierdo CF, Sánchez-de-la-Torre M, Masa JF, Barbé F, García-Río F, Martínez-Nicolás A, García-Mediano B, Solano-Pérez E, Mediano O.** Improving anxiety related to chronic pain through a sleep circadian intervention program: a pilot study. Behav Sci (Basel). 2025; 15(1): 40. Article. IF: 3.2; Q1



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



- **Martínez-García MA, Olveira C, Girón R, García-Clemente M, Máiz L, Sibila O, Golpe R, Rodríguez-Hermosa JL, Barreiro E, Méndez R, Prados C, Rodríguez-López, Oscullo G, de la Rosa D.** Reliability of blood eosinophil count in steady-state bronchiectasis. Pulmonology. 2025; 31(1): 2416836. Article. IF: 5.3; Q1
- **Mediano O, López-Monzoni S, Castillo-García M, Romero-Peralta S, Viejo-Ayuso ME, Silgado-Martínez L, Alvarez-Balado L, Forné C, Resano-Barrio P, García-Rio F, Cano-Pumarega I, Sánchez-de-la-Torre M, Ortigado A, Fidalgo L, Rodríguez A, Álvarez A, Mora JU, García-Mediano B, Azarbarzin A, Solano-Pérez E.** Cardiovascular risk through hypoxic burden in children with sleep apnea. JAMA Netw Open. 2025; 8(10): e2538744. Article. IF: 11.7; D1
- **Oscullo G, Bekki A, Olveira C, Girón R, García-Clemente M, Maíz L, Sibila O, Golpe R, Rodríguez-Hermosa JL, Barreiro E, Méndez R, Prados C, Rodríguez-López J, de la Rosa D, Martínez-García MA.** Persistent blood eosinophilia and eosinopenia: relationship with outcomes in bronchiectasis. Arch Bronconeumol. 2025; 61(8): 484-9. Article. IF: 8.7; D1
- **Oscullo G, Méndez R, Olveira C, Girón R, García-Clemente M, Máiz L, Sibila O, Golpe R, Rodríguez-Hermosa J, Barreiro E, Prados C, Rodríguez-López JL, de la Rosa-carrillo D, Martinez-García MA.** Effect of N-acetylcysteine on bronchiectasis in a real-life study. Data from the Spanish RIBRON Registry. Arch Bronconeumol. 2025; 61(4): 196-202. Article. IF: 8.7; D1
- **Oscullo G, Méndez R, Olveira C, Girón R, García-Clemente M, Máiz L, Sibila O, Golpe R, Rodríguez-Hermosa JL, Barreiro E, Prados C, Rodríguez-Lopez J, de la Rosa D, Martinez-Garcia MA.** What is the optimal dose of N-acetylcysteine in adult patients with bronchiectasis?-data from the RIBRON registry. J Thorac Dis. 2025; 17(10): 9003-12. Article. IF: 2.3; Q3
- **Padilla JM, Alfaro E, Casitas R, Galera R, Martínez-Cerón E, Díaz-García E, Torres MV, López-Fernández C, Pérez-Moreno P, Soler-Cataluña JJ, Cubillos-Zapata C, García-Río F.** Original characterization of inactive copd patients: barriers to physical activity and perceived impact of inactivity. Arch Bronconeumol. 2025; 61(9): 555-63. Article. IF: 8.7; D1
- **Resano-Barrio P, Gracia-Lavedan E, Solano-Pérez E, García-Mediano B, Cubillos-Zapata C, Díaz-García E, Romero-Peralta S, Castillo-Garcia M, Barbe F, García-Río F, Sánchez-de-la-Torre M, Mediano O.** Ischemia-modified albumin and cardiovascular risk in obstructive sleep apnea and acute coronary syndrome. Long term follow-up after treatment from the ISAACC study. Sleep Med. 2025; 136: 106804. Article. IF: 4.1; Q1
- **Rodríguez-Pérez J, Andreu-Martínez R, Daza R, Fernández-Arroyo L, Hernández-García A, Díaz-García E, Cubillos-Zapata C, Lozano-Diez A, Morales A, Ramos D, Aragonés J, Cogolludo A, del Peso L, García-Río F, Calzada MJ.** Oxidative stress and inflammation in hypoxemic respiratory diseases and their comorbidities: molecular insights and diagnostic advances in chronic obstructive pulmonary disease and sleep apnea. Antioxidants. 2025; 14(7): 839. Review. IF: 8.2; D1
- **Romero-Peralta S, Alonso M, Mediano O, Moncadas M, Marcet MC, De Larrinaga AA, Marcet M, Carrero MP, de la Peña M, Zarza JA, García-Río F, Alonso-Fernández A.** Diagnostic performance of a type III portable monitoring device for obstructive sleep apnea in pregnant women: a prospective validation study. J Womens Health. 2025; 34(5): 685-93. Article. IF: 1.8; Q3
- **Villamañán E, Laorden D, Ibáñez ME, De las Vecillas L, Carpio C, Alfonso C, Domínguez-Ortega J, Romero D, Quirce S, Álvarez-Sala R.** Adherence to intranasal corticosteroids in patients with severe asthma and nasal polyposis: pharmacological and clinical factors involved. J Clin Med. 2025; 14(14): 5070. Article. IF: 3.3; Q1

Research projects

- **Cubillos Zapata C.** Mecanismos de la activación y control del inflamasoma en la generación de comorbilidades en la apnea obstructiva del sueño (PI22/01257). ISCIII. 2023-2027. Managment centre: FIBHULP
- **Galera Martínez R.** Evaluación del perfil de hipermetilación de microRNAs para la estimación de riesgo de cáncer de pulmón en pacientes con EPOC (PI22/01764). ISCIII. 2023-2026. Managment centre: FIBHULP
- **García Río FJ.** Evaluación de las vías patogénicas de la asociación apnea del sueño y cáncer para una medicina de precisión (2024.266). FIBHULP. 2024-Ongoing. Managment centre: FIBHULP
- **García Río FJ.** Evaluación de las vías patogénicas de la asociación apnea del sueño y cáncer para una medicina de precisión (PI22/01262). ISCIII. 2023-2026. Managment centre: FIBHULP
- **García Río FJ.** Identificación de mecanismos, biomarcadores e intervenciones en comorbilidad en enfermedades respiratorias hipoxémicas mediante abordajes preclínicos, clínicos y computacionales (S2022/BMD-7224 - INSPIRA-CM). CM. 2023-2026. Managment centre: FIBHULP
- **García Río FJ.** Revolucionando el cribado del cáncer de pulmón: presentación de un papel epigenético como prototipo de herramienta diagnóstica no invasiva que cambiará las reglas del juego (DTS24/00097). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Martínez Cerón E, Zamarrón de Lucas E.** Análisis del impacto de las características del sueño y del microbioma intestinal y respiratorio en la asociación apnea del sueño y diabetes para caracterizar potenciales biomarcadores de riesgo (PI23/00695). ISCIII. 2024-2026. Managment centre: FIBHULP

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Ciber and Retics

- **García Río F.** CIBER de Enfermedades Respiratorias (CIBERes). ISCIII. (31/12/2025). FIBHULP

Clinical trials

- **Alcolea Batres S.** Estudio en fase III, prospectivo, multicéntrico, doble ciego, con doble simulación, aleatorizado, controlado con fármaco activo, de grupos paralelos, de grupos secuenciales, adaptativo y basado en acontecimientos para comparar la eficacia, la seguridad y la tolerabilidad de macitentán 75 mg frente a macitentán 10 mg en pacientes con hipertensión arterial pulmonar, seguido de un periodo de tratamiento abierto con macitentán 75 mg.
  Type/Phase: III
  Sponsored by: Janssen-Cilag España, S.A.
  Signature date: 13/10/2025
- **García Río FJ.** Estudio de obtención de pruebas para la detección de cáncer de roche.
  Type/Phase: OTROS
  Sponsored by: F.Hoffmann-La Roche Ltd.
  Signature date: 19/08/2025
- **Romero Ribate D.** Estudio de 52 semanas de duración, aleatorizado, doble ciego, con doble simulación, de grupos paralelos, multicéntrico, de no inferioridad, para evaluar la tasa de exacerbación, las mediciones adicionales de control del asma y la seguridad en participantes adultos y adolescentes con asma grave con fenotipo eosinofílico tratados con gsk3511294 en comparación con mepolizumab o benralizumab.
  Type/Phase: III
  Sponsored by: Glaxosmithkline Research And Development Limited.
  Signature date: 05/08/2025
- **Gómez Carrera L.** Estudio aleatorizado, doble ciego, controlado con placebo y multicéntrico de 26 semanas de duración para evaluar la eficacia, seguridad y tolerabilidad de axatilimab en pacientes con fibrosis pulmonar idiopática (fpi).
  Type/Phase: IIb
  Sponsored by: Syndax Pharmaceuticals, Inc.
  Signature date: 08/07/2025
- **Alcolea Batres S.** Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, multicéntrico y de grupos paralelos para evaluar la eficacia y la seguridad de treprostinil palmitilo en polvo para inhalación en participantes con hipertensión pulmonar asociada con enfermedad pulmonar intersticial.
  Type/Phase: III
  Sponsored by: Insmed Incorporated.
  Signature date: 01/12/2025
- **Alcolea Batres S.** Estudio de seguimiento a largo plazo abierto para evaluar los efectos de sotatercept añadido al tratamiento de fondo para tratar la hipertensión arterial pulmonar (hap).
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 18/09/2025
- **Alcolea Batres S.** A phase 2, open-label extension study to investigate the safety and efficacy of pf-07868489 administered to adult participants with pulmonary arterial hypertension.
  Type/Phase: II
  Sponsored by: Pfizer Inc.
  Signature date: 25/11/2025
- **Zamarron De Lucas E.** Ensayo de fase IIb, aleatorizado, doble ciego, controlado con placebo, paralelo, de dosis múltiple para evaluar la eficacia, seguridad y farmacocinética de azd0292 en participantes de 12 años de edad en adelante y adultos con bronquiectasias y colonización crónica por pseudomonas aeruginosa.
  Type/Phase: IIb
  Sponsored by: Astrazeneca Ab.
  Signature date: 08/09/2025
- **Prados Sánchez C.** Estudio de fase II, aleatorizado, doble ciego y controlado con placebo sobre el uso de ensifentrina en pacientes con bronquiectasia no asociada a fibrosis quística.
  Type/Phase: II
  Sponsored by: Verona Pharma Plc.
  Signature date: 09/06/2025
- **García Río FJ.** Explorando los efectos anti envejecimiento de la metformina en la epoc.
  Type/Phase: III
  Sponsored by: Fundación Instituto De Investigación Sanitaria De Navarra.
  Signature date: 18/12/2025
- **Romero Ribate D.** A phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the efficacy and safety of pf-07275315 in adult participants with inadequately controlled moderate-to-severe asthma.
  Type/Phase: II
  Sponsored by: Pfizer Inc.
  Signature date: 25/09/2025
- **García Río FJ.** A randomized, double-blind, placebo-controlled, parallel- group study to assess efficacy and safety of verekitug in participants with moderate-to- severe chronic obstructive pulmonary disease (copd).
  Type/Phase: IIb
  Sponsored by: Upstream Bio, Inc.
  Signature date: 13/10/2025
- **Prados Sánchez C.** A phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of bi 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (the airtivity® study).
  Type/Phase: III
  Sponsored by: Boehringer Ingelheim International Gmbh.
  Signature date: 18/06/2025
- **García Río FJ.** Infección por virus respiratorio sincitial en las exacerbaciones de la enfermedad pulmonar obstructiva crónica. respiratory syncytial virus infection in exacerbations of chronic obstructive pulmonary disease.
  Type/Phase: OTROS
  Sponsored by: Fundació Món Clínic Barcelona.
  Signature date: 28/01/2025
- **Romero Ribate D.** Estudio de fase II, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, con dos brazos para investigar la eficacia, seguridad y tolerabilidad de lunsekimig subcutáneo (sar443765) en participantes adultos con asma de alto riesgo que no son actualmente elegibles para tratamiento biológico.
  Type/Phase: II
  Sponsored by: Sa Sanofi-Aventis Recherche Et Developp.
  Signature date: 10/03/2025
- **Alcolea Batres S.** A phase 1 / 2, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single escalating doses of pf-07868489 in healthy adult participants and, additionally, clinical activity of repeat doses in participants with pulmonary arterial hypertension.
  Type/Phase: II
  Sponsored by: Pfizer Inc.
  Signature date: 14/04/2025

Patents and trademarks

- **Díaz García E, Laxman Nanwani K, Quintana Díaz M, García Río F, Cubillos-Zapata C, inventors; FIHULP, CIBER, assignees.** Biomarcadores para el pronóstico de pacientes que han sufrido una hemorragia subaracnoidea aneurismática (SAH). P202130180; 2021 March 3.
- **Villamañán E, Contreras J, Romero D, Carpio C, Álvarez-Sala R, Herrero A, Quirce S, inventors; FIBHULP, assignee.** Expertasma. Nº018981670; 2024 June 14.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.4.4 Regulation of Gene Expression and by Hypoxia

Publications: 1 | Q1: 1

COMPOSITION

Luis del Peso Ovalle.
Profesor Titular. Departamento de Bioquímica. Facultad de Medicina. Universidad Autónoma de Madrid



STRATEGIC OBJETIVES

- Oxygen is essential for the metabolism of all tissues. Therefore, cells respond to hypoxia by activating a series of mechanisms aimed at restoring an appropriate oxygen supply to the tissues and maintaining adequate energy production during hypoxia. These responses are mediated by a molecular machinery in which the transcription factor HIF (Hypoxia-Inducible Factor) plays a central role.
- The primary objective of our group is to deepen our understanding of the molecular machinery involved in the response to hypoxia. Specifically, we aim to identify, using a combination of bioinformatics and molecular biology techniques, the complement of genes induced by hypoxia via HIF and to characterize their function in the hypoxic response. In addition to providing a comprehensive view of the hypoxic response, this line of research may allow the identification of genes that are useful markers for the diagnosis or monitoring of pathologies that involve the development of tissue hypoxia, such as neoplasms and respiratory and cardiovascular diseases

RESEARCH LINES

- Characterization of the molecular mechanisms responsible for the transcriptional response to hypoxia.
- Identification of polymorphisms that affect HIF binding sites and characterization of their functional effect.
- Cellular and molecular mechanism of regulation of angiogenesis by hypoxia.
- Regulation of metabolism by hypoxia and the role of HIF in metabolic diseases.

RESEARCH ACTIVITY

Master Theses

- **Fernández Cañizares M.** Exposure to sustained and intermittent hypoxia mimicking chronic obstructive respiratory disorders: effects on brown adipose tissue[dissertation]. Madrid: UAM: 2025(01/07/2025). Director: del Peso Ovalle L.

Final Degree Theses

- **Sánchez Peña C.** Papel de la ruta HIF/BHLHE40 en la homeostasis metabólica y adaptación a hipoxia[dissertation]. Madrid: UAM: 2025(25/05/2025). Director: del Peso Ovalle L.

Publications

- **Rodríguez-Pérez J, Andreu-Martínez R, Daza R, Fernández-Arroyo L, Hernández-García A, Díaz-García E, Cubillos-Zapata C, Lozano-Díez A, Morales A, Ramos D, Aragonés J, Cogolludo A, del Peso L, García-Río F, Calzada MJ.** Oxidative stress and inflammation in hypoxemic respiratory diseases and their comorbidities: molecular insights and diagnostic advances in chronic obstructive pulmonary disease and sleep apnea. Antioxidants. 2025; 14(7): 839. Review. IF: 8.2; D1

Research projects

- **del Peso Ovalle L.** Contribución de BHLHE40 a la respuesta transcripcional a la hipoxia y su implicación en patologías metabólicas y respiratorias (PID2020-118821RB-I00). MICIN. 2021-2025. Managment centre: UAM
- **del Peso Ovalle L.** Identificación de mecanismos, biomarcadores e intervenciones en comorbilidad en Enfermedades Respiratorias Hipoxémicas mediante abordajes preclínicos, clínicos y computacionales. (P2022/ BMD-7224). CAM. 2023-2027. Managment centre: UAM
- **del Peso Ovalle L.** Beyond cell culture: characterizing early in vivo transcriptional adaptations to hypoxia(PID2024-159980OB-I00). MICIN. 2025-2029. Managment centre: UAM

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.4.5 Nephrology



Publications: 25 | Q1: 16

COMPOSITION

Gemma María Fernández Juárez.
Jefe de Servicio de Nefrología. Hospital Universitario La Paz

- **María José Castro Notario.** *Enfermera. Hospital Universitario La Paz*
- **Olga Costero Fernández.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Gloria del Peso Gilsanz.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **María Elena González García.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Yanieli Hernández Perdomo.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Carlos Jiménez Martín.** *Jefe de Sección de Nefrología. Hospital Universitario La Paz*
- **María Ovidia López Oliva.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Marta Ossorio González.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Almudena Pérez Torres.** *Dietista-Nutricionista. Hospital Universitario Santa Cristina*
- **Begoña Rivas Becerra.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Amir Shabaka Fernández.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Rafael Jesús Sánchez Villanueva.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **María Cristina Vega Cabrera.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- The strategic objective of this clinical research group is to enable patients to access the best available diagnostic and therapeutic interventions by developing in-depth knowledge of the various components of Nephrology (early-stage nephropathies, progression of kidney disease, and specific and general complications of dialysis and kidney transplantation). Each area must have a guaranteed minimum level of research and development activity that reflects innovation within its field. Research lines are sometimes transversal, encompassing all four components of Nephrology.

RESEARCH LINES

1. Glomerular Nephropathy

- Role of PLA2r levels in membranous nephropathy.
- Study of the alternative complement pathway in glomerular pathologies: vasculitis, membranous nephropathy, IgA glomerulonephritis.
- Morbidity, mortality and progression of diabetic nephropathy and other glomerular nephropathies.
- Adult polycystic kidney disease. Family studies and therapeutic approaches.
- Association between cardiovascular disease and progression of nephropathies (NEFRONA multicenter studies).

2. Renal replacement therapy

- Evolution of peritoneal function in peritoneal dialysis. Implications for patient and technique survival. New peritoneal dialysis devices and solutions. Aquaporin 1 and its genetic polymorphisms. Involvement of alternatively activated macrophages and CC.
- Cardiovascular risk in dialysis patients. Study of endocrine alterations in dialysis patients. Role of FGF21 in uremic insulin resistance.
- Murine model for peritoneal dialysis: exploration of the effects of dialysis fluids, pharmacological interventions and genetic manipulation (KO, transgenic).

3. Complication of kidney transplantation

- CMV infection and disease in kidney transplantation. Personalized care.
- Graft tolerance.
- Quality of life of the transplant patient. Patient-reported transplant outcome.
- Individualization of immunosuppression.
- Knowledge of the cortical microcirculation of the graft.
- Active and ongoing collaboration with the Spanish kidney transplant group (SENTRA), some of which are led by the La Paz group: Covid disease, kidney prevention (iSGLT-2), pregnancy in kidney transplantation, bacterial infections, thrombotic microangiopathy, donation after circulatory death, relapses of different kidney diseases after transplantation.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH ACTIVITY

Final Degree Theses

- **Alonso Medela I.** Factores relacionados con la toma de decisiones en la elección de tratamiento en pacientes añosos con enfermedad renal crónica avanzada (ERCA) [dissertation]. Madrid: UAM: 2025(26/06/2025). Director: del Peso Gilsanz G.

Publications

- **Arriero-País EM, Bajo-Rubio MA, Arrojo-García R, Sandoval P, González-Mateo GT, Albar-Vizcaíno P, del Peso-Gilsanz G, Ossorio-González M, Majano P, López-Cabrera M.** Biomarker and clinical data-based predictor tool (MAUXI) for ultrafiltration failure and cardiovascular outcome in peritoneal dialysis patients: a retrospective and longitudinal study. BMJ Health Care Inform. 2025; 32(1): e101138. Article. IF: 6.2; D1
- **Azores-Moreno J, Cases-Corona C, Sánchez-Álamo B, Maldonado M, Leon-Machado L, Rivas B, Vega C, Shabaka A, Fernández-Juárez G.** Acute drug-induced tubulointerstitial nephritis: current perspectives on diagnosis and treatment. Adv Kidney Dis Health. 2025; 32(4): 341-9. Article. IF: 3.1; Q2
- **Barbour SJ, Ronco P, Praga M, Fervenza FC, Induruwage D, Zhu BY, Debiec H, Fernández-Juárez G, Caravaca-Fontán F, Cattran DC.** Predicting Remission in anti-PLA2R antibody-associated membranous nephropathy: a secondary analysis of the GEMRITUX, MENTOR and STARMEN trials. Clin J Am Soc Nephro. 2025; 20(6): 854-65. Article. IF: 7.0; D1
- **Caravaca-Fontán F, Alonso-Riano M, Shabaka A, Villacorta J, de Lorenzo A, Quintana LF, Rodríguez E, Gadola L, Cobo MA, Oliet A, Sierra-Carpio M, Cobelo C, Iglesias E, Cordón A, Praga M, Fernández-Juárez G, Spanish Grp Study Glomerular Dis GLOSEN.** A predicting tool for kidney function recovery after drug-induced acute interstitial nephritis. Nephrol Dial Transpl. 2025; 40(9): 1707-16. Article. IF: 8.3; D1
- **Caravaca-Fontán F, Toledo-Rojas R, Huerta A, Pérez-Canga JL, Martínez-Miguel P, Miquel R, Da Silva I, Verdalles U, Albornoz M, López CMD, Mon C, Fernandez-Juárez G, Praga M.** Comparative analysis of proteinuria and longitudinal outcomes in immune complex membranoproliferative glomerulonephritis and C3 glomerulopathy. Kidney Int Rep. 2025; 10(4): 1223-6. Article. IF: 6.2; Q1
- **Fernández-Lorente L, Shabaka A, Mora-Gutiérrez JM, Caravaca-Fontán F, Maldonado-Martin M, Cabello V, Marco H, Temprado A, Rivera C, Facal L, Barros X, Manrique J, Santos AP, Fernández-Juárez G, González CC.** Atypical anti-glomerular basement membrane disease. Kidney Int Rep. 2025; 11(3): 103732. Letter. IF: 6.2; Q1
- **Fontao SM, Manso P, Audije-Gil J, Gascueña DH, Dapena F, Aresté N, Sánchez-Álvarez E, Molina P, Ojeda R, Goicoechea M, Simó VE, Bezhold GA, Prieto-Velasco M, Lloret MJ, Santos AB, Buades JM, Narváez C, Sánchez-Villanueva R, Pérez-Morales RE, Jiménez MDA, Fdn Renal Espanola Working Grp, Prurito Working Grp.** Quality of life and clinical data in hemodialysis patients with different degrees of pruritus. Sci Rep-Uk. 2025; 15(1): 6222. Article. IF: 4.9; Q1
- **Fuentes-Fernández C, Maldonado-Martin M, García EG, León-Machado L, Jiménez C, López-Oliva MO.** Effect of pre-transplant renal anticoagulation and antiplatelet therapy on post-transplant outcomes: a retrospective single-center study. Transpl P. 2025; 57(1): 19-23. Article. IF: 0.8; Q4
- **García EG, Arroyo T, Galván M, Becerra MJ, Gallego M, Mauro I, Hernández Y, Pérez-Torres A, Oliva MOL, Santana MJ, Jiménez C.** Association between nutritional status and early postoperative infection risk in kidney transplant patients. Nutrients. 2025; 17(11): 1935. Article. IF: 5.8; Q1
- **García EG, Oliva ML, Mancebo E, Santana MJ, Machado LML, Fernández CF, Jiménez C.** Efficacy and safety of a desensitization treatment with rituximab and immunoglobulin in hyperimmunized patients awaiting a cadaveric kidney transplantation. Transpl P. 2025; 57(1): 3-6. Article. IF: 0.8; Q4
- **Ghaddar M, Caravaca-Fontán F, Praga M, Fernández-Juárez G, Lomax-Browne HJ, Cook HT, Daina E, Noris M, Remuzzi G, Induruwage D, Zhu BY, Pickering MC, Barbour SJ.** Clinical and histologic predictors of kidney outcomes in c3 glomerulopathy and idiopathic membranoproliferative GN. Clin J Am Soc Nephro. 2025; 20(8): 1119-31. Article. IF: 7.0; D1
- **León-Machado L, Sierra-Torres G, Shabaka A, Cases-Corona C, Vega C, Rivas B, Cabrera DR, Fernández-Juárez G.** Epidemiological changes in anti-glomerular basement membrane disease in Madrid in the context of the COVID-19 pandemic. Front Nephrol. 2025; 5: 1667652. Article. IF: 2.9; Q2
- **Macía M, Fernández-Juárez G, Ávila AI, Espino M, Espinosa M, Fulladosa X, García-Carro C, Goicoechea M, Morales E, Quintana LF, Rojas-Rivera JE, Praga M.** GLANCE survey: Awareness and implementation of the GLOSEN recommendations for the diagnosis and treatment of lupus nephritis. Nefrologia. 2025; 45(9): 501354. Article. IF: 2.1; Q3
- **Morales E, Rúa-Figueroa I, Rubio JLC, Bernabéu AA, Alonso RB, Xutgla MCC, Juárez GF, Mena-Vázquez N, Blanco JJR, Escola JM, García FJN, Sopeña B, Porras LFQ, Romero-Yusten S, Laqué RS.** Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis. Nefrología. 2025; 45(1): 15-58. Article. IF: 2.1; Q3
- **Moreno JA, Cabañas R, Bellón T, Fernández EG, Raso IV, Aldana S, Maldonado M, León-Machado L, Shabaka A, Becerra BR, Cabrera CV, Juárez GF.** Lymphocyte transformation test: a promising tool for identifying the causative agent in drug-induced acute interstitial nephritis. Kidney Int Rep. 2025; 10(5): 1562-5. Editorial Material. IF: 6.2; Q1
- **Pérez-Sáez MJ, Melilli E, Arias M, Franco A, Martínez R, Sancho A, Molina M, Facundo C, Polanco N, López V, Mazuecos A, Cabello S, García MEG, Suárez ML, Auyanet I, Espi J, Falcón TG, Ruiz JC, Galeano C, Artamendi M, Rodríguez-Ferrero ML, Portolés JM, Santana MA, Martín-Moreno PL, Arhda N, Calvo M, Mendiluce A, Macía M, Pérez-Tamajón ML, de Teresa J, Gascó B, Soriano S, Tabernero G, de la Vara L, Ramos AM, Martínez R, de Espinosa EM, Zalve JL, Pascual J, Rodriguez-Mañas L, Gutiérrez-Dalmau A, Moreso F.** Frailty prevalence and characterization among kidney transplant candidates in spain: a multicenter study. Transpl Int. 2025; 38: 14098. Article. IF: 3.6; Q1
- **Pilco-Terán M, Shabaka A, Furlano M, Ribera AT, Carrillo IG, Gutiérrez E, Torra R, Fernández-Juárez G.** Indications for genetic testing in adults with focal segmental glomerulosclerosis. Nefrologia. 2025; 45(2): 135-49. Article. IF: 2.1; Q3
- **Praga M, Caravaca-Fontán F, da Silva I, Fernández-Juárez G, Gutiérrez E, Sevillano AM, Trimarchi H.** Tailored management strategies for IgA nephropathy based on clinical presentations. Nephrol Dial Transpl. 2025; 40(5): 874-83. Review. IF: 8.3; D1
- **Requena B, Shabaka A, Lanzón B, Martinez S, Carrillo IG, Bada-Bosch T, Sevillano A, Tato-Ribera AM, Barbas C, Medina-Gómez G, González-Riano C, Fernández-Juárez G.** Lipidomics unveils critical lipid pathway shifts in alport syndrome. Kidney Int Rep. 2025; 10(8): 2805-20. Article. IF: 6.2; Q1
- **Rodrigo E, Quintana LF, Vázquez-Sánchez T, Sánchez-Fructuoso A, Buxeda A, Gavela E, Cazorla JM, Cabello S, Beneyto I, Sevillano AM, López-Oliva MO, Diekmann F, Gómez-Ortega JM, Calvo-Romero N, Pérez-Sáez MJ, Sancho A, Mazuecos A, Espi-Reig J, Trujillo H, Jiménez C, Hernández D.** Validation of 2 prognostic models to predict renal allograft outcome after iga

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

nephropathy recurrence. Kidney Int Rep. 2025; 10(7): 2323-33. Article. IF: 6.2; Q1

- **Rodríguez-Goncer I, Ruiz-Arabi E, Herrera S, Sabé N, Los-Arcos I, Silva JT, Pérez-Nadales E, Machuca I, Álvarez R, Valerio M, Castón JJ, Aguilera V, Bodro M, Cano A, Cantón R, Carmona P, Carratalà J, Cordero E, Cruzado JM, Fariñas MC, Fernández-Ruiz M, Fondevila C, Fortún J, García-Cosío MD, Gutiérrez-Dalmau A, Iturbe D, Justo I, Len O, López-Medrano F, Oliva MOL, Martín-Dávila P, Martínez-Martínez L, Mazuecos A, Mirabet S, Muñoz P, Oliver A, Pérez-Sáez MJ, Rodríguez-Gómez J, San-Juan R, Sánchez-Céspedes J, Solé A, Verdú EV, Villa J, Torre-Cisneros J, Aguado JM.** Management of multidrug-resistant gram-negative bacilli infections in adult solid organ transplant recipients: GESITRA-IC/SEIMC, CIBERINFEC, and SET recommendations update. Transplant Rev-Orlan. 2025; 39(3): 100937. Review. IF: 3.2; Q2
- **Rojas-Rivera JE, Caravaca-Fontán F, van de Logt AE, Sevillano A, Shabaka A, Avila A, Rabasco C, Cabello V, Ortiz A, Quintana LF, Goicoechea M, Díaz M, Ronco P, Wetzels J, Fernández-Juárez G, Praga M.** Identification of early predictors of clinical remission in primary membranous nephropathy: a post hoc analysis of the STARMEN trial. Clin Kidney J. 2025; 18(9): sfaf256. Article. IF: 5.3; Q1
- **Sánchez-Álvarez E, Poveda JL, Sánchez-Villanueva R, Cañizares ID, de Arellano AR, Ruiz-Andres O.** Cost-utility analysis of difelikefalin for the treatment of moderate to severe Chronic Kidney Disease associated-Pruritus (CKD-aP) in adult patients receiving haemodialysis in Spain. J Med Econ. 2025; 28(1): 835-47. Article. IF: 3.1; Q1
- **Santos A Sánchez Villanueva R Alonso Bovarro A.** Adequacy of therapeutic effort as a crucial competence in nephrology: case report. Port J Nephrol. 2025; 39(2): 103-5. Article. Not Indexed
- **Torra R, Barros X, Díaz-Encarnación M, Fayos L, Furlano M, Pilco M, Pybus M, Shabaka A, Viera E, Ars E.** When should the nephrologist think about genetics in patients with glomerular diseases? Clin Kidney J. 2025; 18(3): sfaf044. Review. IF: 5.3; Q1

Research projects

- **Del Peso Gilsanz G.** Clinical validation of a continuous flow peritoneal dialysis system, with dialysate regeneration (CORDIAL). UE. 2021-2025. Managment centre: FIBHULP
- **Del Peso Gilsanz G.** Relación de la funcionalidad de la membrana peritoneal y la patología cardiovascular en pacientes en diálisis peritoneal tratados con soluciones biocompatibles. Repercusión sistémica de un problema local (PI22/00574). ISCIII. 2023-2027. Managment centre: FIBHULP
- **Fernández Juárez GM.** Impacto de las variantes genéticas y nivel de activación del complemento en la patogénesis y pronóstico de la nefropatía membranosa y vasculitis anca (2024.725). Fundación SENEFRO. 2025-Ongoing. Managment centre: FIBHULP
- **Fernández Juárez GM.** Impacto de las variantes genéticas y nivel de activación del complemento en la patogénesis y pronóstico de la nefropatía membranosa y vasculitis anca (PI24/01711). ISCIII. 2025-2027. Managment centre: FIBHULP
- **González García ME.** Evaluación de la medición del FGF-21 pre-trasplante como marcador de riesgo de desarrollo de diabetes mellitus postrasplante renal (2024433). Sociedad Madrileña de Trasplantes. 2025-2026. Managment centre: FIBHULP
- **Jiménez Martín C.** Evaluación de la microciculación cortical (mcc) del trasplante renal a largo plazo medida por ecografía con contraste (ec) y su correlación histopatológica por biopsia renal (JIMENEZ MARTÍN-PI-3535 SMT). Sociedad Madrileña de Trasplantes. 2019-Ongoing. Managment centre: FIBHULP

Ciber and Retics

- **Fernández Juárez GM.** Inflamación e inmunopatología de órganos y sistemas (RD21/0005/0030). ISCIII. (31/12/2025). FIBHULP

Clinical trials

- **Costero Fernández O.** Eficacia de la colchicina en prevención secundaria de eventos vasculares y progresión renal en pacientes con enfermedad renal crónica moderada (estudio colchiren).
  Type/Phase: III
  Sponsored by: Fundacion Biomedica Hospital Gregorio Marañon.
  Signature date: 28/03/2025
- **Jiménez Martín C.** Ensayo clínico fase iv, multicéntrico, controlado, aleatorizado y simple ciego, adaptativo, para evaluar la efectividad y coste-efectividad de la estrategia de genotipado pretrasplante para optimizar la dosis de tacrolimus en una cohorte de población con enfermedad renal crónica.
  Type/Phase: IV
  Sponsored by: Fundacion Para La Investigacion Biomedica Hospital Universitario La Paz.
  Signature date: 26/02/2025
- **López Oliva MO.** CMV-specific immune response and relationship to recurrence in solid organ transplant recipients with refractory cmv infection: a prospective observational study.
  Type/Phase: EOm prospectivo
  Sponsored by: Fundacio Hospital Vall D'Hebron.
  Signature date: 10/11/2025
- **López Oliva MO.** Ensayo clínico randomizado de prevención inmunoguiada vs. terapia anticipada para prevenir la infección por citomegalovirus en trasplantados renales de bajo riesgo (estudio inmunovir).
  Type/Phase: III
  Sponsored by: Servicio Andaluz De La Salud.
  Signature date: 09/09/2025
- **López Oliva MO.** Uso de tacrolimus e inhibidores mtor con terapia anticipada vs. tacrolimus y ácido micofenólico con profilaxis universal en receptores renales con alto riesgo de citomegalovirus postrasplante. ensayo clínico fase 4. estudio timtor.
  Type/Phase: IV
  Sponsored by: López Oliva, María Ovidia.
  Signature date: 18/06/2025
- **Vega Cabrera MC.** Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de ravulizumab en participantes adultos con nefropatía por inmunoglobulina a (igan)".
  Type/Phase: III
  Sponsored by: Alexion Pharmaceutical Inc.
  Signature date: 28/04/2025

Patents and trademarks

- **Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees.** Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.
- **Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees.** Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.
- **López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R, Passlickdeetjen J.** Buechel J, Steppan S, inventors; Fresenius Medical Care AG & Co. KGaA, assignee. Method and kit for diagnosing epitelial to mesenchymal transition of the peritoneum (EMT-Chip). WO2017042253, DE102015115158; 2015 September 09.
- **Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J, inventors; Fresenius Medical Care Deutschland GMBH, assignee.** Pharmaceutical compositions containing steviosides. PCT/EP2015/074955, EP3212199, US2017304335, CN107073022; 2014 October 31.
- **Eva María Arriero-País, María Auxiliadora Bajo-Rubio, Roberto Arrojo-García, Pilar Sandoval, Guadalupe Tirma González-Mateo, Patricia Albar-Vizcaíno, Gloria del Peso-Gilsanz, Marta Ossorio-González, Pedro Majano, Manuel López-Cabrera.** "Programa MAUXI (Software entrenado a base de aprendizaje autom.tico y biomarcadores para la predicci.n y el diagn.stico de la duraci.n de tratamiento m.ximo y la causa de fallo de técnica en pacientes de fallo renal en di.lisis peritoneal). N. de patente: 133116z HASD: 8F1D6E3C5700377F74294090A01FD-1D1C455AC70C7D16f03E54.

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.4.6 Diagnosis and Treatment of Allergic Diseases



Publications: 59 | Q1: 36

COMPOSITION

Santiago Eugenio Quirce Gancedo.
Jefe de Servicio de Alergología. Hospital Universitario La Paz

- **Diana Betancor Pérez.** *Médico Adjunto en Alergología. Hospital Universitario La Paz*
- **María Teresa Caballero Molina.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **María Luisa Caballero Soto.** *Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz*
- **Francisco Javier Contreras Porta.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Leticia de las Vecillas Sánchez.** *Facultativo Especialista en Alergología. Hospital Universitario La Paz*
- **Francisco Javier Domínguez Ortega.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Ana María del Carmen Fiandor Román.** *Jefe de Sección de Alergologia. Hospital Universitario La Paz*
- **María del Mar Gandolfo Cano.** *Jefe de Sección de Alergologia Infantil. Hospital Universitario La Paz*
- **Carmen Gómez Traseira.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Rosario González Mendiola.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Juan Alberto Luna Porta .** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **María Magdalena Lluch Bernal.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **María Pedrosa Delgado.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Elsa Phillips Angles.** *Facultativo Especialista de Área en Alergología Pediátrica. Hospital Universitario La Paz*
- **Mónica Rodríguez Álvarez.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **María Rosa Rodríguez Pérez.** *Investigadora Titular. Jefe de Laboratorio. Hospital Universitario La Paz*
- **Margarita Tomás Pérez.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Inés Torrado Español.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

The group members are specialized in different areas of allergic pathology, which allows for clinical studies and basic research on the main allergic diseases (food allergy, asthma and rhinitis, urticaria/angioedema, and drug allergy).

The group's strategic research objectives are:

- Development of new techniques to improve the diagnosis of food allergies by determining the molecular sensitization profile
- Treatment of food allergy with oral desensitization protocols
- Study of hypersensitivity and bronchial inflammation in asthma, as well as the role of allergen exposure and comorbidities in this disease
- Study of the pathogenesis and treatment of eosinophilic diseases of the respiratory tract (eosinophilic bronchitis) and the digestive tract (eosinophilic esophagitis)
- Characterization of the different types of angioedema caused by bradykinin (hereditary and acquired) and improvements in its diagnosis and treatment
- Research on the epidemiology and mechanism of severe adverse reactions caused by immune hypersensitivity reactions to drugs

RESEARCH LINES

- Food allergy: molecular diagnosis (by allergenic components) and new diagnostic tests
- Epidemiology, pathophysiology, diagnosis and treatment of angioedema and urticaria
- Studies on bronchial hyperreactivity to direct and indirect agents and inflammation of the airways
- Eosinophilic diseases of the respiratory tract (eosinophilic bronchitis) and digestive system (eosinophilic esophagitis)
- Persistent and difficult-to-control asthma: a study on the influence of common and occupational allergens, comorbidities, and new therapies
- Aspirin-exacerbated respiratory disease (AERD): inflammatory biomarkers and diagnostic procedures
- Adverse immunological reactions to drugs: a study of the cellular and molecular mechanisms involved
- Identification and characterization of new environmental allergens and allergenicity modulating factors

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH ACTIVITY

Doctoral Theses

- **Palao Ocharan PE.** Calidad de vida en angioedema hereditario por déficit de c1 inhibidor. estudio psicométrico del cuestionario genérico de calidad de vida relacionada con la salud (CVRS) SF-36 versión 2.0 (SF-36V2). Análisis de CVRS y estudio exploratorio de los determinantes de la CVRS mediante el cuestionario SF-36V2[dissertation]. Madrid: UAM: 2025(05/05/2025). Director: Caballero Molina MT.

Final Degree Theses

- **Salinas Lujan A.** Identificación y frecuencia de reconocimiento IgE mediado de los alérgenos del polen de Quercus ilex en pacientes sensibilizados[dissertation]. Alcalá de Henares: UAH: 2025(01/06/2025). Director: Rodríguez Pérez MR.
- **Cózar López R.** Identificación de globulinas en bellota de Quercus ilex como fuente de alergias.[dissertation]. Córdoba: Universidad de Córdoba: 2025(01/05/2025). Director: Rodríguez Pérez MR

Publications

- **Agache I, Annesi-Maesano I, Cecchi L, Biagioni B, Chung F, D'Amato G, Damialis A, del Giacco S, Ortega JD, Galán C, Gilles S, Holgate S, Jeebhay M, Kazadzis S, Nadeau K, Papadopoulos NG, Quirce S, Sastre J, Traidl-Hoffmann C, Walusiak-Skorupa J, Zemelka-Wiacek M, Jutel M, Akdis CA.** EAACI Guidelines on environmental science for allergy and asthma-recommendations on the impact of indoor air pollutants on the risk of new-onset asthma and on asthma-related outcomes. Allergy. 2025; 80(3): 651-76. Article. IF: 11.3; Q1
- **Agache I, Salazar J, Rodriguez-Tanta Y, Saenz FKF, Haahtela T, Traidl-Hoffmann C, Damialis A, Vecillas L, Giovannini M, Nadeau KC, Pali-Schöll I, Palomares O, Renz H, Schwarze J, Pinto BS, Urrutia-Pereira M, Venter C, Vercelli D, Winders T, Sola-Arnau I, Alonso-Coello P, Canelo-Aybar C, Jutel M, Akdis CA.** The impact of rhinovirus, syncytial respiratory virus and helminth infection on the risk of new-onset asthma and other allergic conditions-a systematic review for the EAACI guidelines on environmental science for allergic diseases and asthma. Allergy. 2025; 80(7): 1878-1898. Review. IF: 11.3; Q1
- **Almonacid C, Blanco M, Ferreira J, García G, Morete A, Quirce S, Soto-Campos G, Plaza V.** Key updates in the 2025 Spanish Asthma Guidelines (GEMA 5.5). Open Respir Arch. 2025; 7(3): 100453. Editorial Material. Not Indexed
- **Álvarez J, Parody N, Calzada D, Aranda T, Renshaw A, Serna S, Reichardt N, Beitia JM, González-de-Olano D, Domínguez-Ortega J, Carnes J.** Correlation between N-GLYCAN GNGNXF and the allergic immune response against juniperus ashei pollen. Allergy. 2025; 80(7): 1935-44. Article. IF: 11.3; Q1
- **Alves PB, Pablo-Torres C, Karavelia A, Fernández-Santamaría R, Giovannini M, Vecillas LD, Shamji M, Torres MJ.** Addressing the growing role of junior members in EAACI. Allergy. 2025; 80(9): 2682-5. Editorial Material. IF: 11.3; Q1
- **Arismendi E, Puente-Maestu L, Domingo C, Dávila I, Quirce S, Sánchez-Jareño M, Cea-Calvo L.** Emotions in patients with refractory or unexplained chronic cough: a multicenter, non-interventional study. Ther Adv Respir Dis.. 2025; 19: 17534666251374900. Article. IF: 3.2; Q2
- **Betancor D, Rial MJ, Olaguibel JM, Del Pozo V, Puebla MJA, Arismendi E, Barroso B, Bobolea I, Cárdaba B, Cañas JA, Domínguez-Ortega J, Crespo-Leshman A, Cruz MJ, de la Fuente AG, González-Barcalai FJ, Luna-Portac JA, Martínez-Rivera C, Mullol J, Muñoz X, Plaza V, Quirce S, Soto-Retes L, Valverde-Monge M, Sastre J.** Stability of asthma biomarkers over a two-year period using three distinct classifications in the MEGA cohort. Arch Bronconeumol. 2025; 61(12): 794-6. Letter. IF: 8.7; D1
- **Betancourt A, Martínez-de-Ibarreta C, Calvo LA, Wirth E, Budria S, Antolín-Amérigo D, Colque-Bayona M, de la Rocha-ortiz I, Escalante-Carrero MD, Domínguez-Ortega J.** Asthma exacerbations, meteorological variables, and multipollutant concentrations: Uncovering short-term patterns through Association Rule Mining. Environ Pollut. 2025; 384: 127003. Review. IF: 7.2; Q1
- **Bianchini R, Escolar-Pena A, Pick V, Poli A, Adams R, Basilio J, Cari L, Chauhan J, Chivato T, Vecillas LD, Delgado-Dolset MI, Escribese MM, Grandits M, Bax HJ, Martin-Antoniano IA, Martin-Cruz L, Mayerhofer H, Michelucci A, Nocentini G, Osborn G, Pablo-Torres C, Palomares O, Pascal M, Radzikowska U, Rohr-Udilova N, Sokolowska M, Bergmann C, Jensen-Jarolim E, Karagiannis SN, Rebollido-Rios R, Izquierdo E.** Molecular signatures and functional pathways of human monocytes and macrophages in allergy: An EAACI allergooncology scoping review. Allergy. 2025; 80(10): 2710-25. Article. IF: 11.3; Q1
- **Blanco Aparicio M, Pérez de Llano L, Domínguez-Ortega J.** Severe asthma units in spain: enhancing patient care and research in severe asthma. Open Respir Arch. 2025; 7(4): 100474. Article. Not Indexed
- **Caballero ML, Carpio-Hernández D, Parra P, Giraldo-Sánchez JC, Rodríguez-Álvarez M, Quirce S.** ISO 9001:2015 certification of the allergy laboratory. J Invest Allerg Clin. 2025; 35(2): 152-4. Letter. IF: 6.6; Q1
- **Calzada D, Bartra J, Serrano C, Riggioni S, Moran E, Maseli J, Silva D, Ramírez L, Pascal M, Cacheiro-Llaguno C, Valero A, Carnés J.** Comments to reply to differences in molecular sensitization profiles between spanish and latin american mite-allergic patients. J Invest Allerg Clin. 2025; 35(5): 403-4. Letter. IF: 6.6; Q1
- **Calzada D, Parody N, Beitia JM, Domínguez-Ortega J, González-de-Olano D, Renshaw-Calderón A, Osuna C, Moya R; Carnés J.** Immunological parameters for assessing the in vitro safety and efficacy of allergoid mixtures for immunotherapy. J Invest Allerg Clin. 2025; 35(6): 441-51-. Article. IF: 6.6; Q1
- **Castillo MA, Correa-Borit J, Laorden D, Adrianzen F, Villamanan E, Romero D, Quirce S, Domínguez-Ortega J.** Eosinophil and cationic protein levels in patients treated with dupilumab: a real-life study. Open Respir Arch. 2025; 7(3): 100444. Article. Not Indexed
- **Colque-Bayonai M, Domínguez-Ortegai J, Tomás-Pérez M.** Cat and dog specific immunotherapy impact on quality of life and self-reported satisfaction in a real-world setting. Eur Ann Allergy Clin Immunol. 2025; 57(2): 91-5. Letter. IF: 2.5; Q3
- **Colque-Bayonai M, Laorden D, Romero D, Quircei S, Domínguez-Ortegai J.** Anti-IL5/5R in the treatment of chronic eosinophilic pneumonia and severe asthma. Eur Ann Allergy Clin Immunol. 2025; 57(6): 286-8. Letter. IF: 2.5; Q3
- **Cremades-Jimeno L, López-Ramos M, Fernández-Santamaría R, de Pedro MA, Mahillo I, Rosales-Ariza C, Olaguibel JM, del Pozo V, Caballero ML, Luna-Porta JA, Quirce S, Barroso B, Betancor D, Valverde-Monge M, Sastre J, Baos S, Cárdaba B.** Molecularstudy from the signaling pathways of four potential asthma triggers: AKT1, MAPK13, STAT1, and TLR4. Int J Mol Sci. 2025; 26(13): 6240. Article. IF: 5.6; Q1
- **Davila I, Carretero Gracia JA, Cebollero P, Izquierdo Alonso JL, Martínez-Moragon E, Morales-Garcia C, Pérez Chica G, Quirce S, Soler-Cataluña JJ, Vinas M.** Efficient

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Management of Severe Asthma in the Clinic. Open Respir Arch. 2025; 7(3): 100456. Article. Not Indexed

- **De Agrela-Méndes I, Correa-Borit J, López V, Ifrim M, Turiel C, De Las Vecillas L, Quirce S, Domínguez-Ortega J.** Changes in the Nijmegen Questionnaire in severe asthma patients treated with dupilumab. Rev Alerg Mex. 2025; 72(4): 271-5-. Article. Not Indexed
- **de las Vecillas L, Sánchez-Jareino M, Lluch-bernal M, Quirce S, Domínguez-Ortega J, López-carrasco V, Barranco P.** Nasal challenge with ketorolac: utility and safety in clinical practice. Eur Ann Allergy Clin Immunol. 2025; 57(5): 236-8. Letter. IF: 2.5; Q3
- **Delgado J, Cárdenas R, Gelis S, Domínguez-Ortega J.** Allergen immunotherapy for the control of moderate to severe allergic asthma: an evidence-based conjoint analysis to define candidate patient profiles in Spain and Portugal. Front Allergy. 2025; 6: 1676399. Article. IF: 3.4; Q2
- **Delgado Romero J, Soto-Retes L, Cisneros Serrano C, Blanco-Aparicio M, Ferrando Piqueres R, Díaz-Perez D, López-Carrasco V, Merino-Bohorquez V, Domínguez-Ortega J.** BioCart© opinion-based study on home administration support for biological therapies in patients with severe asthma. Open Respir Arch. 2025; 7(1): 100375. Article. Not Indexed
- **Domínguez-Ortega J, Munoz Gall X, Delgado Romero J, Casas-Maldonado F, Blanco-Aparicio M.** Degree of adherence to recommendations from the spanish consensus on the reduction of oral corticosteroid use in asthma patients: a questionnaire-based observational study. Open Respir Arch. 2025; 7(3): 100452. Article. Not Indexed
- **Domínguez-Ortega J, Narváez-Fernández E, Ramos J, Cancelliere N, García-Criado J, Sánchez-Ocando H, Gallardo-Higueras A, Dávila I.** Evaluation of real-world quality of asthma care according to the spanish consensus protocol: The AsmaNET Project (ESR-20-20897). J Asthma Allergy. 2025; 18(): 1119-1127. Article. IF: 3.3; Q2
- **Domínguez-Ortega J, Virchow JC, Guilleminault L, Incalzi RA, Beyer AP, Ke XH, Ding HL, Boggs R.** Prevalence and burden of possible refractory chronic cough in four European countries. ERJ Open Res. 2025; 11(4): 8882024. Article. IF: 4.4; Q1
- **Doyen V, Thirionet R, Migueres N, Vandenplas O, Sastre J, Valverde-Monge M, Grydeland TB, Munoz X, Romero-Mesones C, Suojalehto H, Suuronen K, van Kampen V, Eisenhawer C, Folletti I, Jacobsen IB, Walusiak-Skorupa J, Mason P, Preiser AM, Quirce S, Walters G, Rifflart C, de Blay F, Svanes C.** Phenotypic characteristics of occupational asthma caused by persulfate salts in hairdressers: a multicenter cohort study. J Allergy Clin Immunol Pract. 2025; 13(6): 1397-404. Article. IF: 7.2; D1
- **Entrala A, Lluch-Bernal MM, Domínguez-Ortega J, Molero-Luis M, Sánchez GC, Quirce S, Rodríguez-Perez R.** Measurement of fecal calprotectin and zonulin as biomarkers in adults with fish-induced food protein-induced enterocolitis syndrome. J Invest Allerg Clin. 2025; 35(3): 2302. Editorial Material. IF: 6.6; Q1
- **Escalera-Balsera A, Robles-Bolivar P, Parra-Pérez AM, Murillo-Cuesta S, Chua HC, Rodríguez-de la Rosa L, Contreras J, Domarecka E, Amor-Dorado JC, Soto-Varela A, Varela-Nieto I, Szczepek AJ, Gallego-Martinez A, Lopez-Escamez JA.** A rare haplotype of the GJD3 gene segregating in familial Meniere's disease interferes with connexin assembly. Genome Med. 2025; 17(1): 4. Article. IF: 10.8; D1
- **Espejo D, Plaza V, Quirce S, Trigueros JA, Munoz X.** Influence of outdoor air pollutants on asthma: a narrative review. Open Respir Arch. 2025; 7(3): 100448. Review. Not Indexed
- **Farkas H, Anderson J, Bouillet L, Caballero T, Cancian M, Craig T, Fukunaga A, Grivcheva-Panovska V, Guilarte M, Honda D, Kanarek H, Kiani-Alikhan S, Kinaciyan T, Leguevaques D, Longhurst HJ, Magerl M, Manning ME, Martinez-Saguer I, Melamed I, O'Connor ME, Peter J, Savic S, Soteres DF, Staevska M, Staubach P, Stobiecki M, Tachdjian R, Valerieva A, Yong PFK, Hao J, Iverson M, Smith MD, Yea CM, Audhya PK, Aygören-Pürsün E, Bernstein JA, Cohn DM, Lumry WR, Riedl MA, Zanichelli A, Maurer M.** Long-Term Safety and Effectiveness of sebetralstat: Interim analysis of KONFIDENT-S open-label extension. J Allergy Clin Immunol Pract. 2025; 13(11): 3094-103. Article. IF: 7.2; D1
- **Fokkens WJ, Backer V, Lund VJ, Barnes PJ, Bernal-Sprekelsen M, Bjermer L, de Corso E, Conti DM, Cornet ME, Diamant Z, Djukanovic R, Gaga M, Gevaert P, Han JK, Hopkins C, Joos G, Landis BN, Lau S, Lee SE, Mullol J, Peters AT, Scadding GK, Schneider S, Senior B, Pavord ID, Quirce S, Ryan D, Wechsler ME, Hellings PW.** Pocket guide: biologics in upper and lower airways in adults. Rhinology. 2025; 63(2): 242-4. Letter. IF: 5.7; D1
- **González-Barcala FJ, Bobolea I, Domínguez-Ortega J, Bañas-Conejero D, Antelo-Cea E, Martínez-Moragón E, Carrillo-Díaz T, Blanco-Aparicio M, Domingo C.** Time is lung: higher preservation of lung function in severe asthma patients after earlier mepolizumab treatment. ERJ Open Res. 2025; 11(1): 2112024. Article. IF: 4.4; Q1
- **Jesenak M, Bobcakova A, Djukanovic R, Gaga M, Hanania NA, Heaney LG, Pavord I, Quirce S, Ryan D, Fokkens W, Conti D, Hellings PW, Scadding G, Van Staeyen E, Bjermer LH, Diamant Z.** Promoting prevention and targeting remission of asthma a EUFOREA consensus statement on raising the bar in asthma care. Chest. 2025; 167(4): 956-74. Article. IF: 9.8; D1
- **Klimek L, Brough HA, Arasi S, Toppila-Salmi S, Bergmann C, Jutel M, Bousquet J, Hox V, Gevaert P, Tomazic PV, Segovia CR, Cingi C, Cuevas M, Gröger M, Huber P, Reitsma S, Rudenko M, Maza-Solano J, Gane S, Karavelia A, van Gerven L, Schiappoli M, Bozkurt B, Becker S, Chaker A, Wollenberg B, Mösges R, Huppertz T, Hagemann J, Palomares O, Bärhold F, Pfaar O, Del Giacco S, Bonadonna P, Moreira A, Agache I, Akdis CA, Fokkens W, Walusiak-Skorupa J, de las Vecillas L, Lozano MA, Giovannini M, Untersmayr E, Feleszko W, Cianferoni A, Sahiner UM, Eguiluz-Gracia I, Shamji M, Jaén MJT.** Otitis media with effusion (ome) and eustachian tube dysfunction: the role of allergy and immunity-an eaaci position paper. Allergy. 2025; 80(9): 2429-41. Article. IF: 11.3; Q1
- **Laorden D, Domínguez-Ortega J, Romero D, Villamañán E, Mariscal-Aguilar P, Granda P, Quirce S, Álvarez-Sala R, ASMAGRAVE HULP Grp.** Efficacy assessment of biological treatments in severe asthma. J Clin Med. 2025; 14(2): 321. Review. IF: 3.3; Q1
- **Longas M, Aponte CS, Laorden D, Romero D, Quirce S, Álvarez-Sala R.** Long term effectiveness of mepolizumab in the treatment of chronic eosinophilic pneumonia. Open Respir Arch. 2025; 7(3): 100462. Article. Not Indexed
- **López-Matas MA, Martín-López L, Vílchez-Sánchez F, Pedrosa M, Rodríguez-Pérez R, Domínguez-Ortega J, Carnés J.** Bioinformatics-based prediction of b-and t-cell epitopes in r-mandelonitrile lyase, a recently described peach allergen. J Invest Allerg Clin. 2025; 35(3): 220-2. Editorial Material. IF: 6.6; Q1
- **López-Matas MA, Vílchez-Sánchez F, Álvarez F, Rodríguez-Pérez R, Domínguez-Ortega J, Carnés J, Pedrosa M.** (R)-Mandelonitrile lyase, a homolog of pru du 10, is a major peach allergen. J Invest Allerg Clin. 2025; 35(2): 122-9. Article. IF: 6.6; Q1
- **Lozano-Espinosa M, Rodríguez-Otero N, Antolín-Amérigo D, Vidal FG, Muriel A, de Pablo R, Quirce S.** Characteristics of asthma patients admitted to the intensive care unit of a tertiary university hospital in madrid, spain: a 5-year experience. J Invest Allerg Clin. 2025; 35(1):50-2. Editorial Material. IF: 6.6; Q1
- **Martínez-Moragón E, Pinedo C, Puente-Maestu L, Muñoz-Esquerre M, Gómez-Bastero A, Ramos J, Díaz-Palacios M, Hermida T, Bañas-Conejero D, Quirce S.** Evaluating the effectiveness and safety of mepolizumab in elderly patients with severe asthma: insights from the REDES study. J Asthma. 2025; 62(7): 1128-32. Article. IF: 1.6; Q3
- **Martín-González E, Hernández-Pérez JM, Pérez JAP, Pérez-García J, Herrera-Luis E,**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



González-Pérez R, González-González O, Mederos-Luis E, Sánchez-Machin I, Poza-Guedes P, Sardón O, Corcuera P, Cruz MJ, González-Barcala FJ, Martínez-Rivera C, Mullol J, Muñoz X, Olaguibel JM, Plaza V, Quirce S, Valero A, Sastre J, Korta-Murua J, del Pozo V, Lorenzo-Díaz F, Villar J, Pino-Yanes M, González-Carracedo MA. Alpha-1 antitrypsin deficiency and Pi*S and Pi*Z SERPINA1 variants are associated with asthma exacerbations. Pulmonology. 2025; 31(1): 2416870. Article. IF: 5.3; Q1

- **Martín-González E, Pérez-Garcia J, Martín-Almeida M, Hernández-Pérez JM, González-Pérez R, Sardón O, Pérez-Pérez JA, González-Carracedo MA, Poza-Guedes P, Sánchez-Machín I, Mederos-Luis E, Corcuera P, López-Fernández L, Román-Bernal B, González-García LM, Cruz MJ, González-Barcala FJ, Martínez-Rivera C, Mullol J, Muñoz X, Olaguibel JM, Plaza V, Quirce S, Valero A, Sastre J, del Pozo V, Villar J, Lorenzo-Diaz F, Pino-Yanes M.** Genome-wide association study of asthma exacerbations in the spanish population. Arch Bronconeumol. 2025; 61(8): 490-4. Letter. IF: 8.7; D1
- **Morejón L, Quirce S, Domínguez-Ortega J, Romero D, Nobleja A, Ríos-Blanco J, De Las Vecillas L.** Mepolizumab as an effective alternative to immunosuppressive and teratogenic therapies for the early treatment of egpa: a case report. J Invest Allerg Clin. 2025; 35(5): 389-91. Editorial Material. IF: 6.6; Q1
- **Murillo-Cuesta S, Contreras J, Chioua M, García-Montoya C, Rodríguez-de la Rosa L, Méndez-Grande I, Piotrowska DG, Glowacka IE, Varela-Nieto I, Marco-Contelles J.** Quinolylnitrone 23 protects from auditory cell oxidative injury and noise-induced hearing loss. ACS Pharmacol Transl Sci. 2025; 8(9): 3007-18. Article. IF: 4.0; Q2
- **Ojanguren I, Quirce S, Bobolea , de Llano LP, del Pozo.** Phenotyping asthma exacerbations: one step further in the management of severe asthma. J Invest Allerg Clin. 2025; 35(1): 1-11. Review. IF: 6.6; Q1
- **Pascal M, Chauhan J, Knol E, Bianchini R, Castells M, de las Vecillas L, Hartmann K, Izquierdo E, Jappe U, Jimenez-Rodriguez TW, Levi-Schaffer F, Mayorga C, Poli A, Redegeld F, Santos AF, Jensen-Jarolim E, Bergmann C, Karagiannis SN, Bax HJ.** Basophil activation test: bridging allergy and oncology for diagnostic, therapeutic and prognostic applications in allergooncology: An EAACI position paper. Allergy. 2025; 80(8): 2097-112. Article. IF: 11.3; Q1
- **Pfaar O, Bilò MB, Csonka P, de Blay F, Gappa M, Gawlik R, Gevaert P, Halken S, Hox V, Kappen J, Krcmová I, Lezmi G, González-Mancebo E, Melen E, Domínguez-Ortega J, Puggioni F, Steinsvåg S, Worm M, Wüstenberg E.** Improvement of the therapeutic management of allergic patients in Europe An expert think tank's position paper on allergen immunotherapy. World Allergy Organ J. 2025; 18(10): 101109. Article. IF: 4.0; Q2
- **Plaza V, Casas-Maldonado F, Cosio BG, García-Rivero JL, González-Pérez R, Moragon EM, Moreno-Ancillo A, Pallares-Sanmartín A, Ramos J, Sánchez S, Domínguez-Ortega J.** Severe asthma management in spain: a survey-based national study. Is it time for a national asthma plan?. Open Respir Arch. 2025; 7(2): 100408. Article. Not Indexed
- **Plaza V, García G, de Llano LP, Quirce S.** Initiating biological treatment of asthma: when is the right time? Arch Bronconeumol. 2025; 61(1): 3-4. Editorial Material. IF: 8.7; D1
- **Pose K, De Las Vecillas L, Tomás-Pérez M, Barranco P, Quirce S, Domínguez-Ortega J.** Domestic hypersensitivity pneumonitis caused by inadvertent exposure to feathers. Rev Alerg Mex. 2025; 72(4): 276-80. Article. Not Indexed
- **Rodríguez-Pérez R, Pulido E, Bellón T, Rodríguez-Álvarez M, Gómez-Traseira C, López-Matas MA, Domínguez-Ortega J, Carnés J, Pedrosa M.** FcεRI-bound OVM-sIgE detection: A promising predictor of boiled egg white OFC outcomes. Pediat Allerg Imm-Uk. 2025; 36(7): e70149. Letter. IF: 4.5; Q2
- **Santamaria RF, Karavelia A, Giovannini M, de las Vecillas L, Bonadonna P, Del Giacco S, Pfaar O, Skorupa JW, Moreira A, Torres MJ, Shamji M, Palomares O.** EAACI clinical and research fellowship program: shaping the future of allergy and clinical immunology. Allergy. 2025; 80(6): 1565-8. Editorial Material. IF: 11.3; Q1
- **Sousa-Pinto B, de las Vecillas L, Riggioni C, Eigenmann P, Giovannini M.** Editorial comment on The effectiveness of an education program based on healthcare transition in adolescents with asthma: A randomized controlled trial. Pediat Allerg Imm-Uk. 2025; 36(10): e70214. Editorial Material. IF: 4.5; Q2
- **Sousa-Pinto B, Schleich F, Louis G, Gemicioglu B, Kvedariene V, Regateiro FS, Loureiro CC, Taborda-Barata L, Amaral R, Antó JM, Bedbrook A, Czarlewski W, Ansotegui IJ, Bergmann KC, Bonini M, Bossios A, Boulet LP, Braido F, Brightling C, Brusselle G, Brussino L, Canonica GW, Cruz AA, Haahtela T, Heaney LG, Hyland M, Ivancevich JC, Klimek L, Kulus M, Kuna P, Kupczyk M, Larenas-Linnemann DE, Makris M, Marqués-Cruz M, Gil-Mata S, Morais-Almeida M, Niedoszytko M, Ollert M, Papadopoulos NG, Patella V, Pfaar O, Porsbjerg C, Puggioni F, Quirce S, Cordeiro CR, Roche N, Samolinski B, Sastre J, Scichilone N, Skrgat S, Toppila-Salmi S, Usmani OS, Valiulis A, Gradauskiene B, Koyuncu IV, Ventura MT, Vieira RJ, Yorgancioglu A, Fonseca JA, Zuberbier T, Petre B, Louis R, Bousquet J.** Daily digital biomarkers in the follow-up and clustering of patients with asthma. Pulmonology. 2025; 31(1): 2532980. Article. IF: 5.3; Q1
- **Sousa-Pinto B, Vieira RJ, Bognanni A, Martini M, Ordak M, Paoletti G, Gil-Mata S, Amaral R, Bedbrook A, Bonadonna P, Brussino L, Canonica GW, Coutinho-Almeida J, Cruz AA, Czarlewski W, Dykewicz M, Giovannini M, Gemicioglu B, Ivancevich JC, Klimek**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

L, Kvedariene V, Larenas-Linnemann DE, Marques-Cruz M, Moreira A, Niedoszytko M, Pereira AM, Papadopoulos NG, Pham-Thi N, Regateiro FS, Toppila-Salmi SK, Samolinski B, Sastre J, Taborda-Barata L, Thomander T, Koyuncu IV, Valiulis A, Vecillas LD, Ventura MT, Walusiak-Skorupa J, Xiang YK, Pfaar O, Fonseca JA, Zuberbier T, Schünemann HJ, di Bona D, Bousquet J. Comparison of allergic rhinitis treatments on patient satisfaction: a MASK-air and EAACI methodological committee report. Allergy. 2025; 80(12): 3319-30. Article. IF: 11.3; Q1

- **Suojalehto H, Jeebhay MF, Sander I, Quirce S, Vrtala S, Walusiak-Skorupa J, Lopata AL, Vidal C, Raulf M.** Occupational mite allergy and asthma: An EAACI task force report. Allergy. 2025; 80(9): 2484-500. Review. IF: 11.3; Q1
- **Tabar AI, Delgado-Romero J, González-Mancebo E, Domínguez-Ortega J, Soto-Retes L.** Safety and effectiveness of allergen immunotherapy in patients with severe allergic asthma. J Asthma Allergy. 2025; 18: 1311-26 . Article. IF: 3.3; Q2
- **Villamañán E, Laorden D, Ibáñez ME, De las Vecillas L, Carpio C, Alfonso C, Domínguez-Ortega J, Romero D, Quirce S, Álvarez-Sala R.** Adherence to intranasal corticosteroids in patients with severe asthma and nasal polyposis: pharmacological and clinical factors involved. J Clin Med. 2025; 14(14): 5070. Article. IF: 3.3; Q1
- **Zuraw BL, Bork K, Bouillet L, Christiansen SC, Farkas H, Germenis AE, Grumach AS, Kaplan A, López-Lera A, Magerl M, Riedl MA, Adatia A, Banerji A, Betschel S, Boccon-Gibod I, Bova M, Boysen HB, Caballero T, Cancian M, Castaldo AJ, Cohn DM, Corcoran D, Drouet C, Fukunaga A, Hide M, Katelaris CH, Li PH, Longhurst H, Peter J, Psarros F, Reshef A, Ritchie B, Selva CN, Zanichelli A, Maurer M.** Hereditary angioedema with normal c1 inhibitor: an updated international consensus paper on diagnosis, pathophysiology, and treatment. Clin Rev Allerg Immu. 2025; 68(1): 24. Review. IF: 11.5; D1

Research projects

- **Rodríguez Pérez MR; Pedrosa Delgado M.** Caracterización alergénica y determinación de la relevancia clínica del polen de encina como alérgeno de interés en pacientes policlínicos y su relación con el desarrollo de síndrome de alergia oral con alimentos (PI22/00221). ISCIII. 2023-2027. Managment centre: FIBHULP
- **de las Vecillas Sánchez L.** Estudio de la inmunomodulación celular inducida en las desensibilizaciones a quimioterápicos tras reacciones alérgicas inmediatas mediadas porIGE y tardías mediadas por linfocitos t específicos (PI24/01046). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Gandolfo Cano M.** Exosomas y microRNAs: nuevas herramientas terapéuticas y diagnósticas en la interacción del asma y la alergia alimentaria (PI-6482). 2025-2027. Managment centre: IIS-Fundación Jiménez Díaz
- **Gandolfo Cano M.** Estudio del metabolismo microbiano del cacahuete durante inmunoterapia oral (PI-6689). 2025-2027. Managment centre: Hospital del Niño Jesús

Ciber and Retics

- **Caballero Molina MT.** Centro de Investigación en Red de Enfermedades Raras. (CIBERer). ISCIII. (31/12/2025). FIBHULP

Clinical trials

- **Caballero Molina MT.** A phase 3, randomized, double-blind, placebo-controlled, 3-part study to evaluate the efficacy and safety of orally administered deucrictibant xr tablet for prophylaxis and deucrictibant soft capsule for on-demand treatment of angioedema attacks in adults with acquired angioedema due to c1 inhibitor deficiency.
  Type/Phase: III
  Sponsored by: Pharvaris Netherlands B.V.
  Signature date: 02/12/2025
- **Domínguez Ortega FJ.** T-ROSS II estudio observacional retrospectivo para caracterizar y evaluar los resultados clínicos de pacientes que recibieron tezepelumab después de la autorización de comercialización en españa.
  Type/Phase: EOm no prospectivo
  Sponsored by: Astrazeneca Farmaceutica Spain S.A.
  Signature date: 22/05/2025
- **Phillips Anglés E.** Estudio en fase III para evaluar la seguridad y farmacocinética de la profilaxis con berotralstat en niños de 2 a <12 años con angioedema hereditario.
  Type/Phase: III
  Sponsored by: Biocryst Pharmaceuticals Inc.
  Signature date: 03/09/2025
- **Phillips Anglés E.** Un estudio abierto para proporcionar acceso a berotralstat a sujetos con angioedema hereditario de tipo 1 y 2 que fueron previamente inscritos en estudios de berotralstat.
  Type/Phase: IIIb
  Sponsored by: Biocryst Pharmaceuticals Inc.
  Signature date: 28/10/2025
- **Tomás Pérez M.** Pragmatic randomized prospective clinical study to evaluate the effectiveness of a digital application to improve aeroallergen immunotherapy adherence in real life. the navigait.me project. Estudio clínico pragmático prospectivo aleatorizado para evaluar la efectividad de una aplicación digital para mejorar la adherencia a inmunoterapia con aeroalérgenos en vida real, proyecto navigait.me.
  Type/Phase: OTROS
  Sponsored by: Tomás Pérez, Margarita.
  Signature date: 17/12/2025
- **Torrado Español I.** Evaluación de la seguridad y efectividad de beltaven® en pacientes con alergia a apis mellifera, polistes dominula o vespula spp.
  Type/Phase: EOm prospectivo
  Sponsored by: Probelte Pharma Sa.
  Signature date: 23/01/2025

Patents and trademarks

- **Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee.** Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.
- **Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee.** Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.

HAE-QoL
HEREDITARY ANGIOEDEMA QUALITY OF LIFE

- **Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees.** Food allergen extracts and methods of producing and using the same. EP16382413.9 (Publication Number pending); 2016 September 06.
- **del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, inventors; FIISFJD, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees.** In vitro method for identifying severity levels in bronchial asthma patients. P201730739; 2017 May 29.
- **Villamañán E, Contreras J, Romero D, Carpio C, Álvarez-Sala R, Herrero A, Quirce S, inventors; FIBHULP, assignee.** Expertasma. Nº018981670; 2024 June 14.

expertasma

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.4.7 Patient Blood Management



Publications: 17 | Q1: 11

COMPOSITION

Manuel Quintana Díaz.
Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz/Profesor Asociado Facultad de Medicina. Universidad Autónoma de Madrid

- **María José Alcaide Martín.** *Facultativo Especialista de Área en Análisis Clínicos. Tutora de residentes de Análisis Clínicos. Hospital Universitario La Paz*
- **Rubén Darío Contreras Escorcia.** *Médico Interno Residente en Medicina Intensiva. Hospital Universitario La Paz*
- **Lucía Curiel Garrido.** *Ingeniera Biomédica. FIBHULP*
- **Aúrea Díez Tascón.** *Facultativo Especialista de Radiodiagnóstico. Hospital Universitario La Paz*
- **Sara Fabra Cadenas.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Hospital Universitario La Paz*
- **Pilar Fernández Calle.** *Facultativo Especialista de Área en Análisis Clínicos. Coordinadora de Calidad de Análisis Clínicos. Hospital Universitario La Paz*
- **José Antonio García Erce.** *Facultativo Especialista de Área en Hematología. Hospital San Jorge de Huesca*
- **Carlos Jericó Alba.** *Jefe de Área de Riesgo Vascular. Hospital Sant Joan Despí Moisés Broggi de Barcelona*
- **Raúl Juárez Vela.** *Profesor Titular de Universidad. Universidad de La Rioja*
- **Milagros Martí de Gracia.** *Jefe de Sección de Radiología de Urgencias. Hospital Universitario La Paz*
- **Ana María Martínez Virto.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Coordinadora Adjunta de Urgencias. Hospital Universitario La Paz*
- **María Soledad Neria Agujetas.** *Subdirectora de Enfermería. Calidad Asistencial y Desarrollo de Personas. Hospital Clínico San Carlos*
- **María Angustias Peinado Quesada.** *Enfermera (Coordinadora Docente). Hospital Universitario La Paz*
- **María Inmaculada Pinilla Fernández.** *Facultativo Especialista de Área en Radiodiagnóstico. Hospital Universitario La Paz*
- **María Angélica Rivera Núñez.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Carmen Sarmiento Iglesias.** *Médico Interno Residente en Medicina Intensiva. Hospital Universitario La Paz*
- **Marcelino Sánchez Casado.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Virgen de la Salud*
- **Ismael del Val Rey.** *Médico Interno Residente en Medicina Intensiva. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- This is a diverse group of specialists in various fields who share a common interest in researching new strategies to optimize the management of patients attending hospital emergency departments. In particular, strategies for rationalizing and optimizing the use of blood components in diverse clinical situations are especially critical in emergency departments. In this regard, and within the field of clinical research, our group's interests have focused on three priority research areas: "Optimization of the use of blood components," divided into two sub-areas mentioned in the following section: "Venous thromboembolism and anticoagulation" and "Risk stratification in critically ill patients."

RESEARCH LINES

- Critical hemorrhage
- Reversible anticoagulation
- Fragility
- COVID-19
- Interrelationship in cardiovascular diseases and care

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH ACTIVITY

Publications

- **Beverina I, Jericó C, Quintana-Díaz M.** Implementing first pillar of PBM in the Emergency Area: a missed opportunity? Blood Transfus-Italy. 2025; 23(1): 50-4 . Editorial Material. IF: 2.7; Q2
- **Burgos-Esteban A, Cordón-Hurtado V, Giménez-Luzuriaga M, Peinado-Quesada M, Gómez-Lage L, Juárez-Vela R, Czapla M, García-Criado J, Navas-Echazarreta N, Rodríguez-Calvo A, Lasa-Berasain P, Quintana-Díaz M.** Intranasal drug administration for psychomotor agitation as a safe and effective prehospital intervention: an integrative review. Nurs Rep. 2025; 15(6): 219. Review. IF: 3.1; Q1
- **Cruz-Garcinuño M, Juárez-Vela R, Chover-Sierra E, Navas-Echazarreta N, Czapla M, Ballestar-Tarín ML, Martínez-Pascual RM, Nanwani-Nanwani K, Serrano-Lazaro A, del Val-Rey I, Quintana-Díaz M, Martínez-Sabater A.** Sex differences and gender-oriented characteristics in intensive care unit admissions for patients with traumatic brain injury in Spain. Front Med (Lausanne). 2025; 12: 1622422. Article. IF: 3.6; Q1
- **Cruz-Garcinuño M, Martínez-Sabater A, Cobos-Rincón A, Czapla M, Sarmiento-Iglesias C, Polo-Andrade E, Álvarez P, Rodríguez-Calvo A, Aguirre U, Tejada-Garrido CI, Juárez-Vela R, Quintana-Díaz M.** Exploratory evaluation of potential crp and ferritin thresholds and survival in critically ill patients: a pilot prospective icu study. J Clin Med. 2025; 14(22): 8172. Article. IF: 3.3; Q1
- **de la Cruz-Garcinuño M, Juárez-Vela R, Lasa-Berasain P, de Vinaspre-Hernández RR, Czapla M, García-Muñoz L, Polo-Andrade E, Sarmiento C, Rodero-Martínez J, Alonso-Arias M, López-Tornero S, Quintana-Díaz M.** Utility of reticulocyte hemoglobin as a new predictor of anemia in intensive care unit patients. Front Med (Lausanne). 2025; 12: 1577047. Article. IF: 3.6; Q1
- **Faso C, Bogossian EG, Rynkowski CB, Moller K, Lormans P, Díaz MQ, Caricato A, Dabrowski W, Perez IG, Steblaj S, Quintard H, Justo P, Righy C, Roman-Pognuz E, Huet O, Mahmoodpoor A, Blandino-Ortiz A, Junttila E, Funes N, Izzo G, Zattera L, Giacomucci A, Dibu J, Rodrigues A, Bouzat P, Vincent JL, Taccone FS.** A Restrictive versus a liberal transfusion strategy in patients with spontaneous intracerebral hemorrhage: a secondary analysis of train randomized clinical trial. Stroke. 2025; 56(9): 2617-26. Article. IF: 11.1; D1
- **Hernández MI, Juliá JB, Fernández RG, Martín SG, Tornero SL, Morente EM, Cárdenas YM, Blanco JR, Dominguez RR, Leiguez JJS, Díez-Sebastián J, Díaz MQ.** Environmentally sustainable waste segregation and linen use in a burn and polytrauma intensive care unit: a nurse-led quality improvement initiative. Nurs Crit Care. 2025; 30(5): e70165. Article. IF: 2.8; Q1
- **Kimmoun A, Girerd N, Duarte K, Bruno J, Schenk J, Levy B, Baudry G, Raasveld SJ, de Bruin S, Reuland MC, van den Oord C, Schaap CM, Bakker J, Cecconi M, Feldheiser A, Meier J, McQuilten Z, Müller MCA, Scheeren TWL, Aubron C, Flint AWJ, Hamid T, Piagnerelli M, Mahecic TT, Benes J, Russell L, Aguirre-Bermeo H, Triantafyllopoulou K, Chantziara V, Gurjar M, Myatra SN, Pota V, Elhadi M, Gawda R, Mourisco M, Lance M, Neskovic V, Podbregar M, Llau JV, Quintana-Díaz M, Cronhjort M, Pfortmueller CA, Yapici N, Nielsen N, Shah AK, de Grooth HJ, Vlaar APJ, Mebazaa A.** Association between red blood cell transfusion and adverse clinical outcomes is Independent of cardiac history: a multicenter observational InPUT study analysis. Crit Care. 2025; 29(1): 526. Article. IF: 11.4; D1
- **Kurucz VC, Flint AWJ, Poole A, Reuland MC, van den Oord C, Schaap CM, Bakker J, Cecconi M, Feldheiser A, Meier J, McQuilten Z, Müller MCA, de Bruin S, Scheeren TWL, Hamid T, Aubron C, Piagnerelli M, Mahecic TT, Benes J, Russell L, Aguirre-Bermeo H, Triantafyllopoulou K, Chantziara V, Gurjar M, Myatra SN, Pota V, Elhadi M, Gawda R, Mourisco M, Lance M, Neskovic V, Podbregar M, Llau JV, Quintana-Díaz M, Cronhjort M, Pfortmueller CA, Yapici N, Nielsen N, Shah A, de Grooth H, Vlaar APJ, Schenk J, Raasveld SJ, InPUT Study Grp.** Global transfusion practices in septic patients in the intensive care unit: insights from the InPUT-study sub-analysis. Transfusion. 2025; 65(12): 2272-85. Article. IF: 2.0; Q3
- **Méndez-Arias E, Abad-Motos A, Barquero-López M, Delestal-Aldaria R, Palacios AMMD, Pajares A, López SA, Fornet I, Quintana-Díaz M, Yanes G, Colomina MJ.** Patient Blood Management: A conceptual and analytical vision from the leadership in Spain. Rev Esp Anestesiol Reanim. 2025; 72(3): 501650. Article. IF: 1.3; Q3
- **Mora L, Pons-Pellicé L, Quintana-Díaz M.** Viscoelastic monitoring of direct oral anticoagulants (DOAC). Blood Transfus-Italy. 2025; 23(1): 59-63. Editorial Material. IF: 2.7; Q2
- **Moral V, Jericó C, Motos AA, Páramo JA, Díaz MQ, Erce JAG.** 2024 critical review of the patient blood management (PBM) recommendations of the spanish enhanced recovery after major surgery (via RICA). Cir Espan. 2025; 103(2): 104-14. Review. IF: 1.5; Q3
- **Pérez-Elvira R, Oltra-Cucarella J, Juan MA, Polo-Ferrero L, Juárez-Vela R, Bosch-Bayard J, Díaz MQ, de la Cruz J, Ruíz AS.** The vibrational signature of alzheimer's disease: a computational approach based on sonification, laser projection, and computer vision analysis. Biomimetics (Basel). 2025; 10(12): 792. Article. IF: 4.2; Q1
- **Pérez-Elvira R, Oltra-Cucarella J, Juan MA, Polo-Ferrero L, Juárez-Vela R, Bosch-Bayard J, Díaz MQ, Neamtu B, Salgado-Ruiz A.** Auditory discrimination of parametrically sonified EEG signals in Alzheimer's disease. J Clin Med. 2025; 15(1): 140. Article. IF: 3.3; Q1
- **Quintana-Díaz M, Godoy DA.** Optimal hemoglobin levels in the neurocritical patient: Are we there yet? Med Intensiva. 2025; 49(7): 502162. Editorial Material. IF: 2.5; Q3
- **Taleb C, Bogossian EG, Rynkowski CB, Moller K, Lormans P, Diaz MQ, Caricato A, Zattera L, Kurtz P, Meyfroidt G, Quintard H, Dias MC, Giacomucci A, Castelain C, Chabanne R, Marcos-Neira P, Bendel S, Alsheikhly AS, Elbahnasawy M, Gay S, D'Onofrio M, Popugaev KA, Markou N, Bouzat P, Vincent JL, Taccone FS, TRAIN Study Trial Grp.** Liberal versus restrictive transfusion strategies in subarachnoid hemorrhage: a secondary analysis of the TRAIN study. Crit Care. 2025; 29(1): 67. Article. IF: 11.4; D1
- **van Wonderen SF, Raasveld SJ, Flint AWJ, Schenk J, van den Oord C, Reuland MC, de Bruin S, Bakker J, Cecconi M, Feldheiser A, Meier J, Müller MCA, Scheeren TWL, Hamid T, Piagnerelli M, Mahecic TT, Benes J, Russell L, Aguirre-Bermeo H, Triantafyllopoulou K, Chantziara V, Gurjar M, Myatra SN, Pota V, Elhadi M, Gawda R, Mourisco M, Lance M, Neskovic V, Podbregar M, Llau J, Quintana-Díaz M, Cronhjort M, Pfortmueller CA, Yapici N, Nielsen ND, Shah A, De Grooth HJ, Mcquilten Z, Vlaar APJ, Aubron C.** Platelet transfusion practices in the ICU: A prospective multicenter cohort study. Crit Care Med. 2025; 53(12): e2526-39. Article. IF: 7.5; Q1

Patents and trademarks

- **Díaz García E, Laxman Nanwani K, Quintana Díaz M, García Río F, Cubillos-Zapata C, inventors; FIHULP, CIBER, assignees.** Biomarcadores para el pronóstico de pacientes que han sufrido una hemorragia subaracnoidea aneurismática (SAH). P202130180; 2021 March 3

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.4.8 Health Care Nurses Research



Publications: 12 | Q1: 4

COMPOSITION

Esther Rey Cuevas.
Directora de Enfermería. Hospital Universitario La Paz

Tamara Domingo Pérez.
Supervisora Investigación I+D+i. Hospital Universitario La Paz

- **Laura Alonso Recio.** *Profesora Contratada. Universidad de Educación a Distancia*
- **María Avilés Martínez.** *Profesora Ayudante Doctora. Universidad Autónoma de Madrid*
- **Jesús Castro Toro.** *Supervisor de Área Funcional. Hospital Universitario La Paz*
- **Víctor Manuel Cornejo del Río.** *Supervisor de Unidad Quirúrgica. Hospital Carlos III- Hospital Universitario La Paz*
- **María Ricardina Delgado Sandoval.** *Enfermera en Servicio de Consultas Externas. Hospital Universitario La Paz*
- **Julia de Villarreal de Arracó.** *Enfermera especialista en Pediatría. Hospital Universitario La Paz*
- **María Luisa Díaz Martínez.** *Profesora Contratada. Universidad Autónoma de Madrid*
- **Isabel Díaz Suárez.** *Supervisora de Enfermería. Hospital Universitario La Paz*
- **María Durán Agüí.** *Enfermera en Servicio de Medicina Interna. Hospital Universitario La Paz*
- **Salomé Herrero Cereceda.** *Enfermera Unidad Quirúrgica. Hospital Cantoblanco-Hospital Universitario La Paz*
- **Judith Hernández Alonso.** *Enfermera. Hospital Universitario La Paz*
- **Ginés Mateo Martínez.** *Profesor Asociado en Enfermería. Universidad Autónoma de Madrid*
- **Yolanda Morán Benito.** *Enfermera especialista en Neurología. Hospital Universitario La Paz*
- **María Begoña Ortiz Ortega.** *Supervisora de Enfermería. Hospital Universitario La Paz*
- **Pedro Piqueras Rodríguez.** *Supervisor de Enfermería en Unidad de Neonatología. Hospital Universitario La Paz*
- **Ana Ramos Cruz.** *Supervisor de Enfermería en Reanimación Maternidad. Hospital Universitario La Paz/Profesora Asociada de Grado de Enfermería . Centro Universitario de Ciencias de la Salud San Rafael-Nebrija*
- **Maria José Rol García.** *Supervisora de Enfermería de Unidades de Puerperio del Hospital Maternal. Hospital Universitario La Paz*
- **María del Carmen Sellán Soto.** *Profesora Contratada. Universidad Autónoma de Madrid*
- **Raquel Torres Luna.** *Enfermera Especialista en Pediatría. Hospital Universitario La Paz*
- **Antonio Vázquez Sellán.** *Profesor Visitante en Enfermería. Universidad Autónoma de Madrid*

STRATEGIC OBJETIVES

- Care is an indispensable activity for survival, since humanity exists. Care has been relevant as a primary function to promote and develop all those activities that make people live.
- This research group aims to collaborate on growing clinical evidence on health care. The real gap between what generates scientific knowledge and the decisions that are made in the day to day is ethically unacceptable. Between 30 and 40% of patients do not receive care consistent with the results of the research and around 20-25% of care may be unnecessary or potentially harmful. Evidence-Based Practice (PBE) or Evidence is based on the fact that greater knowledge and use of research results in clinical practice will contribute to improving the health of the population. Today, it is well known that the implementation of the best scientific evidence available in the clinical practice improves quality of care and clinical outcomes.
- In addition, decision-makers based on available evidence tend to be more satisfied with their role and focus on improving the quality of care given to patients.
- Finally, it should be noted that using evidence in daily practice can achieve health goals at a minimum cost.
- Cost-effectiveness studies have been conducted in which evidence-based care is linked to a reduction in health costs compared to traditional care.
- At the same time, society is facing new economic, political, demographic, social and cultural challenges that require health services capable of meeting the growing health needs of the population.
- It is necessary to investigate in clinical practice the most advanced care in order to achieve the full development of care and ensure the achievement of the best results in terms of overall health and quality of life of patients, Effectiveness of interventions, greater cohesion of health care teams, and of course, all contribute to the sustainability of the health system and user satisfaction.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH LINES

- Advanced Practice Nursing (APN) Care and Patient Experience: Patient-reported outcomes and experience measures (PROM and PREM).
- Vital Processes of Care and Complex Care. Attention to Frailty and Vulnerability. Pediatric care. Women's care. Transitional care and complex chronic care.
- Technological innovation and AI and its application in health care: evaluation of programs and validation of tools and questionnaires
- Professional Identity and Professional Development in Nursing: Historical and Contemporary Perspectives: Identity, profession, professional development, history of nursing.

RESEARCH ACTIVITY

Doctoral Theses

- **Torres Luna R.** Eficacia de la hipnosis como técnica no farmacológica para el control del dolor en pacientes intervenido de cirugía ortopédica mayor[dissertation]. Madrid: UAM: 2025(28/0/2025). Director: Sellán Soto MC
- **Díaz Suárez I.** La imagen de las enfermeras y de la enfermería en la prensa española.[dissertation]. Pamplona: UPN: 2025(12/12/2025). Director: Hildegart Gonzalez L, Choperena A
- **Rol García MJ.** Inlfuencia del dolor, ansiedad y depresión periparto en la atención obstétrica y lactancia materna[dissertation]. Madrid: UAM: 2025(24/04/2025). Director: Bartha Rasero JL, Cuerva González MJ.

Master Theses

- **Etxebarria Cortes R.** Entender las vivencias de las enfermeras en la limitación del esfuerzo terapéutico en la uci quirúrgica de la FJD[dissertation]. Madrid: UAM: 2025(16/06/2025). Director: Sellán Soto MC.
- **Martínez Castillo L.** Experiencia de los padres y madres en el proceso de trasplante cardiaco AB0 incompatible[dissertation]. Madrid: UAM: 2025(16/06/2025). Director: Sellán Soto MC.
- **Martínez Gómez M.** Estrategias más eficaces en la prevención del delirium en el paciente adulto en cuidados intensivos. Una revisión de alcance[dissertation]. Madrid: UAM: 2025(16/06/2025). Director: Díaz Martínez ML.
- **Mariscal de Blas I.** Optimizando la práctica segura en el transporte intrahospitalario del paciente crítico. Revisión sistemática exploratoria[dissertation]. Madrid: UAM: 2025(16/06/2025). Director: Díaz Martínez ML.
- **Díaz López C.** Impacto del síndrome de abstinencia iatrogénico infantil en las experiencias de las madres[dissertation]. Madrid: UAM: 2025(16/06/2025). Director: Vázquez Sellán A.
- **Martínez Dorado E.** Método madre canguro y su influencia en el desarrollo cerebral de los neonatos prematuros extremos[dissertation]. Madrid: UAM: 2025(16/06/2025). Director: Vázquez Sellán A.
- **Huachin Gonzales SM.** Percepción de los padres cuyos hijos con enfermedades raras participan en ensayos clínicos[dissertation]. Madrid: UAM: 2025(16/06/2025). Director: Mateo Martínez G.
- **Hernández García S.** Mejorar el afrontamiento y la salud mental de los estudiantes de enfermería[dissertation]. Madrid: UAM: 2025(16/06/2025). Director: Mateo Martínez G.
- **González Reina S.** Del cuerpo alegórico al rostro clínico. Una hermenéutica de los cuidados enfermeros en salud mental desde el Bosco hasta Géricault[dissertation]. Madrid: UAM: 2025(16/06/2025). Director: Mateo Martínez G.
- **García Saavedra S.** El rol de la enfermería en la recuperación de pacientes con trastorno por consumo de alcohol[dissertation]. Madrid: UAM: 2025(16/06/2025). Director: Mateo Martínez G.
- **Hernández Matellano S.** Programa de educación para la salud a padres/madres/tutores de adolescentes con anorexia nerviosa tras su primer ingreso en unidad de hospitalización breve[dissertation]. Madrid: UAM: 2025(16/06/2025). Director: Mateo Martínez G.
- **Arroyo García C.** Formación y concienciación para docentes sobre el trastorno por déficit de atención e hiperactividad[dissertation]. Madrid: UAM: 2025(16/06/2025). Director: Mateo Martínez G.
- **Morán Benito Y.** Factores determinantes de la calidad de vida del paciente del paciente con ELA en el contexto de cuidado humanizado: de la evidencia a la experiencia[dissertation]. Ávila: UCAV: 2025(16/06/2025). Director: .

Final Degree Theses

- **Bustillo Gómez S.** Experiencia y percepción de la enfermera en los cuidados de fin de vida pediátricos[dissertation]. MADRID: UAM: 2025(25/05/2025). Director: Díaz Martínez ML.
- **Menchén Jareño A.** Eficacia del método madre canguro en la recuperación de los prematuros extremos[dissertation]. MADRID: UAM: 2025(25/05/2025). Director: Vázquez Sellán A.
- **Ríos Ciriero A.** Abordaje enfermero en neonatos con hidrocefalia: principales intervenciones y manejo de sistemas de derivación[dissertation]. MADRID: UAM: 2025(25/05/2025). Director: Vázquez Sellán A.
- **Heredia García M.** Impacto emocional materno tras el ingreso urgente de su hijo en la unidad de hospitalización neonatal para el tratamiento de la ictericia[dissertation]. MADRID: UAM: 2025(25/05/2025). Director: Vázquez Sellán A.
- **Gómez Castro P.** Cuidados de enfermería para la prevención de la hemorragia intraventricular en neonatos prematuros[dissertation]. MADRID: UAM: 2025(25/05/2025). Director: Vázquez Sellán A.
- **Bustillo Gómez S.** Experiencia y percepción de la enfermera en los cuidados de fin de vida pediátricos[dissertation]. MADRID: UAM: 2025(25/05/2025). Director: Díaz Martínez ML.
- **Moreno Gómez M .** Impacto psicosocial de la donación de leche en familas víctimas de duelo perinatal[dissertation]. MADRID: UAM: 2025(25/05/2025). Director: Araque García J.
- **Cobo Martínez L.** Papel de la enfermera en la depresion posparto durante el puerperio tardia[dissertation]. MADRIR: UAM: 2025(25/05/2025). Director: Araque García J.
- **Miranda Amar T.** Papel de la enfermera en el abordaje de la desnutricion del paciente ingresado[dissertation]. MADRID: UAM: 2025(25/05/2025. Director: Calso Gonzalez M.
- **Martínez González M.** Intervenciones enfermeras en los cuidadores principales de pacientes con Alzheimer[dissertation]. MADRID: UAX: 2025(09/06/2026). Director: Piqueras Rodríguez P.
- **Navarro Hernández P.** Revisión sobre el impacto de los cuidados de enfermería en los cuidados paliativos [dissertation]. MADRID: UAX: 2025(09/06/2026). Director: Piqueras Rodríguez P.
- **Cadenas Garcia C.** Ejercicio físico en cuidadores principales de pacientes con demencia. Revisiones sistemática.[dissertation]. MADRID: UAX: 2025(09/06/2026). Director: Piqueras Rodríguez P.
- **Segira Galeote C.** Cuidar al que cuida, ejercicio físico como actividad enfermera para los cuidadores principales de pacientes con demencia [dissertation]. MADRID: UAX: 2025(09/06/2026). Director: Piqueras Rodríguez P.

Publications

- **Cadavid JM, Radakovic R, Radakovic C, Benito YM, Esteban SM, Rodríguez-Santos F, Campos TS.** Spanish adaptation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS). Amyotroph Lat Scl Fr. 2025; 26(3-4): 375-8. Article. IF: 2.4; Q3
- **Calso González M, De la Calle Fernández Miranda M, Armijo Suárez O.** Impacto de las

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



técnicas de reproducción asistida en la sexualidad femenina y la salud mental. Presencia. 2025; 21: e15761. Article. Not Indexed

- **Chocarro González L González Villanueva P Avilés Martínez M Romero Maroto M Vázquez Sánchez JM Alcaide AB de los Santos Mora A.** Paliativos nos ha salvado la vida. Perspectiva de las familias desde la fenomenología. Med Paliativa. 2025; 32(1): 4-12. Article. Not Indexed
- **García JA, Marcos AP, Diego RMA, Santos AP, Perea MEG.** Efficacy of an online nursing consultation to encourage breastfeeding. Matern Child Health J. 2025; 29(10): 1396-404. Article. IF: 1.9; Q3
- **Gómez-Merino A, Luna-Castaño P, Martin-Velasco M, Gonzalez-Martínez N, Piqueras-Rodríguez P, Marcos-Blázquez I, Alvarez-Blanco S, Gutiérrez-Horrillo L, Mas-Company E, Otero-Arbella E, Martín-Camacho E, Arias-Latorre MT, Rodriguez-Flórez S, Morán-Barrio MD, Moreno-Casbas MT.** Monitoring of night-time nursing interventions in Spanish paediatric critical care units. Enferm Intensiva. 2025; 36(3): 500555. Article. IF: 1.7; Q3
- **Mateo-Martínez G, Vázquez-Sellán A, Díaz-Martínez ML, Sellán-Soto MC.** Orthorexia nervosa: Healthy habit or pathology? Experiences and expansion of the consciousness of the correct diet. Heliyon. 2025; 11(3): e42254. Article. IF: 3.6; Q1
- **Mostaza JM, Lahoz C, Salinero-Fort MA, Estirado E, García-Iglesias F, González Alegre T, Cornejo V.** Prevalence of subclinical vascular disease in relation to the estimated cardiovascular risk and the presence of the metabolic syndrome. Med Clin (Barc). 2025; 165(2): 106987. Article. IF: 2.8; Q1
- **Padilla-Lamadrid M, Pardo-Fernández A, Torres-Luna R, García-Gómez A, de Villarreal-Arraco J, García-González E, Frade-Pardo L, Piqueras-Rodríguez P, Muniz-Granda ED.** Perception of needs of relatives of patients at pediatric intensive care units. Enferm Intensiva. 2025; 36(4): 500557. Article. IF: 1.7; Q3
- **Rol MJ, Cuerva MJ, Briones A, Bartha JL.** Peripartum anxiety symptoms and breastfeeding duration: Prospective observational study. Clin Invest Ginecol Obstet. 2025; 52(3): 101038. Article. IF: 0.2; Q4
- **Torres-Luna R, Soto MCS, Reinoso-Barbero F.** Analgesic efficacy of clinical hypnosis in pediatric patients following orthopedic surgery. An Pediatr. 2025; 102(4): 503831. Article. IF: 2.6; Q1
- **Vargas-Martínez AM, Guillén-Martínez D, Pérez TD, Enríquez AS, Zafra-Agea JA, Cillero IH, Lima-Serrano M, Tarriño-Concejero L.** Analysis of the management function of the school nurse in Spain: use of records and interaction with Primary Care, the educational community and other institutions. Enferm Clin. 2025; 35(5): 502200. Article. IF: 1.1; Q3
- **Zafra-Agea JA, Pérez TD, Lima-Serrano M, Vargas-Martinez AM, Soler-Pardo E, Torralbas-Ortega J, Cillero IH.** Availability, perceived need and satisfaction for school nurses in Spain: a cross-sectional study involving the school community. BMC Nurs. 2025; 24(1): 1364. Article. IF: 5.2; D1

Research projects

- **Sellán Soto MC.** Eficacia del masaje terapeutico para aliviar el malestar de niños y niñas con bronquiolitis (CODEM 5508-CARMEN SELLAN). Colegio de Enfermeria de la Comunidad de Madrid. 2022-Ongoing. Managment centre: FIBHULP
- **Piqueras Rodríguez P.** Programa Digital de Alfabetización en Salud y Actividad Física para la mejora de la calidad de vida en Cuidadores de Personas con Demencia. Proyecto CAREFIT. UAX. 2025-Ongoing. Managment centre: UAX

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.4.9 Emergency and Critical Pathology

Publications: 6 | Q1: 5

COMPOSITION

César Carballo Cardona.
Facultativo Especialista de Área en Urgencias.
Hospital Universitario La Paz

- **Gillermina Bejarano Redondo.** *Médico Adjunto en Urgencias. Hospital Universitario La Paz*
- **María Elena Calvín García.** *Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz*
- **Julio Cobo Mora.** *Jefe de la Unidad de Urgencias. Hospital Universitario La Paz*
- **María de los Ángeles García Martín.** *Facultativo Especialista de Área especialista en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Olga González Peña.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Hospital Universitario La Paz*
- **Manuel Jesús González Viñolis.** *Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz*
- **Macarena Lerín Baratas.** *Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz*
- **Maria Lorena López Corcuera.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Alejandro Martín Quiros.** *Facultativo Especialista de Área en Urgencias. FIBHULP*
- **Mikel Rico Briñas.** *Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz*
- **Paloma Isabel Romero Gallego-Acho.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **María José Simón Merlo.** *Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Our group will investigate management strategies for a wide range of pathologies seen in our emergency department, drawing on expertise in various diagnostic and treatment fields. This diverse group of specialists will address six main lines of research, aiming to contribute to a better definition of clinical, diagnostic, and treatment strategies.
- Collaboration with other research groups to study clinical and prognostic utility tests in cardiology, develop treatment and diagnostic strategies for infectious pathology, and research into new antibiotics with the pulmonology group.
- We developed a new and pioneering line of diagnostic imaging, with the emergency ultrasound line, in the field of research in this field, in which we have the active support of private companies.
- Investing in the possibility of supporting clinicians with new technologies in decision-making in the field of diabetes treatment, boosting global initiatives at both the hospital and population levels.
- Finally, we will develop a line of toxicological research, focusing both on the early recognition of the poisoned patient and on the appropriate treatment, in collaboration with the clinical toxicology unit (UTC), with the aim of making them the national reference center in the management of the poisoned patient, as well as in the development of CBRN action protocols for external catastrophe situations.

RESEARCH LINES

- Comprehensive management of treatment and follow-up of diabetic patients.
- Emergency ultrasound.
- Sepsis
- Acute management of SARS-CoV-2 and COVID-19
- Emergency care for infectious diseases.
- Optimization of the management of acutely poisoned patients and the use of chemical substances for terrorist purposes.
- Emergency cardiovascular pathology care.
- Attention to respiratory pathology.

RESEARCH ACTIVITY

Publications

- **Baloira LE, de Lucas EZ, Segura CC, Baratas ML, Velilla MF, Sánchez MIT, Fernández IP, Aguilar PM, Walther RAS, Sánchez CP.** Association between lung parenchymal attenuation in computed tomography and airflow limitation in adults with cystic fibrosis. Diagnostics (Basel). 2025; 15(1): 107. Article. IF: 3.8; Q1
- **Cardona CC.** Waiting for admission: the emergency department's critical frontier. Emergencias. 2025; 37(5): 329-31. Editorial Material. IF: 5.5; Q1
- **Cardona CC.** Emergency departments in critical situation: towards a framework for structural identification and action. Emergencias. 2025; 37(4): 301-3. Editorial Material. IF: 5.5; Q1
- **Hernández-Balnco C, Al-Akioui-Sanz K, Herrera L, Aguirre-Portolés C, Lozano-Ojalvo D, Pérez-Rodriguez L, Cano-Ochando J, Guerra-García P, Martín-Quirós A, Vicario JL, Santos S, Pérez-Vaquero MA, Vesga MA, Borobia AM, Carcas AJ, Balas A, Moreno MA, de Diego RP, Gasior M, Soria B, Eguizabal C, Pérez-Martínez A.** The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19. Iscience. 2025; 28(2): 111698. Article. IF: 4.5; Q1
- **Martín-Quirós A, Soriano A, Tejerina-Picado F, Güerri-Fernández R, Cotarelo M, Molloy B, Fernández-Vigo E, Chacón F.** Baseline medication profile and risk of CYP3A4 mediated drug-drug interactions among COVID-19 hospitalized patients in Spain. BMC Infect Dis. 2025; 26(1): 45. Article. IF: 3.2; Q2
- **Rodríguez-Leal CM, del Castillo JG, Llorens P, Mata DO, Franco BM, Olmeda DM, García EO, Béliz OJS, Frigola AP, Navarro RJD, Faya HM, Román F, Borrego BV, Martin-Quiros A, del Real HVG, López IVT, Moreno MTS, Martín SG, Grinspan MSR, Pérez TP, García RS.** Antiviral prescription of mild to moderate COVID-19 and adherence to official recommendations in Spanish emergency departments. Emergencias. 2025; 37(2): 95-102. Article. IF: 5.5; Q1

Research projects

- **Martín Quirós A.** Impacto del retraso en el inicio de la antibioterapia e identificación de biomarcadores pronósticos en la evolución de pacientes con sepsis a shock séptico (PI20/01589). ISCIII. 2021-2025. Managment centre: FIBHULP

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.4.10 Hospital Pharmacy



Publications: 7 | Q1: 5

COMPOSITION

Alicia Herrero Ambrosio.
Jefa de Servicio de Farmacia Hospitalaría. Hospital Universitario La Paz/ Profesora Asociada. Universidad Complutense de Madrid

- **Susana Andrés Morera.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Cristina Bilbao Gómez-Martino.** *Facultativo Especialista de Área en Farmacia Hospitalaria. FIBHULP*
- **Cristina Cárdenas Serralde.** *Farmacéutico Especialista en Farmacia Hospitalaria. FIBHULP*
- **María Gema Casado Abad.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **María del Río Durango.** *Farmacéutico Especialista en Farmacia Hospitalaria. FIBHULP*
- **Macarena García-Trevijano Cabetas.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Luis González del Valle.** *Jefe de Sección de Farmacia Hsopitalaria. Hospital Universitario La Paz*
- **María Ángeles González Fernández.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Catalina Lara Cátedra.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Marta Moro Agud.** *Farmacéutico Especialista en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Tamara Pérez Robles.** *Facultativo Especialista de Área en Farmacia Hospitalaria. FIBHULP*
- **Elena María Rodríguez Martín.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **José Antonio Romero Garrido.** *Farmacéutico Adjunto. Hospital Universitario La Paz*
- **Rosario Fátima Ros Catellar.** *Farmacéutico Especialista en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Margarita Ruano Encinar.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Luis Sánchez-Rubio Fernández.** *Facultativo Especialista de Área en Farmacia Hospitalaria. FIBHULP*
- **Carmen Sobrino Jiménez.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **María Luisa Testillano Tarrero.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Elena Villamañán Bueno.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- The research lines of Hospital Pharmacy are oriented towards the study, research and innovation of medicines and technologies related to the pharmacotherapeutic process to optimize care practice.

RESEARCH LINES

1. Evaluation of Drugs - Real World Outcomes, especially those associated with high economic impact or with limited clinical evidence. In this regard, our target is to investigate on the following fields:
   - Coagulopathies
   - Oncology
   - Biologic therapies
   - Infectious diseases
   - Rare diseases
   - Gene therapy
   - Molecular biology of the innate immune system
2. Research on early detection and prevention strategies for medication errors in both critically ill patients and patients with complex chronic diseases.
3. Analysis of the impact on medication adherence and health outcomes of innovation in new technologies applied to the medication use process:
   - Telepharmacy programs, with or without home delivery of medications. Evaluation of their impact on medication adherence and health outcomes in different pathologies such as migraine, multiple sclerosis, prostate cancer, and asthma.
   - Research on the effect of predictive analytics and big data on clinical decision-making and the optimization of pharmaceutical outcomes.
   - Identification of signaling pathways that connect alpha7 nicotinic receptors and negative regulators of TLR-mediated inflammation in human macrophages.
4. Development of new medicines:

Advanced therapies

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH ACTIVITY



Publications

- **Arteaga M, López-Duque L, Laorden D, Torrado I, Romero-Ribate D, Villamañán E, Quirce S, Álvarez-Sala R, Domínguez-Ortega J.** Inhaled corticosteroid reduction effects on asthma outcomes after three years of benralizumab treatment in severe asthma patients. Arch Bronconeumol. 2026; 62(2): 130-2. Letter. IF: 8.7; D1
- **Mendoza-Palomar N, Nebot SS, Roig-Soria L, García LA, Anto CI, Ascaso MTG, Pérez DD, Lozano CG, Núñez CJ, López EMR, Gómez MLN, Gallego BC, Vallejo BA, Amador JTR, Manzanares A, Montero BJ, Julian AN, Soler-Palacin P.** Real-life use of isavuconazole in Spanish children and adolescents. J Antimicrob Chemoth. 2026; 81(1): dkaf394. Article. IF: 4.1; Q1
- **Rosas-Alonso R, Salas NR, Wert PP, Hoyo A, Martín-López S, Martínez-Pérez D, Ruiz-Gutiérrez I, Jimenez-Bou D, Peña J, Arias P, Custodio A, Losantos-Garcia I, Borobia AM, Feliu J, Ghanem I.** DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger. Front Pharmacol. 2025; 16: 1645188. Article. IF: 5.4; Q1
- **Villamañán E, Laorden D, Ibáñez ME, De las Vecillas L, Carpio C, Alfonso C, Domínguez-Ortega J, Romero D, Quirce S, Alvarez-Sala R.** Adherence to intranasal corticosteroids in patients with severe asthma and nasal polyposis: pharmacological and clinical factors involved. J Clin Med. 2025; 14(14): 5070. Article. IF: 3.3; Q1
- **Ramos JR, Perrín RS, Martín MAG, Clemente YC, Díez MA, Pinto AD, Díaz AS, Almela AFD, Serrano PS, Grande ASL, Blanco CC.** Adverse drug events associated with emergency departments visits. Emergencias. 2025; 37(3): 196-202. Article. IF: 5.5; Q1
- **Galán-Gómez V, González-Martínez B, Alonso-Saladrigues A, Rives S, Herrero B, Kwon M, Sánchez-Pina J, Minguillón J, Martínez-Romera I, Aguilar IM, Mestre-Durán C, Casado G, Sánchez-Martín M, Echecopar C, González-Pérez C, León-Triana O, Aguirre-Portolés C, Molinos-Quintana A, Barba P, Balsalobre P, Pérez-Martínez A.** Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults. Exp Hematol Oncol. 2025; 14(1): 49. Article. IF: 17.5; D1
- **Sagrado MAR, Criado JA, Pena AEA, Escudero-Vilaplana V, Olias CF, Fernández MH, Nieto CM, Salvador ARR, Fenollera PS, Castillo MJV.** Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer: real-world experience at hospitals in Spain. Target Oncol. 2025; 20(2): 319-27. Article. IF: 5.1; Q1
- **Castillo MA, Correa-Borit J, Laorden D, Adrianzen F, Villamañán E, Romero D, Quirce S, Domiíguez-Ortega J.** Eosinophil and cationic protein levels in patients treated with dupilumab: a real-life study. Open Respir Arch. 2025; 7(3): 100444. Article. Not Indexed
- **de Andrés Morera S, Chajma Izquierdo S, Arancon Pardo A, Villamañán Bueno E.** Implementation of a healthcare network for the pharmacological treatment adjustment in patients with dysphagia in the hospital and primary care settings. Rev Esp Geriatr Gerontol. 2025; 60(3): 101616. Article. Not Indexed

Patents and trademarks

- **Villamañán Bueno E, Gómez L, Carpio C, Álvarez-Sala R, Herrero A, authors; FIBHULP, assignees.** Brand name: ExpertEPID. 019153209. 2025 July 13.

FarmaTOX

- **"Muñoz M, Villamañán E, Álvarez A, Herrero A, Álvarez-Sala R, Quirce S, González de Olano D, Sánchez Cuellar S, Antolín Amérigo D, Domínguez Ortega J, Carpio C, Prados MC, authors, FIBHULP, UAM, FIBioHRC, assignees; Brand Name: CheckList.** 019168760. 2025 August 02.

CHECKLIST Atención Farmacéutica en ASMA GRAVE

- **"Villamañán E, Ros Muñoz S, Carpio C, Gómez L, Prados MC, Rodríguez JL, Álvarez-Sala R, Herrero A, Sobrino C, González García L, Caumel Morales L, authors; FIBHULP, UAM, UNED, IN2AI, Patrimonio Nacional, assignees.** Brand name: FarmaTOX. 019153050. 2025 July 13.

ExpertEPID

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.4.11 Translational Hepatology



Publications: 12 | Q1: 9

COMPOSITION

Francisco Javier García-Samaniego Rey.
Jefe de Sección en Hepatología. Hospital Universitario La Paz/Profesor Titular. Universidad Complutense De Madrid

- **Marina Camblor Murube.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Antonio Madejón Seiz.** *Investigador Postdoctoral. CIBERehd*
- **Antonio Olveira Martín.** *Facultativo Especialista de Área en Hepatología. Hospital Universitario La Paz*
- **Miriam Romero Portales.** *Facultativo Especialista de Área en Gastroenterología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- The laboratory and the Hepatology Department of the hospital actively participate in the national optimization of viral hepatitis micro-elimination processes. This involves implementing rapid screening pathways and systems, quickly referring infected patients to the hospital, and integrating them into the corresponding care cascade. This objective requires inter-hospital collaboration, as well as, especially importantly, collaboration with Primary Care Centers and Drug Addiction Treatment Centers. While the goal is to implement this strategy for all liver virus infections, the model is specifically designed for the HCV micro-elimination system. The Alliance for the Elimination of Viral Infections, led by the group's Principal Investigator, Dr. García-Samaniego, actively participates in this initiative.
- Implementation of sequence analysis systems using NGS techniques for the study of viral evolution.
- Development of collaborations with basic research teams specializing in the study of epigenetic modifications at the histone level, and the composition of the intestinal microbiome.

RESEARCH LINES

- The main focus of the group's work is on the study of hepatitis virus infections [hepatitis B (HBV), C (HCV), delta (HDV) and E (HEV)] and related chronic liver disease, addressing both clinical and basic aspects:

  1. Analysis of the role of epigenetic modifications induced by hepatitis virus infection in the evolution of liver disease and the development of liver cancer, before and after antiviral treatment. Project under development in collaboration with the Department of Biochemistry of the Faculty of Medicine of the Autonomous University of Madrid (UAM) and the Virology Laboratory of the Severo Ochoa Molecular Biology Center.

  2. Design of predictive algorithms for the development of hepatocellular carcinoma in patients with chronic hepatitis C, treated and cured.

  3. Study of the epidemiological situation and optimization of the care cascade for patients with hepatitis delta virus (HDV) infection. Project in collaboration with the Hospital Clínic of Barcelona and the Hospital Infanta Leonor of Madrid, and funded by the HDV DESCRIBE program sponsored by Gilead Sciences.

  4. Study of the variability of the VHD genome in the Spanish population. Impact of variability on newly designed therapies.

  5. Development of HCV micro-elimination strategies through the optimization and implementation of HCV detection and quantification systems at diagnostic points.

  6. Study of the influence of pre-existing liver disease on the evolution of COVID-19.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH ACTIVITY

Publications

- **Alonso-Castellano P, Mariño Z, Tugores A, Olveira A, Ampuero J, Berenguer M, Fernández-Ramos JR, Moreno-Planas JM, Lázaro-Ríos M, Masnou H, González-Diéguez ML, Pinazo-Bandera JM, Molina-Pérez E, Hernández-Guerra M, Romero-Gutiérrez M, Fernández-Álvarez P, Muñoz C, Lorente S, Cachero A, Delgado-Blanco M, Vargas V, Gómez-Camarero J, Cuenca F, Ibáñez-Samaniego L, Fernández-Bermejo M, Álvarez-Suárez B, Iruzubieta P, Arencibia-Almeida A, García-Villarreal L.** Genetic map of Wilson disease in Spain-A great tool to improve diagnosis and screening. Rev Esp Enferm Dig. 2025; 117(5): 249-55. Article. IF: 4.8; Q1
- **Alonso-Castellano P, Tugores A, Mariño Z, Olveira A, Berenguer M, Huarte MP, Fernández-Ramos JR, Lázaro-Ríos M, González-Diéguez ML, Moreno-Planas JM, Hernández-Guerra M, Fernández-Álvarez P, Delgado-Blanco M, Pinazo-Bandera JM, Romero M, Ampuero J, Masnou-Ridaura H, Cachero A, Vargas V, Gómez-Camarero J, Morillas-Ariño MJ, Molina-Pérez E, Miralpeix A, García-Villarreal L.** Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries. Digest Liver Dis. 2025; 57(2): 443-9. Article. IF: 4.9; Q1
- **Berenguer M, García-Villarreal L, Olveira A, Pérez EM, Planas JMM, Romero-Gutiérrez M, Bandera JMP, Ridaura HM, Iruzubieta P, Diéguez MLG, Ampuero J, Ramos JRF, Muñoz C, Almeida AA, Lorente S, Blanco MD, Santamaría DB, Delgado MP, Cachero A, Guerra MH, Camarero JG, Rojas SG, Ríos ML, Soria IC, Carrión G, Bono A, Miralpeix A, Castellano PA, Mariño Z.** Predictive value of liver enzymes in long-term prognosis of hepatic Wilson disease: results from the Wilson AEEH registry. Orphanet J Rare Dis. 2025; 20(1): 288. Article. IF: 3.6; Q2
- **Chafino S, Tarancón-Díez L, Hurtado-Gallego J, Flores-Piñas M, Alcolea S, Olveira A, Navarro ML, Fernández-Arroyo S, Viladés C, Montes ML, Vidal F, Peraire J, Rull A, Sainz T.** Metabolomics for searching non-invasive biomarkers of metabolic dysfunction-associated steatotic liver disease in youth with vertical HIV. Commun Med (Lond). 2025; 5(1): 433. Article. IF: 7.4; Q1
- **Cuadros M, Abadía M, Castillo P, Martín-Arranz MD, Gonzalo N, Romero M, García-Sánchez A, García-Samaniego J, Olveira A, Ruiz-Cantador J, González-Fernández O, Ponz I, Merás P, Merino C, Rodríguez-Chaverri A, Balbacid E, Froilán C.** Role of transient elastography in the diagnosis and prognosis of Fontan-associated liver disease. World J Gastroentero. 2025; 31(11): 103178. Article. IF: 7.7; Q1
- **Hiebert-Suwondo L, Manning J, Tohme RA, Buti M, Kondili LA, Spearman CW, Hajarizadeh B, Turnier V, Lazarus J, Grebely J, Dore GJ, Waked I, Ward JW, (García-Samaniego J).** A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles. Lancet Gastroenterol Hepatol. 2025; 10(7): 685-700. Article. IF: 39.1; D1
- **Hiebert-Suwondo L, Manning J, Tohme RA, Buti M, Kondili LA, Spearman CW, Prabdial-Sing N, Turnier V, Lazarus J, Waked I, Ward JW, (García-Samaniego J).** A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles. Lancet Gastroenterol Hepatol. 2025; 10(7): 671-84. Article. IF: 39.1; D1
- **Laue T, Ballester MP, Meoli L, Grabitz C, Uson E, D'Antiga L, McLin V, Pujadas M, Carvalho-Gomes A, Sahuco I, Bono A, D'Amico F, Viganò R, Diago E, Lanseros BT, Inglese E, Vazquez DM, Broekhoven A, Kikkert M, Morales SPT, Myeni SK, Riveiro-Barciela M, Palom A, Zeni N, Brocca A, Cussigh A, Cmet S, Escudero-García MD, Stocco M, Natola LA, Ieluzzi D, Paon V, Sangiovanni A, Farina E, Dibenedetto C, Sánchez-Torrijos Y, Lucena-Varela A, Román E, Sánchez E, Sánchez-Aldehuelo R, López-Cardona J, Jeyanesan D, Morocho AE, Canas-Pérez I, Eastgate C, Di Cola S, Lapenna L, Zaccherini G, Bongiovanni D, Riva A, Sharma R, Tsou HLP, Harris N, Zanaga P, Sayaf K, Hossain S, Crespo J, Robles-Diaz M, Madejón A, Degroote H, Korenjak M, Verhelst X, García-Samaniego J, Andrade RJ, Iruzubieta P, Wright G, Caraceni P, Merli M, Patel VC, Gander A, Albillos A, Soriano G, Donato MF, Sacerdoti D, Toniutto P, Buti M, Duvoux C, Grossi PA, Berg T, Polak WG, Puoti M, Bosch-Comas A, Belli LS, Burra P, Russo FP, Coenraad M, Calleja JL, Perricone G, Chokshi S, Berenguer M, Clària J, Moreau R, Fernández J, Arroyo V, Angeli P, Sánchez-Garrido C, Ampuero J, Piano S, Nicastro E, Rock N, Shawcross D, Edwards L, Mutschler F, Melk A, Mehta G, Baumann U, Jalan R.** Pediatric liver and kidney transplant recipients demonstrate greater serological response to SARS-CoV-2 Vaccination Than Adults. Transplant Direct. 2025; 11(5): e1787. Article. IF: 2.2; Q2
- **Pocurull A, Broquetas T, Hoyas E, Rodríguez M, Miquel M, Rodriguez M, Roig CA, Herms Q, Rodríguez-Tajes S, García-Samaniego J, Suárez E, Buti M, Forns X, Carrión JA, Lens S.** Determinants of HBsAg loss after nucleos(t)ide discontinuation in a prospective cohort of HBeAg-negative caucasian patients. Liver Int. 2025; 45(11): e70371. Article. IF: 6.2; Q1
- **Razavi HA, Waked I, Qureshi H, Kondili LA, Duberg AS, Aleman S, Tanaka J, Lazarus JV, Low-Beer D, Abbas Z, Abou Rached A, Aghemo A, Aho I, Akarca US, Al-Busafi SA, Al-Hamoudi WK, Al-Naamani K, Alaama AS, Aldar MM, Alghamdi M, Gonzalez MA, Alserehi H, Anand AC, Asselah T, Assiri AM, Athanasakis K, Atugonza R, Ben-Ari Z, Berg T, Brandao-Mello CE, Brown ASM, Brown KA, Brown RS , Bruggmann P, Brunetto MR, Buti M, Cheinquer H, Christensen PB, Chulanov V, Garza LEC, Coffin CS, Coppola N, Craxi A, Crespo J, Cui FQ, Dalgard O, De La Torre A, De Ledinghen V, Dieterich D, Drazilova S, Dufour JF, El-Kassas M, Elbadri M, Esmat G, Mur RE, Eurich B, Faini D, Ferreira PRA, Flisiak R, Frankova S, Gaeta GB, Gamkrelidze I, Gane EJ, Garcia V, García-Samaniego J, Gemilyan M, Gottfredsson M, Gschwantler M, Gurski APM, Hajarizadeh B, Hamid SS, Hatzakis A, Hercun J, Hockicková I, Huang JF, Hunyady B, Hutchinson SJ, Ishikawa N, Izumi K, Izzi A, Janicko M, Jarcuska P, Jeruma A, Johannessen A, Kaliaskarova KS, Kao JH, Kielland KB, Kodjoh N, Kottilil S, Kristian P, Kwo PY, Lagging M, Lam H, Lázaro P, Lee MH, Lens S, Liakina V, Lim YS, Makara M, Manns M, Manzengo CM, Memon S, Mendes-Correa MC, Messina V, Midgard H, Murphy N, Musabaev E, Naveira MCM, Nde H, Negro F, Nim N, Ocama P, Olafsson S, Omuemu CE, Pamplona J, Pan CQ, Papatheodoridis GV, Pimenov N, Poustchi H, Quaranta MG, Ramji A, Rautiainen H, Razavi-Shearer DM, Razavi-Shearer K, Ridruejo E, Ríos-Hincapié CY, Sadirova S, Sanai FM, Sarrazin C, Sarybayeva G, Schréter I, Seguin-Devaux C, Sereno LS, Shiha G, Smith J, Soliman R, Sonderup MW, Spearman CW, Stauber RE, Stedman CAM, Sypsa V, Tacke F, Terrault NA, Tolmane I, Van Welzen B, Voeller AS, Waheed Y, Wallace C, Whittaker RN, Wong VWS, Ydreborg M, Yesmembetov K, Yu ML, Zeuzem S, Zuckerman E.** Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies. J Hepatol. 2025; 83(2): 329-47. Article. IF: 40.1; D1

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



- **Rodríguez-Tajes S, Palom A, Giráldez-Gallego A, Moreno A, Urquijo JJ, Rodríguez M, Alvarez-Argueelles M, Diago M, García-Eliz M, Fuentes J, Martinez-Sapina AM, Castillo P, Casado M, Pérez-Campos E, Muñoz R, Hernández-Conde M, Morillas RM, Granados R, Miquel M, Morillas MJ, Garcia-Retortillo M, Carrión JA, Moreno JM, Montón C, González-Santiago JM, Lorente S, Cabezas J, Mateos B, Vázquez-Rodríguez S, Díaz-Fontenla F, Pinazo JM, Delgado M, Pérez-Palacios D, Horta D, Fernández-Marcos C, López C, Calleja JL, Fernández I, García-Samaniego J, Forns X, Buti M, Lens S.** Characterizing hepatitis delta in Spain and the gaps in its management. Gastroent Hepat-Barc. 2025; 48(2): 502222. Article. IF: 2.0; Q3
- **Virseda-Berdices A, Martín-Escolano R, Berenguer J, González-García J, Brochado-Kith O, Rojo D, Díez C, Hontañon V, Pérez-Latorre L, Ibañez-Samaniego L, Llop-Herrera E, Olveira A, Fernández-Rodríguez A, Barbas C, Resino S, Jiménez-Sousa MA, ESCORIAL Study Grp.** Metabolomic changes associated with the change in HVPG after DAAs therapy in HCV cirrhotic patients. Liver Int. 2025; 45(1): e16204. Article. IF: 6.2; Q1

Research projects

- **García-Samaniego Rey J.** Estudio epidemiológico y molecular de la infección por VHD en una gran área urbana de España. Optimización de la cascada de atención (PI22/00849). ISCIII. 2022-2027. Managment centre: FIBHULP
- **García-Samaniego Rey J.** Búsqueda activa de pacientes con hepatitis crónica viral (VHC Y VHD) no diagnosticada, en población general, desde los Centros de salud de la Comunidad de Madrid. Gilead Sciences S.L. 2022-2026. Managment centre: FIBHULP
- **García-Samaniego Rey J.** Study of the epidemiological situation and optimization of the cascade of care for patients with infection by the hepatitis delta virus (HDV). HDV DESCRIBE (EHD22PE02). Gilead Sciences S.L. 2023-2026. Managment centre: CIBER

Clinical trials

- **Olveira Martín A.** Ensayo de fase III multicéntrico, aleatorizado, doble ciego, comparativo con placebo, de 48 semanas de duración, para evaluar la eficacia y la seguridad de survodutide administrada por vía subcutánea en participantes con sobrepeso u obesidad y esteatohepatitis no alcohólica (ehna) presunta o confirmada.
  Type/Phase: III
  Sponsored by: Boehringer Ingelheim International Gmbh.
  Signature date: 10/10/2025
- **Olveira Martín A.** A randomised, double-blind, placebo-controlled, multicentre, phase iii trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (nash/mash) and (f2) - (f3) stage of liver fibrosis.
  Type/Phase: IIIa
  Sponsored by: Boehringer Ingelheim International Gmbh.
  Signature date: 23/09/2025
- **Olveira Martín A.** A phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated nonalcoholic steatohepatitis/ metabolic dysfunction associated steatohepatitis (nash/mash) cirrhosis.
  Type/Phase: III
  Sponsored by: Boehringer Ingelheim International Gmbh.
  Signature date: 16/09/2025
- **Olveira Martín A.** Characterization of pfic-related genes in adult patients with idiopathic ecurrent and chronic cholestasis in spain-regenic.
  Type/Phase: No EPA
  Sponsored by: Ipsen Pharma, S. A..
  Signature date: 12/11/2025
- **Olveira Martín A.** A phase IIIb randomised, parallel-group, double-blind, placebo-controlled, two-arm study to evaluate the effect of elafibranor 80 mg on normalisation of alkaline phosphatase in adult participants with primary biliary cholangitis (pbc) and inadequate response or intolerance to ursodeoxycholic acid.
  Type/Phase: IIIb
  Sponsored by: Ipsen Bioscience, Inc.
  Signature date: 18/06/2025
- **Olveira Martín A.** Estudio de fase 2a, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de efinopegdutida (mk-6024) en adultos con cirrosis compensada secundaria a esteatohepatitis asociada a disfunción metabólica.
  Type/Phase: IIa
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 13/06/2025
- **Olveira Martín A.** A phase 3 randomized, open-label study to evaluate the efficacy and safety of tobevibart+elebsiran combination therapy in participants with chronic hdv infection not virologically suppressed with bulevirtide (eclipse 2).
  Type/Phase: III
  Sponsored by: Vir Biotechnology.
  Signature date: 19/09/2025
- **Olveira Martín A.** A phase 2b randomized, open-label study to evaluate the efficacy and safety of tobevibart+elebsiran combination therapy versus bulevirtide in participants with chronic hdv infection (eclipse 3).
  Type/Phase: IIb
  Sponsored by: Vir Biotechnology.
  Signature date: 17/10/2025
- **García Samaniego J .** Estudio de fase I/II abierto y multicéntrico para evaluar la seguridad, la tolerabilidad y la eficacia de los macrófagos autólogos de rtx001 en participantes con cirrosis hepática que presentan descompensación hepática (emerald).
  Type/Phase: II
  Sponsored by: Resolution Therapeutics Ltd.
  Signature date: 16/04/2025

Patents and trademarks

- **Castán P, Gil-García AI, Madejón A, Sainz-Martínez E, Montoya JJ, Ouahid Younes, inventors; MIRNAX BIOSENS S.**L., assignee. Bivalent reverse primers Aplication number (EPO): 20382336.4-1118. 2020 April 24.
- **Madejón A; inventor; Agile Life Sciences LTD, assignee.** Kit and methods Aplication number: GB202010372.A. 2020 July 6.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.4.12 Neuro-Cure

Publications: 4 | Q1: 1

COMPOSITION

Javier Marco Martínez.
Gerente. Hospital de Emergencias Enfermera Isabel Zendal

- **Marina Arce Maurin.** *Enfermera. Hospital de Emergencias Enfermera Isabel Zendal*
- **Juan Arribas Guerrero.** *Supervisor de enfermería. Hospital de Emergencias Enfermera Isabel Zendal*
- **Stefano Cabras.** *Catedrático de Universidad. Universidad Carlos III de Madrid*
- **Nazaret Casillas Ramos.** *Facultativo Especialista de Área en Medicina Interna. Hospital de Emergencias Enfermera Isabel Zendal*
- **María Eugenia Castellanos Nueda.** *Catedrática en el Deparamento de Informática y Estadística. Universidad Rey Juan Carlos*
- **Ana Elisabeth García Sipolis.** *Profesora Titular. Universidad Rey Juan Carlos*
- **Guillermo García Pérez de Sevilla.** *Fisioterapeuta. Universidad Europea de Madrid*
- **María García Sánchez.** *Enfermera. Hospital de Emergencias Enfermera Isabel Zendal*
- **Óscar Generoso Gutiérrez.** *Director de Tecnologías de la Información y Excelencia en Ventas. Universidad Rey Juan Carlos*
- **Antonio Martín Alonso.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital de Emergencias Enfermera Isabel Zendal*
- **María del Carmen Marcos Sastre.** *Directora Técnica Centro Especializado de Atención Diurna para pacientes ELA. Hospital de Emergencias Enfermera Isabel Zendal*
- **Enrique Muñoz de Maya.** *Enfermero. Hospital de Emergencias Enfermera Isabel Zendal*
- **Victoria Ruiz Parrado.** *Profesora Contratada Doctor Interino. Universidad Rey Juan Carlos*
- **Clara Simón de Blas.** *Profesora Titular. Universidad Rey Juan Carlos*
- **María Teresa Santos Martín.** *Profesora Titular. Universidad de Salamanca*
- **Natacha María Soto Vargas.** *Enfermera. Hospital de Emergencias Enfermera Isabel Zendal*
- **Ángela Trueba Vicente.** *Facultativo Especialista de Área en Medicina Interna. Hospital de Emergencias Enfermera Isabel Zendal*

STRATEGIC OBJETIVES

- To investigate issues related to the care and rehabilitation of neurological patients.
- Different lines of work will be generated seeking to encompass an interdisciplinary approach that includes technological advances as well as human and holistic strategies to improve the quality of life of neurological patients.

RESEARCH LINES

- Innovation in neurofunctional rehabilitation techniques: Design, implementation and evaluation of advanced therapies based on neuroplasticity; use of technology such as robotics, exoskeletons and virtual reality to enhance rehabilitation; development of personalized protocols for the recovery of motor and cognitive functions
- Comprehensive care for neurological patients: research on patient- and family-centered care models; study of the psychosocial impact of neurological care on patients and caregivers; development of tools to improve the quality of life of patients with neurodegenerative diseases
- Evaluation of assisted technologies and telemedicine: validation of assisted devices for home rehabilitation; implementation and evaluation of tele-rehabilitation and remote monitoring programs; study of the results of artificial intelligence in the prediction of clinical outcomes
- Palliative care in advanced neurological diseases: research on pain and non-motor symptom management strategies; design of interdisciplinary protocols for end-of-life care; analysis of the emotional and psychological impact on patients and their families
- Prevention and management of associated complications: study of strategies to prevent complications such as pressure ulcers, infections and thrombosis in neurological patients; development of programs for early detection of functional deterioration
- Personalized nutrition. design of individualized nutritional plans based on metabolic status and specific needs; study of the impact of specific supplementation on the recovery of cognitive and motor functions. research on dietary strategies to prevent dysphagia-related complications in patients with neurological damage; development of adapted food textures and formulas to optimize intake in patients with dysphagia; evaluation of diets in neurological recovery processes; study of the role of the intestinal microbiota in neurological function and its modulation through nutrition



RESEARCH ACTIVITY

Publications

- **García-Donato G, Castellanos ME, Cabras S, Quiros A, Forte A.** Model uncertainty and missing data: an objective bayesian perspective (with discussion). Bayesian Anal. 2025; 20(4): 1677-778. Article. IF: 3.0; Q1
- **Ruiz-Parrado V, Moreno AB, Sánchez A, Vélez JF.** Graph visualization and complex network theory applied to the analysis of departmental teaching assignment plans. Complex Networks & Their Applications XIII. 2025; 1187: 372-84. Article. Not Indexed
- **Ruiz-Parrado V, Moreno AB, Sánchez A, Velez JF.** Macro-scale analysis of teaching assignment plans based on complex network metrics and graph visualizations. Soc Netw Anal Min. 2025; 15(1): 94. Article. IF: 3.2; Q2
- **Vélez JF, Moreno AB, Ruiz-Parrado V, Sánchez A.** On the use of concept maps to improve student skills in an introductory object-oriented analysis and design course. ICPEC. 2025; 133: 3. Article. Not Indexed


1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.4.13 iPanC: Imaging, Innovation and Clinical Practice in the Pancreas*

COMPOSITION

Eva Marín Serrano.
Facultativo Especialista de Área en Aparato Digestivo. Unidad de Páncreas. Hospital Universitario La Paz

- **Ana Barbado Cano.** *Médico Adjunto en Aparato Digestivo. Hospital Universitario La Paz*
- **María Gema Crespo Sánchez.** *Facultativo Especialista de Análisis Clínicos. Hospital Universitario La Paz*
- **Ana Kerguelen Fuentes.** *Facultativo Especialista de Área en Hematología. Hospital Universitario La Paz*
- **Noemí González Pérez de Villar.** *Facultativo Especialista de Área en Endocrinología y Nutrición. Hospital Universitario La Paz*
- **Eva Martínez-Ojinaga Nodal.** *Facultativo Especialista de Área en Pediatría. Hospital Clínico San Carlos*
- **Samara Palma Milla.** *Facultativo Especialista de Área en Endocrinología y Nutrición. Hospital Universitario La Paz*
- **Olga Rogozina.** *Médico Especialista en Farmacología Clínica. FIBHULP*
- **Laura Tello Arnás.** *Médico Residente de Radiodiagnóstico. Hospital Universitario La Paz*
- **Rubén Fernández Martos.** *Médico Adjunto en Aparato Digestivo. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- iPanC: Imaging, Innovation and Clinical Practice in Pancreas is a clinical and translational research group focused on the study of major pancreatic diseases. Its activities integrate patient care, research, and innovation with a multidisciplinary approach aimed at improving the diagnosis, prognostic stratification, and therapeutic management of patients with pancreatic disease.
- The group promotes research in the Pancreas Unit and develops projects based on questions arising from real clinical practice, incorporating quantitative imaging tools, standardized work procedures, structured clinical records and prospective validation, with a vocation for transfer to clinical practice.
- His scientific activity focuses on priority areas such as pancreatic fat deposition, acute pancreatitis, chronic pancreatitis, pancreatic cystic lesions and pancreatic neuroendocrine tumors, consolidating a collaborative research model with a clear clinical and translational orientation.
- Goals
- To promote clinical and translational research in pancreatic diseases of high healthcare relevance.
- To improve the diagnostic and prognostic characterization of pancreatic pathology through advanced imaging tools and clinical analysis.
- Promote the standardization of procedures, the generation of well-defined cohorts, and the prospective validation of new diagnostic strategies.
- To promote multidisciplinary research and the transfer of results to routine clinical practice.
- To consolidate a line of research excellence in pancreatic pathology within IdiPAZ.

RESEARCH LINES

- Pancreatic fat deposition: study of its clinical phenotypes, metabolic implications and value as a biomarker of cardiometabolic risk and pancreatic disease.
- Acute pancreatitis: analysis of prognostic factors, clinical evolution, complications, morphofunctional assessment and optimization of diagnostic and therapeutic strategies.
- Chronic pancreatitis: abdominal ultrasound and elastographic characterization using transabdominal 2D-SWE, analysis by morphological phenotypes, correlation with endoscopic ultrasound and development of combined morphological-elastographic models.
- Pancreatic cystic lesions: clinical, radiological and endoscopic characterization, risk stratification and development of advanced imaging tools to optimize differential diagnosis, including radiomic models applied to MRCP for ductal connection detection.
- Pancreatic neuroendocrine tumors: study of their diagnosis, classification, follow-up and multidisciplinary approach in a context of personalized medicine.

**Group recently created, january 2026*

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

3.5. Cancer and Human Molecular Genetics Area

Documents: 215 | Originals: 183 | D1: 47 | Q1: 108

Javier de Castro Carpeño



RESEARCH GROUPS

3.5.1 INGEMM - Instituto de Genética Médica y Molecular (Institute of Medical and Molecular Genetics)
Pablo Lapunzina Badía

3.5.2 Translational Oncology
Jaime Feliú Battle

3.5.3 Experimental Therapies and Biomarkers in Cancer
Olga Vera Puente/Javier de Castro Carpeño

3.5.4 Research in Otolaryngology and Head and Neck Surgery
Luis Lassaletta Atienza

3.5.5 Molecular Pathology of Cancer and Therapeutic Targets
David Hardisson Hernáez

3.5.6 Mechanisms of Tumour Progression
José Manuel González Sancho

3.5.7 Research and Diagnosis of Inherited Metabolic Diseases
María Belén Pérez González

3.5.8 Dyslipidemias of Genetic Origin and Metabolic Diseases
Sonia Rodríguez Novoa

3.5.9 Human Genetic Variability
Ana Fernández Santander

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Strategic Objectives	Development forecast for the coming years:	Actions
Cancer and Medical Genetics area is made up of 10 groups and its objective is to deepen its knowledge in all aspects related to neoplastic disease, including the biology of the tumour, identification of therapeutic targets, development of new treatments, analysis of the efficacy of available treatments, identification of biomarkers and carrying out studies aimed at prevention and early diagnosis. In relation to human and molecular genetics, the aim is to identify genetic alterations related to human diseases in order to make an early diagnosis and prevent the development of pathologies.	Research in the area of cancer and genetics is expanding, both in terms of basic and translational research and in terms of clinical research. It is foreseeable that collaboration between groups in the area will continue to increase but also the collaboration with external organisations.	Facilitate the application request for European projects through the IdiPAZ Internalization Platform
	In order to facilitate its development, it will be necessary for the Institution to provide sufficient space and adequate common infrastructures	Support researchers to continue being a reference in the international area.
	It is foreseeable that this expansion will lead to the possibility of applying for European projects and leading consortiums, where once again the support of the Foundation will be essential for their application and management	Promote at international level the different research groups of the area, identifying possible synergies between groups and centers, new partners and funding sources, as well as to forge strategic alliances.

HIGH IMPACT PUBLICATIONS

Pinto-Marín A, Trilla-Fuertes L, Poma JM, Vasudev NS, García-Fernández E, López-Vacas R, Miranda N, Wilson M, López-Camacho E, Pertejo A, Dittmann A, Kunz L, Brown J, Pedroche-Just Y, Zapater-Moros A, de Velasco G, Castellano D, González-Peramato P, Espinosa E, Banks RE, Vara JAF, Gámez-Pozo A. A prognostic microRNA-based signature for localized clear cell renal cell carcinoma: the Bio-miR study. Brit J Cancer. 2025; 133(2): 155-67. Article. IF: 7,8; Q1

Richard E, Marchuk H, Álvarez M, He WT, Chen XX, Desviat LR, Zhang GF. Metabolic flux analysis in hiPSC-CMs reveals insights into cardiac dysfunction in propionic acidemia. Cell Mol Life Sci. 2025; 82(1):-137. Article. IF: 6,5; Q1

Torres RJ, Valentines-Casas G, Cano-Estrada C, Ontiveros N, López JM. Gene Expression analysis of HPRT-deficient cells maintained with physiological levels of folic acid. Cells. 2025; 14(14): 1105. Article. IF: 6; Q2

López-Janeiro A, Brizzi E, Ruz-Caracuel I, Alexandru R, de Andrea C, Berjon A, Yebenes L, Mendiola M, Heredia-Soto V, Montero-Calle A, Barderas R, de los Rios V, Redondo A, Pelaez-García A, **Hardisson D.** The proteomic landscape of CTNNB1 mutated low-grade early-stage endometrial carcinomas. Cells. 2025; 14(21): 1676. Article. IF: 6; Q2

Nevado J, Escalada B, Muñoz-Porrero Y, Adan C, Tenorio-Castaño J, **Lapunzina PD.** Genotype-phenotype associations in Phelan-McDermid syndrome: insights into novel genes beyond SHANK3. Int J Mol Sci. 2025; 26(10): 4653. Article. IF: 5,6; Q1

Scientific Events by Cancer and Human Molecular Genetics

- **21/02/2025** - Seminario Presencial: MAFG is a novel oncogene in melanoma with therapeutic potential
- **17/03/2025** - Lung Cancer Next Generation - From basic research to clinical practice
- **25/03/2025** - Jornada FORTALECE
- **25/04/2025** - Seminario Presencial y Online: iroNKiller: Uniendo las fuerzas de la ferroptosis y las células asesinas naturales para tratar el neuroblastoma
- **30/05/2025** - Seminario Presencial y Online: Control metabólico de la función de ILC3 por HIF-1α y sus implicaciones en el cáncer colorrectal asociado a colitis

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.5.1 INGEMM – Instituto de Genética Médica y Molecular (Institute of Medical and Molecular Genetics)



Publications: 26 | Q1: 17

COMPOSITION

Pablo Daniel Lapunzina Badía.
Facultativo Especialista de Área en Genética. Hospital Universitario La Paz

- **Pedro Arias Lajara.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **Ángel Campos Barros.** *Investigador Senior (Contrato Miguel Servet- I2). Jefe de Laboratorio. Hospital Universitario La Paz*
- **Luis Fernández García-Moya.** *Biólogo. Hospital Universitario La Paz*
- **María Victoria Fernández Montaña.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **Fe Amalia García Santiago.** *Bióloga. Hospital Universitario La Paz*
- **Isabel Gómez Nieto.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **Karen Elise Heath.** *Investigadora Senior (Contrato Ramón y Cajal-I3). Jefe de Laboratorio. Hospital Universitario La Paz*
- **Juan Andrés Jiménez Estrada.** *Investigador Postdoctoral. Hospital Universitario La Paz*
- **Teresa López Timénez.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **Alicia Llorente Alonso.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **María Elena Mansilla Aparicio.** *Genetista. Hospital Universitario La Paz*
- **Pilar Martínez González.** *Bióloga. Hospital Universitario La Paz*
- **José Carlos Moreno Navarro.** *Facultativo Especialista de Área en Genética. Hospital Universitario La Paz*
- **Julián Nevado Blanco.** *Biólogo. Hospital Universitario La Paz*
- **María Palomares Bralo.** *Bióloga. Hospital Universitario La Paz*
- **Víctor Luis Ruiz Pérez.** *Investigador Cientifico de OPIs. Jefe de laboratorio. IIB Alberto Sols*
- **Elena Vallespín García.** *Jefa de Grupo de la Sección de Ofalmogenética Molecular. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- This is a basic and clinical research team that carries out several lines of research in early diagnosis, disease mechanisms and new therapeutic strategies for genetic diseases, developmental disorders and congenital defects.
- It is a heterogeneous group composed of medical professionals, pharmacists, molecular biologists, bioinformaticians, technicians and administra

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH LINES

- Subtelomeric restructurings in patients with idiopathic intellectual disability
- Genetic and functional analysis of the SHOX and SHOX2 genes in human growth
- Overgrowth syndromes. Clinical and molecular analysis
- Genetic determinants of harmonious undergrowth
- Genetic aspects of monogenic diabetes mellitus.
- Genetics of the GHrelin axis in childhood-onset obesity.
- SNP matrices in pharmacogenetics of HIV patients.
- CGArrays and genomic rearrangements in patients with congenital malformations, intellectual disability and tumors.
- Molecular genetics of hypertrophic cardiomyopathy.
- Functional analysis of mutations in CLCN1 causing congenital myotonia.
- Molecular study of endothelial dysfunction in diabetes and aging.
- Molecular characterization of the 22q11.2 region using MLPA, microsatellites and FISH.
- Pharmacogenetics and Pharmacogenomics
- Autosomal recessive osteogenesis imperfecta.
- Pharmacogenetics and Pharmacogenomics
- Autosomal recessive osteogenesis imperfecta
- Genomic tools for diagnosis: BAC, oligos and SNP arrays.
- Macrocephaly-capillary malformations and syndromes with macrocephaly.
- Next-generation sequencing as a new tool in the diagnosis of genetic diseases.
- Classification and ontologies of diseases
- Primary pulmonary hypertension
- Global genomic analysis in the invdup(15) syndrome [idic(15) syndrome]
- Molecular characterization of inv dup del (8p) by karyotyping, SNP arrays 2023 and FISH

RESEARCH ACTIVITY

Publications

- **Andres-Ibarrola P, Maestro IM, Santamaría AFD, Alfonso CB, Rodríguez ES, Almaraz RL, Merino MJB, Rodríguez-Laguna L, Martínez-Glez V, Gutiérrez JCL, Eckert MM, González-Hermosa MR.** Multifocal PIK3CA related congenital hemangioma. Pediatr Dermatol. 2025; 42(6): 1198-201. Article. IF: 1.2; Q3
- **Baca MDP, Palomares-Bralo M, Vanhooydonck M, Hamerlinck L, D'haene E, Leimbacher S, Jacobs EZ, De Cock L, D'haenens E, Dheedene A, Malfait Z, Vantomme L, Silva A, Rooney K, Zhao XA, Saeidian AH, Owen NM, Santos-Simarro F, Lleuger-Pujol R, García-Minaur S, Losantos-García I, Menten B, Gestri G, Ragge N, Consortium Z, Sadikovic B, Bogaert E, Vleminckx K, Naert T, Syx D, Callewaert B, Vergult S.** Loss of function of the zinc finger homeobox 4 gene, ZFHX4, underlies a disorder. Am J Hum Genet. 2025; 112(6): 1388-414. Article. IF: 7.7; D1
- **Bel-Fenellós C, Biencinto-López C, Orio-Aparicio C, da Silva-Mori X, Tenorio-Castaño JA, Lapunzina P, Nevado J.** Family well-being in families with children and young people with Wolf-Hirschhorn Syndrome. Res Dev Disabil. 2025; 160: 104974. Article. IF: 2.9; D1
- **Blanco-Lago R, Málaga I, Tenorio-Castaño JA, Álvarez-Álvarez N, Lapunzina P, Nevado J.** Epilepsy in Wolf-Hirschhorn syndrome: clinical insights from a pediatric cohort and a review of the literature. J Clin Med. 2025; 14(22): 8044. Article. IF: 3.3; Q1
- **Bruel AL, Vulto-vanSilfhout AT, Bilan F, Le Guyader G, Gilbert-Dussardier B, Le Guillou X, Rondeau S, Rio M, Lee KN, Beil A, Suri M, Guerin F, Ruault V, Goldenberg A, Lecoquierre F, Bertsch N, Anderson R, Yang XR, Inness M, Rikeros-Orozco E, Palomares-Bralo M, Hayek JC, Cech J, Jhuraney A, Kumar RD, Mercimek-Andrews S, Ambrose A, Wakeling EN, Wentzensen IM, Torti E, Gooch C, Faivre L, Philippe C, Duffourd Y, Vitobello A, Thauvin-Robinet C.** Heterozygous CELF4 variants in the N-term region crucial for the RNA-binding activity lead to neurodevelopmental disorder and obesity. Eur J Hum Genet. 2025; 33(7): 852-9. Article. IF: 4.6; Q1
- **Cabrera-Alarcon JL, Cruz R, Rosa-Moreno M, Latorre-Pellicer A, de Almeida SD, Riancho JA, Rojas-Martínez A, Flores C, Lapunzina P, Sánchez-Cabo F, Carracedo A, Enriquez JA.** Shaping current European mitochondrial haplogroup frequency in response to infection: the case ofSARS-CoV-2severity. Commun Biol. 2025; 8(1): 33.. Article. IF: 5.8; D1
- **Cecere F, Pignata L, D'Angelo E, Giaccari C, Saadat A, Sparago A, Angelini C, Mele BH, Mussa A, Ferrero GB, Scarano G, Gori G, Di Maria E, Romano C, Tarani L, Piscopo C, Scala I, Tenorio JA, Lapunzina P, Cerrato F, Riccio A.** Highly variable genomic methylation in the Beckwith-Wiedemann syndrome associated with multi-locus imprinting disturbances. Clin Epigenetics. 2025; 17(1): 160. Article. IF: 5.7; Q1
- **Chimirri L, Caufield JH, Bridges Y, Matentzoglu N, Gargano M, Cazalla M, Chen SH, Danis D, Dingemans AJM, Gehle K, Gehle P, Graefe ASL, Gu WH, Ladewig MS, Lapunzina P, Nevado J, Niyonkuru E, Ogishima S, Seelow D, Castaño JAT, Turnovec M, de Vries BBA, Wang K, Wissink K, Yüksel Z, Zucca G, Haendel MA, Mungall CJ, Reese J, Robinson PN.** Consistent performance of large language models in rare disease diagnosis across ten languages and 4917 cases. Ebiomedicine. 2025; 121: 105957. Article. IF: 11.2; D1
- **Greene D, De Wispelaere K, Lees J, Codina-Solà M, Jensson BO, Hales E, Katrinecz A, Molina EN, Pascoal S, Pfundt R, Schot R, Porras MS, Sleutels F, Valenzuela I, Wijngaard R, Carrera IA, Atton G, Casas-Alba D, Donnelly D, Rodríguez AD, Garoz BF, Foulds N, Núñez DGN, Alguacil EG, Jarvis J, Kant SG, Bajo IM, Martínez-Monseny AF, McKee S, Cabrera NVO, Bodi LRR, Jamardo AS, Stefansson K, Sulem P, Suri M, Van Karnebeek C, Vasudevan P, Pajares AIV, Carracedo A, Engelen M, Lapunzina P, Morgan NP, Morte B, Rump P, Stirrups K, Tizzano EF, Barakat TS, O'Donoghue M, Pérez-Jurado LA, Freson K, Mumford AD, Turro E.** Mutations in the small nuclear RNA gene RNU2-2 cause a severe neurodevelopmental disorder with prominent epilepsy. Nat Genet. 2025; 57(6):1367-73. Article. IF: 25.5; D1
- **Guillén-Guio B, Marcelino-Rodríguez I, Lorenzo-Salazar JM, Leavy OC, Allen RJ, Pompa-Mera EN, Riancho JA, Rojas-Martínez A, Lapunzina P, Carracedo A, Wain L, Flores C.** Polygenic risk of idiopathic pulmonary fibrosis and COVID-19 severity. ERJ Open Res. 2025; 11(2): 9782024. Article. IF: 4.4; Q1
- **Guzmán SG, Ruggiero SM, Ganesan S, Ellis CA, Harrison AG, Sullivan KR, Stark Z, Brown NJ, Kana SL, Tuttle A, Tenorio J, Lapunzina P, Nevado J, McDonald MT, Jensen C, Wheeler PG, Stange L, Morrison J, Keren B, Heide S, Keating MW, Butler KM, Lyons MA, Jain S, Yeganeh M, Thompson ML, Schroeder M, Nguyen H, Granadillo J, Johnston KM, Murali CN, Bosanko K, Burrow TA, Morgan S, Watson DJ, Hakonarson H, Helbig I.** Variants in BSN, encoding the presynaptic protein Bassoon, result in a distinct neurodevelopmental disorder with a broad phenotypic range. Am

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

J Hum Genet. 2025; 112(6): 1415-29. Article. IF: 7.7; D1

- **Ivars M, Frieden IJ, Provini L, Wassef M, Weibel L, Theiler M, Lanoel A, Martínez-Glez V, Rodríguez-Laguna L, van der Vleuten C, Guibaud L, Puttgen K, Azaña-Defez JM, Chamlin S, Drolet B, Torres N, Wyrzykowsky D, Colmenero I, López-Gutiérrez JC.** Reply to expanding the phenotypic spectrum of secvaus: report of two cases. Pediatr Dermatol. 2025; 42(3): 681-2. Letter. IF: 1.2; Q3
- **Jolitz L, Helbig I, Fitzgerald MP, Ruggiero SM, Cohen S, Angelini C, Vallespin E, Michaud V, Gerasimenko A, Cogne B, Isidor B, Keren B, Dyment D, Heron D, Karstensen HG, Cuppen I, Christodoulou J, Wilson M, Lake NJ, Biskup S, Syrbe S, Mori T, Becker LL, Kaindl AM.** Phenotype Spectrum of TRPM3-Associated Disorders. Ann Neurol. 2025; 97(3): 561-570. Article. IF: 7.5; D1
- **Lubin EE, González EM, Sangree AK, Durham EL, Klinkhammer H, Li JM, Smith SM, Layo-Carris DE, Clark KJ, Melendez-Pérez AJ, Wang XM, Angireddy R, Weiss EE, Barakat TS, Mercier S, Cogné B, Koene S, Hilhorst-Hofstee Y, Rydzanicz M, Ploski R, Cano MD, Palomares-Bralo M, Arévalo TB, Tan TY, Gallacher L, MacFarland SP, Ahrens-Nicklas RC, Nomakuchi TT, Bhoj EJK.** Coupling deep phenotypic quantification with next-generation phenotyping for 192 individuals with germline histonopathies. Hgg Adv. 2025; 6(3): 100440. Article. IF: 3.1; Q2
- **Miguez MP, García-Min S, Del Pozo A, Suso JJM, Alcalá FJC, Holgado MS, García PA, Rodríguez CJ, Santos-Simarro F, Palomares-Bralo M.** Rapid genome sequencing in neonatal and pediatric intensive care units. Evidence and current situation. An Pediatr. 2025; 103(5): 503956. Article. IF: 2.6; Q1
- **Mirzaa GM, Yan KQ, Relator R, Levesque M, Jayasinghe P, Timpano S, Yalcin B, Collins S, Ziegler A, Pao EMY, Oyama N, Brischoux-Boucher E, Piard J, Monaghan KG, Sacoto MJG, Dobyns WB, Park KL, Fernández-Mayoralas DM, Fernández-Jaén A, Jayakar P, Palomares-Bralo M, Santos-Simarro F, Brusco A, Antona V, Giorgio E, Kvarnung M, Isidor B, Conrad S, Cogné B, Deb W, Stuurman KE, Sterbová K, Smal N, Weckhuysen S, Oegema R, Innes AM, Koboldt DC, Ben-Omran T, Yeh RC, Kruer MC, Bakhtiari S, Papavasiliou A, Moutton S, Nambot S, Chanprasert S, Paolucci SA, Miller K, Burton B, Kim K, O'Heir E, Bruwer Z, Donald KA, Kleefstra T, Goldstein A, Angle B, Bontempo K, Miny P, Joset P, Demurger F, Hobson E, Pang LW, Carpenter L, Li D, Bonneau D, Sadikovic B, Picketts DJ.** Pathogenic variants in SMARCA1 cause an X-linked neurodevelopmental disorder modulated by NURF complex composition. Nat Commun. 2025; 16(1): 9875. Article. IF: 18.1; D1
- **Mora-Gómez M, Feito M, Gallego-Zazo N, Maseda-Pedrero R, Sobral-Costas TG, Miranda-Alcaraz L, Vásquez-Amell V, Rodríguez-Cano M, Parra A, Cazalla M, Arias P, Silván C, Jiménez-Estrada JA, Ruiz-Pérez VL, Nevado J, Lapunzina P, Tenorio-Castano J.** Case Report: Autosomal recessive palmoplantar keratoderma with additional bilateral hearing loss due to a pathogenic frameshift deletion in FAM83G. Front Med (Lausanne). 2025; 12: 1687811. Article. IF: 3.6; Q1
- **Nevado J, Blanco-Lago R, Bel-Fenellós C, Hernández A, Mori-Álvarez MA, Biencinto-López C, Málaga I, Pachajoa H, Mansilla E, García-Santiago FA, Barrúz P, Tenorio-Castaño JA, Munoz-GaPorrero Y, Vallcorba I, Lapunzina P.** Clinician-based functional scoring and genomic insights for prognostic stratification in Wolf-Hirschhorn syndrome. Genes (Basel). 2025; 16(7): 820. Article. IF: 3.1; Q2
- **Nevado J, Ciceri F, Bel-Fenellós C, Tenorio-Castaño JA, Maes T, Xaus J, Buesa C, Lapunzina P.** Phenotype and psychometric characterization of Phelan-McDermid syndrome patients: pioneering towards personalized medicine. Front Psychiatry. 2025; 16: 1511962. Article. IF: 3.8; Q2
- **Nevado J, Escalada B, Muñoz-GPorrero Y, Adan C, Tenorio-Castaño J, Lapunzina PD.** Genotype-phenotype associations in phelan-mcdermid syndrome: insights into novel genes beyond SHANK3. Int J Mol Sci. 2025; 26(10): 4653. Article. IF: 5.6; Q1
- **Parra A, Cazalla M, Jiménez-Estrada JA, Silván C, Miranda-Alcaraz L, Gallego-Zazo N, Mora-Gómez M, Rodríguez-Canó M, Arias P, Rodríguez-Antolín C, Nevado J, Pérez VLR, Tenorio-Castano J, Lapunzina P.** A novel deep intronic variant in nsd1 causing sotos syndrome. Am J Med Genet A. 2025; 197(8): e64074. Article. IF: 1.7; Q4
- **Parra A, Jiménez-Estrada JA, Vásquez-Amell V, Cazalla M, Rodríguez-Canó M, Gallego-Zazo N, Miranda L, Mora-Gómez M, Vallespín E, Mena R, Fernández L, Silván C, Arias P, Domínguez-Jiménez M, Guillén-Navarro E, Nevado J, Tenorio-Castano J, Ruiz-Pérez VL, Lapunzina P.** Identification of a de novo heterozygous frameshift variant in FMR1 in a female with fragile x syndrome. Clin Genet. 2025; 108(2): 224-6. Article. IF: 2.1; Q3
- **Sarno F, Tenorio J, Perea S, Medina L, Pazo-Cid R, Juez I, García-Carbonero R, Feliú J, Guillen-Ponce C, López-Casas PP, Guerra C, Duran Y, López-Acosta JF, Alonso C, Esquivel E, Dopazo A, Akshinthala D, Muthuswamy SK, Lapunzina P, Bockorny B, Hidalgo M.** A Phase III Randomized trial of integrated genomics and avatar models for personalized treatment of pancreatic cancer: The AVATAR trial. Clin Cancer Res. 2025; 31(2): 278-87. Article. IF: 10.9; D1
- **Sentchordi-Montané L, Díaz-González F, Modamio-Hoybjor S, Nevado J, Machado-Fernandes F, Carcavilla A, Salcedo M, Saraiva J, Kant SG, de Bruin C, van Duyvenvoorde HA, González-Cabaleiro I, Rey-Cordo L, Chamorro-Martín JL, Cancela-Muñiz V, Alcón-Sáez JJ, Parrón-Pajares M, Sousa SB, Heath KE.** Moderate to severe short stature and joint involvement in individuals with ACAN deletions. Clin Endocrinol. 2025; 103(2): 177-84. Article. IF: 2.8; Q3
- **Trujillano L, Valenzuela I, Costa-Roger M, Cusco I, Fernández-Álvarez P, Cueto-González A, Lasa-Aranzasti A, Masotto B, Abuli A, Codina-Sola M, del Campo M, Moreno JAR, Domínguez CP, Milla CP, de la Fuente RP, Quesada-Espinosa JF, Nunez-Enamorado N, Gener B, Ballesta-Martínez MJ, Brea-Fernández AJ, Fernández-Prieto M, Trujillo-Quintero JP, Ruiz A, Santos-Simarro F, Rosello M, Orellana C, Martínez F, Martínez-Monseny AF, Casas-Alba D, Serrano M, Palomares-Bralo M, Rikeros-Orozco E, Gomez-Cano MA, Tirado-Requero P, Juste JP, Ramos FJ, García-Arumi E, Tizzano EF.** Comprehensive clinical and genetic characterization of a spanish cohort of 22 patients with bainbridge-ropers syndrome. Clin Genet. 2025; 107(6): 646-62. Article. IF: 2.1; Q3
- **van Oirsouw ASE, Nedbalova P, Hancarova M, Prchal J, Prchalova D, Vlckova M, Bendova S, Monaghan KG, Dyer LM, Chen YM, Carere DA, te Bogt EAM, Fisher H, Scheuerle AE, Riley S, Jain M, Mu WY, Bodurtha JN, van Eerde AM, Stokman MF, Longo N, Balasubramanian M, Spiller M, Costain G, von der Lippe C, Tveten K, Jortveit M, Holla OL, Isidor B, Cogne B, Glinton KE, Vuocolo B, Sierra RA, Angle B, Bontempo K, Koop K, Rabin R, Pappas J, Staffenberg DA, Joset P, Miny P, Filges I, Alali A, Vitalone K, Rosenfeld JA, Bi WM, Bradbrook S, Perrier R, Ramanathan S, Gold JA, Bralo MP, Gomez-Cano MA, Olney AH, Nielsen S, Ziegler A, Bonneau D, Prouteau C, Bruel AL, Caille-Benigni C, Lambert L, Yu AC, Robin NH, Goodloe D, Fischer J, Porrmann J, Hennig YD, Jamra RA, Herman I, Johnson IR, Herissant L, Jouret G, van Gassen KLI, van Binsbergen E, van der Zwaag B, Kamermans A, Oegema R, Sedlacek Z, Fenckova M, van Jaarsveld RH.** Pathogenic XPO1 variants cause

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

a dominant neurodevelopmental disorder. Genet Med. 2025; 27(11): 101555. Article. IF: 6.2; Q1

Research projects

- **Heath KE.** Ánalisis genético y funcional de las displasias esqueléticas (PID2020-116263RB-100). MICINN. 2021-2025. Managment centre: FIBHULP
- **Moreno Navarro JC.** Biomarcadores de disrupción tiroidea gestacional y daño cerebral fetal en el ratón ko para dehal1 y en mujeres embarazadas y sus hijos. ISCIII. 2023-2026. Managment centre: FIBHULP
- **Rodríguez Pérez MR, Pedrosa Delgado M.** Caracterización alergénica y determinación de la relevancia clínica del polen de encina como alérgeno de interés en pacientes policlínicos y su relación con el desarrollo de síndrome de alergia oral con alimentos. ISCIII. 2023-2027. Managment centre: FIBHULP
- **Vallespín García E.** Desarrollo e implementación de un protocolo integral combinado con la búsqueda de nuevos genes de cataratas congénitas bilaterales no sindrómicas. Ferrer Internacional S.A. 2020-Ongoing. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Dinamización de ciencia disruptiva en predictores de enfermedades tumorales, infecciosas y hereditarias como base de la medicina personalizada (FORT23/00006_GRUPO I). ISCIII. 2024-2027. Managment centre: FIBHULP
- **Heath KE.** ERN BOND 2023-2027_European Reference Network on Rare BONe Diseases (BOND2023-2027_HEATH). UE. 2023-2027. Managment centre: FIBHULP
- **Lapunzina Badía PD.** ONTOPREC. Implementación de ontologías, taxonomías y estandarización de las enfermedades crónicas en medicina de precisión. Uso de los escores de riesgo poligénicos como casos de uso. (PMP21/00063). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Palomares Bralo M.** Paving the way for personalized medicine in neonatal and pediatric intensive care units (PI22/01743). ISCIII. 2023-2027. Managment centre: FIBHULP
- **Lapunzina Badía PD.** PROTECT CHILD_A PRivacy-prOTecting Environment for Child Transplants health-related and genomic data integration in the European Reference Network. UE. 2024-2028. Managment centre: FIBHULP
- **Nevado Blanco J.** Implementación de una red pediátrica para la medicina personalizada en enfermedades raras pediátricas. Un proyecto piloto (PMP22/00008). ISCIII. 2023-2026. Managment centre: FIBHULP

Ciber and Retics

- **Lapunzina Badía P.** CIBER Enfermedades Raras. (CIBERer). ISCIII. (31/12/2025). FIBHULP

Patents and trademarks

- **Friedman S, Li D, Narla G, Martignetti J, Heath K, inventors; Mount Sinai School of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein.** PCT/US2001/025046, EP1332362, US2005181374, US2011059899, AU8479001, CA2419064; 2000 August 09.
- **INGEMM, author; FIBHULP, assignee.** Brand name: INGEMM INSTITUTO DE GENÉTICA MÉDICA Y MOLECULAR DEL HOSPITAL UNIVERSITARIO LA PAZ; ESM 2.884.849, USM 77.891.143, CM 8.746.869; 2009 July 16, 2009 December 11, 2009 December 10.



- **INGEMM, author; FIBHULP, assignee.** Brand name: KaryoArray; USM 79.078.751, CM 8.512.907; 2010 January 07, 2009 August 27.



- **INGEMM, author; FIBHULP, assignee.** Brand name: OverGrowthArray; ESM 2.958.709-3, USM 85.334.932, CM 10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.



- **INGEMM, author; FIBHULP, assignee.** Brand name: MetabolArray; ESM 2.958.711-5, USM 85.334.903, CM 10.009.348; 2010 December 02, 2011 June 01, 2011 May 31.




- **Palomares M, Lapunzina P, Nevado J, Vallespin E, Vallcorba I, Melero J, authors; FIBHULP, Hospital Infanta Cristina (Badajoz) Fundesalud, assignees.** Brand name: OncoHematoArray; ESM 2.958.703-4, USM 85.334.842, CM 10.009.181; 2010 December 02, 2011 June 01, 2011 May 31.



- **INGEMM, author; FIBHULP, assignee.** Brand name: OncoArray; ESM 2.962.910, USM 85.363.107, CM 10.091.882; 2011 January 05, 2011 July 05, 2011 July 01.



- **Lapunzina P, Nevado J, Solera J, Vallespin E, Martínez P, Martínez-González V, authors; FIBHULP, assignee.** Brand name: ONCOSeq; USM 85.457.843, CM 9.969.064; 2011 October 27, 2011 May 16.



- **Moreno JC, Moya CM, Vallespin E, Lapunzina P, Nevado J, authors; FIBHULP, assignee.** Brand name: ThyroArray; USM 85.686.688, CM 10.904.951; 2012 July 25, 2012 May 23.



- **Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees.** Brand name: PharmArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.



- **Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees.** Brand name: ClinPharmarray., CM15489511; 2016 May 31, 2016 September 07.




- **Palomares Bralo M, Vallespín García E, del Pozo Mate A, Santos Simarro F, authors; FIBHULP, assignee.** Brand name: RD-Seq Sequencing Rare Diseases; CM 17.911.029; 2018 May 31.



1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.5.2 Translational Oncology



Publications: 40 | Q1: 28

COMPOSITION

Jaime Feliú Batlle.
Jefe de Servicio de Oncología Médica. Hospital Universitario La Paz/Catedrático de Medicina. Universidad Autónoma de Madrid

- **Borja Belandía Gómez.** *Científico Titular. IIB Sols Morreale*
- **Beatriz Castelo Fernández.** *Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz*
- **Paloma Cejas Guerrero.** *Investigadora Postdoctoral. Hospital Universitario La Paz*
- **Ana Belén Custodio Carretero.** *Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz*
- **Enrique Espinosa Arranz.** *Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz/Profesor Titular. Universidad Autónoma de Madrid*
- **Juan Ángel Fresno Vara.** *Investigador Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. Hospital Universitario La Paz*
- **Ángelo Gámez Pozo.** *Investigador Postdoctoral. Hospital Universitario La Paz*
- **Laura García Acebedo.** *Médico Interno Residente. Coordinadora del Registro de Tumores. Hospital Universitario La Paz*
- **Ismael Ghanem Cañete.** *Médico Adjunto en Oncología Médica. Hospital Universitario La Paz*
- **Juan Carlos Lacal Sanjuán.** *Profesor de Investigación. IIB Sols Morreale*
- **Victoria Heredia Soto.** *Investigadora Postdoctoral. Hospital Universitario La Paz*
- **Rocío López Vacas.** *Técnico de Laboratorio (Contrato Técnico de Apoyo). Hospital Universitario La Paz*
- **Virginia Martínez Marín.** *Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz*
- **Ignacio Palmero Rodríguez.** *Científico Titular. IIB Sols Morreale*
- **Juan Pablo Pérez Wertz.** *Facultativo Especialista en Oncología Médica. Hospital Universitario La Paz*
- **Jesús Peña López.** *Facultativo Especialista en Oncología Médica. Hospital Universitario La Paz*
- **Ana Pertejo Fernández.** *Facultativo Especialista en Oncología Médica. Hospital Universitario La Paz*
- **Álvaro Pinto Marín.** *Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz.*
- **Andrés Redondo Sánchez.** *Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz/Profesor Asociado. Universidad Autónoma de Madrid*
- **Nuria Rodríguez Salas.** *Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz*
- **Lucía Trilla Fuertes.** *Investigadora Postdoctoral. Biomedica Molecular Medicine SL*
- **Pilar Zamora Auñón.** *Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz/. Profesor Asociado. Universidad Autónoma de Madrid*

STRATEGIC OBJETIVES

- The purpose of cancer research is to improve our understanding of cancer in all its aspects, including deepening our knowledge of tumor biology, developing new treatments, evaluating the effectiveness of diagnostic tests, and working towards prevention and early diagnosis.
- The Translational Oncology group aims to conduct high-level applied research so that basic research can be rapidly translated into clinical practice. In other words, the goal is for cancer patients at La Paz University Hospital to benefit almost immediately from the research conducted by their own doctors and researchers.
- The main lines of research focus on tumors with the highest incidence and impact on survival, such as lung, colorectal, breast, pancreatic, ovarian, and prostate cancer, although other types of neoplasms, such as gastric cancer, melanoma, endometrial cancer, sarcomas, bladder cancer, and kidney cancer, have been incorporated. A series of fundamental objectives are pursued for these neoplasms, which can be summarized as early diagnosis, molecular classification for therapeutic purposes, and the development of individualized treatments. Most projects have as their primary objective the identification of predictive factors for sensitivity or resistance to antitumor agents and the search for prognostic factors related to tumor progression.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH LINES

- Identification of drug resistance mechanisms in cancer.
- Identification of cancer biomarkers in tissues and liquid biopsy through genomic, proteomic, and metabolomic approaches.
- Study of the mechanisms involved in carcinogenesis.
- Identification of new therapeutic targets in cancer.
- Efficacy and toxicity of antineoplastic therapies.
- The main tumors on which we conduct our research are:
  - Breast cancer
  - Cancers of the digestive tract
  - Gynecological tumors
  - Sarcomas
  - Melanoma
  - Genitourinary tumors
  - Head and neck tumors

RESEARCH ACTIVITY

Doctoral Theses

- **Escudero Ruiz FJ.** Testado de eribulina y su combinación con otros fármacos en líneas celulares de sarcomas[dissertation] Madrid: UAM: 2025(17/06/2025). Director: Redondo Sánchez A.

Master Theses

- **Escamilla S.** SIDLE, una aproximación a caracterizar la microbiota de muestras parafinadas (FFPE)[dissertation]. Madrid: Universidad Francisco de Vitoria: 2025(01/07/2025). Director: Gámez Pozo A.

Publications

- **Alameda-Guijarro M, Rueda-Lara A, Martín-Montalvo G, Higuera O, Gutiérrez-Sainz L, Jiménez-Bou D, Villamayor J, de Castro J, Custodio A, Pérez-Wert P.** Novel therapies targeting delta-like ligand 3 (DLL3) in pulmonary and gastroenteropancreatic neuroendocrine carcinomas. Cancer Treat Rev. 2025; 140: 103022. Review. IF: 10.6; Q1
- **Álvarez-Mercado AI, López-Plaza B, Plaza-Díaz J, Arcos-Castellanos L, Ruiz-Ojeda FJ, Brandimonte-Hernández M, Feliú-Batlle J, Hummel T, Palma-Milla S, Gil A.** Miraculin can contribute to a reduction in inflammatory biomarkers and cachexia in malnourished patients with cancer and taste disorders. Pharmaceuticals (Basel). 2025; 18(5): 622. Article. IF: 5.7; Q1
- **Cabello-Ubeda A, de Quirós JCLB, Mena A, Torralba M, Carbonero LM, Gutiérrez A, Vergas J, Pinto A, Tejerina F, Palmier E, Sanz J, Górgolas M, Pulido F.** Dolutegravir (DTG) plus Lamivudine (3 TC) in antiretroviral-naive adults with hiv with and without genotypic resistance testing results: 96-week effectiveness and tolerability of REDOLA Study. JAICS-J Acq Imm Def. 2025; 100(2): e4-e7. Letter. IF: 2.3; Q3
- **Cerezuela-Fuentes P, de la Rosa CA, Crespo G, Berciano-Guerrero MA, Soria A, Muñoz-Couselo E, Castro RL, Majem M, de Miguel PA, Manzano JL, Bellido L, Lecumberri MJ, Subias MC, Guzmán JCV, Hernández B, Espinosa E, Puértolas T, Sanz LG, Martínez JM, Abril VP, Algarra SM, Márquez-Rodas I.** Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study. Melanoma Res. 2025; 35(6): 399-408. Article. IF: 1.8; Q3
- **Díaz-Riascos ZV, Llaguno-Munive M, Lafuente-Gómez N, Luengo Y, Holmes S, Volatron J, Ibarrola O, Mancilla S, Sarno F, Aguirre JJ, Razafindrakoto S, Southern P, Terán FJ, Keogh A, Salas G, Prina-Mello A, Lacal JC, del Pozo A, Pankhurst QA, Hidalgo M, Gazeau F, Somoza A, Schwartz S , Abasolo I.** Preclinical development of magnetic nanoparticles for hyperthermia treatment of pancreatic cancer. ACS Appl Mater Inter. 2025; 17(2): 2924-39. Article. IF: 7.8; Q1
- **Gallego A, Madariaga A, Estévez-García P, Alberti F, Carbó A, Palacio I, Churruca C, Gálvez F, Ortega ME, Murata P, Manzano A, Masvidal M, Martín-Lorente C, Hernando B, Lozano I, Cueva JF, García-Illescas D, Gost E, Mendiola M, Redondo A.** An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study). Int J Gynecol Cancer. 2025; 35(7): 101903. Article. IF: 5.4; D1
- **Geyer CE, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, D'Hondt V, Conlin AK, Guarneri V, Wapnir IL, Jackisch C, Arce-Salinas C, Fasching PA, DiGiovanna MP, Crown JP, Wuelfing P, Shao ZM, Caremoli ER, Bonnefoi HR, Hennessy BT, Stamatovic L, Castro-Salguero H, Brufsky AM, Knott A, Siddiqui A, Lambertini C, Boulet T, Nyawira B, Restuccia E, Loibl S.** Survival with trastuzumab emtansine in residual her2-positive breast cancer. New Engl J Med. 2025; 392(3): 249-257. Article. IF: 84.5; D1
- **Ghanem I, Pérez-Wert P.** CheckMate 8HW and the future of dual immunotherapy. Lancet. 2025; 406(10516): 2217. Letter. IF: 109.0; D1
- **Gokbayrak B, Altintas UB, Lingadahalli S, Morova T, Huang CCF, Fazlioglu BE, Yu IPL, Kalkan BM, Cejas P, Kung SHY, Fazli L, Kawamura A, Long HW, Acilan C, Onder TT, Bagci-Onder T, Lynch JT, Lack NA.** Identification of selective SWI/SNF dependencies in enzalutamide-resistant prostate cancer. Commun Biol. 2025; 8(1): 169. Article. IF: 5.8; D1
- **Guerrero-Ramos F, Schwenke C, Pinto A, Mulhern-Haughey S, Pisini M, Azough A, Rijken A, Van Beekhuizen S, Freitag A, Campden R, Mayer B.** Systematic review of the definition of cure and of curative-intent treatments in early bladder cancer. Eur Urol Oncol. 2025; 8(6): 1696-706. Review. IF: 8.5; D1
- **Hammel P, Metges JP, Mercade TM, García-Carbonero R, Bouché O, Portales F, Cid RAP, Mineur L, Gracian AC, Trouilloud I, Guimbaud R, Tougeron D, Reina JJ, Feliú J, Sauri T, Fountzilas C, Lecomte T, Molin Y, Ponz-Sarvise M, Forget F, Berardi R, Van Cutsem E, Gelsomino F, Tournigand C, Bockorny B, Bachet JB, Vera MM, Cuyle PJ, Wasan H, Noel M, Van Laethem JL, Kay R, Youssoufian H, El-Hariry I, Hidalgo M.** TRYBECA-1: A randomized phase III study of eryaspase combined with chemotherapy versus chemotherapy as second-line treatment in patients with advanced pancreatic adenocarcinoma. J Clin Oncol. 2025; 43(35):3714-27. Article. IF: 44.7; D1
- **Harano K, Fossati R, Pardo B, Galli F, Hudson E, Antill Y, Lee C, Rabaglio M, Heitz F, Kolovetsiou-Kreiner V, Lai CH, Biagioli E, Manso L, Nishio S, Allan K, Lee YC, Uggeri S, Redondo A, Nakagawa S, Au E, Lombard**

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

J, Gadducci A, Takehara K, Baldini EE, Palaia I, Casanova C, Ardizzoia A, Bologna A, Barretina-Ginesta MP, Colombo N.** Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial. J Gynecol Oncol. 2025; 36(4): e117. Article. IF: 4.2; Q1

- **Hardy-Bessard AC, Pujade-Lauraine E, Moore RG, Montestruc F, Redondo A, Mirza MR, Cibula D, Ciuleanu TE, Gilbert L, Eitan R, Zagouri F, Pignata S, Glasspool R, Pfisterer J, Phaëton R, Anderson CK, Rodrigues M, Gaba L, Bakirtzi E, Fauci JM, Kalbacher E, Musa FB, Gorman S, Duska LR, Gladieff L, Braly P, Joly F, Pepin JT, Ray-Coquard I, Moore KN.** Dostarlimab and niraparib in primary advanced ovarian cancer. Ann Oncol. 2025; 36(12): 1503-13. Article. IF: 80.4; D1
- **Kopp RM, Massari F, Grande E, Schieber TJ, Ürün Y, Kopecky J, Molina-Cerrillo J, Basso U, Kucharz J, Büttner T, Pichler R, Fiala O, Myint ZW, Galli L, Buchler T, Rizzo M, Bolek H, Bourlon MT, Conteduca V, Pinto A, Rizzo A, Rosellini M, Roviello G, Zgura A, Mollica V, Partl A, Yildirim A, Akova U, Buti S, Monteiro FSM, Soares A, Porta C, Bilen MA, Li HR, Santoni M.** Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study. Cancer Immunol Immun. 2025; 74(12): 374. Article. IF: 5.8; Q1
- **Kucharz J, Poprach A, Sikora-Kupis B, Darewicz M, Domanski P, Bezdeková M, Kolousková I, Kolariková E, Kopecky J, Studentova H, Fiala O, Richter I, Lacek M, Buchler T, Pinto A.** Cabozantinib in the first-line treatment of patients with metastatic renal cell carcinoma, real-world data from the czech republic and poland: ICARO-RC Project. Clin Genitourin Canc. 2025; 23(4): 102382. Article. IF: 2.4; Q2
- **Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruiz-Borrego M, Gavila J, Schmid P, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Di Cosimo S, Anton A, Cottu P, Shimizu E, Fernández M, Sampayo-Cordero M, Cortés J.** Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial. Esmo Open. 2025; 10(7): 105309. Article. IF: 10.6; Q1
- **López-Janeiro A, Brizzi E, Ruz-Caracuel I, Alexandru R, de Andrea C, Berjon A, Yébenes L, Mendiola M, Heredia-Soto V, Montero-Calle A, Barderas R, de los Ríos V, Redondo A, Peláez-García A, Hardisson D.** The proteomic landscape of CTNNB1 mutated low-grade early-stage endometrial carcinomas. Cells. 2025; 14(21): 1676. Article. IF: 6.0; Q2
- **Lorusso D, Oaknin A, Borges GS, Damian F, Ottevanger N, Van Gorp T, Paiva CE, Kroep JR, Kim YM, Kim HS, Lee JK, Denys H, Lalisang R, Melo ACD, Redondo A, Reyners AKL, Mora P, Closset C, Melief CJM, Hooftman L, Jamil S, Boersm L, Yoo SY, Seebach F, Lowy I, Fury MG, Mathias M, Colombo N.** Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial. Gynecol Oncol. 2025; 196: 28-35. Article. IF: 4.5; D1
- **Macarrón V, Losantos-García I, Peláez-García A, Yébenes L, Berjón A, Frías L, Martí C, Zamora P, Sánchez-Méndez JI, Hardisson D.** A novel nomogram for estimating a high-risk result in the endopredict® test for estrogen receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative breast carcinoma. Cancers (Basel). 2025; 17(2): 273. Article. IF: 4.8; Q2
- **Matulonis UA, Herrstedt J, Oza A, Mahner S, Redondo A, Berton D, Berek JS, Haslund CA, Marmé F, González-Martín A, Bécourt S, Tinker A, Ledermann JA, Benigno B, Lindahl G, Colombo N, Malinowska IA, Liu WL, Bains M, Monk BJ, Mirza MR.** ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety. Gynecol Oncol. 2025; 195: 192-9. Article. IF: 4.5; D1
- **Mendiola M, Heredia-Soto V, Baillo A, Ruz-Caracuel I, Mena R, Berjon A, Escudero FJ, Pedregosa J, Hernández A, Feliú J, Hardisson D, Redondo A.** Improving the performance of polymerase chain reaction for microsatellite instability testing in endometrial cancer. Sci Rep-Uk. 2025; 15(1): 44262. Article. IF: 4.9; Q1
- **Obispo B, Bailleux C, Cantos B, Zamora P, Jhawar SR, Varghese J, Cabal-Hierro L, Luz P, Berrocal-Almanza L, Xu XQ.** Long-term adverse events following early breast cancer treatment with a focus on the brca-mutated population. Cancers (Basel). 2025; 17(15): 2506. Review. IF: 4.8; Q2
- **Obispo B, Calderón C, Carmona-Bayonas A, Ghanem I, Cano-Cano JM, Jiménez-Fonseca P.** The role of baseline and persistent depression in adjuvant cancer therapy: impact on toxicity and quality of life. Int J Clin Health Psychol. 2025; 25(4): 100640. Article. IF: 4.4; Q1
- **Pichler R, Klinglmair G, Binz K, Grande E, Pirshtuk A, Takeshita H, Ürün Y, Molina-Cerrillo J, Myint ZW, de Liaño AG, Mota A, Salfi A, Fukuokaya W, Sammarco E, Angel M, Kucharz J, Tural D, Fiala O, Rodríguez-Vida A, Morelli F, Poprach A, Safi M, Pinto A, Massari F, Buti S, Gupta S, Monteiro FSM, Soares A, Battelli N, Kanesvaran R, Santoni M.** Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study. Clin Exp Metastas. 2025; 43(1): 1. Article. IF: 3.7; Q2
- **Pinto A, Domínguez M, Gómez-Iturriaga A, Rodríguez-Vida A, Vallejo-Casas JA, Castro E.** The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: A narrative review. Crit Rev Oncol Hemat. 2025; 210: 104678. Review. IF: 6.2; Q1
- **Pinto-Marín A, Trilla-Fuertes L, Poma JM, Vasudev NS, García-Fernández E, López-Vacas R, Miranda N, Wilson M, López-Camacho E, Pertejo A, Dittmann A, Kunz L, Brown J, Pedroche-Just Y, Zapater-Moros A, de Velasco G, Castellano D, González-Peramato P, Espinosa E, Banks RE, Vara JAF, Gámez-Pozo A.** A prognostic microRNA-based signature for localized clear cell renal cell carcinoma: the Bio-miR study. Brit J Cancer. 2025; 133(2): 155-67. Article. IF: 7.8; Q1
- **Plaza-Díaz J, Brandimonte-Hernández M, López-Plaza B, Ruiz-Ojeda FJ, Álvarez-Mercado AI, Arcos-Castellanos L, Feliú-Batlle J, Hummel T, Palma-Milla S, Gil A.** Effect of a novel food rich in miraculin on the intestinal microbiome of malnourished patients with cancer and dysgeusia. Nutrients. 2025; 17(2): 246. Article. IF: 5.8; Q1
- **Povedano E, Pérez-Ginés V, Torrente-Rodríguez RM, Rejas-González R, Montero-Calle A, Peláez-García A, Feliú J, Pedrero M, Pingarrón JM, Barderas R, Campuzano S.** Tracking globally 5-methylcytosine and its oxidized derivatives in colorectal cancer epigenome using bioelectroanalytical technologies. ACS Sens. 2025; 10(3): 2049-59. Article. IF: 10.9; D1
- **Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, Jensen JB, Makaroff L, Jiang SS, Ku JH, Park SH, Torras OR, Ye DW, Maruzzo M, Necchi A, Morales-Barrera R, Giunta EF, Lee JL, Tortora G, Ürün Y, Dolowy L, Erdem D, Pinto A, Grando F, Zou W, Assaf ZJ, Vuky J, Degaonkar V, Steinberg EE, Bellmunt J, Gschwend JE.** ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. New Engl J Med. 2025; 393(24): 2395-408. Article. IF: 84.5; D1
- **Rimel BJ, Pujade-Lauraine E, Moore K, Pfisterer J, Han S, Cibula D, Reyners A, Redondo A, Papadimitriou C, Eitan R, Pignata S, Glasspool R, Mirza MR, Bodnar L, Duska L, Provencher D, Phaëton R, Bains M, Coskuncay E, Hardy-Bessard AC.** Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer. Oncologist. 2025; 30(10): oyaf270. Review. IF: 4.7; Q2

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

- **Rosas-Alonso R, Salas NR, Wert PP, Hoyo A, Martin-López S, Martínez-Pérez D, Ruiz-Gutiérrez I, Jimenez-Bou D, Peña J, Arias P, Custodio A, Losantos-García I, Borobia AM, Feliú J, Ghanem I.** DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger. Front Pharmacol. 2025; 16: 1645188. Article. IF: 5.4; Q1
- **Rueda-Lara A, Viñal D, Martínez-Pérez D, Alameda-Guijarro M, Martín-Montalvo G, Martínez-Recio S, Peña-López J, Jiménez-Bou D, Ruíz-Gutiérrez I, García-Leal A, Zwisler-Contreras P, Ghanem I, Custodio AB, Pérez-Wert P, Gutiérrez-Sainz L, Palacios ME, Feliú J, Rodríguez-Salas N.** Analysis of tumor budding as a prognostic factor for recurrence in patients with stage II and III colon cancer. Experience in a tertiary hospital. Oncologist. 2025; 30(3): oyaf027. Article. IF: 4.7; Q2
- **Santoni M, Roviello G, Grande E, De Giorgi U, Fiala O, Seront E, Molina-Cerrillo J, Pichler R, Myint ZW, Kucharz J, Kanesvaran R, Buettner T, Pichler M, Basso U, Kopecky J, Bourlon MT, Cerbone L, Buchler T, Pinto A, de Liaño AG, Gianni C, Zgura A, Rescigno P, Ansari J, Caffo O, Kueronya Z, Vitale MG, Bhuva D, Catalano M, Vau N, Kopp RM, Buti S, Bamias A, Porta C, Sunela K, Massari F.** Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1). Cancer Immunol Immun. 2025; 74(7): 225. Article. IF: 5.8; Q1
- **Sarno F, Tenorio J, Perea S, Medina L, Pazo-Cid R, Juez I, García-Carbonero R, Feliú J, Guillen-Ponce C, López-Casas PP, Guerra C, Duran Y, López-Acosta JF, Alonso C, Esquivel E, Dopazo A, Akshinthala D, Muthuswamy SK, Lapunzina P, Bockorny B, Hidalgo M.** A Phase III Randomized trial of integrated genomics and avatar models for personalized treatment of pancreatic cancer: The AVATAR Trial. Clin Cancer Res. 2025; 31(2): 278-87. Article. IF: 10.9; D1
- **Soria A, Mauriño PS, Domingo JJS, Galindo RG, Sequero S, Sanz LG, Crespo G, Díaz-Beveridge R, Puértolas T, López P, Rodríguez JF, Castro RL, Aguayo C, Valdivia J, Cunquero-Tomás AJ, Benítez G, de Miguel PA, Espinosa E, Muñoz-Couselo E, Campos B, Sánchez LG, Cerezuela-Fuentes P.** Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAFV600-mutant melanoma in Spain: the BECARE (GEM-2002) trial. Front Oncol. 2025; 15: 1466185. Article. IF: 3.4; Q2
- **Torres-Tenor JL, Bernal-Hertfelder E, Pertejo-Fernández A, Ramón-Patiño JL, Redondo A, Alonso-Babarro A, Bruera E.** Frequency and predictors of caregiver burden among patients with cancer receiving palliative cancer treatment. Clin Transl Oncol. 2025; 27(9): 3827-32. Article. IF: 2.7; Q3
- **Van Laethem JL, Geboes K, Borbath I, Mercade TM, Lambert A, Cassier P, Prenen H, Mitry E, Blanc JF, Pilla L, Feliú J, Garrote MR, Pazo-Cid RA, Gallego I, Smith KE, Nordbladh K, Jimenez DG, Ellmark P, de Coaña YP, Ambarkhane SV, Beatty GL, O'Reilly EM.** CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Cell Rep Med. 2025; 6(10): 102407. Article. IF: 14.0; D1
- **Vaz-Salgado MA, Valverde-Morales C, Álvarez R, Asencio JM, Collado E, de Alava E, Beveridge RD, Gómez-Mateo MC, Alegria IG, Marquina G, Broto JM, Martínez-Trufero J, Narváez JA, Redondo A, Sebio A, Verges R, Viñals JM, del Muro XG.** Diagnosis and therapy of soft tissue sarcomas: spanish group for research in sarcomas (GEIS) guidelines. Cancers (Basel). 2025; 17(19): 3158. Article. IF: 4.8; Q2
- **Weichenthal M, Ellebaek E, Mangana J, Asher N, Gavrilova I, Kandolf L, Ugurel S, Hausschild A, Meier F, Leiter U, Livingstone E, Gebhardt C, Gutzmer R, Ruhlmann CH, Mahncke-Guldbrandt L, Haslund CA, Kopec S, Teterycz P, Bender M, Poudroux W, Muñoz-Couselo E, Berciano-Guerrero MA, Shalamanova G, Depalo DK, Brozic JM, Chiarion-Sileni V, Arance A, Ziogas D, Robert C, Velde AOV, Gassama AA, Shapira R, Benbetzalel G, Grynberg S, Ramelyte E, Bertoldo F, Delprete V, Gaudy-Marqueste C, Mohr P, Dummer R, Ascierto PA, Gogas H, Espinosa E, Lebbé C, Rutkowski P, Haanen J, Schadendorf D, Svane IM.** Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study. Eur J Cancer. 2025; 220: 115339. Article. IF: 7.9; Q1
- **Xu CM, Mannucci A, Esposito F, Oliveres H, Alonso-Orduña V, Yubero A, Fernández-Martos C, Salud A, Gallego J, Martín-Richard M, Fernández-Plana J, Guillot M, Aparicio J, Fakih M, Kopetz S, Feliú J, Maurel J, Goel A.** An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study. Clin Cancer Res. 2025; 31(6): 1002-15. Article. IF: 10.9; D1

Research projects

- **Castelo Fernandez B.** Characterization of cancer-cell plasticity in head and neck cancers: discovery of new therapeutic targets and biomarkers for disease progression and treatment response (PI23/00192). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Castelo Fernandez B.** Identification of new biomarkers to predict patient progression in ductal salivary cancer (2022.424). Gilead Sciences S.L. 2023-Ongoing. Managment centre: FIBHULP
- **Cejas Guerrero P.** Estudio de los cambios estructurales de la cromatina implicados en la resistencia a la quimioterapia en el adenocarcinoma de páncreas y de la posible utilidad de los inhibidores de EZH2 para revertirlos. (PI23/01533). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Custodio Carretero AB.** Perfiles transcriptómicos implicados en el pronóstico y las resistencias terapéuticas a quimioterapia perioperatoria en adenocarcinoma gástrico localmente avanzado. Sociedad Española de Oncología Médica. 2024-Ongoing. Managment centre: FIBHULP
- **Espinosa Arranz E.** Búsqueda de biomarcadores predictivos de respuesta a inmunoterapia en melanoma avanzado (2022.455). Grupo Español Multidisciplinar de Melanoma . 2022-Ongoing. Managment centre: FIBHULP
- **Feliú Batlle J.** Estudio de los cambios estructurales de la cromatina implicados en la resistencia a la quimioterapia en el adenocarcinoma de páncreas y de la posible utilidad de los inhibidores de EZH2 para revertirlos. (PI23/01533). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Feliú Batlle J.** Optimización del tratamiento adyuvante del cáncer de páncreas en función del subtipo molecular determinado por biomarcadores inmunohistoquímicos (2022.334). Fundación SEOM. 2022-2025. Managment centre: FIBHULP
- **Feliú Batlle J.** Predicción de riesgo de cardiotoxicidad en las unidades de cardiooncología. valor de la genética y diferentes biomarcadores. El registro CARDIOTOX (PMP22/00098). ISCIII. 2023-2026. Managment centre: FIBHULP
- **Feliú Batlle J.** validation of biomakers to predict response to anti-egfr therapy identified by shotgun proteomics. FIBHULP. 2018-Ongoing. Managment centre: FIBHULP
- **Ghanem Cañete I.** Análisis integral del perfil de metilación en el cáncer colorrectal juvenil: Un enfoque traslacional (GHETTI2024_IGC). Grupo Español de Tumores Huérfanos e Infrecuentes. 2024-2026. Managment centre: FIBHULP
- **Martínez Sánchez N.** Evaluación del perfil de hipercoagulabilidad de la gestación y su relación con el riesgo tromboembólico materno y disfunción placentaria (PI24/01208). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Perez Wert JP.** Valor pronostico y predictivo

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

de respuesta de la expresión de receptores de somatostatina, variantes de splicing y reguladores postranscripcionales en tumores neuroendocrinos gastroenteropancreáticos y pulmones avanzados grado 1-2 tratados con análogos de somastostatina de liberación prolongada y terapia con radioligandos. Fundacion Getne. 2025-2026. Managment centre: FIBHULP

- **Redondo Sánchez A.** Identificación de marcadores de HRD y predicción de la respuesta a inhibidores de PARP en líneas celulares establecidas y organoides derivados de pacientes con cáncer de ovario. Grupo Español de Investigacion en Cáncer Ginecológico. 2021-Ongoing. Managment centre: FIBHULP
- **Rodríguez Salas N.** Cáncer colorrectal en población joven. estudio farmacogenómico en organoides y efectos del microambiente tumoral (ICI20/00057). ISCIII. 2021-2026. Managment centre: FIBHULP
- **Trilla Fuertes L.** Estudio del papel de la microbiota tumoral en la respuesta a inmunoterapia mediante metagenómica y metaproteómica de muestras parafinadas (2025.148). FIBHULP. 2025-46388. Managment centre: FIBHULP
- **Trilla Fuertes L.** Identificación de biomarcadores séricos predictivos de respuesta y toxicidad al tratamiento sistémico con enfortumab-vedotin + pembrolizumab en carcinoma urotelial metastásico (2025.535). Guard Consortium. 2025-2027. Managment centre: FIBHULP

Ciber and Retics

- **Feliú Batlle J.** Networked Biomedical Research Center for Cancer (CIBERonc). ISCII. (31/12/2025). FIBHULP

Clinical trials

- **Zamora Auñon P.** ribo-age: análisis descriptivo estratificado por edad de las reacciones adversas farmacológicas en pacientes con cáncer de mama avanzado tratado con kisqali (ribociclib) e inhibidores no esteroideos de la aromatasa: estudio retrospectivo de cohortes.
  Type/Phase: EOm no prospectivo
  Sponsored by: Novartis Farmaceutica, S.A..
  Signature date: 24/01/2025
- **Zamora Auñon P.** Estudio de fase III, multicéntrico, aleatorizado y abierto para evaluar la eficacia y la seguridad de giredestrant adyuvante en comparación con la monoterapia endocrina adyuvante elegida or el médico en pacientes con cáncer de mama incipiente con receptores estrogénicos positivos y her2 negativo.
  Type/Phase: III
  Sponsored by: F.Hoffmann-La Roche Ltd.
  Signature date: 21/08/2025
- **Zamora Auñon P.** Elacestrant frente a la hormonoterapia de referencia en personas de ambos sexos con cáncer de mama incipiente con afectación ganglionar, con receptores estrogénicos y sin sobreexpresión del receptor her2 con alto riesgo de recurrencia: estudio en fase III, aleatorizado, sin enmascaramiento, global y multicéntrico (elegant).
  Type/Phase: III
  Sponsored by: Stemline Therapeutics Inc.
  Signature date: 11/03/2025
- **Zamora Auñon P.** A proof of concept study to evaluate treatments' efficacy by monitoring minimal residual disease using ctdna in hr-positive/her2-negative early breast cancer population. the mirador study.
  Type/Phase: II
  Sponsored by: Medica Scientia Innovation Research, S.L.
  Signature date: 26/09/2025
- **Trilla Fuertes L.** Identificación de biomarcadores séricos predictivos de respuesta y toxicidad al tratamiento sistémico con enfortumab-vedotin + pembrolizumab en carcinoma urotelial metastásico.
  Type/Phase: EOm prospectivo
  Sponsored by: Trilla Fuertes, Lucía.
  Signature date: 05/08/2025
- **Rodriguez Salas N.** phase 3 multicenter, randomized, open-label, active-controlled study of sotorasib, panitumumab and folfiri versus folfiri with or without bevacizumab-awwb for treatment-naïve subjects with metastatic colorectal cancer with kras p.g12c mutation(codebreak 301).
  Type/Phase: III
  Sponsored by: Amgen Inc..
  Signature date: 23/01/2025
- **Rodriguez Salas N.** Observational retrospective study to evaluate real-world effectiveness, safety and tolerability of fruquintinib for treatment of advanced colorectal cancer in spain – fresp study.
  Type/Phase: EOm prospectivo
  Sponsored by: Grupo Tratamiento Tumores Digestivos (Gercor).
  Signature date: 03/06/2025
- **Rodriguez Salas N.** Estudio fase 2, abierto, aleatorizado con protocolo maestro para evaluar la seguridad y la eficacia de múltiples combinaciones de tratamientos con telisotuzumab adizutecan en sujetos con cáncer colorrectal metastásico (andrometa-crc-533).
  Type/Phase: II
  Sponsored by: Abbvie Deutschland GMBH & Co. Kg.
  Signature date: 20/02/2025
- **Rodriguez Salas N.** Estudio en fase II, multicéntrico, sin enmascaramiento, aleatorizado y controlado para comparar la eficacia de ro7198457 con la estrategia de actitud expectante en pacientes con cáncer colorrectal resecado en estadio II (riesgo elevado) y estadio III que presenten positividad de adn tumoral circulante (adnct) tras la resección tumoral.
  Type/Phase: II
  Sponsored by: Biontech Se.
  Signature date: 06/02/2025
- **Rodriguez Salas N.** Estudio en fase II, aleatorizado y abierto para comparar telisotuzumab adizutecan (abbv-400) en monoterapia con el tratamiento estándar actual en sujetos con cáncer colorrectal positivo para adntc después del tratamiento adyuvante y con remisión radiológica completa (rrc).
  Type/Phase: II
  Sponsored by: Abbvie Deutschland GMBH & Co. Kg.
  Signature date: 18/07/2025
- **Rodriguez Salas N.** Estudio en fase II, aleatorizado y abierto para comparar telisotuzumab adizutecan (abbv-400) en monoterapia con el tratamiento estándar actual en sujetos con cáncer colorrectal positivo para adntc después del tratamiento adyuvante y con remisión radiológica completa (rrc).
  Type/Phase: II
  Sponsored by: Abbvie Deutschland GMBH & Co. Kg.
  Signature date: 11/04/2025
- **Rodriguez Salas N.** Estudio de la evolución natural del cáncer rectal dmmr/msi-h localmente avanzado en estadio II/III no tratado previamente en pacientes de europa.
  Type/Phase: EPA-SP
  Sponsored by: Glaxosmithkline Research And Development Limited ,.
  Signature date: 10/02/2025
- **Rodriguez Salas N.** Estudio de fase 3 abierto, aleatorizado, perioperatorio de dostarlimab en monoterapia frente al tratamiento estándar en pacientes con cáncer de colon resecable con pérdida del mecanismo de reparación de apareamiento de bases (dmmr)/inestabilidad de microsatélites alta (msi-h), t4n0 o estadio III, no tratado.
  Type/Phase: III
  Sponsored by: Glaxosmithkline Research And Development Limited ,.
  Signature date: 06/10/2025
- **Rodriguez Salas N.** Estudio de fase 3 abierto, aleatorizado, perioperatorio de dostarlimab en monoterapia frente al tratamiento estándar en pacientes con cáncer de colon resecable con pérdida del mecanismo de reparación de apareamiento de bases (dmmr)/inestabilidad de microsatélites alta (msi-h), t4n0 o estadio III, no tratado.
  Type/Phase: III
  Sponsored by: Glaxosmithkline Research And Development Limited ,.
  Signature date: 01/04/2025
- **Rodriguez Salas N.** Estudio abierto, multicéntrico de fase I/II de la vacuna genética nous-209 para el tratamiento de tumores sólidos con inestabilidad de microsatélites.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Type/Phase: I
Sponsored by: Nouscom Srl.
Signature date: 24/02/2025

- **Redondo Sánchez A.** Randomized, controlled, open-label, phase IIb/III study of lubinectedin in combination qith doxorubicin versus boxorubicin alone as first-line treatment in pacients with metastatic leiomyosarcoma.
  Type/Phase: III
  Sponsored by: Pharmamar, S.A..
  Signature date: 29/05/2025
- **Redondo Sánchez A.** Protocolo maestro de fase II, multicéntrico, abierto, para evaluar la eficacia y seguridad de datopotamab deruxtecán (dato-dxd) en monoterapia y en combinación con antineoplásicos, en pacientes con tumores sólidos en estadio avanzado o metastásico (tropion-pantumor03).
  Type/Phase: II
  Sponsored by: Astrazeneca Ab.
  Signature date: 25/08/2025
- **Redondo Sánchez A.** International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory ewing sarcoma.
  Type/Phase: II
  Sponsored by: Grupo Español De Investigacion En Sarcomas.
  Signature date: 31/01/2025
- **Redondo Sánchez A.** Estudio multicéntrico, abierto y de fase II para evaluar la eficacia y la seguridad de zn-c3 en pacientes con cáncer de ovario seroso de alto grado, de trompas de falopio o peritoneal primario.
  Type/Phase: II
  Sponsored by: Zentalis Pharmaceuticals, Inc.
  Signature date: 19/11/2025
- **Redondo Sánchez A.** Estudio en fase II abierto y aleatorizado de farletuzumab ecteribulina (morab-202), un conjugado de anticuerpo y fármaco dirigido al receptor de folato alfa frente a la quimioterapia elegida por el investigador en mujeres con cáncer seroso de alto grado (sag) resistente al platino, de ovario peritoneal primario o de trompas de falopio.
  Type/Phase: II
  Sponsored by: Bristol-Myers Squibb International Corporation.
  Signature date: 27/05/2025
- **Redondo Sánchez A.** Estudio de fase I para evaluar la seguridad, tolerabilidad, farmacocinética y actividad clínica de gsk5733584 en participantes con tumores sólidos avanzados.
  Type/Phase: I
  Sponsored by: Glaxosmithkline Research And Development Limited ,.
  Signature date: 29/07/2025
- **Redondo Sánchez A.** Estudio de fase 3, aleatorizado, comparativo con tratamiento activo, sin enmascaramiento y multicéntrico para comparar la eficacia y la seguridad de mk-2870 en monoterapia frente al tratamiento elegido por el médico como tratamiento de segunda línea en participantes con cáncer de cuello uterino recurrente o metastásico (trofuse-020/gog-3101/engot-cx20).
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 03/11/2025
- **Redondo Sánchez A.** Estudio de fase 3, aleatorizado, comparativo con tratamiento activo, sin enmascaramiento y multicéntrico para comparar la eficacia y la seguridad de mk-2870 en monoterapia frente al tratamiento elegido por el médico como tratamiento de segunda línea en participantes con cáncer de cuello uterino recurrente o metastásico (trofuse-020/gog-3101/engot-cx20).
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 01/08/2025
- **Redondo Sánchez A.** Estudio de fase 3, aleatorizado, comparativo con tratamiento activo, abierto y multicéntrico para comparar la eficacia y la seguridad de mk-2870 en monoterapia frente al tratamiento elegido por el médico en participantes con cáncer de endometrio que han recibido previamente quimioterapia con un derivado del platino e inmunoterapia (engot-en23/gog3095).
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 28/11/2025
- **Redondo Sánchez A.** Estudio de fase 3, aleatorizado, abierto y multicéntrico para evaluar la eficacia y la seguridad del tratamiento de mantenimiento con sacituzumab tirumotecán con o sin bevacizumab frente al tratamiento estándar después de quimioterapia de doblete basada en platino en segunda línea en participantes con cáncer de ovario recurrente sensible a los derivados del platino (trofuse-022/engot-ov84/gog-3103).
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 16/01/2025
- **Redondo Sánchez A.** Estudio de fase 3, aleatorizado, abierto y multicéntrico para comparar la eficacia y la seguridad de sacituzumab tirumotecán en combinación con pembrolizumab frente a pembrolizumab en monoterapia como tratamiento de mantenimiento de primera línea en participantes con cáncer de endometrio con reparación de errores de emparejamiento competente (trofuse-033/gog-3119/engot-en29).
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 13/05/2025
- **Redondo Sánchez A.** Ensayo fase II, multicéntrico y abierto para evaluar la eficacia y la seguridad del trastuzumab deruxtecan (t-dxd, ds-8201a) para el tratamiento de tumores seleccionados que expresan her2 (destiny-pantumor02.
  Type/Phase: II
  Sponsored by: Astrazeneca Farmaceutica Spain S.A..
  Signature date: 25/08/2025
- **Redondo Sánchez A.** Diseño y validación de paneles de proteínas plasmáticas y citocinas para identificar marcadores asociados con la respuesta a niraparib como tratamiento de mantenimiento después de un régimen de primera línea basado en platino en pacientes con cáncer de ovario avanzado.
  Type/Phase: EOm prospectivo
  Sponsored by: Universidad De Navarra.
  Signature date: 29/10/2025
- **Redondo Sánchez A.** A single-arm, open-label phase 4 study of nirogacestat in adult premenopausal females with desmoid tumors/aggressive fibromatosis (dt/af).
  Type/Phase: IV
  Sponsored by: Springworks Therapeutics, Inc..
  Signature date: 09/09/2025
- **Redondo Sánchez A.** A phase III, randomized, multi-site, open-label trial of bnt323/db-1303 versus investigator's choice of chemotherapy in previously treated patients with her2-expressing recurrent endometrial cancer clinical performance trial plan: performance of ventana her2/neu (4b5) iuo assay with ultraview detection on the benchmark ultra® instrument as a diagnostic device for determining her2 status in endometrial cancer for biontech se phase III trial bnt323-01.
  Type/Phase: III
  Sponsored by: Biontech Se.
  Signature date: 16/10/2025
- **Redondo Sánchez A.** A phase 3, randomized, open-label, multicenter study to evaluate the efficacy and safety of sacituzumab tirumotecan (mk-2870) in combination with pembrolizumab with or without bevacizumab compared with standard of care as firstline maintenance treatment for participants with persistent, recurrent, or newly diagnosed metastatic cervical cancer with pd-l1 cps greater than or equal to 1 (trofuse-036/gog-3123/engot-cx22).
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc.
  Signature date: 25/11/2025
- **Redondo Sánchez A.** A phase 3, open-label, multicenter, randomized trial of trastuzumab deruxtecan with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy in her2-expressing ovarian cancer(destiny-ovarian01/engot-ov89/geico144-o/gog-3112).
  Type/Phase: III
  Sponsored by: Daiichi Sankyo Inc.
  Signature date: 11/09/2025

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



- **Redondo Sánchez A.** A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an idh1 mutation, untreated or previously treated with 1 systemic treatment regimen (chonquer study).
  Type/Phase: III
  Sponsored by: Laboratorios Servier, S.L..
  Signature date: 14/03/2025
- **Redondo Sánchez A.** A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants =18 years of age with locally advanced or metastatic conventional chondrosarcoma with an idh1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens (chonquer study).
  Type/Phase: III
  Sponsored by: Laboratorios Servier, S.L..
  Signature date: 21/07/2025
- **Redondo Sánchez A.** A phase 3 randomized, open-label study of rinatabart sesutecan (rina-s) versus treatment of investigator's choice (ic) in patients with platinum resistant ovarian cancer.
  Type/Phase: III
  Sponsored by: Genmab A/S.
  Signature date: 05/05/2025
- **Redondo Sánchez A.** A phase 1, first-in-human, open-label, dose-escalation and expansion study of imgn151 (anti-frα antibody-drug conjugate) in adult patients with recurrent endometrial cancer and recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers.
  Type/Phase: I
  Sponsored by: Immunogen Inc.
  Signature date: 11/03/2025
- **Pinto Marín A.** Uso en la práctica clínica de enfortumab vedotina en pacientes con cáncer urotelial avanzado en españa: estudio enfants.
  Type/Phase: EOm no prospectivo
  Sponsored by: Guard C Onsortium.
  Signature date: 18/02/2025
- **Pinto Marín A.** Tinivo-2: estudio en fase III, aleatorizado, controlado, multicéntrico y abierto para comparar tivozanib en combinación con nivolumab con tivozanib en monoterapia en sujetos con carcinoma de células renales que han progresado tras una o dos líneas de tratamiento en las que una línea tiene un inhibidor del punto de control inmunitario.
  Type/Phase: III
  Sponsored by: Aveo Pharmaceuticals Inc.
  Signature date: 06/06/2025
- **Pinto Marín A.** Estudio multicéntrico aleatorizado fase II, doble ciego, para evaluar la eficacia y seguridad de autogene cevumeran más nivolumab frente a nivolumab como tratamiento adyuvante en pacientes con carcinoma urotelial músculo invasivo de alto riesgo.
  Type/Phase: II
  Sponsored by: Roche Farma, S.A..
  Signature date: 03/11/2025
- **Pinto Marín A.** Estudio en fase II abierto de sacituzumab govitecán en el cáncer urotelial metastásico o localmente avanzado irresecable.
  Type/Phase: II
  Sponsored by: Gilead Sciences Inc.
  Signature date: 24/06/2025
- **Pinto Marín A.** studio en fase 3, aleatorizado, abierto, adaptativo de dos partes, que compara bms-986365 con la terapia de elección del investigador que incluye docetaxel o un segundo inhibidor de la vía del receptor de andrógenos (arpi), en participantes con cáncer de próstata metastásico resistente a la castración (mcrpc) – recharge.
  Type/Phase: III
  Sponsored by: Celgene Corporation.
  Signature date: 02/04/2025
- **Pinto Marín A.** Estudio de fase I/II para determinar la seguridad, farmacocinética y actividad clínica preliminar de bt8009 en pacientes con neoplasias malignas avanzadas que expresan nectina-4.
  Type/Phase: I
  Sponsored by: Bicycletx Ltd..
  Signature date: 01/07/2025
- **Pinto Marín A.** A randomized open-label phase 2/3 study of bt8009 as monotherapy or in combination in participants with locally advanced or metastatic urothelial cancer (duravelo-2).
  Type/Phase: III
  Sponsored by: Bicycletx Ltd..
  Signature date: 16/01/2025
- **Peña Lopez J.** Estudio neopsico: trayectorias de ansiedad y depresión en pacientes con cáncer, factores de riesgo y predictivos y cuidados de soporte; conciencia pronóstica y toma de decisiones compartida.
  Type/Phase: OTROS
  Sponsored by: Sociedad Española De Oncología Médica.
  Signature date: 19/06/2025
- **Martinez Marin V.** Estudio prospectivo, observacional y multicéntrico del tratamiento con sacituzumab govitecán en pacientes con cáncer metastásico de mama o localmente avanzado positivo para receptores hormonales/ negativo para her2 dentro de la práctica clínica habitual en españa.
  Type/Phase: EOm prospectivo
  Sponsored by: Gilead Sciences, S.L..
  Signature date: 17/09/2025
- **Martinez Marin V.** Estudio en fase III, intervencionista, aleatorizado, multicéntrico y abierto de dcc-2618 frente a sunitinib en pacientes con tumores del estroma

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

gastrointestinal avanzados tras el tratamiento con imatinib.
Type/Phase: III
Sponsored by: Deciphera Pharmaceuticals Llc.
Signature date: 02/06/2025

- **Martinez Marin V.** Estudio de fase III, aleatorizado, con enmascaramiento doble y comparativo con placebo de optune® (ttfields, 200 khz) concomitante con la temozolomida de mantenimiento y el pembrolizumab frente a optune® concomitante con la temo.
Type/Phase: III
Sponsored by: Novocure Gmbh.
Signature date: 24/09/2025
- **Martinez Marin V.** A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, esr1-mutated, advanced breast cancer progressing to endocrine therapy and cdk4/6 inhibitors. (the adela study).
Type/Phase: III
Sponsored by: Medica Scientia Innovation Research, S.L.
Signature date: 17/01/2025
- **Martinez Marin V.** A phase 1b/2, open-label, multicohort study of disitamab vedotin in adults with her2 expressing advanced breast cancer.
Type/Phase: I
Sponsored by: Pfizer Inc.
Signature date: 20/11/2025
- **Ghanem Cañete I.** Estudio de plataforma en fase Ib/II, sin enmascaramiento y aleatorizado para evaluar la seguridad y la eficacia de combinaciones terapéuticas con ab928 en pacientes con cáncer colorrectal metastásico.
Type/Phase: II
Sponsored by: Arcus Biosciences Europe Limited,.
Signature date: 27/06/2025
- **Feliú Batlle J.** Primer estudio en humanos, fase 1 / 2a, multicentro, abierto para la evaluación de la seguridad, tolerabilidad, farmacocinética y eficacia de pbp1510 en pacientes con cáncer de páncreas avanzado/metastásico.
Type/Phase: I
Sponsored by: Prestige Biopharma Limited.
Signature date: 14/01/2025
- **Feliú Batlle J.** Primer estudio en humanos, fase 1 / 2a, multicentro, abierto para la evaluación de la seguridad, tolerabilidad, farmacocinética y eficacia de pbp1510 en pacientes con cáncer de páncreas avanzado/metastásico.
Type/Phase: I
Sponsored by: Prestige Biopharma Limited.
Signature date: 11/08/2025
- **Feliú Batlle J.** Estudio en fase i, sin enmascaramiento, de aumento gradual de la dosis y de ampliación de la dosis para evaluar la seguridad, la tolerabilidad, la farmacocinética y la farmacodinámica de ct-01 en monoterapia y en combinación con everólimus en pacientes con carcinoma hepatocelular intermedio o avanzado (estadios b o c según la bclc) con función hepática conservada (child-pugh clase a).
Type/Phase: I
Sponsored by: Captor Therapeutics.
Signature date: 21/01/2025
- **Feliú Batlle J.** Estudio de fase i, con aumento escalonado de la dosis y ampliación de cohortes de tsr-022, un anticuerpo monoclonal anti-tim-3, en pacientes con tumores sólidos avanzados (amber).
Type/Phase: I
Sponsored by: Tesaro Inc..
Signature date: 14/04/2025
- **Feliú Batlle J.** A randomized, placebo-controlled, double-blind, multicenter, phase 3 trial of quemliclustat and chemotherapy versus placebo and chemotherapy in patients with treatment-naive metastatic pancreatic ductal adenocarcinoma.
Type/Phase: III
Sponsored by: Arcus Biosciences Inc.
Signature date: 10/02/2025
- **Feliú Batlle J.** A randomized phase 2 study of casdozokitug in combination with toripalimab plus bevacizumab in participants with unresectable and/or locally advanced or metastatic hepatocellular carcinoma".
Type/Phase: II
Sponsored by: Coherus Biosciences Inc.
Signature date: 04/02/2025
- **Feliú Batlle J.** A phase 1b, open-label, parallel group, multiple-dose study to evaluate the pharmacokinetics, safety, and tolerability of oral decitabine and cedazuridine (astx727) in cancer patients with moderate and severe hepatic impairment.
Type/Phase: I
Sponsored by: Taiho Oncology, Inc.
Signature date: 30/09/2025
- **Espinosa Arranz E.** Neoadjuvant tebentafusp in patients with metastatic uveal melanoma.
Type/Phase: II
Sponsored by: Grupo Español Multidisciplinar De Melanoma Gem.
Signature date: 30/06/2025
- **Espinosa Arranz E.** Neoadjuvant tebentafusp in patients with metastatic uveal melanoma.
Type/Phase: II
Sponsored by: Grupo Español Multidisciplinar De Melanoma Gem.
Signature date: 06/11/2025
- **Espinosa Arranz E.** Estudio en fase II, multicéntrico, sin enmascaramiento y aleatorizado para evaluar la actividad antitumoral de roginolisib en pacientes con melanoma uveal/ocular metastásico/avanzado.
Type/Phase: II
Sponsored by: Orion Santé Sarl.
Signature date: 07/08/2025
- **Espinosa Arranz E.** Estudio de fase III de fianlimab (regn3767, anti-lag-3) + cemiplimab en comparación con pembrolizumab en pacientes con melanoma metastásico o localmente avanzado inoperable no tratado previamente.
Type/Phase: III
Sponsored by: Regeneron Pharmaceuticals, Inc.
Signature date: 19/09/2025
- **Espinosa Arranz E.** Ensayo de extensión de fase IIII, abierto y multicéntrico para estudiar la seguridad y eficacia a largo plazo en participantes con tumores avanzados que actualmente están en tratamiento o en seguimiento en un ensayo de pembrolizumab.
Type/Phase: III
Sponsored by: Merck Sharp And Dohme De España, S.A..
Signature date: 08/04/2025
- **Espinosa Arranz E.** A phase II, open-label, multicenter, non-randomized study of the efficacy and safety of enfortumab vetodin in combination with pembrolizumab previously treated advanced melanoma.
Type/Phase: II
Sponsored by: Grupo Español Multidisciplinar De Melanoma Gem.
Signature date: 09/04/2025
- **Espinosa Arranz E.** A phase 3 randomized, controlled study of imc-f106c plus nivolumab versus nivolumab regimens in hla-a*02:01-positive participants with previously untreated advanced melanoma (prism-mel-301)".
Type/Phase: III
Sponsored by: Immunocore, Ltd.
Signature date: 10/12/2025
- **Custodio Carretero AB.** Randomized interval assessment trial of lu177-dotatate every 8 versus every 16 weeks in slowly progressive g1-2 advanced midgut neuroendocrine tumors (nets) to lower toxicity.
Type/Phase: II
Sponsored by: Grupo Español De Tumores Neuroendocrinos Y Endocrinos.
Signature date: 11/09/2025
- **Custodio Carretero AB.** Phase II study of tarlatamab alone or in combination with chemotherapy in advanced neuroendocrine carcinomas of the digestive system or unknown primary origin.
Type/Phase: II
Sponsored by: Grupo Español De Tumores Neuroendocrinos Y Endocrinos.
Signature date: 26/11/2025
- **Custodio Carretero AB.** Estudio en fase II/III, multicéntrico, aleatorizado y sin enmascaramiento de zanzalintinib frente a everólimus en participantes con tumores neuroendocrinos previamente tratados, irresecables, localmente avanzados o metastásicos.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Type/Phase: II
Sponsored by: Exelixis Inc.
Signature date: 07/01/2025

- **Custodio Carretero AB.** Estudio de fase III, multicéntrico y aleatorizado de zanidatamab en combinación con quimioterapia, con o sin tislelizumab, en sujetos con adenocarcinoma gastroesofágico (age) irresecable, localmente avanzado o metastásico, con her-2 positivo.
  Type/Phase: III
  Sponsored by: Zymeworks, Inc.
  Signature date: 01/10/2025
- **Custodio Carretero AB.** Estudio clínico de fase III, aleatorizado, doble ciego y multicéntrico de hlx22 (inyección de anticuerpo monoclonal recombinante humanizado anti-her2) en combinación con trastuzumab y quimioterapia (xelox) frente a trastuzumab y quimioterapia (xelox) con o sin pembrolizumab para el tratamiento de primera línea del cáncer gástrico y de la unión gastroesofágica localmente avanzado o metastásico.
  Type/Phase: III
  Sponsored by: Shanghai Henlius Biotech.
  Signature date: 07/05/2025
- **Custodio Carretero AB.** Ensayo de fase III, multicéntrico, aleatorizado y en abierto de trastuzumab deruxtecán (enhertu®) más quimioterapia con o sin pembrolizumab en comparación con quimioterapia más trastuzumab con o sin pembrolizumab como tratamiento de primera línea en participantes con cáncer gástrico o de la unión gastroesofágica (uge) positivo para her2 irresecable, localmente avanzado o metastásico (destiny-gastric05).
  Type/Phase: III
  Sponsored by: DaIichi Sankyo Inc.
  Signature date: 20/08/2025
- **Custodio Carretero AB.** Dareon™-7: A phase i, open-label, dose escalation and expansion trial to investigate safety and tolerability of bi 764532 intravenous infusions in combination with standard of care (platinum and etoposide) in first-line treatment of patients with neuroendocrine carcinomas (nec).
  Type/Phase: I
  Sponsored by: Boehringer Ingelheim España S.A..
  Signature date: 14/01/2025
- **Custodio Carretero AB.** A phase 3, double-blind, randomized study of zolbetuximab in combination with pembrolizumab and chemotherapy (capox or mfolfox6) in first-line treatment of locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma in participants whose tumors are her2 negative, claudin (cldn) 18.2-positive and programmed death-ligand 1 (pd l1) positive.
  Type/Phase: III
  Sponsored by: Astellas Pharma Global Development, Inc..
  Signature date: 01/07/2025
- **Castelo Fernández B.** Predicción mediante inteligencia artificial de la secuencia óptima de tratamiento para el carcinoma de células escamosas de cabeza y cuello recurrente/metastásico (predinhance)/predicting optimal treatment sequence in recurrent/metastatic head and neck squamous cell carcinoma using artificial intelligence (predinhance).
  Type/Phase: EPA-OD
  Sponsored by: Merck Healthcare Kgaa.
  Signature date: 21/11/2025
- **Castelo Fernández B.** Ensayo aleatorizado de fase i/II en pacientes con carcinoma de células escamosas de cabeza y cuello (scchn) locorregionalmente avanzado, negativo para vph, de diagnóstico reciente, en el que se evalúa una inmunoterapia dirigida al mutanoma iniciada al finalizar el tratamiento primario o en el momento de la recidiva.
  Type/Phase: I
  Sponsored by: Transgene.
  Signature date: 07/04/2025
- **Castelo Fernández B.** A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab in combination with cetuximab in participants with recurrent or metastatic (r/m) hpv-negative head and neck squamous cell carcinoma (fierce-hn).
  Type/Phase: III
  Sponsored by: Aveo Pharmaceuticals Inc.
  Signature date: 15/07/2025
- **Castelo Fernández B.** A dose-escalation and expansion study of the safety and efficacy of xl092 in combination with immuno-oncology agents in subjects with unresectable advanced or metastatic solid tumors.
  Type/Phase: I
  Sponsored by: Exelixis Inc.
  Signature date: 21/03/2025

Patents and trademarks

- **Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees.** Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.
- **Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees.** Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.
- **Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez Navarro I, inventors; FIBHULP, assignee.** Method for tumor subclassification. P200803509, PCT/ES2009/070533; 2008 December 11.
- **Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee.** Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.
- **Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees.** Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.
- **Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez de Molina AI, Reglero Rada G, Vargas Alonso T, Molina Arranz S, González-Vallinas Garrachón M, inventors; FIBHULP, Fundación Imdea Alimentacion, assignees.** Methods and kits for the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 December 10.
- **Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López Vacas R, Berges Soria J, inventors; FIBHULP, assignee.** Method for tumor subclassification. P201430887, 2014 June 09.
- **Miranda Utrera N, Castellano D, Villacampa Aubá F, Fresno Vara JA, Gámez Pozo A, inventors; FIBH12O, FIBHULP, assignees.** Prognostic method for determining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for same. P201531360, PCT/EP2016/072723, EP16774644.5, US20180346990, CN108174608; 2015 September 23.
- **Feliú Battle, J, Fernández Martos C, Fresno Vara JA, Ghanem Cañete I, Gámez Pozo A, Trilla Fuertes L, inventors; Biomedica Molecular Medicine SL (BMM), Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD), assignees.** In vitro method for the prognosis of anal squamous cell carcinoma. EP19382982.7; 2019 November 11.
- **Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee.** Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.
- **Fernández Martos C, Trilla Fuertes L, Fresno Vara JA, Gámez Pozo A, Ghanem Cañete I, Feliú Battle J, inventors; Biomedica Molecular Medicine SL, Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD), assigne.** In vitro method for the prognosis of anal squamous cell carcinoma. EP19382982.7; 2019; 2019 November 11.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.5.3 Experimental Therapies and Biomarkers in Cancer



Publications: 12 | Q1: 7

COMPOSITION

Javier de Castro Carpeño.
Director Científico de IdiPAZ/Jefe de Sección de Oncología. Hospital Universitario La Paz/Profesor Asociado. Universidad Autónoma de Madrid
Olga Vera Puente.
Investigadora Principal Miguel Servet. FIBHULP

- **Ana Arauzo Cabrera.** *Investigadora Predoctoral. FIBHULP*
- **María José Beato Merino.** *Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz*
- **Miranda Burdiel Herencia.** *Investigadora Postdoctoral. FIBHULP*
- **César Casado Sánchez.** *Profesor Asociado. Universidad Autónoma de Madrid*
- **Patricia Cruz Castellanos.** *Facultativo Especialista de Área en Oncología Médica. Hospital Universitario La Paz*
- **Lucía de Dios Blázquez.** *Bioinformática. FIBHULP*
- **María Dolores Diestro Tejeda.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Ginecología Oncológica. Hospital Universitario La Paz*
- **María Isabel Esteban Rodríguez.** *Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz*
- **Álvaro García Guede.** *Profesor doctor. Universidad Europea de Madrid*
- **Laura Gutiérrez Sainz.** *Facultativo Especialista de Área en Oncología Médica. Hospital Universitario La Paz*
- **Óliver Higuera Gómez.** *Facultativo Especialista de Área en Oncología Médica. HULP*
- **Diego Jiménez Bou.** *Facultativo Especialista de Área en Oncología Médica. HULP*
- **Cristina Manguán García.** *Técnico de Laboratorio. IIB Sols Morreale*
- **Ander Paulo Mayor Ibarguren.** *Facultativo Especialista de Área en Dermatología. Hospital Universitario La Paz*
- **Rocío Moreno Velasco.** *Técnico de Laboratorio. FIBHULP*
- **Olga Pernía Arias.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Carlos Rodríguez Antolín.** *Bioinformático. FIBHULP*
- **Rocío Rosas Alonso.** *Facultativo Especialista de Área en Bioquímica Clínica. Hospital Universitario La Paz*
- **Sara Ruiz Buceta.** *Investigadora Predoctoral. FIBHULP*
- **Darío Sánchez Cabrero.** *Facultativo Especialista de Área en Oncología Médica. HULP*
- **Claudia Sánchez Lara.** *Bioinformática. FIBHULP*
- **Paloma Nerea Yubero Delgado.** *Técnico Auxiliar en Enfermería. FIBHULP*

STRATEGIC OBJETIVES

- Genetic and epigenetic mechanisms play a significant role in tumor progression and the development of treatment resistance. The dynamic nature of tumors and their ability to adapt and resist therapies pose critical challenges in clinical practice. In our research, we have employed various strategies to address these challenges. First, we have focused on identifying novel markers throughout the course of lung cancer, aiming to uncover crucial indicators of disease evolution. Furthermore, we have pursued several approaches to identify specific targets involved in drug response, seeking to improve treatment efficacy. Our research has transcended the realm of theory, extending into the realm of clinical practice through the meticulous analysis of human samples. It is through this granular examination that we have unraveled the alterations that occur at the individual patient level. Moreover, we have successfully identified epigenetic changes in tumor suppressor genes that are strongly associated with drug resistance. Furthermore, we have made significant progress in understanding the role of epigenetic regulators in lung cancer and melanoma, particularly in the context of oxidative stress. These findings shed light on new avenues for therapeutic interventions and provide valuable insights into the complex interplay between genetic, epigenetic, and environmental factors in cancer progression and treatment resistance.
- By applying genomic, transcriptomic, and expression reactivation techniques, we have made significant progress in identifying a wide range of biomarkers, including genes and microRNAs. These biomarkers hold enormous potential for non-invasive cancer diagnosis, particularly in the context of non-small cell lung cancer (NSCLC). Our pioneering research has demonstrated the effectiveness of liquid biopsy as a reliable method for detecting these biomarkers, offering a promising avenue for early lung cancer detection and diagnosis. Furthermore, we have focused our attention on evaluating patients with chronic obstructive pulmonary disease (COPD) to establish the presence of early-stage lung cancer. By leveraging these advanced techniques, we have successfully unraveled the complex transcriptomic alterations at the miRNA level that occur during lung cancer development in COPD patients. These groundbreaking findings not only have great potential to improve the accuracy and efficiency of cancer diagnosis but also pave the way for personalized treatment approaches that can potentially improve patient outcomes.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH LINES

1. Identification of predictive epigenetic biomarkers for the development of treatment resistance in solid tumors.

- Among cancer markers, predictive markers are the most crucial for guiding therapies, as the vast majority of patients are diagnosed when the tumor requires treatment. Platinum-derived compounds are the standard treatment for high-incidence tumors such as those of the lung, ovary, and rectum; therefore, identifying markers of response to their use would allow for patient selection, optimizing treatment and associated healthcare costs.
- Lung cancer:
- In this area, we have identified the methylation of the IGFBP3 gene promoter, whose epigenetic silencing is related to platinum resistance, extending its validation to cohorts of lung cancer patients likely to benefit from its use. Furthermore, the efficacy of this biomarker is being tested in liquid biopsy as a non-invasive test. This line of research has resulted in three related publications (Oncogene 2010 PMID: 20023704, Oncogene 2013 PMID: 22543588, Epigenetics 2014 PMID: 25482372) and a patent in the joint exploitation phase with a Spanish biotechnology company that has licensed the patent. This patent has passed a Pre-Commercial Public Procurement process with the Galician Health Service (SERGAS), and its validation in national phases has been supported by two related RETOS projects.
- Brain Tumors:
- Regarding our work with brain tumors, we have been assessing the methylation status of the MGMT gene in glioblastomas as part of our clinical and research activities since 2014 in our laboratory, developing advanced, highly sensitive technology for its detection in liquid biopsies. The data obtained to date from more than 200 patients in a prospective trial has resulted in a recent publication (Clinical Epigenetics 2021 PMID: 33750464).
- Ovarian Cancer:
- We also have an open line in ovarian cancer, in which we have published a recent article (Clinical Epigenetics 2021 PMID: 34454589) and has allowed us to participate as leaders of work package in a European Transcan project led by Italy, which has just passed the first round of evaluation positively.
- Melanoma:
- In this emerging line of research, we are focusing on characterizing the oncogenic role of MAFG in the response to immunotherapy in melanoma. Dr. Olga Vera recently joined the group as a Sara Borrell postdoctoral researcher to lead this line of research. Olga's previous studies have identified MAFG as a potential oncogene in melanoma with possible therapeutic applications. The successful completion of our study will significantly advance our understanding of the role of MAFG in melanoma, identify new therapeutic targets, and open new lines of research focused on dissecting the oncogenic role of MAFG.

2. Study of the molecular mechanisms underlying simultaneous platinum resistance in cancer, through epigenetic regulation of regulatory non-coding RNAs.

- Along these lines, we are studying changes in the expression of microRNAs and lncRNAs in platinum-sensitive and platinum-resistant human cell lines of NSCLC and ovarian cancer established in our research group. We have identified 7 microRNAs whose expression appears to be under epigenetic regulation. One of them, miRNA-7, is under epigenetic regulation of its regulatory region and is a potential predictive biomarker of platinum response in ovarian cancer in terms of overall survival and time to progression. The development of this line of research has resulted in the publication of an article in the journal (Theranostics 2017 PMID: 29158814), as well as a patent currently in PCT phase. Based on these findings, in 2016 we initiated a collaboration with the Moffitt Cancer Center in Tampa, USA, to study long non-coding RNAs (lncRNAs) and their possible regulation through DNA methylation in these cell lines. With this project, we are evaluating changes in the expression of the This research focuses on lncRNAs and their epigenetic regulation at the level of DNA methylation, characterizing two groups of lncRNAs differentially regulated in the development of cisplatin resistance, thus paving the way for the identification of new ones. This collaboration has yielded highly innovative results in this field (Epigenetics PMID: 29436261 and Translational Research 2018, PMID: 30053382), and ongoing research focused on the characterization of these novel biomarkers is supported by funding from projects PI21/00145 and Caixa Impulse.

3. Identification of new therapeutic targets. In recent years we have also identified the direct regulation of the MAFG gene through miR-7 in our experimental models.

- The function of MAFG is associated with detoxification under oxidative stress, and our in vitro studies have demonstrated its involvement in the development of cisplatin-resistant phenotypes. Our translational approach suggests that MAFG could be a diagnostic marker in lung and ovarian cancer patients treated with platinum-based chemotherapy. To date, this line of research has yielded four articles (Translational Research 2018, PMID: 30053382; Cell Biosci. 2019 PMID: 31406565; Arch Bronconeumol (Engl Ed). 2020. PMID: 31780284; Antioxidants (Basel). PMID: 32492865) and a European patent, which has just been extended to national phases in the US and Europe, describing the clinical use of MAFG in lung and ovarian cancer patients. Currently we have addressed the study and use of MAFG as a therapeutic target through in vitro and in vivo assays after editing the MAFG gene using CRISPR/Cas9 technology, a project funded by the ISCIII (PI18/00050, P21/000145) in addition to expanding and validating its use with the potential development of a kit for clinical use thanks to obtaining a RETOS project (RTC2019-007229-1) from the 2019 call and which is underway with the collaboration of the H. Ramón y Cajal and the companies Aptus and Atrys.

4. Identification of biomarkers in exosomes as a liquid biopsy in patients with lung and ovarian cancer.

- This line of research aims, through an initial basic approach, to characterize and compare the protein and microRNA content of secretome exosomes from paired, sensitive, and resistant lung cancer cell lines. In the translational study of this project, the candidates identified in the cell lines are being validated in circulating exosomes from samples obtained from lung and ovarian cancer patients, which has yielded several results. On the one hand, two candidate miRNAs with prognostic significance in this disease have been identified, and on the other hand, a miRNA with potential universal value as an endogenous agent capable of normalizing the exosomal miRNA content has been identified, both in healthy individuals and in individuals with different tumor types. These results have led to a European patent that is in national phases and to obtaining a Caixa Impulse Validate project for the constitution of a Spin-off, in our institution focused on the development of a first RUO product for the normalization of the exosomal content in human blood samples, in addition to two manuscripts in preparation, as well as the defense of Julia Jiménez's thesis in July 2019.

5. Identification of pharmacogenetic biomarkers associated with the efficacy and toxicity of cancer treatments.

- Led by Dr. R. Rosas. Pharmacogenetics is the field of knowledge that seeks to identify genetic variants to provide information that allows for a better understanding of drug response in terms of efficacy and toxicity, thus contributing to personalized precision medicine. Despite advances in the research and

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

development of new cancer treatments, the efficacy and safety of these drugs vary considerably from patient to patient. In this context, this line of research aims to understand how genetic variations in individuals can influence the efficacy and toxicity of cancer treatments. The use of pharmacogenetic biomarkers is a reality in routine clinical practice and has been shown to improve the efficacy and reduce the side effects of treatments, resulting in a better quality of life for patients and reduced costs for the national healthcare system. Our ultimate goal is to identify new pharmacogenetic biomarkers that will allow for better selection of cancer treatments for each patient, thus advancing the medicine of the future with a personalized and individualized approach. This line of research currently includes two projects awarded through competitive public (PI22/00128) and private (José Luis Castaño Foundation-SEQC) funding calls, led by Dr. Rocío Rosas.

6. Identification of microRNA hypermethylation patterns associated with an increased risk of developing non-small cell lung cancer in patients with mild COPD and moderate to high tobacco use.

- In recent years, the potential role of epigenetic alterations in the development of lung cancer in patients with COPD has gained particular importance. This development is mediated by changes in the activity of various microRNAs, small non-coding RNA molecules (19-25 nucleotides) with a regulatory function in gene expression, which induce the degradation of messenger RNA or inhibit its translation. Therefore, it is interesting to consider whether there may be hypermethylation profiles of different microRNAs that are associated with an increased risk of lung cancer in patients with COPD, which would facilitate appropriate risk selection for screening programs. This line of research currently has one project, awarded through a competitive public call (PI22/001764), under the co-direction of Olga Pernía Arias.

7. Development of high-throughput techniques available to the National Health System (NHS).

- NGS and DNA methylation status characterization. Implicit in the group's cross-cutting lines and in our commitment to supporting the implementation of technological advances derived from our research activity within the NHS, we have developed the characterization of DNA methylation status at the PAZ genetics facilities. This is achieved through the use of these new aspects of NGS applied to the field of epigenetics, both from a global perspective and limited to specific regions, to implement its potential clinical applicability in cancer patients through customized panels for solid tumors, including glioblastomas, using Methylseq technology and 850K EPIC arrays. Furthermore, in recent years we have developed the use of commercial NGS panels in strict compliance with quality standards to address the genetic profiling of tumors in lung cancer patients. Thanks to the addition of Dr. Rocío Rosas and Juan Rodés to our team in 2022, we are beginning the hospital implementation phase, in which we have already tested runs with several platforms from different vendors. Its fine-tuning will allow its use for both research activities and its future application in healthcare, especially in the classification of brain tumors. This activity is funded by the Spanish Group for Transversal Oncology and Rare Orphan Tumors (GETHI), which recently awarded the group a competitive grant for this purpose. Given the group's experience in using big data, we have been able to participate in the EU's ISIDORE project and have begun studying bioinformatics matrices that predict response to platinum-based treatment. We intend to combine information available in public domain databases with relevant clinical information associated with our own experimental results (methylation and gene expression microarrays and microRNAs, bisulfite sequencing, RNAseq, and miRNAseq) to generate a predictive matrix of treatment response. With these analytical models, we aim to identify "global markers" that define a predictive profile for platinum-based treatment in lung and ovarian cancer, based on the transcriptome, microRNome, and/or methylome. This line of research is led by Carlos Rodríguez Antolín, a bioinformatician in the group.

RESEARCH ACTIVITY

Doctoral Theses

- **García Guede A.** Estudio de MAFG como biomarcador en Cáncer de Pulmón No Microcítico: Causa y consecuencia en la regulación de factores implicados en cáncer[dissertation]. Madrid: UAM: 2025(24/07/2025). Director: Vera Puente O

Master Theses

- **Ruiz Buceta S.** Caracterización de los cambios no genéticos en el desarrollo y progresión del melanoma.[dissertation]. Madrid: UCM: 2025(07/07/2025). Director: Vera Puente O
- **Lumbreras García C.** Evaluación del papel de MAFG y sus genes diana en la progresión del melanoma cutáneo[dissertation]. Madrid: UAM: 2025(30/09/2025). Director: Vera Puente O
- **Heredia G Cantón PM.** Desarrollo e implementación de un Beacon Fhir para la interoperabilidad y el acceso seguro a la información genética procedente de estudios de secuenciación masiva.[dissertation]. Madrid: UAM: 2025(23/06/2025). Director: Rodriguez Antolin C.
- **Sánchez Lara C.** Optimización de la detección de CNVS en paneles y exomas mediante secuenciación masiva: implementación y validación clínica[dissertation]. Madrid: UAM: 2025(23/06/2025). Director: Rodriguez Antolin C.

Final Degree Theses

- **Fernández Fernández M.** Estudio de la inducción de MAFG por radiación ultravioleta como evento iniciador en la transformación melanocítica[dissertation]. Madrid: Universidad Francisco de Vitoria: 2025(07/07/2025). Director: Vera Puente O. CP24/00005
- **Ramos López M.** Identificación de biomarcadores farmacogenéticos predictivos de toxicidad a tratamiento en cáncer de colon. [dissertation]. Madrid: Universidad Francisco de Vitoria: 2025(09/06/2025). Director: Rosas Alonso R.

Publications

- **Alameda-Guijarro M, Rueda-Lara A, Martín-Montalvo G, Higuera O, Gutiérrez-Sainz L, Jimenez-Bou D, Villamayor J, de Castro J, Custodio A, Pérez-Wert P.** Novel therapies targeting delta-like ligand 3 (DLL3) in pulmonary and gastroenteropancreatic neuroendocrine carcinomas. Cancer Treat Rev. 2025; 140: 103022. Review. IF: 10.6; Q1
- **de Castro J, Alonso-Fernández P, Castrodeza JJ, Gayete A, Hernando F, Martínez-Olmos J, Massuti B, Paz-Ares L, Sisó-Almirall A, Vicente D, Molins L.** Monitoring of the oncological process for lung cancer in Spain: an expert consensus report. Clin Transl Oncol. 2025; 27(10): 3867-76. Article. IF: 2.7; Q3
- **Sánchez CV, Rodríguez MIE, García AP, Taravilla-Loma M, Rodríguez-Domínguez V, Rodríguez-Antolín C, Rosas-Alonso R, Losantos-García I, Guerrero AI, Gandía-González ML.** Clinical impact of a next-generation sequencing approach for glioblastoma patients. Cancers (Basel). 2025; 17(5): 744. Article. IF: 4.8; Q2
- **Yang JCH, Wang MZ, Doucet L, Fan Y, Lv DQ, Sun ML, Huang DZ, Greillier L, Planchard D, Hong QY, Mazieres J, Felip E, Li XY, Hu Y, Fang J, Bazhenova L, Ghiringhelli F, Dols MAC, Rodríguez LPA, Bearz A, Pellini B, Kim YJ, Bosch-Barrera J, Shim BY, Luo YH, Tiseo M, Yang TY, Carcereny E, Memmott RM, Zalcman G, Carpeño JD, Di Noia V, Parra HS, Streich G, Lee DH, Shum E, Han JY, Jaime JC, Brungs D, John T, D'Arcangelo M, Joaquin AB, Liu GF, Antonuzzo L, Hinojal GF, Le XN, Zheng L, Jänne PA.** Phase II dose-randomized study of sunvozertinib in platinum-pretreated non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations (WU-KONG1B). J Clin Oncol. 2025; 43(29): 3198-208. Article. IF: 44.7; D1

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

- **Rosas-Alonso R, Salas NR, Wert PP, Hoyo A, Martín-López S, Martínez-Pérez D, Ruiz-Gutiérrez I, Jimenez-Bou D, Peña J, Arias P, Custodio A, Losantos-García I, Borobia AM, Feliu J, Ghanem I.** DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger. Front Pharmacol. 2025; 16: 1645188. Article. IF: 5.4; Q1
- **Chadourne M, Griffith C, Jasani N, Xu XN, Brennan E, Vera O, Mecozzi N, Wang KZ, Jaeger AM, Karreth FA.** CDH3-AS1 antisense RNA enhances P-cadherin translation and acts as a tumor suppressor in melanoma. Cell Rep. 2025; 44(10): 116362. Article. IF: 7.7; Q1
- **Rodero BS, Martínez-Toledo C, Nadal E, Molina-Alejandre M, Campelo RG, Gil-González A, Massuti B, García-Grande A, Dómine M, Insa A, Carpeño JD, Vence GH, Majem M, Martínez-Marti A, Megias D, Lobato D, Collazo-Lorduy A, Calvo V, Provencio M, Cruz-Bermúdez A.** Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial). Oncoimmunology. 2025; 14(1): 2513109. Article. IF: 6.2; Q1
- **Ospina-Serrano AV, González-Larriba JL, Nadal E, Trancho FH, Bosch-Barrera J, Calvo V, Bolufer-Nadal S, de la Cruz JLCC, Macía-Vidueira I, Álvarez-Kindelán A, Del Barco-Morillo E, Bernabé-Caro R, Casal-Rubio J, Cilleruelo-Ramos A, Cobo-Dols M, Dómine-Gómez M, Figueroa-Almánzar S, Insa-Mollá A, Jarabo-Sarceda JR, Jiménez-Maestre U, López-Castro R, Majem M, Martínez-Marti A, Téllez EM, Sánchez-Lorente D, López-Valcárcel M, Couñago F, García-Campelo R, de Castro J, Massuti-Sureda B, Provencio M.** Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement. Transl Lung Cancer Res. 2025; 14(9): 3299-322. Article. IF: 3.4; Q2
- **Remon J, Bironzo P, Girard N, Bigay-Game L, Juan-Vidal O, de Castro J, Reguart N, Greillier L, Cousin S, Dansin E, Majem M, Bernabe R, Martínez JM, Díaz M, Meya A, Alcalá-López D, García-Sanz A, Righi L, Novello S, Besse B.** Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. Lancet Oncol. 2025; 26(9): 1215-26. Article. IF: 33.7; D1
- **Gutiérrez-Sainz L, Rosas-Alonso R, Rodríguez-Antolín C, Rodríguez-Jiménez C, Rodríguez IE, Peláez R, Gomez OH, Villamayor J, Cruz-Castellanos P, Peláez-García A, de Cáceres II, Carpeño JD.** A Novel Exon 19 EGFR mutation in a patient with lung adenocarcinoma: A Case Report and Literature Review. Curr Probl Cancer Case Rep. 2025; 18: 100374. Review. IF: 0.5; Q4
- **Calles A, Alonso M, Martín-Martorell P, Gómez A, de Castro J, Martínez-Aguillo M, Estival A, Mosquera J, Martínez-Banaclocha N, Majem M, Reyes R, Azkona E, Ortega AL, Aguin S, Santos A, Aguilar A, Cucurull M, Blasco A, Calvo V, Isla D, Nadal E, Aguado C, Sais E, Juan-Vidal O, Diz-Taín M, Taus A, Villanueva N, Bayona C, Amenedo M, Mielgo X, Arriola E, Baena J.** Efficacy and safety of lorlatinib in patients with ALK-and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain. Cancer Treat Res Commun. 2025; 43: 100905. Article. IF: 3.5; Q2
- **Jasani N, Xu XN, Posorske B, Kim Y, Wang KZ, Vera O, Tsai KY, Denicola GM, Karreth FA.** PHGDH induction by MAPK is essential for melanoma formation and creates an actionable metabolic vulnerability. Cancer Res. 2025; 85(2): 314-28. Article. IF: 22.6; D1

Research projects

- **Cruz Castellanos P.** APP Respira. Boehringer Ingelheim España S.A. 2019-Ongoing. Managment centre: FIBHULP
- **Vera Puente O.** Primera bioherramienta para la normalización del contenido exosomal en biopsia líquida y su aplicabilidad clínica para la estratificación y diagnóstico de pacientes con cáncer de pulmón. FIBHULP. 2021-Ongoing. Managment centre: FIBHULP
- **Vera Puente O.** Early molecular nanodiagnostics of brain tumors using inmune-pet (PLEC2021-008034). MICINN. 2021-2025. Managment centre: FIBHULP
- **de Castro Carpeño J.** Estudio de la plasticidad tumoral epigenética a través de la carcinogénesis y progreción del CPNM en biopsia líquida setup (PI21/00145). ISCIIII. 2022-2026. Managment centre: FIBHULP
- **de Castro Carpeño J.** INtegrative GENomic, digital Imaging and clinical information towars Precision Oncology Optimization – INGENIO. (PMP21/00107). ISCIIII. 2022-2026. Managment centre: FIBHULP
- **Vera Puente O.** Integrated services for infectious diseases outbreak research. UE. 2022-2025. Managment centre: FIBHULP
- **de Castro Carpeño J.** Identificación de nuevos mecanismos genéticos y epigenéticos de resistencia a la inmunoterapia de primera linea en pacientes con cáncer de pulmón no microcítico metastásico (CPNMm) con alta expresión pd-l1. Estudio KEYPREDICT. Fundacion Mutua Madrileña. 2022-2027. Managment centre: FIBHULP
- **Rosas Alonso R.** Estudio de nuevas variantes asociadas a toxicidad por fluoropirimidinas (2022.184). Fundación José Luis Castaño para el Desarrollo del Laboratorio Clínico. 2022-Ongoing. Managment centre: FIBHULP
- **Rodríguez Antolín C.** Evaluación del perfil de hipermetilación de micrornas para la estimación de riesgo de cáncer de pulmón en pacientes con EPOC (PI22/01764). ISCIIII. 2023-2026. Managment centre: FIBHULP
- **Rosas Alonso R.** Farmacogenética de inhibidores tirosina-quinasa en cáncer de pulmón: medicina de precisión más allá de un solo gen (PI22/00128). ISCIIII. 2023-2026. Managment centre: FIBHULP
- **de Castro Carpeño J.** SurvAI: plataforma web para la automatización de la anotación, clasificación e interpretación de variantes genéticas en cáncer a través de algoritmos basado en deep learning. predicción de supervivencia y efecto de variantes de significado incierto (DTS22/00145). ISCIIII. 2023-2027. Managment centre: FIBHULP
- **Vera Puente O.** Validación clínica en biopsia líquida de una firma genética y epigenética como herramienta pronóstica frente a quimioinmunoterapia en pacientes con cáncer de pulmón (CPP2022-009545). ISCIIII. 2024-2026. Managment centre: FIBHULP
- **Vera Puente O.** Dinamización de ciencia disruptiva en predictores de enfermedades tumorales, infecciosas y hereditarias como base de la medicina personalizada (FORT23/00006_GRUPO III). ISCIIII. 2024-2027. Managment centre: FIBHULP
- **Vera Puente O.** Caracterización de las funciones inmunosupresoras de mafg en melanoma y sus potenciales implicaciones para la terapia del cáncer (GEM2023_OVP). Grupo Español Multidisciplinar de Melanoma. 2024-2025. Managment centre: FIBHULP
- **de Castro Carpeño J.** cáncer de pulmón de célula pequeña. de las redes biológicas a la terapia personalizada: apoyo a iniciativas dirigidas a pacientes, prevención y divulgación. Fundación Asociación Española Contra el Cáncer. 2024-2025. Managment centre: FIBHULP
- **de Castro Carpeño J.** The European Comprehensive Cancer Centre Network. UE. 2024-2028. Managment centre: FIBHULP
- **Vera Puente O.** Caracterización de epi-marcadores de la rigidez del estroma tumoral en vesículas extracelulares en cáncer de pulmón no microcítico (PI24/00291). ISCIIII. 2025-2027. Managment centre: FIBHULP
- **Rosas Alonso R.** Optimización del tratamiento con inmunoterapia en pacientes con cáncer de pulmón mediante la integración de biomarcadores farmacogenéticos y proteómicos (optinmun) (2025.325). FIBHULP. 2025-Ongoing. Managment centre: FIBHULP

Ciber and Retics

- **de Castro Carpeño J.** Dinamización e innovación de las capacidades industriales del SNS y su transferencia al sector productivo. ISCIII. (31/12/2026). FIBHULP
- **de Castro Carpeño J.** The European Comprehensive Cancer Centre Network. (EUnetCCC). ISCIII. (46387). FIBHULP

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Clinical trials

- **de Castro Carpeño J.** Estudio en fase II abierto, de un solo grupo y multicéntrico para evaluar la eficacia y la seguridad de taletrectinib en pacientes con cpnm ros1 positivo avanzado o metastásico y otros tumores sólidos.
  Type/Phase: II
  Sponsored by: Anheart Therapeutics Inc.
  Signature date: 15/08/2025
- **de Castro Carpeño J.** A phase III, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer whose tumors express pd-l1 (artemide-lung03)".
  Type/Phase: III
  Sponsored by: Astrazeneca Ab.
  Signature date: 30/10/2025
- **de Castro Carpeño J.** Estudio fase III, aleatorizado, doble ciego, controlado con placebo que evalúa la eficacia y seguridad de pembrolizumab más quimioterapia basada en doblete de platino con o sin canakinumab, como terapia de primera línea para pacientes con cáncer de pulmón de células no pequeñas escamoso o no escamoso, localmente avanzado o metastásico (canopy-1) c".
  Type/Phase: III
  Sponsored by: Novartis Farmaceutica, S.A..
  Signature date: 23/06/2025
- **de Castro Carpeño J.** Estudio de fase ib/II, abierto y aleatorizado de vudalimab en combinación con quimioterapia o pembrolizumab en combinación con quimioterapia como tratamiento de primera línea en pacientes con cáncer de pulmón no microcítico avanzado.
  Type/Phase: II
  Sponsored by: Xencor Inc.
  Signature date: 15/07/2025
- **de Castro Carpeño J.** Estudio de fase III aleatorizado, controlado y multirregional de ivonescimab en combinación con quimioterapia frente a pembrolizumab en combinación con quimioterapia para el tratamiento de primera línea del cáncer de pulmón no microcítico escamoso metastásico (harmoni-3).
  Type/Phase: III
  Sponsored by: Summit Therapeutics, Inc.
  Signature date: 06/06/2025
- **de Castro Carpeño J.** Estudio en fase III, multicéntrico, aleatorizado y sin enmascaramiento de ifinatamab deruxtecán (i-dxd), un conjugado anticuerpo-fármaco (caf) b7-h3 frente al tratamiento elegido por el médico (tpc) en participantes con carcinoma pulmonar de células pequeñas (cpcp) recidivante (ideate-lung02)".
  Type/Phase: III
  Sponsored by: DaIIchi Sankyo Inc.
  Signature date: 07/08/2025
- **de Castro Carpeño J.** Phase 1/2, open-label, multicenter, first-in-human study of ds-3939a in subjects with advanced solid tumors.
  Type/Phase: I
  Sponsored by: DaIIchi Sankyo Inc.
  Signature date: 17/10/2025
- **Gutiérrez Sainz L.** Estudio descriptivo de la evolución en el diagnóstico y tratamiento de pacientes con cáncer microcítico de pulmón en españa" con código clarisse.
  Type/Phase: EOm no prospectivo
  Sponsored by: Investigacion Sobre Cancer De Pulmones En Mujeres Icapem.
  Signature date: 14/08/2025
- **de Castro Carpeño J.** Phase 1b/2 trial of omtx705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with carboplatin, pemetrexed and tislelizumab in patients with advanced/metastatic non-squamous non-small cell lung cancer.
  Type/Phase: I
  Sponsored by: Oncomatryx Biopharma, S.L.
  Signature date: 25/11/2025
- **de Castro Carpeño J.** Estudio en fase I, abierto, de escalada y ampliación de la dosis para evaluar la seguridad, la tolerabilidad, la farmacocinética, la farmacodinámica y la eficacia preliminar de d3s-001 en monoterapia en sujetos con tumores sólidos avanzados con mutación p.g12c en kras.
  Type/Phase: I
  Sponsored by: D3 Bio.
  Signature date: 20/06/2025
- **de Castro Carpeño J.** An open-label, randomized phase 3, global multi-center trial to assess the efficacy and safety of zipalertinib (tas6417) plus pemetrexed and cisplatin or carboplatin, versus pemetrexed and cisplatin or carboplatin, in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 insertion (ex20ins) mutations.
  Type/Phase: III
  Sponsored by: Taiho Oncology, Inc.
  Signature date: 13/06/2025
- **de Castro Carpeño J.** Estudio de fase III aleatorizado, abierto, para evaluar la eficacia y seguridad de divarasib y pembrolizumab comparado con pembrolizumab y pemetrexed más carboplatino o cisplatino en pacientes con cáncer de pulmón no microcítico no escamoso con mutación kras g12c, avanzado o metastásico, no tratados previamente (krascendo 2).
  Type/Phase: III
  Sponsored by: F.Hoffmann-La Roche Ltd.
  Signature date: 17/10/2025
- **de Castro Carpeño J.** Ensayo abierto, multicéntrico, aleatorizado, de fase III de trastuzumab deruxtecán en combinación con pembrolizumab frente a quimioterapia basada en platino en combinación con pembrolizumab como tratamiento de primera línea en participantes con cáncer de pulmón no microcítico, no escamoso, localmente avanzado irresecable o metastático, con sobreexpresión de her2 y tps de pd-l1 <50 % (destiny-lung06).
  Type/Phase: III
  Sponsored by: DaIIchi Sankyo Inc.
  Signature date: 02/09/2025
- **de Castro Carpeño J.** Estudio en fase III, aleatorizado y abierto para evaluar zimberelimab y domvanalimab en combinación con quimioterapia frente a pembrolizumab con quimioterapia, como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico metastásico sin aberraciones tumorales genómicas del receptor del factor de crecimiento epidérmico ni de la quinasa del linfoma anaplásico.
  Type/Phase: III
  Sponsored by: Gilead Sciences Inc.
  Signature date: 27/03/2025
- **Rosas Alonso R.** optimización del tratamiento con inmunoterapia en pacientes con cáncer de pulmón mediante la integración de biomarcadores farmacogenéticos y proteómicos (optinmun).
  Type/Phase: EPA-SP
  Sponsored by: Rosas Alonso, Rocío.
  Signature date: 19/05/2025
- **de Castro Carpeño J.** A randomized, double-blind, placebo-controlled, multi-regional phase III clinical study of toripalimab alone or in combination with tifcemalimab (js004/tab004) as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy.
  Type/Phase: III
  Sponsored by: Shanghai Junshi Biosciences Co, Ltd.
  Signature date: 03/03/2025
- **de Castro Carpeño J.** Estudio de fase 2, multicéntrico, de linfocitos infiltrantes de tumores autólogos (In-145) en pacientes con cáncer de pulmón no microcítico metastásico.
  Type/Phase: II
  Sponsored by: Iovance Biotherapeutics, Inc..
  Signature date: 09/07/2025
- **de Castro Carpeño J.** A phase IIIb study of durvalumab as consolidation treatment for patients diagnosed with limited stage small cell lung cancer who have not progressedfollowing definitive concurrent or sequential platinum-based chemoradiation therapy in spain (alboran).
  Type/Phase: IIIb
  Sponsored by: Astrazeneca Farmaceutica Spain S.A..
  Signature date: 09/06/2025
- **de Castro Carpeño J.** Estudio de fase II, multicéntrico, aleatorizado, abierto, para evaluar la seguridad y la eficacia de bms-986504 en monoterapia en participantes con cáncer de pulmón no microcítico (cpnm) avanzado o metastásico con deleción homocigótica de mtap después de la progresión a tratamientos previos.
  Type/Phase: II
  Sponsored by: Bristol Myers Squibb S.A.U..
  Signature date: 01/10/2025

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

- **de Castro Carpeño J.** Rasolve 301: phase 3 multicenter, open label, randomized study of rmc-6236 versus docetaxel in patients with previously treated locally advanced or metastatic ras[mut] nsclc.
  Type/Phase: III
  Sponsored by: Revolution Medicines Inc.
  Signature date: 08/10/2025
- **de Castro Carpeño J.** A phase III, open-label, sponsor-blind, randomized study of dato-dxd with or without osimertinib versus platinum-based doublet chemotherapy for participants with egfr-mutated locally advanced or metastatic non-small cell lung cancer whose disease has progressed on prior osimertinib treatment (tropion-lung15).
  Type/Phase: III
  Sponsored by: Astrazeneca Ab.
  Signature date: 12/06/2025
- **de Castro Carpeño J.** Estudio pantumoral para el tratamiento a largo plazo de pacientes de cáncer que han participado en ensayos de investigación patrocinados por bms de nivolumab y otros tratamientos contra el cáncer.
  Type/Phase: II
  Sponsored by: Bristol Myers Squibb S.L.
  Signature date: 26/06/2025
- **de Castro Carpeño J.** Estudio fase 3 aleatorizado de la combinación de amivantamab y lazertinib frente a osimertinib como tratamiento de primera línea en pacientes con cáncer de pulmón no microcítico ocalmente avanzado o metastásico con mutación del egfr. mariposa.
  Type/Phase: III
  Sponsored by: Janssen Cilag International Nv.
  Signature date: 25/12/2025
- **de Castro Carpeño J.** Estudio de plataforma de fase 2, aleatorizado, abierto que utiliza el protocolo maestro para evaluar nuevas combinaciones con inmunoterapia en participantes con cáncer de pulmón no microcítico localmente avanzado/metastásico, seleccionados según la expresión del ligando de muerte programada 1, que no han recibido tratamiento previo.
  Type/Phase: II
  Sponsored by: Glaxosmithkline Research And Development Limited ,.
  Signature date: 13/01/2025
- **de Castro Carpeño J.** A phase III, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer whose tumors express pd-l1 (artemide-lung03)".
  Type/Phase: III
  Sponsored by: Astrazeneca Ab.
  Signature date: 25/04/2025
- **de Castro Carpeño J.** A phase i/IIa first-in-human single-arm open-label multicentre clinical trial to investigate the safety, tolerability, pharmacokinetics and anti-tumour activity of ascending doses of a cisplatin-based formulation administered as dry powder for inhalation in combination with first line standard of care in patients with stage iv non-small cell lung cancer.
  Type/Phase: IIa
  Sponsored by: Inhatarget Therapeutics, Srl.
  Signature date: 08/01/2025

Patents and trademarks

- **Perona Abellón R, Sánchez Pérez I, Machado Pinilla R, Sastre Garzón L, Murguía Ibáñez JR, inventors; CSIC, UAM, Universidad Politécnica de Valencia, assignees.** Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof. P200502511, PCT/ES2006/070152, EP1947175, US20090202503, US2015337022, AT469212, CA2625981, DK1947175, JP2009511036, JP5560398, PT1947175; 2005 October 14.
- **Perona Abellón R, Sastre Garzón L, Machado Pinilla R, Sánchez Pérez I, inventors; CSIC, UAM, assignees.** Use of inductor agents GSE24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence. P200703106, PCT/ES2008/070212, EP2216043, US2011300115, JP2011504483, CA2706467; 2007 November 23.
- **Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees.** Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.
- **Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees.** Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.
- **Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees.** Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cáncer. P201130863, PCT/ES2012/070379; 2011 May 26.
- **Martínez Máñez R, Murguía Ibáñez JR, Perona Abellón R, Agostini A, Mondragón Martínez L, Moreno Torres M, Manguán García C, Marcos Martínez MD, Soto Camino J, Sancenón Galarza F, inventors; Universidad Politécnica de Valencia, CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), assignees.** Release of substances into senescent cells. P201231370, PCT/ES2013/070581, EP2893923, JP2015529216, US2015306037; 2012 September 04.
- **Ibáñez de Cáceres I, Belda Iniesta C, Pernía Arias O, Perona Abellón R, Cortés Sempere M; inventors.** FIBHULP, CSIC, UAM, Fundación Hospital de Madrid, assignees. Method for predicting the response to a treatment consisting of radiotherapy combined with cisplatin-based chemotherapy. P201330783, PCT/ES2014/070433, EP3006572, US20160122828; 2013 May 29.
- **Perona Abellón R, Sastre Garzón L, Pintado Berninches L, Carrillo García J, Molina Pachón A, Irradiccio Silva L, Manguán García C, inventors; CSIC, UAM, Advanced Medical Projects, Centro de Investigación Biomédica en Red (CIBER), assignees.** Peptides derived from GSE 24.2 for treating diseases caused by oxidative stress and damage to DNA. P201331573, AU2014338820, CA2931429, EP3061815 PCT/ES2014/070803; 2013 October 25.
- **Ibáñez de Cáceres I, Pernía Arias O, de Castro Carpeño J, Vera Puente O, Jiménez Hernández J, Perona Abellón R, Rojo Todo F, inventors; FIBHULP, CSIC, UAM, Instituto de Investigación Sanitaria FJD, assignees.** Determination of methylation and miRNA levels in response to a platinum-based antitumor compound. P201530997, PCT/ES2016/070516; 2015 July 09.
- **Ibáñez de Cáceres I, de Castro Carpeño J, Vera Puente O, Pernía Arias O, Rodríguez Antolín C, González Muñoz VM, Martín Palma ME, Salgado Figueroa AM, inventors; FIBHULP, FIBIOHRC, assignees.** MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells. EP17382610.8 (Publication Number pending), PCT/EP2018/068156; 2017 September 15.
- **Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Rodríguez Jiménez C, Rosas Alonso R, Cruz Castellanos P, Burdiel Herencia M, Pernía Arias O, Diestro Tejada MD, Esteban Rodríguez MI, inventors; FIBHULP, assignee.** miR-151A-3p as an universal endogenous control for exosome cargo normalization. EP19382252.5 (Publication Number pending); 2019 April 05.
- **Ibáñez de Cáceres I, de Castro Carpeño J, Rosas Alonso R, Pernía Arias O, Martínez Marín V, Esteban Rodríguez MI, inventors; FIBHULP, assignee.** Method for determining the percentage of methylation of the promoter of the gene O6-methylguanine-DNA methyltransferase (MGMT) in circulating exosomes. EP19382299.6 (Publication Number pending); 2019 April 16.
- **Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Vera Puente O, Rosas Alonso R, Pernía Arias O, Losantos García I, inventors; FIBHULP, assignee.** Method for determining the response to treatment of a patient affected by non-small cell lung carcinoma (NSCLC). EP19382614.6 (Publication Number pending); 2019 July 19.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.5.4 Research in Otolaryngology and Head and Neck Surgery



Publications: 19 | Q1: 5

COMPOSITION

Luis Lassaletta Atienza.
Jefe de Sección de Otorrinolaringología. Hospital Universitario La Paz

- **Carolina Alfonso Carrillo.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **Miryam Calvino Fernández.** *Investigadora Adjunta Senior. FIBHULP*
- **Alejandro Castro Calvo.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **Sandra Franco Caspueñas.** *Investigadora Predoctoral. IIB Sols Morreale*
- **Isabel García López.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **Javier Gavilán Bouzas.** *Jefe de Servicio de Otorrinolaringología. Hospital Universitario La Paz/Catedrático. Departamento de Cirugía. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Teresa González Otero.** *Facultativo Especialista de Área en Cirugía Maxilofacial. Hospital Universitario La Paz*
- **Coloma Grau Van Laak.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **Ana María Jiménez Lara.** *Investigador Ramón y Cajal. Investigador Ramón y Cajal*
- **Marta Mancheño Losa.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **José Manuel Morales Puebla.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **Silvia Murillo Cuesta.** *Investigadora Postdoctoral. IIB Sols Morreale*
- **María Fernanda Pedrero Escalas.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **Carmen Ruiz García.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **Isabel Pilar Sánchez Cuadrado.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **María Isabel Varela Nieto.** *Profesora de Investigación. IIB Sols Morreale*

STRATEGIC OBJETIVES

- The systematic use of magnetic resonance imaging (MRI) has significantly increased the diagnosis of patients with vestibular schwannoma (VS). Most patients with VS present with hearing loss or tinnitus, and very few exhibit more debilitating symptoms. Therefore, the approach to a patient with VS is complex, since the goal of tumor treatment is to prevent complications arising from its growth, and not necessarily to improve the patient's quality of life. Currently, there are no factors that allow us to predict the growth of a vestibular schwannoma.
- Recent advances in oncogenetics have led to a better understanding of the development of vascular syndrome (VS). Studying the correlation between clinical variables related to the biological behavior of VS and its genetic and epigenetic alterations aims to identify factors that can predict VS behavior. This will help identify patients who require active tumor treatment and avoid treatment-related morbidity in those who do not.
- The cochlear implant (CI) is currently the only solution to alleviate the situation of patients with severe or profound hearing loss who do not benefit from a conventional hearing aid. It is currently estimated that 120,000 adults in Spain have profound sensorineural hearing loss. In recent years, new auditory implants have been developed, including bone-anchored implants and active middle ear implants. Their excellent, often spectacular, results and low complication rate have transformed the CI from an innovative, experimental technology into a routine, safe, and effective procedure, capable of reintegrating deaf people into the world of the hearing population and ending their isolation.
- Moderate to severe hearing loss is one of the most prevalent medical problems. Sensory hair cells and neurons do not regenerate in mammals, making this the primary cause of sensorineural hearing loss. Mutations that cause deficiencies in insulin-like growth factor I (IGF-I) levels also cause sensorineural hearing loss in humans and mice. IGF-I is an essential factor in postnatal development in mammals, and its levels decline with age. We are studying the role of IGF-I in inner ear development, the pathophysiology of hearing in adults, and the molecular signaling networks that confer specificity to the otic cell response to IGF-I. Studying the signals that regulate otic development and those involved in otic damage is one way to identify key factors for the repair and functional regeneration of inner ear cells.
- In summary, our work contributes to the study of auditory pathophysiology with the ultimate goal of investigating the potential clinical utility of IGF-I in human hearing loss of cochlear origin.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH LINES

- Clinical Research on Cardiotoxicity in Oncohematological Treatments: Bioethical Aspects of Defibrillator Use at the End of Life
- Head and Neck Tumors and Voice Disorders.
- The Role of Cellular Senescence in Inner Ear Development and Hearing Disorders.
- Facial Paralysis: Evaluation, Diagnosis, and Surgery.
- Thyroid cancer
- Vocal Cord Paresis and Paralysis: Evaluation, Diagnosis, and Treatment Options
- Genetic and Molecular Bases of Hereditary Hearing Loss: To study hearing loss associated with deficiencies in insulin-like growth factor type I (IGF-1), its high-affinity receptor, and its intracellular targets–particularly p38/MKP1 and NLRP3–as well as to identify the transcriptional networks that regulate inner ear senescence during aging
- Environment-Genome Interaction in Hearing Loss: Analyze animal models of hearing loss to identify genetic predisposing factors and their interaction with environmental factors such as noise, ototoxic agents, and nutritional status, with a particular focus on the role of oxidative stress and inflammation in hearing damage.
- Study of Human Vestibular Schwannoma: Investigating This Rare Tumor of the Cochleovestibular Nerve from a Molecular and Translational Perspective.
- Development of experimental and translational tools: Develop and maintain advanced platforms, including 2D and 3D primary cultures, animal models, ex vivo cultures, microsurgical techniques and procedures, biomarker panels, and new methods for drug delivery and imaging (NMR) in the inner ear. Application in preclinical studies: i) ototoxicity of new molecules; ii) drug repositioning; iii) otoprotective potential of new molecules; and iv) new biocompatible nanomaterials for drug delivery.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

RESEARCH ACTIVITY

Final Degree Theses

- **Sánchez del Álamo B.** Inflamasoma nlrp3 en pérdida auditiva: exploración de su potencial terapéutico en modelos in vitro.[dissertation]. Madrid: UAM: 2025(27/06/2025). Director: Murillo Cuesta S.

Publications

- **Aljazeeri I, Abdelsamad Y, Alsanosi A, Hagr A, Kim AH, Ramos-Macias A, de Miguel AR, Kurz A, Lorens A, Gantz B, Buchman CA, Távora-Vieira D, Sprinzl G, Mertens G, Saunders JE, Kosaner J, Telmesani LM, Lassaletta L, Bance M, Yousef M, Holcomb MA, Adunka O, Cayé-Thomasen P, Skarzynski PH, Rajeswaran R, Briggs RJ, Oh SH, Plontke SK, O'Leary SJ, Agrawal S, Yamasoba T, Lenarz T, Wesarg T, Kutz W, Connolly P, Anderson I, Alzhrani F.** Minimum intraoperative testing battery for cochlear implantation: the international practice trend. Eur Arch Oto-Rhino-L. 2025; 282(2): 681-9. Article. IF: 2.4; Q1
- **Andries E, Lorens A, Skarzynski PH, Skarzynski H, Calvino M, Gavilán J, Lassaletta L, Tavora-Vieira D, Acharya A, Kurz A, Hagen R, Anderson I, Koinig K, Abdelsamad Y, van de Heyning P, Van Rompaey V, Mertens G.** Impact of cochlear implant indications on outcome, assessed and reported using the international classification of functioning, disability and health model. Eur Arch Oto-Rhino-L. 2025; 282(10): 5153-5167. Article. IF: 2.4; Q1
- **Calvino M, Gavilán J, Lassaletta L.** Use of Meludia to evaluate the effect of music training in cochlear implant users: study protocol of a randomised controlled study. BMJ Open. 2025; 15(4): e092207. Article. IF: 2.5; Q2
- **Castro A, Rodrigáñez R, Toribio I, Ruiz C, Bernáldez R, del Palacio A, Gavilán J.** Oncologic and functional outcomes of open partial laryngectomies: classical techniques still worthy in the transoral and non-surgical era. Acad Oncol. 2025; 2: 3. Article. Not Indexed
- **El-Kholy NA, Salem MA, Ghonim MR, Gavilán J.** Endoscopic tenotomy in Ménière's disease: is it effective? J Laryngol Otol. 2025; 139(10): 950-6. Article. IF: 1.1; Q3
- **Escalera-Balsera A, Robles-Bolívar P, Parra-Pérez AM, Murillo-Cuesta S, Chua HC, Rodríguez-de la Rosa L, Contreras J, Domarecka E, Amor-Dorado JC, Soto-Varela A, Varela-Nieto I, Szczepek AJ, Gallego-Martínez A, López-Escámez JA.** A rare haplotype of the GJD3 gene segregating in familial Meniere's disease interferes with connexin assembly. Genome Med. 2025; 17(1): 4. Article. IF: 10.8; D1
- **Franco-Caspueñas S, García-Montoya C, Contreras J, Lassaletta L, Varela-Nieto I, Jiménez-Lara AM.** Uncovering cellular senescence as a therapeutic target in NF2-related vestibular schwannoma. Hearing Res. 2025; 455: 109165. Article. IF: 3.0; D1
- **Lammers MJW, Raine C, Mertens G, van Rompaey V, Hagen R, Kurz A, Skarzynski PH, Lorens A, Opie J, D'Haese P, Grasso P, Lassaletta L, Calvino M, Anderson I.** Towards an adult hearing screening procedure. Braz J Otorhinolar. 2025; 91(4): 101616. Article. IF: 1.8; Q2
- **Lassaletta L, Calvino M, Sánchez-Cuadrado I, Danesi G, Patelli I, Zana M, de Erenchun-Lasa IR, Zapata MD, Yuste EMM, Schaudel D, Mark C, Conni G, Echegaray PLS, til-Pérez G, Pérez IDG, Pascual EM.** Evaluation of remote programming of cochlear implants under challenging conditions. Acta Otorrinolaringol Esp. 2025; 76(2): 91-8. Article. IF: 1.2; Q3
- **Lassaletta L, Calvino M, Sánchez-Cuadrado I, Morales-Puebla JM, Gavilán J.** Cochlear implantation in vestibular schwannoma: A game changer? A narrative review. Braz J Otorhinolar. 2025; 91(3): 101563. Review. IF: 1.8; Q2
- **Lassaletta L, Calvino M, Sánchez-Cuadrado I, Muñoz E, Gavilán J.** Can anatomy-based fitting improve musical perception in adult cochlear implant users? Braz J Otorhinolar. 2025; 91(2): 101533. Article. IF: 1.8; Q2
- **Lerma MG, Riesco LR, Muñoz AD, Millan RB, Arroyo LD, Bouzas JG, Calvo AC.** Postsurgical hypoparathyroidism: Identification of the high-risk patient. A comparison between the ATA protocol and the SEORL-CCC/SEEN consensus. Acta Otorrinolaringol Esp. 2025; 76(2): 99-105. Article. IF: 1.2; Q3
- **Mato-Patino T, Morales-Puebla JM, Sánchez-Cuadrado I, Terés JP, Suazo J, González-Otero T, Hernández B, Gavilán J, Lassaletta L.** Prognostic factors of facial and tongue functional outcomes following side-to-end hypoglossal-facial nerve transfer: a 20-year multidisciplinary experience. Facial Plast Surg Aesthet Med. 2025; 27(5): 423-30. Article. IF: 1.8; Q2
- **Murillo-Cuesta S, Contreras J, Chioua M, García-Montoya C, Rodríguez-de la Rosa L, Méndez-Grande I, Piotrowska DG, Glowacka IE, Varela-Nieto I, Marco-Contelles J.** Quinolylnitrone 23 protects from auditory cell oxidative injury and noise-induced hearing loss. ACS Pharmacol Transl Sci. 2025; 8(9): 3007-18. Article. IF: 4.0; Q2
- **Murillo-Cuesta S, Seoane E, Cervantes B, Zubeldia JM, Varela-Nieto I.** NLRP3 inflammasome and hearing loss: from mechanisms to therapies. J Neuroinflamm. 2025; 22(1): 225. Review. IF: 11.5; D1
- **Oyer SL, Baptista R, Boahene K, Borschel GH, Byrne P, Chuang DCC, Dey JK, Diels J, Guerreschi P, Gur E, Hadlock T, Hetzler L, Kim J, Klebuc M, Labbé D, Lassaletta L, Loyo M, Mardini S, Miller MQ, Pepper JP, Rozen S, Snyder-Warwick A, Stephan S, Tzafetta K, Azizzadeh B.** International, multispecialty expert consensus on nomenclature for facial paralysis. Facial Plast Surg Aesthet Med. 2025; 27(5): 408-15. Article. IF: 1.8; Q2

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



- **Perganti F, Huybrechts I, Balduzzi AC, Barr R, Biondi A, Bladé AL, Bravo EM, Damasco E, Katsagoni CN, Kattamis A, Lassaletta A, Lera ML, Llort A, López JB, Martínez AP, Massimino M, La Madrid AM, Moreno L, Alonso AM, Nicolas G, Preziati G, Rizzari S, Della Valle S, Vega CM, Walters M, Kozlakidis Z, Ladas EJ.** Southern European prospective investigation into childhood cancer and nutrition (EPICkids): Study design and protocol. Plos One. 2025; 20(9): e0319110. Article. IF: 2.8; Q2
- **Rodrigáñez L, Sistiaga A, López F, Ferrandis E, de Cerio PD, Parente P, Castro A, Gavilán J.** SEORL-CCC consensus on the nomenclature of cervical lymph node dissections. Acta Otorrinolaringol Esp. 2025; 76(3): 512231. Article. IF: 1.2; Q3
- **Zernotti ME, Gavilán J.** Who's afraid of Dura Mater? Braz J Otorhinolar. 2025; 91(3): 101554. Article. IF: 1.8; Q2

Research projects

- **Lassaletta Atienza L.** Análisis de las habilidades musicales y de la voz en niños y adultos con implante coclear (PI21/00147). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Lassaletta Atienza L.** Implantes cocleares y función cognitiva en mayores de 55 años. Confederación Española de Familias de Personas Sordas. 2021-Ongoing. Managment centre: FIBHULP
- **Castro Calvo A.** Caracterización multiómica del carcinoma escamoso de cabeza y cuello mediante biopsia gaseosa y líquida: aplicación diagnóstica, pronóstica y de seguimiento. HN-OMICS. ISCIII. 2023-2025. Managment centre: IDIBAPS
- **Varela Nieto I, Murillo Cuesta S.** Addendum to the contract by and between Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER) and Spiral Therapeutics Inc (SPIRAL) on April 26 2017 for scientific research and development services in the field of hearing loss. CIBER-Spiral Therapeutics. 2017-2025. Managment centre: CIBERER
- **Varela Nieto I.** A sound proteome for a sound body: targeting proteolysis for proteome remodeling (ProteoCure). (CA20113). EU Framework Programme Horizon 2020. 2021-2025. Managment centre: Centro de Investigación Príncipe Felipe, Valencia
- **Varela Nieto I.** Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (BenBedPhar) (CA20121). EU Framework Programme Horizon 2020. 2021-2025. Managment centre: IIBM CSIC-UAM
- **Murillo Cuesta S.** Ayudas para a la adquisición de equipamiento científico-técnico de los laboratorios de la red de laboratorios e infraestructuras científico-técnicas de la Comunidad de Madrid (REDLAB). CAM. 2024-2025. Managment centre: CSIC
- **Murillo Cuesta S.** Nuevas estrategias terapéuticas para el tratamiento de enfermedades raras neurosensoriales (SensoRare). CIBERER. 2024-2026. Managment centre: CIBERER
- **Murillo Cuesta S.** Grupo de Trabajo CIBERER Modelos murinos para el estudio de enfermedades raras. CIBERER. 2024-2025. Managment centre: CIBERER
- **Varela Nieto I.** SENESCENCE2030: Targeting Cell Senescence to Prevent Age-Related Diseases (CA23119). EU Framework Programme Horizon 2020. 2024-2028. Managment centre: CSIC
- **Murillo-Cuesta, Silvia; Varela-Nieto, Isabel.** Hipoacusia neurosensorial y protección auditiva: explorando las bases genéticas y moleculares para desarrollar nuevas estrategias terapéuticas. (PID2023-147347OB-I00). MICIN. 2024-2028. Managment centre: IIBM CSIC

Ciber and Retics

- **Varela Nieto I.** Centro de Investigación en Red de Enfermedades Raras. (CiberER). ISCIII. (31/12/2025). CSIC

Clinical trials

- **Sanchez Cuadrado IP.** Estudio multicéntrico, de dos brazos, doble ciego, doblemente enmascarado, de grupos paralelos, controlado con placebo para la evaluación de la eficacia y la seguridad de la mulación de liberación prolongada de betahistina pr 48 mg una vez al día en comparación con la formulación de liberación convencional de betahistina ir 24 mg, enfermedad de meniere.
  Type/Phase: III
  Sponsored by: Intas Pharmaceuticals, Ltd.
  Signature date: 26/11/2025

Patents and trademarks

- **Polak M, Roca-Ribas Serdá F, Gavilán Bouzas J, Lassaletta Atienza L, Miró Castillo N, Rodrigo Dacosta J, inventors; MED-EL Elektromedizinische Geraete GmbH, assignee.** Hearing treatment in patients with questionable cochlear nerve functionality. US2011275953, PCT/US2011/035312; 2010 May 05.
- **Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Martínez Vega R, Cediel Algovia R, inventors; CSIC, UCM, assignees.** Anechoic acoustic chamber for evaluating the auditory function in laboratory animals. P201031720; 2010 November 23.
- **Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediel Algovia R, inventors; CSIC, UCM, assignees.** Method for designing a reverberating acoustic chamber for hearing test with animals. Procedimiento para diseñar una cámara acústica reverberante para ensayos auditivos con animales. P200802895, PCT/ES2009/070433; 2008 October 14.
- **Marco Contelles JL, Varela Nieto I, Murillo Cuesta S, Rodríguez de la Rosa L, Alcázar Gonzalez A, inventors; CSIC, CIBERER, FIBIOHRC, assignees.** Quinolylnitrone derivatives for use in the prevention and/or treatment of hearing loss. EP22382706.4; 2023 July 22

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.5.5 Molecular Pathology of Cancer and Therapeutic Targets

Publications: 13 | Q1: 2

COMPOSITION

David Hardisson Hernáez.
Jefe de Servicio de Anatomía Patológica. Hospital Universitario La Paz/ Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid

- **Alberto Berjón García.** *Médico Adjunto Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz*
- **Javier de Santiago García.** *Jefe de Servicio de Ginecológica Oncológica. Hospital Universitario La Paz. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Marta Mendiola Sabio.** *Investigadora Postdoctoral. Hospital Universitario La Paz*
- **María Miguel Martín.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **José Juan Pozo Kreilinger.** *Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz*
- **José Ignacio Sánchez Méndez.** *Jefe de Sección en Ginecología y Obstetricia. Hospital Universitario La Paz. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Laura Yébenes Gregorio.** *Médico Adjunto Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- The fundamental interest of our research group is centered in the study of molecular biomarkers that have a direct implication in the handling of the cancer patients with the last aim to identify and to validate therapeutic targets.

Ovarian cancer Research Line

- The ovarian carcinoma is the main cause of gynecological cancer mortality in the western societies. Nevertheless, the classic parameters are imperfect predictors for patients outcome, partly due to the complexity of the molecular genetic events that sublie these tumors and to the fact that they are not totally known. Research on this field could identify more precise markers to correctly stratify the patients according to their probability to recur and response to treatments.
- Angiogenesis, epithelial to mesenchymal transition and hypoxia are processes demonstrated to have an important role in the development of these tumors. The main objective of this line of investigation, therefore, is to identify discrete markers or gene expression profiles related to these events, with predictive and prognostic value for ovarian cáncer patients.

Endometrial cancer Research Line

- Endometrial carcinoma is the fourth most common cancer in women in the developed world. Histomorphologic criteria are not strongly enouygh tools to distinguish more aggressive tumors. Based on molecular characterization, risk stratification systems could be useful for decision making.
- The main objective of this line of investigation, therefore, is to identify molecular markers with predictive and prognostic value for endometrial cancer patients.

Breast cancer Research Line

- Angiogenesis and breast cancer. Angiogenesis is a key process in tumor development. Our group has been working for years on the search of biomarkers related to this process. Specifically on breast cancer, it is important to identify patients that will benefit of evacizumab containing regimes.

Sarcomas Research Line

- Bone and Soft tissue sarcomas includes a group of heterogeneous pathologies that were traditionally treated in the same way. The clinical investigation has allowed the identification of sub-groups with different response to treatments. The objective of this line of work is to find biomarkers for the best stratification of the patients, as well as to get a better knowledge of the molecular mechanisms for the development of these tumors.

In vitro 2- and 3D cell culture models for functional studies.

- The identification of potential markers in different pathologies might be complemented by functional studies, focused on the characterization of cancer and estromal cell features, important for tumor development that it improves the rates of survival.

RESEARCH LINES

- Ovarian and endometrial cancer
- Breast cancer
- Sarcomas
- New in vitro models of disease

RESEARCH ACTIVITY

Doctoral Theses

- **Ruz Caracuel I.** Identificación de factores pronósticos de recaída en carcinomas de endometrio de bajo grado en estadios iniciales mediante técnicas ómicas[dissertation]. MADRID: UAM: 2025(18/06/2025). Director: Hardisson Hernáez D, Peláez García A. Instituto de Salud Carlos III (ISCIII) (PI17/01723)

Final Degree Theses

- **Ochoa Grille I.** Cáncer de endometrio: clasificación molecular y estratificación de riesgo[dissertation]. MADRID: UAM: 2025(04/06/2025). Director: Hardisson Hernáez D.

Publications


- **Banys-Paluchowski M, Hartmann S, Basali T, Gasparri ML, de Boniface J, Gentilini OD, Cakmak GK, Ditsch N, Stickeler E, Schlichting E, Rubio I, Peintinger F, Untch M, Mau C, Federspiel FK, Bucher S, Ramaker K, Paluchowski P, Bauer L, Riemer S, Langanke D, Leuf TD, Schnabel J, von Abel E, Solbach C, Ovalle SC, Hilmer K, Bjelic-Radisic V, Stahl N, Sánchez-Méndez JI, Hagen V, Hansen MH, Krawczyk N, Sezen BA, Jursik K, Thill M, Kolberg HC, Reimer T, Ruf F, Wihlfahrt K, Rief A, Berger T, Schmidt E, Tauber N, Fröhlich S,**

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



Kühn T. Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial. Breast Cancer Res Tr. 2025; 211(1): 203-11. Article. IF: 3.3; Q2

- **Boria F, Chiva L, Fernández-González S, Glickman A, Adan AC, Ponce J, Torne A, de Santiago J, Barahona M, Sanchez B, Chereguini MF, Suils J, Marti L, Zapardiel I.** Comparative analysis of Boria's and Suidan's predictive models for complete cytoreduction in advanced ovarian cancer using 18F-FDG PET/CT. Eur J Obstet Gyn R B. 2025; 313: 114588. Article. IF: 2.3; Q2
- **Fernández-Abad M, Caniego-Casas T, Carretero-Barrio I, Calderay-Domínguez M, Saavedra C, Hardisson D, Palacios J, Pérez-Mies B.** Ipsilateral breast carcinoma recurrence. Am J Surg Pathol. 2025; 49(3): 294-302. Article. IF: 4.2; Q1
- **González-Martínez S, Palacios J, Carretero-Barrio I, Lanza VF, Piqueras MGC, Caniego-Casas T, Hardisson D, Esteban-Rodríguez I, Cortés J, Pérez-Mies B.** Single-Cell RNA sequencing on formalin-fixed and paraffin-embedded tissue identified multi-ciliary cells in breast cancer. Cells. 2025; 14(3): 197. Article. IF: 6.0; Q2
- **Kostun J, Nowosielski K, Jedryka MA, Hardisson D, Restaino S, Gatius S, Novak Z, Lacalle AS, López S, Pesta M, Zebalski M, Lepka P, Diestro MD, Vizzielli G, Matias-Guiu X, Echim T, Urkaray ENC, Rienda I, Slunecko R, Czekanski A, Berjón A, Mariuzzi L, Velasco A, Betenbuk J, Merino IG, Padilla-Iserte P, Stránik P, Smoligová V, Presl J.** One-Step nucleic acid amplification analysis of sentinel lymphatic nodes in endometrial cancer patients (EU-OSNA): a european multicenter diagnostic accuracy study. Cancer Med. 2025; 14(18): e71268. Article. IF: 3.5; Q2
- **Loayza A, Hernández A, Rodríguez AM, López B, González C, Hardisson D, de la Pena I, Serrano M, Arnedo R, Zapardiel I.** HPV E6/E7 mRNA testing in the follow-up of HPV-vaccinated patients after treatment for high-grade cervical intraepithelial neoplasia. Vaccines (Basel). 2025; 13(8): 823. Article. IF: 3.5; Q2
- **Loayza A, Moreno-Palacios E, Frías L, Navarro Y, Meléndez M, Marti C, Garrido D, Berjón A, Hernández A, Sánchez-Méndez JI.** Current Indications for Seed-Marked Axillary Lymph Node Dissection in Breast Cancer. Cancers (Basel). 2025; 17(10): 1682. Article. IF: 4.8; Q2
- **López-Janeiro A, Brizzi E, Ruz-Caracuel I, Alexandru R, de Andrea C, Berjon A, Yébenes L, Mendiola M, Heredia-Soto V, Montero-Calle A, Barderas R, de los Rios V, Redondo A, Pelaez-García A, Hardisson D.** The proteomic landscape of CTNNB1 mutated low-grade early-stage endometrial carcinomas. Cells. 2025; 14(21): 1676. Article. IF: 6.0; Q2
- **Macarrón V, Losantos-García I, Peláez-García A, Yebenes L, Berjón A, Frías L, Martí C, Zamora P, Sánchez-Méndez JI, Hardisson D.** A novel nomogram for estimating a high-risk result in the EndoPredict® test for estrogen receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative breast carcinoma. Cancers (Basel). 2025; 17(2): 273. Article. IF: 4.8; Q2
- **Mendiola M, Heredia-Soto V, Baillo A, Ruz-Caracuel I, Mena R, Berjón A, Escudero FJ, Pedregosa J, Hernández A, Feliu J, Hardisson D, Redondo A.** Improving the performance of polymerase chain reaction for microsatellite instability testing in endometrial cancer. Sci Rep-Uk. 2025; 15(1): 44262. Article. IF: 4.9; Q1
- **Peg V, Abengozar-Muela M, Acosta J, Andres L, García-Rojo M, Hardisson D, Nicolau MJ, Ramos-Oliver I, Rodrigo M, Sánchez-Bernal ML, Sanz J, Garrote L, Ramírez I, Rojo F.** New approach in the interpretation of complex triple-negative breast cancer immunohistochemistry specimens processed with VENTANA PD-L1 (SP142) assay. Appl Immunohisto M M. 2025; 33(1): 15-21. Article. IF: 1.3; Q3
- **Sánchez-Méndez JI, Lombarte M, Abengozar-Muela R, Acosta-Díez J, Alonso-Fernández P, Cañones-Castañon MP, Calderón-Ruiz O, Espinosa-García E, Galocha-Morgado C, Siegrist J, Alonso-Salvador S.** Natural procreative technology (NaProTechnology) for infertility: take-home baby rate and clinical outcomes in a 5-year single-center cohort of 1,310 couples. Front Reprod Health. 2025; 7: 1696679. Article. IF: 3.1; Q2
- **Sorianol V, Vélez O, Sánchez-Méndez JI, González-Rico N, González L.** Research on differences in sexual orientation and identity. Aids Rev. 2025; 27(4): 163-70. Article. IF: 2.0; Q3

Research projects

- **Mendiola Sabio M.** Exploration of 2 and 3d models of angiosarcoma and their farcological sdreening. Grupo Español de Investigacion en Sarcomas. 2019-Ongoing. Managment centre: FIBHULP
- **Hardisson Hernáez D.** Identificación de biomarcadores de recaída en carcinomas de endometrio de riesgo clínico intermedio mediante análisis multi-ómico y de microambiente inmune (PI21/00920). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Mendiola Sabio M.** Identificación de marcadores de HRD y predicción de la respuesta a inhibidores de PARP en líneas celulares establecidas y organoides derivados de pacientes con cáncer de ovario. –- Español de Investigación en Cáncer Ginecológico. 2021-Ongoing. Managment centre: FIBHULP

Patents and trademarks

- **Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee.** Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.
- **Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee.** Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.
- **Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee.** Laparoscopic surgical instrument. P201230950, PCT/ES2013/000139; 2012 June 18.
- **Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee.** Surgical device. P201330532, PCT/ES2014/070277; 2013 April 15.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.5.6 Mechanisms of Tumour Progression

Publications: 3 | Q1:3

COMPOSITION

José Manuel González Sancho.
Catedrático. Universidad Autónoma de Madrid

- **David Albandea Rodríguez.** *Investigador Predoctoral. IIB Sols Morreale*
- **Estrella Arroyo Gascón.** *Personal Investigador en Formación. Universidad Autónoma de Madrid*
- **Antonio Barbáchano Becerril.** *Investigador Postdoctoral. IIB Sols Morreale*
- **Aurora Burgos García.** *Jefe de Sección Unidad de Endoscopias. Hospital Universitario La Paz*
- **Gemma Domínguez Muñoz.** *Profesora Titular. Universidad Autónoma de Madrid*
- **Asunción Fernández Barral.** *Profesora Ayudante Doctor. Universidad Autónoma de Madrid*
- **Arturo González de Aleja Molina.** *Investigador Postdoctoral. IIB Sols Morreale*
- **María Jesús Larriba Muñoz.** *Científico Titular. IIB Sols Morreale*
- **Esther Martín Villar.** *Investigadora Postdoctoral. Universidad Autónoma de Madrid*
- **Alberto Muñoz Terol.** *Profesor de Investigación. IIB Sols Morreale*
- **José Luis Orgaz Bueno.** *Jefe de Laboratorio de Citoesqueleto y Metástasis. IIB Sols Morreale*
- **Silvia Rodríguez Marrero.** *Investigadora predoctoral. IIB Sols Morreale*
- **Johana Alexandra Troya Balseca.** *Lab Manager. FIBHULP*

STRATEGIC OBJETIVES

- Tumor progression, tumorigenesis, or carcinogenesis is the process by which a tumor originates, increases in size, aggressiveness, and ability to spread, ultimately generating metastases in distant organs. For these processes to occur successfully, tumor cells must acquire, as a consequence of genetic and epigenetic changes, the capacity to develop a series of mechanisms: uncontrolled cell growth, resistance to programmed cell death, angiogenesis, degradation of the extracellular matrix, cell migration and invasion, evasion of the immune response, and metastatic colonization.
- The tumor microenvironment or stroma plays an essential role in the progression of cancer, composed of fibroblasts, various types of immune system cells, other cell types (adipocytes, lymphatic and vascular endothelium...), the extracellular matrix and a wide variety of chemical mediators (cytokines, growth factors, etc.).
- Understanding the mechanisms of tumor progression and the different cell types involved in the process is fundamental to identifying new biomarkers and therapeutic targets, which in turn can be very useful for improving the clinical management of patients and for developing more effective and personalized cancer treatment strategies.
- Our group comprises several principal investigators who lead their own lines of research related to tumor progression. The group's main objectives are as follows:

  1. To characterize the antitumor action of vitamin D in stem cells and in the tumor microenvironment in colorectal cancer.

  2. Comparative study of early-onset colorectal cancer (under 50 years of age, Early-onset colorectal cancer or EOCRC) versus late-onset colorectal cancer (over 50 years of age, Late-onset colorectal cancer or LOCRC).

  3. Analysis of tumor invasion and metastasis processes and resistance to therapies in solid tumors.

  4. Identification of biomarkers of tumor progression.




RESEARCH LINES

- Study of the effects of vitamin D on normal and patient-derived colon cancer-associated fibroblasts and organoids
- Comparative study of early-onset colorectal cancer (EOCRC) vs. late-onset colorectal cancer (LOCRC): Effects of vitamin D.
- Identification of early diagnostic markers in liquid biopsy in colorectal cancer.
- Cellular plasticity and tumor metastasis.
- Tumor resistance mechanism.
- Study of celiac disease using advanced models of human intestinal organoids

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH ACTIVITY



Master Theses

- **Giribaldi F.** Implication of ΔNp73 oncogene and its effector targets in the response to neoadjuvant therapy in patients with locally advanced colorectal cancer[dissertation]. MADRID: UAM: 2025(26/06/2025). Director: Domínguez Muñoz G. PI21/01047
- **San Martín A.** Identification of response biomarkers to neoadjuvant treatment in patients with locally advanced rectal cancer [dissertation]. MADRID: UAM: 2025(26/06/2025). Director: Domínguez Muñoz G. PI21/01047
- **Ortiz del Amo M.** Investigando la función inmunomoduladora de podoplanina en la inflamación cutánea[dissertation]. MADRID: UFV: 2025(29/09/2025). Director: Matin Villar E. PID2021-126816OB-I00

Final Degree Theses

- **Delgado Lopez A.** Regulación del citoesqueleto de miosina durante la adaptación a terapias dirigidas en melanoma[dissertation]. Madrid: UAM: 2025(30/06/2025). Director: Orgaz Bueno JL. 2023-5A/BMD-28922

Publications

- **Bartolomé RA, Pintado-Berninches L, Robles J, Calvo-López T, Boukich I, Otero-Núñez P, González-Sancho JM, Casal JI.** Loss of cadherin 17 downregulates LGR5 expression, stem cell properties and drug resistance in metastatic colorectal cancer cells. Cell Death Dis. 2025; 16(1): 475. Article. IF: 12.2; Q1
- **Maiques O, Sallan MC, Laddach R, Pandya P, Varela A, Crosas-Molist E, Barcelo J, Courbot O, Liu YB, Graziani V, Arafat Y, Sewell J, Rodríguez-Hernández I, Fanshawe B, Jung-García Y, Imbert PRC, Grasset EM, Albrengues J, Santacana M, Macià A, Tarragona J, Matías-Guiu X, Marti RM, Tsoka S, Gaggioli C, Orgaz JL, Fruhwirth GO, Wallberg F, Betteridge K, Reyes-Aldasoro CC, Haider S, Braun A, Karagiannis SN, Elosegui-Artola A, Sanz-Moreno V.** Matrix mechano-sensing at the invasive front induces a cytoskeletal and transcriptional memory supporting metastasis. Nat Commun. 2025; 16(1): 1394. Article. IF: 18.1; D1
- **Olivencia MA, Climent B, Barreira B, Morales-Cano D, Sánchez A, Fernández A, García-Gómez B, Romero-Otero J, Rodríguez C, Moreno L, Prieto D, Larriba MJ, Cogolludo A, Angulo J, Pérez-Vizcaino F.** Vitamin D deficiency induces erectile dysfunction: Role of superoxide and Slpi. Brit J Pharmacol. 2025; 182(15): 3669-87. Article. IF: 7.5; Q1

Research projects

- **Barbáchano A.** High-throughput screening platform for precision nutrition in Non-Responsive Celiac Disease through 3d organ models and systems biology (TEC-2024/BIO-167). Comunidad de Madrid. 2025-2028. Managment centre: CIBER
- **Domínguez Muñoz G.** Combinación de técnicas "ómicas" y de imagen para la identificación de marcadores asociados a la respuesta al tratamiento neoadyuvante en pacientes con cáncer de recto: Implicaciones pronósticas y terapéuticas (PI21/01047). ISCIII. 2022-2025. Managment centre: FIBHULP
- **González Sancho JM.** PRECICOLON-CM Hacia la medicina de precisión en cáncer de colon: Biomarcadores, microambiente tumoral y microbiota (P2022/BMD-7212). Comunidad de Madrid. 2023-2026. Managment centre: UAM
- **Martín Villar E.** Podoplanin-mediated crosstalk between cancer cells and the microenvironment controls epithelial carcinogenesis and malignant progression. Opening new therapeutic avenues (PID2021-126816OB-I00). Ministerio de Ciencia e Innovación, Proyectos de generación del conocimiento 2021. 2022-2025. Managment centre: UFV
- **Muñoz Terol A, Larriba Muñoz MJ.** Efectos de la vitamina D sobre las células troncales y el microambiente tumoral en cáncer de colon: diferenciación, metabolismo y comunicación intercelular (PID2022-136729OB-I00). Ministerio de Ciencia e Innovación, Proyectos de Generación de Conocimiento. 2023-2026. Managment centre: CSIC
- **Orgaz JL.** Estudio de la regulación de miosina no muscular de clase II en la progresión del melanoma (MYOMEL) (PID2021-122306OB-I00). Ministerio de Ciencia e Innovación, Proyectos del Programa Estatal de I+D+i orientada a los Retos de la Sociedad. 2022-2025. Managment centre: CSIC
- **Orgaz JL.** Finding new vulnerabilities after inhibition of non-muscle myosin II in melanoma (2023-5A/BMD-28922). Comunidad de Madrid. 2024-2025. Managment centre: CSIC
- **Orgaz JL.** Identifying strategies after targeting the cytoskeleton to eradicate cutaneous melanomas. (CNS2023-143636). Ministerio de Ciencia e Innovación, Ayudas Consolidación Investigadora 2023. 2024-2026. Managment centre: CSIC
- **Rodríguez Salas N, Muñoz Terol A.** Cáncer colorrectal en población joven. Estudio farmacogenómico en organoides y efectos del microambiente tumoral (ICI20/00057). ISCIII. 2021-2026. Managment centre: FIBHULP

Ciber and Retics

- **Muñoz Terol A.** Networked Biomedical Research Center for Cancer (CIBERonc). ISCIII. (31/12/2026). Managment Centre: CSIC

Patents and trademarks

- **Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García A, inventors; UAM, CSIC, assignees.** Method for the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.
- **Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee.** Materials and methods for the derepression of the Ecadherin promoter. US20060003956; 2004 March 03.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.5.7 Research and Diagnosis of Inherited Metabolic Diseases

Publications: 8 | Q1: 3

COMPOSITION

María Belén Pérez González.
Catedrática. Universidad Autónoma de Madrid. CBM Severo Ochoa

- **Patricia Alcaide Alonso.** *Investigadora . CEDEM*
- **Margarita Castro Reguera.** *Investigadora . CEDEM*
- **Magdalena de Ugarte Pérez.** *Directora del CEDEM. CEDEM*
- **Isaac Ferrer López.** *Técnico de Laboratorio. CEDEM*
- **María Alejandra Gámez Abascal.** *Profesora Titular. CBM Severo Ochoa*
- **Fernando García Muñoz.** *Técnico de Laboratorio. CEDEM*
- **Fátima Leal Pérez.** *Técnico de Laboratorio. CIBERER*
- **Rosa María Navarrete López de Soria.** *Técnico de Laboratorio. CIBERER*
- **Eva María Richard Rodríguez.** *Profesora Titular. Universidad Autónoma de Madrid. CBM Severo Ochoa*
- **María Pilar Rodríguez Pombo.** *Profesora Titular. Universidad Autónoma de Madrid. CBM Severo Ochoa*
- **María Lourdes Ruiz Desviat.** *Catedrática. Universidad Autónoma de Madrid. CBM Severo Ochoa*
- **Pedro Ruiz Sala.** *Investigador . CEDEM*



STRATEGIC OBJETIVES

- Our research group maintains a strong commitment to improving patient diagnosis and developing new targeted therapeutic strategies, especially in the field of inherited metabolic diseases (IMD), one of the most prevalent subgroups within rare diseases, with an estimated incidence of 1 in every 800 newborns.
- Our dual mission–shortening diagnostic times and advancing effective therapeutic interventions–guides all our research. We focus on the use of cutting-edge omics technologies, the functional study of genetic variants, the identification and validation of therapeutic targets, the development of personalized treatments, and the generation of cellular and animal models.
- The starting point is the diagnosis of patients with EMH, using advanced tools such as metabolomics (GC-MS, MS/MS), high-precision enzymatic analysis, conventional molecular genetics and state-of-the-art genomic techniques.
- Although high-throughput genomic sequencing has transformed metabolic medicine by facilitating the identification of novel gene-disease associations, one of our main objectives is to overcome its limitations in detecting long repetitive elements (such as LINEs), copy number alterations, structural variations, and epigenetic defects. To this end, we integrate third-generation sequencing technologies into our diagnostic practice, combined with transcriptomic, metabolomic, and epigenomic analyses, and supported by a functional genomics platform to validate the effect of variants of uncertain clinical significance. This strategy allows us to evaluate the clinical impact of splicing defects, variants in coding and non-coding regions, and structural alterations such as transposon movement.
- We have extensive experience in generating patient-derived cell models using human induced pluripotent stem cells (hiPSCs) differentiated into various cell lineages (cardiomyocytes, hepatocytes, neurons, astrocytes), as well as in developing and characterizing animal models for different metabolic syndromes. These models not only reproduce key aspects of the pathophysiology but also allow for the identification of new therapeutic targets and constitute a robust platform for preclinical trials.
- In addition, we extensively use CRISPR/Cas technology to generate knockout and knockin cell and animal models, introducing specific mutations identified in patients.
- In the therapeutic field, we develop proof-of-concept studies for pharmacological chaperones, RNA-based therapies, and gene editing, evaluating different CRISPR/Cas-based genetic engineering strategies. These approaches are combined with safe and targeted delivery technologies, employing biocompatible nanoparticles with potential clinical applications.
- Our group is part of the Biomedical Research Network Center for Rare Diseases (CIBERER) and the Center for Molecular Disease Diagnosis (CEDEM) of the Faculty of Sciences of the Autonomous University of Madrid.

RESEARCH LINES

- Optimization of the diagnosis of inherited metabolic diseases using genomic, transcriptomic, metabolomic, proteomic and epigenomic technologies.
- Functional validation of the effect of genetic variants using functional genomics.
- Identification and characterization of new gene-disease associations.
- Development of cellular and animal models using gene editing for functional and therapeutic studies.
- Development of targeted therapeutic strategies: small molecules, RNA therapies and gene editing.
- Generation of cell models by differentiation of iPSCs into different cell lineages.
- Identification of biomarkers that predict severity and as tools to evaluate therapeutic efficacy.
- Commitment to active collaboration with patient associations to facilitate the transfer of scientific knowledge to society

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH ACTIVITY

Publications

- **Cámara-Checa A, Álvarez M, Rapún J, Pérez-Martín S, Núñez-Fernández R, Rubio-Alarcón M, Crespo-García T, Desviat LR, Delpón E, Caballero R, Richard E.** Propionic acidemia-induced proarrhythmic electrophysiological alterations in human IPSC-derived cardiomyocytes. J Inherit Metab Dis. 2025; 48(3): e70030. Article. IF: 3.8; Q2
- **Cavazza A, Molina-Estévez FJ, Reyes AP, Ronco V, Naseem A, Malensek S, Pecan P, Santini A, Heredia P, Aguilar-González A, Boulaiz H, Ni QQ, Cortijo-Gutiérrez M, Pavlovic K, Herrera I, de la Cerda B, García-Tenorio EM, Richard E, Granados-Principal S, López-Márquez A, Köber M, Stojanovic M, Vidakovic M, Santos-García I, Blázquez L, Haughton E, Yan DN, Sánchez-Martín RM, Mazini L, Aseguinolaza GG, Miccio A, Rio P, Desviat LR, Gonçalves MAFV, Peng L, Jiménez-Mallebrera C, Molina FM, Gupta D, Lainscek D, Luo YL, Benabdellah K.** Advanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working Group. Mol Ther Nucleic Acids. 2025; 36(1): 102457. Review. IF: 6.5; Q1
- **García-Tenorio EM, Álvarez M, Gallego-Bonhomme M, Desviat LR, Richard E.** Novel CRISPR-Cas9 iPSC knockouts for PCCA and PCCB genes: advancing propionic acidemia research. Hum Cell. 2025; 38(3): 64. Article. IF: 2.8; Q3
- **Martínez-Pizarro A, Picó S, Alvárez M, Pose-Utrilla J, Holm LL, Doktor TK, Andresen BS, Lucas JJ, Desviat LR.** Oligonucleotides targeting the 3′ splice site downstream of a microexon as an innovative therapy for autism. Nar Mol Med. 2025; 2(4): ugaf035. Article. Not Indexed
- **Martín-Hernández E, Bellusci M, Pérez-Mohand P, Medina PC, Blasco-Alonso J, Morais-López A, de las Heras J, Olivas SMM, Dougherty-de Miguel L, Couce ML, Villarroya EC, Jiménez MCG, Moreno-Lozano PJ, Vives I, Gil-Campos M, Stanescu S, Ceberio-Hualde L, Camprodón M, Cortès-Saladelafont E, López-Urdiales R, Hurtado MM, Armenteros AMM, Córcoles CS, Peña-Quintana L, Ruiz-Pons M, Alcalde C, Castellanos-Pinedo F, Dios E, Barrio-Carreras D, Martín-Cazaña M, García-Peris M, Andrade JD, García-Volpe C, de los Santos M, García-Cazorla A, del Toro M, Felipe-Rucián A, Monroy MJC, Sánchez-Pintos P, Matas A, Ortega DG, Martín-Rivada A, Bergua A, Belanger-Quintana A, Vitoria I, Yahyaoui R, Pérez B, Morales-Conejo M, Quijada-Fraile P.** Understanding the Natural History and the Effects of Current Therapeutic Strategies on Urea Cycle Disorders: Insights from the UCD Spanish Registry. Nutrients. 2025; 17(7): 1173. Article. IF: 5.8; Q1
- **Pascoal C, Granjo P, Mexia P, Gallego D, Lourenço RA, Sharma S, Pérez B, Castro-Caldas M, Grosso AR, Ferreira VD, Videira PA.** Unraveling the biological potential of skin fibroblast: responses to TNF-α, highlighting intracellular signaling pathways and secretome. Immunol Lett. 2025; 276: 107057. Article. IF: 3.2; Q3
- **Richard E, Marchuk H, Álvarez M, He WT, Chen XX, Desviat LR, Zhang GF.** Metabolic flux analysis in hiPSC-CMs reveals insights into cardiac dysfunction in propionic acidemia. Cell Mol Life Sci. 2025; 82(1): 137. Article. IF: 6.5; Q1
- **Sukanya S, Bellver-Sanchis A, Choudhary BS, Kumar S, Pérez B, Rodríguez ALM, Brea J, Escolano C, Griñán-Ferré C, Malik R.** Exploring 2-Thioxo-1,2,3,4-tetrahydropyrimidines as Dual Acting GSK-3β/Aβ Aggregation Inhibitors: Implications for Alzheimer's Disease Treatment. Drug Develop Res. 2025; 86(4): e70112. Article. IF: 4.2; Q2

Research projects

- **Carrecedo A, Pérez González MB.** IMPACT Genomica 2: Avanzando hacia la medicina de precisión en enfermedades raras y tumores de baja frecuencia (PMPER24/00002). ISCIII. 2024-2026. Managment centre: CIBER
- **Pérez González MB.** Mejora del diagnóstico y desarrollo de terapias para errores congénitos del metabolismo a través del análisis genómico, transcriptómico, epigenómico y funcional de pacientes y modelos (PI22/00699). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Ruiz Desviat LM.** Rare neurometabolic diseases: from research in novel disease models to targeted therapies (PID2022-137238OB-I00 MCINN). MCINN. 2023-2026. Managment centre: UAM
- **Stojiljkoviv M, Pérez González MB.** BRIDGing the research and INnovation Gap for Rare Diseases in Europe by upgrading the excellence of IMGGE (BRIDGING-RD). (Number 101160079). EU. 2024-2027. Managment centre: UAM

Ciber and Retics

- **Pérez González MB.** Centro de Investigación en Red de Enfermedades Raras. (CIBERer). ISCIII. (31/12/2025). UAM



Patents and trademarks

- **Pérez González B, Ruiz Desviat L, Jorge Finnigan A, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, Barnejee R, inventors; UAM, Universidad de Bergen, Universidad de Michigan, assignees; Compounds useful for the treatment of methylmalonic aciduria.** P201330171; 2013 February 11.
- **Pérez González B, Gámez Abascal A, Yuste Checa P, Arduim Brasil S, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, inventors; UAM, Universidad de Bergen, assignees; Compounds for treating congenital disorders of glycosylation.** EP16382373.5; 2016.
- **Ruiz-Desviat L, Martínez-Pizarro A, Picó S, Lucas JJ, Andresen BS, inventors; UAM, CSIC,University of Southern Denmark, assignes; Splice shifting oligonucleotides for use in the treatment of diseases characterized by altered inclusion of microexons.** PCT/EP2022/077882, EP4163373A1 2023 April 12

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.5.8 Dyslipidemias of Genetic Origin and Metabolic Diseases



Publications: 3 | Q1: -

COMPOSITION

Sonia María Rodriguez Novoa.
Facultativo Especialista-área Genética. Responsable del Laboratorio de Genética de Enfermedades Metabólicas. Hospital Universitario La Paz

- **Ana Carazo Álvarez.** *Técnico Superior Especialista en Laboratorio de Diagnóstico Clínico. Hospital Universitario La Paz*
- **Amanda Herranz Cecilia.** *Facultativo Especialista Área Genética. Hospital Universitario La Paz*
- **Irene Hidalgo Mayoral.** *Facultativo Especialista-área Genética. Hospital Universitario La Paz*
- **Carmen Prior de Castro.** *Facultativo Especialista-área Genética. Hospital Universitario La Paz*
- **Carmen Rodríguez Jiménez.** *Facultativo Especialista-área Genética. Hospital Universitario La Paz*
- **Rosa Torres Jiménez.** *Investigadora Senior (Contrato Miguel Servet - I2) Jefe de Laboratorio. FIBHULP*

STRATEGIC OBJETIVES

- Improve early diagnosis of genetic dyslipidemias, especially Familial Hypercholesterolemia (FH), through the use of advanced genomic technologies such as next-generation sequencing (NGS).
- Optimize the identification of affected family members through cascade genetic screening programs, promoting a cost-effective strategy for cardiovascular prevention.
- Develop and apply in vitro functional studies to characterize genetic variants in genes involved in FH (LDLR, APOB, PCSK9), enhancing their clinical classification and understanding their biological impact.
- Promote personalized medicine in patients with genetic dyslipidemias by integrating genetic and functional data to predict treatment response and guide individualized therapeutic decisions.
- Explore new genetic and epigenetic mechanisms involved in non-monogenic or unexplained dyslipidemias, expanding the understanding of the molecular basis of lipid metabolism.
- Promote training, scientific dissemination, and multidisciplinary collaboration, both nationally and internationally, in the field of hereditary cardiovascular diseases.

RESEARCH LINES

1. Molecular Diagnosis of Genetic Dyslipidemias
- Implementation and optimization of NGS sequencing protocols for the study of FH and other genetic dyslipidemias.
- Family screening strategie**s in different healthcare settings.**

2. Functional Studies of Genetic Variants
- Validation of cell-based assays to determine the pathogenicity of variants in LDLR, APOB, and PCSK9.
- Genotype-phenotype correlation based on the variant and its functional impact.

3. Discovery of New Genetic and Epigenetic Causes
- Identification of new candidate genes through genomic studies in patients without known pathogenic variants.
- Investigation of the role of microRNAs in the regulation of LDLR, PCSK9, and other genes involved in lipid metabolism.
- Study of potential epigenetic mechanisms underlying complex forms of dyslipidemia.
- Definition and implementation of a workflow for systematic analysis of variants in the LDLR 3'UTR region in patients with suspected Familial Hypercholesterolemia.

4. Personalized Medicine and Treatment Response
- Evaluation of the influence of variant type on the response to lipid-lowering therapies.
- Pharmacogenetic analysis and study of molecular predictors of therapeutic response or resistance.


5. Rare and Underdiagnosed Dyslipidemias
- Genetic and clinical characterization of rare dyslipidemias (e.g., familial chylomicronemia, dysbetalipoproteinemia).
- Development of diagnostic algorithms integrating genomics, biochemistry, and clinical phenotype.

6. Metabolic Myopathy
- Identification of the genetic-molecular cause in patients with suspected metabolic etiology myopathy.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH ACTIVITY





Publications

- **Odogherty AA, Jiménez CR, Belanger-Quintana A, Novoa SR, Blanco FA.** Fish-eye disease. Altered HDL cholesterol metabolism and corneal involvement: A case report. Endocrinol Diabetes Nutr. 2025; 72(10): 501638. Letter. IF: 1.9; Q3
- **Ortiz López C Rodríguez Roca N Hidalgo Mayoral I Herranz Cecilia A Rodríguez Antolín C Martínez Hernández P Carazo Álvarez A Arrieta Blanco FJ Fernández Hernández S Delgado-Martos MJ Rodríguez Jiménez C Rodríguez-Nóvoa S.** Functional analysis of LDLR variants reveals that the novel p.(Ser610Tyr) variant in the YMDD motif drastically impacts LDL uptake. Medrxiv. 2025; (Preprint) Article. Not Indexed
- **Socuellamos PG, Ruiz-Robles JM, Cruz FM, Macias A, Vera-Zambrano A, Moreno-Manuel AI, Prior C, Carton AJ, Valenzuela C, Jalife J.** MOG1L18F-mediated increase in late sodium current produces Long QT Syndrome.. Medrxiv. 2025. (Preprint) Not Indexedexed.NO

Research projects

- **Hidalgo Mayoral I.** Implementación de un flujo de trabajo para el análisis de variantes en la región 3UTR en el gen LGLRr (2025538). Fundacion José Luis Castaño para el Desarrollo del Laboratorio Clínico. 2025-2026. Managment centre: FIBHULP
- **Rodríguez Novoa SM.** Impacto de las variantes genéticas en región 3UTR de los genes causantes de la hipercolesterolemia familiar: regulación del metabolismo de líquidos mediante miRNAs. (PI21/01239). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Rodriguez Roca N.** Estudio del genoma en pacientes con hipercolesterolemia familiar (2025534). Fundacion José Luis Castaño para el Desarrollo del Laboratorio Clínico. 2025-2026. Managment centre: FIBHULP
- **Torres Jiménez R.** Alteracion del desarrollo neuronal en la enfermedad de Lesch Nyhan: papel de ZMP, hipoxantina y estrés energético. Fundació Marató TV3. 2021-Ongoing. Managment centre: FIBHULP
- **Torres Jiménez R.** Alteraciones del desarrollo neuronal en células pluripotentes humana HPRT deficientes (PID2020-113124RB-C22). MICINN. 2021-2025. Managment centre: FIBHULP

Patents and trademarks

- **Rodríguez Novoa SM, del Monte Vergara A, Rosas Alonso R, Queiruga Parada J, Yuste González F, authors; FIBHULP, assignee.** Trademark name: Pharma Genfinder; CM18332183; 2020 November 05.

PHARMA GENFINDER

- **Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Rodríguez Jiménez C, Rosas Alonso R, Cruz Castellanos P, Burdiel Herencia M, Pernía Arias O, Diestro Tejada MD, Esteban Rodríguez MI, inventors; FIBHULP, assignee.** miR-151A-3p as an universal endogenous control for exosome cargo normalization. EP19382252.5 (EP3719144), PCT/EP2020/059774 PCT Direct, EP20719957.1 (EP3947733), US17/601,657; 2019 April 05.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.5.9 Human Genetic Variability

Publications: 13 | Q1: 5

COMPOSITION

Ana Fernández Santander.
Catedrática de Genética del Departamento de Medicina. Universidad Europea de Madrid

- **Beatriz Antón Pascual.** *Médico Adjunto en Oncología Médica. Hospital Universitario Doce de Octubre*
- **Alberto Carretero González.** *Facultativo Especialista de Área en Oncología Médica. Hospital Universitario de Getafe*
- **María Gaibar Alonso.** *Profesora Titular. Universidad Camilo José Cela*
- **Diego Malón Jiménez.** *Médico Adjunto en Oncología Médica. Hospital Universitario de Fuenlabrada*
- **Apolonia Novillo Villajos.** *Profesora Permanente Laboral. Universidad Complutense de Madrid*
- **José María Rodríguez Piñas.** *Profesor Adjunto. Universidad Europea de Madrid*
- **Alicia Romero Lorca.** *Catedrática de Bioquímica y Biología Molecular. Universidad Europea de Madrid*
- **David Sanz Rosa.** *Director de Investigación. Universidad Europea de Madrid*

STRATEGIC OBJETIVES

- The ultimate goal of our group is to contribute to pharmacogenetics and precision medicine. We aim to identify genetic biomarkers that can be used to predict which patients will experience the best response, benefit, and outcome, and the least toxicity, to specific drugs.

Planned research projects:

- Genetic biomarkers of toxicity in cancer immunotherapy
- Genetic biomarkers of efficacy in cancer immunotherapy
- Global genetic variability of polymorphisms associated with COVID severity

Transfer of results:

- Contributions to national and international conferences
- Publications in JCR journals
- Training and education program:
- Students of medicine, nursing, etc., will be able to join the group as doctoral students

Diffusion:

- Publications in JCR journals and at national and international conferences
- Guides for doctors

Internationalization:

- The team will apply for European programs when specific programs related to our research become available. Quality program for gender equality: Gender equality is achieved in our group because women and men have the same conditions and opportunities to belong to and work with us.

RESEARCH LINES

- Pharmacogenetics and cancer:
- Pharmacogenetics in breast cancer
- Pharmacogenetics in colorectal cancer
- Pharmacogenetics and immunotherapy
- Genetic variability of human populations



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH ACTIVITY

Final Degree Theses

- **Simón Zuquin PS.** Del gen al tratamiento: explorando el rol de las mutaciones en PBRM1 y su impacto en la inmunoterapia del carcinoma renal. [dissertation]. MADRID: UCM: 2025(23/01/2025). Director: Novillo Villajos A.
- **Castro Sánchez-Clemente S.** Análisis de mutaciones en KMT2D en pacientes con cáncer de vejiga y su repercusión en inmunoterapia.[dissertation]. MADRID: UCM: 2025(30/05/2025). Director: Novillo Villajos A.

Publications

- **Farinea G, Antón-Pascual B, Villa JLC, Riesco-Martínez MD.** Change in MMR status as a mechanism of acquired resistance to immunotherapy in a dMMR colorectal cancer. BMJ Case Rep. 2025; 18(12): e264115. Article. IF: 0.4; Q4
- **Neil-Sztramko SE, Bland KA, Alibhai SMH, Capozzi LC, Chalmers A, Copp J, Dinardo R, Gimenez DM, Dufresne SS, Lambert LK, Langelier DM, Lane KN, Mackenzie K, Mcdonald K, Mcneely ML, Nadler MB, Papadakos J, Prestley N, Simmons C, Ashbury FD, Hart NH, Campbell KL.** The Bone Metastases and Exercise (BME) Hub: a MASCC-endorsed knowledge mobilization initiative to advance exercise recommendations for people with bone metastases. Support Care Cancer. 2025; 33(12): 1073. Editorial Material. IF: 3.4; D1
- **Capdevila J, Hernando J, Molina-Cerrillo J, Viñuales MB, García-Carbonero R, Teulé A, Custodio A, Jiménez-Fonseca P, López C, Hierro C, Carmona-Bayonas A, Alonso V, Llanos M, Sevilla I, García-Álvarez A, Alonso-Gordoa T, Jiménez IG, Antón-Pascual B, Sánchez AM, Grande E.** Cabozantinib plus atezolizumab in advanced, progressive endocrine malignancies: a multicohort, basket, phase II trial (CABATEN/GETNE-T1914). Clin Cancer Res. 2025; 31(22): 4655-63. Article. IF: 10.9; D1
- **Pathak N, Di Iorio M, Giménez DM, Berner-Wygoda Y, Savill J, Aljuhani A, Mittal A, Kumar V, Amir E.** Adverse effect of trastuzumab deruxtecan in solid tumours: A systematic review and meta-analysis. Crit Rev Oncol Hemat. 2025; 213: 104787. Review. IF: 6.2; Q1
- **Rodríguez-Piñas JM, Romero-Lorca A, Gaibar M, Novillo A, Rubio M, Malón D, Antón-Pascual B, Camacho FI, Cavanagh M, Luján DR, Martín AM, Khedaoui R, Moreno D, Pinedo F, Boiza M, García-Adrián S, Gómez P, Marrupe D, Fernández-Santander A.** Tumour SNPs associated with immune-related hepatitis in patients with melanoma receiving immune checkpoint inhibitors. Biomedicines. 2025; 13(10): 2351. Article. IF: 4.5; Q2
- **Chang K, Delavan HM, Yip E, Kasap C, Zhu J, Lodha R, Liao SY, Berman SC, Carretero-González A, Basar M, Ozcan GG, Teo MY, Solit DB, Rosenberg JE, Al-Ahmadie H, Ding CCK, Chan EMY, Steri V, Porten SP, Koshkin VS, Friedlander TW, Feng FY, Lee JK, Wiita AP, Chu CE, Chou J.** Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Nat Commun. 2025; 16(1): 8215. Article. IF: 18.1; D1
- **Berner-Wygoda Y, Amir E, Blumenfeld P, Li M, Malon D, Pathak N, Savil J, Zarbiv Y, Kumar V.** Efficacy and safety of metastatic directed treatment of oligometastatic disease: results of a meta-analysis. Adv Radiat Oncol. 2025; 10(7): 101797. Review. IF: 2.9; Q2
- **Berner-Wygoda Y, Li M, Perlon C, Malon D, Pathak N, Di Iorio M, Savill J, Aljuhani A, Nadler MB, Amir E.** Safety and effectiveness of adriamycin and cyclophosphamide followed by dose dense (every 2 weeks) paclitaxel given with trastuzumab as neoadjuvant treatment in her2-positive early-stage breast cancer. Clin Breast Cancer. 2025; 25(6): e750-5. Article. IF: 2.7; Q3
- **Rubio-Cuesta B, Carretero-Puche C, Llamas P, Sarmentero J, Gil-Calderón B, Lens-Pardo A, Antón-Pascual B, Rubio-González E, Cámara-Jurado M, Salamanca J, Rueda-Fernández D, Delcuratolo MD, Soldevilla B, García-Carbonero R.** Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer. Brit J Cancer. 2025; 133(3): 404-19. Article. IF: 7.8; Q1
- **Pathak N, Kumar S, Giménez DM, Di Iorio M, Savill J, Berner-Wygoda Y, Li M, Valiente CM, Cuthbert D, Gupta A, Arteaga DP, Batra A, Amir E, Mittal A.** Continuing cyclin-dependent kinase 4/6 inhibitors beyond progression in advanced breast cancer: a meta-analysis. Cancers (Basel). 2025; 17(10): 1609. Review. IF: 4.8; Q2
- **del Olmo-García M, Hernández-Rienda L, García-Carbonero R, Hernando J, Custodio A, Antón-Pascual B, Gomez M, Milla SP, Suárez L, Bellver M, Alonso V, Serrano R, Valdés N, Melián M, Febrero B, Sampedro-Nuñez MA, Biarnes J, Díaz-Pérez JA, Molina-Cerrillo J, López C, Olmos MAM, Merino-Torres JF, Capdevila J, Pla MA, NUTRIGETNE Grp.** Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study. Oncologist. 2025; 30(2): oyae343. Article. IF: 4.7; Q2
- **Lee CL, Martínez E, Gimenez DM, Muniz TP, Butler MO, Saibil SD.** Female oncofertility and immune checkpoint blockade in melanoma: where are we today? Cancers (Basel). 2025; 17(2): 238. Review. IF: 4.8; Q2
- **Malón D, Molto C, Prasla S, Cuthbert D, Pathak N, Berner-Wygoda Y, Di Lorio M, Li M, Savill J, Mittal A, Amir E, Jhaveri K, Nadler MB.** Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor. Breast Cancer Res Tr. 2025; 210(2): 405-16. Article. IF: 3.3; Q2

Research projects

- **Antón Pascual B.** Evaluación del impacto de la práctica ejercicio físico en salud osteomuscular, emocional y tumoral en pacientes con tumores neuroendocrinos gastroenteropancreáticas u origen desconocido avanzados: FIT-NETs. NET España. 2023-2025. Managment centre: Hospital 12 de Octubre
- **Gaibar Alonso M.** Análisis de la expresión de microRNAs como posibles biomarcadores de toxicidad en inmunoterapia en cáncer genitourinario. Universidad Camilo José Cela. 2024-2025. Managment centre: Universidad Camilo Jose Cela
- **Fernández-Santander A.** Estudio de polimorfimos de tipo SNP y CNV como posibles marcadores de toxicidad en inmunoterapia aplicada a tumores genitourinarios. FIBHULP. 2024-2025. Managment centre: IdiPAZ
- **Fernández-Santander A.** NALUNG – Multi-Omics Analysis for Predicting Response and Adverse Events to Neoadjuvant Treatment in Resectable NSCLC (EPPERMED2025-267-NALUNG). FIBHULP. 2025-2028. Managment centre: FIBHULP
- **Antón Pascual B.** Evaluación del impacto de la práctica ejercicio físico en salud osteomuscular, emocional y tumoral en pacientes con tumores neuroendocrinos gastroenteropancreáticas u origen desconocido avanzados: FIT-NETs. NET España. 2023-2025. Managment centre: Hospital 12 de Octubre

IdiPAZ Instituto de Investigación Hospital Universitario La Paz



3.6. Surgery, Transplant and Health Technologies Area

Documents: 191 | Originals: 151 | D1: 21 | Q1: 82

Area coordinator: Nuria Vilaboa Díaz

RESEARCH GROUPS

3.6.1 Bone Pathophysiology and Biomaterials*
Nuria Vilaboa Díaz

3.6.2 Cellular Engineering
María Paz de Miguel González

3.6.3 Clinical Pharmacology*
Antonio J. Carcas Sansuán

3.6.4 Osteoarticular Surgery Research – GICOA
Enrique Gómez Barrena

3.6.5 Translational Research in Maxillofacial Surgery and Head and Neck Cancer
José Luis Cebrián Carretero/Ana Sastre Perona

3.6.6 Patients Safety and Quality Research
Elena Ramírez García

3.6.7 Translational Research and Innovation in General and Digestive Surgery
Constantino Fondevila Campo

3.6.8 Anesthesia-Resuscitation Maternity
Isabel Valbuena Gómez

3.6.9 Advanced Medical Informatics Laboratory (LIMA)
Paloma Oliver Sáez

3.6.10 AI Health
Juan José Beunza Nuin

**These groups have merged since 2026*

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Strategic Objectives	Development forecast for the coming years:	Actions
Surgery, Transplant and Health Technologies Area is composed of 10 very heterogeneous groups and the absence of common activities between them make the general objectives equivalent to the sum of the research lines of each of the groups. The main objective of the area is to locate points where synergies between groups can be established.	Cellular and organ engineering, underdeveloped.	Support researchers to continue being a reference in the national area.
	Stem and precursor cells. This is one of the most successful lines and the one that has motivated more collaborations between them. It is certainly one of the possibilities for the future	Identify and promote at international level the new research lines identifying as innovative and competitive.
	Animal models. Cellular models. They require personnel trained in cell culture techniques and who masters animal models of human disease	
	Minimally invasive surgery: one of the most important translational fields in recent years, a permanent demand from the population and an indicator of the quality of healthcare systems	

HIGH IMPACT PUBLICATIONS

Hessheimer AJ, Hartog H, Marcon F, Schlegel A, Adam R, Alwayn I, Angelico R, Antoine C, Berlakovich G, Bruggenwirth I, Calatayud D, Cardini B, Cillo U, Clavien PA, Czigany Z, De Carlis R, de Jonge J, De Meijer VE, Dondossola D, Domínguez-Gil B, Dutkowski P, Eden J, Eshmuminov D, Fundora Y, Gastaca M, Ghinolfi D, Justo I, Lesurtel M, Leuvenink H, Line PD, Lladó L, Lopez VL, Lurje G, Marin LM, Monbaliu D, Muller X, Nadalin S, Nasralla D, Oniscu G, Patrono D, Pirenne J, Selzner M, Toso C, Troisi R, Van Beekum C, Watson C, Weissenbacher A, Zieniewicz K, Schneeberger S, Polak WG, Porte RJ, **Fondevila C.** Deceased donor liver utilisation and assessment: Consensus guidelines from the European Liver and Intestine Transplant Association. J Hepatol. 2025; 82(6): 1089-109. Article. IF: 40,1; D1

Molina JDD, Tascón AD, Nieto CJG, de Gracia MM, Pinilla I, Vélez, SO, Cabrero TH, Gordo MLP, Lama PP, **Moll GG.** Endovascularly treatable causes of hemoptysis: guide for emergency radiologists. Radiographics. 2025; 45(10): e250008. Article. IF: 6,2; Q1

García-Carmona AM, Prieto ML, Puertas E, **Beunza JJ.** Leveraging Large Language Models for Accurate Retrieval of Patient Information From Medical Reports: Systematic Evaluation Study. Jmir Ai. 2025; 4(): -e68776. Article. IF: 6,1; Q1

Marco JDG, Acín PA, Gimeno EJ, Calle PF, Martín VL, **González-Casaus ML**. Biochemical evaluation of X-linked hypophosphatemia and tumor-induced osteomalacia: insights into diagnosis and management. Front Endocrinol (Lausanne). 2025; 16: 1702656. Article. IF: 5,7; Q1

de las Huertas AGL, Stewart S, Elizalde MU, Guijarro-Eguinoa J, Seco-Meseguer E, Diago-Sempere E, González MJ, Carcas-Sansuan AJ, Pérez AMB, **Ramírez E**. Disproportionality analysis of the five most widespread neurological effects of covid-19 vaccines from 2021 to 2023: Insights from Eudra Vigilance. Pharmaceuticals (Basel). 2025; 18(5): 636. Article. IF: 5,7; Q1

Scientific Events by Surgery, Transplant and Health Technologies

- **31/01/2025** - IV Curso de Soporte Vital avanzado
- **15/02/2025** – Around Pain 24
- **13/03/2025** - Curso Europeo de Soporte Vital Básico (EPBLS)
- **28/04/2025** - Curso de Marcado CE
- **05/05/2025** - Bioinformática en las técnicas ómicas
- **27/06/2025** - Seminario presencial y Online: Diseño de paneles de citometría de flujo: consejos, soporte y herramientas
- **12/08/2025** - Jornadas de recertificación en soporte vital avanzado pediátrico y neonatal
- **23/09/2025** - Curso de soporte vital básico
- **23/09/2025** - Curso europeo soporte vital avanzado
- **06/10/2025** - Curso de instructores de simulación clínica
- **17/10/2025** - V Curso de soporte vital avanzado
- **12/12/2025** - Jornada de dolor La Paz 2025
- **12/12/2025** - Generic instructor course

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.6.1 Bone Pathophysiology and Biomaterials

Publications: 4 | Q1: 3

COMPOSITION

Nuria Elda Vilaboa Díaz.
Investigadora Senior (Miguel Servet contract - I2) Jefe de Laboratorio. FIBHULP

- **Marcos de Mesa Cáceres.** *Ténico de Laboratorio. FIBHULP*
- **Eduardo García Cimbrelo.** *Médico Emérito de la Comunidad de Madrid. Hospital Universitario La Paz/ Profesor Asociado. Departamento de Cirugía. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Beatriz García Brihuega.** *Técnico de Laboratorio. FIBHULP*
- **Rebeca Garrido Punzano.** *Técnico de Laboratorio. FIBHULP*
- **Carmen Martin Hervás.** *Facultativo Especialista de Área en Radiodiagnóstico. Hospital Universitario La Paz/Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Alonso Carlos Moreno García.** *Facultativo Especialista de Área en Cirugía Orotopédica y Traumatología. Hospital Universitario La Paz*
- **Laura Saldaña Quero.** *Investigadora Senior (Contrato Miguel Servet-Tipo II). Jefe de Laboratorio. FIBHULP*
- **María Recuero Vicente.** *Investigadora Postdoctoral. CIBER*
- **Rodrigo Fernando Serrano Yamba.** *Investigador Predoctoral. FIBHULP*
- **Gema Vallés Pérez.** *Investigadora Senior. Responsables de Cultivos Celulares y de los Laboratorios Comunes de IdiPAZ. FIBHULP*

STRATEGIC OBJETIVES

- The Bone Physiopathology and Biomaterials group includes basic and clinical researchers from IdiPAZ. The group has broad experience in clinical and basic research on biomaterials for orthopaedic implants and bone tissue engineering. The main goal of the group is to improve the clinical outcome of orthopaedic surgery through research on implants and biomaterials used for manufacturing prosthetic devices.
- The group is interested in the study of mechanisms underlying joint diseases, in developing tissue engineering-based therapies as well as in evaluating biomaterials manufactured by collaborative partners. Specific areas of clinical research on implants include follow-up studies on various devices in use for osteoarticular surgery.
- The team is also involved in the manipulation of the heat shock response to generate transcriptional targeting strategies that provide tight control of the expression of therapeutic proteins. Their potential application in bone and wound healing therapies as well as in the generation of influenza vaccines with anti-herpetic activity are being explored. This strategic objective also includes the identification and characterization of the heat shock transcription factor 1 (HSF1) inhibitors as potential antitumoral agents.



RESEARCH LINES

- Clinical research in implants for bone repair
- Study of the pathophysiology of joint diseases and mechanisms involved in bone regeneration.
- Evaluation of new biomaterials, including scaffolds and nanoparticles, for their potential use in wound healing and bone tissue engineering application.
- Development of gene therapy switches to control the expression of transgenes to a) enhance bone regeneration and wound healing or b) generate influenza vaccines. Application of non-invasive near-infrared energy combined with photothermal nanoparticles.
- Identification and characterization of HSF1 inhibitors as antitumoral drugs.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz


1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH ACTIVITY



Doctoral Theses

- **Lerma Juárez MA.** Control espaciotemporal de la expresión transgénica mediante vectores adenovirales[dissertation]. Madrid: UAM: 2025(23/01/2025). Director: Vilaboa Díaz N

Publications

- **García-Rey E, Saldaña L.** Influence of highly cross-linked polyethylene manufacturing characteristics on femoral head penetration in total hip arthroplasty a ten to 22 year follow-up study. Bone Joint J. 2025; 107B(5): 62-9. Article. IF: 4.8; D1
- **Halstead J, Martín-Hervás C, Hensor EMA, Keenan AM, Conaghan PG, Mcgonagle D, Arnold JB, Jones J, Redmond AC.** Association between clinical and MRI-detected imaging findings for people with midfoot pain, a cross-sectional study. J Foot Ankle Res. 2025; 18(1): e70019. Article. IF: 2.3; Q2
- **Saldaña L, Vallés G, Vilaboa N, García-Rey E.** Microstructural and transcriptomic characterization of trabecular bone in idiopathic osteonecrosis of the femoral head. Sci Rep-Uk. 2025; 15(1): 11999. Article. IF: 4.9; Q1
- **Voellmy R, Bloom DC, Vilaboa N.** Regulated microbe vaccines: from concept to (pre-clinical) reduction to practice. Expert Rev Vaccines. 2025; 24(1): 146-56. Article. IF: 5.6; Q1

Research projects

- **Saldaña Quero L.** Osteonecrosis de cabeza femoral: identificación de alteraciones en el hueso trabecular, correlación clínica y factores de riesgo en la fijación de la prótesis total de cadera (PI22/00939). ISCIII. 2023-2027. Managment centre: FIBHULP
- **Vilaboa Díaz NE.** Potencial traslacional de inhibidores del factor de transcripción hsf1 como drogas anticancerígenas (PID2021-126325OB-100). MICINN. 2022-2026. Managment centre: FIBHULP
- **Vilaboa Díaz NE.** Nuevas soluciones terapéuticas para el tratamiento de la piel radiada (RADIOPROTECT-CM) (P2022/BMD-7406). CM. 2023-2026. Managment centre: FIBHULP

Ciber and Retics

- **Vilaboa Díaz NE.** Networked Biomedical Research Center for Bio-engineering, Biomaterials and Nanomedicine. (CIBER-bbn). Carlos III Health Institute. (31/12/2025). FIBHULP

Patents and trademarks

- **González Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich Rodríguez M, Olalde Graells B, Atorrasagasti Goyalde G, Argarate Madariaga N, Pacha Olivenza MA, Fernández Calderón MC, Saldaña Quero L, González Martín ML, Pérez Giraldo C, Gallardo Moreno AM, inventors; CSIC, Fundación Tecnalia Research & Innovation, FIBHULP, Universidad de Extremadura, Centro de Investigación Biomédica en Red (CIBER).** Moldable, biodegradable, biocompatible and bioresorbable implant material, method for its preparation and uses thereof. P201530683; 2015 May 18.
- **Martín Saavedra FM, Vilaboa Díaz NE, Cebrián Hernando V, Arruebo Gordo M, Santamaría Ramiro J, Gómez Navascués L, inventors; FIBHULP, CIBER-BBN, Universidad de Zaragoza, assignees.** Fibrin hydrogel with plasmonic nanoparticles; P201330894, PCT/ES2014/070484; 2013 June 14.
- **Vilaboa Díaz NE, Calzado Martín A, Crespo García L, Saldaña Quero L, Moreo Calvo P, Alastrué Vera V, inventors; FIBHULP, CIBER-BBN, assignees.** Chamber device for dynamic cell culture on biomaterials; P201330040, PCT/ES2013/070819; 2013 January 16.
- **Vilaboa Díaz NE, Gónzalez Carrasco JL, Multigner Domínguez M, Lieblich Rodríguez M, Muñoz Hernández M, Frutos Torres E, Saldaña Quero L, inventors; FIBHULP, CSIC, CIBER-BBN, Universidad Alfonso X El Sabio, assignees.** Magnesium/polymer composite biomaterial for biomedical applications; P201030950, PCT/ES2011/070440; 2010 June 21.
- **Vilaboa Díaz NE, González Carrasco JL, Saldaña Quero L, Frutos Torres E.** inventors; FIBHULP, CSIC, CIBER-BBN, assignees. Method to obtain a metallic-coated biomaterial; P201030949, PCT/ES2011/070400; 2010 June 21.
- **Voellmy R, Vilaboa Díaz NE, inventors; HSF Pharmaceuticals S.**A., assignee. Inhibitors of heat shock factor I and uses thereof. EP3512602B1; 2024 March 27.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.6.2 Cellular Engineering



Publications: 12 | Q1: 7

COMPOSITION

María Paz De Miguel González.
Investigadora Senior (Contrato Miguel Servet - I2) Jefe de Laboratorio. FIBHULP

- **Marta Cadenas Martín.** *Investigador Predoctoral. FIBHULP*
- **María Pilar González-Peramato Gutiérrez.** *Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz*
- **Małgorzata Anna Marć.** *Investigadora Postdoctoral. FIBHULP*
- **Ana Isabel Martín González.** *Investigadora Predoctoral. FIBHULP*
- **Manuel Nistal Martín de Serrano.** *Catedrático Departamento de Histología y Neurociencia. Facultativo de Medicina. Universidad Autónoma de Madrid*
- **Guillermo Sánchez Carrillo.** *Técnico de Laboratorio. FIBHULP*
- **Elsa Umiri Condo.** *Técnico de Laboratorio. FIBHULP*

STRATEGIC OBJETIVES

- Cell reprogramming is a process that involves generating pluripotent stem cells from more differentiated cells. Cell engineering aims to obtain induced pluripotent stem cells that can be isolated and reused autologousally in patients, with applications in regenerative medicine.
- In this context, the research activity of the Cell Engineering Group of IdiPAZ focuses on the comprehensive approach to cell reprogramming processes and their application in tissue regeneration strategies and transplants.
- Study of the mechanisms of cellular reprogramming:
- Cell reprogramming has been approached using various methods, including somatic cell nuclear transfer, fusion with pluripotent cells, incubation with pluripotent cell extracts, retroviral transduction using defined oncogenes, and the use of specific pluripotent cells, such as neural stem cells and primordial germ cells. This group focuses its research on deepening our understanding of the molecular processes that regulate pluripotency and cell differentiation.
- Application of stem cells in tissue regeneration and transplants:
- The group aims to identify and use stem cells to optimize tissue regeneration processes, employing stem cells derived from the stromal vascular fraction of human adipose tissue. Currently, the lack of specific markers to identify true stem cells necessitates the use of heterogeneous cell populations, which limits therapeutic efficacy and increases the risk of unwanted cell interference in the regenerative process.
- In this regard, the group has used the whole cell fraction for corneal stroma regeneration in experimental models. As expected, not all transplanted cells were able to differentiate correctly, causing interference in the regenerative process and moderate haze in the transplanted corneas.
- Identifying cell subpopulations with specific stem cell characteristics would allow us to overcome these limitations, improving the efficiency of transplants not only in the field of ophthalmology, but also in other applications related to regenerative medicine.

RESEARCH LINES

- Molecular Mechanisms of Cell Reprogramming in Normal and Neoplastic Environments
- New Techniques and Therapies in Transplantation

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH ACTIVITY

Master Theses

- **Pérez Calero B.** Estudios preclínicos de colágeno impreso en 3D en condiciones GMP en el tratamiento del melting corneal[dissertation]. Madrid: Universidad CEU San Pablo: 2025(07/07/2025). Director: de Miguel González MP.

Final Degree Theses

- **Domínguez Ruiz S.** Optimización de la bioimpresión 3D de colágeno tipo I bajo el cumplimiento de Buenas Prácticas de Fabricación para la regeneración de la córnea[dissertation]. Madrid: URJC: 2015(09/07/2025). Director: de Miguel González MP

Publications

- **Notario L, Guerrero-Espinosa E, Nistal M, Lauzurica P, Aranda A, Alemany S.** Thyroid hormone deficiency worsens outcomes in vaccinia virus infection. J Virol. 2025; 99(12): e0129425. Article. IF: 4.1; Q1
- **Marcos A, del Cerro MCR, Fernández RM, Pásaro E, Arias-Ramos N, López-Larrubia P, González-Peramato P, Guillamón A, De Miguel MP.** The GnRH agonist triptorelin causes reversible, focal, and partial testicular atrophy in rats, maintaining sperm production. Int J Mol Sci. 2025; 26(14): 6566. Article. IF: 5.6; Q1
- **de Miguel MP, Cadenas-Martín M, Stokking M, Martín-González AI.** Biomedical application of MSCs in corneal regeneration and repair. Int J Mol Sci. 2025; 26(2): 695. Review. IF: 5.6; Q1
- **Berney DM, Colecchia M, Comperat E, Cornejo KM, Gill AJ, Gupta S, Cheville JC, Idrees MT, Kao CS, Maclean F, Matoso A, Michalova K, Raspollini MR, Múgica MR, Tickoo SK, Tsuzuki T, Ulbright TM, Williamson SR, Siegmund S, Sholl LM, González-Peramato P, Acosta AM.** Observer variation in the diagnosis of testicular sex cord-stromal tumors by a genitourinary pathology society and international society of urological pathology panel: paving the way for a new classification. Modern Pathol. 2025; 38(9): 100804. Article. IF: 6.6; D1
- **Pinto-Marín A, Trilla-Fuertes L, Poma JM, Vasudev NS, García-Fernández E, López-Vacas R, Miranda N, Wilson M, López-Camacho E, Pertejo A, Dittmann A, Kunz L, Brown J, Pedroche-Just Y, Zapater-Moros A, de Velasco G, Castellano D, González-Peramato P, Espinosa E, Banks RE, Vara JAF, Gámez-Pozo A.** A prognostic microRNA-based signature for localized clear cell renal cell carcinoma: the Bio-miR study. Brit J Cancer. 2025; 133(2): 155-67. Article. IF: 7.8; Q1
- **Zhang H, del Barrio JLA, De Miguel MP, Alió JL.** Emerging strategies in corneal regeneration: The role of induced pluripotent stem cell-based therapies. Exp Eye Res. 2025; 260: 110631. Review. IF: 3.1; Q2
- **Anderson WJ, Kolin DL, Gonzalez IA, Vargas SO, González-Peramato P, Cornejo KM, Maclean F, Sangoi AR, Colecchia M, Hirsch MS, Ulbright TM, Acosta AM.** Loss of expression of STK11/LKB1 in intratubular large cell hyalinizing Sertoli cell neoplasm. Histopathology. 2025; 87(5): 768-72. Article. IF: 3.8; Q1
- **González-Peramato P, Álvarez-Maestro M, Heredia-Soto V, Sabio MM, Linares E, Serrano A, Álvarez-Ossorio JL, Prieto L, Alcina EL, Rodríguez MA, Berglund E, Alonso FV.** Comparing Prostatype P-score and traditional risk models for predicting prostate cancer outcomes in Spain. Actas Urol Esp. 2025; 49(6): 501788. Article. IF: 1.7; Q3
- **Acosta AM, Colecchia M, Comperat E, Cornejo KM, Gill AJ, Gupta S, Cheville JC, Idrees MT, Kao CS, Maclean F, Matoso A, Raspollini MR, Michalova K, Mugica MR, Tickoo SK, Tsuzuki T, Ulbright TM, Williamson SR, Siegmund S, Sholl LM, González-Peramato P, Berney DM.** Assessment and classification of sex cord-stromal tumours of the testis: recommendations from the testicular sex cord-stromal tumour (TESST) group, an Expert Panel of the Genitourinary Pathology Society (GUPS) and International Society of Urological Pathology (ISUP). Histopathology. 2025; 87(5): 660-76. Article. IF: 3.8; Q1
- **Acosta AM, Saad M, Chaux A, Gordetsky JB, Zheng L, Guo CR, Bikhet M, Osunkoya AO, Collins K, Idrees MT, Leenders GJLHV, González-Peramato P, Cornejo KM, Hirsch MS, Kao CS, Matoso A, Magi-Galluzzi C, Rais-Bahrami S.** Differential outcomes in bladder cancer after neoadjuvant chemotherapy: an international multi-institutional study comparing isolated nodal disease vs persistent muscle-invasive disease. Urology. 2025; 200: 127-34. Article. IF: 2.3; Q2
- **Stokking M, Cadenas-Martín M, Martín-Gonzálezi AI, Fernández-Ferreri A, Arnalich-Montiel F, de Miguel MP.** Three-dimensional-printed collagen scaffold with limbal stem cells derived from adipose-derived mesenchymal stem cells for the treatment of limbal stem cell deficiency. Int J Bioprint. 2025; 11(6): 407-29. Article. IF: 5.0; Q2
- **Edel MJ, Casellas HS, Osete JR, Nieto-Nicolau N, Arnalich-Montiel F, de Miguel MP, Mclenachan S, Roshandel D, Casaroli-Marano RP, Alvarez-Palomo B.** An Optimized method to produce human-induced pluripotent stem cell-derived limbal stem cells easily adaptable for clinical use. Stem Cells Dev. 2025; 34(3-4): 49-60. Article. IF: 1.9; Q3

Research projects

- **Marc MA.** Biomimetic Cornea fabrication by 3D printing and adult Mesenchymal Stem Cell directed differentiation (MIMECOR_MARC). UE. 2025-2027. Managment centre: FIBHULP
- **de Miguel González MP.** Contribución de la modificación metabólica a la reprogramación celular y la transformación oncogénica. Fundación Domingo Martínez. 2017-Ongoing. Managment centre: FIBHULP
- **de Miguel González MP.** Explorando las células madre pluripotentes inducidas como fuente para regenerar el estroma corneal (PI23/00207). ISCIII. 2024-2026. Managment centre: FIBHULP
- **de Miguel González MP.** Córnea artificial biomimética: síntesis mediante impresión 3D de arquitecturas poliméricas basadas en colágeno entrecruzado como soporte celular para regeneración corneal. Zeiss AG. 2024-2027. Managment centre: FIBHULP
- **Jorge Luis Alió del Barrio.** Células madre pluripotentes inducidas como fuente para regenerar el estroma corneal. Fundación Bienvenida Navarro Luciano Tripodi. 2024-2027. Managment centre: FIBHULP
- **Cadenas Martín M.** Células madre derivadas de tejido adiposo en el tratamiento de la insuficiencia endotelial corneal: diferenciación dirigida y cultivo de órgano. FIHULP. 2025-2026. Managment centre: FIBHULP
- **de Miguel González MP.** Contratos de Ayudante de Investigación financiados por el Fondo Social Europeo. Fondo Social Europeo. 2023-2025. Managment centre: FIBHULP

Patents and trademarks

- **de Miguel González MP, Arnalich Montiel F, Royuela MM, inventors; FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Universidad de Alcalá, assignees.** Corneal endothelium injector; P201131222, PCT/ES2012/070543; 2011 July 18.
- **De Miguel González MP.**, Arnalich-Montiel F, Cadenas Martín M, Moratilla Riofrío A.inventors; FIBHULP, FIBHRYC, assignees. Constructos artificiales para su uso en oftalmología, su procedimiento de obtención y utilización del mismo. Patente Europea EP22382119.0 2022 February 14 . PCT/EP2023/053668 2023 February 14.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.6.3 Clinical Pharmacology

Publications: 7 | Q1: 4

COMPOSITION

Alberto Borobia Pérez.
Subdirector Científico de IdiPAZ. Facultativo Especialista de Área en Farmacología Clínica. Hospital Universitario La Paz

- **Antonio Javier Carcas Sansuán.** *Jefe de Servicio. Hospital Universitario La Paz/Profesor Titular. Facultad de Medicina . Universidad Autónoma de Madrid*
- **Pilar Ayllón García.** *Técnico de laboratorio. Universidad Autónoma de Madrid*
- **Raquel de Madariaga Castell.** *Enfermera. Coordinadora de Ensayos Clínicos. FIBHULP*
- **Lucía Díaz García.** *Facultativo Especialista en Farmacología Clínica. Hospital Universitario La Paz*
- **Blanca Duque Bascuñana.** *Responsable de calidad. Universidad Autónoma de Madrid*
- **Jesús Frías Iniesta.** *Catedrático Emérito. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Alberto García Bartolomé.** *Investigador Postdoctoral. Hospital Universitario La Paz*
- **Irene García García.** *Facultativo Especialista en Farmacología Clínica. Hospital Universitario La Paz*
- **Andrea Guzmán de Antonio.** *Investigadora Predoctoral. FIBHULP*
- **Cristina López Crespo.** *Enfermera. Coordinadora de Ensayos Clínicos. FIBHULP*
- **Alicia Marín Candón.** *Medico Especialista en Farmacología Clínica. FIBHULP*
- **Vega Mauleón Martínez.** *Enfermera. Coordinadora de Ensayos Clínicos. FIBHULP*
- **Paloma Moraga Alapont.** *Gestora de proyectos SCReN (Spanish Clinical Research Network). FIBHULP*
- **María Cristina Murano Murano.** *Investigador Postdoctoral. FIBHULP*
- **Rocío Prieto Pérez.** *Gestora de proyectos SCReN (Spanish Clinical Research Network). FIBHULP*
- **Laura Vitón Vara.** *Enfermera. Coordinadora de Ensayos Clínicos. FIBHULP*



STRATEGIC OBJETIVES

- Clinical Pharmacology, as a scientific and professional discipline, aims to achieve the effective and efficient use of medications, both individually and collectively. This means that Clinical Pharmacology is a cross-disciplinary field that must establish collaborations with numerous other disciplines and healthcare professionals.
- In this sense, and in the field of clinical research, the interests of our research group are focused on two fundamental aspects:
  1. Personalization of drug treatments: research and development of techniques and methods that allow for individualized drug use, improving efficacy and reducing risks
  2. Improving therapeutics by obtaining high-quality evidence on the efficacy of clinical trials, strategies for identifying, evaluating and preventing adverse drug reactions (pharmacovigilance programs), and evaluating the suitability of use and effectiveness (drug utilization studies).

RESEARCH LINES

- Development of clinical research and clinical trials to obtain evidence on the efficacy, safety and correct use of medicines for human use through Phase I to IV clinical trials.
- Personalization and precision pharmacotherapy: research and development of techniques and methods that allow for individualized drug use, improving efficacy and reducing risks. This includes techniques such as Therapeutic Drug Monitoring (TDM), pharmacogenetics, and other precision pharmacotherapy techniques.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH ACTIVITY

Doctoral Theses

- **Valle Simón P.** Evaluación de la factibilidad y beneficio de la implementación de un Comité de Medicina Personalizada en un Servicio de Hemato-Oncología Pediátrica en un hospital público de tercer nivel[dissertation]. Madrid: UAM: 2025(14/02/2025). Director: Borobia Pérez AM, Pérez Martínez A.
- **Moraga Alapont P.** Barreras y potenciales herramientas para facilitar el reclutamiento de sujetos en ensayos clínicos de fases tempranas[dissertation] Madrid: UAM: 2025(19/09/2025). Director: Borobia Pérez AM.

Master Theses

- **Bruno M.** Implementation of improvement strategies in a personalized medicine committee in pediatric oncology[dissertation] Madrid: UAM: 2025(09/07/2025). Director: Borobia Pérez AM.
- **Mora Rodríguez M.** Pharmacogenetics in statin therapy: Interim descriptive analysis from the PREVESTATGx trial[dissertation]. Madrid: UAM: 2025(30/09/2025). Director: Borobia Pérez AM
- **McConnachie E.** Un estudio exploratorio de las necesidades y expectativas de las partes interesadas con respecto a la participación de los legos en la investigación biomédica[dissertation]. Madrid: UAM: 2025(09/07/Julio 2025). Director: Borobia Pérez AM.
- **Guadrón Meléndez A.** Exploring potential metabolomic biomarkers in pediatric renal transplant patients treated with tacrolimus[dissertation]. Madrid: UAM: 2025(09/07/2025). Director: Carcas Sansuán AJ.

Publications

- **Corominas J, Garriga C, Prenafeta A, Moros A, Cañete M, Barreiro A, González-González L, Madrenas L, Güell I, Clotet B, Izquierdo-Useros N, Raïch-Regué D, Gallemí M, Blanco J, Pradenas E, Trinité B, Prado JG, Pérez-Caballero R, Bernad L, Plana M, Esteban I, Aurrecoechea E, Abu Taleb R, Mcskimming P, Soriano A, Nava J, Anagua JO, Ramos R, Lluch RM, Comes AC, Romero SO, Martínez-Gómez X, Camacho-Arteaga L, Molto J, Benet S, Bailón L, Arribas JR, Borobia AM, Parada JQ, Navarro-Pérez J, Giner MJF, Lucas RO, Jiménez MDV, Fernández MJL, Álvarez-Mon M, Troncoso D, Arana-Arri E, Meijide S, Imaz-Ayo N, García PM, de la Villa S, Fernandez SR, Prat T, TorroellaÉ, Ferrer L.** Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial. Vaccine. 2025; 47: 126685. Article. IF: 3.4; Q2
- **de las Huertas AGL, Stewart S, Elizalde MU, Guijarro-Eguinoa J, Seco-Meseguer E, Diago-Sempere E, González MJ, Carcas-Sansuan AJ, Pérez AMB, Ramírez E.** Disproportionality analysis of the five most widespread neurological effects of covid-19 vaccines from 2021 to 2023: insights from eudra vigilance. Pharmaceuticals (Basel). 2025; 18(5): 636. Article. IF: 5.7; Q1
- **Galán-Caballero L, Salas-Butrón MR, Lozano-Martin D, Díaz-Rengifo IA, Ortega-Madueno I, Díaz-Garcia L, Terleira-Fernandez AI.** Unexpected falsely high vancomycin concentrations in a patient with endocarditis during routine therapeutic drug monitoring. Eur J Case Rep Intern Med. 2025; 12(7): 5464. Article. Not Indexed
- **Hernández-Balnco C, Al-Akioui-Sanz K, Herrera L, Aguirre-Portolés C, Lozano-Ojalvo D, Pérez-Rodriguez L, Cano-Ochando J, Guerra-García P, Martín-Quirós A, Vicario JL, Santos S, Pérez-Vaquero MA, Vesga MA, Borobia AM, Carcas AJ, Balas A, Moreno MA, de Diego RP, Gasior M, Soria B, Eguizabal C, Pérez-Martínez A.** The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19. Iscience. 2025; 28(2): 111698. Article. IF: 4.5; Q1
- **Murano MC.** La ausencia de la infancia en la ética de la investigación pediátrica. Bajo Palabra. 2025: 39. Article. IF: 0.3; Q3
- **Rosas-Alonso R, Salas NR, Wert PP, Hoyo A, Martín-López S, Martínez-Pérez D, Ruiz-Gutiérrez I, Jiménez-Bou D, Peña J, Arias P, Custodio A, Losantos-Garcia I, Borobia AM, Feliu J, Ghanem I.** DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger. Front Pharmacol. 2025; 16: 1645188. Article. IF: 5.4; Q1
- **Salas-Butrón MR, Laredo-Velasco L, Rivas-Paterna AB, González-Corchon A, Muñoz-Guerra MF, Borobia AM, Acero-Sanz JJ, Pérez-Ingidua C, Abad-Santos F, Cebrián JL, Gálvez-Múgica MA, Serrano-García I, Portolés-Díez C, Llanos L, Martínez D, Sanz N, Calandria C, Vargas-Castrillón E, Martín-Granizo R, Portolés-Pérez A.** Analgesic effect of a novel intravenous ibuprofen-low-dose tramadol combination: a multimodal approach to moderate-to-severe postoperative dental pain. Pharmaceutics. 2025; 17(10): 1248. Article. IF: 6.9; Q1

Research projects

- **Borobia Pérez AM.** Corona Accelerated R&D in Europe (CARE_ALBERTO BOROBIA). UE. 2020-2025. Managment centre: FIBHULP
- **Borobia Pérez AM.** European Tuberculosis Regimen Accelerator (ERA4TB_ALBERTO BOROBIA). UE. 2020-2026. Managment centre: FIBHULP
- **Borobia Pérez AM.** Evaluación de la efectividad y la eficiencia de una estrategia de genotipado anticipado de antidepresivos en pacientes con depresión mayor unipolar refractaria: ensayo clínico adaptativo Predict (PI24/01373). ISCIII. 2025-2028. Managment centre: FIBHULP
- **Borobia Pérez AM.** Fostering a European Research Area for Health Research (ERA4HEALTH_ALBERTO BOROBIA). UE. 2023-2029. Managment centre: FIBHULP
- **Borobia Pérez AM.** LIVERATION_Unravelling the impact of radiofrequency in liver surgery: the key to decrease the local recurrence? (2023417). UE. 2023-2028. Managment centre: FIBHULP
- **Borobia Pérez AM.** Optimización del tratamiento de la dermatitis atópica con ciclosporina mediante el desarrollo de modelos multiómicos de predicción de respuesta (Proyecto DermAtOmics) (PI21/01219). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Borobia Pérez AM.** Proyecto iPHARMGx: estudio colaborativo nacional para evaluar la efectividad y eficiencia de la implementación de biomarcadores farmacogenéticos mediante una estrategia de genotipado anticipado en el SNS (PMP22/00055). ISCIII. 2023-2026. Managment centre: FIBHULP
- **Borobia Pérez AM.** Research in Europe and Diversity Inclusion (REaDI_BOROBIA). UE. 2025-2030. Managment centre: FIBHULP
- **Borobia Pérez AM.** Unidad de Investigación Clínica del Hospital Universitario La Paz – IdiPAZ (UICM24/00029). ISCIII. 2025-2026. Managment centre: FIBHULP
- **Carcas Sansuán AJ.** Dosificación individualizada de Tacrolimus en trasplante renal pediátrico: desarrollo de modelos predictivos, simulaciones y aplicaciones basados en PBPK (ModSimTer-Tacro) (PI21/01507). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Carcas Sansuán AJ.** Eficacia a cuatro años de las vacunas COVID-19 frente a enfermedad graves e infecciones asintomáticas: estudio COVIDVAC@ ESPAÑA (ICI21/00065). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Carcas Sansuán AJ.** Four-year effectiveness of COVID-19 vaccines against severe disease and asymptomatic infection: the covidvac@spain study (PI-4877 COVIDVAC@SPAIN). FIBHULP. 2021-ongoing. Managment centre: FIBHULP
- **Frías Iniesta J.** European Corona Vaccine Trial Accelerator Platform (VACCELERATE_JESÚS FRÍAS). UE. 2021-2025. Managment centre: FIBHULP
- **Frías Iniesta J.** Población en riesgo de hipertemia maligna: Cohorte Ambispectiva (PI20/01444). ISCIII. 2021-2025. Managment centre: FIBHULP
- **Marín Candón A.** Multicentre, randomised, double-blind, parallel-group, phase iii study to evaluate the genetic polymorphisms influence in the response to ranibizumab and bevacizumab treatment in patients with age-associated macular degeneration (2025069). IMIM. 2025-ongoing. Managment centre: FIBHULP

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Ciber and Retics

- **Borobia Pérez A.** Coordinación Plataforma de Apoyo a la Investigación Clínica. (SCReN). ISCIII. (31/12/2026). FIBHULP
- **Borobia Pérez A.** Plataforma de Apoyo a la Investigación Clínica. (SCReN). ISCIII. (31/12/2026). FIBHULP
- **Borobia Pérez A.** European Clinical Research Infrastructure Network. (ECRIN). ISCIII. (31/12/2026) FIBHULP

Clinical trials

- **Borobia Pérez A.** Estudio de fase 3, aleatorizado, con observador ciego, controlado con placebo para evaluar la eficacia, la seguridad y la inmunogenicidad de la vacuna mrna-1647 para el citomegalovirus (cmv) en participantes sanos de 16 a 40 años de edad.
  Type/Phase: III
  Sponsored by: Modernatx, Inc.
  Signature date: 23/09/2025
- **Borobia Pérez A.** Estudio fase I, primera vez en humanos, observador-ciego, aleatorizado y controlado para evaluar la seguridad, reactogenicidad y respuesta inmune de varias dosis de una vacuna en investigación basada en arnm frente al virus respiratorio sincitial (vrs) en participantes sanos de 18 a 45 años de edad.
  Type/Phase: I
  Sponsored by: Glaxosmithkline Biologicals S.A.
  Signature date: 08/07/2025
- **Borobia Pérez A.** Estudio fase IIIB, aleatorizado, abierto, multinacional, multicéntrico, de extensión y vacunación cruzada para evaluar la inmunogenicidad y seguridad de diferentes pautas de revacunación, así como la persistencia de una dosis única de la vacuna rsvpref3 oa en adultos de 60 años o más de edad que participaron en el estudio rsv oa=adj-006.
  Type/Phase: IIIb
  Sponsored by: Glaxosmithkline Biologicals S.A.
  Signature date: 30/05/2025
- **Borobia Pérez A.** Low intervention, open, multicentric, phase iv exploratory clinical trial to evaluate new biomarkers for the diagnosis and treatment monitoring of tuberculosis.
  Type/Phase: IV
  Sponsored by: Fundacion Para La Investigacion Biomedica Hospital Universitario La Paz.
  Signature date: 16/10/2025
- **Marín Candón A.** Randomized, observer-blind, active-controlled, phase 3 study in adults ≥ 60 years of age to assess the safety and immunogenicity of abbott's candidate high-dose influenza vaccine short title: a phase 3 study to assess the safety and immunogenicity of high-dose influenza vaccine in adults ≥ 60 years of age.
  Type/Phase: III
  Sponsored by: Abbott Biologicals B.V..
  Signature date: 07/07/2025
- **Marín Candón A.** Multicentre, randomised, double-blind, parallel-group, phase iii study to evaluate the genetic polymorphisms influence in the response to ranibizumab and bevacizumab treatment in patients with age-associated macular degeneration.
  Type/Phase: III
  Sponsored by: Imim Institut De Recerca Hospital Del Mar Parc De Salut Mar.
  Signature date: 12/09/2025

Patents and trademarks

- **Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee.** Brand name: IBJ IberoAmerican Journals. ESM 3.063.048; 2013 February 12.
- **Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Plus.** ESM 3.063.052; 2013 February 12.
- **Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Clinical Pharmacology.** ESM 3.063.053; 2013 February 12.
- **Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Medicine.** ESM 3.063.049; 2013 February 12.
- **Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees.** Brand name: PharmArray. USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.
- **Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP, assignee.** Brand name: CRDataX. CM 13.681.614; 2015 May 28.
- **Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees.** Brand name: ClinPharmarray., CM15489511; 2016 May 31, 2016 September 07.
- **Borobia Pérez AM, Diago Sempere EI, Dueñas López FC, García García I, Rosas Alonso R, Arias Lajara P, authors; FIBHULP, assignees.** Brand name: Psico Predict. 019178454; 2025 Sept 03.
- **"Borobia Pérez AM, Diago Sempere EI, Dueñas López FC, García García I, Rosas Alonso R, Arias Lajara P, authors; FIBHULP, assignees.** Brand name: Predict Dose.019178452; 2025 Sept 03."



1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.6.4 Osteoarticular Surgery Research – GICOA

Publications: 24 | Q1: 5

COMPOSITION

Enrique Gómez Barrena.
Jefe de Sección de Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz/Catedrático de Cirugía Ortopédica y Traumatología. Facultad de Medicina. Universidad Autónoma de Madrid

- **Samuel Antuña Antuña.** *Jefe de Sección en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz/ Profesor Asociado en Cirugía Ortopédica y Traumatología. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Raúl Barco Laakso.** *Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz*
- **Ana Cruz Pardos.** *Jefe de Sección en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz*
- **Ana de Andrés Torán.** *Médico Interno Residente en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz*
- **Marta Domínguez García-Simón.** *Enfermera Coordinadora de Ensayos Clínicos. Universidad Autónoma de Madrid*
- **Eduardo García Rey.** *Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz/Profesor Asociado en Cirugía Ortopédica y Traumatología. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Pablo Hernández Esteban.** *Facultativo Especialista de Área en Cirugía Ortopédica y Traumatologí. Hospital Universitario La Paz*
- **Luis Rodrigo Merino Rueda.** *Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz*
- **Norma Griset Padilla Eguiluz.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Carlos Emérito Rodríguez Merchán.** *Jefe de Sección de Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz*
- **Juan Carlos Rubio Suárez.** *Jefe de Sección en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Orthopaedic implant studies are required to assess the results of implants, detect the causes of failure, and deepen our understanding of the prevention and solution of these failures. The medical, social, and economic relevance of orthopaedic implants, and their influence on quality of life, place this technology in the centre of translational research in orthopaedic surgery. Reconstruction based on biological strategies and biomaterials is rapidly evolving, and cutting edge research on these topics may offer an advantage in clinical translational research. The group has also developed studies on sports medicine and ligament reconstruction, with various outcome approaches and devices that may enhance surgical results. In this context, a multidisciplinary clinical and basic research group on orthopaedic surgery deepens our understanding of a wide variety of current research topics in the field and provides further progress towards clinical translation.
- In order to contribute to new advances in the field, our main clinical and experimental objectives are addressed by a joint research line that covers issues related to bone and joint reconstruction. These issues include the following:
  - Failed hip and knee prostheses, including the material, biological, and clinical mechanisms of failure. This research may lead to proposals for materials and design modifications in orthopaedic implants and reconstructive devices and techniques. Functional recovery of the patient is the ultimate goal, considering various scenarios from an experimental and clinical point of view.
  - Regenerative medicine approaches to bone and joint reconstruction, to generate preclinical and clinical proposals for bone and joint regeneration and repair, both in traumatic and non-traumatic bone and soft-tissue injuries..



RESEARCH LINES

- Clinical and basic research in Orthopaedics implants, and in bone and joint reconstruction

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH ACTIVITY

Doctoral Theses

- **Díez Sánchez, Blanca.** Artroplastia de cabeza radial en fracturas con inestabilidad compleja aguda del codo. Estudio comparativo entre un diseño anatómico y un espaciador[dissertation]. Madrid: UCM: 2025(17/02/2025). Director: Barco Laakso R, Antuña Antuña S.

Publications

- **Rodríguez-Merchán EC.** Robotic-assisted total knee arthroplasty versus conventional total knee arthroplasty. Arch Bone Jt Surg. 2025; 13(11): 670-2. Editorial Material. IF: 1.6; Q3
- **Rodríguez-Merchán EC.** Total ankle replacement in hemophilia. Arch Bone Jt Surg. 2025; 13(10): 663-7. Article. IF: 1.6; Q3
- **Rodríguez-Merchán EC, Delgado-Martínez AD.** Tissue engineering technologies in the management of bone infections. Arch Bone Jt Surg. 2025; 13(9): 595-9. Article. IF: 1.6; Q3
- **Rodríguez-Merchán EC.** Cemented versus cementless total knee arthroplasty: analysis of the latest literature data. Arch Bone Jt Surg. 2025; 13(5): 299-303. Article. IF: 1.6; Q3
- **Rodríguez-Merchán EC.** The role of periarticular injections for postoperative pain after total knee arthroplasty. Arch Bone Jt Surg. 2025; 13(4): 229-32. Article. IF: 1.6; Q3
- **Rodríguez-Merchán EC, de la Corte-Rodríguez H, Antuña S, Gomez-Cardero P, Álvarez-Rom´sn MT, Jimenez-Yuste V.** Shoulder arthroplasty in hemophilia. Arch Bone Jt Surg. 2025; 13(3): 164-9. Article. IF: 1.6; Q3
- **Rodríguez-Merchán EC.** Repeat revision anterior cruciate ligament reconstruction remains a challenge for orthopedic surgeons. Arch Bone Jt Surg. 2025; 13(2): 114-8. Article. IF: 1.6; Q3
- **Rodríguez-Merchán EC, de la Corte-Rodríguez H.** The role of intraarticular injections of hyaluronic acid and platelet rich plasma for the treatment of articular pain in knee osteoarthritis. Arch Bone Jt Surg. 2025; 13(1): 54-61. Article. IF: 1.6; Q3
- **de la Corte-Rodríguez H, Pasta G, Daffunchio C, Rodríguez-Merchán EC.** Women with bleeding disorders: some concerns regarding osteoporosis. Haemophilia. 2025; 31(5): 1132-5. Letter. IF: 3.0; Q2
- **Rodríguez-Merchán EC, Yohannan B, Escobar MA.** Acute compartment syndrome in congenital and acquired haemophilia. Haemophilia. 2025; 31(3): 373-90. Review. IF: 3.0; Q2
- **de Andrés-Torán A, Padilla-Eguiluz NG, Hernández-Esteban P, Gómez-Barrena E.** Guided personalized surgery (gps) in posterostabilized total knee replacement: a radiological study. J Clin Med. 2025; 14(2): 429. Article. IF: 3.3; Q1
- **García-Rey E, Saldaña L.** Influence of highly cross-linked polyethylene manufacturing characteristics on femoral head penetration in total hip arthroplasty a ten-to 22-year follow-up study. Bone Joint J. 2025; 107B(5): 62-9. Article. IF: 4.8; D1
- **Saldaña L, Vallés G, Vilaboa N, García-Rey E.** Microstructural and transcriptomic characterization of trabecular bone in idiopathic osteonecrosis of the femoral head. Sci Rep-Uk. 2025; 15(1): 11999. Article. IF: 4.9; Q1
- **Rodríguez-Merchán EC, de Andrés-Ares J, Delgado-Martínez AD, Ribbans WJ.** Nanotechnology for pain management in orthopedic surgery. World J Orthop. 2025; 16(10): 110009. Review. IF: 2.3; Q2
- **Rodríguez-Merchán EC.** Cartilage degeneration in hemophilic arthropathy: to focus on prevention or regeneration? Expert Rev Hematol. 2025; 18(11): 893-7. Article. IF: 2.8; Q2
- **Cruz-Pardos A, García-Rey E.** Impaction bone grafting combined with lateral trabecular augments in acetabular revision surgery: a case-control study. Hip Int. 2025; 35(5): 502-9. Article. IF: 1.3; Q3
- **Rodríguez-Merchán EC, Delgado-Martínez AD.** Nonunion of intertrochanteric fractures. Minerva Orthop. 2025; 76(3): 224-33. Review. IF: 0.4; Q4
- **Rodríguez-Merchán EC.** In the prophylaxis era people with hemophilia still need major orthopedic surgery. Expert Rev Hematol. 2025; 18(7): 501-7. Article. IF: 2.8; Q2
- **Rodríguez-Merchán EC, Ribbans WJ, Olmo-Jiménez J, Delgado-Martínez AD.** Arthroscopic ankle arthrodesis for end-stage ankle osteoarthritis. EFORT Open Rev. 2025; 10(5): 213-23. Article. IF: 4.6; Q1
- **Rodríguez-Merchán EC, Ribbans WJ.** Retrieval analysis in total knee arthroplasty. World J Orthop. 2025; 16(3): 102160. Review. IF: 2.3; Q2
- **García-Galán EC, Rezusta FJM, Sarnago H, Burdio JM, Lucía O, Esteban J, Gomez-Barrena E.** Electromagnetic induction disinfection applied to cemented knee arthroplasty implants: safety evaluation of potential changes in the bone cement. J Mater Sci-Mater M. 2025; 36(1): 25. Article. IF: 4.7; Q2
- **Rodríguez-Merchán EC.** Some artificial intelligence tools may currently be useful in orthopedic surgery and traumatology. World J Orthop. 2025; 16(2): 102252. Letter. IF: 2.3; Q2
- **Rodríguez-Merchán EC, de la Corte-Rodríguez H.** Sports practice should be supported in people with severe hemophilia, but patient counseling and tailoring prophylactic treatment with clotting factors and non-replacement therapy is essential. Expert Rev Hematol. 2025; 18(2): 123-34. Review. IF: 2.8; Q2
- **Barrufet C, Zamora V, Lizano-Barrantes C, Torrens C, Burón A, Calvo E, Peidró L, Miquel J, Barco R, Ferrer M.** Relevant treatment outcomes for individuals aged 60 and older with massive rotator cuff tears: a qualitative study with 16 patients. Acta Orthop. 2025; 96: 322-30. Article. IF: 3.4; Q1

Research projects

- **Gomez Barrena E.** Desinfección in vivo de implantes ortopédicos metálicos mediante calor generado por inducción electromagnética. Fundación Mutua Madrileña. 2020-2026. Managment centre: FIBHULP
- **Gomez Barrena E.** ORTHO-ALLO-UNION_ ORTHOpaedic treatment with ALLOgenic combined ATMP in long bone fracture delayed UNION and nonunion. UE. 2023-2028. Managment centre: FIBHULP
- **Garcia Rey E.** Osteonecrosis de cabeza femoral: identificación de alteraciones en el hueso trabecular, correlación clínica y factores de riesgo en la fijación de la prótesis total de cadera. ISCIII. 2023-2027. Managment centre: FIBHULP
- **Antuña Antuña S.** Rigidez articular postraumática en un modelo en la rata: eficacia del celecoxib y el ketotifeno en su prevención. Fundación Sociedad Española de Cirugía Ortopédica y Traumatologia. 2024-Ongoing. Managment centre: FIBHULP
- **Barco Laakso R.** Contractura articular traumática y neurogénica en un modelo experimental en la rata: papel preventivo de celecoxib y ketotifeno. European Society for Surgery of the Shoulder and the Elbow. 2023-Ongoing. Managment centre: FIBHULP

Clinical trials

- **Gomez Barrena E.** A multi-centre, single-arm trial to demonstrate the efficacy of bone marrow allogeneic mesenchymal cells combined with biomaterial (combined atmp) for bone healing in delayed union and non-union after long bone fractures.
  Type/Phase: III
  Sponsored by: Fundación Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda.
  Signature date: 19/11/2025

Patents and trademarks

- **Arenas Vara MA, Conde del Campo A, De Damborenea González JJ, Matykina E, Esteban Moreno J, Gómez Barrena E, Pérez-Jorge Peremarch C, Pérez Tanoira R, inventors; CSIC, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, assignees.** Titanium materials anodised with fluorine. P201030720, PCT/ES2011/070342; 2010 May 14
- **Gomez Barrena E, Cordero García-Galán E, Rico Nieto A, Pozo JJ, Esteban Moreno J, Sarnago H, Lucía Gil O, Acero Acero J, Burdío JM.** Portable desinfection system based on induction heating; September 2022.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.6.5 Translational Research in Maxillofacial Surgery and Head and Neck Cancer

Publications: 10 | Q1: 2

COMPOSITION

José Luis Cebrián Carretero.
Jefe de Servicio de Cirugía Oral y Maxilofacial. Hospital Universitario La Paz
Ana Sastre Perona.
Investigadora senior. FIBHULP

- **Lucía Acero Riaguas.** *Investigadora Predoctoral. FIBHULP*
- **Estefanía Alonso Rodríguez.** *Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz*
- **Íñigo Aragón Niño.** *Médico Interno Residente de Cirugía Oral y Maxilofacial. Hospital Universitario La Paz*
- **Elena Milagros Gómez García.** *Facultativo especialista de Área en Cirugía Maxilofacial. Hospital Universitario La Paz*
- **Javier González Martín-Moro.** *Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz*
- **Ana Belén Griso Acevedo.** *Investigadora Predoctoral. FIBHULP*
- **José Luis del Castillo Pardo de Vera.** *Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz*
- **Pedro Manuel Losa Muñoz.** *Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz*
- **Marta Mascarque Checa.** *Investigadora Postdoctoral. Contrato Sara Borrel. FIBHULP*
- **María José Morán Soto.** *Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz*
- **Marta María Pampín Martínez.** *Facultativo Especialista de Área en Cirgía Oral y Maxilofacila. Hospital Universitario La Paz*
- **César Pérez-Pérez Brotons.** *Bioinformático. FIBHULP*
- **Elena Ruiz Bravo-Bruguillos.** *Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz*
- **Alejandro San Lorenzo Vaquero.** *Investigadora Predoctoral. FIBHULP*
- **Rocío Sánchez Siles.** *Investigadora Predoctoral. FIBHULP*
- **Blanca Tapia Salinas.** *Facultativo especialista de Área de Anestesiología y Reanimación. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- To improve the diagnosis and surgical treatment of patients with Oral Cancer using the latest technologies applied to the field of Head and Neck Oncology planning and treatment. Our goal is to establish a workflow in which technological and technical advances are included as part of the treatment protocol for patients with oral cavity cancer.
- The identification of biomarkers of cancer progression and therapy response in head and neck cancers (HNC). HNC are low frequent tumors with poor outcome and limited treatment options. This is due to a poor understanding on the initial steps in tumor initiation and progression, and the implication of the tumor microenvironment in these processes. Using mouse models and novel patient derived organoid models, we are defining the mechanism driving the most aggressive HNC and developing this knowledge into translational tools to guide patient management. In addition, we are applying novel functional genomics to identify genes involved in driving resistance to chemo and targeted therapies, to uncover biomarkers of treatment response and new therapeutic targets. Overall, our goal is to improve patient survival and to increase patient life quality.

RESEARCH LINES

1. Epigenetic characterization of oral tumors and their association with resistance to chemotherapies and immunotherapies, identification of new biomarkers that predict response: Oral squamous cell carcinomas are an aggressive type of HNC with 370.000 cases per year and 50% 5-year survival rate. This is due to the lack of understanding of the biology of the disease and, in consequence, sufficiently efficient therapies. In this line, we are carrying out an epigenetic characterization of these tumors, analyzing characteristics such as their transcriptome and enhancer landscape using novel massive sequencing techniques on patient samples. Through bioinformatics analysis and monitoring the evolution of patients, we uncovered a population of cancer cells that associates with the most aggressive cancers and predicts patients with worse outcomes. Currently we are evaluating the translational impact of these findings. This research line is funded by CP19/00063, PI20/00329 and PI23/00192 (ISCIII) and a Luis Álvarez PI5102 grant (FIBHULP).
2. Search for vulnerabilities in oral carcinoma cells using functional genomics. To define the vulnerabilities of tumor cells, our group has established CRISPR/Cas9 screens to evaluate the function of genes involved in the response to different therapies such as chemotherapies or immunotherapies. These screens, which target all protein-coding genes, are allowing us to identify in an unbiased way mechanisms of action that will allow us to understand how cells survive chemotherapy or how they are able to escape the action of the immune system. In this way, we will be able to reuse drugs already approved for these targets or design new ones that will allow us to improve the quality of life of patients with oral tumors. This research line is funded by CP19/00063 and PI20/00329 (ISCIII).
3. The implication of the tumor microenvironment in the acquisition of metastatic capacity of oral tumors. In this research line we are analyzing the connection between tumor microenvironment and the induction cancer progression programs. To this end, we are using novel co-cultures of paired organoids and TME cells from patients and measuring the influence at the level of chromatin remodeling and gene expression. This research is financed by an international competitive grant funded by the Worldwide cancer research and Scientific Foundation of the "Asociación Española Contra el Cáncer" (WWRC-23-0272), and FIBHULP Luis Álvarez grant.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

4. Salivary glands malignancies. Salivary gland tumors are rare tumors that account for 5% of head and neck tumors. Their histological diversity and the lack of knowledge of the molecular basis of the disease make their treatment complex. Using NGS techniques we are characterizing the mutations, methylation profiles and tumor heterogeneity of these tumors to identify biomarkers of progression, mutations with targeted therapies and possible targets within the tumor microenvironment. Funding PI22/01512, (ISCIII) and Gilead (GLD22/00166).
5. Study of mechanism of initiation and progression of cutaneous squamous cell carcinoma (cSCC): In this research line, we are exploring the function of several tumor suppressor genes and how their loss of expression affects the composition on the tumor microenvironment and the response to therapy. This project is done in collaboration with L. Sastre, at IIBM Alberto Sols.
6. Application of 3D Medicine in the planning and treatment of head and neck cancer. Virtual design and segmentation of facial structures for generation of biomodels, cutting guides and custom implants. Surgery and personalized medicine. Mutua Madrileña 2022 grant funding.
7. Use of radiotracers and fluorescence with indocyanine green for sentinel node detection in squamous tumors and melanoma of the head and neck.
8. Discovery of new anti-fibrotic treatments for Idiopatic pulmonary fibrosis (IPF) and fibrotic cancers such as oral squamous cell carcinomas. PMP22/00083 and LABAE259399SASTgrants.

RESEARCH ACTIVITY

Publications

- **Andura-Correas M, Chacón-Ferrer G, Vázquez-Salgueiro E, Ortiz-Peces L, Moreiras-Sánchez AD, Noguera-Tomas J, Cebrián-Carretero JL.** Clinical manifestations in the maxillofacial region of acute crisis of sickle cell anemia: a case report. J Clin Exp Dent. 2025; 17(7): e867-70. Article. Not Indexed
- **Anguita MB, Khayat S, Martín SL, Quelle NB, Cuéllar IN, López AL, Carretero JLC, de Vera JLDP, Fernández-Micheltorena PM, Rial MT, Orabona GD, Falahat F, León JZ, Cuéllar CN.** Virtual guided and customized orthognathic surgery in patients with obstructive sleep apnea syndrome: accuracy and clinical outcomes. J Clin Med. 2025; 14(11): 3780. Article. IF: 3.3; Q1
- **López-Martínez C, Aragón-Niño I, García-López-Chicharro A, Pampín-Martínez MM, Cebrián-Carretero JL.** Computer-aided excision of parapharyngeal space pleomorphic adenoma by transcervical approach. J Clin Exp Dent. 2025; 17(3): e350-3. Article. Not Indexed
- **López-Martínez C, González-Martín-Moro J, López-Martínez D, García-López-Chicharro A, Pampín-Martínez MM, Cebrián-Carretero JL.** Assessment of occult cervical metastases in oral cavity squamous cell carcinoma: Findings from a tertiary-level hospital study. J Clin Exp Dent. 2025; 17(11): e1314-9. Review. Not Indexed
- **Mommaerts MY, Acero-Sanz J, Cebrián-Carretero JL, Dadjam D.** Current classifications of midface resections: scoping review and proposal of a new classification. Int J Oral Max Surg. 2025; 54(4): 293-300. Review. IF: 2.5; Q2
- **Ortiz-Peces L, Álvaro-Martínez M, Moreiras-Sánchez AD, Chacón-Ferrer G, Andura-Correas M, de Vera JL, Ortiz-González L, Cebrián-Carretero JL.** Trigeminocardiac reflex in bimaxillary orthognathic surgery: case review. Med Oral Patol Oral. 2025; 30(4): e523. Article. IF: 2.2; Q2
- **Padilla JCR, Peces LO, Martínez PA, Carretero JLC.** Is Simple reimplantation a viable option in pediculated auricular avulsions? a systematic review of the literature. Craniomaxillofac Trauma Reconstr. 2025; 18(3): 36. Review. IF: 1.0; Q4
- **Pérez-Sala A, Fernández-Micheltorena PM, Bobadilla M, Gámez RFV, Goñi JM, Villanueva A, Archanco IC, de Vera JLDP, Carretero JLC, Cuéllar CN, Cuellar IN, Arenas G, López AL, Larrayoz IM, Peláez R.** Evaluation of deviations produced by soft tissue fitting in virtually planned orthognathic surgery. Appl Sci (Basel). 2025; 15(15): 8478. Article. IF: 2.9; Q2
- **Salas-Butrón MR, Laredo-Velasco L, Rivas-Paterna AB, González-Corchon A, Muñoz-Guerra MF, Borobia AM, Acero-Sanz JJ, Pérez-Ingidua C, Abad-Santos F, Cebrián JL, Gálvez-Múgica MA, Serrano-García I, Portolés-Díez C, Llanos L, Martínez D, Sanz N, Calandria C, Vargas-Castrillón E, Martín-Granizo R, Portolés-Pérez A.** Analgesic effect of a novel intravenous ibuprofen-low-dose tramadol combination: a multimodal approach to moderate-to-severe postoperative dental pain. Pharmaceutics. 2025; 17(10): 1248. Article. IF: 6.9; Q1
- **Tapia-Salinas B, Aragón-Niño I, Del-Castillo-Pardo-de-Vera JL, Cebrián-Carretero JL.** Comprehensive anaesthesia management strategies for orthognathic surgical procedure. Med Oral Patol Oral. 2025; 30(1): e56-64. Article. IF: 2.2; Q2

Research projects

- **Sastre Perona A.** Characterization of cancer-cell plasticity in head and neck cancers: discovery of new therapeutic targets and biomarkers for disease progression and treatment response (PI23/00192). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Sastre Perona A.** Dinamización de ciencia disruptiva en predictores de enfermedades tumorales, infecciosas y hereditarias como base de la medicina personalizada (FORT23/00006_ GRUPO VI). ISCIII. 2024-2027. Managment centre: FIBHULP
- **Cebrian Carretero JL.** Identificación de nuevos biomarcadores de predicción de progresión en pacientes con tumores adenoides císticos y ductales de glándula salivar (PI22/01512). ISCIII. 2023-2027. Managment centre: FIBHULP
- **Sastre Perona A.** Integración de las características moleculares, genómicas, morfológicas, y ambientales para mejorar el diagnóstico y tratamiento de precisión en enfermedades pulmonares intersticiales difusas fibrosantes (PRECISION-EPID) (PMP22/00083). ISCIII. 2023-2026. Managment centre: FIBHULP
- **Sastre Perona A.** La comunicación bidireccional entre el tumor y su estroma como inductora de plasticidad epigenética y progresión tumoral en tumores de cabeza y cuello (BTSCEPICAN) (CNS2024-154580). MICINN. 2025-2027. Managment centre: FIBHULP
- **Sastre Perona A.** Targeting tumor-stroma interactions to prevent tumor progression and metastatis spread in head and neck squamous cell carcinomas (LABAE259399SAST). Fundacion Cientifica de la Asociacion Española contra el Cancer. 2025-2029. Managment centre: FIBHULP
- **Tapia Salinas B.** Abordaje personalizado de la vía aera difícil en paceintes con malformaciones craneofaciales a través de biomodelos 3d y simulación virtual. FIHULP. 2021-2025. Managment centre: FIBHULP

Clinical trials

- **Tapia Salinas B.** Escala de clasificación de la videolaringoscopia (vci).
  Type/Phase: OTROS
  Sponsored by: Tapia Salinas, Blanca.
  Signature date: 05/02/2025

Patents and trademarks

- **Cuéllar Navarro C, Cebrián JL, Magaña Menéndez J, inventors; Hospital General Universitario Gregorio Marañón and Hospital Universitario La Paz, assignees.** Dispositivo de determinación de avance mandibular para un usuario con apnea. P202430809; 2024 October 8.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.6.6 Patients Safety and Quality Research

Publications: 5 | Q1: 4

COMPOSITION

Elena Ramírez García. Facultativo
Especialista de Área en Farmacología Clínica. Hospital Universitario La Paz

- **Miguel Avenza Jaén.** *Fisioterapeuta. Hospital Universitario La Paz*
- **Nelson Butrago Sánchez.** *Facultativo Especialista de Área en Radiología Pediátrica. Hospital Universitario La Paz*
- **Luis Castro Parga.** *Facultativo Especialista en Anestesiología y Reanimación. Hospital Universitario La Paz*
- **Susana Francisca Chajma Izquierdo.** *Facultativo Especialista en Medicina Fisica y Rehabilitación. Hospital Universitario La Paz*
- **Pilar Durán de la Fuente.** *Facultativo Especialista en Anestesiología y Reanimación. Hospital Universitario La Paz*
- **María Fernández-Velilla Peña.** *Facultativo Especialista en Radiología. Hospital Universitario La Paz*
- **Miguel González Muñoz.** *Facultativo Especialista de Area en Inmunología. Hospital Universitario La Paz*
- **Alberto Martín Vega.** *Facultativo Especialista de Area en Medicina Preventiva y Salud Pública. Hospital Universitario La Paz*
- **Bárbara Martínez de Miguel.** *Facultativo Especialista en Radiofarmacia. Hospital Universitario La Paz*
- **Ana Isabel Martínez Escandell.** *Unidad hospitalización quirúrgica. Hospital Universitario La Paz*
- **Covadonga Mendieta Azcona.** *Facultativo Especialista en Cirugía Vascular. Hospital Universitario La Paz*
- **Inés Narrillos Martín.** *Enfermera en Cirugía general y del aparato digestivo. Hospital Universitario La Paz*
- **José Jonay Ojeda Feo.** *Facultativo Especialista de Área en Medicina Preventiva y Salud Pública. Hospital Universitario La Paz*
- **Almudena Quintas Viqueira.** *Médico Adjunto en Medicina Preventiva. Hospital Universitario La Paz*
- **Ana Robustillo Rodela.** *Jefe de Servicio de Medicina Preventiva. Hospital Universitario La Paz*
- **Pascual Sanabría Carretero.** *Jefe de Sección Anestesiología Infantil. Hospital Universitario La Paz*
- **Yuri Fabiola Villán Villan.** *Responsable de Seguridad del Paciente. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- The ocurrence of adverse events due to unsafe care is likely one of the 10 leading causes of death and disability in the world. Research into reducing harm to patients can lead to better health outcomes, as well as significant savings in healthcare costs.
- Patient safety is the health care discipline that arises with the increasing complexity of health care systems and the consequent increase in harm to patients. Its objective is to prevent and reduce the risks, errors and damages suffered by patients during the provision of healthcare. A cornerstone of the discipline is continuous improvement based on learning from mistakes and adverse events.

RESEARCH LINES

- Culture of Patient Safety.
- Incident reporting system for notification and analysis of adverse events associated to Healthcare.
- Zero Infections related to Healthcare.
- Safe Surgery Saves Lives, whose purpose is to reduce the risks associated with surgery.
- Safe Medication, reduce the harm of medications.
- Zero venous thromboembolism, in order to reduce complications attributed to hospitalization.
- Safe Health Worker, Safe patients.
- Safe Transfusions, reduce adverse reactions to transfusion.
- Safe Radiations, to the right patient in the right area.
- Safe Diagnostics, reduce errors that can cause harm.
- Septicemia as a medical emergency.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH ACTIVITY

Publications

- **Martín-Lopez S, Rogozina O, Aguilar-Concepcion D, Alvarez-Montero M, Pardo-Puras R, Akatbach-Bousaid I, Jiménez-González M, Feito AM, González-Muñoz M, Ramírez E.** Impact of lymphocyte transformation test on the diagnostic accuracy of the culprit drug in drug-induced cytopenias: a case-control study. Front Pharmacol. 2025; 16: 1601450. Article. IF: 5.4; Q1
- **López FCD, Moreno ZD, Aguilar-Concepcion D, Ruiz-Fernández C, Akatbach-Bousaid I, Rogozina O, Martín-Lopez S, Feito AM, González-Muñoz M, Ramírez E.** The role of the lymphocyte transformation test in immune-related adverse events from immune checkpoint inhibitors: a case series. J Clin Med. 2025; 14(23): 8596. Article. IF: 3.3; Q1
- **de las Huertas AGL, Stewart S, Elizalde MU, Guijarro-Eguinoa J, Seco-Meseguer E, Diago-Sempere E, González MJ, Carcas-Sansuan AJ, Pérez AMB, Ramírez E.** Disproportionality analysis of the five most widespread neurological effects of covid-19 vaccines from 2021 to 2023: insights from eudra vigilance. Pharmaceuticals (Basel). 2025; 18(5): 636. Article. IF: 5.7; Q1
- **Valderrabano P, Silva JBQ, Mena SC, Casado CF, Novoa MPD, Pérez MCS, Fernández EF, Guerra AL, Sambo M, Rojas-Marcos PM, Ramírez PP, Fernández CT, Troyano MJR, Lázaro VA, Vargas ML, García NP.** Evaluation of thyroid ultrasound reports' quality in the Community of Madrid, Spain. Eur Thyroid J. 2025; 14(1): e240390. Article. IF: 4.9; Q1
- **Ballesteros SC, Carretero PS, Parga LC, Vega AM, García LL, Barbero FR.** Clinical study on the predictive utility of high flow CPAP in weaning from prolonged mechanical ventilation in critical paediatric surgery patients. Rev Esp Anestesiol Reanim. 2025; 72(2): 501658. Article. IF: 1.3; Q3

Research projects

- **Ramírez García E.** Análisis de desproporcionalidad de meningitis aséptica para las vacunas covid-19 en europa,versión 1.0 del 21/02/2022. FIBHULP. 2022-2025. Managment centre: FIHULP
- **Ramírez García E.** Efectividad de la Simulación en la mejora de la cultura de seguridad del paciente. FIBHULP. 2018-Ongoing. Managment centre: FIBHULP
- **Guerra García P.** Estudio de fase 1, multicéntrico, abierto, con intensificación de dosis y expansión de cohorte con Niraparib y Dostarlimab en pacientes pediátricos con tumores sólidos recurrentes o refractarios. FIBHULP. 2021-Ongoing. Managment centre: FIBHULP
- **Ramírez García E.** Estudio de incidentes y eventos adersos en el hospital. FIBHULP. 2023-Ongoing. Managment centre: FIHULP
- **Zapatero Larrauri, MN.** Estudio de seguridad cardiovascular de fase 3, aleatorizado, doble ciego, de grupos paralelos, basado en eventos con BI 456906 administrado por vía subcutánea en comparación con placebo en participantes con sobrepso y obseidad con enfermedad cardiovascular establecidad o enfermedad renal crónica, y/o al menos dos complicaciones relacionadas con el peso o factores de riesgo ECV. FIBHULP. 2024-Ongoing. Managment centre: FIBHULP
- **Ramírez García E.** Evaluación de la causalidad de las reacciones adversas graves a fármacos: utilidad de los algoritmos de causalidad y ensayos in vitro: fase II. FIBHULP. 2025-2025. Managment centre: FIBHULP
- **Jonay Ojeda Feo.** La competencia intercultural en la comunicación interlingüística sanitaria" que lidera la Universidad Alcalá de Henares con la colaboración de los Servicios de Ginecología y Genética del hospital. FIBHULP. 2025-Ongoing. Managment centre: FIBHULP
- **Sanabria Carretero P.** Mejora de la humanización de la asistencia sanitaria en el bloque quirúrgico infantil del Hospital La Paz. Fundación Icomem Para la Educación y Formación Sanitarias. 2021-Ongoing. Managment centre: FIBHULP
- **Sanabria Carretero P.** Población en riesgo de hipertemia maligna: cohorte ambispectiva (PI20/01444). ISCIII. 2021-2023. Managment centre: FIBHULP
- **Ramírez Garcia E, Sanabria Carretero P, Peiró Vallejo C.** Registro de parada cardiorespiratoria perioperatoria. FIBHULP. 2017-Ongoing. Managment centre: FIHULP



Clinical trials

- **Parra Ramírez PA.** Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de baxdrostat en participantes con hiperaldosteronismo primario.
  Type/Phase: III
  Sponsored by: Astrazeneca Ab.
  Signature date: 10/09/2025

Patents and trademarks

- **Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee.** Brand name: SINOIRES. CM 13.080.056; 2014 July 14.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.6.7 Translational Research and Innovation in General and Digestive Surgery



Publications: 49 | Q1: 26

COMPOSITION

Constantino Fondevila Campo.
Jefe de Servicio de Cirugía General y Digestiva. Hospital Universitario La Paz

- **Mario Álvarez Gallego.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Raquel Arranz Jiménez.** *Facultativo Especialista de Área en Endocrinología y Mama. Hospital Universitario La Paz*
- **Ramón Cantero Cid.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Ramón Corripio Sánchez.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Francisca García-Moreno Nisa.** *Jefe de Sección de Cirugía de Urgencias. Hospital Universitario La Paz*
- **Joaquín Gómez Ramírez.** *Coordinador Unidad de Cirugía Endocrina. Hospital Universitario La Paz*
- **Jenny Rosario Guevara Martínez.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Amelia Hessheimer.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Javier Muñoz Luque.** *Técnico de Grado Superior. CIBEREHD*
- **Arnau Paniselló Roselló.** *Investigador Postdoctoral. Institute George Lopez*
- **Isabel Pascual Miguelañez.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Maria Isabel Prieto Nieto.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Inés Rubio Pérez.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Juan José Segura Sampedro.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Jordi Vengohechea Llorens.** *Investigador Predoctoral. Universidad de Barcelona*
- **Elisa York Pineda.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- **PROBLEM:** Surgery and perioperative care comprise one of the most expensive and resource-intensive areas of clinical medicine. Patients undergo complex surgical procedures with the aim of curing, or at least alleviating, the symptoms associated with various diseases. However, these same procedures can be ineffective in achieving this goal. Furthermore, complications (morbidity) can occur, further impacting the physical, mental, and emotional well-being of patients.
- **FOCUS:** The Translational Research and Innovation Group in General Surgery (GITIC) is a multidisciplinary group comprised of surgeons, nurses, and biologists with diverse areas of expertise. The GITIC team collaborates to leverage *both surgical innovation and various research initiatives to deliver the highest possible quality of patient care.*
- Thanks to the extensive knowledge and skill set of the members, the projects developed by the GITIC group include lines of basic science and experimental research, preclinical and translational surgical models, clinical research, analysis of post-surgical results, and studies related to economic evaluation and the creation of mathematical models.
- In order to fulfill its broad research interests and initiatives, GITIC actively collaborates not only with other groups belonging to La Paz University Hospital and IdiPAZ, but also with other hospitals and institutions in the public and private sectors, both nationally and internationally. Some of its current collaborations are with the following institutions:
  - Donation & Transplantation Institute (DTI), Barcelona, Spain
  - Guanguong Shunde Innovative Design Institution, Guangdong, China
  - Virgen de la Salud Hospital, Toledo, Spain
  - International University of Catalonia (UIC), Sant Cugat, Spain
  - "A. Gemelli" University Polyclinic, Università Cattolica del Sacro Cuore, Rome, Italy
  - IE Business School, Madrid, Spain.
  - Tekniker, Gipuzkoa, Spain.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH LINES

Damage, inflammation, organ failure, and transplantation:

- Evaluation and implication of chronic inflammation in obesity.
- Experimental models of end-stage liver disease and portal hypertension.
- Applicability and results of liver transplantation in the treatment of acute-chronic liver failure
- Transplantation approaches in patients with complex portal vein thrombosis
- Translational and clinical research on ischemia-reperfusion injury.
- Preservation solutions and new techniques in in situ and ex situ organ perfusion.
- Clinical outcomes and improvement strategies in organ transplantation after circulatory death (DCD)
- Evaluation and clinical implications of graft dysfunction markers after liver transplantation.

Surgical oncology:

- Evaluation of a new multifunctional liquid biopsy platform to predict and improve the response of cancer immunotherapy using innate immunomodulators.
- Evaluation of the usefulness of cryoablation to induce immune activation and response to immunotherapy in primary breast tumors.
- Evaluation of the diagnostic and therapeutic role of new immune checkpoints in colon cancer.
- Development of 3D organoids as biomodels of colon cancer.
- Combination of "omics" and imaging techniques to identify markers associated with response to neo-adjuvant therapy in patients with rectal cancer.
- Effectiveness and safety of intraperitoneal hyperthermic chemotherapy in the prevention of peritoneal recurrence in patients at high risk of colorectal cancer.
- Immunological and molecular prognostic factors in ovarian cancer in patients with a history of endometriosis (Collaboration with the Gynecology Service of HU La Paz).

Innovation and technology in surgery:

- Development and preclinical evaluation of a novel device for ex situ liver perfusion with a machine
- Development and clinical evaluation of the safety and reliability of a new rectoscope for rectal cancer surgery.
- Development and evaluation of the usefulness of new drainage systems in surgery.
- Evaluation of new surgical strategies to reduce drainage after axillary lymphadenectomy in the treatment of breast cancer.

Value-based healthcare:

- Patient protection and prevention of peri-operative infections.
- Evaluation of surgical care benchmarks.
- Evaluation of peri-operative complications, quality of life and postoperative disability in patients after operations in general and digestive surgery.
- Cost-effectiveness and cost-utility of postoperative cancer follow-up strategies.
- Economic evaluation of new surgical methods and technologies.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

RESEARCH ACTIVITY

Doctoral Theses

- **Pastor Morete D.** Identificación de las bases moleculares de la carcinomatosis peritoneal mediante técnicas ómicas. Papel del delta p73[dissertation]. Madrid: UAM: 2025(05/05/2025). Director: Prieto Nieto MI.

Master Theses

- **Curiel L.** Design and Implementation of an Artificial Intelligence System for the Automatic Estimation of the Comprehensive Complication Index (CCI) in Hospital Discharge Reports[dissertation]. Madrid: Universidad Politécnica de Madrid: 2025(17/07/2025). Director: Fondevila Campo C.

Final Degree Theses

- **Gómez de la Morena R.** Electroquimioterapia.Experiencia en el tratmaiento de tumores cutáneos primarioa y secundarios en el Hospital La Paz[dissertation]. Madrid: UAM: 2025(20/05/2025). Director: Prieto Nieto MI.
- **Ponceliz K.** Instauración de un protocolo de estimulación de asa eferente previo a cierre de ileostomía en el Hospital Universitario La Paz[dissertation]. Madrid: UAM: 2025(05/05/2025). Director: Rubio Pérez I.

Publications

- **Abu Hilal M, Hoogteijling TJ, Edwin B, Dagher I, D'Hondt M, Marques HP, Swijnenburg RJ, Boggi U, Sucandy I, Ferrero A, Marsman H, Troisi R, Gumbs AA, Aldrighetti LA, Cherqui D, Alseidi A, Croner R, Rotellar F, Scatton O, Al Saati H, Berardi G, Cillo U, Cipriani F, Ciria R, Cugat E, Di Benedetto F, Diaz-Nieto R, Duncan T, Efanov M, Ettore GM, Fondevila C, Fretland AA, Giuliante F, Hagendoorn J, Han HS, Honda G, Lesurtel M, Lodge P, Ben SL, Memeo R, Menon K, Rashidian N, Ratti F, Campos RR, Russolillo N, Ruzzenente A, Santoyo J, Schmelzle M, Sgarbura O, Sutcliffe RP, Teh CSC, Vivarelli M, Wakabayashi G, White S, Pearce N, Angelico R, Bannone E, Cacciaguerra AB, Bozkurt E, Conticchio M, El Adel S, Famularo S, Guerra M, Kuemmerli C, Lopez-Lopez V, Aranda FP, da Cunha GP, Primavesi F, Saeidi S, Sheel ARG, Sijberden JP, Sucameli F, Taliente F, Veronesi T, Ahmad J, Alfieri S, Ausania F, Baiocchi G, Berti S, Besselink MG, Daradkeh S, De Carlis L, Delvecchio A, Dervenis C, Dokmak S, Ferrari C, Fusai GK, Geller D, Goh BKP, Guglielmi A, Iannitti D, Jaradat D, Jovine E, Kuo-Hsin C, Liu R, Marudanayagam R, Mocchegiani F, Panaro F, Pinna A, Portolani N, Saleh O, Sallemi C, Serrablo A, Smadi S, Suhool A, Taylor MA, van Gulik TM, Siriwardena AK, Asbun HJ.** The Brescia internationally validated European guidelines on minimally invasive liver surgery. Brit J Surg. 2025; 112(6): znaf113. Review. IF: 8.7; D1
- **Acosta-Mérida MA, Sánchez-Guillén L, Gallego MA, Barber X, Luque JAB, Ramos AS.** National survey on data governance and digital surgery: Challenges and opportunities for surgeons in the era of artificial intelligence. Cir Espan. 2025; 103(3): 143-52. Article. IF: 1.5; Q3

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

- **Alcaide-Garcia J, Boughanem H, García-Aranda M, Rivas-Ruiz F, Aguirre U, García DM, Padilla-Ruiz M, Varela-Moreno E, Robles-Lasarte M, Baré M, del Cura I, Varela MMM, Quintana JM, Macías M, Redondo M.** Long-term prognostic implications of type 2 diabetes mellitus in colorectal cancer patients. Colorectal Dis. 2025; 27(10): e70250. Article. IF: 2.3; Q2
- **Alcolea NG, Arranz MDM, Vera BM, Gallego MA, Sebastián JD, Miguelañez IP.** Multidisciplinary management of perianal fistula in Crohn's disease: Protocol implementation and its clinical and quality of life outcomes. Cir Espan. 2025; 103(11): 800230. Article. IF: 1.5; Q3
- **Araujo-Castro M, Ojeda CM, Dos Santos VG, Sanjuanbenito A, Ramírez JG, Mercander E, Hanzu F, Zarain L, Vidal O, García AM, Medina AA.** Surgical outcomes of partial adrenalectomy for pheochromocytoma: A systematic review and meta-analysis. Rev Endocr Metab Dis. 2025; 26(4): 625-40. Review. IF: 8.7; D1
- **Badía JM, Rubio-Pérez I, Morales-Pérez C, Bueno-Lledo J, Rodríguez-Lorenzo LM, Sancho J, Marín-Peña O, Lopez S, Masià J, Balibrea JM.** Closed-incision negative pressure therapy: scoping review and multidisciplinary consensus recommendations of the spanish observatory of infection in surgery. Int Wound J. 2025; 22(10): e70750. Article. IF: 2.2; Q2
- **Blay L, Larranaga I, Rabadan L, York E.** Endoscopic axillary lymphadenectomy: Tips & tricks. Cir Espan. 2025; 103(4): 220-1. Editorial Material. IF: 1.5; Q3
- **Calleja R, Rivera M, Guijo-Rubio D, Hessheimer AJ, de la Rosa G, Gastaca M, Otero A, Ramírez P, Boscà-Robledo A, Santoyo J, Gómez LMM, del Moral JV, Fundora Y, Lladó L, Loinaz C, Jiménez-Garrido MC, Rodríguez-Laíz G, López-Baena JA, Charco R, Varo E, Rotellar F, Alonso A, Rodríguez-Sanjuan JC, Blanco G, Nuño J, Pacheco D, Coll E, Domínguez-Gil B, Fondevila C, Ayllón MD, Durán M, Ciria R, Gutiérrez PA, Gómez-Orellana A, Hervás-Martínez C, Briceño J.** Machine learning algorithms in controlled donation after circulatory death under normothermic regional perfusion: a graft survival prediction model. Transplantation. 2025; 109(7): e362-70. Article. IF: 4.9; Q1
- **Córdoba L, Cueto FJ, Cantero-Cid R, Abad-Moret R, Díaz E, Álvarez-Benayas J, Fernández-Felipe J, Jiménez-Rodríguez J, Arvelo-Rosario D, Mata-Martínez P, Arranz-Alvarez M, Pedroche-Just Y, Nieto-Torrero S, Valentín-Quiroga J, Terrón-Arcos V, Fernández-Pascual J, Gómez-Campelo P, Cubo-Mateo N, Fernández-Medina O, Hurtado-Navarro L, de Santa María GS, del Prado-Montero J, Santos AL, Lozano-Rodríguez R, Del Fresno C, López-Collazo E.** Colorectal air-liquid interface organoids preserve tumour-immune architecture and reveal local treg expansion after pd-1 blockade. Cancers (Basel). 2025; 18(1): 132. Article. IF: 4.8; Q2
- **Craus-Miguel A, Fernández-Moreno A, Pablo-Leis AI, Romero-Hernández M, Munar M, Moyà-Alcover G, González-Hidalgo M, Segura-Sampedro JJ.** Multicenter study protocol: research on evaluation and detection of surgical wound complications with ai-based recognition (REDSCAR-Trial). J Clin Med. 2025; 14(7): 2210. Article. IF: 3.3; Q1
- **del Prado-Montero J, Guevara-Martínez J, Cantero-Cid R, Mata-Martínez P, Cueto FJ, Lozano-Rodríguez R, Terrón-Arcos V, Abad-Moret R, Díaz-Serrano E, de Diego RP, Fernández-Velasco M, del Fresno C, Hurtado-Navarro L, López-Collazo E.** Age-stratified circulating immune signatures reveal non-invasive biomarkers for colorectal cancer detection. Immun Ageing. 2025; 22(1): 40. Article. IF: 8.3; D1
- **Di Maira T, Cailliez V, Domínguez-Gil B, Mahillo B, Alvarez M, Belli LS, Adam R, Fondevila C, Germani G, Hartog H, Berenguer M.** Regional variations and trends in liver transplantation practices across Europe. Jhep Rep. 2025; 7(8): 101424. Article. IF: 8.7; D1
- **Dorcaratto D, Garcés-Albir M, Palomares-Casasús S, Sánchez-Cabús S, Suárez-Artacho G, Jorba-Martín R, Blanco-Fernández G, Cugat-Andorra E, Ausania F, Fondevila-Campo C, Ramia-Angel JM, Sánchez-Hidalgo JM, Serrablo-Requejo A, Martín-Pérez E, De la Hoz-Rodríguez A, Muñoz-Forner E, Mora-Oliver I, Rodríguez-Blanco M, Cepeda-Franco C, Memba R, López-Guerra D, García-Domingo MI, Landi F, Sánchez-Velázquez P, Losa-Boñar N, Rodríguez-Laiz G, Paterna S, Serradilla-Martín M, Ielpo B, García-Romera A, Padillo-Ruiz J, Sabater-Ortí L.** Blumgart anastomosis versus invaginating pancreatogastrostomy for reconstruction after pancreatoduodenectomy. Ann Surg. 2025; 282(5): 699-708. Article. IF: 7.4; D1
- **Dulskas A, Cerkauskaite D, El-Hussuna A, Gallo G, Dardanov D, Svagzdys S, Singh B, Pinkney T, Pellino G, Glasbey J, van Ramshorst G, Chaudhri S, Frasson M, Pata F, Morton D, Knowles CH.** Results of the international audit for faecal incontinence on behalf of the European Society of Coloproctology (ESCP) collaborating group. Colorectal Dis. 2025; 27(10): e70245. Article. IF: 2.3; Q2



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



- **Febrero B, Ros-Madrid I, Revilla-Nuin B, Abellán M, Ruiz-Manzanera JJ, Gómez J, Rodríguez JM.** Could microRNA analysis help in the management of medullary thyroid cancer? Cancers (Basel). 2025; 17(4): 629. Article. IF: 4.8; Q2
- **García-Aranda M, Abitei C, Martín-García D, Fúnez R, Rivas-Ruiz F, Robles-Lasarte M, Alcaide-García J, Téllez T, Aguirre U, Borrero-Martín JJ, del Cura I, Suárez-Varela MMM, Quintana JM, Redondo M.** Long-term prognostic value of apoptotic index in colorectal cancer: a 5-year multicentre cohort study. Pathology. 2025; 57(4): 443-9. Article. IF: 3.9; Q1
- **Gracia M, Fondevila C, Hernández A, Prieto I, Alonso-Espias M, Zapardiel I.** Hepatic hilum cytoreductive surgery for ovarian cancer relapse. Int J Gynecol Cancer. 2025; 35(7): 101881. Editorial Material. IF: 5.4; D1
- **Guerrero-Ortíz MA, Pellino G, Damieta MP, Gimeno M, Alonso S, Podda M, Toledano M, Núeñz-Alfonsel J, Selvaggi L, Acosta-Merida MA, Bellido J, Ielpo B.** Cost-effectiveness of robotic compared with laparoscopic rectal resection. Results from the Spanish prospective national trial ROBOCOSTES. Surgery. 2025; 180: 2025. Article. IF: 3.2; Q1
- **Hamm JJM, van den Berg R, Andrinopoulou ER, Zwanenburg ES, Musters GD, Tanis PJ, Arjona-Sánchez A.** Adjuvant hyperthermic intraperitoneal chemotherapy in patients with colon cancer at high risk of peritoneal metastases: individual patient data meta-analysis. Brit J Surg. 2025; 112(4): znaf076. Review. IF: 8.7; D1
- **Hernández A, Pascual I, Siegrist J, López A, Zapardiel I, Gracia M, Usandizaga R, Muñoz MD, Perez L, Ferreras ER, Alonso E, Carmona A, Spagnolo E.** Pioneering robotic surgery for complex gynecologic conditions: implementation beyond cancer care. J Robot Surg. 2025; 19(1): 627. Article. IF: 4.2; D1
- **Hessheimer AJ, Hartog H, Marcon F, Schlegel A, Adam R, Alwayn I, Angelico R, Antoine C, Berlakovich G, Bruggenwirth I, Calatayud D, Cardini B, Cillo U, Clavien PA, Czigany Z, De Carlis R, de Jonge J, De Meijer VE, Dondossola D, Domínguez-Gil B, Dutkowski P, Eden J, Eshmuminov D, Fundora Y, Gastaca M, Ghinolfi D, Justo I, Lesurtel M, Leuvenink H, Line PD, Lladó L, Lopez VL, Lurje G, Marin LM, Monbaliu D, Muller X, Nadalin S, Nasralla D, Oniscu G, Patrono D, Pirenne J, Selzner M, Toso C, Troisi R, Van Beekum C, Watson C, Weissenbacher A, Zieniewicz K, Schneeberger S, Polak WG, Porte RJ, Fondevila C.** Deceased donor liver utilisation and assessment: Consensus guidelines from the European Liver and Intestine Transplant Association. J Hepatol. 2025; 82(6): 1089-109. Article. IF: 40.1; D1
- **Hunter J, Hosgood S, Moers C, Leuvenink H, Rabelink TJ, Ploeg R, Figueiredo C, Faro LL, Pischke S, Bera K, Jochmans I, Dumbill R, Porte R, Friend P, Ceresa CDL, Nasralla D, de Meijer V, Oniscu G, Knight S, Engelse MA, Kerr-Conte J, Kaisar M, Naesens M, Vermeire T, Branchereau J, Steichen C, Roger S, Boletis J, Haase B, Nicholson M, Darius T, Tsiakas S, Reinders M, Berger S, Husen P, Gallinat A, Alwyn I, Tsoulfas G, Dutkowski P, Hessheimer A, Pirenne J, Monbaliu D, Öllinger R, Line PD, Fondevila C, Lurje G, de Vries D, Hofker S, Johnson P, Pattou F.** Improving outcomes in kidney transplantation through advances in donor organ perfusion. Nat Rev Nephrol. 2025; 21(12): 818-32. Review. IF: 46.7; D1
- **Iglesias GT, Chavarría-Miranda A, López-Molina M, del Fresno C, Mata-Martínez P, Nozal P, Chico-García JL, Fernández-Fournier M, Ballester LL, Sánchez D, Montero-Calle A, Barderas R, Bravo S, Puertas I, York E, Díez-Tejedor E, Gutiérrez-Fernández M, Otero-Ortega L.** Extracellular vesicles as novel biomarkers for tumor association in intermediate-risk paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2025; 12(6): e200483. Article.

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

IF: 8.0; Q1

- **Julián J, Millán O, Titos E, Ruiz P, Fundora Y, Díaz A, Colmenero J, Fondevila C, Puig-Butillé JA, Brunet M.** Donor-derived cell-free DNA and miRNA monitoring for the early prediction and diagnosis of liver allograft rejection and patient outcomes. Front Immunol. 2025; 16: 1604200. Article. IF: 7.0; Q1
- **Larrañaga I, Blay L, Rabadán L, York E.** Endoscopic axillary lymphadenectomy in 10 steps. Cir Espan. 2025; 103(5): 308-9. Editorial Material. IF: 1.5; Q3
- **López-Sanz L, Leon-López M, Egido-Moreno S, Segura-Raya C, López-López J, Segura-Sampedro JJ, Cabanillas-Balsera D, Segura-Egea JJ.** Chronic kidney disease and chronic oral inflammatory diseases: a systematic review and meta-analysis of periodontitis and apical periodontitis. J Clin Med. 2025; 14(22): 7947. Review. IF: 3.3; Q1
- **Medina AA, Dos Santos VG, Ojeda CM, Sanjuanbenito A, Gómez-Ramirez J, Mercader E, Hanzu FA, Zarain L, Vidal O, Muriel A, Araujo-Castro M.** The role of adrenal-sparing surgery in the management of aldosterone-producing adenoma: a systematic review and meta-analysis. Eur J Endocrinol. 2025; 193(3): S36-52. Review. IF: 6.7; Q1
- **Montaner A, Rubio-Pérez I.** Digital tools for the surgeon of today. Cir Espan. 2025; 103(8): 800110. Editorial Material. IF: 1.5; Q3
- **Moratilla-Lapeña L, Sarmiento M, Ramírez C, San Basilio M, Delgado-Miguel C, Álvarez M, Pascual I, Vilanova-Sánchez A, Sánchez-Galán A.** Surgical treatment of external hemorrhoids in pediatric patients. Chirugia-Ital. 2025; 38(6): 449-51. Article. IF: 0.1; Q4
- **2022 European Society of Coloproctology (ESCP) CORREA Collaborating Group.** Towards safer colorectal surgery worldwide: Outcomes and benchmarks from the ESCP CORREA 2022 audit. Colorectal Dis. 2025 Nov;27(11):e70281. Article IF:2.3; Q2
- **Ocanto A, Cantero R, Morera R, Ramírez R, Rodríguez I, Castillo K, Samper P, Couñago F.** Results of radical treatment of locally advanced rectal cancer in geriatric and non-geriatric patients. Rep Pract Oncol Radiother. 2025; 30(1): 54-61. Article. IF: 1.7; Q3
- **Ochoa RAF, Cudos ES, Gallego MA, Pérez-Ramos L, Pinto PH.** Retrospective study of risk markers for developing high-grade anal intraepithelial neoplasm in men who have sex with men living with HIV. Actas Dermosifiliogr. 2025; 116(1): T39-46. Article. IF: 2.9; Q2
- **Panisello-Rosello A, Carbonell T, Rosello-Catafau J, Vengohechea J, Hessheimer A, Adam R, Fondevila C.** Static cold storage and machine perfusion: redefining the role of preservation and perfusate solutions. Int J Mol Sci. 2025; 26(23): 11734. Review. IF: 5.6; Q1
- **Panisello-Rosello A, Palmeira C, Carbonell T, Rosello-Catafau J.** Commentary on: The impact of hypothermic oxygenated perfusion (hope) on immune responses and sterile inflammation in a preclinical model of pancreatic transplantation by mesnard b et al. Transplantation Direct 2025; 11:e1743; doi: 10.1097/TXD.0000000000001743. Transplant Direct. 2025; 11(8): e1842. Letter. IF: 2.2; Q2
- **Peng YF, Liu F, Li B, Wei YG, Tan HL, Syn NL, Fuks D, Soubrane O, Dokmak S, Gruttadauria S, Zimmitti G, Jaber B, Cipriani F, Kato Y, Scatton O, Herman P, Aghayan DL, Marino MV, Croner RS, Mazzaferro V, Chiow AKH, Sucandy I, Ivanecz A, Choi SH, Lee JH, Prieto M, Vivarelli M, Giuliante F, Ruzzenente A, Yong CC, Yin MQ, Fondevila C, Efanov M, Morise Z, Di Benedetto F, Brustia R, Dalla Valle R, Boggi U, Geller D, Belli A, Memeo R, Mejia A, Park JO, Rotellar F, Choi GH, Robles-Campos R, Hasegawa K, Wang XY, Sutcliffe RP, Pratschke J, Lai ECH, Chong CCN, D'Hondt M, Monden K, Lopez-Ben S, Kingham TP, Liu R, Ferrero A, Ettorre GM, Cherqui D, Liang X, Mishima K, Wakabayashi G, Troisi RI, Cheung TT, Sugimoto M, Sugioka A, Han HS, Long TCD, Abu Hilal M, Zhang WG, Chen KH, Aldrighetti L, Edwin B, Goh BKP.** Validation of the Iwate scoring system for the stratification of



laparoscopic liver resections: An international multicenter study. Ejso-Eur J Surg Onc. 2025; 51(7): 109597. Article. IF: 3.5; Q1
- **Perelló-Trias MT, Rodríguez-Fernández A, Serrano-Muñoz AJ, Segura-Sampedro JJ, Tauler P, Ramis JM, Monjo M.** Evaluation of different commercial sealing hemostatic patches for their selection as reservoirs for localized intraperitoneal chemotherapy. ACS Pharmacol Transl Sci. 2025; 8(2): 499-509. Article. IF: 4.0; Q2
- **Rodríguez-Goncer I, Ruiz-Arabi E, Herrera S, Sabé N, Los-Arcos I, Silva JT, Pérez-Nadales E, Machuca I, Álvarez R, Valerio M, Castón JJ, Aguilera V, Bodro M, Cano A, Cantón R, Carmona P, Carratalà J, Cordero E, Cruzado JM, Fariñas MC, Fernández-Ruiz M, Fondevila C, Fortún J, García-Cosío MD, Gutiérrez-Dalmau A, Iturbe D, Justo I, Len O, López-Medrano F, Oliva MOL, Martín-Dávila P, Martínez-Martínez L, Mazuecos A, Mirabet S, Muñoz P, Oliver A, Pérez-Sáez MJ, Rodríguez-Gómez J, San-Juan R, Sánchez-Céspedes J, Solé A, Verdú EV, Villa J, Torre-Cisneros J, Aguado JM.** Management

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

of multidrug-resistant gram-negative bacilli infections in adult solid organ transplant recipients: GESITRA-IC/SEIMC, CIBERINFEC, and SET recommendations update.. Transplant Rev-Orlan. 2025; 39(3): 100937. Review. IF: 3.2; Q2

- **Rosello AP, Chullo G, Pera M, Bataller R, Fundora-Suárez Y, Adam R, Carbonell T, Catafau JR.** Danger biomarkers in perfusates from fatty liver grafts subjected to cold storage preservation in different preservation solutions. Transpl P. 2025; 57(1): 37-42. Article. IF: 0.8; Q4
- **Sartelli M, Mossialos E, Coccolini F, Jammer I, Labricciosa FM, Barie P, Biffl WL, Memish ZA, Maeurer M, Kobinger GP, Ippolito G, Zumla A, Catena F, (Rubio-Perez I).** Global health at crossroads: uniting together to overcome challenges, restore trust and advance priorities for a sustainable future. World J Emerg Surg. 2025; 20(1): 84. Article. IF: 7.7; D1
- **Segura-Sampedro JJ, Craus-Miguel A.** Reflections on the role of diaphragmatic resection techniques in cytoreductive surgery: indications, outcomes, and unresolved questions. Langenbeck Arch Surg. 2025; 410(1): 102. Letter. IF: 2.2; Q2
- **EuroSurg Collaborative and STARSurg Collaborative.** Extended pharmacological thromboprophylaxis and clinically relevant venous thromboembolism after major abdominal and pelvic surgery: international, prospective, propensity score-weighted cohort study. Br J Surg. 2025 Mar 4;112(3):znaf005. Article. IF: 8.7; D1
- **Tinguely P, Salinas CH, Staubli SM, Raptis DA, Fusai GK.** Analysis of short-term outcomes in pancreatic surgery with vascular resection from a prospective multicenter global study. Ann Surg Oncol. 2025; 32(12): 8870-80. Article. IF: 3.8; Q1
- **Toso C, Heimbach J, Fondevila C.** Reply to: On the need for an adult-to-adult liver graft split policy- an appraisal. J Hepatol. 2025; 83(2): e112. Letter. IF: 40.1; D1
- **Tou S, Gallagher AG, Bislenghi G, Farinha R, Wolthuis A, CAPITAL A Study Collaborative.** European expert consensus on a structured approach to circular stapling anastomosis in minimally invasive left-sided colorectal resection. Colorectal Dis. 2025; 27(2): e70037. Article. IF: 2.3; Q2
- **Troisi RI, Giglio MC, Kim J, Broering D, Cherqui D, Wakabayashi G, Teh C, Abu-Hilal M, Lee KW, Soin A, Lerut J, Tang CN, Aldrighetti L, Hermann P, Asbun H, Rela M, Kim KH, Eguchi S, Han HS, Suh KS, Kasahara M, Olthoff K, Geller D, Egawa H.** Current status of minimally invasive surgery for donor hepatectomy: a worldwide survey (a joint initiative of the international laparoscopic liver society and the international living donor liver transplantation group). Transplantation. 2025; 109(11): 1754-64. Article. IF: 4.9; Q1
- **van Leeuwen OB, Nasralla D, Ceresa CDL, Dutkowski P, Friend PJ, Oniscu GC, Porte RJ, de Meijer VE, (Hessheimer AJ).** The IDEAL framework for machine perfusion in liver transplantation. Nat Rev Gastro Hepat. 2025; 22(10): 669-71. Editorial Material. IF: 57.5; D1
- **Vengohechea J, Rodríguez S, Izquierdo A, Muñoz J, Burgos PP, Albiol J, Largo C, Liang MJ, Huo F, Hessheimer AJ, Fondevila C.** Integrating continuous renal replacement therapy into ex-situ normothermic liver machine perfusion. J Vis Exp. 2025; (226): 69214. Article. IF: 1.2; Q3
- **Vengohechea J, Vaquero-Rey A, Fondevila C, Hessheimer AJ.** The role of renal replacement therapy in improving normothermic machine perfusion of liver grafts. Gastroent Hepat-Barc. 2025; 48(4): 502336. Editorial Material. IF: 2.0; Q3
- **Villajos-Guijarro M, Ramírez-Martín R, Mauleon-Ladrero C, Deniz González V, Forero Torres A, García-Moreno NF, González-Montalvo JI.** Impact of malnutrition on the clinical evolution in a cohort of older patients undergoing emergency surgery for abdominal pathology.. Rev Esp Geriatr Gerontol. 2025; 60(2): 101609. Article. Not Indexed

Research projects

- **del Fresno Sánchez C, Cantero Cid R.** Ampliación de la biopsia líquida inmune polifuncional (POLYFIL) al seguimiento de adenomas de colon, diagnóstico de cáncer de recto (PI24/01106). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Fondevila Campo C.** Reproducción de la homeostasis y de los estímulos metabólicos durante la perfusión normotérmica prolongada en el hígado aislado (PI23/00364). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Fondevila Campo C.** Reproducción de la homeostasis y de los estímulos metabólicos durante la perfusión normotérmica prolongada en el hígado aislado (SET2023 FONDEVILA). Sociedad Española de Trasplantes. 2024-2025. Managment centre: FIBHULP
- **Hessheimer AJ.** Estudio piloto sobre la implementación de resultados reportados por el paciente en la cirugía general mayor (PI22/00847). ISCIII. 2023-2027. Managment centre: FIBHULP

Ciber and Retics

- **Fondevila Campo C.** CIBER de Enfermedades Hepáticas y Digestivas (CIBERehd)(31/12/2025). ISCIII. FIBHULP

Patents and trademarks

- **Álvarez Gallego M, Castejón Sisamón C, García Prada JC, Meneses Alonso J, inventors; FIBHULP, UC3M, assignees.** Rectoscope. P201630551, PCT/ES2017/070249, EP17788865.8, US20190200853; 2016 April 29.
- **Álvarez Gallego M, inventor; FIBHULP, assignee.** Device for the extraction of surgical specimens by insufflation and suction. P201031490, PCT/ES2011/002357; 2010 October 07.
- **Salinas Gómez J, García Sanz M; inventors; FIBHULP and DISTRIBUCIONES CLINICAS S.**A. (DICLISA), assignees. Two-way probe for flushing and/or draining. U202100070; 2021 February 19.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.6.8 Anesthesia-Resuscitation Maternity

Publications: 2 | Q1: 1

COMPOSITION

Isabel Valbuena Gómez.
Facultativo Especialista de Área. Hospital Universitario La Paz

- **Carla Rebeca García García.** *Facultativo Especialista de Área de Anestesia y Reanimación en Maternidad. Hospital Universitario La Paz*
- **Teresa Prima Martínez.** *Facultativo Especialista de Área de Anestesia y Reanimación en Maternidad. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- To increase our visibility as a research group by increasing the number and quality of our projects. To strengthen close collaboration with the European Society of Anaesthesia and Intensive Care (ESAIC) and the World Federation of Societies of Anaesthesiologists (WFSA), while also undertaking collaborative projects at the national level, working together within the framework of the Spanish Society of Anaesthesia and Resuscitation (SEDAR).
- Strengthen our collaboration with other research groups led by our senior colleagues, obstetricians, pediatricians, other surgeons, and nurse and midwifery research groups. Encourage young researchers to initiate doctoral projects in an established research area.

RESEARCH LINES

- Analysis of the Spanish data from the EPIMAP study
- Evaluation of point-of-care devices in severe postpartum hemorrhage
- Cesarean section practice in Europe. ACCESS Project
- Initiation of labor analgesia with epidural, DPE or CSE.
- Maintaining epidural analgesia during childbirth with low-pressure solutions versus ultra-low-pressure solutions. Any difference in outcomes and satisfaction?
- Anesthetic and perioperative management of severely preeclamptic patients. An international collaborative project (Israel and Spain)

RESEARCH ACTIVITY

Publications

- **Azem K, Orbach-Zinger S, Ioscovich A, Brogly N, Spiegel E, Shoham A, Shatalin D, Valbuena I, Frenkel A, Isasi LMV, Matatov Y, Fein S, Greenman D, Neeman Y, Guasch E, Binyamin Y.** Anaesthetic strategies for managing placenta accreta spectrum with REBOA. Eur J Anaesth. 2025; 42(9): 791-9. Article. IF: 7.8; D1
- **Valbuena I, Sancho A, Alsina E, Brogly N, Gilsanz F.** Does capnography improve safety in moderate-deep sedation for gastrointestinal endoscopic procedures provided by anaesthesiologists? A prospective cohort study. J Clin Monit Comput. 2025; 39(4): 731-7. Article. IF: 2.6; Q1

Clinical trials

- **Valbuena Gómez I.** Eficacia de la técnica epidural con punción dural con concentración ultra-baja de levobupivacaína 0,0625% (walking epidural) para la analgesia del trabajo de parto. impacto en los resultados anestésicos y obstétricos.
  Type/Phase: IV
  Sponsored by: Valbuena Gómez, Isabel.
  Signature date: 03/09/2025

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.6.9 Advanced Medical Informatics Laboratory (LIMA)

Publications: 8 | Q1: 3

COMPOSITION

Paloma Oliver Sáez.
Subgerente de Procesos Asistenciales y Sistemas de Información. Hospital Universitario La Paz

- **Ángel Abad Revilla.** *Médico Adjunto a la Gerencia. Hospital Universitario La Paz*
- **Lubna Dani Ben Abdellah.** *Coordinadora médica Unidad de Hospitalización a Domicilio. Hospital Universitario La Paz*
- **Mariana Díaz Almirón.** *Científica de datos adjunta. Hospital Universitario La Paz*
- **Jorge Díaz-Garzón Marco.** *Facultativo Especialista de Área en Análisis Clínicos. Hospital Universitario La Paz*
- **Carlos María Elvira Martínez.** *Jefe de Servicio de Admisión. Hospital Universitario La Paz*
- **Irene Iniesta González.** *Enfermera. Hospital Universitario La Paz*
- **Susana Kalko Witruk.** *Investigadora Senior. FIBHULP*
- **Ana Mateos Mata.** *Investigador Predoctoral. FIBHULP*
- **Jesús Morente López.** *Enfermero I+D+i Calidad. Hospital Universitario La Paz*
- **Natalia Paszko Balutowska.** *Investigador Predoctoral. FIBHULP*
- **Óscar Ocampo Pérez.** *Técnico de Gestión de Sistemas y Tecnologías de la Información. Hospital Universitario La Paz*
- **Rosario María Torres Santos-Olmo.** *Médico especialista en Medicina Familiar y Comunitaria. Hospital Universitario La Paz*
- **Rodrigo Torres García.** *Ingeniero de Datos. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Advanced health data processing: development of algorithms and techniques to handle large volumes of clinical and genomic data.
- Annotation and standardization: use of standardized vocabularies to ensure data interoperability and quality.
- Decision-making support and visualization: intuitive tools that enable precise clinical decisions.
- 360° patient data: comprehensive management of genomic, phenotypic, and environmental data.

RESEARCH LINES

- Digital Health
- Data Spaces and Artificial Intelligence (AI)
- Integration of Genetic and Clinical Data
- Environmental Impact on Health

RESEARCH ACTIVITY

Publications

- **Aslan B, Carobene A, Jonker N, Galior K, Boned B, Marqués-García F, Ricós C, Bartlett W, Coskun A, Diaz-Garzon J, Fernandez-Calle P, Gonzalez-Lao E, Simon M, Sandberg S, Aarsand AK.** Systematic review and meta-analysis of biological variation data of urine albumin, albumin to creatinine ratio and other markers in urine. Clin Chim Acta. 2025; 566: 120032. Review. IF: 4.1; Q1
- **Denecke K, López-Campos GH, Ropero J, Torres Santos-Olmo R, Rivera-Romero O, Martín-Sánchez F, Gabarron E.** Participatory health and artificial intelligence: a literature review. Stud Health Technol Inform. 2025; 327: 1323-7. Review. Not Indexed
- **Marco JDG, Acín PA, Gimeno EJ, Calle PF, Martín VL, González-Casaus ML.** Biochemical evaluation of X-linked hypophosphatemia and tumor-induced osteomalacia: insights into diagnosis and management. Front Endocrinol (Lausanne)..2025; 16: 1702656. Article. IF: 5.7; Q1
- **Marqués-García F, González-Lao E, Tejedor-Ganduxé X, Boned B, Díaz-Garzón J, Simón M, García-Lario JV, Perich C, Fernández-Fernández MP, Martínez-Sánchez LM, Muñoz-Calero M, González-Tarancón R, Fernández-Calle P.** Impact of six sigma estimated using the Schmidt-Launsbyn vs. the Wetsgard equation in the Spanish type I EQA program. Adv Lab Med. 2025; 6(3): 327-35. Article. IF: 1.4; Q3
- **Martin Cubillo C, Cebrían Carretero JL, Martín Sánchez F.** B-onic Suite: An integrated platform for personalized medical devices, real-time surgical planning, and enhanced intraoperative navigation. Stud Health Technol Inform. 2025; 329: 901-5. Article. Not Indexed
- **Martin Sánchez F.** La Comisión Europea selecciona a España para implantar una de las siete fábricas de Inteligencia Artificial. I+S Inf. Salud. 2025; 62-3. Article. Not Indexed
- **Martin Sánchez F.** TRAIN-Europe: La iniciativa europea para promover el desarrollo e integración de la Inteligencia Artificial (IA) en Sanidad. I+S Inf. Salud. 2025: 66-6. Article. Not Indexed
- **Prieto BB, Moreno-Parro I, Sufrate-Vergara B, Fabre-Estremera B, Soto AB, Fernández-Calle P, Marco JDG.** Biological variation of cardiac biomarkers in athletes during an entire sport season. Clin Chem Lab Med. 2025; 63(5): 987-94. Article. IF: 4.4; Q1

Research projects

- **Dani Abdel-Lah L.** Shield: Strategic Health Initiatives For Effective Disease Prevention. UE. 2024-2029. Managment centre: FIBHULP
- **Díaz-Garzón Marco J.** Desarrollo y validación de un modelo predictivo-prescriptivo para el diagnóstico temprano y manejo de la progresión de la Enfermedad Renal Crónica en el continuo asistencial (Atención Primaria-Hospitalaria). FIBHULP. 2025-2026. Managment centre: FIBHULP
- **Martín Sánchez F.** ExpoPaz: prediciendo el impacto medioambiental y del cambio climático en la actividad asistencial del Hospital Universitario La Paz (PI24/01627). ISCIII. 2024-2027. Managment centre: IDIPAZ
- **Martín Sánchez F.** OmicSpace: Plataforma Federada para Datos Multimodales-Caso de Uso de farmacogenética. IIS La Fe Instituto de investigación sanitaria. 2022-2026. Managment centre: IIS La Fe

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.6.10 AI Health

Publications: 2 | Q1: 1

COMPOSITION

Juan José Beunza Nuin.
Investigador Principal Catedrático de la Universidad de Medicina. Universidad Europea de Madrid

- **Enrique Puertas Sanz.** *Profesor Ayudante Doctor. Universidad Europea de Madrid*
- **Eva Avilés Álvarez.** *Profesora Asociada. Universidad Europea de Madrid*
- **José Luis Lafuente Carrasco.** *Profesor Ayudante Doctor. Universidad Europea de Madrid*
- **Samuel González López.** *Profesor Asociado. Universidad Europea de Madrid/Facultativo Especialista de Área en Medicina Intensiva - Hospital Universitario HLA Moncloa*



STRATEGIC OBJETIVES

- The strategic objectives of the IASalud group are practical research to implement artificial intelligence tools in clinical practice, focusing primarily on intensive care for patients admitted to ICUs.

RESEARCH LINES

The current lines of work are:

- Development of an intelligent urinometer for automated measurement of diuresis, colorimetry and spectrometry in critically ill catheterized patients.
- Panties for reducing dysmenorrhea pain through TENS electrostimulation.
- Automated capillary refills for peripheral arterial function assessment.
- Thermal camera for automated body temperature analysis and internal perfusion estimation.
- Automated detection of respiratory failure in children in sub-Saharan Africa with HIV through analysis of respiratory sounds.
- Cardiovascular risk prediction using machine learning.
- Automated glucose monitoring in critically ill patients (ICU).
- Automatic monitoring of hand washing in ICU.
- Non-invasive lactate measurement in critically ill patients.
- Early detection of pre-eclampsia in pregnant women through remote monitoring, and analysis of the effectiveness of aspirin as a preventive therapy.
- Fingerprinting and hand vein pattern for the identification of newborn children.

RESEARCH ACTIVITY

Publications

- **Beunza JJ.** Intensivist should lead artificial intelligence implementation in the ICU. Med Intensiva. 2025; 49(9): 502253. Letter. IF: 2.5; Q3
- **García-Carmona AM, Prieto ML, Puertas E, Beunza JJ.** Leveraging large language models for accurate retrieval of patient information from medical reports: systematic evaluation study. JMIR AI. 2025; 4: e68776. Article. IF: 6.1; Q1



3.7. Maternal Infant Child and Youth Research

Documents: 257 | Originals: 214 | D1: 57 | Q1: 156

Area coordinators: Cristina Calvo Rey/Antonio Pérez Martínez

RESEARCH GROUPS

3.7.1 Neonatology
Adelina Pellicer Martínez

3.7.2 Molecular Hepatology
Esteban Frauca Remacha

3.7.3 Maternal and Fetal Medicine
José Luis Bartha Rasero

3.7.4 Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response
Cristina Calvo Rey

3.7.5 Pediatric Systemic Infections; HIV, Tuberculosis, Imported and Emergent Diseases
Talía Sainz Costa

3.7.6 Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy
Antonio Pérez Martínez

3.7.7 Congenital Malformations, Transplantation and Oncological Surgery
Francisco Hernández Oliveros

3.7.8 Research in Endometriosis
Alicia Hernández Gutiérrez

3.7.9 Research on Comprehensive Care for Transplanted Children and Adolescents
María Jesús Pascau González-Garzón/Luz Yadira Bravo Gallego

3.7.10 Food Oxidative Stress and Cardiovascular Health
Silvia M. Arribas Rodríguez

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Strategic Objectives	Development forecast for the coming years:	Actions
The mission of the Maternal, Child and Adolescent Health Area (MIA) is to contribute to the improvement of the health of society by reducing the negative impact of diseases in the pediatric population from birth to adolescence, as well as the mother-child binomial. This recently created area is made up of research groups that cover the entire spectrum of ages from women, through newborns, children and young people. It includes very varied areas of research and proposes to achieve a full development of the adults of the future. To achieve this, we promote and lead cooperative research of excellence, promoting innovation, a multidisciplinary approach, and the translation of scientific results into clinical practice.	Create a stable structure to promote research that encompasses all areas of perinatal medicine, child and adolescent medicine, and women with childbearing potential. Promote collaboration between groups in the area and provide a common space and shared infrastructure and resources that allow joint progress.	Create a portfolio of shared group resources, services and projects for the MIA area that facilitates common work. Hold work meetings to propose shared studies and strategic lines.
	Promote the search for both public and private funding for cooperative research within the MIA area. Promote participation in international projects.	Facilitate the application request for European projects through the IdiPAZ Internalization Platform.
	Promote the incorporation of new technologies in research to advance personalized and precision medicine and the transfer of research results to the scientific community and society: biomedical industry, health administration, general population and any other interlocutor and disseminate the main advances produced as a result of the research.	Promote at international level the different research groups of the area, identifying possible synergies between groups and centers, new partners and funding sources, as well as to forge strategic alliances.

HIGH IMPACT PUBLICATIONS

Galán-Gómez V, González-Martínez B, Alonso-Saladrigues A, Rives S, Herrero B, Kwon M, Sánchez-Pina J, Minguillón J, Martínez-Romera I, Aguilar IM, Mestre-Durán C, Casado G, Sánchez-Martín M, Echecopar C, González-Pérez C, León-Triana O, Aguirre-Portolés C, Molinos-Quintana A, Barba P, Balsalobre P, **Pérez-Martínez A.** Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults. Exp Hematol Oncol. 2025; 14(1): 49. Article. IF: 17,5; D1

Paris-Munoz A, Alcobendas-Rueda RM, Verdu-Sanchez C, Udaondo C, Galan-Gomez V, Gonzalez-Martinez B, Menendez JJ, Martinez-Romera I, Minguillon J, Pertinez L, de Manuel-Gomez C, de la Cruz-benito A, Sanz-Ruperez A, Remesal A, Camara C, Sanchez-Zapardiel E, del Pino-Molina L, Gomez-Zamora A, Serrano-Olmedo MG, Espanol-Rego M, Valbuena MRD, Climent F, Dorao P, Rios-Blanco JJ, Andrade JD, Ruiz-Zurita G, Fernandez-Garcia MA, **Perez-Martinez A.** CD19 CAR-T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease. Med. 2025; 6(8): 100676. Article. IF: 13,3; D1

González-Martínez B, Galán-Gómez V, Navarro-Zapata A, Mirones-Aguilar I, Cobo M, Pernas-Sanchez A, Vallejo S, Sanchez-Zapardiel E, León-Triana O, Echecopar C, Martínez-Romera I, Guerra-García P, San Román-Pacheco S, Escudero A, Izquierdo E, Izquierdo M, Naharro S, Martín-Ayuso A, Bareke H, París-Muñoz A, Hu PR, Schneider D, Orentas RJ, Minguillón J, **Pérez-Martínez A.** Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL. Ebiomedicine. 2025; 118: 105872. Article. IF: 11,2; D1

Fabre-Estremera B, Buño-Soto A, Sotos-Prieto M, Carballo-Casla A, Milla SP, Rodríguez-Artalejo F, Ortolá R. Cardiac biomarkers and malnutrition incidence in community-dwelling older adults without cardiovascular disease: the seniors-ENRICA-2 Cohort. Clin Chem. 2025; 71(4): 474-83. Article. IF: 8,3; D1

Fernandez-Garcia MD, Camacho J, Diez-Fuertes F, de Pedro ER, García-Ibañez N, Navascués A, Berengua C, Antequera-Rodriguez P, Ruiz-García M, Pastor-Fajardo MT, **Cabrerizo M.** Detections of rare enterovirus C105 linked to an emerging novel clade, Spain, 2019 to 2024. Euro Surveill. 2025; 30(6): e2500073. Article. IF: 8,3; D1

Scientific Events by Maternal Infant Child and Youth Research

- **10/01/2025** - Curso Europeo de Soporte Vital Avanzado Pediátrico y neonatal 8ª Edición
- **17/01/2025** - Generic instructor course. Orientado a instructores en soporte vital pediátrico.
- **01/02/2025** - Curso teórico-práctico con simulación en ecmo neonatal
- **06/03/2025** - Curso de asistencia inicial al trauma pediátrico
- **11/03/2025** - Curso actuación en situación de crisis en neonatología
- **14/03/2025** - Curso de simulación en emergencias obstétricas
- **23/04/2025** - Curso atención nefrológica en primaria
- **07/05/2025** - Taller de simulación de administración menos invasiva de surfactante
- **09/05/2025** - Curso europeo soporte vital avanzado pediátrico y neonatal
- **17/06/2025** - XIX Curso de ecografía en el paciente pediátrico crítico
- **12/08/2025** - Jornadas de recertificación en soporte vital avanzado pediátrico y neonatal
- **01/09/2025** - Online course on microsurgery in experimental transplantation models (4th edition)
- **06/10/2025** - Curso de microcirugía en modelos experimentales de trasplante
- **23/10/2025** - Curso de asistencia inicial al trauma pediátrico
- **27/10/2025** - 18º Taller de simulación de administración menos invasiva de surfactante
- **20/11/2025** - 19º Taller de simulación de administración menos invasiva de surfactante
- **28/11/2025** - Curso europeo soporte vital avanzado pediátrico y neonatal
- **03/12/2025** - IV Curso de donación en asistolia controlada pediátrica y perfusión de órganos ex situ

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.7.1 Neonatology

Publications: 27 | Q1: 14

COMPOSITION

Adelina Pellicer Martínez.
Jefe de Sección de Neonatología. Hospital Universitario La Paz

- **Susana Ares Segura.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz*
- **Maria Carmen Bravo Laguna.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz*
- **Antonio Buño Soto.** *Jefe de Servicio de Laboratorio de Urgencias. Hospital Universitario La Paz*
- **Fernando Cabañas González.** *Jefe de Servicio de Pediatría y Neonatología. Hospital Quironsalud. FIBHULP*
- **Marta Cabrera Lafuente.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz*
- **Esperanza Escribano Palomino.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz*
- **Blanca Fabré Estremera.** *Facultativo Especialista en el Área de Análisis Clínicos. Hospital Universitario La Paz*
- **Paloma López Ortego.** *Médico Adjunto en Neonatología. Hospital Universitario La Paz*
- **Miriam Martínez Biarge.** *Facultativo Especialista de Área en Neonatología. Hospital Hammer Smith Londres*
- **María Teresa Montes Bueno.** *Enfermera. Hospital Universitario La Paz*
- **Isabel Moreno Parro.** *Facultativo Especialista en el Área de Análisis Clínicos. Hospital Universitario La Paz*
- **Bárbara Moreno Sanz-Gadea.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz*
- **María Jesús del Olmo Barros.** *Profesora Contratada. Universidad Autónoma de Madrid*
- **María Sánchez Holgado.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz*
- **Laura Sánchez García.** *Médico Adjunto en Neonatología. Hospital Universitario La Paz*
- **Miguel Sáenz de Pipaón Marcos.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz/Profesor Asociado. Universidad Autónoma de Madrid*
- **Belén Sáenz-Rico de Santiago.** *Profesor Contratado Doctor. Universidad Complutense de Madrid*
- **Gonzalo Solís García.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz*
- **Eva Valverde Núñez.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz /Profesor Asociado. Universidad Autónoma de Madrid*
- **Ariadna Witte Castro.** *Investigadora Predoctoral. FIBHULP*
- **Carlos Zozaya Nieto.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- Prevent structural and functional damage to organs and systems in the high risk newborn.
- Reduce the impact of the processes that occurred in the peri-neonatal stage in later life.

RESEARCH LINES

Macro-microcirculación: monitorización no invasiva, procesamiento de señales y *machine learning* (Macro- and microcirculation: non-invasive monitoring, signal processing and machine learning)(Lead: Mª Carmen Bravo/Adelina Pellicer)

- Neurobiología del desarrollo (Developmental Neurobiology) (Lead: Fernando Cabañas/Eva Valverde)
- Nutrición, microbiota y Banco de Leche (Nutrition, mycrobiota and Milkbank (Lead: Miguel Saenz-Pipaón/ Marta Cabrera).
- Infectología perinatal y neonatal. Inmunología y vacunas (Perinatal and neonatal infectology. Inmunology and vaccines) (Lead: Laura Sanchez Garcia).
- Quality improvement (Lead: Adelina Pellicer/Paloma López-Ortego)
- Overall Management at Periviability (Lead: Adelina Pellicer/Gonzalo Solís

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH ACTIVITY

Doctoral Theses

- **Fabré Estremera B.** Role of Cardiac Biomarkers in Clinical Practice and Epidemiological Research[dissertation]. Madrid: UAM: 2025(20/11/2025). Director: Buño Soto A.

Publications

- **Aker K, Syltern JM, Martínez-Biarge M, Stoen R.** Admissions and outcomes after perinatal asphyxia and hypoxic-ischaemic encephalopathy before and after therapeutic hypothermia: a retrospective population-based study. BMJ Paediatr Open. 2025; 9(1): e003530. Article. IF: 2.6; Q1
- **Belfi A, Vega L, Aguar M, Carmen Bravo M, Canizo D, Díaz Rueda L, Camprubi-Camprubi M.** Neuromonitoring and follow-up in patients with congenital heart disease in Spain. An Pediatr (Engl Ed). 2025; 102(2): 503739. Article. Not Indexed
- **Bravo MC, Parrado-Hernández E, McNamara PJ, Pellicer A.** Predictive model of ibuprofen treatment failure in very preterm infants with patent ductus arteriosus using machine learning techniques. J Perinatol. 2025; 45(7): 944-50. Article. IF: 2.3; Q2
- **Castro AW, González CD, Segura SA, de Pipaón MS.** Assessment of post-discharge growth pattern after initial growth faltering and its association with the neurodevelopment status in preterm infants: a cohort study. Nutrients. 2025; 18(1): 125. Article. IF: 5.8; Q1
- **Castro AW, Sánchez-Holgado M, de Pipaón MS.** Bioactive compounds in human milk. Curr Opin Clin Nutr. 2025; 28(3): 243-9. Article. IF: 3.8; Q2
- **Fabre-Estremera B, Buño-Soto A, Sotos-Prieto M, Carballo-Casla A, Milla SP, Rodríguez-Artalejo F, Ortolá R.** Cardiac biomarkers and malnutrition incidence in community-dwelling older adults without cardiovascular disease: The Seniors-ENRICA-2 Cohort. Clin Chem. 2025; 71(4): 474-83. Article. IF: 8.3; D1
- **Fox A, Cuzzilla R, Tarrant A, Reynolds A, Geary M, Martínez-Biarge M, Hayes B.** Author's Reply: Letter to the editor: utility of cranial ultrasound to investigate brain injury in hypoxic-ischemic encephalopathy. Pediatr Neurol. 2025; 172: 136-7. Letter. IF: 2.0; Q2
- **García-Gozalo M, Pellicer A, Bravo MC.** Current practices for bronchopulmonary dysplasia-associated pulmonary hypertension in neonates: a survey study in Spain. Pediatr Pulm. 2025; 60(9): e71259. Article. IF: 2.4; Q2
- **Górriz JL, Gil FA, López MAB, Soto AB, Cabrera FJC, Cisnerosf A, Guerrerog SC, Conejos MD, Cabello IE, Planellesj MCF, García-Matarín L, Jiménezl N, Mauro JCJ, Jiménez DL, Gamote DM, Ramos PM, Ortiz A, Palaur G, Rivera JQ, Sánchez-Álvarez JE, Ajamil RT, Martín CV, Fernández RV.** Improvement in the detection, diagnosis, and early treatment of chronic kidney disease in Spain. The IntERKit Project. Nefrologia. 2025; 45(5): 351-9. Article. IF: 2.1; Q3
- **Haiden N, Luque V, Domellöf M, Hill S, Kivelä L, de Koning B, Köglmeier J, Moltu SJ, Norsa L, De Pipaón MS, Savino F, Verduci E, Bronsky J.** Assessment of growth status and nutritional management of prematurely born infants after hospital discharge: A position paper of the ESPGHAN Nutrition Committee. J Pediatr Gastr Nutr. 2025; 81(2): 421-41. Article. IF: 3.1; Q1
- **Jobst BM, Carandell F, Ajanovic S, Sial H, Jiménez J, Quesada R, Santos F, López-Azorín M, Valverde E, Ybarra M, Bravo MC, Muñoz D, Agut T, Salas B, Carreras N, Alarcón A, Iriondo M, Luaces C, Sidat M, Zandamela M, Rodrigues P, Martins L, Cassia U, Bramugy J, Cossa A, Mucasse C, Buck WC, Arias S, El Abbass C, Tligui H, Barkat A, Amalik N, Zizi I, Ibáñez A, Parrilla M, Elvira L, Calvo C, Pellicer A, Cabañas F, Bassat Q, Petrone P.** Deep learning based non-invasive meningitis screening using high-resolution ultrasound in neonates and infants from mozambique, Spain and Morocco. Commun Comput Inf Sci. 2025; 2240: 63-72. Article.Not Indexed
- **Marqués-Lopes I, Martínez-Biarge M, Martínez-Pineda M, Menal-Puey S.** Optimizing vegan nutrition: current challenges and potential solutions. Appl Sci (Basel). 2025; 15(17): 9485. Review. IF: 2.9; Q2
- **Martínez-Biarge M, Arnáez J, Arca G, Valverde E, Llorens-Salvador R, García-Alix A.** Recommendations for the use of brain MRI in the neonatal period. An Pediatr. 2025; 103(3): 503935. Article. IF: 2.6; Q1
- **Mohamed A, Mohsen N, Solis-Garcia G, Nasef N, Shah PK.** Comparing malposition and complications associated with ultrasound-guided versus radiography-guided central catheter tip-position in neonates: a systematic review and meta-analysis. Neonatology. 2025; 122(5): 537-47. Review. IF: 3.8; D1
- **Moreno-Galarraga L, Vera CG, Rivero-Calle I, Martinón-Torres F, López ID, Cabañas F, Calvo C.** Pediatric research in Spain: challenges and opportunities. An Pediatr. 2025; 103(1): 503854. Article. IF: 2.6; Q1
- **Permuy C, Sánchez-Holgado M, López-Ortego P, Bret M, Labrandero C, Sampedro M, Rey J, Mazarío E, Pellicer A.** Myocardial calcifications in a neonate with surgically corrected truncus arteriosus: Case report. J Neonatal Perinatal Med. 2025; 18(5): 496-500. Article. IF: 1; Q3
- **Petersen JJ, Kamp CB, Olsen MH, Hansen ML, Thorlund K, Pellicer A, Naulaers G, Dempsey E, Hahn GH, Andersen PB, Rasmussen MIS, Pichler G, Dimitriou G, Szczapa T, Ognean ML, Nesargi S, Musante G, Chalak L, Di Maio M, Lakhwani J, Procianoy RS, Tkaczyk J, Fuchs H, Cetinkaya M, Hagmann C, Popat H, Fabres J, Wang LS, Schmölzer G, Piris-Borregas S, Mohora R, Zafra P, Sarafidis K, Alsina-Casanova M, Baik-Schneditz N, Lopez LS, Griesmaier E, Hatzidaki E, Shashidhar A, Dassios T, Arruza L, Greisen G, Jakobsen JC.** Treatment guided by cerebral oximetry in mechanically ventilated newborns: a statistical analysis plan for step one of the SafeBoosC-IIIv randomised clinical trial. Trials. 2025; 27(1): 72. Article. IF: 2.1; Q3
- **Prieto BB, Moreno-Parro I, Sufrate-Vergara B, Fabre-Estremera B, Soto AB, Fernández-Calle P, Marco JDG.** Biological variation of cardiac biomarkers in athletes during an entire sport season. Clin Chem Lab Med. 2025; 63(5): 987-94. Article. IF: 4.4; Q1
- **Quintana-Castanedo L, Maseda R, Pérez-Conde I, Butta N, Monzón-Manzano E, Acuña-Butta P, Crespo MG, Buño-Soto A, Jiménez E, Valencia J, Arriba MC, Zuluaga P, de Lucas R, del Rio M, Vicente A, Escámez MJ, Sacedón R.** Interplay between iron metabolism, inflammation, and EPO-ERFEhepcidin axis in RDEB-associated chronic anemia. Blood Adv. 2025; 9(9): 2321-35. Article. IF: 7.7; Q1
- **Sánchez-Holgado M, Álvarez-García P, Bravo MC, Cabañas F, Azorín ML, Dorronsoro I, Jiménez TC, Maestro M, Diago-Sempere E, Seco-Meseguer E, Jiménez-González M, Pellicer A.** Dose-finding for dobutamine during transitional circulation in the very preterm infant: The study protocol. Plos One. 2025; 20(12): e0338307. Article. IF: 2.8; Q2
- **Sánchez-Holgado M, Johnson MJ, Castro AW, Camargo SC, van den Akker CHP, Álvarez-García P, Cabrera-Lafuente M, Varas MAJ, de Pipaón MS.** Systematic review and meta-analysis of enteral protein intake effects on growth in preterm infants. Pediatr Res. 2025; 98(5): 1696-710. Review. IF: 3.3; Q1
- **Sánchez-Holgado M, Sampedro M, Zozaya C, Romero CP, Álvarez-García P, La Banda-Montalvo L, Nieto C, Pellicer A.** Bemiparin in neonatal thrombosis: therapeutic dosing and safety. J Perinatol. 2025; 45(2): 224-8. Article. IF: 2.3; Q2
- **Solís-García G, Bravo M, Pellicer A.**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Cardiorespiratory interactions during the transitional period in extremely preterm infants: a narrative review. Pediatr Res. 2025; 97(3): 871-9. Review. IF: 3.3; Q1

- **Spagnolo E, Fuentes BD, Lopez A, De Celada RA, Buño A, Ramiro-Cortijo D, Hernández A.** Impact of dietary patterns on pain and quality of life in ovarian and deep endometriosis: observational study for nutritional interventions. BMC Womens Health. 2025; 25(1): 613. Article. IF: 3.3; Q1
- **ten Barge JA, van den Bosch GE, Allegaert K, Bhatt A, Brindley N, Byrne D, Campbell-Yeo M, Camprubi-Camprubi M, Cavallaro G, Durrmeyer X, Embleton N, Eriksson M, Flint RB, Garrido F, Gianni ML, Giannoni E, Kitt H, Klerk D, Kristjánsdóttir G, Amponsah AK, Lapillonne A, Martin CR, Matyas M, Norman E, Ohja S, Pirlotte S, del Rio R, Roué JM, Sevivas C, Slater R, Smits A, de Pipaón MS, Tauzin M, Ukkonen T, Unal S, Villamor E, Molloy EJ, Simons SHP.** Pain management in preterm infants with necrotizing enterocolitis: an international expert consensus statement. Eur J Pediatr. 2025; 184(6): 342. Review. IF: 2.9; Q1
- **Troya MI, Bover J, Hidalgo AC, Malumbres S, Sánchez-Bayá M, Masso E, Coll-Brito V, Anton-Pampols P, da Silva I, Soler-Majoral J, Marcos E, Abril BM, Pérez-Leon N, García MM, Zaragoza JPG, Miguel XJ, Estevez YL, López-Alarcón R, Blanco I, Indiano CM, Gracia-García S, Soto AB, Gorriz JL, Buades JM, Ortiz A, Sánchez E, Araa J.** The importance of disease coding following the diagnosis of chronic kidney disease: from ICD-10 code N18.9 to the role of clinical laboratories. Nefrologia. 2025; 45(9): 501410. Letter. IF: 2.1; Q3
- **Verduci E, Köglmeier J, Haiden N, Kivelä L, De Koning B, Hill S, Luque V, Moltu SJ, Norsa L, De Pipaón MS, Savino F, Bronsky J.** Vegan diet and nutritional status in infants, children and adolescents: A position paper based on a systematic search by the ESPGHAN Nutrition Committee. J Pediatr Gastr Nutr. 2025; 81(5): 1318-45. Article. IF: 3.1; Q1

Research projects

- **Bravo Laguna MC, Pellicer Martínez A.** Predicción de la eficacia de los fármacos cardiovasculares en recién nacidos. ISCIII. 2023-2027. Managment centre: FIBHULP
- **Escribano Palomino E, Sáenz de Pipaón Marcos M.** Ensayo clínico aleatorizado controlado: intervención dietética-nutricional basada en la dieta mediterránea durante embarazo y dos primeros años, mil primeros días, para evaluar el impacto en el neurodesarrollo (PI24/00355). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Pellicer Martínez A.** Alliance for Family Integrated Care (FICare) Implementation in Neonatal Intensive Care Units (RISEINFAMILY_PELLICER). UE. 2021-2025. Managment centre: FIBHULP
- **Pellicer Martínez A.** Búsqueda de dosis de dobutamina durante la circulación de transición en el recién nacido muy prematuro. NEOCIRC-002 (ICI23/00072). ISCIII. 2024-2027. Managment centre: FIBHULP
- **Sáenz de Pipaon Marcos M, Sánchez García L.** Colonización de gestantes por bacterias multirresistentes y transmisión perinatal en <32 semanas: prevalencia y morbilidad (PI-3726 SAENZ DE PIPAON). Fundación de la Sociedad Española de Neonatología. 2019-Ongoing. Managment centre: FIBHULP
- **Sáenz de Pipaón Marcos M.** Estudio de la ingesta de leche materna en la población de prematuros menores de 32 semanas o menores de 1500g en un conjunto de unidades neonatales españolas. Fundación de la Sociedad Española de Neonatología. 2024-Ongoing. Managment centre: FIBHULP
- **Sáenz de Pipaón Marcos M.** Fórmulas nutricionales para el control del déficit de ácido docosahexaenoico DHA y ácido araquinódico en niños extremadamente prematuros (RAMÓN ARECES SAENZ DE PIPAON). Fundación Ramón Areces. 2021-2026. Managment centre: FIBHULP



Ciber and Retics

- **Cabañas González F.** Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin (SAMID). ISCIII. (31/12/2025). FIBHULP

Clinical trials

- **Sáenz de Pipaón Marcos M.** A multi-center, double-blind, randomized, two-arm, parallel-group, placebo controlled study to assess the efficacy and safety of elgn-2112 on intestinal malabsorption in preterm infants.
  Type/Phase: III
  Sponsored by: Elgan Pharma Ltd.
  Signature date: 26/08/2025
- **Pellicer Martínez A.** Salvaguardando el cerebro de nuestros niños más pequeños (safeboosc-iiiv). oximetría cerebral sumada al cuidado estandar versus cuidado estandar en recién nacidos con ventilación mecánica invasiva. un ensayo clínico iniciado por investigadores, pragmático, multinacional, aleatorizado fase iii.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Chip Region Hovedstaden Eu Erhvervelse.
  Signature date: 24/01/2025
- **Sáenz de Pipaón Marcos M.** Estudio multicéntrico, aleatorizado, doble ciego, de dos grupos paralelos y controlado con placebo para evaluar la seguridad de elgn-2112 en poblaciones de interés.
  Type/Phase:
  Sponsored by: Elgan Pharma Ltd.
  Signature date: 16/09/2025

Patents and trademarks

- **Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo C, assignee.** Positioning device for neonates (Utility model). U201330102; 2013 January 31.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.7.2 Molecular Hepatology

Publications: 5 | Q1: 2

COMPOSITION

Esteban Frauca Remacha.
Jefe de Sección de Hepatología Pediátrica.
Hospital Universitario La Paz

- **Paloma Jara Vega.** *Emérita Asistencial. Hospital Universitario La Paz*
- **Loreto Hierro Llanillo.** *Jefe de Servicio Hepatología Pediátrica. Hospital Universitario La Paz*
- **Carmen Camarena Grande.** *Médico Adjunto de Hepatología Pediátrica. Hospital Universitario La Paz*
- **Ángela de la Vega Bueno.** *Médico Adjunto de Hepatología Pediátrica. Hospital Universitario La Paz*
- **Lorena Fernández Tomé.** *Facultativo Especialista en Hepatología y Trasplante Hepática. Hospital Universitario La Paz*
- **Maria Dolores Lledín Barbancho.** *Facultativo Especialista en Hepatología y Trasplante Hepática. Hospital Universitario La Paz*
- **Gema Muñoz Bartolo.** *Médico Adjunto de Hepatología Pediátrica. Hospital Universitario La Paz*
- **María Ángeles Pajares Tarancón.** *Investigador Cientifico. CSIC*
- **Luiz Stark Aroeira.** *Investigador Postdoctoral. Hospital Universitario La Paz*
- **David Vicent López.** *Investigador Senior (Contrato Miguel Servet - I2). Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Study of the molecular mechanisms underlying serious pediatric liver diseases: Identification of therapeutic targets and diagnostic and treatment markers to improve patient management

RESEARCH LINES

- Identification of genetic mutations responsible for cholestatic diseases in children
- Identification of the mechanisms responsible for cholestatic liver damage.
- Identification of therapeutic targets and development of therapies to prevent or slow liver deterioration.
- A study of hepatic metabolic abnormalities in various pediatric liver diseases.

RESEARCH ACTIVITY

Publications

- **de la Cámara RCM, Miguel-Berenguel L, Cámara C, Losantos-García I, Frauca-Remacha E, Hierro-Llanillo L, Muñoz-Bartolo G, Lledín-Barbacho MD, Martínez-Feito A, López-Granados E, Sánchez-Zapardiel E.** Immune monitoring and risk of infection in pediatric liver transplantation: a prospective study. Front Immunol. 2025; 16: 1605716. Article. IF: 7.0; Q1
- **Gallego-Zazo N, Tenorio-Castano J, Parra A, Nevado J, Cazalla M, Lucas-Castro E, Heath KE, Palomares M, Soengas E, Lledín MD, Larrea E, Olveira A, Morte B, Carracedo A, Lapunzina P.** AMOTL1-associated multiple congenital anomalies (craniofaciocardiohepatic syndrome, cfchs): a novel clinical spectrum including craniofacial, heart and liver abnormalities. Clin Genet. 2025; 107(2): 234-6. Letter. IF: 2.1; Q3
- **Lledín MD, Parrón-Pajares M, Andrade-Guerrero D, Quilés-Blanco J, Morais A, Hernández-Oliveros F, Frauca E, Botella-Carretero JI.** Effect of muscle mass on catch-up growth after liver transplant in infants with biliary atresia. Pediatr Transplant. 2025; 29(8): e70219. Article. IF: 1.4; Q3
- **Lozano-Rodríguez R, Hierro L, Quiles MJ, Pascual-Iglesias A, Terrón-Arcos V, Muñoz-Bartolo G, Frauca E, Cueto FJ, Calvo C, Córdoba-García L, Fernández-Felipe J, Hurtado-Navarro L, del Prado-Montero J, María-Diez GSD, Arvelo-Rosario D, Jara P, del Fresno C, López-Collazo E.** Comprehensive immune profiling and predictive modelling of paediatric acute hepatitis of unknown aetiology from a Spanish cohort. Front Immunol. 2025; 16: 1599982. Article. IF: 7.0; Q1
- **Vicente-Santamaría S, Tabares-González A, Gascón-Galindo C, Tutau-Gómez C, Álvarez-Beltrán M, Muñoz-Codoceo RA, Rubio-Murillo M, De-Los-Santos M, Salcedo-Lobato E, Masip-Simó E, García-Romero R, Fernández-Lorenzo AE, Moreno-Álvarez A, Serrano-Nieto J, Hierro-Llanillo L, Loverdos-Eseverri I, Crehuá-Gaudiza E, Juste-Ruiz M, Blitz-Castro E, Morales-Tirado A, López-Cárdenes CM, Bousoño-García C, González-Jiménez D.** Current situation of pediatric cystic fibrosis-related liver disease: results of a Spanish nationwide study. Eur J Gastroen Hepat. 2025; 37(4): 505-9. Article. IF: 2.1; Q3



Research projects

- **Jara Vega P.** ERN TransplantChild 2023-2027. UE. 2023-2027. Managment centre: FIBBHULP
- **Luiz Stark Aroeira.** Activación estratégica de las células T para el control local de la inflamación, promover la tolerancia y la regeneración del tejido dañado y prevención de la fibrosis. FIBHULP. 2025-2026. Managment centre: FIBHULP

Clinical trials

- **Frauca Remacha E.** Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de maralixibat en el tratamiento de participantes con prurito colestásico.
  Type/Phase: III
  Sponsored by: Mirum Pharaceutical Inc.
  Signature date: 12/02/2025
- **Frauca Remacha E.** Estudio clínico de seguridad y resultados clínicos a largo plazo y de bajo nivel de intervención de livmarli® en pacientes con síndrome de alagille en la unión europea.
  Type/Phase: OTROS
  Sponsored by: Mirum Pharaceutical Inc.
  Signature date: 30/06/2025

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.7.3 Maternal and Fetal Medicine

Publications: 26 | Q1: 14

COMPOSITION

José Luis Bartha Rasero.
Jefe de Servicio de Obstetricia y Ginecología. Hospital Universitario La Paz/Catedrático de Obstetricia y Ginecología. Universidad Autónoma de Madrid

- **Irene Bartha de las Peñas.** *Investigador Clínico en Alergia Pediátrica. King's College de Londres and Guy's and St Thomas NHS Foundation Trust*
- **Alejandra Abascal Saiz.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Eugenia Antolín Alvarado.** *Jefe de Sección de Obstetricia y Ginecología. Hospital Universitario La Paz/Profesor asociado. Universidad Autónoma de Madrid*
- **Marta Cortés León.** *Médico Especialista en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Marcos Javier Cuerva González.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **María Amparo Gimeno Sanmartín.** *Médico Especialista en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **María del Mar González Arlazón.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **María de la Calle Fernández-Miranda.** *Jefa de Sección de Tocología de Alto Riesgo y Obstetricia Médica. Hospital Universitario La Paz/Profesora asociada. Universidad Autónoma de Madrid*
- **María de la Cruz González Álvarez.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Beatriz Herrero Ruiz.** *Médico Adjunto de la Sección de Ecografía y Medicina Fetal. Hospital Universitario La Paz*
- **Sara López Magallón.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Francisco López Sánchez.** *Jefe de Sección de Obstetricia y Ginecología. Hospital Universitario La Paz*
- **Fernando Magdaleno Dans.** *Jefe de Sección de Obstetricia y Ginecología . Hospital Universitario La Paz/Profesor asociado. Universidad Autónoma de Madrid*
- **María Elena Martín Boado.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Nuria Martínez Sánchez.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Marta Luisa Muner Hernando.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Inmaculada Orensanz Fernández.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Roberto Rodríguez González.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Sara Ruiz Martínez.** *Investigadora Juan Rodés. Hospital Universitario La Paz*
- **Laura Sotillo Mallo.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Inmaculada Duyos Mateo.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

1. To evaluate the involvement of placental energy metabolism in obstetric pathology
2. Finding new biomarkers in gestational diabetes mellitus and macrosomia
3. To find new biomarkers of fetal and perinatal neurological damage and to establish new prevention strategies
4. New biomarkers in defective placentation
5. To deepen the understanding of the pathophysiology and find new lines of treatment for fetal cardiac damage in Anti-Ro positive women
6. Fetal therapy
7. Infectious diseases. Microbiota

RESEARCH LINES

- Diabetes mellitus, obesity, and metabolic syndrome in pregnancy. Energy metabolism in pregnancy
- Poor placentation
- Fetal neurodevelopment
- Inflammation, autoimmunity, and pregnancy
- Fetal Therapy
- Infectious diseases. Microbiota



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH ACTIVITY

Doctoral Theses

- **Rol García MJ.** Influencia del dolor, ansiedad y depresión periparto en la atención obstétrica y lactancia materna[dissertation]. Madrid: UAM: 2025(25/04/2025). Director: Cuerva González MJ, Bartha Rasero JL

Publications

- **Alcázar JL, Peñate L, Casanova V, Piera C, Engels V, Medina M, Ros C, Sotillo L, Antolín E, Pelayo I, Bermejo C, Pascual MA, Graupera B, Barreche I, Orozco R, Ajossa S, Guerriero S.** Prevalence of contrast intravasation in HyCoSy/HyFoSy. Results of a multicenter study and systematic review of the literature with meta-analysis. Eur J Obstet Gyn R B. 2025; 305: 100-6. Article. IF: 2.3; Q2
- **Bartha JL.** New Evidence on nutrition and metabolic influences on pregnancy outcomes: insights from this special issue. Nutrients. 2025; 17(16): 2628. Editorial Material. IF: 5.8; Q1
- **Bellver J, del Arco A, Pellicer A, Caracena L, Serra V, Labarta E, Castillón G, Fernández G, Barrio A, Ortega I, Fernández I, Torres M, Ballesteros A, Muñoz E, Marqueta J, Ferrando M, Grañeras A, Bartha JL, Garrido N, García-Velasco JA.** Risk of preeclampsia and other pregnancy complications in frozen single euploid embryo transfers after natural versus artificial endometrial preparation: A truncated randomized controlled trial. Placenta. 2025; 163: 1-7. Article. IF: 3.1; Q1
- **Benavent D, Iniesta-Chamorro J, Novella-Navarro M, Pérez-Martínez M, Martínez-Sánchez N, Kaffati M, Juárez-García M, Molinari-Pérez M, González-Torbay A, Gutiérrez M, López-Juanes N, Navarro-Compán V, Monjo-Henry I, Rodríguez-Rosales G, Bachiller J, Calvo-Aranda E, Michelena X, Berbel-Arcobé L, Balsa A, Gómez EJ, Plasencia-Rodríguez C.** Digital health intervention for patient monitoring in immune-mediated inflammatory diseases: cocreation and feasibility study of the IMIDoc platform. JMIR Hum Factors. 2025; 12: e58095. Article. IF: 3.9; Q1
- **Castillo-Marco N, Cordero T, Igual M, Muñoz-Blat I, Gómez-Álvarez C, Bernat-González N, Gaspar-Doménech A, Ortiz-Domingo É, Vives A, Ortega-Sanchís S, Monfort-Ortiz R, Volkov P, Delgado JL, Hernández-Hernández L, Canovas E, Gil MD, Santacruz B, González-González NL, Plasencia W, Perales-Marín A, Marcos-Puig B, Palacios-Marqués AM, Melchor I, Martín-Martínez A, Benítez-Delgado T, Simón C, Garrido-Gómez T.** Maternal plasma cell-free RNA as a predictor of early and late-onset preeclampsia throughout pregnancy. Nat Commun. 2025; 16(1): 9208. Article. IF: 18.1; D1
- **Cuerva MJ, Antolín E, Armijo O, Plaza J, Sanz R, Usandizaga R, Pérez-Medina T, Bartha JL, Zapardiel I.** Homogenization of lessons and materials in different teaching units in obstetrics and gynecology: a quasi-experimental study. Rev Esp Educ Med. 2025; 6(2): 653461. Article. IF: 0.7; Q4
- **Cuerva MJ, Bartha I, Escribano E, Chueca G, de Aguado MP, Espinosa-Martos I, Esteban S, de La Calle M, Jiménez E, Bartha JL.** Gut microbiome differences after vaginal birth in relation to rupture of membranes at term: a prospective longitudinal cohort study of twins. Eur J Pediatr. 2025; 184(8): 511. Article. IF: 2.9; Q1
- **Cuerva MJ, Cortés M.** ERASE: A structured debriefing model. Rev Esp Educ Med. 2025; 6(3): 664001. Article. IF: 0.7; Q4
- **Cuerva MJ, Garrido L, Ramírez-Castan A, Prieto D, López F, Bartha JL.** Is immediate arterial cord blood sampling necessary in vigorous term neonates? A retrospective study of the impact of cord clamping timing on cord blood gas analysis. Eur J Obstet Gyn R B. 2025; 312: 114517. Article. IF: 2.3; Q2
- **Cuerva MJ, Pou M, Cruset M, Llamazares A, Ramírez-Castan A, Cortes M, Lopez F, Bartha JL.** Are all Thierry's spatulas the same? A simulation study comparing various available models. J Gynecol Obstet Hum Reprod. 2025; 54(7): 102979. Article. IF: 1.5; Q3
- **de Winter DP, Verweij EJT, Debeer A, Devlieger R, Lewi L, Verbeeck S, Maurice P, Jouannic JM, Guillemin MG, Mailloux A, dos Santos MCP, Pacheco CADS, Moreira MEL, Vaena MMD, Bohlin K, Tiblad E, Thorup E, Petersen OB, Sanchez-Holgado M, Llorente AV, Poljak B, Khalil A, Le Duc K, Ghesquiere L, Krivec JL, Soltirovska-Salamon A, Dame C, Blank JD, Hohnecker A, Saxonhouse M, Connors NK, Geipel A, Rath J, Prasad S, van Wyk L, Geerts L, Schuler R, Thon N, Leibovitch L, Cohen S, Canul-Euan AA, Kelly E, Raghuram K, Cavigioli F, Colombo SFG, Elanjikal Z, Brayley J, Pfurtscheller D, Pichler G, Grisi AGA, Navarro EJJC, Pereira-Nunes J, Soares H, Zhou M, Borau MJG, Calderon EM, Galletti MF, Mariani GL, Mackin D, Malone F, Lampland A, Tse WT, Castleman J, van der Bom JG, de Haas M, Lopriore E, Fetus Newborn DIONYSUS Investigators (Antolín Alvarado E).** Variations and opportunities in postnatal management of hemolytic disease of the fetus and newborn. JAMA Netw Open. 2025; 8(1): e2454330. Article. IF: 11.7; D1
- **Di Renzo GC, Arduini M, Bartha JL, Froeliger A, Jorgensen JS, Kacerovsky M, Stanirowski P, Wielgos M, Gao LA, Gravett MG.** Clinical utility of a glycosylated fibronectin test (Lumella™) for assessment of impending preeclampsia. J Matern-Fetal Neo M. 2025; 38(1): 2474674. Article. IF: 2.1; Q2
- **Di Renzo GC, Bartha JL, David AL, Devlieger R, Sentilhes L, Surbek DV, Verlohren S, Anumba DOC.** Predicting and preventing preterm birth in Europe: current challenges and gaps. J Matern-Fetal Neo M. 2025; 38(1): 2547687. Review. IF: 2.1; Q2
- **Dudzik D, Atanasova V, Barbas C, Bartha JL.** First-trimester metabolic profiling of gestational diabetes mellitus: insights into early-onset and late-onset cases compared with healthy controls. Front Mol Biosci. 2025; 11: 1452312. Article. IF: 4.4; Q2
- **Fidalgo AM, Aquise A, Molina FS, Youssef A, González-Vanegas O, Brunelli E, Cataneo I, Segata M, Cuerva MJ, Rolle V, Gil MM.** Reproducibility of breech progression angle: standardization of transperineal measurements and development of image-based checklist for quality control. Diagnostics (Basel). 2025; 15(14): 1757. Article. IF: 3.8; Q1
- **Lerma-Puertas D, Aguerri A, Pardina G, Paules C, Lerma-Irureta D, Oros D, Ruiz-Martínez S.** Methodology used in studies aimed at measuring fetal soft tissues by 2d ultrasound for the screening of large for gestational age fetuses. J Ultras Med. 2025; 44(3): 365-79. Review. IF: 2.1; Q2
- **Mateos-Canals N, Ruiz-Martínez S, Sánchez NM, Rasero JLB, Fernández-Miranda MC.** Impact of Social Media use among pregnant women in the Northern Area of Madrid. Clin Invest Ginecol Obstet. 2025; 52(2): 101030. Article. IF: 0.2; Q4
- **Moise E, Moise KJ, Nwokocha M, Lowry K, Hutson E, de Winter DP, Delphi IUT Study**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



Grp, (Antolín Alvarado E). Critical procedural steps in intrauterine transfusion: Delphi survey of international experts. Ultrasound Obst Gyn. 2025; 65(1): 78-84. Article. IF: 5.3; D1

- **Peña-Burgos EM, de la Calle M, Pozo-Kreilinger JJ, García-Díaz C, Regojo-Zapata RM.** Placental pathological findings and clinical outcomes in triplet pregnancies conceived via oocyte donation and non-oocyte donation: a case-control study. Diagnostics (Basel). 2025; 15(21): 2681. Article. IF: 3.8; Q1
- **Peña-Burgos EM, de la Calle M, Pozo-Kreilinger JJ, Regojo-Zapata RM.** Placental pathological findings in triplet pregnancies conceived through assisted reproductive technology: a study of 98 cases. Placenta. 2025; 168: 159-67. Article. IF: 3.1; Q1
- **Peña-Burgos EM, Duyós-Mateo I, Hato-Salmón L, Antolín-Alvarado E, Arribas CB, de León-Luis JAE, Regojo-Zapata RM.** Massive subchorionic thrombohematoma (Breus' mole): An exceedingly rare placental disorder-Case series and systematic review. Placenta. 2025; 168: 276-87. Review. IF: 3.1; Q1
- **Peña-Burgos EM, Duyos-Mateo I, Pozo-Kreilinger JJ, Regojo-Zapata RM, Quirós-González V, de la Calle M.** How have the baseline characteristics and outcomes of triplet pregnancies changed over the last two decades? J Obstet Gynaecol Can. 2025; 47(2): 102735. Article. IF: 2.3; Q2
- **Peña-Burgos EM, García-Munuera E, Pozo-Kreilinger JJ, Regojo-Zapata RM, de la Calle M.** Smaller placentas and maternal vascular malperfusion are associated with worse pregnancy outcomes in triplet pregnancies with a monochorionic component. Placenta. 2025; 170: 75-81. Article. IF: 3.1; Q1
- **Peña-Burgos EM, Regojo-Zapata RM, Caballero-Ferrero A, Martínez-Payo C, Vinuela-Benéitez MD, Montero D, de la Calle M.** The spectrum of placental findings of first-trimester cytomegalovirus infection related to the presence of symptoms in the newborns and stillbirths. Modern Pathol. 2025; 38(9): 100808. Article. IF: 6.6; D1
- **Rol MJ, Cuerva MJ, Briones A, Bartha JL.** Peripartum anxiety symptoms and breastfeeding duration: Prospective observational study. Clin Invest Ginecol Obstet. 2025; 52(3): 101038. Article. IF: 0.2; Q4
- **Silva-Fernández CS, Camacho PA, de la Calle M, Arribas SM, Garrosa E, Ramiro-Cortijo D.** Analysis of maternity rights perception: impact of maternal care in diverse socio-health contexts. Eur J Investig Health Psychol Educ. 2025; 15(2): 10. Article. IF: 3.7; Q1

Research projects

- **de la Calle Fernández-Miranda M.** Evaluación del perfil de hipercoagulabilidad de la gestación y su relación con el riesgo tromboembólico materno y disfunción placentaria (PI24/01208). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Bartha Rasero JL.** Validación de nuevos biomarcadores en diabetes gestacional de inicio tardío (PI23/01837). ISCIII. 2024-2026. Managment centre: FIBHULP

Clinical trials

- **Cuerva Gonzalez Mj.** Evaluación de la seguridad y la capacidad predictiva de parto prematuro del dispositivo de investigación clínica. cervisense tptl: un estudio clínico internacional.
  Type/Phase: OTROS
  Sponsored by: Ultrasound-Innovation Medtech Sl.
  Signature date: 22/09/2025
- **Bartha Rasero Jl.** A phase 3, randomized, placebo-controlled, double-blinded trial to evaluate the safety, tolerability, and immunogenicity of a multivalent group b streptococcus vaccine in healthy pregnant women and their infants.
  Type/Phase: III
  Sponsored by: Pfizer Inc.
  Signature date: 28/08/2025

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.7.4 Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response

Publications: 48 | Q1: 35

COMPOSITION

Cristina Calvo Rey.
Jefe de Sección del Servicio de Pediatría Hospitalaria, Enfermedades Infecciosas y Tropicales. Hospital Universitario La Paz

- **Rosa María Alcobendas Rueda.** *Médica Adjunta en Reumatología Pediátrica. Hospital Universitario La Paz*
- **Sonia Alcolea Ruiz.** *Investigadora Predoctoral. Hospital Universitario La Paz*
- **Patricia Alonso López.** *Facultativo Especialista en Pediatría. Hospital Severo Ochoa*
- **María Mercedes Bueno Campaña.** *Facultativo Especialista de Área en Pediatría. Hospital Fundación de Alcorcón*
- **María Cabrerizo Sanz.** *Investigador titular. Instituto de Salud Carlos III*
- **Sara Camarero Serrano.** *Ayudante de Investigación. Instituto de Salud Carlos III*
- **Inmaculada Casas Flechas.** *Investigador Cientifico de OPIs. Instituto de Salud Carlos III*
- **María de Ceano-Vivas la Calle.** *Jefa de Sección de Pediatría. Hospital Universitario La Paz*
- **Teresa del Rosal Rabes.** *Médico Adjunto de Pediatría Hospitalaria y Enfermedades Infecciosas y Tropicales. Hospital Universitario La Paz*
- **María Dolores Fernández García.** *Científico Titular. Instituto de Salud Carlos III*
- **María Luz García García.** *Jefe de Servicio de Pediatría. Hospital Universitario Severo Ochoa*
- **Paula García Sánchez.** *Médico Adjunto en Servicio de Urgencias Pediátricas. Hospital Universitario La Paz*
- **Isabel González Bertolín.** *Médico Adjunto Urgencias Pediátricas, Pediatría Hospitalaria y Enfermedades Infecciosas. Hospital Universitario La Paz*
- **Carlos Grasa Lozano.** *Contrato Juan Rodés. Hospital Universitario La Paz*
- **Jara Hurtado Gallego.** *Investigadora Postdoctoral. CIBER*
- **María de la Montaña Iglesias Caballero.** *Técnica Superior Especializada de OPIs. Centro Nacional de Microbiología. Instituto de Salud Carlos III*
- **Ana María Méndez Echevarría.** *Facultativo Especialista de Área en Pediatría General. Hospital Universitario La Paz*
- **Mar Molinero Calamita.** *Colaboradora I+D+I. Centro Nacional de Microbiología. Instituto de Salud Carlos III*
- **Juan Francisco Pozo Sánchez.** *Investigador Titular de OPIs. Unidad de Virus Respiratorios y Gripe. Instituto de Salud Carlos III*
- **María Arroyas Sánchez.** *Tutora Residentes de Pediatría. Hospital Severo Ochoa*
- **Alba Tamargo García.** *Investigadora Postdoctoral. Contrato Sara Borrel. FIBHULP*
- **Clara Udaondo Gascón.** *Facultativo Especialista en Reumatóloga Pediátrica. Hospital Universitario La Paz*
- **Patricia Vizuete Cano.** *Técnico de Laboratorio. FIBHULP*

STRATEGIC OBJETIVES

- Infectious diseases are the most common illness in childhood. Our group focuses on the study of pediatric infections, with particular attention to those associated with viruses, from a multidisciplinary perspective. We apply metagenomic techniques to understand these infections and to study the host's immune response.
- Acute respiratory infections (ARIs) of the lower respiratory tract are the most common in humans and account for at least 4 million deaths annually worldwide. A significant proportion of these occur in children. In our country, ARIs are the most frequent cause of hospitalization in children under 2 years of age. By applying metagenomics to the design and development of diagnostic techniques for ARIs, we aim to increase our understanding of viral infections in children of all ages, whether hospitalized or outpatients. Metagenomics can allow us to identify new viruses and deepen our knowledge of existing ones. Any new technological development and its application to respiratory infections will improve the diagnosis of these infections and will be immediately applicable to addressing public health alerts related to respiratory infections, such as MERS-CoV, avian influenza, or other influenza pandemics. The pandemic caused by SARS-CoV-2 and the resulting COVID-19 disease in children has been a major focus of our group's research since its emergence.
- We are also interested in studying the child's immune response to viral infections and the mechanisms that allow the subsequent development of recurrent wheezing and asthma (the most common chronic pathology in childhood).
- Emerging viral infections also play a significant role in childhood illness. Recently, picornaviruses, particularly human parechovirus and enterovirus, have been causing epidemics of severe neurological infections, leading to morbidity and mortality. They are associated with a wide range of illnesses, from febrile syndromes to respiratory, neurological, and systemic conditions. In newborns, these infections can be severe and even fatal. Surveillance of these polio-like diseases is also a public health concern and one of our group's objectives.
- Finally, studying infections in vulnerable and high-risk groups of children who are often overlooked (newborns, children with chronic lung disease, immunocompromised children, cancer patients, etc.) is also a priority for our group. In this regard, we have recently added a line of research on zoonoses and other emerging infections such as invasive fungal infections.



RESEARCH LINES

1. Respiratory viral infections in healthy and high-risk children:

- Respiratory viral infections in hospitalized children. Viral metagenomic methods applied to severe lower respiratory tract infections. SARS-CoV-2 infections in children.
- Respiratory viral infections in children in primary care. Diagnosis and treatment of infectious diseases in primary care.
- Respiratory viral infections in high-risk groups of children (newborns, children with chronic lung diseases, immunodeficiencies, cancer patients, etc.). Torquetene virus in immunocompromised children.
- Application of new technologies such as ultrasound to assess risk conditions in viral infections.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

- 2. Immune response in children and interleukin profile in infants with viral respiratory infections and correlation with the development of recurrent wheezing in the first years of life. Role of the microbiome.
- 3. Detection and characterization of systemic and neurological enterovirus (EV) and parechovirus (PeV) infections in children. Neurological development in children with EV and PeV infections.
- 4. Musculoskeletal infections. Osteoarticular infections. Infections in children with rheumatic diseases. Kawasaki disease.
- 5. Emerging infections in high-risk children: zoonoses and invasive fungal infections.

RESEARCH ACTIVITY

Doctoral Theses

- **García Sánchez P.** Tenencia de mascotas en niños inmunodeprimidos. Evaluación de riesgos para la adquisición de zoonosis[dissertation]. Madrid: UAM: 2025(03/02/2025). Director: Méndez Echevarría AM.
- **de Ceano-Vivas La Calle M.** Evaluación del desarrollo psicomotor en niños con infección del sistema nervioso central por enterovirus y parechovirus[dissertation]. Madrid: UAM: 2025(01/07/2025). Director: Calvo Rey C, García García ML.
- **González Bertolín I.** Analítica sanguínea en la infección urinaria febril pediátrica[dissertation]. Madrid: UAM: 2025(31/01/2025). Director: Calvo Rey C, López López R.

Master Theses

- **del Valle de León N.** Análisis retrospectivo en el proyecto multicéntrico CarbaPED-1. Bacteriemias por bacilos Gram-negativos con resistencia adquirida a carbapenémicos en pediatría. Características clínicas, microbiológicas y factores predictores de mortalidad[dissertation]. Madrid: UCM: 2025(06/10/2025). Director: Grasa Lozano C, Escosa L.

Final Degree Theses

- **López Jorrín M.** Cribado de infecciones importadas en el paciente pediátrico que va a recibir inmunosupresión[dissertation]. Madrid: UAM: 2025(Mayo). Director: del Rosal Rabes T, Sainz Costa T.

Publications

- **Aguilera-Alonso D, Sánchez-Cañete J, McArdle LV, del Rosal T, Santaeufemia FJS, Soto B, Saavedra-Lozano J, Tato LP, Álvarez FJM, Navarro SB, Cercenado E, Marín M, Rivas G, Bueno EC, Abad MJG, Arana DM, Yuste J, Baquero-Artigao F, Calvo C.** Impact of the COVID-19 pandemic on pediatric bacterial community-acquired pneumonia: a multicenter retrospective study in Madrid, Spain. Pediatr Infect Dis J. 2025; 44(2): 151-3. Article. IF: 2.3; Q2
- **Berenguel LM, Gianelli C, Pérez EM, del Rosal T, Echevarría AM, Marhuenda AR, Rodríguez MF, Molina MTC, García LM, Garrido BS, Díaz SH, Martínez LA, Aranda PN, Hijón CC, Granados EL, Pena RR, García-Morato MB.** Molecular assessment of splicing variants in a cohort of patients with inborn errors of immunity: methodological approach and interpretation remarks. Front Immunol. 2025; 15: 1499415. Article. IF: 7.0; Q1
- **Böttcher S, Kreibich J, Wilton T, Saliba V, Blomqvist S, Al-Hello H, Savolainen-Kopra C, Wieczorek M, Gad B, Krzysztoszek A, Pintó RM, Cabrerizo M, Bosch A, Saxentoff E, Diedrich S, Martin J.** Detection of circulating vaccine-derived poliovirus type 2 (cVDPV2) in wastewater samples: a wake-up call, Finland, Germany, Poland, Spain, the United Kingdom, 2024. Euro Surveill. 2025; 30(3): 2500037. Article. IF: 8.3; D1
- **Bravo-Queipo-de-Llano B, Jiménez B, García-Lorenzo M, Melendo S, Carrasco-Colom J, Olteanu-Olteanu FC, Lacuey BR, Calle-Miguel L, Harillo L, Falces-Romero I, Ruiz-Carrascoso G, Marcos DP, de Gopegui ER, Larrosa N, Viñado B, Permuy C, Sampedro M, Ruiz-Azcarate J, del Rosal T, Sainz T, Calvo C, Méndez-Echevarría A.** Community-acquired methicillin-resistant staphylococcus aureus infection in children: Key features and comparison to colonization. Pediatr Infect Dis J. 2025; 44(10): 931-6. Article. IF: 2.3; Q2
- **Cabrerizo M, Fernández-García MD.** The role of the National Polio Laboratory and the network of Sub-National Laboratories in the eradication of poliomyelitis in Spain. Rev Esp Salud Publica. 2025; 99: e202503016. Article. IF: 0.8; Q4
- **Calvo C, García-García ML.** Respiratory syncytial virus prophylaxis with nirsevimab: impact beyond hospitalisations. Lancet Reg Health Eur. 2025; 55: 101349. Editorial Material. IF: 15.7; D1
- **Chorafa E, Iosifidis E, Alkhaaldi AA, Arias A, Cetin BS, De Luca M, Emonts M, Ferreras-Antolín L, Ghimenton-Walters E, Grasa CD, Groll AH, Herrera-Castillo L, Lehrnbecher T, Manzanares A, Masjosthusmann K, Melendo S, Mendoza-Palomar N, Paulus S, Rincón-López E, Romani L, Sdougka M, Solopova G, Strenger V, Tedford K, Tzika C, Warris A, Zsigmond B, Roilides E.** Antifungal prescribing in european pediatric intensive care units: results of a multinational 3-month weekly point-prevalence survey. J Pediatric Infect Dis Soc. 2025; 14(10): piaf081. Article. IF: 3.3; Q1
- **Chorafa E, Iosifidis E, Oletto A, Warris A, Castagnola E, Bruggemann R, Groll AH, Lehrnbecher T, Antolin LF, Mesini A, Alkhaaldi AA, Baquero-Artigao F, Cetin BS, Ebrahimi-Fakhari D, Emonts M, Esposito S, Fainardi V, Ghimenton-Walters E, Gijón M, Guerrero AG, Grasa CD, Kairiene I, Kildonaviciute K, Kourti M, Manzanares A, Mendoza-Palomar N, Noni M, Papakonstantinou E, Paulus S, Perwein T, Rascon J, Rincón-López E, Soler-Palacin P, Solopova G, Spoulou V, Strenger V, Tedford K, Tzika C, Zsigmond B, Roilides E.** Antifungal use in immunocompromised children in europe: a 12-week multicenter weekly point prevalence survey (CALYPSO). J Pediat Hematol Onc. 2025; 47(6): e222-30. Article. IF: 0.9; Q3
- **Cobo-Vázquez E, Aguilera-Alonso D, Grandioso-Vas D, Gamell A, Rello-Saltor V, Oltra-Benavent M, Cervantes E, Sanz-Santaeufemia F, Carrasco-Colom J, Manzanares-Casteleiro A, Martín-Pedraz L, de Arellano ER, Falcón-Neira L, Martínez-Campos L, Colino-Gil E, Jiménez-Montero B, Calavia O, Hernández-Ventura A, del Castillo-Navio E, Matias-Del Pozo V, Calle-Miguel L, Soto B, Fernández B, Camil-Olteanu F, Pareja-León M, López-Segura N, Ara-Montojo F, Ruiz-Sáez B, Calvo-Monge C, Sánchez-Códez M, Reinoso T, Badillo K, Vázquez C, Villalón P, Oteo-Iglesias J, Mellado-Sola I, Cercenado E, Blázquez-Gamero D, Menasalvas A, González-Abad MJ, Guarch B, Ibáñez-Alcalde M, Carazo B, Lung M, Calvo C, Saavedra-Lozano J.** Sharp increase in the incidence and severity of invasive Streptococcus pyogenes infections in children after the COVID-19 pandemic (2019-2023): A nationwide multicenter study. Int J Infect Dis. 2025; 159: 107982. Article. IF: 4.6; Q1
- **de Schrijver S, Vanhulle E, Ingenbleek A, Alexakis L, Johannesen CK, Broberg EK, Harvala H, Fischer TK, Benschop KSM, (Cabrerizo M).** Epidemiological and clinical insights into enterovirus circulation in Europe,

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



2018-2023: A multicenter retrospective surveillance study. J Infect Dis. 2025; 232(1): e104-5. Article. IF: 4.1; Q1

- **del Rosal T, Morillas-Mingorance A, García-Morato MB, Rodríguez-Pena R, Bravo-Gallego LY, Méndez-Echevarría A.** Infectious and inflammatory events in 2 siblings with IRF9 deficiency under immunoglobulin replacement therapy. J Allergy Clin Immun. 2025; 156(5): 1433-5. Letter. IF: 11.7; D1
- **Esperón F, Martín-Maldonado B, Iglesias I, Neves E, Seri E, Garcia-Sanchez P, Morillas-Mingorance A, Méndez-Echevarría A.** Bat-associated hemotropic mycoplasmas in immunosuppressed Children, Spain, 2024. Emerg Infect Dis. 2025; 31(10): 1980-3. Article. IF: 7.9; D1
- **Fernández-García MD, Camacho J, Díez-Fuertes F, de Pedro ER, García-Ibáñez N, Navascués A, Berengua C, Antequera-Rodriguez P, Ruiz-García M, Pastor-Fajardo MT, Cabrerizo M.** Detections of rare enterovirus C105 linked to an emerging novel clade, Spain, 2019 to 2024. Euro Surveill. 2025; 30(6): e2500073. Article. IF: 8.3; D1
- **Franco D, Goya S, Martínez A, Mas V, Moreno B, Valdespino E, Gaitán M, Sáenz L, González C, Moreno A, Capitán-Barrios Z, Carrera J, López-Vergès S, Pascale J, Moltó Y, Moreno L, Rizo B, Urriola E, Delgado T, Iglesias-Caballero M, Casas I, Das S, Arbiza J, Delfraro A, Abrego L.** Genomic insights into respiratory syncytial virus circulation patterns and neutralization by anti-f monoclonal antibodies in Panama (2018-2024). Influenza Other Resp. 2025; 19(10): e70173. Article. IF: 3.9; Q1
- **Gallego BC, Sanchís EM, Campos LM, Medina EML, Coll IA, Hortelano MGL, Rey CC.** Most common flood-associated infectious diseases in children. An Pediatr. 2025; 102(3): 503777. Article. IF: 2.6; Q1
- **García-Boyano M, Alcala FJC, Alonso AR, de Villalta MGF, Alonso OZ, Retolaza IR, Melero IQ, Calvo C, Escosa-García L.** Tracheobronchitis in noncritically ill children with tracheostomy: can quantitative tracheal cultures assist in the management?. Pediatr Pulm. 2025; 60(1): e27489. Article. IF: 2.4; Q2
- **García-Boyano M, Alcalá FJC, Alonso AR, de Villalta MGF, Alonso OZ, Retolaza IR, Melero IQ, Calvo C, García LE.** Antibiotic choice and outcomes for respiratory infections in children with tracheostomies. Hosp Pediatr. 2025; 15(1): 17-27. Article. IF: 2.2; Q2
- **García-Cobos S, Alberca NS, Bravo-Queipo-de-Llano B, Casquero-García V, de Arellano ER, Calvo C, Ruíz-Carrascoso G, Falces-Romero I, Escartín NL, Viñado-Perez B, Martínez-López MA, Pérez SM, de Gopegui ER, Vázquez SP, Carrasco-Colom J, García BA, Pérez-Vázquez M, Méndez-Echevarría A, Iglesias JO.** Genomic analysis of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) causing infections in children-a Spanish multicenter study. Front Microbiol. 2025; 16: 1534840. Article. IF: 5.8; Q1
- **García-García ML, Alonso-López P, Alcolea S, Arroyas M, Pozo F, Casas I, Iglesias-Caballero M, Sánchez-León R, Hurtado-Gallego J, Calvo C.** Impact of Nirsevimab on RSV and non-RSV severe respiratory infections in hospitalized infants. Influenza Other Resp. 2025; 19(5): e70105. Article. IF: 3.9; Q1
- **García-Prats AJ, García-Cremades M, Cox V, Kredo T, Dunbar R, Schaaf HS, Seddon JA, Furin J, Achar J, Radke K, Sachs T, Abubakirov A, Ahmed S, Akkerman OW, Al Ani NA, Amanullah F, Ahmad N, Anderson LF, Asfaw M, Bango F, Bauer T, Becerra M, Boeree M, Brinkmann F, Brown R, Brust J, Campbell JR, Carvalho AC, Carvalho I, Cegielski JP, Centis R, Chan ED, Chauhan S, Chiang SS, Chan PC, D'Ambrosio L, Dalcolmo M, Daneilyan N, de Vries G, Draper HR, Fairlie L, Francis JR, Franke M, Gegia M, Restrepo CG, Guenther A, Gureva T, Haecker B, Harausz E, Hewison C, Hicks RM, Huerga H, Hughes J, Isaakidis P, Kadri SM, Khan MA, Kotrikadze T, Kuksa L, Lachenal N, Lange C, Lecca L, López-Varela E, Lucena S, Mariandyshev A, Mattoo S, Méndez-Echevarría A, Migliori GB, Mitnick C, Mohr-Holland E, Mulanda W, Murzabekova T, Myrzalieve B, Ndjeka N, Niemann S, Ozere I, Padayatchi N, Parmar M, Parpieva N, Manzur-Ul-Alam M, Rybak N, Sachdeva KS, Salmón K, Santiago-García B, Schaub D, Shah I, Shah S, Shah V, Sharma S, Shim TS, Shin S, Sinha A, Skrahina A, Solanki H, Solans BP, Soriano-Arandes A, Toktogonova A, van der Werf T, Velásquez GE, Williams B, Yim JJ, Savic R, Hesseling A.** Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis. Lancet Child Adolesc Health. 2025; 9(2): 100-11. Review. IF: 13.4; D1
- **Gastesi I, Domínguez-Rodríguez S, Le Prevost M, Ramírez A, Giaquinto C, Mesa ML, Ballesteros A, Jackson C, Vásquez-Hoyos P, Moreno CA, Grasa C, Epalza C, Soriano-Arandes A, Moraleda C, Tagarro A.** Comorbidities associated with different degrees of severity in children and young people hospitalized with acute COVID-19. Pediatr Infect Dis J. 2025; 44(5): 439-41. Article. IF: 2.3; Q2
- **Goetzinger F, Caprile AA, Noguera-Julián A, Lo Vecchio A, Baquero-Artigao F, del Rosal T, Brinkmann F, Mouchet F, Velizarova S, Koetz K, Ritz N, Buonsenso D, Song R, Roy RB, Nieminen T, Rau C, Chechenieva V, Welch S, Kaiser-Labusch P, Emonts M, Buxbaum C, Blázquez-Gamero D, Bamford A, Tebruegge M, Martínez-Alier N.** Clinical presentation, diagnostics, and outcomes of infants with congenital and postnatal tuberculosis: a

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

multicentre cohort study of the Paediatric Tuberculosis Network European Trials Group (ptbnet). Lancet Reg Health Eur. 2025; 53: 101303. Article. IF: 15.7; D1

- **González-Bertolín I, Alcolea S, Alonso P, Arroyas M, Castiella IF, Echavarren I, Iglesias-Caballero M, Casas I, García-García ML, Calvo C.** Second-seasonimpact of nirsevimab: clinical outcomes of RSV disease in patients immunized during their first season. Pediatr Infect Dis J. 2025; 44(10): 1009-11. Article. IF: 2.3; Q2
- **Helfferich J, Calvo C, Alpeter E, Andrés C, Antón A, Aubart M, Bova SM, Cabrerizo M, von Eije K, Fabiola S, Felipe A, Iordanova R, Thomsen MK, Knudsen PK, van Loenen F, Lopez N, Mirand A, Molenkamp R, Midgley S, Neves R, Glomb LN, Overbo J, Öztürk G, Palminha P, Pfeiffer HCV, Prochazka B, Ribeiro C, Rodesch M, Schuffenecker I, Shetty J, Siegert S, Solberg SL, Sulik A, Turkdogan D, Ünver O, Verweij J, Vila J, Vuorinen T, Wickström R, Fischer TK, Harvala H, Benschop KSM.** Acute flaccid myelitis in Europe between 2016 and 2023: indicating the need for better registration. Euro Surveill. 2025; 30(21): 2400579. Article. IF: 8.3; D1
- **Huseynov S, Saxentoff E, Diedrich S, Martín J, Wieczorek M, Cabrerizo M, Blomqvist S, Jorba J, Hagan J.** Detection of vaccine-derived poliovirus type wastewater - five european countries, september-december 2024. Mmwr Morb Mortal Wkly Rep. 2025; 74(7): 122-4. Article. IF: 16.2; D1
- **Jobst BM, Carandell F, Ajanovic S, Sial H, Jiménez J, Quesada R, Santos F, López-Azorín M, Valverde E, Ybarra M, Bravo MC, Muñoz D, Agut T, Salas B, Carreras N, Alarcón A, Iriondo M, Luaces C, Sidat M, Zandamela M, Rodrigues P, Martins L, Cassia U, Bramugy J, Cossa A, Mucasse C, Buck WC, Arias S, El Abbass C, Tligui H, Barkat A, Amalik N, Zizi I, Ibáñez A, Parrilla M, Elvira L, Calvo C, Pellicer A, Cabañas F, Bassat Q, Petrone P.** Deep learning based non-invasive meningitis screening using high-resolution ultrasound in neonates and infants from Mozambique, Spain and Morocco. Commun Comput Inf Sci. 2025; 2240: 63-72. Article. Not Indexed
- **Kissling E, Maurel M, Pozo F, Pérez-Gimeno G, Buda S, Sève N, Domegan L, Hooiveld M, Oroszi B, Martínez-Baz I, Guiomar R, Latorre-Margalef N, Mlinaric I, Lazar M, Duran JG, Dürrwald R, Enouf V, McKenna A, de Lange M, Túri G, Trobajo-Sanmartín C, Gomez V, Hagey TS, Vucina VV, Cherciu MC, Vazquez MG, Erdwiens A, Masse S, Bennett C, Meijer A, Kristóf K, Castilla J, Rodrigues AP, Filipovic SK, Ivanciuc AE, Bacci S, Kaczmarek M.** Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1) pdm09: VEBIS primary care multicentre study, 2023/24. Euro Surveill. 2025; 30(23): e2500011. Article. IF: 8.3; D1
- **Lenglart L, Özmen I, Aguilera-Alonso D, Blázquez-Gamero D, Boeddha NP, Buddingh EP, Buonsenso D, Calvo C, Castagnoli R, Daina M, Dourdouna MM, Emonts M, Ezinwoke C, Gouveia C, Vas DG, Hol J, Holm M, Kahlert CR, Kohlmaier B, Ludwikowska K, Marseglia GL, McArdle A, McGalliard R, Michos A, Nagle A, Niederer-Loher A, Nygaard U, Oostenbrink R, Srovin TP, Roisin S, Saavedra-Lozano J, Shan A, Thors VS, Strenger V, Syngelou A, Tilmanne A, Tokarczyk M, Tsilifis C, Tsolia M, Tulling A, Van Kempen E, Van Veen M, Vincek K, Von Both U, Zavadskan D, Zaman M, Nijman RG, Ouldali N, Borensztajn D.** Paediatric invasive group A streptococcal infections and associations with viral infections in 15 European countries after lifting non-pharmaceutical interventions against SARS-CoV-2: an interrupted time-series analysis. Lancet Reg Health Eur. 2025; 59: 101497. Article. IF: 15.7; D1
- **López-Medrano F, Carver PL, Rutjanawech S, Aranha-Camargo LF, Fernandes R, Belga S, Daniels SA, Mueller NJ, Burkhard S, Theodoropoulos NM, Postma DF, van Duijn PJ, de las Revillas FA, del Molino-Bernal**



CP, Hand J, Lowe A, Bodro M, Vanino E, Fernández-Cruz A, Ramos-Martínez A, Makek MJ, Mjahed RB, Manuel O, Kamar N, Calvo-Cano A, Rueda-Carrasco L, Muñoz P, Álvarez-Uría A, Pérez-Recio S, Sabé N, Rodríguez-Álvarez R, Silva JT, Mularoni A, Vidal E, Alonso-Titos J, del Rosal T, Classen AY, Goss CW, Agarwal M, Mejia-Chew C. Clinical management and outcomes of nontuberculous mycobacterial infections in solid organ transplant recipients: a multinational case-control study. Transplantation. 2025; 109(2): e134-41. Article. IF: 4.9; Q1

- **Lozano-Rodríguez R, Hierro L, Quiles MJ, Pascual-Iglesias A, Terrón-Arcos V, Muñoz-Bartolo G, Frauca E, Cueto FJ, Calvo C, Córdoba-García L, Fernández-Felipe J, Hurtado-Navarro L, del Prado-Montero J, María-Diez GSD, Arvelo-Rosario D, Jara P, del Fresno C, López-Collazo E.** Comprehensive immune profiling and predictive modelling of paediatric acute hepatitis of unknown aetiology from a Spanish cohort. Front Immunol. 2025; 16: 1599982. Article. IF: 7.0; Q1
- **Martínez-Baz I, Navascués A, Trobajo-Sanmartín C, Pozo F, Fernández-Hurrta M, Olazábal-Arruiz M, Argente-Colas L, Ezpeleta G, Echeverría A, Casado I, Ezpeleta C, Castilla J.** Effectiveness of influenza vaccination in preventing confirmed influenza cases and hospitalizations in Northern Spain, 2023/24 season: A population-based test-negative case-control study. Int J Infect Dis. 2025; 151: 107364. Article. IF: 4.6; Q1

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

- **Martinez-Laso J, Cervera I, Muñoz-Chimeno M, Casas I, Avellón A.** Could the paediatric acute hepatitis of unknown origin be related to a new autoimmune disease? J Hepatol. 2025; 82(4): e176-7. Letter. IF: 40.1; D1
- **Martínez-Planas A, Baquero-Artigao F, Méndez-Echevarría A, del Rosal T, Rodríguez-Molino P, Toro-Rueda C, Bustillo-Alonso M, Lafuente M, Canet A, Manzanares A, Tagarro A, Sanz-Santaeufemia FJ, Guillén-Martín S, Cilleruelo MJ, Falcón-Neyra L, Santiago B, Rincón E, Lillo M, Soriano-Arandes A, Sedda L, Fortuny C, Monsonís M, González-Martín J, Tebruegge M, Noguera-Julián A.** A 28-year multicenter cohort study of nontuberculous mycobacterial lymphadenitis in children, Spain. Emerg Infect Dis. 2025; 31(3): 536-46. Article. IF: 7.9; D1
- **MC Rose A, Lucaccioni H, Marsha K, Kirsebom F, Whitaker H, Emborg HD, Botnen AB, O'Doherty M, Pozo F, Hameeda SS, Andrews N, Hamiltona M, Trebbien R, Moller KL, Marquess DF, Murphy S, Mcqueeniea R, Lopez-Bernal J, Cottrell S, Bucholc M, Kissling E, Group EI.** Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025. Euro Surveill. 2025; 30(7): 2500102. Article. IF: 8.3; D1
- **Méndez-Echevarría A, Soler-Simon JA, Carro ES, Pérez PF, Garcia RJ, Lucas-Torres BSR, Pérez MT, Alcolea S, Garcia-Garcia ML, Baquero-Artigao F, Calvo C.** Early nirsevimab administration during hospitalization for rsv bronchiolitis may reduce disease severity in non-immunized infants: a descriptive study. Arch Bronconeumol. 2025; 61(12): 787-90. Letter. IF: 8.7; D1
- **Moraleda C, Ludwikowska K, Gastesi I, Okarska-Napierala M, Epalza C, Paredes-Carmona F, Varela AR, Kulboka N, Kursa M, Fumado V, Martínez-Mejías A, Domínguez-Rodríguez S, Mesa-Rubio ML, Kuchar E, Grasa C, Soriano-Arandes A, Szenborn L, Iglesias-Bouzas MI, Roche-Gómez A, Tagarro A.** Both corticosteroids and intravenous immunoglobulin protect from aneurysms in children with multisystem inflammatory syndrome: a multicenter ambispective study. Pediatr Infect Dis J. 2025; 44(12): 1173-80. Article. IF: 2.3; Q2
- **Moreno-Galarraga L, Vera CG, Rivero-Calle I, Martinón-Torres F, López ID, Cabañas F, Calvo C.** Pediatric research in Spain: challenges and opportunities. An Pediatr. 2025; 103(1): 503854. Article. IF: 2.6; Q1
- **Muruzábal C, Rico-Nieto A, Baquero-Artigao F, Fernández-Sampedro M, Buznego PR, Sánchez-Márquez JM, Pizones J, Quiles MI, San Juan I, Grasa C, Calvo C.** Mycobacterium fortuitum: A rare cause of surgical site infection. Pediatr Infect Dis J. 2025; 44(1): e22-4. Article. IF: 2.3; Q2
- **Neth O, Alsina L, Riviere JG, López-Granados E, Seoane-Reula ME, Granado LG, Sánchez-Ramon S, Rodriguez-Gallego C, (del Rosal T).** Spanish consensus on the diagnosis and management of patients With Activated PI3K Delta Syndrome (APDS). J Invest Allerg Clin. 2025; 35(2): 87-102. Review. IF: 6.6; Q1
- **Papaevangelou V, Pedrero-Tomé R, Syridou G, Baquero-Artigao F, Rodríguez-Molino P, del Rosal T, Noguera-Julián A, Ríos-Barnés M, Fortuny C, Villaverde S, Frick MA, Vallejo BA, Soler-Palacín P, Saavedra J, Karagiannidou S, Rincón E, Busselo IS, Zuriarrain OM, Calderón EM, Tagarro A, Malumbres M, Colino E, Llanos EG, Ruiz AM, Mateos MS, Espuny XB, Alonso-Ojembarrena A, Ferreras-Antolin L, Pérez IC, Posse AF, Lyall H, Blázquez-Gamero D.** Severe neutropenia in infants with congenital cytomegalovirus on antiviral therapy. Pediatr Infect Dis J. 2025; 44(11): 1044-50. Article. IF: 2.3; Q2
- **Pischedda S, Gómez-Carballa A, Pardo-Seco J, Viz-Lasheras S, Camino-Mera A, Bello X, Curras-Tuala MJ, Rivero-Calle I, Dacosta-Urbieta AI, Martinón-Torres F, Salas A, (Calvo Rey C).** DNA methylation signatures of severe RSV infection in infants: evidence from non-invasive saliva samples. Epigenet Chromatin. 2025; 18(1): 25. Article. IF: 4.4; Q1
- **Rojas-Castro M, Verdasca N, Monge S, De Mot L, Trobajo-Sanmartín C, Duffy R, Túri G, Kuliese M, Duerrwald R, Borg M, Popovici O, Gómez V, Makaric Z, Launay O, Marques D, Pozo F, Witdouck A, Martínez-Baz I, Fitzgerald M, Oroszi B, Jancoriene L, Buda S, Dziugyte A, Lazar M, Machado A, Tabain I, Nguyen L, Wagner E, Dufrasne F, Castilla J, Domegan L, Velkey V, Majauskaite F, Hackmann C, Nicolay N, Bacci S, Rose A.** COVID-19 vaccine effectiveness against hospitalization in older adults, VEBIS hospital network, Europe, September 2024-May 2025. Influenza Other Resp. 2025; 19(11): e70191. Article. IF: 3.9; Q1
- **Rose AMC, Nicolay N, Mazagatos C, Martínez-Baz I, Launay O, De Mot L, Bella A, Lazar M, Machado A, Kuliese M, Abela S, Vucina VV, van Gageldonk-Lafeber R, Bino S, Dürrwald R, Paradowska-Stankiewicz I, Horváth JK, Duffy R, Husa P, Mcmenamin J, Pozo F, Howard J, Latorre-Millán M, Castilla J, Nguyen LBL, Dauby N, Riccardo F, Ivanciuc A, Gómez V, Jancoriene L, Xuereb G, Petrovic G, Marbus S, Vasili A, Tolksdorf K, Bogusz J, Oroszi B, Domegan L, Soucková L, Marsh K, Bacci S, Kissling E.** Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case-control studies, 2015/16-2023/24. Bmc Med. 2025; 23(1): 602. Article. IF: 8.7; D1
- **Sossa-Alarcón MC, Gutiérrez MP, Becerra N, Ortegón LY, David MC, Vanegas MN, Friedrich G, Vásquez-Hoyos P, Mesa-Rubio ML, Navarro-Ramirez LM, Moreno-López S, Baquero OL, Mejía LM, Piñeros JG, Restrepo-Gualteros S, Álvarez-Moreno C, Díaz-Díaz A, Gutiérrez-Tobar I, Mesa AC, Tuta WRB, Diaz CEG, Africano M, Nieto JM, Camacho PMP, Beltrán-Arroyave C, Trochez RV, Gastesi I, Moraleda C, García AT, Herrero B, Calleja L, Grasa C, Rodriguez P, Melendo S, Soriano-Arandes A, Pastrana IG, García SG, Fumado V, Varela AR.** Phenotypic variation in disease severity among hospitalized pediatric patients with COVID-19: assessing the impact of COVID-19 in the EPICO study. Int J Public Health. 2025; 70: 1607246. Article. IF: 3.2; Q2
- **Tohma K, Jacobsen S, Altmann B, Kendra JA, Landivar M, De La O WE, Fernández-García MD, Gomes KA, Chudnovsky S, Ford-Siltz LA, Pilewski KA, Gao YM, Mazo I, Niendorf S, Parra GI.** GII.17 norovirus re-emerged in the 2020s as a result of dynamic and adaptive evolutionary processes. Nat Commun. 2025; 16(1): 11596. Article. IF: 18.1; D1
- **Viz-Lasheras S, Gómez-Carballa A, Pardo-Seco J, Bello X, Rivero-Calle I, Dacosta AI, Kaforou M, Habgood-Coote D, Cunnington AJ, Emonts M, Herberg JA, Wright VJ, Carrol ED, Paulus SC, Zenz W, Kohlfürst DS, van der Flier M, de Groot R, Schlapbach LJ, Agyeman P, Pollard AJ, Fink C, Kuijpers TT, Anderson S, Calvo C, Martínez-Padilla MD, Pérez-Aragón A, Gómez-Sánchez E, Valencia-Ramos J, Giménez-Sánchez F, Alonso-Quintela P, Moreno-Galarraga L, von Both U, Pokorn M, Zavadska D, Tsolia M, Vermont CL, Moll HA, Levin M, Martinón-Torres F, Salas A, EUCLIDS Consortium, DIAMONDS Consortium, GENDRES Consortium, PERFORM Consortium.** A 5-transcript signature for discriminating viral and bacterial etiology in pediatric pneumonia. Iscience. 2025; 28(2): 111747. Article. IF: 4.5; Q1
- **Wildenbeest JG, Bont L, Cianci D, Azzari C, Brouard J, Calvo C, Cutrera R, Drysdale SB, Epaud R, Gupta A, Herting E, Liese J, Martinon-Torres F, Ruggieri M, Choi Y.** Dynamics of RSV hospitalization rates in ≤ 2-year-old children between 2020-2023 in Europe. Eur J Pediatr. 2025; 184(10): 615. Article. IF: 2.9; Q1
- **Wildenbeest JG, Bont L, Cianci D, Frederix**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

GWJ, Calvo C, Liese J, Cutrera R, Azzari C, Brouard J, Martinón-Torres F, Herting E, Drysdale SB, Epaud R, Gupta A, Ruggieri M, Choi Y. Impact of RSV hospitalization on healthcare costs, caregivers' productivity loss, and quality of life in children ≤ 2 years old in five European countries. Eur J Pediatr. 2025; 184(11): 716. Article. IF: 2.9; Q1

Research projects

- **Alcobendas Rueda RM.** Ultrasonidos e inteligencia artificial en el diagnóstico de monoartritis en niños. FIBHULP. 2025-Ongoing. Managment centre: FIBHULP
- **Bueno Campaña M.** Fortalecimiento de la Detección temprana de IRAs en menores de 5 años mediante herramientas innovadoras en zonas rurales de Guatemala (08-COD1-00128.7/2024 y convenio caixa CO25-00269). Fundación EHAS y TulaSalud, y financiado con 100.000€ por la Comunidad de Madrid. 2024-2026. Managment centre: Fundación Hospital Alcorcón
- **Cabrerizo Sanz M.** Investigación de las infecciones por enterovirus que causan enfermedades neurológicas y respiratorias graves en niños. Vigilancia molecular y serológica de los tipos emergentes (PI22CIII/00035). ISCIII. 2023-2026. Managment centre: ISCIII
- **Calvo Rey C, Aguilera D.** Infecciones invasoras por Strpetococcus pyogenes en niños y adultos: evolución y factores de riesgo microbiológicos, clínicos, genéticos y respuesta inmun. CIBERINFEC. 2024-2025. Managment centre: Fundación HUGM
- **Calvo Rey C.** CLARITY_Causative Link between respirAtory syncytial viRus and chronic lung diseases: Identifying Targets for therapY. UE. 2024-2028. Managment centre: FIBHULP
- **Calvo Rey C.** Impacto a medio plazo de la prevención contra el virus respiratorio sincitial (PI24/00212). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Calvo Rey C.** Impacto del covid-19 materno en la respuesta inmune de los niños. Fundación de LI Asociación Española de Pediatría. 2021-Ongoing. Managment centre: FIBHULP
- **Calvo Rey C.** VERDI_SARS-coV2 variants Evaluation in pRegnancy and paeDIatrics cohorts. UE. 2022-2025. Managment centre: FIBHULP
- **Casas Flechas I.** CLARITY_Causative Link between respirAtory syncytial viRus and chronic lung diseases: Identifying Targets for therapY. UE. 2024-2028. Managment centre: ISCIII/UE
- **Casas Flechas I.** Estudio de los virus respiratorios asociados a las infecciones pediátricas tras el uso de las medidas adoptadas para su control: ¿una nueva situación epidemiológica? (PI24CIII/00013). ISCIII. 2025-2027. Managment centre: ISCIII
- **Casas Flechas I.** VEBIS of COVID-19 and Influenza (OJ/2021/DPR/12924). UE. 2021-2026. Managment centre: ISCIII/UE
- **de Ceano-Vivas M.** RSV in Hospital Emergency Departments in Iberia (RHEDI) Study. GENVIP. 2024-2025. Managment centre: FIBHULP
- **del Rosal Rabés T.** Nuevos biomarcadores para predecir respuesta al tratamiento y recaída en pacientes pediátricos con artritis idiopática juvenil:torque teno virus y proteínas s100 (PI24/00746). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Fernández-García MD.** Vigilancia Molecular y Genómica de Rotavirus en España: estudio molecular de fallos vacunales, rotavirus derivados de vacuna y genotipos emergentes productores de gastroenteritis (PI23CIII/00009). ISCIII. 2024-2026. Managment centre: ISCIII
- **García García ML.** The impact of preventing RSV infections on severe respiratory infections caused by other respiratory viruses in children under one year of age. Merch Sharp and Dome. 2024-2026. Managment centre: Fundación Puerta de Hierro
- **Grasa Lozano CD.** A multicenter study of carbapenem-resistant or carbapenemase-producing gram-netative bacteremia in pediatrics (CARLOS GRASA-ESPID). European Society for Paediatric Infectious Diseases. 2022-Ongoing. Managment centre: FIBHULP
- **Grasa Lozano CD.** Estudio de infecciones por bacterias resistentes a carbapenémicos en pediatría - Carba-PED. Fundación SEIP. 2022-Ongoing. Managment centre: FIBHULP
- **Grasa Lozano CD.** Optimización del uso de Beta-D-Glucano por Wako en el diagnóstico de la candidiasis invasiva en pediatría (PI24/00329). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Grasa Lozano CD.** PERFECT. Estudio de infección fúngica invasiva en pediatría. Gilead Sciences S.L. 2022-Ongoing. Managment centre: FIBHULP
- **Méndez Echevarría AM.** Amigos peludos. Terapia animal para niños en situaciones médicas complejas. Fundación MAPFRE. 2026-2027. Managment centre: FIBHULP
- **Méndez Echevarría AM.** Balance riesgo beneficio de la convivencia con mascotas en niños inmunodeprimidos (PI23/00917). ISCIII. 2024-2026. Managment centre: FIBHULP

Ciber and Retics

- **Calvo Rey C.** Centro de Investigación Biomédica en Res en Enfermedades Infecciosas (CIBERINFEC). ISCIII. (31/12/2025). FIBHULP
- **Casas Flecha I.** Red de Laboratorios Españoles de secuenciación Genómica de SA%RS-CoV-2. (RELECOV). EU. (31/12/2025). ISCIII

Clinical trials

- **Calvo Rey C.** Estudio multicéntrico, abierto, ciego para el evaluador y aleatorizado para evaluar la seguridad y la tolerabilidad de una dosis intravenosa única de oritavancina frente al tratamiento habitual de sujetos pediátricos con infecciones bacterianas agudas de la piel y de la estructura de la piel.
  Type/Phase: II
  Sponsored by: Melinta Therapeutics Inc.
  Signature date: 18/07/2025
- **Mendez Echevarria AM.** Estudio de fase II, de prevención, de grupos paralelos, parcialmente ciego, de múltiples etapas para investigar la inmunogenicidad y la seguridad de formulaciones de la vacuna anti meningocócica pentavalente abcyw en comparación con las vacunas anti meningocócicas autorizadas cuando se administran solas en niños sanos (2 a 9 años de edad) o de forma concomitante con las vacunas pediátricas de rutina en niños pequeños (12 a 15 meses de edad) y lactantes (2 meses de edad).
  Type/Phase: II
  Sponsored by: Sanofi Pasteur Inc.
  Signature date: 21/08/2025
- **Alcobendas Rueda RM.** Ultrasonidos e inteligencia artificial en el diagnóstico de monoartritis en niños.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Alcobendas Rueda, Rosa UMaría.
  Signature date: 21/04/2025
- **Udaondo Gascón C.** Estudio abierto de dosis múltiples para evaluar la farmacocinética, la seguridad y la tolerabilidad de upadacitinib en pacientes pediátricos con artritis idiopática juvenil de evolución poliarticular.
  Type/Phase: III
  Sponsored by: Abbvie Deutschland GMBH.
  Signature date: 13/11/2025
- **De Ceano-Vivas La Calle M.** RSV in hospital emergency departments in iberia (rhedi). study documenting the epidemiological and economic impacts of rsv during the bronchiolitis transmission season in spain and portugal.
  Type/Phase: OTROS
  Sponsored by: Martinon Torres, Federico.
  Signature date: 26/02/2025
- **Calvo Rey C.** Ensayo clínico de fase i, unicéntrico, abierto y de escalado de dosis para evaluar la seguridad y tolerabilidad de la administración intranasal de una solución de linfocitos t de memoria de donante masculino en mujeres adultas.
  Type/Phase: I
  Sponsored by: Calvo Rey, Cristina.
  Signature date: 09/01/2025

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.7.5 Pediatric Systemic Infections; HIV, Tuberculosis, Imported and Emergent Diseases

Publications: 24 | Q1: 12

COMPOSITION

Talía Sainz Costa.
Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz/Profesora Asociada. Universidad Autonoma de Madrid

- **Jorge Atucha Margolles.** *Técnico de Laboratorio. FIBHULP*
- **Fernando Baquero Artigao.** *Facultativo Especialista de Área de Pediatría. Hospital Universitario La Paz*
- **Blanca Bravo Queipo de Llano.** *Facultativo Especialista de Área de Pediatría. Investigadora Rio Hortega. Hospital Universitario La Paz*
- **Jorge Bustamante Amador.** *Pediatra en Atención Primaria. Hospital Universitario La Paz*
- **Francisco José Climent Alcalá.** *Facultativo Especialista de Área de Pediatría. Unidad de Patología Compleja. Hospital Universitario La Paz/Clínico Colaborador docente. Univesidad Autónoma de Madrid*
- **Roberto del Amparo Temporao.** *Investigador Postdoctoral. FIBHULP*
- **Lucía Escolano Taravillo.** *Investigador Predoctoral. Hospital Universitario La Paz*
- **Luis Escosa García.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Jaime Delgado Pérez.** *Investigador Predoctoral. Hospital Universitario La Paz*
- **Miguel García Boyano.** *Pediatra de Atención Primaria. Hospital Universitario La Paz*
- **Marta García Fernández de Villalta.** *Facultativo Especialista de Área de Pediatría. Hospital Universitario La Paz/Clínico Colaborador Docente. Univesidad Autónoma de Madrid*
- **María Milagros García López de Hortelano.** *Facultativo Especialista de Área de Pediatría. Hospital Universitario La Paz/Profesora Asociada. Universidad Autónoma de Madrid*
- **Isabel Mellado Sola.** *Facultativo Especialista de Área de Pediatría. Investigadora Predoctoral. Hospital de El Escorial*
- **María Pérez Pascual.** *Facultativo Especialista de Área de Pediatría. Investigadora Predoctoral. Hospital Universitario La Paz*
- **Roi Piñeiro Pérez.** *Jefe Asociado del Servicio de Pediatría. Hospital General de Villalba*
- **Melisa Pucci Molineris.** *Investigadora Postdoctoral. FIBHULP*
- **Paula Rodríguez Molino.** *Facultativo Especialista de Área de Pediatría. Investigadora postdoctoral Juan Rodes. Hospital Universitario La Paz*
- **María Teresa Sánchez Aparicio.** *Investigadora Marie Sklodwoska-Curie. CIBERInfect*
- **Germán Vallejo Palma.** *Investigador Predoctoral. FIBHULP*



STRATEGIC OBJETIVES

1. Vertically acquired HIV infection in children: Comorbidities, biomarkers, HIV reservoir, new therapeutic approaches.
2. Epidemiology of Paediatric Tuberculosis is Spain: molecular epidemiology of drug resistant strains, new diagnostic tools and new drugs for TB: Pharmacodynamics in children and TB-drugs Off-label use in paediatrics.
3. Congenital infections: burden of disease, prompt diagnosis and in-utero and postnatal management, host immune response.
4. Epidemiology of imported and emergent diseases in children: Identification and management of emergent outbreaks. Immuno-pathogenesis, preventive measures and management. Covid-19 in children
5. Immunization strategies in children: immune response in high risk patient's vaccine effectiveness and barriers.
6. Social Determinants of Health in Pediatrics
7. Infection and immunity: microbiome ate the corssroad of immunity and allergy
8. Health-care associated Infections. Resistant bacteria and antimicrobial stewardship / Infecciones asociadas con la assitencia sanitaria. Resistencias a antimicrobioanos y programas de optimización de antimicrobianos

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH LINES

Vertically acquired HIV infection in children

- Immuno-pathogenesis: Immune-activation, inflammation and biomarkers
- Epidemiology, immuno-virological factors
- Comorbidities, long term follow-up, cardioascular risk, bone disorders, metabolic abnormalities, neurocognitive impairment, renal dysfunction.
- Antiretroviral treatment: new drugs, resistances, dosage, toxicity in children, simplification strategies.
- HIV eradication: barriers, HIV reservoir, new antiretroviral drugs and other strategies to achieve HIV replication control.
- Gut Microbiota and bacterial traslocation intestinal as modulating factors for inflammation and Immune-activation in HIV-infected children.
- Transition to adult care: barriers, strategies to maintain adherence to care.

Epidemiology of paediatric Tuberculosis (TB).

- Epidemiology of paediatric TB. paediatric cases as as a sentinel for burden of diseases.
- Molecular Epidemiology of paediatric TB: resistant strains.
- Immuno-pathogenesis: New diagnostic tools in special Populations: HIV-infected, ID patients
- Management of critical situations. Neonatal TB, multidrug resistant and extra-pulmonary TB.

Omics for the diagnostis of pediatric TB

- New fixed-dosed combinations. Off label drugs in children. Pharmacodinamic and pharmacokinetic. Diagnosis Point of care

Congenital infectious diseases

- Congenital Citomegalovirus and Toxoplasma infections: diagnostic barriers, prognostic factors, new therapeutic approaches.
- CHAGAS disease and congenital TB: diagnostic barriers, prognostic factors, pharmacokinetics in newborns and new drugs.

Epidemiology of imported and emergent diseases in children

- Paediatric International Outbreaks: Epidemiology and public health impact: Zika. Rabies. Dengue. Chikungunya. Haemorragic fevers, Mers-co.
- Imported diseases in Spain: epidemiology and special populations: adopted, migrant, refugees, travelers and ID children. Tropical and parasitic infections in children.
- COVID-19 disease in children: epidemiology , diagnostic markers, treatment.

Immunization strategies in children, including high risk patients

- Immunization and vaccine response in special populations: immunocompromised children, transplant recipients, chronic patients, HIV-infected, migrants.
- Vaccine immunogenicity: barriers in paediatric populations.
- New challengies in vaccinology

Microbiome in pediatric infectious diseases

- Microbiome-related biomarkers in food allergy and intolerances
- Microbiome-related biomarkers in childhood TB and other respiratory infections
- Social Determinants of Health in Pediatrics
- The burden of chronic disease in childhood
- Health-care associated Infections.
- The burden of antimicrobial resistance
- Antimicrobial stewardship in pediatrics

RESEARCH ACTIVITY

Master Theses

- **Bravo Queipo de Llano B.** Profilaxis post-exposición frente al VIH en niños y adolescentes[dissertation]. Madrid: URJC: 2025(28/05/2025). Director: Sainz Costa T.
- **Coccolo Góngora A.** Dificultades en el uso de medicación en pacientes pediátricos con patología crónica y complejidad. Revisión y propuesta de guía clínica[dissertation]. Madrid: UNIR: 2025(18/12/2025). Director: Climent Alcalá FJ.
- **Ascunce Abad M.** Estatus distónico en pediatría: revisión sistemática[dissertation]. Madrid: UNIR: 2025(18/12/2025). Director: Climent Alcalá FJ.
- **de Gea Grla A.** Tendencias, indicaciones y seguimiento en los contactos sexuales de riesgo que requieren profilaxis post-exposición frente al VIH en jóvenes[dissertation]. Madrid: URJC: 2025(28/05/2025). Director: Sainz Costa T.

Final Degree Theses

- **Marcos Fuentes D.** Inmunogenicidad de la vacuna nonvalente frente al VPH en niños y adolescentes inmunocomprometidos[dissertation]. Madrid: UAH: 2025(24/06/2025). Director: Sainz Costa T.
- **Galeano Pablo A.** Torquetenovirus como predictor de respuesta inmune a vacuna en pacientes pediátricos inmunodeprimidos: Optimización de muestras y técnicas[dissertation]. Madrid: UAH: 2025(24/06/2025). Director: Sainz Costa T, Sánchez Aparicio MT.
- **Lominchar J.** Infecciones de transmision sexual tras agresiones sexuales en adolescentes [dissertation]. Madrid: UAM: 2025(03/06/2025). Director: Sainz Costa T
- **Lopez Jarrín M.** Screening de patologia importada en candidatos a inmunosupresión en pediatría[dissertation]. Madrid: UAM: 2025(03/06/2025). Director: Sainz Costa T

Publications

- **Aguilera-Alonso D, Sánchez-Cañete J, McArdle LV, del Rosal T, Santaeufemia FJS, Soto B, Saavedra-Lozano J, Tato LP, Álvarez FJM, Navarro SB, Cercenado E, Marín M, Rivas G, Bueno EC, Abad MJG, Arana DM, Yuste J, Baquero-Artigao F, Calvo C.** Impact of the COVID-19 pandemic on pediatric bacterial community-acquired pneumonia: a multicenter retrospective study in Madrid, Spain. Pediatr Infect Dis J. 2025; 44(2): 151-3. Article. IF: 2.3; Q2
- **Baquero-Artigao F.** Update on congenital infections: toxoplasma and cytomegalovirus. Bol Pediatr. 2025; 65(271): 11-9. Article. IF: 0.1; Q4
- **Bravo-Queipo-de-Llano B, Jiménez B, García-Lorenzo M, Melendo S, Carrasco-Colom J, Olteanu-Olteanu FC, Lacuey BR, Calle-Miguel L, Harillo L, Falces-Romero I, Ruiz-Carrascoso G, Marcos DP, de Gopegui ER, Larrosa N, Viñado B, Permuy C, Sampedro**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

M, Ruiz-Azcarate J, del Rosal T, Sainz T, Calvo C, Méndez-Echevarría A. Community-acquired Methicillin-resistant Staphylococcus aureus Infection in Children: Key Features and Comparison to Colonization. Pediatr Infect Dis J. 2025; 44(10): 931-6. Article. IF: 2.3; Q2

- **Bravo-Queipo-de-Llano B, Tato LMP, Noguera-Julián A, Escosa-García L, Frick MA, Bustillo M, Ramos JT, Martín CG, Collado-Hernández P, Gomez MN, Serrano-Villar S, Costa TS.** Weight gain among children and adolescents on dolutegravir in Spain. J Pediatric Infect Dis Soc. 2025; 14(12): piaf110. Article. IF: 3.3; Q1
- **Chafino S, Tarancón-Díez L, Hurtado-Gallego J, Flores-Piñas M, Alcolea S, Olveira A, Navarro ML, Fernández-Arroyo S, Viladés C, Montes ML, Vidal F, Peraire J, Rull A, Sainz T.** Metabolomics for searching non-invasive biomarkers of metabolic dysfunction-associated steatotic liver disease in youth with vertical HIV. Commun Med (Lond). 2025; 5(1): 433. Article. IF: 7.4; Q1
- **Chorafa E, Iosifidis E, Oletto A, Warris A, Castagnola E, Bruggemann R, Groll AH, Lehrnbecher T, Antolin LF, Mesini A, Alkhaaldi AA, Baquero-Artigao F, Cetin BS, Ebrahimi-Fakhari D, Emonts M, Esposito S, Fainardi V, Ghimenton-Walters E, Gijón M, Guerrero AG, Grasa CD, Kairiene I, Kildonaviciute K, Kourti M, Manzanares A, Mendoza-Palomar N, Noni M, Papakonstantinou E, Paulus S, Perwein T, Rascon J, Rincón-López E, Soler-Palacin P, Solopova G, Spoulou V, Strenger V, Tedford K, Tzika C, Zsigmond B, Roilides E.** Antifungal use in immunocompromised children in europe: a 12-week multicenter weekly point prevalence survey (CALYPSO). J Pediat Hematol Onc. 2025; 47(6): e222-30. Article. IF: 0.9; Q3
- **Gallego BC, Sanchís EM, Campos LM, Medina EML, Coll IA, Hortelano MGL, Rey CC.** Most common flood-associated infectious diseases in children. An Pediatr. 2025; 102(3): 503777. Article. IF: 2.6; Q1
- **García-Boyano M, Alcalá FJC, Alonso AR, de Villalta MGF, Alonso OZ, Retolaza IR, Melero IQ, Calvo C, Escosa-García L.** Tracheobronchitis in noncritically ill children with tracheostomy: can quantitative tracheal cultures assist in the management? Pediatr Pulm. 2025; 60(1): e27489. Article. IF: 2.4; Q2
- **García-Cobos S, Alberca NS, Bravo-Queipo-de-Llano B, Casquero-García V, de Arellano ER, Calvo C, Ruíz-Carrascoso G, Falces-Romero I, Escartín NL, Viñado-Perez B, Martínez-López MA, Pérez SM, de Gopegui ER, Vázquez SP, Carrasco-Colom J, García BA, Pérez-Vázquez M, Méndez-Echevarría A, Iglesias JO.** Genomic analysis of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) causing infections in children-a Spanish multicenter study. Front Microbiol. 2025; 16: 1534840. Article. IF: 5.8; Q1
- **Goetzinger F, Caprile AA, Noguera-Julián A, Lo Vecchio A, Baquero-Artigao F, del Rosal T, Brinkmann F, Mouchet F, Velizarova S, Koetz K, Ritz N, Buonsenso D, Song R, Roy RB, Nieminen T, Rau C, Chechenieva V, Welch S, Kaiser-Labusch P, Emonts M, Buxbaum C, Blazquez-Gamero D, Bamford A, Tebruegge M, Martínez-Alier N.** Clinical presentation, diagnostics, and outcomes of infants with congenital and postnatal tuberculosis: a multicentre cohort study of the Paediatric Tuberculosis Network European Trials Group (ptbnet). Lancet Reg Health Eur. 2025; 53: 101303. Article. IF: 15.7; D1
- **Guarch-Ibáñez B, Carreras-Abad C, Frick MA, Blázquez-Gamero D, Baquero-Artigao F, Fuentes I, Soler-Palacin P.** Response to comment on: Potential bias in the analysis of prenatal treatment for congenital toxoplasmosis. Plos Neglect Trop D. 2025; 19(7): e0013138. Letter. IF: 3.6; Q1
- **Hernanz-Lobo A, Gómez-Valverde JJ, Lancharro A, Sánchez-Jacob R, Ribo JL, Schaaf HS, Delgado LG, Capellán-Martín D, Aguilera-Alonso D, Blázquez-Gamero D, Noguera-Julián A, Rodríguez-Molino P, Minguell L, Bustillo-Alonso M, Soriano-Arandes A, Gómez-Pastrana D, García-Basteiro AL, Augusto O, Ledesma-Carbayo MJ, Lopez-Varela E, Santiago-García B.** Diagnostic performance of chest radiography for pediatric tuberculosis across high- and low-burden settings. Front Pediatr. 2025; 13: 1704149. Article. IF: 2.2; Q2
- **Jiménez-Jiménez AB, Galán-Sánchez F, Hortelano MGL, Fumadó V, Salar-Vidal L, Ramos-Amador JT, Menasalvas-Ruiz AI.** Acute infectious gastroenteritis in childhood: the role of rapid multiplex molecular syndromic panels in diagnosis and clinical management. Rev Esp Quim. 2025; 38(4):258-77 . Review. IF: 2.8; Q3
- **Laso-García F, Díaz-Gamero N, Gallego-Ruiz R, Casado-Fernández L, Díez-Tejedor E, Calzado-González A, Pozo-Novoa J, Otero-Ortega L, de Leciñana MA, Gutiérrez-Fernández M.** Extracellular vesicles from poor-outcome intracerebral hemorrhage patients reveal limited reparative potential in a preclinical model. Int J Mol Sci. 2025; 26(21): 10648. Article. IF: 5.6; Q1
- **López E, Sainz T, Dirajlal-Fargo S, Jao J, Pinto J, Buchanan AM, McKenna M, Milinkovic A, Puga A.** Cardiometabolic Health Burden in Pediatric HIV: Unmet Need in the Contemporary Antiretroviral Therapy Era. Cureus. 2025; 6: e85329. Review. IF: 1.3; Q2
- **Martínez-Planas A, Baquero-Artigao F, Méndez-Echevarría A, del Rosal T, Rodríguez-Molino P, Toro-Rueda C, Bustillo-Alonso M, Lafuente M, Canet A, Manzanares A, Tagarro A, Sanz-Santaeufemia FJ, Guillén-Martín S, Cilleruelo MJ, Falcón-Neyra L, Santiago B, Rincón E, Lillo M, Soriano-Arandes A, Sedda L, Fortuny C, Monsonís M, González-Martín J, Tebruegge M, Noguera-Julian A.** A 28-year multicenter cohort study of nontuberculous mycobacterial lymphadenitis in children, Spain. Emerg Infect Dis. 2025; 31(3): 536-46. Article. IF: 7.9; D1
- **Mellado-Sola I, Ivanova SM, Hortelano MGL, Rodríguez-Molino P, Moraleda C, Alambillaga SO, Martín RF, Díaz FJC, García AS, Velázquez IO, Santiago-García B, Sainz T.** Increase of dengue in pediatric travelers in madrid: a multicentric retrospective experience. Trop Med Infect Dis. 2025; 10(9): 243. Article. IF: 3.1; Q2
- **Méndez-Echevarría A, Soler-Simón JA, Carro ES, Pérez PF, García RJ, Lucas-Torres BSR, Pérez MT, Alcolea S, García-García ML, Baquero-Artigao F, Calvo C.** Early Nirsevimab administration during hospitalization for rsv bronchiolitis may reduce disease severity in non-immunized infants: a descriptive study. Arch Bronconeumol. 2025; 61(12): 787-90. Letter. IF: 8.7; D1
- **Míguez MP, García-Min S, del Pozo A, Suso JJM, Alcalá FJC, Holgado MS, García PA, Rodríguez CJ, Santos-Simarro F, Palomares-Bralo M.** Rapid genome sequencing in neonatal and pediatric intensive care units. Evidence and current situation. An Pediatr. 2025; 103(5): 503956. Article. IF: 2.6; Q1
- **Muruzábal C, Rico-Nieto A, Baquero-Artigao F, Fernández-Sampedro M, Buznego PR, Sanchez-Márquez JM, Pizones J, Quiles MI, San Juan I, Grasa C, Calvo C.** Mycobacterium fortuitum: A rare cause of surgical site infection. Pediatr Infect Dis J. 2025; 44(1): e22-4. Article. IF: 2.3; Q2
- **Papaevangelou V, Pedrero-Tomé R, Syridou G, Baquero-Artigao F, Rodríguez-Molino P, del Rosal T, Noguera-Julián A, Ríos-Barnés M, Fortuny C, Villaverde S, Frick MA, Vallejo BA, Soler-Palacín P, Saavedra J, Karagiannidou S, Rincón E, Busselo IS, Zuriarrain OM, Calderón EM, Tagarro A, Malumbres M, Colino E, Llanos EG, Ruiz AM, Mateos MS, Espuny XB, Alonso-Ojembarrena A, Ferreras-Antolin L, Pérez IC, Posse AF, Lyall H, Blázquez-Gamero D.** Severe neutropenia in infants with congenital cytomegalovirus on antiviral therapy. Pediatr Infect Dis J. 2025; 44(11): 1044-50. Article. IF: 2.3; Q2
- **París-Muñoz A, Alcobendas-Rueda RM, Verdú-Sánchez C, Udaondo C, Galán-Gómez V, González-Martínez B, Menéndez JJ, Martínez-Romera I, Minguillón J, Pertínez**

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

L, de Manuel-Gómez C, de la Cruz-benito A, Sanz-Ruperez A, Remesal A, Cámara C, Sánchez-Zapardiel E, del Pino-Molina L, Gómez-Zamora A, Serrano-Olmedo MG, Espanol-Rego M, Valbuena MRD, Climent F, Dorao P, Ríos-Blanco JJ, Andrade JD, Ruiz-Zurita G, Fernández-García MA, Pérez-Martínez A.** CD19 CAR-T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease. Med. 2025; 6(8): 100676. Article. IF: 13.3; D1

- **Villaverde S, Pedrero-Tomé R, Papaevangelou V, Syridou G, Karagiannidou S, Lyall H, Payne H, Frick MA, Soler-Palacín P, Baquero-Artigao F, Rodríguez-Molino P, Fortuny-Guasch C, Rios-Barnés M, Sánchez-Mateos M, Saavedra-Lozano J, Bringué X, Moliner E, Castells L, Muga O, Vives-Oños I, Gkentzi D, Lombardi G, Tagarro A, Colino E, Couceiro JA, Rojo P, de Vergas J, Blázquez-Gamero D, cCMVnet Registry Study Grp.** Antiviral treatment and risk of hearing loss in asymptomatic and mild symptomatic infants with congenital cytomegalovirus. Pediatr Infect Dis J. 2025; 44(3): 239-45. Article. IF: 2.3; Q2
- **Wedderburn CJ, Evans C, Abrams EJ, Bamford A, Bekker A, Bunders MJ, Epalza C, Foster C, Frigati L, Goetghebuer T, John-Stewart G, Kahlert CR, Moraleda C, Musiime V, Namiba A, Nastouli E, Njuguna I, Pahwa SG, Rabie H, Sainz T, Serghides L, Shibemba M, Tsondai P, Powis K, Thorne C, Prendergast AJ.** Research gaps for children who are HIV-exposed but uninfected: outcomes of a research prioritisation workshop. Lancet Hiv. 2025; 12(11): e802-10. Article. IF: 14.6; D1

Research projects

- **Bravo Queipo de Llano B.** Colonización por bacterias resistentes a los antibióticos en menores recién llegados a España y su evolución tras un año de estancia en nuestro país. Estudio BRICK. Fundación SEIP. 2024-2026. Managment centre: FIBHULP
- **Bravo Queipo de Llano B.** Colonización por bacterias resistentes a los antibióticos en menores recién llegados a España y su evolución tras un año de estancia en nuestro país. Fundación SEIP. 2024-Ongoing. Managment centre: FIBHULP
- **Bravo Queipo de Llano B.** Rio Hortega (CM23/00057). ISCIII. 2023-2026. Managment centre: FIBHULP
- **del Amparo R.** Contrato Sara Borrel. (CM24/00191). ISCIII. 2024-2027. Managment centre: FIBHULP
- **Escosa García L.** CARBAPED-1. Bacteriemias por gramnegativos resistentes a carbapenémicos en pediatría: prevalencia, clonalidad y estrategias para la mejora de la supervivencia en España. (PI23/00391). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Escosa García L.** Estudio de infecciones por bacterias resistentes a carbapenémicos en pediatría - CARBA-PED. Fundación SEIP. 2022-Ongoing. Managment centre: FIBHULP
- **Rodríguez Molino P.** Emergencia de Mycobacterium lentiflavum como causa principal de linfadenitis en niños: un enfoque genómico para comprender su epidemiología y transmisión. Asociación Española de Pediatría. 2025-Ongoing. Managment centre: FIBHULP
- **Rodríguez Molino P.** Estudio de la respuesta vacunal en muestras de sangre seca en población pediátrica. European Society for Paediatric Infectious Diseases. 2022-Ongoing. Managment centre: FIBHULP
- **Rodríguez Molino P.** Impacto del COVID-19 materno en la respuesta inmune de los niños. Asociación Española de Pediatría. 2021-2026. Managment centre: FIBHULP
- **Sainz Costa T, Pucci M.** EXPLAIN-TB: Integración de transcriptoma e inteligencia artificial aplicada a la radiografía de tórax para el diagnóstico preciso de tuberculosis en población pediátrica y adulta. CIBER. 2027-2027. Managment centre: CIBER
- **Sainz Costa T, Pucci M.** Intervenciones basadas en el microbioma en la inflamación asociada al envejecimiento: descubrimiento y validación preclínica de agentes antiinflamatorios. CIBER. 2025-2027. Managment centre: CIBER
- **Sainz Costa T, Sánchez Aparicio MT.** Contrato postdoctoral Marie Curie ARISTOS-MSCA-101081334/23APL30098. UE. 2024-2026. Managment centre: CIBERINFEC
- **Sainz Costa T.** Aplicación de técnicas ómicas para el diagnóstico de tuberculosis en niños y adolescentes: CHILD-TB OMICS (PI20/01490). ISCIII. 2021-2025. Managment centre: FIBHULP
- **Sainz Costa T.** Capacitación de personal sanitario en el abordaje de la sexualidad, la prevención de VIH y otras enfermedades de transmisión sexual en adolescentes. Gilead Sciences S.L. 2022-Ongoing. Managment centre: FIBHULP
- **Sainz Costa T.** Ensayo clínico fase II, randomizado, de Quinacina frente a metronidazol en giardiasis resistente en niños: QUIN4KIDS (ICI22/00065). ISCIII. 2023-2026. Managment centre: FIBHULP
- **Sainz Costa T.** Envejecimiento acelerado en niños que viven con el VIH y niños expuestos intraútero al VIH/TAR: proyecto EPIKIDS (PI23/01493). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Sainz Costa T.** Inmunogenicidad de la vacuna 9 valente frente a VPH en niños inmunocomprometidos. MSD. 2023-2027. Managment centre: SEIMC-GESIDA
- **Sainz Costa T.** Nuevos algoritmos diagnósticos en TB. ISCIII- CIBER. 2022-2027. Managment centre: CIBERINFEC
- **Sainz Costa T.** Proyecto EPIKIDS: envejecimiento epigenético en niños que viven con el VIH y niños expuestos intraútero al VIH/TAR. Gilead Sciences S.L. 2023-2025. Managment centre: FIBHULP
- **Sainz Costa T.** Proyecto MEETOOPREP. Gilead Sciences S.L. 2025-2027. Managment centre: FIBHULP
- **Sainz Costa T.** Utilidad de la ecografía torácica en la indicación de ventilación no invasiva en la bronquiolitis aguda del lactante hospitalizado. Estudio de cohorte. European Society of Pediatric Infectious Diseases. 2017-Ongoing. Managment centre: FIBHULP

Clinical trials

- **Sainz Costa T.** Un estudio sin enmascaramiento de fase 2/3 para evaluar la farmacocinética, la seguridad y la actividad antiviral de bictegravir/lenacapavir en niños y adolescentes con vih-1.
  Type/Phase: IIb
  Sponsored by: Gilead Sciences Inc.
  Signature date: 13/02/2025
- **Baquero Artigao F.** Estudio en fase IIA, multicéntrico, aleatorizado, con enmascaramiento para el observador, de 2 grupos para investigar la farmacocinética, la seguridad, la tolerabilidad y la eficacia de aztreonam-avibactam por vía intravenosa ± metronidazol en comparación con el mejor tratamiento disponible (mtd) en participantes pediátricos de entre 9 meses y 18 años de edad con infecciones graves por bacterias gramnegativas incluidas infecciones intrabdominales complicadas.
  Type/Phase: IIa
  Sponsored by: Pfizer Inc.
  Signature date: 20/03/2025
- **Climent Alcalá FJ.** Estudio clínico no intervencionista para confirmar las fuentes originales y verificar los datos fuente de los datos de pacientes no tratados compilados a partir de publicaciones sobre la tk2d.
  Type/Phase: OTROS
  Sponsored by: Ucb Biopharma Srl.
  Signature date: 06/02/2025

Patents and trademarks

- **Mellado MJ, Piñeiro R, authors; Asociación Española de Pediatría (AEPED), assignee.** Brand name: PEDIAMÉCUM; ESM 3079824; 2013 June13.

PEDIAMÉCUM

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.7.6 Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy



Publications: 21 | Q1: 13

COMPOSITION

Antonio Pérez Martínez.
Jefe de Servicio de Hematoncología Pediátrica. Hospital Universitario La Paz/Profesor Título del Departamento de Pediatría. Facultad de Medicina. Universidad Autónoma de Madrid

- **Cristina Aguirre Pórtoles.** *Project Manager. FIBHULP*
- **Alfonso Alba Bernal.** *Investigador Postdoctoral. FIBHULP*
- **Estefanía Ayala Jiménez.** *Investigador Predoctoral. FIBHULP*
- **Saturnino Barrena Delfa.** *Facultativo Especialista de Cirugía Pediátrica. Hospital Universitario La Paz*
- **Halin Bareke.** *Investigadora Postdoctoral. FIBHULP*
- **David Bueno Sánchez.** *Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz*
- **Adela Escudero López.** *Investigadora Postdoctoral. FIBHULP*
- **Mikel Fernández Artacoz.** *Médico Interno Residente en Hematología y Hemoterapia. Hospital Universitario La Paz*
- **Berta González Martínez.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Pilar Guerra García.** *Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz*
- **Elisa Izquierdo Delgado.** *Investigadora Postdoctoral. FIBHULP*
- **Manuel Izquierdo Pastor.** *Investigador Científico CSIC. IIB Sols-Morreale*
- **Adriana Mañas Núñez.** *Investigadora Miguel Servet. FIBHULP*
- **Laura Martín Fernández.** *Gestora de Propiedad Intelectual. FIBHULP*
- **Isabel Martínez Romera.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Carmen Mestre Durán.** *Investigadora Predoctoral. FIBHULP*
- **Antonio Jesús Muñoz Serrano.** *Facultativo Especialista de Área en Cirugía Pediátrica. Hospital Universitario La Paz*
- **Natalia Riestra Ramos.** *Técnico de Grado Superior. FIBHULP*
- **Pedro María Rubio Aparicio.** *Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz*
- **Beatriz Ruz Caracuel.** *Investigadora Bioinformática. Hospital Universitario La Paz*
- **Javier Ruiz Navarro.** *Investigador Predoctoral. IIB Sols-Morreale*
- **Sonsoles San Román Pacheco.** *Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz*
- **Maria Octavia de Santisteban Tara.** *Ayudante de Investigación. Hospital Universitario La Paz*
- **Clara María Venegas Mascaró.** *Investigadora Predoctoral. FIBHULP*
- **Juan Manuel Zapata Hernández.** *Investigador Científico CSIC. IIB Sols-Morreale*

STRATEGIC OBJETIVES

- The Translational Research Group in Childhood Cancer, Hematopoietic Stem Cell Transplantation, and Cell Therapy at the La Paz University Hospital Research Institute (IdiPAZ), led by Dr. Antonio Pérez Martínez, is a multidisciplinary team of physicians, geneticists, biologists, biochemists, and bioinformaticians. Over the past decade, this group has developed projects ranging from knowledge generation to direct clinical application through clinical trials. Our research focuses on the development of advanced therapies for pediatric oncology, infectious diseases, and pediatric transplantation. In short, our research interests include: 1) the use of hematopoietic stem cell transplantation as a platform for cell therapy; 2) improving human stem cell progenitor transplantation in children; 3) cell therapy with memory T lymphocytes as adoptive immunotherapy; and 4) the use of activated and memory NK cells and CAR T-cells in pediatric oncology. In addition, we lead several projects aimed at studying the efficacy and feasibility of cell therapy against infectious diseases. Finally, we are also working on immunological operational tolerance in solid organ transplantation by inducing mixed hematopoietic chimeras through cell therapy. Since 2023, we have been part of the CNIO Clinical Research Unit as the IdiPAZ-CNIO Pediatric Oncohematology Unit.
- We maintain a firm commitment to patients and improving their quality of life, which directly impacts the well-being of society. To this end, we have several active academic clinical trials and collaborations with industry aimed at developing new, more effective therapies with fewer side effects. We work in direct collaboration with the Advanced Therapy Medicinal Products Production Unit (up-MTA). This unit has non-industrial manufacturing authorization from the Spanish Agency for Medicines and Health Products (AEMPS) for three ATMPs under Good Manufacturing Practice (GMP) guidelines: 1) Allogeneic activated and expanded NK cell therapy (NKAE), PEI 17-129 (Clinical Trial No. EudraCT 2016-003578-42 for the treatment of pediatric, adolescent, and young adult sarcomas). 2) Autologous CART 19/22 cell gene therapy (dual CART therapy) for the treatment of B-cell acute lymphoblastic leukemia/lymphoma in pediatric and adolescent patients. 3) Allogeneic CART45RA-NKG2D gene therapy, PEI 20-091 (EudraCT Clinical Trial No. 2019-004310-33) for the treatment of advanced sarcoma in children, adolescents, and young adults.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH LINES

- Analysis of solid/hematological tumor samples to determine their susceptibility to cell therapy, at the functional, protein expression and genetic levels.
- Cell therapy with activated NK cells in childhood cancer.
- Hematopoietic stem cell transplantation as a platform for cell therapy.
- Cell therapy with memory T lymphocytes as adoptive immunotherapy in hematopoietic stem cell transplantation.
- Optimization of cell therapy by generating a chimeric antigen receptor NKG2D (CAR-NKG2D). Evaluation of its specificity, persistence and activity (in vitro and in vivo) for the treatment of childhood cancer.
- Optimization of NK cell therapy using nanotechnology and chimeric antigen receptors (CARs).
- Induction of immunological tolerance in solid organ transplantation by induction of mixed hematopoietic chimera using cell therapy.
- Development of academic clinical trials and collaborations with the pharmaceutical industry as a strategy for the development of new, more effective therapies with fewer side effects in childhood cancer.
- Cell therapy with cytokine-induced memory NK cells for pediatric solid tumors.
- Cell therapy with memory T lymphocytes from convalescent COVID-19 donors as an innovative therapy for COVID-19.



RESEARCH ACTIVITY

Doctoral Theses

- **Mestre Durán C.** Natural Killer Cells in Pediatric Leukemia: Mechanisms of Immunosurveillance and Their Role in Treatment Efficacy in Haploidentical HSCT[dissertation]. Madrid: UAM: 2025(29/05/2025). Director: Pérez Martínez A, Ferreras Puente C.
- **Valle Simón P.** Evaluación de la factibilidad y beneficio de la implementación de un Comité de Medicina Personalizada en un Servicio de Hemato-Oncología Pediátrica en un hospital público de tercer nivel[dissertation]. Madrid: UAM: 2025(14/02/2025). Director: Borobia Pérez AM, Pérez Martínez A.

Master Theses

- **Sánchez L.** Combination strategies to enhance the efficacy of Natural Killer cell therapy in neuroblastoma[dissertation]. Madrid: UAM: 2025(27/06/2025). Director: Mañas Núñez A.
- **Smith Gallego C.** Terapia combinada en sarcomas pediátricos: células NK de memoria y regorafenib como estrategia inmunoterapéutica[dissertation]. Madrid: Universidad San Pablo CEU: 2025(24/06/2025). Director: Bareke H.
- **Blázquez Valero A.** Impacto de la pérdida de STAG2 en la interacción entre células de sarcoma de Ewing y células NK[dissertation]. Madrid: Universidad San Pablo CEU: 2025(07/07/2026). Director: Bareke H.
- **Ayala Jiménez E.** Terapias personalizadas de células NK adoptivas en sarcomas pediátricos[dissertation]. Madrid: Universidad Complutense de Madrid: 2025(06/2025). Director: Bareke H.

Final Degree Theses

- **Madroñal B.** Preclinical research no CAR T-Cell therapy for pediatric leukemias[dissertation]. Madrid: Universidad San Pablo CEU: 2025(11/06/2025). Director: Minguillón J.
- **Suanzes C.** Estrategias para mejorar la infiltración de la terapia con células NK en modelos de organoides de neuroblastoma[dissertation]. Madrid: Universidad San Pablo CEU: 2025(11/06/2025). Director: Mañas Núñez A.
- **Matesanz A.** Estrategias de mejora de la terapia CAR T NKG2D en tumores cerebrales pediátricos[dissertation]. Madrid: Universidad de Alcalá de Henares: 2025(24/06/2025). Director: Clares L.

Publications

- **Baena-Nuevo M, Vera-Zambrano A, Martínez-Laperche C, Buño I, Muñoz-Calleja C, Valenzuela C, Zapata JM, Pérez-Chacón G.** Indole-3-carbinol is an inhibitor of KV1.3 potassium voltage-gated channel activity in chronic lymphocytic leukemia cells. Eur J Pharmacol. 2025; 1007: 178281. Article. IF: 5.7; Q1
- **de las Heras BM, Rubio-Aparicio PM, Rubio-San-Simón A, Moreno L, Mazorra P, Almaraz RL, López ML, Guill JB, Segura V, Bermúdez M, Jiménez I, Ramal D, Canete A.** Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive disease. Clin Transl Oncol. 2025; 27(8): 3421-31. Article. IF: 2.7; Q3
- **Domínguez-Gil B.** Santander statement: towards global convergence in transplantation: sufficiency, transparency, and oversight. Transplantation. 2025; 109(1): 7-9. Editorial Material. IF: 4.9; Q1
- **Echecopar C, Sánchez DB, Triana OL, Angulo BM, Carabante MIB, Torija IL, del Castillo MT, Fuentes C, Plaza M, Martínez AP, Urtasun A, Riesco S, Muñiz SG, Mozo Y, Sisinni L, Vinagre S, Marsal J, González-Vicent M, de Heredia CD, Perez-Martínez A.** The use of mesenchymal stromal cells in steroid-refractory graft-versus-host disease after pediatric hematopoietic stem cell transplantation: a report of the Spanish group of stem cell transplantation (Geth). Bone Marrow Transpl. 2025; 60(12): 1672-4. Letter. IF: 5.1; Q1
- **Galán-Gómez V, González-Martínez B, Alonso-Saladrigues A, Rives S, Herrero B, Kwon M, Sánchez-Pina J, Minguillón J, Martínez-Romera I, Aguilar IM, Mestre-Durán C, Casado G, Sánchez-Martín M, Echecopar C, González-Pérez C, León-Triana O, Aguirre-Portolés C, Molinos-Quintana A, Barba P, Balsalobre P, Pérez-Martínez A.** Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults. Exp Hematol Oncol.. 2025; 14(1): 49. Article. IF: 17.5; D1
- **Gonzaga A, Martínez-Navarrete G, Macía L, Anton-Bonete M, Cahuana G, Tejedo JR, Zorrilla-Muñoz V, Fernandez-Jover E, Andreu E, Eguizabal C, Pérez-Martínez A, Solano C, Hernández-Blasco LM, Soria B.**

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



Non-viral therapy in COVID-19: where are we standing? how our experience with covid may help us develop cell therapies for long COVID patients. Biomedicines. 2025; 13(8): 1801. Review. IF: 4.5; Q2

- **González-Martínez B, Galán-Gómez V, Navarro-Zapata A, Mirones-Aguilar I, Cobo M, Pernas-Sánchez A, Vallejo S, Sánchez-Zapardiel E, León-Triana O, Echecopar C, Martínez-Romera I, Guerra-García P, San Román-Pacheco S, Escudero A, Izquierdo E, Izquierdo M, Naharro S, Martín-Ayuso A, Bareke H, París-Muñoz A, Hu PR, Schneider D, Orentas RJ, Minguillón J, Pérez-Martínez A.** Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL. Ebiomedicine. 2025; 118: 105872. Article. IF: 11.2; D1
- **González-Pérez C, Fernández-Jiménez E, Morán E, Melero H, Malpica N, Álvarez-Linera J, Puig MA, Plaza D, Pérez-Martínez A.** Study protocol for a randomized controlled clinical trial of a multifaceted cognitive training program using video games in childhood cancer survivors. Plos One. 2025; 20(9): e0314118. Article. IF: 2.8; Q2
- **Hammoudi T, Nucera S, Lucas AGT, Ansari M, Balduzzi A, Bertaina A, Buechner J, Corbacioglu S, Dalle JH, Kalwak K, Lee D, Levine JE, Lindemans CA, Locatelli F, Meisel R, Nierkens S, Ottaviano G, Pérez-Martínez A, Pichler H, Prockop SE, Pulsipher MA, Talano JAM, Tewari S, Schultz KR, Shah NN, Verneris MR, Boelens JJ.** Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group. Blood Adv. 2025; 9(23): 6141-57. Review. IF: 7.7; Q1
- **Hernández-Balnco C, Al-Akioui-Sanz K, Herrera L, Aguirre-Portolés C, Lozano-Ojalvo D, Pérez-Rodríguez L, Cano-Ochando J, Guerra-García P, Martín-Quirós A, Vicario JL, Santos S, Pérez-Vaquero MA, Vesga MA, Borobia AM, Carcas AJ, Balas A, Moreno MA, de Diego RP, Gasior M, Soria B, Eguizabal C, Pérez-Martínez A.** The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19. Iscience. 2025; 28(2): 111698. Article. IF: 4.5; Q1
- **Mestre-Durán C, León-Triana O, Bareke H, Pertíñez L, Clares-Villa L, Bueno D, Lozano-Ojalvo D, Navarro-Zapata A, Sisinni L, Badell-Serra I, González-Vicent M, Beléndez C, Palomo-Moraleda P, Mozo Y, Galán V, Artazcoz MF, Echecopar C, Gasior M, Al-Akioui K, Cano-Ochando J, Guerra-García P, Fernández-Santos ME, Aguirre-Portolés C, Perez-Martínez A.** Ex vivo iL-15-stimulated NK cells as adoptive cell therapy in haploidentical transplantation for pediatric leukemia. Am J Hematol. 2025; 100(10): 1898-901. Letter. IF: 9.4; D1
- **Moreno-Alfonso JC, Delgado-Miguel C, Caballero AM, Martínez AP, Irazábal MCY.** To the editor in response to the letter by Peksöz et al. Regardingdiagnostic value of the derived neutrophil-to-lymphocyte ratio for acute appendicitis. Anz J Surg. 2025; 95(10): 2234-5. Letter. IF: 1.5; Q3
- **Muñoz-Serrano AJ, Ramírez-Amoros C, Delfa SB, Oterino C, Navarro G, Aparicio PR, Pérez-Martínez A, Martínez-Urrutia MJ, Martínez L.** The prognostic role of sarcopenia in wilms tumor: does it influence surgical outcomes and survival? Pediatr Blood Cancer. 2025; 72(8): e31828. Article. IF: 2.4; Q2
- **Ortega-García JA, Shakeel O, Wood NM, Pérez-Martínez A, Fuster-Soler JL, Miller MD.** Beyond precision: ambiomic survivorship in childhood and AYA cancer. Cancers (Basel). 2025; 18(1): 7. Review. IF: 4.8; Q2
- **París-Muñoz A, Alcobendas-Rueda RM, Verdú-Sánchez C, Udaondo C, Galán-Gómez V, González-Martínez B, Menéndez JJ, Martínez-Romera I, Minguillón J, Pertíñez L, de Manuel-Gómez C, de la Cruz-benito A, Sanz-Rupérez A, Remesal A, Cámara C, Sánchez-Zapardiel E, del Pino-Molina L, Gómez-Zamora A, Serrano-Olmedo MG, Español-Rego M, Valbuena MRD, Climent F, Dorao P, Ríos-Blanco JJ, Andrade JD, Ruiz-Zurita G, Fernández-Garcia MA, Perez-Martínez A.** CD19 CAR-T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease. Med. 2025; 6(8): 100676. Article. IF: 13.3; D1
- **Pereda J, Espinosa R, García-Solís B, Guerra-Galán T, Van-Den-Rym A, Kars ME, Mena R, Galán V, de Andrés-Martín A, Rodríguez-Gallego C, López-Lera A, Corvillo F, Pérez-Martínez A, López-Collazo E, Sánchez-Ramón S, Martínez-Barricarte R, Quintana-Murci L, Lorenzo-Salazar JM, Itan Y, Flores C, Pérez-de-Diego R.** IEIVariantFilter: a bioinformatics tool to speed up genetic diagnosis of inborn errors of immunity patients. Nar Genom Bioinform. 2025; 7(2): lqaf069. Article. IF: 3.0; Q2
- **Pérez-Martínez A, Rodrigo AL, Boluda ER, Martínez BG, Sánchez AA, Oliveros FH.** Tabelecleucel in post-transplant epstein-barr virus-associated lymphoproliferative disease: patient and oncologist perspectives. Adv Ther. 2025; 42(7): 3011-9. Editorial Material. IF: 4.7; Q1
- **Perganti F, Huybrechts I, Balduzzi AC, Barr R, Biondi A, Bladé AL, Bravo EM, Damasco E, Katsagoni CN, Kattamis A, Lassaletta A, Lera**

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



ML, Llort A, Lopez JB, Martínez AP, Massimino M, La Madrid AM, Moreno L, Alonso AM, Nicolas G, Preziati G, Rizzari S, Della Valle S, Vega CM, Walters M, Kozlakidis Z, Ladas EJ. Southern European prospective investigation into childhood cancer and nutrition (EPICkids): Study design and protocol. Plos One. 2025; 20(9): e0319110. Article. IF: 2.8; Q2

- **Riller Q, Hauri M, Lum SH, Knippenberg J, Sirait T, Laberko A, Halahleh K, Hashem H, Karakukcu M, Sengeloev H, Porta F, Bruno B, Zecca M, Aksoylar S, Barlogis V, Schuetz C, Buechner J, Faraci M, Wehr C, Holter W, Mellgren K, Locatelli F, Martínez AP, Suarez F, Moshous D, Gennery AR, Balashov D, Albert MH, Slatter M, Güngör T, Neven B.** HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective study. Blood. 2025; 145(21): 2518-27. Article. IF: 23.9; D1
- **Tirado N, Fidyt K, Mansilla MJ, García-Pérez A, Martínez-Moreno A, Vinyoles M, Alcain J, García-Peydró M, Roca-Ho H, Fernández-Fuentes N, Guerrero-Murillo M, Falgàs A, Velasco-Hernandez T, Bueno C, Panelli P, Mulens-Arias V, Apostolov A, Engel P, González EA, Vick B, Jeremias I, Caye-Eude A, Baruchel A, Cavé H, Genesca E, Ribera J, Díaz-Beyá M, Martínez-Sánchez MV, Fuster JL, López AE, Minguillón J, Pérez-Martínez A, Ramírez-Orellana M, Torrebadell M, Díaz VM, Toribio ML, Sánchez-Martínez D, Menéndez P.** CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia. J Hematol Oncol. 2025; 18(1): 69. Article. IF: 47.8; D1
- **Torrent A, Morgades M, Iacoboni G, Reguera JL, Kwon M, Corral LL, Hernani R, Ortiz-Maldonado V, Sanz J, Gonzalez ACC, Guerra L, Pina JMS, Mussetti A, Garcia-Sancho AM, Bastos-Oreiro M, Delgado J, Carpio C, Sancho JM, Perez-Martínez A, Barba P.** Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy. Bone Marrow Transpl. 2025; 60(12): 1675-8. Letter. IF: 5.1; Q1

Research projects

- **Izquierdo Delgado EP.** Utilidad clínica de la biopsia líquida en tumores cerebrales pediátricos, para mejorar el diagnóstico, la estratificación y el seguimiento de los pacientes (PI21/00376). ISCIII. 2023-2026. Managment centre: FIBHULP
- **Mañas Núñez A.** Desarrollo y validación de modelos de xenoinjerto derivado del paciente (PDX) como herramienta de planificación terapéutica en oncología pediátrica (PI24/00269). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Mañas Núñez A.** Joining the forces of natural killer cells and ferroptosis to treat refractory neuroblastoma. UE. 2023-2025. Managment centre: FIBHULP
- **Minguillón Pedreño J.** Validación preclínica y clínica de una terapia CAR-T CD7 para leucemias pediátricas (7CAR4KIDS) (PI23/00229). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Pérez Martínez A.** ANTONIO PÉREZ MARTÍNEZ (CERT22/00065). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Pérez Martínez A.** Aproximación académica mediante car-t en hemopatías malignas con necesidad médicas no cubiertas en niños: estudio de viavilidad, seguridad y eficacia (REALL_CAR-T) (PI22/01226). ISCIII. 2023-2027. Managment centre: FIBHULP
- **Pérez Martínez A.** BRAINTRUCK: turning car t therapy into IIL18 truck as treatment for pediatric central nervous system tumors. Fundación Asociación Española contra el Cáncer. 2022-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Ensayo clínico en fase t memoria expresando un receptor chimérico antigénico con especificidad NKG2D en niños, adolescentes y adultos jóvenes con sarcoma avanzado. Fundación Asociación Española contra el Cáncer. 2019-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Ensayo clínico fase II de infusión intratumoral/intraventricular de células CART-NKG2D O NKIL15 en niños, adolescentes y adultos jóvenes con tumores de alto grado recurrentes/refractarios del sistema nervioso central (CINK-CAR) (ICI19/00052). ISCIII. 2020-2025. Managment centre: FIBHULP
- **Pérez Martínez A.** Implementing Magnetic targeting of nao-guided immune cells. ESF-FKC. 2021-2024. Managment centre: FIBHULP
- **Pérez Martínez A.** Memory-like NK cells: a new therapy for Ewing sarcoma (MEMO4EWING). Sunflowers for Izarbe Foundation. 2022-2024. Managment centre: FIBHULP
- **Pérez Martínez A.** Next Generation CART MAD and STAb Immunotherapies (Next Generation CART MAD). CAM. 2023-2026. Managment centre: UAM
- **Pérez Martínez A.** Optimización diagnóstica y terapéutica del cáncer infantil mediante su caracterización genética avanzada utilizando tecnología de alto rendimiento. Subproyecto: caracterización molecular avanzada de la leucemia linfoblástica aguda en pediatría. Fundación Asociación Española contra el Cáncer. 2022-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** SEHOP-PENCIL: Estrategia nacional para la implementación de la medicina

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

personalizada en niños y adolescentes con cáncer (PMP21/00073). ISCIII. 2022-2026. Managment centre: FIBHULP

- **Pérez Martínez A.** Terapia CAR-T alogénica en hemopatías malignas con necesidades médicas no cubiertas en pacientes pediátricos y aya: estudio de viabilidad y seguridad (7CAR4KIDS-ALLO) (ICI24/00069). ISCIII. 2025-2028. Managment centre: FIBHULP

Ciber and Retics

- **Pérez Martínez A.** RICORS - Terapias avanzadas (RD21/0017/0025). ISCIII. (01/01/2025). FIBHULP
- **Pérez Martínez A.** RICORS - Terapias avanzadas (RD24/0014/0024). ISCIII. (31/12/2027). FIBHULP

Clinical trials

- **Bueno Sánchez D.** Estudio de fase III, abierto, de un solo grupo y con dosis repetidas, para evaluar la seguridad y tolerabilidad, la farmacocinética y la actividad antiviral de maribavir para el tratamiento de la infección por el citomegalovirus (cmv) en niños y adolescentes que han recibido un trasplante de células madre hematopoyéticas (hsct) o un trasplante de órgano sólido (tos).
  Type/Phase: III
  Sponsored by: Takeda Development Center Americas.
  Signature date: 14/10/2025
- **Bueno Sánchez D.** Un estudio de fase III, abierto, de un solo grupo, multicéntrico de ravulizumab junto al mejor tratamiento sintomático en participantes pediátricos (de 1 mes a <18 años) con microangiopatía trombótica (mat) después de un trasplanta de células madre hematopoyéticas (tcmh.
  Type/Phase: III
  Sponsored by: Alexion Pharmaceutical Inc.
  Signature date: 30/05/2025
- **González Martínez B.** An open label complex clinical trial in newly diagnosed pediatric de novo aml patients - a study by the nopho-db-ship consortium.
  Type/Phase: III
  Sponsored by: Princess Máxima Center For Pediatric Oncology.
  Signature date: 22/04/2025
- **González Martínez B.** Estudio prospectivo, aleatorizado, abierto, en fase ii para evaluar la superioridad de inotuzumab ozogamicina en monoterapia frente a allr3 para el tratamiento de inducción de la leucemia linfoblástica aguda infantil de precursores de linfocitos b en primera recidiva de alto riesgo.
  Type/Phase: II
  Sponsored by: Pfizer Inc.
  Signature date: 24/02/2025
- **Guerra García P.** Estudio de fase 1, multicéntrico, abierto, con intensificación de dosis y expansión de cohorte con niraparib y dostarlimab en pacientes pediátricos con tumores sólidos recurrentes o refractarios.
  Type/Phase: I
  Sponsored by: Glaxosmithkline Research And Development Limited.
  Signature date: 06/06/2025
- **Guerra García P.** Estudio en fase 1/2 de determinación de la dosis y ampliación de la dosis de cobolimab en combinación con dostarlimab en participantes pediátricos y adultos jóvenes con tumores recién diagnosticados y recidivantes/resistentes al tratamiento (popstar)".
  Type/Phase: II
  Sponsored by: Glaxosmithkline Research And Development Limited ,.
  Signature date: 29/05/2025
- **Guerra García P.** Estudio en fase I/II de la seguridad, tolerabilidad, farmacocinética y eficacia preliminar de relatlimab más nivolumab en participantes pediátricos y adultos jóvenes con linfoma de hodgkin clásico y linfoma no hodgkin recurrentes o resistentes.
  Type/Phase: I
  Sponsored by: Bristol-Myers Squibb International Corporation.
  Signature date: 30/06/2025
- **Pérez Martínez A.** Ensayo clínico de fase I de terapia con células cart para la leucemia linfoblástica aguda refractaria/recidivante con necesidades insatisfechas en niños, adolescentes y adultos jóvenes: estudio de viabilidad y seguridad (reall_cart).
  Type/Phase: I
  Sponsored by: Fundacion Para La Investigacion Biomedica Hospital Universitario La Paz.
  Signature date: 19/06/2025
- **Rubio Aparicio PM.** A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (pk) of maintenance cabozantinib (xl184) plus best supportive care (bsc) versus bsc in children, adolescents and young adults (aya) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment.
  Type/Phase: II
  Sponsored by: Ipsen Innovation.
  Signature date: 18/06/2025
- **Rubio Aparicio PM.** HR-NBL2: high-risk neuroblastoma study 2.0 of siop-europeneuroblastoma/siopen randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma.
  Type/Phase: III
  Sponsored by: Instituto Investigacion Sanitaria H La Fe.
  Signature date: 01/10/2025
- **Rubio Aparicio PM.** International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory ewing sarcoma.
  Type/Phase: II
  Sponsored by: Grupo Español De Investigacion En Sarcomas.
  Signature date: 31/01/2025
- **Rubio Aparicio PM.** Registro nacional GEIS 78: estudio observacional de la epidemiología e historia natural de tumores mesenquimales.
  Type/Phase: No EPA
  Sponsored by: Grupo Español De Investigacion En Sarcomas.
  Signature date: 10/12/2025

Patents and trademarks

- **Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees.** Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application, IB2019/052042; 2018 March 13
- **Pérez Martínez A, Ferreras Puente C,B, inventors; UAM, FIBHULP, Universidad Miguel Hernández de Elche (UMH), Fundación de la Comunitat Valenciana para la gestión del Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), assignees.** Memory T cells as adoptive cell therapy for viral infections. EP20382850.4 (EP3974029), PCT/EP2021/076516; 2020 September 25.
- **Mayán Santos M, Acea Nebril B, Varela Eirín M, Rodríguez-Candela Mateos M, Díaz Carballa CC, Fonseca Capdevila E, Barrio LC, Escudero López A, inventors; Fundación Profesor Novoa Santos- Instituto de Investigación Biomédica de A Coruña (INIBIC), assignees.** Composición para el tratamiento de los efectos secundarios de la radioterapia y/o quimioterapia. PCT/ES2020/070269: 2020 April 27

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.7.7 Congenital Malformations, Transplantation and Oncological Surgery

Publications: 29 | Q1: 16

COMPOSITION

Francisco Hernández Oliveros.
Facultativo Especialista de Área en Cirugía Pediátrica. Hospital Universitario La Paz

- **Maria Virginia Amesty Morello.** *Médico Adjunto en Cirugía Pediátrica. Hospital Universitario La Paz*
- **Ane Miren Andrés Moreno.** *Facultativo Especialista de Área en Cirugía Pediátrica. Hospital Universitario La Paz/Profesor Asociado. Universidad Autónoma de Madrid*
- **Sara Cabezuelo Ballestero.** *Facultativo Especialista de Área en Anestesiología. Hospital Universitario La Paz*
- **Carlos de la Torre Ramos.** *Médico Adjunto en Cirugía Pediátrica. Hospital Universitario La Paz*
- **Carlos Delgado Miguel.** *Facultativo Especialista de Área en Cirugía Pediátrica. Hospital Universitario Infantil La Paz*
- **José Luis Encinas Hernández.** *Facultativo Especialista de Área en Cirugía Pediátrica. Hospital Universitario Infantil La Paz*
- **Álvaro González Rocafort.** *Facultativo Especialista de Cirugía Pediátrica. Hospital Universitario Infantil La Paz*
- **Juan Carlos López Gutiérrez.** *Jefe de Servicio de Cirugía Pediátrica. Hospital Universitario Infantil La Paz*
- **Ana Lourdes Luis Huertas.** *Facultativo Especialista en Cirugía Pediátrica. Hospital Universitario La Paz*
- **María Nieves Moreno.** *Facultativo Especialista de Área en Oftalmología. Hospital Universitario La Paz*
- **Susana Noval Martín.** *Facultativo Especialista de Área en Oftalmología. Hospital Universitario La Paz*
- **Jesús Peralta Calvo.** *Facultativo Especialista de Área en Oftalmología Infantil. Hospital Universitario La Paz*
- **Esther Ramos Boluda.** *Jefe de Sección. Unidad de Rehabilitación y Trasplante Intestinal. Hospital Universitario La Paz*
- **Fernando Reinoso Barbero.** *Jefe de Servicio de Anestesiología y Reanimación Infantil. Hospital Universitario La Paz*
- **Alba Sánchez Galán.** *Facultativo Especialista de Cirugía Pediátrica. Hospital Universitario La Paz*
- **Javier Serradilla Rodríguez.** *Facultativo Especialista de Área en Cirugía Pediátrica. Hospital Universitario La Paz*
- **Paloma Triana Junco.** *Facultativo Especialista de Área en Cirugía Pediátrica. Hospital Universitario La Paz*
- **María Teresa Vallejo Cremades.** *Jefe de Laboratorio Inmunohisto-química (Contrato de Estabilización de Técnicos de Apoyo). FIBHULP*
- **Leandro Vecchio Dezillio.** *Investigador Postdoctoral. FIBHULP*
- **Alejandra Vilanova Sánchez.** *Médico Interno Residente en Cirugía Pediátrica. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- General objectives for the next 5 years
- Anesthesia, pain management and perioperative intensive care: Develop new strategies to improve safety and efficacy in anesthetic procedures, and investigate the multiple problems of pain management and anesthetic support.
- Vascular anomalies: to investigate the genetic and molecular mechanisms involved in the pathogenesis of vascular anomalies and to evaluate new treatments.
- Cardiovascular surgery: Evaluate different organ perfusion devices and develop new strategies for graft perfusion.
- Congenital malformations: Acquire knowledge about the cellular and molecular mechanisms of malformations using animal models, organ and cell cultures, and genetically modified animals.
- Ophthalmological pathology: To investigate the genetic and molecular mechanisms involved in the pathogenesis of ocular malformations and rare eye diseases.
- Transplantation: Investigating new strategies for graft tolerance/rejection prevention and analyzing the impact of donation after circulatory death with normothermic perfusion in pediatric transplantation. This also includes conditions leading to organ failure, such as intestinal rehabilitation (intestinal transplantation), liver tumors (liver transplantation), and severe uropathies (kidney transplantation).
- Specific scientific objectives for the next 5 years
- Planned research projects
- Anesthesia: We will focus on the safe transfusion of blood products and metabolic monitoring during complex surgical procedures. We will also include any quality initiatives within our reach.
- Vascular anomalies: We will continue our recent project focused on the long-term safety and efficacy of alpelisib in patients with PIK3CA-related overgrowth spectrum (PROS); and we will continue our contribution to the lymphatic malformation program.
- Cardiovascular Surgery: We plan to begin our research on mitochondrial transplantation to improve recovery after myocardial infarction. We will also continue our hemodynamic evaluation of ex vivo perfusion devices. In the clinic, we will prospectively analyze the heart transplant program recently developed by DCD.
- Congenital malformations: We will delve deeper into our study of fetal alcohol syndrome. More specifically, our goal is to further investigate the role of antioxidant agents. We will also continue our research on prenatal instrumental manipulation in spina bifida in collaboration with the research group at Cincinnati Children's Hospital.
- Ocular pathology: We will continue our open line of research into genetic study in congenital non-syndromic bilateral cataracts and myopia with or without nystagmus.
- Transplantation: Finally, as the only group involved in pediatric intestinal transplantation in Spain, we will also continue our efforts to improve graft viability, deepen our understanding of rejection and graft-versus-host disease (GVHD), and promote tolerance through various cell therapies. All this work in animal models will be complemented by human studies in liver and intestinal transplantation.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

RESEARCH LINES

- Anesthesia, pain management and perioperative intensive care: Develop new procedures to improve the safety and effectiveness of anesthetic procedures, and investigate the multiple problems of pain management and anesthetic support.
- Vascular anomalies: Investigate the genetic and molecular mechanisms involved in the pathogenesis of vascular anomalies and evaluate new targeted therapies.
- Cardiovascular surgery: Evaluate different organ perfusion devices and develop new strategies for graft perfusion.
- Congenital malformations: Acquire knowledge about the cellular and molecular mechanisms of malformations using animal models, organ and cell cultures and, eventually, genetically modified animals.
- Ophthalmological pathology: To investigate the genetic and molecular mechanisms involved in the pathogenesis of ocular malformations and rare eye diseases.
- Transplantation: Investigate new strategies for graft tolerance/rejection prevention and analyze the impact of donation after circulatory death with normothermic reperfusion in pediatric transplantation. Additionally, our research would include the treatment of conditions leading to organ failure, such as intestinal rehabilitation (intestinal transplantation), liver tumors (liver transplantation), and severe uropathies (kidney transplantation).
- Transplantation: To investigate new strategies for graft tolerance/avoidance of rejection and to analyze the impact of donation after circulatory death with normothermic reperfusion in pediatric transplantation. Additionally, the management of the conditions leading to organ failure would be included in our topics, like intestinal rehabilitation (intestinal transplantation), liver tumours (liver transplantation) and severe uropathies (renal transplantation).

RESEARCH ACTIVITY

Doctoral Theses

- **Cabezudo Ballesteros S.** Evaluación de un dispositivo de CPAP de Alto Flujo como estrategia de "Weaning" de ventilación mecánica prolongada en pediatría[dissertation]. Madrid: UAM: 2025(07/03/2025). Director: Reinoso Barber F, Sanabria Carretero P.

Publications

- **Alfonso JCM, Barbosa-Velásquez S, Delgado-Miguel C, Caballero AM, Hernández-Martín S, Martínez AP, Irazábal MCY.** Exploring the utility of cellular indices in the diagnosis of ulcerative colitis. Gastroent Hepat-Barc. 2025; 48(8): 502349. Article. IF: 2.0; Q3
- **Ballesteros SC, Carretero PS, Parga LC, Vega AM, García LL, Barbero FR.** Clinical study on the predictive utility of high flow CPAP in weaning from prolonged mechanical ventilation in critical paediatric surgery patients. Rev Esp Anestesiol Reanim. 2025; 72(2): 501658. Article. IF: 1.3; Q3
- **Basilio MS, Rodríguez-Laguna L, Junco PT, Martínez-Glez V, Ramírez-Amoros C, Delgado-Miguel C, Rodriguez-Arias JP, López-Gutiérrez JC.** Association of somatic KRAS variants with osteolysis in arteriovenous malformations. Eur J Pediatr Surg. 2025; 35(5): 362-8. Article. IF: 1.8; Q2
- **Celemín EF, Miguel CD, Domene PO, López JDS, OReilly MH, Cabezudo FS, López JMG, Nieto ALP.** Improving obesity treatment: metabolic and bariatric surgery plus body contour surgery. Surg Obes Relat Dis. 2025; 21(11): 1241-5. Article. IF: 3.2; Q1
- **Delgado-Miguel C, Arredondo-Montero J, Moreno-Alfonso JC, Garavis Montagut I, San Basilio M, Hernández I, Carrera N, Martínez L, Iraola E, Ruiz Jiménez I, Aguado Roncero P, Fuentes E, Díez R, Hernández-Oliveros F.** The role of neutrophil-to-lymphocyte ratio as a predictor of orchiectomy or testicular atrophy after torsion in children: a multicentric study. J Pers Med. 2025; 15(7): 310. Article. Not Indexed
- **Delgado-Miguel C, Arredondo-Montero J, Moreno-Alfonso JC, Montagut IG, Rodríguez M, Jiménez IR, Carrera N, Roncero PA, Fuentes E, Díez R, Hernandez-Oliveros F.** Indocyanine green fluorescence navigation in pediatric hepatobiliary surgery: systematic review. Children (Basel). 2025; 12(7): 950. Review. IF: 2.6; Q1
- **Delgado-Miguel C, Camps J, Montagut IG, Díez R, Arredondo-Montero J, Hernández-Oliveros F.** Robotic-assisted vs. laparoscopic splenectomy in children: a systematic review and up-to-date meta-analysis. J Pers Med. 2025; 15(11): 522. Review. Not Indexed
- **Delgado-Miguel C, Camps JI.** Robotic surgery in newborns and infants under 12-months: Is it feasible? Asian J Surg. 2025; 48(10): 6032-6. Article. IF: 5.2; D1
- **Delgado-Miguel C, Fuentes E, Aguado P, Díez R.** Gynecomastia outpatient surgical treatment in children without closed-suction drain placement: is it safe and effective? Children (Basel). 2025; 12(11): 1571. Article. IF: 2.6; Q1
- **Delgado-Miguel C, Fuentes E, Aguado P, Díez R.** The use of 8-mm powered articulation endostapler for sublobar resection in children. Preliminary Case Series. J Laparoendosc Adv S. 2025; 35(3): 266-70. Article. IF: 1.1; Q3
- **Delgado-Miguel C, Fuentes E, Ruiz-Jiménez I, Carrera N, Aguado P, Díez R.** Suprascrotal approach for testicular prosthesis placement in children after testicular torsion. Arch Esp Urol. 2025; 78(10): 1362-7. Article. IF: 1.2; Q4
- **Delgado-Miguel C, Gómez LF, Morán AG, Miguel-Ferrero M, Díaz M, López-Gutiérrez JC.** Neutrophil-to-lymphocyte ratio as a predictor of short- and long-term complications in pediatric burns. Ital J Pediatr. 2025; 51(1): 10. Article. IF: 3.5; Q1
- **Delgado-Miguel C, Mejía R, Amesty V, Rivas S, Lobato R, López-Pereira P, Martínez-Urrutia MJ.** Dorsal dartos flap for buried penis treatment: surgical technique and long-term outcomes. Pediatr Surg Int. 2025; 41(1): 274. Article. IF: 1.8; Q2
- **Delgado-Miguel C, Reparaz L, Clarkson W, Desai K, Camps JI.** Robotic-assisted surgery in pediatric gynecology: preliminary initial outcomes. J Gynecol Surg. 2025; 41(6): 265-70. Article. IF: 0.3; Q4
- **Estefanía-Fernández K, Triana P, Ramírez-Amorós C, Gaspar-Pérez M, Muñoz-Serrano AJ, Velayos M, San Basilio M, Buitrago NM, Parrón M, Andrés A, Hernández-Oliveros F, Gutiérrez JCL.** Non-involuting congenital hepatic hemangioma: lessons from a case series. Children (Basel). 2025; 12(7): 893. Article. IF: 2.6; Q1
- **Gémez-García E, Granados M, Saceda JM, Moreno MN, Zamorano J, Cebrián JL, Noval S.** Role of computer-assisted surgery in the management of pediatric orbital tumors: insights from a leading referral center. Children (Basel). 2025; 12(12): 1649. Article. IF: 2.6; Q1
- **Li WH, Bokkers RPH, Wildhaber BE, Calinescu AM, Ricoeur A, Marra P, Bravi M, Pinelli D, Minetto J, Dip M, Sierre S, de Santibañes M, Ardiles V, Uno JW, Hardikar W, Bates S, Goh L, Aldrian D, Seisenbacher J, Vogel GF, Neto JS, da Fonseca EA, Costa CM, Ferreira CT, Nader LS, Farina MA, Dajani KZ, Parente A, Bigam DL, Liang TB, Bai XL, Xiang J, Gonsorcikova L, Fronek J, Bohus S, Franchi-Abella S, Gonzales E, Guérin F, Junge N, Baumann U, Richter N, Hartleif S, Sturm E, Rajakannu M, Palaniappan K, Rela M, Pawaria A, Rajakrishnan H, Surendran S, Kumar M, Agarwal S, Gupta S, Asthana S, Sakpal M, Avalareddy A, Spada M, Monti L, Alterio T, Yanagi Y, Uchida H, Komine R, Evans H, Carr-Boyd P, Duncan D, Stefanowicz M, Latka-Grot J, Kolesnik A, Brogering DC, Raptis DA, Marquez KAH, Mali V, Aw M, Beretta M, van der Schyff F, Quintero J, Mercadal-Hally M, Molino-Gahete JA, Andres AM, Hernandez-Oliveros F, Remacha EF, Casswall T, Jorns C, Delle M, Gupte GL, Sharif K, Mcguirk SP, Superina R, Caicedo JC, Jaramillo C, Bitterfeld L, Kastenberg Z, Shah AA, Domenick B, Acord MR, Mazariegos G, Soltys K, Dinorcia J, Patel P, Florman S, Buchholz BM, Herden U, Fischer L, Dierckx RAJO, Hartog H, van der Doef HPJ.** Management of hepatic artery thrombosis and stenosis

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

after pediatric liver transplantation: Variability and agreement in management practices. Liver Transplant. 2025; 31(12): 1533-44. Article. IF: 3.8; Q1

- **Lledín MD, Parrón-Pajares M, Andrade-Guerrero D, Quilés-Blanco J, Morais A, Hernández-Oliveros F, Frauca E, Botella-Carretero JI.** Effect of muscle mass on catch-up growth after liver transplant in infants with biliary atresia. Pediatr Transplant. 2025; 29(8): e70219. Article. IF: 1.4; Q3
- **Moratilla-Lapeña L, Sarmiento M, Ramírez C, San Basilio M, Delgado-Miguel C, Álvarez M, Pascual I, Vilanova-Sánchez A, Sánchez-Galán A.** Surgical treatment of external hemorrhoids in pediatric patients. Chirugia-Ital. 2025; 38(6): 449-51. Article. IF: 0.1; Q4
- **Moreno-Alfonso JC, del Campo-Pedrosa R, Delgado-Miguel C, Arregui MI, Caballero AM, Martínez AP, Irazábal MCY.** Comparison of two combined models of cellular indices and food allergies for the screening of pediatric eosinophilic esophagitis. Rev Esp Enferm Dig. 2025; 117(12): 796-7. Letter. IF: 4.8; Q1
- **Moreno-Alfonso JC, Delgado-Miguel C, Caballero AM, Martínez AP, Irazábal MCY.** Clinical-pathological correlation of endoscopic findings in eosinophilic esophagitis in the pediatric population. Rev Esp Enferm Dig. 2025; 117(12): 765-7. Letter. IF: 4.8; Q1
- **Moreno-Alfonso JC, Delgado-Miguel C, Caballero AM, Martínez AP, Irazábal MCY.** Correlation of endoscopic findings with histological alterations in pediatric ulcerative colitis. Rev Esp Enferm Dig. 2025; 117(12): 769-70. Letter. IF: 4.8; Q1
- **Moreno-Alfonso JC, Delgado-Miguel C, Caballero AM, Martínez AP, Irazábal MCY.** To the editor in response to the letter by Peksöz et al. regarding diagnostic value of the derived neutrophil-to-lymphocyte ratio for acute appendicitis. Anz J Surg. 2025; 95(10): 2234-5. Letter. IF: 1.5; Q3
- **Moreno-Alfonso JC, Delgado-Miguel C, Martin SH, Caballero AM, Martinez AP, Irazábal MCY.** Clinical manifestations of Meckel's diverticulum and analytical distinction with appendicitis: a 20-year diagnostic study. Rev Esp Enferm Dig. 2025; 117(11): 692-4. Letter. IF: 4.8; Q1
- **Papa-Gobbi R, Stringa P, Gentilini MV, Ivanoff I, Machuca M, Arreola NM, Serradilla J, Estefanía-Fernández K, Talayero P, Velayos M, Sánchez-Zapardiel E, Gondolesi G, Andrés-Moreno A, Rumbo M, Hernández-Oliveros F.** Low regulatory T-cells frequency is associated with graft rejection after small bowel transplantation: Clinical and experimental evidence. Plos One. 2025; 20(1): e0307534. Article. IF: 2.8; Q2
- **Perez-Martínez A, Rodrigo AL, Boluda ER, Martínez BG, Sánchez AA, Oliveros FH.** Tabelecleucel in post-transplant epstein-barr virus-associated lymphoproliferative disease: patient and oncologist perspectives. Adv Ther. 2025; 42(7): 3011-9. Editorial Material. IF: 4.7; Q1
- **Pruna A, Reinoso-Barbero F, Jakobsson J, Landoni G.** Volatile anesthetics and greenhouse effect: A clinical perspective. Anesth Analg. 2025; 141(2): e21-2. Letter. IF: 4.7; Q1
- **Seeger P, Preukschas AA, Lücke J, Sabihi M, Stringa P, Lausada N, Moreira J, Dezillio LEV, Serradilla J, Moreno AMA, Oliveros FH, Bennemann S, Machicote A, Zazara DE, Papazoglou ED, Mercanoglu B, Ghadban T, Nentwich MF, Nickel F, Mann O, Hackert T, Gentilini MV, Oh J, Oldani G, Chartier-Plante S, Harriman D, Oldhafer KJ, Huber S, Gondolesi GE, Giannou AD.** Revolutionizing small bowel transplantation in mice and rats: A cutting-edge dry-lab simulation model. Curr Prob Surg. 2025; 73: 101917. Review. IF: 3.1; Q1
- **Torres-Luna R, Soto MCS, Reinoso-Barbero F.** Analgesic efficacy of clinical hypnosis in pediatric patients following orthopedic surgery. An Pediatr. 2025; 102(4): 503831. Article. IF: 2.6; Q1

Research projects

- **Andrés Moreno AM, Hernández Oliveros F.** Influencia del hígado en el injerto intestinal. Estudio de su papel protector de rechazo. Sociedad Madrileña de Trasplantes. 2023-Ongoing. Managment centre: FIBHULP
- **Andrés Moreno AM.** Desarrollo y aplicación terapéutica de un sistema de perfusión normotérmica extracorpórea en trasplante intestinal: el final de la edad de hielo (PI23/01189). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Hernández Oliveros F.** ERN TransplantChild 2023-2027. UE. 2023-2027. Managment centre: FIBHULP
- **Hernández Oliveros F.** Prevención del rechazo mediante transferencia adoptiva de linfocitos T regulatorios en un modelo experimental de trasplante intestinal (PI21/01332). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Hernández Oliveros F.** TRASPLANTAPP: la primera red de comunicación para niños y adolescentes trasplantados. Fundación MAPFRE. 2020-Ongoing. Managment centre: FIBHULP
- **Hernández Oliveros F.** TRASPLANTAPP: la primera red de comunicación para niños y adolescentes trasplantados. Fundación Mutual Médica. 2020-Ongoing. Managment centre: FIBHULP
- **Hernández Oliveros F; Vecchio Dezillio LE.** Estudio clínico y experimental de inducción de tolerancia operacional mediante la combinación de trasplante de progenitores hematopoyéticos y trasplante de órgano sólido. DUALGRAFT (AP-16022/2024). Fundación Mutua Madrileña. 2024-2027. Managment centre: FIBHULP
- **López Gutiérrez JC, Triana Junco P.** Estudio genético y funcional en pacientes con enfermedades de Gorham-Stout (GSD) y anomalías linfáticas generalizadas (GLA). The Lymphatic Malformation Institute. 2018-Ongoing. Managment centre: FIBHULP
- **López Gutiérrez JC.** Trasplante de unidades foliculares en niños con alopecia cicatricial. Proyecto experimental con traslación clínica (PI23/01464). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Luis Huertas AL.** Cirugía Guiada Por Fluorescencia: Realidad aumentada y navegación intraoperatoria con verde de indocianina en el cáncer infantil. Estudio de viabilidad clínica y experimental. FIBHULP. 2024-2026. Managment centre: FIBHULP
- **Noval Martín S.** Protocolo para el diagnóstico precoz de causas sensoriales ocultas de Nistagmus infantil (AI-2024-061). Federación Española de Enfermedades Raras. 2025-2026. Managment centre: FIBHULP
- **Triana Junco P.** Biopsia líquida en malformaciones arteriovenosas (PI24/00250). ISCIII. 2025-2027. Managment centre: FIBHULP

Clinical trials

- **Hernández Oliveros F.** Ensayo de fase I, unicéntrico y abierto para evaluar la seguridad y tolerabilidad de la infusión diferida de un injerto hematopoyético deplecionado de células t naïve con linfocitos t de memoria en receptores de trasplante de órganos sólidos, incluido en el estudio clínico y experimental de inducción de tolerancia operacional mediante la combinación de trasplante de progenitores hematopoyéticos y trasplante de órgano sólido.
  Type/Phase: I
  Sponsored by: Hernández Oliveros, Francisco.
  Signature date: 03/06/2025
- **López Gutiérrez JC.** A phase 2 study of mutant-selective pi3kα inhibitor, RLY-2608, in adults and children with pik3ca related overgrowth spectrum and malformations driven by pik3ca mutation.
  Type/Phase: II
  Sponsored by: Relay Therapeutics, Inc.
  Signature date: 05/09/2025
- **López Gutiérrez JC.** Epik-p4: estudio de fase II de un único grupo que evalúa la eficacia, la seguridad y la farmacocinética de alpelisib (byl719) en pacientes pediátricos y adultos con síndrome de sobrecrecimiento asociado a pik3ca.
  Type/Phase: II
  Sponsored by: Novartis Pharma Services Ag.
  Signature date: 21/11/2025
- **Noval Martín S.** Efficacy and safety assessment of t1695 ophthalmic suspension, versus ciclosporin ophthalmic emulsion, in participants with moderate to severe vernal keratoconjunctivitis (vkc).
  Type/Phase: II
  Sponsored by: Sas Laboratoires Thea.
  Signature date: 25/09/2025
- **Noval Martín S.** Un estudio adaptativo de fase III, aleatorizado, doble ciego, de dosis múltiples, de grupos paralelos controlados con placebo para evaluar la eficacia de la atropina para tratar la progresión de la miopía en niños/as y adolescentes de 3 a menos de 18 años de edad (estudio moderado).
  Type/Phase: III
  Sponsored by: Ocus Innovation Ireland Limited.
  Signature date: 01/03/2025

Patents and trademarks

- **Hernández Oliveros F, Nana Gómez Mayoral N, Raya González L, Guijarro Fernández E, authors; FIBHULP, HePA, U-TAD, Guijarro Fernández E, assignees.** Trademark name:VTR Virtual Transplant Reality; CM18.000.131;2018 December 14.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.7.8 Research in Endometriosis

Publications: 10 | Q1: 5

COMPOSITION

Alicia Hernández Gutiérrez.
Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Ginecología Oncológica. Hospital Universitario La Paz/ Profesor Asociado. Facultad de Medicina. Universidad Autónoma De Madrid

- **Covadonga Álvarez López.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Mario Álvarez Maestro.** *Facultativo Especialista de Área en Urología. Hospital Universitario La Paz*
- **Martina Aida Angelés Fité.** *Ginecóloga especialista en Oncología. Institut Universitaire Du Cancer De Toulouse*
- **Ónica María Armijo Suárez.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Reproducción Asistida. Hospital Universitario La Paz*
- **María Arribas Tejedor.** *Investigadora Predoctoral. FIBHULP*
- **Pedro N. Barri Soldevilla**. *Director del Departamento de Obstetricia, Ginecología y Reproducción Humana. Fundación Dexeus Mujer*
- **María del Carmen Céspedes Casas.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Myriam García Segovia.** *Médico Adjunto en Ginecología. Hospital Universitario La Paz*
- **Juan Antonio García Velasco.** *Director Médico. IVI - RMA*
- **Silvia Iniesta Pérez.** *Ginecóloga especialista en Reproducción. Hospital Ruber Internacional*
- **Ana López Carrasco.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Alejandra Martinez Rodriguez-Marin.** *Subdirector del Departamento de Oncología Quirúrgica. Institut Universitaire du Cancer de Toulouse*
- **Blanca Martínez Serrano.** *Facultativo Especialista de Área en Anestesiología. Hospital Universitario La Paz*
- **Emanuela Spagnolo.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Endometriosis is an estrogen-dependent inflammatory disease of still unknown origin that affects approximately 10% of women of reproductive age, impacting their quality of life and reproductive health. Despite its high prevalence and the extensive scientific research surrounding this disease, its etiology remains a mystery. Although it is a chronic condition that begins to produce symptoms very early in many cases, there are still no predictive markers, no methods for early diagnosis, and no way to modify its highly variable clinical course, causing significant uncertainty for affected women. There is also no etiological treatment or cure, although significant progress has been made in symptom management and in treating the disease holistically, without compromising a woman's fertility.
- The endometriosis research group is committed to the following objectives in the next 5 years: to develop a scientific project for FIS 2023, to encourage young researchers, to organize a Master's Degree in Laparoscopy and Endometriosis, to increase the number of undergraduate and master's theses, to improve the training of gynecological residents and to promote rotations abroad, to produce publications of the results of our ongoing projects (mainly FIS 2020), to design a website for the HULP-Endometriosis group and to publicize the monthly workshops for patients with doctors and professionals from the Endometriosis Unit.
- We also set ourselves the challenge of achieving recognition as an Endometriosis Unit-CSUR and promoting gender equality in research and innovation.
- The strategies proposed to achieve these objectives are the following: Participation in the FIBHULP "Mentor Program", promoting strict collaboration between senior and junior researchers to carry out research projects, oral/poster presentations for congresses, facilitating the "Winner Project" for residents and young gynecologists (this is an educational program for Endoscopic Gynecological Surgery with 3 levels of progression), and fostering cooperation with suppliers in the endoscopic sector such as Storz, Olympus, and Striker.
- In addition, we have the support of Biostatistics from IdiPaz and the IdiPAZ Biobank (PT20 / 00004) integrated into the National Network of Biobanks of Spain, technical assistance from the Information and Bioengineering Service of HULP, as well as active collaboration with national patient associations and dissemination of events in "La Paz Informa".
- The Endometriosis Unit at La Paz Hospital also has numerous strategic alliances, both nationally (Hospital Clínic de Barcelona, Hospital General de Valencia, Clínica Dexeus de Barcelona) and internationally (Oncopole - Oncology Institute of Toulouse (France), University Hospital of Bologna (Italy), University Hospital of Liège (Belgium), University Hospital of Siena (Italy), University Hospital of Malmo (Stockholm)..

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH LINES

- Investigation of immunological and molecular factors involved in the pathogenesis of endometriosis.
- Biomarker research to predict the risk of malignant transformation of endometriosis. Our goal is to identify a panel of immune system markers and specific genetic mutations to predict which endometriosis patients are at higher risk of developing ovarian cancer and to identify factors that would allow the use of immunotherapy in this type of cancer. In both pathologies (endometriosis and ovarian cancer), immune system dysfunction promotes disease progression. In February 2021, the Endometriosis Group received a Health Research Fund from the Carlos III Health Research Institute for the project: "Molecular and immunological factors with predictive value in ovarian cancer associated with endometriosis."
- Research into new non-hormonal drugs to control the symptoms and progression of the disease.
- Clinical research at the surgical level, and in particular on Fluorescence-Guided Surgery (FGS). In our operating rooms, we have state-of-the-art technology that allows for real-time visualization of specific anatomical structures, helping surgeons reduce operative stress and improve their performance. Recently, the intraoperative use of indocyanine green (ICG) has shown advantages in intestinal surgery for endometriosis. ICG is a contrast agent injected intravenously. It quickly reaches the blood vessels of abdominal organs, allowing for fluorescence emission in the near-infrared (NIR) spectral range. This allows for the assessment of vascularization of the colorectal anastomosis after intestinal resection in patients with endometriosis. We are currently investigating the use of a macromolecule bound to ICG, which allows the dye to remain longer in vascularized tissues (rectum) with a single injection at the beginning of surgery. This technique is also useful for delimiting endometriotic nodules before removing them.
- Clinical research related to the early diagnosis of endometriosis in adolescent patients (European Project: Erasmus Project).



RESEARCH ACTIVITY

Final Degree Theses

- **Rey Hernández M.** Impacto de la endometriosis sobre la supervivencia en mujeres con cancer de ovario asociado [dissertation]. Madrid: CEU San Pablo: 2025(26/06/2025). Director: Spagnolo E.
- **Suarez Vega M.** Impacto de la nutrición en la evaluación clínica y en el perfil analitico de las pacientes con endometriosis [dissertation]. Madrid: UAM: 2025(24/06/2025). Director: Hernández Gutiérrez A, Spagnolo E.

Publications

- **Mendiola M, Heredia-Soto V, Baillo A, Ruz-Caracuel I, Mena R, Berjón A, Escudero FJ, Pedregosa J, Hernández A, Feliú J, Hardisson D, Redondo A.** Improving the performance of polymerase chain reaction for microsatellite instability testing in endometrial cancer. Sci Rep-Uk. 2025; 15(1): 44262. Article. IF: 4.9; Q1
- **Spagnolo E, Fuentes BD, López A, De Celada RA, Buño A, Ramiro-Cortijo D, Hernández A.** Impact of dietary patterns on pain and quality of life in ovarian and deep endometriosis: observational study for nutritional interventions. BMC Womens Health. 2025; 25(1): 613. Article. IF: 3.3; Q1
- **Hernández A, Pascual I, Siegrist J, López A, Zapardiel I, Gracia M, Usandizaga R, Muñoz MD, Pérez L, Ferreras ER, Alonso E, Carmona A, Spagnolo E.** Pioneering robotic surgery for complex gynecologic conditions: implementation beyond cancer care. J Robot Surg. 2025; 19(1): 627. Article. IF: 4.2; D1
- **Maldonado-Barrueco A, Almazán-Garate E, Armijo-Suárez O, Iniesta-Pérez S, Sanz-González C, Álvarez-López C, Cacho-Calvo J, Quiles-Melero I.** Detection of bacterial vaginosis-associated bacteria and outcomes during clinical gynaecological conditions using qPCR: A retrospective cohort study. Diagn Micr Infec Dis. 2025; 113(4): 117065. Article. IF: 1.8; Q3
- **Vitis LAD, Bogani G, Raspagliesi F, Sanchez OA, Navarro B, Multinu F, Zanagnolo V, Baiocchi G, De Brot L, Fanfani F, Capasso I, Piedimonte S, DeGuerke L, Buda A, Mauro J, Alessio M, Filipello F, Beiner M, Kadan Y, Papadia A, Vizzielli G, Restaino S, Grassi T, Landoni F, Bianchi T, Grimm C, Polterauer S, Ricotta G, Martinez A, Buderath P, Kimmig R, Chiantera V, Zand B, Zapardiel I, Hernandez A, Gill S, Covens A, Dagher C, Meschini T, Cucinella G, Schivardi G, Occhiali T, Lembo A, Palmieri E, Shahi M, Fought AJ, McGree ME, Suman VJ, Abu-Rustum NR, Ramírez PT, Mariani A, Glaser GE.** Outcomes of low-risk endometrial cancer with isolated tumor cells in the sentinel lymph nodes: a prospective, multi-center, single-arm, observational study (ENDO-ITC study). Int J Gynecol Cancer. 2025; 35(8): 101764. Article. IF: 5.4; D1
- **Loayza A, Hernández A, Rodríguez AM, Lopez B, González C, Hardisson D, de la Pena I, Serrano M, Arnedo R, Zapardiel I.** HPV E6/E7 mRNA testing in the follow-up of hpv-vaccinated patients after treatment for high-grade cervical intraepithelial neoplasia. Vaccines (Basel). 2025; 13(8): 823. Article. IF: 3.5; Q2
- **González-Peramato P, Álvarez-Maestro M, Heredia-Soto V, Sabio MM, Linares E, Serrano A, Alvarez-Ossorio JL, Prieto L, Alcina EL, Rodríguez MA, Berglund E, Alonso FV.** Comparing prostatype P-score and traditional risk models for predicting prostate cancer outcomes in Spain. Actas Urol Esp. 2025; 49(6): 501788. Article. IF: 1.7; Q3
- **Spagnolo E, Ramiro-Cortijo D, Fuentes BD, Vega MS, Calvillo-Fernández L, López A, Hernández A.** To operate or not to operate? The impact of

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



surgical treatment on quality of life in women with ovarian endometriosis. Front Glob Womens Health. 2025; 6: 1606768. Article. IF: 2.5; Q1

- **Loayza A, Moreno-Palacios E, Frías L, Navarro Y, Meléndez M, Marti C, Garrido D, Berjón A, Hernández A, Sánchez-Méndez JI.** Current Indications for seed-marked axillary lymph node dissection in breast cancer. Cancers (Basel). 2025; 17(10): 1682. Article. IF: 4.8; Q2
- **Maldonado-Barrueco A, Almazán-Garate E, Armijo-Suárez O, Iniesta-Pérez S, Sanz-González C, Falces-Romero I, Alvarez-López C, Cacho-Calvo J, Quiles-Melero I.** Utility of sexually transmitted infection screening in diagnosing clinical gynaecological conditions using endometrial specimens. Diagn Micr Infec Dis. 2025; 112(4): 116830. Article. IF: 1.8; Q3

Research projects

- **Hernández Gutiérrez A.** Dinamización de ciencia disruptiva en predictores de enfermedades tumorales, infecciosas y hereditarias como base de la medicina personalizada (FORT23/00006_GRUPO V). ISCIII. 2024-2027. Managment centre: FIBHULP
- **Hernández Gutiérrez A.** Estudio para la implementación de la tecnología ómica en la identificación de marcadores asociados a transformación maligna de la endometriosis ovárica (PI23/00752). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Hernández Gutiérrez A.** Factores inmunológicos en la transformación maligna de la endometriosis. FIBHULP. 2018-Ongoing. Managment centre: FIBHULP
- **Hernández Gutiérrez A.** Identificación de factores inmunológicos y moleculares con valor pronóstico en cáncer de ovario asociado a endometriosis e implicados en el potencial de malignización de la endometriosis (PI20/01368). ISCIII. 2021-2025. Managment centre: FIBHULP

Clinical trials

- **Álvarez Maestro M.** A phase 1/2 study of eg-70 as an intravesical administration to patients with bcg-unresponsive nmbic and high-risk nmbic patients who are bcg naïve or received incomplete bcg treatment.
  Type/Phase: I
  Sponsored by: Engene Inc.
  Signature date: 09/01/2025
- **Álvarez Maestro M.** A phase 1/2 study of eg-70 as an intravesical administration to patients with bcg-unresponsive nmbic and high-risk nmbic patients who are bcg naïve or received incomplete bcg treatment.
  Type/Phase: I
  Sponsored by: Engene Inc.
  Signature date: 31/10/2025
- **Álvarez Maestro M.** Estudio en fase 3, aleatorizado, abierto y multicéntrico para evaluar la eficacia y seguridad del sistema de administración intravesical de erdafitinib tar-210 en comparación con quimioterapia intravesical elegida por el investigador en pacientes con cáncer de vejiga no músculo-invasivo de alto riesgo con alteraciones sensibles del fgfr y que han recibido bacilo calmette-guérin (bcg) intravesical.
  Type/Phase: III
  Sponsored by: Janssen Research & Development, Llc.
  Signature date: 14/07/2025
- **Álvarez Maestro M.** Estudio fase 3, abierto, multicéntrico, aleatorizado para evaluar la eficacia y seguridad de tar-200 en combinación con cetrelimab frente al bacilo de calmette y guérin (bcg) intravesical en pacientes con cáncer de vejiga no músculo-invasivo de alto riesgo (hr-nmibc) sin tratamiento previo con el bcg.
  Type/Phase: III
  Sponsored by: Janssen Cilag International Nv.
  Signature date: 06/04/2025
- **Álvarez Maestro M.** Phase 1/2 study of erdafitinib intravesical delivery system (tar-210) in participants with non-muscle-invasive or muscle-invasive bladder cancer.
  Type/Phase: I
  Sponsored by: Janssen Cilag International Nv.
  Signature date: 26/02/2025
- **Álvarez Maestro.** Estudio clínico de fase 2b para evaluar la eficacia y seguridad de tar-200 en combinación con cetrelimab, tar-200 solo o cetrelimab solo en participantes con cáncer de vejiga no músculo-invasivo (cvnmi) de alto riesgo que no responde a la terapia del baci.
  Type/Phase: IIb
  Sponsored by: Janssen Cilag International Nv.
  Signature date: 14/07/2025
- **Armijo Suárez OM.** A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of a post-coital intravaginal gel of pkb171 in couples with mild male factor infertility (easy study).
  Type/Phase: II
  Sponsored by: Prokrea Bcn S.L.
  Signature date: 01/12/2025
- **Iniesta Perez S.** Estudio observacional prospectivo para evaluar la fertilidad en mujeres de entre 32 a 38 años tratadas con el complemento alimenticio ovosicare® fertility que contiene una combinación de myo/dci en una proporción de 3,6:1, antioxidantes, vitaminas y minerales.
  Type/Phase: OTROS
  Sponsored by: Procare Health Iberia Sl.
  Signature date: 12/02/2025

Patents and trademarks

- **Hernández A, López A, Spagnolo E, authors; FIBHULP, assignees; Brand name: EndoPaz: 018876162.** 2023 May 17, 2023 September 27



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.7.9 Research on Comprehensive Care for Transplanted Children and Adolescents



Publications: 7 | Q1: 6

COMPOSITION

María Jesús Pascau González-Garzón.
Supervisora de Enfermería. Hospital Universitario La Paz
Luz Yadira Bravo Gallego.
Medical Advisor. FIBHULP

- **María Teresa Álvarez Gómez.** *Supervisora de Enfermería de Hospitalización Pediátrica. Hospital Universitario La Paz*
- **Almudena Alonso Márquez.** *Supervisora de Enfermería Unidad de Hospitalización Pediátrica. Hospital Universitario La Paz*
- **Mercedes Hermosilla Mínguez.** *Supervisora de Enfermería de Unidad Pediátrica. Hospital Universitario La Paz*
- **Carlos Martín Saborido.** *Vocal Asesor. Ministerio de Sanidad y Consumo*
- **Paloma Martínez Campos.** *Enfermera pediátrica en unidad de Reanimación y Anestesia Infantil. FIBHULP*
- **Miriam Muñoz Berges.** *Enfermera Especialista en Pediatría en Nefrología Infantil. Hospital Universitario La Paz*
- **Antonia Polo Lucero.** *Enfermera Especialista en Pediatría. Hospital Universitario La Paz*
- **Guillermo Manuel Sibón Sancho.** *Enfermero. FIBHULP*

STRATEGIC OBJETIVES

- Pediatric solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT) have dramatically changed the life expectancy of many children by providing them with treatment they would not otherwise have survived. Worldwide, approximately 150,000 hematopoietic stem cell transplants and 80,000 hematopoietic stem cell transplants are performed annually. Pediatric transplantation accounts for about 10% of all SOTs and 20% of all HSCTs. Between 2012 and 2016, 7,741 SOTs and 14,717 HSCTs were performed in children in the European Union (EU), and the number of transplants performed worldwide continues to rise.
- Pediatric SOT and HSCT replace terminal illness with a more sustainable chronic condition, enabling young people to reach adulthood. However, while transplantation can improve individual health outcomes, it can also be associated with long-term side effects requiring ongoing monitoring and care. Post-transplant follow-up care aims to prevent rejection and transplant-related complications so that each individual can achieve a life expectancy and quality of life (QoL) similar to that of their healthy peers.
- The "Research in comprehensive care for transplanted children and adolescents" group arises from the need to fill the gaps in knowledge about comprehensive care for children and adolescents who receive transplants in the pediatric age.
- The group will focus on researching three specific topics:
  1. Transition and transfer of adolescents and young adults (AYAs) living with a transplant to adult clinics: clinical and psychosocial impact. Transition is a gradual, multifaceted, active, and intentional process involving many important steps and checkpoints. The process consists of three phases: (1) transition planning and preparation, (2) transfer of care, and (3) integration into adult healthcare. Each of these phases presents unique obstacles to success and opportunities for improvement.
  2. Quality of life in the context of pediatric transplantation: patient-reported outcomes and experience measures (PROM and PREM).
  3. Innovation in health education for transplanted children and adolescents and their parents/caregivers/relatives: evaluation of programs and validation of tools and questionnaires.

RESEARCH LINES

- Transition and transfer of adolescent and young adult pediatric transplant recipients to adult care: clinical and psychosocial impact.
- Quality of life in pediatric transplantation: outcome measures and experiences reported by the patient/family (PROMs and PREMs).
- Innovation in health education for transplanted children and adolescents and their parents/caregivers/family: evaluation of programs and validation of tools and questionnaires.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH ACTIVITY



Master Theses

- **Marcos Blasco A, Fierro Castillo C.** Satisfacción familiar con un Programa de Acogida de pacientes pediátricos en espera de trasplante de órgano sólido.[dissertation]. Madrid: UAM: 2025(30/04/2025). Director: Pascau González-Garzón MJ, Martínez Campos P.

Publications

- **Alba-Cano T, Alonso R, Balastegui-Martín H, Bravo-Gallego LY, Sánchez-Mateos P, Martín-López M, Gil-Herrera J.** Impact of CMV latency on T-cell responses to COVID-19 vaccination among predominantly antibody-deficient patients. Front Immunol. 2025; 16: 1659259. Article. IF: 7.0; Q1
- **Amil-Dias J, Kvist PK, Bravo-Gallego LY, Hartmann D, Fracasso P, Suykens J, Tornblom H, Buti M, Dugic A, Torres J, Leone S, Maravic Z, Mishkovikj M, Koltai T, Carboni A, Wickramasinghe K, Alimena L, Burra P.** Transition from youth to adulthood: UEG 2024 roundtable on navigating chronic digestive and liver disease care. United European Gastroenterol J. 2025; 13(10): 2093-5. Article. IF: 6.4; Q1
- **del Rosal T, Morillas-Mingorance A, García-Morato MB, Rodríguez-Pena R, Bravo-Gallego LY, Méndez-Echevarría A.** Infectious and inflammatory events in 2 siblings with IRF9 deficiency under immunoglobulin replacement therapy. J Allergy Clin Immun. 2025; 156(5): 1433-5. Letter. IF: 11.7; D1
- **Fulvio G, Marinello D, Zucchi D, Aguilera S, Benachi A, Biller R, Blanco I, Boiteux MC, Borgards P, Brandi ML, Costafreda E, Fonseca JE, Fredi M, Guimaraes V, Iotova V, Lecointe-Artzner E, Lopes AR, Louisse S, Nalli C, Olesinska M, Onali M, Papenthin W, Power B, Röhl C, Rousset-Jablonski C, Sturz D, Tincani A, Van Vleuten CJD, Vieira A, Dan DRC, Backer JD, Smulders CD, Dufke A, Frank C, Limongelli G, Lorenz B, Kilpiäinen E, Pascau MJ, Raidt J, Ray-Coquard I, Rimmer R, Schneider H, Van Pal HJD, Yap T, Talarico R, Tani C, Mosca M.** Addressing unmet needs in pregnancy and family planning of people living with rare and low-prevalence diseases: results of the ERN transversal working group on pregnancy and family planning survey. Reprod Health. 2025; 22(1): 240. Article. IF: 3.4; Q1
- **González-Torbay A, Reche-Yebra K, Clemente-Bernal A, Serrano YS, Bravo-Gallego LY, López AF, Rodríguez-Pena R, García-Morato MB, López-Granados E, del Pino-Molina L.** Functional insights of an uncommon hypomorphic variant in IL2RG as a monogenic cause of CVID-like disease with antibody deficiency and T CD4 lymphopenia. Front Immunol. 2025; 16: 1544863. Article. IF: 7.0; Q1
- **Molina LD, Manzano EM, Gianelli C, Gallego LY, Fernández JB, Acuña P, Serrano YS, Yebra KR, García-Morato MB, Zapardiel ES, Arias-Salgado EG, Pena RR, Butta N, Granados EL.** Effects of two different variants in the MAGT1 gene on B cell subsets, platelet function, and cell glycome composition. Front Immunol. 2025; 16: 1547808. Article. IF: 7.0; Q1
- **Zucchi D, Marinello D, Tani C, Fulvio G, Aguilera S, Benachi A, Biller R, Blanco I, Borgards P, Boiteux MC, Brandi ML, Costafreda E, Fonseca JE, Fredi M, Iotova V, Louisse S, Nalli C, Onali M, Power B, Rousset-Jablonski C, Sturz D, Tincani A, Vieira A, Capela S, Dan DRC, De Backer J, de Die-Smulders C, Dufke A, Artzner EL, Limongelli G, Lorenz B, Papenthin W, Pascau MJ, Raidt J, Ray-Coquard I, Rimmer R, Roehl C, Schneider H, Yap T, Talarico R, Mosca M.** Pregnancy-related issues in rare and low-prevalence diseases: results of ERN transversal working group on pregnancy and family planning survey. Orphanet J Rare Dis. 2025; 20(1): 112. Article. IF: 3.6; Q2

Research projects

- **Martínez Campos P.** Escape room educativo: promoviendo la salud y el bienestar en adolescentes con trasplante de órgano sólido. Colegio Oficial de Enfermeria de Madrid (CODEM). 2025-2025. Managment centre: CODEM
- **Pascau González-Garzón MJ.** Programa educativo de refuerzo educativo para la transición en trasplante de órgano sólido. Chiesi. 2025-Ongoing. Managment centre: FIBHULP

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.7.10 Food Oxidative Stress and Cardiovascular Health

Publications: 15 | Q1: 14

COMPOSITION

Silvia M. Arribas Rodríguez.
Catedrática de Fisiología Cardiovascular. Universidad Autónoma de Madrid

- **Yolanda Aguilera Gutiérrez.** *Profesora Titular. Universidad Autónoma de Madrid*
- **Alicia Gil Ramírez.** *Profesora Ayudante Doctor. Universidad Autónoma de Madrid*
- **Álvaro Llorente Berzal.** *Profesor Ayudante Doctor. Universidad Autónoma de Madrid*
- **María Ángeles Martín Cabrejas.** *Catedrática en Química Agrícola y Bromatología. Universidad Autónoma de Madrid*
- **María Martín Trueba.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **David Ramiro Cortijo.** *Profesor Ayudante Doctor. Universidad Autónoma de Madrid*
- **Pilar Rodríguez Rodríguez.** *Técnico de Laboratorio. Universidad Autónoma de Madrid*
- **Santiago Ruvira Hernando.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*

STRATEGIC OBJETIVES

- To evaluate the impact of low birth weight and prematurity on cardiometabolic health through follow-up strategies, analyzing the modulating effect of lifestyle.
- To study the physiological mechanisms involved in the association between risk factors and cardiometabolic programming, using animal models of prematurity and intrauterine growth restriction and dietary interventions.
- To evaluate the influence of sociocultural factors on women's health during pregnancy and lactation, and the modulation of biological variables by lifestyle.
- Promoting healthy habits during pregnancy and breastfeeding
- Extract and characterize healthy bioactive components from food by-products and design ingredients and supplements to improve cardiometabolic health.
- Conduct intervention trials in healthy subjects with the designed ingredients, evaluating their anti-inflammatory and antioxidant properties and effect on health.

RESEARCH LINES

- Impact of preterm birth on cardiometabolic health in early life
- Animal models of IUGR and prematurity: evaluation of novel theraeputic strategies
- Development of foods based on plant by-products for health
- Women reproductive health

RESEARCH ACTIVITY

Doctoral Theses

- **Silva Fernández CS.** Factores psicosociales relacionados con la vulnerabilidad materna en la atención sanitaria del embarazo, parto y posparto[dissertation]. Madrid: UAM: 2025(08/10/2025). Director: Garrosa Hernández E, Ramiro Cortijo D
- **Gómez Bris R.** Immune system and cell-specific modulation of lamin a/c as regulators and biomarkers in tumor development and inflammatory bowel disease[dissertation]. Madrid: UAM: 2025(22/04/2025). Director: Arribas Rodríguez SM, González Granado JM. Becaria FPU

Master Theses

- **Aldea Mas C.** Abordaje urgente y emergente al paciente intoxicado por ácido γ-hidroxibutírico (GHB)[dissertation]. Madrid: UB+UAM: 2025(01/05/2025). Director: Ramiro Cortijo D .
- **Gutiérrez Cañas N.** Análisis del impacto de un programa de mindfulness en la omisión de cuidados de enfermería en Unidades de Cuidados Intensivos: estudio de intervención aleatorizado por conglomerados[dissertation]. Madrid: UB+UAM: 2025(401/05/2025). Director: Ramiro Cortijo D .

Final Degree Theses

- **Trejo Bragulat A.** Efecto de una infusión de pulpa de café sobre la inflamación producida por el ejercicio físico en población sana no entrenada[dissertation]. Madrid: UAM: 2025(04/06/2025). Director: Ramiro Cortijo D, Arribas Rodríguez SM.
- **Giraldo Jaldo C.** Aprovechamiento del suero lácteo en la industria alimentaria y farmacéutica: Impacto Medioambiental y Económico[dissertation]. Madrid: UAM: 2025(01/05/2025). Director: Aguilera Gutiérrez Y.
- **Pineda Morales DN.** Nutricosmética sostenible: aprovechamiento de subproductos del café y cacao para la salud y la estética[dissertation]. Madrid: UAM: 2025(01/05/2025). Director: Aguilera Gutiérrez Y.
- **del Pozo López C.** Fomento de la alimentación y el deporte en la infancia para la reducción de problemas cardiometabólicos en niños/as prematuros durante su etapa adulta[dissertation]. Madrid: UAM: 2025(01/06/2025). Director: Arribas Rodríguez SM.

Publications

- **Ruvira S, Rodríguez-Rodríguez P, Iampanichakul M, Cuquerella LG, Ramiro-Cortijo D, Arribas SM.** Cocoa shell extract restores redox balance in developmental hypertension in male rats: roles of Nrf2, SOD2 and p-eNOS. Pathophysiology. 2025; 32(4): 49. Article. IF: 3.5; Q1
- **Spagnolo E, Ramiro-Cortijo D, Fuentes BD, Vega MS, Calvillo-Fernández L, López A, Hernández A.** To operate or not to operate? The impact of surgical treatment on quality of life in women with ovarian endometriosis. Front Glob Womens Health. 2025; 6: 1606768. Article. IF: 2.5; Q1
- **Silva-Fernández CS, Garrosa E, Ramiro-Cortijo D.** Qualitative study of maternity healthcare vulnerability based on women's experiences in different sociocultural context. Nurs Rep. 2025; 15(3): 105. Article. IF: 3.1; Q1
- **Spagnolo E, Fuentes BD, Lopez A, de Celada RA, Buño A, Ramiro-Cortijo D, Hernández A.** Impact of dietary patterns on pain and quality of life in ovarian and deep endometriosis: observational study for nutritional interventions. Bmc Womens Health. 2025; 25(1): 613. Article. IF: 3.3; Q1

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



- **Silva-Fernández CS, Camacho PA, de la Calle M, Arribas SM, Garrosa E, Ramiro-Cortijo D.** Analysis of maternity rights perception: impact of maternal care in diverse socio-health contexts. Eur J Investig Health Psychol Educ. 2025; 15(2): 10. Article. IF: 3.7; Q1
- **Infantino R, Turco F, Guida F, Llorente-Berzal A.** Editorial: Pain and pain-related neuropsychiatric disorders: from mechanistic insights to innovative therapeutic strategies. Front Pharmacol. 2025; 16: 1593890. Editorial Material. IF: 5.4; Q1
- **Di Marino C, Llorente-Berzal A, Diego AM, Bella A, Boullon L, Berrocoso E, Roche M, Finn DP.** Characterisation of the effects of the chemotherapeutic agent paclitaxel on neuropathic pain-related behaviour, anxiodepressive behaviour, cognition, and the endocannabinoid system in male and female rats. Front Pharmacol. 2025; 15: 1505980. Article. IF: 5.4; Q1
- **Ramiro-Cortijo D, Rebollo-Hernanz M, Rodríguez-Rodríguez P, Ruvira S, Arribas SM, Martín-Cabrejas MA.** Untargeted metabolomics and chemometrics elucidate dynamic plasma profile changes induced by cocoa shell in female rats. Nutrients. 2025; 17(5): 885. Article. IF: 5.8; Q1
- **Ramiro-Cortijo D, Ruvira S, de Celada RA, Muñoz-Gómez E, Cañas S, Magalhaes J, Arribas SM.** Relationship between heart rate variability and inflammation induced by physical exercise in a sedentary healthy population. Front Physiol. 2025; 16: 1657812. Article. IF: 4.3; Q1
- **Martín-Trueba M, Hu S, Cañas S, Rebollo-Hernanz M, Arribas SM, Gil-Ramírez A, Martín-Cabrejas MA, Aguilera Y, Benítez V.** A multivariate optimization approach to developing a coffee pulp infusion with maximized phenolic compounds, caffeine, and antioxidant properties, applying a validated UHPLC method. Ind Crop Prod. 2025; 235: 121835. Article. IF: 6.4; D1
- **Rodríguez-Rodríguez P, Ruvira S, Abderrahim F, Morales D, Iampanichakul M, Juárez L, Ramiro-Cortijo D, Arribas SM.** Cocoa shell extract supplementation in hypertensive rats induces outward hypertrophic remodelling in mesenteric resistance arteries, reducing fibrosis. Exp Physiol. 2025; 110(12): 1838-51. Article. IF: 3.0; Q2
- **Gómez-Bris R, Rodríguez-Rodríguez P, Ortega-Zapero M, Ruvira S, Castillo-González R, Fernández-Acenero MJ, Cruz-Adalia A, Sáez A, Arribas SM, González-Granado JM.** Segmental regulation of intestinal motility by colitis and the adaptive immune system in the mouse ileum and colon. Am J Pathol. 2025; 195(2): 204-20. Article. IF: 4.9; Q1
- **Boullon L, Finn DP, Llorente-Berzal A.** Sex differences in the affective-cognitive dimension of neuropathic pain: Insights from the spared nerve injury rat model. J Pain. 2025; 27: 104752. Article. IF: 4.4; Q1
- **Hu S, Martín-Cabrejas MA, Hernández DM, Martín-Trueba M, Cañas S, Rebollo-Hernanz M, Aguilera Y, Benítez V, Gil-Ramírez A.** Tailored recovery of antioxidant fractions enriched in caffeine and phenolic compounds from coffee pulp using ethanol-modified supercritical carbon dioxide. Food Res Int. 2025; 200: 115433. Article. IF: 8.8; D1
- **Canas S, Tosi N, Núñez-Gómez V, Del Rio D, Mena P, Martín-Cabrejas MA, Aguilera Y.** Microbial catabolism of coffee pulp (poly) phenols during in vitro colonic fermentation. Food Chem. 2025; 463: 141354. Article. IF: 10.4; D1

Research projects

- **Arribas Rodríguez SM, Martín Cabrejas MA.** Desarrollo de una infusión de pulpa de café como estrategia para la recuperación tras el ejercicio físico moderado (PID2022-138440OB-I00). ISCIII. 2024-2026. Managment centre: FUAM
- **Ramiro Cortijo D.** Efectos de la prematuridad sobre la salud cardiometabólica en la niñez temprana: estudio clínico observacional. FIBHULP. 2025-2026. Managment centre: FIBHULP
- **Gil Ramírez A, Rebollo Hernanz M.** Unlocking Data Science-based predictive models to explore the potential of coffee by-products on cognitive functioning (CoffeeMinds) (SI4/PJI/2024-00120). UAM-CAM. 2025-2026. Managment centre: UAM

IdiPAZ Instituto de Investigación Hospital Universitario La Paz



3.8. Multidisciplinar Research In Healthy Aging

Documents: 70 | Originals: 62 | D1: 12 | Q1: 31

Area Coordinator: Rocío Menéndez Colino

RESEARCH GROUPS

3.8.1 Aging and Fragility in the Elderly
Rocío Menéndez Colino

3.8.2 Frailty and Healthy Aging
Leocadio Rodríguez Mañas

3.8.3 Frailty, Multimorbidity Patterns and Mortality in the Elderly Population Residing in the Community
Miguel Ángel Salinero Fort

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Strategic Objectives	Development forecast for the coming years:	Actions
The Multidisciplinary Research in Healrhy Aging is a recently created area and is made up of three groups. Its main initial mission is to identify synergies between IdiPAZ research groups with professionals or research groups in the field of primary care and health care with the aim of establishing joint interdisciplinary and competitive projects. It also aims to promote the development of training activities aimed at primary care and health care professionals	Increase the quality of the Area's group publications	Promoting quality and impact publishing
	Ensure generational change in the leadership of projects and groups in the area.	Include junior profiles in the groups and consider transition projects
	Improving the success rate in competitive calls for proposals	Increasing the submission rate to competitive calls for proposals and Increase the use of the Institution's resources and platforms for project applications (Mentor Programme, PAIN Platform, Innovation Support Unit, etc.).
	Implementing gender-sensitive analysis of results	Define studies that consider the gender dimension of pathologies in both patients and models.

HIGH IMPACT PUBLICATIONS

Andrés-Rebollo FJS, Cárdenas-Valladolid J, Abanades-Herranz JC, Vich-Pérez P, de Miguel-Yanes JM, Guillán M, **Salinero-Fort MA.** A different perspective on studying stroke predictors: joint models for longitudinal and time-to-event data in a type 2 diabetes mellitus cohort. Cardiovasc Diabetol. 2025; 24(1): 165. Article. IF: 15,6; D1

Álvarez-Bustos A, Coelho-Junior HJ, Calvani R, Rodriguez-Mañas L, Tosato M, Cesari M, Cherubini A, Cruz-Jentoft AJ, Jónsson PV, Lattanzio F, Maggio M, Roller-Wirnsberger R, Ryznarova I, Schols AMWJ, Sieber CC, Sinclair AJ, Skalska A, Strandberg T, Tchalla A, Topinkova E, Vellas B, von Haehling S, Landi F, Marzetti E. Adherence to physical activity and incident mobility disability in older adults with mobility limitations. J Cachexia Sarcopeni. 2025; 16(3): e13870. Article. IF: 9,9; D1

Gijón-Conde T, Banegas JR, Sánchez CF, Alonso R, Mata P. Clinical profile of familial hypercholesterolemia phenotype in adults attended in primary care in a large healthcare area. Atherosclerosis. 2025; 408(): -120400. Article. IF: 7,1; Q1.SI

Álvarez-Bustos A, Carnicero JA, Sepúlveda-Loyola W, Molina-Baena B, Garcia-Garcia FJ, **Rodríguez-Mañas L.** Sarcopenia, obesity, or both. What is the dominant variable of the associated risks of sarcopenic obesity? Innov Aging. 2025; 9(5): igaf021. Article. IF: 6,2; D1

Sosa P, Angulo J, Sánchez-Ferrer A, Gómez-Cabrera MC, Fernández A, Rodríguez-Mañas L, **El Assar M.** Sex-dependent effects of aging and insulin resistance on skeletal muscle function and structure in rats. Int J Mol Sci. 2025; 26(14): -6783. Article. IF: 5,6; Q1

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.8.1 Aging and Fragility in the Elderly

Publications: 9 | Q1: 2

COMPOSITION

Rocío Menéndez Colino.
Jefe de Servicio de Geriatría. Hospital Universitario La Paz

- **Francesca Argentina.** *Facultativo Especialista en Geriatría. Hospital Universitario La Paz*
- **María Auxiliadora Castillo Delgado.** *Facultativo Especialista de Área en Geriatría. Hospital Universitario La Paz*
- **Patricia Ysabel Condorhuamán Alvarado.** *Facultativo Especialista de Área en Geriatría. Hospital Universitario La Paz*
- **Victoria María Déniz González.** *Enfermera Especialista en Geriatría. Hospital Universitario La Paz*
- **Javier Gómez Pavón.** *Jefe de Servicio de Geriatría y de Cuidados Paliativos. Hospital Central Cruz Roja San José y Santa Adela*
- **Silvia Martín Martín.** *Enfermera Especialista en Familiar y Comunitaria. FIBHULP*
- **Ana Merello de Miguel.** *Facultativo Especialista de Área en Geriatría. Hospital Universitario La Paz*
- **Raquel Ramírez Martín.** *Facultativo Especialista de Área en Geriatría. Hospital Universitario La Paz*
- **Paola Pastora Reinoso Párraga.** *Facultativo Especialista de Área en Geriatría. Hospital Universitario La Paz*
- **Peggy Paola Ríos Germán.** *Médico Interno Residente en Geriatría. Hospital Universitario La Paz*
- **María del Pilar Sáez López.** *Facultativo Especialista de Área en Geriatría. Hospital Universitario Fundación Alcorcón*



STRATEGIC OBJETIVES

- The current research group from HULP and the Single Primary Care Area (Dr. Castroviejo Center), integrated into this research sub-line, emerged around the final phase of the longitudinal study "Aging in Leganés," a cohort implemented in 1993 and completed in 2007 due to cohort attrition. In 2008, a new cohort representative of people over 65 years of age was launched in the Peñagrande area. This cohort belonged to Primary Care Area 5 of Madrid, whose reference hospital is HULP, which represents a new opportunity for the continuity and updating of the initially established objectives. The group's strategic objective is to delve deeper into the study of the factors associated with the onset of frailty in the elderly and the possibilities for its early detection and prevention. In this regard, the group has been part of RETICEF (Cooperative Research Network on Aging and Frailty) since 2007.
- In 2010, the Group joined a European project related to osteoarthritis in the elderly population (EPOSA Project). In 2011, a first wave of follow-up was carried out, which included obtaining samples deposited in the IdiPAZ Biobank (serum and DNA) for future studies.
- Two follow-up assessments were carried out in 2011 and 2012.

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH LINES

- To promote and improve the quality of research in the field of Primary Health Care and Geriatrics in the area of influence of IdiPAZ.
- Continue monitoring of the Group Cohorts: population-based elderly (Peñagrande Study), patients with frailty syndrome (FONDA) and patients with Type 2 Diabetes Mellitus (MADiabetes).
- Advances in the epidemiological study of frailty in older people.
- Consolidate clinical studies related to hip fracture and chronic diseases in the elderly, especially Diabetes Mellitus.
- Point-of-care ultrasound.
- Cardiogeriatrics: A Study of the Impact of Frailty on Transcatheter Aortic Valve Implantation in Older Patients with Severe Aortic Stenosis.
- Cross-Specialty Geriatrics: Joint management of older adults diagnosed with cancer in collaboration with the General Surgery, Medical Oncology and Radiation Oncology, Urology, and Otolaryngology departments at La Paz Hospital.
- Coordination of the National Hip Fracture Registry: A multicenter observational study involving patients from 75 Spanish hospitals who have suffered a fragility hip fracture. The registry collects data from the acute hospital phase and from follow-up one month later.

RESEARCH ACTIVITY

Doctoral Theses

- **Ramírez Martín R.** Impacto de la valoración geriátrica integral y la presencia de fragilidad en la decisión clínica y la evolución de pacientes mayores intervenidos de cáncer colorrecta[dissertation]. Madrid: UAM: 2025(04/03/2025). Director: González Montalvo JI, Menéndez Colino R.

Publications

- **Jiménez EL, Párraga PR, Ramírez AG, Alvarez MN, Saro AA, de la Riva MFG, Bouzón CA, Carrasco VC, Galán GM, Solís JR, Córcoles RA, Martín RR, Hernández CD, Zambom-Ferraresi F, Vásquez BD, González PLS, Merchante IM, Molina RG, Colino RM, Velilla NM, Pretel FA, Jiménez EG, Blesa MS, Zamora EBC, Céspedes AA, Abizanda P.** Normative data of ultrasound quadriceps rectus femoris geometric values. The ECOSARC-2 Study. J Nutr Health Aging. 2025; 29(8): 100608. Article. IF: 5.0; Q1
- **Sáez-López P, Álvarez-Santullano CA, Arboiro-Pinel R, Ubeda JLB, Calvo JCB, García FB, Ogea CC, Alvarado PYC, Berdonces MC, Llopart LC, Martínez NF, García MG, Pérez RMM, Molina BM, Hernández AN, Bilbao JLN, Ojeda-Thies C, Antuñano SPG, Vila MS, Bonel JS, Tarazona-Santabalbina FJ.** Recommendations for the prevention of fragility fractures: a consensus from international experts and Ibero-American scientific societies. Arch Osteoporos . 2025; 20(1): 76. Article. IF: 2.7; Q2
- **de Villaumbrosia CG, Barba R, Ojeda-Thies C, Grifol-Clar E, alvarez-Diaz N, Álvarez-Espejo T, Cancio-Trujillo JM, Mora-Fernández J, Pareja-Sierra T, Barrera-Crispín R, Calle-Egusquiza A, Capdevila-Reniu A, Carrasco-Paniagua C, Díaz MCC, Condorhuamán-Alvarado P, Cotano-Abad L, Cuadra-Llopart L, García-Cárdenas V, González-Chávez S, Hernández-Sánchez LA, Herrero-Pinilla B, López-Castro J, Montero-Fernández N, Muñoz-Pascual A, Muñoz-Vélez M, Ortés-Gómez R, Sáenz-Tejada A, Sanz-Reig J, Torras-Cortada S, Cortés MR, Sáez-López P.** Predictive factors of gait recovery after hip fracture: a scoping review. Age Ageing. 2025; 54(3): afaf057. Review. IF: 7.4; Q1
- **Jiménez-Mola S, Plaza-Carmona M, Gil FJI, Sáez-López P, García PF, Seco-Calvo J.** Functional decline in nonagenarians admitted for hip fracture. Rev Assoc Med Bras. 2025; 71(1): e20240796. Article. IF: 1.6; Q2
- **Ocanto A, Cantero R, Morera R, Ramírez R, Rodríguez I, Castillo K, Samper P, Couñago F.** Results of radical treatment of locally advanced rectal cancer in geriatric and non-geriatric patients. Rep Pract Oncol Radiother. 2025; 30(1): 54-61. Article. IF: 1.7; Q3
- **Garcia-Calderon Díaz MN, Medina Nieto A, Ballesteros Arana M, Manzanilla Meneses V, Barriga Pineda E, García Matta P, Castro Medina G, Tornero Torres O, Gomez Pavon J.** Evaluating ferric carboxymaltose administration in elderly patients: Clinical outcomes, comparative characteristics in different care settings and cost analysis. A five year study. Rev Esp Geriatr Gerontol. 2025; 60(6): 101717. Article. Not Indexed
- **Corral Sastre L, Garay Abanto DG, Menéndez Colino R, Reinoso-Parraga P.** Utility of Point of Care Ultrasound (POCUS) in decision making in Geriatrics. Cardiac tamponade in a nonagenarian patient: A case report. Rev Esp Geriatr Gerontol. 2025; 60(5): 101671. Article. Not Indexed
- **Cabrera Romero V, Ramíez-Martin R, Palacios Revilla CD, Quiles Melero MI, Rico Nieto A.** Septic arthritis related to Lactobacillus sakei: A case report. Rev Esp Geriatr Gerontol. 2025; 60(2): 101562. Article. Not Indexed
- **Villajos-Guijarro M, Ramírez-Martín R, Mauleón-Ladrero C, Déniz González V, Forero Torres A, García-Moreno NF, González-Montalvo JI.** Impact of malnutrition on the clinical evolution in a cohort of older patients undergoing emergency surgery for abdominal pathology. Rev Esp Geriatr Gerontol. 2025; 60(2): 101609. Article. Not Indexed

Research projects

- **Ménendez Colino R.** Ensayo clínico randomizado de intervención multidisciplinaria en pacientes frágiles sarcopénicos con estenosis aórtica severa sintomática (2024211). FIBHULP. 45454-Ongoing. Managment centre: FIBHULP
- **Ménendez Colino R.** Impacto de una intervención multidisciplinaria en el pronóstico de pacientes frágiles con estenosis aórtica severa sintomática: ensayo randomizado (5795 SASPAIN). FIBHULP. 44601-. Managment centre: FIBHULP

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

3.8.2 Frailty and Healthy Aging



Publications: 24 | Q1: 20

COMPOSITION

Leocadio Rodríguez Mañas.
Jefe Servicio de Geriatría. Hospital Universitario de Getafe

- **José Antonio Carnicero Carreño.** *Data Manager. Investigador Senior. Hospital Universitario de Getafe*
- **Betty Davies Urizar.** *Médico Adjunto en Geriatría. Hospital Universitario de Getafe*
- **Mariam El Assar de la Fuente.** *Investigadora Senior. Hospital Universitario de Getafe*
- **Olga Laosa Zafra.** *Farmacóloga clínica. Hospital Universitario de Getafe*
- **Laura Pedraza Sepúlveda.** *Farmacóloga Clínica. Hospital Universitario de Getafe*

STRATEGIC OBJETIVES

- This area of research has been developed over the last 25 years by our group, with outstanding contributions to various aspects of the field, ranging from basic science (endothelial function, role of laboratory and imaging biomarkers, magnetoelectroencephalography, musculoskeletal function...) to clinical and epidemiological research, providing data that have enabled the development of technological devices (a platform to detect, treat and monitor functional impairment in a non-intrusive way) and leading to the creation of a technological SME (MG Biomed).

RESEARCH LINES

- Endothelial dysfunction associated with aging, diabetes, and obesity.
- Clinical aspects of frailty.
- New Technologies Applied to Geriatrics.

RESEARCH ACTIVITY

Doctoral Theses

- **Molina Baena MB.** β-hydroxy-β-methyl-butyrate in Frailty, Sarcopenia, and Sarcopenic Obesity"[dissertation]. Madrid: UAM: 2025(26/11/2025). Director: Rodríguez Mañas L.

Publications

- **Álvarez-Bustos A, Carnicero JA, Sepúlveda-Loyola W, Molina-Baena B, García-García FJ, Rodríguez-Mañas L.** Sarcopenia, obesity, or both. what is the dominant variable of the associated risks of sarcopenic obesity? Innov Aging. 2025; 9(5): igaf021. Article. IF: 6.2; D1
- **Álvarez-Bustos A, Coelho HJ Jr, Carnicero JA, Molina-Hermosilla I, Alfonso-López B, Peinado I, Checa-López M, Rodríguez-Mañas L.** Muscle power predicts frailty and other adverse events across different settings. J Nutr Health Aging. 2025; 29(6): 100555. Article. IF: 5.0; Q1
- **Álvarez-Bustos A, Coelho-Junior HJ, Calvani R, Rodríguez-Mañas L, Tosato M, Cesari M, Cherubini A, Cruz-Jentoft AJ, Jónsson PV, Lattanzio F, Maggio M, Roller-Wirnsberger R, Ryznarova I, Schols AMWJ, Sieber CC, Sinclair AJ, Skalska A, Strandberg T, Tchalla A, Topinkova E, Vellas B, von Haehling S, Landi F, Marzetti E.** Adherence to physical activity and incident mobility disability in older adults with mobility limitations. J Cachexia Sarcopeni. 2025; 16(3): e13870. Article. IF: 9.9; D1
- **Álvarez-Bustos A, Coelho-Junior HJ, Carnicero JA, García-García FJ, Marzetti E, Rodriguez-Mañas L.** Adherence to the mediterranean diet and physical activity in relation to sarcopenia: a cross-sectional epidemiological cohort study. Aging Clin Exp Res. 2025; 37(1): 164. Article. IF: 4.7; Q2
- **Álvarez-Bustos A, Rodríguez-Mañas L, Marzetti E, Coelho HJ Jr.** Comment on effectiveness of mind-body exercise in older adults with sarcopenia and frailty: a systematic review and meta-analysis by wan et al.. J Cachexia Sarcopeni. 2025; 16(3): e13856. Letter. IF: 9.9; D1
- **Coelho HJ Jt, Álvarez-Bustos A, Russo A, Rodríguez-Mañas L, Landi F, Marzetti E.** Operationalizing Short Physical Performance Battery (SPPB) with muscle strength and power: predicting adverse events in older adults from the

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

ilsirente study. Aging Clin Exp Res. 2025; 37(1): 222. Article. IF: 4.7; Q2

- **Coelho-Júnior HJ, Álvarez-Bustos A, Landi F, Aguiar SD, Rodríguez-Mañas L, Marzetti E.** Why are we not exploring the potential of lower limb muscle power to identify people with sarcopenia? Ageing Res Rev. 2025; 104: 102662. Article. IF: 15.5; D1
- **Coelho-Júnior HJ, Álvarez-Bustos A, Ramírez CP, Russo A, Rodríguez-Mañas L, Landi F, Marzetti E.** Exploring the associations between dysphagia and health-related outcomes in older adults: results from the ilsirente study. Nutrients. 2025; 17(13): 2149. Article. IF: 5.8; Q1
- **Coelho-Júnior HJ, Álvarez-Bustos A, Rodríguez-Mañas L, Landi F, Marzetti E.** Comparison of muscle strength and power in the short physical performance battery for predicting negative outcomes in older adults with mobility limitations. J Nutr Health Aging. 2025; 29(9): 100631. Article. IF: 5.0; Q1
- **Coelho-Junior HJ, Álvarez-Bustos A, Russo A, Rodríguez-Mañas L, Landi F, Marzetti E.** Associations between malnutrition and physical performance, sarcopenia, and frailty in older adults. BMC Geriatr. 2025; 25(1): 612. Article. IF: 4.5; Q1
- **El Assar M, García-Gómez B, La Fuente JM, Alonso-Isa M, Martínez-Salamanca JI, Fernández A, Sosa P, Romero-Otero J, Rodríguez-Mañas L, Angulo J.** Targeting TRPC-5 channel inhibition to improve penile vascular function in erectile dysfunction. Int J Mol Sci. 2025; 26(4): 1431. Article. IF: 5.6; Q1
- **García-Aguirre M, Baltasar-Fernandez I, Alcázar J, Alfaro-Acha A, Bareiro-Quiñónez FA, Ara I, Rodríguez-Mañas L, García-García FJ, Alegre LM.** Low relative sit-to-stand power is associated with the development of adverse health outcomes: a 5-year longitudinal study. J Cachexia Sarcopeni. 2025; 16(3): e13852. Article. IF: 9.9; D1
- **García-Aguirre M, Baltasar-Fernandez I, Alcázar J, Losa-Reyna J, Alfaro-Acha A, Ara I, Rodríguez-Mañas L, Alegre LM, García-García FJ.** Cut-off points for low relative 30-s sit-to-stand power and their associations with adverse health conditions. J Cachexia Sarcopeni. 2025; 16(1): e13676. Article. IF: 9.9; D1
- **García-Rojo E, Angulo J, El Assar M, de la Blanca RSP, García-Gómez B, Medina-Polo J, Sevilleja-Ortiz A, Rodríguez-Mañas L, Fernández A, Gutiérrez-Martínez E, Morales-Ruiz E, Rodríguez-Antolín A, Romero-Otero J.** Orai1 expression and vascular function in kidney donors determine graft outcomes at short/mid-term. Cells. 2025; 14(13): 1005. Article. IF: 6.0; Q2
- **Izquierdo M, Barreto PD, Arai H, Bischoff-Ferrari HA, Cadore EL, Cesari M, Chen LK, Coen PM, Duque G, Ferrucci L, Fielding RA, Courneya KS, García-Hermoso A, Gutiérrez-Robledo LM, Harridge SDR, Kirk B, Kritchevsky S, Landi F, Lazarus N, Liu-Ambrose T, Marzetti E, Merchant RA, Morley JE, Pitkälä KH, Ramírez-Vélez R, Rodríguez-Mañas L, Rolland Y, Ruiz JG, de Asteasu MLS, Villareal DT, Waters DL, Won CW, Vellas B, Singh MAF.** Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR). J Nutr Health Aging. 2025; 29(1): 100401. Review. IF: 5.0; Q1
- **La Fuente JM, El Assar M, Fernández A, Rodriguez-Mañas L, Angulo J.** Relevance of STIM/Orai calcium entry system hyperactivation in human prostate contractility in benign prostate hyperplasia. Int J Mol Sci. 2025; 26(18): 8985. Article. IF: 5.6; Q1
- **Laosa O, Topinkova E, Bourdel-Marchasson I, Vellas B, Izquierdo M, Paolisso G, Hardman T, Zeyfang A, Pedraza L, Carnicero JA, Rodriguez-Mañas L, Sinclair AJ.** Long-term frailty and physical performance transitions in older people with type-2 diabetes. The MIDFRAIL randomized clinical study. J Nutr Health Aging. 2025; 29(4): 100512. Article. IF: 5.0; Q1
- **Marcos-Pérez D, Hernández-Vicente A, Cruces-Salguero S, Landa J, Bonvini M, Vicente-Rodríguez G, Pueyo E, Rodriguez-Mañas L, Abizanda P, Otaegui D, Garatachea N, Matheu A.** Resistance exercise intervention restores functional capacity and improves frailty biomarkers in centenarians. J Cachexia Sarcopeni. 2025; 16(5): e70079. Article. IF: 9.9; D1
- **Molina-Baena B, Carnicero JA, Pereira SL, Rueda R, Santos-Fandila A, Álvarez-Bustos A, García-García FJ, Rodríguez-Mañas L.** Predominant role of fat mass in the association between HMB and frailty. J Gerontol A-Biol. 2025; 80(12): glaf203. Article. IF: 4.6; D1
- **Munshi M, Kahkoska AR, Neumiller JJ, Alexopoulos AS, Allen NA, Cukierman-Yaffe T, Huang ES, Lee SJ, Lipska KJ, McCarthy LM, Meneilly GS, Pandya N, Pratley RE, Rodríguez-Mañas L, Sinclair AJ, Sy SL, Toschi E, Weinstock RS.** Realigning diabetes regimens in older adults: a 4S Pathway to guide simplification and deprescribing strategies. Lancet Diabetes Endocrinol. 2025; 13(5): 427-37. Review. IF: 36.3; D1
- **Pascual MJE, Carreño JAC, El Assar M, Rodríguez RO, Sanz AF, Montes PR, Mancebo NG, Ferrer AS, Coronel BI, Bello MA, Muñoz MM, Hernández VC, de Asua MDR, Ybañez SH, Callejas PS, Muñoz MG, Caballero RM, Garcia PA, Egido JAP, Pais JL, Mañas LR, Martín JJA.** A Biomarker-based scoring system to assess the presence of obstructive coronary artery disease in patients with myocardial infarction. Clin Cardiol. 2025; 48(2): e70090. Article. IF: 2.8; Q2
- **Perez-Sáez MJ, Melilli E, Arias M, Franco A, Martinez R, Sancho A, Molina M, Facundo C, Polanco N, López V, Mazuecos A, Cabello S, García MEG, Suárez ML, Auyanet I, Espi J, Falcón TG, Ruiz JC, Galeano C, Artamendi M, Rodríguez-Ferrero ML, Portolés JM, Santana MA, Martín-Moreno PL, Arhda N, Calvo M, Mendiluce A, Macía M, Pérez-Tamajón ML, de Teresa J, Gascó B, Soriano S, Tabernero G, de la Vara L, Ramos AM, Martínez R, de Espinosa EM, Zalve JL, Pascual J, Rodríguez-Mañas L, Gutiérrez-Dalmau A, Moreso F.** Frailty prevalence and characterization among kidney transplant candidates in spain: a multicenter study. Transpl Int. 2025; 38: 14098. Article. IF: 3.6; Q1
- **Rodríguez-Sánchez I, Carnicero-Carreño JA, Álvarez-Bustos A, García-García FJ, Rodríguez-Mañas L, Coelho HJ Jr.** Effects of malnutrition on the incidence and worsening of frailty in community-dwelling older adults with pain. Nutrients. 2025; 17(9): 1400. Article. IF: 5.8; Q1
- **Sosa P, Angulo J, Sánchez-Ferrer A, Gómez-Cabrera MC, Fernández A, Rodríguez-Mañas L, El Assar M.** Sex-Dependent effects of aging and insulin resistance on skeletal muscle function and structure in rats. Int J Mol Sci. 2025; 26(14): 6783. Article. IF: 5.6; Q1

Research projects

- **Rodríguez Mañas L.** Papel de nuevos biomarcadores pronósticos de recuperación funcional tras deterioro catastrófico y no catastrófico en personas mayores vulnerables: Biomarc-RF (PI23/00877). ISCIII. 2024-2026. Managment centre: Hospital Universitario de Getafe
- **Laosa Zafra O.** Research in Europe and Diversity Inclusion-ReaDI (101166227). Innovative Health Initiative Joint Undertaking. 2025-2031. Managment centre: SERMAS (coordinador)
- **Rodríguez Mañas L.** PIPRA: A CE-certified digital technology providing personalized postoperative delirium risk (2024-ITM-8924). EIT Health. 2025-2025. Managment centre: Hospital Universitario de Getafe
- **Laosa Zafra O.** Ecosistema computacional con apoyo motivacional y evaluación funcional para un programa autónomo de ejercicio para un envejecimiento saludable. (PID2022-140214OA-C22). Ministerio de Ciencia e Innovación. 2023-2029. Managment centre: Hospital Universitario de Getafe
- **Rodríguez Mañas L.** Creating Value through digitaly enabled diabetes managment models (2024-NDMH-5173). EIT Health. 2025-2025. Managment centre: Hospital Universitario de Getafe
- **Rodríguez Mañas L.** EFFORT II: Efectos del tratamiento nutricional continuado tras el alta hospitalaria en pacientes con riesgo de desnutricion – Un ensayo prospectivo internacional aleatorizado. Nestle Health Science . 2024-Ongoing. Managment centre: Hospital Universitario de Getafe

Cibers and Retics

- **Rodríguez Mañas L.** Centro de Investigación Biomédica en Red en Fragilidad y Envejecimiento Saludable (CIBERFES). ISCIII. (31/12/2025). FIBHUG

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.8.3 Frailty, Multimorbidity Patterns and Mortality in the Elderly Population Residing in the Community

Publications: 24 | Q1: 9

COMPOSITION

Miguel Ángel Salinero Fort.
Responsable de Gestión del Conocimiento de la Consejería de Sanidad de la Comunidad de Madrid. Consejería Sanidad. Atención Primaria

- **Beatriz Álvarez Embarba.** *Enfermera. Escuela Universitaria de Enfermería Cruz Roja Española*
- **Navid Behzadi Koochani.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria*
- **Juan Cárdenas Valladolid.** *Enfermero. Atención Primaria*
- **María Victoria Castell Alcalá.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria*
- **Teresa Gijón Conde.** *Profesora Honoraria. Universidad Autónoma de Madrid*
- **Paloma Gómez Campelo.** *Subdirectora Ténica de IdiPAZ. Investigadora Postdoctoral. FIBHULP*
- **Borja González Muñoz.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Alicia Gutiérrez Misis.** *Profesor Ayudante Doctor. Universidad Autónoma de Madrid*
- **Víctor Iriarte Campo.** *Médico. Atención Primaria*
- **Juan Pedro Justel Pérez.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria*
- **Carlos Lahoz Rallo.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Paula Lorenzana Honorato.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Miguel Ángel María Tablado.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria*
- **José María Mostaza Prieto.** *Jefe de Sección en Medicina Interna. Hospital Universitario La Paz / Profesor TItular. Universidad Autónoma de Madrid*
- **Paula Reguerio Toribio.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria*
- **Antonio Ruiz García.** *Director de Centro de Atención Primaria. Atención Primaria*
- **Francisco Javier San Andrés Rebollo.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria*
- **María Isabel Uriarte Ayestarán.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria*
- **Pilar Vich Pérez.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria*

STRATEGIC OBJETIVES

- The group's research focuses on the morbidity and mortality risks of elderly patients in the community, with particular attention to modifiable factors such as nutrition, alcohol consumption, smoking, inappropriate medication use, poor treatment adherence, sedentary lifestyle, and vulnerability to climate change. It also examines classic risk factors such as hypertension, diabetes, obesity/overweight, hypercholesterolemia, multimorbidity, and suboptimal control of blood pressure, glucose, and LDL cholesterol. Furthermore, it studies factors that delay urgent/emergency care for time-dependent conditions (*). All of this is considered from a gender and vulnerability perspective throughout the lifespan.

  (*) Those emergency diseases in which the diagnostic or therapeutic delay negatively influences the process's evolution and prognosis since its morbidity and mortality are directly related to the delay in starting treatment.



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH LINES

- Effect of glycemic variability on morbidity and mortality
- Effect of the variability of arterial hypertension on morbidity and mortality
- Predictive model of morbidity and mortality in elderly patients residing in the community
- Predictive model of morbidity and mortality in patients with type 2 diabetes mellitus
- Effect of the product of fasting glucose and triglycerides (TyG index) on incident Type 2 Diabetes Mellitus.
- Sex differences in preventive medicine.
- Incidence of mortality in adult patients diagnosed with epilepsy in the community of Madrid: Retrospective cohort EPILEPSIE-Madrid.
- Mortality rates and causes of death in patients with type 2 diabetes: An analysis of the MADIABETES cohort (Spain)
- Metabolomics, genomics and nutrition for personalized medicine of cardiovascular diseases (OMIC-CARD)
- LADA type diabetes: development and validation of a high-risk score for use in Primary Care.

RESEARCH ACTIVITY

Publications

- **Andrés-Rebollo FJS, Cárdenas-Valladolid J, Abanades-Herranz JC, Vich-Pérez P, de Miguel-Yanes JM, Guillán M, Salinero-Fort MA.** A different perspective on studying stroke predictors: joint models for longitudinal and time-to-event data in a type 2 diabetes mellitus cohort. Cardiovasc Diabetol. 2025; 24(1): 165. Article. IF: 15.6; D1
- **Brotons C, Moral I, Abajo JMG, Mendivelso JC, Rico OC, Díaz A, Elosua R, Pardo DE, Guerrero MMF, Fondado MG, Gorostidi M, Canino MMG, Grau M, Herraiz CG, Lahoz C, Martínez ELC, Rivas NMO, Ortega E, Pallarés-Carratalá V, Rodilla E, Royo-Bordonada MA, Febres LMS, Olmo RS, Torres-Fonseca MM, Velescu A, Zamora A, Armario P.** Practices of low value or unnecessary practices in vascular prevention Document of the Spanish Interdisciplinary Committee for Vascular Prevention. Hipertens Riesgo Vasc. 2025; 42(3): 129-46. Article. IF: 1.2; Q4
- **Campuzano R, Mostaza JM, Barrios V, Egocheaga-Cabello I, Gómez-Cerezo JF, Pallarés-Carratalá V, Martínez-López I, Castellanos M, Hernández-Subirá I, Morant-Talamante N, Parrondo J, Arigita-Lastra L, Gámez JM.** Assessing LDL-C Levels andlipid-modifying therapies in a real-world cohort of patients with atherosclerotic cardiovascular disease: The REALITY Study. J Clin Med. 2025; 14(7): 2340. Article. IF: 3.3; Q1
- **Cintora-Sanz AM, Horrillo-García C, Quesada-Cubo V, Pérez-Alonso AM, Gutiérrez-Misis A.** Prevalence and economic impact of acute respiratory failure in the prehospital emergency medical service of the madrid community: retrospective cohort study. JMIR Public Health Surveill. 2025; 11: e66179. Article. IF: 4.4; Q1
- **Córdoba L, Cueto FJ, Cantero-Cid R, Abad-Moret R, Díaz E, Álvarez-Benayas J, Fernández-Felipe J, Jiménez-Rodríguez J, Arvelo-Rosario D, Mata-Martínez P, Arranz-Alvarez M, Pedroche-Just Y, Nieto-Torrero S, Valentín-Quiroga J, Terrón-Arcos V, Fernández-Pascual J, Gómez-Campelo P, Cubo-Mateo N, Fernández-Medina O, Hurtado-Navarro L, de Santa María GS, del Prado-Montero J, Santos AL, Lozano-Rodríguez R, Del Fresno C, López-Collazo E.** Colorectal air-liquid interface organoids preserve tumour-immune architecture and reveal local treg expansion after PD-1 blockade. Cancers (Basel). 2025; 18(1): 132. Article. IF: 4.8; Q2
- **Gijón-Conde T, Banegas JR, Sánchez CF, Alonso R, Mata P.** Clinical profile of familial hypercholesterolemia phenotype in adults attended in primary care in a large healthcare area. Atherosclerosis. 2025; 408: 120400. Article. IF: 7.1; D1
- **González-Beltrán D, Yévenes-Briones H, Lana A, Cardenas-Valladolid J, Salinero-Fort MA, Rodríguez-Artalejo F, López-García E, Caballero FF.** Prospective association between plasma amino acids and healthy aging in older adults. J Intern Med. 2025; 298(2): 123-34. Article. IF: 7.6; D1
- **López-Pedraza L, Fernández-Alonso V, Velarde-Garcia JF, González-Hervías R, Alcalde MGI, Galiano-Fernández P, Álvarez-Embarba B.** The perspective of young maghrebi people with a migratory background and their social agents on substance use during the migration process: a qualitative study. J Transcult Nurs. 2025; 36(3): 243-52. Article. IF: 1.9; Q2
- **María-Tablado MA.** Diagnosis of hypertension during pregnancy and preeclampsia, the limits of control and treatment. Semergen. 2025; 51(1): 102330. Editorial Material. IF: 1.0; Q4
- **Marín-Serrano E, de Villar NGP, Manuel MPJ, Fernández-Martos R, Cano AB, Martín-Arranz MD.** Pancreatic fat infiltration: A key marker in the metabolic continuum. Pancreas. 2025; 54(9): e757-64. Article. IF: 2.2; Q3
- **Marín-Serrano E, Fuentes AK, Fernández-Martos R, Prieto JM, Llorente AV, Cano AB, Hernández PLM, Martín-Arranz MD.** Treatment of severe hypertriglyceridemia through therapeutic plasma exchange in patients with acute pancreatitis or at risk of developing it. Gastroent Hepat-Barc. 2025; 48(1): 502229. Article. IF: 2.0; Q3
- **Mostaza JM, García-Ortiz L, Tembra S, Calle PT, García JC, Pérez VE, Díaz-Díaz JL, Manzano-Espinosa L, Catapano AL, Ray KK, Moya GD, Montoya JPB.** Failure of LDL-C goals achievement and underuse of lipid-lowering therapies in patients at high and very high cardiovascular risk: Spanish subset from the European SANTORINI study. Rev Clin Esp. 2025; 225(2): 78-84. Article. IF: 1.7; Q2
- **Mostaza JM, Lahoz C, Castro MGD, Campal JMR, Velásquez E, Gutiérrez AI, Diaz JF, Plana N, Rodriguez-Manero M, Garcia-Diaz JDD, Debén FM, de Paz IP, Catapano AL, Moya GD, Ray KK.** Usage of lipid-lowering therapies in patients at high and very high cardiovascular risk from Spain: one-year follow-up of the Spanish subpopulation from the European SANTORINI study. Rev Clin Esp. 2025; 225(8): 502344. Article. IF: 1.7; Q2
- **Mostaza JM, Lahoz C, Salinero-Fort MA, Estirado E, Garcia-Iglesias F, Gonzalez Alegre T, Cornejo V.** Prevalence of subclinical vascular disease in relation to the estimated cardiovascular risk and the presence of the metabolic syndrome.. Med Clin (Barc). 2025; 165(2): 106987-. Article. IF: 2.8; Q1
- **Pallarés-Carratalá V, Ruíz-García A, Serrano-Cumplido A, Fragoso AS, Fernández-Pascual V, Sánchez-Sánchez B, Cervera-Pérez MI, Alonso-Moreno FJ, Arranz-Martínez E, Barquilla-García**

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



A, Rey-Aldana D, García JP, Cinza-Sanjurjo S. Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study. Clin Investig Arterioscler. 2025; 37(1): 100724. Article. IF: 1.9; Q3

- **Pérez-Alonso AM, Horrillo-García C, Mateos-Rodríguez A, Cintora-Sanz AM, Cardenete-Reyes C, Gutiérrez-Misis A.** Factors predictive of success in uncontrolled donation after circulatory death in the community of madrid: an analysis of data from the regional registry of donation and transplantation (CORE Registry). Transpl P. 2025; 57(2): 159-67. Article. IF: 0.8; Q4
- **Rodilla E, Camps MB, Guerra LC, Cabello MIE, Ortiz JG, Tablado MAM, Rivas NM, Pallarés-Carratalá V, García JP, Donaire JAG.** Position paper on the 2024 ESH clinical practice guidelines for the management of arterial hypertension in Spain. Hipertens Riesgo Vasc. 2025; 42(1): 52-8. Review. IF: 1.2; Q4
- **Ruiz-García A, Arranz-Martínez E, Serrano-Cumplido A, Cinza-Sanjurjo S, Escobar-Cervantes C, Polo-García J, Pallarés-Carratalá V.** From metabolic syndrome to cardio-kidney-metabolic syndrome in the SIMETAP study: prevalence rates of metabolic syndrome and its independent associations with cardio-renal-metabolic disorders other than its defining criteria. Biomedicines. 2025; 13(3): 590. Article. IF: 4.5; Q2
- **Ruiz-García A, Pallarés-Carratalá V, Serrano-Cumplido A, Pascual-Fuster V, Arranz-Martínez E, Escobar-Cervantes C.** From the cardiovascular-kidney-metabolic disorders to the atherosclerotic cardiovascular diseases: their prevalence rates and independent associations in the SIMETAP Study. J Clin Med. 2025; 14(11): 3940. Article. IF: 3.3; Q1
- **Sambola A, Campuzano R, Castro A, Goya M, Coronado P, Fernández-Olmo R, María-Tablado MA, Ortiz-Cortés C, Ortolà X, Pallarés-Carratala V, Pijuan-Domenech A, Plata RM, Sánchez-Hernández RM, Siurana JM, Timoteo C, Viejo-Hernández B.** Primary and secondary cardiovascular prevention through life cycles in women. Consensus document of the SEC-GT CVD in Women, ACP-SEC, SEGO, AEEM, SEEN, semFYC, SEMERGEN, AEP, and AEM. Rev Esp Cardiol (Engl Ed). 2025; 78(7): 639-51. Article. IF: 4.2; Q2
- **María Tablado MA.** Continuous vascular risk with high blood pressure levels. Commentary on vascular and HTA PAPPS 2024 recommendations. Aten Prim. 2025; 57(4): 103231. Editorial Material. IF: 1.6; Q2
- **Vich-Pérez P, Taulero-Escalera B, García-Espinosa V, Villanova-Cuadra L, Regueiro-Toribio P, Sevilla-Machuca I, Timoner-Aguilera J, Martínez-Grandmontagne M, Abós-Pueyo T, Álvarez-Hernández-Cañizares C, Reviriego-Jaén G, Serrano-López-Hazas A, Gala-Molina I, Sanz-Pascual M, Salinero-Fort MA.** Sex and age differences in cardiovascular risk factors and lifestyle in patients recently diagnosed with diabetes mellitus: A cross-sectional study in Spanish primary health care. Plos One. 2025; 20(2): e0314519. Article. IF: 2.8; Q2
- **Vich-Pérez P, Taulero-Escalera B, Regueiro-Toribio P, Cárdenas-de Miguel A, Muñoz RS, Salinero-Fort MA.** Renal status in newly diagnosed patients with diabetes mellitus: a descriptive study in primary care and opportunities for improving management. J Clin Med. 2025; 14(8): 2732. Article. IF: 3.3; Q1
- **Vich-Pérez P, Taulero-Escalera B, Regueiro-Toribio P, Prieto-Checa I, García-Espinosa V, Villanova-Cuadra L, Sevilla-Machuca I, Timoner-García J, Martínez-Grandmontagne M, Abós-Pueyo T, Álvarez-Hernández-Cañizares C, Reviriego-Jaén G, Serrano-López-Hazas A, Gala-Molina I, Sanz-Pascual M, Guereña-Tomás MJ, González-González AI, Salinero-Fort MA.** Self-perceived health status of patients with newly diagnosed diabetes in spain: associated factors and sex differences. J Clin Med. 2025; 14(19): 6770. Article. IF: 3.3; Q1

Research projects

- **San Andrés Rebollo FJ.** Efecto de la Variabilidad Glucémica sobre la incidencia de eventos cardiovasculares, mortalidad cardiovascular, por todas las causas y por COVID en las cohortes de DM2 y pre-DM de Madrid (PI22/01499). ISCIII. 2023-2027. Managment centre: FIIBAP
- **Gutiérrez Misis A.** Efecto de la Variabilidad de la Glucosa Plasmática en ayunas y de la Presión Arterial, a largo plazo, sobre la morbimortalidad cardiovascular y mortalidad total en la población ≥75 años de la Comunidad de Madrid (PI24/01156). ISCIII. 2025-2027. Managment centre: FIBHULP

Ciber and Retics

- **Salinero-Fort MA.** Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud. (RICAPPS). ISCIII. (31/12/2025). FIIBAP
- **Castell Alcalá V.** Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud. (RICAPPS). ISCIII. (31/12/2025). FIIBAP

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

Scientific Report 2025

IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz



4 Associated clinicians

- 4.1 Endocrinology and Nutrition Group
- 4.2 Ophtalmology Group
- 4.3 Pediatric Nephrology Group
- 4.4 Urology Group
- 4.5 Angiology and Vascular Surgery
- 4.6 Clinical Analysis

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

4.1 Endocrinology and Nutrition Group

Publications: 28 | Q1:17

COMPOSITION

Cristina Álvarez Escolá

- Beatriz Barquiel Alcalá
- Beatriz Lecumberri Santamaría
- Patricia Martín Rojas-Marcos
- Laura Mola Reyes
- Rosa María García Moreno
- Elena García Pérez de Sevilla
- Noemí González Pérez de Villar
- Natalia Hillman Gadea
- Arturo Lisbona Catalán
- Óscar Moreno Domínguez
- Miriam Zapatero Larrauri
- Gonzalo Miñón Sánchez
- Mary Gaby Llaró Casas
- Maíra Cristina Montes Castillo
- Elvira Maíra Melián Pérez

RESEARCH AREAS

- Surgery, transplantation and health technology

RESEARCH LINES

- Diabetes and Pregnancy
- Technologies Applied to Type 1 Diabetes

RESEARCH ACTIVITY

Publications

- **Araujo-Castro M, Álvarez-Escola C, Casteràs A, Carmona-Bayonas A, Chiara MD, Hanzu FA, Hernando J, Vercher-Conejero JL, Rodríguez-Fraile M, Dos Santos VG, Jiménez-Fonseca P, Giraldo A, Valdés N, Vidal O, Del Olmo-García M, Capdevila J.** Spanish consensus on the diagnosis and management of adrenocortical carcinoma. Endocr-Relat Cancer. 2025; 32(5): e250034. Review. IF: 4.4; Q2
- **Araujo-Castro M, Biagetti B, Menéndez E, Novoa-Testa I, Cordido F, Berrocal VR, Pascual-Corrales E, Guerrero-Pérez F, Vicente A, García-Centeno R, González L, García MDO, Echarri AI, Rodríguez MDM, Novo-Rodríguez C, Calatayud M, Villar-Taibo R, Bernabéu I, Álvarez-Escola C, Jimenez CT, Abellán-Galiana P, Venegas E, González-Molero I, Iglesias P, Blanco C, De Lara FVO, Novoa MPD, Torres ELM, Hanzu F, Lamas C, Rodríguez SA, Aulinas A, Recio JM, Avilés-Pérez MD, Núñez MAS, Cámara R, Fano MP, Fajardo C, Cardoso L, Marques P, Martínez-Sàez E, Ruz-Caracuel I, Marazuela M, Puig-Domingo M.** Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas. Endocr Connect. 2025; 14(7): e250103. Article. IF: 3.4; Q2
- **Araujo-Castro M, Donato S, Sanz IG, Ojeda CM, Hanzu FA, Mora M, Sánchez-Vera RR, Boillos MG, Galiana PA, Lamas C, García MCL, Tous MD, Rodríguez MR, San Millán RB, Recasens M, Gimeno PG, Lazaro CR, Herrero-Ruiz A, Michalopoulou T, Torre EM, Fernández R, Castro PP, Álvarez-Escolá C, Rojas-Marcos PM, García-Centeno R, Novoa PD, Blanco-Carrera C, Valdés N, Calatayud M, Herrera-Martínez AD.** Impact of presurgical beta-blockade on surgical outcomes in patients with PPGLs. Endocr-Relat Cancer. 2025; 32(12): e250308. Article. IF: 4.4; Q2
- **Araujo-Castro M, Gutiérrez MC, Ramírez PP, Torre EM, de Miguel P, Paja M, Mangas MA, Oliveira CL, Hanzu FA.** Update of the guidelines on the management of adrenal incidentaloma from the adrenal group of the Spanish society of endocrinology and nutrition (SEEN). Endocrine. 2025; 90(2): 453-66. Article. IF: 3.3; Q3
- **Araujo-Castro M, Herrera A, Wang YB, Wang ZC, Sledzinski M, Hellmann A, Raffaelli M, Pennestri F, Sywak M, Papachristos AJ, Palazzo FF, Sung TY, Kim BC, Lee YM, Eatock F, Anderson H, Iacobone M, Dauksa A, Makay O, Turk Y, Atalay HB, van Dijkum EJMN, Engelsman AF, Holscher I, Materazzi G, Rossi L, Becucci C, Shore SL, Fung C, Waghorn A, Mihai R, Balasubramanian SP, Pannu A, Tatarano S, Velázquez-Fernández D, Miller JA, Serrao-Brown H, Chen YF, Demarchi MS, Djafarrian R, Doran H, Wang KL, Stechman MJ, Perry H, Hubbard J, Lamas C, Mercer P, Macpherson J, Lumbiganon S, Calatayud M, Hanzu FA, Vidal O, Ojeda CM, Papavramidis T, Gómez PRD, Aldrees A, Altwjry T, Valdes N, Álvarez-Escola C, Sanz IG, Carrera CB, Manjón-Miguélez L, Novoa PD, Recasens M, Centeno RG, Lázaro CR, van den Heede K, Van Slycke S, Michalopoulou T, Aspinall S, Melvin R, Lau JWL, Cheah WK, Tang MH, Oh HB, Ayuk J, Verhoeff K, Sutcliffe RP, Parente A, Int Pheo Study Grp.** Postoperative outcomes in normotensive and hypertensive pheochromocytomas: an international study. J Clin Endocr Metab. 2025; 110(11): e3719-29. Article. IF: 5.4; Q1
- **Araujo-Castro M, Ruiz-Sánchez J, Gonzalvo C, Lamas C, Ramírez P, Marcos-Rojas P, Paja M, Lázaro C, Michalopoulou T, Tous M, González-Boillos M, Recio-Córdova J, Casteras A, Fernández-Álvarez P, Tierno V, Mulatero P.** Genetic testing for primary aldosteronism in spain: results from the spain-aldo registry and review of the literature. J Clin Endocr Metab. 2025; 110(5): e1573-9. Article. IF: 5.4; Q1
- **Araujo-Castro M, Torre EM, Lozano-Aida C, García-Centeno R, Fernandez LG, Idrobo C, Achote-Rea E, Echarri AI, Rodríguez-Argullo MDM, Paja M, Guerrero-Pérez F, Castano JP, García MDO, Novo-Rodríguez C, Tenorio-Jiménez C, Villar-Taibo R, Bernabéu I, Díaz-López E, Calatayud M, Álvarez-Escola C, Rojas-Marcos PM, Recio-Cordova JM, Aulinas A, Roca QA, Avilés MD, Mezquita EL, Fernández-Argueeso M, Molero IG, Ruz-Caracuel I, Aldecoa I, García J, Martínez-Sáez E, Hanzu F, Marazuela M, Puig-Domingo M, Biagetti B.** validation and limitations of the PANOMEN-3 predictive model for tumor recurrence and progression in pituitary tumors. J Clin Endocr Metab. 2025; 110(12): 3391-9. Article. IF: 5.4; Q1
- **Arenillas C, Celada L, Ruiz-Cantador J, Calsina B, Datta D, García-Galea E, Fasani R, Moreno-Cárdenas AB, Alba-Linares JJ, Miranda-Barrio B, Martínez-Montes AM, Álvarez-Escola C, Lecumberri B, García AG, Flores SK, Esquivel E, Ding YL, Peitzsch M, Robles-Guirado JA, Zapata RMR, Pozo-Kreilinger JJ, Iglesias C, Dwight T, Muir CA, Oleaga A, Rodríguez-Monte MEGL, del**

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Cerro MJ, Martínez-Bendayán I, Álvarez-González E, Cubiella T, Lourenço DM Jr, Pereira MAA, Burnichon N, Buffet A, Broberg C, Dickson PV, Fraga MF, Pendás JLL, Soriano JR, Fuentes FB, Toledo SPA, Clifton-Bligh R, Dienstmann R, Villanueva J, Capdevila J, Gimenez-Roqueplo AP, Favier J, Nuciforo P, Young WF Jr, Bechmann N, Opotowsky AR, Vaidya A, Bancos I, Weghorn D, Robledo M, Casteràs A, Dos-Subirà L, Adameyko I, Chiara MD, Dahia PLM, Toledo RA. Convergent genetic adaptation in human tumors developed under systemic hypoxia and in populations living at high altitudes. Cancer Discov. 2025; 15(5): 1037-62. Article. IF: 29.5; D1

- **Artime E, Hillman N, Tinahones FJ, Pérez A, Giménez M, Duque N, Rubio-De Santos M, Díaz-Cerezo S, Redondo-Anton J, Spaepen E, Pérez F, Conget I.** Glucometrics and patient-reported outcomes in individuals with type 1 diabetes mellitus: insights from the correlation of time in range (correlatir) study in real-world settings. Cureus. 2025; 17(2): e79134. Article. IF: 1.3; Q2
- **Asanza EC, Biroli A, Pérez-López C, Araujo-Castro M, Cámara R, Guerrero-Pérez F, Vicente A, Lamas C, Serra G, Echarri AI, Ollero MD, Molero I, Villar-Taibo R, Rodríguez MDM, Feijoo PG, Berrocal VR, Sánchez N, Hurtado AG, Capristan-Díaz V, Simó-Servat A, Gallach M, Pérez ES, Rosa VG, Modino SC, Torre EM, Aulinas A, Iglesias P, Díez JJ, Rodríguez-Hernández V, Puig-Pérez A, Blangini E, Bernabéu I, Álvarez-Escolá C, Sarria-Estrada S, Puig-Domingo M, Abelló FA, Martínez-Sáez E, Biagetti B.** Age-related differences in the clinical features and management of pituitary apoplexy: a cohort study. Eur J Endocrinol. 2025; 192(4): 356-63. Article. IF: 6.7; Q1
- **Barquiel B, Álvarez D, Domínguez OM, de Sevilla EGP, Hillman N, Romero R, Gaspar R, Arévalo M, de Villar NGP.** Diabetic retinopathy remission in patients using an automated insulin delivery system: A prospective controlled study. Diabetes Metab. 2025; 51(6): 101703. Article. IF: 5.8; Q1
- **Biagetti B, Asanza EC, Pérez-López C, Araujo-Castro M, Cámara R, Guerrero-Pérez F, Vicente A, Lamas C, Serra G, Echarri AI, Ollero MD, Molero IG, Villar-Taibo R, Rodríguez MDM, García-Feijoo P, Berrocal VR, Ramirez MNS, Hurtado AG, Capristan-Díaz V, Simó-Servat A, Gallach M, Perez ES, Rosa VG, Civantos S, Asensio-Wandosell D, Martínez-Sáez E, Torre EM, Aulinas A, Iglesias P, Díez JJ, Bernabéu I, Álvarez-Escolá C, Puig-Domingo M.** Pituitary apoplexy: comorbidities, management, and outcomes-a spanish observational ulticenter study. J Clin Endocr Metab. 2025; 110(6): e1811-20. Article. IF: 5.4; Q1
- **Biagetti B, Asanza EC, Pérez-López C, Berrocal VR, Vicente A, Lamas C, Guerrero-Pérez F, Simó-Servat A, Serra G, Echarri AI, Ollero MD, Molero IG, Villar-Taibo R, Rodríguez MDM, García-Feijoo P, Ramirez MNS, Hurtado AG, Capristan-Díaz V, Cámara R, Gallach M, Pérez ES, Rosa VG, Civantos-Modino S, Martínez-Saez E, Torre EM, Aulinas A, Iglesias P, Díez JJ, Bernabéu I, Álvarez-Escolá C, Puig-Domingo M, Araujo-Castro M.** Predictors of conversion to surgery in pituitary apoplexy: Insights from a Spanish multicenter observational study. J Clin Transl Endocrinol. 2025; 40: 100399. Article. IF: 4.9; Q1
- **Biagetti B, Cardona-Arias A, Torre EM, Aulinas A, Ruz-Caracuel I, Centeno RG, González L, Echarri AI, Rodríguez MDM, Paja M, Guerrero-Perez F, Castano JP, García MDO, Novo-Rodríguez C, Tenorio-Jiménez C, Villar-Taibo R, Bernabéu I, Díaz-López E, Calatayud M, Álvarez-Escola C, Rojas-Marcos PM, Recio-Cordova JM, Lozano-Aida C, Roca QA, Avilés MD, Mezquita EL, Argueso MF, Molero IG, Alberoa I, Idrobo C, Achote E, Martínez-Sáez E, Marazuela M, Puig-Domingo M, Hanzu F, Araujo-Castro M.** Predictors of progression after surgery in non-functioning pituitary macroadenomas: a Spanish multicenter study. J Endocrinol Invest. 2025; 48(12): 2857-67. Article. IF: 4.0; Q2
- **Borrego-Soriano I, Parra-Ramírez P, Martín-Rojas-Marcos P, Pérez-López C, García-Feijoo P, Álvarez-Escolá C.** Transsphenoidal surgery for pituitary neuroendocrine tumours (pitnets) in a tertiary hospital: are there differences between young and elderly patients?. Clin Endocrinol. 2025; 103(1): 82-8. Article. IF: 2.8; Q3
- **Borrego-Soriano I, Hernández-Perdomo Y, Rivas B, Parra-Ramírez P, Moreno-Domínguez O, Vega-Cabrera C.** An unusual cause of hypokalemia to consider. JCEM Case Rep. 2025; 3(3): luaf026. Article. Not Indexed
- **Carmona-Bayonas A, Álvarez-Escolá C, Navarro IB, Cubero JH, Cruz MAM, García-Centeno R, Iglesias C, García-Donas J, Picón MJ, Paja M, Batanero LG, García L, Gordoa TA, López C, Hanzu F, Martínez-Trufero J, Febrero B, Saiz-López P, Carrera CB, Cajal TR, Veiguela B, Gressani O, Valdés N, Jiménez-Fonseca P.** Does adjuvant mitotane impact cure rates in adrenocortical carcinoma? Insights from the ICARO-GETTHI/SEEN Registry. J Clin Endocr Metab. 2025; 110(11): 3155-67. Article. IF: 5.4; Q1
- **García IA, Alcalá BB, Pérez PV, Sánchez MCP, de Villar NGP.** Time to change guidelines? Suboptimal glycemic control measures by CGM associated with cystic fibrosis exacerbations despite adequate HbA1c. Acta Diabetol. 2025; 62(3): 429-31. Editorial Material. IF: 3.1; Q3
- **Goi J, Fano MP, Gellida AR, González-Boillos M, Rojas-Marcos PM, Guayerbas LC, Cano AMG, Ruiz-Sánchez JG, Vicente A, Gómez-Hoyos E, Recasens M, San Millán RB, César MJP, Guardiola PD, Perdomo CM, Manjón-Miguélez L, Román AR, Lázaro CR, Recio JM, Calatayud M, López NJ, Núñez MS, Ribas EM, Sánchez AS, Díaz CG, Lamas C, Serrano J, Michalopoulou T, Rodrigo ST, Pascual-Corrales E, Aguila FJ, Rivas NM, Mateo EMM,**



IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Gutiérrez-Medina S, Hanzu FA, Ramírez PP, Araujo-Castro M. Efficacy and safety of medical treatment of primary aldosteronism: a real-world data study in Spain. Eur J Endocrinol. 2025; 193(2): 297-309. Article. IF: 6.7; Q1

- Iriarte-Durán MB, Fano MP, Gellida AR, González-Boillos M, Ramírez PP, Rojas-Marcos PM, Caja L, Cano AMG, Ruiz-Sánchez JG, Vicente A, Gómez-Hoyos E, Recasens M, San Millán RB, César MJP, Guardiola PD, Perdomo CM, Manjón-Miguélez L, Román AR, Lázaro CR, Recio JM, Calatayud M, López NJ, Núñez MS, Ribas EM, Sánchez AS, Díaz CG, Lamas C, Serrano J, Michalopoulou T, Rodrigo ST, Aguila FJ, Mateo EMM, Gutiérrez-Medina S, Hanzu FA, Araujo-Castro M. Impact of primary aldosteronism on calcium phosphate homeostasis. Results from the SPAIN-ALDO. J Endocrinol Invest. 2025; 48(7): 1611-22. Article. IF: 4.0; Q2
- Jiménez-Fonseca P, Álvarez-Escola C, Navarro IB, Cubero JH, Fernández LG, Cruz MAM, Iglesias C, García-Donas J, Picón MJ, Paja M, Batanero LG, García L, Molina J, Maté RJ, Aller J, Romero MDT, Salas JC, Gutiérrez-Buey G, Zunzunegui NE, Navarro M, Lecumberri MJ, Valdés N, Carmona-Bayonas A. External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapy. Eur J Endocrinol. 2025; 193(2): 320-8. Article. IF: 6.7; Q1
- Mclennan S, Verhoeff K, Parente A, Ribano A, Wang YB, Wang ZC, Zhou JL, Wu XR, Chen YH, Sledzinski M, Hellmann A, Raffaelli M, Pennestrì F, Sywak M, Papachristos AJ, Palazzo FF, Sung TY, Kim BC, Lee YM, Eatock F, Anderson H, Iacobone M, Gray D, Chaulk RC, Kosmoliaptsis V, Colucci N, Spiers HVM, Dauksa A, Makay O, Turk Y, Atalay HB, Van Dijkum EJMN, Engelsman AF, Holscher I, Materazzi G, Rossi L, Becucci C, Shore SL, Waghorn A, Fung C, Mihai R, Balasubramanian SP, Pannu A, Tatarano S, Velázquez-Fernández D, Miller JA, Serrao-Brown H, Chen YF, Demarchi MS, Djafarrian R, Doran H, Stechman MJ, Perry H, Hubbard J, Lamas C, Mercer P, Macpherson J, Lumbiganon S, Calatayud M, Hanzu FA, Vidal O, Araujo-Castro M, Ojeda CM, Papavramidis T, Gomez PRD, Aldrees A, Altwjry T, Valdés N, Álvarez-Escola C, Sanz IG, Carrera CB, Manjon-Miguélez L, Novoa PD, Recasens M, Centeno RG, Lázaro CR, van den Heede K, Van Slycke S, Michalopoulou T, Aspinall S, Melvin R, Lau JWL, Cheah WK, Tang MH, Oh HB, Ayuk J, Sutcliffe RP. Evaluation of the effect of tumour size on outcomes for patients undergoing adrenalectomy for phaeochromocytoma: international multicentre analysis. BJS Open. 2025; 9(6): zraf133. Article. IF: 4.9; D1
- Paja M, Soto A, Hanzu FA, Guerrero-Pérez F, Cámara R, Moure D, Gálvez A, Simó-Servat A, Villar-Taibo R, Calatayud M, Vicente A, Recio-Córdova JM, Serra G, Rojas-Marcos PM, Parra-Ramírez P, Araujo-Castro M, Librizzi S, Irigaray A, Ollero D, Aznar S, Muñoz F, Aulinas A, González-Fernández L, García-Centeno R, Egaña N, González-Vidal T, Menéndez E, Delgado AM, Abarca J, Sottile J, Picó AM, Novo C, Ortiz I, Tenorio C, de León R, de Pablos-Velasco P, Crespo C, Peñalver D, Díaz-Soto G, Puig-Domingo M, Biagetti B, Neuroendocrinology Grp Spanish Endocrinol Nutr Soc SEEN. Outcomes of transsphenoidal surgery for pituitary adenomas in Spain: a retrospective multicenter study. Front Endocrinol (Lausanne). 2025; 16: 1529418. Article. IF: 5.7; Q1
- Parente A, Verhoeff K, Wang YB, Wang NB, Wang ZC, Sledzinski M, Hellmann A, Raffaelli M, Pennestrig F, Sywak M, Papachristosh AJ, Palazzo FF, Sung TY, Kim BC, Lee YM, Eatock F, Anderson H, Iacobone M, Dauksa A, Makay O, Turk Y, Atalay HB, van Dijkum EJMN, Engelsman AF, Holscher I, Materazzi G, Rossi L, Becucci C, Shore SL, Fungs C, Waghorn A, Mihai R, Balasubramanian SP, Pann A, Tataranov S, Velázquez-Fernández D, Miller J, Serrao-Brownh H, Chen Y, Demarchi MS, Djafarrian R, Doran H, Wang K, Stechman MJ, Perry H, Hubbard J, Lamas C, Mercer P, MacPherson J, Lumbiganon S, Calatayud M, Hanzu FA, Vidal O, Araujo-Castrok M, Ojeda CM, Papavramidis T, Gomez PRdV, Aldreesoo A, Altwjry T, Valdés N, Álvarez-Escola C, Sanz IG, Carrera CB, Manjón-Miguélez L, Novoa PD, Recasens M, Centeno RG, Lázaro CR, Van den Heede K, Van Slycke S, Michalopoulou T, Aspinall S, Melvin R, Lau JWL, Cheah WK, Tang MH, Oh HB, Ayuk J, Sutcliffe RP. Robotic and laparoscopic adrenalectomy for pheochromocytoma an international multicenter study. Eur Urol Focus. 2025; 11(1): 118-25. Article. IF: 6.3; Q1
- Plaza-Díaz J, Brandimonte-Hernández M, López-Plaza B, Ruiz-Ojeda FJ, Álvarez-Mercado AI, Arcos-Castellanos L, Feliú-Batlle J, Hummel T, Palma-Milla S, Gil A. Effect of a novel food rich in miraculin on the intestinal microbiome of malnourished patients with cancer and dysgeusia. Nutrients. 2025; 17(2): 246. Article. IF: 5.8; Q1
- Soriano IB, Alcalá BB, Domínguez OM, Moreno ALQ, de Sevilla EGP, de Villar NGP. Screening system for the detection of unknown or poorly controlled diabetes mellitus in a tertiary hospital: A retrospective study. J Eval Clin Pract. 2025; 31(1): e14098. Article. IF: 1.5; Q2
- Valderrabano P, Silva JBQ, Mena SC, Casado CF, Novoa MPD, Pérez MCS, Fernández EF, Guerra AL, Sambo M, Rojas-Marcos PM, Ramírez PP, Fernández CT, Troyano MJR, Lázaro VA, Vargas ML, García NP. Evaluation of thyroid ultrasound reports' quality in the Community of Madrid, Spain. Eur Thyroid J. 2025; 14(1): e240390. Article. IF: 4.9; Q1
- Verhoeff K, Parente A, Wang YB, Wang NY, Wang ZC, Sledzinski M, Hellmann A, Raffaelli M, Pennestrì F, Sywak M, Papachristos AJ, Palazzo FF, Sung TY, Kim BC, Lee YM, Eatock F, Anderson H, Iacobone M, Dauksa A, Makay O, Turk Y, Atalay HB, van Dijkum EJMN, Engelsman AF, Holscher I, Materazzi G, Rossi L, Becucci C, Shore SL, Fung C, Waghorn A, Mihai R, Balasubramanian SP, Pannu A, Tatarano S, Velázquez-Fernández D, Miller JA, Serrao-Brown H, Chen YF, Demarchi MS, Djafarrian R, Doran H, Wang KL, Stechman MJ, Perry H, Hubbard J, Lamas C, Mercer P, Macpherson J, Lumbiganon S, Calatayud M, Hanzu FA, Vidal O, Araujo-Castro M, Ojeda CM, Papavramidis T, Gómez PRD, Aldrees A, Altwjry T, Valdés N, Álvarez-Escola C, Sanz IG, Carrera CB, Manjón-Miguélez L, Novoa PD, Recasens M, Centeno RG, Lázaro CR, van den Heede K, Van Slycke S, Michalopoulou T, Aspinall S, Melvin R, Lau JWL, Cheah WK, Tang MH, Oh HB, Ayuk J, Sutcliffe RP, Int Pheo Study Grp. Outcomes for patients with obesity undergoing adrenalectomy for pheochromocytoma: an international multicenter analysis. Ann Surg Oncol. 2025; 32(3): 1709-20. Article. IF: 3.8; Q1

Clinical trials

- Parra Ramírez PA. Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de baxdrostat en participantes con hiperaldosteronismo primario.
  Type/Phase: III
  Sponsored by: Astrazeneca Ab.
  Signature date: 10/09/2025
- Zapatero Larrauri M. A Phase III, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with bi 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (cvd) or chronic kidney disease, or at least two risk factors for cvd.
  Type/Phase: III
  Sponsored by: Boehringer Ingelheim España S.A.
  Signature date: 13/03/2025

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

4.2 Ophtalmology Group

Publications: 7 | Q1:4

COMPOSITION

Félix Armada Maresca

- Ester Carreño Salas
- M. Ventura Hidalgo Barrero
- M. Pino Cidad Betegón
- Ana M. Boto de los Bueis
- Ana Isabel Ramos Castrillo
- Paola Cristina Vázquez Colomo
- Julia Esther Murillo Doria
- Álvaro Arbizu Duralde
- Mónica Asencio Durán
- María Capote Díez
- Oriana D'Anna
- María Granados Fernández
- Irene Canal Foncuberta
- Lilian C. Martínez Godoy
- Ricardo Romero Martín
- Jesús Fraile Maya
- José Vicente Dabad Moreno
- Beatriz Manzano Muñoz
- María Begoña Pastor Nieto
- Margarita Sánchez Orgaz
- Silvana Lubisco Portella
- Irene Rosa Pérez
- Javier F. Coca Robinot
- Rosa María Cordero Ros
- Gloria Amorena Santisteban
- Sofía Katina de Manuel Triantafilo
- Ana María Martín Ucero
- María Castro
- Natalia Arruti Vázquez
- Almudena del Hierro Zarzuelo
- Yolanda Piñero Martínez
- Belén Puente Gete
- Arabella Serrano Arranz
- Laura Gil Ibañez
- Laura Rosal Ruiz
- Gemma Esquivel Benito
- Jose María Jiménez Labrador
- Sira Gómez Lozano
- Maria Luisa Tesón Yudego
- Sara Quirós Llano

RESEARCH AREAS

- Large system pathology

RESEARCH ACTIVITY

Publications

- **Armadá-Maresca F, Capote-Díaz M, Cidad-Betegón MD, Cordero-Ros RM, Martínez-Godoy L, Vázquez-Colomo P, Laín-Olia B, Songel-Sanchís B, Caminos-Melguizo A, Baoud-Ould-Haddi I.** Clinical performance of an interactive platform based on artificial intelligence in ophthalmology: experience in a third-level reference center. Front Med (Lausanne). 2025; 12: 1593556. Article. IF: 3.6; Q1
- **Branford JA, Bodaghi B, Ferreira LB, McCluskey PJ, Thorne JE, Matthews JM, Smith JR.** Use of immunomodulatory treatment for non-infectious uveitis: an International Ocular Inflammation Society report of real-world practice. Brit J Ophthalmol. 2025; 109(4): 482-9. Article. IF: 4.5; Q1
- **Fabiani C, Shantha J, Gangaputra S, Vitale A, Thorne JE, Jabs DA, Fawzi A, Smith JR, Accorinti M, Smet MDD, Agrawal R, Munk MR, Agarwal A, Pichi F, Carreño E, Invernizzi A, Chee SP, Davis JL, Sarraf D, Gupta V.** Is it time to adopt a new nomenclature and classification for white dot syndromes using multimodal imaging techniques? report 1 from multimodal imaging in uveitis (MUV) task force. Ocul Immunol Inflamm. 2025; 33(4): 561-9. Article. IF: 1.7; Q3
- **Fonollosa A, Carreno E, Civera AA, Dick AD, Pellegrini M, Romano F.** Stage 1 extensive macular atrophy with pseudodrusen-like appearance complicated by multiple evanescent white dot syndrome-like reaction. Ocul Immunol Inflamm. 2025; 33(7): 1444-50. Article. IF: 1.7; Q3
- **Gómez-García E, Granados M, Saceda JM, Moreno MN, Zamorano J, Cebrian JL, Noval S.** Role of computer-assisted surgery in the management of pediatric orbital tumors: insights from a leading referral center. Children (Basel). 2025; 12(12): 1649. Article. IF: 2.6; Q1
- **Sota J, Ragab G, AlMaglouth I, Lopalco G, Tufan A, Direskeneli H, Hinojosa-Azaola A, Giardini HAM, Guerriero S, Triggianese P, Sfikakis PP, Piga M, Ruscitti P, Govoni M, Iagnocco A, Carubbi F, Hernández-Rodríguez J, Laymouna AH, Mahmoud AAMA, Ghanema M, Aboabat AA, Asfina KN, Alanazi F, Morrone M, Spedicato V, Kucuk H, Kardas R, Öner FA, Sevik G, Torres-Ruiz J, Kawakami-Campos PA, Antonelli IPDB, Dammacco R, Chimenti MS, Arida K, Floris A, Gentile M, Ruffilli F, Bellis E, Alunno A, Espinosa G, Gentileschi S, Gaggiano C, Vitale A, Caggiano V, López R, Tarsia M, Montis S, Hatemi G, Karakoc A, Frassi M, Giacomelli R, Tharwat S, Thabet M, Ciccia F, Emmi G, Viapiana O, Sahin A, Sebastiani GD, Batu ED, Ozen S, Sener S, Opris-Belinski D, Costi S, Conforti A, Cattalini M, Bartoloni E, Akkoç N, Gunduz OS, Conti G, Maier A, Giardina A, Li Gobbi F, Parronchi P, Puttini PS, Breda L, De Paulis A, Carreño E, La Torre F, Wiesik-Scewczyk E, de-la Torre A, Mejía-Salgado G, Shahram F, Guiducci S, Maggio MC, Aragona E, Rigante D, Ciavarro A, Önen F, Erten U, Insalaco A, Del Giudice E, Barone P, Gicchino F, Brucato A, Lo Gullo A, Mauro A, Karamanakos A, Balistreri A, Mazzei MA, Frediani B, Fabiani C, Cantarini L.** Influence of gender on Behcet's disease phenotype and irreversible organ damage: Data from the International AIDA Network Behcet's Disease Registry. Joint Bone Spine. 2025; 92(2): 105819. Article. IF: 5.0; Q1
- **Tornero-Romero F, Sánchez-Hernández R, Cantero-del Olmo L, Saravia-Moya A, González**

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians



de Rivera-Utrera M, Sánchez-Barbero AI, Carreno-Salas E. Hyperinflammation and Blindness. Screening for ROSAH Syndrome. Eur J Case Rep Intern Med. 2025; 12(4): 4989. Article. Not Indexed

Research projects

- **Arruti Vázquez N.** Caracterización clínica del síndrome alcohólico-fetal: repercusión sobre la función visual y la visión funcional. ONCE. 2024-2026. Managment centre: FIBHULP
- **Armada Maresca F.** Estudio retrospectivo para análisis de datos obtenidos en el cribado de pacientes de oftalmología, remitidos desde atención primaria a atención especializada, mediante el robot Eyelib de Mikajaki. Health Market Consulting S. L. 2025-Ongoing. Managment centre: FIBHULP
- **Carreño Salas E.** Estudio prospectivo para evaluar el efecto de la suplementación con citicolina y ácidos grasos omega-3 enriquecidos en el glaucoma crónico simple en la densidad de células similares a macrófagos de la superficie de la retina por tomografía de coherencia óptica, como marcador subrogado de neuroinflamación. Brudy Technology. 2025-2025. Managment centre: FIBHULP

Clinical trials

- **Armadá Maresca F.** Estudio de fase IIIB multicéntrico de un solo brazo, para evaluar la eficacia, la seguridad y los resultados reportados por el paciente de ranibizumab administrado con el dispositivo port delivery system utilizando una pauta de recarga - intercambio cada 36 semanas, en pacientes con degeneración macular asociada a la edad neovascular.
  Type/Phase: IIIb
  Sponsored by: F.Hoffmann-La Roche Ltd.
  Signature date: 29/10/2025
- **Boto De Los Bueis A.** Revisión retrospectiva de las historias clínicas de pacientes con queratitis por acanthamoeba que han recibido polihexanida 0,8 mg/ml como parte del programa de gestión de medicamentos en situaciones especiales en españa.
  Type/Phase: EPA-OD
  Sponsored by: Sifi S.P.S.
  Signature date: 02/10/2025
- **Carreño Salas E.** Estudio transversal, multicéntrico para describir el estado de la conjuntiva y la cápsula de tenon de sujetos sanos y pacientes con dmaen/emd seguidos en la práctica clínica en españa. a multicenter, cross-sectional study to describe the conjunctiva and tenon's capsule status of healthy subjects and namd/dme patients followed in clinical practice in spain.
  Type/Phase: OTROS
  Sponsored by: Roche Farma, S.A.
  Signature date: 10/01/2025
- **Del Hierro Zarzuelo A.** Estudio prospectivo para la validación de biomarcadores moleculares en muestras de epitelio corneal en pacientes con queratocono.
  Type/Phase: OTROS
  Sponsored by: Corneaproject S.L.
  Signature date: 25/04/2025
- **Vázquez Colomo P.** A randomized, multicenter, double-masked, vehicle-controlled phase 2/3 study to evaluate the safety and efficacy of nexagon® (lufepirsen ophthalmic gel) in subjects with persistent corneal epithelial defects (nexpede-1).
  Type/Phase: II
  Sponsored by: Glaukos Corporation.
  Signature date: 11/02/2025

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

4.3 Pediatric Anesthesiology and Reanimation



Publications: 2 | Q1:1

COMPOSITION

Patricio González Pizarro

- Jesús Carlos de Vicente Sánchez
- Javier Veganzones Ramos
- Marta Vázquez Moyano
- Paloma Sánchez Aznar
- María Isabel Rodríguez Seguín
- Emilio Rodríguez Pérez
- Raquel Pérez González
- Ana Belén Ortega Floria
- María Pilar Morán Martín
- Laura Lopez Garcia
- María Esperanza Jiménez Mateos
- Ivan Huercio Martinez
- Inmaculada Hidalgo Nuchera
- Angeles Herranz Ortega
- Sara Guallar Alegre
- Raquel García Gómez
- Elena Fernandez Dueñas
- Israel Enfedaque Castilla
- Claudia Cuesta González Tascón
- Patricia Cid Boo
- Gemma Campo García
- Lina Builes Cardona
- Mercedes Alonso Prieto
- Julia Albano Polo

RESEARCH AREAS

- Maternal Infant Child and youth research

RESEARCH ACTIVITY

Publications

- **González-Pizarro P, Suárez-Sipmann F.** Acute respiratory distress syndrome definitions in adults and children: A comparative narrative review. J Clin Med. 2025; 14(21): 7644. Review. IF: 3.3; Q1
- **Cecconi M, Hutanu AL, Beard J, González-Pizarro P, Ostermann M, Batchelor A, Latour JM, Grensemann J, Mondino MG, Caballero J, Blobner M, Radtke FM.** Unlocking opportunities to transform patient care: an expert insight on limitations and opportunities in patient monitoring. Intensive Care Med Exp. 2025; 13(1): 24. Review. IF: 2.9; Q2

Research projects

- **González Pizarro P.** Validación del test de aire como método de detección de atelectasias perioperatorias en pediatría: un estudio prospectivo. MR Global (Mindray). 2020-Ongoing. Managment centre: FIBHULP

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

4.4 Urology Group

Publications: 14 | Q1:4

COMPOSITION

Luis Martínez-Piñeiro

- Miriam Serrano Liesa
- Esaú Fernández Pascual
- Pablo Abad López
- Álvaro Javier Yebes
- Alfredo Aguilera Bazan
- José María Alonso Dorrego
- Ramón Cansino Alcaide
- Cristina de Castro Guerín
- Estefania Linares Espinós
- Juan Antonio Maínez Rodríguez
- Emilio Ríos González
- Asier Leivar Tamayo
- Cristina Ballesteros Ruiz
- María Justa Garcia-Matres Cortés
- Eduardo López Pérez
- Juan José Gómez Ruiz
- Ignacio González Valcárcel
- Mireia Heras Alonso
- Claudio Martínez Ballesteros

RESEARCH AREAS

- Large system pathology

STRATEGIC OBJETIVES

- We aim to consolidate a strong research group into:
  - Urologic Oncology
  - Reconstructive surgery
  - Endurologic and minimally invasive surgery
  - Lithiasis
  - Incontinence / Neuro-urology
  - Andrology / Reproduction
  - Identification and validation of predictive biomarkers and a better understanding of the mechanisms of primary and secondary resistance in bladder cancer.
- Through basic and experimental research, clinical research, translational research and clinical trials.
- The results of this projects should be translated into doctoral theses, publications in high impact journals and visibility factor, as to finally achieve patents and trademarks.



RESEARCH LINES

- The group's efforts will focus on the following fields of research:

BLADDER CANCER

- Immunotherapy for Bladder Cancer
- Immunological response in patients with bladder cancer treated with BCG.
- Urinary markers in diagnosis and prediction of response in patients with bladder cancer.
- New immunomodulatory treatments in bladder cancer.
- Efficacy of combined chemo and immunotherapy hyperthermia in bladder cancer.
- Bladder Cancer Treatments Targeting New Targets
- Use of Antibodies Conjugated with Cytotoxic Agents in Bladder Cancer

PROSTATE CANCER

- Castration resistant prostate carcinoma, immune response, and evaluation of predictive markers of therapeutic response.
- Medical treatment of locally advanced and metastatic prostate cancer.
- KIDNEY CANCER
- Research of new therapeutic lines in hereditary renal cancer.
- Medical treatment

RECONSTRUCTIVE SURGERY

- Development and improvement of new reconstructive surgery techniques for complex urethral strictures, genitourinary congenital malformations and genitourinary fistulas.

ENDUROLOGIC AND MINIMALLY INVASIVE SURGERY

- Development of new endourological surgery techniques for minimally invasive treatment of benign prostatic hyperplasia and urinary lithiasis.
- Development of a learning program in laparoscopy and other minimally invasive surgeries.

LITHIASIS

- Study of new inhibitors of crystallization of urine solutes as prevention of lithogenesis.
- Metabolic study of renal lithiasis.

INCONTINENCE AND NEURO-UROLOGY

- Study and treatment of chronic pelvic pain.

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH ACTIVITY

Publications

- **Ayllón-Blanco HR, Maínez-Rodríguez JA, Cansino-Alcaide JR, Toribio-Vázquez C, Pérez-Carral JR, Girón-De Francisco M, Abad-López P, Martínez-Piñeiro L.** Modification of hydroablation technique in a third level hospital. Med Balear. 2025; 40(5): 354. Article. IF: 1.1; Q3
- **De Santis M, Redorta JP, Nishiyama H, Krawczynski M, Seyitkuliev A, Novikov A, Guerrero-Ramos F, Zukov R, Kato M, Kawahara T, Goeman L, Puente J, Hellmis E, Powles T, Radziszewski P, Gust KM, Vasey P, Bigot P, Fradet Y, Hunting J, Armstrong J, Boulos S, Hois S, Shore ND.** Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet. 2025; 406(10516): 2221-34. Article. IF: 109.0; D1
- **Flores JM, Ljubetic BM, Novaes LF, Becher EF, de Toledo IA, Carvajal A, Correa EC, Fernández-Pascual E, Martínez-Salamanca JI, Nelson C, Salter CA, Torremade J, D'Anna M, Valenzuela R, Negrón A, Moreno S, Henríquez C, Atkinson TM, Mulhall JP.** Preliminary psychometric linguistic validation of the satisfaction survey for inflatable penile implant in Spanish. Sex Med. 2025; 13(5): qfaf089. Article. IF: 2.4; Q2
- **González-Peramato P, Álvarez-Maestro M, Heredia-Soto V, Sabio MM, Linares E, Serrano A, Álvarez-Ossorio JL, Prieto L, Alcina EL, Rodríguez MA, Berglund E, Alonso FV.** Comparing Prostatype P-score and traditional risk models for predicting prostate cancer outcomes in Spain. Actas Urol Esp. 2025; 49(6): 501788. Article. IF: 1.7; Q3
- **Ljubetic BM, Thorogood SL, Becher EF, de Toledo IA, Carrion R, Carvajal A, Fernández-Pascual E, Martínez-Salamanca JI, Nelson C, Quesada J, Salter CA, Torremade J, d'Anna M, Valenzuela R, Mulhall JP, Flores JM.** Initial linguistic and cultural validation of the satisfaction survey for inflatable penile implant (SSIPI) in Spanish. Actas Urol Esp. 2025; 49(2): 501700. Article. IF: 1.7; Q3
- **Maínez JA, Galán JA, López JM, Isern-Amengual B, Sanchís-Cortés P.** User profile and engagement with a digital health application for urolithiasis management: A descriptive study of the first 699 users. Actas Urol Esp. 2025; 49(8): 501819. Article. IF: 1.7; Q3
- **Osorio CAM, Sutil RS, Cabo AV, Espinós EL, Backhaus MR, Rivas JG, Planells MC, Breijo SM, Brau NP, Esteban ND, Rodríguez JM, Bonet AS, Cascales AG, Cortés MB, Vives PS, Gallego JMD, Márquez MP, Sanz MG, Alemán JR, Horcajada AZ, Part VR, Roman MH, Concha CR, González ER, de Pablos-Rodríguez P.** Prostate-specific antigen response at six months predicts progression in metastatic hormone-sensitive prostate cancer treated with apalutamide. Prostate. 2025; 85(16): 1507. Article. IF: 2.7; Q2
- **Papatsoris A, Geavlete B, Radavoi GD, Alameedee M, Almusafer M, Ather MH, Budia A, Cumpanas AA, Kiremit MC, Dellis A, Elhowairis M, Galan-Llopis JA, Geavlete P, García JG, Isern B, Jinga V, López JM, Mainez JA, Mitsogiannis I, Christian JM, Moussa M, Multescu R, Acar YO, Petkova K, Pinero A, Popov E, Cebrian MR, Rascu S, Siener R, Sountoulides P, Stamatelou K, Syed J, Trinchieri A.** Management of urinary stones by experts in stone disease (ESD 2025). Arch Ital Urol Androl. 2025; 97(2): 14085. Review. IF: 1.4; Q3
- **Rodríguez JAM, Blanco HRA, Cansino JR, Vázquez CT, Carral JRP, Girón M, Abad P, Martínez-Piñeiro L.** Aquablation, a safe technique?. Cent European J Urol. 2025; 78(3): 347-51. Article. IF: 1.7; Q3
- **Román MH, Mate K, de Pablos-Rodríguez P, Horcajada AZ, Cascales AG, Bonet AS, Vilaseca A, Pazos DVM, Espinós EL, Rodríguez JM, Gallego JMD, Alemán JR, Rivas JG, Formisano L, Fita MJJ, Planells MC, Esteban MD, Márquez MP, Sanz MG, Expósito NG, Picola N, Vives PS, Sutil RS, Durán MAC, Backhaus MR.** Apalutamide use in metastatic hormone-sensitive prostate cancer patients diagnosed by conventional and next-generation imaging. Real world data from 772 patients. Actas Urol Esp. 2025; 49(5): 501742. Article. IF: 1.7; Q3
- **Ruiz CB, Campos-Juanatey F, Martín IP, Biosca SM, Cardesa OG, Guevara JFA, Formoso NG, Pascual EF, Salamanca JIM, Pérez SM, Dorrego JMA, González ER, Talegón SS, Suárez AMA, Pascual EM, García MAB, Polo JM, Clotet LV, Morton AJV, Gil JA, Cambras LS, Vázquez LI, Gutiérrez JH, Castro EMM, Roca JPD, León LT, Lorenzo LMP.** Efficacy and safety of Optilume® paclitaxel-coated urethral dilatation balloon in real-life: experience in a Spanish multicenter study. Actas Urol Esp. 2025; 49(1): 80-5. Article. IF: 1.7; Q3
- **Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, Soria F, Álvarez-Maestro M, Bazán AA, Pradere B, Klatte T, Contieri R, Hurle R, Krajewski W, Subiela JD, Pichler R, Szostek A, Marcq G, Elena JLR, Aranda J, Gontero P, Rouprêt M, Shariat SF, Necchi A, Montorsi F, Briganti A, Xylinas E, Moschini M, EuroGemDoce Study Grp Collaborators, European Assoc Urology - Young Acad Urologists EAU-YAU, Urothelial Carcinoma Working Grp.** Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results. BJU Int. 2025; 135(6): 969-76. Article. IF: 4.1; Q1
- **Sibai M, Cervilla S, Grases D, Musulen E, Lazcano R, Mo CK, Dávalos V, Fortian A, Bernat A, Romeo M, Tokheim C, Barretina J, Lazar AJ, Ding L, Grande E, Real FX, Esteller M, Bailey MH, Porta-Pardo E.** The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity. Cell Rep. 2025; 44(2): 115229. Article. IF: 7.7; Q1
- **Sierra A, Alfambra H, López JM, Mercade A, Peri LL, Espilez R, Álvarez-Maestro M, Martínez-Corral R, Pérez-Fentes DA, Etcheverry B, Colom S, Vigues F, Alcaraz A, Luque MP, Torrecilla C, Musquera M.** Outcomes of percutaneous nephrolithotomy in kidney transplant recipients: results from a multicenter study by the spanish urology association's renal transplant group. World J Urol. 2025; 43(1): 564. Article. IF: 3.3; Q1

Clinical trials

- **Linares Espinós EE.** European registry of next generation imaging in advanced prostate cancer (ring study).
  Type/Phase: OTROS
  Sponsored by: Fundació De Gestió Sanitaria De L'Hospital De La Santa Creu I Sant Pau Fundació De Gestió Sanitaria De L'Hospital De La Santa Creu I Sant Pau.
  Signature date: 27/02/2025
- **Ríos González E.** A phase 3, randomised, multi-centre, open label trial to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade bacillus calmette-guerin (bcg) unresponsive non-muscle invasive bladder cancer (nmibc).
  Type/Phase: III
  Sponsored by: Ferring Pharmaceuticals A/S.
  Signature date: 17/11/2025

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

4.5 Angiology and Vascular Surgery



Publications: 2 | Q1:1

COMPOSITION

Alvaro Fernandez Heredero

- **Elena Marin Manzano**
- **Nieves Aleicel Concepcion Rodriguez.**

RESEARCH AREAS

- Cardiovascular

RESEARCH LINES

- Management and Prevention of Vascular Anomalies
- Endovascular Treatment of Aortic and Iliac Aneurysms
- Management of Complicated Chronic Venous Insufficiency

RESEARCH ACTIVITY

Master Theses

- **Mayor Díaz A.** Estudio prospectivo sobre la adherencia a la terapia compresiva con medias de compresión en pacientes con insuficiencia venosa crónica en nuestro centro[dissertation]. MADRID: UE: 2025(24/06/2025). Director: Fernández-Heredero A.

Publications

- **Oberhuber A, Deglise S, Richter O, Makaloski V, Bracale U, Isernia G, Tines R, Cappelli A, Dorweiler B, Brunkwall J (Fernández Heredero A).** A prospective, multicentre registry on thirty day and one year outcomes of the e-liac stent graft system in patients with unilateral or bilateral aorto-iliac or iliac aneurysms: The PLIANTII Study. Eur J Vasc Endovasc. 2025; 69(6): 847-54. Article. IF: 8.5; D1
- **San Norberto EM, Revilla A, Brizuela JA, Díez,M, Taylor JH, del Moral LFR.** Directional atherectomy with antirestenotic therapy versus PTA/supera stenting for popliteal artery lesions: a propensity-matched analysis. J Endovasc Ther. 2025; 32(4): 1027-37. Article. IF: 1.8; Q2

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

4.6 Clinical Analysis

Publications: 20 | Q1:14

COMPOSITION

Blanca Beumer Prieto

- Raquel Cid Herranz
- Maria Gema Crespo Sánchez
- Marta Duque Alcorta
- Blanca Fabre Estremera
- Belén Fernández Puntero
- Abraham García López
- Ruben Gomez Rioja
- M Luisa González Casaus
- Laura González Iglesias
- José Manuel Iturzaeta Sánchez
- Álvaro Martínez Ortega
- Helena Méndez del Sol
- Marta Molero Luis
- Roberto Mora Corcovado
- Isabel Moreno Parro
- Yilian Nieves Simón
- Marcos Pedrosa Serrano
- Guillermo Pérez Nuño
- Laura Pérez Suárez
- Ruth Pliego Morante
- Daniel Prieto Arribas
- Ana Laila Qasem Moreno
- Andrea Rangel de la Mata
- Cristian Rios Campillo
- Olaia Rodríguez Fraga
- Maria Patricia Sanz de Pedro
- Noelia Seco Moro
- Kenza Sefrioui
- Maria Gemma Serrano Olmedo
- Mariana Serres Gómez
- María Isabel Soler Gallardo
- Berta Sufrate Vergara

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

RESEARCH AREAS

- Large system pathology

RESEARCH LINES

- Management and Prevention of Vascular Anomalies
- Endovascular Treatment of Aortic and Iliac Aneurysms
- Management of Complicated Chronic Venous Insufficiency

RESEARCH ACTIVITY

Doctoral Theses

- **Fabré Estremera B.** Role of Cardiac Biomarkers in Clinical Practice and Epidemiological Research[dissertation]. Madrid: UAM: 2025(20/11/2025). Director: Buño Soto A. .

Publications

- **Caballero Garralda A, Comás Reixach I, García Miralles Cs, Gómez Rioja R, Llopis Díaz MA, Martínez Espartosa D, Nicolas de Blas R, Panades Turro M, Puigvi Fernández L, Rodelgo Jimenez L, Sufrate-Vergara B, Ventura Orriols E.** Uso de la evaluacion externa de la calidad en las fases extraanaliticas de los laboratorios clinicos espanoles: una encuesta de la Sociedad Espanola de Medicina de Laboratorio (SEQCML). Adv Lab Med. 2025; 6(2): 206-12. Article. IF: 1.4; Q3
- **Cortés M, Kallmeyer A, Tarín N, Cristóbal C, Pello AM, Aceña A, Gutiérrez-Landaluce C, Huelmos A, Alonso J, López-Bescós L, Mahíllo-Fernández I, Lorenzo O, González-Casaus ML, Egido J, Tuñón J.** Klotho plasma levels are an independent predictorof mortality in women with acute coronary syndrome. Sci Rep-Uk. 2025; 15(1): 16744. Article. IF: 4.9; Q1
- **Cortés M, Lumpuy-Castillo J, García-Talavera CS, Rivera MBA, de Miguel L, Bollas AJ, Romero-Otero JM, Chapel JAE, Taibo-Urquía M, Pello AM, González-Casaus ML, Mahíllo-Fernández I, Lorenzo O, Tuñón J.** New biomarkers in the prognostic assessment of acute heart failure with reduced ejection fraction: beyond natriuretic peptides. Int J Mol Sci. 2025; 26(3): 986. Article. IF: 5.6; Q1
- **Entrala A, Lluch-Bernal MM, Domínguez-Ortega J, Molero-Luis M, Sánchez GC, Quirce S, Rodríguez-Perez R.** Measurement of fecal calprotectin and zonulin as biomarkers in adults with fish-induced food protein-induced enterocolitis syndrome. J Invest Allerg Clin. 2025; 35(3): 230-2. Editorial Material. IF: 6.6; Q1
- **Fabre-Estremera B, Buño-Soto A, Sotos-Prieto M, Carballo-Casla A, Milla SP, Rodríguez-Artalejo F, Ortolá R.** Cardiac biomarkers and malnutrition incidence in community-dwelling older adults without cardiovascular disease: the seniors-ENRICA-2 cohort. Clin Chem. 2025; 71(4): 474-83. Article. IF: 8.3; D1
- **Górriz JL, Gil FA, López MAB, Soto AB, Cabrera FJC, Cisnerosf A, Guerrerog SC, Conejos MD, Cabello IE, Planellesj MCF, García-Matarín L, Jiménezl N, Mauro JCJ, Jiménez DL, Gamote DM, Ramos PM, Ortiz A, Palaur G, Rivera JQ, Sánchez-Álvarez JE, Ajamil RT, Martín CV, Fernández RV.** Improvement in the detection, diagnosis, and early treatment of chronic kidney disease in Spain. The IntERKit Project. Nefrologia. 2025; 45(5): 351-9. Article. IF: 2.1; Q3
- **Jaffe AS, Sandoval Y, Mills NL, Omland T, Aakre KM.** Challenges of using natriuretic peptides to screen for the risk of developing heart failure in patients with diabetes: a report from the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Clinical Applications of Cardiac Bio-Markers (C-CB). Clin Chem Lab Med. 2025; 63(11): 2130-9. Article. IF: 4.4; Q1
- **Karimi K, Lichtenstein Y, Reilly J, Relator R, Levy MA, Kerkhof J, Bouman A, Symonds JD, Ghoumid J, Smol T, Clarkson K, Drazba K, Louie RJ, Miranda V, Mccann C, Motta J, Lancaster E, Sallevelt S, Sidlow R, Morrison J, Hannibal M, O'Shea J, Marin V, Prasad C, Patel C, Raskin S, Maria-Noelia SM, de Bustamante AD, Marom D, Barkan T, Keren B, Poirsier C, Cohen L, Colin E, Gorman K, Gallant E, Menke LA, Palafoll IV, Hauser N, Wentzensen IM, Rankin J, Turnpenny PD, Campeau PM, Balci**

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



TB, Tedder ML, Sadikovic B, Weiss K. Discovery of a DNA methylation profile in individuals with Sifrim-Hitz-Weiss syndrome. Am J Hum Genet. 2025; 112(2): 414-27. Article. IF: 7.7; D1

- **Leal-Pérez N, Blanco-Colio LM, Martín-Ventura JL, Gutiérrez-Landaluce C, Mahíllo-Fernández I, González-Casaus ML, Lorenzo O, Egido J, Tuñon J.** High levels of galectin-3 and uric acid are independent predictors of renal impairment in patients with stable coronary artery disease. J Clin Med. 2025; 14(15): 5264. Article. IF: 3.3; Q1
- **Marco JDG, Acín PA, Gimeno EJ, Calle PF, Martín VL, González-Casaus ML.** Biochemical evaluation of X-linked hypophosphatemia and tumor-induced osteomalacia: insights into diagnosis and management. Front Endocrinol (Lausanne). 2025; 16: 1702656. Article. IF: 5.7; Q1
- **Marqués-García F, González-Lao E, Tejedor-Ganduxé X, Boned B, Díaz-Garzón J, Simón M, García-Lario JV, Perich C, Fernández-Fernández MP, Martínez-Sánchez LM, Muñoz-Calero M, González-Tarancón R, Fernández-Calle P.** Impact of six sigma estimated using the Schmidt-Launsbyn vs. the Wetsgard equation in the Spanish type I EQA program. Adv Lab Med. 2025; 6(3): 327-35. Article. IF: 1.4; Q3
- **Mas-Fontao S, Tarín N, Cristobal C, Soto-Catalán M, Pello A, Aceña A, Lumpuy-Castillo J, Garces C, Gómez-Guerrero C, Gutiérrez-Landaluce C, Blanco-Colio LM, Martín-Ventura JL, Huelmos A, Alonso J, Bescós LL, Moreno JA, Mahíllo-Fernández I, Lorenzo O, Gonzalez-Casaus ML, Egido J, Tuñón J.** Elevated plasma levels of TNF-R1 predict the development of acute ischemic events in coronary patients with diabetes. Clin Investig Arterioscler. 2025; 37(2): 100735. Article. IF: 1.9; Q3
- **París-Muñoz A, Alcobendas-Rueda RM, Verdu-Sánchez C, Udaondo C, Galán-Gómez V, González-Martínez B, Menéndez JJ, Martínez-Romera I, Minguillón J, Pertíñez L, de Manuel-Gómez C, de la Cruz-benito A, Sanz-Rupérez A, Remesal A, Cámara C, Sánchez-Zapardiel E, del Pino-Molina L, Gómez-Zamora A, Serrano-Olmedo MG, Español-Rego M, Valbuena MRD, Climent F, Dorao P, Ríos-Blanco JJ, Andrade JD, Ruiz-Zurita G, Fernández-García MA, Pérez-Martínez A.** CD19 CAR-T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease. Med. 2025; 6(8): 100676. Article. IF: 13.3; D1
- **Prieto BB, Moreno-Parro I, Sufrate-Vergara B, Fabre-Estremera B, Soto AB, Fernández-Calle P, Marco JDG.** Biological variation of cardiac biomarkers in athletes during an entire sport season. Clin Chem Lab Med. 2025; 63(5): 987-94. Article. IF: 4.4; Q1
- **Quintana-Castanedo L, Maseda R, Pérez-Conde I, Butta N, Monzón-Manzano E, Acuña-Butta P, Crespo MG, Buño-Soto A, Jiménez E, Valencia J, Arriba MC, Zuluaga P, de Lucas R, del Río M, Vicente A, Escámez MJ, Sacedón R.** Interplay between iron metabolism, inflammation, and EPO-ERFEhepcidin axis in RDEB-associated chronic anemia. Blood Adv. 2025; 9(9): 2321-35. Article. IF: 7.7; Q1
- **Rioja RG, Garralda AC, Reixach IC, Miralles CG, Díaz MAL, Espartosa DM, de Blas RN, Turró MP, Fernández LP, Jiménen LR, Sufrate-Vergara B, Orriols EV.** Consensus instability equations for routine coagulation tests. Clin Chem Lab Med. 2025; 63(8): 1620-31. Article. IF: 4.4; Q1
- **Rivero-Santana B, Saldaña-García J, Caro-Codón J, Zamora P, Moliner P, Monzonis AM, Zatarain E, Álvarez-Ortega C, Gómez-Prieto P, Pernas S, Rodríguez I, Soto AB, Cadenas R, Ozores PP, Ramírez SP, Salvador MM, Valbuena S, Gasso LF, Juárez V, Severo A, Terol B, Álvarez TD, Rodríguez O, Brion M, González-Costello J, Albendea MC, González-Juanatey JR, Moreno R, López-Sendón J, López-Fernández T.** Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. 2025; 46(3): 273-84. Article. IF: 45.3; D1
- **Seco-Moro MN, Villanueva-Curto S, Criado-Gómez L, Olmos-Sánchez I, Monterrey DT, García-Junceda E, Sánchez-Moreno I.** Enhanced detection of immune complexed vitamin B12 in human serum by size-exclusion fractionation (SEF): An upgraded tool for reliable diagnosis. Anal Chim Acta. 2025; 1342: 343671. Article. IF: 6.1; Q1
- **Sufrate-Vergara B, Grau CM, Vidal LP, Marín-Reina P, Ríos MJE, Rodríguez-López R.** Pancreatic malformation and heterotaxy syndrome associated with 6q25.1 haploinsufficiency. Pancreas. 2025; 54(6): e571-2. Letter. IF: 2.2; Q3
- **Troya MI, Bover J, Hidalgo AC, Malumbres S, Sánchez-Bayá M, Masso E, Coll-Brito V, Anton-Pampols P, da Silva I, Soler-Majoral J, Marcos E, Abril BM, Perez-Leon N, García MM, Zaragoza JPG, Miguel XJ, Estevez YL, López-Alarcon R, Blanco I, Indiano CM, Gracia-García S, Soto AB, Górriz JL, Buades JM, Ortiz A, Sánchez E, Araa J.** The importance of disease coding following the diagnosis of chronic kidney disease: from ICD-10 code N18.9 to the role of clinical laboratories. Nefrología. 2025; 45(9): 501410. Letter. IF: 2.1; Q3

Research projects

- **Molero Luis M.** Diagnóstico sin biopsia en la enfermedad celíaca: definición de un umbral para cada test de anticuerpos anti-tranglutaminasa IgA. FIBHULP. 2023-2026. Managment centre: FIBHULP

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

IdiPAZ Instituto de Investigación Hospital Universitario La Paz

Scientific Report 2025



SaludMadrid Hospital Universitario La Paz
Hospital Carlos III
Hospital Cantoblanco

SaludMadrid FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA
Hospital Universitario La Paz

SaludMadrid Hospital Universitario de Getafe

UAM Universidad Autónoma de Madrid

ue Universidad Europea